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ABSTRACTS 
Abstracts of Original Contributions: Young Investigators 
Awards Competition 
The purpose of the Awards is to find and encourage the 
Young Investigators of promise on whom the future of 
cardiology depends. Any physician/scientist who is cur- 
rently in a residency or fellowship training program or 
who has been in such a program within the past three 
years is eligible to submit an original investigation. 
Medical students and Ph.D. candidates are also eligible 
for the competition. 
The Judging Committee will select a first and sec- 
ond place winner and three honorable mentions for 
each of the following categories: a) Clinical Investi- 
gations; b) Physiology, Pharmacology, and Pathology; 
and c) Molecular and Cellular Cardiology. The Awards 
will be presented at the 48th Annual Convocation 
Ceremony on Wednesday, March 10, at 6:00 p.m. The 
Young Investigator of the Year (first place) for each 
category will receive a plaque, a certificate and $2,000. 
Second place winners each receive a certificate and a 
check for $1,000. The three honorable mentions each 
receive a certificate and a check for $500. 
The American College of Cardiology Young Inves- 
tigators Awards Competition is supported by a grant 
from Otsuka America Pharmaceutical, Inc. 
Bradford C. Berk, MD, PhD, FACC 
Chair 
1999 Young Investigators Awards Committee 
Young Investigators Awards Competition: 
Physiology, Pharmacology, and Pathology 
Monday, March 8, 1999, 10:30 a.m.-Noon 
Modal Convention Center, Room 228 
10:30 a.m. 
~0-~A Targeted Disruption in Connexin 40 Leads to 
Distinct Atrioventricular Conduction Defects 
Laura M. Bevilacqua, Alexander M Simon, Colin T. Maguire, 
Josef Gehrmann, Amit Rakhit, Craig E. Fleishman, David Paul, Charles 
I. Berul. Boston Children's Hospital, Harvard Medical School, Boston, MA, 
USA 
Gap junctions consist of connexin (Cx) proteins that enable electrical coupling 
of adjacent cells and propagation of action potentials. The Cx40 isoform is 
solely expressed in the atrium and His bundle. The purpose of this study was 
to evaluate atfioventricular (AV) conduction in homozygous Cx4O-deficient 
mice (Cx40-/-). 
Methods: Surface ECGs and intracardiac electrophysiology (EP) studies 
were performed in Cx40 / mutant mice and wild-type (wr) controls. The 
RR, PR, QRS, and QT intervals were measured on ECG. Sinus node recov- 
ery time, AV refractory periods, paced AV Wenckebach and 2:1 block cycle 
lengths, and ventricular effective refractory periods (VERP) were assessed 
by EP study. Arrhythmia inducibility was determined using programmed elec- 
trical stimulation. 
Results: 23 mice completed surface ECG and intracardiac EP testing 
(11 Cx40 -/ , 12 WT). Significant differences in AV conduction were found 
in Cx40 /- mice compared to controls. The PR interval was prolonged in 
Cx40 -/- mice (50.1 :E 1.8 ms vs. 41.9 4- 1.9 ms, p = 0.002), with no 
difference in P wave duration, consistent with His bundle conduction de- 
lay. No differences in QRS or QTc were seen, consistent with the lack of 
Cx40 expression in ventdcular myocytes. EP findings included increased 
AV refractoriness and conduction in Cx40 -I- mice. There was no significant 
difference in VERP between groups. Ventricular tachycardia was induced in 
4/11 Cx40 /- mice with programmed electrical stimulation. 
AVERP100 AV Wencke AV 2:1 VT 
Cx4(3 / 68 -- 4 ms 83 + 3 ms 69 ± 3 ms 33% 
WT 52 :E 1 ms 68 ± 3 ms 55 ± 2 ms 8% 
(p < 0.01) (p < 0.01) (p < 0.01) 
Conclusion: A homozygous Cx40 disruption prolongs AV conduction 
parameters due to abnormal electrical coupling in the specialized conduction 
system, which may also predispose to arrhythmia vulnerability. 
10:45 a.m. 
~ Dietary L-Arginine Reverses the Inhibitory Effect of 
Asymmetric Dimethylarginine on Angiogenesis in 
Hypercholesterolemia 
Hoai-Ky V. Ho, James J. Jang, Shanthi Adimoolam, John P. Cooke. 
Stanford University, Stanford, CA, USA 
It has been shown that fibrovascular growth occurs centripetally into a disc 
angiogenesis system (DAS), a synthetic polyvinyl disc which is implanted 
subcutaneously in mice. We used this system to examine if hypercholes- 
terolemia impairs angiogenesis, and to determine if asymmetric dimethylargi- 
nine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, directly 
causes this impairment. 
Methods: The DAS was implanted subcutaneously in female C57 BL/6J 
mice of the following 4 groups: (a) wildtype [E+], (b) apoE-deficient hyper- 
cholesterolemic [E-], (c) E ÷ + L-nitro-arginine (LNA, 6 mg/100 ml drinking 
water), and (d) E- + L-arginine (LA, 6 g/100 ml drinking water). In another E + 
group, we placed in the center of the disc a pellet containing ADMA coated 
with a copolymer to allow a controlled release of ADMA locally. After two 
weeks, all discs were extracted and sectioned for measurement of fibrovas- 
cular growth by morphometric analysis. The blood plasma was collected for 
ADMA measurement. 
Results: In the E group, endogenous plasma ADMA was 20-fold el- 
evated. The fibrovascular growth area in the E group was about half of 
that in the E ÷ group. This anti-angiogenic effect of hypercholesterolemia was 
reversed by NO precursor LA. In the E ÷ group, LNA suppressed angiogen- 
esis. Similarly, local administration of ADMA directly into the disc reduced 
angiogenesis by 66%. 
Conclusions: The endogenous NO synthase inhibitor ADMA is markedly 
elevated in hypercholesterolemic mice. This abnormality is associated with 
reduced angiogenesis, and can be reversed by the NO precursor L-arginine. 
By contrast, systemic or local administration of NO synthase inhibitors in 
normal mice markedly impairs angiogenesis. This is the first study to indicate 
that ADMA may act as an endogenous anti-angiogenic factor. 
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11:00 a.m.  
~3-]  Anti-Inflammatory Actions of Epoxygenase-Derived 
Eicosanoids 
Koichi Node, James K. Liao. Brigham & Women's Hospital Boston, MA, 
USA 
The epoxygenase-derived eicosanoids are products of the cytochrome p450 
monooxygenase pathway which have properties of endothelial-derived hy- 
perpolarizing factor (EDHF). Epoxyeicosatrienoic acid (EET) hyperpolarizes 
and relaxes vascular smooth muscle by activating calcium-dependent potas- 
sium (Kca) channels, but its role in vascular inflammation is unknown. Here we 
showed that EET modulates endothelial cell activation independent of its hy- 
perpoladzing effects. When cytokine-activated endothelial cells were treated 
with physiological concentrations (1-100 nM) of various EET derivatives such 
as [6,6]-EET, [8,9]-EE, and [11,12]-EET, but not [14,15]-EET, TNF-~-induced 
vascular cell adhesion molecule (VCAM)-I expression was inhibited by 25 
± 4, 28 4- 3, 71 ± 5%, respectively. The effects of EET on VCAM-1 ex- 
pression, however, were not affected by blocker of Kca channels such as 
iberiotoxin or charybdotoxin. To determine the mechanism of EET's inhibitory 
effect on VCAM-1 expression, transfection studies using various VCAM-1 
promoter constructs were performed which demonstrated that [11,12]-EET 
repressed VCAM-1 gene transcription, in part, by inhibiting KB cis-acting 
elements. Indeed, gel-shift assays and Rel A immunofluorescence studies 
indicate that [11,12]-EET, but not [14,15]-EET, inhibited the activation and 
nuclear translocation of NF-~B. Since NF-KB activation is dependent upon 
the phosphorylation and degradation of its cytoplasmic inhibitor, IKB-<x, we 
investigated the effects of EET on bob kinase (IKK) activity and IxB-,x level. 
Treatment with [11,12]-EET, but not [14,15]-EET, inhibited TNF-c~-induced 
IKK activity and prevented IKB-<x phosphorylation and degradation. These 
results indicate a novel function of epoxygenase-derived eicosanoids in at- 
tenuating endothelial cell activation and suggest an important protective role 
of P450 monooxygenase in vascular inflammation and atherogenesis, 
11:15 a.m.  
I~ - ]  Flavopiridol Inhibits Vascular Muscle Smooth Cell 
Proliferation in Vitro and Neointimal Formation in 
Vivo After Carotid Injury in the Rat 
Cam Patterson, Johannes Ruef, Adam Meshel, Zhaoyong Hu, Marschall 
S. Runge. University of Texas Medical Branch, Galveston, TX, USA 
Smooth muscle cell (SMC) proliferation is a component of neointimal forma- 
tion in many animal models of vascular injury, and in human lesions as well. 
Cell cycle inhibition by gene transfer techniques can block SMC proliferation 
and lesion formation, although these methods are not yet applicable to the 
treatment of human disease. Flavopiridol is a recently identified, potent, orally 
available cyclin-dependent kinase inhibitor. 
Results: In human aortic smooth muscle cells, we found that flavopiridol 
(75 nmol/L) resulted in near complete inhibition of basic fibroblast growth fac- 
tor- and thrombin-induced proliferation. Flavopiridol inhibited cyclin-depen- 
dent kinase activity, as measured by histone H1 phosphorylation, but had no 
effect on MAP kinase activation. Induction of cell cycle-related proteins cy- 
clin D1, PCNA, and retinoblastoma protein was also blocked by flavopiridol. 
Flavopiridol had no effect on cellular viability. To test whether flavopiridol had 
a similar activity in vivo when administered orally, we examined neointimal 
formation in rat carotid arteries after balloon injury. Flavopiridol (5 /~g/kg) 
administered by gavage reduced neointimal area by 40% at 7 and 14 days 
after injury. 
Conclusions: Flavopiridol inhibits SMC growth in vitro and in vivo. It's oral 
availability and selectivity for cyclin-dependent kinases make it a potential 
therapeutic tool in the treatment of SMC-rich vascular lesions. 
11:30 a.m.  
~0~ Construction and a Single Functional Evaluation of 
Chain Antibody Fusion Protein With Fibrin-Targeting 
and Thrombin Inhibition After Activation by Factor 
Xa 
Kadheinz Peter, Justin Graeber, Marschall S. Runge, Wolfgang KLibler, 
Melvyn Little, Christoph Bode. Department of Cardiology, University of 
Heidelberg, Germany 
Using the single chain antibody technology a new type of anticoagulant was 
designed that allows fibrin-targeting and that is only active in the presence of 
an activated coagulation system. 
Methods and Results: mRNA of a hybridoma that produces the fibrin- 
specific monoclonal antibody 59D8 was prepared and reverse transcribed. 
The variable regions of the heavy and light chain were amplified and fused 
with a (Gly4Ser)3 linker by PCR. The obtained single chain antibodies were 
expressed on M13 Phage and high affinity clones were selected by ten rounds 
of panning on the fibrin-specific B#15-22 peptide and sequenced. The se- 
quence encoding hirudin was fused to the C-terminal end of the variable 
region of the light chain. To expose the functionally necessary N-terminus of 
hirudin and at the same time to introduce a preferential activation at the clot, 
a factor Xa cleavage site was added between the single chain antibody and 
hirudin. The fusion protein (up to 10 mg/51 bacterial culture) was character- 
ized on SDS-PAGE before (36 kDa) and after cleavage by factor Xa (7 and 
29 kDa). Binding to the peptide B/~ 15-22 and anti-thrombin activity only after 
cleavage by factor Xa could be demonstrated. 
Conclusion: A fusion protein was constructed that binds to a fibrin-spe- 
cific epitope and exhibits anti-thrombin activity only after activation by factor 
Xa. This new type of anticoagulant can be produced at large scale and low 
cost and may provide a highly effective clot-localized anti-thrombin activity 
without systemic inhibition of the coagulation system and bleeding problems. 
Young Investigators Awards Competition: 
Molecular and Cellular Cardiology 
Monday,  March  8, 1999, 2:00 p .m. -3 :30  p.m. 
Mor ia l  Convent ion  Center ,  Room 228 
2:00 p.m. 
[4 -~- ]  Localization of a Gene Responsible for 
Arrhythmogenic Right Ventricular Dysplasia to 
Chromosome 3p23 
Ferhaan Ahmad, Dauxiang Li, Akihiko Karibe, Oscar Gonzalez, 
Terry Tapscott, Rita Hill, Donald Weilbaecher, Peter Blackie, Michael Furey, 
Martin Gardner, Linda L. Bachinski, Robert Roberts. Baylor College of 
Medicine, Houston, TX, USA 
Background: Arrhythmogenic right ventricular dysplasia (ARVD) is an auto- 
somal dominant familial cardiomyopathy prevalent at >6/10,000. It is char- 
acterized by replacement of myocytes with fatty and fibrous tissue. TUNEL 
assays suggest the involvement of myocyte apoptosis. Clinical manifesta- 
tions include structural and functional abnormalities of the right ventricle and 
arrhythmias, leading to a sudden death rate of 2.5% per year. No gene has 
yet been identified, but four loci have been mapped. We have established a 
novel locus for ARVD. 
Methods and Results: We identified a family of 280 members with ARVD 
affecting 10 living individuals. The diagnosis was based on international di- 
agnostic criteria utilizing history, physical examination, electrocardiogram, 
echocardiogram, fight ventricular angiogram, endomyocardial biopsy, and 
24-hour ambulatory electrocardiography. Blood was collected from 151 family 
members and DNA extracted. Genotyping with 257 polymorphic microsatel- 
life repeat markers followed by genetic linkage analysis excluded previously 
known loci for ARVD and identified a novel locus at 3p23. Analysis of an 
additional 20 markers further defined the region. A peak LOD score of 6.91 
was obtained with marker D3S3613 at e = 0% recombination. Haplotype 
analysis identified a shared region between markers D3S3610 and D3S3700 
of <10.6 cM. 
Conclusions: A novel locus for ARVD has been mapped to 3p23 and the 
region narrowed to 10.6 cM. Identification of the gene will make possible a 
definitive genetic diagnosis of a disease which is difficult o diagnose because 
of protean nonspecific findings. In addition to elucidating the pathogenesis 
of this disease, it should improve understanding of cardiac chamber-specific 
gene expression and the mechanism of myocyte apoptosis. 
2:15 p.m. 
~ B o n e  of Endothelial Cells Marrow Transplantation 
Jay M. Edelbarg, Yuko Soneoka, Wilfred S. Mamuya, Richard C. Mulligan, 
Robert D. Rosenberg. Beth Israel Deaconess Medical Center, Boston MA, 
USA 
We hypothesized that bone marrow is a potential source of endothelial precur- 
sor cells and that bone marrow transplantation (BMT) may transfer endothe- 
lial cells which could integrate into host vasculature. Syngeneic BMT was 
performed employing donor bone marrow harvested from transgenic murine 
lines in which transgene expression is restricted to the endothelium: TMLacZ 
is pan-endothelial; and vWFLacZ-2 is restricted to the microcirculation of 
brain, skeletal muscle and heart. Three months post-BMT the transplanted 
bone marrow was stained for the transgene product. In addition, neovascu- 
larization was induced by isogeneic heart and lung transplantation. These 
organs were then sectioned and stained for the transgene product. 
Results: The bone marrow of both TMLacZ and TMLacZ-BMT mice 
stained for the transgene, whereas that of the vWFLacZ-2 and vWFLacZ-2-BMT 
mice did not. In addition, sections revealed that the BMT-derived endothelial 
cells integrated into the transplanted organs. The heart transplants of both 
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the TMLacZ and vWFLacZ-2-BMT mice stained for the transgene. How- 
ever, only the TMLacZ-BMT mice revealed staining for the transgene in the 
transplanted lungs, with lack of staining in the vWFLacZ-2-BMT mice. 
Conclusions: These results demonstrated that BMT-dedved endothelial 
cells integrated into beth the host bone marrow as well as into newly formed 
blood vessels. These studies suggest that BMT may be employed in the 
future as vehicle for endothelial cell-based therapy in the treatment of both 
local and systemic cardiovascular diseases. 
2:30 p.m. 
[ -~  Characterization of the mUBC9 Sites Binding 
Required for E2A Protein Degradaton 
Gordon S. Huggins, Michael T. Chin, Nicholas Sibinga, Shwu-Luan Lee, 
Edgar Haber, Mu-En Lee. Harvard School of Public Health, Boston MA, USA 
The E2A proteins (E12 and E47) assist cardiac and skeletal muscle devel- 
opment by interacting with tissue-specific transcription factors. Like many 
other transcription factors, the E2A proteins are partly regulated by their 
degradation through the ubiquitin-proteasome system. Degradation by this 
system requires targeting by an ubiquitin-conjugating enzyme (Ubc), and 
previously we found that Ube9 interacted with the E2A proteins. We hypothe- 
sized that the E2A domain that interacted with Ube9, E2A (477-530), served 
as the degradation domain (DD). An E47 protein lacking this region, E47A 
(477-530), was degraded more slowly than wild-type E47 (half-life >3 hours 
versus 55 minutes), yet DD deletion had no effect on E2A protein's DNA 
binding and transcriptional activity. Using a yeast two-hybrid interaction ex- 
periment we mapped the Ubc9-bioding site to two conserved regions within 
the DD. Deletion of the second Ubc9 interacting region from full-length E47 
produced a more stable protein, thereby implicating Ube9 as a crucial regu- 
lator of E2A protein degradation. Finally, we produced a chimedc protein of 
the DD with a stable onceprotein. The chimeric protein was destabilized by 
the DD (half-life I hour versus >3 hours for the parent protein), suggesting 
that the DD can transfer its degradation signal to a heterologous protein. 
Understanding the molecular regulation of E2A degradation may provide 
insight into novel regulatory mechanisms of muscle cell differentiation and 
regeneration. 
2:45 p.m. 
~ Expression a Hypertrophic of Human 
Cardiomyopathy Mutation in Transgemic Mice 
Impairs Left Ventricular Systolic Function, Detected 
by 17STa Radionucleide Angiography, Which 
Precedes Histological Changes 
Leslie Oberst, Gulling Zhao, Jong-Tae Park, Keith Youker, Mark Entrnan, 
Lloyd H. Michael, Jeffrey Lacy, Robert Roberts, All J. Marian. Bay/or College 
of Medicine, One Baylor Plaza Room #543E, Houston, TX 77030, USA 
Background: Hypertrophic cardiomyopathy (HCM) is a disease of sarcom- 
eric proteins. Cardiac froponin T (cTnT) is a major HCM gene. Expression 
of mutant cTnT impairs contractility of the cultured cardiac myocytes. To 
study the impact of mutant cTnT on cardiac structure and function in-vivo, we 
produced transgenic (Tg) mice expressing normal (Arg 92) or mutant (Gin 92) 
human cTnT, the latter causes HCM in man. 
Methods: A full-length human cTnT cDNA was cloned and mutated. 
Normal and mutant cDNAs were placed 3' to a full-length mudne c~-myosin 
heavy chain promoter. Tg mice were produced and screened by polymerase 
chain reaction and Southern blotting. Transgene expression was confirmed 
by northern and immuno- blotting. Histology was examined by H&E and sirius 
red staining. Left ventdcular (LV) function and wall thickness were assessed 
by echocardiography and 178Ta radionucleide angiography (RNA). 
Results: 3 normal and 3 mutant Tg lines were established. Tg and the 
total cTnT mRNA were increased (several folds). Tg protein constituted up 
to 90% of the total cTnT protein pool in all 3 normal and 2 mutant lines. 
However, total cTnT protein remained unchanged, indicating tight regulation 
of the cTnT protein levels. 178Ta RNA showed a 36% reduction in LV ejection 
fraction in the mutant mice (53 ± 6 vs. 39 ± 7, p = 0.009). LV dimensions 
and wall thickness were normal. The E/A ratio was decreased by 50% in the 
mutant mice (6 & 2 vs. 3 ± 2, p = 0.005). Cardiac histology showed myocytes 
disarray ranging from 1-20% of the total myocardium and increased intersti- 
tial collagen in the mutant mice. Impaired LV function preceded histological 
changes. 
Conclusion: Expression of the mutant cTnT-GIn 92, responsible for human 
HCM, caused systolic and diastolic dysfunction in Tg mice without significant 
LV dilatation. Impaired function preceded histological changes. 
3:00 p.m. 
~~-]  The TGF~-Activated Kinase, TAK1, Is Activated in 
the Myocardlum by Pressure-Overload and Is 
Suff ic ient to  Trigger Heart Failure in Transgenic Mice 
Dou Zhang, George Taffet, Miho Yameda, Vincianne Gaussin, Robert 
J. Schwartz, Lloyd H. Michael, Paul A. Overbeek, Michael D. Schneider. 
Bay/or College of Medicine, Houston, TX, USA 
TGF#-activated kinase (TAK1) is a member of the mitogen-activatad protein 
kinase (MAPK) kinase kinase family, which couples extracellular stimuli to 
gene transcdption. The function, mediators, and nuclear targets of TAK1 
are not fully understood. Here, we investigated the potential involvement 
of TAK1 in cardiac hypertrophy. (1) TAK1 protein was expressed in cardiac 
myocytes and was down-regulated during heart development; conversely, 
TAK1 activity was induced in adult mouse myocardium by aortic banding. 
(2) In cultured cardiac myocytes, endogenous TAK1 was activated by TGF~ 
within minutes, and was required for induction of the skeletal ~-actin (SkA) 
promoter, shown using dominant-negative TAK1; conversely, constitutively 
active TAK1 (TAK1 AN) was sufficient o induce the promoter, working through 
p38 MAPK. (3) Shown using site-directed mutagenesis, synthetic promoters, 
and GAL4 fusion proteins, TAK1 activated the SPA promoter via serum re- 
sponse factor (SRF) - at least in part via the SRF activation domain or an 
activation domain-associated protein. (4) TAK1 AN, expressed selectively in 
myocardium of transgenic mice, resulted in cardiac hypertrophy, interstitial 
fibrosis,/%myosin heavy chain mRNA induction, severe myocardial dysfunc- 
tion, as assessed by pulsed-wave Doppler echocardiography, and sudden 
death, typically before two weeks of age. Thus, TAK1 kinase activity is up- 
regulated during load-induced cardiac hypertrophy in vivo, and is sufficient 
to provoke structural and functional aspects of hypertrophy and failure. 
Young Investigators Awards Competition: 
Clinical Investigations 
Monday ,  March  8, 1999, 4:00 p .m. -5 :30  p.m. 
Moda l  Convent ion  Center ,  Room 228 
4:00 p.m. 
[4~- ]  The Power-Velocity Integral at the Vena Contracta: 
A New Method for Direct Quantification of 
Regurgitant Volume Flow 
Thomas Buck, Ron Mucci, J. Luis Guerrero, Godfred Holmvang, Mark 
D. Handschumacher, Robert A. Levine. Massachusetts Genera/Hospital, 
Boston, MA, USA 
Quantifying regurgitation has been limited because Doppler (DOP) mea- 
sures velocity, not volume. Since returning DOP power reflects number of 
scatterers, power x velocity should be proportional to volume flow rate. Early 
studies, however, suggested this held only for laminar flow, not for regurgitant 
jets, in which turbulence augments scatter. We therefore hypothesized that 
this DOP power pdnciple can be applied at the vena contracta where flow is 
laminar prior to entrainment, so that the power x velocity integral (PVI) should 
vary linearly with flow rate (Q) and its time integral (PVTI) should vary linearly 
with regurgitant stroke volume (SV). This was tested in vitro using steady and 
pulsatile flow through 0.2-0.8 cm 2 orifices and in 36 hemodynamic stages in 
vivo, replacing the LA of open-chest dogs with a dgid chamber and column 
for direct visual recording of mitral regurgitant SV (MRSV) as blood excur- 
sion in the column. In each model/animal, power in the narrow high-velocity 
spectrum from the vena contracta was calibrated against that from a narrow 
reference beam of known area. In 10 patients, MRSV was also compared 
with LV ejection volume - Aortic forward SV, by DOP and (n = 3) by MRI. 
Results: Calculated and actual Q and SV correlated and agreed well in 
vitro (r = 0.99, 0.99; mean error = -1.6 • 2.5 ml/s, -2.4 :E 2.9 ml), in vivo 
(MRSV: r = 0.98, mean error = 0.04 ± 0.87 ml, NS vs. 0), and in patients (r 
= 0.99, mean error = -2.1 ± 3.9 ml, NS vs. 0). Current beam size limited 
power recording for >0.5 cm 2 orifices (severe MR). 
Conclusion: Prior limitations of using DOP power in regurgitation can 
be overcome by sampling the laminar flow at the vena contracta, where 
the integral of power x velocity vades lineady with regurgitant Q and SV. 
A dual-beam technique corrects for attenuation in each individual, providing 
absolute values for regurgitant flows measured the first time directly. 
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4:15 p.m. 
~-]  Accurate Noninvasive QuanUtation of 
Atherosclerosis by Wavefront Analysis and 
Transthoracic Echocardiography 
Patrick Hunziker, Christophe Imsand, Vania Barbosa, Noah Liel, 
Chdstoph Kaiser, Matthias Pfisterer, Peter Buser. University Hospital, Basel, 
Switzerland 
Study Purpose: Development and validation of a new noninvasive method 
for quantification of atherosclerosis. Recent studies have proved the efficacy 
of lipid lowering drugs in prophylaxis of atherosclerotic events, but also have 
led to an intense debate about who should be treated. Selection of patients 
for primary prophylaxis is often based on surrogate markers of atheroscle- 
rosis, but noninvasive quantitation of atherosclerosis is desirable. This novel 
method measures the severity of atherosclerosis through determination of 
elastic aortic properties. It is based on transthoracic echo, wavefront analy- 
sis, and th e Moens-Korteweg relation. The method was validated clinically 
by direct visualization of aortic plaque burden by transesophageal echo. 
Aortic elasticity versus plaque extent 
J: 
~jS- Y = ,S16 + .111 * X 
is4- R 2 = .ass 
p < .0001 
/ .  
2" ,DO • 
Plaque extent 
/ w - [%c i rcumference]  
0 , 
0 1'0 2'0 3'0 
Results: In 16 consecutive patients (53 + 13 y, range 30-73), an excellent 
correlation of elasticity E.h with extent (p < 0.0001) and thickness (p < 
0.0001) of aortic plaques was found. (E: Young's modulus, h: wall thickness). 
In multivariate analysis, the results were independent of age, sex, blood 
pressure, and aortic diameter. In comparison to conventional measures of 
pulse wave-vessel walt interaction (pulse pressure, aortic compliance, wave 
propagation velocity), multivariate analysis found the new method to be 
the strongest predictor of severity of atheroscterosis. Notably, even mild, 
preclinical atherosclerotic hanges were detected by the method. 
We conclude that accurate noninvasive quantitation of the severity of 
atherosclerosis is possible by combining transthoracic echocardiography 
with wavefront analysis, promizing improved stratification of cardiovascular 
risk and better targeting of primary prophylaxis. 
4 :30 p.m. 
[41~ Tenfold Augmentation of Myocardial Uptake of 
Vascular Endothelial Growth Factor With Ultrasound 
After Systemic Administration 
Debabrata Mukherjee, James Wong, Brian P. Griffin, Stephen G. Ellis, 
Thomas Porter, Subha Sen, James D. Thomas. Cleveland Clinic 
Foundation, Cleveland, OH; University of Nebraska, Omaha, NE, USA 
Background: A limitation of tissue-targeted drug delivery is the need for di- 
rect arterial cannulation. We postulate a mechanism by which agents injected 
via a peripheral vein may be targeted to a tissue using ultrasound (US) and 
ultrasonic contrast agents. 
Methods: We used a rat model to test the ability of US and an ultrasonic 
contrast agent Perflurocarbon exposed sonicated dextrose albumin (PESDA) 
to increase uptake of vascular endothelial growth factor (VEGF) in the my- 
ocardium. Continuous wave (CW) Doppler ultrasound (0.6 watts/sq.cm at 1 
MHz for 15 minutes) was applied to the chest wall overlying the myocardium 
during intravenous injection with either VEGF (100/~gs/kg) alone or a combi- 
nation of VEGF and PESDA (0.1%). Control rats had VEGF infused without 
US or PESDA. VEGF uptake was measured quantitatively in the heart, lung, 
liver and kidneys by ELISA (ng/g tissue) and morphologically by fluorescence 
microscopy. 
Results: There was 8-fold increase in VEGF uptake in the heart by 
ultrasound alone (16.86 ± 1.56 Vs 2.11 + 0.953 ng/g tissue, p < 0.0001 ) and 
13-fold increase with US + PESDA (26.78 ± 2.88 Vs 2.11:1:0.953 ng/g tissue, 
p < 0.0001) as compared to controls. There was no significant increase in 
VEGF uptake in other organs. Fluorescence microscopy revealed deposition 
of VEGF in the endothelium of small intramyocardial arterioles. 
Conclusions: These results show a marked increase in VEGF uptake 
with ultrasound and ultrasound + PESDA. Thus, ultrasound, either alone or 
in conjunction with myocardial contrast agents, may be used to augment 
myocardial VEGF uptake 10-13 fold. 
4 :45 p.m. 
[~-~ Oscillatory Breathing Patterns During the 
Wakefulness in Patients with Heart Failure - Clinical 
Implications, and the Role of Augmented Peripheral 
Chemosensitivity 
Pictr P. Ponikowski, Stefan D. Anker, Andrew J.S. Coats. Cardiac Medicine, 
NHLI, London, UK 
Oscillatory breathing (with apnea: Cheyne-Stokes respiration, [CSR] or with- 
out: periodic breathing, [PB]) occurs during the daytime in chronic head 
failure (CHF). In 74 pts with stable CHF, spectral analysis was applied to 
30-min recordings of respiration during the daytime to detect CSPJPB. We 
assessed autonomic balance (with heart rate variability), barorefiex sensitiv- 
ity, and peripheral chemosensitivity (CHEMO, transient hypoxic method). The 
effects of CHEMO suppression with hyperoxia or dihydrocodeine (1 mg/kg, 
double-blind, placebo-controlled) on the CSR/PB were also studied. 
Results: Forty nine (86%) pts had a cyclical breathing: 22 CSR, 27 
PB. The presence of CSR or PB was associated with more severe CHF 
symptoms. Pts with PB or CSR had more impaired autonomic balance, and 
increased CHEMO (0.80 vs 0.75 vs 0.34 L/min/%SaO2, p < 0.001, CSR, 
PB vs normal breathing). Hyperoxia abolished the oscillatory breathing in 
7/8 pts. A fall in CHEMO after dihydrocodeine (-42%, p = 0.05) correlated 
with improvement in respiratory pattern. In pts with cyclical breathing 2-year 
survival was 67% vs 96% in those with normal breathing (p = 0,008). Cyclical 
breathing predicted a poor 2-year survival (RR: 9,41, p < 0.01 ), independently 
of treadmill peak oxygen consumption (p = 0,04). 
Conclusion: An oscillatory breathing pattern during the daytime reflects 
impaired autonomic regulation and predicts poor outcome. Overactive pe- 
ripheral chemoreceptors are suggested to be causally related to oscillatory 
breathing in CHF. 
5:00 p.m. 
~ ]  The Possible Role of Hepatitis A Virus in the 
Pathogenesis of Atherosclerosis 
Jianhui Zhu, Arshed A. Quyyumi, James E. Norman, Gyorgy Csako, 
Stephen E. Epstein. Washington Hospital Center, Washington, DC; NHLBI, 
National Institutes of Health, Bethesda, MD, USA 
Background: Previous studies suggest possible atherogenic roles of several 
infectious agents. These agents are all intracellular pathogens, and all estab- 
lish persistent circulating antibodies after infection. We determined whether 
hepatitis A virus (HAV), which shares these attributes and infects about 50% 
of individuals in developed countries, contribute to coronary artery disease 
(CAD). 
Methods: Blood samples were collected from 233 patients (pts) under- 
going coronary arteriography and tested for IgG antibodies to HAV and 
C-reactive protein (CRP). 
Results: Of the 233 individuals studied, 125 (54%) had lgG antibodies 
directed against HAV. The prevalence of CAD was 79% (99/125) in the HAV 
seropositive pts and 55% (59/108) in the seronegative pts (P = 0.0001). 
The association between CAD and HAV seropositivity retained significance 
after adjustment for either known CAD risk factors alone (P = 0.001), or 
for these risk factors plus four other infectious agents (CMV, Chlamydia 
pneumoniae, HSV1 and HSV2) (P = 0.004). Because of the association 
between inflammation and CAD, we ascertained the relationship between 
HAV and CRP. CRP levels were higher in HAV seropositive pts than in 
seronegative pts (mean 0.85 mg/dL, n = 125 vs. 0.69 mg/dL, n = 108, P = 
0.0002). The significant association between elevated CRP levels and HAV 
seropositivity persisted after adjustment for CAD risk factors (P = 0.0005), or 
for risk factors plus the four other infectious agents (P = 0.009). A multiple 
logistic regression analysis showed that HAV seropositivity is an independent 
determinant of both CAD risk and CRP levels. 
Conclusion: Our findings suggest that HAV infection independently con- 
tributes to the development of CAD, and that the capacity of the virus to 
induce a chronic inflammatory state appears to constitute one of the respon- 
sible mechanisms. 
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Abstracts of Original Contributions: Computer Applications 
The American College of Cardiology received 58 ab- 
stracts of original contributions involving computer 
technology. Twelve abstracts have been scheduled for 
demonstration at the info@ACC area in the exhibit 
hall which will bring together activities related to com- 
puter technology. Six abstracts have been scheduled 
for an oral session entitled "New Approaches to Digital 
Management of Clinical Data". 
In addition, info@ACC will feature a series of pre- 
sentations related to various information technology 
issues, a hands-on classroom for mastering basic com- 
puter skills, hardware and software advising, as well as 
displays of computer-related ACC products. 
Many excellent programs are planned, and we look 
forward to an exciting meeting. 
David J. Skorton, MD, FACC 
Chair 
Information Technology Committee 
New Approaches to Digital Management of 
Clinical Data 
Tuesday, March 9, 1999, 4:00 p.m.-5:30 p.m. 
Morial Convention Center, Room 228 
4:00 p.m. 
~-~ The Integrated Paperless Multimedia Electronic 
Patient Record - Coming of Age in a Multi-Centered 
Hospital Environment 
Ross D. Fletcher, Ronald E. Jones, Dan Femicola, Ruth A. Dayhoff, 
Elsie Casugay, Chiao M. Wu, Kevin Crawford, Christopher McManus. 
Department of Veterans Affairs and Georgetown University Medical 
Centers, Washington DC, USA 
Background: In a multi-centered hospital system, the need for a mobile, 
paperless patient record instantaneously available throughout he hospital is 
a necessity, The Department of Veterans Affairs has developed a high-speed 
network of multimedia workstations and servers to present the patient record 
with rfiultimedia images. In the Washington VAMC, the complete electronic 
record is available at over 900 workstations. An exchange of information 
between participating hospitals is possible through a secure Intranet connec- 
tion. An Internet link provides search capabilities as well as connections for 
the review of current guidelines and recommendations for treatment. 
System: The network was built using standard off the shelf hardware 
components. The workstations are running Windows NT, the VA software, 
Intemet Explorer, and MS Office 98. All textual information is accessed 
using a legacy database with pointers to images on a two-terabyte jukebox. 
Servers are used to keep frequently accessed records immediately available. 
Images can be adjusted for size, contrast, brightness, zoom, reverse image, 
and panning. Cardiology images such as echoes, coronary artedograms, 
ventriculograms, MUGA, thallium studies, X-rays, and ECG tracings, as 
well as multispecialty images from Oncology, Radiology, Surgery, Dentistry, 
Endoscopy, and Pathology to name a few are available. The Cardiology 
database includes records of over 5,693 Caths; 6,528 Holters; 67,776 ECGs; 
17,801 Echocardiograms; 8,030 El-l-s; and 1,393 EPs. 
Conclusions: The electronic record is available at over 900 in hospital 
locations, providing accurate and timely patient information. Practitioners in 
participating hospitals can also view pertinent information using the VA In- 
tranet o provide up-to-the minute information on patients that travel between 
locations served by various VA hospitals. 
4 :15 p.m. 
~2- -~ Interoperable Cardiological Data Cards: Italian 
Nationwide Implementation Phase G7 
CARDIO-ANMCO Project 
Christian Pristipino, Marco Tubaro, Giancado Carini, Fabio Fonda, 
Andrea Marchesini, Pierfranco Ravizza, Aldo Maggioni, Massimo Santini, 
Nicola Mininni, Attilio Maseri, Domenico Cianflone. On behaff of the 
G7CARDIO-ANMCO project; Rome, Italy 
Background: The G7-CARDIO has begun the implementation phase, to- 
gether with the Associazione Nazionale Medici Cardiologi Ospedalied (AN- 
MCO), of a national Web-aware Extranet Database and an integrated car- 
diological data card (CDC). The CDC structure follows the G7CARDS and 
EUROCARDS guidelines with a first layer (low confidentiality) for demo- 
graphic, medical insurance and emergency data and a second layer (high 
confidentiality) for specific cardiological data. The content of the high confi- 
dentiality layer has never been standardized in existing projects. 
Methods: Each 8 Kb smart~CDC contains up to 110 records and fol- 
lows the one-to-many database paradigm. Each record includes a record 
type attribute pointing to a global dictionary of descriptors (e.g. clinical 
diagnosis, risk factor and diagnostic tests) and semiquantitative variables 
whose relevant range of interest is made available in a list-box of choices 
according 1o the value/type area of the individual record. The dictionary, 
and list-boxes are designed to inter-operate with G7CARDIO database 
items. The card also contains the URL pointing to the Web-aware global 
database. 
Results: This distribution and validation phase involves about 150 na- 
tional centers of which 80 are coronary-care units and a distribution of 
50.000 CDC will be made available nationwide at the end of the validation 
phase. 
Conclusion: To our knowledge this project is the first implementation at 
national level of an interoperable CDC integrated with a web-aware extranet 
accessible global database and now ready for international validation. 
4:30 p.m. 
~ A  Model-Based Expert System for Improving 
Assessment of Patients With Cardiovascular 
Diseases in Intensive Care Units 
Ruilin Zhao, Roger G. Mark, Peter Szolovits. Massachusetts Institute of 
Technology, Cambridge, MA, USA 
Background: Physicians in intensive care units (ICU) usually face "infor- 
mation overload", in dealing with very large, complex and ever-changing 
quantities of clinical data. Our system is intended to help physicians to di- 
agnose and track the cardiovascular diseases of ICU patients based on 
quantitative analysis of the hemodynamic data. 
Methods: A lumped-parameter cardiovascular model is used in our ex- 
pert system to represent he patient's hemodynamic state. The cardiovascular 
simulator (CVsim) is a dynamic computer simulator of human cardiovascu- 
lar hemodynamics. It is implemented on SUN workstations running the X 
Window system. In our expert system, we first establish an initial value for 
each of the CVsim input parameters. Then we run CVsim. From the output 
variables of CVsim, such as arterial blood pressure, mean central venous 
pressure, systemic arterial pulse pressure, an inference engine was used to 
determine which input parameter(s) need to be changed in order to decrease 
the differences between the outputs from CVsim and the patient. 
Results: A number of pathological simulations of cardiovascular diseases 
have been successfully analyzed, including examples of hypertension, left 
and right ventdcular failure, hypovolemia, and pulmonary hypertension. In 
90% of the cases studied, the system was able to provide quantitative pa- 
tient-specific model parameters. Then we asked a cardiologist to participate 
in the qualitative evaluations of the results and give him three options to 
rate the performance: excellent, acceptable, and unsatisfactory. 70% of the 
results from case studies suggested by the system were rated as excellent, 
25% were rated as acceptable and 5% were rated as unsatisfactory. 
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Conclusion: We conclude that our approach is practical, and provides 
a mechanism for transforming and reducing real-time physiological data into 
pathophysiologic hypotheses relevant to the management of patients. 
4:45 p.m. 
18~-]  Graphical Plotting of Framingham Risk Scores for 
Office Use 
Jon G. Keevil, Patrick McBride. U. of Wisconsin, Madison WI, USA 
Background: The Framingham study elucidated the interactive effects of 
multiple cardiac risk factors. Attempts to bring this complex mathematical 
assessment into the clinician's office (plastic spinning disks, paper charts and 
programmed calculators) have met with limited success, as implementation 
is time consuming and results lack comparison with known populations. 
Desktop computers in offices and exam rooms have the potential to make 
the risk calculations quickly available and useful. 
Methods: We developed a program using Microsoft Visual Basic ®: for 
Excel ® that graphs a patient's absolute risk of developing coronary artery 
disease (CAD) over time, based on entered risk factors. One-hour teaching 
sessions were held with physicians and residents in Internal Medicine, Family 
Practice, Cardiology and the staff of a Preventive Cardiology clinic. 
The program was made available to interested practitioners. 
Results: The program graphs 1he patient's absolute risk of developing 
CAD, against a backdrop of the AHA "ideal" and "average" risk vs. age curves. 
Changing the risk factors dynamically changes the graph, which can be 
printed for the patient to take home. The program also calculates the number 
of patients needed to treat to save one event. The small program file transfers 
easily by E-Mail or disk and works on Windows ~ or Macintosh ~' computers 
running Microsoft Excel ~ 5.0 or above. A version is also available for palmtop 
computers. Our Preventive Cardiology clinic has used the program effectively 
for over two years to teach and motivate residents and patients. 
Conclusions: The program visually presents the complex interactions 
of multiple cardiac risk factors in a novel format that is useful for patients 
and physicians. It calculates the change in absolute risk expected with risk 
factor modification. In our experience, it can effectively educate and motivate 
practicing physicians, residents and patients toward managing cardiac risk. 
5:00 p,m. 
~-~-~ Use of a TeleCardiology System Speed Up to 
Therapeutic Decision-Making: A Pilot Center 
Approach 
Dominique Robert, Ron Davidson, Carole Conti, Hayette Bouchakour, 
Veronique Garreau, Marie-Claude Morice, Pierre Dumas, Herve Joly 1 , 
Pierre Librez ~ , Jamal S~oud 1 . Institut cardiovasculaire Paris-Sud, Antony; 
Centre hospitalier Laennec, Creil, France 
In a high-volume PTCA center, therapeutic decisions must be made as 
quickly as possible. The main obstacle, however, is the distance between 
interventional cardiologists, surgeons and referring physicians, who generally 
work in perfect collaboration and organize staff meetings to decide whether a 
patient should undergo PTCA or CABG. At a time when multimedia systems 
are beginning to be used in Cardiology Departments, a software named 
TeleCardiology System (TCS) has been developed to lake up the challenge 
of distance. 
From Sept. 1997 to Aug. 1998, we used TCS, which is a multi-task system, 
to transfer patient angiograms in the form of dynamic images with audio 
annotations and reports, through video and modem, to a remote referring 
center (80 km away), equipped with a TCS viewing station. The workstation is 
equipped with a TCS acquiring system (PC and modem) connected directly 
to the X-Ray system, to acquire automatically the cardiac procedures by the 
X-Ray system, and convert the data to digital format. Transmission speed 
is 35 MB/h, and moderate image compression is used to reduce transfer 
duration without affecting image quality. 
Results: Over a 12-month period, 102 pt files were transferred, 46 pts 
were eligible for PTCA, 4 for CABG. The remaining 52 pts were medically 
treated. Mean transmission time: 30 min; annotations: 2 min. 30 sec; report 
alone: 45 sec. All decisions were made in 45 min. to 1 h. 
Conclusion: TCS currently meets our center's requirements and permits 
rapid transfer of data to optimize therapeutic decision-making and patient 
comfort and safety; moreover, it is reliable, cost-effective and enables all 
physicians to participate in the decision process, eliminating unnecessary 
patient visits to the various centers involved. It also provides the research 
nurses with a time-saving, multi-task, user-friendly tool. 
5:15 p.m. 
~6-]  ProCOR: A Global Electronic Conference for 
Promoting Cardiovascular Health in Developing 
Countries 
Samer Jabbour, Max A. Luna, Robert J. Goldberg, Bernard Lown. Lown 
Cardiovascular Center, Brookline; SatelLife, Boston, MA, USA 
Background: Cardiovascular diseases (CVDs) are rising at an alarming rate 
in developing countries (DCs) due to a variety of contributing factors. An 
epidemic of CVDs, however, is not inevitable. Lack of coordinated interna- 
tional efforts and absence of relevant information are important obstacles to 
improving CVD health in DCs. 
Methods: In summer, 1997, Lown Cardiovascular Center and SatelLife, a 
non-profit organization dedicated to health promotion in DCs through commu- 
nication technology, initiated ProCOR, a global electronic conference aimed 
at addressing and improving all aspects of cardiovascular health in DCs. 
ProCOR creates a platform for dialogue and exchange of information among 
health professionals and policy makers. 
Results: Since its launching, ProCOR has attracted participants from 
45 countries. Scientific dialogue messages, aimed at exchange of informa- 
tion and expertise, have been actively posted by participants. Literature re- 
viewers, including several ACC affiliatesqn4raining, summarize on a weekly 
basis landmark research articles to address lack of availability of printed 
peer-reviewed literature in DCs. Monthly expert commentaries are provided 
on salient CVD-related topics. Key scientific presentations of international 
conference are posted. A global cardiovascular specialist registry is be- 
ing established to create a network of professionals who are interested in 
collaboration on research and policy issues. An Advisory Committee of rep- 
resentatives from internationally recognized institutions guides the direction 
of ProCOR. Expert moderators ensure its high scientific quality. 
Conclusions: ProCOR can be a useful tool for exchange of information 
and international collaboration to promote improved worldwide CVD health. 
Reaching out to health professionals globally is a main priority. The ACC 
computer presentation will engage attendees in all aspects of ProCOR and 
invite their continued participation in this electronic conference. 
• 0 •  Computer-Based Modeling Techniques 
Sunday,  March  7, 1999, 1:30 p .m. -5 :00  p.m. 
Morial  Convent ion  Center ,  Booth  3347 
1:30 p.m. 
~ Utilization Artificial Neural Network for of an 
Mortality Risk Adjustment in the Cooperative 
Cardiovascular Project 
William J. Oetgen, Peter B. Snow, Jeffrey M. Brandt. )(aim, Inc., Colorado 
Springs, CO; Delmarva Foundation for Medical Care, Inc., Easton, MD, USA 
Background: The Cooperative Cardiovascular Project (CCP) is a Health 
Care Financing Administration and Peer Review Organization collaboration 
to improve the quality of care provided to Medicare beneficiaries hospitalized 
with acute myocardial infarction. An artificial neural network (ANN) is a 
distributed network of computing elements which is capable of identifying 
relationships in input data which may not be readily apparent using common 
analytic techniques. 
Methods: Ninety-three variables were selected as being potentially useful 
in the prediction of 30-day mortality for patients in the CCP database. A 
subset of 15,212 CCP patients were randomly selected for both ANN and 
multivariate regression analysis (MRA). The subset was further randomly 
divided into an ANN training cohort of 5,000 cases and an ANN validation 
cohort of 520 cases. An advanced cascade correlation ANN was developed 
utilizing 96 hidden neurons and 2 output classifier neurons. Following training, 
the ANN was asked to make predictions concerning 30-day mortality on the 
validation set. MRA was performed on the validation set, and the results were 
compared to the ANN results. 
Results: Study results are summarized in the following table: 
Neural Network Regression 
Sensitivity 37% 21% 
Specificity 98% 97% 
Positive Predictive Value 81% 62% 
Negative Predictive Value 88% 84% 
Overall Accuracy 87% 83% 
Conclusion: An ANN may developed which provides superior results to 
MRA when predicting 30-day mortality in patients in the CCP cohorl. The 
positive predictive accuracy of the ANN (81%) is substantially greater than 
the positive predictive accuracy of MRA (62%). 
JACC February 1999 ABSTRACTS - info@ACC 7A 
1:30 p.m. 
-~A Model to Simulate ECG Based New Computer on 
Ionic Channels 
Michael Winklmaier ~ , Wemer Moshage I , Stephan Achenbach ~ ,
Dieter Swandulla 2, Gerd Kobal 2 , Wemer G. Daniel 1 . IDept. of Internal 
Medicine II; 2Dept. of Exp~menta/ and C/inica/ Pharmacology and 
Toxicology, University of Er/angen-Nuremberg, Germany 
Background: Aim of the study was to simulate the electrocardiogram (ECG) 
based on ionic channels, which has not been reported before. 
Methods: In a computer model, the cardiac action potential of single my- 
ocytes was calculated based on the properties of ionic channels (two sodium, 
two calcium and four potassium channels) using Hodgkin and Huxley formal- 
ism. The simulated myocytes were arranged in a 3-dimensional heart model 
in two perpendicular planes with 300 myocytes each. The activation se- 
quence used an algorithm similar to Huygen's principle of constructing wave 
fronts, triggered by a sinoatrial pacemaker cell. To obtain the physiologic re- 
polarisation, each cardiac cell had its unique potential duration represented 
by variations of the slow inward current and the time-dependent potassium 
current. The ECG resulted from dipole vectors due to transmembrane poten- 
tials. Pathologic ECGs such as hyperpotassemia were simulated by varying 
the ionic concentrations. Effects of iechemia, sympathetic tone and drugs 
were modelled by variation of the channel currents. It was possible to com- 
bine pathophysiologic onditions with drug effects, especially in the case of 
premature excitation of the cardiac cells. 
Results: Simulated Hyperkaliemia resulted in a prolonged QRS complex 
and increased T-wave amplitude, sympathetic tone in a prolonged QT interval 
and also an increased T-wave amplitude. Ischemia resulted in descending 
ST-segment depression (0.3 mV), myocardial infarction in ST-segment eleva- 
tion (0.4 mV). All simulated drugs prevented premature excitation, lidocaine 
and amiodarone showed the best overall effectiveness, propranolol was most 
effective in ischemia. 
Quinidine Lidocaine Propafenone Propranolol Amiodarone Verapamil 
QT % +14.3 -15.4 +1.6 +11.6 +14.3 -8.3 
QRS % +12.5 0 +25 0 0 0 
Conclusion: Our model generated ECG traces which closely corre- 
sponded to clinical experience. An additional advantage of our model is 
the step by step reconstruction from ionic currents to the action potential and 
ECG traces. 
Three-dimensional Computer-Based 
Visualization Techniques 
Monday, March 8, 1999, 9:00 a.m.-12:30 p.m. 
Modal Convention Center, Booth 3347 
9:00 a.m. 
~ Thrse  Dimensional Reconstruction of  Computer 
Patient Coronary Arteries from Two, 
Non-Orthogonal Single Plane Angiograms 
J, Larry Klein, Russell G, Folks, John W. Peifer, James G. Hoff, Emest 
V. Garcia. Emory University Hospital and Georgia Institute of Technology, 
Atlanta, GA, USA 
Background: Through extensive training and experience angiographers 
learn to mentally reconstruct he three dimensional (3D) relationships of the 
coronary arterial branches. Graphic computer technology can assist angiog- 
raphers to more quickly visualize the coronary 3D structure from limited initial 
views. Since many procedures are performed in single plane cath labs, we 
evaluated our 3D-raconstruction algorithm using not necessarily orthogonal, 
non-simultaneously acquired anglogrems. 
Methods: Twenty-five patients undergoing routine diagnostic anglogra- 
phy who had at least 4 views of the left coronary artery were assessed. 
For each patient two or more 3D models were generated from the non- 
simultaneously acquired angiogrems, The reconstructions were assessed by 
mathematically compadng the 3D model centedine points from the separate 
reconstructions. These results were also compared with 3D model centerline 
points generated from simultaneously acquired biplane angiograms. 
Results: Five different single plane comparisons were performed on a 
total of 174,860 distinct points. The average centarline point offset was 6.7 
± 4.6 mm (range 6.4-7.1 mm). These offset values are nearly identical with 
those derived by comparing the two 3D models generated with the simulta- 
neous angiograms (7.1 ~ 3.2 mm) and with the intra-observer variability of 
the technique (6.7 + 4.5 ram). 
Conclusions: These data provide support that the 3D reconstructions 
from single plane anglograms compare quite favorably to biplane recon- 
structions, thus allowing more widespread use of this technique. 
9:00 a.m. 
~ Object Virtual  Real i ty  Display of Congenital 
Cardiovascular Pathologic Specimens 
Giles Wesley Vick, Debra L. Keamey. Bay~or Co//ege of Medicine, Houston, 
TX, USA 
Background: Congenital cardiovascular malformations contain many com- 
plex three-dimensional spatial relationships that are difficult to appreciate 
from two-dimensional photographs. 
Methods: We have developed techniques for acquiring object virtual re- 
ality representations of cardiovascular pathologic specimens with a standard 
personal computer using a readily available digital video camera and an 
inexpensive gantry system. The electronic camera is linked by serial cable 
to the personal computer and produces rapid image updates. Sequential 
electronic images are acquired at arbitrary equal (usually 10 ~) increments as 
the gantry and specimen are rotated. The images are combined to form a 
navigable digital virtual "world", with the specimen at the center. Both sin- 
gle and multibanded virtual "worlds" may be created by these techniques, 
enabling the observer multiple degrees of freedom for rapidly navigating the 
virtual specimen "wodd' via pointing device or keyboard. The displays can be 
calibrated so that quantitative morphologic measurements can be performed 
with computer assistance. 
Results: Virtual digital representations were made of pathologic speci- 
mens taken from patients with a variety of congenital cardiovascular mal- 
formations, including tetralogy of Fallot, transposition of the great arteries, 
tricuspid atresia, hypoplastic left heart syndrome, coarctation of the aorta, 
complete atrioventdcular canal, and pulmonary atresia with intact ventdcu- 
lar septum. Representations included examples of native malformations as 
well as of corrective and palliative surgical repairs. The digital representa- 
tions were readily displayed on standard computer systems and embedded 
in HTML pages for use in educational intranets and on the intemet. Digi- 
tal compression techniques were easily applied to reduce file sizes when 
advantageous. 
Conclusion: Object virtual reality displays facilitate viewing of pathologic 
specimens of congenital cardiovascular disease. Object virtual reality dis- 
plays are easily used, efficient, inexpensive teaching tools that can increase 
access to unusual pathologic specimens and minimize specimen damage. 
Education and Computer-Enhanced 
Communication 
Monday, March 8, 1999, 1:30 p.m.-5:00 p.m. 
Modal Convention Center, Booth 3347 
1:30 p.m. 
~ Accelerating the Improvement Community in 
Cardiovascular Health Using Web-Enhanced 
Project Development 
Peter A. McCullough, Martha Newman, Leanne Kaiser Carlson, Joe Flower, 
Barry Tuchfeld. Henry Ford Health System, Detroit MI; The Hea/thcare 
Forum, San Francisco CA, USA 
Background: Despite advances in the diagnosis and treatment of cardiovas- 
cular disease (CVD), translation of these benefits into preventive strategies 
for communities has been difficult. In fact, many population studies of CVD 
risk have indicated a worsening of risk profiles (obesity, hypertension, and 
dietary fat intake) over time. 
Methods: The Healthcare Forum is a nonprofit agency with a mission to 
improve the health of communities through grassroots efforts. In May of 1998, 
the Healthcare Forum launched the first cardiovascular health fellowship by 
selecting 30 U.S. healthcare leaders (including 13 physician cardiovascu- 
lar specialists) to collaborate using a combination of face-to-face meetings 
and web-based dialogues for rapid exchange of information and spread of 
innovation. 
Results: Thirty separate projects have been initiated in a range of com- 
munities (10,000 to 8 million persons) which span rural to urban settings. 
Using the intemet and a professionally facilitated electronic discussion, there 
have been 545 transfers of information concerning 345 "threads" or separate 
ideas between the participants and their related community projects over four 
months. The monthly rate of transfers has shown no decrement over time. 
Conclusions: We conclude that a combination of face-to-face meetings 
and an ongoing facilitated electronic discussion, enabled by the web, is a 
feasible means of rapid and sustainable spread of innovation for translation 
into improved community cardiovascular health. 
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1:30  p.m. 
~ A  Sounds Tutorial and Self Computer-Based Heart 
Assessment Program for Students and House 
Officers 
Panes C. Voukydis, Ricardo Wellisch, Eva Gassiraro, Eric Flint. Mount 
Auburn Hospital, Cambridge, MA, USA 
Background: To facilitate learning of the heart sounds and murmurs for 
house officers and medical students training at our facility, we developed an 
introductory computer-based interactive tutorial that the trainees may use as 
they start their rotation in the medical wards. 
Methods: The heart sounds of patients were recorded and external noises 
were reduced using signal averaging. The individual sounds and murmurs 
were extracted from the recordings and used for reconstruction of the spec- 
trum of normal and abnormal heart sounds in health and disease. 
Description of the Program: The Macromedia Director c~ is used as a 
vehicle. The sounds are introduced starting from the simple and advancing 
to the more complex. The basic physiological concepts are introduced in a 
dialectic form with interactive buttons. Comparisons of similar sounds appear 
on the same frame so that the trainee can become familiar with the subtle 
differences between them. It takes someone with a basic background in 
anatomy and physiology about 8 to 10 hours to go through the tutorial. After 
the trainees go through the program they are invited to the bedside to listen 
to patient volunteers and compare their findings with what they have learned 
from the computer-based tutorial. 
Conclusion: We believe that this computer-based tutorial facilitates learn- 
ing of the heart sounds and at the same time reduces the time the faculty 
has to devote to heart sounds instruction. 
DICOM Applications 
Tuesday ,  March  9, 1999,  9 :00  a .m. -12 :30  p.m. 
Mor ia l  Convent ion  Center ,  Booth  3347 
9 :00  a.m. 
~ Interoperability of DICOM Can Be Implementations 
Enhanced Significantly by a QC Approach Using 
Automated Validation Tools 
Marco Eichelberg 1 , Maarten H. Baljon 2, Maarten G. Gerritsen 2, 
Peter Jensch I . ~ OFFIS, R&D Institute for Computer Science Tools and 
Systems, Oldenburg, Germany, 21ClN, Interuniversity Cardiology/nstitute of 
the Netherlands, Utrecht, the Netherlands 
Background: The overwhelming success of the acceptance of the DICOM 
standard by industry and the cardiology users has brought o the market many 
devices that are sold as being DICOM conformant. In practice interoperability 
between different DICOM devices is not always accomplished easily and/or 
completely. 
Methods: Implementations of cardiac X-ray Anglo DICOM data-sets on 
CD-R from 10 vendors were tested by 2 DICOM validation applications: 
(a) a checker that checks the conformance taking into account conditional 
rules and value domains to which data elements are restricted. 
(b) an application profiler to define AP's, application profiles, and to check 
conformance to the defined Application Profiles. 
5 DICOM CD-R viewers were used to see whether interoperability for 
viewing purposes did correlate with the results of the validation programs. 
Results; Only 2 out of 10 tested implementations turned out to deliver 
data-sets on CD-R that were fully in conformance with the DICOM standard. 
The other 8 implementations contained errors that ranged from minor to major 
disrespect of the DICOM rules. The viewer interoperability test showed a high 
correlation with our validation results: For the 3 CD-R's that contained most 
serious errors most viewers were not able to show the images the way they 
should be shown. 
Conclusion: Vendors' claims to be fully DICOM compliant could not all 
be sustained when the CD-R data sets were checked thoroughly. This un- 
desirable situation may be improved significantly if proper DICOM validation 
tools will be used during DICOM application development. DICOM's chances 
for reaching device interoperability will be greatly increased if this approach 
is strictly adhered to. 
9 :00  a .m.  
~ - ~  First Experiences with DICOM Images and 
Waveforms Integration 
Henry Con, Enno T. van der Velde, Anja Kleijhorst, Gaby de Steur, 
Simon Meij, Niek H. van der Putten, Maarten G.J.M. Gerritsen, Maarten 
H. Baljon. Leiden University Medical Center, Leiden, The Netherlands 
Background: In cardiology, DICOM is now widely accepted and used as 
standard for exchange of images acquired e.g. during catheterization. How- 
ever, in clinical practice it would be very advantageous to be able to store and 
display the images together with the waveforms (ECG, pressure) recorded 
simultaneously. To this end, a new supplement will be added to the DI- 
COM standard. To gain experience with this DICOM-WF supplement, and to 
get comments from prospective users, we have initiated a project to create 
combined DICOM data-sets and to develop a viewer for time-synchronized 
display of DICOM images and waveforms, based on a draft version of the 
new DICOM-WF supplement. 
Methods: Images from a Philips Medical Systems angiography system 
were combined with waveforms from a Siemens cathlab system (Cathcor). 
The waveforms were exported in Sifor (Siemens Interchange Format for 
Medical Records) format, converted to DICOM format and combined with the 
images already in DICOM format. Time-synchronization has been realized 
by recording a sync signal from the imaging equipment on the Cathcor. 
Results: All variables required for the DICOM-WF format were available 
in the Cathcor file, allowing unambiguous conversion. The application allows 
time-synchronous display of images and matching waveforms, with a cursor 
in the waveform window corresponding to the image displayed. 
Conclusion: The first results of this project show that in our setting the 
new DICOM-WF standard can be implemented fairly easily, and that the 
possibility of combined viewing of images and waveforms is very beneficial 
in clinical practice. A more generic solution for the time-synchronization 
problem will be developed in cooperation with the DICOM committee and 
vendors of the equipment. Future plans are: inclusion of annotations, addition 
of waveforms and images from other modalities and optimization of the 
user-interface in close consideration with the cardiologists. 
Computer-Based Clinical Support Decision 
Tuesday ,  March  9, 1999,  1 :30  p .m. -5 :00  p.m. 
Mor ia l  Convent ion  Center ,  Booth  3347 
1 :30  p.m. 
[ - ~  Inductive Decision Trees a Demonstrate Seasonal 
Pattern of PericardiUs Admissions 
Daniel M. Shindler, Michael Maraventano, Alan C. Wilson, Maureen Bueno, 
Clifton R. Lacy, Joseph F. John, John B. Kostis. UMDNJ, Robert Wood 
Johnson Medical School, New Brunswick, New Jersey, USA 
Background: The viral etiology of some cases of pericarditis raises the 
question of a seasonal occurrence. Inductive decision trees are computer 
techniques that attempt o uncover patterns in seemingly unrelated data such 
as hospital admissions. 
Methods: We screened admissions over a twelve year period to a sub- 
urban university hospital in central New Jersey for dates when at least one 
admission in a given 24 hour period resulted in a discharge diagnosis of 
pedcarditis. There were 615 (14%) such days out of 4383. The total number 
of pericarditis admissions was 673. Daily temperatures, rainfall, snowfall, 
extreme weather, and season of the year were used as variables. 
Results: Chi-square analysis did not show significant differences in rates 
of admission by season. We then processed the data using an inductive 
decision tree program, which created "if...then rules along with an estimated 
predictive accuracy for each rule. Simple rules (summer - no pericarditis, 
mild weather - no pericarditis) were only 70% predictive. More involved rules 
however, had up to 96% predictive accuracy. The usefulness of any individual 
rule could easily be determined by scrutinizing the logic and the predictive 
value. The rules and decision trees are available for reference on the Internet 
at the following Web address: http://www2.umdnj.edu/~shindler/rules.html 
Conclusion: Data mining computer techniques can identify patterns when 
standard statistical methods fail to do so. Inductive decision trees, in this case, 
generated understandable seasonal and climate patterns for pericarditis 
admissions. 
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~ - ~  Identification of Circulatory Parameters by Use of a 
Computer Model Coupled With a Nonlinear 
Optimization Algorithm 
Ying Sun, Sang H. Kim, Ahmad Hadid, Richard J. Lucariello, MaMn 
B. Weiss, Salvatore A. Chiaramida. University of Rhode Island, Kingston, 
RI; Our Lady of Mercy University Hospital, Bronx, NY, and New York 
Medical College, Valhalla, NY, USA 
Background: The clinical applicability of advanced computer models capa- 
ble of simulating realistic hemodynamic phenomena is often limited by the 
capability of parameter identification from available clinical data. In this study 
a nonlinear optimization method is employed to identify parameters in the 
cardiovascular system. 
Methods: A simplex-based nonlinear optimization algorithm is applied to 
a previously developed model consisting of 28 differential equations with over 
100 circulatory parameters. The simplex-based algorithm interacts with the 
model-based simulation by iteratively adjusting a set of model parameters to 
reach a target response. The model and system identification software has 
been implemented in the C programming language on a Macintosh computer. 
Results: As illustrated by an example, the method attempts to identify 5 
model parameters: afterload resistance and 4 parameters related to left atrial 
and left ventricular elastance and contractility. The response consists of 7 
clinically measurable hemodynamic indexes: cardiac output, ejection fraction, 
systolic arterial pressure (AP), end-diastolic left ventricular pressure, mean 
left atrial pressure, mitral flow E/A ratio, and S/D ratio of pulmonary venous 
flow velocity (PVFV). The simplex algorithm converges after 69 iterations. 
As shown on the right, hemodynamic waveforms are brought from initial 
condition (broken) to final condition (solid) within 0.4% error of the target 
waveforms (dotted). 
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Conclusion: By coupling nonlinear optimization with model-based simu- 
lation a new platform is created for characterizing cardiovascular dynamics 
based on clinical data. 
Computer-Enhanced Diagnosis 
Wednesday, March 10, 1999, 9:00 a.m.-Noon 
Modal Convention Center, Booth 3347 
9:00 a.m. 
~ A  Computer Program for Automatic Noninvasive 
Analysis of Multiple Ventricular Repolarization 
Abnormalities 
Thomas Hilbel, Juargen Laude, Marc A. Reitar, Johannes Brachmann, 
Robed L. Lux, Morrison Hedges 1 . University of Heidelberg, Germany; 
Minneapolis Heart institute Foundation, Minneapolis, USA 
Several noninvasive measurements of ventricular repolarization parameters 
on the 12-lead ECG are currently under investigation for their potential use- 
fulness in predicting life-threatening arrhythmias. We have developed a com- 
puter program for analyzing multiple ventricular epo!arization parameters on 
the 12-lead ECG. Use of Windows 95 and Visual Studio 97 allows for a user- 
friendly graphical interface for calculating and controlling all measurements, 
including manual correction if needed. Standard resting 12-lead ECG data 
or continuous 12-lead Holter ECG data recorded digitally can be measured 
by the computer program. Analysed repolarization parameters obtained on 
either the resting or the Holter ECG include the following: 1) automatic mea- 
surement of QT interval (global); 2) manual measurement of QT Dispersion 
(longest QT minus shortest QT); 3) automatic Principal Component Analysis 
of the T-wave, including the ratio of the second to first eigenvalue of the 
T-wave vector which describes the complexity of the T-wave, and has been 
shown to be markedly abnormal in patients with the Iong-QT syndrome; 4) 
automatic measurement of the Activation-Recovery Interval (ARI), which is a 
better estimator of action potential duration than is the QT interval itself (dis- 
persion of ARIs in V1-V6 is measured). The repolarization measurements 
can be stored and exported to spreadsheets or statistical programs for further 
analysis of the data. 
Thus, this analysis program provides a convenient means for further 
investigation of ventricular repolarization parameters, especially for the value 
of these parameters as predictors for the risk of ventdcular arrhythmias. It is 
a useful tool that can contribute to the definition of normal and pathological 
values for Principal Component Analysis of the T-wave and dispersion of ARI 
values. 
9 :00 a.m.  
~ Computer Environment for Qualitative/Quantitative 
Myocardial Perfusion Analysis in the Women's 
Ischemia Syndrome Evaluation Study 
M. Eduardo Kodright, Mark Doyle, Edward G. Walsh, Anthon R. Fuisz, 
William J. Rogers, Gerald M Pohost. University of Alabama at Birmingham, 
Birmingham, AL, USA 
Background: Assessing ischamia by MRI first-pass contrast agent dynam- 
ics has shown promise in animal models. Extension to clinical studies entails 
multi-slice acquisitions with cardiac gating, free respiration, poor signal to 
noise, and susceptibility artifacts. To meet these demands, a software pack- 
age, Myocardial Perfusion Analysis (MPA), was developed in Matlab. 
Methods: Respiratory Motion Correction: cardiac images are registered 
using image-derived "navigators" defined along vertical and horizontal di- 
mensions. A graphical interface permits targeting high contrast features for 
input to a correlation optimization algorithm. Qualitative Analysis: registered 
and temporally filtered images are displayed as cine loops for visual detection 
of delayed contrast. Subtraction of baseline signal is possible to observe only 
contrast passage. Susceptibility artifacts, however, can be misinterpreted as 
regions of underperfusion, and quantitative methods are needed. Quantita- 
tive Anaiysi~ manually drawn regions of interest are defined, from which 
time-intensity curves are plotted and analyzed to produce statistics including 
peak intensity and initial slope. MPA allows comparison of curve parame- 
ters from rest and stress data sets. To alleviate problems of motion blurring 
and poor contrast, which diminish the ability to accurately target regions of 
interest, MPA generates a similarity map for any given time-intensity curve, 
instantaneously highlighting all regions with similar perfusion patterns. MPA 
also allows fitting gamma-variate or other functions to extract absolute flow 
characteristics. The underlying environment facilitates modifying and adding 
to existing components as the need arises. 
Experiences: The software has been used to process over 120 data 
sets in the Women's Ischemia Syndrome Evaluation (WISE) study, and has 
proven flexible, extensible, and easy to use. MPA's functionality, previously 
unavailable in any single package, has substantially contributed to clinical 
development of MR pedusion imaging. 
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Abstracts of Original Contributions: 48th Annual Scientific Session 
The American College of Cardiology is pleased to 
announce that more than 7,150 abstracts of original 
contributions were submitted to the Program Commit- 
tee of the 48th Annual Scientific Session. Space and 
time considerations this year allowed the selection of 
2,258. 
Each abstract was peer reviewed by a panel of 
graders; chosen abstracts are presented in either oral 
or poster format. 
The American College of Cardiology thanks the 
thousands of abstract participants and the hundreds of 
category graders and chairs for their efforts. 
Robert Wayne Alexander, MD, PhD, FACC 
Co-Chair 
1999 Annual Scien@c Session Program Committee 
John S. Douglas, Jr., MD, FACC 
Co-Chair 
1999 Annual Scientific Session Program Committee 
Douglas C. Morris, MD, FACC 
Co-Chair 
1999 Annual Scientific Session Program Committee 
POSTER 
Adjunctive Use of Platelet GPIIb/llla 
Inhibitors in Angioplasty 
Sunday, March 7, 1999, Noon-2:00 p.m. 
Modal Convention Center, Hall F 
Presentation Hour: 1:00 p.m.-2:00 p.m. 
~ A  Randomized Trial of Media C___qontrast Utilization 
in High Risk PTCA (The COURT Trial) 
Chades J. Davidson, Warren K, Laskey, J. Kevin Harrison, James 
B. Hermiller. William Matthai Jr., Ronald E. Vlietstra, Jeffrey A. Brinker, Dean 
J. Kereiakes, Joseph B. Muhlestein, Jeffrey Popma, Maurice Buchbinder, 
John W. Hirshfeld Jr.. Northwestern Univ,, Chicago, /L, USA 
A multicenter prospective randomized double blind trial was performed in 
856 high risk pts undergoing coronary intervention to compare the isosmolar 
nonionic dimer iodixanol (n = 420) with the low osmolar ionic dimer ioxaglate 
(n = 436). The primary objective was to evaluate the incidence of in-hospital 
major adverse clinical events (MACE). Prior to angiegraphy, pts with acute 
ischemic syndromes were randomized; acute MI = 277, unstable angina = 
466, post-Ml ischemia = 113. 
Devices used were stants in 31%, balloon in 61%, and other in 8%. 
Angiographic and procedural results were assessed by core lab. 
Results: 
In-Hospital Outcome 
Iodixanol Ioxaglate 
Abrupt Closure (%) 0.7 2.4 
Periprocedural Mt (>3x Control) (%) 2.0 4.4 
CABG (%) 0.5 0.7 
Stroke (%) 0.2 0.2 
Thromboembolic Event (%) 0,5 1.0 
Emergent Recath/rePTCA (%) 2.2 3.9 
Cardiac Death (%) 0.7 0 
Composite MACE (%) 5.2 9,5 
"p = 0.009 
Out of hospital composite MACE to 30 days was similar 4.4% vs. 4.0%, p 
= 0.60. Abciximab use was similar in both groups (41% vs. 41%). In-hospital 
MACE for those treated with abciximab was 9.9% vs. 11.5%, and for those 
not treated 1.7% vs. 8.1%, for the iodixanol and ioxaglate group, respectively. 
Multivariate analysis is pending. 
Conclusions: In this prospective multicenter trial, the cohort receiving 
the nonionic dimer, iodixanol, experienced 45% less in-hospital MACE when 
compared to ioxaglate. The improved outcome in the iodixanol group was 
apparent regardless of abciximab use. 
• Comparison of the Protection Restenosis Against 
Afforded by Stenting or Abciximab 
Femando A. Cura, Philippe L, L'Allier, Shelly Sapp, A. Michael Lincoff, 
Stephen G. Ellis, Eric J. Topoi. Forthe EPISTENTInvestigators; The 
Cleveland Clinic Foundation, Cleveland, Ohio, USA 
Backgound- In the 6 months follow-up of the EPISTENT randomized trial, 
the combined use of piatelet glycoprotein lib/Ilia inhibitor, abciximab (Abx), 
with coronary stents in patients undergoing coronary interventions reduces 
not only the acute complications but also the rate of target vessel revas- 
cularization (TVR). However, there is variance in the extent of restenosis 
protection for Abx and stents. 
Method: In the EPISTENT trial, patients were randomized to one of 
the three arms: Stent + Abx, Balloon angioplasty (PTCA) + Abx or Stent + 
Placebo. Calculation of TVR protection is derived from pairwise comparison 
of the 2 stent arms and the 2 abciximab arms. 
Results: Six months incidence of TVR and the % of reduction provided 
by stents and abciximab are summarized below: 
6 months Stent/ Stent/ PTCA/ Reduction Reduction 
Abx Placebo Abx by Abx by Stent 
(n = 809) (n = 809) (n = 809) 
TVR all patients 8.7% 10,6% 15.4% 18% 43.5% 
TVR in diabetics 8,1% 16.6% 18.4% 51,2% 55.9% 
Abx provided an 18% of TVR reduction in the whole population, with a 
major impact of 51% (p = 0.02) reduction in the diabetic patients. Stents 
provided a 43% (p < 0.001) of TVR reduction in the whole population with a 
56% (p < 0.001) reduction in the diabetic group. 
Conclusion: Stenting provides maximal reduction in repeat target vessel 
revascularization with more than 40% supression. In comparison abciximab 
is approximately half as effective (18%) and its in-stent TVR protection is 
chiefly found in diabetics. 
~ Rescue ReoPro Does not (Abciximab) Improve 
Peri-Procedural Outcomes in Patients Undergoing 
High Risk Angioplasty of Degenerated 
Saphenous Vein Grafts 
Javed M. Ahmed, Mun K. Hong, Roxana Mehran, Kenneth M. Kent, 
Augusto D. Pichard, Lowell F. Satler, Ann Greenberg, Debra Deforty, 
Steve Slack, Hongsheng Wu, Gregg W. Stone, Martin B. Leon. Washington 
Hospital Center, Washington, DC, USA 
Background: Prophylactic use of ReoPro (Abciximab) reduces acute is- 
chemic complications during PTCA. However, it is often used as a "rescue" 
therapy during PTCA when complications occur. Furthermore, its benefit in 
degenerated saphenous vein grafts (SVG) is unknown. 
Method: To determine the impact of rescue ReoPro therapy in pts un- 
dergoing high risk PTCA in degenerated SVG, we compared the procedural 
outcome of 45 pts (77 lesions) treated with rescue ReoPro vs 300 pts (523 
lesions) without ReoPro therapy. 
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Results: Baseline characteristics were similar between the groups. 
No ReoPro Rescue ReoPro 
Procedural success (%) 95.5 95.2 
Major ischemic comp (%) 3.0 2.4 
Death/QWMI/CABG (%) 1 ~1/0.8/1.7 1.2/1.2/0 
Major vascular comp (%) 6.4 8,9 
Non-Q wave Mt (%) 17.7 40.5" 
Comp = complications; QWMI = Q-wave myocardial infarction; CABG = coronary artery 
bypass surgery; p = 0.001 
Conclusion: "Rescue" use of ReoPro in pts undergoing high risk PTCA of 
the degenerated SVG is associated with high procedural success and similar 
major ischemic complications, comparable to those without ReoPro therapy, 
Additional studies are mandated to determine if standard prophylactic ReoPro 
can importantly reduce peri-procedural ischemic events in the degenerated 
SVG population, 
~ Older Women Benefit From Balloon PTCA Rather 
Than Stenting When Combined with lib/Ilia 
Anti-Platelet Therapy: A Gender Specific 
Treatment Interaction From EPISTENT 
JoAnne Micale Foody, Craig Balog, Leslie Cho, A. Michael Lincoff, Eric 
J. Topoi. The Cleveland Clinic Foundation, Cleveland, Ohio, USA 
Background: Higher complication and lower success rates have been re - 
ported for women undergoing coronary interventions. In the era of combined 
coronary stenting and GP lib/Ilia inhibitors, gender differences have not been 
examined. 
Methods: At 63 hospitals in the United States and Canada, 2399 pa- 
tients with symptomatic coronary disease and a significant coronary le- 
sion were randomly assigned to stenting/plecebo, stenting/abciximab or 
PTCA/abciximab. 
Results: While the primary composite endpoint of death, MI or ur- 
gent revasculadzation was reduced by abciximab in all groups, in women: 
PTCA/abciximab was superior to stent/abciximab (Table). This treatment in- 
teraction among women was only manifest in those > 65 years of age. The 
treatment interaction of stent/abciximab compared with PTCAJabciximab by 
gender was significant (p = 0.01). 
Primary 30-day Event Rates for men and women: EPISTENT 
StenV Stent/ PTCN HR (95% CI) HR (95% Ct) 
placebo abcix abcix Stent/stent Stent/PTCA 
Female 11.7 8.7 5.1 0.74 (0.40, 1.37) 0.42 (0.20, 0.88) 
Male 10.5 4.2 7.6 0.39 (0.24, 0.61) 0.71 (0.48, 1.04) 
F _> 65 12.3 14.4 2.2 1.22 (0.56, 2.70) 0.17 (0.04, 0.78) 
F < 65 11.1 3.8 7.4 0.32 (0.10, 1.0) 0.65 (0.27, 1.59) 
Conclusions: While women undergoing interventions consistently benefit 
from abciximab therapy, older women, in particular, had improved outcome 
with PTCA vs. stent. A smaller target vessel size among women, especially 
in the elderly, in combination with a minimum sfent size of 3.0 mm, may have 
accounted for this finding. This finding demonstrates the need for evaluation 
of age and gender-based revascularization strategies, 
• Adjunctive Use of Abciximab Improves Clinical 
Outcomes in Acute Myocardial Infarction Patients 
Presenting With Cardiogenic Shock 
Satyendra Girl, Joseph F. Mitchel, Francis J. Kieman, Raymond G. McKay, 
Daniel B. Fram, Linda D. Gillam, David D. Waters, Jeffrey A. Hirst. Hartford 
Hospital, Hartford, CT, USA 
Although primary angioplasty (PA) improves the clinical outcomes of patients 
presenting with an acute myocardial infarction (AMI) in cardiogenic shock 
(CS), prognosis still remains unfavorable. Abciximab use an adjunct to PA 
appears to improve outcomes in the setting of AMI, however no data currently 
exists regarding its role in AMI pts presenting with CS. 
Methods: Out of 582 consecutive AMI pts treated with PA _< 12 hrs of 
symptom onset from 07/95 to 06/98, 79 (13.6%) presented in CS (Systolic 
BP < 80 mmHg despite fluid resuscitation and requiring inotropic support 
with a cardiac index < 2.2 or evidence of hypopeffusion. Angiograms were 
reviewed using quantitative coronary angiography. Clinical information was 
obtained by interview and review of medical records. 
Results: Abciximab pts (34.2%) compared to non-abciximab pts (65,8%), 
were similar (p > 0.05) in age, gender, cardiac risk factors, and use of in- 
traaortic balloon pump, intubation, temporary pacemakers, and intracoronary 
stents. Angiographic features of TIMI grade flow < 3, persistent no reflow, 
persistent residual thrombus and residual diameter stenosis in the infarct- 
related artery were also similar between the two groups. Stepwise logistic 
regression analysis which evaluated the independent predictive value of clin- 
ical, angiographic, and adjunctive therapies, selected abciximab use and 
(TIMt < 3 flow as multivariate predictors of 30 day clinical events [death, 
repeat AMI and target vessel revascularization (I'VR)]. 
No Abciximab(n=52) Abciximab (n=27) 
[]  30 day clinical event 
60% 58% 
~.p ~ ~. []  Inhospital clinical event 
30%t  30%1" 
Outcome prediclom Odds Ratio (95% CI) p 
Abciximab use 0.33 (0.11-0.93) 0.03 
TIMI grade flow < 3 5.58 (1.61-19.35) 0.007 
Conclusion: In AMI pts presenting with CS, failure to establish TIMI 
grade 3 flow in the infarct artery is associated with a less favorable prognosis. 
Furthermore, adjunctive abciximab use significantly improved inhospital and 
30-day clinical outcomes, suggesting an incremental benefit of glycoprotein 
lib/Ilia blockade in AMI with CS. 
• Safety of Platelet Glycoprotein lib/Ilia Inhibitor 
and Stents in Multivessel Coronary Intervention 
Fernando A. Cura, Philippe L. L'Allier, Shelly Sapp, A. Michael Lincoff, Eric 
J. Topoi, Stephen G. Ellis. For the EPISTENT Investigators; Cleveland Clinic 
Foundation, Cleveland, Ohio, USA 
Background: Multivessel coronary intervention (MCI) has been reported to 
have a high incidence of acute complications and repeat revascularization 
procedures, Coronary interventions using abciximab (abx) and stents have 
lower rate of acute and long term events. However, despite the increased 
use of potent platelet inhibitors and coronary stents, data are lacking to show 
the safety of the multivessel coronary interventions. 
Methods: From 2399 patients of EPISTENT study, both arms that used 
Abx. with or without direct stenting, were separated in two groups: patients 
with a MCI (n = 133) and patients with single coronary intervention (SCI) (n 
= t380). Both arms of Abx were studied together due to the small number of 
MCI. 
Results: 
(30 days) MCI SCi p value 
Stent Used 60.9% 59.1% 0.69 
Death/MI/urg intervention 6.0% 5.7% 0.89 
Death 0.8% 0.4% 0.60 
Q-wave MI 2.3% 1.7% 0.61 
Non-Q MI 3.8% 4.0% 0.89 
Urgent CABG 0% 0.7% 0.35 
Any major bleeding 0% 1.4% 0.17 
TVR at 6 months 16.1% 10.7% 0.07* 
TVR = target vessel revascularization / CABG = Coronary Bypass Surgery 
There were no differences between groups in the acute complications. 
TVR for multivessel intervention was less than twice the TVR seen with single 
vessel intervention. 
Conclusion: With multivessel intervention there was surprisingly safety 
with respect to a low incidence of urgent CABG and non-Q myocardial infarc- 
tion. An increase in subsequent TVR as expected in multivessel intervention 
patients, was demonstrated. 
POSTER 
Outcomes of Contemporary Coronary 
Intervention 
Sunday, March 7, 1999, Noon-2:00 p.m. 
Modal Convention Center, Hall F 
Presentation Hour: 1:00 p.m.-2:00 p.m. 
~ Clinical, Angiographic and Physiologic Predictors 
of Major Adverse Cardiac Events (MACE) After 
Stent Implantation 
Lucia Di Francesco, Carlo Di Mario, Joseph De Gregorio, Jeffrey Moses, 
Emily Lawrence, Antonio Colombo. On behaff of the DESTINI-CFR (Doppler 
Endpoint Stenting International Investigation-Coronary Flow Reserve) 
Investigators; Columbus Clinic, Milan, Italy and Lenox Hill, New York, USA 
Aim of the study is to identify in a population of "all-comers", including mul- 
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tivessel disease, long lesions, small vessels, bifurcation lesions, the factors 
predictive of death, acute myocardial infarction (AMI), target lesion revascu- 
larization (MACE) in patients undergoing elective stent implantation. 
In the prospective tdal DESTINI-CFR quantitative angiography (QCA) 
and Doppler flow Coronary Flow Reserve (CFR) were assessed before and 
after interventions, with half of the patients randomized to elective stent 
implantation 
Methods: 273 patients (mean age 62 + 10 years, 78% male, 38% multiple 
vessel disease) showed at follow-up (6.1 ± 1.4 months) an incidence of 
death of 0.7%, AMI of 1.9%, TLR of 14.6% (overall MACE = 17.2%) and 
were divided into two groups (MACE yes & MACE no). Univariate analysis 
identified the following factors to be significantly more prevalent in the MACE 
group. 
Results: 
MACE predictors MACE yes MACE no P value 
Hypertension 62% 44% 0.025 
Lesion Length (mm) 14 ± 5.6 12 ± 5.1 0.04 
Bifurcation Lesion 30% 11% 0.0015 
Stent Length (ram) 26.6 ± 8.4 18.4 ± 9.6 0.0001 
Final DS (%) 12.5 ± 7.6 7.6 ± 7.8 0.003 
Final MLD (mm) 2.74 ± 0.73 2.97 ± 0.45 0.005 
Final distal CFR 2.16 ± 0.7 2.49 ± 0.8 0.014 
MLD = Minimal Lumen Diameter, DS = Diameter Stenosis 
Conclusion: This study confirms that stent length, lesion length, final DS 
and MLD are highly predictive of cardiac events after stenting and shows for 
the first time that a physiologic parameter, a low CFR, is also associated with 
higher incidence of MACE after stenting. 
~ R i s k  for Early Major Adverse Cardiac Events 
(MACE) After Coronary Stent Placement in the Era 
of Ticlopidine 
Helmut SchQhlen, Adnan Kastrati, J0rgen Pache, Martin Hadamitzky, 
Julinda Mehilli, Josef Dirschinger, Albert Sch6mig. 1. Medizinische Klinik 
rechts der Isar & Deutsches Herzzentrum, Technische Universitdt, Munich, 
Germany 
Background: Previous risk analyses for MACE dudng the first 30 days have 
stressed the importance of ticlopidine therapy and of an optimal angiographic 
result. Data focussing on patients with ticlopidine therapy are not available. 
Methods: Analysis of all 3676 patients with ticlopidine therapy after suc- 
cessful stenting 3/94-7/98 (without cardiogenic shock). Risk analysis by Cox 
proportional hazard models included 23 clinical, aogiographic and procedural 
factors. 
Results: The overall MACE rate was 3.4% (death, 1.1%; myocardial 
infarction, 1.0%; TLR, 2.1%); 50.0% of all events occurred during the first 3 
days, 77.8% duriog the first 2 weeks. The significant and independent dsk 
factors identified are illustrated in the graph. 
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Conclusions: This retrospective analysis illustrates the risk associated 
with older age, diabetes, acute myocardial infarction, impaired LV function, 
smaller vessel size and an intrecoronary thrombus at the end of a proce- 
dure. The most prominent factor however, an uncovered residual dissection, 
underscores the need for an optimal angiographic result. 
• Multiple Stenting Compared to Multiple Vessel 
Vessel Angioplasty: In-Hospital Outcome and 
Long-Term Follow-up 
Barry D. Rutherford, Philip G. Jones, James L. Vacek, Warren L. Johnson, 
Jr., Lee V. Giorgi, Kenneth C. Huber, Steven B. Laster. Mid America Heart 
Institute, Kansas Ci~ Missouri, USA 
Background: A paucity of data exists on multiple vessel stenting (MVST) 
compared to multiple vessel angioplasty (MVPTCA). This study therefore 
compares patients undergoing MVPTCA & MVST. 
Methods: We compared three groups of patients undergoing simultane- 
ous intervention in two or three of the major coronary systems. Group (Grp) 
1, 1993-94 MVPTCA n = 582: Grp 2, 1995-98 MVPTCA with bailout stent- 
ing n = 375: Grp 3, 1995-98 MVST n = 151. Two vessel and three vessel 
intervention was undertaken in Grp 1, 81% and 19%, Grp 2, 84% and 16% 
and Grp 3, 82% and 18%. 
Results: Mean age, age > 70 yrs, diabetes, unstable angina, pdor CABG, 
LVEF, number of diseased vessels, restenotic lesions and number of vessels 
treated were similar in these three grps. 
In hospital outcome and follow-up are shown in table. 
Group 1 (%) Group 2 {%) Group 3 (%) P Value 
Procedural 
Success 86.0 93.3 96.7 <0.601 
Death/AMI/ NS 
EmCABG 1.7/2,4/0.5 0.8/1,9/0.3 1.3/1,3/0 NS 
Dissection 28.0 22,0 3.3 <0.001 
Repeat PTCA 2.7 3.5 1.3 NS 
Combined Major 
Complications 18.2 10.9 7.3 <0,001 
24 Month Survival 85 84 84 NS 
TVR 12/24 Mo 36/40 30/37 31/36 NS 
Conclusion: Elective MVST compared to either MVPTCA or MVPTCA 
with bailout-stenting is associated with a higher procedural success and 
lower in-hospital complications. However, long-term survival and TVR rates 
are similar. 
• Coronary Stent Placement in 2 or More Vessels: 
1-Year Clinical and Angiographic Outcome and 
Comparison With Single-Vessel Stenting 
Adrian Kastrati, Josef Dirschinger, Shpend Elezi, J0rgen Pache, 
Helmut Sch(Jhlen, Franz-Josef Neumann, Albert Sch6mig. Deutsches 
Herzzentrum and I. Meal. Klinik, TU MOnchen, Germany 
Background: The issue of the optimal treatment option for patients (pts) 
who need multivessel revasculadzation is not fully resolved. They are of- 
ten referred to aortocoronary bypass surgery. However, recent advances in 
interventional cardiology may be beneficial also for this category of pts. 
Methods: A consecutive series of 3212 pts without acute myocardial 
infarction (MI) is included. Pts were divided in 2 groups: group MV composed 
of 334 pts with same session stenting in >_ 2 vessels (309 in 2 vessels, 25 in 
3 vessels), and group SV composed of 2878 pts with single-vessel stenting. 
All pts had 1-year clinical follow-up. 6-month angiography was performed in 
2700 pts. All angiograms were assessed with QCA. 
Results: In comparison with pts in the SV group, pts in the MV group 
were older, more often men, with higher frequency of diabetes and unstable 
angina, more often reduced left ventdcular function, prior bypass surgery and 
MI. One-year follow-up results are presented: 
MV SV P 
Procedural success, % 98,8 98.3 0.52 
Death, % 4.8 3.6 0.28 
Death or MI, % 6.9 5.4 0.27 
Bypass surgery, % 5.1 2.5 0.007 
Target lesion repeat angioplasty, % 16.9 16.9 0.99 
Any of the above events, % 28.4 22.7 0.02 
Angiographic late lumen loss, mm 1.23 ± 0,87 1.17 ± 0.84 0.16 
Angiographic restenosis rate, % 36,0 32.5 0.15 
Conclusions: Despite the more frequent presence of high dsk charac- 
teristics, stanting multiple vessels in these pts is not associated with any 
significant increase in mortality and MI rate as compared with single-vessel 
stenting. If corroborated by randomized studies, this may become a strategy 
of choice for pts needing multivessel revascularization. 
I1 [ The Effectiveness of the Combination of Plavix 007-55
] 
and Aspirin Versus Ticlid and Aspirin After 
Coronary Stent implantation 
Xiangdong Wang, Matthew Oetgen, Roberfa Maida, Emily Lawrence, Mary 
Jo Peters, Deborah Zucker, Nancy Cohen, Issam Moussa, Sdram tyer, 
Edward Krsps, Michael Collins, Gary Roubin, Antonio Colombo, 
Jeffrey Moses. Lenox Hill Hospital, New York, NY, USA 
The combination of aspirin (ASA) and Ticlid has been shown to be an effective 
pharmacological regimen to reduce stent thrombosis after coronary stenting. 
Plavix (clopidogrel) is a new potent antiplatelet agent that has entered clinical 
use recently. The purpose of this report is to compare the effectiveness of 
Ticlid and ASA (TAt versus Plavix (P) and ASA (PAt in preventing stent 
thrombosis after successful coronary stenting. The TA group consisted of 
1192 patients (1525 lesions) and the PA group consisted of 312 patients (423 
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lesions). Patients who required coumadin or did not have one month follow 
up were excluded. The study groups represent 94% of the total cohort. The 
occurrence of stent thrombosis, gastrointestinal side effects, skin rash and 
MACE (myocardial infarction, CABG or death) were recorded at one month 
post procedure and the results are shown in the table below: 
TA PA p value 
Pre REF (mm) 2.82 ± 0.68 2.79 ± 0.56 0.54 
Lesion Length (mm) 11.11 ± 6.1 11.63 ± 7.0 0.17 
Post REF (mm) 3.45 4- 0.56 3.41 ± 0.47 0.28 
Post MLD (ram) 3.10 ± 0.54 3.09 ± 0.43 0.78 
# Stent for pre Lesion 1.34 ± 0.72 1.30 + 0.56 0.31 
Stent Thrombosis (%) 0.98 0.95 0.94 
Diarrhea (%) 4.70 2.88 0.16 
Bone Marrow Suppression (%) 0.34 0.00 0.30 
Rash (%) 7.30 1.92 <0.001 
MACE (%) 1.51 1.92 0.60 
Conclusion: 1 ) The use of Plavix and ASA after coronary stent implanta- 
tion is as effective as Ticlid and ASA in preventing stent thrombosis. 2) The 
combination of Plavix and ASA is associated with lower incidence of GI side 
effects, skin rash and bone marrow suppression. 
I1 I Comparison an Intravenous Bolus of 
I 
007-56 of 
Enoxaparin Versus Unfractionated Heparin in 
Elective Coronary Angioplasty 
Maher M. Rabah, Jerome Premmereur, Mar±ann Graham, Jawed Fareed, 
Debra A. Hoppensteadt, Sandeep Khurana, Lorelei Grines, Cindy Grines. 
Division of Cardiology, William Beaumont Hospital, Royal Oak, MI, USA 
Background: Enoxaparin, a low molecular weight heparin, has a more pre- 
dictable effect than unfractionated heparin (UFH). This randomized, blinded 
study was performed to determine if ant±coagulation could be safely achieved 
without repeated ACTs using enoxaparin during PTCA. 
Methods: Prior to coronary intervention, sixty patients were randomized 
(30 each) to single IV bolus enoxaparin (1 mg/kg) or IV bolus of UFH 10,000U 
with subsequent bolus to maintain ACT > 300 seconds. No attempts to 
titrate enoxaparin were made. Measurement of anti-Xa, anti-Ila, aPTT, TFPI, 
prothrombin fragment 1.2, and t-PA were drawn at baseline, 5 minutes, and 
4 hours post bolus. PTCA procedures followed standard methods and all 
operating physicians were blinded. 
Results: The mean drug dose of enoxaparin was 89.6 ± 16 mg and 
11,066 ± 2,132 units of UFH. Nine (30%) patients in the UFH group required 
re-bolus to achieve target ACT before PTCA. All patients in the enoxaparin 
group had adequate ant±coagulation as determined by anti-Xa levels. 
Core Lab Enoxaparin UFH P value 
ACT (sec) Baseline 130 ± 19 131 ± 20 0.83 
5 minute post 188 ~ 29 381 ± 67 <0.0001 
4 hour post 125 ~E 12 204 ± 57 <0.0001 
AntiXa:Anti Ila 5 minute post 1.33 = 0.67 1.10 ± 0.54 0.15 
4 hour post 2.89 ± 1.55 1.27 ± 0 .83  <0.000! 
At 4 hours, aPTT, and TFPI levels were lower (P < 0.0001) with enoxa- 
parin. No drop in D-Dimer was seen in either group, and there was a trend 
toward decreases in t-PA levels from baseline to 5 minutes in both groups. 
PTCA success rates and adverse events were similar in the groups. 
Conclusion: A single bolus of intravenous enoxaparin (1 mg/kg) can 
be used safely and simplify the performance of PTCA without the need for 
measuring the ACT or aPTT. 
1007-891 Polish-American Local Nir Stent Lovenox 
I 
Asessement Study (POLONIA): Final Results 
R. Stefan Kiesz, Pawel Buszman, Jack L Martin, Ezra Deutsch, M. 
Marius Rozek, Marek Rewicki, Piotr Seweryniak, Maciej Kosmider, 
Ewa Gaszewska, Michal Tendera. UTHSC, San Antonio, TX; Jefferson 
Health System, Philadelphia, PA; Come# Medical Center, New York, NY, 
USA; Upper Silesian Cardiology Centre, Katowice; National Cardiology 
Institute and Internal Ministry Hospital, Warsaw, Lodz Medical School Lodz, 
Poland 
Our hypothesis was that local delivery of Enoxaparin (LDD) with reduced 
systemic heparinization wilt prevent stent thrombosis and an ant±proliferative 
effect will reduce the late luminal loss, thus favorably affecting restenosis 
rates. One hundred pts underwent randomization to systemic heparinization 
(SH) and LDD immediately, prior to NIR stent placement. The LDD group 
received 2,500 U Heparin iv and 10 mg of Enoxaparin to the treated site 
during predilation with the Transport catheter, and the SH group received 
10,000U Heparin iv. All pts received ticlopidine, 250 mg BID and ASA, 325 
mg a day, 72 hours prior to the procedure, which was continued for 6 weeks. 
Results: At the end of the procedure, ACT values were: 145.1 ± 41.1 
sec. in the LDD group, and 366.7 ± 177.1 sec. in the SH group. By QCA, the 
SH group mean ref. diam. was 2.83 ± 0.36 mm, post stent MLD rose from 
0.62 ± 0.28 to 2.72 ± 0.37 mm, and the diameter stenosis (DS) fell from 78.0 
± 9.6 to 3.0 ± 13.2 (both p < 0.001). In LDD group, mean ref. dia. was 2.94 
± 0.41 mm, post stent MLD rose from 0.83 ± 0.39 mm to 2.78 ± 0.42 mm, 
and the DS fell from 72.0 ± 12.6 ± to 2.0 ± 11.4 (both p < 0.001). Acute 
gain was 2.00 ± 0.50 mm in the SH group and 1.95 ± 0.50 mm in the LDD 
group (NS). No death, acute MI, emergent CABG, or groin complications 
occurred in the LDD group either at the time of the procedure or during 30 
days of follow-up. There was 1 subacute stent closure in the SH group with 
non-Q wave MI, successfully treated with PTCA. Six month angiographic and 
clinical follow-up were available in 84 pts: 41 pts in the LDD and 43 in the SH 
group. Late loss was significantly lower in the LDD group when compared 
with the SH group: 0.63 ± 0.48 mm vs. 0.83 ± 0.43 mm, respectively (p < 
0.05). TLR occurred in 4 pts in the LDD group, and in 9 pts in the SH group. 
Conclusions: Local delivery of Enoxaparin prevented stent thrombosis 
and allowed for a reduced heparinization during the procedure. Long term 
FU suggests reduction of late luminal loss in the LDD group. Final results will 
be presented. 
New 
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• Readministration of Abciximab Is as Effective as 
First Time Administration With Similar Risks: 
Results from the ReoPro Readministration 
Registry (R 3 ) 
James E. Tcheng, Greg Braden, Dean Kereiakes, Mark B. Effron, 
Robert Jordan, Mary Ann Mascetli, Lakshmi Damaraju, Elliot Bamathan, 
Mary Ann Langrall. For the ReoPro Readministration Registry Investigators; 
DCRL Durham, NC, USA 
Background: Abciximab (Abx) is a monoclonal antibody inhibiting platelet 
aggregation with proven efficacy to prevent ischemic complications of per- 
cutaneous coronary interventions (PCI). Since little prospectively collected 
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data exists regarding the safety and efficacy of Abx readministration, we 
established a prospective multicentered registry for patients who have had 
Abx readministered. 
Methods: In hospital clinical events and serum for human antichimeric 
antibody (HACA) titer data were collected prospectively from patients at 22 
centers since March, 1997. A simultaneous log of all patients undergoing 
PCI was kept with 13,833 patients enrolled as of 5 Mar 98. 
Results: 41.5% of the patients in the log were treated with Abx with 
2.4% retreated with Abx. Clinical data from the first 329 retreated patients 
show: Number of prior Abx treatments: 1--89.4%, > 2-10.6%; PCI success: 
Overall - 96%, 1 st reedministration - 96%, >_ 2 nd readministration - 97%; 
Thrombocytopenia: < 100 K - 3,6%, <50 K - 2.1%; Death, intracranial bleed, 
retroperitoneal bleed, allergic reaction, or anaphylaxis: 0%, Groin bleeding 
needing therapy: 2.7% 
In the first 178 retreated patients, HACA titer was positive prior to'Abx 
therapy in 10.7% (19/178). HACA positive pts did not differ from HACA 
negative pts in PCI success rate or incidence of thrombocytopenia. 
Conclusion: Readministration of Abx appears to be as safe and effective 
as first time Abx administration with a similar risk profile. HACA and clinical 
outcome data from all Registry pts will be available for presentation. 
~ Abciximab Is Cost-effective in Patients 
Undergoing Percutaneous Coronary Intervention 
With Stents 
Mohan V. Bala 1 , Keaven M. Anderson 1 , Beth L. Barber 1 , P.A. Malvem 2 . 
~ Centocor, Inc.; 2Eli Lil/y and Company, Indianapolis/N, USA 
Background: Aboiximab, an antagonist to GPIIb/llla and O~v,83 receptors on 
platelets and vascular cells, reduces iscbemic events and repeat revascular- 
ization among pemutaneous coronary intervention (PCI) patients receiving 
stents. Even though abciximab is effective in stented patients, the issue of 
cost-effectiveness remains to be resolved. 
Methods: Survival benefit of abciximab was based on six month out- 
comes in patients randomized to receive stents in the EPISTENT study. The 
expected years of survival in patients who are alive at six months were es- 
timated to be at least 14 years (11.5 discounted years) based on published 
long term survival data. The cost difference was based on hospital bills col- 
lected dudng index hospitalization. We also conducted sensitivity analysis by 
setting the incremental cost of abciximab therapy to its acquisition cost. 
Results: The absolute reduction in mortality with aboiximab in stented 
patients was 0.74 percent, while its incremental cost was $1,255. The life 
years gained with aboiximab were 0.085 and the cost per life year gained 
was $14,765. When the incremental cost of using abciximab was set equal 
to its acquisition cost, the cost per life year saved was $15,882. 
Conclusion: The use of abciximab in PCI patients receiving stents is 
cost-effective based on commonly used threshold values of cost per life year 
saved. 
~ O n e  Year Clinical Results of Stent Follow-up 
Versus Atherectomy Randomized Trial 
Etsuo Tsuchikane, Tomoko Kobayashi, Toshinod Nakamura, 
Satoru Sumitsuji, Motohiro Kidno, Makoto Sakurai, Toru Kobayashi. Osaka 
Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 
START (STent versus Atherectomy Randomized Trial) is a prospective trial 
compadng clinical and angiographic outcomes between primary coronary 
stenting and optimal directional coronary atheractomy (DCA). One hundred 
twenty-two patients (pts) with suitable lesions for both Palmaz-Schatz (P-S) 
stenting and DCA were randomly assigned to the stent arm (62 pts) or the 
DCA arm (60 pts), Single or multiple P-S stents were implanted to fully cover 
lesion with high pressure post-dilatation in the stent arm, Aggressive debulk- 
ing was performed in the DCA arm using intravascular ultrasound. Clinical 
success was obtained in all pts of both arms without any major complication, 
By 1 year, there was one death in the stent arm (sudden death 90 days 
after the procedure) for a mortality rate of 1.6%. There was no death in the 
DCA arm. Q-wave myocardial infarction (QMI) was not observed in both 
arms. Target lesion revasculadzation (TLR) by 1 year was needed in 18 pts 
(29.0%) of the stent arm and 9 pts (15.0%) of the DCA arm; the incidence 
tended to be slightly lower in the DCA arm (p = 0,06), In both arms target 
vessel revasculadzation (TVR) was needed in other 2 pts because of another 
stenosis in the target vessel, The incidence of TVR was lower in the DCA arm 
(32.3% vs. 18,3%; p = 0.08), Corenary-aorto bypass surgery was conducted 
in 2 pts in the stent arm; 1 pt due to refractory instent restenosis and 1 pt 
due to progression of left main trunk lesion after stenting in circumflex artery. 
Target vessel failure, defined as either death, QMI, or TVR, was also lower 
in the DCA arm (33.9% vs. 18,3%; p = 0.05). in the DCA arm, number of 
percutaneous intervention for TLR was one time for 8 pts and two times for 1 
pt. However, in the stent arm more than two times of TLR was needed for 3 
pts due to refractory instent restenosis (three for 2 pts and four times for 1 pt). 
Conclusion: Aggressive DCA strategy provides more favorable tong-term 
clinical outcomes than pdmary stentng. 
• Long-Term of Unprotected Left Main Outcome 
Coronary Stenting in Patients With Normal Left 
Ventricular Function: Is Debulking Atherectomy 
Prior to Stenting Benefitial? 
Seung-Jung Park, Seong-Wook Park, Cheol Whan Lee, Myeong-Ki Hong, 
Jae-Joong Kim. Department of Medicine, University of U/san, Asan Medical 
Center, Seoul, Korea 
Objectives: The aim of this study was to evaluate the long-term clinical out- 
comes of elective coronary stenting for unprotected left main coronary artery 
(LMCA) stenosis in selected patients with normal left ventricular function. 
Methods and Results: Seventy-four consecutive patients (men 50, women 
24; age 56 + 10 years) with significant unprotected LMCA stenosis underwent 
elective stent implantation with (n = 24) or without debulking atherectomy (n 
= 50). Coronary artery lesions were located at the ostium (47.3%), body 
(16.2%) and bifurcation sites (36.5%) of LMCA. All patients were clinically 
evaluated at 1,3, and 6 months, and then every 4 months after stent implan- 
tation. Stenting procedure was successful in all patients. Clinical follow-up 
was average 15.4 i 10.1 months. Subacute stent thrombosis occurred in 
one patient (1.4%), and 3 patients died during the follow-up (1 in cardiac ori- 
gin, 2 in non-cardiac origin). Angiographic restenosis rate (> 50% diameter 
stenosis) was 16.7% (9/54; angiographic follow-up rate, 92.3%), and target 
lesion revascularization rate was 12.2% (9/74). The need for repeat revascu- 
ladzation was more frequent in stenting group than in debulking atherectomy 
plus stenting group (0/25 vs 9/49, respectively, p = 0.02). Event-free survival 
rate (death, myocardial infarction, repeat revasculadzation) was 81.5 5: 5.1% 
at the end of the follow-up period. 
Conclusions: Stenting of unprotected LMCA stenosis was associated 
with a favorable long-term clinical outcome, and debulking atherectomy prior 
to stenting may be petter than stenting alone. 
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• Comparison of Results With the Palmaz Stent and 
Walletent for Carotid Stent Supported Angioplasty 
John R. Laird Jr., Lowell F. Sailer, Lee Monsein, George Danges, 
Roxana Mehran, Alexandra J. Lansky, Emily Parsons, Regina Deible, 
Ann Greenberg, Martin B. Leon. Cardiology Research Foundation, 
Washington Hospital Center, Washington, DC, USA 
Purpose: To compare the acute procedural results and 30 day outcomes for 
pts undergoing carotid stent supported angioplasty (CSSA) with either the 
balloon-expandable Palmaz stent (PS) or the self-expanding Wallstent (WS). 
Methods: Over a two and a half year period, we performed 128 CSSA 
procedures in 123 pts (mean age 70 =E 12 yrs, 72% male) using either the 
PS (n = 71) or WS (n = 57). Five patients underwent treatment of bilateral 
disease. Procedural quantitative angiography, pre, post and f/u neurologic 
assessment and carotid duplex studies were performed in all cases. 
Results: Technical success was achieved in 100% of cases. There were 
no procedure-related deaths and no major permanent neurologic events in 
either group. Permanent minor neurologic events occurred in 3.1% of cases 
(PS = 4.2%. WS = 1.8% p = ns.). 
Results PS WS p value 
Final MLD (mm) 4.5 :E 0.9 4.2 5:1.1 ns 
Final %DS 1 5: 14% 11 ± 15% 0.003 
Procedural hypotension 36.2% 16.7% 0.04 
Procedural bradycardia 7.3% 3.7% ns 
MLD = minimat lumen diameter; DS = diameter stenosis 
Conclusions: 1) CSSA can be performed with high technical success 
rates and a low risk of death or major stroke using either the PS or WS. 
2) Use of the PS provided a better angiographic result at the expense of 
a higher incidence of procedural hypotension and a trend towards more 
frequent procedural bradycardia and minor stroke. Thus, reduced radial 
force, more simplified implantation, and no external deformation may favor 
the self-expanding WS for CSSA. 
~> 
O 
(D 
o3 
~6 
t.O 
O~ 
16A ABSTRACTS - ACCIS'99 JACC February 1999 
I1 008-96 ] After Carotid Stent Postprocedural Hypotension 
I Implantation: Incidence and Clinical Sequelae 
George Dangas, John R. Laird, Jr., Lowell F. Satler, Lee Monsein, 
Roxana Mehran, Alexandra J. Lansky, Michael Peterson, Steven Slack, 
Regina Deible, Anne Greenberg, Emily Parsons, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
The development of a hypotension (systolic blood pressure [SBP] drop >40 
mmHg, with SBP < 90 mmHg post-procedure) has been noted after carotid 
stenting, and may be due to a baroreflex, related to overstretch of the carotid 
bulb. To assess the impact of post-procedural hypotension on short and 
long term outcomes, we studied 133 patients with 158 lesions treated with 
carotid stenting. Persistent hypotension after stenting (group I) occurred in 28 
patients (21%), while 105 did not have hypotension (group II.). For the entire 
cohort, age was 71 ± 9 years, 71% were men, and 77% were hypertensive 
(group I vs. II, p = NS). 
Variables Group I Group II p 
Diabetes (%) 14.3 28.6 0.03 
H/o major stroke (%) 17.9 6.4 0.07 
H/o Rest angina (%) 21.4 3.6 0.04 
Max. balloon size (mm) 6.6 ± 0.2 6.2 ± 0.1 0.04 
Palmaz stent (%) 75.8 50.0 0.01 
Wallstent (%) 27.3 46.8 0.04 
In-hosp any neuro event (%) 22.2 5.6 0.02 
ICU stay (days) 2.7+ 0.2 0.2 + 0.1 <0.01 
LOS after procedure (days) 7.5 ± 1 2.0 ± 1 <0.01 
ICU = intensive care unit, LOS = length of stay. 
During long-term follow-up (mean 10 months), there was no difference in 
recurrent neurologic events (7.4% group I vs. 3.9% group II, p = NS), but 
group I had a greater cumulative "all cause" mortality than group II (18.5% 
vs. 5.6%, p < 0.05). 
Conclusions: Post-procedural hypotension after carotid stenting is a 
strong predictor of in-hospital complications and "all cause" late mortality. 
Prevention, and early aggressive management of hypotension is warranted 
after carotid stenting. 
J 1008-97 I A New Technique of Percutaneous Closure of 
Pseudo-Aneurysms Femoral Artery 
Max Amor, Michel Henry, Narendra N. Khanna, Isabelle Henry, 
Kidl Tzvetanov, Zukai Chati. Polyclinique, Essey-les-Nancy, France 
Purpose: Pseudo-aneurysms of femoral artery are not uncommon after 
endovascular interventions through femoral approach. Although echodoppler 
guide compression can close some of these, many a time, it fails (especially 
in the presence of obesity, large haematoma, arteriovenous fistula, pain and 
vasovagal reaction). Many strategies (coil embolization, covered stents and 
surgery) have been proposed but they have certain disadvantages (leaving 
foreign body inside, restenosis, prolonged hospital stay, scar, inability to use 
the same access in the future). This new technique developed by us is 
reversible and does not leave anything inside the body. 
Methods: 11 pts (age: 68 ± 7.2 years, range: 60-80, M: 9, F: 2) of pseudo- 
aneurysms (size: 14 ± 2 mm, range: 10-17 mm), in whom echoguided man- 
ual compression failed to obliterate the aneurysm were included in this study. 
Selective angiography was performed through contralateral approach. The 
pseudoaneurysms were then directly punctured by 16F Seldinger needle 
and completely obliterated by packing with 0.035" × 150 cm removable wire 
(Medicorp, Villers-les-Nancy, France) under roadmapping. Manual compres- 
sion was applied for 2-6 hours and angiography was repeated in the end to 
confirm the obliteration. The wire was then removed under fluoroscopy. 
Results: Complete obliteration was achieved in all 11 cases (success: 
100%) within 2-6 hours (mean: 3.8 J~ 1.4 hours). There was no recurrence on 
echodoppler follow-up. In 1 patient the same access was used for coronary 
stenting 
Conclusion: This is a new, simple and effective method of closing femoral 
artery pseudo-aneurysms without surgery or leaving anything inside the body. 
Larger studies are however required for better evaluation of this technique. 
J 1008-134 J Percutaneous Interventions of Subclavian Artery 
I I Occlusive Disease 
Ratan K. Ahuja, Gregory J. Mishkel, Raymond L. Kacich, Robert W. Ligon, 
Krishna J. Rocha-Singh. Prairie Heart Institute, Springfield, IL, USA 
Background: Endovascular therapy in subclavian arteries has become in- 
creasingly common but there is limited data on long term outcome. We 
evaluated the efficacy and safety of percutaneous endoluminal treatment in 
subclavian artery occlusive disease (SAOD). 
Methods: Between January 1993 and March 1998, 96 patients with 
SAOD underwent percutaneous interventions (mean age 64 years, 67% fe- 
males). Procedural success was defined as post-procedure systolic pressure 
gradient < 10 mm Hg and residual stenosis of <20% without major complica- 
tion (occlusive dissection, acute stent thrombosis, embolization, myocardial 
infarction, emergency surgery or death). Indications included arm claudica- 
tion (n = 42), compromised intemal mammary graft inflow (n = 30), subclavian 
steal (n = 23), upper extremity paresis and/or paraesthesia (n = 19), and tran- 
sient ischemic attacks (n = 2). Mean follow-up was 22.8 months. 
Results: Palmaz stents (n = 90) and Wallstents (n = 7) were deployed 
in 90 patients. Stand-alone angioplasty was performed in 6 patients. In 84 
(87.5%) patients the lesion was located in left subclavian artery. Procedural 
success was achieved in 95 patients (99%). Brachial artery embolization 
requiring thrombectomy occurred in one patient. There was one access site 
bleeding complication requiring blood transfusion. 
Follow-up: Long-term follow-up is available in 82 patients (85.4%). Ten 
patients died of unrelated causes. Target vessel revascularization was re- 
quired in 6 of 72 patients (8.3%), 5 underwent repeat angioplasty and one 
carotid-subclavian bypass surgery. 
Conclusions; Percutaneous endovascular therapy of SAOD is safe with 
a high success rate and a low rate of target vessel revascularization. 
1008-135 ] In i t ia l  Clinical Experience With the Instent 
Nitinol Stent 
Michel Henry, Max Amor, Isabelle Henry, Kidl Tzvetanov, Zukai Chati. 
Po/yc/inique, Essey-les-Nancy, France 
Purpose: To evaluate a new self expandable nitinol not coated stent in 
peripheral arteries, designed as a helical coil, released in the artery by 
pulling a release wire. 
Methods: 174 lesions in 160 symptomatic patients (M: 120, F: 40, mean 
age: M: 64.3 ± 11.8 years (20-90), F: 74.8 ± 9.5 years (45-90)) received 
Instent stents. Lesions location: lilac in = 31) (stenoses:28, occlusions:3), 
femoral (n = 75) (sten.:61, occ1.:14), popliteal artery & tibio-peroneal trunk 
(n = 65) (sten.:38, 0cc1.:27), bypass stenoses (n = 3). Mean % stenosis: 
84.9 i 6.9 (70-100). Mean lesion length: 46.1 ~ 22 (20-150). 198 stents 
implanted percutaneously (length: 40, diameter: 5-8 mm) (femoral approach: 
153, popliteal:2, contralateral: 5) for suboptimal results (n = 108), dissection 
(n = 43), restenosis (n = 9). 
Results: Technical success achieved in all cases but one (unsatisfactory 
deployment). Excellent immediate patency, good angiographic/ultrasono- 
graphic adherence to the arterial wall. Post-angioplasty % stenosis de- 
creased from 30.6 ± 9.9% to 3.1 zE 3.2%. 3 thromboses at 24 hours (2 
at the femoral, 1 at the popliteal level). Eligible pts underwent angiographic 
follow-up at 6 months and echodoppler every 6 months (angiography if re- 
stenosis is suspected). Mean follow-up was 25.5 -- 16.3 months (1-75). 10 
restenoses at 6 months (5 treated by new PTA, 3 by surgery) and 2 medically. 
After 6 months, t0  other restenoses (2 treated by new PTA, 6 by surgery 
and 2 medically. Primary (PI) and secondary (Pit) patencies at 5 years: all 
lesions: P1:82%, PI1:90%, iliac:Pl:93%, PI1:96%, femoral: P1:78%, PI1:91%, 
popliteal: P1:87%, PI1:95%. 
Conclusion: The Instent stent seems safe, effective, with favourable 
long term results, with possible removal in selected cases. Its flexibility and 
resistance to external compression allows its placement in tortuous arteries 
and joint locations. 
1008-136]  Endoluminal Treatment of Sub-Clavian 
Occlusive Diseases. Percutaneous Angioplasty 
and Stenting 
Michel Henry, Max Amor, Isabelle Henry, Kiril Tzvetanov, Zukai Chati. 
Polyclinique, Essey-les-Nancy, France 
Purpose: To review feasibility, risks, long term results of PTA of subclavian 
artery with and without Palmaz stent placement. 
Methods: Over 9 years, 113 patients (pts) underwent percutaneous treat- 
ment of sub-clavian occlusive diseases. M: 67, F: 46, mean age: 63 ± 13 
years. Indications for PTA: vertebro-basillar insufficiency (n = 70), superior 
arm ischemia (n = 50), angina pectoris, before/after internal mammary inter- 
nal coronary bypass (n = 12). 6 pts had coronary steal syndrome, 94 arteries 
were stenosed, 19 were occluded. Mean % stenosis: 80.1 ± 7.0 (70-100). 
Mean lesion length: 24 ± 8 mm (10-50). Percutaneous techniques included 
standard retrograde femoral (n = 81), brachial artery (n = 26) access or beth 
(n = 11 ), with balloon dilatation of the lesion. Since 1989, Palmaz stents were 
implanted for 46 lesions: in case of suboptimal PTA (n = 37), and in case of 
important dissection (n = 9). 
Results: 103/113 lesions were successfully treated (91%), 9 occlusions 
were recanalized (47%). We observed 3 procedural complications (2.6%): 
1 T.I.A., 1 major stroke, 1 arterial thrombosis 24 hours after the procedure, 
treated medically. Eligible pts underwent echodoppler/angiographic ontrol 
at 6 months and echodoppler every 6 months thereafter. 16 restenoses were 
treated by new PTA (n = 4), by PTA + stent (n = 7), by surgery (n = 5). 
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Primary (PI) and secondary patency (PII) for all treated lesions (n = 113) at 8 
years follow-up: 75,3 and 81.5%. Without stent, respectively 68.6 and 76%, 
with stent 87.4 and 94.3%. PI and PII for recanalized lesions (n = 103), 83%, 
89.9%, without stent: 81%, 89.7%, with stent: 87.4% and 94.3% respectively. 
Conclusion: PTA with and without stenting is safe and effective to treat 
sub-clavian artery occlusive diseases with good tong term patencyo Occluded 
vessels do not respond well to PTA. Stents (implanted only for suboptimal 
PTA results) do not seem to improve long term results. 
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~ Follow-up Angiographic Comparison the Low of 
Dose Vs High Dose Phosphorus-32 Radioactive 
Isostent. Results from Expanded IRIS and Milan 
Dose A Studies 
Alexandra J. Lansky, Jeffrey J. Popma, Antonio Columbe, Richard E. Kuntz, 
Steve Bailey, Paul Teirstein, Stephen Ellis, Martin B. Leon, Jeffrey Moses. 
Washington Hospital Center, Washington DC, USA 
The Isostent for Restenosis Intervention Study (IRIS) pilot established the 
feasibility of implanting the 0.5-1.0 microCurie (/~c) beta emiting phospho- 
rous-32 coated PS stent (Isostent) for the treatment of native coronary le- 
sions. Two subsequent dose ranging studies, the expanded IRIS (N = 32) 
with the 0.7-1.5/~c Isostent and the Milan dose A study (N = 31) with the 3-6 
/~c BX Isostent, have been performed to establish the optimal therapeutic 
radiation dose for focal non-complex native lesions requiring a single stent. 
Procedure and follow-up (FU) quantitative angiography (CMS-GFT) was per- 
formed in all pts in the expanded IRIS, and in 21 of 31 pts with available 4 
month FU in the Milan Dose A study. The "stent" analysis was confined to 
the stent itself, whereas the "segment" analysis included the stent and its 5 
mm borders. 
IRIS Expanded Milan Dose A 
Reference Diameter, mm Pre 2.98 ± 0.56 2.85 ± 0.38 
Follow-up 2.95 ± 0.56 2.76 ± 0.31 
Diameter Stenosis, (DS) % 
Pre procedure 63 • 13 66 ± 20 
Final Segment 15 =E 10 16 ± 12 
Final Stent 6 ± 8 5 ± 8 
Follow-up Segment 46 ± 23 35 ± 18 
Follow-up Stent 44 ± 23 16 ± 23 
Restenosis Rate, (RS) % 
Segment 39 19 
Stent 33 9.5 
Loss Index, Segment 0.70 0.38 
Stent 0.70 0.25 
We conclude: Unlike the 0.7-1.5/~c Isostent where RS was both within 
the stent and at the edges, the 3-6 /~c BX Isostent had a lower stent RS 
rate, but similar edge RS rate at FU. The 3-6 /~c Isostent is effective in 
suppressing intimal hyperplasia within the stent, however the falloff dosing 
at the stent edges appears to exaggerate the proliferative response. 
• Seeding of Novel Covered Stents With 
Transfected Autologous Smooth Muscle Cells 
Katsumi Miyauchi, Noel Caplice, Robert D. Simari, LaDonna J. Camrud, 
Allan R. Camrud, Paula J. Carlson, Birgit Kantor, David R. Holmes Jr., 
Robert S. Schwartz. Mayo Clinic and Foundation, Rochester, MN, USA 
Stenting is limited by restenosis and smooth muscle cell (SMC) proliferation. 
Since seeding of stents with transfected SMC might offer an alternative 
approach for the prevention of restenosis, we designed an intracoronary 
stent covered with a novel, porous steel mesh matedal that permitted in vitro 
SMC seeding and implantation into porcine coronary arteries. This mesh has 
multiple interstices, permitting SMC ingrowth. SMCs were harvested from 
the carotid arteries of 6 pigs, and were subcultured. Mesh stents were placed 
in the cultured media where the stents became completely seeded with 
SMCs. The SMCs were subsequently transfected with liposomes containing a 
marker gene (Green Fluorescent Protein, GFP). Examination of these stents 
in vitro showed excellent GFP transfection rates (10-15%) by 2 days. Eight 
such stents with GFP transfected SMCs were implanted into coronary arteries 
of the same pig from which cells had been obtained from culture. After 28 
days, the stents were harvested to determine survival of the recombinant cells 
within the stent using confocal microscopy and FITC to detect GFP. Although 
diffuse intimal thickening occurred near the mesh, substantial numbers of 
viable SMC were found as judged by continued GFP expression. 
Conclusion: This steel mesh coated stent shows excellent biocompati- 
bility. Stents with this mesh showed excellent survival of recombinant cells 
expressing a marker gene at 28 days. This mesh stent with transfected SMC 
may allow introduction of gene transfected SMC directly into the vessel wall. 
/ •  Proliferation in Human Distribution of Neointimal 
Coronary Arteries Treated With 
Polytetrafluorethylene Stent-Grafts 
Math±as Eisner, Martina Britten, Wolfgang Auch-Schwelk, Dirk H. Walter, 
Volker Sch&chinger, Andreas M. Zeiher. Medizinische Klinik IV, Dep. of 
Cardiology, J. W Goethe-Universi~ Frankfurt a.M., Germany 
Background: Stent.grafts [SG] containing a polytetrafluorethylene [PTFE-] 
membrane have recently become available for implantation into human core- 
nary arteries. The microporous PTFE-layer in the body of the SG may inhibit 
restenosis by eliminating plaque protrusion, attenuating diffusion of cytokines 
and hindering transmigration of inflammatory cells. There are no data avail- 
able on the pattern of neointima [NIl formation in these novel devices. 
Methods: We performed intravascular ultrasound [IVUS] in 13 patients 
at 3-6 months follow-up after coronary SG-implantation (9 native coronary 
arteries, 4 saphenous vein grafts). 
Results: During deployment, a characteristic 'dog-bone'-effect was seen 
on balloon inflation, with immediate opening of the SG-edges, whereas com- 
plete expansion of the SG-body was achieved only at pressures up to 18 
atm. Angiographic minimal lumen diameter before and after intervention and 
at follow-up was 0.45 ~E 0.47, 3.00 ± 0.44 and 2.06 :t: 0.87 mm respectively. 
At follow-up, there was complete SG-apposition in all cases and no indication 
of PTFE-membrane disruption. 
IVUS: Proximal edge SG-body Distal edge 
SG-area 7.15 i 2.18 7.30 ± 1.63 7.76 ± 2.09 
NI-aree 1.45 ± 1.14 0.72 ~: 1.41" 1.72 ± 1.16 
Max. Nl-thickness 0.29 ± 0.20 0.14 ~: 0.14" 0.37 ± 0.28 
"P < 0.05 
Conclusions: Neointimal proliferation in PTFE stent-grafts occurs pre- 
dominantly at the edges not covered by the PTFE-membrane. There is only 
minimal proliferation in the body of PTFE stent-grafts, indicating an ant±pro- 
liferative effect of hermetically sealing the vessel wall. 
~ T h e  Importance Centering Intracoronary of  for 
Radiation Therapy in Stented Arteries. An 
Ultrasound-Dosimetry Analysis of 4 Commercial 
Systems Utilizing ,y and/3 Emitters 
Ron Waksman, Rosanna C. Chan, Chris Soares, Alexander Abizaid, Gary 
S. Mintz. Washington Hospital Center Washington DC, USA 
The need of centering with catheter based systems for vascular brachyther- 
apy is still controversial. To determine the importance of centering intravascu- 
lar ultrasound (IVUS) measurements of 100 consecutive lesions after treat- 
rnent for in-stent restenosis were analyzed. The maximum and minimum 
distances from the center of the lumen and the IVUS catheter to the media 
were recorded for small (mean 3.6 ± 0.3 ram) and large (mean 4.5 ± 0.3 
mm) vessels. Monte Carlo calculations used to determine the % additional 
dose to the media of 4 commercial systems. Dose gradient to the media was 
calculated based on a prescription of 15 Gy to 2 mm from the source for ~921r 
centered (C), 1921r non-centered (NC), 9Oy C and 9°Sr/Y NC. In-homogeneity 
of the dose was detected only in the non-centered systems for both emitters. 
(Table). The use of NC ~ emitters in larger arteries resulted in a maximum 
dose gradient to the media of 7.5-33.5 Gy versus 15.4-15.6 Gy with the use 
of a C 7' source p < 0.001. 
Diameter Max-Min 1921r C 1921r NC 9Oy C g°Sr/Y NC 
<4.00 mm Max 4.3% 95.5%* 5.5% 108.2%** 
>4.00 mm Min 2.9% -31.9% 3.4% -42.5%" 
<4.00 mm Max 4.0% 101.0% 7.0% 137.9% 
>4.00 mm Min 2.9% -31.5% 5.1% -46.9%** 
P < 0.000001, "'p < 0.005 
Thus centering catheters may be required especially with the use of/~ 
emitters to optimize the dose homogeneity in larger stented arteries. 
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I 1010-44 Relationship Baseline (Pre-intervention) Between Remodeling and Arterial Responses in the First 
Month Post-intervention: An Intravascular 
Ultrasound Analysis from the SURE Trial 
Gary S. Mintz, Takeshi Kimura, Jeffrey J. Popma, Masakiyo Nobuyoshi, 
Martin B. Leon. Washington Hospital Center, Washington, DC, USA; Kokura 
Memorial Hospital, Kitakyushu, Japan 
Sedal intravascular ultrasound was performed in 61 lesions pre-intervention 
and immediately and @ 1 month post-PTCA or DCA. Pre-intervention lesion 
remodeling was classified as negative (lesion arterial area < distal reference), 
intermediate (proximal reference > lesion arterial area > distal reference), 
and positive (lesion artedal area > proximal reference). Overall, the early 
(within 1 month) increase in plaque area was accompanied by an equal or 
greaterincrease in arterial area (r = 0.67, p < 0.0001) resulting in an increase 
in lumen area. This response was observed in lesions with pre-intervention 
charactedstics of negative (r = 0.59, p < 0.0001, Figure A), intermediate (r 
= 0.69, p < 0.0001, Figure B), or positive remodeling (r = 0.78, p < 0.0001, 
Figure C). 
h artery ~ anew ~ anery 
-4  -4  
-12  - -12  , ' , 
-12  -4  4 12 - t2  -4  4 12 -12  -4  4 12 
z~ plaque ~ plaque t~ plaque 
We conclude: The arterial response (to plaque accumulation) which 
prevents lumen compromise during early atherogenesis is restored in the 
first month post-PTCA or DCA irrespective of the baseline lesion remodeling 
characteristics. 
• Comparison of in the Coronary Remodeling 
Culprit Lesion in the Acute Coronary Syndrome 
and Stable Angina Pectoris 
Mamco Nakamura, Hideo Nishikawa, Sei Mukai, Morimichi Setsuda, 
Hiroya Tameda, Hiroyuki Suzuki, Takahiro Ohnishi, Yutaka Kakuta, David 
P. Lee 1 , Alan C. Yeung 1 . Yamada Red Cross Hospital Mie, Japan; 
Stanford University Medical Center, Stanford, CA, USA 
Background: Several remodeling patterns have been described in coronary 
artery disease. We examined the remodeling patterns in the culprit lesions of 
patients with an acute coronary syndrome (ACS) and stable angina pectoris 
(SAP) with the use of intravascular ultrasound (IVUS). 
Methods: 78 patients (35 ACS, 43 SAP) were studied with IVUS prior to a 
planned percutaneous coronary intervention. ACS included acute myocardial 
infarction and unstable angina pectoris. The culprit lesion was defined by the 
combination of clinical and angiographic findings. Vessel area (VA) was 
measured at the culprit lesion site and at relatively disease-free proximal and 
distal reference sites. Coronary remodeling patterns were divided into two 
groups: (1) compensatory enlargement (CE) with VA-lesion > VA reference 
and (2) non-CE with VA-lesion < VA-reference. 
Findings: CE was seen in 74% of the ACS patients and 37% of those 
with SAP (p < 0.001). Although the culprit lesion VA was not significantly 
different between the two groups (ACS: 17.2 ± 6.9; SAP 14.8 ~ 4.9; p = 
0.09), the ratio of VA-tesionNA-reference was significantly larger in the ACS 
group (1.13 ± 0.10 vs.0.96 :E 0.13; p = 0.002), suggesting that the degree of 
CE was better in the ACS patients. 
Conclusions: In patients with the acute coronary syndrome, the culprit 
lesion more often has compensatory enlargement and to a greater degree 
when compared to patients with stable angina pectoris. 
• Local Geometrical Determinants of Vascular 
Remodeling in Coronary Atherosclerosis: 
An Intravascular Ultrasound Study 
Tekafumi Hire, Takashi Fuji±, Shinji Yoshitake, Tetsuya Kawabata, 
Takayuki Okamura, Kyoneri Yasumoto, Masafumi Yano, Toshiro Miura, 
Michihiro Kohno, Masunori Matsuzaki. Yamaguchi Universi~ Ube, Japan 
Background and Methods: This study hypothesized that coronary remod- 
eling is determined in part by shear or circumferential stress which is affected 
by local vascular geometrical architecture. To clarify the local geometrical 
determinants of coronary remodeling by intravascular ultrasound (IVUS), we 
imaged 141 proximal coronary segments with a length of 3 mm from patients 
with mild coronary artery disease. Vascular area, lumen area and plaque 
area (PA) were first measured. Then, percent change of PA (%d-PA), mean 
eccentricity index of plaque (El), mean vascular cross-sectional shape in- 
dex (V-shape) and luminal shape index (L-shape) were obtained for each 
segment. El was defined as deviated distance between geometric center of 
lumen and that of artery, divided by vascular radius. The shape indices were 
defined as 4 × :~ x (area)/(pedmeter) 2, representing the degree of round- 
ness. The segments were classfied into two groups: Group A (adequate 
remodeling: n = 32), in which lumen was preserved despite an increase in 
PA, Group B (Inadequate remodeling: n = 109), in which lumen was compro- 
mised due to an increase in PA. Mean % area stenosis of each segment was 
matched between the two groups (A: 46 + 12, B:48 ± 11, ns). 
Results: There were significant differences in %d-PA (A: 12 ± 11, B:21 
± 19, p < 0.01), El (A:0.11 ± 0.06, B:0.17 ± 0.09, p < 0.005), V-shape (A: 
0.92 ± 0.01, B:0.91 ± 0.03, p < 0.05) and L-shape (A: 0.91 ± 0.03, B:0.88 
± 0.04, p < 0.01) between the two groups. 
Conclusions: In atherosclerotic arterial portion with sharper change in 
plaque area, more eccentric plaque distribution, or more elliptical vascular or 
luminal cross-section, plaque formation was more likely to compromise lumen 
area. These data suggests that coronary remodeling is partly determined by 
changes in local arterial geometry. 
~ Coronary Artery Remodeling Disease: Arterial 
and Clinical Presentation 
Pieter C. Smits, Gerard Pasterkamp, Michael A. Quarles van Ufford, Frank 
D. Eefting, Pieter R. Stella, Peter P. de Jaegere, Cornelius Borst. 
Department of Cardiology, Utrecht University Hospital, Utrecht, The 
Netherlands 
Background: De novo atherosclerotic remodeling of coronary artery seg- 
ments ranges from compensatory enlargements to shrinkage. We investi- 
gated the hypothesis that large plaques in compensatory enlarged segments 
are associated with acute coronary syndromes, whereas smaller plaques in 
shrunken segments are associated with stable angina pectoris. 
Methods: Patients selected for PTCA procedure were divided in two 
groups, one with stable angina pectoris (Stable Group, n = 37) and one with 
unstable angina or post myocardial infarction angina of the infarct related 
artery (Unstable Group, n = 32). In both groups, remodeling at the culprit 
lesion site was determined by intravascular ultrasound prior to the interven- 
tion. Remodeling was calculated as relative vessel area: (vessel area culprit 
lesion site/mean vessel area of both proximal and distal reference sites) 
× 100%. Compensatory enlargement was defined as remodeling ~ 105%, 
whereas shrinkage was defined as remodeling < 95%. 
Results: In the Unstable Group, the vessel area at the cultprit lesion site 
was larger compared to the Stable Group, 18.1 q. 5.3 versus 14.6 ± 5.4 mm 2 
(p = 0.008), respectively. Lumen areas, however, were similar. Consequently, 
plaque area and percentage remodeling were larger in the Unstable Group 
than in the Stable Group, 14.8 ± 4.8 versus 11.6 ± 4.9 mm 2 (p = 0.009) 
and 112 :E 31% versus 95 ± 17% (p = 0.005), respectively. Significantly 
more cultprit lesion sites were classified as shrunken in the Stable Group 
(21/37) compared to the Unstable Group (8/32, p = 0.014). On the other 
hand, more lesion sites were classified as enlarged in the Unstable Group 
(16/23) compared to the Stable Group (8/37, p = 0.022). 
Conclusion: In patients selected for PTCA, the mode of remodeling is 
related with clinical presentation. 
~ Prevalence and Predictors of Coronary Artery 
Remodeling Patterns: An Intravascular 
Ultrasound Study 
Sei Mukai, Hideo Nishikawa, Modmichi Setsuda, Mamoo Nakamura, 
Hiroya Tameda, Hiroyuki Suzuki, Takahiro Ohnishi, Yutaka Kakuta, David 
P. Lee 1 , Alan C. Yeung 1 . Yamada Red Cross Hospital, Mie, Japan; 
Stanford University Medical Center, Stanford, CA, USA 
Background: Two major coronary remodeling patterns are compensatory 
enlargement (CE) and constrictive remodeling (CR). We examined the preva- 
lence of remodeling patterns and their associations with cardiac risk factors. 
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Methods: 65 patients (50 men, 15 women) were studied with intravascu- 
lar ultrasound (IVUS) prior to a planned percutaneous coronary intervention. 
Vessel area (VA) was measured at the target lesion site and at a relatively 
disease-free proximal and distal reference site. We defined: (1) CE as VA- 
lesion > VA proximal reference; (2) CR as VA distal reference > VA lesion 
and (3) intermediate remodeling (IR) as VA proximal reference > VA lesion 
> VA distal reference. We also studied plaque characteristics (soft or fibro- 
calcific). Coronary risk factors included age, gender, diabetes, hypertension, 
smoking, hyperlipidemia, obesity and family history. 
Findings: No significant differences in remodeling patterns were seen 
with respect to gender, family history, or hypertension. CE was seen in 30 
patients (46%), CR in 21 (32%) and IR in 14 (22%). Smokers tended to have 
more CE (54% vs. 41%) but less IR (14% vs. 27%) while hypedipidemic 
patients had more IR (41% vs. 14%) than CR (28% vs. 36°/o). CR was seen 
more often in patients over the age of 65 (49% vs. 11%), obese patients (42% 
vs. 28%) and in diabetics (82% vs. 18%). CR was more often associated with 
fibrocalcific plaque than CE (57% vs. 10%). 
Conclusions: Several risk factors including age, smoking, diabetes, obe- 
sity, and hypedipidemia may influence remodeling patterns. The type of 
remodeling pattern may be associated with different plaque characteristics. 
~ Various Responses of Remodeling in a Vessel 
Saphenous Vein Graft After Coronary Artery 
Bypass Grafting Demonstrated by Intravascular 
Ultrasound 
Yoh Fujimoto, Nobuyuki Komiyama, Shin-ichiro Nishiyama, 
Shigemoto Nakanishi, Shin-ichi Momomura. Toranomon Hospital, Tokyo, 
Japan 
Background: A recent study with an intravascular ultrasound (IVUS) re- 
vealed that adequate compensatory enlargement is absent in body of a 
saphenous vein graft (SVG) after coronary artery bypass grafting (CABG). 
Objecting to the report, we revaluated the characteristics of remodeling re- 
sponse of SVGs. 
Methods: Twenty-three SVGs in 23 patients were studied at 7 months to 
21 years after CABG using a 3 Fr catheter-based IVUS before intervention 
or as a diagnostic procedure. IVUS images were recorded on a video tape 
during the motorized slow pullback (0.5 mm/sec) from the distal anastomosis. 
In subsequent off-line analysis, a targeted lesion (TL) was selected in each 
SVG as a site with the smallest lumen and a reference position (REF) without 
a plaque was placed at a site >_ 10 mm apart from TL. Total vessel area (VA), 
lumen area (LA) and plaque area (PA = VA - LA) were measured at both 
sites using a computerized planimeter. 
Results: 1) Compensatory enlargement was shown at 5 TLs (22%; 9.0 
+ 5.8 years after CABG) with significantly larger VA and PA than REFs (22.8 
± 11.4 vs 13.3 + 8.3 mm 2, p < 0.05; 16.8 ± 8.9 vs 5.9 ± 3.1 mm 2, p < 
0.05), resulting in similar LA to REFs (7.8 ± 3.3 vs 8.3 ± 6.3 mm 2, p = NS). 
2) Absence of compensation was revealed at 12 TLs (52%; 9.6 ± 2.1 years 
after CABG) with similar VA to REFs (17.6 ± 4.9 vs 17.2 ± 4.7 mm 2, p = NS) 
in spite of substantially larger PA than REFs (11.1 ± 3.9 vs 6.0 ± 2.2 mm 2, p 
< 0.01), resulting in significantly smaller LA than REFs (6.8 ± 1.8 vs 11.9 ± 
3.4 mm 2, p < 0.01 ). 3) Vessel shrinkage was observed at 6 TLs (26%; 2.0 + 
5.2 years after CABG) with substantially smaller VA than REFs (10.1 ± 2.6 
vs 17.9 ± 3.5 ram, p < 0.01) although similar PA to REFs (3.7 + 2.1 vs 4.3 ± 
1.7 mm 2, p = NS), resulting in significantly smaller LA than REFs (6.4 ± 0.5 
vs 13.0 ± 3.1 mm 2, p < 0.01). 
Conclusion: Compensatory vessel enlargement without narrowing can 
sometimes (22%) appear in a SVG. Interestingly, vessel shrinkage may 
contribute to luminal narrowing in a SVG at eady phase (around 2 years) 
after CABG. 
~ Assessment of Serial of the Changes Coronary 
Arterial Remodeling from the Mechanical View 
Point, in Acquisition of Initial Luminal Gain 
Merle Igarashi, Tadanori Aizawa, Ken Ogasawara, Hajime Kirigaya, 
Hiroshi Sate, Kazuyuki Nagashima, Kuni Miyoshi, Yusuke Tsubokou, 
Shinichi Usui, Kazuzo Kate. The Cardiovascular Institute, Tokyo, Japan 
Background: In human coronary arteries, coronary arterial wall shrinkage is 
often recognized after coronary intervention during chronic state. 
Pourpose: To evaluate the serial changes in the coronary arterial remod- 
eling from the mechanical viewpoint, while getting initial luminal gain, after 
successful directional coronary atherectomy (DCA). 
Methods: From November 1992 to March 1998, 398 patients with angina 
pectoris underwent DCA. From this group, 90 patients underwent intravas- 
cular ultrasound (IVUS), using a motorized auto-pullback system, every 0.5 
mm per second, at the stages of pre and post coronary intervention, 3 or 6 
month follow up. From the mechanism of getting initial luminal gain, these 
90 patients were divided into two subgroups; 53 patients (Debulking group), 
whose initial luminal gain at the lesion site was brought by mainly plaque 
reduction and the other 37 patients (Dotter group), whose that was brought 
by mainly vessel expansion. We compared two groups pre and post DCA, 
and chronic state using vessel cross sectional area (VA), lumen area (I_A) 
and plaque area (PA) defined by IVUS. 
Results: 
Debulking roup Dotter group 
pre post  follow-up pre post  follow-up 
VA 17.7 ',- 4.5 17.4±4.4 17.2 :E 4.5 17.1±5.2 19.4 ± 5.2" 18.4 ± 5.5 *t 
LA 2.8 ± 1.4 9.0 ± 2.8" 6.6 ± 3.7"t 2.8 ± 1.5 9.3 ± 2.8" 6.9 ± 4.6 "t 
PA 14.9 ± 4.1 8.4±3.2* 10.6 ± 3.6 "t 14.3±5.2 10.1 ± 4.1" 11.5 ± 4.0 *'i" 
(mean ± S.D.) (": P < 0.03 vs pre, t: p < 0.05 vs post) 
Conclusion: In the Debulking group; the VA lasted throughout the pro- 
cedure, and the loss of LA at the chronic state was reduced by neointimal 
hyperplasia. In contrast, in the Dottor group; the VA enlarged significantly 
after DCA and decreased significantly during follow-up term, but the trend 
of vessel expansion was maintained, and the loss of LA at the chronic state 
was evoked by neointimal hyperplasia and vessel remodeling. 
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177-11 Intrecoronary Gamma Radiation to Reduce In-Stent 
Restenosis: The Multicenter Gamma I Randomized 
Clinical Trial 
Martin B. Leon, Paul S. Teirstein, Alexandra J, Lansky, Jeffrey W. Moses, S. 
Chiu Wong, James Willerson, Stephen Ellis, DUsher M. Nawaz, 
Dean Kereiakes, James B. Hermiller, David R. Holmes, Barry S. George, 
Bryan Kluck, Richard E. Kuntz. Washington Hospital Center, Washington, 
DC, USA 
Background: Gamma I is an FDA approved double-blinded randomized trial 
in 253 patients with in-stent restenosis from 12 investigator sites. 
Methods: Patient inclusion criteda were >_ 1 episode of in-stent restenosis, 
lesion length <45 ram, in 2.75-4.0 mm diameter native coronary arteries. Af- 
ter treatment of in-stent restenosis with balloon PTCA, athero-ablation, and/or 
additional stents, a non-centered 4.7 Fr closed endlumen catheter was posi- 
tioned to span the stented segment for delivery of either 192-1r seeds (source 
lengths 23 mm, 30 mm, and 55 ram) or placebo. 192-1r dosimetry was based 
upon prespecified IVUS measurements of longest/shortest arget-EEM dis- 
tance to deliver 8-30 Gy to the EEM. The primary endpoint is 9-month target 
vessel failure (including all post-procedure death, Q and non-Q MI, and target 
vessel revasculadzation) 
Results: The entire cohort has been enrolled and baseline charactedstics 
were well matched; overall, mean age was 60 ± 12 years, 74% were men, 
31% diabetics, and 91% had unstable angina. Mean lesion length was 18.5 
+ 9.0 mm, pre-prooedure diameter stenosis (DS) was 63% in both groups, 
and final stent DS was 6% and 9% (p = 0.32). In-hospital and one-month 
MACE (major adverse coronary events = death, Mi, and TLR) were similar, 
although tending to favor one therapy (MACE @ 1 month: 1.6% for Group 1 
and 4.1% for Group 2, p = 0.2) 
Conclusions: Preliminary results from the Gamma I trial indicate that (1) 
baseline characteristics for the two groups are well matched; (2) delivery of 
192-1r via dedicated catheters is safe and patients can tolerate dwell times up 
to 20 minutes; (3) 6-month clinical and angiographic results will be available 
for presentation. 
1:45 p.m. 
~-]  Intracoronary Beta Radiation Therapy for In-Stent 
Restenosis: Preliminary Report From a Single Center 
Clinical Study 
Ron Waksman, R. Larry White, Rosanna C. Chan, Balram Bhargava, 
Mark Parker, Bill G. Bass, Lowell F. Satler, Roxana Mehran, Jose Basalga, 
Kenneth M. Kent, Augusto D. Pichard, Martin B. Leon. Washington Hospital 
Center, Washington DC, USA 
Background: Intracoronary gamma radiation therapy was shown to reduce 
~> 
Cb 
£3 
~o 
O9 
m 
20A ABSTRACTS - ACCIS'99 JACC February 1999 
the restenosis rate in patients with in-stent restenosis. BETA WRIST is the 
Washington Radiation for In-Stent restenosis Trial with the beta emitter 
90-Yttrium (90Y). 
Methods: Forty consecutive patients with in-stent restenosis in native 
coronaries underwent PTCA, laser angioplasty, rotational atherectomy, and 
or additional stents. Following PTCA a segmented balloon catheter 2.5-4.0 
mm in diameter was positioned at the treated segment and automatically 
loaded with 90Y source 0.014" wire, 29 mm in length to deliver a dose of 
20.6 Gy prescribed at 1.0 mm from the surface of the balloon. The dose rate 
varied from 16.0-5.6 Gy/min. In 12 patients stepping of the radiation catheter 
was preformed for lesions >25 mm in length with an overlap of up to 2 mm 
at the stented segment. 
Results: The radiation was automatically delivered successfully and tol- 
erated well in all patients with a mean dwell time of 3 4- 0.4 minutes. Frac- 
tionation of the dose due to ischemia was required in 11 patients (27%). The 
radiation exposure at the patient chest was 7 mR/h and at the bedside was 
0.8 mPJh. There were no procedural or in-hospital adverse events related to 
the radiation procedure at 30 days. 
Conclusion: Beta radiation for patients with in-stent restenosis using 
a 90Y source delivered automatically into a centering catheter is feasible 
and safe. Six months angiographic follow-up and comparison to the gamma 
cohort of WRIST will be available at presentation. 
2 :00  p.m. 
~7~3-] Is Intravascular Ultrasound Necessary for Dose 
Prescription During Intracoronary Radiation Therapy? 
Robert J. Russo, Vincent Massullo, Prabhakar Tdpuraneni, Shirish Jan±, 
Patricia D. Silva, Paul S. Teirstein. Scripps Clinic, La Jolla, CA, USA 
Background:The SCRIPPS (Scripps Coronary Radiation to Inhibit Prolifer- 
ation Post-Stenting) trial is a double-blind, placebo-controlled, randomized 
study using a non-centered gamma radiation source (19210 to treat in-stent 
restenosis. 
Methods: To assess the requirement for intravascular ultrasound (IVUS), 
dosages determined by IVUS during the trial were compared to those esti- 
mated from an angiographic model and a fixed-dose strategy. True dosimetry 
was calculated from IVUS images obtained during pullback. The distance 
from the center of the IVUS catheter (equivalent to the position of lg21r 
source) to target (media) was measured and rain and max values were used 
for dosimetry (target min and max doses of 800 and 3000cGy). 
Results: 119 pts were evaluated. Using IVUS, mean min and max tissue 
doses of 773 4- 69cGy and 2581 4- 526cGy were delivered with 10.9% of 
targets receiving <700cGy (believed to be subtherapeutic). An angiograpic 
model was constructed and min distance from lS21r source to target was 
assumed to be 1.0 mm. The mean reference vessel diameter by angio. 
was determined (core lab analysis) and 1.0 mm subtracted to derive the max 
distance from 1921r source to target. Assuming a max tissue tolerance of 3000 
cGy, the mean calculated min dose is 751 + 144cGy using this model, with 
38.7% of pts receiving a min dose of <700cGy. Using a fixed-dose strategy 
of 1500cGy delivered at 2 mm from the source, the mean calculated min 
dose is 859 4- 164cGy with 17.9% of targets receiving <700cGy. However 
this strategy results in 41.5% of targets receiving > 3000cGy. A significant 
difference is noted in the rate of subtherapeutic dosimetry when an angio. 
model is compared to IVUS dosimetry (38.7% vs. 10.9%; p < 0.001), while 
the rate of undertreatment with the fixed-dose strategy is similar to IVUS 
(17.9% vs. 10.9%; p = n.s.) 
Conclusion: IVUS based dosimetry is necessary for non-centered, radi- 
ation therapy as angiography prescribed an inadequate target dose and a 
fixed-dose strategy resulted in an excessive near-field dose. 
2 :15  p.m. 
~7~-~ Yttrium-90 Delivered via a Centering Catheter and 
Afferloader, Given Both Before and After Stent 
Implantation, Completely Inhibits Neointima 
Formation in Swine Coronary Arteries 
Ron Waksman, Balram Bhargava, Jorge F. Saucedo, Rosanna C. Fermin, 
O. "rio, Yoram Vodovotz, Vital± Verin. Washington Hospital Center, 
Washington DC, USA; University Hospital, Geneva, Switzerland 
Background: Intracoronary radiation (IR) studies showed variability in reduc- 
tion of neointima formation (NF) following stent implantation with ,8 emitters 
loaded via a non-centered catheter system. This was explained in part by 
shielding of the ,8-rays by the stent metal. The purpose of this study was 
to compare IR before versus after stent implantation in reduction NF, using 
Yttrium-90 (90Y a pure # emitter) delivered via an automatic afterloader to a 
centering catheter. 
Methods: 16 pigs (32 coronary LAD, LCX, and RCA) underwent 3.5 mm 
stent implantation. IR was administered in 8 arteries before and in 8 arter- 
ies after stenting. A 2.5-3.5 mm segmented balloon catheter automatically 
loaded with a 90Y.0014" wire was introduced into the arteries to deliver a 
dose of 20.6 Gy @ at 1.0 mm from the balloon surface at a dose rate that 
varied from 11.9-5.6 Gy/min. Four weeks after radiation and stenting the an- 
imals were sacrificed, arteries were perfusion fixed, stained and the intimal 
area (IA) was analyzed. 
Control Radiation Before Stenting Radiation After Stenting 
n=8 n=8 n=6 
Injury Score 1.95 ± 0.7 1.45 4, 0.8 1.08 4- 0.9 
IA (mm 2) 2.72 4, 1.2 0.09 ± 0.09" 0.00± 0.00" 
• P = 0.022 radiation before and after stenting versus control 
Conclusions: IR with 90Y delivered via a centering catheter both prior 
or post stent implantation is safe and effective with homogenous and nearly 
complete inhibition of NF in the coronary porcine model. 
2 :30  p.m. 
~ Dose Rate and Cumulative Dose Effects of P-32 
Radioactive Stents 
Andrew J. Carter, James S. Jenkins, Lynn R. Bailey, Russ Jones, 
William Sweet, Tim A. FischeU, Renu Virmani. Washington Hospital Center, 
Washington, DC; Oschner Clinic, New Orleans, LA; Armed Forces Institute 
of Pathology, Washington, DC; Heart Institute at Borgess, Kalamazoo, MI, 
USA 
Background:Radioactive stents have been proposed as a means to prevent 
restenosis. 
Methods: We evaluated the dose rate and cumulative dose effects of 0 
to 58 #Ci 32p radioactive stents at 3 months after implant in a porcine model 
of restenosis. Seventy-six 0 to 58 #Ci 32p radioactive stents were implanted 
in normal porcine coronary arteries at stent to artery ratio of 1.2-1.3:1 in ran- 
domized blinded multicenter experimental study. After 3 months, quantitative 
analysis of coronary angiography and vessel histology were completed. The 
dose rate to the adventitial border 0 to 14 days after implant and cumulative 
dose were calculated for each stent. 
Results: Quantitative coronary angiography revealed a lower % diameter 
stenosis in the body (13 4- 13) but not the margins (48 4- 8) of the stents 
with cumulative doses of > 150,000 cGy as compared with non-radioactive 
stents (25 4- 15, p < 0.001). On histology, a dose rate of 3 to 5 cGy/hr 0 to 
14 days after implant resulted in a 40% reduction in neointimal thickness as 
compared to non-radioactive stents (p = 0.03). A cumulative dose > 7500 
cGy was associated with edventitial fibrosis, hypertrophy of the adventitial 
microvasculature, and promoted the formation of a hypocellular matrix rich 
neointima. Histologic evidence of delayed vascular repair, persistant fibrin 
thrombus, was evident with a cumulative dose > 150,000 cGy. 
Conclusions: Low dose rate irradiation delivered by a 32p radioactive 
stent is sufficient to reduce neointimal formation after 3 months in a porcine 
model of restenosis. Clinical efficacy of a radioactive stent will depend on 
delivery of an appropriate dose rate to the target tissue to inhibit neointimal 
formation 
2 :45  p.m. 
[ -7 -~ Acute and 6-Month Follow-Up Results of 32p 
Radioactive/3-Emitting Stent Implantation in Patients 
With CAD. The Milan BX Dose-Response Study 
Remo Albiero, Joseph De Gregorio, Nobuyuky Kobayashi, Milena Adam±an, 
Nicola Corvaja, Marco Vaghetti, Issam Moussa, Bernhard Reimers, Carlo Di 
Mar±o, Antonio Colombo. Centro Cuore Columbus, Milan, Italy 
Background: In-stent restenosis is mainly due to intimal hyperplasia. In the 
animal model, 32p radioactive #-emifting stents have been shown to reduce 
neointimal hyperplasia in a substantial dose related manner. Aim of this 
dose-finding study was to evaluate the safety and efficacy at 6 month FU 
of implanting 32p radioactive stents with initial increasing activity levels in 
patients with CAD. 
0.75-1.5 #zCi 1.5-3 #Ci 3--6 ~Ci 6-12 #Ci 
Lesions n = 12 n = 15 n = 32 n = 19 
Radioactivity, ,uCi 1.14 ± 0.18 1.88 4- 0.21 4.10 ± 0.68 9.22 4- 1.1 
Rel. diam, mm 2.7 4- 38 3.0 ~- 0.61 3.0 ± 0.35 3.2 4, 0.38 
Balloon-to-artery atio 1.354-0.13 1.22±0.20 1.22±0.13 1.11 4.0.10 
MLD pre, mm 0.97 4- 0.37 0.88 4. 0.41 0.77 4- 0.38 0.79 ± 0.50 
MLD post stent, mm 2.9:5 0.41 3.2 ± 0.52 3.1 ± 0.39 3.0 -E 0.45 
MLD FU, mm 1.25 ± 0.95 1.82 ± 1.14 1.90 ± 0.88 
Late Loss, mm 1.63 4, 0.89 1.40 ± 0.97 1.19 ± 0.85 
Restenosis, %DS > 50 5/8 (62.5) 6/12 (50) 12/28 (42.8) 
MLD = minimum lumen diam; IVUS = intravascular ultrasound; CSA = cross sectional 
area 
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Methods: From Oct 1997 to May 1998, 96 32 p radioactive/~-particle-emit- 
ting stents were implanted in 78 lesions (70 patients). Two types of slotted 
tubular stents (15 mm long) were implanted: initially the Palmaz-Schatz 
(PS153) and later the BX Isostent, with 4 different initial activity levels of 
0.75-1.5, 1.5-3, 3--6 and 6-12 /~Ci. Pre-QCA, post-stenting QCA + IVUS 
were performed. 
Results: There were no procedural events. At 6-month FU in the first 3 
groups and at 3 month FU in the 6-12 /xCi group, no deaths, MI or stent 
thrombosis occurred. Angiographic and IVUS results are shown in the table. 
Conclusion: In patients with CAD, the use of 32 p radioactive stents is safe 
without death, MI or stent thrombosis at 6 month FU. Intra-lesion restenosis 
was 43-62% due to a high late lumen loss proximal and distal to the stent 
edges, while in-stent neointimal hyperplasia was reduced in a dose related 
manner. At the time of presentation the 6-month results of all the groups will 
be available. 
3:00 p.m. 
[ -~-~ B-Particle Emitting Radioactive Stent to Prevent 
Restenosis 
A.J. Wardeh; , A.L. Gijzel ~ , W.J. van der Giessen 1 , J.M.R. Ligthart; ,
V .LMA.  Coen 2, M.S. Sabatd 1 , P.C. Levendag 2, A. den Boer 1 , 
P.W. Serruys 1 . ~ Thoraxcenter, Heart Center Rotterdam; 2Department of 
Radiotherapy, Daniel den Hoed Cancer Center Rotterdam, Netherlands 
Introduction: The Isostent for Restenosis Intervention Study (IRIS) is a mul- 
ticenter trial with the purpose to evaluate safety and efficacy of the radioactive 
Palmaz-Schatz (PS) and BX Isostent in single native coronary artery disease 
(lesion length upper limit 28 ram) with 6-month quantitative angiographic 
(QCA) and intravascular ultrasound (IVUS) follow-up and 12-month clinical 
follow-up. 
Methods and Study Population: The Isostents are impregnated with 
phosphorous-31 (P-31) and made radioactive in a cyclotron by proton bom- 
bardment to create P-32, a/3-particle emitter with a half-life of 14.3 days. The 
activity of the stents is 0.75-1.5/~Ci. After balloon predilatation an Isostent 
was implanted with a stent delivery system with integral sheath. A plastic 
radiation shield is attached to the distal end of the stent delivery system 
to protect personnel and patient against radiation-exposure. On-line QCA- 
measurements were performed pre- and post-procedure and final results 
were measured using IVUS with motorized pullback. From 11-97 till 5-98 we 
treated 26 pts (5 PS, 21 BX stents) according to the IRIS protocol. The pts 
(18 men, 8 women, aged 43-74 yrs) had AP CCS 2 (n = 3), CCS 3 (n = 10) 
or CCS 4 (n = 13). Treated lesion was the RCA (n = 8), RDA (n = 12) or RCX 
(n = 6). 
Results: All stents were successfully implanted. 5 pts received additional 
(non-radioactive) stents for several reasons. All results are presented as 
mean 4- SD. Lesion length: 12.8 + 3.9 mm. Pre- --* post-procedure QCA- 
results: minimal lumen diameter (MLD) 0.85 ± 0.27 --* 2.90 ± 0.39 mm, 
diameter stenosis (DS) 71 ± 9 ~ 14 ± 5% and reference diameter (RD) 
2.95 ± 0.45 ~ 3.35 ± 0.49 ram. Final results on IVUS: MLD 3.03 ± 0.54 
mm, minimal lumen cross-sectional area 8.21 ± 2.46 mm 2, residual plaque 
burden 37.8 5: 7.7%. There were no deaths or myocardial infarctions (MI) at 
6-month follow-up. So far 16 pts returned for angiographic follow-up. There 
were 3 (19%) target segment restenosis. QCA-results at follow-up: MLD 1.80 
± 0.72 mm, DS 37 5: 22%, RD 2.85 ± 0.60 ram, Late loss index (LLI) 0.54 5: 
0.37. 
Conclusions: The use of radioactive stents is feasible and safe, with no 
deaths or MI at 6-month follow-up. Our first 16 pts show 19% restenosis with 
a LLI of 0.54 5: 0.37. At the time of presentation all 26 pts will have returned 
for 6-month follow-up. 
3:15 p.m. 
I~ -~ Intracoronary Radiation Using a/3-Particle-Emitting 
Gold Stent Increases Neointima Formation in a 
Porcine Coronary Restenosis Model 
Christian Schulz, Christina Niederer, Christian Andres, Robert A. Herrmann, 
Wemer Panzer, Clemens Herrmann, Ingo Wolf, Eckhard All. L Medizinische 
Klinik, Nukleermedizinische Klinik, Klinikum rechts der /sar, Technische 
Universit~t MEmchen and GSF Forschungszentrum, MOnchanLNeuherberg, 
Germany 
Background: Recent studies using ionizing radiation have been shown to 
reduce neointimal formation after balloon angioplasty and stent implantation 
in experimental models of restenosis. One objective of the study was to deter- 
mine the radial dose distribution of a new/~-particle mitting radioactive gold 
stent by radiochromic film measurements. In addition, the dose-response 
relationship of the radioactive gold stent was evaluated by means of the 
coronary overstretch model of the pig. 
Methods: G6ttinger minipigs underwent placement of 11 nonradioactive 
and 33 p-particle emitting stents with activitiy levels of 55.4, 35.8, 22.8, 14.9, 
and 10.4/zCi of ~gSAu. Three months after stent implantation, mean vessel 
injury, percent area stenosis, naointimal thickness, neointimal area, and cell 
densities were analyzed by quantitative histomorphometry. 
Results: The lifetime radiation doses at a depth of 1 mm were 18, 11, 
7, 5, and 3 Gy for the different activity groups. There were no significant 
differences between the control and radioactive slants with respect to vessel 
injury score. In the control group, significantly lower neointimal formation 
and less luminal narrowing was seen when compared with the p-particle 
emitting stents (p < 0.001). There was no dose response relations,ship for 
the radioactive stents with respect to percent area stenosis (p = &297), 
mean necintimal thickness (p = 0.82), and mean neointimal area (p = 0.65). 
Increasing activities did not affect cellular density in the neointima (0.179), 
media (p = 0.07), or adventitia (p = 0.159). 
Conclusion: Neointimal formation in pigs is markedly increased by 
/~-perticle emitting stents using ~98Au as the radioisotope. This study gives 
evidence that p-particle irradiation of the activities studied via endovascu- 
lar stents induces rather than inhibits neointimal proliferation in the animal 
model. 
ORAL 
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Modal Convention Center, Room 265 
1:30 p.m. 
~-]  Four Year Experience With Carotid Stenting 
Sriram lyer 1 , Gary Roubin 1 , Jiri Vitek ~ , Roger Bonomo ~ , Matthew Oetgen 1 , 
Emily Lawrence ~ , Anirudh Khanna 1 , Issam Moussa ~ , Deborah Zucker 1 , 
Jeffrey Moses ~ , Virginia Yates 2, Larry Dean 2 . ILanox Hill Hospital, New 
York, NY; 2University of Alabama at Birmingham, Birmingham, AL, USA 
Background and Aim: To determine whether changes in patient selection 
and technique made at various points during our four year experience with 
this procedure influenced the outcome of carotid stenting 
Methods: Between 9/94 and 9/98 elective carotid stenting was performed 
in 404 symptomatic and asymptomatic patients (445 vessels). Patients with 
severely tortuous atherosclerotic and calcified origins of the great vessels, 
total occlusions and baseline large neurological defects became ineligible. 
Technical changes included strict adherence to periprocedural antiplatelet 
protocols, lowering target ACT (200 sec) routine predilatation with small 
coronary balloons, use of the 10 mm x 20 mm Wallstent regardless of size of 
the internal carotid artery and conservative post dilatation with 0.018 compat- 
ible _<6.0 mm balloons. Bilateral high grade stenosis was treated in a staged 
fashion and same session extra carotid interventions were avoided unless 
it was needed for vascular access. This protocol has remained constant for 
the last 121 patients. 
Results: Annualized in hospital and 30 day outcomes are shown 
9/94-9/95 9/95-9/96 9/96-9/97 9/97-9/98 
Patients 89 100 132 83 
Vessels 97 119 137 92 
Major Stroke 1 1 1 0 
Minor Stroke 7 (7.2%) 8 (6.7%) 6 (4.4%) 2 (2.2%) 
Neure Death" O 0 3" 0 
"2 had occluded arteries; 1 carotid rupture (post 7 mm balloon dilatation) 
In our last 121 patients (123 vessels) there were 3 minor strokes (2.5%), 
no major strokes or neurological deaths. 
Conclusion: With judicious patient selection and meticulous technique 
carotid stenting can be performed with very low complication rates. 
1:45 p.m. 
I -7"~ One Year Outcome Following Carotid Stent Supported 
Angioplasty (CSSA) 
John R. Laird, Lowell F. Satler, Lee Monsein, George Dangas, 
Roxana Mehran, Emily Parsons, Alexandra J. Lansky, Ahn Bao Bui, 
Ann Greenberg, Martin B. Leon, Cardiology Research Foundation, 
Washington Hospital Center, Washington, DC, USA 
CSSA has been proposed as an alternative to carotid endarterectomy for 
stroke prevention in patients with obstructive lesions of the extracranial 
carotid artery bifurcation. However, the long-term clinical results following 
CSSA are poorly understood. 
Methods: Over a two and a half year period, we performed 140 CSSA 
procedures in 133 patients (mean age 71 ± 9 years, 71% male). Seven 
~> 
f3 
03 
~6 
tD 
0'3 
m 
22A ABSTRACTS- ACCIS'99 JACC February 1999 
patients underwent treatment of bilateral disease. Complete one year fol- 
low-up including neurologic assessment and Carotid Duplex is available for 
60 patients (65 procedures). Repeat carotid angiography was performed if 
there was evidence of restenosis on Carotid Duplex study. 
Results: Acute procedural success was achieved in 139/140 cases 
(99.3%). There were no procedure-related eaths or permanent major neu- 
rologic events. Permanent minor neurologic events occurred in 2.9%. At one 
year follow-up there were three (5%) deaths (all non-neuro related) and two 
(3.3%) late ipsilateral neurologic events (one TIA and one minor stroke). 
Restenosis occurred in four (6.2%) cases (3 due to compressive deformation 
of Palmaz stents). One patient underwent successful carotid endarterectomy 
for asymptomatic restenosis within a deformed Palmaz stent. 
Conclusions: 1) CSSA can be performed with high technical success, 
low risk of death or major stroke, and an acceptable risk of permanent minor 
stroke. 2) Restenosis and late neurologic events are infrequent following 
CSSA and may be reduced further with new evolving self-expanding stent 
technology. 
2:00 p,m. 
I~3- ]  Renal Artery Stents: Characteristics and Outcomes 
After 363 Procedures 
Robert J. Lederman, Farrell O. Mendeisohn, Adam B. Greenbaum, Harry 
R. Phillips, Richard S. Stack, James J. Crowley. Duke University Medical 
Center, Durham, NC, USA 
Background and Methods: During the period June 1993 through February 
1998, 300 pts underwent 363 renal artery angioplasty and primary stenting 
(PTRAS) procedures on 358 arteries. 
Results: Malignant hypertension (HTN) was the indication in 13.0%, 
benign renovascular HTN in 74.0%, and other in 1.0%. Renal insufficiency 
(CRI: Cr > 1.5 mg/dL) was present in 37.0%. Mean age was 63.4 i 22.2 
years. There was de novo RAS in 343 (94.5%), post-PTA restenosis in 13 
(3.6%), in-stent restenosis in 5 (1.4%), and aortorenal graft stenosis in 2 
(0.6%). RAS was unilateral in 48.7%, bilateral in 47.7%, and involved a 
solitary functioning kidney in 3.6%. 
PTRAS was successful in 100% of pts. There were no procedural deaths 
or emergency renal surgery procedures. Follow-up clinical data are available 
for 88.3% of pts a median of 1.11 (0.52, 1.98) years after PTRAS. In 259 pts 
treated for HTN, long-term BP improved in 71.1% of pts. Mean systolic BP 
fell from 164 4- 29 to 142 :E 19 (p < 0.001). The number of antihypertensive 
medications did not change (2.48 baseline vs 2.54 follow-up). In pts with 
HTN and no baseline CRI, late creatinine rose from 1.08 4- 0.23 to 1.19 4- 
0.42, p < 0.001. In 92.2% of these patients however there was long-term 
stabilization of renal function. 
In pts with CRI, late mean creatinine fell (>0.4 mg/dL) in 15.2%, remained 
unchanged in 58.7%, and increased in 26.1% Mean systolic BP improved 
(163 4- 29 baseline vs 143 4- 20 follow-up, p < 0.001). 
Survival was determined for 294 pts (99.0%). Follow-up mortality was 
10.2% a median of 1.t (0.52, 2.0) years after PTRAS. Mortality was higher 
in pts with CRI (19.1% vs 4.3%, p < 0.001). 
Conclusion: PTRAS is safe and effective. It improves BP and stabi- 
lizes progressive renal insufficiency in most but not all pts. Further study is 
warranted to identify pre-procedural determinants of efficacy. 
2:15 p.m. 
[7~ Blunt Controlled Micro-Dissection for Percutaneous 
Revascularization of Chronic Total Occlusions in 
Peripheral Arteries 
M. Selmon, 11 Hinohara, J. Vetter, P. Mossop, M. Dake, J. Simpson. SL 
Vincent's Hospital, Melbourne, Victoria, Australia; Stanford University 
Hospital, Stanford, CA, USA 
Introduction: Chronic total occlusion (CTO) of peripheral arteries remains a 
significant cause of morbidity which frequently results in the need for surgical 
revascularization. Percutaneous revascularization techniques often fail due 
to inability to cross the occlusion with a guide wire. The purpose of this study 
is to report the initial experience with a new catheter designed for crossing 
peripheral CTO's using a micro-dissection technique. 
Methods: Thirteen CTO's of five lilac arteries, seven SFA's and one 
infrapopliteal artery in nine patients were attempted with a new controlled 
micro-dissection (CMD) catheter. CTO length ranged from 4 cm to 45 cm 
(average 11.2 cm). Seven of thirteen lesions had moderate to severe cal- 
cification. All patients had severe claudication, rest pain and/or threatened 
limb loss. All cases were refractory to crossing with conventional guide wire 
technique. 
Results: 13/13 CTO's were successfully crossed using the CMD catheter. 
Three of thirteen attempts resulted in subintimal wire position beyond the 
CTO which required assisted redirection of the guide wire to reenter the 
true lumen distally. ~me to cross with the CMD catheter ranged from 4 
minutes to 40 minutes (average 12.5 minutes). After guide wire crossing, 
all lesions underwent either balloon angioptasty or stenting. No perforations, 
complications or other acute adverse events occurred. 
Conclusion: 1) Initial experience with a new blunt controlled micro-dis- 
section catheter for crossing chronic total occlusions appears to be safe and 
effective in peripheral arteries. 2) Time to cross was short (average 12.5 
minutes). 3) Blunt CMD may offer an alternative to conventional guide wire 
technique for crossing chronic total occlusions. 
2 :30 p.m. 
~-- ]  Wallgraft Versus Wallstent Endoprosthesis for 
Treatment of Complex Stenotic Arterial Lesions: 
Three Months Follow-Up of a Multicenter, 
Randomized Study 
Zvonimir Krajcer, Munir Zaqqa, Edward Diethnch, Gary Ansel, John Lipman, 
Timothy Murphy. Texas Heart Institute, Houston; Arizona Heart Institute, 
Phoenix; Riverside Hospital, Columbus; Piedmont Hospital, Atlanta; Rhode 
Island Hospital, Providence, USA 
Purpose: to assess the safety, efficacy, and clinical patency rate of the 
polyester-covered Wallgraft endoprosthesis, compared to the bare metal 
Wallstent endoprosthesis, in treating complex (>3-cm-long, calcified, eccen- 
tric, or totally occluded) lilac lesions. 
Methods: From February 1997 through June 1998, 136 patients (pts) 
(83 men, 53 women; average age, 63.7 4- 10.7 years) with 161 lilac lesions 
were randomized to either receive a Wallgraft (n = 83) or Wallstent (n = 78). 
Both groups had similar demographics and lesions characteristics. All pts 
had intermittent claudication prior to intervention. 
Results: There was no significant difference between the two treatments 
at 3 months follow-up (Table). The prevalence of in-stent stenosis was 7% 
with the Wallgraft and 8% with the Wallstent. 
Outcome variables rate Wallgraft Wallstent 
Immediate success 98% 9% 
Secondary success (freedom from surgery) 96% 99% 
Major complications (Death, CVA, MI, embolism, 22% 21% 
transfusion, intrastent stenosis or occlusion) 
Freedom from claudication at 3 months 48% 47% 
Ankle-Brachial Index: base line/3 months* 0.53/0.76 0.61/0.89 
Percent increase in Ankle-Brachial Index 43% 46% 
• Significant difference between baseline and 3 months 
Conclusion: Wallgraft and Wallstent have excellent immediate success 
rate with equivalent safety and efficacy. Longer follow-up in a larger group of 
pts is needed to determine if Wallgraft reduces the incidence of restensosis. 
2:45 p.m. 
I -~~ Abdominal Aortic Aneurysm Repair by Percutaneous 
Implantation of Uncovered Wire Mesh Stents and Coil 
Embolization of the Aneurysm 
Richard W. Smatling, All E. Denktas, Carlos J. Cafri, Alan M. Cohen, Nabil 
E Maklad, Bharat Raval, Oscar R. Rosales, Carlos E. Ruiz*. University of 
Texas Medical School and Hermann Hospital, Houston, Texas, USA 
Background: Percutaneous repair of abdominal aortic aneurysms with cov- 
ered stent grafts requires large vascular access (_>22 F). The feasibility of 
percutaneous placement of uncovered wire mesh stents with trans-stent 
coil embolization of the aneurysm cavity, secondary fibrosis and long-term 
healing has been demonstrated previously in animals. 
Methods: To evaluate this approach in humans, four male and two fe- 
male patients, mean age 75.3 ± 7.8 (61 to 82) years, with infrarenal aortic 
aneurysms; mean diameter 4.30 ± 0.74 cm, were treated. Maximum sheath 
size was 12 Ft. Waltstents (1.7 ± 1.4 per patient, size: 24 x 7.5 and 4.5 
mm (aorta) and 22 × 10 mm (lilac)) with a mean total length of 16.2 -- 7.6 
cm were used. Four patients required reconstruction of the aortic bifurcation 
by bilateral kissing stents. Fluoroscopy time was 49 ± 29 minutes and total 
procedure time was 160 ± 44 minutes. Ultrasound follow-up was used. 
Results: Pre-existing intra-luminal thrombus precluded coil embolization 
of the aneurysm cavity in 2 patients. No 30-day mortality was observed. 
Doppler scanning at 2 months demonstrated low levels of flow outside the 
stent in the coiled patients. Additional coiling in 1 patient obliterated the 
residual cavity, which has remained closed and stable for 18 months. 
Conclusion: This initial human experience of endoluminal treatment of 
abdominal aortic aneurysms using uncovered wire mesh stents and trans- 
stent coil embotization appears feasible as previously shown in animals. The 
small access site(s) has permitted percutaneous vascular closure, and may 
result in fewer vascular complications, early discharge and the possibility of 
outpatient performance of the procedure. 
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I--7-8--7-1 Percutaneous Endovascular Treatment of Aortic 
Bifurcation Occlusive Diseases 
Michel Henry, Max Amor, Isabelle Henry, Kiril Tzvetanov, Zuka~ Chati. 
Po/yclinique, Essey-les-Nancy, France 
Purpose: Patients with bilateral pelvic obstructions at the aortic bifurcation 
are usually treated by surgical approach. The aim of the study is to analyse 
feasibility, safety, primary and long-term results of simultaneous bilateral 
angioplasty with or without stent implantation. A new classification of the 
lesions is proposed. 
Methods: 162 arteries in 72 symptomatic patients (M: 62, F: 10, mean 
age: 57.2 ± 10.3 years, (29-78)) with bilateral proximal obstruction of the 
common lilac artery only (54 pts-108 arteries) or associated with abdomi- 
nal aortic lesions (18 pts-54 lesions) were treated by percutaneous kissing 
balloon angioplasty alone (25 lesions) or completed with stent (137 arter- 
ies). 146 stents were implanted (Palmaz: 105, others: 41). 128 arteries were 
stenosed (aorta: 14, lilac: 114), 34 occluded (4 abdominal aorta). Fibrinolysis 
was used in 8 cases by brachial approach for abdominal aorta (n = 4) or by 
contralateral approach (n = 4) for iliec arteries. 
Results: Complete technical success obtained in 70 pts, partial success 
in 2 (who presented total occlusion of abdominal aorta and both lilac arteries 
just one lilac was recanalized and stented. A femoro-femoral bypass graft 
was performed surgically). ABI increased from 0.64 ± 0.11 to 0.94 ± 0.12. 
No immediate complication. Mean-follow-up: 30.6 ± 26.8 months (1-100). 
12 pts (21 arteries) restenosed (50% after 30 months) treated by new PTA 
(7 arteries), new PTA + stent (7 arteries), or surgery (7 arteries). At 6 years 
follow-up primary patency (PI) was 74%, secondary patency (PII) 90% for 
all lesions, for common iliec lesions: PI: 76%, PIh 96%, for lilac lesions 
associated with aortic lesions: PI: 93%, PII: 98%, with no difference between 
stented or not stented arteries, occlusions or stenoses. 
Conclusion: Percutaneous endovascular treatment of the aortic bifurca. 
tion is a safe/effective method with good primary and long-term results, an 
alternative to surgical interventions and the first treatment o be proposed. 
3 :15  p.m. 
[-~8--~ First  Cl inical  Exper ience  With New Nit inol  
Self-Expandable Stsnts  in Peripheral Arteries 
Michel Henry, Max Amor, Isabelle Henry, Kidl Tzvetanov, Zuka'i Chati. 
Polyclinique, Essey-les-Nancy, France 
Purpose: To evaluate 3 new nitinol self-expandable stents {Instant, Ex- 
pander, Sinus stent) in peripheral arterial diseases, to define indications in 
comparison with balloon expandable stents, in a retrospective study, 
Methods: 516 lesions in 431 pts (M: 334, F: 97, mean age: 66.2 ± 
11.3 years, (19-95)) treated with nitinol stents. Location of the lesions: lilac: 
129 (stenoses: 108, occlusions: 21), superficial femoral artery (SFA): 291 
(sten.: 203, occl.: 88), popliteal artery: 96 (sten.: 60, occlusions: 36). 83% 
of the patients were in stage lib of Fontaine's classification, 9% in stage 
III, 8% in stage IV. Mean % stenosis: 84.7 + 8.9 (70-100). Mean lesion 
length: iliac: 54 ± 27.4 ram, SFA: 62.9 ± 42.1 mm, popliteal: 45.6 ± 20.6 
ram. All stents were implanted percutaneouaiy. Indications: post-PTA residual 
stanosis: 76%, dissection: 15%, restenosis: 9%. 
Results: Immediate technical success: 514/516. 2 misplacements of 
stents required surgery. No acute thrombosis. Mean % residual stenosis 
after stenting: 3.2 ± 2.6. ABI increased from 0.64 ± 0.12 to 0.91 ± 0.14. 
Clinical success: 98%. Echodoppter, angiographic ontrols performed at 6 
months in all eligible patients, echodoppler every 6 months. Mean follow-up: 
13.5 ± 13.2 months (1-75). 337 pts had more than 6 months follow-up, We 
report 44 restenoses (13%): iliac: 9,3%, SFA: 14.5%, popliteal: 16%. Lesions 
< 8 cm: 12%, lesions > 8 cm: 18%. For stenoses: 11%, occlusions: 19%. No 
statistically significant difference. 23 restenoses treated by new angioplasty, 
18 required surgery, 3 treated medically. Primary (PI) and secondary (PII) 
patency: (4-year follow-up): lilac: PI: 89%, PII: 97%, SFA: PI: 82%, PII: 
91%, pop.: PI: 84%, PII: 95%. No statistically difference according to site, 
occlusions and stenoses, 
Conclusion: These new nitinol stents seem safe and efficient to treat 
not only lilac but also femoropopliteal lesions. Their flexibility and uncom- 
pressibility allow placement in the low part of the SFA and at joint locations 
(popliteal artery). Their results in long lesions are encouraging. 
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~ Percutaneous Coronary Angioplasty Transluminal 
of Left Main S tenos is  - Resu l ts  o f  the German 
PTCA-Reg is t ry  
Sinisa Miketic I , Joerg Cadsson 1 , Tassilo Bonzai 2, Karl-Ludwig Neuhaus 3 , 
Ulrich Tebbe 1 . For the "Arbeitsgemeinschaft Leitender Kardiologischer 
Krankenhaus~Fzte (ALKK)'-study group," I Klinikum Lippe-Detmold; 
2 St~dtisches K/inikuni Fu/da; 3 Stadtische Kliniken Kassel, Germany 
Background: In cases with protected left main by previous bypass-surgery 
or as an emergency intervention in cases with myocardial infarction and 
cardiogenic shock percutaneous transluminal coronary angioplesty (PTCA) 
is performed as an alternative treatment o emergency CABG, 
Methods: 1992 the ALKK-study group established an angioplasty registry 
representing one third of all PTCA procedures in Germany. All procedures 
classified as left main angioplasties were required for a review by a central 
core laboratory conceming left main protection and procedural and clinical 
outcome, The left main protection was graded in: not protected, partially 
protected by collaterals to either left coronary artery, and protected by open 
bypass grafts to either left coronary artery. 
Results: Between October 1992 and September 1997 580 coronary in- 
terventions were classified as left main angioplasties. From 320/580 (55%) 
reviewed angioplasties 58 (18%) were PTCA of proximal left anterior de- 
scending or proximal eft circumflex arteries. The remaining 262 procedures 
were either angioplasties of protected left main stenosis, or emergency inter- 
ventions in patients presenting with acute myocardial infarction or cardiogenic 
shock. The procedural mortality in patients without left main protection was 
9.1% (4/44), in patients with collaterals 4,8% (1/21) and 0.5% (1/197) with 
open bypass grafts to either left coronary artery. As compared with the pro- 
cedural mortality of the overall angioplasty cohort there was a signifficant 
difference in cases without (p < 0.001) or patriaily protected (p = 0.002) left 
main stenoais, whereas in patients with protected left main stenosis there 
was no difference in mortality (p = 0.82). 
Conclusion: In patients with open bypass grafts to either left coronary 
artery PTCA of left main stenosis can be performed with the same procedu- 
ral risk as compared with the risk of the overall angioplasty cohort. In cases 
without protection left main angioplasty carried a significantly higher mortality 
as compared with the mortality of the overall angioplasty cohort and should 
not be performed even in cases of emergency interventions. The risk stratifi- 
cation of the procedure can easily be evaluated by the proposed grading of 
left main protection. 
~ D o  Peri-Procedure Creatine Kinase Elevations in 
Trials of Percutsneous Intervention Reflect Those 
Observed in Clinical Practice? 
Shamir R. Mehta, Madbu K. Natarajan, David M. Gcodhart, 
Sandra Millencoff, Catherine Kreatsoulas, Salim Yusuf. McMaster 
Universi~ Hamilton, Canada 
There has been controversy over the apparently high pod-procedure my- 
ocardial infarction (MI) rate (defined as CKMB > 3X upper limit of normal) 
in recent clinical trials of pemutaneous intervention (PI). These event rates 
were as high as 7.5% and 8% in EPILOG and EPISTENT (whose enrolment 
criteria were intended to reflect clinical practise), respectively. The main rea- 
son cited for these high MI rates was the systematic measurement of CKMB 
following each procedure in these trials. In order to evaluate whether these 
event rates are reproduced in actual clinical practise, we systematically and 
prospectively measured creatine kinase (CK) and troponin in 666 consecu- 
tive patients undergoing PTCA from July, 1997-July, 1998 at our institution. 
CK and troponin I were measured at 1, 8 and 16 hours post procedure in 
all patients. Twenty-eight patients underwent primary PTCA for acute MI and 
were excluded. The AHA/ACC lesion classification for type A, B1, B2 and C 
lesions were 10%, 31%, 28% and 31%, respectively. Indications for PI were 
60% unstable angina, 38% stable angina and 2% other. Of all cases, 59% 
received a stent, 3% abciximab, 14% both and 24% neither. 
CK>2 CK3-5X CK:-5X Tropl>0.5 Death Qwave UrgRvsc 
All cases 28 10 5 40 6 6 12 
N = 638 4.4% 1.6% 0.8% 6.3% 0.94% 0.94% 1.9% 
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Conclusion: Despite similar risk patients, comparable lesion character- 
istics and the use of a less sensitive measure of MI (total CK, which yields 
higher MI rates than CKMB), the event rates for CK elevations greater than 
3X normal (2.4%), are considerably lower than those reported in clinical trials 
such as EPILOG and EPiSTENT. 
Implication: In routine clinical practice, when CK elevations are measured 
prospectively and systematically, peri-procedure MI rates are substantially 
lower than those reported in clinical tdals of percutaneous intervention. 
~ T h e  European Registry Coronary of Interventions: 
Structure, Results, and Implications 
Willibald Maier, Stefan Windecker, Bernhard Meier. Cardiology, University 
Hospital Bern, Switzerland 
Background: The working group Coronary Circulation of the European Soci- 
ety of Cardiology conducts an annual PTCA registry. This is presently the only 
international registry covenng 1996 a population of 546 million inhabitants in 
28 countries with profoundly different economic conditions. Its structure and 
major results will be presented. 
Methods: A questionnaire containing 46 items for 1996 was sent out to 
designated delegates of the national societies of cardiology to be distributed 
to all catheterization sites. The completed forms were recollected, pooled, 
and the summary data entered into a central database for analysis. 
Results: A total of 327237 PTCAs were reported in 1996 yielding a 
mean of 599 per 106 inhabitants (mio). There was a wide variation between 
1548/mio in Germany (D) and 17/mio in Romania; the numbers for major 
countries in terms of absolute population size being: France (F) 1092/mio, 
Spain (E) 380/mio, Great Britain (GB) 359/mio, Italy (I) 342/mio, and Poland 
(PL) 129/mio. The average stent rate was 44%, the highest in F (57%) and 
the lowest in Bulgaria (6%). Expressed per gross domestic product (GDP) 
per capita and related to a million of population, D invested 52 PTCAs, PL 42, 
F 41, E 27, GB 19, 118. The relatively highest investment was determined for 
the Czeck Republik with 76 and Turkey with 56, whereas the country with the 
highest GDP, Switzerland (CH), invested only 26 percutaneous interventions. 
Conclusions: Despite of inherent methodological limitations, national and 
supranational PTCA registries provide indispensable information for assess- 
ment and steering of health care expenditure. Assuming correct indications, 
adjusted to GDP an economically unjustifiable overuse of PTCA in afflu- 
ent countries was not present when compared with developing European 
countries. 
• Changes in Clinical Practice in California 
Following Publication of the ACCIAHA Hospital 
PTCA Volume Guidelines 
Velisar L. Rill, Brian Strizik, David L. Brown. Albert Einstein College of 
Medicine, Bronx NY, USA 
Background: The annual number of percutaneous transluminal coronary 
angioplasty (PTCA) procedures performed by a hospital has an important ef- 
fect on procedural outcome. In recognition of that fact, in 1993 the ACC/AHA 
issued guidelines suggesting that hospitals perform at least 200 PTCA an- 
nually. 
Methods: We examined data derived from the 1989 and 1995 California 
Office of Statewide Health Planning and Development data bases to de- 
termine whether since publication of these guidelines there has been: 1) a 
reduction in the number of hospitals performing PTCA or 2) a re-distdbu- 
lion of PTCA cases from lower volume (<200 PTCNyear) to higher volume 
(>400 PTCA/year) centers. 
Results: In 1989 24,883 PTCAs were performed in 110 centers in Califor- 
nia. In 1995, 37,118 PTCA were performed in 146 centers. The mean number 
of PTCA performed per hospital increased from 225 in 1989 to 254 in 1995. 
A total of 64 (58%) hospitals performed <200 PTCA in 1989 compared to 
67 (46%) (p < 0.05) in 1995. In 1989, 6945 (28%) PTCA were performed 
in low volume hospitals compared to 4642 (12.5%) (p < 0.0001) in 1995. In 
1989, 9611 (39%) PTCAs were performed in high volume facilities compared 
to 21,298 (57.5%) in 1995 (p < 0.0001). 
Conclusion: Following publication of the 1993 ACC/AHA guidelines, 
the number of centers performing PTCA in California expanded by 25%. 
However, there was an increase in the average number of procedures per 
institution and a shift in procedures from lower to higher volume centers. 
~ Risk Factors Predicting In-Hospital Mortality 
Following Balloon Angioplasty Versus Elective 
Stenting 
William C. Daniel, Steven B. Laster, Philip G. Jones, James L Vacek, 
Warren L. Johnson, Jr., Lee V. Giorgi, Kenneth C. Huber, Barry 
D. Rutherford. Mid America Heart Institute, Kansas City Missouri, USA 
Background: We have previously reported the risk factors (RFs) predicting 
in-hospital mortality following balloon angioplasty (BA) and now we report 
the comparison to elective stenting (ES). 
Methods: In a consecutive series of 4,499 patients we compared the 
factors that predict in-hospital mortality following coronary intervention in two 
separate groups: BA (Group 1) 1993-1994, n = 2,853, and ES (Group 2) 
1995-1998, n = 1,916. The groups were similar with regard to sex, age, 
LVEF, creatinine (Cr), diabetes, hypertension, prior CABG, prior intervention, 
and cardiogenic shock. The patients in Group 2 had a higher incidence of 
unstable angina (USA), n = 1,068 (57%) versus n = 1,361 (53%), p = 0.02 
and three vessel disease (3VD) n = 859 (45%) versus n = 835 (32%), p < 
0.001. There was no difference in in-hospital mortality for Group 1, n = 30 
(1.2%) versus Group 2, n = 27 (1.4%), p = NS. Multivariate analysis revealed 
no differences in major RFs for in-hospital death between the two groups. 
The major RFs for in-hospital mortality (% mortality BA, % mortality ES) 
were LVEF < 0.40, (3.1, 3.t), Cr > 1.5, (4.8, 5.9) 3VD (2.3, 2.4), age > 70, 
(2.1,2.9) and USA (1.8, 1.6). The combination of RFs significantly increases 
mortality with 0, 1 or 2 RFs (mortality 0.53%) versus 3 or 4 RFs (4.5%) versus 
5 RFs (18%). 
Conclusion: 1) Risk factors for in-hospital mortality following balloon 
angioplasty versus elective stenting are similar. 2) The major risk factors for 
death relate to complex patients, not complex lesions, those with LVEF < 
0.40, creatinine > 1.5, 3VD, age > 70 or USA. 3) The combination of risk 
factors is associated with increased in-hospital mortality. Consideration of 
alternative management strategies is critical in this patient population. 
~ Predictors of Death Death/MI/CABG In-Hospital or 
Following Catheter-Based Intervention in the 
NHLBI Dynamic Registry 
Peter C. Block, Wanlin Yeh, Sheryl F. Kelsey, David O. Williams. 
Providence/St. Vincent Medical Center, Portland, OR; University of 
Pittsburgh, Pittsburgh, PA, USA 
To determine the predictors of death and of Death (D)/MI/CABG following 
catheter-based intervention, data from 2329 patients in the NHLBI Dynamic 
Registry were evaluated. Significant (with p < 0.001) predictors and COrre- 
sponding odds ratios (OR) for the two outcomes are: 
Death D/MI/CABG 
Risk Factor n = 33 events (1,4%) n = 119 events (5.1%) 
>65 yrs 3.4 1,9 
Renal disease 7.4 3.1 
Diabetes 5.3 
Hx CHF 5.0 - 
Current CHF 13.1 4.7 
Risk for CABG 
High 8.9 3.5 
Inoperable 44.4 7.3 
High risk for PTCA 31.5 7.2 
LVEF <50% 7.5 - 
Left or balanced dominance - 1.8 
Acute MI setting 7.8 2.0 
Emergent procedure 14.6 3.9 
Low mortality precluded multivariate analysis but the combined endpoint 
of D/MI/CABG could be examined. After adjustments, significant (p < 0.05) 
independent predictors of D/MI/CABG were: current CHF (OR = 2.4), renal 
disease (OR = 2.2), high risk for PTCA (OR = 3.9), left or balanced dominance 
(OR = 1.9), and emergent procedure (OR = 2.5). 
Conclusions: Despite analysis of objective factors, "high risk for PTCA" 
by operator is the most powerful independent predictor. Objective indices 
alone may not adequately predict risk for major complications. Though high 
risk for PTCA is a subjective variable, it should be considered for inclusion in 
interventional databases. 
• Significant Differences Baseline in 
Characteristics of African-American Patients 
Undergoing Coronary Interventions 
David Scott Marks, George A. Mensah, Elizabeth D. Kennard, David 
R. Holmes, Jr.. Medical College of Georgia, Augusta, GA; Mayo Clinic, 
Rochester, MN, USA 
Background: African-American (AA) patients are largely underrepresented 
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in clinical tdals. Little information is available on the impact of race after 
coronary interventions. Specific data regarding AA patient demographic and 
lesion characteristios are poody described. To elucidate the charactedstics 
of AA patients undergoing coronary interventions, we analyzed the New 
Approaches in Coronary Interventions (NACI) Registry. 
Methods: Patients (hA = 200, non-African-American (NA) = 4279) un- 
dergoing coronary interventions in NACI registry were compared. 
Results: AA patients were significantly younger** (age = 59 ± 11 vs. 
63 ± 11 years), obese** (29.6 ± 6 vs. 27.5 ± 4.8 kg/m2), female** (50 
vs. 34%), diabetic** (34 vs 21%), and hypertensive** (71 vs. 52%). AA 
were significantly more likely to have single vessel disease* (48 vs. 40%) 
and less likely to have undergone coronary artery bypass grafting* (26 vs. 
34%). AA were significantly more likely to have a discrete lesion** (85% 
vs 62%) with less thrombus* (7 vs 12%), tortuosity* (17 vs. 25%), and 
an ulcerated appearance* (5 vs. 10%). Despite these significant baseline 
differences, no significant difference was seen in the procedural success (80 
vs. 82%) and major adverse events (Death, Q-wave myocardial infarction, 
any revascularization) at one year (39 vs. 34%). (*p < 0.05, **p < 0.001) 
Conclusions: Although there are differences in traditional risk factors 
between hA and NA, they do not impact on procedural success or one year 
outcome. Differences in baseline charactedstics demonstrate the need for 
further investigation and may help focus targeted coronary disease preven- 
tion in this population. 
• Primary Coronary Angioplasty in Acute 
Myocardial Infarction Using Transradial Approach 
Nicolas Delarche, Raphael Lasserre, G~rard Estrade, Michel Le Blay. 
Service de Cardiotogie, Centre Hospitalier, Pau, France 
Background: The aim of this prospective study was to evaluate feasibility 
and safety of dght transradial approach for primary coronary angioplasty 
(PTCA) in acute myocardial infarction (AMI). 
Methods: 173 patients (pts) with AMI (less than 6 hours after the onset of 
symptoms) and non ischaemic Allen test underwent emergency PTCA using 
6 French right transradial approach. 
R6sults: Selective coronary catheterization was unsuccessfull in 5 pts 
(2,9%) for anatomic abnormalities, with no failed radial puncture. In 10 pts 
(5.8%), PTCA was not attempted (too distal lesions in 8 pts, severe left main 
stenosis which needed emergency CABG in 2 pts). In the 158 remaining 
pts (127 males, 31 females, mean age 63 ± 13 years) procedure was 
successfully performed (TIMI 3, and residual stenosis < 30%) in 156 pts 
(98.3%) 210 mn± 165 after the onset of symptoms. AMI related vessel was 
left anterior descending artery in 63 pts, circumflex branch in 16 pts, right 
coronary artery in 64 pts, diagonal branch in 3 pts, marginal branch in 9 pts 
and saphenous graft in 1 pt. TIMI grad was 0 or I in 115 pts (73%), and II or 
III in 41 pts (27%). Stenting was necessary in 114 pts (72.1%) for dissection 
(31 pts) or residual stenosis and recoil (83 pts). Eady rethrombosis needed 
a second PTCA (with Rheopro) using the same approach in 4 pts. Inhospital 
mortality was 2.5% (3 pts in Killip 4, 1 pt with intestinal bleeding). There 
were 3 asymptomatic radial occlusions. Earlier getting up and out of hospital 
discharge could be allowed in 117 pts (75%). 
Conclusion: 6 French PTCA using right transradial approach in AMI 
can be safely performed with high rate success and without any major local 
complication. 
• Coronarylnterventions: Is Woman Risk Being a a 
Factor? 
Milena Adamian, Joseph De Gregorio, Nobuyuki Kobayashi, 
Nicola Corvaja, Lucia Di Francesco, Remo Albiero, Issam Moussa, 
Marco Vaghetti, Cado Di Mado, Jeffrey Moses, Antonio Colombo. Centro 
Cuore Columbus, Milan, italy; Lenox Hill Hospital, New York, USA 
Increased awareness to women's health issues has prompted considerable 
interest in assesing the outcome of coronary artery disease in the female 
population. Our purpose was to evaluate whether outcome in coronary inter- 
ventions can be a gender related phenomenon. 
Methods: We analyzed the results of percutaneous revascularization in 
247 consecutive women (374 lesions) and 2113 men (3468 lesions) treated 
between 1995-98. All patients were treated with antiplatelet herapy. 6 month 
angiographic follow-up was obtained in 75% of patients. 
Results are shown in the table. 
Sub-analysis shows that differences in clinical outcome became insignifi- 
cant (p = NS) when vessel size in the two groups is matched. 
Conclusion: Female patients have a significally lower procedural success 
and higher incidence of acute, intermediate and long-term MACE, most 
probably, because of the differences in clinical and lesion charactedsUc-s with 
smaller vessel size playing a major role. 
Female Male Female Male 
Mean age* 64±10 59+10 Ref diem, mm* 2.8±0.5 2.9±0.6 
EF,% 62 :E 11 61±11 Pr MLD, mm ° 0.7+0.5 0.8±06 
Unst ang, %* 38 28 Fin MLD, mm* 2.7 ± 0.8 2.8 + 0.8 
Asymp. pt, %" 11.7 17.9 B/A ratio 1.2 ± 0.2 1.2 ± 0.2 
Hyperten, %" 61.5 49.3 Pro success%* 94.8 98.3 
Elev. choles, % 64.3 58.6 Fin CSA, mm* 7.7 ± 2.6 9.5 + 3.3 
Diabetes, %" 14.9 8.3 St thromb, %* 2.0 0.8 
Smoker,* 34.4 60.5 TLR, % 27.2 27.7 
MVD, %* 53.3 63.7 Restenosis, % 37.2 34.6 
C, ompl. les, % 66.2 63.3 MACE, % 
Ost and prox 66.7 48.6 Hospital* 3.6 0.9 
~ocation, %* 1 month* 4.8 1.3 
Les leng, mm 12.7 :E 9 13 • 8 6 month* 9.6 4.7 
"p < 0.05; MLD minimal lumen diameter; MIP maximal inflation pressure; MVD multives- 
set disease; TLR target lesion revascularization; 6 month MACE = post procedure MI, 
CABG, death. 
[•  Restenosis, Late Vessel Occlusion and Left 
Ventricular Function 6 Months After Balloon 
Angioplasty in Diabetic Patients 
Edc Van Belle, Kaveh Abolmaali, Chdstophe Bauters, Eugene P. Mc 
Fadden, Jean-Marc Lablanche, Michel E. Bertrand. Department of 
Cardiology, University Hospital, Lille, France 
Background: It was recently reported that diabetic patients (pts) have a 
worse clinical outcome than non diabetics after balloon angioplasty while 
prognosis was better in diabetics treated by bypass surgery rather than 
balloon angioptasty (BARI). 
Methods: In view of the lack of information on mid-term results in these pts 
we determined the 6-month coronary angiographic outcome, using quantita- 
tive coronary angiography, and the effects on left ventdcular function in 485 
consecutive diabetics (627 lesions) treated by traditional balloon angioplasty 
on one vessel or more (1993-1995). 
Results: The procedure was successful in 455 (94%) pts and anglo- 
graphic follow-up was available in 377 pts (83%). At follow-up, 13% of the 
lesions were occluded (TIMI = 0 or 1) while the rate of non-occlusive reste- 
nosis (stenosis > 50% and TiMI >_ 2) was 49%. Four independent predictors 
of late vessel occlusion were identified: treatment with insulin, angioplasty 
at a saphenous vein graft (SVG), a TIMI flow < 3 and the degree of resid- 
ual stenosis after angioplasty. Five independent predictors of non-occlusive 
restenosis were identified: the presence of organ damage, angioplasty at a 
SVG, a bifurcation lesion, a TIMI flow < 3 and the degree of residual steno- 
sis. Vessel occlusion at successfully dilated site(s) was observed in 15% of 
pts. This rate ranged from 11% for a 1-site procedure to 37% for a 3-site 
procedure and was associated with a deterioration in ejection fraction (EF, 
see Table). 
Pts without Pts with Pts with P 
restenosis non -occlusive occlusive 
restenosis restenosis 
Baseline EF, % 60.9 ± 15.9 58.6 • 14.6 57.0 ± 14.0 NS 
6-month EF, % 59.6 ± 15.2 59.1 ± 15.2 50.8 ± 12.4 0.0005 
Changes in EF, % -1.3 i 9.5 +0.5 ± 9.9 -6.2 ± 9.9 0.0001 
Conclusion: These results show that vessel occlusion is a frequent mode 
of restenosis in diabetic pts treated by traditional balloon angioplasty. The 
deleterious effect on ventricular function may partly explain the poor long 
term outcome in diabetics after balloon angioplasty, 
~ BifurcaUon the Modern Era - Lesions: Outcome in 
The NHLBI Dynamic Registry 
David R. Holmes, Jr., Charanjit S. Rihal, Howard A. Cohen, Wanlin Yah, 
Katherine Detre. Mayo Medical Center, Rochester, Minnesota, USA 
Background: The treatment of bifurcation lesions remains complex with in- 
creased potential for inadequate initial angiographic improvement, increased 
early complications and increased restenosis rates. 
Methods: The role of newer technology in this subset was evaluated 
in the NHLBI Dynamic Registry of patients undergoing treatment from July 
1997 to February 1998. 
Results: Of the total of 2,321 patients treated dudng this time there were 
306 patients with 396 bifurcation lesions. In 226 patients (74%) only one of 
the bifurcation limbs was treated, while in 80 patients (with 170 lesions) two 
or more bifurcation limbs were treated. The arterial segment involved was 
the left antedor descending in 53.8%, circumflex in 26.5%, dght coronary 
artery in 16.4%, and left main coronary artery or vein graft in the remainder. 
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The mean reference vessel was 2.92 ram. The devices and procedures used 
were: 
PTCA alone 32.3% 
PTCA and RA" 7.6% 
PTCA and stent 48.5% 
PTCA and RA and stent 5.3% 
Other 6.3% 
• Rotational Atherectomy 
Complication rates were increased in bifurcation lesion groups compared 
with the nonbifurcation group. Myocardial infarction 3.3 versus 2.3%, CABG 
2.6% versus 1.1%, side branch occlusion 7.9% versus 2.4% (p < 0.001), 
Death, MI, any CABG 7.2% versus 4.7%. Complete angiographic success 
defined as at least 20% improvement in angiographic stenosis and <50% 
residual stenosis was achieved in only 81.0% of bifumation patients versus 
90.5% of nonbifurcation lesion patients. 
Conclusion: Despite the widespread use of newer percutaneous devices, 
treatment of bifurcation remains difficult and associated with decreased suc- 
cess rates and increased complications compared with nonbifurcation le- 
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Clinical Outcome in African-Americans 
Undergoing Coronary Intervention 
David Scott Marks, George A. Mensah, Elizabeth D. Kennard, David 
R. Holmes, Jr.. Medical College of Georgia, Augusta, GA; Mayo Clinic, 
Rochester, MN, USA 
Background: The predictive features of major cardiovascular events after 
coronary interventions for the African-Amencan (AA) population are largely 
unknown. To elucidate clinical characteristics associated with major cardiac 
adverse events, we evaluated the New Approaches in Coronary Interventions 
(NACI) Registry. 
Methods: Patients (AA = 165, non-Afdcan-American (NA) = 3536) un- 
dergoing planned coronary interventions in NACI registry were followed 
prospectively. Kaplan-Meier survival estimates and Cox regression models 
were used to predict adverse events (death, Q-wave myocardial infarction, 
coronary artery bypass grafting). 
Results: Predictors of adverse events for NA patients included diabetes 
(RR = 1.24, 1.0-1.5) and high risk status (RR = 1.58, 1.26-1.91). No gender 
differences were present in NA patients. Predictive characteristics of adverse 
events for AA patients included only gender (RR = 3.45, 1.27-9.35, p = 0.02). 
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Conclusions: There are difference in predicators in adverse events be- 
tween AA and NA. In AA, only gender predicts adverse events. Further 
investigation is required to understand the mechanisms for this gender dif- 
ference. 
t 1 036-50 I CKMB Enzyme Rise After In-Lab Adverse Events 
I During Coronary Intervention in EPISTENT 
James C. Blankenship, Nikki K. Godfrey, Craig Balog, S. Lee Demko, 
Robert M. Califf, A. Michael Lincoff, James E. Tcheng, Eric J. Topoi. 
Geisinger Medical Center, Danville PA; Cleveland Clinic, Cleveland, Ohio, 
USA 
Background: The significance of procedural adverse events (AEs) occurring 
during coronary intervention is unclear. 
Methods: EPISTENT randomized 2399 patients undergoing coronary 
intervention to abciximab (Abc)/PTCA, Abc/stent, or placebo/stent. Investi- 
gators rated in-lab AEs. 
Results: 
CKMB (X normal imit) 
Adverse Event N > 1 X >_3X >5X _> lOX 
>_50% final stenosis 67 28% 9% 3% 2% 
Coronary dissection 478 34% 15% 10% 5% 
Residual thrombus 36 53% 28% 25% 17% 
Final TIMI flow < 3 78 54% 32% 26% 21% 
Transient occlusion 43 58% 47% 33% 20% 
Urgent CABG 15 60% 53% 47% 33% 
Distal embolization 33 64% 42% 30% 18% 
Sidebranch occlusion 68 69% 38% 27% 10% 
Any AE 622 39% 18% 12% 5% 
No AE 1752 26% 8% 4% 2% 
Conclusions: Dissection and >50% residual stenosis, the "stentable" 
AEs, elevate CKMB less often than do other AEs. Among the other AEs not 
usually treated with stents, the incidence of large CKMB rise is lowest with 
26% of patients with no in-lab AE, but these elevations are less severe than 
in 0atients with in-lab AEs. 
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~ RepetiUve Balloonangioplasty for Recurrent 
In-Stent Restenosis: Results of First and Second 
PTCA in Focal and Diffuse Stenosis 
Andreas Wolf, Franz Schwarz, Manfred Hofmann, Stefan Gdhring, 
Hans Stdrger, Nicolaus Reifart. Main-Taunus Heart Institute, Bad Soden, 
and Red Cross Hospital, Frankfurt, Germany 
Background: With the increasing use of coronary stents, in-stent restenosis 
(ISR) has become a malignant iatrogenic disease with a high recurrence 
rate, irrespective of treatment modality. 
Methods: To investigate repetitive balloon angioplasty (PTCA) as a treat- 
ment strategy for recurrent ISR, 302 patients were randomly selected from a 
group of 1,267 patients with angiographically documented ISR out of 3,859 
patients who underwent coronary stent placement. 225/302 patients (74.4%) 
underwent PTCA for in-stent restenosis and were further analyzed. 
Results: PTCA for focal ISR (length < 5 mm, 28.5% of patients) had 
a higher clinical success rate (96.7% vs. 87.8%) and lower residual steno- 
sis (12.8% vs 23.6%) than diffuse lesions (>5 mm, 71.5%). Complications 
included death (0.9%), emergent CABG (0.9%), subacute stent thrombosis 
(0.4%), non-Q-wave MI (2.2%), and minor bleeding (1.8%). F/u after 151 
87.7 days revealed death in 1.9% (2/4 non-cardiac causes). Compared to 
focal lesions, diffuse stenoses had a higher TLR (39% vs 27.9%) and an- 
giographic restenosis rate (44.3% vs. 27.9%, p < 0.05). Subsequent PTCA 
for recurrent ISR in 70 patients (28 focal, 42 diffuse lesions) revealed similar 
results: angiographic restenosis 44.2% (focal lesions: 29.4%; diffuse reste- 
nesis: 53.8%, p < 0.05) and TLR 31.4% (focal restenosis 21.4%, diffuse 
restenosis 38.1%). 
Conclusions: Diffuse ISR is significantly more common than focal prolif- 
eration. PTCA as treatment for ISR is technically easy with a high success 
rate, and few procedural complications. The recurrence rate is acceptable 
in focal lesions but significantly more common in diffuse ISR. Subsequent 
PTCA for recurrent ISR yields similar Iongterm results as the initial attempt, 
leaving approximately 75% of patients successfully treated after two relatively 
low-risk interventions. 
1037-52 I PTCA Alone Versus Stent Alone for Focal Therapy 
i In-Stent Restenosis: Acute and Long-Term 
Results 
Roxana Mehran, George Dangas, Gary S. Mintz, Mun K. Hong, Alexandra 
J. Lansky, Michael Peterson, George Hanzel, Alain Laroche, Steve Slack, 
John R. Laird, Jr., Augusto D. Pichard, Kenneth M. Kent, Lowell F. Seller, 
Gregg W. Stone, Martin B. Leon. Washington Hospital Center, Washington, 
OC, USA 
In-stent restenosis (ISR) is due to neointimal hyperplasia and focal (<10 
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mm in length) ISR is usually treated with balloon angioplasty (PTCA). Stents 
achieve the largest final lumen dimensions without tissue recoil compared 
to PTCA, and may elicit superior results for the treatment of ISR. To eval- 
uate the impact of stent alone therapy in focal ISR lesions on target lesion 
revascularization (TLR), we studied 357 lesions in 281 patients. Baseline 
demographics were similar between the two groups, although stent alone 
was used more frequently for articulation and edge ISR (80%) and PTCA 
alone was used more frequently for ISR within the stent body (82%). 
PTCA Stent p-value 
n = 240 n = 117 
N-Q MI (%) 7.9 18.6 0.0025 
Lesion L. (mm) 7.3 ± 2.1 8.1 ± 1.3 NS 
Final DS (%) 23 ± 3 11 ± 2 <0.001 
Final CSA (ram 2) 6,07 ± 0.3 8.92 ± 0.5 <0.001 
1-year Death/MI (%) 4.5/0.0 5.2/0.0 NS 
1-year TLR (%) 25% 27% NS 
L = length, N-Q MI = post procedure non-Q wave MI, DS = diameter stenosis, CSA = 
cross sectional area by IVUS, TLR = target lesion revascularization. 
Conclusions: Despite improved acute angiographic results (without early 
recoil), stenting for focal ISR lesions is associated with more frequent in-hos- 
pital non-Q MI and similar late TLR, compared with PTCA alone. Adjunct 
ant±proliferative modal±ties, uch as vascular brachytherapy, are warranted 
for the treatment of even focal ISR. 
1037-53 1 Predictors of Recurrent Restenosis After Balloon 
I 
Angioplasty for Stent Restenosis: Statist ical 
Analysis 
Hiroyoshi Yokoi, Takashi Tamura, Yoshihisa Nakagawa, Naoya Hamasaki, 
Hideyuki Nosaka, Takeshi Kimura, Masakiyo Nobuyoshi. Kokura Memorial 
Hospital, Kitakyushu, Japan 
Stent restenosis (SR) still remains a major limitation after coronary stent 
implantation because of a higher recurrent restenosis rate after balloon an- 
gioplasty (BA) of SR as compared with primary stent placement. The purpose 
of the present study was to identify the predictor of recurrent restenosis after 
BA for SR, the clinical, procedural and angiographical parameters in SR 
lesions (les) were analyzed. From consecutive 334 lesions with SR (JJIS 
144 les, Cook I 104 les, Strecker 25 les, Cordis 22 les, ACS t2 les, Wall 27 
les), repeat BA was performed in 285 les and angiographic FU was obtained 
244 les (86% of eligible les) at 3 months (M) after repeat BA. The binary 
recurrent restenosis (defined as >50% diameter stenosis at 3 MFU) rate was 
51.2%. According to angiographic appearance, SR occurred diffusely in 156 
les (46%), focally inside the stent in 99 les (30%) and focally at the stent 
border in 79 les (24%). Univariate analysis revealed 1 procedural and 7 an- 
giographical significant factors of recurrent restenosis. The procedural factor 
was type of stent (Strecker, Cook I, Walt) (P = 0.039). The angiographical 
factors were ostialles (P = 0.0098), pattern of SR (diffuse type) (P = 0.0001), 
minimal lumen diameter (MLD) at FU after stent implantation (P = 0.0001), 
% diameter stenosis at FU after stent implantation (P = 0.0001), late loss 
after stent implantation (P = 0.0001), loss index after stent implantation (P = 
0.0001), post MLD after repeat BA (P = 0.0006). These 8 factors were tested 
with multivariate logistic regression analysis. The only one factor of pattern 
of SR (diffuse type) was identified as the independent predictor of recurrent 
restenosis after BAfor SR (P = 0.0016) 
Conclusion: BA in diffuse type SR was limited approach associated with 
a higher frequency of recurrent restenosis after BA. The other modal±ties may 
be necessary to overcome some of these limitations. 
I1037-54 I Outcome and Predictors of Recurrent Long-term I Restenosis After Percutaneous Transluminal 
Rotational Atherectomy for Treatment of Diffuse 
In-Stent Restenosis 
Juergen vom Dahl, Heinrich G. Klues, Peter Radke, Phillip Haager, 
Frank Kastrau, Thorsten Reffelmann, Uwe Janssens, Peter Hanrath. 
University Hospital RWTH Aachen, Germany 
Background: Recurrent in-stent restenosis (ISR) presents an increasing 
problem, particularly in diffuse lesions where high rates of recurrent stenosis 
have been reported following PTCA for ISR. 
Methods: To achieve optimal "debulking" within the ISR, rotational atherec- 
tomy (PTRA) was performed in 100 patients (pts) with ISR 5 ± 1 months 
after stent implantation (2.1 ± 1.4 stents; diameter: 3.0 ± 0.4 mm, length: 
31 ± 14 mm). Target lesion length prior to PTRA was 21 ± 8 mm with a 78 
± 17% diameter stenosis including 29 total stent occlusions with a length 
of 44 ± 23 mm. Adjunctive tow-pressure PTCA was performed in 92% and 
stenting in 9%. Clinical success (remaining stenosis < 30%, no in-hospital 
complications) was 97%. 
Results: No cardiac event occurred during 5 ± 4 month clinical followup. 
72 pts underwent follow-up angiography with a target lesion re-intervention for 
symptomatic recurrent ISR in 35% and an angiographic restenosis (>_50% 
diameter) rate of 49% (35/72 pts). Stepwise logistic regression analysis 
revealed the stent length, the length of the first ISR and total stent occlusion 
as predictors of recurrent ISR. The rate of recurrent ISR correlated (p < 0.01) 
with the baseline ISR length: 
Lesion tength (ram) _< 10 11-20 21-40 >40 
n (at follow-up: n = 72) 14 27 13 18 
Recurrent ISR > 50% (%) 9 42 69 78 
The initial lesion length in pts with recurrent ISR was 35 ± 14 mm in 
contrast to pts without the need for reintervention with a length of 22 ± 17 
mm (p < 0.05). 12/35 pts with recurrent ISR had stent occlusion at follow-up. 
All 12 pts had recanalization of a complete stent occlusion at baseline with a 
length of 44 ± 14 mm. 
Conclusions: PTRA is a safe and effective "debulking" approach for 
treatment of ISR with good acute results. Whereas the angiographic long- 
term outcome is rather good in short and intermediate lesions, recurrent ISR 
rate in very long and diffuse lesions is high. 
I •  Residual Dissections After Coronary Stent 
Implantation not Covered by Additional Stents 
Bernhard Reimers, Leonardo Spedicato, Salvatore Saccb., Issam Moussa, 
Placido Benenati, Pietro Pascotto. Ospedale Mirano, Italy 
Before adequate stent dilatation and aggresive antiplatelet therapy were 
commonly used the presence of residual dissections after coronary stenting 
has been regarded as a potential risk for acute and subacute thrombosis. 
This study evaluates the impact of residual post-stent dissections on the 
short-term clinical outcome. In 41 of 312 consecutive patients (13%) who 
underwent successful stent implantation a residual dissection (type C or less 
and not located in the left main artery or at an ostium of a major branch) 
was not covered by additional stents. In 59% of cases dissections occurred 
during stent expansion and in 41% of cases dissections occurred dudng 
angioplasty and were only partially covered by stents. In the first 15 patients 
a transstenostic pressure gradient was measured and accepted without 
further treatment when <15 mmHg. 46 slotted tube stents were implanted 
at 16 ± 3 arm (balloon artery ratio 1.16 ± 0.29). Residual dissections were 
classified: type A 25%, type B 27% and type C 48%. Reference diameter 
was 3.09 ± 0.30 mm and lesion length 15 ± 4 mm. Diameter stenosis 
was 74 ± 8% before the procedure and 12 ± 7% after the procedure. The 
mean dissection length was 7 ± 6 mm. Abciximab was given in 15% of 
cases. Patients recieved antiplatelet herapy only (Aspirin and Tictopidine). 
Procedural complications were 2 non Q wave myocardial infarctions (5%). 
The incidence of major adverse cardiac events dudng the follow-up of mean 
85 ± 30 days (range 60-150) was 5% (2 patients with re-PTCA for instent 
restenosis). The incidence of procedural complications and of MACE at 2 
months were not different (p = ns) between patients with (n = 41) and without 
residual post stent dissection (n = 271). 
Conclusions: Residual dissections _< type C after otherwise successful 
stent implantation were not associated with adverse short-term outcome. It 
appears that extensive stenting for <type C dissections could be avoided 
without compromising patients safety and with potential cost savings. 
I1 I Debulking Prior to Stenting be Justified as 
I 
037-56  Can 
Standard Treatment for Right Coronary Artery  
Ostial Lesions? 
Michael Peterson, Andrew Carter, Roxana Mehran, Ran Komowski, 
Bdgette Golden, Manuela A. Negotia, Augusto D. Pichard, Lowell F. Satler, 
Kenneth M. Kent, Gary S. Mintz, Alexandra J. Lansky, Gregg W. Stone, 
Martin B. Leon. Washington Hospital Center, Washington, DC, USA 
Right coronary artery (RCA) ostial lesions are commonly treated with me- 
chanical debulking and/or stenting. However, the long-term benefits of de- 
bulking prior to stenting of RCA ostial lesions are unknown. 
Methods: We reviewed all patients with solitary RCA ostial stenosis from 
January 1993 to July 1998 and compared those treated with stenting alone to 
debulking (atherectomy or excimer laser angioplasty) before stent placement. 
Baseline demographic clinical features were equivalent in each group. Mean 
follow-up was 15 months. 
Results: When compared to stenting alone (n = 88), the group with 
debulking prior to stenting (n = 64) had more vessel calcification by IVUS 
(P < 0.05). The minimum lumen diameters increased from 1.02 i 0.51 in 
the debulking group and 1.07 ± 0.48 in the stenting alone group to 3.29 ± 
0.63 and 3.02 ± 0.64, respectively (P = NS). This decreased the diameter 
stenoses from 67 ± 15% in the debulking group and 65 ± 15% in the stent 
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alone group to -1 ± 13% and 4 ± 20%, respectively (P = 0.05). Overall 
procedural success (98%) was excellent for each strategy with no significant 
difference in peri-procedural complications. Notably, the debulking plus stent 
group had neither a significant increase in CK-MB release, nor in non-QWMI 
when compared to stent alone. Long-term outcomes: 
Debulking(n =64) Stentalone(n = 88) P 
Death(°) 2 5 0.34 
MI(%) 0 0 NS 
TLR (%) 18 20 0.78 
Conclusion: Despite improved lumen dimensions with debulking and 
stenting for RCA ostial lesions, long-term clinical outcomes are similar com- 
pared with stenting alone. Thus, prior debulking should be reserved for only 
heavily calcified ostial stenoses to facilitate stent implantation. 
~ T h e  STOP A Randomized Multicenter Study 
Israeli Study for _Stents in Total Occlusion and 
Restenosis Prevention 
C. Lotan, R. Krakover, Y. Turgeman, O. Ayzenberg, R. Beyar, E. Disegni, 
Y. Almagor, I. Tamari, Y. Ben-Horin, A. Bakst, B. Peled, M.S. Gotsman. 
Israel Working Group for Interventional Cardiology; Cardiology Dept., 
Hadassah Hospital Ein Kerem, Jerusalem 91120, Israel 
Background: Several studies have noted an increase in restenosis and 
re-occlusion rates in-patients undergoing balloon angioplasty for chronic 
total occlusion. In view of the hypothesis that additional stent implantation 
may lead to a significant decrease in restenosis rates, we organized a 
multi-center randomized study in Israel to assess the benefit of additional 
coronary stenting (using the AVE Microstent) in chronic (>10 days) occluded 
coronary arteries. 
Methods: After obtaining optimal PTCA results, patients were randomized 
either to no further treatment or additional stent implantation. All patients are 
expected to undergo 6-month angiographic follow-up to assess restenosis. 
Results: Ninety-six patients (81 males, mean age 59.1 ± 10.3 yrs.) have 
been enrolled (STENT = 48, PTCA = 48). Mean time of coronary occlusion 
was 45 ± 20 days. Both groups were well balanced with regard to risk 
factors, clinical and angiographic findings. Final MLD in the stent group was 
3.13 mm compared with 2.42 mm in the PTCA group (p < 0.05). Major 
clinical events during 6 months follow up, did not differ between the two 
groups, but target vessel revascularization was more frequent in the PTCA 
group (38.7%) compared to the stent group (18.9%). 
The study design, acute and long-term results of the entire cohort will be 
presented. 
• Stenting of Arteries: Interim Small Coronary 
Report From a Randomized Multicenter Trial in 
Patients with a Vessel Reference Diameter of 
2.3-2.9 mm 
Serge Douchet, Martin J. Schalij, Mathy Vrolix, Bernard De Bruyne, 
Patrick Chenu, David Hilton, Wasan Udaychalerm. Ashok Seth. Montreal 
Heart/nstitute, Montreal Canada; Leiden University Medica/ Center, 
Leiden, The Netherlands 
Background: The Stenting In Small Arteries trial (SISA) is a worldwide, 
randomized stent study in 350 pts with a reference diameter (RD) of the 
target vessel between 2.3-2.9 ram. Angiographic FU after 6 mos and clinical 
FU at 12 mos will be obtained. 
Methods: Pts with one de-novo lesion in native coronary arteries and 
stable angina are included. Either a standard PTCA procedure was performed 
or a Medtronic Be-stent (8 mm or 15 mm length) was implanted. Before 
inclusion the RD of the target vessel was calculated using on-line quantitative 
coronary analysis (QCA) measurements. During the procedure pts received 
10.000-15.000 U of heparin. After the procedure pts were treated with aspirin 
and ticlopidin (stent pts only) for 28 days. 
Results: Thus far 160 pts (73 stent pts, 87 PTCA pts, age: 60.9 Y, 40 
F) have been included. The RD before inclusion was: 2.53 ± 0.20 (stent 
pts) and 2.48 ± 0.24 mm (PTCA pts). The procedural success rate (<50% 
residual diameter stenosis (DS) with a decrease in DS of >20% after the 
procedure) was 97.5% for the whole group. Crossovers: Stent to PTCA: 3 
(4%); PTCA to Stent: 11 (13%). The clinical success rate (procedural succes 
without complications at discharge) was 93.4%. Complications at one month 
(n = 121 ): Re-PTCA: 1 (1%), CABG: 2 (2%), Q-wave Mh 1 (1%), Non Q-wave 
Mh 4 (3%). 
Conclusion: Stenting of small vessels with a RD of 2.3-2.9 mm is fea-. 
sible and relatively safe. Interim results for 350 patients will be available at 
presentation. 
~ Stents not Improve Acute and Long-Term Do 
Clinical Outcomes in Patients With Chronic Renal 
Failure and Coronary Disease 
Luis Gruberg, Roxana Mehran, Mun K. Hong, Alexandra J. Lansky, Augusto 
D. Pichard, Michael Peterson, Candice T. Waiters, Mandy Murphy, John 
R. Laird, Lowell F. Satler, Kenneth M. Kent, Gregg W. Stone, Martin 
B. Leon. Washington Hospital Center, Washington, DC, USA 
Background: Pts with chronic renal failure (CRF) have an increased dsk of 
peri-procedural complications and a high rate of restenosis after PTCA. The 
impact of stents in this high risk subset is unknown. 
Methods: To evaluate the impact of stenting on the early and late events 
in CRF pts, we followed 4411 patients after elective Palmaz-Schatz stent 
placement in 6903 lesions between 1994-1997. Of these, 340 pts had CRF 
(baseline creatinine > 2.0) and 53 had end stage CRF (ESRD) on dialysis. 
Results: Baseline characteristics were similar except for more frequent 
hypertension and diabetes in pts with CRF and ESRD [p < 0.05 vs normal 
renal function (NRF)]. *p < 0.03 vs. NRF 
ESRD CRF NRF 
In-hospital n = 53 n = 340 n = 4018 
Death/MI/CABG (%) 4.9"11.6/1.6 3.2"/0.5/0.8 0.8/0.5/1.2 
Follow-up 
Death/MI (%) 34*/0 13.7"/0.3 4.1/0.4 
TLR (%) 16 8.9" 14 
Event free survival (%) 45.3" 73.6 76.6 
Independent predictors of late mortality included: diabetes (OR 2.0, p = 
0.0001), SVG lesion (OR: 1.8, P < 0.001), and CRF (OR: 4.87, P = 0.0001). 
Conclusion: Patients with CRF (especially on dialysis), despite aggres- 
sive stenting, have significantly higher early and late event rates (driven by 
mortality). Although TLR is favorable in CRF patients after stenting, long-term 
event-free survival is still markedly reduced, at least part due to the presence 
of co-morbid conditions. 
• Coronary Disease Revascularization With Artery 
the Jomed Jostent®: A Two Center Experience 
Richard R. Heuser, Alejandro Lopez, Nicolaus Reifart, Hans Stoerger. 
Phoenix Heart Center, Phoenix Arizona, USA; Red Cross HospitaL 
Frankfurt, Germany 
Background: Endoluminal Graft-Stents (ELG) have been used sparingly in 
the coronary arteries due to limited applicability in the smaller and branching 
coronary arterial tree. With the recent development of the Jorned Jostent ®, 
an ELG stent can be applied in specific clinical situations. The Jostent ® 
is a balloon expandable prosthesis consisting of two flexible thin tubular 
stainless steel stents and a polytetrafluoroethylene (PTFE) membrane of 75 
/~m in between. It comes in lengths of 6-22 mm and at diameters of 2.5-5.0 
mm. 
Methods and Results: We implanted 83 stents in 76 patients aged 60.5 
i 10.3 years. The vessels included: SVG (n = 24), RCA (n = 26), LAD (n = 20), 
and LCX (n = 6). Indications included aneurysm (n = 22), friable SVG (n = 15), 
thrombotic plaque (n = 7), perforation (n = 4), de novo (n = 20), and restenosis 
(n = 8 with six have multiple in-stent restenosis). Patients were treated with 
ASA 300 mg and Ticlopidine 2 x 250 mg (3 weeks). Angiographic success 
was 97% (74/76) and all four perforations were sealed successfully. A 6 F 
guiding catheter was used 33% (25/76). Maximum balloon size was 3.7 ± 
0.7 mm with a maximum pressure of 12-24 bar. Pre-procedure stenosis was 
81.5 ± 15.4% and post-procedure stenosis was 7.6 ± 18.1%. Complications 
included one subacute thrombosis after 7 hours. Six month angiographic 
follow-up was available in 6 patients and revealed restenosis in 33% (1 with 
diffuse 60% narrowing and 1 with focal restenosis at the stent ends). 
Conclusion: The PTFE covered Jostent ~ is easy to insert in larger coro- 
nary arteries and SVGs and can be used to cover aneuryms, vessel ruptures, 
and perforations or as a treatment for focal repetitive restenosis. Further in- 
vestigations are warranted to evaluate the 6 month binary restenosis rate 
and target vessel revascularization rate. 
• Coronary Stent Placement in Patients Acute With 
Myocardial Infarction Complicated by Cardiogenic 
Shock, One-Year Clinical Follow-Up 
Josef Dirschinger, Adnan Kastrati, Helmut SchLihlen, J~rgen Pache, 
Jutinda Mehilli, Franz-Josef Neumann, Albert Sch6mig. Medizinische Klinik 
rechts der Isar & Deutsches Herzzentrum, Technische Universit~t, Munich, 
Germany 
Background: Myocardial infarction (MI) complicated by cardiogenic shock 
is associated with a very high mortality. Previous studies have shown the ad- 
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vantages of reperfusion strategies in these patients. Comprehensive studies 
on the role of coronary stenting are not available. 
Methods: Starting in January 1995, coronary stent placement has been 
the pdmary goal in the treatment of these patients referred to our institu- 
tion. This intention-to-treat analysis provides a complete one-year clinical 
follow-up of all patients with carcliogenic shock referred to us after January 
95. 
Results: Of 108 patients admitted to our institution, one patient was 
treated conservatively, 107 underwent coronary angioplasty and 100 were 
treated with additional stent placement. These procedures were successful in 
96.3%. Dudng the first 30 days, 38.9% died, 2.8% had a repeat nonfatal MI, 
and 2.8% needed a repeat intervention (overall adverse event rate 41.7%). 
After one year, 45.4% had died, 4.6% had a repeat nonfatal MI, and 8.3% 
required a repeat intervention (overall adverse event rate 51.9%). 
Conclusions: This analysis suggests that coronary stent placement in 
myocardial infarction complicated by cardiegenic shock is feasible and can 
be achieved with a high pdmary success rate. Major adverse events occur 
mainly during the first 30 days. Patients surviving this early critical phase 
expedence a very favorable Iongterm follow-up. 
1037-94 ] Six Month of Percutaneous Follow-Up 
I TransMyocardial Revascularization in Patients 
With Refractory Angina 
Patdck L. Whitlow, William D. Knopf, William W. O'Neill, Upendra Kaul, 
Hugo Londero, Fayaz Shawl. Cleveland Clinic Foundation, Cleveland, OH, 
USA 
Background: To assess the safety and efficacy of percutaneous transmy- 
ocardial revasculadzation (PTMR) in pts with medically refractory class Ill-IV 
angina, the Eclipse Holmium fiberoptic laser was used on 41 pts at 7 centers 
for completion of a Phase I trial. 
Methods: Pts considered not eligible for CABG or PTCA had echocardio- 
graphy performed pdor to PTMR to ensure LV wall thickness _> 9 mm. A 9Fr 
guiding catheter was introduced into the left ventricle via the femoral artery. 
Up to 30 1 mm channels were made from the endocardium 5 mm into the 
myocardium. Mean age was 62 5: 8, 85% were men, EF was 42% 5:11 and 
angina class was 3.7 + 0.5. Most (68%) had prior CABG, 63% prior PTCA, 
63% prior MI, and 74% triple vessel disease. Naughton ETT was performed 
at baseline with a mean time of 250 5:144 seconds. 
Results: Procedure time was 61 4- 23 m/n; 17 5:5 channels (range 9-33) 
were created; first to last channel time was 20 5:13 rain. Peri-operatively, no 
pt had death, MI, CABG or tamponade. One pt had VT requiring card/overs/on 
and required an IABP for hypotension; 1 had a transient ischemic attack; 1 
had transient 3rd degree AV block. Pts were discharged 1.9 + 1.2 days post 
procedure. At 3 months there were no Q and 1 non-Q MI. Mean angina class 
at 3 months was 1.3 5:1.0 (p < 0.01), 90% of pts improved to <angina class 
2, and 80% of pts improved >2 angina classes. One pt returned for repeat 
PTMR and died on day 8. One pt had compassionate CABG and died dudng 
the procedure. At 6 months there were no additional deaths; one Q and no 
non-Q Ml's were reported. One patient had PTCA; no other revescularization 
was reported. Mean angina class at 6 months was 1.2 ± 1.1, 90% improved 
to <angina class 2, and 85% improved ->2 angina classes (n = 35). Naughton 
ETT was performed at 6 months with a mean time of 500 5:208 seconds (p 
< 0.05). 
Conclusions: PTMR as sole therapy in patients with severe refractory 
angina ineligible for other interventions is feasible and is performed with 
reasonable safety. Angina improvement is reported in the majority of pa- 
tients. Phase II randomized trials comparing PTMR to medical therapy are 
underway. 
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~ Stenta Conventional PTCA in Unstable Versus 
Angina 
Mandeep Singh, David R. Holmes, Kirk N. Garratt, Malcolm R. Bell, Peter 
B. Berger, Charanjit S. R/hal, Robed S. Schwartz, LaVon Hammes. Mayo 
Medical Center, Rochester, Minnesota, USA 
Background: Randomized clinical trials of eady PTCA versus medical ther- 
apy in patients with unstable angina have not found improved outcome with 
eady PTCA treatment. The usefulness of stents in this setting however has 
not been addressed in large studies. 
Methods: We retrospectively evaluated the results of PTCA in patients 
with unstable angina (5656 patients) and compared their in-hospital outcome 
and 1 year follow-up results with patients who received stents and/or PTCA 
(1976 patients). 
Results: (Table) The baseline characteristics in the two subgroups were 
comparable. 
Vadable PTCA (%) Stent ± PTCA (%) P value 
(n = 5656) (n = 1976) 
Clinical Success 83.8 95.9 <0.00001 
In.hospital Deaths 2.6 1.5 0.003 
CABG < 24 Hrs 3.6 0.9 <0.00001 
Q MI 1.1 1.0 0.62 
FoUow-up (1 year): Death 3.4 3.0 0.25 
: CABG 19.6 6.5 <0.00001 
: Angina 47.4 23.5 <0.00001 
: QMI 1.9 0.4 <0.00001 
: Repeat Procedure 30.6 13.8 <0.00001 
Conclusion: Application of stent technology in patients with unstable 
angina results in marked improvement in outcome compared with conven- 
tional PTCA. New randomized clinical tdals of stent implantation versus 
medical treatment should be performed. 
E •  Follow-Up of the Study Population PSAAMI (Primary Stenting vs. Angioplasty in Acute 
Myocardial Infarction) 
Bruno Scheller, Benno Hennen, Sabine Severin-Kneib, Torsten Markwirth, 
Thomas Doerr, Gunther Berg, Hermann Schieffer, Cem (~zbek. On beha/fof 
the PSAAMI study group; Internal Medicine/11 (Cardiology), University of 
Saar/and, Germany 
Background: In the setting of an acute myocardial infarction the implantation 
of a coronary stent might be of advantage as stenting is capable to tackle 
dissections and adhere them to the vessel wall, thus to further improve the 
luminal diameter and also to prevent he recoiling phenomenon after balloon 
angioplasty. 
Methods and Patient Population: The objective of this prospective, 
randomized, controlled study is to compare the clinical outcome of primary 
stenting vs. angioplesty in AMI. Patients (pts) are included within 24 hours 
after the onset of AMI as far as coronary angiography reveals an indication 
for angioplasty. So far, Juli 1998, 88 pts were randomized. There were 
no differences in base-line data between the two groups; 26% had a prior 
thrombelysis, 26% had a three-vessel disease. 
Results: There was a significant difference of the pdmary endpoint by 
pdmary stenting. 
Angioplasty group Stent group p 
# of patients 44 44 
Follow-up 192 ± 109 days 188 + 100 days ns 
Death 9% 7% ns 
Reinfarction 5% 2% ns 
."target lesion revascularisation 36% 14% 0.013 
Ischemic events 16% 2% 0.029 
Disabling disorder 5% 0% ns 
Primary endpoint 57% 21% 0.001 
Conclusion: Pdmary stenting in AMI is feasible. It is not associated 
with an increased subacute thrombosis rate. Short term results suggest that 
stenting is supedor to balloon angioplasty. Six-month follow-up results are 
awaited. 
I •  Primary Stenting Versus on PTCA Acute Myocardial Infarction: In Hospital Results From 
the Brazilian Intarventional Registry 
I_uiz Mattos, Amanda Sousa, Cantidio C. Neto, Andr(~ Labrunie, Claudia 
R. Alves, Heitor Carvalho, Jamil Saad. Brazilian Society of Interventionel 
Cardiology, S&o Paulo, Brazil 
Background: The Brazilian Society of Interventional Cardiology designed 
a large data base registry in 1991 (CENIC), to assess the performance of 
percutaneous cardiac interventions in Brazil. 
Methods: CENIC gathered 24.667 procedures during the years 1996/97. 
Of these, 2.798 (11%) underwent primary PTCA within the first 12 hours from 
acute MI. Accordingly to operator discretion, 780 (28%) were submmitted 
to primary stenting. The end point is the comparison of in hospital results, 
between primary stenting and PTCA in this large cohort. 
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Results: 
Variables / pts Stenting 780 (28%) PTCA 2018 (72%) p 
Age > 70 yrs 121 (15.5%) 302 (14.5) 0.7 
Female gender 188 (24%) 616 (30%) 0.001 
Anterior MI 436 (56%) 1017 (50%) 0.009 
Killip Ill/IV 72 (9%) 300 (15%) 0.0001 
Multivessel disease 314 (40%) 885 (44%) 0.08 
lesion length > 10 mm 436 (56%) 812 (40%) 0.0001 
Sucess + TIMI 3 757 (97%) 1696 (84%) 0.0001 
% stenosis post 13°1o 29% 0.0001 
Reinfarction 13 (1.6%) 80 (3.9%) 0.002 
Emergency CABG 5 (0.6%) 11 (0.5%) 0.7 
Death - Kiltip 1/11 13 (1.6%) 46 (2.2%) 0.9 
Death- Killip ill/IV 13 (18%) 94 (31%) 0.02 
Conclusions: When compared to PTCA, stenting on acute MI offers 
higher sucess rate, less residual stenosis, reduced ReMi and death rate. 
PTCA pts were more often female, had inferior MIs and were in higher Killip 
class at admission. However, the greater benefit of primary stentlng was 
established in high risk subgroups (Killip Ill/IV, anterior MIs and long lesions). 
1038-1341 Stent Within the Infarct Multiple Implantation 
I Vessel in Patients With Acute Myocardial 
Infarction 
David Antoniucci, Guia Moschi, Giovanni M. Santoro, Leonardo Bolognese, 
Maurizio Trapani, Reanato Valenti, Enrico Taddeucci, Paolo D. Pucci, Pier 
Filippo Fazzini. Division of Cardiology, Careggi Hospital, Florence, Italy 
Bachground: Stenting of the infarct vessel is associated with improved 
clinical and angiographic outcome in patients (pts) with AMI. The efficacy 
of multiple stent (MS) implantation to cover diffuse disease or multiple focal 
lesions within the infarct vessel is unknown. 
Methods: Clinical and angiographic outcome of 116 pts with AMI and 
MS implantation were compared to those of 258 pts with single stent (SS). 
Inclusion criteria were all pts with AMI presenting within 6 h from symptom 
onset, and a reference vessel diameter > 2.5 ram, Patients with cardiogenic 
shock, or left main disease, or severe vessel tortuosity were included, and 
no upper age limit was used. 
Results: see table 
MS n = 116 SS n = 268 p value 
Age 64 ± 12 63 ± 12 0.357 
Male 86 (74%) 199 (77%) 0.529 
Anterior AMI 77 (66%) 146 (57%) 0.074 
Cardiogenic shock 16 (14%) 33 (13%) 0790 
Muitivessel disease 60 (52%) 128 (50%) 0.706 
Bailout stenting 56 (48%) 59 (23%) <0.001 
Mean stented length (mm) 39.6 :~ 13 19.7 ± 5.5 <0.001 
Six-month Death/MIFrVR 18/79 (23%) 26/160 (16%) 0.220 
Six-month restenosis 18/56 (32%) 32/133 (24%) 0.250 
Six-month patency rate 100% 97% 0.188 
Conclusion: MS implantation for diffuse disease of the infarct vessel in 
pts with AMI is associated with acceptable clinical and angiographic outcome 
as compared to results with SS implantation. 
1038-1  ] Cl inical Outcome Stenting 35 After Rescue in 
Patients With Acute Myocardial Infarction 
Josef Dirschinger, J~rgen Pache, Adnan Kastrati, Helmut Sch~hlen, 
Albert Sch6mig. Deutsches Herzzentrum and 1. Med. Klinik, TU M£mchen, 
Germany 
Background: The effectiveness of intracoronary stenting as a rescue in- 
tervention in patients with acute myocardial infarction and unsuccessful 
thrombolysis has not been assessed. Since an extensive intimal disruption is. 
frequently the reason for failure of thrombolytic therapy, coronary stent place- 
ment seems to be well suited in this setting. The objective of the present study 
is to assess the clinical outcome of patients with acute myocardial infarction~ 
failed thrombolysis and rescue coronary stent implantation. 
Methods: The analysis is referred to 167 consecutive patients, 60 • 11 
year old and 23% women. Nineteen patients were in cardiogenic shock. 
Patients were followed-up for 1 year after the intervention. 
Results: On average 1.2 + 0.7 stents were implanted in each patient 
using a mean balloon pressure of 13.3 ± 2.9 arm and a balloon-to-vessel 
ratio of 1.03 ± 0.10. Stent placement procedure was successful in 98.2°/,, 
of the patients. Within the first 30 days after the procedure, stent vessel 
occlusion occurred in 1.2%; the combined endpoint of cardiac death or 
recurrent myocardial infarction was recorded in 1.4% of patients without 
shock and 47.4% of those with cardiogenic shock. At one year the probability 
of death or myocardial infarction was 4.7% in patients without shock and 
52.6% in those with cardiogenic shock. 
Conclusion: These findings suggest that in this particularly high risk 
cohort of patients with acute myocardial infarction and failed thrompolysis, 
rescue coronary stenting is associated with favorable short- and long-term 
clinical outcome in comparison with historical data for this subset. 
[ 1038-136 J  "Microvascular Stunning" in Acute Coronary 
Syndromes: Early Recovery of Coronary Flow 
Reserve After Stenting is Associated With 
Improvement in Diastolic Function 
Manuel Pan, Jos@ Su~rez de Lezo, Alfonso Medina 1 , Miguel Romero, 
Enrique Hern~ndez I , Jos@ Segura, Djordje Pavlovic, Antonio Ramirez, 
Francisco Meli~.n 1, Jose A. Cabrera 1 . Reina Sofia Hospital University of 
C6rdoba; 1Pino Hospital University of Las Palmas, Spain 
Background: Coronary flow reserve (CFR) immediately after successful 
revascularization is frequently normalized following epicardial stenosis re- 
lief. In the setting of acute coronary syndromes, the treatment with stents 
may induce capillary microembolization and reperfusion injury, which may 
compromise CFR recovery. 
Methods: To test this hypothesis we studied the immediate and 24 hour 
changes in CFR, as measured by Doppler flow-wire, in 21 patients with acute 
coronary syndrom who received combined stent and ReoPro (intracoronary 
bolus + 12 hour-iv infusion) treatments. 
Results: The mean age was 55 ± 13 years; 10 had acute evolving 
myocardial infarction and 11 had perHnfarction angina; 13 had complete 
occlusion of the related artery; in the remaining 8, angiography showed a 
large thrombus at the responsible lesion. A stent was successfully implanted 
at the lesion site. Then, distal coronary flow velocity was monitored at baseline 
and post adenosine, obtaining CFR. The same study was repeated 24 hours 
later, following angiographic documentation of a persistent optimal result. 
The left ventricular (LV) end-diastolic pressure (EDP) and ejection fraction 
(EF) were measured before treatment and 24 hours later. The distal CFR 
after stent implantation was 1.3 ± 0.3 and improved to 1.9 i 0.6 (p < 0.01) 
after complete ReoPro infusion. Eady change, in CFR was higher in pts who 
showed eady decrease in LVEDP (r = 0.82; p < 0.01) and was unrelated with 
changes in EF. 
Conclusions: In acute coronary syndromes treated with stents, the im- 
mediate CFR is frequently impaired despite the absence of flow-limiting 
stenosis. An early (24 hours) recovery of microvascular function is asso- 
ciated with favourable changes in LVEDP and seems to be facilitated by 
profound inhibition of platelet agregation. 
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~ Humanized Platelet-Derived Growth Factor-~ 
Receptor Antibodies Decrease Neointima 
Formation at 30 Days in Baboon Stented Carotids 
Nicolas A. F. Chronos, Ulrich Martin 1 , Stefan Verheye, Keith A. Robinson, 
Mark E. Leimbach, Stephen R. Hanson. Yerkes Regional Primate Research 
Center, Emory University School of Medicine, Atlanta, GA, USA; 
1Boehringer Mannheim, Penzberg, Germany 
Background: In-stent restenosis remains a major limitation of clinical stent- 
ing and is predominantly due to migration and proliferation of smooth muscle 
cells. Platelet-Derived Growth Factor (PDGF) is an important growth factor 
involved in the recruitment and proliferation of vascular smooth muscle cells 
(SMC). We evaluated whether antibodies to the PDGF-~ receptor, which 
block PDGF binding to SMC, may prevent neointima formation following 
stent placement in primates. 
Methods: Dose determination of Anti-PDGF-/~ receptor was based on in 
vitro studies with baboon vascular SMC. A loading bolus dose of 0.75 mg/kg 
with a maintenance bolus dose of 0,25 mg/kg for 5 days was given to the 
treated group. Stent implantation based on angiographic and intravascular 
ultrasound guided sizing was performed in both carotid arteries of all juvenile 
baboons. At 30 days, animals were euthanized and vessels were prepared 
for histomorphometric assessment. 
Results: Ten animals in each group were incorporated in this study. 
Histomorphometry results are shown (LA = luminal area; MIT = maximal 
intimal thickness; IA = intimal area; MA = medial area, IS = injury score). 
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LA (mm) MIT (mm) IA (mm 2) MA (mm 2 ) IS INIS 
Control 10.30 0.24 0.96 1.74 1.01 0.95 
Treated 10.03 0.21 0.83 1.7 1,01 0.62 
p-value 0.57 0.01 0.006 0.705 0.63 0.006 
Conclusions: Humanized antibodies to the PDGF-/3 receptor lead to a 
substantial reduction in necintimal area in stented carotid artedes of juve- 
nile baboons at 30 days. This study demonstrates that PDGF is partially 
responsible for neointima formation by proliferation and migration of vascular 
smooth muscle cells in the stented baboon model of vascular injury. 
• Overlapping Stents Result in Coronary an 
Increased NeoinUmal Hyperplasla Response. 
Insight From a Porcine Coronary Stent Model 
Ivan De Scheerder, Kai Wang, Xiao Rong Zhou, Qiang Bei Ping, 
Huang Yanming, Huang Jianhua, Liu Xiaoshun, Monica Szilard, 
Eric Verbeken, Xu Zhu, Frans Van de Werf, University Hospitals Leuven, 
Belgium 
Clinical experience suggests that overlapping coronary stents result in an 
increased in-stent restenosis. This study investigates the underlying mech- 
anisms in a porcine coronary model. Single or two ovedapping self-made 
stainless steel single wire sinusoidal helical coil stents were randomly de- 
ployed in the right coronary artery of 20 crossbred pigs (weight 20-25 kg). 
The pigs underwent a control angiogram at 6 weeks and were then sacdficed. 
Quantitative coronary analysis before, immediately after stent implanta- 
tion and at 6 weeks, was performed using the semiautomated Polytron 1000 ® 
system. Morphometry was performed using a computerized morphometric 
program. 
Angiographic analysis revealed a decreased recoil in the overlapping 
group (1% vs. 4%: p < 0.02) and a significantly larger minimal stent lumen 
diameter at follow-up in the single stent group (2.87 ± 0.16 vs. 2.58 ± 0.22 
mm: p = 0,005). 
Histopathology showed a significantly increased injury (1.27 ± 0.43 vs. 
0.83 ± 0.44, p = 0.042) and a significantly increased inflammatory reaction 
surrounding the stent filaments (1.51:1:0.11 vs. 1.09 ± 0.54: p = 0.035) in 
the ovedapping stent group. 
Morphometric analysis showed a significantly higher neointimal hyperpla- 
sia (3.34 ± 0.68 vs. 2.16 ± 1.48 ram2: p = 0,034) in the overlapping stent 
group. 
Conclusion: Ovedapping stents result in more pronounced coronary 
vessel injury resulting in more inflammation and neointimal hyperplasia com- 
pared to single stents. 
~ Clinical Presentat ion of Restenosis is Associated 
With the Extent  of  Atherosc lerot ic  Inflammation of 
the Initial Coronary Lesions 
Martijn Meuwissen, Steven A. J. Chamuleau, Jan J. Piek, Karel T. Koch, 
Allard C. van der Wal, Anton E. Becket. Academic Medical Center, 
University of Amsterdam, The Netherlands 
Background: There is limited information regarding the association between 
the extent of atherosclerotic inflammation and the incidence of restenosis 
after coronary angioplasty. 
Methods: A totat of 110 patients with stable (n = 46) or unstable angina (n 
= 64), according to Braunwald's classification, underwent directional coronary 
atherectomy (DCA). Cryostat sections of atherosclerotic plaques were im- 
munohistochemical stained with the monoclonal antibodies, c~-actin (smooth 
muscle cells; SMC), CD-68 (macrophages; MAC), CD-3 (T-cells) and C3/43 
(HI_A-DR molecules; HI_A). The extent of atherosclerotic inflammation of the 
initial lesion was determined by MAC, HLA and T-cells, planimetrically quan- 
tified as the percentage immunopositive tissue area of the total tissue area. 
Patients were followed for 12 (4-6) months. Clinical restenosis (Clinical RE) 
developed in 35 patients (32% presenting as stable angina in 19 patients 
and unstable angina in 16 patients. 
Results: MAC and SMC were not different in patients with or without 
restenosis. (MAC: 15.8 ± 11.8 vs. 18.8 ± 13.9, SMC: 26,0 ± 1.9 vs. 26.5 
± 15.3). The table shows initial plaque inflammation in patients with clinical 
restenosis. 
Clinical RE % MAC % T-cells % HLA % SMC 
Stable (n = 19) 8.3 ± 4.0 11.6 ± 9.9 17.7 :~ 4.9 28.8 ± 17.0 
Unstable (n = 16) 24.7 ± 11.7" 27.4 ± 13.61" 25.3 ± 12.1t 21.4 ± 11.2 
*p < 0.0001 compared to group stable, 1" P < 0.05 compared to group stable. 
Conclusion: The extent of initial plaque inflammation is not associated 
with clinical restenosis, but relates to the manifestation of recurrent anginal 
symptoms. 
I •  C~v/33 Receptor Blockade Reduces Restenosis Following Balloon Angioplasty in the 
Atherosclerotic Rabbit 
Gregory G. Bishop, John A. McPherson, John Sanders, Michael 
J. Feldman, Lawrence W. Gimple, Michael Ragosta, Eric R. Powers, Shaker 
A. Mousa, lan J. Sarambock. University of Virginia, Charlottesville, VA; 
DuPont Merck Pharmaceub'cal Company, Wilmington, DE, USA 
C~v/~3 integdn receptors play a key role in cell-cell and cell-matdx interac- 
tions and are upregulated in atherosclerotic tissue. Efficacy of ~v/~3 receptor 
blockade in reducing restenosis after angioplasty of atherosclerotic artedes 
has not been previously examined. We hypothesized that following BA of 
atherosclerotic arteries, inhibition of the <Xv~]3 receptor by XT199, a novel 
non-peptide avP3 selective antagonist (~xv/~3 IC5o = 0.05/~M, <XHb~3 tCso > 
10/~M) would reduce cross sectional area narrowing of the lumen by plaque 
(CSAN-P), a histologic marker of restenosis, at 4 weeks. 
Methods: Bilateral focal femoral atherosclerosis was induced in rabbits 
by air desiccation injury and a 0.5% cholesterol diet for 4 weeks. Rabbits 
then underwent femoral BA (2.5 mm balloon, three 60 sec., 10 atm inflations) 
and received 1 of 4 therapies for 14 days; XT199 2.5 mg/kg IV bolus plus 2.5 
mg/kg/d IV by osmotic pump (n = 14), XT199 3.75 mg/kg IV bolus plus 11.25 
rng/kg/d in 3 SQ daily doses (n = 8), vehicle IV (n = 9), or vehicle SQ (n = 5). 
Results: Steady state plasma levels of XT199 in the IV group were 7 
:< ICso and trough levels in the SQ group were 3 × ICs0. Femoral aderies 
of rabbits treated with vehicle IV or SQ had similar CSAN-P, 0.54 ± 0.15 
and 0.54 ± 0.25, respectively. CSAN-P of the femoral arteries in the rabbits 
treated with XT199 IV or XT199 SQ were 0.38 ± 0.15 and 0.36 ± 0.14, 
respectively, a reduction of 30% versus vehicle, p < 0.02. 
Conclusion: Specific ~v/~3 receptor blockade using XT199 for 14 days 
following BA reduced restenosis following balloon angioplasty in the athero- 
sclerotic rabbit femoral artery model. 
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[81-~-1 Changing Outcome of  Percutaneous Intervent ion in 
Patients With Unstable Angina 
Mandeep Singh, David R. Holmes, Kirk N. Garratt, Malcolm R. Bell, Peter 
B. Berger, Charanjit S, Rihal, LaVon Heroines. Mayo Medical Center, 
Rochester, Minnesota, USA 
Background: Randomized trials of PTCA versus medical therapy for unsta- 
ble angina have not documented improvement in outcome with the former. 
During the performance of these trials, new interventional approaches have 
been developed which may improve outcome. 
Methods: To assess the impact of the changing technical approach to 
unstable angina (UAP), we evaluated the in-hospital and intermediate term 
post hospital outcomes in patients with unstable angina undergoing coro- 
nary interventions (CI) during three-time periods: 1979-1989, 1990-1993, 
1994-1998. 
Results: 
Variable Year P value 
1979-1989 1990-1993 1994-1998 
N % N % N % 
Number of patients 2209 28.9 2212 29.0 3211 42.1 
Mean Age (%) 62.1 64.8 64.6 
Male (%) 71.2 70.9 69.2 
Diabetes 292 13.3 440 19.9 661 20.6 <0.0000t 
Successful CI" 1689 76.5 1925 87.0 3020 94.1 <0.00001 
Mortality in hospital 67 3.0 54 2.4 57 1.8 0.009 
QMI 39 1.8 22 1.0 24 0.7 0.001 
CABG < 24 hrs 108 4.9 40 1.8 21 0.7 <0.00001 
Follow-up (1 year): Death 53 3.1 81 4.2 74 2.8 0.004 
:QMI 11 0.7 17 0.9 7 0.3 0.0001 
:CABG 179 10.7 161 9.5 182 7.0 0.0001 
"Successful CI was defined as <50% residual stenosis without in-hospital death, MI, or 
CABG. 
Conclusion: As experience with coronary interventions has increased, 
there has been dramatic improvement in success rates and significant re- 
duction in the in-hospital mortality, CABG and QMI in patients with unstable 
angina particularly in the last 5 years. Intermediate follow-up at year shows 
sustained improvement over the years. 
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~ Value of the American College of Cardiology/ 
American Heart Association (ACCIAHA) Stenosis 
Morphology Classification as a Predictive Factor of 
Procedural Success and Late Angiographic and 
Clinical Outcome After Coronary Stent Implantation 
Adnan Kastrati, Shpend Elezi, J~rgen Pache, Helmut SchShlen, 
Josef Dirschinger, Franz-Josef Neumann, Albert Sch0mig. Deutsches 
Herzzentrum and 1. Med. Kiln±k, TU MOnchen, Germany 
Background: ACC/AHA lesion morphology is predictive of success rates 
after PTCA but little is known on its value in predicting the procedural and 
late angiographic and clinical outcome after coronary stenting. 
Methods: The study includes 2944 consecutive patients (pts) who un- 
derwent coronary stenting. Only pts with acute myocardial infarction before 
stenting were excluded. There were 264 pts (9%) with type A, 634 (22%) 
with type B1, 1152 (39%) with type B2 and 894 (30%) with type C lesions. 
Lesions of type B2 and C were combined to form the group of complex 
lesions. All pts had a 1-year clinical follow-up; death, myocardial infarction 
[,~J~ a,ggJ I,~r~e~ .lesJo.o .r~v£~t.cuJiJ.rJ2a~Jo.r)s were recorded as so'verse eve.nts. 
All angiograms were assessed with QCA. 
Results: 
B2/C type NB1 type P 
Procedural success, % 97.6 98.9 0.02 
Thrombosis rate (30-day), % 2.7 1.3 0.02 
Death (30-day), % 1.2 0.7 0.21 
Death or MI (30-day), % 2.6 1.2 0.02 
Angiegraphic late lumen loss, mm 1.19 ± 0.83 0.99 ± 0.73 <0.001 
Angiographic restenosis rate, % 33.2 24.9 <0.001 
Event-free survival (1-year), % 75.6 81.1 0.001 
In multivariate analysis, the adjusted probability of restenosis was 0.26 in 
B2/C pts and 0.21 in A/B1 pts (P = 0.009). The adjusted event-free survival 
was 76.9% in B2/C pts and 81.3% in A/B1 pts (P = 0.01). 
Conclusions: ACC/AHA lesion morphology classification has a strong 
predictive value not only for the procedural success rate but also for the late 
angiographic and clinical outcome after coronary stent placement. 
4:00 p.m. 
~8~]  Restenosis After Coronary Stenting - Clinical And 
Angiographic Predictors in 1906 Lesions 
Nobuyuki Kobayashi, Leo Finci, Massimo Ferraro, Joseph DeGregodo, 
Remo Albiere, Lucia di Francesco, Carlo Di Marie, Antonio Colombo. 
Centre Cuore Columbus, Milan, Italy 
We performed uni- and multivariate analysis of restenosis predictors in 1670 
consecutive patients (1670 lesions) having coronary stent implantation in our 
institution. Stents were implanted using mean balloon pressure of 15 ± 5 atm, 
IVUS in 60% with 2 year clinical follow-up in 90% and angiography follow-up 
in 66% of pts. Predictors of restenosis by univariate analysis were stent 
indication e.g., acute or threatened closure (37%), chronic total occlusion 
(33%) elective (25%); lesion tength, vessel size, vessel type e.g., LAD (25%), 
venous graft (46%) and presence of diabetes. However, after performing 
logistic regression analysis on 42 variables, only lesion length and vessel 
size kept high statistical significance (p < 0.0001). The figure shows the 
results: 
Restenosis 
Rate i~:~ ] . 
30 ! ~ 
10 10.1-20 
0 <10 
<3 3-3.5 >3,5 
Vessel Size (ram) 
Conclusions: Restenosis after coronary stenting is influence by several 
procedural and angiographic factors, but the two most important are lesion 
length and vessel size. The operator has to kept it in mind while making the 
decision for stent implantation. 
4:15 p.m. 
~-)  EPISTENT: A Large Scale Randomized Trial of 
Primary Versus Provisional Coronary Stenting With 
Background Platelet Glycoprotein lib/Ilia Blockade 
Philippe L. L'Allier, Fernando A. Cura, Shelly Sapp, Michael A. Lincoff, Eric 
J. Topoi. For the EPISTENT investigators; The Cleveland Clinic Foundation, 
Cleveland, Ohio, USA 
Background: Stenting has been demonstrated superior to balloon angio- 
plasty with regards to the need for repeat revascularization in selected pop- 
ulations. However, it has been advocated that optimal angiographic results 
after balloon angioplasty predicts similar outcomes than primary stenting. 
Therefore, provisional stenting could be the strategy of choice for percuta- 
neous revascularization. 
Methods: Patients were randomized to primary stenting plus abciximab 
or balloon angioplasty with abciximab and provisional stenting. A total of 19% 
of patients had provisional stenting in the balloon angioplasty group. 
Results: 
intention to Treat: 6 Month analysis 
N = 796 N = 794 value 
Mortality 1.8% 0.4% 0.018 
Death/Q-MI 3.7% 1.8% 0.02 
Death/Ml/any TVR 20.5% 13.0% <0.001 
Death/Mllurgent TVR 9.2% 6.4% 0.04 
TVR 154% 8.7% <0001 
TVR = target vessel revascularization 
Conclusion: We conclude that primary stenting, when compared to pro- 
visional stenting in a diverse population of ischemic heart disease patients 
and background abciximab is associated with better outcomes, including 
survival. 
4:30 p.m. 
~ Stenting for Small Vessel Using New Generation 
Flexible Stent - Comparison of Balloon Angioplasty 
and Paimaz-Schatz Stent 
Naoya Hamasaki, Hideyuki Nosaka, Takeshi Kimura, Hiroyoshi Yokel, 
Yoshihisa Nakagawa, Masakiyo Nebuyoshi. Kokura Memorial Hospital, 
Kitakyushu, Japan 
To evaluate safety and efficacy of new generation flexible ACS multilink 
stent (ACS) for small native vessel (<3.0 mm), we made a retrospective 
comparative study of balloon angioplasty (POBA), Palmaz-Schatz (JJIS) and 
ACS stent from a single center. Patients were selected from 3 intervention 
era, namely, pre stent era (POBA; 199 pts, 90.1), first generation stent era 
(JJIS; 1005 pts, 90.6-94.12) and second generation stent era (ACS, 303 
pts; 95.4-97.12). All analysis was performed using CAAS II system and total 
occlusions before intervention were excluded in this study. Study end points 
were initial success rate, angiographic binary restenosis rate (%DS > 50%) 
and target lesion revascularization (TLR) at follow-up (F/U). Study patient of 
small vessel intervention was comprised of 416 lesions (POBA; 118, JJIS; 
228, ACS; 70). 
POBA JJIS ACS P value 
Age 64 :L 10 65 ± 9 66 ± 8 
% diabetes 29 30 28 
Clinical success 87 92 92 0.03 
% calcified Is. 27 38 41 0.02 
% post dilatation / 69 34 
% elective indication 97 70 60 
Lesion length (mm) 10.5 ± 6.6 11.3 ± 7.0 16.5 ± 9.9 <0.0001 
Reference (mm) 2.33 ± 0.87 2.44 ± 0.33 2.44 ± 0.39 
MLD pre (ram) 0.87 ± 0.25 0.81 ± 0.27 0.86 ± 025 <0.0001 
MLD post (ram) 1.66 ± 0.37 2.43 ± 0.29 2.36 ~ 0.33 <0.0001 
MLD FlU (mm) 1.17 ± 0.48 1.49 ± 0.62 1.45 4- 0.53 0.0004 
Restenosis (%) 56 31 23 0.0002 
TLR (%) 40 19 13 0.0002 
In conclusions, 1) In spite of unfavorable background for stenting, stenting 
for small vessels provided better clinical and angiographic outcome than 
balloon angioplasty. 2) More favorable clinical outcome was predicted by 
using second generation stent for small vessel 3) Expanding stent indication 
for small vessel would be a promising modality for a selected cohort by 
means of flexible stent. 
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4:45  p.m. 
[ -8~A Matched Comparison Between Spot Stenting and 
Traditional Stenting for the Treatment of Long Lesions 
Joseph De Gregorio, Nobuyuki Kobayashi, Milena Adamian, Nicola Corvaja, 
Issam Moussa, Marco Vaghetti, Leo Finci, Yoshio Kobayashi, Remo Albierc, 
Carlo Di Mado, Jeffrey Moses, Antonio Colombo. Centro Cuore Columbus, 
Milan, Italy; Lenox Hill Hospital, New York, USA 
Various approaches in the treatment of long lesions have to date yielded dis- 
appointing results. In this retrospective analysis we compared the technique 
of utilizing long stent lengths (LS) with full lesion coverage vs the approach of 
spot stenting (SS) where IVUS guided PTCA is performed and short stents 
are placed only in the segments of a lesion where IVUS criteria are not met 
(CSA of >_5.5 mm 2 or >_50% of reference vessel CSA at the lesion site). The 
SS group (70 patients with 87 lesions) and the LS group (688 patients with 
769 lesions) bad similar baseline clinical and lesion characteristics including 
lesion complexity and reference vessel diameter (2.97 ± 0,5 vs 3.04 ± 0.5, 
p = ns). However, the SS group contained significantly longer lesions (28 :E 
11 vs23 ± 8, p < 0.01). 
Charac~elistic SS LS p 
Mean age 60 5- 11 60 5- 10 ns 
LVEF% 60 5- 11 60 ± 12 ns 
3 vessel disease, n (%) 24 (37) 190 (28) ns 
Calcified lesion, n (%) 27 (31) 125 (17) <0.05 
Stents/Lesion 1.3 ± 0.6 1.6 5_ 1.0 <0.05 
Stent length (mm) 21 ~: 13 29 ± 17 <0.05 
Max inflation press. (atm) 14.6 ± 3.5 15.3 5- 3.4 <0.05 
Balloon/artery atio 1.25 ± 0.2 1.18 ± 0.2 <0.05 
Min lumen diameter pre (mm) 0.7 ± 0.4 0.8 5- 0.5 <0.05 
Final rain lumen diameter (mm) 2.8 5- 0.7 3.0 5- 0.5 <0.05 
Stent thrombosis, n (%) 1 (1.1) 15 (1.9) ns 
Procedural MACE, n (%) 3 (4.3) 32 (4.7) ns 
Restenosis, n (%) 14 (25) 183 (39) <0.05 
Target lesion revasc., n (%) 12 (17) 165 (31) <0.05 
Angiographic follow-up was achieved in 77% of eligible lesions. 
Conclusions: Despite the use of shorter stent lengths to treat longer 
lesions, the SS group had similar short-term event rates but significantly 
better long-term outcome with lower restenosis rates and TLR. 
5 :00  p.m. 
~-]  Primary Stenting Versus PTCA in Diabetic Patients 
with Acute Myocardial Infarction: Six Months Results 
of the Stent PAMI Trial 
Luis Mattos, J. Eduardo Sousa, Gregg Stone, Marie C. Modce, 
Judith Boura, William O'Neill, David Cox, Eulogio Garcia, Olivier Madonna, 
Cindy Gdnes. Institute Dante Pazzanese of Cardiology, S&o Paulo, Brazil," 
William Beaumont Hospital, Royal Oak, Michigan, USA 
Background: The PAMItrial randomized 900 pts with AMI < 12 hours at 
62 centers to either primary PTCA or Stenting Diabetic (D) pts have poorer 
results of elective coronary interventions than non diabetic; however, few 
data exist regarding diabetes treated with stents in AMI. 
Methods: We compared the cumulative occurrence of major coronary 
events at 6 months, between diabetic vs. non diabetic pts, randomized to 
primary Stenting or PTCA with bailout stenting. 
Results: The diabetic pts were older than non D (64 vs. 59 yrs, p < 
0.001), more often female (38 vs 23%, p < 0.001), more multivessel disease 
(54 vs 43%, p = 0.05) and had smaller arteries (2.8 vs. 3.0 mm, p = 0.05). 
The 6 mos, TVR were similar (10 vd 10%, p = 0.8), but at 6.5 mos, D pts had 
smaller MLD (1.8 vs 1.5 ram, p = 0.008). 
6 months Non Diabetic (n = 758) Diabetic (n = 134) 
Events/pts Stent (377) PTCA (381) Stent (71) PTCA (63) 
ReMI 3.1% 3.6% 1.5% 3.3% 
Death 3.6% 2.5% 1.5% 1.6% 
Angina 10.6% 16.1%" 9.2% 13.3% 
TVR 6% 14%* 7% 13% 
Post MLD 2.6 + 0.4 mm 2.1 5- 0.4 ram* 2.5 ± 0.4 mm 2.1 ± 0.5 mm" 
6.5 mos MLD 1.9 5- 0.6 mm 1.7 5- 0.7 mm" 1.5 5:0.7 mm 1.5 5- 0~6 mm 
Restenosis > 50% 19% 33%* 36% 32% 
"p < 0.05, Stent vs. PTCA 
Conclusion: Despite the presence of many unfavorable variables, major 
coronary events were similar between diabetic and non-diabetic patients. 
Only non-diabetics had benefit from stents with reduced angina, TVR and 
angiographic restenosis. 
5:15 p.m. 
I81-~-1-8 Stent Treatment for Unprotected Left Main Coronary 
Artery Stenosis: Long Term Follow-Up Result 
Takashi Tamura, Takeshi Kimura, Hideyuki Nosaka, Naoya Hamasaki, 
Hiroyoshi Yokoi, Yoshihisa Nakagawa, Masakiyo Nobuyoshi. Kokura 
Memorial Hospita/, Kitakyushu, Japan 
To evaluate the efficacy and safety of stent treatment for unprotected Left 
Main Coronary Artery (LMCA) stenosis, we analyzed consecutive 50 patients 
(pts) treated with Palmaz Schatz stent in 40 pts, ACS slant in 10 pts from 
March 91 to September 97:38 males (76%), mean age of 67:5 14 years. 
Stenting was planned in 48 pts and provisional in 2 pts due to suboptimal 
result after PTCRA. Treated pts were divided into two groups; good candidate 
group (GC) without nsk factor for CABG, 23 pts and poor candidate group 
(PC) with one or more risk factors for CABG, 27 pts, The expected risk 
factor for CABG of the PC group were related to old age (_>75 yrs) in 14 
pts, cerebrovascular disease in 9 pts, poor LV function (ejection fraction 
(EF) < 40%) in 5 pts, prior CABG in 5 pts, COPD in 5 pts, poor run off 
in 1 pt, cancer in 1 pt. Decision of stent implantation in the GC group 
was chiefly based on anatomical suitability for stenting. LMCA stenting was 
performed successfully in all pts. There was 1 in-hospital death due to acute 
closure of the right coronary artery dilated one week later. However, there 
were no major complications (death, emergent CABG, myocardial infarction 
(MI)) related to LMCA stenfing nor stent thrombosis during hospital stay. 
Angiographic follow-up was performed in 48 pts (96% of eligible pts). Clinical 
follow-up data obtained in all pts at a mean interval of 22 + 15 months 
revealed 3 LMCA-related-deaths (PC group 2 pts, GC group 1 pt), 2 MIs, 2 
CABGs. LMCA-related-death was defined as all deaths except for definite 
non-cardiac death or cardiac death with evident stent patency. The 1- and 
2-year patient survival rates for freedom from LMCA-related-death were 92% 
and 92%. The 1- and 2-year patient survival rates for freedom from death, 
MI, CABG were 87% and 81%. The 1- and 2-year patient survival rates for 
freedom from death, MI, CABG, TLR were 82% and 77%. 
Conclusion: Stent treatment for unprotected LMCA had no LMCA- 
related-death since one year later after procedure and a good long term 
follow-up result, and could be a challenging alternative to CABG in selected 
patients, deserving further careful clinical evaluation. 
5 :30  p.m. 
~-1 Argentine Randomized Study Optimal Coronary 
Balloon Angiopiasty and Stenting vs. Coronary 
Bypass Surgery in Multiple Vessel Disease (ERACl II): 
In Hospital and 30 Days Results 
Alfredo E. Roddguez, Liliana Grinfeld, Nestor Perez Bali~o, Jos~ Navia, 
Julio Baldi, Roberto Grinfeld, Marcelo Garrido, Daniel Vogel, 
Alejandro Delacasa, Eduardo Mele, Jorge Martinez, Raul Oliveri, Igor 
E Palacios, William O'Neill. On behalf of ERACl II Investigators; Otamendi 
Hospital, Italian Hospital - CECl, Buenos Aires, Argentina 
Background: The use of stents during coronary interventions reduce acute 
complications and late restenosis. The aim of this study was to compare 
coronary angioplasty with stents (PTCA) vs coronary by pass surgery (CABG) 
in patients with multiple vessel coronary artery disease (CAD). 
Methods: From November 1996 to September 1998, 440 pts with multi- 
ple vessel CAD were included and randomized to PTCA (219 pts) or CABG 
(221 pts). The end point of this study was to compare major adverse cardiac 
events (MACE) defined as death, myocardial infarction (AMI) and require- 
ment of repeat, PTCA/CABG at 30 days, one, three and five years after 
the randomization. At 30 days stroke was also included as MACE. At this 
moment we will present the in hospital and 30 days outcome. 
Results: Basal demographic and angiographic characteristics were sim- 
ilar, Unstable Angina class II, III, and C 93% vs 90.2%; three vessels 59% vs 
61%; diabetics 18.5% vs 18.7% in PTCA and CABG groups respectively 
Hospital and 30 days outcome: PTCA CABG P 
Death 0,9% 5.8% = 0,012 
AMI (Q) 0.9% 5.8% = 0.012 
Death + AMI (Q) 1.8% 11.6% = 0.0002 
Stroke 0% 0.9% 
Emergent PTCA 1.8% 0% 
Emergent CABG 0% 0% 
MACE 3.6% 12.5% = 0.003 
Conclusions: Patients randomized to PTCA plus stenting had signifi- 
cantly lower, 30 days MACE than patients randomized to CABG group. Six 
months follow up data will be available at the time of this presentation. 
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ORAL 
Adjuncts for Coronary Stenting: Can We 
Possibly Make Stenting Better? 
Sunday,  March  7, 1999, 3 :30 p.m.- -4:45 p.m, 
Mor ia l  Convent ion  Center ,  Room 265 
3:30 p,m. 
~'~ Clopidogrel versus Ticlopidine for Coronary Stents 
Peter B. Bergar, Victoria Bellot, Steven Melby, Malcolm R. Bell, Kirk 
N. Garratt, Charanjit S. Rihal, David R. Holmes Jr.. For the Cardiac 
Catheterization Laboratory, Mayo Clinic, Rochester, MN, USA 
Ticlopidine (Ticl) combined with aspirin (ASA) reduces the frequency of 
coronary stent thrombosis, but Ticl causes neutropenia or thrombotic throm- 
bocytopenic purpura in >1% of pts. Clopidogrel (Clop) is a thienopyridine 
closely related to Ticl in chemical structure and function but able to achieve 
more rapid platelet inhibition when a loading dose is used and with fewer 
side effects. We compared the 30-day event rate in 500 consecutive stent 
pts treated with ASA and Clop (300 mg oral load immediately prior to stent 
placement followed by 75 mg/day for 14 days) between 3/13/98 and 7/31/98 
in whom angiographic success was achieved with the event rate in 827 con- 
secutive pts treated with ASA and Ticl (500 mg load followed by 250 mg BID) 
in a prior study of Ticl for just 14 days. Most baseline characteristics between 
the Clop and Ticl pts were similar; the use of Multilink (47%) and AVE stents 
(35%) predominated in the Clop cohort vs Palmaz-Schatz (78%) stents in the 
Ticl cohort. Abciximab was administered to 32% vs 37% of pts, respectively; 
10% of pts in both groups had an MI within 24 hrs. 
Results: Stent thrombosis within 30 days was suspected or confirmed in 
0.2% of Clop vs 0.7% of Ticl pts (p = 0.20); Clop had been discontinued 5 
days after stent placement in the only Clop pt with thrombosis 3 days before 
thrombosis occurred. Other adverse events included death in 0.4% of Clop 
vs 0.7% of Ticl pts; non-fatal MI in 0 vs 0.5%; and CABG or re-PTCA in 0.4% 
vs 0.5% of pts, respectively. Any of these adverse events occurred in 0.8% 
of Clop pts vs 1.6% of Ticl pts within 30 days (p = 0.23). 
Conclusions: Clop may be safely substituted for Ticl in pts receiving 
coronary stents. Larger studies are required to determine whether the more 
rapid onset of action of Clop results in greater safety and efficacy than Tict. 
3:45 p.m. 
~-~ Clopidogrel for the Prevention of Stent Thrombosis 
Gregory J. Mishkel, Charles L. Lucore, Robert W. Ligon, Janiece Trokey. 
Prairie Cardiovascular Consultants, Southern Illinois Universi~ Springfield, 
Illinois, USA 
The ISAR trial demonstrated that the combination of ticlopidine and ASA 
has a stent thrombosis rate of 0.8%. The CAPRIE study has demonstrated 
CIopidogrel to be an effective antiplatelet agent in patients with a variety 
of vascular conditions, with the advantage of once daily dosing, excellent 
tolerability, and a low incidence of neutropenia. 
We prospectively followed all patients administered clopidogrel after coro- 
nary stenting subsequent to its general market release. From 3/1/98 through 
7/31/98, a total 990 patients underwent coronary stenting, 345 (34.8%) of 
whom received 75 mg clopidogrel in combination with ASA for two to four 
weeks to prevent stent thrombosis. Half of these patients had single vessel 
disease and 30 patients had saphenous vein stenting. Multiple stents were 
utilized in 133 patients (38.5%). The average stent size was 3.15 mm (2.25 
mm to 6.0 mm). The average EF was 45.6%. UA or MI was the admitting 
diagnosis in 288 patients (83%). Adjunctive liB/IliA inhibitors were used in 
246 patients (71.3%) and 28 received (8.1%) low molecular weight heparin 
during their hospitalization. Coumadin was utilized in 13 patients. 
The major adverse cardiac event rate was 2.0% (5 Ml's, 1 CABG, 2 
deaths) Abrupt closure secondary to stent thrombosis occurred in 3 patients 
(0.87%), all within 2 hours of the procedure, none of whom had received their 
first dose of clopidogrel. One month follow-up is available for all patients, and 
no sub-acute stent thromboses, MI or deaths were noted. 
In conclusion, clopidogrel appears to offer similar efficacy to ticlopidine 
for the prevention of sub-acute coronary stent thrombosis. A randomized tdal 
appears warranted to determine its exact role in the future. 
4 :00 p.m. 
~-~ Mortality from Ticlopidine Associated Thrombotic 
Thrombocytopenic Purpura (TTP) following Coronary 
Stent Placement 
Charles L. Bennett, Peter D. Weinberg, Mark D. Feldman, Chades 
J. Davidson. Northwestern University and the Chicago VA Healthcare 
System; Chicago, IL; and the University of Texas at San Antonio Health 
Sciences Center, San Antonio, TX, USA 
Ticlopidine-associated TTP is a life-threatening disease that previously has 
been described primarily in the stroke prevention setting. To date, only 8 
cases have been described in coronary stent patients. We recently reported 
the incidence of ticlopidine-associated TTP following cardiac stenf placement 
as 1 in 1,600 patients. 
To elucidate the clinical sequelae of ticlopidine-associated TTP following 
coronary stent placement, 24 cases were identified using reports from mul- 
tiple sources including hematologists (n = 10), plasmapheresis centers (n = 
7), the FDA MedWatch program (n = 5), and published cases (n = 2). The 
mean age was 60.8 • 11.1 years. Normal platelet counts within two weeks 
of onset of TTP were documented in >90%. Concomitant medications were 
aspirin (50%), beta blocker (38%), warfarin (17%), and nitroglycerin (13%). 
Ticlopidine was used for 2 weeks in 8%; 2 to 3 weeks in 54%; and 3 to 4 
weeks in 33%. Platelet counts < 20,000 mm 3 occurred in 79%; hemoglobin 
< 9 gm/dL in 42%; serum creatinine > 2.5 mg/dL in 25% and neurologic 
abnormalities were noted in 75%. Over 75% had plasmapheresis. 
Mortality due to TTP was 21%. The only factor predictive of mortality was 
nonuse of plasmapheresis (60% vs. 11%) (p < 0.01). None of 5 pts who died 
underwent plasmapheresis within 2 days of the onset of TTP, while 12/19 
(64%) of surviving pts had plasmapheresis initiated within two days of the 
onset of TTP (p = 0.05). 
Conclusions: Fatal TTP may occur within 2 weeks of ticlopidine therapy 
following coronary stent placement. Survival is highest when plasmapheresis 
is initiated within 2 days of onset of TTP. 
4:15 p,m. 
~-]  Marked Benefit in Diabetic Patients Treated With Stent 
and Abciximab Combination: 6 Month Outcome of the 
EPISTENT Trial 
A. Michael Lincoff, James E. Tcheng, Catherine F. Cabot, Robert M. Califf, 
Joan E. Booth, Shelly Sapp, Eric J. TopoL For the EPISTENTInvestigators; 
The Cleveland Clinic Foundation, 9500 Euclid Ave. Cleveland Ohio, USA 
The efficacy of abciximab (Abcix) and other GP lib/Ilia inhibitors in diminishing 
clinical restenosis following percutaneous coronary revascularization has 
been inconsistent in different trials. Pts with diabetes mellitus (DM) are 
at greater risk for than non-diabetics for late restenosis and target vessel 
revascularization (TVR) after PTCA or stenting. We evaluated the impact of 
Abcix and stents on TVR rates and angiographic restenosis among pts with 
and without DM in the randomized EPISTENT trial. A total of 2399 pts, 491 
(21%) of whom were diabetic, were randomized to placebo + stent (n = 809), 
Abcix + PTCA (n = 796), or Abcix + stent (n = 794). Two secondary endpoints 
of the study were the composite of death or MI and the need for TVR by 6 
months: 
Placebo / Stent Abcix / Stent Abcix / PTCA 
DM - Death/MI 12.7 6.2" 7.8 
DM -TVR 16.6 8.1" 18.4 
No DM - Death/MI 11.0 5.4* 7.8* 
No DM -TVR 9.0 8.8 14.6" 
"p < 0.05 
Angiographic outcome in an Angiographic Substudy of 899 lOtS, of whom 
183 (20.4%) had DM, will also be presented. 
Thus, Abcix reduces death and MI among all pts, regardless of DM status. 
Among pts without DM, TVR was reduced by stenting, but not by Abcix. In 
contrast, among pts with DM, stents did not reduce TVR (compared with 
PTCA + Abcix), while Abcix did reduce TVR following stenting. Abcix may 
therefore reduce restenosis among diabetic pts treated with stents. 
4 :30 p.m. 
Clinical Evaluation of a Biocompatible 
Phosphorylcholine-Coated Coronary Stent 
Hong Zheng, Paul Barragan, Thierry Corcos, Jean-Baptiste Simeoni, 
Xavier Favereau, Pierre-Olivier Roquebert, Yves Gu~dn, Jo61 Sainsous. 
Centre Medico-Chirurgical de Party II, Le Chesnay, and Polyclinique les 
Alpilles, Marseilles, France 
Background: The BiodivYsio TM stent is a new stent coated with phospho- 
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rylcholine, a cell membrane molecule, which was designed to reduce the 
formation of thrombus and potentially the risk of restenosis. 
Methods: We prospectively studied 224 consecutive patients who un- 
derwent elective (67%) or bail-out implantation of 303 BiodivYsio TM stents in 
286 lesions. Most lesions (62%) had unfavorable characteristics (type B2 
or C) and 50% had thrombus and/or chronic occlusion. Clinical follow-up 
was obtained in all patients at one month and in the first 132 patients (147 
lesions) at six months. Repeat angiography was undertaken in all patients 
with recurrent ischemia. 
Results: Successful stent deployment was achieved in 284 lesions 
(99.3%). Angiographic success rate (post-intervention stenosis < 30%) was 
98.3% (281/286). There was 1 (0.4%) subacute stent thrombosis (with 
Q-wave myocardial infarction), and 2 (0.9%) non stent-related in-hospital 
deaths. No emergency CABG was required. Reference diameter was 2.82 
± 0.32 mm. Minimal luminal diameter increased from 0.38 ± 0.25 to 2.97 
± 0.35 mm and diameter stenosis decreased from 83.8 ± 12.1% to 5.8 ± 
9.7%. No cardiac event occurred during the first month after intervention. At 
6 month follow-up, repeat target lesion revascularization was required in only 
8 lesions (5.4%). 
Conclusion: The implantation of phosphorylcholine-coated stents ap- 
pears to be safe and efficacious in the treatment of complex coronary lesions 
and is associated with an extremely low target vessel revascularization rate. 
Randomized studies are warranted to compare this coated stent with cur- 
rently available non-coated stents. 
ORAL  
Coronary Interventions: 1999 
Monday ,  March  8, 1999, 10:30 a .m. -Noon 
Moda l  Convent ion  Center ,  Room 265 
10:30 a.m. 
~~--~ Early Ambulation After PTCA in Anticoagulated 
Patients With the Prostar-Perclose Percutaneous 
Suture Device and the Angioseal Device - A 
Randomized Trial 
Horst Sieved, Torsten Becket, Thomas Wander, Sabine Mfissig, 
Matthias Dickopf, Eva Bartsch, Charlotte Gilzinger. Cardiovascular Center 
Bethanien CCB, Frankfurt, Germany 
In a randomized study 300 consecutive patients undergoing uncomplicated 
PTCA were assigned to receive either immediate sheath removal and percu- 
taneous suture of the femoral artery access site with the 8 F-Prostar Perclose 
system or puncture site closure with the Angioseal device or conventional 
sheath removal after 6 hours with a pressure dressing and additional bed- 
rest for 6 hours. Patients were allowed to ambulate 2 hours after Perclose or 
Angioseal, respectively. Clinical follow up was obtained one day and 2 weeks 
(n = 298) after sheath removal. 
Baseline characteristics were comparable in the three groups. The primary 
success rate was 92% for the Prostar device and 97% for the Angioseal 
device (N.S.). No complications occurred during the procedure. 
Prostar Angioseal Control P 
Major complications (%) 4 1 1 N.S. 
Minor complications (%) 14 1 3 <0.01 
Immediate sheath removal and ambulation after two hours is possible 
with both devices in fully anticoagulated patients without significant increase 
of major peripheral vascular complications. However, minor complications 
have been more frequent after Prostar. 
10:45 a.m.  
~--~ Contemporary Intervention for Unstable Coronary 
Angina: A Report from the NHLBI Dynamic Registry 
Charanjit Kapoor, David O. Williams, Wanlin Yeh, Howard A. Cohen, David 
R. Holmes, Alice K. Jacobs, Richard Holubkov, Sheryl F. Kelsey, Katherine 
M Detre. Rhode Island Hospital, Brown Universi~ Providence, Rhode 
Island, USA 
Background: Unstable angina (UA) has been identified as a risk factor 
for complications following coronary angioplasty. Whether this relationship 
persists with contemporary interventional techniques is unknown. 
Methods: We compared the baseline features and in-hospital outcomes 
of patients (pts) with either UA (n = 1088) or stable angina (SA, n = 583) 
enrolled in the 1997-98 NHLBI Dynamic Registry. 
Results: Pts with UA were older (63.3 vs 62.4 years, p < 0.01), more 
likely to be female (37.9% vs 32.9%, p < 0.05), have a history of prior 
myocardial infarction (45.4% vs 33.3%, p < 0.001), prior heart failure (9.7% 
vs 7.8%, p < 0.001), an urgent or emergent intervention (34.6% vs 3.6%, p 
< 0.001) and a lower left ventricular ejection fraction (56.3% vs 58.7%, p < 
0.001) than SA pts. Complex lesions characteristics (total occlusion, ostial 
location, thrombus, decreased TIMI flow) were more common (p < 0.05) 
in UA than SA pts while calcified lesions were less frequent (p < 0.001). 
Disease distribution was predominantly multivessel in both groups. A lib/Ilia 
receptor antagonist was used more commonly in UA than SA (22.4% vs 
13.2%, p < 0.001). Stent usage was similar (p = ns) for UA (56.9%) and SA 
(54.4%) pts. Procedural success (angiographic success without in-hospital 
death, Q-wave MI or emergency CABG) was high and similar for both groups 
(95.3% vs 94.9% p = ns). 
Conclusion: Pts with UA more often had evidence of advanced and 
complex CAD as well as factors associated with unfavorable outcome fol- 
lowing revascularization. With current techniques including judicious use of 
Ilbllla antagonist therapy, these pts had similar procedural and in-hospital 
outcomes as those with SA. 
11:00 a.m.  
[ -8 -~ The Economic Impact of Complications After 
Percutaneous Coronary Revascularization 
Deborah A. Taira, Todd B. Seto, Ronna Berezin, Roberta Cosgrove, Donald 
E. Cutlip, Kalon K.L. Ho, Richard E. Kuntz, David J. Cohen. Beth israel 
Deaconess Medical Center, Boston MA, USA 
Background: Understanding the incremental cost of procedure-related com- 
plications is important in determining optimal treatment strategies and in 
assessing cost-effectiveness of new technologies. 
Methods: To determine the costs attributable 1o complications of per- 
cutaneous coronary revascularization during the initial hospitalization, we 
developed multivariable linear regression models using data from two large- 
scale interventional device trials (n = 1,537). Catheterization laboratory costs 
were based on measured resource utilization and 1997 unit costs. Other 
hospital costs were obtained by multiplying hospital charges by cost-center 
specific cost-to-charge ratios. 
Results: Myocardial infarctions (MI) and vascular complications were sig- 
nificantly related to costs (see table). After controlling for death ($1,685, p = 
0.51), repeat diagnostic catheterization ($1,093, p = 0.22), repeat percuta- 
neous revascularization ($5,160, p < 0.001), bypass surgery ($15,839, p < 
0.001), costs of MIs diminished but remained significant. 
Complication incremental cost 
Unadjusted Adjusted for Repeat Procedures 
Q-wave MI $9,753 (p < 0.001) $7,222 (p < 0.001) 
Non q-wave MI $6,518 (p < 0.001) $3,675 (p < 0.001) 
(CKMB > 8x norm) 
Non q-wave MI $2,824 (p < 0.001) $2,496 (p < 0.001) 
(CKMB 3-8x norm) 
Non q-wave MI $599 (p = 0.29) $730 (p = 0.16) 
(CKMB 1-3x norm) 
Vascular comp. $9,263 (p < 0.001) $8,071 (p < 0.001) 
Conclusion: Procedure-related MIs and vascular complications add sig- 
nificantly to the initial cost of percutaneous coronary revascularization. Ther- 
apies designed to reduce these complications may significantly improve 
outcomes while lowering costs. 
11:15 a.m.  
~-~- ]  Effect of Percutaneous Coronary Revascularization 
on Health-Related Quality of Life in the Elderly 
Todd B. Seto, Deborah A. Taire, Manish Chauhan, Ronna Berezin, Donald 
E. Cutlip, Kalon K. Ho, Richard E. Kuntz, David J. Cohen. Beth Israel 
Deaconess Medical Center, Boston MA, USA 
Background: Despite similar rates of technical success after percutaneous 
coronary revascularization, previous studies have found a higher incidence 
of procedure-related myocardial infarction and death in the elderly. Little is 
known regarding the relationship between age and health-related quality of 
life (HRQOL) following percutaneous coronary revascularization. 
Methods: Quality-of-life outcomes were assessed using the SF-36 survey 
at baseline, 6 mo, and 1 yr follow-up survey for 1372 pts who underwent per- 
cutaneous coronary revascularization as part of 2 multicenter, interventional 
device trials. Changes in HRQOL relative to baseline were compared for the 
elderly (>70 yr, n = 286) and non-elderly (<69 yr, n = t086) after adjust- 
ing for clinical (severity of CAD, LVEF, comorbidities) and sociodemographic 
(gender, age, education level) factors. 
Results: At 1 yr follow-up, the elderly reported marked improvements in 
HRQOL, with significant improvement in 7 of 8 scales in the SF-36 (physical 
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functioning A = 12.2, p < 0.001 ; role physical ~. = 21.9, p < 0.001; bodily pain 
A = 14.4, p < 0.001; vitality ~ = 6.7, p < 0.001; social functioning & = 11.2, 
p < 0.001; role emotional ,~. = 17.4, p < 0.001; and mental health Z~ = 3.4, 
p = 0.002). Adujsted gains in HRQOL at I yr were similar for the elderly and 
non-elderly cohorts for 6 of 8 SF-36 scales. Compared with the non-elderly, 
the elderly reported somewhat less improvement in physical functioning (13.0 
vs 16.2, p = 0.01) and the role physical scale (21.5 vs 25.9, p = 0.02). 
Conclusions: HRQOL improves dramatically in elderly patients following 
percutaneous coronary revascularization. Despite more frequent procedural 
complications, long-term quality of life improvements in the elderly are com- 
parable to those for younger patients. These findings suggest that age alone 
should not influence the decision to perform PTCA. 
11:30 a.m. 
[ -~-6~ Are We Making Progress with Percutaneous 
Saphenous Vein Graft Treatment? Comparison of 
1990-94 and 1995-98 Results 
Mun K. Hong, Roxana Mehran, Kenneth M Kent, Augusto D. Pichard, 
Lowell F. Satler, Gary S. Mintz, Hongsheng Wu, Ann Greenberg, 
Steve Slack, Martin B. Leon. Washington Hospital Center, Washington, DC, 
USA 
Background: Angioplasty of saphenous vein graft (SVG) lesions has been 
associated with frequent procedural and late cardiac events. 
Methods: We compared the baseline characteristics and results of 2019 
patients with 2727 SVG lesions treated at Washington Hospital Center be- 
tween 1990-94 (Group 1; 1055 pts with 1412 lesions) and 1995-1998 (Group 
2; 964 pts with 1315 lesions), 
Results: Despite more unfavorable characteristics in Group 2, the pro- 
cedural success was similar between the groups (96.6% vs 96.1%) and the 
1-year outcome was improved in Group 2. Changes in treatment strategies 
between the two time periods have included maneuvers to minimize distal 
embolization (smaller devices, stenting without pre- or post-dilatation, staged 
procedures) and the increased use of stents. 
Group t Group 2 
Graft age (mos.} 95 ± 53 100 ± 63" 
Lesion length (ram) 9 ± 7 12 ± 11" 
SVG degeneration (%) 36.5 60.2* 
Stents (%) 54.0 64.9" 
Any Date cardiac event (%) 33.4 27.5* 
TLR (%) 26.2 18.9* 
TLR = target lesion revascularization; *p< 0.05 between groups 
Conclusion: These results suggest that with strategies to reduce distal 
embolization, procedural success remains high despite higher risk lesions, 
and the use of stents significantly reduces late cardiac events in saphenous 
vein graft lesions. 
11:45 a.m. 
[806~-~ Percutaneous Coronary Intervention: Changing 
Practice Patterns and Outcomes 1995-1997 
Michael A. Lauer, Eric J. Topoi, Elisa F. Cascade, Jennifer A. Karweit, 
Nancy D. Lin. Cleveland Clinic Foundation, Cleveland, OH; The Lewin 
Group, Fairfax, VA, USA 
The practice of PCI continues to evolve with development of new drugs, 
devices, and techniques. We examined changes in practice patterns and 
outcomes from 10/95 to 10/97 using hospital claims data from a nationally 
representative sample of 37,088 patients who underwent PCI. 
Results: Heparin use and bleeding (patient requiring a transfusion; major 
bleed > 2 units, minor bleed < 2 units) declined significantly (p < 0.001) over 
the 2-year period, but remained constant from 4/96 to 3/97. Minor bleed rates 
were constant at about 1%. Acute evenls (CABG, death, repeat PTCA) and 
10/95-3/96 4/95-9/96 10/96-3/97 4/97-10/97 
Stent use 29.9% 37.3% 36.5% 44.4% 
Abciximab use 3.3% 6.7% 9.9% 7.9% 
Stent + abciximab 2.1% 7.3% 11.1 % 13 1% 
Mean heparin units 101,812 88,003 86,768 76,538 
Length of stay, d 5.2 4.5 4.1 3.8 
"i3me to event, d 2.6 2.4 2.2 2.2 
Bleed rate 7.8% 6.5% 6.9% 5.4% 
CABG 3.4% 3.0% 2.6% 2.1% 
Deaths 1.9% 1.8% 1.4% 1.6% 
Repeat PTCA 13.3% 11.2% 8.4% 7.1% 
Cost-no bleed $10,939 $10,984 $10,323 $9,825 
Cost-major bleed $27,474 $26,496 $25,900 $26,642 
average LOS decreased overall (p < 0.001), and use of stent, abciximab, or 
both increased (p < 0.001). Average days between hospital admission and 
the procedure (time to event) decreased marginally. 
Conclusion: Parallel trends in the data suggest a correlation between 
improved outcomes and use of new drugs/devices and between heparin 
dose and bleeding. Bleeding remains a target area for improvement in PCI 
because of its frequency (5.4%) and association with considerable costs. 
ORAL 
1 -~ Stents and Stent Grafts: Meeting New 
Challenges 
Monday, March 8, 1999, 10:30 a.m.-Noon 
Modal Convention Center, Room 279 
10:30 a.m. 
~ Coronary Stent Graft Versus Conventional JoStent ® 
Stent Design in Complex Coronary Lesions 
Ulrich Gerckens, Ralf M011er, Norbert Cattelaens, Sascha Rowold, 
Eberhard Grube. Heart Center Siegburg, Siegburg, Germany 
The JoStent ® Coronary Stent Graft (CSG) combines a flexible stent (ST) with 
a layer of expandable PTFE graft material placed between 2 ST (sandwich 
technique, 2.5-5.0 mm). CSG might influence the restenosis rate favorably. 
In order to assss the safety, efficacy and restenosis rate of this new ST 
type we performed a study comparing the stent graft with a lesion matched 
control group treated with a conventional JoMed stent design (CONV). Up to 
now we enrolled 46 patients with 47 lesions (pts; mean 64.1 years, 40 male): 
6 bypass graft lesions (>20 mm), 5 coronary aneurysms, 12 complex/ostial 
lesions, 17 instent-restenosis and 7 multiple balloon restenosis. 
We implanted the CGS with a low-compliance balloon (mean size 3.8 
mm ± 0.36 mm) and a mean inflation pressure of 19.1 ± 2.9 atm. IVUS 
(EndoSonics 30 mHz) was performed during implantation and follow-up 
angiography. Post PTCA treatment consisted of ASA (100 mg/day) and 
Ticlopidine (2 x 250 mg/day for 14 days). 
Complication: one ventricular fibrillation after CSG in the proximal RCA, 
one stent-thrombosis at day 13. Side branch occlusion was observed in 6 
patients (CK mean 190 u/I) Follow up data is available on 15/46 CSG pts.: 
within the grafted stent segment no intimal hyperplasia was visualized by 
angle or IVUS except one lots.: 6/15 pts. had a plaque burden at the proximal 
and distal edge (not covered by PTFE layer) of 30% ± 12 resp. 36% ± 12. All 
reinterventions are due to intimal hyperplasia at the stent-edges (first stent 
design). The angiographic restenosis data compared to the CONV. will be 
presented. 
We conclude, that the CSG can be safely implanted with low acute 
complication rate. Preliminary data shows no intimal hyperplasia within the 
grafted segments. Current signs of restenosis are due to the uncovered stent 
edges. Follow-up data comparing both stent-designs is pending. 
10:45 a.m. 
~ T h e  French Registry of Coronary Stent Grafts: Acute 
and Term Results 
Marie-Claude Morice, Rajendra Kumar, Thierry Lefevre, 
Christophe Loubeyre, Jean-Francois Morelle, Gilles Traisnel, 
Philippe Commeau, Pierre Labrunie, Jacques Berland, Thierry Royer, 
Michel Henry. ICPS, Antony, France 
Given the limited experience reported with coated stents, a registry was set 
up when the coated stents (Jostent) became available in France to assess 
the feasibility, safety and mid-term results of their implantation. 
To this day, 48 patients have been treated (mean age 63.5, 16.6% fe- 
males). At the time of PTCA, 20 pts (41.7%) were stable, 7 (14.6%) unstable, 
2 (4.2%) in the post MI phase, 4 (8.3%) had restenosis, post CABG in 9 
(18.75%) and 6 (12.5%) were treated at the acute phase of MI. 
Femoral approach was selected in 43 (89.6%) of cases, radial in the 5 
(10.4%) remaining patients, 21 (43.7%) procedures were performed with 8 
F catheters, 18 (37.5%) with 7 F and 7 (14.6%) with 6 F. Vessel treated was 
the LAD in 12 (25%) patients, circumflex in 3 (6.6%), RCA in 9 (18.75%), and 
graft in 22 (45.8%). 7 lesions were <10 ram, 26 from 10 to 20 mm, 9 from 20 
to 30 mm and 2 > 30 mm. The lesion was an ulceration in 17 (35.4%) cases, 
a fistula in 3 (6.2%), an aneurysm in 14 (29.2%), a restenosis in 9 (18.75%), 
a perforation in 3 (6.2%) and a lesion on a graft in 22 (45.8%). 54 stents 
were implanted at a mean pressure of 16.7 arm with a 3.5 mm balloon. 1 
procedure failed (coronary rupture, lesion uncrossed and death). During the 
in-hospital phase, 1 patient had non-Q-wave MI, none had CABG or vascular 
complications. 
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In conclusion, although they proved more rigid, stent grafts were success- 
fully implanted in 98% of cases. The absence of in-hospital complications, 
especially occlusions, seems very promising, this particular stent allowing 
treatment of so far percutaneously inaccessible lesions such as fistulae, 
aneurysm and coronary rupture. The 6-month clinical follow-up will be avail- 
able for the ACC meeting. 
11:00 a.m.  
~-~- - ]  Periprocedural Infarction After Vein Graft Myocardial 
Stenting: Incidence and Predictive Factors 
Michael P. Savage, David L. Fischman, Stephen Ellis, Spencer King, 
Sheldon Goldberg, Diane Rehmann, Donald Cutlip, Kalon K.L. Ho, Martin 
B. Leon. For the RAVES Trial Investigators; Jefferson Medica/ College, 
Philadelphia, PA, USA 
Background: Myocardial infarction (MI) due to thrombeembolic complica- 
tions remains problematic for transcatheter vein graft intervention. The goal 
of this study was to assess the frequency and predictive factors of beripro- 
cedural MI during vein graft stent placement. 
Methods: The study population consisted of 201 patients enrolled in the 
Reduced Anticoegulation after VEin graft S_tenting (RAVES) trial. All patients 
underwent elective Palmaz-Schatz stent implantation in diseased venous 
bypass grafts (3-5 mm in diameter) using high pressure deployment (_>16 
atm) and aspirin/ticlopidine therapy. Exclusion criteria included the presence 
of thrombus or total occlusion. Cardiac enzymes were obtained at 6 and 24 
hours post-procedure. 
Results: Periprccedural MI occurred in 57 of the 201 patients (28%). 
There were 5 Q-wave MI and 52 non-Q wave MI. Among the 52 patients with 
non-Q wave MI, 37 (71%) had CKMB > 3 times normal and/or major new 
ST-T wave changes. The development of MI was not predicted by any patient 
demographic variable or cardiac risk factor. Vein graft age was comparably 
old in patients with and without MI (10.7 vs 10.5 years, p = ns). On the other 
hand, periprocedural MI was significantly associated with lesion morpholegic 
characteristics. The incidence of complications significantly increased with 
ACC/AHA lesion complexity: Type A (14%), B1 (29%), B2 (35%), C (50%) (p 
< 0.01). Lesion length was highly predictive of MI: 17% for <10 mm, 35% for 
10-20 mm, 54% for >20 mm (p < 0.001). MI was more frequent in eccentric 
than concentric lesions (37 vs 20%, p < 0.01) and in complex, degenerative 
lesions (46 vs 24%, p < 0.01). 
Conclusions: Periprocedural MI during vein graft stenting: (1) remains 
alarmingly common using contemporary techniques of high pressure deploy- 
ment and antiplatelet herapy; (2) is not predicted by patient-related clinical 
factors; and (3) is significantly related to lesion morphology. 
11:15 a.m.  
~-~ Final of Randomized Wallstent ® Results the 
Endoprostheeis in Saphenoue Vein Graft Trial 
(WINS) 
Robert D. Safian, Barry Kapian, Theodore Schreiber, John Waters, 
Jeffrey Moses, Martin H. Leon. WINS Investigators; William Beaumont 
Hospital, Royal Oak MI, USA 
Background: Balloon expandable stents are widely used for revasculariz- 
ing patients with stenoses in saphenous vein grafts (SVG). Results of the 
new self-expanding coronary Wallstent endoprosthesis (WS) have not been 
reported. 
Methods: A prospective multicenter randomized trial was designed to 
compare the immediate results and 6-month outcome of WS vs. Palmaz- 
Schatz coronary stent (PSS) in SVG. 
Results: 269 patients were randomized; baseline demographic, clinical, 
and angiographic characteristics were similar. There were no differences in 
lesion morphology (ACC/AHA lesion class B + C in 87%, thrombus in 8.5%), 
lesion length (13 • 8 mm), or reference diameter (3.2 ± 0.6 mm), Final 
stenosis, angiographic restenosis (defined as 6-month stenosis > 50%), and 
major adverse cardiac events (MACE, defined as death, MI, stroke, or target 
lesion revascularization ['FLR]) were similar: 
WS (n = 139) PS5 (n = 130) 
In-hospital (%) 
Final stenosis 14 + 11 16 :E 10 
MACE 7.2 7.7 
Stent hrombosis 0.7 0.8 
QMI/nonQMI 1.4/6.5 0/6.9 
6-months (%) 
MACE 23.7 16.2 
TLR 12.2 7.7 
Anglo Restenosis 38.6 40.8 
Conclusions: In-hospital and 6-month outcome are similar for the coro- 
nary Wallstent and Palmaz-Schatz stent in SVG. 
11:30 a.m.  
[ -80 -~ The SAFE Study. Multicenter Evaluation of a 
Protection Catheter System for Distal Embolization 
in Coronary Venous Bypass Grafts (SVG's) 
Eberhard Grube, John Webb. For the SAFE study group; Heart Center 
Siegburg, Siegburg, Germany; St. Paul's Hospital, U. of British Columbia, 
Vancouver, Canada 
Background: A major limitation in diseased saphenous vein grafts has 
been the frequency of distal embolization and "no-reflow" situation. Distal 
embolization has been attributed to soft, friable atherosclerotic plaques as- 
sociated with thrombus. The Guardwire TM provides a method of containing 
and retrieving this material. In a multinational, multicenter study we evalu- 
ated the effectiveness and safety of the Guardwire TM emboli protection system 
(PercuSurge Inc.). 
Description of Device: The PercuSurge TM emboli containment system 
consists of a hollow 0.014" PTCA wire incorporating a compliant inflatable 
distal occlusion balloon. During occlusion of the distal graft, PTCA and stent 
placement can be performed in a standard manner. A monorail aspiration 
catheter allows removal of potentially embolic debris prior to deflation of the 
occlusion balloon. 
Methods: 100 patients with previous bypass surgery and SVG's will be 
enrolled in this multicenter study. A standard PTCA and stent placement 
is performed over the Guardwire TM system and the loosened material is 
aspirated through the aspiration catheter. The primary endpoints are MACE 
and TIMI flow post-procedure. Secondary endpoint is MACE after 30 days 
phone call follow-up. 
Results: 52 patients out of the 100 are presently enrolled in SAFE. 
Grossly visible debds was contained in all cases and the aspirated blood and 
debris is currently under histological evaluation. 
Conclusion: The PercuSurge Guardwire TM system is compatible with 
routine angioplasty procedures, is capable of containing and retrieving ath- 
erosclerotic and thrombotic debris, and may aid in the prevention of distal 
embolization and no-reflow in diseased saphenous vein grafts. Final results 
of all patients will be available at the time of presentation. 
11:45 a.m.  
I -8 -~- ]  Reduction Restenosis in Venous Graft of Bypass 
Lesions After Implantation of a Covered Graft Stent 
Stephan Baldus, Andreas Zeiher 1 , Jacobus Reimers, Matthias Eisner 1 , 
Klaus P. Schaps, Ulrich Gerckens, Eberhard Grube, Lutz B011esfeld, 
Christian W. Hamm. Department of Cardiology, University Hospital 
Hamburg; ~ Department of Cardiology, University Hospital Frankfurt; 
Department of Cardiology, Hospital Siegburg, Germany 
Percutaneous coronary angioplasty (PTCA) of lesions in aortocoronary ve- 
nous bypass grafts (CABG) is associated with a high restenosis rate. We 
investigated a new graft stent, which is characterized by an expandable poly- 
tetrafluorethylene (PTFE) membrane in between two layers of struts. In a 
multicenter registry we prospectively followed 50 patients (pts) (aged 67 ~: 
6 years, 12% female) who received a total of 64 graft stants between 10'97 
and 8'98. The median graft age was 127 months (range 1-249 months); 
18% of the grafts were anastomosed to the right coronary artery, 42% to the 
LAD, and 40% to the CFX. Graft stents of sized 9 mm (n = 11), 12 mm (n 
= 17), 19 mm (n = 29) and 26 mm (n = 7) were implanted with balloons of 
2.5 to 5.0 mm (median 3.5 mm). Median inflation pressure for stent deploy- 
ment was 16 atm (range 10-21 atm). Abciximab was administered in 24% 
of the pts. Stent deployment was successful for all but two stents, which 
were misplaced proximally to the lesion. Postintervantional complications: 1 
pt. had minor CK-elevation (CK max. 200 U/I) due to sidebranch occlusion 
distally to the graft. Currently 25 consecutive pts who have received 29 graft 
stents completed 6-months follow-up angiography: There were 2 deaths of 
which one occurred sudden after documented graft patency and another in 
association with thrombotic graft occlusion on day 126. In 1 pt silent graft oc- 
clusion was documented and in 1 pt repeat PTCA was performed. Event-free 
survival without restenosis was 84%. 
Conclusions: The investigated stent proved to be an efficient ool treating 
this complex subgroup of lesions in CABG. The current experience suggests 
that membrane-covered stents are associated with a low recurrence rate of 
restenosis in CABG. 
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POSTER 
Protection of Left Ventricular Function 
During Angioplasty 
Monday, March 8, 1999, Noon-2:00 p.m. 
Morial Convention Center, Hall F 
Presentation Hour: 1:00 p.m.-2:00 p.m. 
~ Cardioprotective Effect of/3-Blocker Therapy in 
Reducing CK-MB Release After Coronary 
Intervention 
Samin K. Sharma, Annapoorna Kini, Subhash Kini, George Dangas, 
Eppie Brown, Jonathan D. Marmur, John A. Ambrose. Mount Sinai Hospital 
New York, NY, USA 
It has been shown that patients on fl-blocker therapy sustaining myocardial 
infarction (MI) have lower infarct size compared to those not on f-blockers 
most likely mediated by blunting the heightened adrenergic tone and de- 
creasing myocardial oxygen demand. CK-MB enzyme elevation has been 
shown to occur in 10--33% of cases after successful coronary intervention. 
To evaluate whether f-blockers exert similar protective benefit after coronary 
intervention, we analyzed the incidence of post procedure CK-MB elevation. 
We analyzed 1351 consecutive patients undergoing coronary interventions; 
of these 483 (36%) patients were taking f-blockers prior to their intervention 
and 868 (64%) were not on fl-blockers. Incidence of CK-MB release was 
13.6% in patients on f-blockers as compared to 20.5% in the patients who 
were not on f-blocker therapy (p < 0.001). Among the various factors an- 
alyzed in a multiple linear regression model, no f-blocker use (p < 0.001), 
diffuse/multiple lesions (p < 0.01), peripheral vascular and aortic disease 
(p < 0.01), non-balloon devices (p < 0.001), stent use (p < 0.02) and CCS 
angina class Ill-IV (p < 0.02) independently correlated with CK-MB elevation. 
Dudng mid-term follow-up at 15 ± 3 months, there have been 4 deaths in the 
f-blocker group (0.62%) and 18 deaths in the no/~-blocker group (1.73%); p 
= 0.06. 
Conclusion: These non randomized data suggest that prior #-blocker 
therapy has a beneficial effect in limiting the CK-MB release during coronary 
interventions. This intriguing observation needs to be verified in a prospective 
manner or by pooled data analysis of several previous interventional trials 
reporting CK-MB release in relation to fl-blocker use. 
• Clinical Factors Associated With Neurological 
Complications Following Percutaneous Coronary 
Interventions 
S. Chiu Wong, Stylianos Papadakos, Carl Rosenberg, Rhonda J. O'Brien, 
Gregory Gustafson. The New York Hospital Medical Center of Queens, 
Flushing NY; New York State Department of Health, Troy NY, USA 
Cerebral vascular accident (CVA) is one of the most dreaded complications 
following percutaneous coronary interventions. Using the 1995 New York 
State PTCA registry database, we seek to determine the frequency and 
clinical predictors for stroke post coronary angioplasty. 
CVA No CVA P value 
(N = 38) (N = 22700) 
• Effect on Outcome in Patients With of PTCA 
Silent Ischemia After Myocardial Infarction: 
Results of the Swiss Interventional Study on 
Silent Ischemia II (SWlSSl II) 
Paul Erne, Dieter Burckhardt, Matthias Pfisterer, Paul Dubach, 
Michel Zuber, Wolfgang Kiowski. Div of Cardiology, Kantonsspital, Luzem; 
University Hospitals, Basel; Zurich, Switzerland 
Background: Silent ischemia (SI) post myocardial infarction (MI) adversely 
affects outcome. We studied the influence of PTCA or antiischemic drug 
therapy (Rx) on survival free of death, MI, or unstable angina (UA). 
Methods: 201 patients (pts; 1 or 2 vessel disease) with SI (stress echo, 
MIBI or radionuclide ventriculography) were randomized after angiography 
(<3 months from MI) to PTCA of MI and ischemia related vessel(s) (n = 96) 
or drug therapy (Rx (n = 105): bisoprolol, amlodipine, molsidomine alone or 
combined; acetylsalicylic acid in all). 
Results: Groups did not differ at baseline. Event free survival (median 
follow up (FU) 3.1 years) was not different in both groups. 
• Rx == 
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Endpeints (Rx/PTCA) were: death 0/2 (1 liver failure), M111/8, UA 17/19). 
During FU, ejection fraction decreased more in Rx pts (8.8% vs 3.9%, p 
< 0.01) suggesting less ventricular impairment in the PTCA group despite 
similar event rates. 
Conclusions: PTCA of Sl post MI does not influence occurrence of 
ischemic events as compared to drug therapy but may limit ischemic my- 
ocardial damage. 
~ Global and Regional Left Ventricular Function 
Improve After Late Recanalization of the 
Infarct-Related Coronary Artery 
Gabor Sutsch, Hans Rickli, Ernst Schuiki, Wotfgang Kiowski, F. 
Wolfgang Amann. Cardiology, University Hosp#al Zurich, Switzerland 
Background: Early recanatization (Rec) of infarct-related coronary art-eries 
preserves LV function and improves clinical outcome. Little is known about 
late Rec of chronically occluded vessels. 
Methods: To assess the effects of delayed Rec (>3 weeks after Q-wave 
infarction) on LV function after successful reopening of the infarct-related 
vessel global (biplane) and regional ("centerline"-method) LV ejection frac- 
tions (EF) and end-diastolic volume index (EDVI) were determined before 
and 3 months after Rec in 70 patients (pts, 61 male, age 60 ± 10 years) 
using standard planes (RAO 30°-/LAO 60% 
Results: In 62 pts the infarct-related vessel was patent at 3 months. 
Global EF was 61 ± 10% before and 63 ± 9% (p = 0.06) after Rec. EDVI was 
98 ± 28 ml/m 2 before and 97 J~ 27 ml/m 2 after Rec, respectively. Changes of 
regional EF (AEF in % from baseline) are listed according to the reopened 
vessel. 
Pt Demographics: RAO view 
Age (years)/Male (%) 66 J~ 10/47 62 ± 12/69 0 01/0.007 Vessel Antero Antero Antero Infero- Intero- Infero- 
Hx diabetes/hypertension (%) 24/79 19/60 NS/0.02 -basa} -medial -apicaq apical medial basal 
Hx CHF/MI {%) 8/68 5/51 NS/0.03 
Hx smoking/prior CABG (%) 18/26 2513 NS/0.03 LAD 1 2 2.4 2.4 1.1 1.4 0.9 
Hx multivessel disease/LVEF (%) 61/47 i 15 44/53 ± 12 0.05/0.05 LCX -0.1 0.1 -2.2 0.9 13.5" 2.3 
Hx thrombolysis/prior st oke (%) 8/11 7/3 NS/0.02 RCA 1.4 1.2 0.1 0.9 7.4" 2.9 
Hx PVD/Multi-lesion PTCA (%) 34/37 9 /28  <0.0001/NS 
Device Used: LAO view 
Balloon/RotaJDCA (%) 92/8/5 94/8/6 All NS Vessel Postero- Postero- Postero- Septal-  Septal-  Septal- 
StentJLasar/TEC (%) 183/3 28/1/0.2 All NS basal medial apical apical medial basal 
Major Cardiac Events: 
Death/Q-wave MI/CABG (%) 24/3/0 1/0.3/1.5 <0.0001/NS/NS LAD 0.2 -0.8 0.7 9.5" 10.8" 13.2" 
LCX 3.5 2.1 0.5 -5.4 0.4 --2.6 
RCA 2.7 0.7 2.4 3.4 6.6" 5.3 
Multivariate logistic regression analysis revealed that both history (Hx) of 
peripheral vascular disease [PVD, P = 0.009, OR = 2.98, 95%CI = 1.3-6.8] 
and female gender [P = 0.03, OR = 2.25, 95%CI = 1.1-5.0] are independent 
predictors for stroke post PTCA. 
We Conclude: 1) The overall stroke rate post PTCA is low (0.17%). 2) 
Importantly, stroke post PTCA is associated with high (24%) mortality rate. 3) 
Both female and patients with hx of PVD have increased risks for neurological 
events post PTCA. 
*p < 0.05 vs changes in non-infarcted areas 
Conclusion: Delayed recanalization of chronically occluded coronary 
arteries causes a significant improvement of the regional ejection fraction in 
the infarct-related area and prevents ventricular enlargement. 
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~ Quantitative Estimation of Salvage Myocardial 
After Primary Coronary Angioplasty in Patients 
With Angiographic no Reflow 
Seishi Nakamura, Shinichi Hamada, Tetsuro Sugiura 1 , Toshinori Fujimoto, 
Masato Baden, Junko Watanabe ~ , Toshiji Iwasaka 1 . Takarazuka Hospital. 
Hyogo; ~ Kansai Medical Universi~ Osaka, Japan 
Background: Reduced epicardial flow (angiographic < TIMI 2 flow grade) 
after primary coronary angioplasty (PTCA) is defined as no reflow (NRF), 
which implicate ongoing structural or functional problem in the distal micro- 
circulation. To estimate the effect of NRF on myocardial salvage in pts with 
acute myocardial infarction (MI), baseline (area at risk: before PTCA) and 
predischarge (infarct size: 1 month after the onset of MI) perfusion imaging 
with Tc-99m tetrofosmin was performed in 82 pts undergoing pdmary PTCA. 
Methods: Left ventricle was divided into 13 segments and perfusion 
defect was estimated quantitatively. The area of ischemia (peffusion defect) 
was defined as complete defect or severely reduced segments and perfusion 
defect/left ventdcular (LV) mass (%) was obtained. NRF was observed in 12 
lots (G-l) and 70 pts (G-2) had good reflow after PTCA. 
Results: There were no significant differences between the two groups 
in elapsed time to PTCA, collateral grade or TIMI flow grade before PTCA. 
Despite no difference in the area at risk between the 2 groups (G-1 = 40 
± 19 and G-2 = 42 ± 17), the final infarct size was significantly larger in 
G-1 than G-2 (31 ± 16 versus 19 ± 7, p < 0.05); perfusien defect reduced 
significantly in G-2 (p < 0.001), but not in G-1. The salvage index [(area 
at risk - infarct size)/area at risk x 100 (%)] was significantly lower in G-1 
than G-2 (13 + 41 versus 53 :E 57, p < 0.05). When successful salvage 
was defined scintigraphically as improvement of >_30% area at risk (before 
PTCA), sensitivity of NRF in estimating successful myocardial reperfusion 
was 33% and specificity was 93%. 
Conclusion: NRF is a highly specific angiographic marker of impaired 
myocardial reperfusion after primary PTCA. 
I 1067-43~7 Left Ventricular Dysfunction is Related to  Macro- 
and Microcirculatory Dysfunction After Effective 
Coronary Stenting 
Luisa Gregorini, Michaela Koz~kov~,, Cado Palombo, Isabelle Marco, 
Irene Bossi, Monique Bemies, Gianni Anguissola, Salvatore Romano, 
Jean Fajadet, Jean Marco. CNR Inst. of Clinical Physiology, Pisa; Ospedale 
Maggiore-lRCCS, Milano, Italy; Clinique Pasteur, Toulouse, France 
Effective coronary stenting reduces poor distal run-off and improves ischemic 
LV dysfunction consequent o flow limiting stenosis. 
Aim of the study was to investigate the effects of PTCA plus Stent on 
coronary vascular resistance (CVR) and epicardial arteries diameters, as 
well as their correlation with LV function. 
Methods: In 80 patients undergoing PTCA plus Stent under neuroleptic 
analgesia, we evaluated coronary diameters by QCA. CVR by intracoronary 
Doppler and LV function by TEE. Measurements were obtained before and 
15 rain after Stenting with no residual stenosis. LV fractional area changes 
(FAC) and wall thickening (%Th) were quantified. % Th was measured in 
PTCA-dependent region and in 3 control regions. 
Results: FAC transiently increased soon after Stent (from 37 ± 10% to 41 
± 9%), but decreased 15 rain later to 30 :E 10% (p < 0.05). Fifteen rain after 
Stent, % Th decreased in control and in transiently ischemic myocardium: 
% Th became 22 ± 16% and 31 ± 16% in Stent and non-Stent dependent 
regions, respectively from 32 • 8% and 42 ± 18% before Stent (p < 0.05) 
and 42:1: 18% and 47 ± 17% soon after stent (p < 0.05). CVR shortly 
decreased immediately after stent by -18 ± 9% (ns), but increased 15 min 
later by 60 ± 10% (p < 0.05 vs before-Stent values), Epicardial arteries 
diameter decreased 15 min after Stent in both dilated and control vessels by 
20 ± 7% (p < 0.05 vs before-Stent). 
Conclusions: in coronary patients treated with effective PTCA plus Stent, 
despite transient improvement in coronary flow and LV function immediately 
after reperfusion, t 5 rain later a diffuse vasoconstriction involving both ca- 
pacitance and resistance artedes leads to a significant decrease in global LV 
function. 
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~ Use the Rapid Platelet Analyzer of Function 
(RPFA) to  Evaluate Platelet Function in Patients 
Receiving Incremental Bolus Dosing of 
Abciximab During Percutaneous Coronary 
Interventions (PCl) 
Peter J. Casterella, Dean J. Kereiakes, Steve R. Steinhubl, Russell 
E. Raymond, Eric J, Topoi, Karen Patel, Michelle Mueller, 
Monique Rosenthal, Paul S. Teirstein. Scripps Clinic, La Jo//a, CA; Lindner 
Center for Clinical Cardiovascular Research, Cincinnati, OH; Cleveland 
Clinic Foundation, Cleveland, OH, USA 
Background: RPFA is a whole blood assay that allows rapid bedside as- 
sessment of platelet aggregation. Using this new technology, we evaluated 
platelet aggregation dose response to abciximab during PCI. 
Methods: At three centers, 55 patients received incremental bolus doses 
of abeiximab at 10-20 minute intervals as follows: an initial dose of 0.125 
rng/kg (50% of recommended bolus), and either a second dose of 0.125 
mg/kg, or 2 subsequent doses of 0.0625 mg/kg. RPFA samples were obtained 
at 10-20 minute intervals after each bolus. 
Results: The percentage of patients achieving >_80% inhibition of platelet 
aggregation after 50%, 75% and 100% of the abciximab bolus was 34%, 78%, 
and 89% respectively. By linear regression analysis, presence of diabetes 
mellitus, current smoking, hematecdt, platelet count, and presenting clinical 
syndrome did not correlate with abciximab response. 
o~ 20 
O~ . . . . . . . . . . .  
Conclusions: Platelet aggregation dose-response to abciximab is vari- 
able. Recommended dosages are higher than necessary to achieve target 
platelet inhibition in the majodty of patients, yet inadequate in a minority of 
patients. Point-of-care platelet function assays may play an important role 
in future dosing and monitoring of therapy with glycoprofein liB/IliA receptor 
antagonists. 
• Episodic Activation of 2 in Cyclooxygenase 
Patients With Unstable Angina 
Antonio G. Rebuzzi, Andrea lanni, Eugenia De Marco, Antonino Buffon, 
Giulia Renda, Paola Patrignani, Cado Patrono, Aftilio Maseri. Institute of 
Cardiology Catholic University Roma; Institute of Pharmacology, University 
of Chieti, Italy 
Background: We have previously shown that, in pts with stable angina, 
the increased thremboxane (Tx) biosynthesis observed following PTCA, was 
totally suppressed by aspirin. We repeated the study in pts with UA in order to 
assess the possible activation of cyclooxygenase 2 (Cox2) in inflammatory 
cells (not blocked by antiplatelet doses of aspidn) and its correlation with 
serum C Reactive Protein (CRP) levels. 
Methods: We measured urinary 11-dehydro-TxB2 excretion in 9 pts with 
UA in sequential urinary samples collected for five days during which ischemic 
episodes were continuously recorded and PTCA was performed. Ten to 28 
urinary samples were obtained from each ptfor a total of 143 samples. Blood 
samples for CRP measurement were collected on admission. 
Results: 42 (29%) udne samples had 11-dh-TxB2 levels higher than 200 
mg/pg creatinine, but only 11 of these samples were associated with episodes 
of ischemia or PTCA. No difference was observed in mean metabolite ex- 
cretion between ischemic and non ischemic pedods (240 :E 292 vs 181 ± 
150 pg/mg creatinine; p = ns). Only 15% of samples with elevated Tx pro- 
duction was associated with ST segment changes; only 27% of iechemic 
ECG changes were associated with increased 11-dh-TxB2 excretion. Mean 
C~ 
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metabolite excretion was 101 ± 71 pg/mg creatinine in samples before PTCA 
and 301 ± 272 after (p < 0.05). CRP levels were closely correlated with the 
increase of metabolite excretion after PTCA (r = 0.783, p < 0.02). 
Conclusions: 1 ) Contrary to what observed in stable angina, suppression 
of platelet Tx production by aspirin does not block episodic Tx production 
in pts with UA. 2) The increase in urinary 11-dh-TxB2 after PTCA is closely 
correlated with the intensity of inflammation as assessed by CRP levels, 
compatible with the activation of Cox2 in inflammatory cells. 
• Eptifibatide Protects Against Adverse Cardiac 
Complications both Before and During 
Percutaneous Intervention in Patients With Acute 
Coronary Syndromes Without ST-Elevation 
Martijn Akkerhuis, Eric Boersma, Robert A. Harrington, Jaap W. Deckers, 
Robert M. Califf, Maarten L. Simoons. For the PURSUIT Investigators; 
Erasmus University, Rotterdam, The Netherlands; Duke University, Durham, 
NC, USA 
Question: Eptifibatide treatment reduces the rate of severe complications in 
acute coronary syndrome patients without ST-elevation. Is there an additional 
benefit among those undergoing a percutaneous intervention (PTCA)? 
Methods: In PURSUIT, 9461 patients presenting within 24 h of ischemic 
chest pain without persistent ST-elevation were randomised to receive epti- 
fibatide (180/~g/kg bolus + 2.0/~g/kg/min infusion) or placebo for a period of 
72 h. A subgroup of 1249 patients underwent a PTCA during study drug infu- 
sion (619 eptifibatide and 630 placebo). The occurrence of death or non-fatal 
myocardial infarction (MI) was evaluated (a) in the entire population during 
study drug infusion until the time of the intervention (if any) and (b) in the 
PTCA patients, from the time of the procedure onwards. 
Results: At 72 h after enrollment, the rate of death or non-fatal MI was 
significantly reduced by eptifibatide (2.2% vs. 3.8% in placebo; p < 0.001). 
In the early intervention group, the treatment effect was further enhanced 
during the first 48 h following the PTCA (event rates 2.8% vs. 6.8%; p = 
0.001). No difference in clinical events was observed after this time period 
(2.5% vs. 2.2%; NS). 
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Conclusion: In addition to the beneficial effect of medical treatment only, 
eptifibatide reduces the rate of procedure-related complications during PTCA. 
~ l s  Clopidogrel a Adjunctive Safe and Effective 
Anti-Platelet Therapy for Coronary Artery 
Stenting? 
Philippe L. L'Allier, Herbert D. Aronow, Jay S. Yadav, Jakob P. Schneider, 
Eric J. Topoi, Stephen G. Ellis. Cleveland Clinic, Cleveland, OH, USA 
Background: Recent reports of fatal tictopidine-associated thrombotic throm- 
bocytopenic purpura have lead many interventional cardiologists to admin- 
ister clopidogrel instead of ticlopidine for coronary artery stent implantation. 
However, despite clopidogrel's more favorable safety profile, data are lacking 
to support such a change in current practice patterns. 
Methods: Between April 1 and July 15, 1998 232 patients underwent 
coronary stent implantation and received periprocedural regimens containing 
ctopidogrel (300 mg × 1; 75 mg PO QD × 1 month) and aspirin. In a 
prospective cohort study, we evaluated in-hospital and 30-day outcomes, in 
these patients. 
Results: Follow-up was 97.4% complete. Mean age was 63.6 years, 
71.6% were male, 20.6% smokers, and 26.6% diabetics. An unstable coro- 
nary syndrome was the indication for the procedure in 79.7%. Stenting for 
bailout occurred in 3.4%. Abciximab was administered in 62.1% patients. Le- 
sions were modified ACC/AHA type C in 16.8% and thrombus was present 
in 11.1% at the time of stenting. Residual dissection was present after stent- 
ing in 4.2%. In-hospital death occurred in 0.5%, QMI in 0%, NQMI in 3.2%, 
urgent repeat revascularization in 0.9%, CABG in 0%, peripheral vascular 
complications in 1.4%, and blood product transfusion in 4.5%. At 30 days, 
the risk of death was 0.4%, MI 0.9%, repeat PTCI 1.7%, and no CABG Thus, 
based on target vessel related MI and repeat PTI at 30 days, there was an 
estimated subacute stent thrombosis rate of 2.6%. 
Conclusion: Outcomes with clopidogrel, aspirin and often abciximab, ap- 
pear similar to those reported for ticlopidine-containing regimens in coronary 
artery stent implantation. Further prospective trials, including a significant 
extension of our registry experience, are ongoing. 
~ D o e s  Ticlopidine Reduce Reocclusion After 
Successful Balloon Angioplasty of Coronary 
Occlusions? Insights from TOSCA 
Peter B. Berger, Vladimir Dzavik, Ibrahim AI-Rashdan, lan M Penn, James 
P. Zidar, Diane Catetlier, Christopher E. Buller. For the TOSCA Investigators; 
Rochester, MN, USA; Vancouver, Canada 
Ticlopidine (TCD) reduces thrombosis after coronary stent placement, but its 
effect after balloon angioplasty (BA) is unknown. In the TOSCA trial, a ran- 
domized study of heparin-coated stents vs. BA in patients (pts) with coronary 
occlusions in which 6 month (mo) angiographic follow-up was obtained, 195 
pts received BA per protocol of whom 101 (52%) received TCD & ASA at 
discharge and 94 (48%) received ASA alone. To determine whether TCD use 
was associated with sustained patency (TIMI 3 flow) in BA pts in TOSCA, 
baseline and 6 mo clinical and angiographic variables were analyzed accord- 
ing to TCD treatment. 
Results: BA pts receiving TCD & ASA were similar to those treated with 
ASA alone with respect to gender, prior MI, CHF, HTN, DM, reference vessel 
diameter and both pre- and post-procedural MLD, but had longer treated 
segments (37 vs. 29 mm, p < 0.01) and a higher prevalence of TIMI 0 flow 
at baseline (71% vs. 52%, p < 0.01). At 6 mo, failure to sustain patency was 
observed in 26% of BA pts treated with TCD & ASA vs 16% in BA pts treated 
with ASA alone (p = NS). Percent stenosis at 6 mos was higher in the TCD 
treated group (65% vs. 58%, p < 0.05), as was TVR (19% vs. 5%, p < 0.05). 
MI was infrequent in both the TCD and no-TCD groups (2.0% vs 3.2%, p = 
NS). 
Conclusion: No benefit in maintaining patency was seen in TCD treated 
BA pts; similarly, TCD failed to reduce restenosis and TVR. The higher rate of 
TVR and restenosis, and trend towards a lower patency rate in the TCD pts 
likely reflects differences in baseline angiographic characteristics between 
the 2 groups of pts. 
• Comparison of Cilostazol and Ticlopidine After 
Coronary Artery Stenting: Immediate and 
Long-Term Results 
Young-sup Yoon, Doo-hee Lee, Wook-bum Pyun, In-jae Kim, 
Yangsoo Jang, Won-Heum Shim, Seung-Yun Cho. Yonsei University 
College of Medicine, Seoul, Korea 
Background: Cilostazol, a new synthetic, anti-platelet drug which inhibits 
cyclic AMP phosphodiesterase, is known to inhibit both platelet aggregation 
and intimal hyperplasia. In comparison with ticlopidine we evaluated thera- 
peutic efficacy of cilostazol for preventing stent thrombosis and restenosis 
after stent implantation. 
Methods: 145 consecutive patients were randomized to receive either 
cilostazol (C) 200 mg/day (70 pts, 77 lesions) or ticlopidine (T) 500 mg/day 
(75 pts, 84 lesions). All pts received aspirin 100 mg/day. Cilostazol was 
administered from prestent 1 day to poststent 1 to 4 months (mo) (average 
2.5 mo). Ticlopidine was administered from prestent 1 day to poststent 1 mo. 
Coronary angiography was performed 6 mo after stenting in 107 pts (74%): 
52 pts (74%) in C and 55 pts (73%) in T. 
Results: There were no differences in baseline clinical, angiographic and 
procedural characteristics between two groups. During the poststent 1 mo, 
clinical events were not different between 2 groups (2.9% vs 4%, P: NS): 
subacute stent thrombosis (1.4% vs 1.2%), retinal hemorrhage (1.4% vs 
0%), leukopenia (0% vs 2.7%). During the follow-up period (10 ± 4 mo), 
there were no deaths, myocardial infarctions, or emergency bypass surgery. 
Group C Group T P 
PreRD (mm) 3.14 ~ 0.44 3.18 ± 0.39 NS 
PreMLD (mm) 0.71 ~- 0.35 0.65 ± 0.40 NS 
postMLD (mm) 3.11 ± 0.45 3.15 i 0.43 NS 
FuMLD (mm) 2.21 ~ 0.54 2.02 ± 0.61 <0.05 
Late loss (ram) 0.90 ± 0.66 1.14 ~ 0.68 <0.05 
Restenosis (%) 13 21 <0.05 
(RD: reference diameter, MLD:minimal luminaJ diameter) 
Conclusion: As compared with ticlopidine, cilostazol has similar effect on 
preventing stent thrombosis and better effect on poststent restenosis rate. 
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~ Clinical Outcomes "Rescue" Following 
Administration of Abciximab in Patients 
Undergoing Percutaneous Coronary Angioplasty 
Shmuel Fuchs, Ran Kornowski, Roxana Meharan, George Dangas, Lowell 
F. Satler, Augusto D. Pichard, Steve T. Slack, Ajith Purush, Kenneth 
M. Kent, Martin B. Leon. Washingtom Hospital Center, Washington DC, USA 
Background: Pre-ietervention administration of abciximab (ReoPro) in pa- 
tients at "high-risk" for coronary angioplasty has been shown to reduce 1 
and 6-month adverse clinical iscbemic events. The role of intraprocedural 
(i.e. "rescue") ReoPro administration is not fully elucidated. We assessed 
the clinical outcomes associated with "rescue' administration of abciximab 
during percutaneous coronary interventions. 
Methods: We studied the in-hospital and long-term (1 year) outcomes 
(death, MI and target lesion revascularization = TLR) of 186 consecutive pa- 
tients (78% men, age 62 i 11, 72% with acute coronary syndrome) treated 
with abciximab for thrombus containing lesions, sub-optimal angioplasty re- 
suits and/or procedural related complications. 
Results: Stents were used in 60% of procedures. Procedural successes 
was 95.3% and overall major in-hospital complications was 4.7% (death 
2.1%, Q wave MI 1.0%, and emergent CABG 1.6%). Angiographic compli- 
cations included Type >_ C dissections (20%) and abrupt/threatened closure 
(7%). Non-Q wave MI (defined as CK-MB > 5 time normal) occurred in 
24.7%. Long-term (1-year) outcomes included death (2.8%), MI (1.1%), and 
TLR (24.9%) and cardiac event-free survival was 71.1%. 
Conclusions: "Rescue" intra-procedural edminislration of aboiximab is 
associated with 1) acceptable in-hospital and long-term outcomes in patients 
with sub-optimal angioplasty results and/or procedural-related complications, 
2) relatively high peal-procedural non-Q wave MI rate. A clinical and cost- 
effective comparison between provisional and "rescue" administration of 
aboiximab may be warranted. 
~ Abciximab (Reopro TM) Is Rapidly Effective and 
Promptly Arrests Established Platelet 
Aggregation In Vitro: An Explanation for the 
Remarkable Efficacy of This Drug as 'Bail Out' 
Therapy in Angioplasty Complicated by 
Thrombus 
Miles C.D. Dalby, Simon J. Davidson, John F. Burman, Simon W. Davies. 
Royal Brompton Hospital, London, UK 
Background: The platelet glycoprotein lib/Ilia antagonist abciximab reduces 
the ischaemic complications of angioplasty when given prior to the procedure, 
It is also used, with remarkable and rapid success, particularly in the UK, 
during interventions as a 'bail out' option when angioplasty is complicated by 
intracorenary thrombus. This study sought to establish how quickly aboiximab 
blocks the aggregation of both quiescent and activated platelets to explain 
this rapid efficacy, 
Methods: Platelet rich plasma was prepared from 10 healthy volunteers 
and optical aggregometry was performed with ADP 10 uM/ml agonist. Aboix- 
imab 5 ug/ml was added in each case with saline control 5 minutes before 
agonist, 10 seconds before agonist and during aggregation. 
Results: In all cases abciximab administered 5 minutes before agonist 
completely inhibited aggregation (median = 0% range = 0-0%) compared 
with control (median = 71% range = 50-95%) p < 0.001. When administered 
10s before agonist a small initial degree of aggregation occurred but this was 
rapidly reversed (time to reversal: median = 2 mins range = 1-4.5 rains) to low 
levels of aggregation (median = 16.5% range = 0-22%) when compared with 
control (median = 72,5% range = 55-95%) p = 0.002. When administered dur- 
ing aggregation, in all cases the rise in the aggregometry tracing was rapidly 
arrested (time to arrest: median = 1.5 mine range = 0.1-3 mins) with no further 
aggregation occurring (median = 42% range = 30-57%) when compared with 
control (median = 80% range = 60-100%) p = 0,002. These results have been 
reproduced with the independent method of impedance aggregometry. 
Conclusions: In addition to the recognised prophylactic administration of 
abciximab prior to angioplasty, these data indicate that when administered 
during a procedure in which thrombus load has occurred, further aggregation 
is effectively stopped 'on the end of the needle'. Furthermore this applies not 
only to quiescent platelets arriving at the site of thrombosis but also ptatelets 
already exposed to agonist, activated, and undergoing aggregation. 
~ Abciximab in Unstable Syndromes: Coronary 
Benefits and Costs in a Group Model Non-Profit 
Health Maintenance Organization 
Robert J. Lundstrom, Chris J. Colby, Ayad Jindeel, Robert L. Hay. 
Kaiser-Permanente Medical Center, San Francisco CA; Division of 
Research, Permanente Medical Group, Inc., Oakland CA, USA 
Background: Thrombus is common in unstable coronary syndromes. Stent 
placement improves results compared to balloon angioplasty, however, stent 
thrombosis causes high morbidity and mortality. Abciximab may improve 
outcomes in unstable coronary disease, with acceptable economic impact. 
Methods: Databases were reviewed to identity cases from contiguous 
periods before the Palmaz-Schatz stent, before abciximab, and after both 
were available. 1932 cases accrued: 614 balloon angioplasties/16 mo before 
the PS stent, 199 angiopasties and 42 stents/6 mo after the PS stent and 
before abciximab, and abciximab was used in 99 of 398 angioplasties and 
225 of 679 stents in 22 mo. The cohort was analyzed for patient and clinical 
characteristics and results. Repeat revascularization, myocardial infarction 
and death were determined at 1,6, and 12 too; costs were measured. Analy- 
sis of variation was applied to cases grouped by angioplasty or stent, with or 
without abciximab. A proportional hazards model was applied to outcomes. 
Cost was dependent in a cost analysis model with multiple variables. 
Results: During the study practice shifted to higher cost technology and 
increased severity of disease. Stents and abciximab were employed in more 
severely and acutely ill patients. Despite this bias, outcomes with abciximab 
were indistinguishable from the lesser diseased cohort. Early (2 weeks) 
revascularization for any reason after angioplasty was 8% without abciximab 
and 4% with, and after stent placement 3% without and 2% with abciximab. 
Costs per case by 6 mo were reduced $6744 in angioplasty with abciximab 
(p < 0.05) and $2523 in stents with abciximab (p = 0.32, NS). 
Conclusion: Abciximab improves early and one year outcomes in high 
risk coronary interventions and reduces costs of care. 
~ Incidence of Intra-Cranial in Trials of Hemorrhage 
Glycoprotein lib/Ilia Receptor Inhibitor Drugs 
James C. Blankenship, Francis J. Menapace, S. Lee Demko. Geisinger 
Medical Center, Danville, PA, USA 
Background: Trials of glycoprotein (GP) lib/Ilia receptor inhibitors have 
excluded patients with prior stroke or CNS structural abnormality because of 
concern over intra-cranial hemorrhage (ICH). 
Methods: We reviewed 14 published trials of intravenous GP lib/Ilia ther- 
apy to determine the incidence of ICH in GP I Ib/lla patients and hepadn-alone 
patients. 
Results: 
Treatment Group Incidence of ICH 
heparin 9/8740 (0.10%) 
heparin + abciximab 6/5540 (0.11%) 
heparin + other lib/Ilia receptor inhibitors 9/5488 (0.16%) 
other lib/Ilia receptor inhibitors 2/2976 (0.07%) 
Chronic infusions (>24 hrs) caused ICH in 0.05% of heparin patients and 
0.08% of GP lib/Ilia patients. Brief infusions (<24 hrs) caused ICH in 0.13% 
of hepadn patients and 0.11% of GP lib/Ilia patients. 
Conclusion: GP lib/Ilia receptor inhibitors, alone or in combination with 
heparin, do not cause an excess of ICH compared to heparin alone. Pro- 
longed infusions do not increase the risk of ICH compared to short infusions. 
This data does not support the exclusion of patients with non-hemorrhagic 
central nervous system disease from trials of GP lib/Ilia receptor inhibitors. 
~ HPA-3 of the Platelet Polymorphism Fibrinogen 
Receptor Is not Associated With an Increased 
Risk of Thrombosis or Restenosis After Coronary 
Stent Placement 
Adnan Kastrati, Werner Koch, Nicolas von Beckerath, Corinna Kettling, 
Shpend Elezi, Holger Seidl, Meinrad Gawaz, Albert Sch6mig. Deutsches 
Herzzentrum and 1. Med. Klinik, TU MOnchen, Germany 
Background: Platelet glycoprotein (GP) lib/Ilia receptor plays a central role 
in platelet aggregation. While the association between the HPA-1 polymor- 
phism of GP Ilia and thrombosis and restenosis has already been studied, 
there are no data about the significance of the HPA-3 polymorphism of GP lib 
in the outcome of patients undergoing percutaneous coronary interventions. 
Methods: The study included 2178 consecutive patients (pts) with suc- 
cessful coronary stent placement with 1-year clinical follow-up in all and a 
6-month angiography in 1731 patients (80%). HPA-3 genotype was deter- 
mined with the aid of polymerase chain reaction. Angiogrems were assessed 
quantitatively. 
Results: Of the 2178 pts, 789 (36%) were HPA-3 a/a, 1023 (47%) HPA-3 
a/b, and 366 (17%) H PA-3 b/b. There were no significant differences between 
these groups with respect to clinical, angiographic and procedural parame- 
ters. Stent vessel occlusion occurred in 1.7% of the HPA-3 a/a pts, 1.7% of 
the HPA-3 a/b pts and 1.6% of the HPA-3 b/b pts (P = 1.0). Angiographic 
restenosis (>_50% diameter stenosis at follow-up) was encountered in 37.7% 
of the HPA-3 a/a pts, 33.8% of the HPA-3 a/b pts and 30.7% of the HPA-3 
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b/b pts (P = 0.23). Late lumen loss was also comparable. In addition, no sig- 
nificant differences were recorded between these 3 groups in the incidence 
of death, myocardial infarction and target lesion revascularization at 1 year 
after the intervention. 
Conclusions: HPA-3 polymorphism of the platelet membrane GP lib is 
not associated with an increased dsk of vessel thrombosis or restenosis after 
coronary stent placement. 
1068-941 Mechanisms of Reduction Restenosis After 
I 
Coronary Balloon Angioplasty by Cilostazol 
Etsuo Tsuchikane, Keita Yamasaki, Nobuhisa Awata, Motohiro Kirino, 
Tomoko Kobayashi, Toshinod Nakamura 1 , Ryuichi Modshita 1 . Osaka 
Medical Center for Cancer and Cardiovascular Diseases; ~ Dpt. of Geriatric 
Medicine, Osaka Universi~ Japan 
We previously reported that cilostazol, an antiplatelet medication, significantly 
controls restenosis after PTCA. One of the mechanism of reduction reste- 
nosis by cilostazol is considered as the direct inhibition of smooth muscle 
cells proliferation. Cilostazol was also reported to accelerate endothelial cells 
(EC) growth through the activation of local hepatocyte growth factor (HGF), 
a potent EC-specific growth factor, in vitro. To examine whether cilostazol is 
associated with re-endothelialization after PTCA, we measured serum HGF 
by ELISA method (normal: 0.19 4- 0.05 ng/ml) in 100 patients (pts) who 
underwent successful PTCA without stenting, serially before, 2 days and 
1 week after, and 1 month and 3 months after PTCA. Thirty-six pts were 
given cilostazol (200 mg/day) (C group) and 64 pts were given aspirin (250 
mg/day) (A group) until 3 month follow-up angiography. No differences in 
baseline characteristics and procedural results were observed between the 
two groups. Target lesion revascularization rate was 17% for the C group 
and 39% for the A group (p = 0.02). Serial change in serum HGF value are 
shown in the figure. 
(ng/ml) 
ii1 I .34"38 ~ .  *• : C group p<0.05 vs A 
pre 2days I week 1 Me 3 Me (Me: month) 
Conclusion: These data suggest that as another mechanism of reduction 
restenosis, cilostazol activates re-endothelialization after PTCA which results 
in the decrease of serum HGF level during the follow-up. 
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1069-95 [ Evaluation of New Self a Expanding Micorporous 
I 
Multilayered Stent: Improved Vessel Expansion 
With Minimal Vessel Trauma 
Steven R. Bailey, Yvonne Schilling, Lucas Brennecke. University of Texas 
Health Science Center, San Antonio, TX, USA 
Implantation of endoluminal stents has been associated with increased neoin- 
timal proliferation that has been related to the degree of injury deep to the 
internal elastic lamina. We report the initial experience with a new multilay- 
ered self expanding (SE) multiporous "MATRIX" stent that has chronic vessel 
expansion without laceration of the internal elastic lamina. The SE stent is 
constructed with multiple microborous openings that measure 800 microns 
in diameter. The stent design departs from current stents in that surface 
coverage is greater than 80% as opposed to the 15% seen with balloon 
expandable stents. 
Methods: 18 non-atherosclerotic swine received 34SE stents and five 
Palmaz (P) stents in the aortic and iliac positions. These animals were 
sacrificed at 48 hours, 28 days, 60 days and 180 days. Angiographic as well 
as histopathologic examinations were performed. 
Findings: Acute vessel expansion was equivalent in both the SE and P 
stents. The expansion seen with the SE stent however was accomplished by 
a thinning of the media and adventitia compared to both the control segments 
proximal and distal to the stent site as well as that seen in the P segments. 
Long term patency was maintained in all stented segements without acute 
or subacute thrombosis. In addition patentcy of all side branches was main- 
tained including larger vessels such as the renal and inferior mesenteric 
vessels. At 28 days the neointimal proliferation over the SE was less 168 4- 
118 #m compared to the P 286 4- 145/xm. This correlated with less trauma 
to the internal elastic lamina. In addition the vessel diameter was larger at 
the SE sites for both iliac (5.84 4- 1.92 mmSE vs 5.16 4- 1.54 mmP) as well 
as aortic (11.58 4- 2.68 mmSE vs 10.24 4- 2.93 mmP). 
Conclusions: A new SE stent provides less traumatic expansion of 
peripheral vessels with preservation of sidebranches. This resulted in larger 
vessel diameter at both 28 and 160 days compared to the P stent. This stent 
may have specific application for carotid arteries. 
~ Elective Carotid Artery Stenting for 
Radiation-Induced Extra-Cranial Carotid Artery 
Occlusive Disease 
Nadim AI-Mubarak, Gary S. Roubin 1 , Ming W. Liu, Larry S. Dean, Camilo 
R. Gomez, Virginia Yates, Sriram S. lyer 1 , Jiri J. Vitek 1 . 1Universityof 
Alabama, Birmingham AL; Lenox Hill Hospital New York NY, USA 
Background: Carotid endarterectomy (CEA) for radiation-induced carotid 
artery stenoses is very difficult due to poor accessibility of the lesions and 
the extremely fibrotic arterial layers that make it hard to separate the plaque 
from the media. The efficacy of carotid stenting as an alternative treatment 
in these patients is not known. 
Methods: Fourteen patients with extracranial carotid stenoses after neck 
radiation for malignancy underwent carotid stenting. All patients (15 vessels) 
had stenosis >_60%. Follow-up was obtained in all patients. 
Results: There were 10 males. Mean age was 61. Six patients presented 
with TIA, 2 had prior stroke and.6 were asymptomatic. Thirteen patients had 
previous ipsilateral radical neck resection, 4 had permanent racheotomies 
and 1 patient had a history of CEA. Technical success was achieved in all 
patients with reduction of the mean percent stenosis from 77 ± 6.4 to 8 :~ 2. 
A total of 13 Walletents and 2 Palmaz stents were used. Two patients had 
concomitant stenting of 2 vertebral arteries. One patient had a minor stroke 
after the procedure that changed the NIH stroke scale by 1. He recovered 
completely. No other procedural or in-hospital complications occurred. At 18 
4- 2 months, 6 patients had follow-up carotid angiography and 3 others had 
carotid Duplex ultrasound. No restenosis (obstruction >_50%) was observed. 
Three patients died from non-neurologic causes. One patient had successful 
balloon dilatation of a restenotic vertebral artery. No neurological events 
occurred and no repeat interventions were required in any of the remaining 
patients. 
Conclusion: Carotid stenting in patients with severe radiation-induced 
occlusive disease is associated with favorable immediate and late outcomes 
and may be considered a reasonable alternative to surgery. 
I 1069-971 Palmaz Stenting Reverses Progressive Renal 
F I Dysfunction in Patients With Global Renal 
Ischemia Due to Atherosclerotic Renal Artery 
Stenosis 
Ratan K. Ahuja, Sherri L. Poler, Krishna J. Rocha-Singh. Prairie Heart 
Institute, Springfield, IL, USA 
Background: Atherosclerotic renal artery stenosis (ARAS) contributes to 
progressive renal dysfunction. Surgical revascularization may improve renal 
function; however, it is associated with significant mortality and morbidity. The 
role of renal artery stenting to prevent or slow progressive renal dysfunction 
in patients with global renal ischemia i.e., bilateral renal artery stenoses or a 
stenotic solitary kidney, is undefined. 
Methods: Serum creatinine (Scr) values were tracked for one year prior to 
Patmaz stent deployment and for 2 years post-stenting in 33 patients (42.4% 
male, mean age 71.8 years) with global renal ischemia. Renal dysfunction 
progression was determined by analysis of the absolute slope of the mean 
reciprocal Scr (1/Scr) curve verses time over a 3 year period. 
Results: Palmaz stent deployment was successful in all 29 patients with 
bilateral and 4 patients with a stenotic solitary kidney. Renal dysfunction 
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progressed during the one year prior to stenting (slope 1/Scr: -0.092 dl 
mg ~ year -~ , p < 0.003); post-stenting renal function improved (slope 1/Scr: 
+0.082 dl mg 1 year-~ p < 0.012) during the 2 year follow-up period. 
Conclusion: Palmaz stenting reverses progressive renal dysfunction in 
patients with global renal ischemia due to ARAS. 
l 1 069-134J  Percutaneoua Exclusion of Abdominal 
Aneurysm With Wallstent-PTFE Endoluminal 
Grafts: Immediate and Early Results 
Munir Zaqqa, Carina Alfaro-Franco, Reza Khoshnives, Arup Achari, 
David Le, Zvonimir Krajcer. Texas heart institute, Houston, TX, USA 
Purpose: to evaluate the safety and efficacy of the PTFE covered self- 
expandable Wallstent in percutaneous endoluminal exclusion of infra-renal 
abdominal aortic aneurysms (AAA). 
Methods: From September 1996 through May 1998, 39 procedures were 
performed on 33 patients who were high-risk surgical candidates (27 males, 6 
females; mean age, 73 ± 7 years). Endoluminal grafts were placed as aortic 
tubular grafts in 27 patients, aortoiliac grafts followed by elective fern-fern 
bypass in 3 patients, and aortobiliacs grafts in 9 patients. 
Results: Immediate procedural success rate was 100%, The average 
procedure time was 299 ± 72 minutes and hospital stay was 3.7 ± 3.3 days. 
Patients were followed over a mean period of 13 ± 5.8 months (range 3 to 23 
months). There were no major procedural complications and no early nor late 
mortality. However, 4 months following an aortobiliec exclusion one patient 
developed thrombosis in an lilac graft and was treated by surgical by-pass. 
Minor complications included transfusion in 6 patients, and entry site bleeding 
(n = 3) or pseudoaneurysm (n = 2) requiring surgical repair. Endovascular leak 
was detected in 24 patients (20 small, 4 large). Leak resolved spontaneously 
in 9 patients. Nine patients, including those with large leaks, were treated by 
repeat endoluminal exclusion (n = 6, successfully in 3), coil embo!ization (n 
= 2), or surgery (n = 2). Ten patients with minor leaks are being followed by 
sedal ultrasound and CT scan. 
Conclusion: Wallstent-PTFE endoluminal graft is a feasible, safe and 
efficient technique for percutaneous endoluminal exclusion in high-risk pa- 
tients. Most commonly encountered problem was minor endoluminal leak. 
Long-term follow up is needed to document efficacy of this technique in 
preventing further aneurysmal enlargement and rupture. 
11069-135] Percutan~us Endoluminal Treatment of Iliac 
Aneurysms. A Single Center Experience With a 
Series of 25 Aneurysms 
Michel Henry, Max Amor, Isabelle Henry, Kiril Tzvetanov, Claude Amicabile~ 
Jean-Michel Buniet, Zuka'f Chati. Polyclinique, Essey-les-Nancy, France 
Purpose: To evaluate feasibility, efficacy, primary and long-term results of 
percutaneous treatment of lilac aneurysms. 
Methods: 24 patients (pts) (M: 20, F: 4, age: 65.4 ± 10.3 years, range: 
47-85) with 25 lilac aneurysms were treated with covered stents (Corvita: 
13, Passager: 7, Jomed: 2, Endotex: 1), stent grafts (n = 1), non-covered 
stent (Palmaz: 1). 22 aneurysms were located in the common lilac artery. 
In 2 cases, internal iliac artery originated from aneurysm and in 1 case, 
the aneurysm was located in the internal lilac artery. 23 aneurysms were 
atheromatous, 2 infectious. Before treatment, all pts underwent echodoppler, 
angiography, CT-scan, to evaluate proximal part of lilac artery (necessity of a 
neck to implant the stent), length, diameter of the aneurysms, and location of 
the internal iliac artery. Mean lesions length: 54.7 ± 30.8 mm (10--150), mean 
diameter: 29 ± 13.5 mm (19-80). Stents (8-12 mm in <>, 30-80 mm in length) 
were implanted through 7-10 F sheaths using retrograde femoral approach 
in 24 pts, contralateral in 1 pt (internal ilac aneurysm). Coil embolizations of 
the internal iliac artery performed in 3 cases using contralateral approach. 
Results: Immediate technical success: 24/25. Mean stent <>: 8.5 ± 1.7 
ram. Mean stented lesion length: 70.2 ± 30.3 mm. 1 leak 2 days later. 
We observed 2 thromboses: 1 with a Corvita stent at Day 1, treated by 
Fogarty, and 1 at Day 15 with the new Endotex stent, treated surgically 
(femoro-femoral bypass graft). All other stents remained patent at a maximum 
follow-up of 6 years. 
Conclusion: Percutaneous treatment of iliac aneurysms seems safe, 
effective, with good long-term results. It could be an alternative to surgical 
bypass in well defined indications. 
L 1069-136 1 Femoral  Ar tery  STEnt STudy (FASTEST) 
Horst Sievert ~ , Erhard Starck 2, Anja Wurzel 1 , Andreas Fach 1 , 
Rainer Schr~der 1 , Detlef Scherer 1 , Hartmut Mede 1 , Hans Spies 1 , 
Roland Ensslen 1 . I Cardiovascular Center Bethanien CCB; e Red Cross 
Hospital Frankfurt, Germany 
FASTEST is a prospective randomized trial to compare conventional balloon 
angioplasty alone (PTA), implantation of conventional stents and implantation 
of Dacron covered stents (Endo-Pro/Passenger) in superficial femoral artery 
lesions. 
Patients were randomized after successful conventional balloon angio- 
plasty with a residual stenosis of <50%. Follow-up (FU) angiogram was 
performed after 6 months or eadier, if indicated for clinical reasons. 
PTA Stent Dacron-stent P 
n 40 41 25 
Proc. success 40/40 41/41 24/25 N.S. 
Thrombus/emboli 0 4/41 * 4/25* <0.05" 
MLD pre (mm) 0.7 ± 0.9 0.8 ± 0.9 0,8 ± 0.9 N.S. 
MLD pest (mm) 3.7 ± 0.7 5.2 ± 1.0" 4.2 ± 1.0" <0.01" 
MLD FU (mm) 2.0 ± 1.5 2.8 ± 1,5 2.1 ± 1.7 N.S. 
Re-Stenosis (>50%) 24/37 13/37" 13/22 <0,05" 
Total occlusion FU 5/37 4/37 5/22 N.S. 
Thus, implantation of conventional stents as well as implantation of 
Dacron covered stents in the superficial femoral artery led to improved 
acute results compared to conventional balloon angioplasty (PTA) alone. 
However, there is an increased risk of acute and subacute thromboembolic 
complications. After 6 months there was a trend towards better results af- 
ter implantation of conventional stents but not after implantation of Dacron 
covered stents. 
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• /3-Emitting lSSRhenium Balloon Liquid-Filled 
Catheter for Endovascular Irradiation to Prevent 
Restenosis: Safety and Efficacy Preclinical 
Studies 
Keith A. Robinson, David W. Pipes, Richard Van Bibber, Madna Ferguson, 
Jianhua Cui, Stefan Verheye, Mahomed Salame, 13mothy Fox, 
lan R. Crocker, Jan McDonald, Edward Smith, James Mazeika, 
Spencer B. King III, Nicolas A.F. Chronos. Departments of Medicine 
(Cardiology) and Radiation Onco/ogy, Emory University School of Medicine, 
Atlanta, GA; Biosupport Inc., Redmond, WA; Mal/inckrodt Medica/ Inesc., 
SL Louis, MO, USA 
Endovascular irradiation (El) to prevent resteeosis is promising. 
Methods: A balloon catheter containing 186Re (1.1 MeV, 3.7 d half-life; 
200-250 mCi/mt) was used to deliver 0 (controls), 15, 20, or 30 Gy after 
balloon angioplasty in pig coronaries. Treatment was delivered in 5 to 13 
rain depending on activity and desired dose. Safety studies to examine 
biedistdbution after direct coronary injection were also performed. 
Results: /~-radiation reduced neointima and increased lumen size in a 
dose-dependent fashion (table). 
0 Gy 15 Gy 20 Gy 30 Gy 
lumen (mm 2 ) 1,29 1.2 2.14" 2.17* 
neointima (ram 2) 1.08 0.89 0.31 *'* 0.14"** 
"p < 0,05 vs 0 Gy; **p < 0.01 vs 0 Gy; ***p < 0.001 vs 0 Gy 
In biodistribution studies y-camera imaging indicated that after coronary 
injection 186 Re transiently appeared in the heart. By 15 min activity localized 
in thyroid, salivary glands, and stomach; at 30-.60 min activity was seen in 
bladder. At 6 hr most of activity was in urine and stomach contents (table). 
Fluid volume loading accelerated urinary excretion and reduced stomach 
uptake (table). 
% activity in body fluid and tissue 
urine stomach contents blood 
controls 10% 23% 21% 
fluid loaded 33% 18% 18% 
Conclusions: Endovascular irradiation using a 186Re liquid-filled balloon 
is feasible and effective. In the event of system failure with escape of iostope 
into the circulation, intravenous fluid loading will augment urinary excretion 
of lS6Re. Further study should be directed towards implementing a system 
for clinical testing. 
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I1070-581 Low in Case of Radioactive Body Exposure 
' Balloon Leakage - A Biodistribution and 
Elimination Study of 188 Rhenium in Pigs 
J6rg Hausleiter, Alex Li, F.F. Russ Knapp 1 , Neal Eigler, James Whiting. 
Cedars-Sinai Medical Center, Los Angeles, CA; ~ ORNL, TN, USA 
Background: The/~-emitting isotope 188Re-perrhenate (Re) is being used 
in a liquid-filled balloon system to treat restenosis after coronary angio- 
plasty. To study potential hazards for humans in case of balloon leakage, 
this animal study analyzes the biodistribution and elimination of Re and in- 
vestigates drug regimens to decrease the radioactive dose to critical organs. 
Since extensive biodistdbution data are available for the chemically similar 
99mTc-pertechnetate (Tc) in humans and pigs, it is hypothesized that the 
biological behavior of Re is comparable to Tc. 
Methods: Balloon leakage is simulated by simultaneous coronary injec- 
tion of Re and Tc in pigs sacrificed after 30 min, 2, 6, 24 and 48 hours. Drug 
regimens with potassium perchlorate (KCIO4) or furosemide plus KCIO4 ad- 
ministered after isotope injection, are investigated in pigs sacrificed after 6 
hours. Blood, urine and tissue samples are analyzed for biodistribution and 
elimination of Re and Tc as well as critical organ dose calculations. 
Results: So far a total 15/28 pigs have been studied. Re and Tc had 
comparable biological blood half-lives of 4.4 and 5.2 hours, respectively 
(figure). In the thyroid gland the concentrations of both Re and Tc were 80-fold 
higher than in blood. The administration of KCIO4 after isotope injection 
reduces the activities in the thyroid gland about 80-90%. 
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Conclusions: The preliminary data suggest that Re and Tc behave bio- 
logically similar. The short biological half-lives in combination with the short 
physical half-lives of both isotopes reduce the total radioactive body ex- 
posure. Thyroid activities are considerably reduced by KCIO4. Final study 
results will be presented. 
1070-591 Localization of Tissue and the Minimum Target 
i Effective Dose in Intracoronary Radiation Therapy 
J6rg Hausleiter, Alex Li, Raj Makkar, James Whiting, Neal Eigler, 
Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Background: Several isotopes and intracoronary radiation delivery systems 
have inhibited neointima thickening after stenting or balloon injury in the 
pig coronary model. We hypothesized that comparison of studies with widely 
disparate depth/dose functions could yield the location of the tissue that most 
closely correlates with a beneficial effect and could also yield the minimum 
dose needed to be effective. 
Methods: We retrospectively compared 12 protocols of 6 studies corn- 
pdsing 106 arteries irradiated with Ir 1~, Sr/Y 9°, and Re 1# delivered from 
wires, seeds, and liquid filled balloons. Studies with balloon overstretch in- 
jury as well as stent placement were included. Depth vs. dose functions 
were recalculated for 0 to 2.0 mm radial depth from the arterial surface at 
0.25 nun intervals. Inhibition of neointimal area was calculated relative to 69 
non-radiated arteries. 
Results: Inhibition of neointima growth was close related irrespective of 
tissue location but the best correlation's were at 1.0 to 1.5 mm depth from the 
vessel surface (r 2 ranging from 0.93 to 0.95). At vessel surface the correlation 
between dose and inhibition of neointimal area was significantly lower (r ~ = 
0.72; p < 0.05). At 1.0 mm a minimum dose > 10 Gy is required to achieve 
>50% inhibition of neointima area. 
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Conclusions: This analysis supports earlier histochemical data indicating 
that the adventitia is the target tissue for radiation therapy. The data support 
that the dose prescription point should be between 1.0 and 1.5 mm radial to 
the vessel/lumen interface and that a minimum dose of 10 Gy is needed to 
achieve acceptable results. 
I 1070-601 Effects of Endovascular Irradiation I on Platelet i 
Recruitment at Sites of Balloon Angioplasty in 
Pig Coronary Arteries 
Mahomed Satame, Jon Lampkin, Stephen P. Mulkey, Jianhua Cui, 
Stefan Verheye, Richard A. HiUstead, lan R. Crocker, Nicolas A.F. Chronos, 
Spencer B. King III, Keith A. Robinson. The Andreas Gruentzig 
Cardiovascular Center, Dept. of Medicine (Cardiology), and Dept. of 
Radiation Onco/ogy, Emory University School of Medicine, Atlanta, GA; and 
Novoste Corporation, Norcross, GA, USA 
Background: Endovascular irradiation (El) is effective in animals to prevent 
neointima formation after balloon angioplasty, and is in clinical trials for 
restenosis prevention. Little is known however, about the vascular biological 
consequences of El. In this study we examined the effect of El at therapeutic 
and supra-therapeutic doses on platelet deposition in coronary arteries at 
serial time points after angioplasty. 
Methods: Adult Yucatan miniature pigs received balloon angioplasty in 
all 3 epicardial arteries. They were immediately treated with doses of 0 (con- 
trols), 15, or 30 Gy at 2 mm from the source center. Autologous platelets 
were isolated from whole blood and labeled with 1111n-oxine (labeling effi- 
ciency was consistently >90%) then reinjected the same day or 1,3, 7 or 28 
d after angioplasty. Two hr after injection hearts were harvested and perfu- 
sion fixed; coronary arteries were excised and radioactivity determined in a 
y-counter. Platelets/vessel was determined from activity and platelet counts 
of whole blood sampled at the time of tissue harvest. 
Results: El had no effect on ptatelet recruitment compared to control 
except 30 Gy at 28 d (table). 
time number platelets/vessel segment]t0 -6
control 15 Gy 30 Gy 
0 d 32.6 ~: 8.6 6.8 • 4.6 14.5 ± 7.3 
1-3 d 13.9 ± 5.1 12.6 ± 7.7 77.6 
7 d 4.4 :J: 0.9 t5.7 ± 24.9 5.8 ± 1.3 
28d 2.1 :E0.3 --- 15.3 :E 8.6" 
"P = 0.03 compared to 28 d control 
Conclusions: El at a dose (15 Gy) within the range currently employed 
in clinical trials had no effect on platelet deposition in pig coronary arteries 
through 1 wk after angioplasty. However with twice this dose (30 Gy) in this 
initial series, more platelets were recruited at the angioplasty site at one 
month after the procedures. Caution needs to be exercised in using higher 
dose El for restenosis prevention. Studies are ongoing to extend these data. 
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1071-44 1 Blood Flow: A Quantifying Coronary  Comparison 
I 
of the TIMI Frame Count Method With 
Intracoronary Doppler and Intracoronary 
Ultrasound 
Russell F. Kelly, Misael Marquez, Durand E. Bums, Lloyd W. Klein, Maria 
R. Costanzo, Joseph E. Parrillo, Steven M. Hollenberg. Rush Medical 
College and Cook County Hospital, Chicago, IL, USA 
Background: The TIMI frame count (TFC), measured by counting the num- 
ber of cineangiographic frames required for injected contrast to reach a 
specified distal landmark in a coronary artery, has been proposed as a 
simple method for quantifying coronary blood flow, and possibly disordered 
resistance vessel function. TFC has not been compared to other previously 
validated techniques for measuring coronary blood flow or reststance vessel 
function. 
Methods: We determined TFC, coronary blood flow, and resistance ves- 
sel function in the LAD in 20 patients. Coronary blood flow was calculated 
from coronary blood velocity (measured by intracoronary Doppler) and lumen 
area (measured by intravascular ultrasound). Coronary flow reserve (a mea- 
sure of resistance vessel function) was calculated by measuring coronary 
blood flow at baseline and after intracoronary infusion of 32 mcg adenosine 
(flow reserve = maximal flow after adenosine + baseline flow). 
Results: 
TFC vs: r value p value 
Baseline peak blood velocity -0.51 0,02 
Baseline mean blood velocity -0.49 0.03 
Baseline coronary blood flow -0.30 0.19 
Maximal coronary blood flow -0.02 0.95 
Coronary flow reserve 0.13 0.64 
Coronary lumen area 0.14 0.56 
Conclusions: Although TFC does not accureately measure coronary 
aretery blood flow or resistance vessel function, TFC does provide a quanti- 
tative estimate of coronary artery blood ve/ocitythat is relatively independent 
of coronary artery size. 
J1071-451 Direct Demonstration of Collateral Coronary 
I Recruitment During Brief Vascular Occlusions 
Michael Billinger, Martin Fleisch, All Garachemani, Franz Eberli, 
Bernhard Meier, Christian Seller. Cardiology, University Hospita/, Bern, 
Switzerland 
The extent by which coronary collaterals in humans are recruitable, i.e. reveal 
a flow increase during brief proximal vascular occlusions, is unclear. The 
availability of intracoronary (i.c.) Doppler- and pressure-guidewires allows 
the quantification of the collateral circulation to a vascular region of interest, 
and thus, the degree of collateral recruitment (CR) as well as associated 
factors during brief coronary balloon occlusions (PTCA). 
Thirty patients (58 :E 10 years) scheduled for PTCA were included into 
the study. A coronary artery was occluded for 2 minutes, 3 times, separated 
by a 5 minute interval. During each occlusion, measurements of the distal 
i.c. pressure (Poccl) and the mean aortic pressure (Pao) were continuously 
recorded. An i.c. ECG from the pressure wire, and a qualitative assessment 
of angina pectoris with a standardized score were obtained. The collateral 
flow index (CFI) was calculated as follows: (Poccl - CVP)/(Pao - CVP), CVP: 
Central venous pressure = 5 mmHg. The extent of collateral recruitment was 
computed as the difference between CFI at the onset and at the end of 
occlusion. An increase in ischemia during balloon occlusion was assessed 
by the angina pectoris score change (AA.p.) and ST-segment change (AST) 
of the i.c. ECG lead. 
CFR < 25% CFR > 25% P 
n 22 8 
age 58 - 10 55 ± 8 NS 
%-S 82 :L 11 89 ± 8 NS 
z~CFI 0.04 ± 0.03 0.07 ± 0.03 0.005 
AAP 3.0 ± 1.0 2.0 ± 1.1 0.03 
~ST 0.27 ± 0.15 0.13 ± 0.07 0.02 
%-S: %-stenosis of the occluded lesion 
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Conclusions: 1) In humans, a coronary collateral flow increase of ap- 
proximately 25% during brief vascular occlusions can be demonstrated even 
in cases with pcody developed collaterals. 2) The extent of collateral opening 
to a vascular region in need is directly related to the structural status of the 
anastomoses before occlusion. 
I 1071-46 I Corrected Coronary Flow Velocity Reserve: 
A New Concept for Assessing Coronary Perfusion 
Heinrich Wieneke 1 , Michael Haude 1 , Chdstoph Altmann 1 , Junbo Ge 1 , 
Clemens von Birgelen 1 , Dietrich Baumgart 1 , Dirk Welge 1 , Nikolas Dagres 1 , 
Sigrid Kaiser 2, Raimund Ethel 1 . ~ Department of Cardiology; 2Institute for 
Medica/ Informatics, Biometry and Epidemiology, University Essen, 
Germany 
Background: The normal range of coronary flow velocity reserve (CFVR) 
remains controversial due to large variations. Although baseline average 
peak velocity (bAPV) is the most significant physiological determinant of 
CFVR, no correction for this parameter has been done in clinical practice. 
Methods: To establish a statistical regression model for correcting CFVR 
values for bAPV, we performed intracoronary Doppler measurements in 168 
patients with typical angina and absence of significant luminal narrowing. 
Doppler was done in the left descending artery and CFVR was calculated 
as the ratio of hyperemic APV (intracoronary bolus of 18/~g adenosine) to 
bAPV. 
Results: CFVR was 3.02 ± 0.8 (range 1.4-5.5), bAPV was 15.7 
6.4 cm/s (range 5.1-38.5 cm/s). Using a non-linear regression model the 
estimated CFVR (eCFVR) could be calculated most exactly by the following 
equation: 
eCFVR = 101"03-049.1°g 10(bAPV) (r = 0.69, p < 0.0001). (1) 
Based upon this regression model individual CFVR-values (iCFVR) were 
transformed in corrected CFVR-values (cCFVR) by relating them to a mean 
bAPV of 15.7 cm/s. cCFVR can be calculated in individual subjects using the 
following equation: 
cCFVR = 2.78 • iCFVR/eCFVR. (2) 
Conclusion: The concept of corrected CFVR standardizes CFVR for 
bAPV as a main physiological determinant. This approach reduces the high 
variability of CFVR significantly. It offers a better discrimination between 
normal and pathological values. 
1071-47 1 Intracardiac Doppler Hemodynamics and Flow: 
New Phased Array Ultrasound Tipped Catheter 
Charlas J. Bruce, Douglas L. Packer, James B. Seward. Mayo Clinic and 
Mayo Foundation, Rochester MN, USA 
Background: The feasibility of human intracardiac Doppler hemodynamic 
and flow evaluation using a novel underblood ultrasound tipped catheter (10 
F, 3.2 mm diameter, 4-way articulation) with 5.5 to 10 MHz frequency agility, 
longitudinal plane image, and phased vector array transducer (Sequoia, 
Acuson) was studied. The transducer has full Doppler capability, including 
Pulsed and Continuous wave, Color Flow and Tissue Doppler. 
Methods: Four human patients were studied under an IRB approved 
protocol. The catheter was navigated into the superior and inferior vena 
cavae and right heart chambers via venous sheath access. Intracardiac sites 
were visually navigated using ultrasound images. Doppler hemodynamics 
and flow were obtained from right and left cardiac chambers and surrounding 
great vessels. Attention was directed to Doppler signal quality, ability to obtain 
diagnostic Doppler hemodynamics and flow studies and the ability to access 
all areas of interest. 
Results: AU Doppler signals were diagnostic and of high quality and best 
recorded at the lowest aliasing velocity (5.5 MHz) while visual navigation was 
best at 7.5 to 8.5 MHz. Doppler access to all areas was possible (including 
all valves, individual pulmonary veins, inter-atrial septum, aorta, vena cavae 
and hepatic veins). Pulsed Doppler clearly demonstrated transvalvular and 
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venous filling hemodynamics. Continuous Wave Doppler was used to inter- 
rogate high velocity jets and gradients. Color Flow Doppler visualized small 
shunt flow and velocity distributions. Tissue Doppler demonstrated mitral 
annular excursion replicating characteristic physiologic information recorded 
from a surface study. 
Conclusion: Intracardiac catheter based Doppler hemodynamics and 
flow assessment is feasible using a new fully complemented intracardiac 
phased array ultrasound tipped catheter. This investigation opens the pos- 
sibility of performing operator initiated simultaneous high quality underblood 
imaging and Doppler hemodynamics. 
1071-481 Underestimation of "True" Flow Coronary 
I Reserve by Adenosine? 
Michael Billinger, Christian Seiler, Martin Fleisch, Franz Eberli, 
Bernhard Meier, Otto Hess. Cardiology, University Hospital Bern, 
Switzerland 
Background: Coronary flow reserve (CFR) has been used as a functional 
parameter for the clinical assessment of coronary artery lesions. CFR is 
defined as the ratio of maximal divided by resting flow (normal value > 
2.5). The purpose of the present study was to determine a) whether CFR 
after intracoronary (i.c.) adenosine (ADO) is maximal and b) whether the 
pharmacologic resp. hyperemic CFR is correlated to the severity of the 
coronary stenosis. 
Methods: Coronary flow velocity was measured with the Lc Doppler flow 
wire in 70 patients (68 ± 11 years). Pharmacologic CFR was assessed with 
i.o. administration of ADO with either 12 /~g for the right or 18 ~g for the 
left coronary artery. In a subgroup of 20 patients (57 ± 10 years) byperemic 
CFR was determined after 1 minute balloon inflation with and without i.v. 
adenosine (140/~g/kg x min)according to a standardized protocol (figure). 
Results: Flow velocity was 18 ± 4 cm/s at rest, 45 • 15 after 1 minute 
balloon inflation, 38 ± 13 after ADO, respectively 47 ± 19 after balloon 
inflation plus ADO i.v. (figure). CFR was as follows: 2,1 ± 0.9 with ADO, 2.6 
± 1.0 after balloon inflation (p < 0.05), respectively 2.6 :E 1.1 with ADO i.v. 
plus ischemia (p < 0.91). Pharmacologic CFR was significantly correlated to 
coronan stenosis severity (r = 0.79, p < 0.0091). 
hyl~[emi Z. . . .  hyperemia÷ADO i.v 
40 A A 
"~ before / \ ~ / X CFR~' 
~20.  i CFRADO: 
Conclusions: The postischemic stimulus is stronger for induction of max- 
imal coronary vasodilation than the pharmacologic stimulus. Nevertheless, 
pharmacologic CFR is significantly correlated to the severity of the coronary 
lesion. Thus, "true" CFR is underestimated by adenosine when compared to 
ischemia. 
1 071-49 I of Measurement Safety Intracoronary Doppler 
Using Intracoronary FloWire®: Experience with 
892 Cases 
Juying Qian, Junbo Ge, Michael Haude, Dietrich Baumgart, Dirk Welge, 
Stefan Sack, Raimund Erbel. Department of Cardiology, University-GHS 
Essen, Germany 
The purpose of the study was to evaluate the safety of intracoronary flow 
measurement using intracoronary FloWire ®. From 1993 to 1998, a total of 
892 patients (pts) (684 males, 56.7 ± 11.0 years old) were examined with 
a 0.014 or 0.018 inch FIoWire ® (Cardiometrics). For hyperemic provocation, 
either papavenne (10 mg for left coronary arteries, 8 mg for right coronary 
artery) or adenosine (18 #g for left coronary arteries, 12 #g for right coronary 
artery) was used. 
Results: Of the pts studied, 596 pts underwent diagnostic coronary proce- 
dures (Group I), 220 pts underwent coronary interventions (Group II), and 76 
pts were after heart transplantation (Group Ill). A total of 26/892 (2.91%) pts 
occurred procedure related complications. Bradycardia (transient asystole 
or atrioventricular block) occurred in 15 pts (RCA = 14, LAD = 1), coronary 
spasm in 9 pts (RCA = 6, LAD = 3), ventricular fibrillation in 1 patient (LAD), 
angina pectoris in 2 pts and hypotension with bradycardia in 1 patient. One 
patient had both bradycardia and coronary spasm. Of the 76 pts with head 
transplantation, 9 (11.84%, p < 0.001) had complications. Of all the compli- 
cations, 21/26 (81%) occurred in the RCA, 5/26 (19%) occurred in the LAD. 
In one patient, chest pain occurred both in the RCA and LCX. 
Group I Group II Group Ill 
N = 596 N = 220 N = 76 
Bradycardia 7 (1.2%) 1 (0.5%) 7 (9.2%)* 
Coronary spasm 7 (1.2%) 0 2 (2.6%) 
Chest pain 2 (0.3%) 0 0 
Ventricular fibrillation 1 (0.2%) 0 0 
*P < 0.001 
Conclusion: Intracoronary Doppler flow measurement using FloWire ® is 
a safe method. However, severe bradycardia and coronary spasm have to 
be taken into account especially when examining the RCA or transplanted 
hearts. 
~ Direct Comparison of Intracoronary Pressure and 
Doppler Derived Parameters of Intermediate 
Lesions in Multivessel Disease 
Steven A. Chamuleau, Martiln Meuwissen, Karel 12 Koch, Carl 
E. Schotborgh, Rob J. de Winter, Berthe L. van Eck-Smit, Jan J. Piek. 
Academic Medical Center, Amsterdam, The Netherlands 
Background: Preliminary data suggest that the relative coronary flow reserve 
(rCFR) is better correlated to fractional flow reserve (FFR) than absolute 
coronary flow reserve (CFR). 
Methods: In 53 patients (62 lesions), coronary lesion severity was mea- 
sured by quantitative coronary angiography. FFR and CFR were measured 
distal to the coronary narrowing and CFR also in an angiographically normal 
reference artery. Hyperemia was induced using adenosine i.c. Scatter plots 
and linear regession analysis were performed. 
Results: Coronary lesions varied between 38 and 80% (mean 56%). 
Scatterplots are shown in the figures. 
CFR versus FFR rCFR versus FFR 
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Conclusion: No improvement was observed using the relative CFR or the 
FFR in relation to absolute CFR in assessing intermediate coronary lesion 
severity in multivessel disease. 
ORAL  
Newer, More Aggressive Approaches for 
Coronary Intervention 
Monday,  March  8, 1999,  2 :00  p .m. -3 :30  p.m. 
Mor ia l  Convent ion  Center ,  Room 279 
2 :00  p.m. 
~ - ]  Balloon Dilatation Guided by Intravascuiar 
Ultrasound: Acute and Long-Term Results of the 
UPSIZE Pilot Trial 
Andreas Baumbach, Heiko Mahrholdt, Stephen Schroeder, Karl K. Haase, 
Christian Herdeg, Anastasios Athanasiadis, Martin Oberhoff, Karl 
R. Karsch. Medical Clinic III, University of TE/bingen, Germany 
Background: Recent trials report a reduction of restenosis using intracoro- 
nary stents and suggest that this is a result of the high immediate luminal 
gain. The present study was based on the assumption that optimizing balloon 
dilatation may result in equivalent outcome. 
Methods: Preinterventional intravascular ultrasound was performed in 
252 patients (pts) with 271 lesions. Quantitative assessment of the vascular 
dimensions was performed online. The balloon diameter was strictly adapted 
to the diameter of the external elastic membrane, regardless of dimensions 
assessed by quantitative coronary angiography. The mean balloon diameter 
was 4.1 ± 0.5 mm. 
Results: Acute events occurred in 5 patients (two repeat-PTCA, one 
CABG, two CABG with death). Angiographic dissection occurred in 157 pts 
(58%). Stent implantation for flow limiting dissection was necessary in 3 pts. 
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A GPIIb/llla antagonist was administered in 5 pts. The one year cUncal event 
rate was 15%: 5 10ts experienced a myocardial infarction, 15 repeat PTCA 
of the target vessel, 8 pts underwent elective CABG. Control angiography 
was performed in 178 patients (71%). The angiogrephic restenosis rate was 
19%. 
Conclusion: Despite the use of larger balloons, the strategy of balloon 
dilatation guided by preinterventional intravascular ultrasound appears to 
be safe in the acute setting. The Iongterm outcome in this initial series 
seems to be favorable and is comparable to the results achieved with stent 
implantation. These results warrant verification in a randomized tdal. 
2 :15  p.m. 
~6~ Doppler and QCA Guided Aggressive PTCA has the 
Same Target Lesion RevascularizaUon of Stent 
Implantation: 6-Month-Results of the DESTIN! Study 
Cado Di Mario. The DEST/NI-CFR (Doppler Endpoints Stent INternational 
Investigation) Study Group; Columbus Clinic, Milan, Italy; Lenox Hi// 
Hospital, New York, NY, USA 
Background: Based on the encouraging results of the DEBATE trial, the 
multicenter randomized study DESTINI enrolled 731 patients patients having 
all their significant lesions suitable for stent placement to compare Elective 
Stent placement and Doppler and angiographic Guided PTCA. 
Methods: In the patients randomized to guided angioplasty, all the follow- 
ing end-points had to be met: final residual diameter stenosis (DS) _< 35%, 
final coronary flow velocity reserve (CVR) > 2.0, and absence of dissections 
at risk of abrupt closure. Despite broad inclusion criteria, multivessel treat- 
ment was actually performed in 5% of patients but angiographically complex 
lesions were treated, (type B2 or C lesions in 59% of cases), with an average 
lesion length and reference vessel diameter of 12.7 4- 4.2 mm and 3.07 4- 
0.3 mm, respectively, similar in the Guided PTCA and Stent groups. Of the 
386 lesions randomized to Guided PTCA all the predetermined end-points 
were achieved in 167 arteries (43%) while the remaining lesions entered the 
Provisional Stenting subgroup. 
Results: 
Elective Stent PTCA alone Provisional Stent 
Patienls n = 383 n = 167 n = 219 
MLD (ram) 2.95 ± 0.60 2.30 4- 0.50 2.84 4- 0.52 
Residual DS (%) 8.4 ~: 11.0 26.2 :~ 10.4 9.2 4- 9.6 
6-mths MACE's* 17.2 20.5 15.6 
6-mths TLR" 14.6 16.1 12.3 
MACE = major adverse cardiac events; MLD = minimal lumen diameter; TLR = target 
lesion revasculadzation; *F-up available 554/731 pts (76%) The odds ratio (4- 95% con- 
fidence intervals) for cumulative MACE's of the Stent group vs the Guided PTCA group 
was 0.97 (0.55-1.76). 
Conclusion: When optimal angiographic and physiologic end-points are 
met after PTCA, the early and late clinical outcome is equivalent to the 
outcome observed after elective stent implantation. In the Guided PTCA 
group, however, a minority (43%) of patients could achieve the predetermined 
end-points and the remaining patients ultimately received a stent, limiting the 
practical and econonomical advantage of this strategy. 
2 :30  p.m, 
[ -~-~ Percutaneous In-Situ Coronary Artery Bypass 
(PICAB): Current Development Status and 
Preliminary Results of a Novel Myocardial 
Revascularization Technique 
A.C. Yeung 1 , M. Hayase 1 , P. Fitzgerald 1 , R. Virmani, M. Tumas, T. Lamson, 
J.C. Flaherty, J. Makower, S.N. Oesterle 1 . 1Stanford University Medical 
Center, Stanford, California, USA 
We have previously reported on the concept of using the coronary venous 
system as a conduit to revasculadze the heart percutaneously. We are de- 
veloping two different approaches: PICAB, Percutaneous In-Situ Coronary 
Artery Bypass - the use of the vein as an in-situ bypass conduit and PICVA, 
Percutaneous In-Situ Coronary Venous Arterialization - the use of the ar- 
terialized vein to directly peffuse the myocardium. Percutaneously via the 
coronary sinus, artedo-venous connections are created and the venous seg- 
ment is isolated using a system of novel catheter devices. 
Since March of 1998, we have been working to iteratively develop these 
procedures to a state where they can be repeatable and predictable. In a 
development sedes of 29 chronic procedures in a porcine model, 21 PICABs 
and 8 PICVAs were attempted with procedural completion and successful 
recovery in 18 and 7 animals, respectively. In 3 animals an LAD artery 
stenosis was created 2 weeks prior to the procedure, and in the remaining 
26 the LAD artery was occluded at the time of the procedure. No anatomical 
or other selection criteria were applied to this group. At the end of the 
procedure, flow was TIMI III (n = 16) and TIMI II (n = 2). In 14 of the 18 cases, 
no electrocardiographic indications of ischemia were noted. A subset of 
these animals were sacrificed at timeframes up to 1 month and assessed by 
angiographic, IVUS, electrocardiographic and histologic examination. These 
data will be presented. 
Conclusions: PICAB and PICVA hold promise for human applications. 
Further investigation is ongoing. 
2 :45  p.m. 
~-~4- ]  Cost-Effectiveness of Rheolytic Thrombectomy for 
Thrombus-Containing Coronary Lesions: Results 
from the VEGAS 2 Trial 
David J. Cohen, Roberta Cosgrove, Ronna Berezin, Jeffrey J. Popma, 
Martin B. Leon, Richard E. Kuntz, Stephen Ramee. Beth Israel Deaconess 
Medical Center, Boston, MA, USA 
Background: Despite advances in mechanical and pharmacologic therapy, 
thmmbus-containing coronary lesions are at high risk for adverse events and 
remain a challenging subset for pemutaneous coronary intervention. Rhe- 
olytic thrombectomy with the Angiojet device can safely remove intraooronary 
thrombus, but the overall cost-effectiveness of this approach is unknown. 
Methods: We determined in-hospital and 1-year follow-up costs for 347 
patients with thrombus-containing lesions who were randomized to treatment 
with intracoronary urekinase (6 to 30 hour infusion, n = 169) or immediate 
thrombectomy with the Angiojet device (A J, n = 178). Catheterization labora- 
tory costs were based on measured resource utilization and 1997 unit costs, 
while all other costs were estimated from hospital charges and cost-center 
specific cost-to charge ratios. 
Results: Compared with standard UK infusion, AJ reduced the incidence 
of periprocedural MI (CKMB > 3x) (12.2% vs. 30.3%, p < 0.001) and major 
vascular complications (4.5% vs. 17.7%, p < 0.001) and shortened length 
of stay by neady one day (4.1 vs. 4.9 days, p = 0.02). As a result, AJ 
reduced procedural costs, ancillary costs, and physician fees (see Table) 
and produced net cost savings of more than $5000 per patient ($17,314 vs. 
$22,982, p < 0.001). These cost savings persisted at one-year follow-up. 
Initial Hospital Costs 
Anglo jet Urokinase P-value 
Initial procedure $8211 ± 2739 $9200 + 3709 0.06 
Repeat procedures $449 4- 1431 $1320 4- 2609 <0.001 
Hospital stay $7046 + 5941 $8963 + 6008 <0.001 
MD fees $1608 + 459 $3449 + 905 <0.001 
Total $17,314 + 7428 $22,932 + 9613 <0.001 
Conclusions: Compared with standard treatment with intracoronary UK, 
rheclytic thrombectomy both improves clinical outcomes and reduces overall 
medical care costs for patients with thrombotic oronary lesions. 
3 :00  p.m. 
~-1-~ One Year Clinical and 3-Month Angiographic 
Follow-Up of Cutting Balloon Angioplasty Versus 
Plain Old Balloon Angioplasty Randomized Study in 
Small Coronary Artery (CAPAS) 
Masahiro Izumi, Etsuo Tsuchikane, Masanobu Funamoto, Satoru Otsuji, 
Hitone Tateyama, Tohru Kobayashi, Nobuhisa Awata. Osaka Medical 
Center for Cancer and Cardiovascular Diseases, Osaka, Japan 
The CAPAS trial was designed to evatuate the efficacy of cutting balloon 
angioplasty (CBA) to the clinical and angiographic outcome in small coronary 
arteries, compared with plain old balloon angioplasty (POBA). Two hundred 
forty-eight lesions (232 Pt.) were enrolled and randomized to CBA (121 
lesions; 114 Pt.) group or POBA (127 lesions; 118 Pt.) group. Inclusion 
criteda were as follows; type B/C lesions, reference diameter < 3.0 mm by 
visual image. 
Results: There was no significant difference in baseline characteristics 
between the two groups, Protocol success was 82% in CBA vs 84% in POBA 
group (p = NS). Stent implantation was required in 11 (9%) lesions in POBA 
vs 7 (6%) lesions in CBA (p = NS). 7 lesions in CBA Group crossed over 
to POBA because of the inability to reach the lesion. At thirty day, MACE 
was not observed in both groups. Three-month angiographic follow-up has 
been completed in 95% of eligible lesions. Binary restenosis in CBA was 
significantly lower than that in POBA group (22% vs 41%, P < 0.01). As of 
today, one year clinical follow-up is available in 96%. By 1 year, three patients 
were dead in both groups (mortarity rate: 2.7%, 1: sudden death, 1: bleeding 
in stomach at re-PTCA, 1: malignancy in CBA vs. mortarity rate: 2.5%, 1: Vf 
induced to DCM, 1: GVHD after blood transfusion, 1: sudden death in POBA 
group). Q-wave myocardial infarction (QMI) was not observed in both groups. 
There was no patient conducted to bypass graft surgery in both groups. By 
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1 year, the incidence of target lesion revascularization was lower in CBA 
group than that in POBA group; 22% vs, 29%; which did not reach a stastical 
significance. 
Conclusion: CBA in small coronary artery reduces restenosis and pro- 
vides more favorable long-term clinical outcomes than POBA. 
3 :15  p.m. 
{~1 Lesions at Coronary Artery Bifurcations: Incidence 
and Outcome From the New Approaches to 
Coronary Interventions (NACI) Registry 
Jorge F. Saucedo, Elizabeth Kennard, J. David Talley, Katherine Detre. 
University of Arkansas for Medical Sciences, Little Rock, AR; University of 
Pittsburgh, PA, USA 
The incidence and outcome of lesions treated at coronary artery bifurcation 
(BL) in pts undergoing new device angioplasty (NDA) is not well documented. 
To address this issue, we reviewed the clinical and angiographic findings in 
2113 pts with native coronary artery disease included in the NACI Registry. 
Quantitative angiography was performed using standard methods (Artrek). 
Pts were classified into 3 gps: 1) No BL, 2) BL with no side branch compromise 
(BLNO) and 3) BL with side branch compromise (BLSB). All patients with 
BLSB only had treatment of the parent vessel. In hospital events were similar 
in all groups. Outcomes at 1 year are shown. 
No BL BLNO BLSB P value 
n = 1324 n = 545 N = 144 
Death, % 3.4 4.3 5.6 NS 
Q-MI, % 2.2 2.0 1.4 NS 
CABG, % 11.3 13.2 15.3 NS 
PTCA, % 21.7 24.7 19.4 NS 
Q-MI = Q wave myocardial infarction, CABG = bypass surgery, PTCA = percutaneous 
transluminal coronary angiop~asty. 
By Cox regression analysis the risk for death/Q wave MI/target lesion 
revascularization at 1 year was similar in pts with BLNO, RR: 1.05 (CI 
0.88-1.26, p = NS) and BLSB, RR: 1.19 (CI 0.87-1.62, p = NS) when 
compared to pts with No BL. We conclude that 1) BLSB are infrequent 
(7%) in pts undergoing NDA and 2) are not associated to unfavorable long 
term outcome when a less aggressive approach of leaving the side-branch 
untreated is followed. 
POSTER 
Nonballoon Angioplasty Approaches to 
Percutaneous Angioplasty 
Monday,  March  8, 1999,  3 :00  p .m, -5 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hal l  F 
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~ Rotational of Chronic Total Atherectomy 
Coronary Occlusion is Associated With Very Low 
Clinical Rates: The Treatment of Choice 
Gregory A. Braden, Teresa M. Young, Wendy M. Love, Cindy S. Pinnix, 
Kevin M. Rankin, Robert J. Applegate. WFU School of Medicine 
Winston-Salem, NC, USA 
Background: Percutaneous treatment of chronic total coronary occlusions 
(CTO) with angioplasty has been associated with high acute complication 
rates and very high restenosis rates. Since CTO's are composed of fibro- 
calcific plaque, high speed rotational atherectomy (PTCRA) which effectively 
ablates fibro-calcific plaque may reduce these problems. 
Methods: Accordingly, we evaluated the acute and long-term results of 
PTCRA for CTO in 139 consecutive patients in whom CTO could be crossed 
with a guidewire. 94 males, 45 female with a mean age of 60.2 ~ 1 year, 
53 LAD, 37 CX, and 52 RCA's were studied. 2.1 4- 0.1 burrs (range 1-4) 
were used and patients were generally treated with low pressure oversized 
balloons, however, other adjunctive therapy was used, including stents (20%) 
and DCA (2%). 
Results: By QCA, lumen size increased from 0 to 1.95 i 0.05 mm with 
only 22% residual stenosis, p < 0.001. Acute complications were low: No 
Q-wave MI, 9 non-Q wave MI (7.5%) 2 emergency CABG (1.6%) and death 
(2%) (1 vascular complication and 1 acute renal failure). Late follow-up data 
was available in 122 of 139 (88%) at a mean of 46.2 ± 6 months. Clinical 
restenosis occurred in 20% of patients which was subsequently confirmed 
angiographically. There have been 7 late deaths (2 cardiac, 5 non-cardiac) 
in the group (6%). 
Conclusion: PTCRA of CTO is associated with low complication rates 
and very low clinical recurrence rates. Thus, rotational atherectomy should 
be considered the treatment of choice for CTO. 
• Cutting Balloon Angioplasty for Small Size 
Vessels 
Kenji Tamaki, Eiji Nozaki, Tadashi Sugie, Toru Takahashi, 
Yoshito Yamamoto, Hidenari Hozawa, Hiroyuki Oura, Masafumi Sugi, Iwate 
Prefectural Central Hospital, Iwate, Japan 
Background: To elucidate the efficacy of cutting balloon angioplasty for small 
vessels, we divided 191 consecutive patients who underwent angioplasty into 
a small vessel group (reference diameter < 2.6 mm, n = 99) and larger vessel 
group (reference diameter >_ 2.6 mm, n = 92). 
Methods: In each group, we compared the immediate and 4 months follow 
up results between conventional balloon angieplasty (n = 93) and cutting 
balloon angioplasty (n = 98). Cutting balloon angioplasty was performed with 
low pressure (4-6 atm) and long duration (max: 180 sec) balloon inflation. 
Results: There were no differences between the conventional and cutting 
balloons in the procedure success rate, major complication rate, frequency 
of larger coronary dissection and % diameter stenosis before angioplasty. 
% diameter stenosis immediately after angioplasty was significantly smaller 
in the cutting balloon group than in the conventional balloon group. In the 
larger vessel group, both % diameter stenosis at follow up angiography and 
the binary restenosis rate were not different between conventional balloon 
(n = 44) and cutting balloon angioplasty (n = 48). In the small vessel group, 
% diameter stenosis at follow up angiography was significantly smaller (39.7 
4- 29.7 vs. 51.0 i 20.2%, p < 0.05) and the binary restenesis rate was 
significantly lower (26 vs. 48%, p < 0.05) in the cutting balloon group (n = 
50) than in the conventional balloon group (n = 49). 
Conclusion: Angioplasty of small vessels with the cutting balloon yields 
a lower restenosis rate, suggesting that it is the most suitable tool for treating 
small vessels. 
• Intracoronary Beta radiation effects on dissection 
resolution 
David Meerkin, Raoul Bonan, Michel Joyal, Jean-Claude Tardif. Montreal 
Heart Institute, Montreal, Canada 
Background: The antirestenotic effects of intracoronary brachytherapy are 
considered to be due to the impairment of excessive vessel healing. Ex- 
cessive impairment of healing however may complicate an early beneficial 
result with vessel weakness and increased risks of aneurysm formation. To 
determine the effect of beta radiation on vessel healing, IVUS detected dis- 
section resolution at 6 month was compared in the non stented groups of 
patients in the Beta Energy Restenosis Trial (BERT Canadian arm) and the 
Multivitamins and Probucol (MVP) trial. 
Methods: 26 non stented patients treated with intracoronary beta radia- 
tion (BR). and 94 non stented patients treated with Probucol (P), multivitamins 
(M), both (B) or placebo (Pl) underwent IVUS examinations immediately post 
procedure and at 6 month follow up. These were analysed prospectively for 
the presence of dissection (D) and its grade. 
Results: 
BR P M B PI total MVP 
pts 26 21 25 20 28 94 
D acute 17 7 9 6 8 30 
D FU 5 0 1 1 1 3 
There was no correlation between dissection resolution and IVUS vessel 
characteristics. 
Conclusions: Higher acute dissection rates were noted in the BERT, 
reflecting more aggressive angioplasty. Post-angioplasty resolution of dis- 
section was not complete at 6 months in the MVP trial. BR resulted in 
more than expected dissection non resolution although effective healing was 
maintained in the majority of cases. 
• Cutting vs Balloon Balloon Conventional 
Angioplasty, Subgroup Analysis of a Prospective 
and Randomized Trial 
JesUs Dominguez, Jose A. Rodriguez, Manuel Gomez-Recio, 
Armando Bethencourt, Jose L. Lambert, Vicente Mainar, Jose 
M. Hernandez, Vicens Marti, Javier Zueco, Javier Goicolea. For the CUBA 
investigators. Hospital Clfnico San Carlos, Madrid,, Spain 
Background: The CUBA Study has shown a moderate decrease in reste- 
nosis following cutting balloon (CB) when compared to conventional balloon 
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(BAL) angioplasty. In order to investigate the influence of vessel size, ves- 
sel location and clinical presentation on this benefit, we have performed a 
subgroup analysis. 
Methods: The CUBA study is a prospective and randomized comparison 
of CB vs BAL in native non restenotic coronary arteries. A total of 306 patients 
were included and protocol success was obtained in 90%. Vessel size was 
classified by tertiles of reference diameter (RefD). Non LAD locations were 
grouped, and compared with LAD lesions, Finally clinical presentation was 
categorized as either unstable or stable angina. 
Vessel Size Global RefD < 2.75 2.75 < RefD < 3.25 RefD >_ 3.25 
Rest. BAL (%) 42 39.6 44 41.4 
Rest. CB (%) 31 35.3 31 22.6 
Relative Risk 1.37 1.12 1.39 1.83 
95% CI (0.99-1,89) (0.63-1.99) (0.88-2.19) (0.83-4) 
p 0.05 0.8 0.19 0.16 
Stable Angina Unstable Angina LAD Non LAD 
Rest gal (%) 33 47 52 33 
Rest. CB (%) 21 36 41 22 
Relative Risk 1.54 1.29 1.27 1.51 
95% CI (0.81-2.94) (0.89-1.87) (0.85-1.88) (0.89-2.55) 
p 0.19 0.19 0.26 0.14 
When restenosis rate was adjusted for vessel size, vessel location and 
clinical presentation the relative risk for restenosis after BAL when compared 
to CB was 1.73 (95% CI 1.02-2.92, p = 0,03). 
Conclusions: This analysis confirms the lower restenosis rate after CB 
vs BAL  The greatest benefit, contrary to previous suggestions, was found in 
larger arteries and non LAD locations. 
~ Mechanisms of Acute Luminal Gain and Late 
Lumen Loss from Rotational Atherectomy, 
Preliminary IVUS Results from the Rotablator and 
Restenosis Study 
Gregory A. Braden, Wendy M. Love, Cindy S. Pinnix, Teresa M. Young. 
Wake Forest University School of Medicine, Medical Center Boulevard, 
Winston-Salem, NC 27157-1045, USA 
Background: Moderate debulking with rotational atherectomy (RA) followed 
by low pressure balloon inflations in the Rotablator and Restenosis Study 
(R&R) led to low clinical (15%) and angiographic (28%) restenosis rates. The 
relative contribution of plaque ablation vs. vessel stretching to acute lumen 
gain as well as the relative contribution of neointimal proliferation and chronic 
constriction (remodeling) to late lumen loss can only be determined using 
intravascular ultrasound (IVUS). 
Methods: Patients in the R&R Study were treated with RA using a stepped 
burr approach followed by 1 atm inflations with oversized balloons. The mean 
of 3 IVUS lesion site measurements of vessel area (VA), plaque area (PA), 
and lumen area (LA) were compared pre-PTCRA, post-PTCRA, and at late 
follow-up. 
Results: The data on the first 20 patients with complete IVUS analysis 
are presented below. 
VA LA PA 
Pre-PTCRA 12.19 ± 0.64 2.07 ± 0.19 10.25 ± 0.63 
Post-PTCRA 12.37 5:0.57 4.88 ± 0.19 7.49 5:0.44 
Follow-Up 13.36 5:0.54 3.49 ± 0.16 9.86 ± 0.51 
Acute Gain 0.47 ± 0.32 2.72 :E 0.11" 2.76 5: 0.023' 
Late Loss 0.99 ± 0.09 1.39 ± 0.10" 2.37 5: 0.32" 
*P < 0.001 
Conclusion: Luminal gain from RA employing this minimally traumatic 
technique is due to plaque removal. Late lumen loss is from neointimal 
proliferation, however, there is chronic positive remodeling of the vessel wall 
helping to preserve the lumen. 
~ Percutaneous In-situ Venous Arter ia l  Coronary 
Bypass: Initial Results of Retrograde Myocardial 
Perfusion in a Porcine Model 
Andrew J. Carter, Ran Komowski, Theodore Lamson, Lynn Bailey, 
Sara Collins, Margaret W. Tumas, Joshua Makower, J. Christopher Flaherty, 
Martin B. Leon. Washington Hospital Center, Washington, DC, USA 
Background: Several novel techniques of myocardial revascularization are 
currently undergoing investigation for the treatment of patients with severe 
coronary artery disease refractory to medical therapy and who are not can- 
didates for surgical or percutaneous revasculadzation. 
Methods: We have developed a technique for selective percutaneous in- 
travascular coronary venous arterial bypass to provide myocardial perfusion. 
Results: Six 30 to 50 kg juvenile swine underwent in-situ coronary ve- 
nous arterial anastomosis via a coronary sinus catheter using a 22 gauge 
ultrasound guided artedotomy needle followed by balloon angioplasty and 
stenting to create an artedo-venous channel. Following creation of the coro- 
nary arterio-venous fistula, the proximal anterior or great cardiac vein was 
occluded with a membrane covered self-expanding stent to allow maximal 
retrograde myocardial perfusion and prevent left to dght heart shunting. Five 
of six procedures were successful with angiographic TIMI 2 (n = 1) or TIMI 3 
(n = 4) flow in the arterialized coronary venous conduit. One procedure was 
unsuccessful due to focal guide wire perforation of the anterior cardiac vein. 
Conclusions: Percutaneous in-situ arterial venous bypass is technically 
feasible. Further study is warranted to refine procedural techniques and to 
determine efficacy of myocardial berfusion. 
• /3-Energy To Prevent Restenosis. The Rotterdam 
Contribution To The BERT 1.5 Trial 
A.L. Gijzel 1 , A.J. Wardeh 1 , P.W. Serruys 1 , V.LM.A. Coen 2, M.S. Sabate 1 , 
J .MR. Ligthart 1 , P.C. Levendag 2, W.J. van der Giessen 1 . Thoraxcenter, 
~ Heart Center Rotterdam and Department of Radiotherapy; 2Daniel den 
Hoed Cancer Center Rotterdam, The Netherlands 
Introduction: BERT 1.5 is a mutticenter trial at Emory University Hospital, 
Rhode Island Hospital-Providence, the Montreal Heart Institute and the Tho- 
raxcenter Rotterdam to evaluate safety and efficacy of/3-irradiation following 
PTCA to prevent restenosis in pts with de novo single lesions in coronary 
arteries. 
Methods: After successful balloondilatation a 30 mm train of 12 Stron- 
tium-90/3-emitting seeds was hydraulically railed to the lesion through a 5 
F radiation deliverycatheter. Pts were randomized to a dose of 12, 14 or 
16 Gy After a dwelling time of at maximum 3.33 min.(16Gy) the elements 
were returned into a transfer device and the catheter was removed. In 26% 
additional stenting was performed for recoil or dissection. At the end of the 
procedure volumetric assessment of the results was performed by ECG- 
gated motorized pullback IVUS (Intravascular Ultrasound) 
Results: From Apr to Dec 1997 we enrolled 21 male and 10 female pts 
in the BERT 1.5 trial. Pts had stable angina CCS 2 (n = 7), 3 (n = 14), 4 (n 
= 4) or unstable angina bectods Braunwald class 1C (n = 2) or 2B (n = 2). 
Lesions treated were in LAD (n = 16), LCX (n = 7) and RCA (n = 8). In 1 pt the 
Beta-catheter could not cross a proximal calcified plaque. No major adverse 
cardiac events occurred in hospital. At 1-month follow up all pts but 2 had a 
reduction in anginal class. 27 pts have returned for angiographic follow up 
at 6-months, 3 patients refused angiegraphic follow-up and 1 is pending. 14 
pts had no angina, 11 pts had stable angina and 2 pts had unstable angina. 
Angiographic restenosis (DS > 50% in irradiated segment) was seen in 26%: 
Quantitative Coronary Analysis of these 27 angiograms showed a median 
late loss index of 0.28 (range -0.81 to 3.43). 
Conclusion: Our experience with 31 pts indicates that the technique is 
feasible and safe. A restenosis rate of 26% was observed. 
~ Rotational Achieves A Acute Atherectomy Higher 
Luminal Gain vs, PTCA in the Treatment of 
Diffuse In-stent Restenosis: Insight From the 
Randomized ROSTER Trial 
Samin K. Sharma, Annapoorna Kini, Eli Shalouh, Traci King, 
Amar Garapati, Margarita Santiago, Subhash Kini, Jonathan D. Marmur. 
Mount Sinai Hospital New York, NY, USA 
Background: Although both PTCA and rotational atherectomy (PRCA) have 
been reported to be effective in the treatment of in-stent restenosis (ISR), 
post procedure MLD has been reported to be smaller than the MLD attained 
after initial stenting. Since ISR occurs solely due to intimal hyperplasia, 
debulking by PRCA may achieve a greater acute luminal gain (similar to the 
baseline stenting) as compared to PTCA, In order to evaluate how much 
of the late loss can be regained, we compared the acute gain after initial 
stenting to the acute gain after treatment of diffuse ISR with PRCA vs. PTCA 
Quanatitative Coronary Analysis PRCA PTCA 
(mm) (n = 50) (n = 50) 
Pre-procedure MLD at initial S 0.86 + 0.16 0.89 ± 0.18 
Post-procedure MLD at initial S 3.06 ± 0.31 3.01 ± 0.28 
Acute luminal gain at initial S 2.42 5:0.21 2.36 5:0.19 
Pre.procedure MLD at tSR 0.84 ± 0.21 0.91 4- 0.32 
Post procedure MLD at ISR 2.88 5:0.26 2.61 ± 0.31 
Acute luminal gain at ISR 2.08 5:0.21" 1.72 5:0.21" 
S = stent, "p < 0.02 
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in a randomized trial (ROSTER). Quantitative Coronary Measurements were 
done off-line with CMS Medis QCA system. 
Results are shown in the table. 
Conclusions: Acute luminal gain after ISR treatment is lower compared 
to the acute gain at the time of initial stenting. PRCA achieved significantly 
higher luminal gain compared to PTCA in the treatment of diffuse ISR. This 
observation of "bigger is better" may explain lower TLR in the PRCOA group 
compared to the PTCA group (20% vs. 38%; p < 0.02) in the ROSTER Trial. 
Therefore, PRCA should be preferred over PTCA in the treatment of ISR. 
• /3-Irradiation for treatment of recurrent in-stent 
restenosis 
A.L. Gijzel 1 , A.J. Wardeh 1 , W.J. van der Giessen 1 , V.LMA. Coen 2, 
M.S. Sabate 1 , JM.R. Ligthart, P.C. Levendag 2, P.W. Serruys 1 . 
Thoraxcenter, ~ Heart Center Rotterdam and Department of Radiotherapy; 
2Daniel den Hoed Cancer Center Rotterdam, The Netherlands 
Introduction: In an initial randomized tdal ;/-irradiation was shown to be 
effective in the prevention of recurrent restenosis in patients with restenosis 
after PTCA (Teirstein et al NEJM 1997)./~-irradiation is easier to implement 
in a coronary catheterisation lab but its efficacy still remains to be proven. 
Purpose: We studied the feasibility, safety and efficacy of ,8-irradiation in 
patients with recurrent in-stent restenosis. 
Methods: From May 97 till Aug 98, 10 male and 4 female pts (age 44-76 
years) were treated for recurrent instent restenosis. Lesion characteristics: 
4 th (n = 1) and 3 rd (n = 2) restenosis in venous bypass graft, 3 r~ (n = 1) and 
2 nd (n = 2) restenosis in circumflex and 2 nd restenosis in LAD (n = 4), I st (n 
= 1), 2 nd (n = 1) and 3 rd (n = 2) restenosis in RCA. The average time interval 
for recurrence was 3 months (range 1-12). The average stent-length was 
18 mm (range 19-39 mm). 6 pts were pretreated with eccentric laser, 3 with 
concentric laser and 5 with balloonangioplasty. After successful treatment 
(diameter stenosis < 35%) pts received intracoronary ,8-irradiation in a dose 
of 16 Gy, using the Betacath System (Novoste Co. USA) with a 5 F delivery 
catheter. One in-hospital event was observed (distal dissection, caused by 
balloondilatation, treated with stenting followed by non-Q MI). The first 7 
pts underwent coronary angiography at 6 months. There were 2 restenosis, 
including 1 occlusion. Excluding the pt with the occlusion the Quantitative 
Coronary Analysis of the other 6 pts showed an average MLD of 1.58 ± 0.53 
mm (41 ± 15% diameter stenosis), compared with 1.91 ~: 0.38 mm (27 ± 
6% diameter stenosis) immediately after treatment. 
Conclusion: In this small pilot study we show that in our 14 pts intracoro- 
nary ,8-irradiation with the Novoste Betacath system is safe and feasible for 
the treatment of recurrent in-stent restenosis in coronary arteries and bypass 
grafts. This abstract reports on compassionate use and shows preliminary 
results that are promising and may justify the planning of a randomized 
prospective trial. 
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I1 I Contemporary Intervention: A Report 099-51 Vein Graft from the NHLBI Dynamic Registry 
David R. Holmes, Jr., Peter B. Berger, David O. Williams, Sheryl Kelsey, 
Wanlin Yeh. Mayo Medical Center, Rochester, Minnesota, USA 
Background: Treatment of vein graft disease continues 1o evolve with the 
widespread application of newer technology such as stents and adjunctive 
therapy. Whether this has resulted in improved outcome remains uncertain, 
Methods: We evaluated the outcome of vein graft (VG) interventions 
in NHLBI Dynamic Registry from 1997-1998 (Group A) compared with the 
NHLBI Registry from 1985-1986 (Group B). There were 164 VG interventions 
in Group A and 97 in Group B. Group A patients were older 67 years versus 
62 years, more frequently diabetic 33.8% versus 16.5%, and had more 
hypertension 69.9% versus 42.9%, and had more congestive heart failure 
18% versus 8.6% (all p < 0.05). Female gender and history of prior myocardial 
infarction were similar. Stents were used in 70%, rotational atherectomy in 
2.4%, and thrombectomy in 1.4% of Group A patients but were not available 
in the Group B patients. In hospital outcome of treatment was: 
Percentage Group A Group B P-Value 
Angiographic success 93.3 76.0 <0.001 
Acute closure 2.0 1.7 NS 
Embolization 4.4 
Myocardial infarction 5.5 5.2 NS 
CABG 1.2 3.1 NS 
Death 1.8 2.1 NS 
Death/MI/CABG 8.5 9.3 NS 
* not recorded routinely 
Conclusions: Despite more adverse baseline patient characteristics in 
the Dynamic Registry, with improved technology in treating VG disease, event 
rates are comparable or even lower compared with those in the 1985-1986 
Registry. 
1099-52 1 Procedural Clinical Outcomes Results and Late 
i Following Multiple Saphenous Vein Graft Stenting 
Balram Bhargava, Ran Kornowski, Mun Hong, Kenneth M. Kent, Augusto 
D. Pichard, Lowell F. Satler, Charles Duncan, Roxana Mehran, Martin 
B. Leon. Washington Hospital Center, Washington DC, USA 
Background: Percutaneous angioplasty in patients with multiple saphenous 
vein grafts (SVGs) disease has been previously limited by high rate of 
procedural complications and long term mortality and restenosis. This study 
intended to evaluate our current experience with multiple SVG stenting. 
Methods: We evaluated in-hospital and long-term (18 months) clinical 
outcomes (death, MI, repeat revascularization rates) in 719 consecutive 
patients (1,147 SVGs lesions) undergoing a non-staged multi-SVGs stenting 
(93% of patients with 2 SVGs treated) versus single SVG stenting procedure. 
Results: (Table) 
# SVG's (# Patients) Single (649) Multi (70) P 
(%) (%) 
Procedural Success 97.3 97.2 0.94 
Death/MI/CABG 1.3/1.1/0.8 2.8/0/0 0.29/0.37/0.44 
Non-Q MI 15.5 27.9 0.009 
Repeat Revascularization 17.7 18.8 0.38 
Death/Mr 5.3/2.9 5.6/4.3 0.92/0.55 
Event-free survival 61.8 59.4 0.75 
Conclusions: Multiple SVGs stenting in carefully selected patient candi- 
dates and suitable lesions has 1) similar in-hospital procedural success and 
major complication rates, 2) increased peri-procedural non-Q wave MIs, and 
3) similar long-term (18 month) clinical outcomes compared to single SVG 
stenting. 
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~ Final Results of the Wallstent ® in Endoprosthesis 
Large Saphenous Vein Graft (WINS Registry) 
Robed D. Safian, Barry Kaplan, Theodore Schralber, John Waters, 
Jeffrey Moses, Martin H. Leon. WINS investigators; William Beaumont 
Hospital Royal Oak MI, USA 
Background: No stents are approved for revasculadzing patients with stenoses 
in large saphenous vein grafts (SVG). 
Methods: A prospective multicenter nonrandomized registry was de- 
signed to assess the immediate results and 6-month outcome of the self- 
expanding coronary Wallstent (WS) in SVG (reference diameter = 4.1-5.5 
mm; lesion length _< 0.35 mm). 
Results: Registry patients (n = 210; 230 lesions) were high risk based 
on angina class 3-4 (62%); prior MI (71%) or CVA (11%); diabetes (31%); 
ACC/AHA lesion class B + C (94%); and thrombus (17.4%). 
In-hospital 6-months 
Reference diameter (mm) 3.7 ± 0.7 
Final stenosis (%) 15 ± 15 45 ± 33 
Death, MI, TLR, CVA (%) 12.4 23.3 
Stent Thrombosis (%) 1.9 5.2 
QMI/nonQMI (%) 3.3/11.4 3.3/13.8 
TLR I%) 1 8.6 
Anglo Restenosis (%) 30 
Conclusions: The coronary Wallstent is useful for revascularizing large 
vein grafts, and is associated with a low incidence of stent thrombosis and 
late revascularization. 
• Myocardial Infarctions After Vein Saphenous 
Graft Revascularization: Comparison of 
Angioplasty, Stenting, and Transluminal 
Extraction Catheter Atherectomy 
Kenneth J. Winters, Megumi Taniuchi, Stacy C. Smith, Howard I. Kurz, John 
M. Lasala. Washington University School of Medicine, St. Louis, MO, USA 
Background: Transluminal extraction catheter atherectomy (TEC) may re- 
duce distal embolization and myocardial infarction (MI) in adjunctive stenting 
of complex saphenous vein grafts (SVG). 
Methods: Between 1/95 and 1/98 294 consecutive SVG cases were 
performed in 255 patients (85 TEC, 127 1 ~ Stenl, 82 PTCA). MB-CK levels 
were obtained at 0, 8, and 16 hrs. Procedural MI was defined as an MB-CK > 
2X (> 14 ng/ml). Major in-hospital complications (death. QMI, CABG) were 
recorded prospectively. 
Results: 
Variable (%) TEC 1 ~ Stent PTCA P 
Type C lesions 52.9 35.4 37.8 0.01 
Multiple lesions 52.9 33.1 28.0 0.002 
Adjunctive stent use 85.9 19,5 <0.001 
Abcixirnab use 28.2 22.0 22.0 0.52 
Angiographic success 98.8 99,2 87.8 <0.001 
Clinical success 94.1 94.5 84.1 0.02 
Post-procedure MI 
>2X MB-CK 15.3 18.9 8.5 0.12 
>5X MB-CK 7.1 14,2 4,9 0.05 
> 10X MB-CK 4.7 6.3 3.7 0.69 
MI in type C lesions 17.8 20.0 16.1 0.91 
Conclusions: Both TEC and stenting improve angiegraphic and clinical 
success in SVGs compared to PTCA, although at the cost of increased 
MB-CK release. TEC with adjunctive stenting decreases MIs > 5X MB-CK 
compared to stenting alone. However, TEC does not appear to reduce larger 
MI (> 10X MB-CK) or decrease the overall incidence of MI in complex SVG 
lesions. 
~ Multivessel Stenting Reduces In-Hospital 
Complication Compared With Repeat 
Aortocoronary Bypass Surgery 
Roxana Mehran, Ran Komowski, George Danges, Alexandra J. Lansky, 
Mun K, Hong, Augusto D. Pichard, John R. Laird, Lowell F. Satler, Kenneth 
M. Kent, Gregg W. Stone, Martin B. Leon. Washington Hospital Center, 
Washington, DC, USA 
The optimal revascularization strategy for patients with previous bypass 
surgery (CABG) has not been established. Percutaneous interventions in 
these patients are associated with procedural complications. Similarly, redo- 
CABG has higher in-hospital complications. Between 1/1/94 and 6/30/97, 
1653 pts with prior CABG underwent elective stenting. To compare in-hospi- 
tal events between an interventional vs. redo sugical strategy, we studied all 
prior CABG pts treated with multiveseel stenting (n = 224, 83% men, age 66 
9, 33% diabetes) and those who had redo-CABG (n = 499, 83% men, age 
67 ~ 9, 21% diabetes) during the same 18-month pedod. Valvular surgery 
and repeat redo-CABG were excluded. 
Results: The two groups did not differ significantly with respect to baseline 
clinical characteristics. 
In-Hospital Multi-vessel stenting Redo-CABG P 
Death (%) 0.0 5.4 0.012 
Q-wave MI (%) 1.1 2.0 NS 
CABG/PTCA (%) 0.6 0.0 NS 
Stroke (%) 0.0 2.6 0.011 
Post-op stay (days) 4 :E 5 9 ± 9 0.009 
We conclude that in patients with prior CABG, a strategy of multi-vessel 
stenting is feasible, associated with lower overall in-hospital complications 
(death and stroke), and a shorter length of stay, compared to redo-CABG. 
Ongoing analysis of late clinical outcomes will help to determine if an inter- 
ventional strategy is superior to redo CABG in this challenging patient cohort 
with prior CABG. 
~ Percutaneous of Patients With Revascularization 
Prior Coronary Bypass Surgery: Saphenous Vein 
Graft or Native Coronary Stenting? 
Roxana Mehran, Alexandra J. Lansky, Mun K. Hong, George Dangas, 
Ran Komowski, Michael Peterson, John R. Laird, Jr., Ron Waksman, 
Augusto D. Pichard, Lowell F. Satler, Kenneth M, Kent, Gregg W. Stone, 
Martin B. Leon. Washington Hospital Center, Washington, DC, USA 
The relative risks and advantages of native coronary vs. saphenous vein 
graft (SVG) percutaneous intervention in patients with prior coronary bypass 
surgery (who present with SVG disease) are peorly understood. Therefore we 
evaluated the in-hospital and one year major adverse cardiac events (MACE) 
including death, MI, target lesion revasculadzation (TLR) after elective stent- 
ing in 1092 native coronary lesions compared with 1451 SVG lesions in 1653 
consecutive patients with prior CABG. Baseline characteristics were similar 
and adjunct Abciximab was used in 15.2% of the cases. In hospital MACE 
was similar (1.9% vs. 1.8%, p = NS), however SVG stenting was associated 
with a higher incidence of non-q wave MI (18% vs. 13%, p = 0.04) compared 
to native coronaries. 
# of Patiems n = 718 n = 935 P 
Follow-up (1 year) Native Coronaries SVG 
Death (%) 4.3 9.1 0.001 
MI (%) 2.3 4.5 0.001 
TLR (%) 19.1 16.9 NS 
MACE (%) 29.6 32.7 NS 
Independent predictors of late deatl'VMI included SVG location (OR 2.1), 
pest procedural non-Q wave MI (OR 2.5), and LV ejection fraction (OR 0.80). 
We conclude that in patients with prior CABG, SVG stenUng is associ- 
ated with higher post procedural CPK release and higher late major events 
including death and MI, compared with native coronary stenting. These data 
suggest that when given a choice between native vs. SVG intervention in 
patients with prior CABG, stenting of the native vessel should be preferred. 
~ Percutaneous Revascularization of the Internal 
Mammary Artery Graft: In-Hospital and 
Long-Term Outcome 
Luis Gruberg, Roxana Mehran, Mun K. Hong, George Dangas, 
Ran Komowski, John R. Laird, Jr., Michael Peterson, Lowell F. SaUer, 
Augusto D. Pichard, Kenneth M. Kent, Gregg W. Stone, Martin B, Leon. 
Washington Hospital Center, Washington DC, USA 
The left internal mammary artery (LIMA) is considered the conduit of choice 
for coronary adery bypass surgery (CABG) due to favorable long-term pa- 
tency. Although infrequent, obstructive lesions can develop in the LIMA, and 
balloon angioplasty (PTCA) has been the technique of choice. 
Methods: We evaluated the in-hospital and late outcomes of 165 con- 
secutive revascularization procedures of LIMA in a total of 158 patients. 
Results: Either PTCA (87%) or tubular slotted stents (13%) were used 
selectively in various lesions; 73% of lesions were at the distal anastomosis. 
Mean age was 63 years, 65% were men, 25% diabetics, 59% with prior MI; 
the mean ejection fraction was 0.42 :E 0.13 Procedural success was 97.5%. 
Stent n = 22 PTCA n = 143 Total 
Ref diam (ram) 2.63 + 0.44 2.12 ± 0.43 2.21 ± 0.47 
Pre diam sten (%) 60.8 ± 16 60.3 ± 20 60.4 ± 19 
Final diam sten (%) 1 ± 20 29 ± 15 23.6 ± 19 
P-inal MLD (ram) 2.66 ± 0.79 1.43 ± 0.53 1.64 ± 0.74 
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There was no in-hospital death, Q-wave MI or emergency CABG. Non-Q- 
wave MI (CKMB > 5Xnormal) rate was 7.1%. At 1-year follow up, mortality 
was 3.9% and target lesion revascularization (TLR) was 9.4%. 
Conclusion: Percutaneous intervention of LIMA can be performed safely 
and effectively with PTCA and stents and appears to have lower TLR than 
that for other lesion subsets. 
• Stenting of Left Main A Viable Coronary Artery: 
Alternative in Patients With Prohibitive Surgical 
Risk 
Robert Siegel, Ambika Bhaskaran, Paul Underwood, Barbara Barker, 
Warren Breisblatt, Alvin Nuttall, Jennifer Vermillion, Debbie Swanson, 
Peter Santos. Advanced Cardiac Specialists, Phoenix, Arizona, USA 
Significant left main coronary artery (LMCA) stenosis is known to negatively 
impact survival. Surgical revascularization has been the mainstay of treat- 
ment. PTCA results have been discouraging, in part due to accentuated 
elastic recoil of the proximal left main. We evaluated the effects of stenting 
(ST) of LMCA lesions in a selected patient cohort. From 1/97 to 8/98, we 
performed ST of the LMCA in 24 patients (age range 44-83 years) with 
prohibitive surgical risk. Seven (29%) had unprotected LMCA disease; 33% 
had ostial/proximal disease. Of these, 85% had prior CABG with graft failure 
and 25% had moderate-to-severe LV dysfunction. Mean global LVEF was 
43.9%*. The procedure was emergent in 38%; 17% presented in frank car- 
diogenic shock. Adjunctive IABP was used in 42% and ventilatory support in 
8.3%. Multiple brief balloon pre-dilatations were performed (mean inflations 
4.4), with post-ST high-pressure inflations (mean 18.6 atm). Prior debulking 
was done in 3 cases. Additional lesions dilated at the same time included 7 
proximal LAD, 8 proximal Cx and 3 RCA. 
Results: Procedural success was 100%, with unevenftul post-procedure 
hospital stay. 
12-month follow (95.6% complete; mean 7.6:1:4.8 days) 
Fle-PTCA CABG Death Event-Free Mean LVEF 
1 (4.2%) 2 (8.3%) 1 (4.2%) 20 (83.3%) 52.5%*; p = 0.25 
Conclusions: 1) Stenting of critical LMCA stenosis was safe and effective 
in a selected patient cohort with prohibitive surgical risk. 2) Favorable acute 
outcomes were obtained across all age groups, independent of LV systolic 
function. 3) At 12-month follow-up, mortality and clinical restenosis rates were 
low, with high event-free survival. 4) LV systolic function showed discernible 
upward trend. 5) Our series indicates that improving epicardial coronary 
artedal flow via stenting in severe LMCA disease appears to be an effective 
alternative to high-risk surgery, with favorable clinical outcomes. 
~ Thrombus Sequestration Coronary in Human 
Arteries by the Autologous Vein Graft-Covered 
Stent: A New Therapeutic Approach 
Konstantinos Toutouzas, Chdstodoulos Stefanadis, Eleftherios Tsiamis, 
Pavlos Toutouzas. Hippokration Hospital, University of Athens, Greece 
Background: Subacute thrombosis and restenosis are increased after stent- 
ing in thrombus-containing lesions (TCL). The purpose of this study was to 
sequestrate the thrombogenic lesion by the implantation of autologous vein 
graft-covered stent (AVGCS) in TCL, and assess the immediate and mid-term 
results. 
Methods: A 3-4 cm vein graft was removed from the right cephalic vein 
of 25 patients (pts). Then, the vein graft was secured on the external surface 
of a Multilink TM stent by the application of 3 sutures (Prolene 7-0) at each end 
of the stent. The AVGCS was implanted in 15 TCL of 15 pts suffering from 
acute myocardial infarction or unstable angina (12 males, mean age 61 ± 13 
yrs). Ostial lesions were not excluded from the study. Pts left hospital under 
acetylsalicylic acid and ticlopidine treatment. 
Results: The preparation and delivery of AVGCS was easy and there were 
no complications. All pts had a negative treadmill stress test 3 months after 
AVGCS implantation, with the exception of one who suffered from subacute 
thrombosis 20 days after the procedure. The pts were free of angina 4.8:1: 
2.8 months after the procedure. In 7 pts repeated angiography 6 months after 
the AVGCS implantation revealed no restenosis (immediately after: 3.18 ± 
0.3, 6 months: 2.97 ± 0.4 mm). 
Conclusion: Implantation of AVGCS in TCL is a feasible and uncom- 
plicated procedure with favorable immediate and mid-term results, which 
seems to be thromboresistant. Further studies are needed in order to in- 
vestigate the efficacy of AVGCS to reduce the incidence of thrombosis and 
restenosis in TCL. 
~ Effect Stenta by Autologous Vascular of Covered 
Grafts on Endothelialization, Intimal Hyperplasia 
and Vascular Injury in Porcine Coronary Arteries 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, 
Lubna Khaldi, Dorothea Tsekoura, Nikolaos Giatrakos, Pavlos Toutouzas. 
Hippokration Hospital, University of Athens, Greece 
Background: Covered stents have been proposed to eliminate current prob- 
lems of stenting. The aim of this experimental study was to compare stents 
covered by autologous arterial or venous grafts with conventional uncovered 
stents. 
Methods: The study was performed in 19 swines (20-26 kg). The arterial 
graft was harvested from the femoral artery and the venous graft from the 
cephalic vein. Both grafts were stabilized on the external surface of Multilink TM 
stents by the application of 3 sutures (Prolene 7-0) at each end. Fourteen 
arterial-covered stents (AC), 14 venous-covered stents (VC) and 10 uncov- 
ered Multilink TM stents, serving as control group, were implanted. The animals 
were sacrificed between a period of 7 days-2 months. The luminal area cov- 
ered by endothelial cells (EC) was quantified by computer-assisted digital 
planimetry. The vascular injury score was assigned: IO: intact internal elastic 
lamina (IEL); I1: fragmentation of IEL; 12: stent penetration into the media; 
13: fragmentation of external elastic lamina. 
Results: The injury score, the maximal intimal thickness (MIT), and the 
EC were similar between AC and VC. The uncovered stents had less EC. 
However, AC and VC groups had less vascular injury score (p < 0.001 by 
Mann-Whitney test) and MIT compared to the control group (Table). 
Table 
10 I1 12 13 MIT (#m) EC (%) 
AC n=13 n=l - - 112.24±43.64 81±12 
VC n = 14 - - - 107.48 ± 35.51 74 ± 15 
Control n=l n=5 n=2 n=l 151.314-47.45 * 55±14" 
"p < 0.05 
Conclusion: Covered stents by autelogous arterial- or venous-graft had 
similar effect on endothelialization, vascular injury, and neointimal hyperpla- 
sia. However, covered stents have favourable results compared to uncovered 
stents in the porcine model. 
~ Abciximab Flow" During Direct Decreases I '  S~OW 
Angioplasty for Acute Anterior Myocardial 
Infarction: A Randomized Study 
David W. Smyth, A, Mark Richards, Chris Hart, John M. Eiliott. Cardiology 
Dept, Christchurch Hospital, Christchurch, New Zealand 
Background: Previous studies suggest that slow flow (delayed transit of 
contrast hrough epicardial aderies without critical stenosis) predicts a worse 
outcome after direct angioplasty (DPTCA) for myocardial infarction (MI), and 
that slow flow is mediated by platelets, We have conducted a prospective ran- 
domized open trial to assess the effect of Abciximab, a GP Ilbllla antagonist, 
on the incidence of slow flow. 
Methods: Immediately after diagnostic angiography, consecutive patients 
with first anterior MI with complete occlusion of the left anterior descending 
(LAD) coronary artery and pain < 12 hrs duration, were randomized to receive 
Abciximab (R, 0.25 mg/kg bolus plus 10 mg/min for 12 hrs, n = 20) or heparin 
(H, 2500 IU iv, n = 20) in addition to iv heparin 100 U/kg. The heparin group 
received the same dose of R at the end of the DPTCA. Cineangiograms of 
the LAD were obtained every 5 minutes during the procedure. The composite 
endpoint was pre-specified as angiographic failure (<TIMI 3 flow or residual 
stenosis <50% at the end of the procedure) or slow flow during the procedure 
(defined as a transient or persistent reduction in TIMI flow by > 1 grade after 
opening the artery, analysis blinded to treatment). 
Results: Baseline characteristics were similar in the 2 groups including 
age, gender, previous angina, time from pain onset to decision to DPTCA 
(3.7 (1.6-6.9, median, 95% CI) hrs in R vs 4.4 (1.8-9.6) hrs in H), ACT 
levels prior to balloon inflation (287 (225-460) vs 270 (215-420)), and site 
of occlusion (proximal LAD in 10 vs 9). There were no significant differences 
in procedure time, screening time, or in the decision to deploy a stent (12 vs 
13 patients). The primary endpoint occurred in 2 R patients compared with 7 
in the heparin group (p = 0.04) and final TIMI frame counts were 27 (22-36, 
median, 95% CI) and 39 (28-53, p = 0.048). 
Conclusion: Abciximab may reduce the incidence of slow flow during 
direct angioplasty. 
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• Cardioprotective Effects of Adenosine Transport 
Inhibition During Reversible lechemia in Patients 
With Coronary Artery Disease 
Jan Paul Ottervanger, Pavel Gregor, Petr Widirnsk~, Felix Zijlstra, Ed de 
Kluiver, Arnoud van't Hof, Harry Suryapranata. Hospita/De Weezen/anden, 
Zwo/le, The Netherlands 
Background: Adenosine plays a major role in protecting ischemic my. 
ocardium. Inhibition of nucleosine transport inhibition may enhance these 
favorable effects. 
Design: Randomized, double blind, placebo controlled study, to investi- 
gate nuclecside transport inhibition. 
Patients and Methods: Elective left anterior descending (LAD) coronary 
angioplasty was used to produce reversible iechemia in 24 patients with 
stable angina and a single LAD lesion. The nucleoside transport inhibitor 
draflazine or placebo, were infused between the 2nd and 3rd balloon infla- 
tion. Pdmary end point was ischemia induced wall motion abnormalities as 
measured by left septal echo amplitude, which was plotted against time to 
produce an area under the curve, 
Results: No differences were observed in the systemic hemedynamics or 
the myocardial collateral circulation of the two groups. The ischemia induced 
regional wall motion abnormalities improved significantly after draflazine, 
while no difference was observed in the placebo group. This improvement 
was even more pronounced in patients with low caffeine levels compared to 
those with high caffeine levels. 
Conclusions: Draflazine is associated with a significant improvement in 
regional myocardial function of the ischemic area, without affecting systemic 
or collateral circulation, when compared to placebo. This implies that nu- 
cleoside transport inhibitors may have a cardioprotective ffect in ischemic 
myocardium. High caffeine blood levels reduce these effects. 
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~ Radiation Doses Received Arteries by Coronary 
During Interventional Procedures 
Demosthenes Katritsis, Socrates Korovesis, Efstathios Efstathopoulos, 
Sophia Betsou, Keith Faulkner, Michael Webb-Peploe. Onassis Cardiac 
Surgery Center, Athens, Greece; Newcastle Genera/Hospital Newcastle; 
SL Thomas' Hospital, London, England 
Coronary irradiation can result in reduction of post-angioplasty restenosis. 
The radiation dose received by the coronary arteries (CA) during coronary 
angiography or intervention has not been investigated. 
Methods: Thermoluminescent dosimeters (TLDs), suitably calibrated and 
mounted on a specially designed catheter which was advanced to the left 
or dght sinus of Valsalva, were used to measure the dose received by the 
CA of 57 pts undergoing coronary angiography and/or PTCA. Effective dose 
received by patients was assessed by using a dose-area product (DAP) to 
effective dose conversion factor, which was estimated with the help of a 
Rando phantom. 
Results: Mean CA irradiation doses were 24.0 ± 2.5 mGy for coronary 
angiography, 31.0 ± 3.6 mGy for PTCA, 43,6 ± 7.2 mGy for PTCA followed 
by stent implantation, 55.0 ± 7.5 mGy for angiography followed by ad hoc 
PTCA and 64.7 ± 5.6 mGy for angiography followed by ad hoc PTCA and 
stent implantation. A linear relationship of the DAP and the dose at the CA 
was found: DAP + 3390 mGycm 2 = 1337 cm 2 x (coronary dose). A DAP to 
effective dose conversion factor was estimated and the mean effective dose 
received by pts was calculated. 
Conclusions: Radiation dose to CA during interventional procedures 
is not negligible, particulady following complicated, multivessel PTCA. Our 
method can be used for the calculation of the radiation dose delivered to CA 
during the procedure by using external dosimeters and assist the titration of 
irradiation doses during vascular brachytherapy for prevention of restenosis. 
• Cross-Sectional Measurements After Treatment of 
In-Stent Restenoeis: An Intravascular Ultrasound 
Guide for Intracoronary Radiation Dosimetry 
Balram Bhargava, Gary S. Mintz, Borjanca Oljaca Leiboff, Chrysoula 
K. Pappas, Renee Y. Reed, Bryan Curry, Javed Ahmed, Ron Waksman. 
Washington Hospital Center, Washington, DC, USA 
To understand the potential impact of lesion eccentricity on dose homo- 
geneity during brachytherapy for in-stent restenosis, we used intravascular 
ultrasound (IVUS) to study 56 naive artery in-stent restenosis lesions after 
PTCA (n = 16), rotational atheractomy +PTCA (n = 14), excimer laser + 
PTCA (n = 11), or additonal stent (N = 15). Four measurements were made 
every 5 mm of lesion and adjacent reference segment length in systole and 
diastole: (#1) IVUS catheter to media, (#2) IVUS catheter to stent, (#3) IVUS 
catheter to center of lumen, and (#4) center of lumen to media. Maximum 
and minimum measurements and their differences (4) in mm are 
Maximum Minimum ,~ 
#1 2.99 ± 0.43 (1.6-3.8) 1.08 ± 0.22 (0.7-1.7) 1.91 4` 0.50 
#2 2.45 :E 0.41 (1.4-3.8) 0.80:1:0.16 (0,5-1.2) 1,65 4- 0.46 
#3 0.82 ± 0.23 (0,4-1.4) 0,24 + 0.15 (0,-0.5) 0.58 4` 0.23 
#4 2.58 .-~ 0.46 (1.6-3.7) 1.43 ± 0.22 (0.9-2.1) 1.15 4` 0.51 
The above measurements varied both with lesion length and lumen di- 
mensions, but more so with lesion length. This was true regardless of the 
theoretical source location: site of the IVUS catheter (#1 and #2) or cen- 
ter of the lumen (#4). Variability was similar regardless of initial treatment 
modality. 
We conclude: There is significant variability in distances from potential 
point source locations to the media which may cause dose inhomogeneity. 
This variability increases with increasing lesion length and lumen size. Dosing 
strategies may have to be altered to prevent recurrence, especially in long 
lesions in large vessels. 
• Intracoronary Gamma Radiation Reduces Intimal 
Hyperplasia Volume 6 Months After Treatment of 
In-Stent Restenosis: An Intravascular Ultrasound 
Analysis from Radiation Clinical Trial 
Batram Bhargava, Ron Waksrnan, Lisa M. Gierlech, Martin B. Leon, 
Rosanna C. Chan, Avinoam Shiran, Gary S, Mintz. Washington Hospita/ 
Center, Washington DC, USA 
The effects of gamma radiation on the intimal hyperplasia (IH) formation in 
patients with in-stent restenosis were studied by intravascular ultrasound 
(IVUS). We compared baseline and follow-up IVUS findings of 12 patients 
from radiation trials who were treated with gamma radiation 192Iridium (15 
Gy dose prescribed at 2 mm from the source) to 6 placebo patients who 
did not receive radiation. All the patients in this analysis were asymptornatic 
at 6 months follow-up with a patent artery and <30% diameter stenesis on 
angiogram. IVUS was performed using automated pullback (0.5 mnYsec) 
immediately post intervention and at 6 months. Stent, lumen, and IH (stent- 
lumen) areas were measured at 2-ram intervals within the stent and volumes 
were calculated using Simpson's rule. An observer blinded to the treatment 
analyzed the IVUS findings for IH volume and the IH burden (IH/stent vol- 
ume). 
Results: 
Placebo Irradiated P 
Mean stent length mm 24.8 4` 8.9 35.0 4- 16.9 NS 
Baseline IH burden % 26 4` 7 28 ± 5 NS 
-~6 months IH burden % 17.7 :E 11 0.8 i 12 0.01 
,~. IH volume mm 3 +88.0 4` 69.8 -7.1 4` 10.4 0.02 
Conclusion: Compared with standard therapy, intracoronary gamma ra- 
diation significantly reduces IH burden in patients with in-stent restenosis, by 
essentially "freezing" IH accumulation at 6 months follow-up. 
• Intravascular Ultrasound Almost Always Detects 
Unstable Lesion Morphology Within 72 hours of 
Onset of Acute Myocardial Infarction 
Andrea S. Abizaid, Gary S. Mintz, Lowell F. Satler, Augusto D. Pichard, 
Alexandm Abizaid, Carol L. Walsh, Borjanca Oljaca Leiboff, Preveena 
R. Solipuram, Alain Laroche, Kenneth M. Kent, Martin B. Leon. Washington 
Hospital Center, Washington, DC, USA 
In the last 3 yrs, we performed pre-intervention intravascular ultrasound 
(IVUS) in 59 pts within 72 hrs of the onset of a Q-wave myocardial in- 
farction (MI). In 53 (90%) lesions there was evidence of plaque rupture 
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(narrow-mouthed, wide-bodied intraplaque cavities communicating with the 
true lumen). In 50 (85%) lesions there was evidence of thrombus forma- 
tion (mobile, pedunculated intraluminal elements with microchannels, often 
partially filling the intraplaque cavity). Plaque rupture and~or thrombus was 
present in 58 (98%) lesions (Figure): 
Conclusions: 1) As mechanical intervention restores flow into the oc- 
cluded infarct vessel, the ref, dia. increases. 2) QCA consistently underesti- 
mates vessel size compared to IVUS. 3) Nonetheless, the device to lumen 
ratios chosen by interventionalists meet generally accepted standards (ratio 
1-1.1 : 1). 4) The relatively low cross sectional area achieved predicts fre- 
quent restenosis after AMI intervention. 5) Significant remodeling is present 
at the lesion and reference site which may allow larger devices to be used, 
potentially lowering restenosis. 
Any amount (even focal) lesion calcification was rare. Positive or interme- 
diate lesion arterial remodeling was the rule occurring in 51 (86%) lesions. 
Reference segment plaque burden tended to be modest (34 ± 10%) with cal- 
cification in 6/59 (10%), suggesting that Q-wave MI lesions occur in arterial 
segments with only modest disease. 
We conclude: IVUS detects unstable lesion morphology in almost all 
lesions within 72 hours of a Q-wave MI, confirming the importance of plaque 
rupture i thrombus formation to this event. Conversely, the rare appearance 
of lesion site calcification suggests that calcium is a poor marker for unstable 
lesions prone to rupture. 
~ Characteristics of the Lesions Culprit Coronary 
and Estimation of the Interventional Treatments in 
Patients With Acute Myocardial Infarction by 
Coronary Angioscopy 
Katsumi Yamada, Hiroshi Morio, Kuniko Terasawa, Osamu Hasegawa, 
Yoshiharu Fujimori, Akira Matsuo, Masaaki Osegawa, Yasumi Uchida t . 
Narita Redcross Hospital; i Toho University Sakura Hospital, Chiba, Japan 
Background: Information of the culprit coronary lesions derived from coro- 
nary angiography is not enough to investigate pathogenesis of acute my- 
ocardial infarction (AMI) and to decide appropriate therapeutic strategies. 
Methods: We observed the culprit coronary lesions in 47 patients with 
AMI by percutaneous angioscopy, before and after interventional treatment. 
Result: Before treatment (41 patients), the plaques were yellow in 34 
and white in 7 lesions. Intimal flaps were found in 17 lesions. Fresh thrombi 
were observed in 27 lesions, red thrombi in 8, mixed thrombi in 11, and white 
thrombi in 8. Plaque rupture was found in 3 yellow lesions with red thrombi, 
but in none with white. After treatment of PTCA, PTCR, STENT, or those 
combination (27 patients), thrombi were found in 19 lesions and intimal flaps 
similarly in 19. Thrombi were found less frequently in PTCA alone group than 
in combined treatment group (3 of 11.27% vs 16 of 18.89%, p < 0.001). 
Intimal flaps were found frequently in both groups. 
Conclusion: Angioscopic estimation of the culprit coronary lesions in AMI 
provides important informations on the pathogenesis of AMI and those for 
selection or addition of therapeutic strategies. 
~ D o  Interventionalists Undersize Devices During 
Acute Infarct Intervention? Comparison of 
Angiographic and Intravascular Ultrasound 
Measures from the PAMI Stent Randomized Trial 
Frank A. Flachskampf, Khaled M Ziada, M. Pieper, Timothy Crowe, Steven 
E. Nissen, Murat Tuzcu, Bruce R. Brodie, John Griffin, Fred Felt, 
Costantino Costantini, Gary S. Mintz, Cindy L. Grines, Gregg W. Stone. 
Cleveland Clinic, Cleveland, Ohio; Washington Hospital Center, Washington 
DC, USA 
Restenosis rates after primary PTCA and stenting in AMI are higher than 
in the elective setting. As the major determinant of restenosis is the MLD, 
operator device undersizing in vessels initially underfilled from reduced an- 
tegrade flow may be responsible. Blinded IVUS was performed after primary 
PTCA or stenting in 116 pts at 16 sites in the IVUS substudy of the PAMI 
Stent Trial. TIMI 2-3 flow was present in only 23% of Isns pre-PTCA, vs. 
100% post procedure. Matched corelab QCA and IVUS comparisons appear 
below. The initial ref. dia. by QCA pre-PTCA was 2.80 ± 0.46 (p ~-- 0.001 vs. 
QCA ref dia. post procedure in table). 
QCA IVUS P value 
Ref. dia. post (mm) 3.08 ± 0.41 3.22 ± 0.46 0.002 
Max device size (ram) 3.39 ± 0.34 
Device/artery atio 1.12 ± 0.12 1.07 ± 0.13 0.003 
Vessel (EEM) dia. (mm) - 4.51 ± 0.67 - 
Final result: MLD (mm) 2.34 ± 0.46 2.76 ± 0.45 <0.0001 
Cross sectional area (mm 2) - 6.1 =- 2.0 - 
EEM dia. - lesion (mm) - 4.82 ± 0.71 - 
Max devicelEEM ratio - 0.72 ± 0.12 - 
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~ TGF-~31, TGF-/32, and MCP-1 Secretions Respond 
to Irradiation in a Dose Dependent Manner in 
Cultured Smooth Muscle Cells 
Anne T. Nguyen, Hans-Peter Stoll, Wendy L. Winkle, Gary D. Hutchins, 
Keith L. March. Indiana University Indianapolis IN, USA 
Background: The TGF family of cytokines is known to influence tissue fibro- 
sis and remodeling as well as smooth muscle cell differentiation. Adventitial 
macrophages are thought to trigger the restenosis process by cytokine se- 
cretion. We used a cell culture model to study the impact of radiation on 
cytokine secretion and cell proliferation utilizing the positron emitter Ga-68 
we proposed earlier for liquid filled balloon brachytherapy. 
Methods: Bovine smooth muscle cells were plated at confluence, growth 
arrested for 72 h, and subsequently irradiated with Ga-68 at doses ranging 
from 1 to 12 Gy. The activity was delivered into cell culture wells and exposed 
in contact with the bottom of the insets holding cultured cells. Dosimetry 
was established by irradiating GAFchromic film under the same geometry. 
Irradiated cells were replated at 104cm -2. At multiple time points cells were 
counted with Trypan blue staining and media conditioned for 4 days were 
assayed for TGF-/31, -#2, and macrophage chemotactic protein (MCP- 1) by 
ELISA. Cytokine concentrations were normalized to cell counts. 
Results: 
Dose: Cell Count TGF-/31 TG F-/~2 MCP-1 
(Gy) (103cm 2) (pg/103 cells) 
0 118 ± 1.7 37.4 5.6 1.32 
1 92 ± 2.1 42.6 10.1 1.26 
3 71 ± 0.2 49.2 15.4 0.20 
6 12 ± 0.2 104 75.3 0.00 
12 7 ± 0.2 130 120 0.00 
ED50 was 6.2 Gy for TGF-#I, 2.7 Gy for TGF-/32, and 1.0 Gy for MCP-I. 
Conclusion: Irradiated smooth muscle cells in culture show growth in- 
hibition, upregulation of TGF-#1/2, and downregulation of MCP-1 in a dose 
dependent manner. We hypothesize that the efficacy of brachytherapy is in 
part contributed te cytokine mediated smooth muscle cell differentiation and 
marophage chemoattraction. 
~ Gallium-68 Positron Radiation Effectively 
Reduces Neointima Proliferation in the Porcine 
Coronary Overstretch Model 
Hans-Peter Stoll, Wendy L. Winkle, Gary D. Hutchins, Jeffrey Howard, C. 
Robert Appledorn, Keith L. March. Indiana University Indianapolis IN, USA 
Background: We have recently proposed the use of Ga-68 for liquid filled 
balloon brachytherapy since it combines anti-proliferative efficacy in cell 
culture assays with markedly superior safety in case of balloon failure, based 
on its short half-life (68 min). This study investigates the impact on neointima 
proliferation in the porcine coronary overstretch model. 
Methods: 25-50 mCi 6eGaCI3 eluted from a Ge-68/Ga-68 generator was 
delivered into the fluid port of conventional autoperfusion balloon catheters 
and used to irradiate sites of coronary overstretch (B:A ratio = 1.3; n = 25) in 
juvenile farm pigs (n = 15). Therapeutic doses were directed to a prescription 
point 1 mm beyond the intimal surface and included groups of arteries 
treated with 8 Gy, 12 Gy, 16 Gy, and 24 Gy. Overstretched but unirradiated 
arteries served as control. Animals were sacrificed 28 days later and hearts 
were perfusion fixed. Serial sections were evaluated by histomorphometric 
analysis. Intimal area (IA), intimal area to fracture length ratio (IA/FL), and 
maximal intimal thickness (MIT) were measured. 
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Results: 
n = IA (ram 2) INFL (mm) MIT (rnm) 
Control 9 0.51 ± 0.04 0.47 ± 0.06 0.40 ± 0.05 
8 Gy 5 0.75± 0.15 0.68 -+- 0.10 0.62 ± 0.08* 
12 Gy 3 0.46 ± 0.16 0.34 ± 0.12 0.32 :t: 0.11 
16 Gy 3 0.07 ± 0.04" 0.05 ± 0.03" 0.09:1: 0.01" 
24 Gy 5 0.07 ± 0.02* 0.05 ± 0.02* 9.98 ± 0.04* 
Data are mean ± SEM, *p < 0.05 vs control 
Conclusion: Ga-68 positron radiation significantly reduces neointima 
formation in the porcine model in both high dose groups. Since Ga-68 is 
effective, safe, and available from a generator it should be considered as an 
isotope optimally suited for liquid filled balloon brachytherapy. 
I 1101-97 1 Radioactive 133-Xenon Gas-Filled Balloon to 
Prevent Restenosis: Efficacy, Dosimetry and 
Safety Considerations 
Ron Waksman, Rosanna C. Chan, Yoram Vodovotz, Bill G, Bass, Marc 
G. Apple. Washington Hospital Center Washington DC, Parkview Memorial 
Hospital, Fort Wayne, IN, USA 
A novel system for vascular brachytherapy using a 133-Xenon radioactive 
gas-filled balloon to prevent restenosis was tested in 33 porcine coronary 
arteries subjected to balloon injury (BI). Following BI, a 3.5 mm diam/45 ram- 
length balloon was positioned to overlap the injured segment. After vacuum 
was obtained in the balloon, 2.5 cc of 133-Xe gas with an average activity of 
123 mCi was injected to fill the angioplasty balloon. Doses of 0, 7.5, 15 and 
30 Gy were delivered to a distance of 0.25 mm from the balloon surface. The 
dwell time of the gas-filled balloon ranged from 1.0-4.0 minutes depending on 
the dose, Localization of the 133-Xe in the balloon was verified by a gamma 
camera, during treatment and following retrieval of the gas and the catheter 
from the artery. The average activity in the balloon was measured 67.7 -- 
12.1 mCi and the total diffusion loss was 0.26%/min of the injected dose. 
Bedside radiation exposure measured between 2-6 mWh and the shallow 
dose equivalent was calculated to be 0,037 mRem per treatment, Histomor- 
phometric analysis of irradiated arteries in all doses taken two weeks after 
the radiation showed inhibition of intimal area (IA) and the IA corrected for 
medial fracture length (IA/FL) compared to control (p < 0.001). 
Control (6) 7.5 Gy (9) 15 Gy (12) 30 GY (t5) 
tA (mm 2) 1.51 ± 0.35 0,32 ± 0.53 -0.17 ± 0.09 0.34 4- 0.11 
tNFL 0.76 ± 0.05 0.12 ± 0.89 0.07 ± 0.24 0.26 ± 0.08 
Conclusions: 133-Xe gas-filled balloon system is feasible and effective 
in reducing NF in the porcine coronary model and appears safe for clinical 
use during human coronary brachytherapy. 
1101-134 I Effects of the Cell of Rat ,-f-irradiation on Cycle 
r 
Smooth Muscle Cells 
Hyo-Soo Kim, In-Ho Chae, Sun-Jung Park, Dae-Won Sohn, Byung-Hee Oh, 
Myoung-Mook Lee, Young-Bee Park, Yun-Shik Chol, Young-Woo Lee. 
Seout National University Hospital, Seoul, Korea 
Background: In spite of the clinical introduction of brechytherapy to reduce 
restenosis, biologic responses of vascular smooth muscle cells (VSMC) 
to radiation have not been well studied. We investigated the effects and 
mechanisms of y-irradiation on cell cycle of VSMC using primary culture of 
rat aortic VSMC and 137Cs as a radiation source. 
Methods & Results: The cell counts after irradiation of 0, 2, 8, 16 Gray 
(Gy) (n = 9, each) were 3.28, 2.34, 1.94, 1.30 x 10S/ml at 24 h, and 5.10, 
2.00, 1.80, 1.20 × 105/ml at 48 h. DNA synthesis of VSMC, as measured 
by [3H] thymidine incorporation, was significantly inhibited by 56-74% at 24 
h after 8 Gy irradiation. The proportions of cells at G0/GI:S:G2/M phase, 
as measured by Fluorescence Activated Cell Sorter, were 64:3:33% (control 
in log phase, 68:14:18%) at 24 h, 77:2:21% (control in confluent phase, 
87:2:11%) at 48 h after irradiation of 16Gy, which showed the G1 & G2 arrest 
at 24 h and continuous G1 arrest and partial release of G2 arrest at 48 h 
after irradiation. In immunoblot analysis and kinase assay, y-irradiation of 8 
or 16 Gy increased the expression of P21, universal cell cycle inhibitor, and 
decreased the expression of cyctin D1 and CDK4, most important complex in 
G1 progression, as well as the expression and activity of CDK2 and CDK1, 
important kinase in G1/S and G2/M phase transition, respectively. 
Conclusion: y-irradiation can effectively inhibit VSMC proliferation through 
cell cycle arrest at G1 phase by enhancing P21 expression and suppressing 
cyclin D1 and CDK4 as well as at the following S/G2/M phases by suppress- 
ing CDK2 and CDKI. 
J1101-135 I Effects of Low Dose-Rate /3-Irradiation on I 
Smooth Muscle Cells: Comparison With High 
Dose-Rate Exposure 
Olivier F. Bertrand, Rosaire Mongrain, Eric Thorin, Shidey Lehnert. Montreal 
Heart Institute. McGill Universi~ Canada 
Introduction: Radiation Therapy (RT) has been shown to limit cellular pro- 
liferation after vessel injury, Catheter-based RT delivers single doses at high 
dose-rate (HDR), whereas radioactive stents provide continuous low dose- 
rate (CLDR) delivery. We have compared the dose response at HDR and 
CLDR of pig aortic smooth muscle cells (SMC). 
Materials and Methods: For HDR, cells were irradiated with a S°Co 
source at a dose-rate of 1,5 Gy/min, For LDR, cells were irradiated with a 
45Ca source at a dose-rate of 0.675 Gy/h. Cells were plated at increasing 
densities and colonies were counted after 10-15 days, 
,o 0 
1¢rl ~ 
HDR \ 
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Conclusion: At HDR and LDR, RT induces a dose-dependent decrease 
in cell survival. This may explain short term reduction of neointima forma- 
tion after v~ssal injury. However, due to significant sub-lethal damage repair, 
much higher doses are required after CLDR than HDR to limit cell prolif- 
eration. This has important implications for the dosimetry of a radioactive 
stent. 
I 1101-1 36 1 ~A Rat Carotid Artery Model of In-Stent 
Restenosis 
Frank D. Kolodgie, Anita Tang, Herman K. Gold 1 , Aloke Finn I , Sweta 
S. Shroff, Renu Virmani. Armed Forces Institute of Pathology, Washington 
DC; ~ Massachusetts Genera/Hospital Boston, USA 
Background: In-stent restenosis remains a vexing problem in clinical prac- 
tice, The availability of inbred strains of rats would facilitate studies of risk 
factors on restenosis; however, an adequate model of stent deployment in 
the rat is lacking. Accordingly, we developed and characterize a rat model of 
carotid artery stenting. 
Methods: For these studies, seventeen "2-cell" ACS Multi-Link" stents 
(1.5 mm × 5 mm) were positioned in the left common carotid artery by balloon 
expansion. Stents were introduced through an arteriotomy site in the external 
carotid. Histology and quantitative morphometry were examined in plastic 
sections at 7, 14, 28 and 60 days after stent placement. Replication of (x-actin 
positive SMCs was determined by S phase labeling with bromodeoxyuridine 
(BrdU). 
Results: (means ± SEM), EEL = external elastic lamina 
Days EEL mm 2 Stenosis (%) BrdU (%) Cells/0.1 mm 2 
7 1.22 ± 0.13 16.9 ± 3.8 19.3 ± 6.9 464 ~ 103 
14 1.16 ± 0.14 44.8 ± 9,2 4,6 ± 2.8 568 + 100 
28 1.25 ± 0.13 42,9 ± 6.9 2.4 ± 0.7 693 ± 108 
60 1.41 ± 0.06 *27.2 ± 3.9 "1.5 ± 0.2 733 ± 274 
P NS <0.05 <9.01 NS 
Arterial stenosis was maximal by day 14 and decreased significantly 
beyond day 28 independent of cell density. SMC proliferation was maximal 
at day 7 and decreased significantly, thereafter. 
Conclusion: The reparative phenomena after stent placement in the rat 
is similar to that observed in normal arteries of larger animals. The current 
model should constitute a more economical approach to address the roles 
of genetic modifiers, hormones, adjunctive drugs, and risk factors on in-stent 
restenosis. 
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~8~ Effects of Radiotherapy in Stented and 
Nonstented Coronary Arteries 
Monday,  March  8, 1999,  4 :00  p .m. -5 :30  p.m. 
Morta l  Convent ion  Center ,  Room 279 
4 :00  p.m. 
~ ~  Intracoronary Radiation to Prevent Restenosis in 
Native Coronary Lesions: The Results of the Pilot 
Phase of the ARREST Trial 
David P. Faxon, Maudce Buchbinder, Michael W. Cleman, James 
R. Wilentz, Samuel F. Liprie, Richard Kuntz, Gary S. Mintz, Jeffrey 
J. Popma, Louis Harrison, Juliana Pisch, Anti Mehra, Zbigniew Petrovich, 
Nancy Ricci, Jerry A. Varkey. University of Southern Cafifomia, Los 
Angeles, CA, USA 
The safety of intracoronary radiation 1o prevent restenosis in single native 
coronary lesions was evaluated in 25 patients from 4 centers. A novel 0.014" 
nitinot guidewire with a 3 cm tip encapsulating a 0.5 Ci 192-Iridium core was 
used (U.S. Surgical Angiorad System). A portable afterloader stored and 
delivered the source into a spacing balloon catheter. The patients averaged 
64 years old, 80% were men, 32% had diabetes, 12% had prior CABG, 
44% were CCS class III or IV, and 52% had single vessel disease. The 
pre-procedural vessel size was 2.58 ± 0.61 mm, while pre-procedural percent 
diameter stenosis was 64.9% and lesion length 14.4 mm. The LAD and 
RCA were most commonly treated. Sixty-four percent were ACC/AHA class 
B2/C. Angiographic success from balloon angioplasty alone was 96% and 
post-procedure stenosis was 32.4%. Following determination of vessel size 
by IVUS, all patients underwent successful delivery of 12 Gy to the adventitial 
medial border with a maximum dose to the intima not to exceed 50 Gy. Mean 
radiation source dwell time was 9.7 ± 2.6 minutes. Total procedural success 
(angiographic success without complications) was 96% (24/25 patients). As 
determined by an independent clinical events committee, there were no major 
adverse inhospital clinical events. There were no out-of-hospital adverse 
events in the first 30 days. Followup angiography at 6 months is pending. 
Complete followup data will be presented at the time of presentation. 
Conclusion: The results of the ARREST pilot study demonstrate that 
intracoronary radiation with a novel 192-1r guidewire is safe and can be easily 
used in small coronary vessels. A multicenter randomized trial is planned to 
evaluate efficacy in preventing restenosis in native vessels. 
4 :15  p.m. 
~-3~ Three-Year Clinical and Angiographic Follow-Up 
After Catheter-Based Intracoronary Radiotherapy 
Paul S. Teirstein, Vincent Massullo, Shirish Jani, Jeffrey J. Popma, Gary 
S. Mintz, Robert J. Russo, Richard A. Schatz, Erminia M. Guarneri, 
Stephen Steuterman, Kathy Sirkin, Shela Norman, Martin B. Leon, 
Prabhakar Tripuraneni. Scripps Clinic, La Jo/la, CA, USA 
Background: While early safety and efficacy of intracoronary radiotherapy 
is encouraging, long-term results are unknown. 
Methods: In the SCRIPPS I trial, 55 patients with restenosis receiving 
stents were randomized to Ir-192 or placebo. Initial follow-up angiograms 
were obtained at 6 months. Latest clinical follow-up was obtained at a mean 
of 34 ~ 7.8 months in placebo vs. 35 ± 3.4 months in Ir-192 patients (p = 
ns). Three-year follow-up angiograms will be completed by 12/98. 
Results: 
Placebo (n = 29) Ir-192 (n = 26) p 
Death (%) 3 (10.3) 2 (7,7) ns 
MI (%) 2 (6.9) 3 (11,5) ns 
TLR (%) 15 (52.2) 4 (15.4) 0.005 
Non-TLR (%) 7 (24.1) 6 (23.1) ns 
TVR (%) 3 (10.3) 4 (15.4) ns 
Non-TVR (%) 4 (13.8) 2 (7.7) ns 
Death, MI, TLR (%) 17 (58.6) 8 (30.1) 0.038 
Death, MI, TLR, non-TLR (%) 21 (72.4) 11 (42.3) 0.024 
MI = myocardial infarction; TLR = target lesion revascularization; TVR = target vessel 
revascularization 
A total of 23 TLR procedures (including repeated TLR's in the same 
patient) were undertaken in placebo compared to only 5 TLR procedures in 
Ir-192 patients. 
Conclusion: At near three-year clinical follow-up after intracoronary ra- 
diotherapy, significant clinical benefit is maintained. Three-year angiography 
results will be presented. 
4 :30  p.m. 
~-~ Results from the ARTISTIC Feasibility Study of 
192-Iridium Gamma Radiation to Prevent Recurrence 
of In-stent Restenosis 
Ron Waksman 1 , Michael S. Porrazzo 1 , Rosanna C. Chan 1 , Nancy 
B. Morris ~ , Warren Sherman 2 , Juliana Pisch 2, Denise McDermott 2, Sam 
F. Liprie 3 , Nancy A. Ricci 3 . ~ Washington Hospital Center, Washington DC; 
ZBeth Israel Hospital NYC, NY; 3US Surgical Norwalk, CT, USA 
ARTISTIC - Angiorad Radiation Therapy for In-Stent resTenosis Intra Coronary 
study - is designed to determine the effectiveness and safety of gamma radi- 
ation to prevent recurrence of in-stent restenosis in native coronaries. In the 
feasibility phase, two centers enrolled 26 patients who presented with sin- 
gle in-stent restenotic lesion _<26 mm. Rotational ablation was used in 8/25 
(32%) pts, balloon angioplasty alone in 13/25 (52%), and additional stents 
were placed in 2/25 (8%) pts. Following the PTCA, a high activity (500 mCi) 
~921ridium source wire (0.014") 29 mm in length delivered via a mechanical 
afterloader into a 2.25 mm closed end lumen non-occlusive balloon catheter 
and positioned at the angioplasty site. The prescnption dose was 12 Gy for 
vessels size 2.5-3.0 mm, 15 Gy for vessels 3.1-4.0 mm, and 18 Gy for 
vessels 4.1-5.0 ram. 
Results: Radiation was delivered successfully to 25/26 sites (96.2%). 
Mean dwell time was 10.30 ± 2.10 minutes and was tolerated by all patients. 
The max and min dose to the vessel wall calculated by IVUS was 45 and 
10 Gy respectively. Radiation exposure measured at the chest wall was 2.8 
R/hr, at the bedside 145 mR/hr and at the control room 0.5 mR/hr. There 
were no procedural, in hospital or 30-day major adverse cardiac events. At 6 
months 4/25 (16%) of pts presented with clinical restenosis. 
Conclusion: Gamma radiation to treat in-stent restenosis can be de- 
livered successfully and safely via a small wire and a low profile balloon 
catheter. The clinical restenosis in this small cohort is lower than previously 
published using conventional therapy for in-stent restenosis. 
4 :45  p.m. 
[ -~-~ Endovascular Irradiation of Coronary Arteries 
Inhibits Lumen Loss and Neointima Formation in 
Stent-Grafts 
Stefan Verheye, Keith A. Robinson, Stephen P. Mutkey, J. Jeffrey Marshall, 
Spencer B. King III, Nicolas A.F. Chronos. Andreas Gruentzig 
Cardiovascular Center, Dept. of Medicine (Cardiology), Emory University 
School of Medicine, Atlanta, GA, USA 
Background: Stent-graft hybrid devices (SG) are useful to limit plaque ex- 
trusion during stenting. However, excessive neointima formation (NF) is 
observed in animal models, which might also limit SG clinical utility. En- 
dovascular irradiation (El) prevents NF after coronary stenting. We tested 
whether El could prevent NF in pig coronary SG. 
Methods: A non-grafted stent (S) was placed in the LAD and a SG was 
implanted in the LCX and RCA of pigs after overstretch balloon injury. Sites 
selected for SG or S received 30 Gy El prior to implant. Controls were not 
irradiated. QCA was done at implant and prior to harvest at 28 d. Sections 
were prepared by saw-and-grinding after plastic embedding and measured 
by computer-assisted microscopic histomorphometry. 
Results: QCA showed no difference in reference diameter, balloon to 
artery ratio or post stent diameter between groups with S or SG. Lumen 
loss (post to restudy) was 0.79 mm in SG with El, but 2.50 mm in SG 
without El (p < 0.05). In S, the MLD increased from 2.75 to 3.07 in the 
El group but decreased from 3.21 to 1.69 in the non-El (p < 0.05). There 
was a profound neointimal response to the SG in controls. The neointima 
consisted of foreign-body response and organized thrombus close to the SG 
with smooth muscle-like cells and collagen matrix in the adluminal region. 
In contrast in SG with El neointima was almost exclusively thrombus and 
foreign-body response. Lumen was increased and NF decreased with El. 
Luminal area Intimal area Vessel area 
Control SG 2.17 ± 0.86 6.58 ± 1.77 13.28 ~ 8.84 
SG with El 5.37 -- 1.08 2.19 ± 1.00 10.87 ± 0.33 
P 0.003 0.008 NS 
Conclusions: Despite high dose El in stent grafts, NF although less 
pronounced was still present with different morphology. Circulating cells and 
thrombus contribute to but are not exclusive elements in NF of SG. El does 
not influence the inflammatory response to this type of injury. 
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~-~ Clinical and Angiographic Outcomes of Patients 
With In-Stent Restenosis Crossing Over from 
Placebo to Radiation Therapy 
Ron Waksman, R. Larry White, Rosanna C. Chan, Balram Bhargava, Gary 
S. Mintz, Lisa M. Gierlach, Alexandra Lansky, Lowell F. Satler, 
Roxana Mehran, Kenneth M. Kent, Augusto D. Pichard, Martin B. Leon. 
Washington Hospital Center, Washington DC, USA 
In WRIST - the Washington Radiation for In-Stent restenosis Trial - patients 
with recurrence of in-stent restenosis at follow-up were eligible to receive 
radiation therapy, if initially randomized to placebo. This report presents 
the clinical and angiographic outcome of patients who crossed over to the 
radiation arm. Forty symptomatic patients (31 native coronades and 9 vein 
grafts) with positive thallium stress test and angiographic restenosis who 
initially received placebo were crossed over to radiation therapy. All had 
repeat similar intervention methods using balloon, athero-ablative devices 
or stenfing. After obtaining a good angiographic result, a non-centered 5 Fr 
closed-end lumen catheter was positioned and a dbbon with active 192-1r 
seeds was delivered by hand. Different ribbon lengths were used to cover 
lesions up to 47 mm. The prescribed radiation dose was 15 Gy to a 2 mm 
radial distance from the center of the source. 
Results: Thus far, 20 patients who crossed over (15 native coronaries 
and 5 vein grafts) completed 6 month clinical and angiographic follow-up. 
Of these, 17 (85%) in 12 native coronaries and 5 vein grafts were asymp- 
tomatic and their angiograms demonstrated patency at the stented site with 
<30% residual stenosis, The angiographic patterns of the failures were total 
occlusion in = 2) and focal stenosis (n = 1 ). 
Conclusion: Intracoronary gamma radiation nearly "cured" recurrence 
(15% frequency) of in-stent restenosis in patients who were refractory to 
conventional intervention therapy. 
5:15 p.m. 
~8~~-]  External Beam Irradiation Reduces Neointima 
Formation and Augments Lumen Size After 
Coronary Stenting in Pigs 
Stefan Verheye, Keith A. Robinson, Jianhua Cui, S. Pat Mulkey, Nicolas 
A.F. Chronos, Spencer B. King III, Timothy R. Fox, lan R. Crocker. The 
Andreas Gruentzig Cardiovascular Center, Dept. of Medicine (Cardiology); 
DepL of Radiation Oncology, Emory University School of Medicine, Atlanta, 
GA, USA 
Background: Endovascular radiation is successful in the prevention of reste- 
nosis. External beam irradiation (EBI) is an alternative method for vascular 
radiotherapy and provides a very homogenous dose distdbution. EBI at 21 
Gy prevents restenosis-like changes in pig coronary artedes after balloon an- 
gioplasty. Effects of EBI on neointima formation and lumen size after stenting 
in pig coronaries were determined in this study. 
Methods: Stents were placed in all 3 epicardial arteries of 15 pigs. 
Immediately after angioplasty pigs received either EBI at 21 Gy to the entire 
heart, or no further treatment (controls). Quantitative coronary angiography 
(QCA) was done at implantation and prior to harvest at 28 days. Sections of 
stented arteries were prepared by saw-and-grinding after plastic embedding 
and measured by computer-assisted microscopic histomorphometry. 
Results: QCA revealed no between-groups difference in reference diam- 
eter, balloon to artery ratio or post stent lumen diameter. Lumen loss (post 
to restudy) was 0.08 mm for EBI and 1.21 mm for controls (P < 0.05). See 
table for histomorphometry (means ± SD). 
Lumen area Intima area intima/injury intima thick 
Control 4,69 J_ 1,87 3.67 ± 1,94 2.90 ± 1.44 0.76 ± 0.36 
21 Gy EBI 7.40 ± 1.40 0.39 ± 0.60 0.36 ~: 0.57 0.12 ± 0.13 
P 0.003 <0.001 <0.001 <0.001 
Conclusions: EBI at 21 Gy reduces neointima formation and augments 
lumen size after stent implantation in pig coronary arteries. EBI by linear 
accelerator for clinical in-stent restenosis prevention warrants further inves- 
tigation. 
ORAL 
Optimizing Coronary Intervention 
Tuesday, March 9, 1999, 8:30 a.m.-10:00 a.m. 
Modal Convention Center, Room 279 
8:30 a.m. 
[ - -~-~ Impact of Cilostazol on Restenosis Following 
Percutaneous Coronary Angioplasty for Diabetics 
Etsuo Tsuchikane, Keita Yamasaki, Motohiro Kidno, Yoshikazu Nakaoka, 
Masahiro Izumi, Satoru Otsuji, Hitone Tateyame, Makoto Sakurai, 
Toru Kobayashi, Nobuhisa Awata. Osaka Medical Center for Cancer and 
Cardiovascular Diseases, Osaka, Japan 
It has been reported that percutanecus transluminal coronary balloon angio- 
plasty (PTCA) for diabetics (DM) is associated with a higher restenosis rate 
compared with non-DM We previously reported that cilostazol, a platelet- 
aggregation inhibitor, significantly reduces restenosis following PTCA. This 
study aimed to determine the impact of cilostazol on restenosis following 
PTCA for DM Two hundred ninety-one lesions (DM: 103, non-DM: 188) 
dilated successfully by PTCA (balloon angioplasty alone 252, directional 
coronary atheractomy 39) were randomly assigned to the cilostazol (C) (200 
rag/day) group (143 lesions) or the aspirin CA) (250 rag/day) group (148 
lesions). Medication was continued until follow-up (Fu) angiogram. Sedal 
quantitative coronary angiography (QCA) was performed at pre-and post-pro- 
cedure, and at Fu using a Cardiovascular Measurement System. Restenosis 
was defined as percent diameter stenosis >_50% at Fu. Fu angiography was 
performed 121 ± 53 days after PTCA. There were no significant differences 
in baseline characteristics between the two groups. QCA data are shown in 
the table. 
DM non-DM 
C(n=51)  A (n = 52) C (n = 92) A(n= 96) 
RD (ram) 2,51 :k 0.46 2.45 ± 0.58 2.60 ± 0.45 2.64 ± 0.52 
post MLD (turn) 1.83 ± 0.51 1.77 ± 0.55 2.00 ± 0.52 2.05 ± 0.53 
Fu MLD (mm) 1.58 ± 0.56" 1.33 ± 0.62 1.83 ± 0.61 ° 1.49 ± 0.59 
Loss index 0.20 ± 0.46" 0.45 ± 0.53 0.12 ± 0.46" 0.46 ± 0.49 
Restenosis (%) 21.6" 42.3 12.0" 35.4 
(RD: reference diameter, MLD: minimal lumen diameter, "p < 0.05 vs. A) 
Conclusion: Cilostazol significantly reduces restenosis following PTCA 
for diabetics as well as non-diabetics. 
8 :45 a.m.  
[ 83---~-2 Restenosis Prevention After PTCA With Omega-3 
Fatty Acids: Results of the Randomized "ESPRIT" 
Study 
A. Maresta, M. Balducalli, R. De Catedna, M. Marzilli, E. Stragliotto, 
E. Varani. For the ESPRIT Investigators, Italy 
N-3 fatty acids have demonstrated a favourable influence on lipid metabolism, 
platelet activity and, possibly, myointimal proliferation. Several clinical stud- 
ies on restenosis have yielded contradictory results. Important limitations 
of these trials were the short duration and low dosage of treatment before 
PTCA. Aim of this randomized, double-blind study is to demonstrate an- 
giographic restenosis reduction with 6 g. EPNDHA (ESAPENT, Pharmacia, 
Milan) treatment vs placebo starting at least four weeks before the procedure. 
Patients received either ASA 325 mg or Indobufen 200 mg bid as anti-platelet 
throughout the study. 339 patients with significant coronary artery disease 
and clinical demonstration of myocardial ischemia were randomized in 18 
centers. 286 patients were considered eligible. Principal clinical charachter- 
istics were well matched between groups: 239 were male, mean age 60 yrs, 
60 (20%) actual smokers, 136 (48%) had a previous myocardial infarction, 
231 (81%) had angina, 36 (12%) diabetes and 111 (40%) hypertension. 317 
lesions were dilated.. Patients were followed up clinically and 264 had a re- 
peat angiography at 6 months. Angiographic restenosis as determined with 
QCA (Artrek, Image-Comm, Sunnyvale) in a single core-laboratory is the 
following: 41% vs 31% per patient (p = 0.054) and 40% vs 29% per vessel 
(p = 0.038) (placebo and omega-3 respectively). 
In conclusion Omega-3 fatty acids at the dosage employed in this trial 
show a positive trend of restenosis reduction in patients treated with PTCA 
while significantly reduces per vessel restenosis. Probably final number of 
patients is insufficient o demonstrate a statistically significant benefit of the 
treatment. 
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~3~ "Optimal" Instead of "High" Balloon Pressure 
Dilatation During Coronary Stent Placement 
Adnan Kastrati, Shpend Elezi, Helmut Sch0hlen, Julinda Mehilli, 
Josef Dirschinger, Franz-Josef Neumann, Albert Sch~mig. Med. Klinik & 
Deutschea Herzzentrum, TU MOnchen, Germany 
Background: High balloon pressure (BP) dilatation has often been advo- 
cated as a means to improve the outcome of patients (pts) after coronary 
stenting. However, recent randomized trials have shown no superiority of high 
BP. We tested the hypothesis whether there is any optimal BP range, beyond 
the simple "low-high" division, that is associated with a lower incidence of 
restenosis after stenting, 
Methods: Subject of this study were 4000 consecutive patients with in- 
tracoronary stenting. A 6-month control angiography was carded out in 3253 
cases (81%). An automated quantitative system was used for angiographic 
analysis. The relation between BP and restenosis (defined as an anglo- 
graphic diameter stenosis 50%) was assessed using logistic regression and 
adjusting simultaneously for balloon-to-vessel ratio and vessel size. Factors 
were entered into the model as nonlinear variables. 
Results: Restenosis rate was 32%. BP, balloon-to-vessel ratio and ves- 
sel size were independently correlated with restenosis. Graph on the left 
shows that there is a BP range (12-15 arm) associated with a lower risk for 
restenosis. 
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Conclusions: There is a range of BP (12-15 atm) associated with a 
lower dsk for restenosis after stenting. Using either a lower or higher BP 
may increase the incidence of this complication. These data suggest that 
substituting "optimal" for "high" BP may improve the results of coronary 
stenting. 
9:15 a.m. 
[8~-~ Stent Longitudinal Flexibility Before and After 
Expansion: A Comparison of 13 Coil, Hybrid or 
Slotted Tube Designs 
John A. Ormiston, Mark W,I. Webster, Peter N. Ruygrok, lan Minchington, 
James T. Stewart. Mercy and Green Lane Hospitals, Auckland and 
/ndustria/ Research Ltd, Wellington, New Zealand 
Background: An ideal stent should be highly flexible when unexpanded to 
negotiate tortuous anatomy. When expanded it must be sufficiently flexible to 
conform to vessel contour minimizing stent/vessel junction distortion, but still 
have adequate radial strength and vessel coverage. In vitro testing of unex- 
panded and expanded stent flexibility/stiffness may aid the interventionalist 
in clinical stent selection. 
Methods: A 3 point bend test was performed using an Instron to mea- 
sure the force needed to bend stents 1.5 mm. Stent stiffness (slope of the 
E ~ )OExpandedl3.5mm) z ~ .~ 
o  ,,L  bfldidlJliflHIH, 
force/displacement plot), was determined for 13 designs in the unexpanded 
state (internal diameter 1.64 mm) and after expansion with a 3.5 mm balloon. 
Results: Stents are depicted according to stiffness in the unexpanded 
state (figure). 
Conclusions: All stents became stiffer when expanded. There is a wide 
range of flexibility with coil stents (Wiktor-i, Crossflex) being more flexible 
than the hybrid designs (AVE GFX, BARD XT) which are in turn more flexible 
than the "slotted tube" type stents. 
9:30 a.m. 
~~-- I  Tubular Slotted Stents: A "Breakthrough Therapy" 
for Women Undergoing Coronary Interventions. 
Pooled Results from the STARS, ACSENT, SMART, 
and NIRVANA Randomized Clinical Trials 
Alexandra J. Lansky, Jeffrey J. Popma, Roxana Mehran, George Hanzel, 
Donald Cutlip, Kalon K. Ho, Brian Proctor, Joelle A. Happi, Richard E. Kuntz, 
Donald S. Bairn, Richard Heuser, Mark Midei, Chades O'Shaughnessy, 
Martin B. Leon. Washington Hospital Center, Washington DC, USA 
Although the outcomes of women after coronary interventions have improved, 
in-hospdal mortality is consistently higher in women than men. Randomized 
clinical trials (RCTs) have demonstrated long-term benefits in patients un- 
dergoing stenting, however the impact of stent use in women is unclear. 
To address this issue we compared the outcomes of 3155 men and 1361 
women undergoing elective stenting of non-complex native coronary lesions 
with a tubular slotted stent (424 NIR, 331 AVE micro II, 520 ACS Multilinks, 
3241 JJIS stents) from recent RCTe. All data and angiographic analyses 
were performed at the same centers, and equivalent clinical outcomes of 
individual stents to the JJIS were demonstrated by the RCTs. Women were 
older (64 vs 62 yrs, p = 0.0001), had more diabetes (25.8% vs 16.6%, p = 
0.001), unstable angina (62.8% vs 71.0%, p = 0.001 ), and smaller reference 
vessel size (2.92 vs 3.05 mm, p = 0.0001). The binary restenosis rate (RS) 
was the same in men and women (19.9 vs 20.1%, p = NS). 
Men Women OR p Value 
In-hospital, Death 0.1 0.2 1.74 NS 
MI 4.8 4.6 0.96 NS 
TLR 1.1 1.0 0.90 NS 
Vasc. Comp. 2.1 5.1 2.3 0.003 
9 Month FU, Death 1.0 1.8 1.74 0.04 
TLR 11.4 9.3 0.82 0.04 
We concluded that compared to men, the use of stents in women has (1) 
equalized in-hospital mortality despite more cardiac risk factors, (2) despite 
smaller vessel sizes, the RS and TLR rates were equally low, further substan- 
tiating the benefits of stenting in women, however (3) unadjusted follow-up 
mortality remains slightly higher in women. 
9:45 a.m. 
~-33~ Dissections Post Coronary Stenting: Is It Worth 
Extending Your Stent Length to Cover All 
Dissections? 
Nobuyuki Kobayashi, Joseph De Gregorio, Milena Adamian, 
Marco Vaghetti, Issam Moussa, Nicola Corvaja, Bernhard Reimers, 
Leo Finci, Remo Albiero, Carlo Di Mario, Jeffrey Moses, Antonio Colombo. 
Centro Cuore Columbus, Milan, Italy; Lenox Hill Hospital, New York, USA 
Recent studies have shown that longer stent lengths increase restenosis. 
Therefore limiting stent length by not covering all apparent dissections may 
afford a distinct advantage. We analyzed the short and long-term outcome 
of coronary dissections post stent placement. 670 consecutive patients with 
916 lesions treated with stents between 6/97 and 6/98 were divided into two 
groups according to the absence (non-D group n = 805) or the presence (D 
group n = 111) of angiographic dissections (table 1). All included lesions had 
a final % diameter stenosis <50% and TIMI 3 flow. A subanatysis of group D 
lesions (n = 64) which had IVUS evaluation is seen in table 2. 
Table 1 
D non-D D with IVUS 
MACE: 1 month 0;9% 0.5% 0% 
: 6 month 1.1% 0.9% 0% 
Acute or subacute 1.8% 0.5% 0% 
thrombosis 
Restenosis rate 31% 33%* 19%* 
TLR 20% 20% 15% 
*p < 0.1: non-D group vs D with IVUS, CFR or PG group. MACE = major adverse cardiac 
event (death, Q-MI and CABG), TLR = target lesion revascularization 
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Table 2 
Minimal umen diameter (mm) 2.76:1- 0.49 
Maximal umen diameter (mm) 3.34 ± 0.51 
Final IVUS lumen CSA (ram 2) 7.35 ± 2.12 
Final IVUS % stenosis 41.4 ± 0.14 
CSA = cross-sectional area 
Conclusion: Coronary dissections with IVUS evaluation of a final lumen 
CSA < 50% residual stenosis after successful stent implantation may be left 
untreated. This would decrease total stent length and possibly concomitantly 
reduce restenosis. 
ORAL 
~4~ New Strategies for the Prevention of 
Restenosis 
Tuesday, March 9, 1999, 8:30 a.m.-10:00 a.m. 
Modal Convention Center, Room 265 
8:30 a.m. 
~-- ]  The Infection of Chlamydia Pneumoniae Accelerates 
Neointimal Hyperplasia Associated With In-stent 
Restenosis 
Nacto Inoue, Takaomi Tokura, Akiko Matsuo, Tetsuya Tanaka, 
Hiroshi Fujita, Takuya Kuriyama, Makoto Kitamura, Kenji Miyao, 
Masato Nishimura 1 . Kyoto Second Red Cross Hospita/, Kyoto; I Kyoto 
Prefectura/ University of Medicine, Kyoto, Japan 
Backgrounds: We have previously reported that patients with in-stent re- 
stenosis are more positive for anti-Chlamydia pneumoniae (C.pneumoniae) 
titer than patients without restenosis. In-stent restenosis has been mainly 
caused by neointimal hyperplasie because stents scaffold the inner vascular 
lumen preventing recoil and remodeling. We sought to evaluate the role of 
the infection of C.pneumoniae in neointimal hyperplasia associated with in 
stent restenosis by quantitative coronary angiography (QCA). 
Methods: From Nov. 96 through Feb. 98 102 stents were implanted. 
Those lesions were classified into positive and negative titer groups. Identifi- 
cation of C. Pneumoniae was carded out with enzyme linked immunosorbent 
assay (ELISA) method. The cut off index of anti C.pneumoniae titer (IgG) was 
assessed, values > 1.10 being considered positive. Follow up angiography 
was obtained at 6 months after stenting. The QCA analysis was done at pre, 
post and F/U angiography. 
Results: Baseline clinical characteristics were similar. The QCA data was 
expressed as follows. 
Positive IgG (n = 53) Negative IgG (n = 49) 
Post MLD (mm) 2.63 ± 0.57 2.65 ± 0.51 n.s. 
Acute gain (ram) 2.00 ± 0.52 2.12 ± 0.62 n.s. 
F/U MLD (mm) 1.23 ± 0.85 1.72 ± 0.94 p < 0.01 
Late loss (ram) 1.31 ± 0.84 0.85 ±0.96 p < 0.05 
Restenosis rate 57.4% 33.3% p < 0.05 
Conclusions: The QCA analysis suggests that the infection of C. pneu- 
moniae accelerates neointimal hyperplasia after intracoronary stenting. 
8:45 a.m. 
~ Pretreatment With Oral Inhibitors to Thromboxane 
A2, Serotonin, and ADP Reduces Intimal Hyperplasia 
in a Hypercbolesterolemic Canine Coronary 
Angioplasty Model With Atherosclerotic Lesions 
H. Vernon Anderson, Janice McNatt, Fred J. Clubb, L. Maximilian Buja, 
James T. Willerson. University of Texas Medical School and Texas Heart 
Institute, Houston, TX, USA 
Background: High cholesterol (CHOL) stimulates platelet aggregation and 
intimal hyperplasia (IH) after coronary angioplasty (PTCA) or stenting. We 
have reported that combined administration of oral inhibitors of platelet throm- 
bexane A2 (TxA2), serotonin (5HT2), and ADP can attenuate III after PTCA 
in normal dogs. We tested the hypothesis that pretreatment with these oral 
agents reduces IH in dogs with CHOL-diet-induced coronary lesions. 
Methods: We fed 29 dogs a 4% CHOL diet for > 8 months, raising serum 
CHOL levels and inducing typical coronary plaques. Flow probes were then 
implanted on LAD coronary arteries at PTCA, remaining in place until sacrifice 
8 weeks later. Eleven clogs received no treatment (NONE), while 18 clogs 
were pretreated for 3 weeks before and until 3 weeks after PTCA with oral 
aspirin alone (ASA, n = 8), or the 3 oral inhibitors together: ridogrel [TxA2], 
ketanserin [5HT2], and clopidogrel [ADP] (RKC, n = 10). 
Results: Platelet aggregation was abolished in RKC dogs only; bleeding 
times (BT) were proportionally prolonged. Occurrence of cyclic flows (CFVs), 
eady sudden death (SCD) from acute coronary thrombosis, intima-to-media 
(I/M) ratios, and %-lumen-area stenosis are shown below: 
Group CFVs SCD BT, sec l/M Ratio %-Stenosis 
NONE Yes 6/11 = 55% 65 i 5 0.65 ± 0.15 42 ± 16 
ASA Yes 1/8=13% 139±15 0.26 ± 0.07 22±6 
RKC No 0/10 = 0 696 ~- 16 0.24 ± 0.08 11 ± 3 
p-value 0.02 0.001 0.02 0.03 
Conclusion: Pretreatment with oral inhibitors of TxA2, 5HT2, and ADP 
before and continuing after PTCA attenuates intimal hyperplasia in this hy- 
percholesterelemic anine model with coronary lesions. 
9:00 a.m. 
[ -~-~ Adenoviral Mediated NOS3 Gene Transfer in Porcine 
Coronary Arteries Reduces In Stent Restenosis 
O. Varenne 1"2 , P. Sinnaeve 2, H. Gillijns 1 , H.K. Gold 3, F. Van de WeB,  
R.D. Gerard I , D. Collen 1 , S. Janssens t2. rFlanders Interuniversity Institute 
for Biotechnology; 2Department of Cardiology, University of Leuven, 
Belgium; acardiac Unit, M G H, Boston, U.S.A. 
Although intracoronary stent implantation significantly reduces restenosis 
compared with balloon angioplasty, in-stent restenosis due to neointima (NI) 
formation is frequently observed. 
After injury of the LAD, and either the right or the left circumflex coronary 
artery (3 x 30 sec inflations at 8 atm) in juvenile pigs. recombinant adenovirus 
(1.5 × 109 PFU) encoding endothelial nitric oxide synthase cDNA (AdNOS3, 
n = 22) or no cDNA (AdRR5, n = 22) was blindly injected at the site of 
PTCA using the Infiltrato( ~ catheter. After gene transfer, a Palmaz Schatz" 
stent was locally deployed in the center of each transduced area, using 
two balloon inflations at 14 atm for 30 seconds. Coronary angiograms were 
obtained after stent implantation (MLDd0) and at 28 days, pigs to evaluate 
in-stent stenosis (MLDd28). Coronary arteries were then harvested, pressure 
fixed and embedded in plastic. Five-,um sections were prepared every 200 
Jim and stained with hematoxyliin and eosin for subsequent analysis. NI 
area (NIA), vessel area (VA), lumen area (LA) were calculated at the site 
of maximal NI formation. MLDd0, MLDd28 and VA were similar in AdNOS3 
and AdRR5. NI area was significantly reduced, and LA was significantly 
increased in stented arteries transduced with AdNOS3. 
AdNOS3 AdRR5 P value 
MLDd0 (mm) 2.97 ± 0.06 2.87 ± 0.07 NS 
MLDd28 (mm) 2.33 + 0.12 2.03 ± 0.19 NS 
VA (mm2) 10.0 + 0.34 9.85 ± 0.57 NS 
LA (ram2) 5.04 ± 0.53 3.60 ~- 0.49 0.020 
NIA (mm2) 2.92 ± 0.47 4.56 ± 0.69 0.046 
These results suggest a beneficial action of NOS3 gene transfer in stented 
porcine coronary arteries and may hold promise to target in-stent restenosis. 
9 :15  a .m.  
p ~  
/ 834-4 1 Gene Transfer of Tissue Inhibitor of 
L /  
Metalloproteinase-2 Does Not Prevent Restenosis in 
an Atherosclerotic Model 
Charles Landau, Robert S. Me±dell. UT Southwestern Medical Center, 
Da//as, TX, USA 
Background: Arterial remodeling, which requires reorganization of vessel 
wall structural elements through degradation of collagens and extracellular 
matrix, contributes to restenosis and may be facilitated by matrix metal- 
Ioproteinases. This family of enzymes is inhibited by tissue inhibitors of 
metalloproteinase (TIMP). To explore the potential of TIMPs to interfere with 
post-angioplasty restenosis, we overexpressed TIMP-2 in arteries following 
balloon angioplasty. 
Methods: Following lilac artery denudation, NZ white rabbits were fed a 
diet supplemented with 1.5% cholesterol for 4 weeks. Stenosed lilac artery 
segments identified angiopraphically were subjected to balloon angioplasty, 
and 0.5 × 101° pfu of either a control (n = 15) or a TIMP2 encoding adenovirus 
(n = 20) were delivered locally to the vessel wall. Four weeks later, angiog- 
raphy was repeated and minimal luminal diameters (MLD) were determined 
by computer-assisted automated edge detection. 
Diameter TIMP 2 Control 
Measurement n = 20 n = 15 p 
Reference segment (mm) 2.06 ~- 0.37 2.27 ± 0.42 NS 
Balloon:artery ratio 1.25 3_ 0.24 1.14 ± 0.20 NS 
MLDpre (mm) 0.93 3_ 0.26 0.82 ± 0.30 NS 
MLDpost (mm) 1.25 ± 0.20 1.15 ~- 0.23 NS 
MLD4 weeks (ram) 0.87 i 0.43 0.65 ± 0.47 NS 
:1> 
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Conclusion: These data demonstrate that local gene transfer with the 
adenoviral vector encoding TIMP-2 does not result in a larger luminal diame- 
ter 4 weeks following angioplasty, and therefore does not prevent restenosis 
in this double-injury model. 
9 :30 a.m.  
[~- - ]  Successful Gene Transfer to the Arterial Wall Using 
a DNA-eluting Polymer-coated Intracoronary Stent in 
Swine 
Bruce D. Klugherz, Well±am Chen 1 , Peter L. Jones ~ , Nicolas Meneveau, 
Fran Wade-Whittaker, Robert Levy 1 , Robert L. Wilansky. University of 
Pennsylvania Medical Center; 1 Children's Hospital of Philadelphia, 
Philadelphia PA, USA 
Background: Gene transfer to the arterial wall has the potential to modify 
pathologic vascular processes. Catheter-based gene delivery has been lim- 
ited, however, by the need for unacceptably long incubation times in order to 
achieve efficient transgene expression. A DNA-eluting stent may overcome 
this limitation by acting as a sustained release gene delivery vehicle. 
Methods: A proprietary DNA coating was prepared using a polyester 
copolymer mixed with reporter plasmid DNA encoding green fluorescent 
protein, and applied to the surface of Crown coronary stents (Cordis, War- 
ren, NJ). The coated stents were then hand-crimped on 3.0 or 3.5 mm 3 
angioplasty balloons and deployed in swine left anterior descending and 
left circumflex coronary arteries (n = 8 arteries) using standard techniques. 
Unstented vessels, or vessels with non-DNA-eluting polymer-coated stents 
served as controls. Swine were euthanatized at 5 or 6 days following inter- 
vention, and the coronary arteries harvested for analysis. Endothelial and 
smooth muscle cells in the intima, media, and adventitia which exhibited 
fluorescence were counted for determination of transfection efficiency. 
Results: Reporter transgene expression was observed in all arteries in 
the DNA-treated group. None of the control arteries expressed the transgene. 
Transfection efficiency was 5.4--7.5% in medial smooth muscle cells. 
Conclusions: This study demonstrates for the first time successful gene 
transfer to the arterial wall via an eluting polymer-coated stainless steel intra- 
coronary stent. As an approach to the treatment of vascular diseases such 
as atherosclerosis or restenosis following stent deployment, this technique 
may prove to be particularly useful. 
9 :45 a.m.  
[ - -~  Local Delivery of Chimeric DNA: RNA Ribozymes 
Targeting PCNA with the Cordis Crescendo Catheter 
Inhibits In-Stent Restenosis in a Porcine Model 
Martin Sebastian, Hidehiko Honda, Raj Makkar, Herbert Cordero, 
Joan Robbins, Jack Barber, Neal Eigler, Frank Litvack. Cedars-Sinai 
Medical Center, Los Angeles, California, USA 
Background: To inhibit neo-intimal hyperplasia we have designed a chimeric 
DNA:RNA hammerhead ribozyme (RZ) targeting mRNA for proliferating cell 
nuclear antigen (PCNA). We evaluated the efficacy of this RZ combined with 
cationic liposomes delivered by a new FDA-approved local drug-delivery 
catheter (Crescendo; Cordis, Miami, FL) for inhibiting restenosis. 
Methods: RZ stability (in serum and human vascular smooth muscle cell 
lysate) and cleavage activity were confirmed in vitro. We then evaluated 
RZ effects in a non-lipemic adult porcine stent model. 29 vessels (15 LAD, 
14 RCA) were stented. 8 vessels (4 LAD, 4 RCA) were pre-treated with 1 
mg RZ cemplexed with the liposomes delivered via the Crescendo. At 4 
weeks angiography was repeated, then sacrifice and tissue processing for 
histomorphometry were performed. 
Results: 
Quantitative coronary angiography data are: 
N Ref. Vessel Late Less Mean % Stenosis 
(ram) (mm) 
Control 21 2.69 i 0.27 2.00 ± 0.56 48.9 + 18.6 
PCNA 8 2,80 ± 0.29 1.42 ± 0.76* 30.2 ± 19.2" 
"P < 0.05 versus control. Histomorphometry data will be presented. 
Conclusion: Ribozymes targeting PCNA mRNA, complexed with cationic 
liposomes and delivered by the Crescendo catheter significantly inhibit in- 
stent restenosis in a porcine model. Plans for clinical evaluation are under- 
way. 
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~ Stent Implantation Technique: Aggressive Versus 
Nonaggressive Approach 
Milena Adam±an, Nobuyuki Kobayashi, Joseph De Gregorio, Issam Moussa, 
Bernhard Reimers, Lucia Di Francesco, Nicola Corvaja, Remo Albiero, 
Carlo Di Marie, Antonio Colombo. Centre Cuore Columbus, Milan, Italy 
There is controversy regarding which is the best technique for stent implan- 
tation. We compared 287 consecutive patients (332 lesions), who underwent 
an aggressive stent implantation - group A (B/A ratio > 1.2 and maximal 
inflation pressure (MIP) >12 arm) with 108 patients (136 lesions), who had 
nonaggressive stent deployment - NA (B/A ratio < 1.2 and MIP < 12 atm). 
All patients had angiographic and clinical follow-up. The two groups were 
divided according to three levels of reference vessel diameter (RVD). 
Results: 
2.5-3.0 mm 3.01-3.50 mm >3.5 mm 
A NA A NA A NA 
RVD, mm 2,8:1-0.1 2 .8±0.2  3 .18±0.1  3 .24±0.1  
PreMLD, mm 0.7 4- 0.4 0 .6±0.4  0 .8±0.5  0 .7±0.6  
FUMLD, mm 1.9~-0.9 1 .5±0.7  2 .3±1.0  1 .9±0.9  
Acute Gain, mm 2 .3±0.6  2 .0±0.5  2 .6±0.6  2 .3±0.8  
Late lo ,~,mm 1.1 ±0.9  1.1 ::1:0.7 1.1 ± 1.0 1 .2±0.9  
Resten, % 30.4 40.4 25.3 34.1 
TLR, % 27.2 32.0 21.1 26.8 
3.9±0.4  3 .9±0.3  
1.1 ± 0.8 1.0 ± 0.7 
3.0 ± 1.0 2.6 J,- 0.9 
3 .1±0.8  2 .6±0.9  
1.2 ± 1.1 1.2 ± 1.2 
20,0 23.6 
13.3 14.7 
*p < 0.05; MLD minimal lumen diameter. 
When data was pooled for all three levels, RVD in group A was 2.8 ± 0.4 
mm vs 3.2 ± 0.5 mm in NA group (p < 0.001). 
Conclusion: Overall, aggressive stent implantation vs nonaggressive 
yields a larger final MLD and follow-up MLD at any RVD with no signifi- 
cant difference in late loss, restenosis and TLR. Tne aggressive approach 
compared with nonaggressive is more frequently applied to smaller vessels 
where historically a greater late loss is reported to occur. 
~ T h e  Amount of Residual Burden After Plaque 
Coronary Stent Implantation is Associated With 
the Development of Late In-Stent Neointimal 
Proliferation. An Intravascular Ultrasound Study 
Francesco Prati, Carlo Di Marie ~ , Antonio Parma, Issam Moussa 1 , 
Bernhard Reimers 1 , Maria Teresa Mallus, Antonella Labellarte, 
Ernesto Lioy, Antonio Colombo 1 . S. Camille Hospital, Rome; ~Centro Cuore 
Columbus, Milano, Italy 
Background: The aim of this study was to evaluate the relationship between 
residual plaque burden after coronary stent implantation and development of 
late in-stent neointimal proliferation. 
Methods: Between January 1996 and May 1997, 50 patients under- 
went intravascular ultrasound (IVUS) interrogation at 6 4- 1.2 months after 
coronary stent implantation in native coronary arteries. IVUS images were 
acquired with a motonsed pull-back and cross sectional measurements were 
performed within the stents at 1 mm intervals. The following measurements 
were obtained: 1) lumen area (LA); 2) stent area (SA); 3) area delimited 
by the external elastic membrane (EEMA); 4) % neointimal area calculated 
as (SA minus LA/SA) × 100; and 5) % residual plaque area calculated as 
(EEMA minus SA)/EEMA x 100. Volume measurements within the stented 
segments were calculated applying the Sympson rule. 
Results: In the pooled data analysis of 876 cross-sections, linear regres- 
sion showed a significant positive correlation between % residual plaque 
area and % neointimal area (r = 0.50, y = 45.03 + 0.29x, p < 0.01). There 
was significant incremental increase in mean % neointimal area for stepwise 
increase in % residual plaque area. Mean % neointimal area was 16.3% ± 
10.3% for lesions with a % residual plaque area < 50% and 27.7% ± 11% 
for lesions with a % residual plaque area >_ 50% (p < 0.001). The volumetric 
analysis showed that the residual plaque volume was significantly greater 
in restenotic lesions compared to nonrestenotic lesions (58.7% ± 4.3% vs 
51.4% ± 5.7%, respectively) (p < 0.01). 
Conclusions: The amount of residual plaque burden after coronary stent 
implantation significantly influences the degree of late in-stent neointimal 
proliferation. These data support to the concept of plaque removal pdor to 
stent implantation. 
~ Full Lesion Stent Coverage Reduces Subsequent 
Target Lesion RevascularizaUon: An Intrevascular 
Ultrasound Study 
Myeong-Ki Hong, Gary S. Mintz, Lowell F. Satler, Chrysoula K. Pappas, 
Augusto D. Pichard, Kenneth M. Kent, Michael Petereon, Mandy Murphy, 
Gregg W. Stone, Martin B. Leon. Washington Hospital Center, Washington, 
DC, USA 
Two approaches to stenting of diffuse lesions have been advocated: "spot" 
stanting of only severe stenoses or full lesion coverage anchoring stents into 
"normal" reference segments. To determine which technique has the lower 
target lesion revascularization (TLR) rate, we used intravascular ultrasound 
(IVUS: motorized pullback @ 0.5 mrn/sec) to study 390 consecutive lots with 
native coronary diffuse lesions treated with multiple Palmaz-Schatz stents. 
IVUS guidance was used to optimize final lumen dimensions. Lesion length, in 
vivo measured stant length, stentJlesion length ratio, and reference segment 
plaque burden were included in multivariate models for TLR. Overall, TLR 
was 23% (90/390). 
TLR Non-TLR p 
Final lumen area (mm 2) 6.4 ± 1.5 7.8 ± 1.9 <0.0001 
Lesion length (ram) 22 ± 11 18 ± 10 0.017 
Stent length (ram) 33 ± 11 32 ± 10 NS 
StenUlesion length 1.8 ± 0.9 2.2 ± 1.4 0.019 
Reference plaque burden (%) 46 ± 10 44 ± 11 0.095 
GRII PS 
Independent predictors of TLR included (1) increasing final lumen area 
(p < 0.0001), (2) LAD location (p = 0.022), (3) increasing stentJ]esion length 
ratio (p = 0.028), and (4) decreasing reference segment plaque burden (p = 
o.058). 
We Conclude: The final lumen area is still the strongest predictor of 
TLR after stenting of diffuse lesions. Increased stent/]esion length ratio and 
decreased reference segment plaque burden in non-TLR pts indicate that 
full lesion coverage may be superior to the spot stenting technique. 
~ In-Stent Restenosis: Predictors of the 
Angiographic Pattern and Long-Term Clinical 
Outcome 
Flavio Ribichini, Antonello Vado, Valeria Ferrero, Giuseppe Steffenino, 
Antonio Dellavalle, Paolo Russo, Eugenio Uslenghi. Divisione di 
Cardiologia, Ospeda/e Santa Croce di Cuneo, Cuneo, Italy 
Background: Restenosis remains the major limitation of coronary stents 
(CS), the diffuse form of restenosis has a particulady poor clinical outcome 
after re-interventions. The identification of predictive variables related to 
restenosis is crucial to identify patients (pts) that may benefit from different 
repertusion treatment. 
Methods: We analyzed the in-stant restenotic cohort of our laboratory. A 
total of 131 pts out of 537 angiographic follow-up had a DS% >_ 50 (global 
restenosis rate 24%). Pts with total occlusions (18), and with PS-153 stenf 
that developed focal R at the junction site (6) were excluded. 
Results: From 107 in-stent R 48 (45%) were focal (<10 ram), and 59 
(55%) were diffuse. From the analysis of clinical, angiographic, procedural, 
biochemical, and QCA variables only the following were associated with a 
diffuse pattern of R after a multivariate logistic regression analysis: the length 
of the lesion before stenting (p = 0.0001), the use of >14 atm for stent 
expansion (p = 0.006), a D-ref < 3.0 mm after CS, and the basal level of 
angiotensin converting enzyme (ACE) -in 86 pts without ACE-inhibition- (p = 
0.003). Basal ACE plasma level, being a potential risk factor for diffuse R, 
identifiable "a priod" was analyzed as a continuous variable of the length of 
the restenotic fract at follow up after log-transformation: r = 0.63, p = 0.01, 
and in a categodcal analysis (diffuse vs focal R). Maximizing the sensitivity 
for predicting diffuse R in pts without ACE-inhibition a cutoff value of ACE 
= 34 U/L was obtained; 30 pts (70%) out of 43 with ACE >_ 34 had diffuse 
restenosis, versus 45% of pts with ACE < 34, p = 0.02. Clinical Follow-up 
was obtained in all pts at 6 months. Recurrence of ischemic symptoms were 
observed in 35% of patients with focal R, and 51% of pts with diffuse R (p = 
0.3). The use of a second intervention was identical in the 2 groups (56%), 
but a third intervention was needed in 36% of pts with diffuse R and in 8% of 
pts with focal R (p = 0.004). 
Conclusion: Pts with diffuse in-stent R have a worse clinical outcome 
after a second reintervention. No baseline clinical variable was correlated 
with diffuse R. Long lesions before PTCA, small vessels and high pressure 
after CS are correlated to diffuse R. Plasma ACE level is correlated as a 
categorical variable with diffuse R, and as a continuous variable with the 
length of the restenotic tract. 
t •  Patterns of In-Stent Hyperplasia in the 
Gisnturco-Roubln II Compared to the 
Palmsz-Schatz Stents. Results from the GRII 
Randomized Clinical Trial 
George Hanzel, Alexandra J. Lansky, Jeffrey J. Popma, Roxana Mehran, 
Michael J. Curran, Barry George, James Hermiller, Gary Roubin, 
Kartik Desai, Moses Tarawali, Constantin Negoia, Jennifer Kerr, Larry Dean, 
David Cox, Chades D. O'Shaughnessy, Martin B. Leon. Washington 
Hospital Center, Washington DC, USA 
In the Gianturco-Roubin H (GRII) randomized clinical trial (RCT), the re- 
stenosis rate was higher in the GRII than in the Palmaz-Schatz (PS) stent 
group (43% vs 19%, p < 0.001), To gain insight into the patterns of in-stent 
hyperplasia, we analyzed all follow-up cineangiograms (GRII-108, PS = 103) 
in the angiographic arm of the RCT. Shoulder to shoulder lesion length was 
measured for any amount of luminal narrowing, and the maximum diameter 
stenosis (DS) was measured at the proximal and distal margins of the stent 
and at the proximal, mid and distal regions within the stent. 
('3 
GO 
Mean Hyperplasia Length, mm 26.12 ± 8.70 19.55 ± 8.76 t1. 
Length < 10 mm (%) 2.8 8.71. 
Length 10-20 mm (%) 19.4 45.6$ 
Length > 20 mm (%) 77,8 45.6$ 
Instent % DS 
Prox 33.19 ± 22.88 22.18 ± 17.0 :~ 
Mid 40.73 ± 23.53 30.57 ± 22.73 ~ 
Distal 31.69 ± 24.84 22.02 ± 20.29 $ 
Stent Margin % DS 
Prox 11.74 ± 21.32 10.77 ± 19,93 
Distal 14.30 ± 25.97 10.83 :E 19.42 
tp = 0.06, $p < 0.001 
We conclude that (1) hyperplasia associated with the GRII stant is diffuse 
and almost always >20 mm, (2) at all locations within the stent, the DS is 
worse with the GRtl than the PS, (3) the maximum DS tends to be in the 
middle of the stent for both stent types, and (4) stent margin hyperplasia is 
equally uncommon in both the GRII and the PS stent. 
[•  In-Stent Restenosis: Predictors of Subsequent 
Target Lesion Revascularization After Repeat 
Intervention 
Irene Bossi, Cathedne Klersy 1 , Rosario Cortina, Monique Bemies, Jean 
Claude Laborde, Bernard Cassagneau, Jean Fajadet, Jean Marco. Unit~ de 
Cardiotogie Interventionnelle, Clinique Pasteur, Toulouse, France; 
I I.R.C.C.S. Policlinico S. Matteo, Pavia, Italy 
Background: Repeat percutaneous procedures (rePTCA) can be safely 
performed to treat in-stent restanosis (ISR) despite significant rate of target 
lesion revasculadzation (TLR). 
Methods: 262 rePTCA for ISR performed in 239 pts between May 1995 
and January 1998 were retrospectively analyzed to identify any possible 
predictors of subsequent TLR. RePTCA included POBA (89%) and non- 
elective additional stenting (11%). Unstable angina was reported in 54%, 
stable angina in 43% (silent ischemia in 38%), and recent MI in 3%. Mean 
1SR lesion length measured by QCA was 16.7 + 8.6 ram. Lesion character- 
istics were defined as focal (_<10 ram), diffuse (>10 mm within the body of 
the stent), proliferative (> 10 mm beyond the stent margins) or total occlusion 
and were present in 37%, 30%, 29% and 4% respectively. ISR Reference 
Diameter was 3.08 ± 0.36 mm and post-rePTCA MLD was 3.07 ± 0.35 ram. 
Results: The long-term clinical follow-up (394 ± 232 days) obtained 
in 229 pts (96%) showed: 1.7% total mortality and 19,1% TLR. Six-month 
event-free survival rate was 0.83 ± 0.02 (95% CI = 0.78-0.87). 
Univadate analysis results are shown in Table: 
Variables Odds ratio 95% CI p 
"lime to ISR < 90 days 3.82 2.16-6.74 <0.0001 
Unstable angina 2.73 1.45-5.14 0.002 
Pattern Anglo ISR 1.38 1.01-1.89 0.044 
Post-rePTCA MLD 0.27 0.12-0.64 0.003 
ISR Ref. Diam. 0.26 0.10-0.67 0.005 
Using multivariate logistic regression analysis, the only predictors of sub- 
sequent TLR were: time to ISR < 90 days and post-rePTCA MLD. 
Conclusion: Smaller post-rePTCA MLD and eady intimal proliferation 
are independent predictors of TLR after repeat PTCA for ISR. 
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• Treatment of Instent Restenosis: Short and 
Midterm Results of a Pilot Randomized Study 
Between Balloon and Cutting Balloon 
Bernard Chevalier, Thierry Royer, Philippe Guyon, Bernard Glatt. Centre 
Carcliologique du Nord, Saint-Denis, France 
Conventional balloon angioplasty is the workhorse tool to treat instent reste- 
nosis (ISR) but has limitations: worse angiographic result than first procedure 
and high late TLR. In order to evaluate the potential benefit of cutting balloon 
(CB) in this indication a single center randomized pilot study was conducted 
in non-focal ISR. Pts underwent PTCA and 24 hours angiographic control; 
a subgroup had IVUS examination. Stent use was discouraged. Data and 
results were: 
Balloon CB p 
N lesions 20 25 
Artery diameter (ram) 2.88 ± 0.45 2.77 ± 0.4 NS 
Balloon/artery 1,17 ::E 0.14 1.21 ± 0.16 NS 
Technical success (%) 100 96 NS 
Pressure (atm.) 10.2 ± 2.5 9 ± 1.2 NS 
Acute gain (ram) 1.74 ~ 0.58 2.1 ± 0.47 <0.05 
Loss at day 1 (mm) 0.68 ± 0.51 0.5 ± 0,46 NS 
Net gain at day t (mm) 1.07 + 0.46 1.6 ± 0.46 <0.001 
Re-PTCA at day 1 (%) 33 10 NS 
Stent use at day 1 (%) 28 5 NS 
9 month TLR (%) 20 12 NS 
(target late revascularization). 
Thus, CB achieves a better and more stable angiographic result than 
balloon in the setting of ISR PTCA and is associated with a low 9 m TLR 
rate. These data support the launching of a multicenter andomized tdal in 
this indication. 
~ H o w  Safe and Effective Is Percutaneous 
Treatment of In-Stent Restenosis? 
robin H. Lim, Kirti Salunkhe, Tam± L Bait, Sanjeev Trehan, Labros 
A. Karagounis, Joseph B. Muhlestein. LDS Hospital and University of Utah, 
Salt Lake Ci~ Utah, USA 
Background: Coronary stent deployment remains plagued by a significant 
incidence of in-stent restenesis. As an alternative to coronary artery bypass, a 
variety of percutaneous coronary interventional (PCI) techniques have been 
attempted in its treatment, including balloon angioplasty (BA), rotational 
atherectomy (RA) and second stent deployment (SS). Acute procedural 
success under these circumstances has been reported to be similar to other 
percutaneous coronary interventions. We sought to determine the long-term 
safety and efficacy of these procedures. 
Methods: We studied 125 consecutive patients (mean age = 62 years, 
males = 82%, diabetes = 18%, hyperlipidemia = 71%, hypertension = 72%) 
with prior stent implantation and angiographic documentation of in-stent 
restenosis who subsequently underwent repeat PCI (BA, n = 52; RAn = 37, 
SS, n = 36). Six month telephone follow-up and review of medical records 
was performed to determine clinical outcome. No significant differences were 
detected between RA and SS, and therefore they were analyzed together. 
Results: 
Over-all BA RA or SS P-value 
Death or MI after discharge 7.2% 15.4% 1.4% 0.002 
Admitted for unstable angina 15.2% 23.0% 9.6% 0.038 
Repeat Restenosis 28% 34.6% 23.3°/° 0.16 
Conclusion: The over-all six month incidence of death/MI or admission 
for unstable angina after percutaneous treatment of in-stent restenosis was 
similar to previously published reports for initial PCI therapies. However, 
complication rates were significantly higher for BA compared to RA or SS. 
Repeat restenosis was higher than previously reported for primary stenting 
in all groups. This study confirms the safety of the treatment of in-stent 
restenosis using RA or SS, but also emphasizes its limited efficacy due to 
high repeat restenosis rates, 
• Early Lumen Loss After Repeat Angioplasty for 
In-Stent Restenosis 
Sanjay Malhotra, Jack Sweeny, Jeff Anderson, Thomas Lynch, 
David Cloutier, Vincent Massulo, $hdsh Jan±, Richard A. Schatz, Paul 
S. Teirstein. Scripps Clinic and Research Foundation, La Jolla, CA, USA 
Background: Restenosis within stents is largely due to intimal hyperplasia 
through stent struts. After catheter based intervention, tissue intrusion may 
contribute to early lumen loss. 
Methods: Coronary segments (N = 39) were divided into 2 groups ac- 
cording to treatment strategy. Using quantitative angiography, 2 independent 
observers evaluated the effect of balloon angioplasty alone versus repeat 
stenting, on early lumen loss in patients undergoing treatment for in-stent 
restenosis. Mean inter-observer difference in MLD was 0.08 ~E 0.31 ram. 
Results: 
Balloon Re-stent p 
(N = 22) (N = 17) 
Reference vessel MLD 2.87 ± 0.46 mm 2.80 ± 0.53 mm n.s. 
Baseline MLD 0.87 ± 0.45 mm 0.89 ± 0.55 mm n.s. 
MLD After Final Inflation 2.76 t 0.36 mm 2.88 ± 0.41 mm n.s. 
Delay tnterval (min) 67 ± 13 76 ± 19 n.s. 
MLD After Delay 2.42 ~ 0.51 mm 2.87 ± 0.60 mm 0.01 
Early Loss 0.35 & 0.34 mm 0.01 ± 0.34 mm 0.004 
Early Loss Index 12.8 ± 12.9% 0.7 ± 12.1% 0.003 
Delay interval = time between final balloon inflation and final angiography. Early loss = 
change in MLD over the delay interval. Early loss Index = Early loss/Acute Gain. 
Conclusion: During the first hour after repeat balloon angioplasty for 
in-stent restenosis, renarrowing of the lumen diameter is common and results 
in an early loss of almost t3%. This eady loss is possibly secondary to tissue 
intrusion through stent struts and is eliminated by repeat stenting, 
• Optimal Treatment of In-Stent-Restenosis: 
Excimerlaser-Angioplasty, Rotational 
Atherectomy or Conventional Angioplasty? 
Bemward Lauer, Eike Schmidt, Heiko Ambrosch, Klaus Diederich, 
Rainer Hambrecht, Hans Krankenberg, Andreas Kuhn, Peter Sick, 
Rainer Zotz, Gerhard Schuler. University of Leipzig-Heart Center, Germany 
Background: Optimal treatment of restenosis after stent implantation re- 
mains to be determined. Tissue debulking with excimer-laserangioplasty 
(ELCA) or rotational atherectomy (PTRA) may be more efficious than con- 
ventional balloon angioptasty (PTCA) alone. Therefore, the present study 
evaluates the acute and long-term results after ELCA, PTRA or PTCA for 
in-stent restenosis. 
Methods: 292 lesions (L) in 228 patients with in-stent restenosis were 
treated with ELCA (78 L), PTRA (83 L) or PTCA (124 L), respectively. After 
ELCA or PTRA, additional PTCA was performed to achieve optimal acute 
procedural results. Coronary angiogramms were analyzed by quantitative 
angiography (QCA), 
Results: QCA data are given in the table. 
Acute intervention Long-term results 
n MLD at MLD after MLD after n MLD at follow- 
baseline debulking intervention up (6 months) 
ELCA 76 0.91 ± 0.52 1,81 ± 0.47 2.59 ± 0.52 t 37 1.35 ± 0.45 
PTRA 83 0.92 ± 0.59 1.83 + 0.42 2,62 ± 0.511 37 1.71 ± 0.88" 
PTCA 124 0.83 ± 9.52 - 2.34 J. 0.65 40 1.57 ± 0.81 
MLD: minimal lumen diameter (ram), t p < 0.05 vs PTCA, ": p < 0.05 for PTRA vs ELCA 
Conclusions: ELCA and PTRA for in-stent restenosis result in significant 
ablation of restenotic tissue. Acute gain with ELCA and PTRA is better than 
with PTCA alone. However, in the present study, MLD after 6 month is 
significantly greater only after PTRA compared to ELCA. 
• Excimer Laser vs. Rotational Atherectomy for the 
Treatment of Diffuse In-Stent Restenosis: Acute 
and Long-Term Results 
Roxana Mehran, George Dangas, Gary S. Mintz, Mun K. Hong, Alexandra 
J. Lansky, Michael Peterson, Andrea S. Abizaid, Javed M. Ahmed, 
Ran Kernowski, Augusto D. Pichard, Lowell F. Satler, Kenneth M Kent, 
Gregg W. Stone, Martin B. Leon. Washington Hospital Center, Washington, 
DC, USA 
Debulking with either excimer laser angioplasty (ELCA) or rotational atherec- 
tomy (RA) appear to improve late recurrence in diffuse in-stent restenosis 
ELCA RA p 
SVG Rx % 43.4 5.6 <0.001 
Lesion length (mm) 16 ~ 2 18 ± 2 NS 
Ref. diam (ram) 2.98 ± 0.57 2.85 ± 0.41 0.02 
Final diam. Sten. (%) 18.1 ± 5 18.7 ± 4 NS 
In-hosp non-Q MI (%) 9.8 7.9 NS 
In-hosp. MACE (%) 3.4 0 0.06 
One-year TLR (%) 31.4 22.5 0.08 
MACE = death/MI/urgent revasc; TLR = target lesion revasc 
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(ISR) lesions, but there have been no comparative studies. Therefore, we 
compared 250 diffuse ISR lesions in 182 patients treated with ELCA (n = 
124) or RA (n = 126). Baseline patient characteristics, total occlusions (8%), 
stent use (27%), and angiographic success (100%) were similar in the two 
groups. 
Conclusions: (1) similar procedural results are achieved with both athero- 
ablative techniques; (2) there is a trend towards reduced in-hospital MACE 
with RA (? due to fewer SVG lesions); (3) despite smaller vessel size, RA has 
lower TLR, suggesting that higher ablation effciiency may impact late clinical 
outcomes. A randomized clinical trial comparing these different athero-abla- 
tive strategies for diffuse in-stent restenosis is indicated. 
~ Excimer Laser in In-Stent Coronary Angioplasty 
Restenosis: Acute and Long-Term Clinical 
Outcomes 
Robert Siegel, Ambika Bhaskaran, Paul Underwood, Warren Breisblatt, 
Barbara Barker, Alvin Nuttall, Debbie Swanson, Peter Santos, 
Jennifer Vermillion, Advanced Cardiac Specialists, Phoenix, Adzona, USA 
In-stent restenosis (ISR) is a serious limitation of coronary stenting (ST). 
Debulking procedures have been advocated in ISR to reduce in-stent neoin- 
timal tissue, improve final luminal diameter, and decrease the incidence of 
subsequent recurrence. We report our experience in the use of excimer 
laser coronary angioplasty (ELCA) for the treatment of ISR. From 1/98 to 
8/98, ELCA was performed in 16 patients (mean age 63 years) presenting 
with angiographic evidence of ISR (>50% diameter reduction), Mean time 
following initial stent implantation was 4.1 months. Stents included Palmaz- 
Schatz (62.5%); GRII (25%); and AVE Microstent (12.5%). Of these, 31% 
presented with acute MI, while 56% presented with unstable angina. Target 
vessel distribution included: LAD (37.5%); RCA (56.3%); LMCA: 1. Lesions 
were ostial/preximal in 9 (56.3%); 2 lesions (12.5%) were in vein grafts. Ten 
stents had diffuse, proliferative restenosis while 6 stents showed intrastent 
focal lesions, Multiple passes were made with eccentric catheters to enhance 
the debulking procedure. Post-ELCA balloon dilatation was performed in all 
cases, with mean inflation pressure of 17.3 atm. 
Results: Successful laser crossing and debulking (residual < 40%) was 
achieved in all cases, with post-balloon residual stenosis _< 20% and TIMI 3 
flow, There was 1 major dissection post-ELCA, treated with prolonged balloon 
inflation. There were no major in-hospital events. At 12-month follow-up, 19% 
had clinical recurrence, requiring re-PTCA. There was no incidence of CABG 
or death. Event-free survival was 81%. 
Conclusions: 1) ELCA with adjunctive balloon angiopiasty appears to be 
safe and effective in the management of ISR. 2) Acute success is excellent. 3) 
At 1-year follow-up, TLR rates are acceptable with no death reported in this 
series. 4) Our initial experience indicates that debulking neointimal tissue 
by ELCA, with adjunctive balloon angioplasty, appears to be a promising 
treatment medality in in-stent restenosis, 
~ In-Stent Restenosis: Equalizer" - "The Great 
Disappointing Clinical Outcomes With ALL 
Interventional Strategies 
Roxana Mehran, George Daogas, Gary S. Mintz, Ron Waksman, Mun 
K. Hong, Alexandre Abizaid, Andrea S. Abizaid, Ran Kornowski, Alexandra 
J. Lansky, John R. Laird, Jr., Kenneth M. Kent, Augusto D. Pichard, Lowell 
F. Satler, Gregg W. Stone, Martin B. Leon. Washington Hospital Center, 
Washington, DC, USA 
In-stent restenosis (ISR) is due to neointimal hyperplasia and has increased 
in frequency with expanded stent use in complex lesions, This report summa- 
rizes the acute and long-term results of all interventional therapies (excluding 
brachytherepy) used for ISR in 821 consecutive lesions at the Washington 
Hospital Center. Baseline demographics were similar among the groups. 
ELCA, RA, and Stent were followed by PTCA in all cases. 
Overall PTCA ELCA RA Stent 
n=821 n=314 n=250 n=126 n=131 
Diabetes (%) 39.3 40.5 39.5 41.1 33.0 
LL (mm) 13±5 11 +2 16±3 19±3 18±2 
Final %DS 19±4 21±2 17±4 22±3 110±1 
Final CSA (mm 2") 7.3 • 3.2 6.6 ± 0.8 6.9 ± 1 6.4 ± 0.5 19.7 ~: 1 
1 -year TLR (%) 27.9 26.6 31.0 23.1 27.0 
tp ANOVA < 0.05, PTCA = balloon, ELCA = excirner laser, RA = rotational therec- 
tomy, CSA = lumen area by intravascular ultrasound, DS = diameter stenosis, LL = lesion 
length, TLR = target lesion revascularization. 
Using multivariate logistic regression analysis, independent predictors for 
TLR were: diabetes (OR: 1.63, p = 0.037), prior ISR (OR: 1.51, p = 0,041), 
and diffuse (LL > 20 mm) ISR (OR; 2.5, p = 0.001). Device choice was not a 
predictor of TLR. 
Conclusions: Despite differences in interventional strategies, mecha- 
nisms of lumen enlargement, and final angiographic results, late clinical 
outcomes after treatment of ISR remain disappointing, and surprisingly in- 
dependent of device choice. Thus, a definitive "cure" for ISR will require 
additional adjunct antiproliferative therapy, such as radiation vascular ther- 
apy which is under investigation. 
L ~  Patterns of In-Stent Restenosis Angiographic 
Lesions that Failed Radiation Therapy 
Ron Waksman, R. Larry White, Rosanna C. Chan, Balram Bhargava, Gary 
S. Mintz, Lisa M. Gierlach, Alexandre Lansky, Lowell F, Satler, 
Roxana Mehran, Kenneth M. Kent, Martin B. Leon. Washington Hospital 
Center, Washington DC, USA 
In WRIST-the Washington Radiation for In-_Stent restenosis Trials - pa- 
tients were randomized to placebo versus gamma radiation following PTCA. 
Twelve patients (7 native coronaries and 5 vein grafts) retumed with re- 
current angina and angiographic evidence >50% stenosis despite radiation 
therapy. The purpose of this analysis was to characterize the angiogrephic 
and intravascular ultrasound (IVUS) patterns of lesions with recurrent steno- 
sis despite radiation. The angiogrephic patterns of recurrent stenosis were: 
focal stenosis n = 2, diffuse pattern (_>10 mm in length) n = 1, total occlu- 
sion n = 4, and edge stenosis n = 5. In 5 patients with edge stenosis the 
radiation dbborVlesion length ratio was 1.05 suggesting inadequate cover- 
age of the treated area by the radiation ribbon. Dosimetry analysis of the 
last seed in the ribbon (3 mm) detected 25% decrease in the dose com- 
pared 1o a seed located in the center of the ribbon. The 4 patients who 
presented with total occlusion were treated with a 13 seed ribbon (51 mm in 
length) and the ribbon/lesion length ratio was 1.54. IVUS analysis indicated 
increased lumen loss in larger stents and in larger vessel sizes with exag- 
gerated tissue proliferation at the site of recurrence. The failed patients were 
treated with CABG n = 4, medical therapy n = 3 and repeat angioplasty n = 
5. 
Conclusions: The predominant patterns of radiation failures are edge 
stenosis and total occlusions. Special attention should be taken to position 
the source with wide treatment margins and to consider prolonged antiplatelet 
therapy when longer lesions are treated. 
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F ~  Long-Term Follow-Up After  Stent ing for  li lac 
Stenoses and Occlusions 
Malte Schr6der, Dierk Scheinert, Gesine Dcerr, Giancado Biamino. 
Charite-Campus Virchow Klinikum Humbo/dt-Universi~ Berlin; Center for 
Cardio/ogy and Vascular Intervention, Hamburg, Germany 
Implantation of endovascular stents is a commonly used technique for per- 
cutaneous treatment of iliec stenoses. In contrast, the long-term efficiency of 
stents after recanalization of long lilac c<~lusions (LIO) remains uncertain. 
The objective of this study was to compare the results after stent-supported 
recanalization of lilac artery stenoses and occlusions. 
In 246 patients a total number of 436 stents were implanted to stabilize 
suboptimal results after recanalization of high grade iliec stenoses (mean 
84.7 ~ 10.5%) (group A: n = 108) or total occlusions (group B: n = 138). The 
target lesion was localized in the common lilac artery (A: n = 56, B: n = 38), 
the external lilac artery (A: n = 33, B: n = 67) or both vessel segments (A: 
n = 19, B: n = 38). Length of the stented segment was significantly larger in 
group B (8.6 cmvs. 5.17 cm, p < 0.01). 
Accordingly, more stents were needed after recanalization of LIO (1.99 
vs. 1.49, p < 0,01). Comparing the clinical situation, we found a shorter 
walking capacity in group B as well as a reduced Ankle-Brachial-lndex (ABI), 
measured after standarized treadmill test (0.57 + 0.25 vs, 0.49 ± 0=15). 
Results: A pdmary technical success (residual stenosis < 30%) could be 
achieved in 98.1% (group A) and 96.4% (group B) of patients, respectively. 
Clinically, a marked improvement of +2 or +3 grades according to the AHA- 
criteria was found in 62 pts. (57.4%, group A) and 117 pts. (84.8%, group B), 
During the mean follow-up of 19.5 months the primary patency rates were 
87.0% in group A and 87,7% in group B (p = n.s). In the majodty of cases 
reobstruction could be successfully treated by PTA, leading to secondary 
patency rates of 96.3% (group A) and 97.1% (group B), 
In conclusion, endovascular stenting provides an effective treatment op- 
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tion for iliec stenoses as well as LID. A high long-term patency has been 
proven in both groups. 
~ Novel Model of Arterial Calcification Direct by 
Intramural Hydroxyapatite Injection 
Khalid Ashai, Birgit Kantor, Paul Keelan, Katsumi Miyauchi, Renu Virmani 1 , 
Robert S. Schwartz. 1Armed Forces Institute of Pathology, Washington, DC; 
Mayo Clinic, Rochester, MN, USA 
Background: While animal models of fatty streak and eady atherosclero- 
sis have been developed and tested successfully, 'large-animar models of 
complex plaque containing calcium and luminal stenesis, representative of 
human disease are lacking. Ablative interventional devices often suffer in 
preclinical testing because of poor representative animal models of such 
calcified plaques. We assessed the feasibility of mimicking plaque-like intra- 
mural calcification and neointimal hyperplasia by direct injection of calcium 
hydroxyapatite, the principal anion of atherosclerotic alcification, into porcine 
vessel walls. 
Methods: We injected 0.5 mL of different concentrations of calcium hy- 
drot(¥aJpatite~ dissolved in HCI~ irtto 3 am se(~mertta of arterial wait usirt~ a 
30G needle and 1 mL tuberculin syringe. Two carotid and 2 femoral arteries 
were injected with calcium hydroxyapatite 35°/° w/v in 6N HCI and the vessels 
evaluated at 1,2, 3 and 4 weeks. Calcium hydroxyapatite 25% w/v in 3N HCl 
was injected into 7 vessels (5 carotids and 2 femorals) and assessed in 1, 2 
and 3 weeks. Contrast angiography determined vessel patency, while H&E 
and Von-Kossa staining confirmed the presence of Calcium in the vessel 
walls 
Results: Arterial wall calcification was confirmed by Von Kossa staining 
in all of the vessel segments injected. Hydroxy-apatite 25% w/v in 3N HCI in- 
jection resulted in circumferential deposition of calcium deeper 1o the Internal 
Elastic Lamina involving at least half thickness of the media and moderate 
neointimal hyperplasia. All vessels were patent even in the presence of mod- 
erate medial necrosis. The higher concentration of HCI, however, caused 
thrombosis and severe medial necrosis. 
Conclusion: We have developed a novel model of marked calcification in 
the porcine large-vessel wall by direct injection of 25% calcium hydroxyapatite 
in acidic medium. This is a major step forward in the development of a 
complex calcific plaque in a 'large-animal' model. Future efforts will focus 
at percutaneous catheter delivery of hydroxyapatite into porcine coronary 
arterial wall, combining it with a stenosis model, to obtain a reproducible 
calcified plaque, that is best suited for interventional device testing. 
11[•-30•-4• Successful Percutaneous Treatment of Common Femoral Artery Occlusion Complicating 
Anglo-Seal Deployment 
Gary M. Ansel, Barry S. George, Alice A. Noethen. MidWest Cardiology 
Research Foundation, Columbus, Ohio, USA 
Background: Hemostatic puncture closure devices are becoming increas- 
ingly popular for use following interventional procedures. Complications, 
though infrequent, may include occlusion of the treated common femoral 
artery (CPA). 
Purpose: To evaluate the efficacy and safety of nonsurgical mechanical 
thrombectomy and balloon angioplasty (PTA) in CFA occlusion complicating 
Anglo-Seal (AS) deployment. 
Method: A prospective analysis of consecutive patients was undertaken 
utilizing baseline and post procedure angiography. Contralateral access was 
gained and the occlusion treated with Anglo Jet ® (A J) and adjunctive angio- 
plasty. Clinical exam was performed at 30 days and six months, with duplex 
scan and ankle brachial index (ABI) at six months. 
Results: Of 1200 AS placements at our institution, six resulted in CFA 
occlusion. All occluded vessels had significant underlying atherosclerosis. 
Successful recanalization was achieved in 6/6. There were no complications. 
Thirty-day followup was available in 4/6, with one patient having symptomatic 
claudication. At six months, one patient had symptomatic restenosis treated 
with directional atherectomy, and five patients had normal ABI and <50% 
residual stenosis by duplex scanning. 
Conclusion: AJ and PTA appear to be safe and effective alternatives to 
the surgical treatment of CFA occlusion complicating AS deployment. Further 
investigation and followup is ongoing. 
• Wallgraft Endoprosthesis for Endoluminal 
Treatment of Traumatic and Aneurysmal 
Peripheral Vascular Disease 
Zvonimir Krajcer, Munir Zaqqa, Nell Strickman, Ali Mortazavi, 
Edward Dietrrich, Gary Ansel, John Lipman, Timothy Murphy. Texas Heart 
Institute, Houston; Arizona Heart Institute, Phoenix; Riverside Hospital, 
Columbus; Hospital, Atlanta; Rhode Island Hospital, Providence, USA 
Purpose: to evaluate the use of Wallgraft, a polyester covered endoprosthe- 
sis, in the treatment of arterial aneurysm and traumatic vessels disruptions 
in peripheral vessel 5-11 mm in diameter. 
Method: From October 1997 through August 1998, 32 high-risk surgical 
patients (26 males, 8 females, average age 69 ± 13.2 years) underwent this 
procedure. Six lesions were traumatic and 26 were aneurysmal. The location 
of the lesions were lilac in 65.9%, popliteatl in 17.1%, femoral in 12.2%, 
subclavian in 2.4% and an A-V graft in 2.4% 
Results: The acute procedural success was 90%; device success rate 
was 98%. Major complication rate, which was defined as death, MI, stroke, 
bleeding requiring transfusion, any complication that is procedure related 
and requiring a surgical intervention, and extended hospital stay, was 8.1% 
Co~ctusiaa- Watt~ra~ s a-sate a~d. a~ectb~a matb,c,d, far t~e~tm~ot ot b,~b, 
risk surgical patients with arterial aneurysm and trauma. Longer follow-up in 
a larger number of patients is needed to determine if Wallgraft reduced the 
morbidity and mortality in comparison to surgical repair. 
~ Recurrent Restenosis After Carotid Artery 
Stenting (CAS) Versus Operative Management of 
Neointimal Hyperplasia Following Carotid 
Endarterectomy 
Elie Y. Chakhtoura, Robert W. Hobson II, Jonathon E. Goldstein, 
Zafar Jamil, Frank T. Padberg, Peter J. Pappas, Michael B. Silva. Saint 
Michael's Medical Center & University of Medicine and Dentistry of New 
Jersey, Newark N J, USA 
Background: CAS has been employed as an alternative to operative man- 
agement for carotid restenosis (CR) after prior carotid endarterectomy (CEA), 
particularly for neointimal hyperplasia occurring within 3 years of CEA. How- 
ever the incidence of recurrent restenosis (RCR) following these procedures 
remains ill defined. We retrospectively compared the results of CAS and 
operative management of CR during the last 8 years. 
Methods: Symptomatic and asymptomatic patients (pts) (n = 31, 18 
women and 13 men) with restenosis of >_ 80% on duplex ultrasound (DU) 
were treated operatively while CAS was performed on pts after 1996 (n = 
17, 18 procedures). All pts were followed clinically and with DU (ICAVL - 
approved laboratory) at 3-6 month intervals. Incidence of RCR with CAS was 
compared to RCR for previously employed operative management. Data are 
presented for stenoses of 30-49%, 50-79% and >_ 80%. 
Results: Age, gender, and risk factors were compared between pts 
treated with CAS and operation. No 30 day periprocedurat deaths or strokes 
occurred in either group. During a mean follow-up period of 6 ± 1.5 months, 
RCR was observed in 2 pts after CAS (2/18, 11%) and 1 patient after operation 
(1/16, 6.25%). All pts are currently being followed medically on antiplatelet 
therapy. Of the CAS pts, 1 stenosis at 30-49% (40% angiographically) and 1 
at 50-79% (60%, DU) occurred as compared to the 1 patient after operation 
with a 50-79% stenosis (60%, DU). All pts remain asymptomatic and none 
have undergone subsequent intervention. 
Conclusion: CAS is accompanied by a low incidence of RCR. Coupled 
with its comparable safety to operative management, we recommend CAS 
for management of neointimal hyperplasia after CEA. 
~ ls Carotid Stenting the Preferred Treatment in 
High-Risk Surgical Carotid Endarterectomy 
Patients? 
George Dangas, John R. Laird Jr., Lowell F. Sailer, Emily Parsons, 
Ann Greenberg, Regina Deible, Lee Monsein, Luis Gruberg, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
Although overall clinical indications for elective carotid stent-supported an- 
gioplasty (CSSA) remain controversial, perhaps the most important cohort 
would include patients with high-risk or unfavorable characteristics for surgi- 
cal carotid endarterectomy (CEA). Of the 140 consecutive CSSA procedures 
performed in 131 patients over the last two years, 39 (28%) were performed 
in 37 patients at high-risk for CEA. High risk criteria included (1) total occlu- 
sion of the contralateral carotid, (2) prior ipsilateral CEA, (3) prior radiation 
therapy of the neck and (4) carotid bifurcation above the mandible (requiring 
more complex surgical exposure). Overall patient characteristics included 
mean age 71 years, 70% male gender, 77% hypertensives, 26% diabetics, 
42% prior CABG, and 38% prior stroke; high-risk patients had similar clinical 
characteristics. In this high-risk cohort, angiographic and procedural success 
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was 100%, there were no in-hospital deaths, and only one (2.7%) in-hospital 
minor neurologic event which resolved within 24 hours. At follow-up, (mean 
duration 10 months), there have been two non-neurologic deaths (5.7%), 
one minor transient neurologic event (2.9%), and no CEA or repeat carotid 
interventions. 
Conclusions: In patients at high-risk for CEA based upon accepted 
criteria, CSSA is a safe and efficacious alternative with encouraging long-term 
clinical outcomes. If these results are duplicated in larger series, CSSA should 
be advocated as the preferred treatment for these high-risk patient cohorts. 
• Recanalization of Total Occlusions of the Chronic 
Abdominal Aorta and the lilac Arteries 
Horst Sievert, Hans-J(~rgen Schultze, Jutta Peters, Roland Ensslen, 
Hartmut Merle, Detlef Scherer, Andreas Fach. Cardiovascular Center 
Bethanien CCB, Frankfurt, Germany 
Background: Catheter recanalization of the common lilac arteries and the 
distal aorta is considered to have a low success rate and a high rate of 
complications. 
Methods: In 76 consecutive patients, we attempted recanalizing 83 chron- 
ically occluded common iliac arteries and/or the distal aorta (n = 9). Con- 
ventional wires and recanalization catheters were used, in 26 patients in 
combination with local fibrinolysis. After successful crossing of the occlusion, 
a balloon dilatation was performed. In 2 patients, 1 to 4 stents and in 5 
patients an endoluminal bypass were implanted. 
Results: The procedure was successful in 76/83 occlusions (91%). Distal 
thromboembolization in occurred in 4 patients. This was treated successfully 
with local fibrinolysis and/or catheter aspiration embolectomy. Perforation of 
the lilac artery occurred in 3 patients and was treated successfully with long- 
term balloon inflation in one, implantation of a Dacron covered endoprosthe- 
sis in one and surgically in the other (uneventful). No further complications 
occurred. 
Conclusion: Recanalization of the lilac arteries and the infrarenal aorta 
is possible with a high success rate and a comparatively low rate of compli- 
cations. 
~ Incidence and Outcomes of Prolonged 
Hypotension Following Carotid Artery Stenting 
Nadim AI-Mubarak, Ming W. Liu, Larry S, Dean, Camilo R. Gomez, 
Kimberley Kretzer, Diane Aired, Sriram S. lyer 1 , Jiri J. Vitek t , Gary 
S. Roubin 1 . University of Alabama, Birmingham, AI; 1Lenox Hill Hospital, 
New York NY, USA 
Background: Prolonged hypotension requiring pressor therapy has been 
noted in some patients following carotid stenting procedures. Its incidence 
and outcomes is not known. 
Methods: Between 7/94 and 12/97, 307 internal carotid artery stenting 
procedures were performed. In 33 (11%) of these, prolonged hypotension 
(systolic BP < 90 mm Hg) was noted in the immediate post-procedural period 
requiring dopamine infusion. 
Results: There were 27 (82%) males. The mean age was 66 • 4 years. 
On presentation, 15 patients were symptomatic. Twenty-nine patients (89%) 
had a history of hypertension. All patients had successful stenting procedures 
(residual stenosis < 30%). Wallstents were used in 30 patients (91%), Palmaz 
stents in 3. The mean baseline systolic blood pressure (SBP) was 147 mm Hg 
(range: 105-196) at a mean heart rate (HR) of 69/min. Hypotension occurred 
at a mean of 3.5 hours after the procedure (range 0-16) and lasted for a mean 
of 22 hours (range: 3-44). Nine patients complained of generalized weakness 
and nausea during hypotension, 5 had dizziness. The remaining patients 
were asymptomatic. Lowest mean SBP was 75 mm Hg (range: 50-88) at 
a mean HR of 60/min (range: 51-74). The mean SBP prior to discharge 
was 115 ± 8 mm Hg. Three unrelated in-hospital minor strokes occurred. All 
recovered completely. No other complications were noted otherwise. Except 
for one non-neurological death, all patierds remained stable during 30 days 
follow-up. 
Conclusion: Prolonged hypotension requiring pressor therapy occurred 
in 11% of the patients following carotid artery stenting. If recognized eady 
and managed appropriately it does not appear to be associated with adverse 
clinical outcomes. 
• Femoropopliteal Results - Indications. Stenting: 
Choice of the Stent 
Michel Henry, Max Amor, Isabelle Henry, Kiril Tzvetanov, Zuka:i Chati. 
Potyclinique, Essey-les-Nancy, France 
Purpose: To retrospectively study safety, efficacy, mid/long-term results of 
femoro-popliteal stenting. To try to select the best suited stent depending on 
the location and characteristics of the lesion and the access site. 
Methods: 700 lesions in 669 symptomatic patients (M: 66%, F: 34%, 
mean age: 65.9 ± 10.3 years) with femoro-pop, occlusive diseases (stenoses: 
373, occlusions: 312, aneurysms: 15) were treated with 3 typos of stents: 
balloon expandable (Palmaz: 126, Long Medium Spiral: 68), self-expandable 
nitinol (Sinus: 150, Instent: 143, Medicorp Expander: 94), covered (Cragg: 
93, Corvita: 26). Indications: post-PTA residual stenosis: 78%, dissection: 
13%, restenosis:9%. Mean lesion length: Palmaz: 3.8 cm, Long Medium: 6.8 
cm, nitinol: 5.9 cm, covered stent: 9.5 cm. 
Results: Immediate technical success: 98%, clinical success: 97%. Acute 
thrombosis more frequent with covered stents (9% vs 2,5%). In the lower 
part of the superficial femoral artery (SFA) and in the popliteal artery, balloon 
expandable slents can be compressed and lead to a higher restenosis rate 
than nitinol stents (50% vs 15%). Primary (PI) and secondary patency (PII): 
Palmaz stents at 4 years: PI: femoral: 65%, popliteal: 50%, PII respectively: 
95%, 69%. Long Medium Spiral at 3 years: femoropop : (upper part of pop. 
artery): PI: 77.5%, PII: 90%. Nitinol stents at 4 years: PI: femoral: 82%, 
popliteal: 84%, PII respectively: 91 and 94% (no difference for lesions < or > 
8 cm). With covered stents at 27 months at femoro-popliteal evel: Ph 64%, 
PII: 76%. 
Conclusion: Femoro-popliteal stenting seems safe, efficient. Balloon- 
expandable stents seem particularly indicated for the two upper thirds of SFA 
(should be avoided for lower part and for popliteal artery). Self-expandable 
nitinol stents may be implanted in any artery and are particularly indicated in 
popliteal artery and flexion sites. Their results are very promising. Covered 
stents are rather indicated for aneurysms. Their results are not better than 
nitinol stents for the treatment of long lesions. 
~ Angioplasty and of Extracranial Carotid Stenting 
Arteries in High Risks Patients 
Michel Henry, Max Amor, Isabelle Henry, Kiril Tzvetanov, Zuka'l Chati. 
Polyclinique, Essey-les-Nancy, France 
Purpose: To study feasibility/safety of endovascular treatment (angioplasty 
+ stents) of atherosclerotic stenosis of the extracranial carotid artery to 
determine if it could be an alternative to surgical endarterectomy. 
Methods: Carotid angioplasty was attempted in 199 arteries, 186 pts 
(M: 126, F: 45, mean age: 71.2 -I- 9.7 years (17-93)). Mean lesion length: 
15.1 ± 4.1 mm. Mean arterial O: 5.6 ± 0.7 mm. In 11 pts, contralateral 
carotid artery was thrombosed. 35% of the pts were symptomatic, 65% 
were asymptomatic (55% of the pts had severe coronary disease, 34% had 
peripheral vascular diseases). Stents deployed in all carotids but 1: Palmaz 
(n = 129), Wallstent (n = 64), other stents (n = 9). Without cerebral protection, 
149 carotid arteries were treated (fern. approach: 134, direct puncture: 13, 
brachial approach: 2) and 50 were treated with cerebral protection. Pts had 
neurological examination, CT-scan, echodoppler, angiography, before/after 
the procedure and at 6 months follow-up. 
Results: Immediate technical success: 198/199. Mean % stenosis drop 
from 83.8 ± 2.9 to 2.9 ± 7. Neurological complications: 10 (5%): 4 TIAs, 
3 minor and 3 major strokes. 7 appeared after Palmaz stent implantation 
(5.7%), 3 after Wallstent (4.6%). 4 appeared despite cerebral protection. 3 
access site hernatomas. No death, no myocardial infarction. At 6 months, 
151 pts were followed-up. We observed 1 mild compression of a Palmaz 
stent; 6 restenoses (4%). 1 symptomatic and 5 asymptomatic restenoses 
treated by new PTA alone (n = 3), new PTA+stent (n = 1), surgery (n = 1), 
medical treatment (n = 1). Maximum follow-up: 40 months, mean foUowup 
period: 14.7 ± 9.3 months. No ipsilateral neurological complication. Primary 
patency: 96% at 3 years, secondary potency: 99%. 
Conclusion: Carotid angioplasty with the use of stents seems safe, 
effective, and can be considered as an alternative to surgical treatment of 
atheresclerotic stenoses at least in some specific indications. Randomized 
studies will be necessary. 
I ~  Percutaneous Endovascular Treatment of 
Abdominal Aortic Occlusive Diseases 
Michet Henry, Max Amor, Isabelle Henry, Kiril Tzvetanov, Zuka:i Chart. 
Polyclinique, Essey-les-Nancy, France 
Purpose: Patients (pts) with abdominal aortic occlusive diseases are usu- 
ally treated surgically. Aim of the study: to analyse feasibility, safety, pal- 
mary/long-term results of porcutaneous endovascular techniques balloon 
angioplasty with or without stent implantation. 
Methods: We treated 64 lesions in 28 symptomatic pts (M: 23, F: 5, age: 
M: 60.3 ± 12.4 years (29-82), F: 46.2 ± 11.2 years (31-61)). 23 pts were in 
stage lib of Fontaine's classification, 5 presented with distal embolic lesions. 
Lesions characteristics: 10 isolated infra renal aortic lesions: stenoses: 9, 
occlusion: 1. 18 aortic bifurcation occlusive diseases (stenoses: 38 - aorta: 
13, iliac: 25) (occlusions: 16 - aorta: 5, lilac: 11). 65% of the lesions were cal- 
cified, 45% ulcerated. Fibrinolysis was used for 4 aortic occlusions (brachial 
approach) an d for 3 lilac occlusions (contralateral approach). Aortic bifur- 
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cation lesions were treated by kissing balloon technique and isolated aortic 
lesions by angioplasty with a large balloon. 43 stents (Palmaz: 28, others: 15) 
were implanted in case of dissections or residual stenosis post-angioplasty. 
Results: Complete technical success obtained in 26 pts, partial success 
in 2 who presented total occlusion of abdominal aorta and both lilac artedes, 
just 1 lilac was recanalized and stented. A femoro-femoral bypass graft was 
performed surgically. Distal lesions due to emboli healed completely. ABI 
increased from 0.62 + 0.12 to 0.94 ± 0.11. No immediate complication. 
Mean follow-up: 24.3 ± 21 months (1-103). 3 pts with aortic bifurcation 
disease restenoses treated by new angioplasty (n = 1) or surgery (n = 2). At 
6 years, follow-up, pdmary patency is 83% and secondary patency 86% for 
all pts. Patency is 100% for isolated aortic lesions. 
Conclusion: Percutaneous endovascular treatment of abdominal aortic 
occlusive diseases is a safe/effective method with good primary and long- 
term results, an alternative to surgical interventions and the first treatment to 
be proposed. 
• Malignant Hypertension Associated With Renal 
Artery Stenosis: Successful Treatment by 
Percutaneous Stenting (PTRAS) 
Robert J. Lederman, Farrelt O. Mendelsohn, Adam B. Greenbaum, Harry 
R, Phillips, Richard S. Stack, James J. Crowley, Duke University Medical 
Center, Durham, NC, USA 
Background: Renal artery stenosis (RAS) may manifest as malignant hy- 
pertension (MRH), defined as paroxysmal hypertension (HTN) directly asso- 
ciated with life-threatening pulmonary edema, encephalopathy, or angina. 
Methods: We compared the outcome of PTRAS in 39 patients with MRH 
and 221 with benign renovascular hypertension (BRH). 
Results: Presenting symptoms included pulmonary edema 25 (64%), 
encephalopathy in 7 (18%), and severe angina from uncontrolled HTN in 
7 (18%). MRH pts had more frequent CRI (56.4% vs 24.4%, p < 0.01), 
higher baseline creatinine (1.95 vs 1.29, p < 0,01), more antihypertensive 
medications (3.2 ± 1.2 vs 2.4 ~ 1,2, p < 0.01), more severe CAD (2.3 vs 
1.7 vessels diseased, p = 0.01), and more LV dysfunction (33% vs 18%, p 
= 0.02) than pts with BRH. Vessel size, stenosis severity, and frequency of 
bilateral RAS were similar between groups. PTRAS was successful in all 
patients, Median follow-up was 1.15 years (0.59, 2.1). Systolic BP improved 
in both groups (MRH: 175 • 26 mmHg to 148 ± 19, p < 0.01, BRH: 161 
26 to 142 • 19, p < 0.01), although antihypertensive medication count did 
not change in either. Crsatinine remained normal in the majority of patients 
(MRH 80.0% vs BRH 93.7%, p = 0.06) unless they had baseline CRI (stable 
in 61.1% with MRH vs 77.8% with BRH, p = 0.18), Mortality was higher in 
MRH (23% vs 6.3%, p < 0.01). 
Conclusion: (1) RAS should be considered in the evaluation of pts 
with malignant HTN. (2) PTRAS effectively lowers BP in pts with MRH. (3) 
Nevertheless, MRH confers a higher late mortality and a worse renal outcome 
after PTRAS 
• Stenting Releases Silent Microemboli from 
Plaque. (Pulse Doppler and Pathological Finding 
of Microemboli in lilac Artery) 
Akio Aoki, Yoshiaki Yokoi, Shinichi Higashiue, Takaaki Chikugo. Kishiwada 
Tokushukai Hospital, Kishiwada-ci~ Japan 
Purpose: Percutaneous angioplasty has a risk of distal embolization by 
destruction of plaque. We examined whether silent microemboli occurred or 
not in iliac artery stenting, by using Pulse Doppler and aspiration of blood at 
distal vessels. 
Methods: We studied 16 patients who underwent Palmaz stent implan- 
tation for symptomatic iliac artery stenosis. During balloon dilatation, tran- 
scutaneous Pulse Doppler were monitored continuously at femoral artery in 
the first 8 patients. In the next 8 patients, 20 cc blood was aspirated from 
side-arm of the sheath each time of pre-dilatation and stent deployment. The 
aspirated blood was filtered to be identified microscopically. 
Results: Pulses with reflection of microemboli were observed in all 8 
cases immediately after pre-dilatation and stent deployment, Mean duration 
of the reflection was longer at stenting than at pre-dilatation. No emboli was 
observed in any 8 cases of aspirated blood at pre-dilatation. Embolic debris 
(size 0.5-1.5 mm) was filtered from aspiration at stenting in 6 of the 8 cases. 
Microscopical finding revealed those emboli were be a part of atherosclerotic 
tissue. No clinical sequel of distal embolization happened. 
Conclusion: Silent microemboli were released from destroyed plaque in 
uncomplicated stenting. More emboli were released at the moment of stent 
deployment than pre-dilatation. 
POSTER 
Evaluation of Atherosclerosis by New 
Imaging Techniques 
Tuesday,  March  9, 1999, 9:00 a .m, -11 :00  a.m.  
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  10:00 a .m. -11 :00  a.m. 
~ Atherosclerotic Lesions Classification by 
Time-Resolved Laser Induced Fluorescence 
Spectroscopy: Clinical Identification of Lipid-Rich 
Lesions 
Laura Marcu, Jean-Michel Maarek, Michael Fishbein, Warren Grundfest. 
Cedars-Sinai Medical Center and Biomedical Engineering, University of 
Southern California, Los Angeles, CA, USA 
Background: This study investigates the use of Time-Resolved Laser-Induced 
Fluorescence Spectroscopy (TR-LIFS) for clinical characterization of athero- 
sclerotic lesions, particulady for identification lipid-rich lesions which may be 
prone to rupture. 
Methods: Transient pulse fluorescence emission of 93 excised samples 
of human aorta (14 subjects, 11-85 years old) was induced with Nitrogen 
laser (337 nm, 3 ns) and detected in 360-510 nm at 5 nm intervals. Using AHA 
histological classification, the samples were sorted in five groups: normal (Grl 
= normal + Type I, 35 samples), fatty-streaks (Gr2 = Type II, 23), lipid-rich 
lesions (Gr3 = Types Ill + IV, 14), collagenous lesions (Gr4 = Type Va, 15), 
calcified lesions (Gr5 = Type Vb, 6). Spectral intensities and time-dependent 
decay constants r l ,  r2 derived from the time resolved spectra of arterial 
samples were used for tissue characterization. 
Results: The spectra changed with increasing extent of atherosclerosis. 
We observed 1) in spectral domain: intensity at 450-480 nm gradually de- 
creased from ~80% peak intensity for normal samples to ~20% for Type 
Va; 2) in time domain: longer lasting emission for advanced lesions (at 390 
nm emission ~16 ns Type Va vs. ~11 ns normal). The decay constants 
changed as a function of emission wavelength and lesion type (at 390 nm: 
rl = 0.95 + 0.1 ns, ~2 = 5.7 ± 0.2 ns for normal; r l  = 2.1 ± 0.2 ns, r2 = 
7.45 ± 0.4 ns for Type Va). Stepwise discriminant analysis using selected 
decay constants at 390 and 430 nm and intensity values at 440 and 490 nm 
as predictor variables classified (cross-validated data) the five tissue groups 
with the following accuracy: Grl (sensitivity vs. specificity [%]) 81.5/91.1; Gr2 
80.3/90.2; Gr3 96/98; Gr4 100/100; Gr5 80/100. 
Conclusion: These results show the ability of TR-LIFS to finely discrimi- 
nate between types of atherosclerotic lesions and to accurately differentiate 
between lesions with lipid pools (Types III + IV) and lesions with thick collage- 
nous layers (Type Va). Our findings suggest that TR-LIFS technique could 
complement current diagnostic procedures for identification of atherosclerotic 
lesions which may be prone to rupture. 
~ Characterization of Vulnerable Plaques by Near 
infrared Spectroscopy in an Atherosclerotic 
Rabbit Model 
Pedro R. Moreno, Robert A. Lodder, William N. O'Connor, Valed A. Vyalkov, 
K. Raman Purushothaman, James E. Muller. University of Kentucky, Gill 
Heart Institute, Lexington, KY, USA 
Background: Non-stenotic, lipid-dch plaques are at dsk for rupture, the 
main cause of acute coronary syndromes. A method is needed to identity 
such plaques in living patients. Near infrared spectroscopy (NIRS) provides 
non-destructive characterization of tissue composition and could be utilized 
for vulnerable plaque identification. 
Methods: We tested the ability of NIRS to identify the histologic features 
of plaques in 144 aortic post-mortem specimens from six rabbits fed with 
a pulsed 1% high cholesterol diet for 10 months. Elastic-trichrome stained 
slides were analyzed to identify thin fibrous cap (<65 microns by morphom- 
etry), lipid pool, macrophages and calcium. Data from a training set of 72 
randomly selected samples was entered into a super-computer to determine 
the NIR spectra of {these plaques. The remaining set of 72 samples was 
prospectively tested in a blinded fashion. 
Results: 
Near Infrared Spectroscopy 
Thin Cap Lipid Pool Macs Calcium 
His to logy  + + + - + - 
+ 62  7 70  1 69  3 58  0 
- 0 3 0 1 0 0 5 9 
Conclusion: In this atherosclerotic animal model, near infrared spec- 
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troscopy correctly identified plaques with histologic features of vulnerability. 
Since this method is easily adapted to a catheter based-approach, vulnerable 
plaques can be studied prospectively in this model and ultimately in humans 
by near infrared spectroscopy. 
~ T h e  Atherosclerotic Lesions in the Temperature of 
Hypercholesterolemic Rabbit Double Injury Model 
are Elevated Following Angioplasty 
Michael A, Lauer, Zhong M, Zhou, Farhad Ferudi, A, Michael Lincoff, 
Stephen G. Ellis, Eric J. Topoi. Cleveland Clinic Foundation, Cleveland OH, 
USA 
Background: Human atherosclerotic plaques from carotid endartectomy 
specimens have been shown to display thermal heterogeneity, with areas 
of increased temperature correlating with clusters of macrophages, suggest- 
ing a possible modality for detecting vulnerable plaques. The hypercholes- 
terolemic rabbit double injury is a model of restenosis in which lesions have 
a high proportion of macrophages and foam cells. 
Methods: Lesions were induced by air desiccation in femoral arteries of 
15 New Zealand White rabbits. After 28 days (d) of a high cholesterol diet, 
balloon angioplasty of the lesions was performed. At 0 h, 1 d, 2 d, 5 d, 7 
d, or 14 d following angioplasty, the lesions were isolated and exposed via 
longitudinal incision. A digital thermistor with a 27-gauge needle tip was used 
to measure luminal surface temperature at 27 points proximal to, within, and 
distal to the lesion, as well as in the surrounding tissue. Because temperature 
decreased sharply with increased distance from the abdomen, temperatur e 
difference was determined between artedal surface and surrounding tissue. 
Two factor ANOVA and t-tests were performed. 
Results: Prior to angioplasty, the arterial temperature was 0.54 ~ 0.10 
-°C (mean ± SE) less than the surrounding. The temperature increased to 
0.25 ± 0.06 ~C (p = 0.02) less than surrounding at 2 d. The temperature 
then decreased to 0.88 ± 0.07 -=C (p = 0.02) less than surrounding at 5 d, 
and to 1.25 ± 0.14 -°C (p = 0.007) at 7 d. There were no areas of marked 
temperature heterogeneity 
Conclusion: The temperature of lesions in the hypercholesterolemic 
rabbit double injury model are elevated two days after angioplasty, but are 
decreased at 5-7 days following angioplasty. The temperature changes were 
relatively homogenous throughout the lesions, consistent with the diffuse 
infiltration of macrophages in this model. 
• Damages of Endothelial Cells Are Cronary Easily 
Caused Even by Floppy Guide Wire - In Vivo 
Staining Angioscopic Study 
Katsumi Yamada, Yoshiharu Fujimori, Hiroshi Merle, Kuniko Terasawa, 
Osamu Hasegawa, Akira Matsuo, Masaaki Osegawa, Yasumi Uchida. 
Narita Redcross Hospital, Toho University Sakura Hospital, Chiba, Japan 
Background: Although many interventional devices are introduced in order 
to treat coronary artery lesions, they sometimes cause adverse effects on 
normal segments of the same arteries. 
Methods: We angioecopicaly observed coronary arteries in 35 patients 
with ischemic heart disease before or after intervention. To reveal endothelial 
damages, we performed intracoronary staining with Evans blue. Angioscopic 
observation was repeated before and immediately after intracoronary staining 
with 1 ml of 2% Evans blue. 
Results: Before intervention, stained segments proximal to the lesions 
were observed in 22 of 35 patients, which were caused by mechanical 
injury by guide wire or angioscope. In 5 of them, thin staining like a streak 
were observed, which may be caused by guide wire alone. In all 3 patients 
observed after intervention, large surfaces of the segments proximal to the 
lesions were stained. 
Conclusion: Endothelial damages in the segments outside the lesions 
are easily caused even by floppy guide wire. Angioscopic observation by in 
vivo staining with Evans blue clearly revealed those damages. This may be 
the first report on dye staining angioscopy of endothelial esions in patients. 
~ A  Intravascular Catheter for the in Vivo Novel 
Thermography of Coronary Arteries 
Chdstodoulos Stefanadis, Leonidas Diamantopoulos, 
Charalambos Vlachopoulos, Eleffherios Tsiamis, Pavlos Toutouzas. 
Hippokration Hospital, Athens Medical School, Athens, Greece 
Background: Activated macrophages play an important role in the patho- 
genesis of acute ischemic syndromes by weakening fibrous cap of plaques 
and leading to plaque rupture. Previous ex-vivo studies have shown that 
there is temperature (T) heterogeneity in carotid atherosclerotic plaques. 
However, thermal heterogeneity of coronary or pedpheral arteries has not 
been investigated in vivo. 
Methods: For this purpose, we designed and developed a 3F thermog- 
raphy catheter which has at its distal end a thermistor (Th, accuracy: 0.05 
-°C; time constant: 300 msec, spatial resolution 0.5 ram, fig. A). By virtue of 
a hydrofoil (HF), the bloodstream drives the Th against the wall (fig. B). This 
was vedfied in in-vitro studies with donor blood circulating in a coronary glass 
model at vadous combinations of pressure (Millar catheter) and flow (Flowire). 
Efficacy and safety of the catheter was tested in 12 non-atherosclerotic pigs 
(LAD: 6, LCx: 3, RCA: 3) 
Results: In all cases, the catheter could be inserted over a standard 
guidewire (GW, rapid exchange system) and positioned easily and without 
complications in the coronary arteries. Coronary wall measurements in each 
animal were constant varying by only 0.05 ~C (range of SD: 0-0.0258 -°C). 
After each procedure, no thrombi were observed on the catheter. No embolic 
events were observed in any animal. Scanning electron microscopy disclosed 
neither thrombus formation nor endothelial denudation of the artedal surface. 
Light microscopy revealed no internal elastic lamina or deep wall damage. 
HF 
Conclusions: This new catheter-based technique is suitable for detecting 
thermal heterogeneity of coronary or peripheral arteries in vivo and may prove 
useful for predicting plaque rupture or thrombosis. 
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Angioscopic Evaluation Coronary m 
J Lesions by Staining with Evans Blue in Patients 
with Acute Myocardial Infarction 
Yoshiharu Fujimod, Hiroshi Merle, Katsumi Yamada, Kuniko Terasawa, 
Osamu Hasegawa, Akira Matsuo, Masaaki Osegawa, Yasumi Uchida. 
Narita Redcross Hospital, Toho University Sakura Hospital, Chiba, Japan 
Background: Plaque disruption plays an important role in onset of acute 
myocardial infarction (AMI). It is necessary to evaluate details of the cul- 
pdt lesions, especially endothelial damages of the plaques which initiate 
thrombus formation. 
Methods: We angioscopicaly observed the culprit lesions in 14 patients 
with AMI before treatment. Observation was repeated before and immediately 
after intracoronary staining with 1 ml of 2% Evans blue solution. 
Results: Seven of 9 intimal flaps observed were stained with Evans blue. 
Of 6 ulcers observed, only one ulcer was stained partially, and other 5 were 
not stained. Thrombi were observed in 10 lesions, and were not stained. In 
the segments proximal to the lesions, stained luminal surfaces were observed 
in 8 patients, which were attributable to mechanical injury by guide wire or 
angioscope insertion. 
Conclusion: Angioecopic observation by staining with Evans blue cleady 
revealed endothelial damages at the site of coronary plaque disruption in 
patients with AMI. This may be the first report on dye staining angioscopy of 
endothelial lesions in patients. 
1131-135 ~ Distribution of Atherosclerosis in Human 
Coronary Arteries in Dependence of High and 
Low Shear Stress Zones 
Allen Jeremias, Heike Huegel, David P. Lee, Andreas Wolf, Alan C. Young, 
Paul G. Yock, Peter J. Fitzgerald. Stanford University Mec/ica/Center, 
Stanford, CA, USA 
Background: In non-branching vessel segments, atherosclerotic plaque de- 
position is spatially related to regions of low shear stress associated with 
laminar flow conditions. 
Methods: We studied 30 consecutive patients pre-intervention using in- 
travascular ultrasound and measured vessel area (VA), lumen area (LA) and 
plaque area (PA = VA - LA) during motorized pullback at 1 mm intervals. 
Only vessel segments not within 5 mm of a branch were chosen for analysis. 
Atherosclerotic plaques were classified to be either concentric or eccentdc. 
All eccentric plaques were further divided with respect to their spatial ori- 
entation in the vessel into quadrants: myocardial (inner curve, lower shear 
stress), epicardial (outer curve, higher shear stress) and lateral (2 quadrants 
intermediate) based on perivascular landmarks. 
Results: A total of 857 cross sections were analyzed in 14 LAD, 10 RCA 
and 6 LCX arteries. Plaque distribution was concentric in 412 and eccentric 
in 446 cross sections. PA was significantly larger for concentric than for 
eccentdc plaques (7.48 ~ 3.97 mm 2 vs. 6.9 J~ 3.68 mm 2, p = 0.01). Of all 
eccentric plaques, 264 cross sections were oriented towards the myocardial 
side (59.2%) compared to only 94 towards the epicardial side (21.1%) and 
88 in the 2 lateral quadrants (19.7%, p < 0.001 by Chi-Square analysis). No 
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difference in PA (6.93 4- 3.93 mm 2 vs. 6.68 4- 2.72 mm2), plaque-angle (123.4 
4- 50.3 ~ vs. 124.6 4- 49.6~), plaque depth (1.17 4- 0.5 mm vs. 1.2 4- 0.43 mm) 
or plaque type was noted between myocardial or epicardial plaques. 
Conclusion: These results suggest that atherosclerotic plaques develop 
more frequently at the myocardial side (inner curve) of the vessel wall in 
areas of lower shear stress. However, plaque size and plaque consistency is 
similar on the epicardial and myocardial side. 
1-136]  Does Single Vessel Intravascular Ultrasound 1 31 
Imaging Adequately Reflect the Prevalence and 
Severity of Transplant Vasculopathy? 
Samir R. Kapadia, Khaled M. Ziada, Volkan Ozduran, William A. Magyar, 
James B. Young, Randall E. Starling, Steven E. Nissen, E. Murat Tuzcu. 
The Cleveland Clinic Foundation, Cleveland OH, USA 
Background: Studies of transplant vasculopathy have considered single 
vessel intravasoular ultrasound (IVUS) to represent disease in the entire 
coronary tree. However, this methodology has not been rigorously tested. 
Methods: Cardiac transplant recipients (n = 111) were studied using 
IVUS at baseline (within 2 months), and again at 1, 2 and 3 years after 
transplantation, attempting to image all three coronary arteries. In each 
imaged CASS segment, the site with the greatest intimal thickening was 
selected for measurement. A lesion defined as a site with maximal intimal 
thickness (Pmax) _> 0.5 mm. A donor lesions was defined as a site with Pmax 
>_ 0.5 mm at baseline exam. Lesions identified at follow-up exam occurring 
at a previously normal sites were defined as de novo lesions. 
Results: Due to technical considerations, one or two vessels were imaged 
in some patients. The prevalence of donor atherosclerosis (42-55%) was 
slightly higher when more vessels were imaged, but did not reach statistical 
significance. However, the incidence of de novo vasculopathy was strongly 
influenced by the number of vessels imaged, increasing from 39% when 
a single vessel was examined, to 53% when two vessels were imaged, 
reaching 74% when all three coronaries were examined. 
Artedes n Donor Disease De novo Disease (1-3 years) 
Imaged Abnormal Abnormal 
1 31 13 (42%) 12 (39%) 
2 49 26 (53%) 26 (53%) 
3 31 17 (55%) 23 (74%) 
Conclusions: Donor atherosclerosis can be adequately sampled by 
imaging one vessel (LAD) with intravascular ultrasound within two months 
following transplantation. However, to optimally describe the development 
of transplant vasculopathy, three vessel imaging is required for maximum 
accuracy. 
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~-~- ]  Results of Coronary Stenting with Expanded 
Indications 
Nobuyuki Kobayashi, Leo Finci, Massimo Ferraro, Joseph DeGregorio, 
Remo Albiero, Lucia di Francesco, Carlo Di Mar±o, Antonio Colombo. 
Centro Cuore Columbus, Milan, Italy 
Coronary stenting has become an accepted treatment modality for selected 
indications, in clinical practice indications expanded significant±y. 
Methods: Coronary stents were implanted in five groups of pts for ex- 
panded indications: non protected left main coronary lesions (LM), calcified 
lesions (C), small vessels < 3 mm (S), vessels > 3 mm with diffuse dis- 
ease (D; > 3 ram), vessels _< 3 mm with diffuse disease (D-s), bifurcation 
LM C S D>3 D-s B-B B-S 
n 36 256 896 237 196 45 91 
Multiple St % 17 38 33 54 44 100 52 
Acute event % 11 8 5 3.6 6.6 2 0 
SST % 0 1.3 1.1 0.8 1.4 3.2 0 
Restenosis % 14 27 28 28 42' 42" 29 
Loss index 0.31 0.51 0.55 0.53 0.61 0.69 0.43 
± 0.2 9- 0.4 9- 0.4 9- 0.5 ± 0.4 ± 0.4 ± 0.3 
MACE % at 6 months 41 43 39 34 43 62* 37 
"p < 0.01; SST = subacute stent thrombosis 
lesion with stents in both branches (BB) or in only a single branch (BS). The 
immediate and long term results were analyzed. The primary success rate 
(95-99%) and complication rate (0-2.9%) were comparable in all groups. 
The table shows global results. 
Conclusions: Coronary stenting is feasible in expanded indications with 
acceptable long term results except for bifurcation lesion with stents in both 
branches. Restenosis after coronary stenting is the major problem in all ex- 
panded indications, and is particularly high in small vessels with long lesions 
and in bifurcations stented in both branches treated with stents implanta- 
tion in both branches. These finding may help to guide stent implantation in 
clinical practice. 
10:45 a.m. 
r~-~ Stent Implantation in Small Vessels Using 
Ultrasound Guided Implantation: Comparison of 
Late Outcome of LAD and Non-LAD Lesions 
Steven R. Bailey, R. Stefan Kiesz, Thomas J. Linnemeier, Geraldine 
M. Cooper-Reade, David K. Roberts III, Frederick G. St. Goar, Gregg Stone. 
University of Texas Health Science Center, San Antonio, TX; Washington 
Hospital Center, Washington, D.C., USA 
Recent retrospective reports suggest that LAD stent implantation in small 
vessels is associated with an increased risk of in-hospital and late clinical 
events. This finding has not been verified in a prospective study. 
Methods: We prospectively evaluated 202 patients enrolled in a con- 
trolled study of stent implantation with intravascular ultrasound guidance in 
vessels _< 2.75 mm in diameter. Follow-up was available at 6 months in 
179 patients. Cinefilms and IVUS were analyzed at an independent core lab 
(Stanford). 
Results: The population was analyzed as Lad (n = 82) and Non-lad 
{Nlad} (n = 97). The age for both groups was similar 60.1 i 11.5 years. 
The incidence of diabetes, hyptn, smoking and class 3-4 angina were also 
similar in both groups. There were 12% females included in both groups. 
The incidence of prior myocardial infarction (24.7% vs 42.6% P < 0.01) as 
well as prior ptca (30.1% vs 44.0% P = 0.059) were higher in NLAD. The 
angiographic variables were the same except for smaller reference vessels 
in Lad (2.72 ± mm 2 vs 44.0% P = 0.059) and smaller measured balloon 
diameters during stent expansion (2.69 + 0.44 mm 2 vs 2.83 +, 51 mm 2 P < 
0.006). In hospital clinical events included only one SAT (Lad) and overall 
complications were equally low (8.7% vs 6.6%). Late clinical events were 
events (Lad 0, Nlad 2.4%), CABG (Lad 2.9% vs 3.1%), MI (Lad 0.59% vs 
Nlad t .8%) and TVR (Lad 4.2% vs Nlad 5.4%). Cumulative events were Lad 
8.6% vs Nlad 6.1%. 
Conclusions: Stent implantation in small vessels when guided by IVUS 
has a low acute and late complication rate. Despite smaller vessel size 
the Lad was not associated with an increased rate of in hospital or late 
complications with a low TVR. These findings will be correlated with the late 
angiographic findings. 
11:00 a.m. 
~3~ Bail-Out Stenting in Small Vessels: Preliminary 
In-Hospital Results of the ULTRA Acute or 
Threatened Closure Registry 
Adam B. Greenbaum, Jeffrey J. Popma, Charles D. O'Shaugnessy, J. 
Tift Mann, James G. Hoff, David A. Cox, Laura H. Gardner, Azin Parhizgar, 
James P. Zidar. For the ULTRA Investigators," Duke Clinical Research 
Institute, Durham, NC, USA 
Background: A multicenter egistry was designed to evaluate the AVE GFX TM 
2.5 mm stent for acute or threatened closure after percutaneous revascular- 
ization, where options remain limited in vessels < 2.7 mm. 
Methods: Two hundred patients with chest pain, ECG changes, resid- 
ual stenosis _>50%, NHLBI type B-F dissections < 24 mm length or TIMI 
grade 0-2 flow after initial PTCR in 2.2-2.7 mm diameter vessels, were 
eligible. Primary endpoints were acute success and 30-day incidence of 
death, Q-wave MI and target lesion revascularization. Secondary endpoints 
included angiographic measures and late cardiac events. 
Results: In-hospital results of the first 50 patients follow: median age 
65, 59% male, 39% diabetic, 67% hyperlipidemic, 43% prior MI, 43% prior 
PTCA, 65% class III or IV angina, 41% multivessel disease, 39% class B2 
and C lesions. Stents were successfully deployed in 95.5% of patients (mean 
deployment pressure 9.8 4- 2.5 arm) with 100% procedure success. Acute 
Pre-Enrollment Pre-Stent Post-Stent 
Mean RVD* (mm) 2.27 ± 0.32 2.35 ± 0.36 2.37 9- 0.32 
Mean MLD 1 (mm) 0.81 ± 0.32 1.38 ± 0.31 2.14 ± 0.29 
Mean Stenosis (%) 63.6 ± 15.5 39.8 ± 16.3 8.75 ± 13.4 
*RVD = reference vessel diameter tMLD = minimal umen diameter 
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gain was 1.33 -l- 0.41 mm (see table); 6% of patients had residual dissection. 
There were no deaths, Q-wave MIs or TLR post procedure. Adverse events 
included stroke (2%) and NQWMI (4%). 
Conclusion: For acute or threatened closure, bail-out stenting with the 
GFX TM 2.5 mm stent resulted in high success and excellent angiographic 
outcome with minimal complications. 
11:15 a.m. 
~-~ Procedural Results and Late Clinical Outcomes 
Following Percutaneous Interventions Using Long 
(-->25 ram) Stents 
Ran Komowski, Roxana Mehran, Alexandra J. Lansky, Shmuel Fuchs, 
Lowell F. Satler, Bryan Curry, Augusto D. Pichard, Kenneth M Kent, 
Ann Greenberg, Martin B. Leon. Washington Hospital Center, Washington 
DC, USA 
Background: The use of long slotted-tube stents has been recently approved 
in U.S. to treat long lesions or dissections. Procedural results and long-term 
outcomes using long vs. short stents have not been established. 
Methods: We evaluated procedural success, major in-hospital compli- 
cations, repeat revasculadzation and clinical outcomes @ 6 mos in 1,045 
consecutive patients (1,072 native coronary lesions) who underwent a single 
vessel intervention using a single long (>_25 mm) or short (<20 mm) tubu- 
lar-slotted stent. Patients treated with long stents had more diffuse (> 10 mm 
length) lesions (64% vs 29%, p < 0.01). 
Results: (Table) 
Long (71) Short (974) P 
Procedure success (%) 95.8 98.8 0.07 
In-hospital MACE (%) 4.2 1.2 0.07 
Stent hrombossis (%) 1.4 0.8 0.59 
Non-Q MI (CK-MB >_ 5 nl) (%) 21.7 8.4 0.001 
Death/MI (6 mos) (%) 0/0 1.3/0.2 0.33/0.70 
TLR (6 rnos) (%) 11.6 9.8 0.53 
Event-free survival (6 mos) (%) 88.6 88.7 0.94 
The mean stent length and final minimal lumen diameter (long vs shod) 
was 28 + 5 vs 15 :~ 2 mm (p < 0.001) and 19 :E 11 vs 9 ± 15% (p = 
0.007), respectively. Importantly, target lesion revascularization did not vary 
significantly among different stent to lesion length ratios (p = 0.88). 
Conclusions: The use of single coronary long (>_25 ram) vs. short stents 
is associated with 1) somewhat increased major procedural complications, 
2) significantly higher frequency of peri-procedural non-Q wave MIs, and 3) 
equivalent repeat revasculadzation risk and event-free survival. 
11:30 a,m. 
~-~- - ]  Stent ing for Long Lesion With Long GFX Stent 
Yoshihisa Nakagawa, Kunio Yufu, Takashi Tamura, Hiroyoshi Yokoi, 
Takeshi Kimura, Naoya Hamasaki, Hideyuki Nosaka, Masakiyo Nobuyoshi. 
Kokura Memorial Hospital, Kitakyushu, Japan 
Coronary stenting has been shown to be effective in reducing late resteno- 
sis in stent ideal lesions (shod stenosis with large reference). But in long 
lesions, the stent efficacy has not proven and follow-up data are lacking. 
AVE GFX stent is one of the second generation stents, and long stents are 
available. To identify restenosis rate of long stent, angiographic follow-up 
study was prospectively performed. All cinefilms were measured with QCA 
system (CASS II). From Dec. 1996 to Feb. 1998, GFX stent implantation was 
attempted in 151 lesions. Procedure success was 146/151 = 97%. Delivery 
failure of GFX stent was occurred in 3 lesions (2%). In 6 lesions, GFX stent 
was successfully delivered and implanted after delivery failure of other types 
of stent. Procedural and follow-up data are shown as follows. 
Stent length, rnm all 12 or 18 24 30 
n 146 64 56 26 
Success rate 97 97 96 96 
Lesion length, rnm 17.1 ± 9.1 12.5 ± 5.0 21.5 ± 9.7"* 24.0 ± 10.9"" 
Reference, mm 2.78 ± 0.59 2.89 ± 0.54 2.86 ± 0.59** 2.43 ± 0.61"" 
Pre MLD. mm 0.85 ± 0.44 0.99 ± 0.40 0.78 4- 0.46 0.64 ± 0.42 
Pre % DS 69±15 65±12 72±16" 73±17" 
Post MLD 2.50 ± 0.40 2.49 ± 0.36 2.56 ± 0.47 2.38 ± 0.28 
Post % DS 18~9 19±9 18±8 17±8 
Follow-up MLD 1.60 ± 0.60 1.76 ± 0.60 1.51 ± 0.62" 1.38 ± 0.41" 
Follow-up % DS 44:1:17 39 :1 :16  47±19" 48±12" 
Restenosis (%DS >_ 50) 32.2% 23.4% 35.7% 46.2%" 
TLR 20.5% 14.1% 21.4% 34.6% °
"p = 0.05, "*p = 0.01 "'*p = 0.001 compared to 12 or 18 mm. 
In conclusion; 1) Long lesions are linked with small vessels compared to 
short lesions. 2) Long AVE stent can be delivered and implanted with high 
success rate. 3) Long stents in long lesions shows significantly high resteno- 
sis rate compared to short stent. 4) 30 mm length stent shows significantly 
high restenosis and TLR rate. 
11:45 a.m. 
[ 84-8-~-6 Modi f ied "T" Stenting Technique for Kissing Stents 
in Bifurcational Coronary Lesions: Clinical 
Feasibility and Immediate Angiographic Results 
Imad Sheiban, Federica Marsico, Paolo Pagnotta, Mattec Montorrano, 
Angelo Anzuini, Giuseppe Rosano, Piersergio Sabe, Carlo Di Mario, 
Antonio Colombo, Sergio L. Chierchia. Interventional Cardiology Unit, Dep. 
of Cardiology, IRCCS H San Raffaele, Milano, Italy 
Coronary angioplasty (PTCA) of bifurcation lesions (BL) is often complicated 
by plaque shifting or side branch occlusion. A modified "T" stenting approach 
for BL treatment was assessed in 38 consecutive patients (pts) (31 males, 7 
females, aged 48--73 years) with BL who underwent PTCA in our laboratory 
over a 9 month period. BL were sited on the LAD- 1st Diagonal in 25 pts, 
on LCX -1st marginal in 10 pts and on protected Left main in 3 pts. Two 
guide wires were placed in the main vessel and side branch. An adequate 
predilatation was performed by the kissing balloon technique in all pts. A 
stent was then implanted in the side branch with a simultaneous inflation of 
a second balloon in the main vessel to match the proximal edge and to avoid 
profusion in the main vessel of the side branch stent. Thereafter, the guide 
wire and the balloon were removed from the side branch and the procedure 
was completed by stent deployment in the main vessel, adding on to the side 
branch stent in a "T" configuration. A primary success was obtained in 37 pts 
(97%) with an optimal angiographic result in 33 pts (86.8%). In 5 pts a "gap" 
was present between the stents in the side branch and in the main vessel. 
This was mainly due to inadequate deployment or excessive shortening of 
the side branch stent. In 1 of these patients the side branch stent which was 
occluded following stent deployment in the main vessel and was reopened 
through the main stent struts. A total of 94 stents with diameters varying 
from 3 to 4 mm were deployed (2.5 stent/pt). No major periprccedural or 
in-hospital complications occurred. 
In conclusion; these data show that this modified "T" stenting technique 
is safe and feasible. It could shorten the procedure time and enable a more 
precise matching of the stent to the ostium of the side branch avoiding 
stent protrusion in the main vessel; at the same time it conserves all the 
advantages of the classic "T" technique with more security to deploy both 
side branch and main vessel stents. 
ORAL  
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~--~-~ Abciximab Reduces Vascular Lesion Formation in 
Non-Human Primates 
Moniqus M. Marijianowski, Marian T. Nakada, Birgitta I. Sundell, Andrew 
B, Kelly, Robed E. Jordan, Joseph A. Jakubowski, Nicolas A.F. Chronos, 
Stephen R. Hanson. Emory Universi~ Atlanta GA, USA 
Background: Thrombosis and restenosis complicate interventional proce- 
dures for arterial revascularization and repair. The monoclonai antibody ab- 
ciximab (c7E3 Fab, ReoPro TM) against platelet glycoprotein lib/Ilia (~llbfl3) 
has been shown to reduce thrombo-occlusive events. Abciximab also tar- 
gets the vitronectin receptor (c~v/33) and inhibits platelet-mediated thrombin 
generation, clot retraction, smooth muscle cell migration and proliferation. 
Methods: To evaluate the effect of abciximab after vascular injury in 
primates, 17 baboons underwent femoral artery balloon angioplasty, Ten an- 
imals received a bolus injection of 400/zg/kg abciximab and a 0.3/~g/kg/min 
infusion for 48 hours (n = 3) or a 0.9 #g/kg/min infusion for 5 days (n = 7). 
The remaining 7 animals served as controls. All vessels were harvested at 
30 days. 
Results: During the infusion of abciximab at either dose, platelet GP 
lib/Ilia receptor occupancy by the antibody exceeded 85%. Correspondingly, 
ADP-induced platelet aggregation was abolished. However, only the higher 
infusion rate of abciximab (0.9/~g/kg/min) maintained plasma levels > 400 
ng/ml which, based on functional in vitro assays, would be expected to effec- 
tively inhibit ~v/33-mediated pathways. Morphometdc analysis showed that 
neointima formation was reduced in a dose-dependent fashion. Neointimal 
area was reduced minimally (by 18%; p = 0.42) by the lower dose regimen 
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of antibody, and was reduced significantly (by 43%; p = 0.006) following the 
higher dose regimen. The corresponding reductions in the neointima/media 
ratio were 11% (p = 0.59) and 39% (p = 0.009), respectively. 
Conclusion: This study documents that 5 days of treatment with abcix- 
imab, at a dose which effectively blocks both ~llbp3 and c~v,83, significantly 
reduces neointimal lesion size at one month following balloon angioplasty in 
primates. These results support the view that in addition to reducing acute 
thrombotic events, early therapy with abciximab also inhibits pathways lead- 
ing to the intimal proliferation of vascular smooth muscle cells. 
10:45 a.m. 
[ ~  Dose Rate Mediated Vascular Remodeling of Porcine 
Coronary Arteries Following Intracoronary 
/3-Radiation 
Grzegorz L. Kaluza, John M Buergler, Daryl G. Schulz, Albert E. Raizner, 
Nadir M. All. Baylor College of Medicine, The Methodist Hospital and VA 
Medical Center, Houston, TX, USA 
Background: The optimal dose rate of Intracoronary/~-Radiation (ICR) for 
prevention of coronary restenosis has been defined as <50 cGy/s based on 
preliminary evidence that higher dose rates promote neointimal formation 
and unfavorable vascular remodeling (VR). These observations were based 
on sub-optimal total radiation dose of < 1900 cGy to advent±tin. However, the 
effect of dose rate > 50 cGy/sec on lumen and external elastic lamina (EEL) 
areas at optimal adventitial doses has not been evaluated. 
Methods and Results: We subjected 45 pig coronary artedes to balloon 
injury alone or followed by ICR with a centered 32-P source at dose rates 
of 25, 75 or 125 cGy/s. The total dose at all dose rates was 3500 cGy to 
advent±tin. At 4 weeks coronary arteries were harvested for morphometry. 
The lumen and EEL areas of the injured, proximal (P) and distal (D) reference 
segments were measured. In order to normalize for vessel size, the mean 
lumen and EEL areas in the injured segment were divided by the average of 
the P and D reference lumen and EEL areas (table). 
Control 25 cGy/s 75 cGy/s 125 cGy/s 
Injury Lumen 1.63 i 0.09 2.01 ± 0.23* 2.67 ± 0.21" 2.99 ± 0.23* 
Injury EEL 2.79 ± 0.12 3.17 ± 0.24* 3.73 ± 0.25* 4.22 ± 0.24" 
Mean Ref. Lumen 1.81±0.12 1.44±0.12 217±0.14 1.85±0.09 
Mean Ref. EEL 2.64±0.15 2.15±1.18 2.93±0.14 2.55±0.17 
Normalized Lumen 0.93 ± 0.06 1.51 ± 0.29" 1.30 ± 0.15 1.62 ± 0.12* 
Normalized EEL 1.08 ± 0.05 1.59 & 0.26" 1.30 ± 0.10 1.67 i 0.07* 
"p < 0.05 vs control by ANOVA, values are mean &. SE 
Conclusions: The study demonstrates favorable VR effect with higher 
dose rates of ICR when optimal dose is delivered to the advent±tin. The 
favorable effects of ICR at dose rates > 125 cGy/sec may facilitate the clinical 
application of/~-radiation by shortening treatment time while maintaining or 
possibly improving efficacy. 
11:00 a.rn, 
~ ]  Locally Delivered Adenovirus Stimulates Neointimal 
Formation and Negates the Potential Benefit of 
Adenovirus Hirudin Construct in a Rabbit Arterial 
injury Model 
Gregory G. Bishop, Pete Wiegman, Coteen McNamara, Salah Din, 
John Sanders, Mike Feldman, John A. McPherson, John E. Humphries, 
Marie-Louise Hammarskjold, Lawrence W. Gimple, Michael Ragosta, Eric 
R. Powers, David Dichek 1 , Gary K. Owens, Inn J. Sarembock. University of 
Virginia, Charlottesville, VA; 1 Gladstone Institute of Cardiovascular Disease, 
San Francisco, CA, USA 
tt is unclear if the present generation adenovirus can effectively serve as a 
vector for transgenes to limit restenosis. In the rabbit, local arterial delivery of 
an adenovirus elicits an exuberant inflammatory response. Also in the rabbit, 
prolonged thrombin inhibition with systemic hirudin is additive to early hirudin 
administration in attenuating restenosis. To determine if the inflammatory 
response elicited by the adenovirus would negate the potential benefit of a 
therapeutic transgene, we hypothesized that prolonged thrombin inhibition 
via locally delivered adenovirus-hirudin construct (Ad-Hir) plus early systemic 
hirudin (EH) would limit the arterial response to BA compared to EH alone 
in the cholesterol fed rabbit. Vessel wall thrombin activity measured by 
fibrinopeptide A generation was reduced by 79% at 48 hrs after BA in the 
Ad-Hir group compared with vehicle (4.90 ± 4.27 vs. 20.0 ± 15.3 ng/mg 
tissue, p = 0.05). Subsequent rabbits underwent femoral BA and received 
either EH + Ad-Hir (n = 9), EH + adenovirus-galactosidase (EH + Ad-Gal) (n 
= 7), EH + vehicle (EH + Veh) (n = 10), or EH alone (n = 9). There was a 
significant increase in plaque area (mm 2) in the EH + Ad-Hir (0.7t ± 0.34) 
and EH + Ad-Gal (0~75 ± 0.26) versus EH + Veh (0.48 :}: 0.10) or EH (0.28 ± 
0.22) treated arteries, (p < 0.05). Cross sectional area narrowing by plaque 
(CSAN-P) and T cell infiltration were increased in the adenovirus treated 
arteries and CSAN-P correlated with T cell density (r = 0.62, p < 0.01). In 
summary, thrombin activity was significantly suppressed in the vessel wall 
48 hrs after BA via local transduction with Ad-Hir. However this strategy 
increased rather than decreased neointimal growth at 28 days. Our results 
suggest that this adverse effect resulted from an inflammatory response 
elicited by the adenovirus vector. 
11:15 a.m. 
~-~ Increased Collagen Synthesis and Content in 
Stented Versus Balloon Treated Arteries 
Warren. J. Cantor, Chris W. Li, Ranga Robinson, John N. Wylie, Alan 
W. Barolet, Winston Tsui, Chris Mar, Bradley H. Strauss. St. Michael's 
Hospital, Toronto, Canada 
Although balloon angioplasty (BA) upregulates arterial wall collagen syn- 
thesis and collagen content, it is unclear which layers of the vessel wall 
are involved. Furthermore, the collagen response after arterial stenting has 
not been studied. We studied collagen synthesis and content in the various 
layers of the vessel wall after stenting and BA. In a double-injury model in 
normocholesterolemic rabbits, adjacent lilac arteries underwent BA (3.0 mm) 
or stent placement (Nir, 3.0 mm × 16 mm). Animals were sacrificed at 1 (n = 
5) and 10 weeks (n = 15). The intima was separated from the medial-adven- 
titial layer. These were incubated ex-vivo in C14-proline containing medium 
for 6 hours. Collagen content (14g OHprol) and synthesis (cpm/segment) 
(mean ± SEM) were determined by assays for C14-OHproline and total 
hydroxyproline, respectively. 
Collagen intima med/adv intima med/adv 
synthesis 1 wk 1 wk 10 wk 10 wk 
BA 963 ± 610 906 ± 349* 155 ± 46' 384 ± 96" 
STENT 1638 ± 421 3390 ± 865 472 ± 137 818 ± 123 
Total intima med/adv intima med/adv 
collagen 1 wk 1 wk 10 wk 10 wk 
BA 29 ± 9 158 ± 41" 46 ± 7" 184 ± 22" 
STENT 36 ± 6 280 ± 28 105 ± 10 389 ± 50 
(*p < 0.05 Stent versus BA) 
Stenting significantly increases collagen synthesis (2-3 folds) and content 
(2 folds) at I and 10 weeks compared to balloon angioplasty. This effect is 
present in both the intima and media-adventitial layers. 
11:30 a.m. 
~ - ]  Response to Balloon Injury Is Vascular Bed Specific 
Michael R Ward 1'2 Peter Kanellakis I , Debbie Ramsey 1 , Garry 
L, Jennings 1 , Alex Bobik 1 , I Baker Medical Research Institute, Melbourne, 
V/C, Australia; 2Stanford University Medical Center, Stanford CA, USA 
Background: Relative contributions of remodeling and neointimal hyperpla- 
sin to restenosis after coronary angioplasty have been inferred from studies 
using lilac and femoral arteries, despite differences in structure/function, and 
smooth muscle cell lineage. 
Methods: We compared the response of coronary arteries (C) and sim- 
ilar sized branches of the lilac arteries (I) to balloon overstretch injury using 
preinjury vessel diameter (P), inflated balloon size in vivo (B) and the man- 
ufacturer predicted inflated size (M) to examine arterial compliance, as well 
as resulting injury score (0-3; Schwartz et al JACC 1992; 19: 267) and 
morphology in perfusion fixed vessels. 
Results: Despite similar degrees of oversizing (B/P) in the coronary and 
lilac arteries (C: 1.44 ± 0.04, I: 1.51 ± 0.02), the compliance to overstretch 
(B-P/M-P) of the coronary arteries (0.70 ± 0.06, n = 16) was significantly 
greater than that of the lilacs (0.50 ± 0.03, n = 18) (P < 0.05) and was 
associated with a higher injury score (C: 1.64 ± 0.31, I: 0.39 ± 0.18 P < 
0.05): - only 5/18 iliac vessels had rupture of the IEL compared with 13/16 
in the coronary bed. In a subgroup of animals (C (n) = 8, I (n) = 7) whose 
vessels were perfusion fixed at 28 days after injury, coronary arteries had 
greater intimal area (C: 1.03 ± 0.42; I: 0.10:1:0.03 mm 2, P < 0.05) but larger 
luminal area (C: 1.61 ± 0.71; I: 0.76 ± 0.51, P < 0.05) due to less inward 
remodelling or greater area within EEL (C: 3.38 ± 0.49; I: 1.49 ± 0.54, P < 
0.05) 
Conclusions: The injuries resulting from similar degrees of vessel over- 
stretch in the coronary and the lilac arteries are different and affect healing 
responses - lilac arteries remodel more while coronary arteries develop 
more intimal hyperplasia. These results indicate caution is warranted when 
extrapolating results from the lilac to the coronary artery when investigating 
restenosis. 
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11:45  a .m.  
[~-~ Intrapericardial Apolipoprotein A'IMILANO Reduces 
Intimal and Adventitial Hyperplasia in Porcine 
Coronary Overstretch Injury Model 
Sanjay Kaul, Artin Terhakopian, Bojan Cercek, Juliana Yano, Ninet Sinaii, 
Prediman K. Shah. Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Background: We previously reported inhibition of intimal hyperplasia in 
injured rabbit artedes by systemic administration of high-dose (50 mg/kg IV) 
recombinant apolipoprotein A'IM~LANO (A-IM). In this study, we utilized a local 
perivascular drug delivery approach via the pericardial space to examine the 
effects of A-IM on luminal narrowing in a porcine coronary overstretch injury 
model. Delivery into the pericardial space provides for enhanced delivery 
efficiency while minimizing agent loss into the circulation. A bolus dose of A-IM 
complexed with a phospholipid carrier (2 mg/kg in 20 ml PBS, total amount 
of 40-50 mg per pig) and PBS control were administered intrapericardially 
(IP) via a special pericardial access device, the PerDUCER TM, prior to balloon 
injury (balloon:artery ratio = 1.3:1; n = 6 in each group). Animals were 
euthanized at day 28 following angiography and coronary arteries peffusion 
fixed and tissues prepared for hisfomorphometric analysis. Plasma A-IM 
levels were determined by ELISA. 
Results: 
Histomorphometry Data Angiography Data 
IA INFL AA Lumen Loss Stenosis 
(ram 2) (Ratio) (mm 2) (ram) (%) 
Control 1.66 J: 0.71 1.34 ± 0.51 2.51 ± 0.78 1.1 ± 0.5 35 ± 15 
Apo M 0.91 5: 0,25" 0,95 :E 0.21" 1.58 ± 0.49" 0.5 ~ 0.2* 20 J: 8" 
Mean :E SD; "P < 0.05 vs. control; IA = intimal area; FL = fracture length; AA = adventitial 
area. 
Post-injury lumen diameter was similar in both groups (2.98 ± 0.32 vs. 
2.79 ± 0.31 ram). Plasma A-IM levels peaked at day 5 (>0.1 g/ml) with 
minimal levels still detectable at sacrifice. 
Conclusion: IP delivery of low-dose A-IM significantly inhibited coronary 
luminal narrowing in the porcine balloon overstretch model through reduction 
of both intimal and adventitial hyperplasia. 
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~ Tirofiban Prevents Platelet Induced Aggregation 
by Rotational Atherectomy in an In Vitro Model 
Mark Reisman, R. Fei, David Dillard, Shellie Bogosian, Verna Harms. 
Seattle, WA, USA 
Background: Tirofiban (T), a glycoprotein lib/Ilia antagonist, was tested to 
assess its efficacy in reducing platelet aggregation (PA) induced by shear 
stress with rotational atherectomy (RA). 
Methods: Shear induced platelet aggregation was measured by optical 
microscopy after exposure of the human blood to the rotating burr in an in 
vitro artery model. 
Results: Dose response curves showed that a dose of 250 ng/ml was 
needed to achieve 90% inhibition of shear induced platelet aggregation. The 
clinically recommended dose 10 ug/kg (conc. 50-70 ng/ml) achieved a 60% 
inhibition as shown below. 
Number of Shear Induced Aggregates after RA at 180K 
Conc. T (ng/m]) 0 50 100 250 1000 
# PA 2486 1208 764 347 264 209 
Based on the dose response curve, we measured #PA using T at 65 ng/ml 
or 250 ng/ml vs. rotational speed with the following results. 
Number of Platetet Aggregates < 100 u/ml blood 
180K 180K 180K 140K 140K Control 
T = 65 T = 250 T = 250 
429 :E 2893 1142 :E 552 258 + 215 2563 ~ 1385 438 + 349 333 ± 387 
n=20 n=5 n=t0  n=5 n=5 n=20 
Conclusions: Shear induced platelet aggregation was prevented by 
tirofiban. In order to obtain maximal inhibition of platelet aggregation dur- 
ing rotational ablation a dose in excess of the recommended dose may be 
required. Potentially this could be given directly into the coronary artery per- 
haps via the flush solution during the brief intervals of rotational atherectomy. 
~ T h e  Proliferative Vessel Reaction After Stenting 
Lasts Longer Than After Ballon Angioplasty 
Christina Unterberg, Jens Stevens, Ralf Felgendreher, Marco Zilz, 
Thomas Meyer, Arnd B. Buchwald. Dept. of Cardiology, University Clinic, 
G~ttingen, Germany 
Background: While restenosis after balloon angioplesty is mainly due to 
remodelling of the whole vessel wall, neointimal proliferation is the more 
important mechanism after stenting. 
Methods: In 28 minipigs (MP) either stents (3.0 mm STE) were implanted 
in 2 coronary arteries or one coronary was dilated by a balloon (3.5 mm 
8AL). Vessel diameter amounted to 2.4 to 2.7 mm. Hearts were perfusion 
fixed after 2 days (n = 2), 3 days (n = 2), 1 week (n = 5), 2 weeks (n = 6), 
8 weeks (n = 2) and 12 weeks (n = 5). 5 slides were analyzed per segment 
[luminal area, neointima (NIN), media, adventitia (ADV)]. Proliferating cell 
nuclear antigen (PCNA) was stained by immunochemistry and is given in 
positive cells (P-POS) per mm 2. 
Results: [MW ± SD] In segments with deep injury with lacerated lamina 
elastica interna NIN (2.4 ± 0.6 mm 2) and ADV (2.6 ± 0.8 mm 2) in STE 
show a maximum after 4 weeks, similar in BAL (NIN 0.85 ± 0.28 mm 2, ADV 
0.66 :E 0.36 mm2). P-POS numbers increase after BAL and STE in NIN and 
ADV after 2 days and reach a maximum in BAL after 1 week with 167 ± 33 
P-POS/mm 2 (NIN) and 157 ± 47 P-POS/mm 2 (ADV). However, P-POS are 
increasing up to 2 weeks after STE (NIN: 601 ± 127 P-POS/mm2; ADV: 194 
± 59 P-POS/mm2). After 8 weeks, P-POS are only detectable in STE. 
Conclusion: STE results in a longer lasting active proliferative reaction 
than BAL. This can have important implications for pharmacologic strategies 
to avoid in stent-restenosis. 
~ N e w  Approaches to Evaluate Coronary 
Dissections Post Coronary Intervention: All 
Dissections Are not Malignant 
Nobuyuki Kobayashi, Joseph De Gregorio, Milena Adamian, 
Marco Vaghetti, Issam Moussa,, Nicola Corvaje, Bemhard Reimers, 
Leo Finci, Remo Albiero, Carlo Di Mario, Jeffrey Moses, Antonio Colombo. 
Centro Cuore Columbus, Milan, Italy; Lenox Hill Hospital, New York, USA 
To evaluate the acute, intermediate and long-term outcome of coronary 
dissections post percutaneous intervention we analyzed 878 consecutive 
patients with 1519 lesions treated between 6/97 and 6/98. Lesions were 
divided according to the absence (nonoD group n = 1295) or the presence 
(D group n = 224) of angiographic dissection after a successful procedure 
with TIMI 3 flow. These groups were compared for clinical outcome including 
results for the D group which had morphological or functional evaluation 
(table 1). We also sub-analyzed intravascular ultrasound (IVUS), coronary 
flow reserve (CFR) and pressure gradient (PG) data for 112 lesions in the D 
group (table 2). 
Table 1 
D Non-D D with IVUS, CFR or PG 
MACE: 1 month 0.4% 0.4% 0% 
: 6 month 1.1% 0.7% 0% 
Acute or subacute closure 1.3% 0.4% 0.9% 
Restenosis rate 32% 34%* 21%" 
TLR 15% 16% 12% 
* p < 0.05 (non-D vs D with IVUS, CFR, or PG); MACE = major adverse cardiac event 
(death, Q-MI and CABG), TLR = target lesion revascularization 
Table 2 
n = 112 
Final tVUS lumen CSA (ram 2) 107 cases 6.75 + 2.20 
Final IVUS % stenosis 44.0 • 0.13 
Mean CFR 5 cases 2.54 ± 0.20 
Mean PG (mmHg) 3 cases 0.0 + 0.0 
# 61 lesions were treated with stent; CSA = cross-sectional area 
Conclusion: The presence of an angiographic dissection with a residual 
lumen by IVUS larger than 50% of the vessel CSA is not associated with 
an increased risk of acute or subacute complications following coronary 
intervention and is associated with a lower angiographic restenosis rate on 
long-term follow-up. 
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• Coronary Perforation and Pericardial Tamponade 
Risk in the Abciximab Era 
Christopher T. Bajzer, Patrick L. Whitlow, A. Michael Lincoff, David 
J. Molitemo, Eric J. Topoi, Stephen G. Ellis. The Cleveland Clinic 
Foundation, Cleveland, Ohio, USA 
Background: Recent anecdotal experience has raised concerns about the 
incidence of coronary perforation and tamponade with the adjunctive use of 
Abciximab with coronary interventions. The perforation and tamponade risk 
with Abciximab as an adjunct to modern coronary interventional practice is 
not known. 
Methods: Between 9/1/95 and 12/31/97, 5500 patients underwent coro- 
nary interventions. Abciximab was used adjunctively in 1701 (31%) of patients 
undergoing coronary intervention. Patients were followed prospectively 1or 
periprocedural complications. 
Results: There were a total of 75 (1.36%) perforations with resultant tam- 
ponade in 18 (0.32%) patients. All patients received preprocedural aspirin. 
Average adjunctive dosage of heparin was 9400 units without Abciximab and 
4841 units with Abciximab. Of the patients with tamponade, percutaneous 
drainage of the pericardium was performed in 16 patients and/or surgical 
drainage in 11 patients. Periprocedural death occurred in 9 patients with 
perforation and/or tamponade. 
Perforations Tamponade Death 
Abciximab 25 (1.47%) 7 (0.41%) 6 (0.11%) 
No AbcixJmab 50 (1.32%) 11 (0.29%) 3 (0.05%) 
X 2 p value 0.65 0.46 0.02 
Conclusion: Modern coronary intervention with adjunctive use of Abcix- 
imab confers no significantly increased risk of coronary perforation or tam- 
ponade. Once the complication of perforation or tamponade occurs, patients 
who received Abciximab have a higher risk of death. However, the increased 
death risk may reflect intrinsic differences between the group of patients who 
received Abciximab versus those who did not receive Abciximab. 
~ Restenosis After Stent of Implantation: Impact 
Preintervention Ticlopidine and the Duration of 
Postintervention Ticlopidine Treatment 
Thomas Rau, Michael SchlLiter, Joachim Schofer, Detlef G. Mathey. Center 
for Cardiology Othmarschen, Hamburg, Germany 
The combination of ticlopidine (T, 500 mg/d) and ASS (100 mg/d) has been 
shown to reduce the incidence of subacute stent thrombosis after implan- 
tation of coronary stents. It is currently not known if pretreatment with T 
and a varying duration of postinterventional intake of T affect the resteno- 
sis rate. To address this question, we retrospectively analyzed the data of 
1261 consecutive pts who had undergone high-pressure stent implantation. 
Repeat angiographic data had been obtained from all pts within 6 months. 
In 126 pts (10%), T had been given at least 1 week before the intervention. 
Postinterventional treatment with T lasted 12 weeks in 737 pts (993 lesions; 
7/94-12/95; group 1), 6 weeks in 330 pts (445 lesions; 1/96-7/96; group 2), 
and 4 weeks in 194 pts (262 lesions; 8/96-12/96; group 3). The 3 patient 
groups were not different with regard to demographics and the degree of 
coronary heart disease. In group 1, stents exceeding 15 mm in length were 
significantly less often deployed than in groups 2 and 3. 
Results: There was no statistically significant difference between the 
restenosis rates in pts pretreated with T versus pts not pretreated with T 
(27% versus 29%, p = 0.64). The restenosis rates in the 3 groups of pts 
treated with T for different lengths of time after the intervention were also 
statisticafly not different (group 1: 29%, group 2: 29%, group 3: 25%, p = 
0.49). 
Conclusions: The restenosis rate after stent implantation is not affected 
by preinterventional treatment with T or by different durations of postinterven- 
tional treatment with "12 Postinterventional treatment with T needs not exceed 
4 weeks. 
~ Lower Re-PTCA Rates Balloon Angioplastie After 
Alone: is Optioned Stent Implantation a 
Practicable Method to Avoid the Placement of 
Stents and Therefore for Instent Restenosis? 
A.W. Frey, J. Petersen, K. Werner, H. BQttner, H-P. Bestehorn, 
H. Roskamm. Heart Center Bad Krozingen, Germany 
Background: BENESTENT and STRESS have shown that restenosis rates 
are significantly lowered after primary stent implantation. However, in clinical 
routine restenosis rates are remarkably higher because stents are usually 
used in more complex and problematic lesions. 
Methods: In the framework of an optional strategy (OS) we have deployed 
stents in 2 cases: a) if no optimal result after balloon angioplastie alone 
(POBA) could be achieved (i.e. angiographic restenosis < 25%) or b) in case 
of a severe dissection. We investigated with QCA 187 lesions (49% with 
stents) in the acute phase and in a 3 month follow up. 
Results: OS led to a higher rate of stent use in bigger vessels (POBA: 
2.9 J~ 0.6 mm, STENT:3.1 ± 0.6 mm), in longer lesions (>10 mm, 57%) and 
to better angiographic results in the acute phase. Despite of the better acute 
results in bigger vessels in particular for the POBA group, in the 3 month 
follow up the STENT group revealed the same overall % diameter stenosis 
and restenosis rates and even higher Re-PTCA rates as compared to the 
POBA group (see Table). 
Conclusion: In the 6 month follow up OS had identical QCA results for 
POBA and STENT groups and a better clinical outcome for the POBA group. 
Therefore OS seems to be a practicable solution for the optimization of PTCA 
and for the reduction of instent restenosis as a clinical problem. 
Diameter stenosis Gain in Vessel size Restenosis Re-PTCA 
[%] [%] [mm] [mm] [%] [%] 
Acute Follow up Acute Follow up Acute Follow up 
POBA 34 47 1.31 0.87 38 22 
STENT "11 45 *2.03 0.88 36 31 
p < 0.00001 
• Eptifibatide During Immediate Percutaneous 
Coronary Intervention (PCI) in the Acute Coronary 
Syndromes (ACS): Findings from the PURSUIT 
Study 
T.J. Lorenz, S. Greenberg, N.S. Kleiman, E. Boersma, M.A. Lincoff, 
R.A. Harrington, M.M. Kitt, M.L. Simoons. COR Therapeutics, Inc., South 
San Francisco, Ca., Duke Clinical Research Institute, Durham, NC, USA 
Background: Eptifibatide (E), an inhibitor of GP lib/Ilia, is effective for pa- 
tients presenting with ACS and to prevent he ischemic complications of PCI. 
Estimation of the treatment effect in the subgroup of patients who underwent 
PCI in the PURSUIT study (at a dose known to result in > 90% receptor 
occupancy) is difficult, however, because patients were not randomized to 
this procedure at baseline, crealing the possibility of selection bias. 
Methods: Selection bias was reduced by examining cohorts of patients 
undergoing PCI within the first few hours of enrollment. The composition of 
these subgroups is unlikely to have been influenced by study treatment. 
Results: 
Death/MI at 30 Days in Immediate PC1 
PCI < 2 Hours PCI <- 4 Hours PCI < 6 Hours 
N=145 N=221 N =266 
Placebo Eptifib Placebo Eptifib. Placebo Eptifib. 
16.5% 9.1% 16.1% 9.7% 15.1% 9.4% 
The cohort from PURSUIT who received E and underwent PCI immedi- 
ately (<2 hours) had a 7.4% decrease vs. placebo (relative 45% decrease) 
in death/MI at 30 days. Similar results were noted when the PURSUIT sub- 
group was progressively enlarged to include all patients who underwent PCI 
within 4 and 6 hours of enrollment (6.4% and 5.7% decreases in death/MI). 
Conclusion: This analysis suggests that among patients presenting with 
ACS who underwent PCI early in the course of their disease, therapy with E 
was associated with a beneficial effect. 
I 1157-58~ Radiodermat i t i s  Fo l lwing Coronary Angioplasty 
Hitone Tateyama, Keita Yamasaki, Masahiro Izumi, Etsuo Tsuchikane, 
Satoru Otsu}i, Tomoko Kebasyashi, Makoto Sakurai, Tohru Kobayahi, 
Nobuhisa Awata. Osaka Medical Center for Cancer and Cardiovascular 
Diseases, Osaka, Japan 
Coronary angiography using fluoroscopy and cineradiography delivers no- 
tably higher radiation doses than almost any other routine procedures expos- 
ing patients to ionizing radiation, Even higher levels of radiation may result 
from PTCA, which is a more complicated and lengthier procedure. In the 
past 2 years we have observed 10 patients who developed radiodermati- 
tis following multiple cardiac catheterization and a therapeutic interventional 
angioplasty. 
The purpose of this study is to investigate the nature and circumstances 
of these injuries and find out steps which can be taken to reduse the potential 
for such injuries. All our patients had undergone coronary angiography and 
PTCA. None of our patients mentioned any acute radiodermatitis immediately 
after the procedure. However, the time between the PTCA and the patient's 
first observation of cutaneous changes was within 1 month in our patients. 9 
patients of all had a chronic total occlusion (CTO) of RCA and skin lesions 
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in right upper back or right upper limb, the other had a CTO in LCX and 
radiodermatitis in left upper back. 
In all patients skin injuries caused by exposure to over 18 Gy X-rays 
after 2 times or more PTCAs. The cumulative radiation doses to which these 
patients were retrospectively calculated to be a mean of 45 Gy per patient, 
with a range of 18.9 to 82.5 Gy. 
Radiodermatitis is a threat in patients undergoing coronary angioplasties, 
especially that undergone PTCA in CTO of RCA and exposed of high dose 
X-rays from the same direction. These cases suggest that whenever PTCA 
in CTO of RCA is done, all interventionarist must give attention to exposure 
time and direction of X-rays. 
~ Characterization of Vascular Emission Acoustic 
During Angioplasty Using a Novel Catheter-Based 
Sensor 
Ashwin Nagaraj, John M. Fildes, Chades J. Davidson, Mike Madden, 
Jack Fagan, William Berthiaume, Lyle F. Mockros, David D. McPherson, 
Northwestern Universi~ Chicago, IL. USA 
Background: We have demonstrated that atherosclerotic (ATH) arterial tis- 
sue emits sound as it undergoes mechanical disruption. These acoustic 
emissions (AE) may distinguish helpful (plaque fracture) from harmful (arte- 
rial dissection) events during balloon angioplasty (BA). 
Purpose: To determine if a catheter-based AE sensor with signal analysis 
could separate angioplasty events. 
Methods: A ceramic piezoelectric transducer was mounted inside the 
balloon of a BA catheter. Postmortem human iliofemoral arteries (n = 13) 
exhibiting varying degrees of ATH (normal to calcified) were subjected to 
BA. The AE were amplified (150x) and digitized, and spectrograms were 
computed by applying a sliding time-window across each signal. Since events 
at angioplasty (balloon inflation, plaque fracture, medial dissection) tend to 
occur to varying degrees simultaneously, principal component (PC) analysis 
(with 6 PC, PC1-PC6) was used. Frequencies associated with the ten largest 
coefficients of the eigenvector for each PC were summed and tabulated for 
each artery. 
Results: The catheter-based sensor was able to detect sounds associ- 
ated with BA events. Two PC's, PC1 (p = 0.032) and PC2 (p = 0.038) were 
able to distinguish plaque fracture. Two PC's for the normal arteries, PC2 (p 
= 0.003) and PC5 (p = 0.026), and one for the ATH arteries, PC6 (p = 0.018), 
were able to identify dissection. These data demonstrated that different PC's 
point to different sound events that occur during BA and that this analysis can 
be used to separate out the sounds of interest from each composite sound 
signal. 
Conclusions: We have demonstrated that a catheter-based acoustic 
emission sensor with signal analysis can be used to separate normal from 
pathologic vascular injury and provides a way to monitor and optimize balloon 
angioplasty. 
~ Elimination of Excess Vascular Access Site 
Bleeding During Coronary Intervention With 
Abciximab 
James C. Blankenship, Nikki Godfrey, S. Lee Demko, Robert M. Califf, A. 
Michael Lincoff, James E. Tcheng, Eric J. Topoi. Geisinger Medical Center, 
Danville PA and Cleveland Clinic, Cleveland, Ohio, USA 
Background: Abciximab (Abc) frequently caused vascular access site (VAS) 
bleeding in initial coronary intervention trials. Since then, decreased weight- 
adjusted hepadn (WAH) dosing and VAS management protocols have been 
progressively refined. 
Methods: We compared VAS bleeding (using TIMI cdteria) in the EPIC 
(1991-92), EPILOG (1995), and EPISTENT (1996-97) tdals. 
Results: Abc produced excess major and minor VAS bleeding in EPIC, 
minor (but not major) VAS bleeding in EPILOG, and no significant excess 
bleeding (minor or major) in EPISTENT, compared to heparin-only groups 
(see Table). 
Study (abciximab and heparin protocol) ACT Major Minor 
EPIC:Abc + non-WAH + PTCA >300 7.1% 13,1% 
EPIC:non-WAH + PTCA >300 2.3% 5,9% 
EPILOG:Abc + WAH + PTCA > 300 1.3% 6.3% 
EPILOG:Abc + low-dose WAH + PTCA >200 0.7% 3.3% 
EPILOG:WAH + PTCA >300 0.7% 2.1% 
EPISTEN~Abc + low-dose WAH + PTCA >200 0.4% 2.0% 
EPISTENT:Abc + low-dose WAH + stent >200 0.5% 1.6% 
EPISTENT:WAH + stent >300 0.7% 1.0% 
Conclusions: Excess VAS bleeding associated with Abc in EPIC and 
EPILOG was eliminated in EPISTENT. VAS complications in patients with 
hepadn alone during coronary intervention have also decreased during these 
three studies. VAS management protocols, low-dose WAH, and lower target 
ACT's may be partly responsible. 
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~ Reduced for Restenosis: The Reintervention 
Major Clinical Benefit of Increased Stent Usage in 
the "Real World" 
S.J. Evans; , J.T. Stewart, MW. Webster, J.A. Ormiston, P.N. Ruygrok, 
H.D. White, B. O'Shaughnessey. ;Green Lane Hospital Auckland, New 
Zealand 
Background: In highly selected patients, randomised trials have shown that 
coronary stent implantation reduces angiographic restenosis. 
Methods: We used our angioplasty database to assess the effect of 
increasing stent usage on clinically driven reintervention rates in routine 
clinical practice from 1990 to 1997. 
Results: From 1990-94, 2188 coronary interventional procedures were 
performed; 1770 were performed between 1995 and 1997, with 672 in 1997. 
Coronary stenting increased from 0.7% of interventional procedures in 1992 
to 13% in 1994, 33% in 1995, 55% in 1996 and 79% in 1997. From 1990-94, 
23% of interventions were performed for symptomatic restenosis, compared 
with 16% from 1995-97 (p < 0.001, x 2 test). In 1997 only 12% of interven- 
tional procedures were for restenosis, but of these 43 (68%) had "in-stent" 
restenosis. 
Conclusions: The use of stents at Green Lane hospital has increased 
markedly in recent years while both the need for urgent CABG and the propor- 
tion of patients returning for clinical restenosis has fallen progressively. There 
is growing concern about the problem of "in-stent" restenosis with increasing 
stent use. However, numerically the incidence of "in-stent" restenosis is small 
and is offset by the dramatic reduction in the need for reintervention overall 
that accompanies liberal stent use. 
• Influence of Residual Stenosis After PTCA and 
Stent Implantation on Stent Thrombosis Rate and 
Restenosis Rate 
Peter Sick, Tobias H0ttl, Matthias Gutting, Tanja Ostertag-Fiehn, 
Bemward Lauer, Rainer Hambrecht, Gerhard Schuler. University of Leipzig, 
Heart Center; Leipzig, Germany 
Background: One of the strategies employed to minimize restenosis after 
stent implantation was moderate overdilatation (balloon/vessel ratio > 1.0) 
resulting in a "negative residual stenosis" (group 1 and 2). The purpose of 
this study was to assess the effect of this strategy on late lumen loss at 6 
months and the incidence of stent thrombosis. 
Methods: In 538 patients with 598 stenosis, late lumen loss, defined as 
minimal lumen diameter (MLD) immediately after implantation of a single 
stent minus MLD at follow up at 6 months was analyzed by QCA 
Results: 
Group 1 2 3 4 
Residual stenosis >_ -15% -15% - 0% 0% - + 15% +15% - +30% 
Restenosis rate 36.9% 25.9% 27.9% 25.2% 
Late lumen loss 1.65 ~- 0.94 1.23 - Off 1.08 ! 0.88" 0.8 :L 0.83" 
Stentthrombosis rate 0 0.08% 2% 2.9% 
Conclusions: In this prospective study oversizing of stents was associ- 
ated with a significant increase of late lumen loss. The relative restenosis rate 
and the incidence of stent thrombosis were similar in all groups. Therefore 
the results of this study do not support the concept of overdilatation with the 
aim of preventing restenosis. 
~ Restenosis After of Occluded Versus Stenting 
Nonoccluded Coronary Lesions: A Matched 
Comparison 
Thomas Rau, Joachim Schofer, Michael SchhJter, Detlef G. Mathey. Center 
for Cardiology Othmarschen, Hamburg, Germany 
It is not known whether the higher restenosis rates found after balloon 
}> 
#3 m 
u} 
(.D 
U 
(.9 
l 
74A ABSTRACTS - ACCIS '99 JACC February 1999 
angioplasty of occluded as opposed to nonocctuded coronary arteries are 
still present after placement of coronary stents in lesions matched for factors 
known to affect angiographic outcome. In a retrospective analysis of 1032 
patients who had undergone coronary stent placement and in whom 6-month 
angiographic follow-up was available, we identified 148 patients with a total 
coronary occlusion (O) which matched a nonoccluded coronary lesion (NO) 
in another 148 patients. Lesion pairs matched with respect to patient gender 
and history of diabetes, lesion type (de novo or restenotic), type of stent, 
target vessel, reference vessel diameter (± 0.3 mm), and stented vessel 
segment length (~ 8 mm). 
Results: After stenting, statistically identical minimum lumen diameters 
(MLDs) had been achieved in both groups (O: 2.74 ± 0.35 mm, NO: 2.77 
± 0.32 mm, p = 0.45). At follow-up, MLDs were not different (O: 1.65 :E 
0.77 mm, NO: 1.73 ± 0.78 mm, p = 0.29), reflecting an identical late loss 
for occlusions and nonoccluded lesions. Because of the significantly larger 
acute lumen gain, loss index was significantly lower for occluded vessels 
(0.40 ± 0.27 versus 0.53 ± 0.38, p = 0.003). Corresponding restenosis rates 
were 32% (O) and 29% (NO; p = 0.40). The lack of difference in restenosis 
rates persisted in subgroups obtained by dichotomizing MLD post-stenting, 
reference vessel diameter, balloon/vessel ratio at final stent expansion, and 
stented vessel segment length at the group medians of 2.75 mm, 2.75 mm, 
1.13, and 18 ram, respectively. For stented vessel segment lengths > 18 mm, 
restenosis rates were markedly higher (O: 41%, NO: 38%) than for stented 
vessel segment lengths < t8 mm (O: 24%, NO: 23%). 
Conclusions: In O and NO coronary lesions matched for factors known 
to affect the angiographic outcome, no difference in restenosis rates was 
observed within 6 months of coronary stenting. Thus, either type of coronary 
lesion appears to exhibit the same propensity for neointimal hyperplasia. 
l l  I Effect of Negative Following 1 58-93  Residual Stenosis Stenting on Angiographic Restenosis 
Yoshio Kobayashi, Joseph De Gregorio, Nobuyuki Kobayashi, 
Marco Vaghetti, Remo Albiero, Cado Di Mar±o, Leo Finci, Antonio Colombo. 
Centro Cuore Columbus, Milan, Italy 
Background: Limited information is available on the effect of stent overdilata- 
tion (negative residual stenosis) on the incidence of angiographic restenosis. 
Methods: Between April 1993 and July 1997, 1,306 lesions with > 3 
mm reference vessel diameter underwent successful stenting. Lesions were 
divided according to the final % diameter stenosis achieved after stenting; 
1) Group with a positive residual stenosis (n = 835) defined according to the 
presence of a final % stenosis > 0 and < 30%, 2) Group with a negative 
residual stenosis (n = 471, final % stenosis < 0%). 
Positive Negative P 
Multiple stents (%) 30 29 NS 
Stent thrombosis (%) 1.1 0.6 NS 
Reference (ram) 3.47 -r 0.40 3.37 ± 0.33 <0.01 
Lesion length (mm) 12.0 ± 7.4 10.6 ± 6.1 <0.01 
Pre-MLD (mm) 0.94 ± 0.58 0.92 ± 0.53 NS 
Final MLD (mm) 3.21 ± 0.47 3.60 --_ 0.44 <0.01 
Final % stenosis 8.7 ± 6.3 -6.9 ± 5.0 <.0.01 
F/U MLD (mm) 2.21 ± 1.06 2.39 ± 0.92 0.01 
Restenosis (%) 23.5 16.2 <0.01 
MLD: minimum lumen diameter, F/U: follow-up 
Follow-up angiography was performed in 925 of the 1,288 lesions (72%) 
eligible for follow-up. 
Conclusion: Dilatation of a stent at a diameter larger than the reference 
vessel has a positive impact on restenosis rate. 
• Restenosis is not Reduced by Ant±thrombotic 
Therapy After PTCA: A Randomized Angiographic 
Follow-up Study 
All R. Garachemani, Martin Fleisch, Katja Ehrhard, Stephan Windecker, 
Bernhard Meier. Cardiology, University Hospital, Bern, Switzerland 
Background: Post-injury thrombosis and smooth muscle cell proliferation 
may play a central role in the occurrence of late restenosis after PTCA. 
Heparin inhibits both mechanisms. The purpose of the present study was 
to determine whether prolonged postprocedural ant±thrombotic therapy with 
hepadn followed by 6 month oral ant±coagulation does reduce the incidence 
of angiographic restenosis after successful PTCA. 
Methods: 196 patients with uncomplicated PTCA were randomized into 
two groups a~er consent: One group was discharged with ASA 100 mg only 
(G1) and the other group was treated with 12-24 hours of hepadn-infusion 
and oral ant±coagulation for 6 months (G2). Six month angiographic follow-up 
was obtained in 88% of both groups. 
Results: The two groups were comparable with respect to age, gender, 
coronary risk profile, and clinical presentation. Stents were implanted in 33% 
and 36% of the patients, respectively. Myocardial infarction occurred in 4% 
of the G1 patients and 3% of the G2. One patient in G1 died of subacute 
stent thrombosis (day 3). Long-term angiographic data: 
G1 G2 
Patients (Lesions) 94 (100) 102 (120) 
Reference diameter (ram) 2.8 ± 0.7 2.9 ± 0.8 
MLD (ram) 
- before 0.9 ± 0.5 0.8 ± 0.4 
- after 2.3 ± 0.5 2.4 :~ 0.6 
- 6 months 1.7 ± 0.9 1.7 ::E 0.8 
Stenosis (%) 
- before 74 ± 16 72 ± 15 
- attar 23 ~ 11 23 ± 10 
- 6 months 40 ± 29 39 ± 24 
Acute gain (ram) 1.5 ± 0.7 1.5 ± 0.6 
Late loss (mm) 0.7 ± 1.0 0.6 ~: 0.9 
Net gain (mm) 0.8 ± 0.9 0.7 ± 0.8 
Restenosis (>50%) 30% 33% 
Conclusions: Ant±thrombotic therapy with heparin infusion and oral anti- 
coagulation has no effect on the incidence of restenosis. 
J l j One Year Follow-up After Intravascular Ultrasound 
i 
1 58-95  
Guided Coronary Stenting of 2075 lesions 
Roxana Mehran, Gary S. Mintz, George Dangas, Mun K. Hong, 
Michael Paterson, Ran Kornowski, Alexandra J. Lansky, Kenneth M. Kent, 
Augusto D. Pichard, Lowell F. Satler, Gregg W. Stone, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
We report the one-year target lesion revascularization (TLR) from a consec- 
utive and unselected series of 2075 lesions in 1717 patients treated with 
intravascular ultrasound (IVUS) guided tubular-slotted or muir±cellular stent 
implantation in native coronary arteries. Important clinical, angiographic, and 
procedural characteristics were: age 62 ± 2 years, 70% men, 76% unstable 
angina, 25% diabetes mellitus (10% insulin-treated), 5% chronic renal insuffi- 
ciency, 35% LAD and 14% ostial lesion location, 3% chronic total occlusions, 
19% restenotic lesions, 50% ACC/AHA type B2/C lesions, QCA reference 
lumen diameter = 2.93 • 0.59 mm, lesion length = 12 i 7 mm, and 1.9 ± 
0.9 stents/lesion. Pre-determined IVUS endpoints were minimum lumen area 
(CSA) > 80% of the mean reference lumen area or a minimum lumen CSA 
> 7.5 mm 2. 
Results: Mean final IVUS lumen CSA was 7.7 ± 2.5 mm 2 and mean 
final QCA diameter stenosis 5.5 ± 16%. Overall one-year TLR was 13.3%. 
Importantly, in the subset of 1396 lesions (1108 patients) with an angiographic 
reference lumen diameter > 3.0 mm (which were otherwise also unselected), 
the one-year TLR was 9.7%. In contrast, the one-year TLR was 20.9% for 
lesions with a reference diameter < 3.0 mm. 
Conclusions: IVUS-guided stenting has excellent long-term clinical out- 
comes. At one year, 87% of all patients in this unselected consecutive series 
of complex patients and lesions were TLR-free. A comparative trial examin- 
ing late clinical outcomes and cost-effectiveness measures comparing IVUS 
vs. non-IVUS stenting is warranted. 
1158-96 ] Side Branch Evaluation After Stent Implantation 
P. Coussement, J. Dens, W. Desmet, J. Piessens, B. Bijnens, I. De 
Scheerder. University Hospital Gasthuisberg, Leuven, Belgium 
Background: Although deterioration and occlusion of small side branches 
in the stented segment is a common problem after stent implantation, very 
little is known about the incidence, the risk factors and the outcome. 
Methods & Results: We performed a retrospective analysis in 91 patients 
with LAD lesions, in which side branches were involved, in whom 104 coil 
stents (Freedom stent) were implanted from January 1995 until December 
1996. Every patient underwent a 6 months follow-up angiography. The total 
number of side branches involved was 144, with a mean number per patient 
of 1.67 and per stent of 1.50. The incidence of deterioration of a side branch 
after PTCA, after stent implantation and at follow-up was 26%, 33% and 26% 
respectively, and was significantly higher in the group with no initial disease of 
the side branch compared to the group with initial disease (P= 0.03, P= 0.002 
and P < 10 6 respectively). The mean acute gain after the intervention was 
significantly higher in the group with side branch improvement, compared to 
the group with deterioration (P = 0.015 after PTCA, P = 0.019 after stenting 
and P = 0.005 at follow up). Deterioration or occlusion of a side branch 
was not associated with periprocedural ECG changes or CK elevations. Late 
deterioration of side branches was strongly correlated with late loss of the 
stented segment (P = 0.003). 
Conclusions: These data demonstrate that side branches, that are cov- 
ered by a coil stent, only temporarily deteriorate, probably due to a transient 
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spasm at their odfica. Because of the small size of these branches (54% < 
2 mm and 91 _< 2.5 mm), deterioration and occlusion are not associated with 
periprocedural myocardial infarction. Initial disease of the side branch has no 
influence on subsequent deterioration, furthermore, stabilization or improve- 
ment are determined by the acute angiographic result of the intervention in 
the main vessel. Late detedoration occurs more frequently in patients with 
in-stent restenosis. 
• Length of Stay Predictors Following Coronary 
Artery  Stenting 
Herbert D. Aronow, Patricia A. Peyser, Kim A. Eagle, Pamela L. Russman, 
Mar/ha Crum, Kathi Hards, Mauro Moscucci. University of Michigan, Ann 
Arbor, MI, USA 
Background: The identification of clinical, angiographic and treatment fac- 
tors that influence the length of stay (LOS) following contemporary coronary 
artery stenting would be useful. Such information could aid in patient selec- 
tion, permit attenuation of modifiable dsk, and provide important prognostic 
information. 
Methods: Between 2/14/95 and 3/31/97, 359 consecutive patients un- 
derwent coronary artery stenting with adjunctive ticlopidine and aspirin at our 
Center. Using an interventional registry containing prospectively collected 
in-hospital and follow-up data, we conducted a cohort study to identify clini- 
cal, angiographic, and treatment factors that predict LOS following coronary 
artery stenting. After dividing our data into training and validation sets, con- 
secutive multiple linear regression models were developed in the training set, 
combined, and applied to the validation set. 
Results: In the training set, we found that acute MI (,8 = 0.408, p = 0.001 ), 
diabetes mellitus (DM) (,8 = 0.303, p = 0.001), complex coronary lesions (,8 = 
-0.268, p = 0.043), need for pre-procedure i.v. heparin (,8 = 0.215, p = 0.012), 
and need for post-procedure treatment with either i.v. heparin (,8 = 0.365, p 
= 0.001) or nitroglycerin (,8 = 0.350, p = 0.001 accounted for a significant 
amount of the variability in post-procedure LOS (model adjusted R square 
= 0.464, p < 0.001). All variables except diabetes and complex coronary 
lesions were significant predictors in the validation set (model adjusted R 
square = 0.391, p < 0.001). 
Conclusion: A significant amount of the variability in LOS following con- 
temporary coronary artery stenting can be explained by patient clinical, anglo- 
graphic, and treatment charactedstics. These findings may facilitate patient 
selection, management, and provision of important prognostic information. 
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I l l  59 -44  1 Vessel Shows Unimodal Coronary Remodeling an 
Normal Distribution: An Intravascular Ultrasound 
Study in Humans 
Francesco Pratt, Filippo Crea 1 , Maria Teresa Mallus, Antonella LabeUarte, 
Antonio Pagano, Alessandro Boccanelli. Cath Lab S. Giovanni Hospital, 
Rome; 1Institute of Cardiology Catholic Universi~ Rome, Italy 
Background: Coronary arteries may undergo both compensatory enlarge- 
merit and paradoxical constriction in response to plaque accumulation. It is 
unknown however the distribution of different remodeling patterns in patients 
with obstructive coronary atherosclerosis. In the present study the frequency 
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distribution of the intravascular ultrasound (IVUS) index of vessel remodeling 
was analysed in coronary artery lesions. 
Methods: Seventy non-branching segments of native coronary arteries 
with de hove, focal, nonostial lesions were imaged with IVUS. Images were 
acquired with a motorized pull-back at a speed of 0.5 mrn/s. 
The area circumscribed by the external elastic membrane (EEM), the 
plaque + media complex (p + m) and the lumen area (LA) were measured at 
the narrowest site (cross section with minimal lumen area) and in the refer- 
ence segment (average of proximal and distal reference cross sections, de- 
fined as the most normal locking sites). The IVUS index of vessel remodeling 
was calculated as: (narrowest site EEM - Reference EEM)/Reference EEM 
x 100. The index was tested for normality using the Kolmogorov-Smirnov 
gocdoess-of-fit test. 
Results: The frequency distribution of IVUS remodeling index showed a 
normal pattern (P = 0.60) as depicted in the figure. 
Conclusions: Frequency distribution of vascular remodeling of the-novo 
coronary lesions is unimodal with a mode value close to zero. Thus in 
man vascular remodeling is highly negligible. Furthermore, compensatory 
enlargement and paradoxical constriction represent the extremes of a con- 
tinuous spectrum. 
[•  Proximal Reference Vessel Undergoes more 
Plaque Progression than Distal Reference Vessel 
After Coronary Stenting; One Year Serial 
Intracoronary Ultrasound Follow Up 
Javed M Ahmed 1 , Muhammed Y. Salame 1 , Steve Fearn 1 , 
Sarah Anthonies 1 , Clare Wales ~ , Paul N. Silverton ~ , Alex V. Zezulka 1 , 
Robert J, Siegel 2, David C. Cumberland ~ .;Northem Genera/Hospital, 
Sheffield, UK; 2Cedars Sinai Medical Center, LA, USA 
Aim: Delivery of a stent to the lesion site may result in de-endothelialisation 
and vessel trauma to the proximal vessel with consequent plaque progres- 
sion. We therefore examined the proximal as well as the distal reference 
vessel on intracoronary ultrasound (ICUS) using 3.5 Fr 20 MHz catheter 
immediately, at 15 minutes and at one year.post stenting 
Method: Patient charactedstics: n = 12; males = 10, mean age 58.5 
(range 49-75) with Canadian Class (11-111), smokers 83%, diabetes 17%, 
hypertension 25%. Lesion characteristics: 8 LAD, 3 RCA, 1 LCX, lesion 
length 10.2 (5.3). Pre-intervention ICUS of lesion; Eccentric 3, Dissection 0, 
Calcified 7, thrombus 2, soft 5. 
Result: Unlike the distal reference, the proximal reference vessel showed 
a significant decrease in MLD and lumen area due to a significant increase 
in plaque burden seen at 1 year ICUS follow up, 
Conclusion: The passage of stents through the proximal vessel on route 
to the lesion may result in vessel trauma and consequent neointimal hyper- 
plasia in the coronary artery proximal to the lesion. 
Plague progression i  proximal and distal reference vessel 
ICUS Proximal reference vessel Distal reference vessel 
Parameters 15 min (A) 1 year (B) 15 min (C) 1 year (D) 
MLD 3.9 (0.7) 3.4 (0.7) 3.4 (0.7) 3,3 (0.7) 
AvsB, p = 0.004 
Lumen 13.3 (4.9) 10.9 (3.7) 10.5 (4.1) 9.6 (4.0) 
area AvsB, p = 0.007 CvsD, p = 0.4 
Vessel 20.6 (6.2) 21.6 (6.9) 15.8 (6,6) 14.9 (7.5) 
area AvsB, p = 0.3 CvsD, p = 0.2 
Plaque 7,3 (4.2) 10.7 (6.5) 5.3 (3.6) 5.2 (4.0) 
area AvsB, p = 0.01 CvsD, p = 0.8 
%Paque 35.7 (14.1) 48,0 (18.3) 32.5 (13.1) 31.9 (11.4) 
area AvsB, p = 0.005 CvsD, p = 0.9 
1159-46 1 Increases in Vessel Wall Thickness of Biphasic 
i Grafted Saphenous Vein: Evidence From 
Intravascular Ultrasound 
Ko Nakamura, Kenichi Ito, Satoshi Daikoku, Satoshi Nakatani, 
Kunio Miyatake, Soichiro Kitamura, Masakazu Yamogishi. National 
Cardiovascular Center, Suita Osaka, Japan 
Background: Although more than 30 years have passed since the first coro- 
nary-aorta bypass grafting (CABG) using the saphenous vein was done, few 
clinical data exist regarding the natural changes in vessel wall morphology 
after grafting in situ. Therefore, to define the time course changes in vessel 
wall morphology, we performed intravascular ultrasound (IVUS) examination 
in patients with CABG. 
Methods: The IVUS examination was performed in 40 pts at the vari- 
ous time after surgery (0-168 months), using 3.5 Fr low profile transducer 
operating at 30 MHz. The IVUS transducer was carefully pulled back at the 
relatively straight portion of the graft without angiographic disease. Percent 
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area of neointima with or without atherosolerotic hange was calculated by 
the formula: (TA - LA)/TA, where the TA (Total vessel area) was deter- 
mined by tracing the leading edge of the second echogenic zone, and the LA 
(lumen area) was determined by tracing the boarder between lumen and inti- 
mal leading edge. We also determined the maximal (max) and minimal (min) 
thickness of the vessel wall for the determination of vessel wall eccentricity 
that was determined by the formula: (max-min)/max. 
Results: The thickened intima distributed circumferentially giving tie ec- 
centricity index of 0.21 ± 0.11. The percent area of intima vaded from 0 to 
66%, and there was linear correlation between these values and the period 
after surgery (y = 0.12x + 29, r = 0.62, p = 0.002). However, this became 
much closer when correlation was fit by polynomial regression (y = 2.044" 
10 3 × 3 _ 0.O07x 2 + 0.833x + 16.9, r = 0.76, p = 0.0013), indicating the 
presence of two phases of the rapid increase in vessel wall thickness during 
the disease process. 
Conclusion: The wall thickness of the grafted saphenous vein circumfer- 
entially increases bythe biphasic fashion. We suggest that the early phase is 
related to the reactive intimal hyperplasia to the pressure load, and the late 
phase to the process of the atherosclerosis. 
• Equipment Related Factors Influence Accuracy of 
Intravascular Ultrasound Measurements 
Helmut Kuecherer, Raft± Bekeredjian, Alexander Hansen, Armin Just, 
Stefan Hardt. University of Heidelberg, Heidelberg, Germany 
Background: Intravascular ultrasound (IVUS) is frequently used as an ad- 
junct to coronary angiography to guide revascularization procedures, and, 
more recently, to estimate atherosclerotic plaque volumes. Although accu- 
racy of IVUS imaging and analysis is crucial for these measurments, available 
data is scarce and focusses on intra- and interobserver-variabilities. There is 
no information on the potential for equipment related variability. The purpose 
of this in-vitro study was to determine, whether equipment related factors 
influence measurement accuracy. 
Methods: Cross-sectional views of tubular vessel phantoms (diameters 
2-14 mm) were acquired using a 3.2 F catheter sequentially connected to two 
different ultrasound systems (systems A and B). In system B two software 
versions were used to analyze ultrasound images. Intra- and interobserver- 
variabilities were also determined. 
Results: There was an evident difference in measurement characteristics 
when comparing system A with system B and when using different software 
versions in system B. Absolute measurement errors increased linearly from 
0.36 to 4.5 mm 2 in system B but in a nonlinear fashion from -0.01 to 2.4 
mm 2 in system A with increasing phantom diameters. Relative error was a 
Iogadthmic function of phantom cross-sectional area, decreasing from 11.4% 
to 2.9% in system B (positive off-set error), but increasing from -0.28% to 
1.9% in system A (negative off-set error) with increasing phantom size. 
When using updated software in system B off-set error was negative and 
relative error diminished from -1.34% to 0.44% with increasing phantom 
size. Measurements performed by one observer at two different occasions 
correlated closely (r = 0.98, p < 0.0001 ) with a mean difference of 0.3 ± 0.48 
mm 2. Measurements performed by two observers also correlated well (r= 
0.99, p < 0.0001) with a mean difference of -0.3 ± 0.52 mm 2. 
Conclusion: Aside from observer related variability, equipment related 
factors influence accuracy of intravascular ultrasound measurements. Ultra- 
sound equipment and measurement software should be calibrated before 
using it for quantitative measurements in order to avoid systematic errors. 
~ T h e  Discrepancy Between Quantitative Coronary 
Angiography and Intravascular Ultrasound in 
Determining True Vessel Size: A Homogenous or 
a Selective Phenomena? 
Issam Moussa 1 , Jeffrey Moses 1 , Joseph De Gregodo 2 , Milena Adam±an 2,
Remo Albeiro 2, Cado Di Mario 2 , Antonio Colombo 1,2 . ~Lenox Hill Hospita/ 
NY, USA; 2 Centro Cuore Columbus, Milan, Italy 
Background: Data suggest that coronary angiography (QCA) underesti- 
mates vessel size compared to intravascular ultrasound (IVUS). However, it 
is not clear whether this phenomenon differs in magnitude among different 
pt subsets. 
Methods: We studied 334 pts (382 lesions) who had pre-intervention 
IVUS and QCA analysis. The difference between IVUS and QCA in mea- 
suring vessel size at the lesion site was calculated as: IVUS mean vessel 
diameter (media-to-media) minus QCA interpolated reference. 
Results: QCA underestimated vessel size as measured by IVUS by 0.92 
± 0.65 mm. Among the vadous factors tested by multivariate logistic regres- 
sion, the following were independently predictive of a larger discrepancy: 
smaller angiographic reference diameter (<2.75 mm) (p = 0.00001), dia- 
betes (p = 0.02), and proximal coronary segment location (p = 0.02). The Bar 
graph below shows the interaction among these factors in determining the 
discrepancy between IVUS and QCA: 
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Conclusions: 1) QCA underestimates true vessel size compared to IVUS; 
2) the degree of discrepancy is not homogenous among all lesion subsets, 
but is higher for lesions located in angiographically small vessels, in diabetics, 
and in proximal arterial segments. 
i l  [ Impact of a Novel Blood Noise Reduction I 1 59-49  
Algorithm on Interobserver Variability for 
Morphometric Measurements 
Kiyoshi Hibi, Atsushi Takagi, Xiangmin Zhang, Tat-Jin leo, 
Yoshiki Kobayashi, Hiroyuki Okura, Paul G. Yock, Peter J. Fitzgerald. 
Stanford Universi~ Stanford, Boston Scientific, San Jose, CA, USA 
Background: Ultra high frequency (40-50 MHz) intravascular ultrasound 
(IVUS) improves image quality compared to conventional 20-30 MHz IVUS. 
However, as the frequency of IVUS increases, high intensity backscatter from 
blood may cause difficulties in discrimination between the lumen and arterial 
wall. The purpose of this study was to evaluate the effect of a new blood 
noise reduction (BNR) algodthm on interobserver variability for quantitative 
coronary ultrasound measurements. This BNR algorithm reduces blood noise 
based on the fact that blood speckles have higher spatial and temporal 
variations. A two-dimensional transform descdptor is used to characterize 
the difference. 
Methods: IVUS studies using a 40 MHz transducer were performed in 
8 patients with coronary artery disease. Several frames from direct digi- 
tal signals were randomly selected to test the BNR algorithm. A total of 
418 gray-scale images (209 pairs) were displayed with (BNR+) and without 
(BNR-) this algodthm. All images were analyzed randomly by two indepen- 
dent observers. The observers traced lumen border using a computer-based 
analysis system and lumen cross-sectional area (LA) were determined. 
Results: Using the BNR algorithm, the interobserver correlation coeffi- 
cient for LA was significantly improved from 0.66 to 0.98 (Figure). Variability 
expressed as percentages of difference between measurements was smaller 
for the BNR+ group than for the BNR- group (3.0 ± 15.3 vs. 11.8 ± 30.4, P 
< 0.0001). 
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Conclusions: Digital BNR algorithm may be an important adjunct to ultra 
high frequency IVUS imaging. 
~ T h e  (Often) Four-layer Apparence of Coronary 
Arteries by Intravascular Ultrasound: The Tun±ca 
Adventitia 
Gilles Rioufol, Gerard Finet, Alain Tab±b, Jacques Beaune. Department of 
Hemodynamics, Cardiovascular Hospital, Lyon, France 
Background: Usually, the tunica adventitia (A) has not been imaged by 
intravascular ultrasound (IVUS). However, certain anatomical configurations 
(e.g. pedcardial detachment, a hypoechogenic periadventitial interstitium) 
lead to the creation of a periadventitial acoustic interface which gives dse to a 
four-layer apparence. The accuracy of measurements of A was subsequently 
confirmed by histology. 
Methods: With in vivo IVUS (30 MHz), we explored 29 pathological (P) 
and 22 normal (N) left anterior descending arteries. The A was visible in 37 
N IVUS sections and 155 P IVUS sections. 
Results: The adventitial thickness (AT) of N arteries was 233 ± 42 ,urn 
for a combined intima + media (I + M) thickness of 252 ± 46 ,um. The 
AT of P arteries was 360 ± 88 pm (p < 0.0001 vs N) for plaques of a 
measured thickness of 888 ± 550 #m (p < 0.0001 vs N). No correlation 
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was observed between A and the parietal area or the total area for either N 
arteries (respectively r = 0.19 and r = 0.01) or P arteries (respectively r = 0.1 
and r = 0.06). 
i~  ~ ~ ~ 
Conclusion: If the anatomical configuration is suitable, the tunica ad- 
ventitia can be accurately measured using a few IVUS sections. The tunica 
adventitia of atheromatous arteries is significantly thicker than that of normal 
artedes. 
~ W a l l  Thickening of Saphenous Vein Bypass Grafts 
Begins in Relatively Early Stage after Surgery 
Yoshiharu Higuchi, Atsushi Hirayama, Nobuhiko Kondo, Takayoshi Adachi, 
Yuuji Okuyama, Kazuhisa Kodama. Osaka Police Hospital, Osaka, Japan 
Background: The long-term patency of saphenous vein grafts (SVGs) is 
reported to be 40% to 60% for grafts > 10 years old after coronary saphe- 
nous veins bypass graft surgery. The closure of SVGs soon after surgery is 
reported to be caused by thrombosis, whereas late closure of SVGs is due 
to vessel wall thickening. The aim of this intravascular ultrasound (IVUS) 
study is to examine when the vessel wall thickening of SVGsbegins after 
surgery. 
Method: Eleven SVGs were studied by IVUS two weeks to one month 
after surgery (1 M group). Ten SVGs were studied 5 months to 1.5 years after 
surgery (E group). In each SVGs, lumen area (mm 2) and vessel area (mm 2) 
were measured. The vessel wall area (VWA) was calculated by subtracting 
the lumen area from vessel area. The VWA ratio was defined (VWA ratio = 
VWA / vessel area). 
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Results: The average VWA was 5.21 in 1 M group and 14.4 in E group 
(p < 0.01). The average VWA ratio was 25.7% in 1 M group and 53.2% in E 
group (p < 0.01). VWA ratio increased over 40% as early as 5 months after 
the surgery. 
Conclusions: These in vivo IVUS study demonstrate that the vessel wall 
thickening process in SVGsbegins relatively eady after surgery. 
i 1159-52  t Gender Differences in Size Coronary Artery i Assessed by Intravascular Ultrasound 
Stuart E. Sheller, Michael R. Canos, Ravi Chad, Umesh K. Arora, Farrell 
O. Mendelsohn 1 , Bernard J. Gersh, Nell J. Weissman. Division of 
Cardiology, Georgetown University Medical Center, Washington, DC; 
Diwsion of Cardiology, Duke University Medical Center, Durham, NC, USA 
Background: Women have worse outcomes after myocardial infarction and 
coronary revascularization. The explanations are likely multifactodal, but 
may include smaller coronary artery size. Smaller luminal diameter has been 
confirmed angiographicaily; however, due 1o possible confounding effects of 
coronary remodeling, angiographically silent atherosclerosis, and body size, 
it is not clear if there is a true gender influence on arterial size, 
Methods: We therefore performed intravascular ultrasound on disease- 
free left main (LM) and proximal left anterior descending (LAD) coronary 
artedes in 52 men and 26 women. Arterial and luminal area (AA, LA) were 
measured by planimetry. 
Results: Univadate comparisons revealed that mean LM and LAD AA 
were significantly smaller in women (21.58 vs. 27.08 mm 2, p = 0.001; and 
14.44 vs. 19.92 mm 2, p < 0.001; respectively), as were mean LM and LAD 
LA (15.85 vs. 18.76 mm 2, p = 0.047; and 9.69 vs. 12.21 mm 2, p = 0.019; 
respectively). After adding body surface area, age, and hypertension into 
multiple regression analyses, gender persisted as an independent predictor 
of LM AA (p = 0.003) and LAD AA (p = 0.008), but not of LA. No other 
independent predictors were identified. 
Conclusions: LM and LAD arteries are smaller in women, independent of 
body size. This suggests an intrinsic gender effect on coronary dimensions. 
Future studies should investigate underlying mechanisms. An understanding 
of these mechanisms may lead to novel therapeutic strategies and improved 
outcomes. 
I •  Comparison of Intravascular Ultrasound and Quantitative Angiographic Measurement of 
Lesion Length in 1938 Lesions 
Gary S. Mintz, Alexandra J, Lan.sky, Myeong-Ki Hong, Borjanca 
Oljaca Leiboff, Lowell F. Satler, German Lorrain, Praveena K. Solipuram, 
George Hanzel, Augusto D. Pichard, Kenneth M. Kent, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
We compared intravascular ultrasound (IVUS) and angiographic (QCA) mea- 
surements of stenosis length in 1938 native vessel lesions. IVUS length was 
measured from the most normal-looking proximal to the most normal-looking 
distal reference. QCA length was measured from shoulder to shoulder in 
the least foreshortened view. IVUS and QCA correlated moderately well (r = 
0.58, p < 0.0001). There was a negligible mean (IVUS-QCA) difference (0,6 
mm), but the standard deviation was large (7.2 mm): 
IVUS (mm) IVUS-QCA (mm) 
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These correlations and differences did not vary with reference plaque 
burden or size and were similar in LM vs LAD vs LCX vs RCA, ostial vs 
nonostial, and calcified vs noncalcified lesions. 
We conclude: There are significant and unpredictable differences be- 
tween IVUS and QCA measurements of lesion length. These differences 
become important when attempting to match stent to lesion length and an- 
chor stents in healthy reference segments. 
~ Mechanism of Acute Lumen Enlargement After 
Rotaional Atherectomy With Cutting Balloon 
Assessed by Serial Intravascular Ultrasound 
Masahiro Izumi, Etsuo Tsuchikane, Tomoko Kobayashi, Satoru Otsuji, 
Hitone Tateyama, Tohru Kobayashi, Nobuhisa Awata. Osaka Medical 
Center for Cancer and Cardiovascular Diseases, Osaka, Japan 
It is considered that cutting balloon angioplasty (CBA) has an advantage in 
plaque compression compared with plain old balloon angioplasty (POBA). 
The aim of this study was to examine the mechanism of acute lumen enlarge- 
ment by CBA following rotational atherectomy (RA) using sedal intravascular 
ultrasound (IVUS) compared with POBA. Seventy-seven lesions after suc- 
cessful RA, were enrolled and randomized to adjunctive CBA (39 lesions) 
or POBA (38 lesions) in calcified or diffuse lesions. Serial IVUS study was 
performed at pre- and post-RA, post-BA, and at follow-up. Vessel area (VA) 
and lumen area (LA) were measured and plaque area (PA) was calculated. 
In thirty-one lesions (17 lesions: CBA, 14 lesions: POBA), eligible sedal IVUS 
images was available. 
Results: There was no significant difference in baseline characteristics 
between the two groups. Mean balloon/artery ratio (1.27 vs 1.32) did not 
differ, however maximum inflation pressure was larger in CBA than POBA 
(4.4 vs 3.3 atm, p < 0.05). There were no major complications. Pre VA, LA, 
and PA were dot differ between the two groups. 
by RA by BA Total 
(mm 2 ) CBA POBA p CBA POBA p CBA POBA p 
AVA -0.1 0.2 NS 1.3 0.6 0.20 1.2 0.8 NS 
APA -2.0 -1.7 NS -0.8 -0.8 NS -2.8 -2.6 NS 
,',LA 1.9 1.9 NS 2._/1 1.5 0.11 4._00 3.4 0.19 
(BA: balloon angioplasty, 4: between pre- and post-procedure 
Conclusion: Lumen enlargement by adjunctive CBA following is larger 
than POBA, which is provided by the facilitation of vessel expansion. Chronic 
vessel response will be presented. 
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I l l  59-551 Do the Vessels in Diabetics Why Coronary Appear i to Be Angiographically Small? 
Issam Moussa 1 , Jeffrey Moses 1 , Xangdong Wang ~ , Joseph De Gregorio 2, 
Milena Adamian 2, Remo Albeiro 2, Carlo Di Mario 2, Antonio Colombo 1,2. 
r Lenox Hill Hospital, NY, USA; 2Centro Cuore Columbus, Milan, Italy 
Background: It is a common observation that patients with diabetes mellitus 
(DM) have angiographically smaller coronary arteries than pts without DM. 
The purpose of this study was to investigate the reason for this phenomena 
using intravascular ultrasound (IVUS) imaging. 
Methods: We studied 59 consecutive diabetic pts (76 lesions) and 275 
consecutive non-diabetic pts (306 lesions) who underwent pre-intervention 
IVUS imaging and quantitative angiographic analysis (QCA). Vessel diameter 
was measured at the lesion site by QCA (interpolated reference) and by 
IVUS (mean media-to-media diameter). Plaque burden was expressed as 
% plaque area (%PA) which was calculated as: (vessel cross sectional area 
(CSA) minus lumen CSA divided by vessel CSA. 
Results: Diabetics included more females than non-diabetics did (24%) 
Vs 13%, p = 0.04). The QCA and IVUS measurements are shown below: 
DM (n = 76) No DM (n = 306) P 
QCA vessel diameter (mm) 2.84 ~ 0.57 3.05 4- 0.59 0.007 
IVUS measurements: 
Vessel diameter (mm) 3.90 4- 0.71 3.94 4- 0.68 ns 
Lesion site % PA 7g ± 8 79 ± 9 ns 
Proximal reference % PA 47 ± 14 40 ± 15 0,003 
Distal reference % PA 44 4- 19 33 ~- 17 <0.0001 
Conclusions: Also in this study, pts with diabetes had angiographically 
"smaller vessels" compared to non-diabetics, but IVUS imaging showed 
similar vessel size and plaque burden at the lesion site in both groups. The 
phenomena of "angiographically small vessels" in diabetics is not a valid 
anatomic observation but is due to the presence of a large plaque burden in 
the reference segments, an observation that can not be detected by coronary 
angiography. 
• Reproducible Assessment of Lumen, Vessel and 
Plaque Volume in Serially Acquired Intravascular 
Ultrasound (IVUS) Images Obtained From 
Femoropopliteal Arteries 
E.J. Gussenhoven, T. Hagenaars, J.A. van Essen, C.H.A. Wittens, 
S.E. Kranendonk, J. Honkoop, A. van der Lugt. Erasmus University Medical 
Center Rotterdam, Sorbo Heart Foundation, ICIN, The Netherlands 
Background: To document the effect of lipid lowering drugs on the athero- 
sclerotic plaque volume, an analysis system was developed which performs 
automated detection of lumen and vessel borders in a three-dimensional 
stack of IVUS images. This IVUS study was aimed to determine the repro- 
ducibility of volume measurements from femoropopliteal arterial segments 
assessed with the automated contour analysis system. 
Methods: Patients (n = 15) were serially imaged with IVUS. A displace- 
ment sensing device was used to document he location of acquired images. 
The 2 series of images were matched with the use of side-branches. Matched 
vascular segments (range 3 to 4 cm) were analyzed for lumen, vessel and 
plaque volume using an automated contour analysis system. Volume mea- 
surements assessed by 2 independent observers and in the first and second 
series were compared. 
Results: The median length of the vascular segments studied was 3.7 
cm. Interobserver differences in volume measurements were small (0.2% to 
0.4%), showing low coefficients of variation (0.4% to 1.7%) and high correla- 
tion coefficients (r = 1.00). Volume measurements obtained in the first series 
agreed well with those in the second series showing small differences (0.6% 
to 2.6%), low coefficients of variation (5.6% to 8.6%) and high correlation 
coefficients (r = 0.97 to 0.99). 
Conclusions: The automated analysis system is a reliable tool for serial 
assessment of volumes from IVUS images in peripheral arteries. Thus, IVUS 
may play a major role in a longitudinal study to document the effect of lipid 
lowering drugs on plaque volume. 
• Effects of Arterial Remodeling on Degree the of 
Discrepancy between Quantitative Coronary 
Angiography and Ultrasound Imaging in 
Determining True Vessel Dimensions 
Issam Moussa 1 , Jeffrey Moses 1 , Joseph De Gregorio 2, Milena Adamian 2, 
Remo Albeiro 2, Carlo Di Mario 2 , Antonio Colombo 1,2. rLencx Hill Hospital, 
NY, USA; 2 Centro Cuore Columbus, Milan, Italy 
Background: The impact of arterial remodeling on the degree of discordance 
between intravascular ultrasound (IVUS) and coronary angiography (QCA) 
is not well defined. 
Methods: We studied 218 pts (247 lesions) who had IVUS and QCA anal- 
ysis prior to elective coronary intervention. The discordance between IVUS 
and QCA in measuring vessel size was calculated as: IVUS mean vessel 
diameter (media-to-media) minus QCA interpolated reference. Remodeling 
index (RI) was calculated as: vessel CSA at the lesion site divided by vessel 
CSA at the proximal reference. A RI < 0.78 was considered inadequate 
remodeling (IR), while a RI > 0.78 was considered adequate remodeling 
(AR). 
Results: Figure t shows the relationship between RI and (IVUS-QCA) 
discordance. IR was present in 82 lesions (33%), while AR was present in 
165 lesions (67%). Figure 2 shows mean (IVUS-QCA) discordance for all 
lesions, lesions with IR and lesions with AR. 
~" Figure 1 
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Conclusions: These results suggest that QCA underestimates true ves- 
sel size as measured by IVUS. This discrepancy is higher in lesions with 
adequate remodeling and lower for lesions with inadequate remodeling. 
POSTER 
Understanding Restenosis 
Tuesday ,  March  9, 1999,  Noon-2 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour :  1 :00  p .m. -2 :00  p.m. 
I1 60-134 ] Re-Express ion  of  the CytoskeletaI-Associated 1 
Protein Moesin in the Media of Carotid-Arteries 
After Balloon Angioplasty 
Karin Hoffmeister, RL~diger Blindt, Kerstin Seifert, J0rgen vom Dahl. Medical 
Clinic I, RWTH Aachen, Germany 
Background: Migrating cells like myofibroblasts in restenosis change their 
cell shape and form cellular protrusions like filopodia. A prerequiste for 
filopodia formation is the rearrangement of actin cytosketeton. An essential 
rote of moesin (78 kD) is described for Rho- and Rac-dependant assembly of 
actin filaments. In vivo moesin is not observed in mature smooth muscle cells. 
During the process of restenosis we assumed that moesin is reexpressed in 
transformed, migrating myofibroblasts in order to form cellular protrusions. 
Methods: 12 hours after balloon angioplasty pig carotid arteries were 
embedded in paraffin after methanol/ethanol-fixation. Carotid cryosections 
from the rat-restenosis were obtained after 1 day, 7, 14 and 28 days. Sections 
were stained with specific antibodies against moesin and smooth muscle cell 
actin. Anti-moesin antibodies were achieved by immunisation of chickens 
with isolated moesin. 
Results: 12 hours after angioplasty moesin expression was observed in 
myofibroblasts as well as in dividing cells within the media of the pig carotid 
artery. To determine the start of moesin expression in the rat-restenosis model 
immunfluorescence with antibodies against moesin and smooth muscle aotin 
at 1 day, 7 days and 28 days after angioptasty. Even in the early period (1 
day) angioplasty tissue staining was positive for moesin and smooth muscle 
cell actin whereas in the non-dilated control tissue no specific moesin staining 
could be observed. Some cells were also positive for PCNA (proliferating cell 
nuclear antigen). 
Conclusion: These findings demonstrate for the first time a de novo 
expression of moesin within the arterial media after arterial injury and indi- 
cate that moesin may be important for migration and proliferation of myofi- 
broblasts. This indicates a possible role of moesin in the pathogenesis of 
restenosis after angioplasty and stent implantation. 
[ 1160-1351 Late Luminal Gain post Angioplasty due to 
Compensatory Enlargement and Neointimal 
Regression - Long-Term Animal Data 
Randolph Hutter, Gerhard Bauriedel, Berndt L0deritz. DepL of Cardiology, 
University of Bonn, Bonn, Germany 
Background: Arterial remodeling and neointima formation (N) are critically 
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implicated in restenosis. However, their spatiotemporal interaction is not 
completely understood. 
Methods: N area, cell density and the proportion of programmed cell 
death (apoptosis) of N as well as luminal (L) and internal elastic membrane 
(IEL) diameters (D) were systematically studied. Injured carotid arteries (2F; 
n = 6 rats/time post angioplasty) were assessed by histomorphometry and 
by TdT mediated dUTP nick end (TUNEL) labeling to identify apoptosis. 
Results: N area increased 3-fold from day 14 to month 4 post trauma. 
Concordantly, IEL-D increased by 50%, thereby preventing significant L 
narrowing and compensating neointimal growth. Cell density decreased due 
to matrix deposition and apoptosis, since the proportion of TUNEL+ cells 
advanced from 14.0 ± 8.3% to 41.8 ± 23%. At month 5, interestingly, N area 
regressed by 50%, coinciding with structural defects and lower cellularity due 
to persistent apoptosis. Irregular L borders indicated mechanical instability 
and tissue loss of N. At the same time, IEL-D regressed, whereas L-D 
did not change significantly. However, both parameters remained elevated 
compared to day 10. 
"rime N Area N Cells D L D IEL 
(x 0.1 mm 2) (x 103/mm 2 (ram) (mm) 
Day 14 0.9 ± 0.3 11.4 ± 2,4 0.52 ± 0.08 0.62 ± 0.05 
Month 4 3.0±0.3 5.3±0.7 0,70±0.13 0.93±0.08 
Month 5 1.4±1.3 4.3±0.9 0.61±0.11 0.75+0.08 
Conclusion: In the long-term course post injury, intimal hyperplasia is fol- 
lowed by late atrophy due to apoptosis, thereby mediating intimal regression. 
The L-D reflects the net result of N changes and IEL response. Late luminal 
gain is determined by persisting compensatory enlargement and a toss in 
previous necintima size. Thus, a deficiency of either one or both of these 
remodeling events preventing luminal narrowing may underly late human 
restenosis. 
l l l  60 -136  ] St imulat ion of  Fibrotic Remodeling by 
1 
Exogeneous Endothelin-1 in the Rabbit Double 
Injury Model of Restenosis 
Pierre Picerd, Alan W. Barolet, Ranga Robinson, Winston Tsui, John 
N. Wylie, Azar Azad, Duncan J. Stewart, Bradley H. Strauss. Terrence 
Donnelly Heart Centre, St. Michael's Hospital University of Toronto, 
Ontario, Canada 
Background: The well known vasoconstrictor and fibroproliferative ffects 
of endothelin-1 (ET) suggest a central role for this peptide in neointimal 
formation during restenosis. 
Methods: This study assessed the ability of exogenously administered 
ET (600 pmol/day for 1 week) to potentiate restenosis in the rabbit iliec artery 
double injury model. 20 animals were randomized into four groups receiving 
either subcutaneous ET-1 or placebo time-release pellet and sacrificed at 
either 1 or 10 weeks post-angioplasty. While synthesis and accumulation 
of collagen was measured by C14-hydroxyproline assays, wall and lumen 
dimensions were derived from intravascular ultrasound measurements and 
by histological staining and computerized planimetry. 
Results: At 1 week post angioplasty, ET stimulated synthesis and ac- 
cumulation of collagen, increase in neointimal and adventitial area, as well 
as vessel thickness while decreasing lumen diameter when compared with 
placebo (table). However, by 10 weeks these changes were no longer ob- 
served. 
1 week post-angioplasty ET-1 Placebo p value 
Collagen synthesis (cpm) • 6740 ± 991 530 ± 360 0.00001 
Collagen content (/~g) 300 ± 12 97 ± 29 0,000001 
Neointimat rea (mm 2) 1.6 ± 0.5 0,8 ± 0.2 0.0000003 
Adventitial rea (mm 2) 1.4 ± 0.4 1.0 ± 0.2 0.002 
Lumen size (mm 2) 2.0 ± 0.8 2.5 ± 0.7 0.06 
Vessel thickness (mm) 0.48 ± 0.06 0.39 ± 0.10 0.007 
Although ELISA assays revealed increased plasma levels of ET in the 
ET supplemented groups, no increase in blood pressure was found in these 
animals. 
Conclusions: During the period of ET treatment, adverse remodeling 
is stimulated. However, these effects are transient and not maintained long 
term after withdrawal of ET stimulation. 
ORAL  
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Tuesday,  March  9, 1999, 2 :00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 279 
2:00 p.m. 
[ - ~  Pravastat in Reduces both Clinical and Angiographic 
Restenosis Two Years After Percutaneous 
Transluminal Coronary Angioplasty: An Analysis of 
the PTCA Stratum of the REGRESS Trial 
Han J.G.I-I. Mulder, Johan W. Jukema, Egbert T. Bal, Aeilko H. Zwinderman, 
Ad J. van Boven, Johan H.C. Reiber, Albert V.G. Bruschke. DepL of 
Cardiology, Leiden University Hospital, Leiden; SL Antonius Hospital, 
Nieuwegein, The Netherlands 
Background: In spite of experimental evidence suggesting that restenosis 
following PTCA may be reduced by lipid lowering therapy, thus far clinical 
trials have failed to demonstrate this. The earlier published REGRESS (Re- 
gression Growth Evaluation Statin Study) trial, comprised a PTCA group of 
221 pts. We herewith present the results of the sub-analysis of this group. 
Methods: In the REGRESS trial we randomly assigned patients to receive 
pravastatin (40 mg. once daily) (Pray) or placebo (Plac). Pts. of the PTCA 
stratum underwent elective angioplasty of a native vessel and received ther- 
apy for two years. End point was the %.-diameter stenosis of the index lesion 
at follow-up angiography, as assessed by digital caliper measurements or 
quantitative coronary arteriography. 
Results: Of the 885 pts. in REGRESS, 221 underwent a scheduled PTCA 
at baseline of one or more segments, of which 201 were successful. 178 Pts. 
underwent angiographic restudy. At baseline, the pts. in the Prav. group (n 
= 100) and the Plac. group (n = 101) were similar with respect to clinical, 
angiographic, and laboratory characteristics. At baseline the mean (+ sd) 
%-diameter stenosis, was 78 ± 14 percent in the Pray. group, and 80 ± 14 
percent in the Plac. group (p = 0.46). At follow-up angiography, % diameter 
stenosis was 32 ± 23 percent in the Prav. group, and 45 ± 29 percent in 
the Plac. group (p < 0.001). Clinical restenosis was significantly lower in 
the Prav. (7%) group compared to the Plac. (29%) group (p < 0.001). Also 
target vessel revasculadzation, was significantly lower in the Prav. group 
(6%) compared to the Plac. (26%) group (p < 0.001). 
Conclusions: Pravastatin treatment, initiated at the time of PTCA, re- 
duces the occurrence of restenosis in two years of follow-up. 
2:15 p.m. 
~ Incomplete Revascularization, Long-Term Outcome 
and Functional Status in Patients Undergoing 
Percutaneous Coronary Interventions 
Joseph B. Muhlestein, Donna N. Frommater, Tami L. Bair, Diane M Trecy, 
Judy A. Cossey, Susan K. Goldberg, Donald L. Lappe. LDS Hospital, 
Intermountain Health Care, Salt Lake Ci~ Utah, USA 
Background: Patients receiving percutaneous coronary intervention (PCI) 
for symptomatic coronary artery disease often are left with stenetic lesions 
that are not treated because they were felt to be either hemodynamically 
insignificant or not approachable. Procedural success of patients undergo- 
ing culpdt vessel angioplasty or incomplete revasculadzation (ICR), defined 
as the residual presence of at least one >_ 50% stenotic lesion within the 
coronary tree, has been reported to be similar to those undergoing complete 
revascularization (CR). We sought to determine the tong-term outcome and 
functional status of both of these groups. 
Methods: 449 patients (mean age = 64 ± 11 yrs, males = 79%, diabetes = 
14%, post-MI = 34%, stents used = 75%, multivessel PCI = 16%) undergoing 
successful PCI at our institution, of which 315 (70%) underwent CR and 
134 (30%) underwent ICR. Baseline variables did not differ between the two 
groups. Patients were contacted after one year and their clinical outcome 
and functional status assessed. The results are described below. 
CR ICR p-value 
Death or MI 9.2% 11.2% 0.52 
Evaluated for angina 8.0% 14.6% 0.035 
Repeat PCI 10.3% 21.2% <0,002 
CABG 2.3% 4.7% 0.18 
Over-all functional status core at one year 62.0 63.1 NS 
Conclusion: Despite similar in-hospital clinical results, patients under- 
going PCI with ICR experienced more episodes of angina and more revas- 
cularization procedures in one year than those with CR. Death or MI and 
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functional status did not differ. Whether more aggressive multivessel PCI or 
referral for CABG can affect this outcome remains to be determined. 
2:30 p.m. 
~ Chlamydia Pneumoniae Seropositivity Predicts the 
Risk of Restenosis after Percutaneous Transluminal 
Coronary Angioplasty 
Kazutaka Hayashida, Masaru Tanaka, Hideaki Morita, Fujio Hayashi, 
Tsukasa Inada, Hiroshi Suzuki, Takaaki Sakamoto, Masayuki Katsuragawa, 
Hirofumi Kambara. Cardiovascular Center, Osaka Red Cross Hospital, 
Osaka, Japan 
Background: Recent studies indicate that latent infection of Chlamydia pneu- 
moniae is associated with and could be causative of atherosclerosis. How- 
ever, it is unknown whether this infection is involved in the mechanism of 
restenosis after PTCA. 
Methods: We prospectively studied 62 consecutive patients (73 target 
lesions) with symptomatic oronary artery disease who underwent successful 
PTCA (conservative balloon angioplasty for 28 lesions and stent implantation 
for 45 lesions). Before PTCA, blood samples were collected to measure 
the serum levels of anti-C.pneumoniae IgG antibodies to examine whether 
seropositive patients were prone to restenosis. Follow-up angiography was 
performed within six months after PTCA, and restenosis was evaluated in 
terms of loss index, which was defined as late loss divided by early gain. 
Results: There were no significant differences in mean minimal luminal 
diameter before and after PTCA, mean reference vessel diameter, and mean 
length of target lesions between seropositive and seronegative patients. 
However, lesions of seropositive patients had a greater mean loss-index 
(0.80 ± 0.10 vs. 0.41 ± 0.10 p < 0.01). 
The multivariate analysis showed that seropositivity was the only indepen- 
dent predictor of high loss index, over the other covadates, such as smoking, 
diabetes, male sex, dyslipidemia, and hypertension. 
Conclusions: Seropositive patients with C. pneumoniae were prone to 
restenosis after PTCA. Prior infection with C. pneumoniae could play an 
important role in the pathogenesis of restenosis. 
2 :45 p.m. 
~ - ~  Levels of C-Reactive Protein Before Coronary 
Angioplasty Predict Outcome in Both Stable and 
Unstable Angina Patients 
Antonino Buffon, Giovanna Liuzzo, Luigi M. Biasucci, Vito Ramazzotti, 
Stefane Rigattied, Gianluca Comerci, Filippo Crea, Attilio Maser±. 
Cardiology, Catholic Universi~ Rome, Italy 
Background: An accurate pro-procedural risk stratification of patients under- 
going coronary angioplasty (PTCA) would be useful for planning adjunctive 
procedure. We investigated whether early and late outcome following single- 
vessel PTCA could be predicted by baseline levels of acute-phase reactants. 
Methods: Levels of C-reactive protein (CRP), serum amyloid-A protein 
(SAA) and fibrinogen were measured in 52 stable angina and 69 unstable 
angina patients undergoing single vessel PTCA. 
Results: Intraprocedural and in-hospital complications were observed 
in 22% of 69 patients with high serum levels (>0.3 mg/L) of CRP and in 
none of 52 patients with normal CRP levels (P < 0.001). CRP levels were 
the most powerful independent predictor of early adverse events (RR = 
12.2, P < 0.001). The other independent predictors of early adverse events 
were female gender (RR = 4.1, P = 0.033), and systemic hypertension 
(RR = 4.3, P = 0.046). At one year follow-up, clinical restenosis, confirmed 
angiographically, developed in 63% of patients with high serum CRP levels, 
and in 27% of those with normal CRP levels (P < 0.001). CRP levels (RR = 
6.2, P = 0.001) and residual diameter stenosis (RR = 3.2, P = 0.007) were 
the only independent predictors of restenosis. 
Conclusions: Pro-procedural evel of CRP is a powerful and independent 
predictor of both early and late outcome in patients undergoing single vessel 
PTCA, and suggest that early complications and restenosis are influenced 
by the pro-procedural degree of inflammatory cell activation. 
3:00 p.m. 
~--46~ Long-term Influence of on CPK-MB Elevation 
Mortality After Percutaneous Intervention - Analysis 
of 7359 Patients 
Gregg W. Stone, Roxana Mehran, Alexandra J. Lansky, Gary S. Mintz, 
Ann Greenberg, Steve Slack, Ran Kornewski, Mun K. Hong, John R. Laird, 
Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Martin B. Leon. 
Washington Hospital Center, Washington DC, USA 
The prognostic importance of CPK-MB elevation after percutaneous inter- 
vention (PCI) remains controversial. We therefore analyzed the long-term 
results of 7359 consecutive pts undergoing elective PCI of native coronary 
arteries. Mean age was 63 ± 11 years; 29% were women, 59% had hyper- 
tension, 26% diabetes, 50% prior MI, 29% pdor CABG, and 5% chronic renal 
failure. Unstable angina was present in 68% of pts. A mean of 1.9 :E 1.0 le- 
sions were treated/pt. Post procedure the CPK-MB (measured serially q8-12 
hrs) was elevated in 36.9% of pts (25 4- 46 IU, range 5-684). At follow-up 1.3 
± 1.0 yrs, 224 pts (3.0%) had died (Fig., stratified by MB). A weak trend was 
present for increased mortality with greater CPK-MB (leg-rank p = 0.10). By 
Cox multivariate regression analysis, independent correlates of death were 
age (p < 0.0001), chronic renal failure (p < 0.0001), diabetes (p = 0.0001), 
female gender (p = 0.03), and prior MI (p = 0.04); post PCI CPK-MB was not 
predictive of mortality, even when stratified by <>5x nl (p = 0.27, OR = 1.2, 
95% CI 0.8, 1.7). 
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Conclusions: In a high risk referral population, CPK-MB is frequently 
elevated post PCI. However, the major determinants of long-term prognosis 
post PCI are adverse baseline risk factors, and not post procedural CPK-MB 
elevation. 
3:15 p.m. 
~46-~ What Is the Clinical Significance of an Elevated 
CPK-MB Band Fraction After Percutaneous 
Intervention if the Total CPK Is Normal? 
Gregg W. Stone, Roxana Mehran, Alexandra J. Lansky, Steve Slack, 
Ann Greenberg, Gary S. Mintz, Ran Kornowski, Mun K. Hong, John 
R Laird, Lowell F. Satler, Kenneth M Kent, Augusto D. Pichard, Martin 
B. Leon. Washington Hospital Center, Washington DC, USA 
An elevated CPK-MB within 24 hours of percutaneous intervention (PCI) 
has been associated with increased early and late mortality. However, the 
significance of an elevated CPK-MB ff the total CPK is normal is unknown. 
We therefore examined the outcomes in 5717 consecutive pts undergoing 
PCI of native coronary arteries in whom the post procedural CPKs (measured 
serially q8-12 hrs) were nl; 4010 pts also had nl MB fractions (<4 IU), while 
1707 pts (29.9%) had elevated MB (mean 11.8 J~ 8.8, range 5-86). Baseline 
features: age 63 i 11 yrs, 29% women, 25% diabetes, 49% prior MI, 66% 
unstable angina, 29% CABG. Over a mean follow-up period of 1.4 ± 1.1 
yrs, 175 pts (3.1%) died. There was no relationship between MB elevation 
and late mortality (Fig.). Mortality was 2.9% with nl MB, 3.4% with MB 1-3x 
nl, 4.0% with MB 3-5x hi, and (p = 0.46). Independent predictors of late 
mortality by Cox regression were age (p < 0.0001), diabetes (p < 0.0001), 
and unstable angina (p = 0.05); elevated CPK-MB was not associated with 
death (p = 0.43). 
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Conclusions: Elevated CPK-MB fractions are common after PCI of native 
vessels, occurring in up to 30% of pts. However, in the absence of an elevated 
total CPK, an isolated CPK-MB is not of prognostic importance. Therefore, 
total CPK should be measured post PCI, in addition to CPK-MB, for accurate 
risk stratification. 
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Modal Convention Center, Hall F 
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~ 2 . 5  Year Follow-Up Study - of the CLOUT 
Long-Term Implications for an Aggressive IVUS 
Guided Balloon Angioplasty Strategy 
Gregg W. Stone, Axel Frey, Tom Linnemeier, Fred. St. Gear, Harald Mudra, 
Helen Sheehan, John Hodgson. Washington Hospital Center, Washington 
DC, USA 
The CLOUT study established that IVUS identification of atherosclerotic 
remodeling permits the safe use of balloons traditionally considered over- 
sized, resulting in improved luminal dimensions. To examine the long-term 
outcomes of this strategy, f/u was obtained at a median time of 2.5 yrs 
(25%-75% range 1.8-3.3 yrs) in 97 of 100 pts from CLOUT discharged 
without CABG. 
Results: Median age was 63 yrs; 29% were women, 21% had diabetes, 
41% prior MI, and 61% multivessel ds. The mean ref. vessel dia. was 2.68 4- 
0.48 ram. PTCA was performed with mean bal. dia. 3.38 4- 0.43 ram, with a 
bal. to art. ratio of 1.30 4- 0.16. By corelab QCA, the %DS was reduced from 
72% 4- 16 to 19% ± 14. By corelab IVUS, the final rain. area was 4.3 ± 1.2 
mm 2. At 2.5 yrs f/u, 6.3% pts died (2.1% cardiac), 4.1% had MI, and 27.5% 
had TLR (including 5.2% CABG and 22.3% re-PTCA). Thus, cardiac death, 
MI or TLR occurred in 28 (28.9%) pts. Non-TLR also was required in 19.6% 
pts. Independent multivariate predictors of TLR were diabetes (p = 0.04), ref. 
segment plaque area (p = 0.04) and vessel (EEM) size (p = 0.02). 
8 
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Conclusions: Despite improved procedural results with IVUS guided bal- 
loon sizing in the relatively small vessels in CLOUT, late adverse events still 
occurred frequently from recurrent ds. at the target site and progressive ds. 
elsewhere. Future strategies must therefore focus on even more aggressive 
approaches to reduce restenosis and stabilize athercscleretic plaque. 
1187-39 1 of  Surgery Versus Comparison Coronary Bypass 
Coronary Angioplasty in Patients With Chronic 
Renal Failure 
F. Gradaus, K. Ivens 1 , F.C. Schoebel, M. Leschke, P. Heering 1 , 
B. Grabensee ~ , B.E. Strauer. Department of Cardiology, ~ Department of 
Nephrology, Heinrich-Heine Universitdt DOsse/dorf, Germany 
Patients with end-stage renal disease (ESRD) have an increased risk of de- 
veloping coronary artery disease (CAD), their rate of cardiovascular mortality 
is 5-10 times higher than in the general population. The incidence of CAD is 
ranging between 30--60% often prompting myocardial revascularisation. 
In a retrospective study the outcome of PTCA (n = 40) and CABG (n = 
65) in patients with ESRD was compared. Both groups were comparable for 
gender, mean duration on dialysis (33 4- 36 vs. 41 ± 44 months) and number 
of risk factors, patients undergoing PTCA were younger (53 4- 12 vs. 57 4- 8 
y, p < 0.05) and more often diabetics (30% vs. 14%, p < 0.05). 
In the CABG group there were significantly more patients with triple-ves- 
sel diesease (62% vs. 40%, p < 0.05); most patients in both groups had 
a multi-vessel disease (95% vs. 77%). PTCA was primarily sucessful in 
95% of the patients, while complete revascularisation was achieved in 91% 
of the patients undergoing CABG. The perioperative mortality after CABG 
was 4.8% as compared to none after interventional revascularisation. The 
cumulative freedom of angina after 6, 12 and 24 months after intervention 
was significantly lower after PTCA. After 12 months 40% of the patients 
after angioplasty were free of angina versus 90% after bypass surgery (p < 
0.001). After 24 months 23 patients after PTCA need an additional revas- 
cularisation (15 patients underwent a second PTCA, 8 patients underwent a 
subsequent CABG) as compared to only 2 patients after CABG (1 × PTCA, 
1 × CABG). The rate of myocardial infarctions were similar in both goups 
after a follow-up of 24 months (10% vs. 9%). The survival rate after 12 and 
24 months was 95% and 82% after PTCA and 93% and 86% after CABG, 
respectively. 
Altough patients with ESRD receiving CABG present a more severe 
coronary artery disease the overall mortality was comparable and clinical 
outcome was improved compared to patients after PTCA. 
~ Favourable Clinical Outcomes With Standard 
Balloon Angioplasty when Stent-Like Results are 
Achieved 
Warren J. Cantor, Nancy M. Wildermann, Michael H. Sketch Jr., Eric 
D. Paterson, James P. Zidar, James E. Tcheng, Robert M. Califf, E. 
Magnus Ohman. Duke University Medical Center, Durham, NC, USA 
Background: Controversy exists as to whether stenting is necessary when 
"stent-like results" (SLR) are achieved with angioplasty (PTCA) alone. We 
sought to determine the clinical outcomes of patients with SLR. 
Methods: The Angioplasty Trials Pool Database contains data on 9728 
patients from six trials and a registry. After excluding grafts (n = 334), left main 
(n = 155), "bailout" stenting (n = 160) and DCA procedures (n = 1374), 7401 
cases using standard balloon angioplasty with and without SLR (defined as 
final diameter stenosis < 25% with no major dissections) were identified. 
Clinical outcomes at six months were compared in the two groups. 
Results: A SLR was achieved in 1196 (16%) of cases. Clinical outcomes 
with PTCA and SLR were similar to trials of stent placement. 
With Without p- 
SLR SLR value 
Number of patients 1196 6205 
Death (%) 1.8 1.2 0.1 
MI (%) 10.8 10.1 0.5 
Repeat 13•1 19.5 0.001 
Revascularization (%) 
Death/MI/Repeat Revasc. (%) 22.6 26.7 0.006 
Conclusions: A SLR can only be achieved in the minority of patients 
undergoing standard PTCA, but is associated with lower rates of repeat 
revasculadzation. The need for stenting when SLR is achieved, and the cost 
implications of a provisional stenting strategy warrant further investigation. 
~ Infarct Artery Following Primary Reocclusion 
Angioplasty, Stent Placement and Thrombolytic 
Therapy for Acute Myocardial Infarction 
Stephanie H. Wilson, Kent R, Bailey, David R. Holmes Jr, Peter B. Berger. 
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, 
USA 
Background: The benefits of thrombelysis in acute myocardial infarction 
(AMI) are limited by reocclusion of the infarct related artery in 25-30% 
of patients following successful reperfusion. The frequency of reocclusion 
following balloon angioplasty (BA) and stenting is less well documented. We 
analyzed the frequency and timing of reocclusion following BA and stent 
placement during AMI from all available studies compared with previously 
published reocclusion rates following thrombolysis. 
Methods and Results: The thrombolysis data included 6061 pts in stud- 
ies with >_75 pts. BA studies with >_50 pts and stent studies with >_30 pts 
with routine angiographic follow-up in >_60% of pts were included. Ten BA 
studies with a total of 1943 pts were analyzed with follow-up angiography 
in 72%• The 7 stent studies included 698 pts with follow-up angiography in 
90%. Using logistic regression analysis, there was a lower rate of reocclusion 
following BA (p < 0•008, odds ratio 0.76 (0.62-0.94)) and stent placement (p 
< 0.0001, odds ratio 0.12 (0.1-0.2)) compared with thrembolysis. 
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Conclusions: Reocclusion following BA and stent placement dudng AMI 
is less frequent than following thrombolysis. This may contribute to the 
supedor outcome of patients treated with BA and stent placement compared 
with thrombolytic therapy in AMI. 
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11 87-42 I A of Diabetics With Restenosis to Comparison 
P 
Diabetics Without Restenosis 
Joseph De Gregorio, Nobuyuki Kobayashi, Milena Adamian, Nicola Corvaja, 
Issam Moussa, Bernhard Reimers, Leo Finci, Lucia DiFrancesco, 
Remo Albiero, Cado Di Mado, Jeffrey Moses, Antonio Colombo. Centro 
Cuore Columbus, Milan, Italy; Lenox Hi//Hospital, New York, USA 
To understand why diabetics are said to have higher restenosis rates we an- 
alyzed 355 consecutive patients (539 lesions) with diabetes who underwent 
intervention and compared diabetics with restenosis (R) to diabetics without 
restenosis (NR), 
Results: The only significant difference found between these groups was 
reference vessel size treated (3.02 ± 0.5 mm in NR vs. 2.88 ± 0.5 mm in the 
R (p = 0.01). All other lesion and patient characteristics were similar including 
lesion length and complexity. When all diabetic vessels treated were divided 
into > or <2.9 mm the restenosis rates are significantly different (27% for 
vessels >2.9 and 42% for vessels <2.9, p = 0.01). The following graph 
depicts this relationship between vessel size and angiographic restenosis. 
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Multivariate logistic regression analysis showed that the only variable which 
correlated significantly to restenosis was the reference vessel diameter treated. 
Conclusion: The most significant attributable charactedstic which pre- 
disposes a diabetic patient to restenosis is when percutaneous intervention 
is performed on lesions which are located in smaller vessels. 
~ Are There Clinical and Procedural Outcome 
Differences Between African and White American 
Undergoing Percutaneous Coronary 
Interventions? 
S. Chiu Wong, Stylianos Papadakos, Carl Rosenberg, Rhonda J. O'Brien, 
Gregory Gustafson. The New York Hospital Medical Center of Queens, 
Flushing NY; New York State Department of Health, Troy NY, USA 
Coronary artery disease is the leading cause of death in both Afdcan and 
White Americans. Whether a racial discrepancy exists in clinical and proce- 
dural outcomes following PTCA is less clear. Using the 1995 New York State 
PTCA Registry database, we compared patient demographics and clinical 
outcomes between these two patient groups. 
African (N = 1137) White (N = 20464) P value 
Pt Demographics 
Age (years)/Male (%) 59.5/53.9 62.3/69.7 Both < 0.0001 
Hx diabetes/hypertension (%) 32.5/75.6 18.1/59.3 Both < 0.0(}01 
Hx MI/CHF (%) 50.9/6.9 50.9/5.0 NS/0.007 
Hx smokinghMVD # (%) 27.3/43.3 25.6/44.6 Both NS 
Hx CABG/LVEF (%) 8.0/51 13.5/53 Both < 0.00(3 
Device Used 
Balloon/Rota @ (%) 94.1/7.7 94.5/7.7 Both NS 
DCAt/Stent (%) 4.8/21.5 5.4/28.6 NS/<0.0001 
Laser/'l'EC" (%) 0.6/0.3 0.8/0.2 Both NS 
in-hospital Events 
Death/Q wave MI/CABG (%) 0.9/0.4/0.8 0.9/0.3/1.5 NS/NS/0.01 
MVD # = multi-vessel disease, ROTA @ = rotablator, DCA $ = directional coronary atherec- 
tomy, TEC* = transluminal extraction catheter 
We Conclude: 1) Compared with white American patients, African Amer- 
ican patients were younger, more frequently female with higher cardiac risk 
profiles and underwent less stent placement procedures. 2) Despite these 
differences, Afdcan Amedcan fared as well as the white American patients 
and were less likely to require CABG post PTCA. 
~ F a t e  of Jailed Side Branch Following Stenting: Six 
Month Angiographic Follow-Up 
Praveen Chandra, Atul Mathur, Narinder N. Khanna, Praveer Agarwal, 
Dhananjay K. Jhamb, "13dechan S. Kler, Suman Bhandari, Ashok Seth. 
Escorts Heart Institute and Research Center, New DelhL India 
Background: "Jailing"of a side branch is an important concern while deploy- 
ing stent in a main vessel. 
Methods: We analyzed serial coronary angiograms of 69 vessels where 
the stent covered the origin of the side branches and reviewed the fate of SB 
immediately after stent deployment and at 6-month angiographic follow-up. 
Results: Mean diameter of the stented vessel was 3.2 ± 0.5 ram. The 
target vessel was the LAD in 47%, RCA in 20% and Cx in 33% cases. Seventy 
percent lesions were AHNACC type B and 14% were type C. Stents used 
included: MICRO II (47%), Palmaz-Schatz (36%), Multilink (3%) and others 
(14%). At baseline, 14/69 (20%) SB had >50% ostial stenosis. Side branch 
dilatation was done in 2 cases, prior to main vessel dilatation. Of the 55 
normal side branches at baseline, 8 developed _>50% stenosis immediately 
post-stent, but 6/8 had normalized again at 6-month angiographic follow-up. 
Of the 14 diseased side branches, 9 showed no change post-procedure, but 
5 (36%) showed further increase in diameter stenosis. At 6-month follow-up, 
3/5 had improved. Hence, at 6-month follow-up, only 4/69 (6%) side branches 
showed overall worsening of which 3 had associated restenosis of the main 
vessel. 
Conclusion: 1 ) Jailed side branches, with no disease at baseline, remain 
largely unaffected after stent deployment in the main coronary vessel. 2) 
Diseased side branches also remain largely, unaffected. 3) However, occa- 
sionally, the stenosis sevehty may increase may increase and this is often 
associated with restenosis of the main vessel. 4) Side branch jailing does 
not appear to be a major concern while stenting the main vessel in coronary 
artery disease. 
,[ 11 87-58 I Procedural Outcomes of  Aorto-Ost ia l  vs. 
Coronary-Ostial Lesions 
Jason B. Wischmeyer, Kenneth C. Huber, Warren J. Johnson, Lee V. Giorgi, 
ASteven B. Laster, William C. Daniel, Barry D. Rutherford. MidAmerica 
Heart Institute, Kansas City, Missouri, USA 
PTCA of ostial stenoses have lower procedural success rates and higher re- 
stenosis rates compared to non-ostial lesions. Debulking and stenting have 
been suggested to improve outcomes. We examine immediate results and 
six-month revascularization rates for PTCA, primary stenting (PS), and de- 
bulking devices (D) in 323 patients with either aorfo-ostial (AO; n = 178) or 
coronary-ostial (CO; n = 145) lesions. Procedural success rates were high 
across all treatment groups. Immediate complications including death, MI, 
and urgent CABG were low and not statistically different between treatment 
groups. Arterial dissection rates were highest for PTCA treated lesions fol- 
lowed by D lesions. PS reduced dissection rates significantly for AO lesions. 
Acute closure was rare and did not occur with PS. The 6-month TLR rates 
were similar for both AO and CO lesion groups. Comparing treatment groups, 
TLR rates were lowest for lesions treated with D and highest for PS lesions, 
however, this was not statistically significant. 
Conclusion: AO and CO lesions can effectively be treated with PTCA, 
debulking devices or etenting with low complication rates. Stenting improves 
acute outcome significantly, however, there appears to be no difference 
between treatment strategies at 6 months. 
AOn= 178 COn= 145 
PTCA D PS P value PTCA D PS P value 
Patients 73 32 73 98 24 23 
Success% 97.3 100 100 0.66 92.9 100 100 0.27 
Dissection% 21.9 15.6 1.4 <0.01 15.3 8.3 0 0.10 
Closure% 4.1 3.1 0 0.23 2 0 0 1 
6 Me TLR% 22.2 18.8 25 0.79 16.3 17.4 28.6 0.42 
~ Influence of Percutaneous Coronary Intervention 
at the Time of Diagnostic Catheterization on 
Hospital Cost 
Jane A. Leopold, Carl F. Moxey, Nicholas A. Ruocco, Thomas J. Ryan, Alice 
K. Jacobs. Boston Medical Center, Boston, MA, USA 
Percutaneous coronary intervention (PCI) performed at the time of diagnos- 
tic catheterization, (ad-hoc (AH)-PCI), has been suggested to offer a cost 
advantage compared to staged revascularization procedures. To compare 
the costs incurred by undergoing diagnostic catheterization and PCI at two 
separate institutions with AH-PCI, we evaluated patients undergoing AH-PCI 
(n = 81) and patients undergoing scheduled (S)-PCI following a diagnostic 
procedure at a community hospital (n = 69). Hospital cost was determined 
utilizing Medicare cost-to-charge ratios for each institution. AH-PCI patients 
were similar in age (62.5 ± 13 vs 63.9 ± 9 years) and female gender (31 vs 
30%) and had a similiar incidence of hypertension (43 vs 50%), diabetes (14 
vs 25%), hypercholesterolemia (60 vs 65%), prior CABG (11 vs 14%), prior 
MI (20 vs 18%), and number of vessels diseased (1.5 vs 1.7) compared to 
S-PCI patients. The incidence of unstable angina and urgent procedures was 
similar between groups as were procedural characteristics including number 
of lesions attempted, device choice and success rate. Hospital cost is shown. 
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Mean SD p value 
S-PCI  $13,725.73 $5342 
AH-PCI $10,043.67 $5145 <0.0001 
Hospital length of stay was similar between groups but did not include 
the outpatient procedural day at the community hospital. This pilot study 
suggests that AH-PCI may be an effective strategy to decrease hospital cost 
and further implies that patients who are likely to undergo PCI should have 
diagnostic catheterization at centers performing PCI; however, the effect of 
AH-PCI on patient convenience and procedural complications will require 
further evaluation. 
• Effect of Gender on Transradial and Transfemoral 
Access for Coronary Procedures 
C.J. Cooper, D.M. Weisshaar, J.K. Gelderman. Department of Medicine, 
Medical College of Ohio, Toledo, OH, USA 
Vascular complications are more common in women after transfemoral ac- 
cess for coronary angioplasty. Whether gender effects other access-related 
outcomes in patients undergoing transradial or transfemoral procedures is 
unknown. 
Methods: We performed a randomized single-center trial in which 99 
patients underwent ransfemoral access (TFA)and 101 underwent ransradial 
access (TRA) for diagnostic cardiac catheterization. Of the 200 patients 
62 were females, 138 were male. Quality of life was measured with the 
SF-36 and visual analog scales at baseline, one day and one week. Patients 
were examined at one day and one week after for complications. Costs 
were measured prospectively. The influence of gender on access-related 
outcomes were assessed. 
Results: One female had unsuccessful TRA, no females had unsuccess- 
ful TFA. The total procedure time was longer in women than men undergoing 
TRA (37.7 ± 26 vs 29.1 ± 12.0 min, p < 0.05) but this was not different with 
TFA (28 ± 117 vs 36.4 4- 95 min, p = ns). This was attributed to a longer 
time to sheath insertion (10.2 4- 10.2 vs 7.2 ± 7.5 min, p = ns) and removal 
in women (6.9 4- 12 vs 3.9 ± 2.0 min, p < 0.05). There was no relationship 
between body surface area and TRA sheath insertion time (r = 0.02, p = ns), 
or total procedural duration (r = 0.06, p = ns). TRA in women was associated 
with better post-procedural quality of life at 1 day with less bodily pain (p < 
0.05), back pain (p < 0.005) and at 1 week with better role-physical function 
(p < 0.01 ), walking ability (p < 0.05) and less back pain (p < 0.05). In women 
overall cost with TRA was not lowered significantly, when compared with TFA 
($2001 [1730, 2588] vs $2312 [1933, 3212] p = ns) although bed costs were 
significantly lower with TRA than TFA $339 [339, 385] vs $457 [457, 679], p 
< 0.0001). 
Conclusion: TRA results in longer procedural duration in women, which 
was independent of body size, suggesting the need for further refinements 
in TRA for women. Despite this, TRA may be warranted in women with the 
improved post procedural QOL. 
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~ A  New Precedent Coronary in Percutaneous 
Intervention: Less than 9% Subsequent Target 
Vessel Revascularization in a Large Scale, 
Diverse Patient, Randomized Trial of Stenting 
Femando A. Cura, Philippe L. L'Allier, Shelly Sapp, A. Michael Lincoff, 
Stephen G. Ellis, Edc J. Topoi. For the EPISTENT investigators; Cleveland 
Clinic Foundation, Cleveland, Ohio, USA 
Backgound: Despite the advances in the clinical use of coronary interven- 
tions, there still are a high incidence of repeat revascularizafion procedures. 
There are multiples randomized trials that demonstrated a significanl reduc- 
tion in the restenosis rate in pts treated with stenls comparing to balloon 
angioplasty. 
Methods: The purpose of this study was to compare from an external 
reference the six month target vessel revascularization (TVR) results from 
the E PISTENT (n = 794 pts) (arm of combined abciximab and direct coronary 
stent) and stent arm from the Benestent I (n = 259 pts), Benestent II (n = 414 
pts) and Stress (n = 204 pts) were analyzed. 
Results: Six months follow-up of the stent assigned patients of the 4 
largest stent randomized tdals are summarized below. The definition of MI 
have some variations between the trials. 
EPtSTENT Benestent  Benestent II Stress 
Death 0.4% 0.8% 2% 1.5% 
MI 3.7% 4.2% 1.5% 6.3% 
TVR 8.7% 17.4% 10.4% 12.2% 
The other three trials have restricted entry to pts with single, discrete, de 
novo in the large native coronary arteries; however, the EPISTENT trial has 
included all type of lesions, including vein grafts, multivessel intervention, 
long lesions, and multilesions. Despite this, the combination of stent and ab- 
ciximab was assessed with the lowest rate of target vessel revasculadzation 
thus far reported. 
Conclusion: With the combined use of stenting and platelet lib/Ilia block- 
ade in a large and diverse population of patients, we have demonstrated a 
new low precedent of target vessel revascularization. 
11 88-52 ] StenUng of Coronary Lesions. A Prospective 
Single Center Observational Study 
Thierry Lef~vre, Yves Louvard, Marie-Claude Morice, Pierre Dumas, 
Christophe Loubeyre, Abdel Benslimane, Rajendra Kumar./nstitut 
Cardiovascu/aire Paris Sud, Massy, France 
Background: PTCA of coronary bifurcations is associated with a lower rate of 
success and a higher risk of complications and target vessel revaculadzation 
compared with non-bifurcated lesions. 
Methods: The strategy of systematic coronary stenting in this setting was 
prospectively evaluated in a single center study. Because technical approach 
and stents used were evolutive, results were compared among 2 periods: I 
(1/1 to 31/8/97) and II (1/9/97 to 31/7/98). 
Results: The study included 341 Pts (346 bifurcation lesions). They were 
62 ± 11 yrs. old, 78% male, 47% had unstable angina and 9% AMI. The side 
branch was stented in 62% of cases and the main branch in 95% (2 branches 
in 56%). The main characteristics of the 2 groups were comparable. 
Period I Period II p value 
Patients 196 145 
6-French approach (%) 73.2 89.3 <0.001 
Procedural success main branch (%) 98.9 100 NS 
Procedural success 2 branches (%) 96.3 97.2 NS 
Tubular stent main branch (%) 49.5 99.3 <0.001 
Final kissing balloon inflation (%) 28.8 73.8 <0.001 
TVR 6 month (%) 24.9 8.9 <0.001 
MACE* 6 month (%) 30.1 18.8 <0.001 
Subacute closure, Acute MI, Death, PTCA or CABG 
Conclusion: Coronary stenting of bifurcation lesions is associated with a 
high procedural success rate. During the study, incidence of "FVR and MACE 
at 6-month follow-up decreased dramatically in relation with a higher Use of 
tubular stents in the main branch and kissing balloon inflation. 
~ Cutting Balloon Prior to Is Angioplasty Stenting a 
Usefuf Strategy for the Reduction of Stent 
Restenosis 
Masato Nakamura, Masato Yamamoto, Tomotake Suzuki, Hidehiko Hara, 
Kenichi Matsuda, Takuro Takagi, Takahiro Nishida, Kazuhisa Mitsuo, 
Tetsu Yamaguchi. Toho University Ohashi Hospital, Tokyo, Japan 
Cutting balloon angioplasty is a strategy proposed to reduce vessel injury 
and vessel stretch. Therefore, cutting balloon prior to stenting may decrease 
vessel expansion and reduce stent restenosis. 
Methods: To investigate our hypothesis, immediate and long term follow 
up outcomes were compared between 118 patients (123 lesions) underwent 
primary stenting (PS) and 73 patients (74 lesions) underwent cutting balloon 
angioplasty followed by stenting (CS). Mean predilatation balloon size and 
predilatation inflation pressure were not different in both groups. Mean stent 
inflation pressure was 11 ± 3 atm in CS, and 14 4- 3 atm in PS respectively 
(p < 0.0001). Quantitative coronary angiography (QCA) measurements are 
as follows. 
QCA measurements PS CS 
Ref. (mm) 3.0 ± 0.5 3.1 ± 0.6 
Pre %DS 64 ± 14 67 4- 11 
Pre MLD (mm) 1.0 ± 0.4 1.0 ± 0.4 
Post %DS 2.6 ± 6.5 4.7 ± 9.5 
Post MLD (mm) 3.2 ~: 0.4 3.4 ± 0.7 
Follow up angiogram was performed in 129 patients out of 132 eligible 
lesions (98%) at 6 ± 1 months. Angiographic restenosis occurred 17 lesions 
(20%) in PS and 5 lesions (10%) in CS. 
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Conclusions: Excellent angiographic results are achievable at lower 
deployment pressure in CS. The favorable long term outcome in CS may 
indicate that cutting balloon angioplasty prior to stenting is a feasible strategy 
for the reduction of stent restenosis.. 
~ R o l e  of Cutting Balloon Angioplasty Prior to 
Coronary Stent (GFX) Implantation 
Seong-Wook Park, Cheol Whan Lee, Myeong-Ki Hung, Jae-Joong Kim, 
Houri-K± Park, Seung-Jung Park, Department of Medicine, University of 
Ulsan, Asan Medical Center, Seoul, Korea 
Objective: Cutting balloon angioplasty is a strategy to reduce vessel wall 
injury. The aim of this study was to evaluate the impact of cutting balloon 
angioplasty (CBA) prior to GFX stenting on in-stent restenosis. 
Methods and Results: One hundred and sixty-six patients with 185 
lesions receiving GFX stenting (<18 mm length) were grouped according to 
the techniques of atenting: group A (high pressure ~ 12 atm), group B (low 
pressure, 9 atm), C (CBA & low pressure, 9 arm). Predilation was performed 
using undersized conventional balloon (group A, B) or cutting balloon (group 
C). There were no differences of baseline characteristics among 3 groups. 
In-sent restenosis tended to be lower in group C than in other groups (Table, 
p = NS) 
Group A, n = 70 Group B, n = 60 Group C, n = 55 
Success rate (%) 100 100 100 
Stent thrombosis (%) 0 0 0 
Balloon/artery atio 1.11 ± 0.08 1.08 ± 0.09 1.11 ± 0.08 
Reference (ram) 3.4 ± 0.4 3.3 ± 0.3 3.3 ± 0.4 
Pre MLD (mm) 0.8 ± 0.5 0.7 ± 0.4 0.8 ± 0.5 
Post MLD (mm) 3.4 ± 0.4 3.2 ± 0.4 3.3 ± 0.4 
F/U MLD (ram) 2.1 ± 0.8 2.0 ± 0.8 2.4 ± 0.6 
Angiographic F/U (%) 94.5 92.9 92.0 
Restenosis (%) 13/52 (25.0) 5/26 (19.2) 2/23 (8.7) 
Success: procedural success, MLD: minimal lumen diameter, F/U: follow up, TLR: target 
lesion revascularization. 
Conclusions: Cutting balloon angioplasty prior to stenting may provide 
a benefit for reduction of in-stent restenosis, as compared with conventional 
predilation technique. Further follow-up data will be followed. 
~ Final Results of a Prospective Comparison of 
Angiography Guided Stent Implantation With 
High- vs Very High Balloon Inflation Pressure 
Barry F. Uratsky, George A. Stouffer, Pedro Estella, Stamatios Lerakis, 
Matt Smiley, Fen Wei Wang, Monica Tocchi, Salvatore Rosanio. University 
of Texas Medical Branch, Galveston, TX, USA 
Background: The impact of high pressure stenting on long-term clinical and 
angiographic outcomes is unclear. 
Methods: We prospectively evaluated the long-term effects of a strategy 
of angiographically-optimized high (12-18 arm) pressure (HP) stent expan- 
sion vs. a pre-specified very high (20 atm) pressure (VHP) strategy in 136 
consecutive pts receiving a single Palmaz-Schatz stent in vessels _>3 mrn. 
Major cardiac events [MACE: death, myocardial infarction and target lesion 
revascularizaUon (TLR)] were monitored for a minimum of 6 months. 
Results: Post-stent minimal lumen diameter (3.1 vs. 3.0 ram) and acute 
gain (2.1 vs 2.0 mm) were similar for VHP and HP. Overall subacute throm- 
bosis rate was 0.7%. After 405 :E 148 days, 27 pts had MACE (29% VHP vs 
9.5% HP, p = 0.005) In pts with angina recurrence undergoing angiography, 
VHP showed a greater late lumen loss (VHP 2.15 ± 0.36 vs HP 1.83 ± 
0.57 mm, p = 0.02) and a more frequent pattern of diffuse restenosis (VHP 
71% vs HP 16%, p = 0.06). By multivariate Cox regression analysis, VHP 
(OR 3.5; 95% CI, 1.4-8.8), 3 vessel CAD (OR 5.5; 95% CI, 2.3-13.5), LAD 
stenting (OR 2.6; CI 1.1-6.3), and smoking (OR 2.6; 95% CI, 1.1-6.2) were 
significant predictors of MACE among 38 variables. 
Conclusion: Angiography-optimized HP proved a safe and effective 
stenting approach, whereas VHP was associated with worse long-term out- 
comes. These findings support the utilization of a less aggressive stent 
expansion strategy to minimize vascular injury by optimizing, rather than 
attempting to maximize, balloon inflation pressure. 
~ Effect of Residual Dissection After Coronary Stent 
Implantation on Early and Late Results 
Thomas C. Gerber, David R. Holmes. Kirk N. Garratt. Mayo Clinic and Mayo 
Foundation, Rochester, MN, USA 
Background: Significant residual dissections after stent placement may 
create an impediment o blood flow end affect outcome. This study compares 
the risk of early and late cardiac events in patients with and without mild or 
severe residual dissections after stent placement. 
Methods: From a database of patients randomized to Gianturco-Roubin 
(GR II) or Palmaz-Schatz (PS) stents, 606 patients without, 64 patients with 
mild (NHLBI type NB) and 42 patients with severe (NHL81 type C/D/E) 
residual dissection (by independent core lab) after stent implantation were 
identified. Patients with vessel occlusions (NHLBI type F) were excluded. 
Results: Pooled for both stent types, the difference in 30d major cardiac 
event (MCE = myocardial infarction, death, PTCA, CABG) and stent throm- 
bosis (ST) rates between the 3 groups was not significant. 12 mo MCE rates 
were 21.1%, 23.4%, and 38.1%, respectively (p < 0.05). Pts randomized to 
GRII stents were more likely to experience a dissection that pts randomized 
to PS stents (p < 0.001) MCE and ST rates for the 3 groups separated by 
stent type are given below. 
GR li PS 
Dissection: No Mild Severe No Mild Severe 
n 286 42 30 320 22 12 
30 d MCE's 3.5% 4.8% 6.7% 0.6%" 4.6%" 8.3%" 
30 d ST 4.9% 4.8% 6.7% 0%§ 4.6%§ 0%§ 
12 mo MCE's 26 .9% 31.0% 33.3% 15.9% 1 4.6% 1 50% 1`  
('p < 0.05, lp < 0.001, §p < 0.001 bychi square test) 
Conclusions: (1) Early MCE's or ST's occur at a rate of 4-7% in patients 
with residual dissection after stent implantation. (2) The rate of late MCE's is 
related to the degree of residual dissection after stent deployment. (3) The 
risk of dissection appears related, in part, to type of stent used. 
~ Difference in Security of Stent Jail Among 
Palmaz-Schatz Stent, NIR Stent, and Multi-Link 
Stent: Effect of Balloon Inflation Through Stent 
Struts 
Takahiko Kinoshita, Yoshio Kobayashi, Mizuo Nameki, Nakabumi Kuroda, 
Yutaka Yamamoto, Akira Miyazaki, Yoshiaki Masuda. Chiba Universi~, 
Chiba, Japan 
Background: Coronary stents are now being implanted in complex lesions 
such as bifurcational lesions. After stenting in a main vessel, dilatation of 
stent struts may be performed to treat the lesion in a side branch and/or 
deliver another stent into a side branch. 
Methods: We made a model of a bifurcation at an angle of 45L The diam- 
eters of the main vessel and the side branch were 3.5 mm. The deployment 
of a Palmaz-Schatz stent (PS, n = 5), NIR stent (n = 5), or Multi-Link stent 
(n = 5) was performed in the main vessel with a 3.5 mm balloon catheter 
inflated to 6 atm. A 3.5 mm balloon catheter was inflated to 6 atm at the 
ostium of the side branch. The minimal lumen diameter (MLD) and cross 
sectional area (CSA) surrounded by dilated stent struts at the ostium of the 
side branch and stenosis within the stent by stent deformity were measured. 
Kissing balloon dilatation with two 3.5 mm balloon catheters was performed. 
Stenosis by stent deformity was measured again. 
Results: 
PS NIR Multi-Link P 
Stent struts MLD (mm) 1.6 :c 0.1 1.7 ± 0.1 2.4 ± 0.1 <0.01 
Stent struts CSA (mm 2) 2.7 := 0.3 2.5 ± 0.3 4.9 ± 0.5 <0.01 
Stenosis in main vessel (%) 
After side branch inflation 34 ± 9 25 ::L 8 34 ± 7 NS 
After kissing 12 ± 1 10 ± 3 14 ± 3 NS 
Conclusions: The MLD and CSA surrounded by dilated stent struts of 
the Multi-Link stent were greater compared with those of the Palmaz-Schatz 
stent or the NIR stent. Balloon inflation through stent struts caused stent 
deformity that resulted in stenosis within the stent in the main vessel. Kissing 
balloon inflation reduced this stenosis, but some residual stenosis remained. 
• Improving Visualization Strategy for Bifurcation 
Lesions in Coronary Interventions 
John D. Carroll, S.-Y. James Chen, John C. Messenger, Bertron M. Groves, 
J.E.8. Burchenal, Keith E. Hellman, Kathy Proulx, Senhu Li. University of 
Colorado Health Sciences Center, Denver, CO, USA 
Background: Optimal views that eliminate or at least minimize vessel fore- 
shortening and overlap (VFO) are a prerequisite for the accurate angiographic 
determination of a stenotic lesion. When a coronary lesion occurs at a bifur- 
cation, the traditional standard views based on single arterial segment are 
likely to be inadequate. 
Methods: A 3D coronary reconstruction technique was utilized to obtain a 
patient-specific coronary arterial tree based on routine angiograms acquired 
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at any two viewing angles. The desired bifurcation region was manually 
indicated as a Tor fork junction on the projection of the 3D coronary tree. An 
optimal strategy map (OSM) with respect to the selected bifurcation region 
was constructed that defines the relationship between the gantry orientation 
(Le., LAO-RAO angles defining the x-axis, CRAN-CAUD angles defining 
the y-axis) and the degrees of VFO (Le., serving as z-axis). OSM allows 
for a computer-simulated projection of the coronary image generated with 
the optimal measurements of VFO relative to any selected gantry angles 
and facilitates subsequent angiographic acquisitions for the interventional 
procedure. 
Results: More than 400 cases of coronary arterial trees have been recon- 
structed. The optimal views associated with the bifurcation at PDA in 30 RCA 
trees were identified and compared with the traditionally suggested views re- 
vealing differences of 15 °- ± 10 ~ in LAO/RAO and 230- ± 80- in CAUD/CRAN 
The accuracy of similarity between the additional computer-generated pro- 
jections versus the actual acquired views was demonstrated with the average 
root-mean-square errors of 3.09 mm and 3.13 mm in 20 LCA and 20 RCA 
cases, respectively. 
Conclusions: The OSM provides an efficient and comprehensive mech- 
anism to define the complex visual projection of coronary arterial structures 
and gantry orientations, minimizing patient and operator x-ray exposure and 
decreasing the use of contrast agents. The assessment of bifurcation lesions 
can be optimized in interventional cases and may prove beneficial in use of 
new coronary devices (Le., bifurcation stents). 
• Acute and Subacute Stent Occlusion: 
Risk-Reduction by Combined Use of Non-Ionic 
and Ionic Contrast Media 
Bruno Scheller, Benno Hennen, Adel Azmy 1 , Thomas Doerr, 
Torsten Markwirth, Hermann Schieffer. Internal Medicine III (Cardiology), 
Saarland Universi~ Germany; 1 Cardiology Department, Faculty of 
Medicine, Cairo Universi~, Egypt 
Background: Data concerning reduction of thrombotic complications by 
using ionic contrast media (CM) in coronary interventions are conflicting. 
Moreover there are no published data about adverse reactions of combined 
use of non-ionic and ionic contrast media. 
Methods: We included in this registry 1.790 patients (pts) who underwent 
coronary angiography using non-ionic CM followed by coronary stenting 
either applying non-ionic CM also (group I, n = 1.233) or switching to ionic 
CM (Ioxaglate) during the interventional procedure (group II, n = 533). All 
pts had 320 mg ASA and 500 mg ticlopidine per day for 1 month after stent 
implantation. 
Results: There was no significant difference in acute reactions between 
the two groups (11.7% in group I vs. 12.7% in group II). Acute stent occlusion 
(AOS) _< 72 hrs as well as subacute stent thrombosis (SAT) _< 14 days, 
however, were significantly more frequent in group I (AOS: 1.7% in group I 
vs. 0.2% in group II with a p-value of 0.008; SAT: 3.0% in group I vs. 1.7% in 
group II with a p-value of 0.001). 
Conclusion: Although combined application of non-ionic CM for diag- 
nostic angiography followed by ionic CM for coronary interventions cause a 
non-significant increase of acute adverse reactions, it significantly reduces 
thrombotic complications after coronary stenting. 
• Impact of Ionic (Ioxaglate) and Non-Ionic 
(Ioversol) Contrast Media on PTCA Related 
Complications 
Martin Fleisch, Bruno M~lhauser, All Garachemani, Franz Eberli, Otto Hess, 
Stephan Windecker, Giovanni Pedrazzini, Bernhard Meier. Cardiology, 
University Hospital Bern, Switzerland 
Background: The interaction of contrast media with the blood coagulation 
system during PTCA can lead to serious thrombotic /embolic events. Al- 
though in vitro experiments show an advantage of ionic (IC) over nonionic 
(NC) contrast media, clinical trials are inconclusive. 
Methods: We are enrolling 2000 consecutive patients (pat) into a prospec- 
tive, randomised, double-blind study. The incidence of PTCA related com- 
plications in the first 629 randomised PTCA pat (367 males, 15 to 82 years, 
mean age 62) are expressed as risk in %. 
Results are shown in the table 
Conclusion: In the ionic contrast group, there is a trend towards less 
thrombo-embolic and other cardiac endpoints like myocardial infarctions, 
temporary occlusions, arrhythmias, reinterventions and use of bailout Re- 
oPro. In subgroups more prone to thrombosis like stented or unstable pa- 
tients, this trend is even stronger. Stents which are implanted in our lab 
freely, whenever a primary result is not perfect, were needed less frequently 
in the IC-patients. This difference reaches statistical significance in unstable 
patients. 
All PTCA Stent Pat Unstable Pat 
Risk (%) (n = 629) (n = 356) (n = 104) 
NC IC p NC IC p NC IC p 
Any event 22 17 0.1" 26 18 0.2" 46 36 0.3" 
Death 2 3 0.6 1 1 0.6 2 4 0.4 
Infarction 10 9 0.6 13 10 0.3 35 27 0.4" 
RepeatPTCA 2 2 0.8 3 2 0.4 4 6 0.5 
ReoPro-BA 10 9 0.6 16 11 0.2" 23 28 0.82 
Stents 256 220 0.2* 256 220 0.2" 67 34 0.02 
*According to statistical power analysis these will be significant if trend continues. BA = 
Bailout. 
However, the advantage of IC is at the cost of a significantly higher 
incidence of nonserious adverse effects like skin rash or vomiting. 
~ D o e s  Non Ionic Contrast Medium Still Modify 
Angioplasty Results in the Stent Era? 
Bernard Chevalier, Thierry Royer, Bernard Glatt, Philippe Guyon. Centre 
Cardiologique du Nord, Saint-Denis, France 
Previous reports emphasized an extrarisk of thrombotic event in case of non 
ionic contrast medium (NICM) use during coronary interventions. In order to 
evaluate the role of NICM assiocated with new ant±thrombotic drug regimen 
(ticlopidine/aspirin) and a high rate of coronary stenting, we retrospectively 
studied 2 times period in a single center: from 03/96 to 02/97, 1713 consecu- 
tive PTCA have been performed using low osmolarity ionic contrast medium 
(ICM) and from 03/97 to 02/98, 1826 PTCA have been performed using 
NICM. Clinical and angiographic data were similar in both groups, including 
15 and 17% of acute MI PTCA. All pts received heparin bolus with systematic 
ACT check; ACT values were not diffrent in both groups. Stenting rate (by 
pt) were respectively 82.5% and 84.5%. 
Results were: 
ICM NtCM p 
Clinical success (%) 94.8 95.6 NS 
Onset of thrombus (%) 0.2 0.4 NS 
Distal embolization (%) 1.3 1.7 NS 
No flow (%) 2.8 2.7 NS 
Side branch occlusion (%) 1.2 1.6 NS 
Stent thrombosis (%) 1.3 1.4 NS 
Q MI (%) 0.8 t .1 NS 
Death (%) 1.1 1.1 NS 
No pt underwent emergent CABG. 
Thus, in the real wodd, NICM use does no longer increase minor or major 
thrombotic event rate during PTCA. 
~ Local Delivery of Weight Heparin Low Molecular 
After Stent Implantation to Prevent Neo Intimal 
Proliferation. Results of the Intravascular 
Ultrasound Sub-Study 
Fran(;ois Schiele, Marie France Seronde, Sanjiv Gupta, Denis 
Pales Espinosa, Jean-Pierre Bassand 1 , Gilles Grollier, 
Emmannuel Delecluse 2, I University Hospital Saint-Jacques, Besan~on; 
2CHU Caen, Caen, France 
Background: Intravascular ultrasound (IVUS) makes possible reliable as- 
sessment of neo intimal tissue volume after stent implantation. The IMPRESS 
study compared the 6 months clinical and angiographic outcome of patients 
after placement of a single Palmaz Schatz stent, randomly allocated to re- 
ceive by local delivery, either placebo or 5000 IU nadroparin (Sanofi, GentiUy, 
France). 
Methods: 72 out of 245 patients from the IMPRESS study were included 
in the IVUS sub-study to assess 6 month neointimal tissue volume. Anglo- 
graphic data were analysed by quantitative coronary angiography, and IVUS 
data by computer-assisted planimetry (Indec system). The lumen (L-Vol) and 
stent volumes (S-Vol) were calculated from area measurement at each can- 
timetre along the stent. The neo intimal tissue volume (T-Vol) was calculated 
as S-Vol - L-VoI. Results were compared using Anova. 
Results (table): IVUS images were suitable for the substudy in 56 pa- 
tients: (31 from control arm and 25 from nadroparin arm). No significant 
control (n = 31) Nadro (n = 25) P 
MLD FU 1.67 ± 0368 1.75 ± 0.49 0.46 
%DS FU 38 ± 20 36 ± 15 0.54 
Lumen '4ol (ram 3) 84.3 ± 23 84.52 :~ 21 0.97 
Stent Vol (mm 3) 131.6 ± 31 t36.0 :E 25 0.57 
Tissue Vol (mm 3) 47.3 ± 11 51.5 ± 13 0.20 
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differences were found either in pre-procedure or in post-stent implantation 
data. No difference was shown in the 6 months angiographic results and the 
T-Vol was similar among the two groups. 
Conclusion: The IVUS sub-study demonstrated the lack of reduction in 
nee intimal tissue volume after local delivery of nadroparin. 
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~ Intravascular Ultrasound Findings of the Patients 
With Abnormal Coronary Flow Reserve Afetr 
Stent Implantation 
Toshiya Muramatu, Reiko Tukahara, Man± Hou, Shigeki Ito, Takehiko Inoue, 
Tatuo Akimoto, Keisuke Hirano. Division of Cardiology, Social Insurance 
Kawasaki Hospital Kawasaki, Japan 
Perpose: We evaluated Intravascular Ultrasound (IVUS) findings of the Pa- 
tients with abnormal coronary flow reserve afetr Stent Implantation. 
Method: We analysed 137 consecutive patients (147 lesions) who re- 
ceived Palmaz-Schatz stents by intravascular ultrasound catheter (CVIS 2.9 
F, 30 MHz) and intravascular Doppler Flow±re. There were 54 (39.4%) patients 
(57 lesions), with abnormal coronary hyperemic response (CFR < 2.0) to the 
intracoronary infusion of 50 ug adenosine after successful stent implantation. 
We analysed that % diameter stenosis (%DS) on coronary angiography, and 
IVUS parameter were per± lesion plaque burden, calcium, % plaque area at 
most severe narrowing and dissection after stent implantation. The % plaque 
area was leaded from total vessel area-lumen area/total vessel area. We 
evaluated that clinical and IVUS findings between normal coronary flow res 
erve group (90 lesion: 57.2 years, 35 females) and abnormal coronary flow 
reserve group (57 lesion: 64.4 years, 23 females). 
Results: 
CFR _> 2.0 CFR < 2.0 p value 
Diabetes Mellitus 48.1% 70.3% P < 0.05 
Calcium 33.3% 43.8% n. s 
per± lesion plaque 42.2% 73.6% P < 0.05 
pre%DS 76.2 ± 9.7 72.2 ± 8.8 n. s 
post%DS 28.4 ± t3.3 30.2 ± 12.2 n. s 
pre %plaque area 79.3 ± 22.4 82.2 ± 16.6 n. s 
post %plaque area 56.5 ± 23.3 65.5 ± 24.5 n. s 
post stent dissection 16.7% 35.1% P < 0.05 
Conclusion: We concluded that diabetes mellitus, residual plaque and 
dissection after stent implantation may lead to the abnormal coronary flow 
reserve. 
~ Pre-lntervention Arterial Remodeling: A New Risk 
Factor for Restenosis After Non-Stent Coronary 
Interventions 
George Dangas, Gary S. Mintz, Roxana Mehran, Ran Kornowski, 
Alexandra J. Lansky, Mun K. Hong, Michael Peterson, Beth Keers, Augusto 
D. Pichard, John R. Laird, Jr., Lowell F. Satler, Kenneth M. Kent, Martin 
B. Leon. Washington Hospital Center, Washington, DC, USA 
To understand the impact of baseline arterial remodeling (REM) on long-term 
outcome after non-stent coronary intervention we used pre-intervention in- 
travascular ultrasound (IVUS) to study 1195 native de hove lesions in 1058 
patients with. REM was determined by comparing the lesion external elastic 
membrane area (EEM) to the mean reference EEM. REM was classified as 
negative (-REM: lesion/Reference EEM < 1.0, n = 690) or positive (+REM: 
lesion/Reference EEM > 1.0, n = 505). Patients were followed for a mean of 
18 months to determine the target lesion revascularization rate (TLR). 
-REM +REM p 
Diabetes (%) 24.8 24.2 0.8 
Reference lumen area (mm 2) 9.5 ± 0.2 9.1 ± 0.2 0.1 
Final lumen diameter (mm) 2.4 ± 0.03 2.5 ± 0.03 0.1 
Final lumen area (mm 2) 6.1 ± 0.1 6.5 ± 0.1 0.01 
TLR (%) 18.7 24.3 0.03 
Using multivariate logistic regression analysis, increasing +REM (odds 
ratio, OR = 4.0, p < 0.01) was an independent predictor of TLR. 
Conclusions: De novo coronary lesions with -REM, as defined by pre- 
intervention IVUS, have lower TLR than +REM despite smaller final lumen 
dimensions. The probability of TLR decreases with increasing +REM, and 
decreases with more -REM. The lower TLR of lesions with -REM at base- 
line may imply a less aggressive proliferative response to intervention or 
absence of late -REM. 
~ C a n  Intracoronary Ultrasound (ICUS) Guided 
"Stent-Like" Balloon Angioplasty Convey a 
"Stent-Like" 6-month Angiographic and ICUS 
Outcome? 
Tatsuya Yasukawa, Yukio Ozaki, Masato Maekawa, Hideto Tukamoto, 
Masashi Kakihana, Hiroshi Shinjo, Kazuaki Takagi, Yoshitaka Oki, 
Tadashi Kobayashi. Aichi Medical Universi~ Nagakute, Japan 
Background: We hypothesized that stent-like balloon angioplasty (BA) 
guided by ICUS may convey a favourable 6-month outcome. 
Methods: To test this hypothesis, we prospectively performed ICUS 
guided BA and 6-month angiographic and ICUS follow-up (fup) in 60 pa- 
tients. Balloon sizing was performed using ICUS guidance where maximum 
balloon size was related to max. vessel area at the lesion site. A "stent-like" 
result was defined as a minimal luminal area (MLA) > 70% of reference 
lumen area (Ref-LA) by ICUS, <30% residual diameter stenosis by QCA, 
and no dissection. When stent-lJke results were not achieved by BA alone, a 
stent was implanted to fulfill this criteria. Thirty four patients (57%) underwent 
BA alone and 26 (43%) required stent implantation as well. Angiographic re- 
stenosis was defined as >50% diameter stenosis by QCA. Complete (100%) 
QCA and ICUS data (pre, post and fup) were available in all patients. 
QCA: ICUS-guided BA Stent p-value 
Ref. Diam pre (ram) 2.79 ± 0.57 2.87 ± 0.46 ns 
MLD pre (mm) 0.99 ± 0.37 0.96 ± 0.39 ns 
MLD post (ram) 2.00 ± 0.45 2.57 -- 0.48 <0.01 
MLD fup (mm) 1.64 ± 0.56 1.83 ± 0.42 ns 
ICUS: 
MLA post (ram2) 5.19 ±: 1.17 7.79 ± 1.92 <0.01 
MLA fup (mm2) 4.43 ± 1.69 5.17 ± 2.94 ns 
Restenosis rate 26% 23% ns 
Conclusions: Although it was only possible to achieve a stent-like re- 
sult using ICUS guided BA in 57% of cases, this does convey a 6-month 
angiographic and ICUS outcome similar to stent implantation. 
~ Intravascular Ultrasound Predictors of 
Angiographic Restenosis in Lesions Treated with 
Directional Coronary Atherectomy 
Hiroyo Uesugi, Etsuo Tsuchikane, Tomoko Kobayashi, Masahiro Izumi, 
Satoru Otsuji, Hitone Tateyama, Tohru Kobayashi, Nobuhisa Awata. Osaka 
Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 
Recently several studies have reported that optimal directional coronary 
atherectomy (DCA) using intravascular ultrasound (IVUS) is associated with 
favorable long-term outcome. The purpose of this study is to determine 
IVUS predictors of restenosis after DCA. One hundred twenty-two lesions 
successfully dilated by DCA alone or DCA with adjunct balloon angioplasty 
without stenting were analyzed, which were eligible for pre- and post- pro- 
cedural IVUS images and 6 month follow-up angiography. Serial IVUS was 
performed using automatic pullback system. The vessel cross-sectional area 
(CSA), lumen CSA, vessel CSA, vessel diameter (VD) and lumen diameter 
(LD) were measured serially at the most narrowest lesion pre-procedure. 
The plaque plus media area (PA) was calculated as vessel CSA minus lu- 
men CSA. Angiographic follow-up was performed 216 ± 29 days afler the 
procedure. 
Angiograpic restenosis (>50% diameter stenosis) was 19.6% (24/122). 
Univariate analysis of IVUS parameters detected three predictors of reste- 
nosis shown in the table below. 
Restenosis Nen-restenosis p value 
(n = 24) (n = 98) 
Pre vessel CSA (mm 2) 14.3 ± 4.2 16.5 ± 4.2 0.028 
Post lumen CSA (mm 2) 7.6 ± 1.6 8.9 ± 1.9 0.0018 
Post minimal LD (ram) 2.9 ± 0.4 3.1 ± 0.4 0.027 
Multivariate logistic regression analysis revealed that the most powerful 
independent predictor was post lumen CSA (p = 0.0048). 
Conclusion: Post-procedual lumen area predicts restenosis following 
optimsl DCA 
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~ A  Randomized Comparison of the Effects of 
Gradual Inflation at Optimum Pressure Versus 
Stent Implantation on Early and Late Outcome 
Kiyoshi Hibi, Yoshiki Kobayashi, Akiko Maehara, Shuichi Oshima, 
Kenji Kato, Junji Takazawa, Hideo Tamai, Takashi Kashiwagi, Peter 
J. Fitzgerald, Paul G. Yock, Taro Saito. Stanford University, Stanford CA, 
USA; Kumamoto Central Hospital, Kumamoto, Japan 
Background: Recent reports have indicated that gradual and prolonged 
balloon inflation using a perfusion balloon catheter (GPBA) may cause less 
arterial trauma and produce a larger arterial umen compared to standard bal- 
loon angioplasty. The purpose of the Gradual Inflation at Optimum Pressure 
Versus _Stent Implantation (GIPSI) trial was to compare GPBA to conventional 
stent implantation (SI) for procedural and long-term clinical outcomes. 
Methods: To date, 97 patients with angiographically documented coro- 
nary artery disease have been randomly assigned to GPBA (n = 48) or to SI 
(n = 49). Intravascular ultrasound (IVUS) studies have been fully analyzed 
before and after intervention in 59 patients (GPBA: 28, Sh 31). 
Results: There were no significant differences in baseline clinical or 
quantitative coronary angiographic (QCA) characteristics between the two 
groups. The patients who underwent SI had a larger immediate increase in 
the diameter of the lumen as determined by QCA than those who under- 
went GPBA (1.58 ± 0.08 vs. 1.22 ± 0.09 ram, P = 0.0036) and a larger 
luminal diameter (2.58 ± 0.07 vs. 2.27 ± 0.07 mm, P = 0.0026) following 
the procedure. The minimal lumen diameter as determined by quantitative 
coronary IVUS was larger in patients who underwent SI compared to those 
who underwent GPBA (2.64 ± 0.07 vs. 2.35 ± 0.08 ram, P = 0.0069), but 
no significant difference was noted in lumen cross-sectional area between 
the groups (6.77 ± 0.32 vs. 5.95 ± 0,32 mm 2, P = 0.08). The 6-month rates 
of target lesion revascularization (TLR) were similar between the groups (SI: 
10,2, GPBA: 8.3%, P = 1.0). 
Conclusions: GPBA results in modestly smaller acute lumen dimensions 
compared with SI. So far, in the GIPSI trial, no benefit in TLR is observed 
between the two groups. Target enrollment and follow up on 400 patients will 
be completed by early 1999. 
~ Distribution of Plaque Volumes Neointimal Six 
Months After Coronary Stent Placement: 
An Intravascular Ultrasound Study 
Thosaphol Limpijankit, Yoshiki Kobayashi, Motoya Hayase, Matthew 
L. Kolz, David P. Lee, Richard E. Kuntz 1, Peter J. Fitzgerald, Paul G. Yock. 
Beth Israel Deaconess Medical Center, Boston, MA; Stanford University 
Medical Center, Stanford, CA, USA 
The frequency distributions of angiographic measures of restenosis following 
stent implantation have been shown to deviate from a gauss±an pattern. 
Intravascular ultrasound provides a direct measurement of neointimal plaque 
within a stent at follow-up. Using motorized pullback, neointimal plaque 
volume (NPV) within the stent can be determined. The purpose of this study 
was to assess if the frequency distribution for instent NPV approximates 
a gauss±an distribution and to determine the overall biological variation of 
neointimal plaque growth within stents at follow-up. 
Methods: Intravascular ultrasound was analyzed at follow-up for 65 bal- 
loon-expandable (15 mm) stents with the use of a motorized pullback system 
at a constant velocity of 0.5 mrn/sec. Images were digitized at I mm intervals 
throughout a stent length. Lumen and stent areas were traced at each intervat 
throughout he complete stent length and NPV assessed by Simpson's rule. 
Results: At an average follow-up period of 194 ± 18 days, the mean 
NPV at follow-up was 42.9 ± 17.6 mm 3 (range 7.1-83.4 mm3). Using mean 
and standard deviations of the data set, we performed chi-square goodness 
of fit analysis. The observed frequency distribution closely approximated a 
gauss±an distribution (p-value = 0.41). 
Frequency 
5,0 1$.0 25.0 36.0 4~0 ~.0 6~O "/5.0 85,0 
Noolntlmal Plaque Volume (ram s) 
Conclusion: The frequency distribution of IVUS-measured NPV within 
balloon-expandable stents approximates a gauss±an distribution. The stan- 
dard deviation of NPV growth inside a stent may be used to estimate sample 
size for treatment effects. 
~ Restenosis Following Six Months Administration 
of Xemilofiban, an Oral lib/Ilia Antagonist: 
A Sub-Study of the EXCITE Trial 
Patrick W. Serruys, William W. O'Neill, Merrill Knudtson, Roger Dreiling, 
Robed Anders, Jay H. Kleiman, Gerrit-Ann van Es. The Excite Investigators 
Thoraxcenter and Cardialysis, Rotterdam, The Netherlands; Win. 
Beaumont Hospital, Royal Oak MI; G.D. Searle & Co., Skokie, IL, USA 
Background: The EXCITE trial is a multicenter, international, randomized, 
placebo-controlled study of the oral GPIIb/llla antagonist xemilofiban (xemi) 
prior to and after percutaneous coronary revasculadzation (PTCR). The pri- 
mary objective of this study of 7246 patients (pts) is to assess the efficacy and 
safety of two doses of chronic (6 month) oral maintenance xemi to prevent 
the thrombotic endpoints of death, MI and urgent revascularization. The sub- 
study objectives are to assess the effects of xemitofiban on the progression 
of disease in the index lesion following PTCR using intravascular ultrasound 
(IVUS) in stented pts and quantitative coronary angiography (QCA) in pts 
treated with angioplasty only. 
Methods: The percentage of in-stent volume obstruction was assessed 
by six month follow-up IVUS in a random subset of the three treatment groups. 
IVUS acquisition was obtained using a motorized pullback system with 3-D 
reconstruction of the boundaries of the lumen and stent using automated 
contour detection based on a minimum cost algorithm. With 130 lesions in 
each treatment arm a power of 90% is obtained, assuming a 25% reduction 
of in-stent neo-intimal volume. Stent restenosis is defined as a minimal lumen 
IVUS area within the stent of less than 25% of the mean reference segment 
lumen area assessed 3-5 mm away from the sent margins. A secondary 
objective of the substudy is to compare the late restenosis rate of the three 
treatment groups for all lesions. 
Conclusions: From October 1997 to the end of April 1998, 732 patients 
from 45 selected sites were included in the substudy. The follow-up IVUS and 
QCA assessments, to be completed by the end of 1998, will be presented. 
POSTER 
Vascular Responses to Injury 
Tuesday,  March  9, 1999,  3 :00 p .m. -5 :00  p.m. 
Moda l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour:  4 :00 p .m. -5 :00  p,m. 
~ Separate and Combined Effects of Continuous 
Intravenous Administration and Local Delivery of 
Beta-Cyclodextrin Sulfate (CDT) on Intimal 
Hyperplasia After Angioplasty in Swine 
Nicolas Meneveau, Bruce Klugherz, Fran Wade-Whittaker, 
Brahim Chaquour, Ed Macarak, Paul Weisz, Robert Wilensky. University of 
Pennsylvania Medical Center, Philadelphia, USA 
Background: Beta-cyclodextrin-sulfate (CDT) binds fibroblast growth fac- 
tors, is anti-coagulative, and reduces intimal hyperplasia after continuous IV 
infusion or per±vascular placement in rats. 
Methods: We assessed the separate and combined effects of continuous 
IV administration and local delivery of CDT on neointimal formation in porcine 
coronary artedes following balloon injury, using a 2 x 2 factorial design. Pigs 
were randomized into 4 groups: 1) control, 2) continuous IV infusion of 100 
mg CDT/kg/d, 3) intramural delivery of 1250 mg CDT, 4) IV infusion plus 
intramural delivery, Continuous infusion was achieved with a peristaltic pump 
and started 2 days before PTCA. Intramural delivery was performed using 
a Cordis Crescendo Catheter following PTCA. Vessels were harvested at 
14 days and evaluated for the maximal intimal thickness (MIT) and intimal 
area (IA) which was normalized to the injury index (11). Damage related to 
the local delivery was assessed by the II and combined histological criteria 
including adventitial rupture, retromedial hematoma, aneurysm formation and 
adventitial dissection. 
Control Local IV iV + local 
(n = 22) (n = 22) (n = 22) (n = 22) 
MIT (mm) 0.45 ± 0.1 0.38 ± 0.11" 0.29 ± 0.6* 0.27 ± 0.1" 
II 0.21 ± 0.1 0.25 ± 0.2 0.26 ± 0.1 0.22 ± 0.1 
IA/II (mm 2) 2.82 ± 0.6 3.03 ± 4 i" 1.67 ± 0.7" 1.95 ± 0.8" 
Damage (%) 6 (27%) 5 (23%) 7 (32%) 7 (32%) 
Mean ± SD; *p = 0.005 vs control; tp < 0.05 vs IV and IV + local 
Conclusion: IV administration of CDT had a substantial effect on intimal 
hyperplasia while intramural delivery had no effect. No additional arterial 
injury is appreciated after delivery with a medication with anti-coagulation 
properties. 
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• Metalloproteinase Inhibition Reduces Constrictive 
Arterial Remodeling Following Balloon 
Angioplaety: A Study in the Atheroeclerotic 
Yucatan Micropig 
B.J.G.L. de Smet 1,2, J.L. Robertus 1 , J.M.J. Rebel 1,2, Y.JM. van der Helm ~ ,
C. Borst ~ , M.J. Post ~,2.3 . 1Heart Lung Institute, Utrecht University Hospital; 
21nteruniversity Cardiology Institute of the Netherlands, Utrecht, The 
Netherlands; 3 Cardiovascular Division, Beth Israel Deaconess Medical 
Center, Boston, MA, USA 
Background: Arterial remodeling after balloon angioplasty has been rec- 
ognized as a major determinant of restenosis. Pertubation of collagen 
metabolism is likely to play a key role in this process. After balloon injury, ma- 
trix metalloproteinases (MMP) expression is upregulated. We investigated 
the effect of Batimistat, a nonspecific MMP inhibitor, on late lumen loss, 
arterial remodeling and neointima formation after balloon dilation. 
Methods and Results: In atherosclerotic lilac arteries of 11 Yucatan mi- 
cropigs, balloon dilation was performed, with serial intravascular ultrasound 
and quantitative angiography before and after balloon dilation and at 42 days 
follow up. The animals were randomly divided in two groups, the Batimastat 
group (n = 5) and the placebo group (n = 6). All animals were intraperitoneally 
injected with either Batimastat or a vehicle, immediately, two weeks and four 
weeks after balloon dilation. Angiographic and echographic late lumen loss 
in the Batimastat group versus the placebo group was 0.4 ± 0.2 mm versus 
0.8:1:0.1 mm (p = 0.031) and 2.4 ± 0.6 mm 2 versus 4.9 ± 0.7 mm 2 (p = 
0.015), respectively. Late media-bounded area loss was used as a measure 
of remodeling after balloon dilation and was 1.1:1:0.7 mm 2 in the Batimastat 
group compared to 3.8 ± 0.8 mm 2 in the placebo group (p = 0.014). Neoin- 
tima formation was 1.4 ± 0.3 mm 2 in the Batimastat group and 1.0 ± 0.2 
mm 2 in the placebo group (p = 0.403). 
Conclusion: MMP inhibition by Batimastat resulted in a 50% reduction 
of late lumen loss after balloon angioplasty by inhibition of constdctive ar- 
terial remodeling, whereas neointima formation was not inhibited by MMP 
inhibition. 
~ T h e  Effects of Tissue Inhibitor of 
Metalloproteinase-2 Gene Transfer on Arterial 
Remodeling 
Chades Landau, Robed S. Meidell. UT Southwestern Medical Center, 
Dallas, TX, USA 
Background: Following balloon arterial injury, there is a late loss in luminal 
area, largely due to remodeling. This process, which involves restructuring of 
extracellular matrix, alters vessel dimensions. To determine whether remod- 
eling could be favorably altered by inhibiting metallopreteinase (MP) activity, 
a gene encoding a tissue inhibitor of MP (TIMP-2) was overexpressed in the 
vessel wall following balloon injury. 
Methods: Four weeks following lilac artery balloon denudation and feed- 
ing of a 1.5% cholesterol diet, 0.5 × 101° plaque forming units of the aden- 
oviral vector encoding TIMP-2 was delivered locally following angioplasty of 
stenosed lilac artedes in New Zealand white rabbits (n = 20). Control animals 
received an identical dose of an irrelevant virus (AdRR5, n = 14). Animals 
were sacrificed 4 weeks later, and pressure-perfused serial sections were 
van-Giesson elastin stained for analysis of vessel compartments. Data below 
represent measurements at the minimal luminal area site of each artery. 
Vessel Areas TIMP 2 Control 
(mm 2) n = 20 n = 14 p 
Lumen area 0.45 ± 0.32 0.36 :I: 0.21 NS 
Plaque area 3.64 :t: 0.88 3.07 ± 0.64 0.05 
EEL area 4.09 ± 0,82 3,43 ± 0.64 0.02 
EEL = external elastic membrane, a surrogate for artery size 
Conclusion: Local gene transfer with the adenoviral vector encoding 
TIMP-2 yields a larger vessel area 4 weeks following angioplasty, reflecting an 
improvement in arterial remodeling. Due to a maladaptive increase in plaque 
area among TIMP-2 treated vessels, this beneficial effect on remodeling 
does not result in a larger lumen. 
I1 90-134 J Pharmacokinetic Profile Intrapericardial 
1 
1 of 
Administration of NO Donors Crit ical ly 
Modulates the Vascular Response to Injury 
Sanjay Kaul, Ral R. Makkar, Artin Terhakopian, Ninet Sinaii, Prediman 
K. Shah. Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Background: Nitric oxide (NO) plays an important role in modulating the 
vascular response to injury. 
Methods: The effects of intrapericardial (IP) delivery of two types of NO 
donors in reducing coronary arterial luminal narrowing were examined in a 
porcine coronary overstretch injury model (B:A ratio = 1.3:1; n = 6 in each 
group). Diazeniumdiolated human serum albumin (HSA/NO, 545 mg, mol 
wt. 73,100, NO release tl/2 of >2 wk., pedcardial residence time of >24 
hr.), diaminoethyl diazeniumdiolate (DETA/NO, 16.25 rag, tool wt. 166, NO 
release h/2 of 20 hr., perieardial residence time of 5 hr.) and their controls 
(HSA and DETA) were administered IP via the perDUCER device using 
a percutaneous subxyphoid approach. Animals were euthanized at day 28 
following angiography, coronary artedes perfusion fixed and tissues prepared 
for histomorphometric analysis. Data are mean ± SD, "p -< 0.05, *'p < 0.001 
vs. DETA. h intima, A: adventitia, I/FL: intima to fracture length ratio. 
Morphometric data (mm 2) 
I A I/FL 
HSNNO 1.36 :I: 0.36 2.38 N 0.53 1.24 N 0.19 
HSA 1.15 :l: 0.82 1.95 ± 0.64 1.06 :~ 0.66 
DETNNO 0.68 :i: 0.51" 1,81 ± 0.66" 0,42 :E 0.35** 
DETA 1.05 :I: 0.16 2.49 ± 0,66 0.87 :t: 0.10 
No significant changes in hemodynamic variables were observed with IP 
delivery of NO donors. Area under the NO concentration-time curves were 
similar, but peak NO concentrations were 100-fold higher with DETA/NO. 
Conclusion: In the porcine balloon overstretch model, a high-dose short- 
duration burst of NO released by IP DETNNO produced a significant re- 
duction in coronary luminal narrowing through reduction of both intimal and 
adventitial hyperplasia. In contrast, a low-dose long-duration NO release by 
HSNNO had no effects. Thus, the pharmacokinetic profile of IP delivered 
NO donor critically modulates the vascular response to injury. 
11 90-1 35  / Role of Cell Cycle Regulators in Experimental 
L J Restenosis 
Merce Roque, Carlos Cordon-Cardo ~ , Valentin Fuster, Juan J. Badimon. 
Cardiovascular Institute, Mount Sinai School of Medicine, New York; 
~ Memorial Sloan-Kettering Center, New York, USA 
Background: Vascular smooth muscle cell (VSMC) proliferation is one of the 
major contributors to restenosis. To ensure a good homeostasis between ceil 
proliferation and programmed cell death, the cell cycle is tightly controlled by 
a series of positive and negative regulators. We have previously reported that 
Rapamycin (R) reduces restenosis. The proposed mechanism of action is 
blockade of cell signal transduction pathways mediated through an increase 
in p27 expression. 
Methods: Expression of p27, ki67 and apoptotic cell death (TUNEL tech- 
nique), were assessed in porcine coronary specimens, harvested from 1 hour 
to 4 weeks after a standard PTCA. Animals received R (i.m.) for 3 days prior 
to PTCA and for 2 weeks after the procedure. 
Results: Expression of p27 is markedly increased in the media layer of 
all coronary specimens between 1 and 2 weeks after PTCA. ki67 expres- 
sion peaked 1 week after the procedure and was significantly reduced by 
rapamycin throughout he restenotic process. Inversely, apoptotic cell death 
was increased in those specimens. Data obtained at 4 weeks are summa- 
rized in the table below: 
p27" ki67" TUNEL* % Stenosis 
Control (n = 14) 22 • 2.8 4.8 :l: 0.7 20.8 ± 6.9 63 :t: 4 
Rapamycin (n = 10) 28 + 5.8 2.0 ± 0.6 49.7 :l: 5.2 36 :L 4.5 
"Data expressed as percent positively stained nuclei (X :t- SEM) 
Conclusions: Our data suggest that the observed inhibitory effect of R in 
restenosis is mediated via a reduced proliferative response and an increased 
apoptotic activity. Cyclin-dependent kinase inhibitor p27 seems to play a key 
role in the regulatory mechanisms involved in cell proliferation and may have 
potential therapeutic implications in the prevention of restenosis. 
1190-136 1 in Versus Inflammatory Component De Novo 
J Restenotic Lesions: Immunohistological Study 
of Coronary Atherectomy Specimens 
M. Marius Rozek, Romuald Wojnicz, Bysani Chandrasekar, Christine 
W. Chang, R. Stefan Kiesz. University of Texas Health Science Center, San 
Antonio, TX, USA 
To assess the role of the inflammatory component in de novo versus 
restenotic atherectomy lesions, we studied 97 specimens obtained by di- 
rectional coronary atherectomy from 93 patients. Based on two criteria: the 
presence of internal elastic lumina and cellular density of the sections (>30 
cells per high power view) 40 specimens were selected (21 de novo, 19 
restenotic). The presence of HLA class II antigens (DR), ICAM-1 (CD 54), 
macrophage (HAM 54), and SMC were examined using monoclonal anti- 
bodies and an avidin-biotin complex method (LSAB®+/AP from DAKO). The 
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intensity of staining was analyzed semi-quantitatively: 0 negative staining, 
1+ mild staining, 2+ moderate and 3+ heavy staining. Only cells with staining 
indexes _>2+ were considered to be positive and were used in calculations 
for this study. Quantitative analysis included images from sections digitized 
by video a 3CCD Sony camera (24 bit RGB resolution, TIFF format) and 
analyzed by Lucia 3.51 software. Positive cells were counted from three 
different images on the same slide (image area 200,000 pixels). The mean 
value was used for statistical analysis. The results were analyzed using t-test 
for independent samples. 
Results: 
Quantitative analysis 
De novo Restenotic p value 
HLA-DR 9.5 ± 2.9" 6.9 ± 3,4 0.04 
ICAM-1 7.8 ± 1.1 6.6 ± 0.7 0.004 
M 9.0 ± 2.5 6.0 ± 3.1 0.01 
mean number of cells ± SD; "p < 0.05 
Both HLA*DR and ICAM- 1 immunoreactivity were prevalent on macrophages 
and endothelial cells from de novo lesions as compared to restenotic lesions. 
No immunoreactivity for HLA-DR or ICAM-1 was present on smooth muscle 
cells in de novo or restenotic lesions. 
Conclusions: De novo lesions express a significantly higher level of in- 
flammatory component surface antigens than restenotic lesions. The inflam- 
matory process appears to be mediated by macrophages and endothelial 
cells but not by smooth muscle cells. 
ORAL  
Evaluation of Coronary Dynamics: Flow 
Reserve and IVUS 
Tuesday,  March  9, 1999, 4:00 p .m. -5 :30  p.m. 
Moda l  Convent ion  Center ,  Room 271 
4:00 p.m. 
r~- ]  Comparison of Deferral Versus Performance of 
PTCA Based Upon Fractional Flow Reserve: The 
DEFER Study 
G. Jan Willem Bech, Bernard De Bruyne I , N/co H.J. Pijls. On behaff of the 
DEFER investigators; Catharina Hospital Eindhoven, The Netherlands; 
1 Cardiovascular Center Aalst, Belgium 
Background: Many patients are admitted for PTCA, without previously doc- 
umented proof of inducible ischemia. This study compares clinical outcome 
after deferral versus performance of PTCA, in patients without documented 
ischemia, based upon fractional flow reserve (FFR). 
Methods: Included were 303 patients with chestpain, admitted for PTCA 
of 1 stenosis without previously documented ischemia at non-invasive testing. 
Just prior to PTCA, FFR of the target lesion was determined at maximum 
hyperemia by a pressure-wire. If FFR < 0.75 this was considered as proof 
of inducible ischemia and PTCA was performed as scheduled. If FFR _> 0.75 
patients were randomized to either deferral or performance of PTCA. 
Results: In total 303 patients were included. In 163 patients FFR was 
>_0.75. These patients were randomly assigned to deferral (n = 76, group A) 
or performance of PTCA (n = 87, group B). In the remaining 140 patients 
(group C) FFR was <0.75 and PTCA was performed anyhow. Baseline and 
QCA characteristics were identical in all 3 groups. After an average follow-up 
of 6 ± 3 months event rates were 4%, 9%, and 14% in group A, B, and C, 
respectively. Event free survival at 1-year in group A, B, and C was 81%, 
81%, and 67%, respectively. During follow-up no differences in functional 
class were present between group A and B, whereas group C improved from 
average CCS class 2.6 to 1.2. 
Conclusions: Of all patients, admitted for PTCA without previous docu- 
mented ischemia, in 46% inducible ischemia could still be proven invasively 
by coronary pressure derived FFR < 0.75. These patients improved signifi- 
cantly by PTCA. In the remaining 54% of patients without inducible ischemia, 
as confirmed by FFR > 0.75, performance as compared to deferral of PTCA 
did not improve event-free survival nor functional class at 1 -year follow-up. 
4:15 p.m. 
186~]  The French Optimal StenUng Trial (FR.O.S.T): 
A Multicenter, Prospective Randomized Study 
Comparing Systematic Stenting to 
Angiography/Coronary Flow Reserve Guided 
StenUng: 6 Month Clinical and Angiographic 
Follow-Up 
Antoine M. Lafont. The FROST Study Group; Paris, France 
Background: The French Randomized Optimal Stenting Trial aimed to com- 
pare the outcome of systematic stenting with that of angioplasty (PTCA) 
guided by intracoronary doppler (CVR) and quantitative coronary angiogra- 
phy (QCA). 
Methods: 253 patients undergoing elective PTCA of discrete (15 mm 
long) stenoses in vessels >2.7 mm and without previous infarction in that 
territory were randomized. In the guided-PTCA group (1), stenting was per- 
formed if post-PTCA CVR was <2.2 and/or residual stenosis > greater than 
35%. In the systematic stenting group (2), all patients underwent placement 
of Palmaz-Schatz 153. Clinical (MACE) and angiographic follow up were 
performed at 6 months. 
Results: 
MLD Residual Restenosis Stenosis MACE TLR 
(6 months) (6 months) Rate (6 months) (6 months) 
Group 1 1.90 ± 0.7 36.4 ± 23.2% 26.8% 15.9% 15.1% 
Group 2 2.03 ± 0.69 32.5 ± 20.1% 18.9% 16.6% 13.4% 
Conclusions: Six month clinical and angiographic follow-up appear sim- 
ilar with the 2 strategies, despite the fact that onty 48.4% of the patients in 
the guided PTCA group required a stent. 
4 :30 p.m. 
F-~ Efficacy of Intracoronary Adenosine 5~-Triphosphate 
(ATP) for Coronary and Fractional Flow Reserve 
(CFR, FFR) 
Allen Jeremias, Steven D. Filardo, Robert J. Whitboum, Robert S. Kernoff, 
Alan C. Young, Peter J. Fitzgerald, Paul G. Yock. Stanford University 
Medical Center, Stanford, CA, USA 
Background: Coronary flow reserve (CFR) and fractional flow reserve (FFR) 
have been shown to be reliable indicators of coronary stenosis severity when 
calculated at maximal hyperemia. However, the standard agent, adenosine, is 
expensive and poody tolerated by some patients. The aim of this study was to 
test the equivalency of adenosine 5'-triphosphate (ATP) to adenosine (ADN) 
in CFR and FFR measurements as compared to the maximal hyperemic 
response of complete coronary occlusion. 
Methods: An open chest canine model was used to create 35 different 
stenoses of the left circumflex coronary artery in 6 animals using a ligature. 
A second ligature placed distally was used for complete occlusion without 
changing stenosis severity. CFR was measured by a 0.014" Doppler-tipped 
wire (FloW/re ®, EndoSonics). FFR was measured simultaneously using a 
0.014" high fidelity pressure wire (PressureWire ~, RADI). 
Results: An excellent linear correlation was noted between ATP and ADN 
for both CFR and FFR (Figures). The mean difference in CFR was 0.15 ± 
0.31 and in FFR 0.007 ± 0.041. However, hyperemia with either ATP or ADN 
was less than post-occlusion hyperemia, resulting in significantly different 
reserve measurements (CFR: 1.93 ± 0.66 and 2.08 ± 0.81 vs. 2.35 • 0.97, 
p < 0.001 ; FFR: 0.62 i 0.24 and 0.63 ± 0.23 vs. 0.58 ± 0.2, p < 0.001). 
CFR FFR 
y-O. .~l l .~.Ts l  x • I~ .00~O J~41t 
Conclusions: 1 .) Intracoronary ATP was equivalent o adenosine in CFR 
and FFR measurements. 2.) Coronary occlusion yielded a better hyperemic 
response with an increase in CFR and correspondingly lower FFR than 
either drug, indicating that maximal hyperemia was not achieved by the 
pharmaceutical agents. 
)> 
C~ 
C3 i 
09 
C~ 
C) 
<~ 
90A ABSTRACTS - ACCIS'99 JACC February 1999 
4:45  p .m.  
~ - ~  Effect of Collateral and Collateral-Adjacent Vascular 
Resistance Alterations on the Coronary Flow 
Reserve of a Collateral-Receiving Artery 
Michael Billinger, Martin Fleisch, All Garachemani, Franz Eberli, 
Bernhard Meier, Christian Seller. University Hospital, Cardiology, Bern, 
Switzerland 
Background: It has been hypothesized that vascular resistance changes 
during hyperemia in the collateral (Rco,) as well as the collateral-supplying 
(contralateral, Rcontra) and -receiving (ipsilateral, Ripsi) areas may influence 
the coronary flow reserve (CFR) of an ipsilateral region (CFR < 1 : coronary 
steal). 
Methods: This study in 20 pts (60 4- 10 years) undergoing percutaneous 
coronary revascularization measured adenosine-induced CFR during vessel 
patency distal to the stenosis using an intracoronary (i.c.) 0.014 H Doppler 
wire. Subsequently and during vessel occlusion, simultaneous distal ipsilat- 
eral flow velocity and pressure (Poccl) as well as contralateral velocity mea- 
surements via a third i.c. wire were obtained before and during adenosine 
infusion (140 mg/kg/'; figure). From those measurements and simultaneous 
mean aortic pressure (Pao, mmHg), a collateral flow index (CFI) as well as 
the vascular resistance indices Rcott, Rcomra and Rips± were computed. CFI = 
(Pocd -5)/(Pao -5).  The study population was subdivided into a group with 
CFI _> 0.15 and a group CFI < 0.15. 
Results: CFI ranged from 0.0-0.58. The coronary stenosis to be dilated 
was similarly severe in the two groups: 84 4- 13% versus 77 4- 11% (NS). 
Rips± remained unchanged during adenosine, and CFR was not associated 
with Ripsi: CFR = 1.6 4- 0.6; r = 0.04. 
Doppler- and I I~1 Doppler- 
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Conclusions: Aside from the influence of the stenosis severity on the 
downstream CFR, hypermia-induced alterations of vascular resistances of 
the collateral bed itself and also of the collateral-supplying vascular area 
cedetermine CFR directly and inversely, respectively. These interrelations of 
vascular areas do not occur in pts with poorly developed collaterals (figure), 
and they are manifest in the absence of ipsilateral resistance changes. This 
is the first study in humans to demonstrate comprehensively the validity of a 
theoretical model explaining the occurrence of coronary steal via collaterals. 
5:00 p,m. 
~4-~- I  How Much Coronary Collateral Flow Protects 
Against Myocardial Ischemia? 
Michael Billinger, Martin Fleisch, All Garachemani, Franz Eberli, 
Bernhard Meier, Christian Seller. Cardiology, University Hospital, Bern, 
Switzerland 
Purpose: The purpose of this study was to determine how much collateral 
flow is necessary to protect the ipsilateral myocardial area against ischemia 
during vessel occlusion. 
Methods: in 201 patients (pts) undergoing percutaneous transluminal 
coronary angioplasty (PTCA) an index of collateral flow (CFI) was determined 
using intracoronary (i.c.) pressure- or Doppler-guidewires. Mean aortic (Pao) 
and distal occlusive (Pocc0 pressure dudng PTCA or distal flow velocity 
dudng (Viocc0 and after (Vi,~-occ0 PTCA were measured continuously. The 
pressure derived CFI was calculated as follows: (Pocc~ - CVP)/(Pao - CVP), 
CVP: Central venous pressure = 5 mmHg. The ratio between Vi,,-occ, and 
Vioccl was used for the determination of Doppler-derived CFI. The degree of 
collateral±sat±on to the vessel to be dilated was also graded angiographically 
(Rentrop; grade 0-3). 
Results: Based on the absence or the presence of ST-segment changes 
(< or >1 ram) on i.c. ECG during balloon occlusion, 50 pts were in the group 
with sufficient collaterals and 151 pts in the group with insufficient collaterals. 
There was an overlap of 15/201 data points (CFI) between the 2 groups. By 
defining a value of CFI >- 38% as sufficient collaterals, there were 5 false 
negative and 10 false positive test results (figure). 
Sufficient Insufficient P 
Collaterals Collaterals 
n 50 151 
age 59 4- 10 58 +10 NS 
CFI 0.48 4- 0.18 0.17 -- 0.09 <0.0001 
Rentrop (0-3) 2.0 ± 0.7 0.8 ± 0.8 <0.0001 
AP 9% 91% <0.0001 
AP: Angina pectoris during PTCA, CFh Conatera] flow index 
,T i 
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Suff~ient Insufficient 
collaterals collaterals 
Conclusions: A collateral flow of >_38% relative to normal flow through 
the patent vessel predicts protection against myocardial ischemia with 94% 
specifity and 89% sensitivity. 
5 :15  p .m.  
[ -~-~ Adaptive Coronary Remodeling Is Evident in Later 
Stages of Transplant Vasculopathy: A Serial 
Intravascular Ultrasound Study 
Khaled M. Ziada, Samir Kapadia, Timothy D. Crowe, Christopher T. Bajzer, 
Suzanne M. Rodkey, Volkan Ozduran, Steven E. Nissen, E. Murat Tuzcu. 
The Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: Remodeling prevents lumen loss in early stages of coronary 
atherosclerosis. Few data exist about the role of remodeling and its time 
course in allograft vasculopathy. We examined the remodeling response to 
progressive vasculopathy by serial intravascular ultrasound imaging. 
Methods: In 38 patients, 78 coronary arteries were imaged at 4 weeks, 
1, 2, and 3 years after cardiac transplantation. Repeated measurements 
of matched sites included lumen area, vessel area, and maximum plaque 
thickness (Pmax). Plaque area represented the difference between vessel 
and lumen areas. Vasculopathic lesions were defined as sites with no disease 
at baseline and Pmax > 0.5 mm at 3 years 
Results: Lesions were identified in 83 of 195 sites. Plaque area increased 
consistently from 4 weeks to 3 years, During the 1 st year, the vessel area 
did not increase, resulting in significant lumen reduction. Between 2 and 3 
years, the vessel area increase overcompensated for progressive disease, 
resulting in a significant increase in lumen size (Table). 
4 weeks 1 year 2 years 3 years 
Plaque Area (mm 2) 1.0 4- 1.4 3.3 4- 2.7 5.1 ± 2.9 6.6 ± 3.1 
<0.0001 <0.0001 <0.0001 <0.0001 
Vessel Area (mm 2 ) 15.9 ± 4.7 16.0 4- 4.6 17.4 ± 5.6 19.6 4- 6.3 
0.60 0.60 <0.0001 <0.0001 
Lumen Area (mm 2 ) 14.9 ± 4.5 12.7 4- 4.4 12.3 ± 4.6 13.0 ± 4.8 
<0.0001 <0.0001 <0.0036 <0.0036 
Conclusions: During the 1st year following transplantation, the remod- 
eling response is inadequate leading to luminal narrowing. Interestingly, in 
the subsequent 2 years, adaptive remodeling compensates for progressive 
vasculopathy resulting in the preservation of the lumen size. 
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Special Topics in Coronary Stenting 
Wednesday ,  March  10, 1 999,  8 :30  a .m. -1  0 :00  a.m. 
Mor ia l  Convent ion  Center ,  Room 271 
8 :30  a .m.  
~-~ Improved Inhospital Outcome With Expanded Use of 
Coronary Stents: Results From the NHLBI Dynamic 
Registry 
David P. Faxon, David O. Williams, Wanlin Yeh, Anil Mehra, 
Richard Hotubkov, Katherine Detre. University of Southern Cafifornia, USA 
The expanded use and acute outcome of stent placement (ST) as compared 
to balloon angioplasty (BA) was evaluated in 2329 patients enrolled from 
7/97 to 2/98 from 15 centers participating in the NHLBI Dynamic Registry. 
344 pts were excluded for multi-device use. Of the remaining patients, 69% 
(1374) had a stent placed. Stents were more commonly placed in males, 
whites, nondiabetics, those without prior P-i-CA or stent, and with higher risk 
lesions (p < 0.01). 93.5% were on ticlopidine and aspirin, lib/Ilia antagonists 
were used in 26%. IVUS was infrequently used (10.7%). Of the 2784 lesions, 
stents were placed in 1718:1233 elective, 331 for a suboptimal BA, 82 for 
bailout, and 72 for reasons unknown. Inhospital outcome for BA and ST 
(elective and suboptimal results) are shown. 
Outcome (%) BA (n = 1066) ST (n = 1564) P 
Final % stenosis 21.2 4.2 <0.001 
Angio success 90.2 97.4 <0.001 
Procedure success 92.0 96.8 <0.001 
Bleeding requiring transfusion 0.3 1.6 <0.001 
Embolization 0.9 1.9 <0.05 
Side branch occlusion 1.1 4.4 <0.001 
Abrupt closure - in lab 1.2 1.7 NS 
Abrupt closure - out of lab 0.2 0.7 NS 
MI - all 1.3 3.1 <0.05 
MI - Q-wave 0 0.6 NS 
CABG, nonelective 1 .O 0.4 NS 
Death 1.3 1.3 NS 
D/QMI/Emer CABG 2.0 1.9 NS 
Conclusion: This contemporary registry experience shows stent use 
occurs in 70% of patients and is associated with better acute outcome 
and equal major complications, but a slightly higher incidence of minor 
complications. 
8 :45  a .m.  
~2-~ Timing of Coronary Stent Thrombosis in Patients 
Treated With Ticlopidine and Aspirin 
Stephanie H. Wilson, Charanjit S. Rihal, Malcolm R. Bell, David R. Holmes 
Jr, Peter B. Berger. Division of Cardiovascular Diseases, Mayo Clinic, 
Rochester, Minnesota, USA 
Background: In patients (pts) receiving coronary stents treated with coumadin 
and aspirin (C/A), the peak incidence of stent thrombosis occurs on the fifth 
and sixth days following the implantation procedure. Little is known about the 
timing of stent thrombosis in pts treated with ticlopidine and aspirin (T/A). We 
aimed to compare the timing of coronary stent thrombosis in pts treated with 
T/A with those receiving C/A. 
Methods: A retrospective databank analysis was performed with 3007 
patients identified who underwent a successful stent implantation procedure 
treated with T/A of which 21 (0.7%) developed stent thrombosis within 30 days 
of stent placement. In contrast, 1096 patients treated with C/A underwent 
successful stent implantation of which 18 patients (1.7%) developed stenl 
thrombosis. 
Results: The median time from stent implantation to stent thrombosis in 
the T/A group was 12 hours (interquartile (IQ) range; 6-72 hrs) compared 
with 4 days in the C/A group (IQ range; 21-168 hrs) (p < 0.0001 ). There was 
no significant difference between the timing of stent thrombosis in pts treated 
with abciximab in addition to T/A (median 17 hours, IQ range; 6-29) versus 
those who did not receive abciximab (median 11 hours, IQ range 9-12, p =: 
0.57). 
Conclusion: In pts who receive coronary stents, stent thrombosis occur.'; 
much earlier following the procedure in those pts treated with ticlopidine and 
aspirin compared with pts treated with anticoagulation therapy. 
9 :00  a.m. 
[8~-~ Availability of Coronary Stents Is Associated With a 
Reduction in Abrupt Vessel Closure Rates 
W. Warren Suh, Diane E. Grill, Charanjit S. Rihal, Malcolm R. Belt, David 
R. Holmes, Jr., Kirk N. Garratt. Mayo Cfinic, Rochester, MN, USA 
Background: Abrupt vessel closure (AC) accounts for the most serious 
complications associated with coronary intervention. Coronary stents have 
improved procedural outcome despite their application to increasingly more 
complex lesions. Whether the availability of coronary stents has lead to a 
decline in AC rates is unknown. 
Methods: A series of consecutive patients (pts) was identified retro- 
spectively from a single center coronary intervention registry databank. Two 
cohorts were analyzed: pts treated between 1988 and 1992 (n = 3617) when 
coronary stents were not generally available and pts treated between 1994 
and 1997 (n = 4518) when stents were available. 
Results: The late treatment cohort consisted of more females (p < 
0.0431), had more comorbidities (hypertension [p < 0.0001], hypercheles- 
terolemia [p < 0.0001], diabetes [p < 0.0001], family history of heart disease 
[p < 0.0001], history of prior bypass surgery [p < 0.0032]), and were more 
likely to be complicated by pre-procedure CHF (p = 0.0008), pre-procedure 
shock (p < 0.0001), MI < 24 hours prior to procedure (p < 0.0132), and emer- 
gency procedures (p < 0.0001). However, there was a significant reduction 
in the AC rates between the two time periods (7% vs 4%, p < 0.0001). In 
a multivariate analysis for AC, after adjusting for female gender (odds ratio 
[OR] = 1.5, upper and lower 95% confidence intervals [CI] = 1.2-1.8, p = 
0.0001), thrombus (OR = 1.9, CI = 1.6-2.3, p = 0.0001) and bend in lesion 
(OR = 1.5, CI = 1.2-1.8, p = 0.0001), the late treatment period remained 
significantly associated with decreased risk of AC (OR = 0.6, CI = 0.5-0.7, p 
= 0.0001). 
Conclusion: Availability of coronary stents is associated with a significant 
reduction in the AC rates among pts undergoing coronary intervention. The 
decline may be explained by earlier, elective deployment of stents in pts who 
otherwise may have been at risk for AC with other non-stent devices. 
9 :15  a .m.  
~-~ Immediate and Long Term Results "T" Stenting in 
Bifurcational Coronary Lesions 
Imad Sheiban, Remo Albiero, Federica Marsico, Carlo Di Marie, 
MatteD Montorfano, Paolo Pagnotta, Flavio Airoldi, Angelo Anzuini, 
Mauro Carlino, Antonio Colombo, Sergio L Chierchia. Interventional 
Cardiology Unit, Dept. of Cardiology, IRCCS, H San Raffaele, Milan, Italy 
Background: The trans-catheter treatment of bifurcational coronary lesions 
(bif) is still a subject of controversy. Aim of the present study was to evaluate 
immediate and long-term results of bifurcational coronary treated by "T" 
stenting approach on both vessels involved. 
Methods: Lesions (les) in which DCA was done, a Gianturco roubin 
stent was implanted and LAD-CFX bifurcation was stented, were excluded, 
The study group consisted of 108 les (54 bif) treated with different coronary 
stents designed for vessels >3.0 mm. Six-month follow-up angiography was 
performed in 76 les (70%). Lesions were separated in four groups based on 
the restenotic vessel: M = restenosis only in the main branch; S = restenosis 
only in the side branch; B1 = restenosis in both branches; B2 = no restenosis 
in both branches. 
Results: A primary success was obtained in all lesions (100%) with 
no major periprocedural complications. Mean angiographic pre-procedural 
reference in the main vessel was 2.84 ± 0.51 mm with pre-procedural MLD 
= 0.94 ± 0.50 mm and post-procedural MLD = 2.76 ± 0.57, while mean 
angiographic reference 9 in the side branch was 2.22 ± 0.57 mm with 
pre-procedural MLD = 0.87 ± 0.58 mm and post-procedural MLD = 2.29 ± 
0.68 mm. At six month follow-up restenosis occurred in 34/'76 lesions (44.7%) 
with a restenosis rate in 23/38 bifurcations (60.5%) with total M involved in 
restenosis in 27/76 lesions (35.5%) and S involvment in 29/76 lesions (38%). 
Conclusions: Although coronary stenting of bifurcation lesions on both 
vessels is associated with optimal immediate procedural success, restenosis 
rate per lesion is high. In nearly 50% restenosis involves both bifurcation 
branches. Improvements in stent design, dedicated stents or the use of 
mini-stent to treat side branches are required and could improve long term 
results. 
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9:30 a.m, 
~-~-~ Comparison of Coronary Stenting in Emodialysis 
and Non Hemodialysis Patients 
Gregoire Dambrin, Claude Le Feuvre, Jean-Philippe Metzger, 
Jean-Paul Bat±see, Farzyn Beygui, Didier Catuli, G@rard Helft, 
St@phane Tabet, Andr@ Vacheron. Necker Hospital Paris, France 
Background: End stage renal disease has been found to increase morbidity 
and restenosis in patients undergoing PTCA. It's not known if this difference 
still remains after coronary stenting. 
Methods: Between January 1995 and december 1997, we performed 
coronary stenting of a total of 232 lesions, in hemodialysis patients (group 
1:25 lesions in 21 patients) and non hemodialysis patients (group 2:207 
lesions in 186 patients). We compared immediate angiographic results, and 
clinical follow-up (2-28 months, obtained for 96% of patients), to analyse 
the effect of hemodialysis after stenting and especially on the need of target 
lesion revascularisation (TLR). 
Results: 
Group 1 Group 2 p 
Age 55 ± 10 62 ± 12 0.003 
Multivessel disease (%) 56 45 NS 
Reference diameter pre-PTCA (mm) 3.2 ± 0.3 3.1 ± 0.3 NS 
% stenosis pre-PTCA 74.3 75.9 NS 
% stenosis post coronary stenting 17.8 10.8 0.03 
Procedura~ success (%) 96 97 NS 
MACE during hospital course (%) 12 3 NS 
MACE during follow-up (%) 32 20.7 NS 
TLR (%) 3"L5 23.5 NS 
Total mortality (%) 19 2 <0.0001 
(MACE: death, PTCA, bypass, or myocardial infarction.) 
Conclusion: Despite a similar initial success rate, coronary stenting in 
hemodialysis patients is associated with a higher immediate residual stenosis 
and a worse outcome. 
9:45 a.m. 
~-~ Final Procedural Diameter Stenosis and Its Influence 
on the 6 Months Outcome After Primary PTCA: 
Results From the Stent PAMI Trial 
Luiz Mattes, Cindy L Grines, J. Eduardo Sousa, Gregg Stone, Marie 
C. Morice, Judith Boura, David Cox, Bruce Brodie, Olivier Madonna, 
William O'Neill. Institute Dante Pazzanese of Cardiology, S~o Paulo, Brazil; 
William Beaumont Hospital Royal Oak, Michigan, USA 
Background: In elective PTCA trials, pts that obtained stent like results (final 
DS < 30% by QCA) had similar late outcome to coronary stenting. Whether 
primary PTCA pts with "stent like" results also have favorable outcomes is 
unknown. The Stent PAMI trial randomized 900 pts with AMI < 12 hrs, at 62 
centers worldwide, either to primary PTCA or heparin coated Palmaz-Schatz 
stent. 
Methods: At the 6.5 mos. anglo follow-up, 553 cine films were available 
for analysis. On an intention to treat basis, we divided them in three groups 
according to final procedural diameter stenosis (DS) analyzed by core lab 
QCA: A) stenting, DS _< 30%, 266 (94%), B) PTCA, DS < 30%, 159 (60%) 
and C) PTCA, DS 31-49%, 107 (40%) pts. 
Results: 
Events/pie A B C P 
AxB; BxC; AxC 
Bailout stenting 26% 2.8% <0.053; 
Dissection 4% 23% 28% <0.05; NS; <0.05 
Post MLD (ram) 2.6 ± 0.4 2.3 ± 0.4 1.9 ± 0.4 <0.05; <0.05; <:0.05 
6 months - ReMI 2.6% 2.6% 2.8% NS; NS; NS 
TVR 5.2% 12% 14% <0.05; NS; <0.05 
All PTCAJCABG 10% 18% 21% <0.05; NS; ,:0.05 
Restenosis > 50% 20% 28% 23% NS; NS; NS 
6.5 mos, MLD (ram) 1.8 ± 0.6 1.8 ± 0.6 1.6 ± 0.7 NS; <053; <0.05 
Conclusions: A final DS < 30% was obtained in 94% of stent group. 
Primary stenting had significantly larger final MLD, lower rates of dissection 
and 6 months TVR. Despite of being favored by 26% of cross-over to stent, 
PTCA with stenosis < 30% had similar late results with pts with stenosis > 
30%. 
POSTER 
[ ~  Refinements in the Approach to Coronary 
Angioplasty 
Wednesday ,  March  10, 1999, 9 :00 a .m. -11 :00  a.m. 
Moda l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour:  1 0:00 a .m. -11 :00  a.m. 
~ Arterial Access a Novel Sealing Site Closure With 
Device: Duett TM 
G0nter Heyer, Herbert Meixl, Hubert Wallner, Bernhard Strohmer, 
Christian Lampersberger, Gary Gershony. Landeskrankenhaus, Salzburg, 
Austria 
Background: Conventional management of arterial access sites following 
diagnostic catheterization and PTCA is associated with patient discomfort, 
prolonged bedrest and local complications. We evaluated a new vascular 
sealing device, the Duett, which is comprised of a balloon delivery catheter 
(~ 3F) and a flowable procoagulant consisting of thrombin and collagen in a 
buffered suspension. 
Methods: Immediately following femoral artery catheterization a total of 
79 patients (age, 66.2 ± 10.3 yrs.) were treated with the Duett sealing device. 
Of these patients, 57 had undergone a diagnostic procedure (2-5F, 54-6F, 
1-7F) and 22 had undergone PTCA (14-6F, 7-7F, 1-8F). All diagnostic 
patients received 5,000 U of intravenous heparin during the procedure. 
Results: The Duett was successfully deployed in all 79 patients imme- 
diately following completion ef the procedure utilizing the same introducer 
sheath that had been used during the catheterization regardless of the level 
of anti-coagulation. The time to hemostasis ranged from 3-5 minutes. All 
patients were ambulated 2-5 hours following the procedure unless a compli- 
cation had occurred. No patient experienced leg ischemia, required surgical 
repair of the artedal access site or developed an infection at the site. In 
one patient (1.3%) a pseudoaneurysm was noted 2 days following the pro- 
cedure and was successfully treated using ultrasound-guided compression. 
In 2 other patients a blood transfusion was given (one following PTCA, the 
other post-diagnostic catheterization). No late complications were observed 
following hospital discharge. 
Conclusions: Initial experience with this new vascular sealing device 
demonstrates its ability to achieve rapid hemostasis and early ambulation 
following diagnostic catheterization and PTCA with a high level of success 
and a low incidence of complications. 
• Monocyte Triggered by Activation 
Platelet-Monocyte Adhesion: A Novel Target to 
Improve Outcome Following Coronary 
intervention? 
Hossam El Gendi, Antony G. Violaris, Ameet S. Bakhai, Dadington 
O. Okonko, Desmond J. Sheridan. Academic Cardiology Unit, Division of 
NHLL Imperial College, St Mary's Hospital London, UK 
Background: Monocyte activation induces pro-coagulant and pro-adhesive 
inflammatory responses and may thus play an important role in thrombotic 
complications after coronary intervention. Platelet-monocyte adhesion (PMA) 
may trigger these effects. 
Method: PMA and monocyte activation was prospectively examined in 
16 patients undergoing left coronary system intervention (9 males, mean 
age 64). Coronary sinus and peripheral samples were obtained at base line, 
post 1 sT balloon inflation, immediately after intervention and 24 hrs later. For 
PMA, a novel technique was used. Blood samples were labelled with CD14 
(Monocyte specific marker) and GPlb (Platelet specific marker). The % of 
CD14-GP1b positive particles (platelet-monocyte aggregates) was measured 
with flow cytometry. Monocyte activation was assessed by down-regulation 
of L-selectin. 
Results: A significant increase in PMA was seen in coronary sinus sam- 
ples immediately after the 1st balloon inflation (51.4 + 4.9 vs 37.7 ± 2.4 
at baseline P = 0.019), this was transient and returned to baseline levels 
immediately after angioplasty (37.8 ± 2.2 vs 37.7 ± 2.4 at baseline, p = ns). 
No increase was seen in peripheral samples (37.7 ± 2.4 (baseline) vs 37.7 
± 2.4 (after 1st inflation) vs 36 ± 3.5 (post procedure)). Monocyte activation 
(assessed by measuring L-selectin mean channel fluorescence) increased 
from a baseline level of 66.4 ± 5.1 to 50.7 ± 5 (p = 0.06) immediately after 
angioplasty and 46.9 ± 6 (p = 0.02 vs baseline) 24 hrs later. 
Conclusion: Our data suggests that PMA is transiently increased at the 
balloon injury site during angioplasty. This adhesion results in prolonged 
monocyte activation and may play an important role in the development of 
complications following coronary intervention. 
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'-J1216-401 Quality of DICOM-Compatible Coronary 
Angiographic Images Obtained With a Portable 
Fluoroscopic Imaging System Compared to 
Conventional Fixed Lab System 
Gregory Y.F. Szto, Thomas J. Linnemeier, James B. Hermiller, Ronald 
J. Landin, Martin R. See, Janice L. Coverdale, Nancy Stephens. The Care 
Group, Indiana Heart Institute, Indianapolis, IN, USA 
Purpose: Advances in technology have produced increased resolution of 
radiographic images obtained with portable fluoroscopic imaging systems. 
To test the quality of coronary angiograms using one of these systems, we 
compared images obtained with a portable imaging system (OEC Series 
9600) to a conventional fixed cath lab system (Toshiba CAS-200A). 
Methods: Informed consent was obtained on 20 pts undergoing routine 
left heart cathetedzation. Diagnostic coronary angiography was performed 
using the Toshiba system, followed immediately by the OEC system. Images 
from the Toshiba system were stored on D-2 digital videotapes and im- 
ages from the OEC were stored on DICOM-compatible CD-ROM Qualitative 
blinded analysis of images was performed with respect to presence/absence 
of lesions, stenosis severity (mild, moderate, severe), presence/absence of 
thrombus, calcium, ulceration and TIMI flow. The coronary tree was divided 
into 20 major segments. 
Results: Of the 20 pts, 11 (55%) were males, age 63 5:11 (range 
37-74). To date, 100 of 400 possible segments have been analyzed. Abnor- 
mal lesions were identified in 15/16 segments from the Toshiba system vs. 
12/16 segments from the OEC system. Stenosis severity of all OEC-dedved 
segments were graded similarly to Toshiba system. Calcification, thrombus, 
ulceration and TIMI flow correlation were also similar. Complete analysis will 
be available at ACC 1999. 
Conclusion: Preliminary analysis indicates a high correlation between 
images obtained with the OEC system and the Toshiba system. This has 
profound implications for portable coronary angiography in the ER, CCU and 
possibly in the office setting in the future. 
~ Differing Coronary Responses to Arterial Balloon 
Angioplasty Between Stable and Unstable 
Lesions. A Combined Study of Intravascular 
Ultrasound and Angioscopy 
Yoshiharu Higuchi, Atsushi Hirayama, Masaaki Uematshu, 
Takayoshi Adachi, Osamu Yamaguchi, Kazuhisa Kodama. Osaka Police 
Hospital, Osaka, Japan 
Background: The restenosis after coronary intervention has been attributed 
not only to plaque proliferation but to vessel shrinkage. In this combined study 
of intravascular ultrasound (IVUS) and angioscopy, we sought to elucidate 
the restenosis processes by comparing those between stable angina pectoris 
(SAP) and acute coronary syndrome (ACS). 
Method: We examined twenty-five patients with SAP and twenty-five 
patients with ACS who had been submitted to coronary interventions (plain 
old balloon angioplasty only). Serial IVUS and angioscopic observations were 
performed immediately after the intervention and after six months follow-up. 
The vessel area (ram 2) and the lumen area (ram 2) were measured. The 
plaque area was calculated by subtracling the lumen area from vessel area. 
Results: (1) In SAP group, 71% of the decrease in the lumen area (from 
5.7 ± 1.9 to 4.0 5: 2.2) was attdbuted to the vessel shdnkage (from 17.7 
5:5.0 to 16.5 ± 4.6) and 29% to the plaque proliferation (from 12.0 ± 3.8 
to 12.5 5: 4.0). In ACS group, 29% of the decrease in lumen area (from 
7.4 5:2.8 to 6.0 ± 4.2) was attributed to the vessel shrinkage (from 19.7 
± 6.3 to 19.3 ± 7.5) and 71% to the plaque proliferation (from 12.3 5:4.8 
to 13.3 5: 5.8). (2) Angioscopicalty, in SAP group, 82% of culprit lesions 
contained yellow plaques and 46% contained thrombi. In ACS group, all 
culprit lesions contained yellow plaques and thrombi. Hence, ACS group had 
angiographicatly more vulnerable plaques than SAP group. 
Conclusions: These findings suggest that coronary arterial responses 
to balloon angioplasty are different between SAP and ACS. Differing plaque 
characteristics observed by angioscopy may have a role in the differing 
artedal responses after balloon angioplasty. 
~ Microvascular Dysfunction Immediately Exists 
After Coronary Intervention: Coronary Flow 
Reserve Improvement During Follow-up 
Junbo Ge, Rahul Bhate, Juying Qian, Dietrich Baumgart, Dirk Welge, 
Michael Haude, Stefan Sack, Raimund Erbel. Department of Cardiology, 
University-GHS Essen, Germany 
Studies have shown improvement of coronary flow reserve (CFR) after coro- 
nary interventions. The purpose of the study was to investigate CFR changes 
immediately after coronary intervention and during long-term follow up. In- 
tracoronary Doppler flow measurement was performed in 23 patients (21 
males, age 59 5:10 years), of which, 4 patients underwent PTCA alone and 
the other 19 patients with subsequent stenting. CFR was performed pre-, 
immediately post- and at 6 months after coronary interventions using a 0.014 
in FloWire ® (Cardiometrics). 
Results: Improvement of CFR was seen in 19/23 patients (83%) after 
coronary interventions (1.90 4- 0.53, pre-PTCA vs. 2.94 + 0.75, post-inter- 
vention, p < 0.001). A further increase of CFR was found in 12/23 patients 
at 6-month follow up (2.43 ± 0.68, post-intervention, vs. 3.07 5: 0.58, at 
6-month follow up, p < 0.001). Of which, only 1 (8%) occurred restenosis 
at 6 months. CFR reduction or no change was seen in the other 11 patients 
at follow-up, of which, 7 (64%) of 11 patients were found with occurrence of 
restenosis. In 4 patients, a reduction of CFR immediately after intervention 
was observed. Improvement at 6 months was found in 3 (75%) of 4 patients. 
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Conclusion: A large proportion of patients showed increase of CFR after 
coronary intervention. A further improvement of CFR was found in neady 
half of the patients and even in patients with a CFR reduction immediately 
after interventions. Therefore, microvascular dysfunction exists in a consid- 
erable proportion of patients post coronary interventions. The immediate post 
interventional CFR does not predict the occurrence of restenosis. 
~ A g e  as a Major and Adverse Risk Factor for Minor 
Clinical Events in PTCA: A Report From the 
NHLBI Dynamic Registry 
Howard A. Cohen, David Williams, David R. Holmes, Jr., Wanlin Yeh, 
Sharon Lawlor, Richard Holubkov, Sheryl Kelsey, Katherine Detre. 
University of Pittsburgh, Pittsburgh, PA, USA 
Previous studies have demonstrated that age is a significant risk factor for 
major adverse clinical events (ACE) in patients undergoing PTCA. The NHLBI 
Dynamic PTCA Registry was designed to reflect contemporary practice and 
in particular the effect of new technology on short and long term outcomes. 
Between July 1997 and February 1998, 2301 consecutively treated patients 
were entered into the Dynamic Registry and divided into three age groups: I 
< 65, II 65--80 (older) and III > 80 (elderly). 
Age at baseline ~65 65-80 >80 p 
Patients (n) 1286 880 135 
Female % 26.7 44,3 55.6 <0,001 
Prior CABS % 11.9 22,4 21 <0.001 
Severe non cardiac disease % 21,4 38,4 45.1 <0.001 
History CHF % 6.0 13,3 23.3 <0.001 
3 vessel disease 19.4 31.3 47.7 <0.00t 
ACC/AHA lesion > B2, C% 67,2 65.1 68.7 <0.001 
Balloon only % 17.8 15.1 8.2 <0,01 
Perforation % 0,2 1.0 1.0 <0.05 
Vascular complications % 1,7 4.2 6.7 <0.001 
Bleeding and transfusion % 0,3 2.4 4.5 <0.001 
Death % 0,7 2.4 2.2 <0.01 
Death. MI, CABS % 3.7 6.7 7.4 <0.01 
PTCA success 92.8 91.6 90.3 NS 
After adjusting for risk profile, age > 65 was independently predictive of 
death, MI and CABS (RR = 1.5, p < 0.05). 
Conclusion: Older and elderly patients were more likely to have prior 
CABS, history of CHF, more complex disease and more severe non cardiac 
disease. Although new technology may allow for the treatment of more 
complex disease in sicker patients, there remains an increased dsk for major 
and minor ACE in the older and elderly population. 
~ Persistent Intracoronary Activity Thrombin After 
Bailout Coronary Stenting 
Kenneth J. Winters, Stacy C. Smith, Paul R. Eisenberg. Washington 
University School of Medicine, SL Louis, MO, USA 
Background: Bailout stenting increases the risk of subacute stent thrombo- 
sis, but the role of thrombin activity is unknown. 
Methods: in this study, fibdnopeptide A (FPA), a specific marker of throm- 
bin activity, was measured in the coronary sinus in 91 patients during coronary 
interventions. Weight-adjusted hepadn doses of 50 to 100 U/kg were given 
if) 
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to maintain ACT values > 300 sec. FPA concentrations were measured dur- 
ing bailout stenting (n = 15) and were compared to levels obtained during 
elective or adjunctive stenting (n = 40) as well as to values from unstented 
patients (n = 36). 
Results: Heparin induced a significant decrease in FPA levels during 
coronary interventions. However, persistent hrombin activity was evident af- 
ter bailout stenting despite mean heparin levels >_ 2.5 anti-Xa U/ml. Subacute 
stent thrombosis occurred in 20.0% of bailout stents as compared with 6.7% 
of patients after adjunctive stents and in 0% after elective stents (P = 0.03). 
(FPA nmol/L) Baseline Heparin Stent Final 
All patients 4.0 ± 0.4 3.2 ± 0.3 2.0 ± 0.2 2.2 ± 0.3 # 
Bailout stents 5.3 ± 1.4 3.9 ± 0.9 2.6 ± 0.5 4.4 ± 1.5" 
Elective stents 3.0 ± 0.4 2.6 ± 0.4 1.7 ± 0.2 1.5 ± 0.2 
Unstented 4.5 ± 0.6 3.5 ± 0.6 2,0 ± 0.2 
# P < 0.001 final vs baseline (ANOVA), "P < 0.05 bailout vs elective 
Conclusions: We conclude that thrombin activity does not acutely in- 
crease during uncomplicated elective or adjunctive stenting after weight- 
adjusted heparin. In contrast, heparin-resistant thrombin activity during bailout 
stenting appears to be a potential mediator of subsequent stent thrombosis. 
~ T h e  Influence of Diabetes on Outcome of 
Percutaneous Coronary Intervention: The NHLBI 
1997--98 Dynamic Registry 
Alice K. Jacobs, Wanlin Yeh, David O. Williams, Sheryl F. Kelsey, Katherine 
M. Detre. Boston Medical Center, Boston, MA; University of Pittsburgh, 
Pittsburgh, PA, USA 
To determine whether diabetes (D) adversely impacts in-hospital outcome 
in patients (pts) undergoing contemporary percutaneous coronary revascu- 
larization (PCR), we evaluated 2,287 pts in the NHLBI Dynamic Registry of 
whom 496 (22%) had D treated with insulin or oral agents. Pts with D were 
older (63.8 vs 62.0 years, p < 0.01), more likely female (45.8 vs 32.0%, 
p < 0.001) and had more hypertension (74.0 vs 55.7%, p < 0.001), prior 
CHF (17.8 vs 7.4%, p < 0.001), prior CABG (20.7 vs 15.1%, p < 0.05) and 
comorbid disease (38.1 vs 26.5%, p < 0.001) compared to non D pts. Mean 
LVEF was lower (52.1 vs 55.7%, p < 0.001) and multivessel disease higher 
(67.5 vs 55.1%, p < 0.001 ) although a similar number of vessels and lesions 
were attempted in D and non D pts respectively. More D pts were treated 
with balloon angioplasty only (28.3 vs 25.7%, p < 0.05) and fewer received 
stents (53.1 vs 60.6%, p < 0.05) and more were judged by the operator to 
be at moderate or high dsk (51.6 vs 42.7%, p < 0.001) compared to non D 
pts. Procedural success (94.3 vs 95.1%) was similar. In-hospital outcomes: 
D No D p value 
Death (%) 3.2 0.8 <0.001 
Any MI (%) 1.6 2.9 NS 
Death/Q wave/MI/Em CABG (%) 3.2 1.5 <0.05 
Multivadate analysis adjusting for baseline differences between groups 
revealed that D was not an independent predictor of in-hospital outcome 
(odds ratio 1.5, 95% CI, 0.7, 2.9). 
Conclusion: D pts undergoing contemporary PCR have a four fold in- 
crease in-hospital mortality compared to non D pts. This highlights the im- 
portance of developing additional adjunctive therapies in this high risk group 
of pts. 
~ Initial Results of the CURE Trial: Coronary Safety 
Brachytherapy With Radioactive-Liquid-Filled 
Balloons 
Judah Weinberger, Howard I. Amols, Peter B. Schiff, Fdeda Trichter, 
Theodore S.-T. Wang, Andrew Berke, David Brogno, Jack Flier, Hal 
S. Wasserman. Columbia Universi~ New York, NY, USA 
Background: The Columbia University Restenosis Elimination (CURE) Safety' 
Tdal is a safety study of radiation treatment with the ~Re-MAG3 beta ra- 
dioactive liquid system of native coronary lesions as an adjunct to conven- 
tional percutaneous revascularization. 
Methods: Patients with either de novo or restenotic native coronary 
lesions undergoing PTCA or stent-based revascularization, were treated with 
13 Gy (adventitial dose) of beta radiation using a solution of 188Re-MAG3 
to inflate an ACS-Lifestream balloon positioned at the lesion site. Vessel 
geometry was defined with IVUS in all cases. Dwell times were calculated 
on-line by the physicist using custom software. 
Results: In the first 25 patients, radiation was delivered successfully and 
tolerated well, with a mean dwell time of 7.56 ± 1.9 minutes. No treatment 
fractionation was required. There have been no procedural complications or 
major adverse coronary events in the first thirty days. Incremental procedure 
time for the IVUS/radiation procedure was approximately 20 minutes. 
Conclusion: In CURE, radiation therapy for patients with native coronary 
lesions using lSSRe delivered through a perfusion balloon catheter has been 
feasible, safe, and without early adverse cardiac events. Interim results of 
angiographic follow-up from the study group will be presented. 
~ Coronary Revascularization in the Elderly: 
Contemporary Experience 
Jane A. Leopold, Gabriel Aldea, L. Adrienne Cupples, Oz Shapira, Thomas 
J. Ryan, Alice K. Jacobs. Boston Medical Center, Boston MA, USA 
Since percutaneous coronary intervention (PCI) is attendant with less post 
procedural morbidity than CABG it is becoming the preferred method for 
revascularization in the elderly (_>75 years). To test the validity of this strategy, 
we evaluated consecutive patients (pts) undergoing CABG (n = 143) and 
PCI (n = 236) at a single center. CABG pts were of similar gender (48.3 vs 
48.8% female) and unstable anginal status (58.7 vs 57.3%) but had more 
hypertension (85.3 vs 62.3%, p < 0.001), diabetes (30.8 vs 19.5%, p < 
0.01), smoking (52.1 vs 19.5%, p < 0.001), hypercholesterolemia (62.2 vs 
20.8%, p < 0.001), prior MI (62.6 vs 17.8%), CHF (30.1 vs 8.5%, p < 0.001), 
peripheral vascular disease (25.9 vs 13.3%, p < 0.001), COPD (19.6 vs 
8.9%, p < 0.003), and multivessel disease (91.6 vs 48.1%, p < 0.001). The 
incidence of in-hospital death, 1.4 vs 2.5%), stroke (2.1 vs 0.85%), respiratory 
failure (2.8 vs 0.85%), elevated creatinine post procedure (4.9 vs 2.3%), were 
similar between pts treated with CABG and PCI respectively. Major vascular 
complications were less frequent (0.7 vs 3.4%, p = 0.09) and transfusions 
more frequent (25.8 vs 9.3%, p < 0.001) in pts treated with CABG compared 
to PCI. Myocardial infarction (defined differently) occurred in 0% of pts treated 
with CABG (Q-wave) and 3.8% of patients treated with PCI (CK elevation > 
two times upper limit of normal). Multivariate analysis adjusting for baseline 
differences revealed CABG was an independent predictor of minor (elevated 
creatinine, transfusion, respiratory failure) odds ratio 3.25, 95% CI 1.937, 
5.474, p = 0.0001 but not major (death, stroke) odds ratio 1.03, 95% CI 
0.331, 3.220 complications. These data suggest that elderly pts represent 
a high risk group, particularly those treated with CABG. Major morbidity 
is similar and only minor complications higher in pts treated with CABG 
compared to PCI. 
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~ T h e  Relation Between Stent Metal Surface Area, 
Tissue Protrusion and Recoil in Coiled Wire 
Stents 
Eugene V. Pomerantsev, Eberhard Grube, Yoshiki Kobayashi, 
Marcus Herchenbach, Peter J. Fitzgerald, Simon H. Stertzer. Stanford 
University Hospital Stanford, CA, USA 
Methods: In order to establish if the amount of recoil depends on the degree 
of stent area coverage, we compared acute and late results of the deployment 
of Wiktor stents (7-9% area) in 128 coronary segments in 111 consecutive 
patients and AVE GFX stents (20% area) in 50 coronary segments of 45 
patients. QCA was performed pre, post procedure and at follow-up. 
Results: Corresponding binary restenosis rates were 25.3% and 24.6%. 
Radiopacity of both stents allowed automated edge detection of deployed 
stent in non-opacified vessel. Acute lumen recoil (ALR) was calculated as the 
difference between the average diameter of largest inflated balloon (BD) and 
MLD post procedure. Acute stent recoil (ASR) was obtained as a difference 
between BD and average stent diameter (SD) post deployment. Late stent 
recoil was computed as the difference between SD post deployment and at 
follow-up. Average follow-up duration was 6.1 ± 1.3 months. 
Parameter Wiktor AVE G FX P 
ALR, mm 0.59 -I- 0.37 0.38 ± 0.34 <0.001 
ASR, mm -0.03 ± 0.38 0.02 ± 0.35 NS 
LSR, mm 0.15 ± 0.41 0.16 ± 0.5 NS 
There was no significant relation between the amount of ALR, ASR and 
LSR and restenosis. The difference between ALR and ASR is attributable to 
the tissue protrusion between widely spaced struts. 
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Conclusion: Higher metal surface coverage may be an important con- 
sideration when stenting lesions with large plaque burden. 
~ Matched pairs comparison of ACS Multilink and 
AVE GFX Stents in Coronary Artery Disease 
Stefan R. G6hdng, JLirgen Haase, Hans St6rger, Nicolaus Reifart. 
Main-Taunus Heart Institute, Bad Soden and Red Cross Hospital Frankfurt, 
Germany 
The two stainless steel stents Multilink and GFX differ with respect to design 
(slotted tube vs corrugated ring), flexibility, profile, cell size, and metal cov- 
erage. We used beth stents for all types of lesions including e.g. tortuous, 
thrombotic, >20 mm length. To compare the long term results we screened 
1,989 patients with Multilink and 1,239 with GFX stent treated in 1996 and 
1997 and selected 221 patients for each stent that were matched for vessel 
diameter, ostial location, old eaphenous vein graft location, chronic occlusion, 
and lesion length > 20 mm. 
Results: 
ACS-Multilink AVE-GFX 
Vessel diameter (ram) 3.16 3.20 
MLD post (mm) 2.93 3.03 
Residual Stenosis (%) 7.3 5.1 
Acute stent thrombosis 2 1 
Death in hospital 0 0 
CABG 4 4 
Follow up: 
MLD 6 months (mm) 1.99 2.15 
% stenosis 6 months 31.9 32.3 
Restenosis (_>50%) 28% 32% 
Q-MI 2.4% 0% 
CABG 6.4% 6.2% 
Death 4.7% 2.1% 
Re-PTCA 25.8% 27.6% 
Target lesion revasc. 29% 32% 
Conclusion: With both stents a similar low residual stenosis can be 
achieved due to a favourable radial strength. At 6 mos follow up the Multilink 
as well as the GFX presented with comparable angiographic and clinical 
results. 
~ Randomized Comparison of Gold-Plated Steel 
Stent With Conventional Steel Stent: Results of 
the Angiographic Follow-Up 
Albert Sch6mig, Adnan Kastrati, Josef Dirschinger, J0rgen Pache, 
Julinda Mehilli, Helmut Sch0hlen, Shpend Elezi, Franz-Josef Neumann. 
Deutsches Herzzentrum, 1. Med. Kiln±k, TU ME~nchen, Germany 
Background: Stent coating with various agents has frequently been in- 
vestigated as a strategy for reducing thrombosis and restenosis. Despite 
encouraging experimental results, we have recently reported a less favor- 
able clinical outcome in patients randomly assigned to receive steel stents 
plated with a pure gold surface. In this report, we present the results of the 
angiographic follow-up. 
Methods: This randomized trial was designed to assess the influence 
of a gold surface on the outcome after coronary stent placement. Before 
the procedure, 729 patient (pts) were randomly assigned to receive either 
conventional, non-coated steel stents (SS: 363 pts) or steel stents with a 
complete gold surface, 5 mm in thickness (GS: 366 pts). Both stent types 
were slotted tube stents with identical design. Follow-up angiography at 6 
months was performed in 71% of the patients. All angiograms were evaluated 
with an automated quantitative system. Restenosis was defined as a diameter 
stenosis _> 50% at follow-up angiography. 
Results: There were no differences in baseline clinical, angiographic and 
procedural data. The follow-up results are displayed in the table. 
GS SS P 
Diameter stenosis, % 52.6 ± 32.3 45.6 ± 29.6 0.005 
Minimal lumen diameter, mm 1.46 ± 1.04 1.64 ± 1.00 0.02 
Late lumen loss, mm 1.56 ± 0.94 1.33 ± 0.89 0.002 
Restenosis rate, % 48.3 37.7 0.005 
Target lesion revasculadzations, % 24.3 16.0 0.005 
Conclusions: this randomized trial demonstrates that plating the steel 
stent with a gold surface exacerbates the hyperplastic response of the vessel 
wall after stenting. These findings underscore the relevant impact of stent 
surface on the process of restenosis after this intervention. 
~ Procedural and Late Outcomes Following 
Multi-Link DUET TM Coronary Stent Deployment: 
Final Report for the U.S. Registry 
Dean J. Kereiakes, Mark Midei, James Hermiller, Richard Schlofrnitz, 
Charles O'Shaughneesy, Marina Sievers, Marye Ellen Valentine, 
Lynn Vandertie. The Lindner Center, Cincinnati, Ohio, USA 
Background: The Multi-Link DUET (MLDuet) is the next generation MULTI-LINK ® 
(ML) stent with enhanced strut width, radiopacity, radial strength and flexibil- 
ity, mounted on a low profile, high pressure (16 atm) stent delivery system. 
Methods: To show safety/efficacy using a primary endpoint of Major 
Adverse Cardiac Events (MACE) at 30 days, 270 patients with single, de 
novo, native coronary stenoses _<25 mm length received 295 MLDuet stents 
(diameters 3.0, 3.5, 4.0 mm; lengths 8, 18, 28 mm). 
Results: Individual/composite MACE; lesion and procedural characteris- 
tics compared with the ML ASCENT trial are shown. 
MULTI-LINK DUET ASCENT MULTI-LINK 
(n = 269) (n = 518) 
% (count) % (count) 
MACE (hierarchial) 3.0% (8) 4.6% (24) 
Death 0.4% (1) 0% (0) 
Q/non QMI 2.2% (6) 3.7% (19) 
Stent Thrombosis 1.1% (3) 0.6% (3) 
Device Success* 99.6% (268) 96.2% (492) 
Ref Vessel Diameter (mm)~ 2.99 ± 0.54 2.96 ± 0.49 
Lesion Length (ram)'1" 11.9 ± 5.9 10.6 ± 5.9 
% Residual Stenosis*l" 6.2% ± 10% 6.0% :~ 11% 
* p < 0.05; t = mean ± SD 
Conclusion: The MLDuet demonstrates enhanced performance and low 
% MACE despite longer lesion length compared with the ML stent. Complete 
6 month angiographic followup will be presented. 
~ Clinical Events and Angiographic Results of the 
First 142 Patients Randomized in the BESMART 
Study 
Ren~ Koning, Khalife Khalife, Martine Gilard, Philippe Commeau, 
Philippe Brunel, Marc Bedossa, Marie-Claude Morice, Luc Maillard, 
Thierry Lef~vre, Bernard Citron, Francois Schiele, Nicolas Danchin, 
Michel Zupan, Phillipe Guyon, Alain Cdbier, Jacques Puel. On behaff the 
BESMART study group, University of Rouen, France 
Background: The BESMART (BEstent in SMall ARTeries) Study is an ongo- 
ing french multicenter randomized trial comparing etent (Bestent, Medtronic 
inc.) implantation versus balloon angioplasty in small coronary arteries in or- 
der to evaluate the immediate results and 6-month angiographic restenosis 
rate. 
Methods: Pts with documented myocardial ischemia and with a de novo 
lesion in a native coronary artery <3 mm diameter were included. The use of a 
balloon _>3 mm diameter was an exclusion criteria. The Bestent was manually 
crimped on a balloon of 2.5 or 2.75 mm diameter. After stenting, Pts received 
ticlopidine (500 mg/d) and aspirin (160 mg/d). The CMS 3.0 version (edge 
detection) was used by an independent corelab for quantitative angiographic 
analysis (QCA) of reference diameter, minimal lumen diameter (RD, MLD) 
and % diameter stenosis (%DS). 
Results: 142 consecutive Pts (59:1:10 yrs) with 148 lesions were ran- 
domized to PTCA (n = 72 pts) or stent (n = 70). On intention to treat ba- 
sis, procedural success rate was 99% with both techniques. Major adverse 
events were: death (PTCA 0, stent 0), myocardial infarction (PTCA 1, stent 
1), rePTCA (PTCA 0, stent 1) and hematoma (PTCA 0, stent 1). In 15 Pts 
of PTCA group (21%) there was a crossover to the stent group because of 
unsatisfactory results of PTCA. QCA results: 
PTCA STENT 
Pre Post Pre Post 
RD (ram) 2.11 - 0.37 2.27 ± 0.36 2.11 ± 0.37 2.41 ± 0.33 
MLD (mm) 0.75 ± 0.24 1.68 ± 0.47 0.71 + 0.09 2.07 ± 0.35 
%DS 65±9 27±14 66+11 14±11 
Conclusions: These preliminary in-hospital results show that stenting is 
feasible and safe in small coronary arteries. The results of stenting are at 
least comparable to those of PTCA. 
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1217-89 ] Do We Still Need Pressure Stent High 
I 
Implantation With the New Less Rigid Second 
Generation Stents Mounted on Non-Compliant 
Balloons? 
Rainer Hoffmann, Phillip Haager, Heinz Klues, J0rgen V. Dahl, 
Uwe Janssens, Peter Hanrath. University RWTH Aachen, Germany 
Background: First generation stents were limited by excessive regidity and 
nonuniform expansion patterns. 
Methods: To analyze whether the new ACS HP MultiLink stent (15 mm 
length) mounted on a non.compliant high-pressure ballon still requires high 
pressure implantation quantitative angiography and intravascular ultrasound 
was performed for 70 native lesions randomily assigned to low pressure stent 
implantation (10 atm) or high pressure implantation (16-18 atm). Minimal 
lumen diameter and reference diameter were determined by angiography. 
Intravascular ultrasound was used to determine stent cross-sectional area 
(CSA) and minimal lumen diameter at 1 mm increments as well as reference 
CSA. 
Results: Stent apposition was complete in all 70 lesions. A lumen/reference 
CSA ratio ~ 70% was obtained in 61 vs 75% of stents using low vs. high 
pressure stent implantation techniques. 
Low pressure High pressure P 
(n = 35) (n = 35) 
QCA reference (ram) 3.01 ± 0.50 3.13 ~_ 0.40 0.104 
QCA MLD final (ram) 2.60 ± 0.47 2.81 ± 0.46 0051 
IVUS lumen CSA final (ram 2) 6.03 ± 1.41 7.50 ± 1.22 0.001 
IVUS MLD final (ram 2) 2.33 ~E 0.35 2.65 ± 0.28 0.002 
Lumen CSA/Ref. CSA 0.80 ± 0.21 0.88 ± 0.19 0.255 
Conclusion: Implantation of the less rigid MultiLink stent with a non-com- 
pliant balloon results in good stent apposition already at low implantation 
pressure. However, to obtain good stent expansion throughout the whole 
lesion length high balloon pressures are still required. 
1 7-90 1 A Randomized Trial Comparing by 21 Multicenter 
Intravascular Ultrasound the Acute and Subacute 
Recoil of 4 Stents 
Herve Le Breton, Remi Sabatier, Philippe Commeau, Gilles Grollier, 
Bruno Huret, Marc Bedossa. Department of Cardiology, Rennes, France 
Method: This is a multicenter prospective randomized intravascular ultra- 
sound study comparing 4 stents with different designs: Palmaz-Schatz (PS), 
Cord±s; NIR, Boston Scientific; Wiktor (W), Medtronic; Gianturco Roubin It 
(GRII), Cook. All stents were evaluated by angiography and IVUS immedi- 
ately after stenting (Ho) and at 24 hours (H24). At IVUS, the stent diameters 
(SD) were evaluated in 8 to 9 sections for each stent, after implantation (H0) 
and the day after (H 24) and a mean diameter was calculated. At angiography 
(ANGLO), the minimal lumen diameter (MLD) was measured. SD and MLD 
were compared to the balloon diameter (BD). 
Results: 
NIR (n = 11) PS (n = 11) 
HO H24 HO H24 
IVUS SD 3.4 ± 0.4 3.4 ± 0.4 3.5 ± 0.4 3.5 i 0.4 
SD/BD (%) 100 ± 10 100 ± 10 101 ± 6 102 ± 6 
ANGLO MLD 2.7 ± 0.5 2.6 ± 0.4 2.9 ± 0.5 2.9 ~ 0.5 
MLD/BD (%) 81 ± 8 79 ± 8 84 ± 11 83 = 12 
W (n = 12) GR II (n = 9) 
H0 H24 H0 H24 
IVUS SD 3.4±0.4 3.4±0.4 3.1 ±0.2 3.0±0.1 
SD/BD 98 ± 5 98 ± 6 86 ± 3 86 ± 4 
ANGLO MLD 2.9 ± 0.3 2.9 ± 0.3 2.6 ± 0.3 2.5 ± 0.3 
MLD/BD 83 ~: 8 84 ± 7 72 ± 7 69 ± 10 
A significant acute recoil was only observed with the GR II stent. N 
subacute recoil at 24 hours was detected whatever the stent design. 
Conclusion: This study point out that the stent design may influence the 
immediate results of stenting and the occurrence of acute recoil. 
1217-91 I Stent Diameters Coronary are Systematically 
f 
Overestimated 
Carsten W.T. Nolte, Uwe Nixdorff, German Pritzel, Josef Ludwig, 
Alois Wortmann, Werner G. Daniel. Univ. of Er/angen-NEimberg, Germany, 
Background: Intravascular ultrasound and quantitative coronary angiog- 
raphy [edge detection (ED)] have demonstrated an overestimation of the 
Palmaz-Schatz-stent diameters. The aim of the study was to evaluate the 
ED measurements (M) of metalUc coronary stents (S) under different X-ray 
conditions. 
Methods: A coronary phantom (P) was designed to simulate 13 acutely 
implanted S of different manufacturers inside the P-wall. Inner S-diameter 
and lumen outside the S were 3.5 mm and were filled with contrast agent, 
to mimic a 1:1 S-vessle relation. Angiograms of the P were performed with 
66, 85 and 105 kilovolts (kV) by Hicor X-ray unit (Siemens AG). ED was 
assessed with the QCA- CMS (Medis). 
Results: The graphs show mean diameters (MD • SD, 15 M each) an- 
alyzed inside the S compared with M outside the stents at corresponding 
kV-levels. Right: S with good X-ray visibility resulted in a significant overesti- 
mation by ED up to 105 kV (p < 0.001 ). Left: S with poor X-ray visibility were 
overestimated, but only up to 85 kV (p < 0.001). 
Phantom 
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(ram) 3.0 3.25 3.5 3.7S 4.0 (ram) 
Conclusions: Diameters of acutely implanted S are overestimated by 
ED. These data are essential for QCA-guided S-implantation and should 
be considered in angiographic studies dealing with the effects of coronary 
stenting. 
I1 I Experience With the PTFE Covered Stent in i 21 7 -92  
Percutaneous Coronary Interventional 
Procedures: Indications and Outcome 
Joseph De Gregorio, Nicola Corvaja, Milena Adam±an, 
Nobuyuki Kobayashi, Issam Moussa, Bernhard Reimers, Lucia Di 
Francesco, Marco Vaghetti, Leo Finci, Yoshio Kobayashi, Remo Albiero, 
Carlo Di Mar±o, Antonio Colombo. Centro Cuore Columbus, Milan, Italy 
One of the new tools in coronary interventions is the PTFE (polytetraflu- 
oroethylene) covered stent by JOMED. The purpose of this report is to 
communicate our single center experience regarding the various situations 
and outcome in which this device has been utilized. 
Methods: We report the results of 33 consecutive patients with 35 lesions 
where 42 covered stents were implanted for various conditions: 22 denovo 
lesions (20 in saphenous vein grafts [SVG]); 6 coronary aneurysms; 4 vessel 
rupture; 3 restenosis. 
Results: 
Mean age 65 i 11 Stent length (ram) 22 ± 13 
Diabetes, n (%) 7 (21) Lesion length (ram)* 13 ± 10 
Hypertension,  (%) 22 (67) Ref vessel dial  (ram)" 3.6 ± 0.6 
Unstable angina, rl (%) 12 (36) MLD pre (ram)* 0.94 ± 0.6 
LVEF% 57 i 15 MLD post (ram)" 3.6 ± 0.7 
Previous CABG, n (%) 20 (57)  Procedure Success 94% 
Time to CABG (yrs) 8.3 ± 5 Acute thromb, n (%) 0 
3 vessel disease, n (%) 25 (71)  Subacute thromb, n (%) 0 
Type C lesion, n (%) 29 (83) Hosp QMI, n (%) 1 (3) 
Ostial & prox site n (%) 23 (66) Hosp CABG, n (%) 0 
Balloon/artery atio 1.1 ~ 0.1 Hosp Death, n (%) 1 (3) 
Max Inf Press (arm) 17.0 ± 4 30-day MACE, n (%) 3 (9) 
"QCA data is for non-aneurysmal lesions only. MLD = minimal lumen diameter. MACE = 
major adverse cardiac event. 
There was one case of coronary rupture which ended in hospital death 
that was unrelated to the stent. 30-day MACE includes two in-hospital MACE 
and one CABG 4 weeks post intervention. 
Conclusions: Short and intermediate-term clinical outcome with this de- 
vice show it to be a safe and effective tool especially for the treatment of 
SVG disease. The results of long-term outcome will be discussed the time of 
presentation. 
~ ~  Stent-Grafts Containing a Polytetrafluorethylene- 
Membrane: Emerging Indications for Implantation 
into Human Coronary Arteries 
Math±as Eisner, Wolfgang Auch-Schwelk, Dirk H, Walter, 
Volker Sch&chinger, Andreas M. Zeiher. Medizinische Klinik IV, Dep. of 
Cardiology, J.W. Goethe-Universi~ Frankfurt a.M, Germany 
Background: Coronary stent grafts consist of two coax±ally alligned stain- 
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less steel stents which encompass a microporous PTFE-membrane. These 
devices provide a hermetic sealing of the vessel wall which may prove bene- 
ficial for 1) eliminating protrusion of residual plaque; 2) providing a barrier to 
the transmigration of inflammatory cells and diffusion of macromolecules and 
3) reconstructing vessel integrity after coronary rupture during conventional 
PTCA. 
Methods: In a prospective observational szudy a total of 48 PTFE stent- 
grafts [SG] was implanted in 40 patients for treatment of degenerated saphe- 
nous vein grafts [SVG] (group A), in-stent restenosis [ISR] in native coronary 
arteries (group B) or bailout situations for coronary rupture or threatening 
closure (group C). Clinical outcome at 3-6 months follow-up was evaluated. 
Results: Coronary rupture during conventional PTCA resulting in car- 
diac tamponade could effectively be treated by immediate SG-implantation, 
obviating emergency surgery. Follow-up: 
Patients: Total: Group A: Group B: Group C: 
N = 40 14 14 12 
Comb. Endpoint 1 15 (37.5%) 2 (14.3%)* 6 (42.9%) 7 (46.7%) 
Re-PTCA 13 (32.5%) 2 (14.3%) 5 (35.7%) 6 (50%) 
1 : Death, MI, occlusion, CABG, target lesion revascularization. *: P < 0.05 
Conclusions: Implantation of coronary PTFE stent-grafts 1) is very 
promising for treatment of degenerated SVG; 2) is not suitable for treat- 
ment of in-stent restenosis in native coronary arteries; 3) is highly efficient as 
bailout following PTCA-induced coronary rupture. 
~ Treatment of Using a Bifurcation Lesions New 
Tubular Stent 
Ivan De Soheerder, Jo Dens, Walter Desmet, Patrick Coussement, 
Jan Piessens, Frans Van de Weft. University Hospitals Leuven, Belgium 
Background: Treatment of bifurcation lesions remains one of the major 
limitations of most tubular stents. The V-Flex T'~ stent (Global Therapeutics, 
Broomfield, CO) was especially designed to easy access sidebranches and 
to allow opening of the stent cells up to 4 mm without breaking the stent 
filaments. 
Methods: Twenty-one bifurcation lesions (14 LAD, 5 RCA and 2 main 
stem lesions) have been treated using the double overlapping stent tech- 
nique. First the largest vessel was stented using a 16 to 24 mm stenL After 
placing a guidewire in the sidebranch by crossing the first stent, balloon 
dilatation of the stent cell was performed with an appropriately sized balloon. 
The proximal part of the second stent was located within the first stent and 
the distal part in the sidebranch. After deployment of the second stent, both 
stents were finally inflated simultaneously with two 'kissing' balloons. 
Results: Procedural success was 100%. The total procedure duration 
was 54 ± 23 min and the total contrast volume was 260 -E 54 ml. There 
was one (not stent related) in-hospital death in this study. There were no 
acute or subacute thrombotic stent occlusions, however, 2 pts had a mild 
CK raise (_<300 IU) without ECG changes. Three pts had temporahly renal 
malfunction. All pts are scheduled for control 6 m angiographic follow-up. 
Conclusion: Treatment of bifurcation lesions is feasible and safe with this 
new tubular V-Flex '~ stent. However, it remains a more challenging technique, 
requiring a considerable amount of contrast dye. 
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~ Glycemic Control and Adverse Cardiac Major 
Events After PTCA in Patients With Diabetes 
Mellitus 
Ibrahim R. AI-Rashdan, James M. Rankin, Tom G. Elliott, Christine 
W. Wong, Ron G. Carere, J. David Hilton, Mark A. Henderson, Robert 
I. Hayden, John J. Spinelli, Christopher E. Bulter. The University of British 
Columbia, Vancouver, Canada 
Background: Diabetics are at increased risk for major adverse cardiac 
events (MACE) after PTCA. Whether optimal glycemic control reduces this 
risk is unknown. 
Method: Prospectively collected outcome data for all coronary inter- 
ventions performed on residents of British Columbia between April 94 and 
November 97 were obtained from the BC Cardiac Registries. Diabetics with 
known HbAlc level within 6 months of intervention (n = 411) were classified 
according to American Diabetes Association Guidelines as having optimal 
(HbAlc < 7%, n = 124) or sub-optimal (HbAlc >_ 7%, n = 287) glycemic 
control. MACE (Death, MI, re-PTCA or CABG) for each diabetic group and 
all 9175 non-diabetics were compared using Kaplan Meier analysis. 
Results: Mean age (62.7 yr) and stent rates (38.3%) were similar in 
the three groups. Sub-optimally controlled diabetics were more likely female 
(38.7%, p < 0.001) than those with optimal control or no diabetes (29.0 vs 
25.9%, p = 0.43). At one year, there was no difference in MACE between 
diabetics with optimal control and non-diabetics (23.5% vs 24.6%, p = 0.32). 
MACE was significantly higher in diabetics with sub-optimal control than those 
with optimal control (36.5 vs 23.5%, p = 0.009). This effect was independent 
of gender with an adjusted relative risk for sub-optimal control of 1.86 (95% 
CI 1.18-2.91). 
Conclusion: Following PTCA, diabetics with optimal glycemic control, 
have rates of MACE indistinguishable from non-diabetics. Diabetics with 
sub-optimal control are at higher risk. These encouraging data showing het- 
erogeneity of outcome amongst patients with diabetes warrant prospective 
evaluation. 
• Stenting During Coronary Improves Intervention 
Procedural and Long-Term Clinical Outcomes in 
Diabetics 
Ambika Bhaskaran, Robert Siegel, Barbara Barker, Paul Underwood, 
Warren Breisblatt, Alvin Nuttalt, Debbie Swanson, Jennifer Vermillion, 
Peter Santos. Advanced Cardiac Specialists, Phoenix, Arizona, USA 
Diabetes is an adverse risk factor for restenosis following transcatheter inter- 
vention. Limited data is available on long term outcomes following stenting 
(ST) in diabetics. We evaluated procedural and 12-month clinical outcomes 
following ST versus optimal PTCA in diabetics who underwent coronary inter- 
vention at our center. From 1/96 to 8/98,758 diabetic patients (mean age 64 
years; 45% female) presenting with acute coronary syndromes, underwent 
PTCA (N = 570) or ST (N = 188). Co-morbid factors included age > 70, 32%; 
prior MI, 31%; prior CABG, 24%; EF < 40%, 22%; multivessel disease, 18%; 
cardiogenic shock, 3%. ST vessels were >3.0 mm in diameter. Adjunctive 
IABP support was employed in 17.4%. 
Results: Procedural success was 96% with PTCA and 99.5% with ST (p 
= 0.00t). CABG rate was 0.5% with PTCA and 0 with ST (p.'0.13), with 3 
(0.5%) deaths in the PTCA group (p = 0.13). No subacute ST thrombosis. 
12-Month Follow-up (952%; mean 7.65 ± 4.18 mos) 
Re-PTCA CABG Death Event-Free Mean rise in 
LVEF 
PTCA 52 (9.1%) 41 (7.2%) 29 (5.1%) 78.1% 3.21% 
ST 12 (6.4%) 3 (1.6%) 5 (2.6%) 90.9% 4.48% 
'p' value 0.34 0.58 0.04" 0.03' 0.94* 
Conclusions: 1 ) In a select diabetic population, procedural success was 
significantly better in coronary lesions treated with ST, compared to optimal 
PTCA. 2) In-hospital event rates were comparable. 3) At 1-year follow-up, 
absolute and event-free survival were significantly betler in the ST group. 4) 
Long-term index lesion revascularization rates were lower with ST. 5) The 
ST cohort showed significant increase in LV systolic function, compared to 
the PTCA group. 6) In diabetics, routine stenting of coronary lesions should 
be considered, as acute and long-term clinical outcomes, including survival, 
appear to be significantly superior to optimal balloon PTCA results. 
1 2 1 • •  Insulin Treatment of Diabetic Women Predicts a Worse Outcome After Intracoronary Stenting. 
Clinical Results of 564 Consecutive Patients 
Alexandra J. Lansky, Roxana Mehran, Jeffrey J. Popma, George Hanzel, 
Kenneth M. Kent, Gregg W. Stone, Felicia Breedy, Geraldine Tepordei, 
Nicole Burwell, Augusto Pichard, Lowell F. Satler, Martin B. Leon. 
Washington Hospital Center, Washington DO, USA 
Although the use of intracoronary stents has improved the clinical outcome 
of women after coronary interventions, the impact of stenting on the outcome 
of women with diabetes mellitus (DM) has not been defined. To evaluate the 
clinical impact of stenting in diabetic women, we reviewed the clinical and 
angiographic outcome of 564 consecutive women (no DM, N = 386; DM on 
oral agent, N = 76; DM on insulin, N = 102) undergoing stenting between 
1994 and 1996. Insulin treated women were younger (63 yrs vs 68 vs 67 
years, p = 0.004), had less ACC/AHA B2/C lesions (25% vs 49% vs 65%, 
p = 0.02), smaller reference vessel size (2.80 mm vs 3.07 mm vs 3.12 mm, 
p = 0.007), and a similar final diameter stenosis (3% vs 4% vs 5%, p = 0.7) 
compared to no DM or DM patients on oral agents. 
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No DM Oral DM Insulin DM 
In hospital (%) 
Death/MI/CABG 0,7/0.5/1.5 1,3/0.0/0.0 2.7/2.61/0.9 
1 Year FU (%) 
Death/MI/TLR 1.7/0.7/13.4 3.8/0.0f10.4 0.9/2.7/26,95 
MACE (%) 12,4 12.2 26.9 t
MACE: Major Adverse Cardiac Events; tp < 0.01 ; Tp < 0.001 
Multivariate predictors of TLR included age (OR 0.98, p = 0.05), lesion 
length (OR 1.05, p = 0.005), and insulin treated DM (OR 2.11, p = 0.01). We 
concluded that after stenting, women with insulin treated DM have (1) similar 
favorable procedural success, (2) insulin and not oral treatment of diabetics 
is predictive of TLR in women, (3) exaggerated neointima formation re- 
quires adjunctive antiproliferative therapy (possibly vascular brachytherapy) 
to definitively reduce restenosis in insulin-treated DM women. 
I1 34] of Mellitus on the Initial and 
| 
21 8-1 Influence Diabetes 
Long-Term Outcome of Patients Treated With 
Coronary Stenting 
Joaquin J. Alonso, Francisco Fem~ndez-Aviles, Juan M. Duran, 
Benigno Ramos, Ana Serrador, Isabel Garcimartin, Luis de la Fuente, Juan 
C. Mufioz, Emilio Garcia-Mor~m. Hospital Universitario, Valladolid, Spain 
Background: Data are scant regarding the clinical and angiographic evolu- 
tion of diabetic patients undergoing coronary stenting. 
Methods: We compared the evolution after stenting of 134 diabetics (149 
lesions) with the outcome of a control group of 849 non-diabetic stented pts 
(960 lesions). Diabetics were older (64 ± 9 vs 61 ± 11 years, p < 0.001 ) and 
had a higher rate of female gender (23% vs 11%, p = 0.001). Hypertension 
and heart failure occurred more frequently among diabetics (48 vs 38%, p 
= 0.014 and 11.5% vs 4.8%, p = 0.031 respectively). Diabetics had longer 
stented segments (23 ± 12 vs 21 ± 12 mm, p = 0.026) and lower minimal 
lumen diameter after stenting (3.3 ± 0.5 vs 3.4 ± 0.5 mm, p = 0.025). No 
other differences between diabetics and non-diabetics were found. Follow-up 
was completed for 92% of pts at 28 ± 19 months. 
Results: Diabetics and non-diabetics had similar clinical success at one 
month (93 vs 92%). However, angiographic restenosis rate, loss index and 
incidence of major adverse events during the follow-up were significantly 
higher among diabetics. Diabetes was identified as an independent predictor 
of restenosis, greater loss index and occurrence of adverse events. 
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Conclusion: The initial outcome of diabetic pts after coronary stenting 
is similar to that of non-diabetic pts. Nevertheless, diabetes independently 
predits a worse clinical and angiographic long-term evolution 
1218-135 j Patients With 
1 
Coronary Stent Implantation in 
Non-Insulin Dependent Diabetes Mellitus 
Murat Gencbay, Muzaffer Degertekin, Ismet Dindar, Fikret Turan. Kosuyolu 
Heart and Research Hospital /stanbu/, Turkey 
Background: There were conflicting data about the outcome of coronary 
stenting in patients with non-insulin dependent diabetes mellitus (NIDDM). 
The objective of this study was to determine the effect of NIDDM on the 
outcomes of coronary stenting. 
Methods: We evaluated major in-hospital complications (death, MI, or 
CABG), the acute Quantitative angiographic (QCA) results, and late (>6 
NIDDM (n = 96) No DM (n = 96) 
Stent implanted (n) 106 106 
Lesion stented (n) 108 107 
In-hospital major complications (%) 
Death 1 0 
MI 2 1 
CABG 0 0 
Reference diameter (mm) 3.2 :E 0,7 3.2 ± 0.6 
Pre-MLD (mm) 0.98 ± 0.33 1.01 ± 0,29 
Post-MLD (mm) 2.86 ± 0.50 2.88 ± 0.41 
Thrombosis (%) 2 1 
6 month F/U MLD (ram) 2.12 ± 0,77 2.06 ± 0.64 
Binary restenosis (%) 17 18 
months) QCA results of 96 patients with NIDDM. This group was compared to 
another individually matched group of patients with non-diabetic patients (96 
pts). Matching criterias were; patient's age and gender, indication for stenting, 
clinical presentation of the patients, coronary angiographic characteristics 
(type of stented vessel, pre-, and post-procedural MLD, reference diameter of 
target lesion, lesion lenght, stent lenght), maximal stent deployment pressure, 
left ventricular ejection fraction. 
Results are shown in the table. All p's were >0.05. 
Conclusion: Procedural success, clinical outcomes, and restenosis rates 
following stenting in NIDDM was comparable to non-diabetic pts. 
I1218-136 / The Impact of Diabetes on the Outcomes After 1 
Treatment of in Stent Restenosis 
Roxana Mehran, Alexandra J. Lansky, George Dangas, George Hanzel, 
Javed M. Ahmed, Mare Byrne, Michael Peterson, Gregg W. Stone, Kenneth 
M. Kent, Augusto Pichard, Lowell F. Satler, Martin B. Leon. Washington 
Hospital Center, Washington DC, USA 
Patients with diabetes have a higher in-stent restenosis (ISR) and revascu- 
larization rates after stenting of native coronary artery lesions. The effect of 
diabetes (DM) on outcomes after treatment of in stent restenosis are unclear. 
We reviewed the clinical outcome of 515 pts (no DM, n = 348; DM, n = 167) 
undergoing treatment of ISR in native coronary arteries (67.7%) or saphe- 
nous vein grafts (32.3%). DM group had more hypertensives (82% vs 61%, 
p < 0.05) and women (40.12% vs 20.34%, p < 0.01). Angiographic findings 
include similar lesion length (13 ± 12 mm vs 14 ± 11 mm) and vessel size 
(3.0 mm vs 2.88 mm) in DM and non DM pts, but more severely calcified 
lesions in the DM group (7.09% vs 3.45%, p < 0.05). Angiographic success 
(100% vs 99.5%) and final diameter stenosis (20% vs 19%) were similar in 
both groups. 
No DM (n = 348) DM (n = 167) 
In hospital (%) 
MACE 5.6 6.8 
1 year Follow-up (5) 
Death 4.51 8.911- 
MI 0.75 0,50 
TLR 24.35 32.021- 
MACE: Major Adverse Cardiac Events; 1 P < 0.05 
We conclude that DM patients undergoing treatment of ISR have a similar 
in hospital event rate as non DM, however at 1 year follow-up diabetes is an 
important predictor of recurrence and is associated with a significantly higher 
mortality rate than non diabetics. 
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• Relationship Between Fractional Flow Reserve 
and %stenosis Measured With Quantitative 
Angiography and Intravascular Ultrasound After 
Coronary Angioplasty 
Nobuhiko Kondo, Atsushi Hirayama, Masaaki Uematsu, Takayoshi Adachi, 
Kazunori Kashiwase, Kazuhisa Kodama. Osaka Police Hospital 
Cardiovascular Division, Osaka, Japan 
Background: The percentage of coronary stenosis (%stenosis) measured 
with quantitative angiography (QCA) or intravascular ultrasound (IVUS) is a 
morphological index for coronary stenosis, and myocardial fractional flow re- 
serve (FFR) measured with a pressuere wire is a functional one. To determine 
weather %stenosis is also available for functional assessment of coronary 
stenosis after percutaneous transluminal coronary angioplasty (PTCA), we 
examined the relation between FFR and %stenosis before and after PTCA. 
Methods: We measured %stenosis with QCA (%-diameter stenosis) and 
IVUS (%-area stenosis), and FFR with a pressure wire before and after PTCA 
in 32 patients with coronary artery disease. FFR was measured at maximum 
myocardial hyperemia after intravenous administration of adenosine. %-area 
stenosis was defined as lumen area of stenosis lesion/lumen area of proximal 
reference artery. FFR was defined as mean distal coronary pressure from 
stenosis lesion at maximum hyperemia/mean arterial pressure at maximum 
hyperemia. 
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Results: %-diameter stenosis decreased from 79 ± 14% to 35 ± 16%, 
and %-area stenosis decreased from 80 ± 19% to 45 ± 21% after PTCA. 
FFR increased from 0.65 4- 0.19 to 0.80 ± 0.09 after PTCA. Both %-diameter 
stenosis and %-area stenosis was correlated with FFR before PTCA (r = 0.64 
and r = 0.67, respectively). After PTCA, %-area stenosis was correlated with 
FFR (r = 0.63), whereas %-diameter stenosis was not correlated with FFR (r 
= 0.41 ). 
Conclusion: Our results suggested that %stenosis measured with IVUS 
is available as a functional index for coronary stenosis after PTCA although 
%stenosis measured with QCA is not. 
1219-45 1 Modified AHA/ACC Lesion Classification: Effect 
i on Fractional Flow Reserve in Patients With 
Single Vessel Coronary Artery Disease 
Simon Biggart, Simon Redwood, Michael Webb-Peploe. Cardiothoracic 
Centre, Guy's and St. Thomas' Hospital NHS Trust, St Thomas' Hospital, 
London, UK 
Investigation with intermediate stenoses continues to be difficult. Diame- 
ter stenosis (DS) is routinely used to assess the significance of coronary 
artery stenoses, but the relationship between DS and myocardial perfusion 
remains imprecise. Fractional flow reserve (FFRmyo) aids assessment of 
the functional significance of coronary stenoses. A variable correlation be- 
tween FFRmyo and %DS has been reported. We therefore investigated the 
relationship between FFRmyo and %DS, assessed by quantitative coronary 
angiography (QCA) according to lesion type (modified AHA/ACC). Trans- 
stenotic pressure was measured using 0.014" pressure monitoring guide 
wire in patients with isolated left anterior descending (LAD) stenoses. Aortic 
pressure (Pa), post-stenotic pressure (Pd) and right atrial pressure (Pv) were 
measured. FFRmyo = (Pd-Pv)/(Pa-Pv) at maximal vasoditatation. 
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47 patients were studied (Age 56.5 J: 10.4 (mean ± SD), 76% male). The 
effect of lesion type on %DS and FFRmyo are shown. Type A/B1 = closed 
circles/solid line (r = 0.82, p = 0.001). Type B2/C = cross/dashed line (r = 
0.68, p = 0.002) FFRmyo was lower in more complex lesions (0.76 ± 0.17 
vs 0.64 + 0.21, p = 0.04) which was not due to change in %DS (46.2 ± 18.9 
vs 49.6 ± 17.5, p = 0.2). A weaker correlation was noted between FFRmyo 
and %DS in the more complex lesions (A + B~: r = 0.82, B2 + C: r = 0.68). 
We conclude that: (1) Despite similar %DS, more complex lesions have 
a lower FFRmyo, implying under estimation of lesion severity by using QCA 
alone, and (2) For FFRmyo < 0.75, in order to achieve a given FFRmyo, one 
requires a more severe type A/B~ than B2/C stenosis. 
~ Fractional Absolute and Relative Flow Reserve, 
Coronary Blood Flow Velocity Reserve in Relation 
to 99mTc-MIBI Spect Scintigraphy in Intermediate 
Coronary Lesions 
Steven A. Chamuleau, Jan J. Pick, Karel T. Koch, Rob J. de Winter, Carl 
E. Schotbergh, Marfijn Meuwissen, Berthe L. van Eck-Smit. Academic 
Medical Center, Amsterdam, The Netherlands 
Background: No direct comparison have been performed between fractional 
flow reserve (FFR), coronary blood flow velocity reserve (CFR) and relative 
CFR (rCFR) in relation to myocardial perfusion in intermediate lesions. 
Methods: In 53 patients (62 lesions) dipyridamo199rnTc-MIBI Spect scintig- 
raphy (MIBI) was performed. Coronary lesion severity was measured by 
quantitative coronary angiography. FFR and CFR were measured distal to 
the coronary narrowing and CFR also in an angiographically normal ref- 
erence artery. Hyperemia was induced using adenosine i.c. The predictive 
value of FFR, CFR and rCFR in determining reversible defects as detected 
n AUC BCV Agreement MIBI 
FFR 62 0.69 J:: 0.09' 0.83 58% 
CFR 61 0.66 ± 0.09" <1.9 77% 
rCFR 58 0.79 ± 0.05" <-0.9 66% 
• Differences not statistically significant 
by MIBI was evaluated by 1he area under the curve (AUC) of the receiver- 
operaling-charactedstic curves. 
Results (see table): Reversible defects were present at 13 (21%) areas of 
interest. Mean percentage diameter stenosis of the lesions was 56% (range 
38-80%). 
Conclusion: The diagnostic accuracy of fractional flow reserve, absolute 
and relative coronary blood flow velocity reserve is similar for functional 
evaluation of intermediate coronary lesions. 
I 1  9-471 Versus Adenosine for Fractional Flow 21 IV IC i 
Reserve (FFR): The "Early FORECAST" Study 
Allen Jeremias ~ , Robert J. Whitboum 1 , Steven D. Filardo I , Alan C. Yeung I , 
David J. Cohen, William Anderson, Alexander Abizaid, Murat E. Tuzcu, 
Peter J. Fitzgerald 1 , Morton J. Kern 2, Paul G. Yock 1 . IStanford Universi~ 
Stanford, CA; 2St. Louis University, St. Louis, MO, USA 
Background: Clinical validation studies of Fractional Flow Reserve (FFR) 
have been performed using intravenous (IV) adenosine (ADN) as the hyper- 
emic stimulus. Intracoronary (IC) ADN for FFR would be more convenient, 
less expensive and potentially safer. The pilot or "Early" phase of the FORE- 
CAST study (FFR Or RFVR Evaluation of Coronary Artery Stenosis vs. 
Thallium) was designed to test whether there are significant differences in 
FFR measurements using IC versus IV ADN. 
Methods: At 6 centers in the U.S. patients undergo FFR measurements 
using a 0.014" solid-state pressure wire (PressureWire ® , RADI Medical). To 
date, 28 lesions in 25 patients have been studied (the total cohort will be 60 
patients). IV ADN was administered in a dose of 140/~g/Kg/min and IC ADN 
was used in a dose of 15-20 izg inthe right and 18-24/zg in the left coronary 
artery. 
Results: There was an excellent linear correlation between FFR mea- 
surements with IV and IC ADN (Figure). The agreement between the two sets 
of measurements was also high with a mean difference in FFR of -0.0013 
± 0.035. No adverse events occurred with IC ADN administration, but in 2 
patients severe side effects were noted during the IV infusion (1 patient with 
bronchospasm and 1 patient with severe nausea). 
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Conclusion: With 25/60 patients completed, the Early FORECAST re- 
sults suggest that IC is equivalent o IV adenosine in determining FFR. Since 
smaller doses are used, the safety profile for IC adenosine may be superior. 
~ Intravascular Ultrasound Assessment of 
Pulmonary Valve Ring and Pulmonary Artery Wall 
Stiffness, Distensibility and Compliance in 
Pediatric Patients With Pulmonary Stenosis 
YeongBong Park, Suthep Wanitkun, Mary J. Rice, Takahiro Shiota, David 
J. Sahn. Oregon Health Sciences University, Portland, OR, USA 
The purpose of our study was to assess segmental pulmonary artery (PA) 
stiffness, distensibility and compliance before and after balloon dilation in 
13 patients with valvular and supravalvular pulmonary artery stenosis, and 
6 with peripheral pulmonary stenosis studied by standard scanning catheter 
and transballoon intravascular ultrasound (IVUS). Vessel diameters and 
cross-sectional areas in systole and diastole were determined using IVUS 
at prestenotic, stenotic and post-stenotic PA segments. In 8 of 19 patients, 
these were compared pre- and post-balloon dilation. Using pulmonary pres- 
sures measured at the same locations, a stiffness index "beta (/~)" was 
calculated as In (Ps/Pd)/(Ds-Dd), where Ds is systolic diameter and Dd is 
diastolic diameter. PA distensibility and compliance were also calculated. For 
valvular PS after successful dilation, stiffness of the valve and the annulus 
decreased (mean index changed from 3.32 to 0.66). Distensibility and com- 
pliance increased (4.6 to 5.4 and 8.48 to 11.3, respectively). For 6 patients 
with peripheral stenosis (11 stenoses total), the proximal segments of PA 
were much less stiff (/~ = 2.8) than the stenotic (/~ = 6.87) or post-stenotic 
segments. As suggested by our measurements, these very stiff stenoses 
and diseased distal segments could not be dilated successfully. IVUS also 
provided unique anatomical information such as non-circular stenosis cross- 
sections and localized regional non-distensible or calcified segment arcs. Our 
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observation may aid in determining and predicting outcomes of pulmonary 
artery balloon dilation procedures. 
I1 I The Intravascular Ultrasound During i 21 9-49 Benefits of  Carotid Artery Stenting 
Imad A. Alhaddad, Richard Blair, Debra Wuensch, Robert Schainfeld, 
Gunter Rauh, David Thaler, Kenneth Rosenfield. St. Elizabeth Medical 
Center, Boston MA; Bronx Lebanon Hospital Center, Bronx NY, USA 
Carotid Artery (CA) stenting is an evolving technique for CA revascularization. 
To determine the potential utility of intravascular ultrasound (IVUS), we per- 
formed serial IVUS examination in 54 consecutive CA stenting procedures. 
IVUS parameters, obtained at baseline and post-stenting, were compared 
with quantitative carotid angiography (QCA). In all cases, balloon and stent 
sizes were selected based on IVUS measurement at reference site. The 
NASCET criteria of stencsis was used. Results = Mean ± SEM 
Ivus QCA P 
R. minimal diameter (ram) 4.9 ± 0.1 4.7 ± 0.2 NS 
R. maximal diameter (mm) 5.4 ± 0.2 4.7 • 0.2 <0.01 
R. CSA (mm 2) 22 ~ 1 18 i 1 <0.02 
BL diameler stenosis (%) 67 ± 1 81 ± 2 <0.01 # 
Poststent diameter stenosis (%) 14 ± 2 9 ± 2 NS 
Calcification (%) 77 38 <0.001 
R = Reference, BL = Baseline, CSA = Cross sectional area. #IVUS probe precluded 
accurate measurement of minimal dimensions. 
Final balloon diameter used (5.7 ± 0.1 mm), was equal to reference max- 
imal diameter by IVUS (P = NS), but was larger than reference diameter by 
QCA (P < 0.01 ). In 5 cases, qualitative IVUS findings directly altered therapy: 
a) In 3 CA, IVUS identified underexpanded stents, requiring redilation; b) A 
post-procedure common CA dissection, detected by IVUS but not by angiog- 
raphy, was stented successfully; c) In one patient with a remote common CA 
stenosis, IVUS confirmed adequate lumen size, thus obviating the need for 
additional stenting. 
Conclusions: IVUS during CA stenting: 1) is safe; 2) can be used to size 
devices; 3) facilitates optimal stent deployment; and 4) provides information 
which may favorably impact clinical outcome. 
~ D o e s  Higher Frequency Intravascular Ultrasound 
Improve Discrimination Among Various 
Thrombus Stages? A Video-densitometry Study 
Atsushi Takagi, Matthew L Kolz, Hireyuki Okura, Paul G. Yock, Peter 
J. Fitzgerald. Stanford Universi~ Stanford, CA, USA 
The ability of intravascular ultrasound to detect various stages of throm- 
bus has been limited. Improvement in axial resolution by increasing fre- 
quency may allow more precise discrimination of stages between red cell 
rich thrombus (RRT) and plasma rich thrombus (PRT). Accordingly, we com- 
pared conventional 30 MHz imaging to 40 MHz imaging in controlled thrombi 
preparations. 
Methods: Thrombi were made from different fractions of human whole 
blood and plasma (4:0, 3:1, 2:2, 1:3, 0:4) with additive thrombin. Twenty 
thrombi were imaged with 30 MHz & 40 MHz systems (CVIS / Boston Scien- 
tific). In each thrombus specimen, five frames were digitized, and videoden- 
sitometry (VD) intensity was measured at regions of interest (ROI) within the 
focal zone of transducer. 
Results: A total of 200 ROIs was analyzed. At both frequencies, PRT 
could be distinguished from RRT by VD intensity (30 MHz: 55.2 ± 7.4 vs. 
45.8 ± 7.8, p = 0.010; 40 MHz: 44.3 + 2.8 vs. 32.8 ± 10.5, p = 0.0037). 
However with mixed thrombi, there were no significant differences at either 
frequency. 
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Conc lus ions :  Increasing frequency from 30 to 40 MHz does not improva 
the ability to discriminate mixed thrombi. Other techniques uch as radio 
frequency analysis may be required to further address this problem. 
ORAL 
Beyond Angiography: Ultrasound for 
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[ -~  One Year Follow-Up of 300 Pts After Coronary 
Intervention Was Deferred Based on Intravascular 
Ultrasound Findings 
Andrea S. Abizaid, Gary S. Mintz, Roxana Mehran, Lowell F. Satler, 
Augusto D. Pichard, Carol L. Walsh, Ann Greenberg, Alexandre Abizaid, 
Steven Slack, Vanessa Laroche, Kenneth M. Kent, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
We determined the 1 yr event rate after coronary intervention was deferred 
in 357 intermediate de novo native artery lesions in 300 pts based on in- 
travascular ultrasound (IVUS) findings, In general, an IVUS minimum lumen 
area (MLA) > 4.0 mm 2 was used as the cutoff. The IVUS minimum lumen 
diameter correlated poorly with angiography (r = 0.339). At follow-up the 
overall event rate {death, MI, or target lesion revascularizaton (TLR)} was 
8% (2% death/MI and 6% TLR). Importantly, the overall event rate was 4% 
in lesions with an IVUS MLA > 4.0 mm 2. The only independent predictor of 
death/MI/-rLR was the IVUS MLA (odds ratio: = 0.57, p = 0.0041); the only 
independent predictors of TLR were diabetes (odds ratio = 2.90, p = 0.0493) 
and IVUS MLA (odds ratio = 0.52, p = 0.0042): 
Deaf WMI/f LR (%) 
2-3 3-4 4-5 ~5 2-3 3-4 4-5 ~S 
(n=17) (n=36) (n==55)(11.=193) (n=17) (n=36) (n=55)(fl:lg3) 
IVUS MLA (mm z) IVUS MLA (mm z) 
We Conclude: (1) IVUS MLA predicts events in intermediate lesions. (2) 
If the MLA is >4.0 mm 2, the 1 yr event rate is very low (4%); and intervention 
can be safely deferred. (3) In pts with diabetes, there should be a lower 
threshold to intervene, especially if the MLA is <4.0 mm 2. 
10:45 a.m. 
~-8-~ Triglitazone Reduces Intimal Hyperplasia After 
Coronary Stent Implantation in Patients With Type 2 
Diabetes Mellitus: A Serial Intravascular Ultrasound 
Study 
Tsutomu Takagi, Kiyoshi Yoshida, Takashi Akasaka, Takeshi Hozumi, 
Atsushi Yamamuro, Shigefumi Morioka. Kobe General Hospital, Kobe, 
Japan 
Troglitazone, an insulin sensitizer, inhibits intimal hyperplasia (IH) in diabetic 
animal models. To determine whether troglitazone reduces IH after coronary 
stent implantation in patients with type 2 diabetes mellitus (DM), we studied 
28 stented lesion with Palmaz-Schatz stent in 24 patients (pts) with fasting 
plasma glucose concentration (PG) < 140 mg/dl and a PG > 200 mg/dl 
2 hours after 75 g oral glucose challenge (OGTT). The study pts were 
randomized into two groups: troglitazone group, 12 pts (14 stents) treated 
with 400 mg of troglitazone and diet stabilization, and control group, 12 pts 
(14 stents) treated with diet stabilization only. All pts underwent OGTT before 
and after 6 months treatment period. Total PG (ZPG = fasting PG + 1 hr PG 
+ 2 hr PG), and total inulin level (EIRI = fasting IRI + 1 hr IRI + 2 hr IRI) were 
measured. Serial (postintervention and follow-up at 6 months) IVUS was 
performed using automatic pullback at 0.5 mm/s. A cross sectional image 
within stent was selected every 1 mm pullback, and stent area (SA), lumen 
area (!.A), IH area (IHA = SA - LA), IH index (IHI = IHA/SA x 100%) were 
Control group Troglitazone group 
12 pts (14 stents) 12 pts (14 stents) 
'£PG (mg/dl) before 544 ~: 43 560 ± 68 p = 0.75 
EPG (mg/dl) f/u 518 ± 56 420 ~- 36 p < 0.0001 
ZIRI (.~M/ml) before 230 • 127 221 ~ 90 p = 0.89 
~;IRI (~zM/ml) f/u 230 ± 158 143 :J_ 71 p = 0.14 
SA (mm 2) before 8.2 i 3.0 8.2 ± 1.5 p = 0.22 
SA (mm 2} f/u 8.1 :L 3.0 8.2 ± 1.4 p = 0.24 
IHI (%) f/u 49 4- 15 28 ± 14 p = 0.009 
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measured using computer planimetry and averaged over number of selected 
frames. 
Results are shown in the table. 
Conclusion: Serial IVUS analysis showed that troglitazone reduces in- 
timal hyperplasia after coronary stent implantation in patients with type 2 
DM 
11:00 a .m.  
I 886~ Acute Lumen Gain After Cutting Balloon 
Angioplasty in Calcified and Non Calcified Lesions: 
Intravascular Ultrasound Analysis of the REDUCE 
Study 
Hiroyuki Okura, Motoya Hayase, Hiroaki Hosokawa, Takahire Suzuki, 
Tetsu Yamaguchi, P.G. Yock, P.J. Fitzgerald. For the REDUCE Investigators; 
Stanford University Medical Center, Stanford, CA, USA 
Intravascular ultrasound (IVUS) studies have shown that mechanisms of 
luminal enlargement following balloon angioplasty include plaque compres- 
sion, redistribution and vessel stretching. The purpose of this IVUS subanal- 
ysis of the REstenosis ReDUction by Cutting Balloon Evaluation (REDUCE) 
is to clarify the mechanisms of acute lumen enlargement after cutting balloon 
(CB) angioplasty compared with balloon angioplasty (BA). A total of 168 
patients (83 randomized to CB and 85 to BA) with pre and post IVUS images 
were analyzed from the REDUCE registry. Teal vessel area (VA), lumen area 
(I_A) and plaque area (PA) were measured before and after angioplasty and 
the changes in these parameters were calculated. 
Results: Baseline lesion severity was similar between the CB and BA 
groups. Although balloon size was similar (3.5 ± 0.4 vs 3.4 ± 2.4 mm, p = 
ns), maximal inflation pressures were significantly lower in the CB group (7.7 
± 1.5 vs 10.4 ± 3.7 atm, p < 0.01). Target lesion calcification was detected 
in 50% of the CB group and 37% of BA group. Incidence of dissection was 
similar between both groups (67% vs 65%, p = ns). For non-calcified lesions, 
ALA was similar between CB and BA (4.0 ± 1.9 vs 3.6 ± 2.5 mm 2, p = ns). 
APA was significantly larger (-3.0 ± 2.0 vs -2.1 ± 2.0 mm 2, p < 0.05) and 
5.VA showed a trend toward less increase after CB (0.8 ± 1.6 vs 1.5 ± 1.8 
mm 2, p = 0.07). For calcified lesions, there were no significant differences 
in ALA, AVA and APA between CB and BA. Dissection in association with 
calcified lesions showed a trend toward less increase in ALA in the BA group 
(dissection 3.1 ± 1.2 vs no dissection 3.8 ± 1.5 mm 2, p = 0.19) but greater 
increase in the CB group (dissection 4.0 ± 1.3 vs no dissection 3.2 ± 1.5 
mm 2, p = 0.09). 
Conclusions: In non-calcified lesions CB performed with lower balloon 
inflation pressures than BA achieves the same luminal dimensions with in- 
creased plaque compression/redistribution and less vessel expansion than 
BA. In calcified lesions, the overall results of CB were similar to BA, except 
when CB generated dissections resulting in larger lumen than BA with dis- 
section. The impact of these acute observations on the follow up results are 
in progress. 
11:15 a .m.  
-~-~ In Ultrasound Measured Stent Vivo Intravascular 
Lengths Do not Predict Subsequent Target Lesion 
Revascularization 
Myeong-Ki Hong, Gary S. Mintz, Lowell F. Satler, Mun K. Hong, Augusto 
D. Pichard, Ann Greenberg, German Lorrain, Javed M. Ahmed, Kenneth 
M. Kent, Martin B. Leon. Washington Hospital Center, Washington, DC, USA 
Angiographic and clinical assessment of implanted stent length is limited 
by radiolucency, foreshortening, unpredictable overlap, and possible short- 
ening during stent expansion. Therefore, we used intravascular ultrasound 
(IVUS: motorized transducer pullback @ 0.5 mm/sec) to measure stent 
lengths in vivo in 390 consecutive pts with native vessel lesions treated with 
IVUS-guided implantation of multiple Palmaz-Schatz stents. Measured stent 
lengths ranged from 21-90 mm (mean = 33 ± 10 mm). Target lesion revascu- 
larization (TLR) according to IVUS post-intervention lumen areas and stent 
lengths is shown in the table. 
Stent length Post-intervention lumen area (ram 2) p 
<6 6.0-7.5 7.5-9.0 >9.0 
20-30 mm 17/39 (44) 15/60 (25) 10/50 (20) 3/43 (7) 0.001 
30~40 mm 12/28 (43) 7/40 (18) 5/28 (18) 1/21 (5) 0.008 
>40 mm 12/20 (60) 4/24 (17) 3/25 (12) 1/12 (8) 0.001 
p 0.42 0.56 0.75 1.0 
Regardless of post-intervention lumen area, increasing stent length did 
not impact on TLR. Conversely, regardless ofstent length, smaller final lumen 
areas resulted in higher TLR rates. 
We Conclude: Long-term effectiveness of stent implantation procedures 
is determined not by how much metal is implanted, but by the adequacy of 
the final lumen dimensions. 
11:30 a .m.  
[~- ]  Optimal Intravascular Ultrasound Criteria for Stent 
Deployment: Comparison of Different Ultrasound 
Criteria on the 6 Months Restenosis Rate 
Fran(;ois Schiele, Marie France Seronde, Sanjiv Gupta, Nicolas Meneveau, 
Alain Vuillemenot, Denis Pales Espinosa, Jean-Pierre Bassand. University 
Hospital Saint-Jacques, Besanfon, France 
Background: We compared the restenosis rate of subgroups of patients, 
according to different IVUS criteria for optimal stent deployment. 
Methods: 229 patients had IVUS imaging at stent implantation, and 6 
month angiographic follow-up. IVUS images were analysed off line. Sub- 
groups of patients were selected according to 4 different IVUS criteria for op- 
timal stent implantation: MUSIC criteria (#1), lumen ratio, stent level (L-CSA) 
over average of reference levels (ref-CSA) with cut-point set at 0.9 (#2), at 
0.8 (#3), and the L-CSA more or less than 7 mm 2 (#4). The restenosis rate 
in the 4 groups was compared. 
Results: The MUSIC criteria were reached in 48%, criterion #2 in 46%, 
criterion #3 in 64% and criterion #4 in 48% of the patients. At 6 months, 
angiographic restenosis rate was 23.6%. By univariate analysis, only criterion 
#4 was a predictor of restenosis. Multivariate logistic regression showed that 
the only independent predictor of restenosis was the L-CSA as absolute 
value; the odds ratio was 0.65 per additional mm 2 of lumen CSA. 
Restenosis Rate Criterion+ Criterion- P 
MUSIC criteria (# 1 ) 23/103 (22%) 30/112 (26%) 0.20 
L-CSA/ref CSA > 0.9 (#2) 19/95 (20%) 30/112 (26%) 0.25 
L-CSA/ref CSA > 0.8 (#3) 13/132 (23%) 18/75 (24%) 0.90 
L-CSA > 7 mm 2 (#4) 13/100 (13%) 36/107 (33%) 0.001 
Conclusion: The angiographic restenosis rate was not predicted by the 
MUSIC criteria, nor by the ratio of lumen areas, or stent level over reference 
level, but only by the absolute value of the L-CSA. 
11:45 a .m.  
~~-]  Feasibility Study of Percutaneous Transmyocardial 
Revascularization With Forward-Looking A-Mode 
Ultrasound for Real-Time Wall-Thickness 
Measurements 
William W. O'Neill, Eberhard Grube, Hans de Swart, Frits B~.r. William 
Beaumont Hospital, Royal Oak, MI, USA; Heart Center-Siegberg, Siegberg, 
Germany 
Background: Ongoing clinical tdals are in process to determine safety and 
feasibility of Percutaneous Transmyocardial Revascularization (PTMR). In 
PTMR, laser channels (Eclipse Ho:YAG) are made from the endocardium 
partially through the myocardium. To avoid making transmural channels, pts 
are pre-screened with 2D echocardiography (echo) to determine minimum 
myocardial wall thickness of 9 mm. It is suspected that trebeculae, former MIs, 
and mechanical thinning may yield site-specific variations not identified by 2D 
echo. Real-time wall thickness measurements from A-mode forward-looking 
ultrasound (US) were evaluated as a supplement to current measurement 
methods. 
Methods: 9 pts at 3 institutions were selected to evaluate this technol- 
ogy. Pts were pre-screened according to the standard protocol, including 
wall thickness measurements by 2D echo. A PTMR catheter with a for- 
ward-looking US transducer affixed to the distal tip was placed into the LV 
using standard techniques. In 8 pts, real time wall thickness measurements 
were taken to compare to the pre-screens. Channels were then placed using 
standard fluoroscopic guidance and a combination of the pre-screen and 
real-time wall-thickness measurements. 
Results: Minimum wall thickness measurements in target areas from the 
pro-screens averaged 9.6 ± 1.7 mm. Real-time wall thickness measurements 
were successfully taken in 74% (67/90) of attempts and averaged 9.2 ± 2.9 
mm. Predominantly they confirmed pre-screen measurements; however, in 
all pts some measurements were below the pre-screen minimums, and in 
5 pts, targets <6 mm were identified where treatment was avoided. 14 ± 
4 channels were placed. Time for channel creation was 28 ± 23 minutes, 
which is similar to experience without US. 
Conclusions: Preliminary experience suggests that forward-looking US 
in combination with PTMR is feasible, safe and provides valuable supple- 
mental information about real-time, site-specific wall thickness. 
~> 
O 
C) 
o') 
(.6 
JACC February 1999 ABSTRACTS - Arrhythmia Management 103A 
POSTER 
~ - ~  Atrial Fibrillation 
Sunday,  March  7, 1999, Noon-2 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  1:00 p .m. -2 :00  p.m. 
1022-146]  Predictors of Sinus Rhythm at One Year 
Following Cardioversion for Atrial Fibrillation: 
Lessons from the ACUTE Trial Registry 
Wael A. Jaber, David L. Prior, Maran Thamilarasan, Craig R. Asher, 
Deborah A. Agler, Susan E. Jasper, Kristopher L. Arheart, Richard 
A. Gdmm, Allan U Klein. The Cleveland Clinic Foundation, C/eve/and, Ohio, 
USA 
Background: Long term maintenance of normal sinus rhythm (SR) post 
cardioversion from atrial fibrillation (AF) carries a lower risk of stroke and 
may avoid the risks associated with anticoagulation. We sought to determine 
the clinical and echocardiographic predictors of maintained SR at one year 
following initial successful cardioversion from the ACUTE trial registry. 
Methods: Our study population comprised 161 patients (M: F = 45:116, 
age 67.9 yrs) for whom clinical, transthoracic (I-I-E), and transesophageal 
(TEE) echocardiographic variables were recorded prior to cardioversion and 
in whom SR was present at 24 hrs. The relation between those variables 
and the presence of SR at one year was examined using univariate and then 
multivariate logistic regression analysis. 
Results: SR was present in 87 pts (54%) at one year. By univariate 
analysis, use of class III antiarrhythmic agents (p = 0.008) and previous coro- 
nary artery bypass graft surgery (p = 0.035) were clinical factors associated 
with a higher rate of SR. Age, hypertension, duration of AF, left ventricular 
ejection fraction, presence of heart failure, use of other antiarrhythmics, pre- 
vious valve surgery and previous cardioversion did not predict SR at one 
yr. Increasing left (p = 0.005) and right (p = 0.04) atrial areas by TTE and 
TEE were associated with recurrence of AF at one year. Factors associated 
with SR by multivariate analysis were class III agents (OR 4.26; p = 0.04), 
previous CABG (OR 5.61; p = 0.006), LA dimension by TTE (OR 0.25; p = 
0.03). 
Conclusion: In the ACUTE registry, SR post cardioversion was present 
in half the cohort at one year. Among pharmacologic interventions, use of 
class III antiarrhythmics was the only predictor of SR at one year. Traditional 
adverse clinical parameters were not associated with failure to maintain SR 
and therefore should not preclude attempts at cardioversion. Larger atria 
remained a risk factor for recurrence of AF. 
1 47] Atrial Fibrillation in Human Conduction ] 022-1 Heritable 
System and Myocardial Disease 
Elizabeth A. Sparks, Steven D. Nelson, Harry L. Graber, 
Harisios Boudoulas, Charles F. Wooley. Ohio State Universi~ Columbus, 
Ohio, USA 
Background: That atrial fibrillation (AF) of heritable origin may occur as a 
phenotype within the framework of heritable cardiac conduction and myocar- 
dial disease is not well defined. 
Methods: We identified 36 family members (FM) with heritable AF as 
part of a 9 generation study in a German family with heritable (chromosome 
1p1-1q1) cardiac conduction and myocardial disease; this is an autosomal 
dominant disorder with a long natural history manifested by prolonged PR 
interval in the fourth decade and complete A-V block in the fifth decade; 
overt ventncular myopathy occurs late; sudden cardiac death (SCD) occurs 
in clusters. 
Results: Eleven FM with heritable AF were born to a parent with AF; 
16 were born to a parent with a pacemaker (PM); 22 were born to a parent 
with SCD. PR interval prolongation has been documented in the decades 
prior to the onset of AF in 28 FM AF occurred at mean age 42.9, either 
spontaneously in 9 at mean age 36, or in association with A-V conduction 
disease requiring PM in 26 at mean age 45. Age at PM in FM with AF was 
46.7 years (27 to 68 years) and occurred 0-18 years prior to PM (n = 18) or 
1-10 years after PM (n = 8). Congestive heart failure occurred in 12 FM with 
AF at mean age 52.6 (43 to 60) years; SCD in 8 FM with AF occurred at mean 
age 56.1; non SCD in 3 FM with AF occurred at mean age 60. Mean age at 
death in all 11 deceased FM with AF was 57.2 (45 to 68) years. Autopsy in 6 
FM at late stage disease confirmed atrial dilatation, atrial interstitial fibrosis. 
and atrophy of atrial myocytes. 
Conclusions: We conclude that the etiopathogenesis of AF includes 
complex heritable molecular disorders requiring multigeneration family study, 
pedigree development, and long term follow-up for identification. 
1 Electrocardiographic Events Preceding Atrial 022-1 48 
Fibrillation Captured by an Implantable Loop 
Recorder: Observations and Potential Utility 
David Schwartzman, Christine Wackowski, Mark L. Brown, Rahul Mehra. 
University of Pittsburgh, Pittsburgh, PA and Medtronic, Inc. Minneapolis, 
MN, USA 
Background: Previous experience has demonstrated the utility of a subcu- 
taneously implanted loop recorder (Reveal TM, Medtronic, Inc.) for capturing 
electrocardiographic (EKG) events associated with arrhythmic syncope. We 
hypothesized that this device would also be useful for capturing EKG events 
preceding the spontaneous onset of atrial fibrillation (AF) and that certain 
events, if reproducible, might recommend specific therapeutic interventions. 
Methods: 8 patients (6 men; age 48-64 years; structural heart disease 
present in 4) with paroxysmal AF underwent implantation of a Reveal in the 
right parasternal space. Each patient was subsequently observed for 1-4 
months, off antiarrhythmic agents. Patients were instructed to activate their 
device after the onset of an AF episode. Devices were programmed to store 
21 continuous minutes of EKG prior to activation, thus resulting in a variable 
pre-AF period available for analysis, depending on when the device was 
activated relative to AF onset. "Admissible" AF episodes were defined as: 1. 
preceded by _> 30 seconds of interpretable EKG, 2. not previously occurring 
in a 24 hour period, and 3. lasting ~ 30 seconds. 
Results: 5 of 8 patients had _> 1 admissible AF episodes. The number 
of episodes analyzed ranged from 1 to 6 per patient. In 4 patients, AF 
onset was consistently triggered by a single atriat premature complex (APC). 
In 1 patient, episodes of AF were preceded by runs of a rapid, regular 
monomorphic atrial tachycardia. Subsequent endocardial mapping in this 
patient revealed a focal left atrial tachycardia. In no patient was AF preceded 
by significant bradycardia or a pause. 
Conclusions: In the majority of this cohort, single APCs triggered AF. In 
1 patient a uniform atrial tachycardia eliciting AF was identified. The utility of 
EKG information preceding AF onset for recommending specific therapeutic 
interventions remains to be established. 
1022-149 The Duration of Atrial Fibrillation Paroxysmal 
Episodes Correlates With the Frequency of 
Fibrillatory Activity on the Surface ECG 
Andreas Bollmann, Kai Sonne, Hans-Dieter Esperer, Ines Toepffer, 
Daniela Polywka, Ekaterini Hecht, Jonathan J. Langberg 1 , Helmut U. Klein..  
University Hospita/ Magdeburg, Germany; 1Emery University Hospita/, 
Atlanta, GA, USA 
Background: The duration of paroxysmal atrial fibrillation (pAF) episodes is 
unpredictable. The average rate of fibrillatory activity correlates with spatial 
organisation and AF severity. The aim of this study was to evaluate the AF 
frequency spectrum in humans (pts) from Holter ECG recordings using a 
newly developed algorithm and to correlate peak frequency with the duration 
of pAF episodes. 
Methods: Holter ECG recordings were analyzed for 7 pts with pAF (age 
67 ± 16 years, 2 male, 5 female, no underlying heart disease). The fre- 
quency content of the fibrillatory baseline of the first 30 sec of each episode 
was then quantified using digital signal processing. After bandpass filtering 
QRST complexes were subtracted using a template matching algorithm. The 
resulting fibrillatory baseline signal was subjected to Fourier transformation 
and displayed as a frequency power spectrum. The frequency spectrum was 
quantified by measuring the peak frequency (f). 
Results: Fourty-two pAF episodes were observed. Duration ranged from 
45 sec to 665 rain (32 ± 126 min). Frequency spectra derived from Holter 
recordings were characterized by a single sharp peak. Mean peak f mea- 
sured 5.1 i 0.8 Hz (range 3~1-7.0). Within-pts variation off in consecutive AF 
episodes ranged from 0 to 2.4 Hz. There was a positive correlation (Spear- 
man) between I and pAF duration (R = 0.60, p = 0.01). AF of less than 5 rain 
duration showed a lower f (4.8 ± 0.7 Hz) when compared with longer lasting 
episodes (5.9 ± 0.6 Hz, p < 0.001). 
Conclusion: The duration of pAF episodes correlates with the peak 
frequency of fibrillatory activity on the surface ECG. Thus, this test may 
prove useful for quantification of AF severity. 
1022-150] Rate Control Versus Conversion Strategy in Post 
Operative Atrial Fibrillation: A Prospective, 
Randomized Pilot Study 
John K. Lee, George J. Klein, Raymond Yee, Andrew Krahn, 
Christopher Simpson, Allan Skanes, Kelly Zarnke, Bonnie Spindler. The 
Univeristy of Western Ontario, London, Ontario, Canada 
Background: Atrial fibrillation remains a frequent complication after car- 
diac surgery. The optimal treatment strategy for the condition has not been 
established. 
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Methods: Patients with atrial fibrillation of > 1 hour duration after car- 
diac surgery were randomized to a strategy of antiarrhythmic therapy (so- 
talol, propafenone, procainamide, amiodarone) ± electrical cardioversion or 
ventricular ate control (diltiazem, metoprolol, atenolol, digoxin). Both arms 
received antithrombotic therapy with heparin overlapped with Coumadin. 
Choice of drug therapy within each arm was individualized. Time to conver- 
sion to sinus rhythm were determined in both groups. Atrial fibrillation relapse 
rates after conversion were monitored while in hospital, at t week, 4 weeks 
and 6--8 weeks after discharge. 
Results: Survival analysis utilizing the Kaplan-Meier method to compare 
distributions of time to conversion to sinus rhythm showed no significant 
difference between antiarrhythmic therapy (n = 23) and ventricular ate control 
(n = 16) [12.5 hrs ± 3.8 vs 12.5 hrs ± 4.3; p = 0.50]. In hospital relapse rates in 
the antiarrhythmic arm were 30% compared to 57% in the rate control arm (p 
= 0.169). Furthermore, relapse rates of atrial fibrillation were not significantly 
different at 1 week (27% vs 33%; p = 1.0), 4 week (8% vs 20%; p = 0.57) and 
6-8 weeks (6% vs 20%; p = 0.535). At the termination of the study 80% of 
the patients in the rate control arm were in sinus rhythm versus 94% in the 
antiarrhythmic arm (p = 0.5). 
Conclusion: There was no difference in outcome between a rate control 
strategy and an antiarrhythmic conversion strategy. The great majority of 
patients will be in sinus rhythm at 2 months. 
[ 1 022-1  51 Impact of Atrial Fibrillation on Quality of Life: 
" ' A Prospective, Mutticenter Study 
Werner Jung, Susanne Herwig, David Newman, Masood Akhtar, 
Kathy Wood, Greg Ayers, Berndt Luderitz. For the InControl Quafity of Life 
Investigators. University of Bonn, Germany 
The long term impact of atrial fibrillation (AF) on quality of life (QoL) is not yet 
well defined. The aim of this multicenter study was to prospectively assess 
the influence of AF on patient (pt) health related QoL using validated ques- 
tionnaires (SF-36 & the Symptom Checklist [SCL]). 175 AF pts completed 
the questionnaires at baseline, 3, 6, & 12 mos intervals. 
SF 36 Scale Baseline 3 mos 6 rues 12 rues General 
Population 
Vitality 49-}-21 53±2t  51 ±21 52±22 61 :~21 t 
Physical Function 68 ± 27 69 ± 26 70 ± 25 71 ± 28 84 ± 231 
Social Function 73 J~ 27 77 ± 24 75 ± 26 77 ± 26 83 ± 231 
Mental Function 69 ± 18 69 ± 19 71 ± 17 71 ± 19 74 ± 181 
Role-Emotiona~ 65 ± 41 57 ± 21 71 ± 39 71 ± 40 81 ± 33 t 
General Health 56 ± 21 57 & 21 57 ± 21 56 ± 21 72 ± 201 
Symptom Checklist 
Frequency 22±10 20±9 20±10 20 ± 11" N/A 
Severity 18±8 17±9 17±9 15±9" N/A 
Conclusion: These findings demonstrate health dysfunction for pts with 
AF when compared to previously published norms for this instrument (tp < 
0.05). The mean frequency and severity of symptoms on the SCL decreased 
over time ('p < 0.05). However, the magnitude of these changes is prob- 
ably clinically irrelevant. There was no change in the scores for the SF-36 
subscales over the follow-up period (p > 0.05). At baseline the impact of 
AF significantly lowers one's QoL in addition, traditional therapy does not 
appear to greatly improve AF patient QoL over time. 
1 521 Gender Differences 'Quality of Life' in Atrial 
] 
022-1 in 
Fibrillation 
Angela J. Bygrave, Johan E.P. Waktare, A. John Camm, Werner Jung, 
Jasbir Sra, Paul Dorian, Minney Paquette, Kathy Wood. GreyAyres for the 
InControl QOL Investigators, Redmond, WA, USA 
Introduction: Atrial Fibrillation (AF) is the most common cardiac arrhyth- 
mia, and causes significant morbidity. In addition, Quality of Life (QOL) is 
impaired, but whether gender influences the perceived impact of the disorder 
is unknown. 
Methods: Comprehensive, validated QOL tools were administered to a 
representative spectrum of patients with AF attending hospital follow-up in 
UK, Germany and Canada. These were SF-36, Goldman Specific Activity 
Scale (SAS), Illness Intrusiveness Scale (IIS), all translated and/or modified 
for local use. Data collected included age, gender and class of AF (parox- 
ysmal, persistent or permanent), as well as echocardiographic data and 
demographic characteristics. 
Results: We enrolled 147 pts: mean age 58 ± 12 yr; 72% male; mean 
ventricular EF 61 ___ 16%; mean LA size 42 ~- 6 mm. Table shows gender 
differences in the dimensions of SF-36. Overall QOL score was significantly 
worse in women by multivariate analysis on SF-36 (p = 0.02) and on SAS (p 
= 0.001) but differences in the IIS were non-significant. 
Conclusion: In the study population the impact of AF on QOL is greater 
in women. This was particularly true for measures of physical limitation and 
was independent of age. 
Vital Soc R.L- R.L.- Phys Pain Ment Gen 
Fun Emot Phys Funct Health Health 
Men 51.4 74.9 69.1 52.6 74.5 71.0 67.8 55.0 
Women 42.8 66.6 59.5 33.1 53.5 67.6 70.0 51.9 
p value <0.05 NS NS <0.05 <:0.001 NS NS NS 
(Vital = vitality, SocFun = social functioning, R.L.-Emot = role limitation due emotional 
problems, -Phys = due to physical problems, MentHealth = mental health, GenHealth = 
general health perception) 
I1 I Pharmacoeconomic Analysis of Ibutilide Versus 022-1 53  
Electrical Cardioversion for Patients With Atrial 
Fibrillation or Flutter 
Alisha Dunn, Prabashni Reddy, C. Michael White, Moses S.S. Chow, 
Jeffrey Kluger. Hartford Hospital, Hartford, C'£ University of Connecticut, 
School of Pharmacy, Storrs, CT, USA 
Background: At our institution, ibutilide successfully converted 50% of pa- 
tients with atrial fibrillation or atrial flutter who received the dru~] from August 
1996 to March 1998 (n = 60), with 67% of these remaining in sinus rhythm 
at hospital discharge. Whether or not the use of ibutilide as first line therapy 
results in cost savings has not been directly measured. 
Methods: The cost of first line ibutilide plus electrical cardioversion (EC) 
for ibutilide failures in this patient population was compared to the projected 
cost of first line EC from a hospital (provider) and a managed-care (payor) 
perspective. Charges for EC and drug administration were obtained from 
the hospital database and converted to costs using cost4o-charge ratios. 
Hospital costs included drug, drug administration, and the cardiac intensive 
care laboratory fee (included nursing personnel, EC equipment and facility). 
The managed care calculation included all of the above plus estimated car- 
diologist and anesthesiologist fees associated with EC. The cost of adverse 
effects management was estimated and included in both calculations. 
Results: Three patients experienced non-sustained polymerphic ventric- 
ular tachycardia (PTV), and no patient had sustained PVT. From a hospital 
perspective, the cost of first-line ibutilide was greater than the total cost of 
first-line EC ($325 vs. $138 per patient). However, from a managed care 
perspective, the use of ibutilide saved approximately $138 per patient ($904 
vs. $1042). 
Conclusions: In contrast to a previous decision analysis model, the use 
of ibutilide was not associated with cost-savings from a hospital perspective. 
Our findings may not be generalizable to all institutions. 
1 54 I Electrical Cardioversion of Atrial Fibrillation: Is 
I 
022-1 
Postcardioversion Atrial Stunning Caused by 
Electrical Energy or by Atrial Fibrillation Itself? 
Heyder Omran, Wemer Jung, Rami Rabahieh, Stefan IIlien, 
Susanne Spehl, Christian Woipert, Burghard Schumacher, Bemdt LL~deritz. 
Department of Cardiology, University of Bonn, Bonn, Germany 
Background: The hypothesis of this prospective study was that atrial cham- 
ber and appendage stunning after electrical cardioversion is not caused by 
the applied energy but is related to the duration of atrial fibrillation (AF). 
Methods: Transesophageal echocardiography (TEE) was performed in 
9 patients with acute AF (duration 14 ± 3 h) and 9 patients with chronic 
AF (127 ~ 104 days) to assess the effect of electrical shocks on left atrial 
chamber and appendage function. Peak emptying velocities of the left atrial 
appendage (LAAv) and spontaneous echo contrast (SEC) were assessed 
before and after the procedure. Seven patients with paroxysmal AF and 
spontaneous restoration of sinus rhythm (SR) during a TEE examination 
served as controls. 
Results: In patients with spontaneous cardioversion, SEC was detected 
neither before nor after restoration of SR. In addition, LAAv were not affected 
by spontaneous restoration of SR (0.7 i 0.13 m/s versus 0.7 i 0.14 m/s). 
Likewise, restoration of SR after electrical cardioversion of acute AF did 
not affect the degree of SEC and LAAv (0.61 i 0.15 versus 0.57 ± 0.22). 
In contrast cardioversion of chronic AF resulted in the intensification and / 
or generation of SEC in 5 of 9 patients and LAAv decreased from 0.36 ± 
0.11 m/s to 0.25 ± 0.09 m/s (p = 0.002) after the procedure. Furthermore, 
ineffective shocks during both acute and chronic AF affected neither LAAv 
nor SEC. 
Conclusions: Atrial chamber and appendage stunning after electrical 
cardioversion is caused by AF itself and is related to its duration. These 
findings have important clinical implications for anticoagulation therapy in 
patients with paroxysmal AE 
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1022-155 ] Plasma Atrial Natriuretic Peptide After 
Restoration of Sinus Rhythm: Relation With 
Different Modal)ties of Card)aversion from Atrial 
Fibrillation 
Anna Vittoria Matt)eli, Daniela Vivoli, Emma Tarabini Castellani, 
P~o/a Borella ~. Gior~io Maffiofi. Card/b/ogy OO~.: ~B~bmedfc D~. ~nwersify 
of Modena, Italy 
(pts) with atrial libdllation {AF). To evaluate the effects of different modal)ties 
of card)overs)on from AF, ANP was checked in a group of 107 consecutive 
pts. 
Methods: ANP was evaluated at baseline during AF (ANP0) and imme- 
dia.~e;-3,' e#er rest~rat~ ~ s;'t~s tr64;em 4A~P} ~ ar~ a,~er 2 ~}ay,s ~AN'P2~t, ,~ 
month (ANP3). At these time atrial function was assessed by Doppler echo- 
cardiography and the following parameters were measured: transmitral peak 
A velocity (A) and integral (At), atrial ejection force (AEF), peak E velocity (El 
ard integral (EI'I. Forty-one qfs sqonfaneousf¥ restored sl'nus rh~hm (Grouq 
A) and the remaining pts were randomized to drug therapy (Group B) or DC 
shock (Group C). *p < 0.01 
Results: Results are shown in table: 
ANP0 ANP1 ANP2 ANP3 
Group A 125 ~ 5~ 4~±~1 ~l& 31 35 & 30 
Gl~# ~ ~3,~±%',3 65=3~ ~T ± ~T %'5± ~T 
Group C 127~ 71 78 ~52" 64 ±37* 39~23 
Conclusion: ANP levels were elevated in all pts during AF and sig- 
nificantly decreased after restoration of sinus rhythm. A subgroup of pts 
mantained elevated levels of ANP immediately after cardioversion. This dif- 
ference was not reported at 1 month. A relation was observed between ANP 
levels and the recovery of atdal mechanical function. 
I1 56] Abnormalities of Hypercoagulability in Atrial 022-1 
Fibrillation: Relationship to Asymptomatic 
Embolisation Detected by Transcranial Doppler 
Gregory Y.H. Lip, Andrew D. Blann, Marisa Cullinane 1 , Hugh Markus ~ .
University Department of Medicine, City Hospital, Birmingham; ~ Clinical 
Neurosciences, lost)rue of Psychiatry, London, England 
Background: Atrial fibrillation (AF) is associated with abnormalities of haemosta- 
sis that confers a hypercoagulable or prothrombotic state. Embolic signals 
(B=S,) us)no transcranial DqqDler may be associated with thromboembolic risk 
im A'F an~'tnese'naemo~a.hc ~enorm~lilt~es. 
Methods: Measurement of plasma fibrin D-dimer (an index of thrombo- 
genesis, ELISA), yon Willebrand factor (vWf, an index of endothelial dysfunc- 
tion) and fibrinogen in AF patients undergoing transcranial Doppler record- 
ings of the middle cerebral artery. 
Results: 84 patients with nonrheumatic AF (57 males, mean age 73.7 
years) were studied: 62 were not on antithrombotic therapy (Group 1 ) whiisl 
22 were taking warfarin (Group 2). Results were compared to 56 healthy 
controls in sinus rhythm. Our results are as fellows: 
Mean (s.d.) Group 1 Group 2 Controls p 
F~b,~n,~jen [g;'~'( 3.1 ~.5) 3.4 {~.5) ~:2 {O.5) O.r.~",~l 
vWf ()U/I)" 136 (26) 136 (29) 119 (28) 0.001 
D-dimer (ng/ml)'" 295 (633) 105 (317) 26 (52) 0.0001 
"ANOVA, **Kruskal-Wallis test rail p = NS} Group 1 patients were classified as symp- 
tomatic (n = 21) if they had a stroke or TIA within 1 year prior to study, with ES on 
transcranial Doppler as positive (+ve) / negative (--ve). 
Asymptomatic Symptomatic [Wadarin, Gp2] 
~mbolic sLona}s +'~e -'~e ÷re -'~e ÷'~e -'~e 
vWf ()U/I) 133 (25) 139 {21) 149 (17) 129 (26) 122 (18) 147 (31) 
E)-dimer in g/m!) 425 183 164 417 33 146 
There was no significant correlations between plasma fibrinogen, vWf 
In conclusion, patients with AF demonstrate abnormalities of fibrinogen, 
vWf and fibrin D-dimer, suggesting abnormal thrombogenesis and endothelial 
~yslunct~en in this condition. "there was no relationship 0I these marl{ors te 
the presence or embo~ic Wgnals u~ng transcra~a~ Doppler. 
1022-157 J Catheter Ablation of Organized Atr ial  
1 
Dysrhythmias Associated With Atrial 
Fibrillation: Transtelephonic Monitoring May 
Guide Patient Selection 
Jay Curwin, Nagesh Chopra, Amir Modarressi, Robed Coyne, Glenn Weiss, 
Aria Baqt~sta. Wifham Wesloske.. John Banns.. ~ter2hen Winters. M~rnM.~wn 
Memorial Hospital Morristown, New Jersey, USA 
"bac~Kproun~: ~ece~i'~ re3)ons su~t  ~at  ,~3a~e~ts "W~33 or~zec3 ~r~,3~ 
dysrhythmJas lOADs) [atdal premature beats ,(APBs), athal tachycardJa ~AT), 
atrial flutter (AFL)] in association with paroxysmal atrial fibrillation (PAF) may 
be amena#)e ~0 curat)ve e)ec~roc~e cat#eter a#la~on. We condueteO a ~t~ot 
study to determine the incidence of OADs in pts with PAF and the potential for 
~rens~ ¢'rk.,"~o/¢r¢~, (77M) teai@ ~ the pr~"th3r t  o[ S~t"~ t~.nts 
(pts). 
Methods: Of 3313 consecutive patient chads reviewed from a commer- 
cial TTM service (Raytel, Inc.), 158 revealed ~ 1 episode of PAF. Three 
elec~roqhvslofoc~sfs Ihdegenden(/v, evaluated 29"2" TTfvf traclhc$s from 24 q~S 
with respect to the occurrence of OADs pnor to and/or during episodes of 
atrial fibrillation. 
Results: Eleven pts (46%) had > 1 TTM recording of OADs prior to PAF. 
Six of these pts. transmitted ~ 2 episodes of OADs pnor to the onset of PAF. 
OADs were recorded in 9.2% (n = 27) of all TTM recordings. Specific TTM 
included: APB's - 3 pts; AT -3 pts; AFI - 4 pts; mulYffocal atrial tachycardia- 
lpt .  
Conclusion: A substantial incidence of OADs exists pnor to the onset and 
during PAF. TTM may be useful to document such episodes, and to identify 
pts who may benefit from electrode catheter ablation to prevent associated 
atrial fibrillation. 
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I L 1.Q2_~-1.78 1 C~i ,&ae .  Q.t a. I~to.~et I~i~m~.~i~ ~/&~eY.m:.m. ~i.t.b. 
a #am~.ed Sirre Water Mono~.has~c Waveform fo r  
Suneet Mittal, Shervin Ayati, Kenneth M. Stein, Bradley P. Knight, 
David Schwadzman, Doris Cavlovich, Edward V. Platia, Hugh Calkins, 
Patrick J. Tchou, John M. Miller, J. Marcus Whadon, Ruey J. Sung, David 
J. Sletwiner, Steven M. Markowitz, Bruce B. Lerman. The New York 
HospitaI-Comefl Medical Center, NY, NY," Zofl Medical Corporation, 
Burlington, MA. USA 
Background: The superiority of biphasic (BI) over monophasic (MONO) 
w.~ve.fo reP, s49r..oPr39sc~i~ dc+f4,~br.~!~e,.t~en h -b~"~ o¢,~.k~!id.J=~.. , 'M~le~ .be~ .- 
#,:fit. fez:. Pal. wa..velofmP,_ may.. al,£-,o_ .a.gL~y. to_ tftPa3stho~acic~ de:[i.h[(tJr3.tJDD ...°,.J.ocP~ 
~n~g~er nergy" sb, ocks may be associated w~t~ myoca~ia'~ iu~, t3~ shocks 
offer the potential advantage of defibrillation with tower energy than MONO 
shocks. 
Methods: We compared the defibrillation efficacy of BI shocks (120 J) 
with standard damped sine wave MONO shocks (200 J) in a prospective, 
randomized, multicenter study of patients undergoing transthoracic ventnc- 
ular defibrillation. The defibrillator (Zoll PD-2100) delivers a novel biphasic 
waveform, consisting of a constant current first phase (equivalent average 
ant, peak curre~\~ an6 a ~.r~cale6 ex.oone~*~a , secor~£~ Y~ase. 
to a 120 J BI (n = 101) or 200 J MONO (n = 85) shock. The first-shock 
e'fllcacy dl '(he Tall snodk was #rearer than lhe e'ff~cac.v dt fOe IV'IUNO snodK 
(99% vs 92%, p = 0.03). In addition, successful defibrillation with BI shocks 
was achieved with 58% less current than that delivered with MONO shocks 
1,14 4-. 2 vs 33 ± 8 am#,# < Q.0001/,. There were no camel)cations related to 
the 81 or MONO shock. 
Conclusions: Our data demonstrate a superior efficacy of BI shocks, 
comoared with MONO shocks, for transthoracic defibrillation. More impor- 
tant(% b~,~e~e[~  sb~,c, ks dellbr(tl&ted ,~itD ~earl,~ 6Q% less current. T~e 
combination of increased efficacy and decreased current requirements sug- 
gest that, compared with MONO shocks, BI shocks are advantageous for 
transthoracic defibrillation. 
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1023-179 1 Mechanism of the Difference of Defibrillation 
i Efficacy of Anodal Versus Cathodal Monophasic 
Waveforms 
Yoshio Yamanouchi, Yuanna Cheng, Patrick J. Tchou, Igor R. Efimov. 
Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: We have recently demonstrated that defibrillation shocks pro- 
duced virtual electrode induced phase singularity (VEIPS) responsible for 
subsequent arrhythmias and defibrillation failure. 
Methods: We sought to determine the role of VEIPS in genesis of ar- 
rhythm±as induced by anodal versus cathodal monophasic shocks (100-V, 
8-ms), applied from a transvenous defibrillation lead at various phases of 
action potential (AP) during ventricular pacing (CL = 300-ms). High-resolu- 
tion fluorescent imaging and potentiometdc dye were used to map epicardial 
electrical activity from Langendorff-perfused rabbit hearts (n = 7). 
Results: Virtual electrode pattern was produced by shocks of both polar- 
ities at any AP phase. But, VEIPS and arrhythmias were more likely induced 
at the T-wave. Arrhythmias were induced in 33.2 ± 30.1% and 53.1 ± 39.3% 
cases (p = 0.0075), for anodal and cathodal shocks, respectively, with sus- 
tained arrhythmias observed in 10.5 ± 13.5% and 25.8 ± 29.7% of the cases 
(p = 0.0195), respectively. Optical mapping revealed that shock-induced ar- 
rhythm±as occurred via VEIPS at any AP phase. Anodal shocks produced 
pairs of re-entries propagating in an inward direction with respect to the 
electrode. These re-entries could easily collide and annihilate, frequently re- 
suiting in only a few extrabeats. In contrast, cathodal shocks produced pairs 
of re-entries which propagated in an outward direction, more likely evolving 
into sustained arrhythmia. 
Conclusions: Our data is consistent with clinical observations that anodal 
defibrillation monophasic shocks are more efficient han cathodal shocks. We 
have found a higher pro-arrhythmic effect of cathodal shocks compared with 
anodal shocks may be related to direction of shock-induced reentrant waves 
and their post-shock interaction. 
1023-1 80 ] Kinetics of Defibrillation Shock-Induced 
J Response: Implications to Design of the Optimal 
Defibrillation Waveform 
Kent A. Mowrey, Yoshio Yamanouchi, Patrick J. Tchou, Todor N. Mazgatev, 
Igor R. Efimov. Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: Numerous empirical studies have attempted to determine an 
optimal defibrillation waveform. However, the optimization was not based 
on knowledge of cellular responses, but driven by the available technology 
being limited to a capacitive discharge. 
Methods: We used optical techniques to map epicardial electrical activity 
during defibrillation shocks free of shock-induced artifacts with high temporal 
resolution (528 /~s). Monophasic shocks (100 or 200 V, 150 ~F, 8 ms) 
of either polarity were applied at 50% of action potential duration using 
transvenous defibrillation lead system in-vitro in Langendorff-perfused rabbit 
hearts analogous to a hot-can configuration. Pairs of positive and negative 
polarizations were approximated with single-exponential fits from a total of 
722 recording sites from 3 hearts. 
Results: 
Polarization Time constant Transmembrane voltage (mV) 
(ms) before shock after shock difference 
Positive 2.5 ± 0.8 -11.1 ± 6.7 29.8 ± 13.7 40.8 ± 15.6 
Negative 2.2 ± 1.3 -12.6  ± 6.8 56.3 ± 13.9 -43.7 ± 11.9 
Conclusions: Currently available defibrillation therapy may be improved 
by departing from conventionally used truncated exponential waveform Time 
constants suggest that fast (100 p.s) onset of the defibrillation shock is not 
followed by cellular response. Therefore, the onset of the shock may be 
slowed to 1 ms. Since 86.5% polarization is reached in two time constants, 
the duration of the shock may be shortened to 5 ms. This might reduce tissue 
damage during the onset of the shock as well as reduce delivered energy at 
the end of the shock. 
1023-181 ] Optimal Energy by Field Distribution Determined 
Catheter Mapping 
Todd O'Buckley, Eckhard AIt, D. Curtis Deno, John Rosborough. I. 
Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische 
Universit~t, MOnchen, Germany 
Background: A further reduction in size of implantabte cardiovascular defib- 
rillators is effected by a decrease of the total energy requirements. Assuming 
that a homogeneous minimum energy density is required for successful 
defibrillation, equalized field distribution should be achieved. 
Methods: A 3.5 cm standard right ventricular (RV) defibrillation coil was 
placed in the RV of six mongrel dogs. Shocks were applied between the 
coil and a subcutaneous can that was either fully conductive or conductive 
only along the outer edge. An additional subcutaneous ring electrode was 
placed over the apex of the left ventricle, connected to the can in parallel 
for active mode and disconnected for passive. Shocks of increasing voltage 
from 100 to 600 V were applied. Measurements made at the apex of the left 
ventricle (LV), the mid-coronary sinus (CS), and the right ventricular outflow 
tract (RVOT) were recorded via a custom designed 3-dimensional electrical 
field sensor (EFS) system, based on 5-F catheters. 
Results: The EFS system shows a linear correlation between shock 
voltage and electric field (V/cm) strength, with high reproducibility. For shocks 
applied between the RV and an uncoated can, a normalized electric field of 
0.82 V/cm/100 V was found in the LV apex; 1.54 V/cm/100 V in the CS; and 
2.38 V/cm/100 V in the RVOT. By using the coated can, the LV electric field 
was increased to 0.95 V/cm/100 V. Furthermore, the addition of the active 
subcutaneous ring to the coated can increased the LV electric field to 1.69 
V/cm/100 V. 
12 ~ I~Vq/~coQted C=1 
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Conclusion: During RV-can defibrillation, there is an inhomogenous elec- 
trical field distribution. By adding a small active or passive subcutaneous ring 
electrode, an important increase in LV field density can be brought about 
without an increase in energy. 
1023-182 ] The Optimal Exponential Monophasic 
Waveforms for External Defibrillation 
Yoshio Yamanouchi, James E. Brewer, Mike Olson, Donald G. Hills, Kent 
A. Mowrey, Ann M. Donohoo, Todor N. Mazgalev, Bruce L. Wilkoff, Patrick 
J. Tehou. Cleveland Clinic Foundation, C/eve/and, OH; SurVivaLink 
Corporation, Minneapolis, MN, USA 
Background: Recent external defibrillation studies have demonstrated that 
an exponential monophasic waveform is better than a traditional damped 
sine waveform. The purpose of this study was to determine the optimal 
exponential monophasic waveform. 
Methods: In a swine model of external defibrillation (n = 6, 33 ± 4 kg), 
9 exponential monophasic waveforms obtained with 3 capacitors (30, 60 
and 120 /~F) and 3 tilt values (55%, 75% and 95%) were tested randomly 
to evaluate the stored energy at 50% defibrillation success (E50). E50 was 
determined by Bayesian technique. 
Results: E50 (J) and pulse width (ms) in parentheses are shown in table. 
Capacitor Tilt 
55% 75% 95% 
30~F 109±11(0 .9 I±0.1)  101±11(1 .6±0.1)  94±10(3 .7 -+0.3)  
60,~F 124 ± 49 (1.9 ± 0.1) 112±27(3 .3=0.2)  135±44- (7 .3±0.5)  
120,uF 117±45(3 .9±3)  124163(6 .6±0.5)  235±84"(14 .5±1.0)  
"p = 0.001 vS all another waveforms, "*p < 0.05 vs 30 h:F 95% waveform 
The lowest E50 for the 30, 60 and 120/~F were 95%, 75% and 55% tilt 
waveforms, respectively. The lowest E50 for all tilt waveforms was the 30/~F 
wave form. 
Conclusion: Capacitor and tilt values affect external defibrillation effi- 
cacy. The E50 are more sensitive to tilt values changes in larger capacitor 
waveform. 
1023-1831 Transvenous 
1 
Internal Atrial Card±overs±on: 
J A Randomized Study On Asymmetrical Versus 
Symmetrical Biphasic Shocks 
Giuseppe Boriani, Mauro Biffi, Romano Zannoli, Angeto Branzi, 
Bruno Magnani. Institute of Cardiology, University of Bologna, Italy 
Aim of the study was to compare, according to a randomized cross-over 
design, two different biphasic waveforms (6.5/2.5 ms and 3.0/3.0 ms phases 
duration, respectively) for low energy internal atrial cardioversion (CV). 
Methods: Nineteen patients (pts) with chronic persistent atrial fibrilla- 
tion (AF)(mean duration 16 ± 20 months) were submitted to internal atrial 
CV (shock delivery between catheters in right atrium and coronary sinus, 
respectively) and randomly allocated to baseline CV with an asymmetrical 
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biphasic shock (6.5/2.5 ms) or with a symmetrical biphasic shock (3.0/3.0 
ms), according to a step up protocol. After baseline CV a sustained AF was 
reinduced and the pts crossed to the alternative waveform. The procedure 
was performed without routine administration of sedatives and shock in- 
duced discomfort was monitored by a subjective score (1 to 5). Sedatives or 
anesthetics were administered at patient's request. 
Results: The procedure was effective in all the pts and was performed 
without need for sedatives/anesthetics in 17/19 pts (89%). Data on effective 
shocks: 
Shock Leading voltage (V) Energy delivered (J) Pain score 
6.5/2.5 ms 290 ± 76 7,74 =: 4.25 4.18 ± 0.73 
3.0/3.0 ms 337 ± 104"* 8.65 ± 5.94 4.59 ± 0.62" 
Legend: "" = P < 0.001;" = P < 0.02. 
Conclusions: Delivery of biphasic asymmetrical shocks (6.5/2.5 ms) 
results in lower leading edge voltage of effective shocks and better patients 
tolerability compared with conventional biphasic symmetrical shocks (3.0/3.0 
ms). These findings are of interest both for transvenous internal CV of chronic 
persistent AF and for implantable atrial defibrillators. 
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I1 841 Dispersion no Impact on Mortal i ty 024-1 QT has in 
Patients With Moderate and Severe Left 
Ventricular Dysfunction: Results from a Cohort 
of 2263 Patients 
Sriram Padmanabhan, Jatin Am±n, Helme Silvet, Ramdas G. Pai. Loma 
Linda University and VA Medical Center, Loma Linda, CA, USA 
Background: Increased QT dispersion on the surface ECG has been as- 
sociated with propensity to ventricular tachycardia in those with underlying 
myocardial disease. However, whether this results in a reduced survival in 
those with LV dysfunction is not clear. This issue was investigated in a large 
cohort of patients with moderate to severe LV systolic dysfunction. 
Methods: 2263 consecutive patients with an LV ejection fraction (EF) of 
_< 40% were identified from the echo data base. All had simultaneous ECGs. 
The mean EF was 30%, age 70 years and mean follow up 1007 days. The QT 
dispersion was computed using the QT Guard software (Marquette Medical 
systems) on the digitally stored ECG data on the MUSE system. There were 
688 deaths. Kaplan-Meier curves and tog rank tests were used for mortality 
analysis. 
Results: The global QT dispersion (QTd) was analyzable in 1496 patients. 
The mean QTd was 35 ms. The 7 year cumulative mortality was 46% and 
was totally unaffected by QTd. Patients with an EF >_ 30% had a 7 year 
mortality of 40% compared to 65% for those with an EF < 30% and both 
were identical in those with QTd shorter and longer than 35 ms. In addition, 
neither the precordia[ QT dispersion, nor the QT dispersion area impacted 
the overall survival. 
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Conclusions: In patients with LV dysfunction, automated measures of 
QT dispersion do not seem to impact survival at any level of LV systolic 
dysfunction. 
l l  85~ Dynamic Changes of QT Dispersion and its 
] 
024-1 
Relationship With Clinical Variables and 
Arrhythmic Events After Acute Myocardial 
Infarction 
Yee Guan Yap, Gang Yi, Xiao-Hua Goa, Kudret Aytemir, A. John Camm, 
Marek Malik. St. George's Hospital Medical School, London, UK 
Background: No information is available regarding the relationship of QT 
dispersion {QTd) with clinical variables. In addition there has been conflicting 
evidence on QT dispersion as a predictor of ventricular arrhythmias due to 
inconsistently in timing of QTd measurement. 
Methods: We examined prospectively 81 patients (61 males, 20 females, 
mean age 63 zE 12) following AMI using Marquette ECG (MAC VU) equipped 
with software (QT Guard) which analysed QTd automatically from digitaly 
stored ECGs. 10 ECGs were recorded from day 1 to day 5 after the day of 
index infarct and the mean QTd calculated on each day 
Results: QTd exhibits significant changes for day t to day 5 after MI, 
being highest on day 2 (p = 0.008). Using student's t-test, age, sex, previous 
MI, presence of Q wave, door-to-needle time, peak CK did not have any 
influence on QTd. Patients received thrombolytic therapy had increased 
QTd than those did not on day 1 only (55.5 ± 23.0 vs 37.423.5 ms, p = 
0.034). Anterior AMI patients had significantly increased QTd than inferior 
AMI patients from day 1 to 5 except on clay 3 (day 1:62.5 ± 23 vs 42.3 
± 19.2 ms, p = 0.0001; day 2:68.5 ± 33.2 vs 46.7 ± 31.2 ms, p = 0.004; 
day 3:57.0 ± 24.0 vs 45.4 ± 28.3, p = 0.077; day 4:51.5 i 25.3 vs 34.7 
± 22.1, p = 0.005; day 5:52.0 ± 25.4 vs 37.0 ± 23.4, p = 0.018). There 
was no difference in QTd between patients with and without positive exercise 
test and between patients that underwent revascularisation procedures (n = 
21) and those didn't. During the follow-up (131 ± 102 days), 6 AMI patients 
with ventricular arrhythmic events had higher QTd only on day 1 than those 
without (75.5 ± 12.2 vs 50.8 ± 23.6 ms, p = 0.002), but not on other days. 
Univariate analysis showed only day 1 QTd is predictive of arrhythmic events 
(r = 0.26, p = 0.02). 
Conclusions: 1 ) QTd exhibits a dynamic change after AMI and the timing 
of QTd recording is therefore crucial. 2) QTd is affected by thrombolytic 
therapy on day 1 only whereas the infarct site has a persistent influence on 
QTd for 5 days after AMI. 3) QTd is not predictive of subsequent exercise 
test result and need for revascularisations. 4) Only QTd on day 1 after the 
index infarct is predictive of subsequent ventricular arrhythmic events and 
should be used for risk prediction. 
I1 I Interval and Cycle Length Normal I 024-1 86 QT Cardiac in 
Subjects, Myocardial Infarction and 
Hypertrophic Cardiomyopathy: New Insight into 
Mechanisms of Arrhythmogenesis? 
Irina Savelieva, Yee Guan Yap, Gang Yi, Katerina Hnatkova, A. John Camm, 
Marek Malik. St. George's Hospital Medical School London, UK 
Background: An abnormal increase in ventricular repolarization at s~ower 
heart rates may reflect autonomic imbalance and increase risk of arrhythmo- 
genesis in patients with heart disease. 
Methods: The relation between QT, QTpeak (QTp), Tpeak-Tend (TpTe) 
intervals and cardiac cycle length was evaluated in 70 normal subjects, 48 
patients with myocardial infarction (MI) and 37 patients with hypertrophic 
cardiomyopathy (HC). A set of 10 ECG was assessed in each subject using 
automatic measurement by QT Guard software (Marquette Medical Systems, 
Milwaukee, WI). The slopes of linear regressions of QT, QTp and TpTe 
intervals plotted against the corresponding RR interval were compared. 
Results: There was no difference in mean cycle length between groups. 
A strong linear correlation between QT, QTp and RR intervals was observed 
in normal subjects, MI and HC patients (r = 0.65 - 0.59, 0.82 - 0.77, 0.79 - 
0.74 resp., p <: 0.0001). TpTe interval only showed a weak correlation with 
heart rate in normal subjects (r = 0.24, p < 0.05) and was rate-independent 
in both patients groups (p = NS). Compared to normals, slopes of regression 
between QT, QTp intervals and RR interval were significantly steeper in 
MI and HC patients (0.0990 - 0.0883, 0.1597 - 0.1551, 0.1653 - 0.1486 
resp.). Regression lines were neither parallel nor identical (T > 1.96, Z > 
3.07). There was no difference in steepness for TpTe/RR slopes between 
groups (0.0110, 0.0076, 0.0163 resp.). TpTe/QTp ratio was similar in normals, 
MI and HC patients (0.30 i 0.03, 0.31 i 0.07, 0.30 ± 0.04 [mean ± SD], 
resp.) in the absence of any correlation between QTp and TpTe intervals, 
suggesting disproportional prolongation of both components of QT interval 
at slower heart rates. 
Conclusion: A progressive increase in ventricular repoladzation duration 
with an increase in cardiac cycle length in MI and HC patients compared to 
normals, may indicate an enhanced rate-variability of QT interval and is likely 
to be associated with longer vulnerable periods and predisposing to lethal 
ventricular arrhythmias. 
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1024-187/ Effect of Acute Infarction QT Myocardial on 
.J 
Dispersion: A Longitudinal Study 
Ervin R. Fox, B. Keith Ellis, James V. Talano, Saner R. Dibs. Tulane 
Universi~ New Orleans, LA; University of CA, San Francisco, CA, USA 
Background: Several studies have found increased QT dispersion (QTD) in 
patients with myocardial infarction (MI), compared to those without MI. No 
study has documented change in QTD with acute MI. Our objective was to 
evaluate the effect of acute MI on QTD, using patients' pre-MI ECG's as their 
baseline. 
Methods: We searched the computer ECG databases of two urban uni- 
versity hospitals for patients in a 3-year period with ECG diagnosis of 'acute 
MI'. Patients who had another ECG within preceding 12 months were eligible 
for study. Patients were excluded if their ECG's showed atrial fibrillation, in- 
terventricular conduction block, ventricular pacing, unmeasurable QT in >4 
leads or if diagnosis of acute MI was unconfirmed. Patients were excluded if 
they had clinical evidence of acute ischemia at the time of baseline ECG or if 
they had acute MI in the 3 months preceding the baseline ECG or in the inter- 
val between the baseline and acute MI ECG's. Simultaneous 12-lead ECG's 
were printed at 20 mm/mv and 50 mm/s settings and scanned digitally. T 
end was determined as the intersection between the steepest tangent to the 
terminal part of T and the Q-Q baseline. QTD was calculated as difference 
between the longest (QTmax) and shortest (QTmin) QT. QT was corrected 
for heart rate (QTc) using the Bazette equation. 
Results: Of 540 patients with acute MI on ECG, 165 were eligible for the 
study. 15 patients remained after applying exclusion criteria (8 F & 7 M, age 
41-92 years). Mean interval between baseline and MI ECG's was 56 (range 
2-180) days. Heart rate was 75 4- 5 bpm at baseline and 92 ± 4 bpm with 
acute MI (p = 0.01). QTD increased with acute MI from 58 ± 6 ms to 88 4- 10 
ms (p = 0.005). QTDc increased from 65 4- 7 ms to 109 4- 13 ms (p = 0.002). 
QTmax-c increased from 444 4- 12 ms to 466 4- 10 ms (p = 0.02). There was 
no significant change however in QTmin-c. 
Conclusion: This study of an unselected cohort is the first to show an 
increase in 12-lead QT dispersion with acute MI compared to baseline. The 
increase in QT dispersion with acute MI was found to be mainly secondary 
to QT max lengthening. 
1024-188] Beta Blockade Decreases T Wave Adrenergic 
J Alternans 
Malcolm M. Kirk, Michael Cooklin, Stephen R. Shorofsky, Michael R. Gold. 
University of Maryland, Baltimore, MD, USA 
Background: Microvolt T wave alternans (TWA) is a heart rate dependent 
predictor of arrhythmia vulnerability and inducible ventricular tachycardia 
(VT) at electrophysiology study. The effect of autonomic modulation on TWA 
in humans is unknown. 
Methods: We measured TWA at baseline and during acute intravenous 
beta blockade with esmolol in 21 patients with inducible VT. TWA was mea- 
sured in sinus rhythm and with atrial pacing at 600 and 500 ms cycle lengths. 
TWA was defined as positive (+) if the altemans amplitude was _> 1.9 I,~V 
with a ratio > 3 in sinus rhythm or at either pacing rate 
Results: The patients had a mean age of 68 4- 10 years, a mean ejection 
fraction of 32 ± 14%, and 86% were males. Mean heart rate decreased with 
esmolol from 82 4- 11 to 70 4- 9 bpm (p < 0.001). Of these patients, 17 
(81%) were TWA + at baseline, but only 9 (38%) were TWA + with esmolol 
(p < 0.01). Moreover, TWA voltage in the vector magnitude lead (see Table) 
decreased 48%-74% with esmolol over the range of heart rates evaluated 
(ANOVA, p < 0.001). 
TWA voltage Sinus 600 ms 500 ms 
Baseline 0.74 4- 0.97/~V 2.4 :t- 3.6 #V 2.9 ± 2.2 #V 
Esmolol 0.19 4- 0.24/zV 1.1 4- 1.9 I,LV 1.5 4- 2.4 ~V 
Conclusions: An acute esmolol infusion markedly decreases TWA am- 
plitude, and reduces the sensitivity of TWA for predicting inducibility of VT, 
despite achieving only partial beta blockade. This effect may be a mecha- 
nism underlying the role of beta blockers in reducing arrhythmias and sudden 
death. 
1024-189J Effects of Beta-adrenergic on 1 Blockade 24-hour 
QT Interval Variability in Newborn Infants With 
Prolonged Ventricular Repolarization 
Kadne Goulene, Dimitdos Rodis, Marco Stramba-Badiale. Istituto 
Auxologico Italiano IRCCS and Centro di Fisiologia Clinica e Ipertensione, 
University of Milan, Ospedale Maggiore, Milan, Italy 
Background: Infants with a prolonged QT interval have a higher risk of 
Sudden Infant Death Syndrome suggesting the opportunity of a prophylaxis 
with beta-adrenergic blockers (BB) in this population. However, the effects of 
BB on the QT interval measured from a short standard ECG is minimal and 
does not allow the evaluation of the individual response to therapy. 
Methods: Twenty-four hour Holter were recorded in 24 consecutive new- 
borns with long QT (LQTN) before and during the oral administration of 
2 mg/Kg of propranolol and in 24 healthy newborns with normal QT (HN) 
matched for age and gender. A dedicated algorithm (ELA Medical) automat- 
ically measured QT and RR interval from 2880 30-sec segments. 
Results: LQTN showed a greater 24-hour QTc variability than HN. Both 
the difference between the higher and the lower value of hourly QTc (QTc- 
max-min) and the standard deviation of QTc were greater in LQTN than in 
HN (70 ± 50 vs 39 4- 24 ms; p = 0.032 and 19 Jc 14 vs 10 i 7 ms; p = 0.02, 
respectively). In LQTN BB did not affect the QTc measured from the standard 
ECG, while it reduced the mean 24-hour QTc automatically measured from 
the Holter recordings (from 481 4- 28 to 458 4- 23 ms; p = 0.002). BB reduced 
also the hourly QTcmax-min (from 70 4- 50 to 39 4- 17 ms; p = 0.016) and 
the standard deviation of QTc (from 19 4- 14 to 10 4- 5 ms; p = 0.047), 
with no effects on the standard deviation of RR interval. Of note, during BB 
LQTN showed values of QT interval variability similar to those observed in 
the control group. 
Conclusion: Newborns with long QT have a higher 24-hour QT variability 
than those with normal QT. Beta-adrenergic blockade significantly reduced 
this increased variability. This effect may contribute to the protective action of 
beta-blockers in infants with prolonged repolarization and can be assessed 
by the automatic measurement of QT interval from Holter recordings. 
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I1052-146 / of Left Atrial Linear Lesions 7 Influence Right or 
d on Heart Rate Response in Canine Pacing Model 
of Atrial Fibrillation 
Yoshinad Goseki, Franz X. Roithinger, Karl S. Liese, Carol Stillson, 
Jennifer Powers, Paul R. Steiner, Michael D./esh. University of California 
San Francisco, San Francisco, CA, USA 
Background: We hypothesized a slowing and regularization of the ventric- 
ular response (VR) to atrial fibrillation (AF) when lesions render AF more 
organized. 
Methods: After 6-10 weeks of atrial pacing at 800 bpm, we studied 12 
dogs (21-25 kg) with chronic AF. Using a custom multi-coil ablation catheter, 
initial RF ablation was first in the left atrium (LA) in 7, and first in the right 
atrium (RA) in 5 dogs. AF cycle length (AFCL) was measure on the RA 
septum (one spline of 50-pole basket) and coronary sinus (CS) during a 
random 10 s interval before and after initial lesions along with RR interval 
(ms) and coefficient of variation (COV, standard deviation / mean) for AFCL 
and RR. 
Results: On average, 2.8 4- 0.5 linear lesions with a total length of 12.6 
± 2.1 cm in LA, and 2.6 4- 0.9 lesions with 12.8 4- 1.8 cm in RA (p = n.s.) 
were identified. Although lesions in only the LA or RA did not terminate AF, 
AF terminated and was not inducible in 5/10 dogs with additional ablation in 
the contralateral atrium. 
Before LA After LA Before RA After RA 
RR (ms) 517 :J_ 136" 686 ± 138" 475 ± 100 541 4- 181 
COV 0.26* 0.20" 0.21 0.23 
RA AFCL (ms) 124 4- 23 126 4- 21 122 4- 23 129 5.: 27 
COV 0.19 0.17 0.19 0.21 
CS AFCL (ms) 126 4- 34 127 ± 26 121 4- 28 122 4- 27 
COV 0.27" 0.20* 0.23 0.21 
(*:p < 0.01) 
Conclusion: 1 ) LA long linear lesions resulted in marked slowing and reg- 
ularization of VR, whereas RA lesions with the same length had no significant 
effect. 2) Neither LA nor RA lesions affected mean AFCL, so the mechanism 
of ventricular slowing needs further study. 3) Symptomatic improvement after 
unsuccessful curative AF ablation in patients, as some studies have shown, 
might result from slowing and regularization of ventricular esponse. 
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1 47J Temporal Stability of the Spatial of 
] 
052-1 Distribution 
Dominant Frequencies During Acute Atrial 
Fibrillation in the Isolated Sheep Heart 
Sanjay Dixit, Moussa C. Mansour, Ravi Mandapati, Jay Chen, 
Dhana~ja'~"~'~u"9~, & t '~a~'a~L~ 3~q J~,"~-~'~i(~. 3-~'N',~,%~-~'~ 
Science Center, Syracuse, NY, USA 
Back~pro~nb:'bes~he'fne seeni)nd)y ~an0om a c'i~va~ on ~a'hems ~)~o aTh a') 
fibrillation (AF), spectral analyses of atrial electrograms consistently reveal 
distinc', ~".J~h','~'t, "~;~ ',~¢~{ ~G~', ~?..~,~. T~-J~ Q,E', %' '~'~r'~ a  ?J;'a~'c,.,~, ~, 
stable underlying reentrant sources. We investigated the temporal stability of 
the spat(at dis~b~tion of OF~ dadnc~ sustained AE 
rapid burst pacing in the presence of a constant concentration of acetyl- 
choline (ACh; 0.2-0.6 mM). Optical recordings from the left atrial appendage 
(LAA;20,000 pixels; 3 sec) were obtained simultaneously with bipolar record- 
ings from the pulmonary vein (PV) region, coronary sinus, and Bachmann's 
bundle every 5 minutes. Spatial distribution of DF on the epicardial surface 
of LAA were evaluated from maps denved by spectral analysis of recorded 
signals from individual pixels. 
Results: Sustained AF (>30 rain) was induced in all heads. The mean AF 
duration was 50.6 ± 4.5 min. A total of 37 recording periods was analyzed. 
The highest DFs (15.4 ± 3.1 Hz) was consistently found in the posterior LA 
including PV region. In all AF episodes, the mean coefficient of variation (CV) 
of DF of individual pixels was 0.03 ± 0.02 suggesting stability of the spatial 
profile over 1}me.'3'ne 6ffie~ence ma.~ behve6 'q~ sd~rac1~o lne}n~1}~ 'noTn 
the final DF map during each AF episode yielded a mean difference ef 0.58 
± 1.32 Hz (p = 0.38; NS) further corroborating temporat stability o! DFs. ~n 
addition, optical movies also showed spatio-temporally stable sequences of 
activation that persisted for 30.3 ± 13.1 min. In two animals, an increase in 
ACh (0.2 to 0.4 mM) increased DF (from 11.7 to 17.4 Hz and 12.4 to 14.2 
Hz, respectively). 
Conclusions: Spatio-temporal stability of DFs suggests that atrial fibril- 
lation in the isolated sheep heart is the result of stable reentrant sources in 
the left atd(~m. 
1052-1 z~ ]3r~erent Belated to  Anatom'=ca'l S',te ",n Pattern 
Atrial Cycle Length Before Spontaneous 
Termination of Atrial Fibrillation 
Yoshinari Goseki, Franz X. Roithinger, Michael D. Lesh. University of 
California San Francisco, San Francisco, CA, USA 
esized that the smooth iS) right atrium iRA) and Jeff atrium (LA) are the 
"drivers" during AF, that the trabeculated iT) RA is a passive bystander, and 
that therefore progressive organization ieadirig to terminatiot~ would occur 
first enlne?~3~, anb corona~ s~nus ~G). 
Methods: We studied 10 episodes of spontaneous termination of AF 
episcobes ~'h~C'n'nab'~as'vab > ~o-~o ~'n yS~ ~ h ~, "nigh.im ~ "b~)~ ".FZh % :z ~ 
kg) with AF following chronic rapid atrial pacing. Endocardial mapping was 
perfcrmed usin~ a 5@pole basket catheter ia the RA ac~ a 2Q-gale catheter in 
CS 3 s before termination of AF. Mean AFCL (ms) and coefficient of variation, 
used as a measure of organization, (COV, standard deviation/mean) at 3 
one-second intervals prior to termination were analyzed on the TRA, SRA 
and distal CS. 
Results: 
AFCL ms (COV) 
2-3 s 1-2 s 0-1 s 
TRA 134 ± 19 (0,14) 134 ± 17"(0.13) 142 ± 17"(0.12) 
SRA 126 ± 21"(0.17) 129 ± 22 (0,18") 134 ± 19"*(0.14") 
CS 114 • 19"'(0.17) 119 ~: 24 (0.20*) 122 ± 18"*(0.15") 
*p < o.05; **p < O.Ol 
Conclusion: 1) A gradual increase in AFCL and organization was noted 
in the SRA and CS, prior to AF termination, whereas the TRA slowing did 
not ©co~ ~)n'~h~)~s'~ f)or '~o'~rm)na1~on. ~)5~a~ o~.gan~;~a%on ~'~'t~ 5~,'a~b 
CS is the first event leading to AF termination implies that these regions are 
the "driver" and that the trabeculated RA, possibly because of protection by 
anatomic barriers, is a passive component AF in this canine model. 
1052-149 ] Regulation of Ryanodine Receptor by Cyclic 
ADP-Ribose in Guinea-Pig Isolated Ventricular 
Myocytes: Possible Inotropic and 
Arrhythmogenic Actions 
~ ~iLj'~'~ ;it;L#' ~, ,Vt~'~X) ~ ;'~ra';;', " "; ~ i  ~, 3~%'~ a'~ •F~t,"~ k?-, AYa",.,q ~ • &~i b'~ ?~ '~L, 
Derek A. Terrar 2 . ~ First Department of Internal Medicine, Nagoya University 
School of Medicine, Nagoya, Japan; 2 De(~artment of PharmacoloqK 
O'nfi/ers~/ oKCTxfor~, CTXrOra; OK" 
reported to enhance calcium induced calcium release (ClCR) by modulating 
ryaaodiae recegtors in mammaryan heart ceils. We have inves~ated the 
Methods: Contractions of guinea-pig ventricular myocytes in response 
to action potentials tAP) were measured. First a perforated whole-cell patch 
configuration was used for the measurement of control contractions. Each 
cell was stimulated at one rate (0.1-3 Hz) for 5 rain under this condition and 
then changes in contraction in response to intracellular application of drugs 
via the electrode were measured 5 min after rupture of the patch membranes. 
Results: At 36-°C, contraction was influenced by cytosolic application 
of cADPR in a concentration-dependect manner. 5 ~ M cADPR caused 
33 ~ 4% increase in peak contraction at 1Hz stimulation (n = 15). The 
application of its antagonist 8-amino-cADPR reduced contraction. At room 
temperature (20-24-°C), no significant effects were detected. The treatment 
with mixture of ryanodine and thapsigargin to suppress the sarcoplasmic 
r~hc~h~m 5~n~}on .Dre~n~e8 the ~ons  o5 ~b3~3h anb 1~s an~aoon~ a~ 
36°-C. CADPR failed to enhance contractions when added with calmodulin 
antagonists. The effects of cADPF{ were ~arger at s~ower stimulation rate. 
The effects of 8-amino-cADPR were larger at faster rate. When isoproterenol 
was applied extracellularly, spontaneous AP and contractions were evoked 
between stimulated AP at 1Hz. Such spontaneous activities were completely 
suppressed by 8-amino-cADPR. 
Conclusion: These observations are consistent with an action of cy- 
tosolic cADPR to enhance CICR through ryanodine receptors in guinea-pig 
veatdcc~lar myocytes at 36-°(]. Ca(modc(lia, temperature and stimulatica rate 
have been shown to strongly influence this mechanism. 
j 1052-150/  Mechanism of Termination of Atrial Fibrillation 
J by Flecainide in a Canine Model of Atrial 
Fibrillation 
Kunihiro Matsuo, Yasushi Tomita, Celeen M. Khrestian, Albed L. Waldo. 
Case Western Reserve University, Cleveland, OH, USA 
by a singJe, stable left a/hal reentrant drcuJf of very shod cycle length (Type 
II atrial flutter). This study tested the hypothesis that flecainide terminated 
atha} Ftbn~)ation i this m~te} by term}nat'mg the 7y~P. }} atha} flutter. 
stedle pericarditis, ECG lead II along with 372 unipolar electrograms were 
first demonstrated that induced atrial fibrillation was generated by Type II 
~tdat flutter aad was sustataed >_5 m~a. Cont~nuin~j to ma(~, we then infused 
flecainide (2 mg/kg) i.v. over 2 min. Activation maps consisting of 8-14 
consecutive windows (1.2 sec duration) were analyzed from each episode of 
sustained atrial fibrillation (>_5 min duration) and at the termination of atrial 
fibrillation. 
Results: During each episode of induced atdal fibrillation, the left atnum, 
in whole or in pad, was activated at a regular cycle length (range 97-115 
ms, mean 105 ± 6 ms) by a stable reentrant circuit consistent with Type II 
atrial flutter. In contrast, the right atrium did not follow the very short Type 
II atrial flutter "drive" cycle length in a 1:1 manner, resulting in fibrillatory 
conduction associated with coarse atrial fibrillation in lead I1. atrial fibrillation 
was terminated after completion of flecainide infusion in all of these 7 dogs. 
At the drug induced termination of atrial fibrillation, the cycle length of the 
reentrant circuit prolonged significantly (range 128-202 ms, mean 157 :L 
26 ms, p = 0.002) and became irregular. With prolongation of the reentrant 
cycle length, the ECG looked more like atrial flutter, though irregular. Then, 
t_eJ:~an, at. tb.e T~(~e ~t a:~Ea[ flutter occurred Eo 5/7 do~s~ resultinc~ in 
restorabon of s~nus rhythm, ln 2/7- dogs, the data coufd not be compFeteFy 
analyzed, but were also consistent with this mechanism. 
Conclusion: Flecainide induced termination of atrial fibrillation in this 
model occurred following the interruption of the Type II atrial flutter reentrant. 
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I1 I Efficacy of the Potassium Channel Antagonist 052-1 51 
Tedisamil in a Model of Sustained Atrial 
Fibrillation 
Peter S. Fischbach, Benedict R. Lucchesi, Fred Morady, Rajiva Goyal. 
University of Michigan, Ann Arbor, MI, USA 
Background: Tedisamil is a new class III antiarrhythmic agent which inhibits 
several cardiac potassium channels including the transient outward current, 
the delayed rectifier current and the ATP-gated potassium channel. Tedisamil 
has proven effective in terminating and preventing the induction of ventricular 
arrhythmias and atrial flutter in experimental animals. The ability of the drug 
to terminate sustained atrial fibrillation (SAF) has not been reported. 
Methods: A previously described canine model of SAF was used in this 
study. Briefly, an endocardial pacing toad was positioned in the right atrial 
appendage and rapid atrial pacing (50 Hz) was performed via an implantable 
neural stimulator in six dogs weighing 35.3 ± 2.1 Kg. Pacing was initiated on 
post-implant day one and the dogs were evaluated periodically in the electro- 
physiology lab for SAF (>30 min. duration) using surface electrocardiograms 
(ECG). If sinus rhythm (NSR) or nonsustained atrial fibrillation (NSAF) was 
present when the stimulator was turned off, a burst pacing protocol (50 Hz 
x 4 sec. every 2 minutes for a total of 10 bursts) was performed. When SAF 
was documented, or upon completion of the burst pacing protocol, tedisamil 
(1 mg/Kg) was administered intravenously over 2 minutes. In those trials with 
SAF, the ECG was monitored for conversion to NSR. If NSR was present 30 
minutes after the tedisamil infusion, the burst pacing protocol was repeated. 
Results: SAF was induced in 5/6 dogs (1 dog with a lead fracture) within 
14 days of implantation (range 7-14). 11 episodes of SAF were studied in 
these 5 dogs on post pacing days 7-29. Tedisamil converted all 11 episodes 
of SAF to NSR within 149 ± 90 sec. (range 48-300). SAF could not be 
reinduced using the pacing protocol 30 min. following tedisamil infusion 
in any of the 11 trials. When NSAF was present (6 episodes), tedisamil 
decreased the incidence of NSAF induced via the pacing protocol compared 
with baseline (90% 54/60 vs. 27% 16/60; p < 0.01). 
Conclusions: Tedisamil rapidly terminated SAF and prevented its re±ni- 
t±at±on. Tedisamil also decreased the inducibility of NSAF. No episodes of 
proarrhythmia or other significant side effects were observed. 
POSTER 
Focal Atrial Fibrillation 
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1053-152 I Identification of Left Atrial Tract (Marshall) 
I Potential From Left Pulmonary Vein 
Hiroshi Nakagawa, Kagan Matsudaira, Benjamin J. Scherlag, Jan V. Pitha, 
William S. Yamanashi, Patrick Schauerte, Marie D. Genzalez, Nayyar Shah, 
Kenichiro Otomo, Ralph Lazzara, Warren M. Jackman. Univ. of Oklahoma, 
OKC, OK, Japan 
Focal atrial fibrillation, in some pts, may originate from the left atrial tract (LAT) 
1. Anterior 2. Posterior 
LA Pacing CS Pacing 
-9 
.... s s~ ~ 
within the ligament of Marshall located lateral to the left superior (LS) and 
inferior (LI) pulmonary veins (PV). The purpose was to determine whether 
LAT potentials could be recorded from LSPV and LIPV and differentiated 
from LA and PV musculature potentials. 
Methods and Results: Six dogs (24-31 kg) underwent a left thoracotomy. 
Four 20-electrode catheters (2-4-2 mm spacing) were placed in the coronary 
sinus (CS), LSPV, LIPV and along the ligament of Marshall (LAT) on the 
epicardium. During anterior LA pacing, a late LAT potential was recorded 
in addition to LA and PV musculature potentials from LSPV (6/6 dogs) but 
not from LIPV (fig 1). LAT potential propagated in the inferior to superior 
direction, suggesting an inferior LA-LAT connection. During posterior CS 
pacing, LAT potential fused with LA and PV musculature potentials in LSPV, 
suggesting simultaneous activation (fig 2). To confirm the origin of potentials, 
LAT potential was eliminated by epicardial RF ablation at the inferior portion 
of the ligament of Marshall, and PV musculature potential was eliminated by 
ablation within the LSPV. 
Conclusions: 1) LAT potential can be recorded from LSPV, and 2) LAT 
and PV musculature potentials are separated by anterior LA pacing and 
fused with posterior CS pacing. 
tl  I Pulmonary Vein Angiography 053-1 53 Selective 
Improves Accuracy of Catheterization and 
Mapping in Patients With Paroxysmal Focal 
Atrial Fibrillation 
V.S. Prakash, Ming-Hsiung Hsieh, Chin-Feng Tsai, Ching-Tai Tai, 
Yu-An Ding, Mau-Song Chang, Shih-Ann Chen. Division of Cardiology, 
National Yang-Ming University and Veterans General HospitaI- Taipei, Taiwan 
Background: Ablation of pulmonary vein (PV) focal tissue could eliminate 
focal atrial fibrillation (AF) originating from PV. However, anatomy and mor- 
phology of PVs varied widely. We propose that selective PV angiography 
could provide a guide to proper mapping and ablation of focal AE 
Methods: Forty symptomatic patients with paroxysmal AF triggered by left 
atrial premature contractions (positive P in V1 and negative in I, aVL) under- 
went selective PV angiography of all four PVs. Group I (n = 20) underwent 
PV angiography after placement of diagnostic catheters in the presumed 
PVs from which atrial triggers were detected. Group II (n = 20) underwent 
PV angiography prior to placement of electrode catheters. 
Results: 
Group I Group II 
Accuracy of catheterization 12/20 (60%) 20/20 (100%)" 
Catheter along whole length of PV 10/20 (50%) 20/20 (100%)* 
Delineation of PV ostium 4/20 (60%) 20/20 (100%/" 
Procedure time (min) 62 ± 14 40 ~_ 10" 
Fluoroscopy time (min) 38 ± 12 20 -- 8" 
Cardiac tamponade + 1/20 (5%) 0/20" 
(+Occured due to accidental perforation of left atrial appendage while attempting cannu- 
lation of left inferior PV) (" = p < 0.05, Group I vs II) 
Conclusion: (1) Accuracy with enhanced safety of catheterization of the 
PVs was noted in Group II patients with proper delineation of PV anatomy. 
(2) Selective PV angiography is a good guide for proper catheterization 
of individual PVs with decrease of fluoroscopic and procedure times, as 
also ensuring accurate mapping of trigger points of AF and reducing the 
complications. 
I1 541 Dilated Pulmonary Veins in Focal Atrial I 053-1 
Fibrillation Originating From Pulmonary Veins 
V.S. Prakash, Ming-Hsiung Hsieh, Chin-Feng Tsai, Ching-Tai Tai, 
Yu-An Ding, Mau-Song Chang, Shih-Ann Chen. Division of Cardiology, 
National Yang-Ming University and Veterans General Hospitak TaipeL Taiwan 
Background: Pulmonary veins (PV) are noted to be the most common foci 
for atrial triggers of focal atrial fibrillation (AF). The purpose of this study 
was to delineate the angiographic changes of PVs in patients with focal AF 
originating from PVs. 
Methods: Group I included 35 patients (66 ± 6 yr, M/F = 29/6) with focal 
AF from PVs. Group II included 10 age/sex matched patients (63 ± 8 yr, M/F 
LSPV RSPV LIPV RIPV 
LAO RAO LAO RAO LAO RAO LAO RAO 
Group I 1.5 # 1.6 # 1.7 # 1.5 # 0.8 0.8 0.7 0.6 
± 0.7 = 0.8 ± 05 ± 0.6 ± 0.5 ± 0.6 ± 0.7 ± 0.6 
Group II 1.0" 1.1 * 1.0" 0.9" 1.0 1.0 0.9 0.9 
• -0.3 ::0.2 --0.2 --0.3 --0.1 ~0.3 ±0.1 --0.1 
(LS/RS = left/right superior; LI/RI = left/right inferior) (" = p < 0.01, Group I vs II; # = p < 
0.01, superior vs inferior PV in Group l) 
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= 8/2) without any arrhythmia. After atrial transseptal procedure, selective 
PV angiography using a biplane system in RAO 30, LAO 60, and cranial 20 
degrees were performed. 
Results are shown in the table. The PV ostial diameter was corrected for 
the patient's body mass index. 
Conclusion: (1) Patients with focal AF had larger diameter of superior 
PV ostium, but normal inferior PV ostium; (2) Controls had normal diameters 
of four PVs. 
1 / Mechanism of Focal Atrial 
1 
053-1 55 Electrophysiologic 
J Fibrillation Originating From Pulmonary Veins 
Shih-Ann Chert, Ming-Hsiung Msieh, Ching-Tai Tai, Chin-Feng Tsai, 
Wen-Chung Yu, V.S. Prakash, Yu-An Ding, Mau-Song Chang. Division of 
Cardiology, National Yang-Ming Universi~ Veterans Genera/ 
HospitaI-Taipei, Taiwan, ROC 
Most of left-side focal atrial fibrillation (AF) are considered to originate from 
pulmonary vein (PV); however, the electrophysiologic mechanism is not clear. 
Methods: Thirty patients (22 male, 8 female, 60 ± 9 y/o) had spontaneous 
onset of AF triggered by atrial premature contractions (APCs) from PVs. 
Couple interval (Cl) of PV spikes between sinus beat and APC, sinus beat 
and trigger beat of AF, density of APCs, and density of burst AF were 
assessed before and after intravenous propranolol (0.2 mg/kg), verapamil 
(0.15 mg/kg), or procainamide (15 mg/kg). 
Results: Spontaneous onset of sustained AF was totally prevented after 
the three drugs. APCs and burst AF were significantly decreased (" = p < 
0.01 vs baseline). 
Baseline Propranolor Verapamil Procainamide 
CI: Sinus-APC (ms) 260 ± 40 275 ± 18" 284 ± 12" 290 ± 30" 
Ci: Sinus-AF (ms) 179 ± 44 230 ± 29" 240 ± 22* 244 ± 28" 
APCs/min 16±4 0.6 ± 0.4" 0 .5±0.5*  0 .5±0.4*  
Burst AF 3±0.7  0.1 ±0.2*  0.1 ±0,2* 0.1 ±0.1"  
(episode/min) 
Conclusion: (1) shorter couple interval between sinus beat and prema- 
ture contraction was easier to induce AF; (2) abnormal automat±city was 
the possible mechanism of trigger beats from PVs because beta receptor, 
calcium and sodium channel blockes could effectively suppress these trigger 
points. 
1053-156 I Bezold-Jarisch-Like Reflex During 
Radiofrequency Ablation of the Pulmonary Vein 
in Patients With Paroxysmal Focal Atrial 
Fibrillation 
Chin-Feng Tsai, Ching-Tai Tai, Chuen-Wang Chiou, V.S. Prakash, 
Wen-Chung Yu, Ming-Hsiung Hsieh, Yu-An Ding, Shih-Ann Chen. National 
Yang-Ming Universi~ Veterans General HospitaI-Taipei, Taiwan, ROC 
Background: Information about the occurrence of ablation-related prom- 
rhythmic events during application of radiofrequency energy at the pulmonary 
veins in patients with paroxysmal focal atrial fibrillation is lack. The purpose 
of this study was sought to assess the theoretical risk of reflex bradycardia 
and hypotension response during radiofrequency ablation of these regions 
rich in endocardial nerve terminals. 
Methods and Results: Among the consecutive 40 patients undergoing 
superior pulmonary veins ablation for left focal atrial fibrillation, 6 (15%) pa- 
tients developed bradycardia-hypotension syndrome during energy delivery. 
A single atrial fibrillation trigger focus in left or right superior pulmonary vein 
was found in 3 and 1 patients, respectively. Two patients had two trigger foci 
originating from the orifice or proximal part of both superior pulmonary veins. 
After radiotrequency current was applied for a period of 14 ± 10 seconds, 
two patients developed junctional rhythm and sinus bradycardia, another two 
patients had profound sinus bradycardia, one patient had two episodes of 
sudden onset of complete atrioventricular block with resultant 9.5-second 
asystole, and the remaining one patient showed profound sinus bradycardia, 
transient atrioventricular block, and a 8-second asystole due to sinus arrest. 
Blood pressure felt when any substantial bradyarrhythmias occurred. All six 
patients were free of rhythm disturbances during the post-ablation follow-up 
period (mean 8 ± 2 months). 
Conclusion: Radiofrequency catheter ablation of the pulmonary vein 
tissues could evoke a variety of profound bradycardia-hypotension response. 
The Bezold-Jarisch-like reflex might be of the underlying mechanism. 
L1053-157l Vein in Patients Pulmonary Electrophysiology 
J With Left-Side Focal Atrial Fibrillation 
Shih-Ann Chen, Ming-Hsiung Msieh, Ching-Tai Tai, Chin-Feng Tsai, 
Wen-Chung Yu, V.S. Prakash, Yu-An Ding, Mau-Song Chang. Division of 
Cardiology, National Yang-Ming University and Veterans General 
HospitaI-TaipeL Taiwan, ROC 
Several studies demonstrated that most focal atrial fibrillation (AF) was trig- 
gered by premature beats from pulmonary veins (PV), and elimination of 
these premature contraction foci could cure AF. However, the PV electro- 
physiology has not been investigated. 
Methods: 30 patients (22 male, 8 female, 60 ± 9 y/o) with paroxysmal AF 
were included. Decapolar electrode catheters (5 mm interelectrode space) 
were put into PVs. Maximal amplitude (mV) and duration (ms) of PV spike 
potential in four PVs, effective refractory period (ERP, ms) and conduction 
velocity (CV, m/sec) of the superior PVs were measured. 
Results: 
Amplitude Duration CV ERP-P ERP-D 
LSPV 0 .39±0,22"  45±11"  1 .2±0.2"  197 ::L 18 180±13 + 
RSPV 0,29 ~- 0.16 36±6 0 .9±0.2  196±20 150±16 + 
LIPV 0.23 ± 0.12 29 J, 7 0.8 ± 0.2 
RIPV 0.18 ± 0.07 27 ± 8 0.8 ± 0.2 
(I.JR = left/right; SII = superior/inferior; P/D = proximal/distal) (* = P < 0.05, by ANOVA 
among the four PVs: ÷ = P < 0.05, ERP-P vs ERP-D) 
Conclusion: (1) Superior PVs, especially the LSPV, were better devel- 
oped and full of myocardial cells than the inferior ones; (2) Longer ERP in 
the proximal PV provides a protection mechanism to filter the continuously 
rapid impluses from the distal end of PV. 
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l l  054-1781 The Middle Cardiac Vein - A Novel Pathway to 
Reduce the Defibrillation Threshold 
Paul R Roberts, Jon F. Urban ~ , David E. Euler 1 , Michael J. Kallok ~ , John 
M Morgan. Wessex Cardiothoracic Centre, Southampton, UK, ~ Angeion 
Corporation, Minneapolis, MN, USA 
Background: Defibrillation energy requirements of epicardial implantable 
cardioverter defibrillator systems are generally lower than endovascular sys- 
tems currently used. The former has the disadvantage of requiring a thora- 
cotomy and so has a greater morbidity and mortality than an endovascular 
procedure. The middle cardiac vein (MCV) is an epicardial structure that 
is accessible by a non-thoracotomy approach. This study investigated the 
merits of ventricular defibrillation from the middle cardiac vein. 
Methods and Results: Defibrillation thresholds (DFT) were measured 
in 10 anesthetized pigs (mean weight 39 kg). An Angeflex (Angeion Corp.) 
electrode (1.7 mm × 50 mm) was introduced via the left external jugular 
vein to the right ventricutar apex. The MCV was identified with standard 
angiography techniques and a 4080 (Angeion Corp.) defibrillation electrode 
(1.6 mm x 65 mm) introduced into the vein. An active can was implanted 
in the left subpectoral region (43 cc). The defibrillation thresholds (DFT) of 
the following defibrillation configurations were assessed using a modified 
four-reversal binary search: RV -+ Can, MCV -~ Can and RV + MCV --, 
Can. LEC/LEV = leading edge current/voltage. 
RV MCV RV + MCV 
DFT (J) 15.5 ± 2.8 13,7 ~- 2.4 10.8 + 3.4"/*" 
Impedance (~) 49 ± 3.5 46.9 ± 3.1" 40.2 ± 4.6" 
LEV (V) 377 ± 40 347 ± 36 283 ± 50"/'* 
LEC (A) 7.7 ± 0,7 7.4 ± 0.6 7.1 ± 1.2 
* = p < 0.05 compared to RV, "" = p < 0.05 comparedto MCV 
Conclusions: Defibrillation is possible through the MCV and incorporat- 
ing an electrode in the MCV with RV-Can configuration can reduce the DFT 
by 30%. 
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1054-1791 Lead Electrode Dual Chamber A New Single for 
J 
ICD Systems in the Acute Human Clinical 
Evalution 
Michael Niehaus, Andreas Schuchert, Stefan Thamasett, Dietrich Pfeifter, 
Roberto Belke 1 , Juergen Tebbenjohanns. For the German VDD investigator 
group; 1Dept. of Cardiology, Medical School Hannover, Biotronik, Germany 
Background: Common available dual chamber ICD systems use two sepa- 
rate leads for sensing and pacing in atrium and ventricle. Complications due 
to the atrial (A) lead have been reported. We designed and evaluated a new 
single lead dual chamber VDD-lead for dual chamber ICDs. 
Methods: In a German multicenter study we tested a prototype VDD-lead 
(a single-coil defibrillation electrode with 2 additional fractally coated rings 
for bipolar sensing in the atrium) in 20 pts.. A. arrhythmias were induced 
using a bipolar stimulation catheter or an A. screw tip electrode. A. and 
ventricular (V.) signals were recorded during sinus rhythm (SR), A. flutter 
(AFLU), A fibrillation (AF) and V tachycardia (VT) or ventricular fibrillation 
(VF). Terminations of V. arrhythmias were performed by internal DC-shock. 
The position of the A. sensing rings was in close contact to the lateral A. wall. 
Results: In 19 of 20 pts. (95%) implantation of the electrode was suc- 
cessful. Mean A. pacing threshold was 2.49 V/O.5 ms, mean A. impedance 
was 214.8 ± 30 [Z. The mean V. sensing was 14.3 :E 1.13 mV, mean V. 
impedance was 533 Q. A. sensing was good during all rhythms. P-wave 
detection by Phylax06 was reliable (Table 1) 
Table 1 
SR [mV]/SD Aflu [mV]/SD AF [mV]/SD SR during VF [mV]/SD 
A. channel. VDD 2,34/0.33 1.22/0.32 0.86/0.45 1.0/0.34 
A. detection by Phylax 99.5% 88.6% 55.6% 83.7% 
Conclusions: A new designed VDD dual chamber electrode with fractally 
coated atrial sensing rings provides stable detection of atrial and ventricular 
signals in the acute clinical experiment. 
I 1 054-1 801 Evaluation of Coronary Vein Accessibility for Implant of a Defibrillating ICD and/or Pacing 
Lead System 
Dietrich Pfeiffer, Christian Butter, Eckhard Meisel, Michael EIdar, 
Lothar Engelmann, Stephen J. Hahn, Bernd D. Schubert, Ulrich Michel. 
University Hospital, Leipzig; Virchow Clinic & Berlin Heart Center, Berlin, 
Germany 
Background: Pacing and ICD lead systems that incorporate an electrode 
inserted transvenously into coronary veins residing on the left ventricle have 
been proposed. 
Methods: A study was conducted in twenty-four patients (pts) receiving 
an ICD system to evaluate the ease of placing a lead into two different 
presetected coronary target veins. The prototype lead emulated a left venous 
access (LVA) defibrillation lead and consisted of a modified 0.018" guidewire. 
The LVA lead was inserted from the subclavian vein into the coronary sinus 
via a guide catheter. Pts were randomized to attempt LVA lead insertion into 
either the anterior interventricular (AIV) or posterior vein (PV). Positioning 
was guided by a venogram. A crossover to the other vein location was 
allowed only if the initially randomized vein was not accessible. 
Results: The LVA lead was successfully positioned in either the AIV or 
PV in all pts (100%). The LVA lead was successfully inserted into the AIV 
in 12/13 Pts attempted (92%). In one patient the AIV was very narrow and 
therefore the LVA lead could not be passed. Mean time for insertion into the 
AIV was 16.0 ± 13.6 min (median = 10 min, range 3-38 min). The LVA lead 
was successfully inserted into the PV in 12/14 Pts attempted (86%). In 2 pts, 
the PV was too tortuous for placement of the LVA lead. Mean time insertion 
into the PV was 16.3 ± 14.64 min (median = 11 min, range 1-50 min). 
Conclusion: This is the first major study of the accessibility of coronary 
veins located on the left ventricle as potential sites for pacing or ICD lead 
system implantation. Results showed these sites can be accessed with a 
high degree of success. Pacing or ICD systems, particularly for patients with 
congestive heart failure, utilizing a lead placed distally into a coronary vein 
residing on the left ventricle are feasible. 
-1054-181 I Transvenous Defibrillation Low-Energy Using a 
I Single Atrial Lead System in Patients With 
Chronic Atrial Fibrillation 
Maika Mende, Annerose Neugebauer, Petra Kluge, Dietrich Pfeiffer. 
University Hospital of Leipzig, Leipzig, Germany 
Background: Recent studies have shown first results in using single atrial 
lead systems for low-energy transvenous defibrillation. The aim of this ran- 
domized study was to investigate the efficacy and safety using those systems 
compared to double atrial lead systems. 
Methods: In 12 patients (pts) with chronic atrial fibrillation (AF) low- 
energy transvenous defibrillation was performed. The duration of AF ranged 
between 2 months and 2 years. R wave triggered biphasic shocks were 
delivered between right atrium (RA) and coronary sinus (CS). For de- 
termination of the atrial defibrillation threshold (aDFT) a step up protocol 
(0.5/1/2/3/4/5/8/10/15J) was used. After successful defibrillation in 6/12 pts 
using first the single atrial lead system, AF was reinduced by right atrial burst 
pacing. If AF persisted for at least 2 minutes aDFT was determined using 
the double lead system. Than, in 6/12 pts the protocol was started with the 
double atrial lead system. Coil electrodes (6F) TADCATH'~Model 8029 were 
used as single lead system. Two defibrillation coils were located on the lead. 
The proximal coil was positioned in RA and the distal coil in CS. VASCOS- 
TIM TC 3 + 1 CK coil electrodes (6F) were used as double lead system and 
positioned in RA and CS and for R wave triggering in the apex of the right 
ventricle. 
Results: Low-energy transvenous defibrillation was successful in all pa- 
tients. During the application of a total of 152 shocks no adverse events were 
observed. There was no significant difference in atrial defibrillation thresholds 
using both systems (single lead 5.8 ± 3.8 J vs double lead 6.3 ~- 4.7 J, range 
1-15 J). 
Conclusions: Low-energy transvenous defibrillation with single atrial lead 
systems is feasible and safe in termination of chronic AF. This advanced 
technique is less invasive and less price intensive in clinical usage than 
double lead systems. 
1054-182] Use of a Single Coil Transvenous Electrode With 
Abdominally Placed Implantable Cardioverter 
Defibrillator in Children 
Peter S. Fischbach, lan H. Law, Macdonald Dick, Sarah Leroy, Ralph 
S. Mosca, Gerald A. Serwer. University of Michigan, Ann Arbor, MI, USA 
Background: While transvenous defibrillator electrode placement avoiding 
a thoracotomy is preferable, electrode size, a large intercoil spacing and the 
need for subclavicular device placement have precluded this approach in 
most children. Development of a smaller diameter single coil electrode would 
enable use of the transvenous approach in many smaller children if the ICD 
using the can as the second high voltage electrode could be placed in an 
abdominal pocket. Whether abdominal placement will still provide adequate 
defibrillation thresholds (DFTs) with the altered energy vector is unknown. 
Methods: We investigated the utility of a single RV coil to abdominally 
placed ICD system in children. Four children ages 81o 16 yrs, weighing 21 to 
50 Kg, mean 35 Kg underwent ICD placement following syncopal events with 
documented ventricular tachycardia. Diagnoses were Long QT, hypertrophic 
cardiomyopathy, post tetralogy of Fallot repair and polymorphic ventricular 
tachycardia. Placement of a single coil Medtronic model 6932 or 6943 elec- 
trode was performed via a percutaneous left subclavian vein approach using 
a 10F introducer. The electrode was positioned in the RV apex with the coil 
lying along the RV diaphragmatic surface. The ICD (Medtronic Micro Jewel II 
model 7223Cx) was implanted in a left upper abdominal quadrant pocket with 
the lead tunneled from the infraclavicular region along the anterior axillary 
line to the pocket. Electrode lengths of 75 cm and 100 cm were used. 
Results: At implant, all defibrillation thresholds (DFTs) were <10 joules 
using a biphasic waveform. DFTs rechecked 1 week post implant were 
unchanged. Lead impedance at implant ranged from 38 to 56 ~ mean 51 
~. Follow-up has been 10 to 12 months (total 43 months) with no etectmde 
dislodgment, lead fractures or inappropriate discharges. Two of the four 
patients have had successful appropriate ICD discharges. 
Conclusions: Transvenous ICD electrode placement can be performed 
in children as small as 20 Kg in weight with the device implanted in a 
cosmetically acceptable abdominal pocket which is well tolerated. Excellent 
defibrillation thresholds can be achieved. This approach avoids a thoraco- 
tomy in all but the smallest child, does not require subclavicular placement 
of the device, and avoids use of a second intravascular coil. 
I1054-1831 in Patients With Lead-Related Complications 340 
J an Implantable Cardioverter/Defibrillator Over a 
Period of 7 Years 
Harald Schwacke, Axel Dr6gemLilter, Gregor Siemon, Monika Rameken, 
Jochen Senges, Karlheinz Seidl. Heart Center Ludwigshafen, 
Ludwigshafen, Germany 
Aim of this study was to evaluate the rate of lead-related complications 
(LRC) in 340 consecutive patients (pts) with an implantable cardioverter/defibrillator 
(ICD). 
Methods: From 2/91 till 5/98, 340 pts had an ICD implanted. Mean age 
was 64 .~ 9 years, ejection fraction 38 ± 14%, 82% of pts were male, 60% 
had coronary artery disease, 31% dilative cardiomyopathy, 9% others. The 
indication for an ICD was in 57% of pts ventricular tachycardia and in 43% 
ventricular fibrillation. 93% of pts received a single-chamber ICD and 7% a 
JACC February 1999 ABSTRACTS - Arrhythmia Management 113A 
dual-chamber ICD. In 8% of pts additional patch or array electrodes were 
implanted. In 27% implantation site was abdominal, in 73% pectoral. 
Results: Over a period of 7 years 38 LRC occurred (9,7%), after a median 
of 2 months after implantation. Diagnosis was made by routine chest x-ray 
in about 55% of LRC, by clinical presentation (inadequate therapy, pain) in 
24% and by electrical parameters in 21%. In pts with abdominal implantation 
site LRC occurred in 20%, in contrast to 6% in pts with pectoral implantation 
site (p < 0.0001). Regarding pts with pectoral implantation site, LRC were 
observed in 12% of pts with a dual-chamber ICD vs 4% with a single-chamber 
ICD (p = 0.05), due to dislocation of atrial electrodes with dual-chamber ICD. 
There were no differences in clinical parameters between pts with pectoral 
vs abdominal and between single vs dual-chamber ICD. 
Conclusions: 1. In ICD pts with abdominal implantation site LRC were 
three times more frequent than in pts with pectoral implantation site. 2. 
Regarding Lots with pectoral implantation site, LRC occurred three times 
more frequent in pts with dual-chamber than in pts with single-chamber ICD. 
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1 84] Predictive Value of QT Dispersion for Sudden 055-1 
Cardiac Death in Patients With Arrhythmogenic 
Right Ventricular Dysplasia 
Marcio L.A. Fagundes, Ivan G. Maia, Femando E.S. Cruz Filho, Olga 
F. Souza, Silvia Boghossian, Jose Carlos Ribeiro, Paulo Alves, Roberto S& 
Pro-Card(ace Hospital, Rio de Jane±to, Brazil 
Background: QT dispersion (QTD) in a standard 12-lead ECG may reflect 
regional variation of ventrieular epoladzation time. Increments in dispersion 
have been observed in patients (pts) with ventricular arrhythmias. QTD in 
pts with arrhythmogenic right ventricular dysplasia (ARVD) have not been 
carefully evaluated. 
Methods: In order to identify pts at risk for sudden cardiac death (SCD) 
we examined QTD (Q to end of T wave - maximum minus minimum value 
in ms) measured in a 12-lead ECG in a group of 21 pts with ARVD (positive 
signal-averaged ECG, abnormal right ventricular echocardiogram and mag- 
netic resonance image) without antiarrhythmic drugs. There were 16 males 
pts with a mean age of 34.4 ± 12.1 years. Results were compared with a 
control group (C) of normal pts matched in age and gender. 
Results: (mean / 1SD and minimal and maximal values): QTD in pts with 
ARVD: 57.6 ± 13.7 ms (range: 40 to 80 ms). C: 36.6 i 10.1 ms (range: 20 
to 60 ms) - p = 0.000. During a mean follow-up of 41 ± 11 months (range 8 
months to six years) all pts had at least one sustained VT episode and there 
were four SCD (19%) with a mean QTD in this group of 57.5 ± 13.4 ms (60, 
80, 40, 50 ms respectively) versus 57.6 ± 13.4 ms in the group without SCD 
(p = 0.985). With a cutoff point of 70 ms the method was able to identify pts 
at high risk for SCD with a sensitivity of 25%, specificity of 77%, positive and 
negative predictive value of 20% and 82% respectively. 
Conclusions: QTD intervals are significantly prolonged in pts with ARVD 
when compared with a control group. Nevertheless, QTD has a very low 
predictive value to detect pts at risk for SCD. 
I 1055-185/  IS T-Wave Related to Alternans Delayed 
J Myocardial Activation or Inhomogeneity of 
Ventricular Repolarization? 
Takanao Mine, Hiroki Shimizu, Takanori Inazumi, Tadaaki Iwasaki. Hyogo 
College of Medicine, Nishinomiya, Japan 
Background: Detection of microvolt T wave alternans (TWA) is a non-inva- 
sire method to identify patients (pts) for sudden cardiac death. However, it 
is uncertain whether TWA is associated with delayed myocadial activation or 
inhomogenous ventricular repolarization. 
Methods: In 80 pts with coronary artery disease, we studied TWA, signal 
averaged electrocardiogram (SAECG) and recovery time (RT). TWA was 
measured using a bicycle ergometer and the CH 2000 (Cambridge Heart, 
MA, USA). Filtered QRS duration (f-QRS) and root mean square voltage 
of the terminal 40 ms of the QRS (RMS40) in SAECG were measured. RT 
defined as the interval between QRS onset and the time of maximum dV/dt 
in ST-T segment was measured from 87 leads body surface mapping and RT 
dispersion (RTD: the difference between maximum and minimum RT) was 
calculated. 
Results: TWA was positive in 39 pts (TWA (+)) and negative in 41 pts 
(TWA (-)). There was no significant difference in RMS40 and f-QRS between 
the two groups. RTD was significantly increased in TWA (+). 
n RMS4O (#V) f-QRS (ms) RTD (ms) 
"[3NA (+) 39 16.6±7.6 128±20 172±40 # 
]'3NA ( - )  41 17,5±7.3 124±25 156±31 
# p < 0.05 
Conclusion: It suggested that TWA may be related to spatial inhomo- 
geneity of ventricular repolarization not to delayed myoeadial activation in 
pts with coronary artery disease. 
1 I Age and Changes of 
I 
055-1 86 Gender-Related 
Beat-to-Beat Variability in Amplitude of the 
Repolarization Segment in Healthy Subjects 
J.P. Couderc, W. Zareba, J. Konecki, J. Ruta, M. Karcz, S. Dubner, 
C. Madoery, P. Maison-Blanche, P. Deedwania. X. Vino/as for the/DEAL 
Investigators. Uni~ of Rochester, Rochester, NY, USA 
The objectives of this study was to investigate the influence of age and gender 
on the magnitude of beat-to-beat (or temporal) variability in the amplitude of 
the repolarization segment (TVA) and to determine normal TVA values by 
studying ECGs of healthy subjects. 
Method: Using wavelet transformation, we quantified the beat-to-beat 
changes in amplitude of the repolarization segment in 5-minute ECGs ob- 
tained from digital Holter recordings in supine position in 112 healthy subjects. 
We filtered segments beginning 100 ms after the R peak and ending 220 
ms before the following R peak and quantified the beat-to-beat changes of 
spectro-temporal components of these segments in each consecutive beat 
of the 5-minute ECGs. The healthy group was divided according to age (9-25 
yrs, 25-40 yrs and 40-72 yrs) and gender. 
Results: Age and gender-related TVA values are as follow: 
Group / Age All Male Female 
9 -25  yrs 11.8 ± 10.8 10,2 ± 13.8 12.1 i 8.2 
(n = 33) (n = 14) (n = 19) 
25-40  yrs 7,1 ± 5.8" 6.3 ± 4.4"* 9.4 ± 6.3 
(n = 39) (n = 18) (n = 21) 
40-72  yrs 6.0 ± 6.5* 5,3 ± 7.9** 7.0 ± 5.0 
(n = 40) (n = 17) (n = 23) 
(Mann-Whitney Test: " p < 0.05, "* p < 0.0001 in comparison to < 25 yrs) 
Conclusions: 1) The beat-to-beat variability declines with age being 
significantly higher in adults <25 than above 25 years old. 2) No significant 
differences were found between the male and the female group, however, 
the decline in TVA values with age is more pronounced in males than in 
females. 3) The upper limit of TVA in healthy subjects does not exceed 26%. 
1055-1871 Is QT Dispersion Heart Rate Dependent? What 
I 
Are the Values of Correction Formulas for QT 
Interval? 
Nidat Maarouf, Kudret Aytemir, Mark M. Gallagher, Yee Guan Yap, A. 
John Carom, Marek Malik. St. George's Hospita/ Medica/ School London, 
UK 
Background: QT dispersion (QTd) has been proposed as a powerful non- 
invasive tool to predict ventricular tachyarrhythmias. There is still a con- 
troversy regarding the need rate correction in QTd but no study has been 
performed to evaluate this. 
Methods: Twenty-one healthy subjects (15 men, 6 women, mean age 
37±10 years) were enrolled in this study. All subjects performed bicycle 
exercise test with serial ECG recording (mean 15) to achieve a heart rate 
of 120 beats per minute. QT interval and QTd were measured automatically 
using the research version of QT-guard software package (Marquette Medical 
System). In all ECGs, QT intervals were corrected by Bazett's (QT/RR), 
Fridericia's (QT/RR), Hudge's [QT + 1.75 (rate-60)], Framingham [QT + 0.154 
(1-RR)] formulas and the Nomogram correction (QT + correction number). 
The slopes of linear regression for QT interval, QTc and QTd against RR 
interval calculated. One sample student t-test and univariate analysis were 
used for statistical analysis. 
Results: There was a positive correlation between QT and RR intervals 
(slope = 0.72, p < 0.001). Using of Bazett's (slope = -0.1013, p = 0.14). 
Hudge's (-0.085, p < 0.001), Framingham's (0.203, p = 0.001) formulas 
and Nomogram-correction (-0.063, p = 0.001) showed correlation between 
QTc and RR intervals. However the slope of linear regression for Fridericia's 
formula was close to zero (i.e. a horizontal line) and there was no significant 
correlation between the QTc-Fredericia and heart rate (slope= -0.0025, p 
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= 0.885). Regarding to QTd there was no correlation between QTd and 
corresponding RR interval (slope = 0.008, p = 0.623) 
Conclusion: 1) Fredericia's formula for correcting the QT interval duration 
for heart rate is significantly superior to the more widely used Bazett's formula, 
and to the others tested. 2) QT dispersion is however independent of heart 
rate and does not require correction. 
1 88j Increased QT-Interval Dispersion Is Associated 
1 
055-1 
With Malignant Ventricular Arrhythmias in 
Patients With Syncope 
Silvia Aguiar, Andreas Zimmerman, Michael A. Weber, Joel A. Strom, Hal 
L. Chadow. Brookdale University Hospital, Brooklyn NY, and SUNY Health 
Science Center, Brooklyn, NY, USA 
Background: QT-interval dispersion is a marker for susceptibility to ventric- 
ular tachyarrhythmias in hereditary prolonged QT syndrome and other forms 
of heart disease. It is currently not known whether increased QT-interval 
dispersion predicts malignant ventricular arrhythmias in patients with cardiac 
syncope. 
Methods: We evaluated 18 patients (mean age: 65.9 yrs, 10 men) pre- 
senting with syncope who subsequently developed sustained venthcular 
tachycardia, fibrillation, or who had sustained monomorphic ventricular tachy- 
cardia induced by electrophysiologic testing (group I). In addition 12 age and 
gender matched patients (mean age 65.2 yrs, 10 men) with noncardiac 
syncope or syncope of unknown cause served as controls (group II). The 
admission surface electrocardiogram was evaluated in a blinded manner. 
QT-interval dispersion (QTmax - QTmin) was calculated. Left ventricular 
ejection fraction (LVEF) was calculated by echocardiography. 
Results: The mean QT-interval dispersion was significantly increased 
in group I (mean: 122 msec, range: 40-220 msec) compared with group II 
(mean: 62 msec, range: 40-100 msec) (p = 0.01). Three patient in group 
I had QT dispersion _<60 msec, while only 1 patient in group II had a QT 
dispersion > 60 msec. LVEF was lower in group I (44.2%) than in Group II 
(65.4%) (p < 0.01 ). A weak but significant correlation was found between the 
QT dispersion and LVEF (r = 0.42, p = 0.01). 
Conclusions: increased QT-interval dispersion may be predictive of ma- 
lignant ventricular arrhythmias as the etiology of the episode in patients with 
syncope. 
1 891 Principal Component Analysis of Spatial 055-1 
Dispersion of Repolarization in LQT1 and LQT3 
Gone Carriers 
W. Zareba, J.A. Konecki, K. Timothy, A.J. Moss, M.G. Vincent, L. Zhang. 
University of Rochester, Rochester, NY; LDS Hospital, Salt Lake Ci~ UT, 
USA 
Purpose: We recently found significantly higher lethality of cardiac events in 
LQT3 than in LQT1 pts. The aim of this study was to compare the magnitude 
of spatial dispersion of repolarization (SDR) in resting ECGs of genotyped 
members of LQT1 (n = 88) and LQT3 (n = 23) families. 
Methods: SDR was evaluated in digital 12-lead ECGs using the QT Guard 
system (Marquette Electronics, Inc.) measuring automatically: QTd (max-min 
QT), QTpd (max-min QTpeak), and the PCA2 (from principal component 
analysis allowing for the quantification of SDR morphology). 
Results: The results of SDR analysis in LQT1 and LQT3 gone carriers 
and noncarriers are as follows (similar when gender-adjusted, not shown): 
Noncarriers Carriers 
LQT1 LQT3 LQT1 LQT3 
(n = 48) (n = 10) (n = 40) (n = 13) 
Age at ECG (y) 28±17 24±15 29±23 30±16 
HR (bpm) 71±12 69±18 69± 13 57±15' 
QTc (ms) 424±:23 414±25 488±36 # 560±61 # 
QTd (ms) 27±18 24± 10 32±26 38±20 # 
QTpd (ms) 28±17 23± 11 33±20 53±33 # 
PCA2 13±6 14±6 14±8 30-- 1 t TM 
* p < 0.05 for LQT3 vs, LQT1 carriers; # p < 0.05 for carriers vs. noncarriers within 
genotypes 
Conclusions: In comparison to LQT1 carriers and LQT3 noncarriers, 
LQT3 carriers have a significantly higher magnitude of SDR, as shown by 
PCA2. increased SDR in LQT3 carders may predispose them to an in- 
creased lethality of cardiac events. The lack of significant difference in PCA2 
between LQT1 carders and noncarders suggests that in resting conditions, 
the potassium channel abnormalities of LQT1 may contribute to SDR of a 
lesser degree than is observed in LQT3 carriers. 
ORAL  
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1 0:30 a.m.  
[ -~  Factors Determining Implantation of Defibrillators 
Following Trial Termination in Patients Randomized 
to Drug Therapy in the Antiarrhythmics Versus 
Implantable Defibrillators (AVID) Trial 
Richard C. Klein, Eleanor Schron, Ellen Graham Renfroe, 
Cados Rizo-Patron, Nicholas Tullo, Scott Lancaster. The AVID 
Investigators; University of Utah Health Sciences Center and VA Medical 
Center, Salt Lake Ci~ Utah, USA 
In the AVID trial patients (pts) randomized to defibrillators (ICD) had improved 
survival compared to pts randomized to antiarrhythmic drugs (AAD) through- 
out the trial with the greatest benefit observed by 12 months. This study 
analyzed potential factors determining eady (within 3 months of trial termina- 
tion) ICD implant following AVID termination in pts treated in the AAD arm for 
less than 12 months (Grp A) and those treated for more than 12 months (Grp 
B). At trial termination, 333 pts were in the AAD arm: 11t in Grp A and 222 
in Grp B. Early ICD implant was done in 52/111 (45%) of Grp A and 40/222 
(18%) of Grp B pts (p < 0.001). Reasons for no ICD in Grp A pts included pt 
choice (49%), physician recommendation (19%), pt too ill/died (17%), other 
(15%). The same factors accounted for 35%, 45%, 11%, and 9% of reasons 
for no ICD implant in Grp B pts. Among both Grp A and Grp B pts there were 
no differences in clinical characteristics between those receiving and those 
not receiving early ICD, including gender, cardiac diagnosis, ejection fraction, 
heart failure, beta-blocker or other cardiac therapy, and noncardiac disease. 
However, Grp A pts undergoing ICD implant were younger (63 v. 68 yr, p < 
0.03), more frequently working (27% v. 7%, p < 0.005), and more likely to 
have private insurance (27% v. 13%, p < 0.05) than those not receiving ICD. 
These factors were not significant among Grp B pts. 
Conclusion: The decision to implant ICD in AAD pts following termination 
of AVID was primarily due to time on AAD. Socioeconomic factors and 
individual pt perception of clinical status may have influenced early ICD 
implant decision in pts on AAD for <12 months. 
1 0:45 a.m. 
1-80~ Prophylactic ICD Implantation After Prospective 
Risk Stratification in Postinfarction Patients 
Georg Schmidt, Petra Barthel, Raphael Schneider, Claus Schmitt, 
Andreas Plewan, Kurt UIm 1 , Albert Sch~mig. 1. Medizinische K/inik & 
Deutsches Herzzentrum, Technische Universit~t M£mchen; I Institut for Med. 
Statistik, Technische Universit&t MEmchen, ME~nchen, Germany 
Background: Aim of the study was to prospectively evaluate a risk stratifica- 
tion protocol in patients (pts) with acute myocardial infarction (AMI) treated 
by PTCA and stenting. 
Methods: Risk stratification (24-hour ECG, SAECG, ventriculography) 
was performed in more than 1000 patients two weeks after AMI. The individ- 
ual risk was assessed by a predefined score system (1 risk point each for 
> 10 VPBs/h or nonsustained VT, SDNN < 80 ms, positive late potential and 
LVEF 40%-50%, 3 risk points for LVEF < 40% or spontaneous sustained 
VT). According to the risk score, pts were assigned to 4 groups: group 1 (0 
points); group 2 (1 point); group 3 (2 points); group 4 (~3 points). In group 
4, programmed ventdcular stimulation (PVS) was done. Pts with inducible 
sustained monomorphic VT (cycle length > 230 ms) received an internal 
defibrillator (ICD). All other pts stayed without antiarrhythmic therapy. The 
endpoint of the study was cardiac mortality or first adequate ICD intervention. 
Results: (interim analysis, 496 pts, 11/1996): 192 pts were assigned to 
group 1, 155 to group 2, 63 to group 3, and 87 to group 4. During follow-up 
(318 days, median), 14 pts reached the endpoint. After 1 year, the probability 
of cardiac death was 0.5% in group 1, 0% in group 2, 6.5% in group 3 and 
12.5% in group 4 (p < 0.001 ). Within group 4, PVS identified two subgroups: a 
low risk group (cardiac mortality 5%) and a high risk group (1 -year ICD-shock 
free survival 54%). The final results (1000 pts., 12/1998) will be presented. 
Conclusion: The risk stratification protocol tested allows selection of 
post-MI patients, in whom prophylactic ICD implantation is beneficial. 
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[ -8~-~ Efficacy and Safety of Oral d,I-Sotalol in Patients 
With Implanted Defibrillators: Results of a 
Prospective, Double-Blind, Randomized, 
Placebo-Controlled Multicenter Trial 
Stefan H. Hohnloser ~ , Antonio Pacifico, John H. Williams, Eric 
N. Prystowsky. For the Sotalol-ICD Investigators; ~ J. ~1~ Goethe Univ., Div. of 
Cardiology, Frankfurt, Germany 
Background: Concomitant antiarrhythmic drug therapy is often prescribed 
in patients (pts) with implanted cardioverter/defibrillators (ICD) for various 
reasons. However, the efficacy and safety of such combined therapy has 
not been systematically assessed in prospective studies. Therefore, a ran- 
domized placebo-controlled trial was conducted to evaluate the effects of 
oral dl-sotalol (S) in pts with life-threatening vehicular tachyarrhythmias who 
were fitted with an ICD. 
Methods: Qualifying pts were randomly assigned to blindly receive 
placebo (P) or S (80-160 mg BID). All pts were followed for 12 months 
(intention-to-treat analysis). The primary study endpoint consisted of time to 
first all-cause ICD shock therapy or death. 
Results: 302 pts were recruited at 42 sites in the US and Europe with 
151 pts randomized to receive either P or S (mean daily dose: 207 ± 
55 mg). There were no significant differences with respect to important 
demographic or clinical variables, indications for ICD therapy, and type of 
ICD. LVEF averaged 39 ± 14% in the P and 37 ± 12% in the S group. At 
12 months, the Kaplan Meier estimates for ICD shock therapy/death were 
54% in P-pts compared to 34% in S-pts (p < 0.001 ; see fig). The relative risk 
for shock/death for S-treated pts compared to the P group was 0.52 (95% 
CI: 0.36-0.74). Patients with EF < 0.30 and >0.30 benefited similarly from 
S treatment (relative risks 0.49 and 0.51). The incidence of nonfatal serious 
adverse events was comparable between the 2 groups. Drug discontinuation 
rates due to adverse events or lack of efficacy were 29% for S and 26% for 
P. 
~oa s~ul~l 
Conclusion: In pts with an ICD, administration of S results in a signif- 
icantly longer time to first all-cause ICD shock or death. The incidence ol 
non-fatal serious adverse events was comparable to that observed in the P 
group. S is safe and effective for reduction of the frequency of ICD shocks. 
11:15 a.m. 
~ Simultaneous Atrial and Ventricular 
Tachyarrhythmias in Defibrillator Recipients: Does 
AF Beget VF? 
Kenneth M. Stein, Mike Hess, Cole H. Hannon, Rahul Mehra, Suneet MittaL 
Steven M. Markowitz, Bruce B. Lerman. Cornell University Medical College, 
New York, NY; Medtronic Inc., Minneapohs, MN, USA 
Background: The incidence of dual tachycardia in pts with implantable car.- 
dioverter defibrillators (ICDs) - ventricular fibrillation or tachycardia (VF/V-i-) 
preceded by paroxysmal atrial fibrillation or atrial tachycardia (AF/AT) - has 
not been reported, nor has the possible role of AF/AT in facilitating VFNT 
been examined. 
Methods: 202 pts underwent implantation of the Medtronic 7250 dual 
chamber ICD for the primary treatment of VT/VF. 75% had previously doc- 
umented paroxysmal AF/AT. In addition to VT/VF detection, the device in- 
dependently detects AT and AF based on atrial cycle length and regularity. 
All episodes were reviewed for appropriateness of detection and to identify 
episodes of AT/AF in progress at the time of appropriate VT/VF detection. 
Results: During a mean follow-up of 5.0 ± 3.3 months, 65 pts had 
spontaneous VT/VF. 16 pts (8%) experienced dual tachycardia. Of 536 VT 
episodes, 15 (3%) were associated with dual tachycardia. In contrast, of 
230 VF episodes, 42 (18%) were associated with dual tachycardia (p vs. VT 
< 0.0001). Episodes of dual tachycardia occurred in 12/158 pts (8%) with 
pre-implant AT/AF vs. 4/53 pts (8%) without documented pre-implant AT/AF 
(p = NS). The overall distribution of atrial arrhythmias in the population was 
25% AF vs. 75% AT. However, in 75% of dual tachycardia episodes the atrial 
rhythm was AF. The AF/AT preceding dual tachycardia was of short duration 
with 60% present for _<10 minutes and 87% present for <24 hours. 
Conclusions: 1. Dual tachycardia occurs in a significant percentage of 
ICD recipients, irrespective of previously documented AT/AF. 2. The majority 
of episodes of AT/AF preceding VTNF are of short duration. 3. There is 
a striking increase in VF episodes during paroxysms of AF. Whether this 
represents a causal relationship or is an epiphenomenon related to ischemia 
and/or changes in autonomic tone requires further investigation. 
11:30 a.m.  
~-~]  Long Term Efficacy of Antitachycardia Pacing for 
Treatment of Ventricular Tachycardia in Patients 
With Implantable CardioverterlDefibrillator (ICD) 
Michael Fiek, Uwe Dorwarth, Dieter M011er, Ellen Hoffmann, 
Gerhard Steinbeck. Med. Hospital I, University of Munich, Munich, Germany 
Antitachycardia pacing techniques (ATP) have proved useful for termination 
of ventricular tachycardia (VT). However, little is known about the efficacy 
and safety of ATP during long term follow-up in a larger study population. We 
analyzed the data of 80 ICD patients (pts) with spontaneous monomorphic 
VT, mean age 59 ± 12 years, the mean follow-up was 26 ± 17 months. 50 
pts (62.5%) had coronary artery disease, 18 (22.5%) dilative cardiomyopathy 
(DCM), the remaining 12 pts (15%) had no or other cardiac diseases. Left 
ventricular ejection fraction (LVEF) was 44 ± 17%, the NYHA class 2 ± 
0.7. ATP therapy modes were programmed with coupling intervals between 
53-97% (mean 84 ± 9%) and 5 ± 2 extrastimuli (1-12). 64/80 pts (80%) had 
2926 episodes of ventricular tachycardia (cycle length 349 ± 51 ms, 240-520 
ms) with the consequence of 3508 ATP therapies. Overall efficacy was 89.9%, 
acceleration occurred in 4% of VTs. RAMP therapies were superior to BURST 
therapies (p < 0.04), acceleration rates did not differ. Success of ATP did not 
correlate with positive ATP testing on induced arrhythmias, LVEF, NYHA class 
or aneurysm. Neither undedying heart disease nor antiarrhythmic medication 
had impact on the ATP success rate. ATP efficacy was linked significantly 
to VT cycle length (240--300 ms, p < 0.01) and coupling interval (91-97%, 
p < 0.01). Acceleration occurred in 32% of pts and in 4% of VT episodes; it 
was also dependent on cycle length (240-300 ms, p < 0.001) and coupling 
interval (lowest rate 91-97%, p < 0.03). 
Conclusion: Success and acceleration rate of ATP depend on VT cycle 
length and coupling interval, therefore aggressive ATP modes should be 
carefully applied in patients with VTs faster than 300 ms. 
11:45 a.m. 
[ ~  Safety and Performance of a New Dual-Chamber 
Implantable Cardioverter-Defibriliator (ICD): Results 
from a European Multicenter Study 
Burkhard H0gl 1 , Rainer Hambrecht 1 , Gerhard Hinddcks, Hans Kottkamp, 
Tanja Ostertag-Fiehn, Antoine Cuijpers, Jaak Minten Gerhard Schuler. ~On 
behalf of the Multicenter European GEM-DR-Investigators; University 
Leipzig, Heart Center Leipzig, Germany 
The purpose of this prospective multicenter (36 European centers) study 
was to evaluate the safety and performance of a new dual-chamber ICD 
(Medtronic Model 7271 GEM DR). Between 11/97 and 5/98 a total of 216 pa- 
tients (pts) were implanted. Indications (non-exclusive) for ICD implant were 
survival of sudden cardiac death (56%), recurrent poorly tolerated sustained 
VT (75%) or MADIT (3%). The typical pt was a 61 years old male (79%) 
suffering from coronary artery disease (64%) and/or dilated cardiomyopathy 
(22%), with an ejection fraction of 39%. During a follow up (FU) pedod of 2.9 
± 1.4 months 70 pts experienced 1108 ventricular tachyarrhythmia episodes 
and 48 lots experienced 486 supraventricular tachycardia (SVT) episodes, 
of which EGM was stored by the device. All VTNF (of which 99.6% were 
treated successfully) and the majority (71%) of the SVT episodes (untreated) 
were appropriately detected. During the FU period 110 pts experienced 187 
adverse events (AE). Inappropriate VT/VF detection occurred in only 26 pts 
(12%). AEs resulting in death (6), requiring surgical intervention (37) or hos- 
pitalization (52) were classified as severe and occurred in 66 pts (31%). Four 
pts died of heart failure and two pts died of electromechanical dissociation. 
None of the deaths were considered to be device related. Severe Device 
Related AEs, including 10 lead dislodge-ments and 10 inappropriate VT/VF 
detections, occurred in 29 pts (13%). 
Conclusion: The new Dual-Chamber ICD proved to be safe and effective 
with a low rate of adverse events. The new PR-Logic algorithm seems to be 
very useful for the correct discrimination of supraventricular from ventricular 
arrhythmias. 
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Atrial Flutter 
Monday ,  March  8, 1999, Noon-2 :00  p.m. 
Moda l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour:  1:00 p .m. -2 :00  p.m. 
11084-146 J/ Concealed Entrainment in Radiofrequency 
Catheter Ablation of Atypical Atrial Flutter in 
Patients Without Prior Cardiac Surgery 
Frank Bogun, Birgit Bender, Y.-Gang Li, Stephan H. Hohnloser. JWGoethe 
Universi~ Division of Cardiology, Frankfurt, Germany 
Background: Mapping techniques for atypical atrial flutter (atyp. aflu.), have 
not been evaluated in a systematic fashion. In this study we sought to 
evaluate the utility of mapping techniques for ablation of atyp. aflu. 
Methods: Participation of the isthmus between the inferior vena cava 
and the tricuspid annulus was excluded by the lack of concealed entrainment 
(CE) during isthmus pacing. CE was present if P wave morphology as well 
as the intraatdal conduction sequence during pacing and during tachycardia 
were identical as iudged by a 12 lead ECG and by a 20 polar halocatheter 
positioned in the dght atrium. Pacing was performed with a quadripolar 
(2-5-2 mm) ablation catheter with a 4 mm tip electrode via electrodes 1 and 
3. Radiofrequency (RF) energy was only applied if CE could be demonstrated. 
Results: 7 patients (pts) without prior cardiac surgery (5 men, age 63 ± 
13 yrs, EF 0.48 ± 0.17, LA size 44 ± 6 mm) were referred for ablation of atyp. 
aflu. All pts were in atyp. aflu. at the time of the electrophysiologic procedure. 
CE could be demonstrated in all the clinical tachycardias. 12 different forms 
of atyp. aflu. were targeted for RF ablation (CL 255 ± 32 msec). 10/12 (83%) 
targeted forms of atyp. aflu. could be successfully ablated: 1 in the left upper 
pulmonary vein, 2 at the posterior roof of the left atrium, 5 at the free wall 
of the right atrium, 1 at the upper and 1 at the lower part of the right atrial 
septum. RF energy was applied at 29 sites demonstrating CE. Successful 
sites had a longer endocardial activation time (EGM-P) {161 ~ 73 vs 113 
:~ 39 msec, p = 0.02) whereas the stimulus-P interval (S-P) tended to be 
longer at successful sites compared to ineffective sites (150 ± 72 vs 107 ± 
57 msec, p = 0.1), Successful sites were more frequently associated with a 
match of the EGM-P wave and the S-P interval < 10 msec and with double 
potentials dudng tachycardia (p = 0.001, p = 0.003) 
Concluaion: Ablation of atyp. aflu. can be achieved in a high percentage 
of cases with single lesions using conventional' mapping techniques. The 
anatomical substrate in pts without prior cardiac surgery is tess well defined 
than in typical atrial flutter or postoperative atrial tachycardias. 
I 1084-147]  Character±tics of Conduction within Non-incisional Atypical Atrial Flutter Circuits 
John G. Kall, Albert C. Lin, C. Timothy Johnson, Philip Cooke, Doug Kopp, 
Martin Burke, Ralph Verdino, Zhong Wang, Michael Fuomo, David Wilber. 
University of Chicago, Chicago, IL, USA 
Background: Data from experimental models of atdal flutter (AFL) indicate 
macroreentrant circuits may be confined by anatomic and/or functional bar- 
riers remote from the tricuspid annulus-inferior vena cava (TA-IVC) isthmus. 
Data characterizing these tachycardias in man is limited. 
Methods: Magnetic electro-anatomical mapping (Biosense/Cordis Web- 
ster) was used to localize atypical (non-TA-IVC isthmus-dependent, non-inci- 
sional) AFLs to the dght atrial free wall (RAFW) in 3 pts and left atrium (LA) 
in 1 pt. Conduction velocity (CV) was determined at multiple locations within 
the reentrant circuit using the electroanatomical map (160-410 recording 
sites/map). Structural heart disease was present in 2/4 pts. 
Results: In the pts with RAFW AFL (cycle lengths 236, 283, and 330 
ms), multiple (2-3) discrete areas of slow conduction (CV < 0.4 m/s) were 
identified within each circuit. In the remaining portions of the circuit CV ranged 
from 0.8-1.4 m/s. The lengths of the central lines of conduction block were 
2.0, 2.2, and 2.4 cm. In the pt with LAFL (cycle length 253 ms), activation was 
observed around an electrically silent area in the posterior LA. A single slow 
conduction zone was located in the inferior LA between the mitral annulus 
and the postedor electrically silent area. 
Conclusions: In pts with these atypical AFLs, CV is not uniform within the 
reentrant circuit. Areas of markedly slow conduction appear to be required 
in these tachycardias. These data should be taken into consideration when 
using conventional mapping techniques to investigate atypical AFL 
I1 4~J and Ablation of Left Side 084-1 Clinical Characteristics 
Atrial Flutter 
Andrea Natale, Mark Richey, Gery F. Tomassoni, Salwa Beheiry, 
Kathleen Rajkovich, Brandon Wides, Debra Nickell, Fabio M. Leonelli, 
University of Kentucky, Lexington KY, USA 
In patients undergoing ablation for left-sided flutter we report the success 
of catheter ablation and the clinical conditions associated with this type of 
arrhythmia. A total of 13 patients were included in this study. At the time of the 
procedure 4 patients had a structurally normal heart, The remaining 9 patients 
had history of either lung or heart surgery. This included left pneumonectomy 
in 4 patients, mitral valve replacement in 5 patients, The flutter cycle length 
ranged from 190 msec to 260 msec. In the patients with either mitral valve 
replacement surgery or pneumonectory, the eadiest site of activation was 
identified in the left superior pulmonary vein region. In the patients with 
no evidence of structural heart disease, the earliest site of activation was 
observed along the inferoseptal region of the left atrium in correspondence 
of the coronary sinus. When atrial flutter involved the pulmonary vein region 
successful ablation was performed by extending a linear lesion from the 
ostium of the left superior pulmonary vein down to the mitral annulus. In 
patients with no structural heart disease successful ablation was achieved 
eXtending a linear lesion from the ostium of the right inferior pulmonary vein 
to the septal portion of the mitral annulus. None of the patients with normal 
heart expedence recurrence at follow up. Recurrence of the same arrhythmia 
was observed in 3 of the remaining 9 patients. In conclusion, atrial flutter on 
the left side seems to involve specific regions in the majority of patients. 
The clinical history can predict the area which is critical to the arrhythmia 
and need to be targeted for a successful ablation. The high recurrence 
rate may reflect incomplete understanding of the underlying mechanism and 
inadequate ablation catheter design for this type of arrhythmia. 
l l  J Progressive Delay During Atrial Flutter 084-1 49 Isthmus Ablation: the Critical Importance of 
Isthmus-Spanning Electrodes for Distinguishing 
Conduction Delay From Block 
Paul A. Friedman, Alexis M. Fenton, Thomas M, Munger, Stephen 
C, Hammill, Robert F, Rea, Win K. Shen, Michael J. Osborn, David Luria, 
Douglas L. Packer. Mayo Clinic, Rochester, MN, USA 
Background: Bidirectional isthmus block is associated with successful atrial 
flutter ablation, whereas creation of increased isthmus conduction delay 
without block can be proarrhythmic. Often, halo catheter electrodes fail to 
provide adequate sub-Eustachian isthmus recordings. 
Methods: A 20-pole deflectable catheter was positioned across the 
sub-Eustachian isthmus (from the coronary sinus os [CSO] to 7:00 on the 
tricuspid valve annulus [TVA] clock-face) in 8 patients undergoing atrial flutter 
ablation. During sinus rhythm, conduction time was measured from the CSO 
to the 7:00 position while pacing the CSO. Measurements were repeated 
after each linear lesion and after conduction block was achieved. 
Pacing CL Conduction Coed. Time Jus t  Conduction ]]me 
(msec) ]]me (baseline) Prior to Success After Block 
600 54 :E 9 100 ± 19' 155 ± 30 
400 52 ± 8 99 ± 23" 162 - 28 
300 63 ± 14 105 ~- 23 ° 161 ± 24 
"p < 0.01 (compared to baseline) 
The marked delay prior to complete block resulted in reversal of the 
activation sequence in electrodes at TVA 7:00, creating the false appearance 
of isthmus block; the isthmus electrodes clearly distinguished delay from 
block. 
Conclusion: Catheter ablation results in progressive isthmus conduction 
delay prior to the creation of complete block. Electrodes spanning the isthmus 
(and line of block) are critical for distinguishing conduction delay from block. 
1084-150/  A Randomized of 8 Prospective Study mm 
J versus 4 mm tip Electrodes for Radiofrequency 
Current Ablation of Atrial Flutter 
Christian Weiss, Stephan Willems, Matthias Hoffmann, Thomas Me±hertz. 
University Hospital Eppendoff, DepL of Cardiology, Hamburg, Germany 
Background: Recent reports suggest a higher efficacy rate for radio&e- 
quency current (RFC) ablation of type I atrial flutter (AFL) using larger tip 
ablation catheters. Aim of the study was a randomized comparison between 
standard ablation catheter with 4 mm and catheters with a 8 mm for AFL 
ablation. 
Methods: 31 consecutive patients (pts) referred for treatment of AFL 
were randomized for RFC ablation. 16 pts were assigned to 4 mm tip and 
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15 ptm P~ ~ ,~ m*4,~ ,,#', ~".,~<"~)~r 7-...C>-~ A'@~.~ #'~,~ ,~; ,~b ~),~3..~ , ~),',~a~jl.'-a~, 
technique using the 4 mm tip catheter and with a point by point ablation 
using the 8 mm tip catheter. Target site for RFC was the posterior isth- 
mus between tncuspid annulus and vena cava inferior. Endpoint for RFC 
was the induction of bidirectional (bi) conduction block via the posterior 
isthmus. To improve catheter stability long introducer sheaths were used. 
After 12 failed RFC pulses (target temerature 70~C, energy: 50 - 60 W, 
pulse duration 90 sec) crossover of the patient to the opposite strategy was 
performed. 
Results: ~i b/oc~ could be achieved in f5 ~te (94%( started with the 
4 mm tip and in 13 pts staded with the 8 min tip (87%). Crossover to the 
in which RFC ablation was staded with a 4 min tip catheter (1/16 pts (75%) 
vs. 5/15 pts (33%)). However there was no significant difference regarding 
RFC peses [17 + 9 vs. 18 + 13), fluoro time (44 + 1B vs 49 + 28 min) and 
sessile)) b#~al)t>n #~,.~ +-)~ vs. 23~- ~-3'2 r#)#) ' or 3c, o'lD .0~ol)7> D') 7>al>en~s. 
be successfully achieved more often using a 8 mm tip catheter compared 
to a 4 mm tip catheter. However RFC ~b~tic~n of A.FL st~rtin~j with ,~ 8 mm 
tip catheter could not significantly reduce the number of pulses and session 
duration with fluoro time. 
l l  1 of Unipo|ar Electrograms to Confirm 084-1 51 ttsefuiness Isthmus Block After Radiofrequency Ablation of 
Typical Atrial Flutter 
Juliam" ~)'i~laca~,ti 0.3esus "Aimen~r~.}, ~,ne i ~ren~),'~larcebes ~.9 ~iZ,'Nica sic 
P. Castellano, Sergio Gonzalez, Diego Velasco, Bartolome Vallbona, Juan 
L. Delcan. Hospital G Maranon, Madrid, Spain 
Obje¢'fi~e- "To e:~arfi)ne ~e t l~  e~ 'toe t)n~Yflereb ~H)po~ar e~ec~Dgrams 
annulus (TAr and the inferior vena cava (IVC). We hyphotesized that pacing 
from the coronary sinus ostium (CSos), the UNIP recorded at the other side 
of th~e'))ne 5} rab)6}rep~en~y a~.bbc,t"bon. 6)ose~o~e)fi}e)b)ahera)3~. coD)b 
chan~e %tom a ~}p~nagic "'RS" mor~'no~ogy Isu99es%)ve 05 con~uc'~on a~on 9
the TA-IVC isthmus) before, to a positive monophasic"R" UNIP morphology 
(suggestive of termination of the wave front against the line of block) after 
achievement of clockwise isthmus block (CIB). Similar findings could be 
obsewed after counter-clockwise isthmus block, ICCIB), pacing from the 
inferolateral TA. 
Methods: In fifteen consecutive patients (P) who underwent ablation of 
TA-IVC isthmus. It was confirmed by comparing the timing and the sequence 
of 10 standard bipolar electrograms of a catheter positioned along the TA. 
Results: Pacing at a cycle length of 500 ms from the CSos before CIB, the 
UNIFP recorded at the inferolateral TA was "RS" in all P. AfterCIB. the interval 
between the stimulus artifact and the UNIP increased a mean of 45 4- 13 ms 
TA before CCIB, the UNIP obtained at the septal side of the line of block, was 
"RS" in all P, After CCIB, the interval between the stimulus artifact and the 
UNIP increased a mean of 43 4-11 ms and changed to an small "R" in 14 P and 
to "Rs" in 1 E Pacing from the CSos, in two P we observed a prolongation 
time of the stimulus-UNIP interval after RF applications despite showing 
"RS" morphology. In both of them, additional maneuvers were needed to 
obtain CIB which was coincidental with conversion from "RS" to "R" UNIP 
morl:helogy. 
Conclusion: UNIP are useful to recognize bi-directional TA-IVC isthmus 
block, even in the presence of slow conduction through the TA-IVC isthmus 
and could reduce the number of catheters (and recording channels) for RF 
ablation of AFI. 
1084-1521 of Atrial Isthmus Ablation the Effect Right on 
Occurrence of Atrial Fibrillation: Observations in 
Four Patient Groups Having Type I Atrial Flutter 
With or Without Associated Atrial Fibrillation 
Ashish Nabar, Luz-Maria Rodriguez, Carl Timmermans, Adri vd Cool, Joep 
L.R.IM. Smeets, Hein J.J. Wellens. Department of Cardiology, Academic 
Hoslpital Maaastricht, Maastricht, The Netherlands 
Objtec"b-0e: 30 "~es3 "the ~y~otne,g)s lna~ the bcc~rTence o~ ~l"lha"l 'i~n%h~"i)on 
(AF) in at least some pts with coexisting type I atrial flutter (AFL), is based 
on a macro-reentry involving the right atrial iRA) isthmus by evaluating AF 
recurrences following successful radiofrequency ablation (RFA) of AFL. 
Methods: Eighty-two consecutive pts with type I AFL, with or without 
conc~w(fc~'~t', 'AT, ,~P' , J~f ,  ?,E'A ~, ~&'re 'R,'A ~ '~ ",',',',',',',',','~'gr'9 ,  -aq,,~to..mi¢..~ 
approach. The results were analyzed in 4 groups of pts: group I [only AFL; 
29. pts], group II [AFL > AF; 22 pts], group III [AF > AFL; 15 pts] and group IV 
for AF, the "class IC AFL"; 16 pts]. 
Results: In all groups, RFA of type I AFL was performed with a high 
(>93%) procedural success rate. In group I, only 2 (8%) pts had AF following 
RFA of AFL (follow-up, 18 4- 14 mo). These figures were 38% (20 • 14 mo) 
and 86% (13 4- 8 mo) in group II and group III pts respectively. Group IV pts 
(4 4- 2 mo) had a 73% freedom of AF recurrences with continuation of the 
class IC agent. 
Conclusions: Following RFA of the RA isthmus: 1) Incidence of new 
,4.F (s van/low, mak(r~ (t urq(ket,¢ ~t~( ra~(o(eeq~cy (as~c~s ~e~mat.~ t~ 
development of AF 2) AF recurrences are reduced to a greater extent in 
a possible involvement of the RA isthmus in maintainance of AF in some 
pts 3) RFA of "class IC AFL" in pts with therapy resistant AF provides a 
nove~ therapeutic approach. 4) Careful clinical classification of AF patients is 
l 1084-153j High Prevalence of Left Atrial Thrombi in 
Patients With Typical Atrial Flutter and Left 
Ventricular Systolic Dysfunction 
David M Gilligan, Miguel Butch, Ithiel A. Fuller, Andy W, Prinz, Kwame 
O. Akosah, Dan Dan, Brian K. Holdaway. Veterans Affairs Medical Center, 
Richmond, VA 
Background: Atrial flutter (Aflu) has not generally been considered a sub- 
strate for atrial thrombus formation or a significant risk factor for thrombo- 
erfib61ism.~-~ecent ~lata'l~asguestior~d]hese assUrnr~ttons. 
Methods: Transesophageal echocardiography (TEE) was performed in 
all patients (pts) with atrial tachyarrhythmias being considered for cardiover- 
sion without prior anticoacjulation of at least 1 month duration at a Veterans 
this indication. 
Results: Of these 261 pts, 82 (31%) had typical Aflu, all were male, 
mean a~e 70 i 10 v rs and mean ei~ction fraction i EFI 38 +_14°/,. Left_atrial 
Ot/~'(Tfiromdl; qreobmihan[i~/in rde C~ a0qene&(~e, were aetecieaby f'-CCIh 
10 pts with typfcaf Affu, for a prevalence rate of 12%. This compared to a 
prevalence rate for LA thrombi of 23% (30/128 pts) in atdal fibrillation, and 
20% (10/51 pts) in atypical Aflu in this population. The risk of LA thrombus in 
typical Aflu was strongly associated with left ventncular systolic dysfunction; 
LA thrombi were not seen fn Affu pts with EF > 35%, while the prevalence of 
LA thrombus was 30% (12/40) in Aflu pts with EF < 35%. 
Conclusions: LA thromb( associated with atrial tachya.rrh~thmlas are 
frequent in this elderly, male population. Thrombi are found just as frequently 
in atypical Aflu as in atrial fibrillation. Even in typical Aflu the prevalence of 
LA thrombi is hicsh at 12%. but this risk is exclusivel'~ associated with severe 
LV systolic dysfunction. 
PD~qT-E~ 
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1 54 / Adverse Cardiovascular Events Associated With 
5 
085-1 
Nutritional Supplements Containing Ma Huang 
(Ephedra) 
David Samenuk, Mark S. Link, Robed Contreras, T.C. Theoharides, Paul 
J. Wang, N.A. Mark Estes III. New England Medical Center, Boston, MA, 
USA 
Background: Nutritional supplements containing ma huang, a natural source 
of ephedrine, are widely sold in the United States for a variety of purposes 
including weight loss, energy enhancement, and body building. There is 
concern that these ephednne-containing products may be associated with 
a,d'~arse c~rd(a~ascLL(&r evertts. 
Methods: We reviewed a comprehensive detailed data base contain- 
,i% ~ ~,'~.se ~'~'  ,~n~n~s ,~s.~"~,~ ~llt'~, ~ a'se M ~ ,  .~pq.,n~,;,~ 
Results: Of the 926 cases of possible ephedrine toxicity in the data 
base, 50 contained senous cardiovascular events. We identified 14 sud- 
den deaths, 6 noncardiovascular deaths, 13 strokes (including 2 deaths), 
2 transient ischemic attacks, 9 myocardial infarctions, and 6 supraventric- 
of 41.8+14.2 years (range 19-69). Reasons for ma huang usage include 
weight loss in 27 individuals, energy enhancement in 15, recreational in 1. 
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Chronic usage described as greater than 1 week occurred in 80% of these 
patients. Forty-eight patients had no history of cardiovascular disease. Of 
the 14 patients with sudden death, 10 autopsies were performed. In these 
autopsies, atherosclerosis was found in 3, other cardiomyopathies in 3, and 
normal hearts in 4. 
Conclusion: Nutritional supplements containing ma huang are associ- 
ated with serious adverse cardiovascular complications. Sudden death can 
occur even in the absence of any structural heart disease. Adverse car- 
diovascular events are more commonly reported in women. Awareness of 
the potential harm associated with these products is critical to an informed 
public. 
1085-155J RR Intervals and Heart Rate Variability 
3 
Rise 
Gradual ly  Then Dec l ine Rapid ly  Before the 
Onset  of Susta ined Ventr icular  
Tachyar rhythmias  
Kelley P. Anderson, Vladimir Shusterman, Benhur Aysin, Raul Weiss, 
Susan Brode, David Schwartz.man, Venkateshwar Gottipaty. For the 
ESVEM Investigators. University of Pittsburgh, Pittsburgh, PA, USA 
Changes in RR intervals (RRI) and RR interval variability (RRV) have been 
documented in the hour preceding sustained ventricular tachyarrhythmias 
(VTA), but little is known about longer-term changes which could reflect 
slower alterations of neurohormonal activity. 
Methods: We identified 11/1646 tapes from a clinical trial recorded in 
the absence of antiarrhythmic drugs in which 16 h of sinus rhythm preceded 
the onset of recorded, spontaneous sustained VTA. RRV power was com- 
puted in the high (HF: 0.15-0.4 Hz), low (LF: 0.04-0.15 Hz), very low (VLF: 
0.0033-0.04 Hz) and total (TP) frequency ranges at 30 min intervals before 
the onset of the VTA episode. 
Results: There were 6 men, 5 women, age: 64 ± 9; LVEF: 40 ± 15%; 
ischemic heart disease: 82%. RRI rose (p < 0.0001, by ANOVA) from 14 to 
6 h, were relatively stable 6-3 h, and declined 3-1 h before V'FA (Figure). LF 
rose and fell in a similar pattern during this period (p < 0.0001), whereas HF, 
VLF, TP and LF/HF did not change significantly. The maximum RR intervals 
occurred during the night in 43% of pts and during the day in 57% (6-10am: 
13%; f0am-4pm: 22%; 4-11 pro: 22%). 
,~, 9oo. 
i 7 4 0  
~" 7 0 0 ' ' "  
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Time before VT [hr] 
Figure 1. RR intervals vs. time before VTA 
Conclusions: A pattern of changes in RRI and the LF of RRV consisting 
of a gradual rise, plateau and rapid decline occurred before the onset of 
sustained VTA. These observations suggest that the long-term pattern of 
neurohormonal activity may be related to the initiation of VTA in this group of 
patients. 
1 / Ventr icular  Fibri l lation Is Predictor  of 
1 
085-1 56 Inducib le a J 
Recurrent  Ar rhythmias  in Pat ients Present ing 
With Syncope or Card iac  Arrest  
Mark S. Link, Neera Gupta, Munther K. Homoud, N.A. Mark Estes III, Paul 
J. Wang. New England Medical Center, Boston, MA, USA 
Background: Ventricular fibrillation (VF) induced at electrophysiological 
study (EPS) is thought to be a nonspecific arrhythmia except in patients 
presenting with a cardiac arrest (CA). 
Methods: To evaluate whether induced VF has prognostic significance 
in patients presenting without CA, we evaluated 115 consecutive patients 
presenting with syncope or presyncope (78 patients), or cardiac arrest (37 
patients) from 1/91 to 5/97, who had induced VF, nonsustained polymorphic 
ventricular tachycardia (NSPMVT) of >_ 10 beats, or ventrieular flutter (VFL) 
(c1200-240) at their initial EPS. 
Results: With a follow-up of 31 ± 19 months there has been recur- 
rent arrhythmias in 29 patients including 17 who presented with syncope 
or presyncope. Predictors of recurrent arrhythmias included the presence 
of spontaneous arrhythmias (including NSVT) and EF _< 30%. Clinical pre- 
sentation, age, diagnosis of heart disease, ease of inducibility, cycle length, 
and induced arrhythmia (sustained or nonsustained) did not predict for re- 
currences of arrhythmia. 
Conclusion: VF, NSPMV-r, and VFL induced at EPS may have prognostic 
significance for arrhythmia recurrence even in those patients presenting with 
1 
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syncope or presyncope. Treatment with implantable cardioverter defibrilla- 
tors or antiarrhythmic agents may be necessary for not only those patients 
presenting with CA, but also for those patients presenting with syncope or 
presyncope. 
1 085-157  / of Ventr icular  of 
1 
Init iation Tachycard ia:  Ana lys is  
J 
Intracardiac E lect rograms in Pat ients With 
Internal Card ioverter  Def ibr i l lator 
Mohammad Saeed, Sriloy Mahapatra, Maid Mouded, David Tzeng, 
Robert Contreras, Vivian Jung, Craig Swygman, Mark S. Link, N.A. 
Mark Estes III, Paul J. Wang. New England Medical Center, Boston MA, 
USA 
Objective: To characterize and gain insight into the mechanism of initiation 
of spontaneous monomorphic ventricular tachycardia. 
Methods: 268 episodes of stored ICD electrograms of monomorphic VT 
from 52 patients were reviewed. Events were divided into 1) sudden onset, 2) 
extrasystolic or 3) pace, based on the presence or absence of premature and 
paced beats pdor to VT. Coupling interval was the interval between paced 
beat or PVC and the preceding beat, or the first beat of VT and the preceding 
beat for the sudden onset. Coupling interval was normalized to preceding 
interval to calculate prematurity index. Pause dependency was assessed by 
presence of short-long-short sequence. 
Results: Extrasystolic initiation was the most frequent pattern (177/268) 
followed by sudden onset (75/268) and pace (16/268). The majority of 
episodes in the extrasystolic group (137/178) were preceded by multiple 
PVCs with morphology different from the subsequent VT. There were 40 
episodes of extrasystolic initiation that were preceded by single PVC, out 
of which 28 were of the same morphology as the VT. In the sudden onset 
group the first beat of VT was similar in morphology and closely coupled to 
the subsequent VT in all the events. In the pace group, 12 of 16 episodes 
of VT were due to inappropriate ventricular pacing as a result of undersens- 
ing of previous beat. VT episodes following a sudden onset initiation were 
slower (mean CL 384 ± 98) as compared to extrasystolic (mean CL 336 
5: 87, p < 0.0002) and pace (mean CL 313 ± 85, p < 0.02) initiation. The 
mean prematurity index was 0.80 (± 0.57) and was not significantly different 
among groups. There were 33 episodes of short-long-short sequence among 
7 patients. 
Conclusion: Majority of VT episodes in ICD patients are initiated by 
premature polarizations, that are multiple and different in morphology from 
the subsequent tachycardia. Sudden onset VT initiation, although less com- 
mon, may have a distinct electrophysiologic mechanism. Pause dependent 
initiation of VT is infrequent, and may be reduced further by use of pacing 
strategies. R wave undersensing with resultant premature paced ventricular 
beats can initiate VT. 
1 085-1 78 j Out-of -Hospi ta l  Card iac  
1 
Arrest :  Relat ion 
Between Bystander  Bas ic  Life Suppor t  and 
Ventr icular  Fibri l lation 
Reinier A. Waalewiln, R.W. Koster, J.G.P. Tijssen. Academic Medical 
Center, University of Amsterdam, The Netherlands 
Background: Bystander basic life support (BLS) doubles the chance of 
successful resuscitation. The mechanism is thought to be the maintenance 
of cerebral and/or myocardial blood flow. 
Methods: In a prospective study over 26 months, data from out-of-hospi- 
tal bystander witnessed cardiac arrests were collected. BLS, initial recorded 
cardiac rhythm and time intervals were registered. Logistic regression mod- 
els were fitted for the probabilities of recording ventricular fibrillation (VF), 
asystole or other rhythms in patients (pts) with and without BLS in relation to 
the time of the recording. 
Results: Included were 1036 pts. VF was recorded in 514 pts (50%) and 
asystole in 255 pts (25%). BLS was performed in 50% of all pts, 61% had VF 
and 38% asystole as initial rhythm. VF decreased and asystole increased as 
time to the recording elapsed. BLS reduced these trends significantly. This 
effect was not seen for the other rhythms. 
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odds ratio 95% CI 
Expected VF per minute delay 
with BLS 0.95 0.92-0.97 
without BLS 0.88 0.65-0.91 
Expected Asystole per minute delay 
wit~l BLS 1.07 1.04-1.10 
without BLS 1.11 1.08-1.14 
0.8- 
>,0.6" ~ q",m 
~ 0.4- %- 
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o ' ~ ' lb ' t~ '2~'  2 '5 '3~ 
Ume to rhythm recording in minutes 
Conclusions: BLS delays the transition of VF to asystole, probably by 
maintaining coronary perfusion and so protecting the myocardium. 
VF with BLS 
VF without BLS 
Asystole with BLS 
Asystole without BLS 
1085-179 I of in Double Analysis Repolarization Changes a 
I Blind Crossover Study on Dofetilide Versus 
Sotalol for Ventricular Tachycardia 
Giuseppe Boriani, Mauro Biffi, Nicola DeSimone, Letizia Bacchi, 
Federica Bitonti, Romano Zannoli, Ghazwan Butrous, Angelo Branzi, 
Bruno Magnani. Inst. of Cardiology, Univ of Bologna, Italy and Pfizer Res, 
UK 
Background: Aim of this study was to assess if response to class 3 antiar- 
rhythmic agents is related to a different pattern of repolarization changes. 
Methods: A group of 57 pts. with ischaemic heart disease and inducible 
ventricuiar tachycardia (VT) by programmed electrical stimulation (PES) par- 
ticipated in a randomized double-blind, crossover study comparing treatment 
of dofetilide (D) (500 mcg bid) with sotalol (S) (160 mg bid). The ECG trac- 
ings were analyzed blindly and RR, QT (maximum value over 12 leads), 
QTc (Bazett's formula), QT dispersion (QTD)(QT max-QT min over 12 leads) 
and QTc dispersion (QTcD) were calculated at baseline and at 3rd day of 
treatment (4 hrs after dosing). All pts underwent PES on both drugs. 
Results: At PES 21/57 pts. responded to D and 22/55 to S (2 pts. on S 
were withdrawn before PES because of side effects). There was significant 
increase in the QTc on the 3rd day compared to baseline on both D and S 
(mean ± SD in msec) in both responders [Fi'] and non-responders [NR'j (D 
QTc = 474 + 30 vs. 443 ± 31, p < 0.002; D NR: QTc = 482 4- 28 vs. 448 =E 
24, p < 0.001 ; S R: QTc = 475 4- 35 vs. 458 4- 25, p < 0.02; S NR: QTc = 
455 ± 29 vs. 438 4- 26, p < 0.005). However both drugs showed a significant 
decrease in QTcD, in both R and NR (D Ft. QTcD = 34 ± 8 vs. 50 ± 25, p 
< 0.01; D NR: QTcD = 34 ± 12 vs. 49 ± 14, p < 0.001; S Fit QTcD = 31 ± 
10 vs. 54 4- 22, p < 0.001; S NR: QTcD = 32 4- 10 vs. 46 ± 16, p < 0.001 ). 
There was no correlation between the change in the QTcD with both drugs 
in R and NR groups. 
Conclusion: Treatment with either D or S was associated with an increase 
in QTc and a decrease in QTcD. In contrast with previous reports the decrease 
in QTcD showed no correlation with the inducibility of VT during PES. 
1085-180 j  Right Bundle Branch Block, Right Precordial 
ST-Segment Elevation and Sudden Death: 
A Variant of Arrhythmogenic Right Ventricular 
Cardiomyopathy? 
Domenico Corrado, Cristina Basso, Gianfranco Buja, Andrea Nava, 
Gaetano Thiene. University of Padua, Italy 
Background: Patients with the EGC pattern of right bundle branch block 
(RBBB) and right precordial (RP) ST-segment elevation may experience 
ventdcular fibrillation either due to an underlying arrhythmogenic right ven- 
tricular cardiomyopathy (ARVC) or a functional right ventricular electrical 
disorder (Brugada Syndrome). 
Methods: The present study addressed prevalence, substrates, and clin- 
ical profile of patients with this ECG pattern in a series of 300 young sudden 
death victims (_<35 years) that were prospectively studied from January 1979 
to June 1998. Clinical and pathological findings were compared in SD victims 
from ARVC with and without RP ST-segment elevation. 
Results: Twelve-lead ECG was available in 98 cases (33%). Fourteen 
of these young SD victims (12 males, 2 females; mean age 24 ± 9 years) 
with available ECG (15%) had RP ST-segment elevation, either isolated 
(8 cases) or associated with RBBB (4 cases). At autopsy, 12 patients had 
ARVC and 2 had no evidence of structural heart disease. As compared with 
other 19 young SD victims with ARVC and no ST-segment abnormalities, 
those with ARVC and RP ST-segment elevation significantly more often died 
suddenly at rest or during sleep (p = 0.02), showed dynamic ECG changes 
over the time (p = 0.15), and experienced polymorphic ventricular tachycardia 
(P = 0.016). There were no significant differences with regard to age, sex, 
familiarity, ventricular arrhythmias, heart weight, right ventricular aneurysms 
and inflammatory infiltrates. 
Conclusion: RP ST-segment elevation was found in 15% of ECG from 
young SD victims and mostly reflected an underlying ARVC. Like patients with 
Brugada Syndrome, ARVC patients with RP ST-segment elevation showed a 
propensity to die suddenly at rest as well as to have dynamic ECG changes 
and polymorphic ventricular tachycardia. 
1085-1 ] Does Sports Activity Enhancethe Risk of 
1 
81 
Sudden Death in Young People? 
Domenico Corrado, Cristina Basso, Geetano Thiene. Depts. Cardiology and 
Pathology, University of Padua, Italy 
Methods: We prospectively studied the incidence and the cause of sudden 
death (SD) in both competitive athletes and nonathletes (<35 years) in the 
Veneto Region of Italy from January 1979 to June 1998 according to a 
specific clinico-pathologic protocol of investigation. During the study period 
the young population of the Veneto Region averaged 2,009,600 persons with 
a rate of participation in competitive athletics of 9.6%. 
Results: There were 300 sudden deaths (0.85 per 100,000 persons per 
year): 55 among competitive athletes (1.6 per 100.000 per years) and 245 
among nonathletes (0.77 per 100,000 per year). The estimated relative risk of 
SD among athletes as compared with nonathletes was 2.1 (95% confidence 
interval, 1.5 to 2.8; p < 0.0001). The Table shows the main causes of SD in 
young athletes vs nonathletes: 
Cause Total Athletes Nonathletes 
(N = 300) (N = 55) (N = 245) 
Obstructive coronary artery disease 54 (18%) 10 (18%) 44 (18%) 
Right ventricular cardiomyopathy 35 (12%) 13 (24%)* 22 (9.0%) 
Myocarditis 32 (11%) 5 (9.0%) 27 (11%) 
Mitral valve prolapse 27 (9.0%) 6 (11%) 21 (8.6%) 
Disease of conduction system 24 (8.0%) 4 (7.2%) 20 (8.2%) 
Hypertrophic cardiomyopathy 18 (6,0%) 1 (1.8%) 17 (6.9%) 
Anomalous coronary artery origin 7 (2.3%) 6 (11%)'" 1 (0.4%) 
Other 103 (34%) 10 (18%) 93 (38%) 
*p = 0.005; "*p < 0.001 for the comparison with nonathletes 
Conclusions: The incidence of SD was increased 2.1 times in young 
competitive athletes as compared with nonathietes. Arrhythmogenic right 
ventricular cardiomyopathy and anomalous coronary artery origin were the 
only cardiovascular conditions significantly associated with SD during sports. 
1085-1821 Relationship of Coronary Perfusion and 
Stenosis to Arrhythmic Events in the 
Antiarrhythmics Versus Implantable 
Defibrillators (AVID) Trial 
Jonathan S. Steinberg, Nicholas G. Tullo, Jeffrey L. Anderson, 
Karen Beckman, Barry J. Crevey, Peter L Friedman, H. Leon Greene, Greg 
C. Larsen, Carlos Rizo-Patron, Andrea M. Russo, Douglas P. Zipes, Richard 
T. Moore, Alfred P. Hallstrom. The AVID Investigators, 1111 Amsterdam 
Avenue New York, NY 10025, USA 
After acute MI, patency of the infarct-related artery (IRA) and higher TIMI 
grade perfusion are associated with better outcome. In a substudy of the 
AVID trial, we examined the hypothesis that good perfusion to the site of 
previous MI results in a lower risk of recurrent VTNF. Pts with CAD and 
previous MI who underwent coronary angiography dudn 9 hospitalization for 
index AVID event were analyzed: N = 148, 66 i 10 years, 87% male, 
44% VF/56% VT, EF = 0.32 ± 0.11, and 48% treated with ICD/51% with 
antiarrhythmics. Endpoints, defined as appropriate ICD therapy, recurrent 
VT/VF or arrhythmic death, occurred in 51 pts (35%). 
Results: See Table, organized by sites of MI with TIMI status of presumed 
prior IRA. 
Inferior/RCA Anterior/LAD Lateral/LCX 
TIMI 0/1 TIMI 2/3 TIMI 0/1 TIMI 2/3 TIMI 0/1 TIMI 2/3 
(N = 56) (N = 29) (N = 32) (N = 47) (N = 7) (N = 18) 
>_1 Endpt 38% 55% 25% 34% 29% 33% 
Note some pts had > 1 site of MI. P = ns for all comparisons. 
Pts with TIMI 0/1 flow to >1 site (n = 117) were as likely to have an event 
as pts with TIMI 2/3 flow to all sites (n = 26) (35% vs 35%, p = ns). There 
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were no differences in proportion of pts with _>70% stenosis of the coronary 
vessel supplying infarct zone between pts with/without endpoint. 
Conclusion: Better coronary perfusion or fewer high grade stenoses did 
not correlate with lower risk of recurrent tachyarrhythmias in CAD pts who 
had survived V-FNF. 
[ 1085-183 I Does Type of Prior Revascularization Predict 
I I Mode of Presentation with Malignant Ventricular 
Arrhythmias 
James Martins, John Herre, Anne Gill±s, Roger Marinchak, Mark D. Carlson, 
Karan Beckman, Anna Olarte, Judy Powell, Qing Yao. The AVID 
Investigators, University of Iowa, Iowa Ci~ IA, University of Washington, 
Seattle, WA, USA 
Background: The Bypass Angioplasty Revascularization Investigation demon- 
strated greater out of the hospital myocardial infarction (MI) and cardiac mor- 
tality with percutaneous transluminal coronary angioplasty (PTCA) versus 
coronary artery bypass grafting (CABG). Our purpose was to analyze retro- 
spectively the influence of prior PTCA or CABG on malignancy of presentation 
of ventricular arrhythmias in the Antiarrhythmics Versus Implantable Defibril- 
lators (AVID) registry (including non-randomized and randomized patients). 
Methods: The registry collected data on 2,225 patients with coronary 
artery disease and qualifying cardiac arrest due to ventricular fibrillation (VF) 
or an episode of symptomatic sustained ventdcular tachycardia (VT). Patients 
were divided into VF and v-r groups. 
Results: In patients who had undergone no revasculadzation procedure 
prior to the presenting arrbythmia, 47% of 1337 presented with VF. Similarly, 
in patients with prior PTCA alone, 49% of 163 presented with VF. However, 
in patients having undergone previous CABG only 41% patients of 725 
presented with VF (p = 0.012). The lower frequency of VF in patients with 
prior CABG was not significant in a multivariant analysis but the model 
suggested a trend (p = 0.15) especially in patients without a pdor MI; in this 
latter subgroup 66% of 417 patients without revasculadzation, 67% of 24 
patients with PTCA and 50% of 127 patients with CABG presented with VF 
(p = 0.005). 
Conclusion: These retrospective data raise the question whether evas- 
cularization with CABG surgery shifts mode of arrhythmic presentation from 
cardiac arrest due to VF toward symptomatic VT. 
POSTER 
Pathophysiological  Signif icance of 
Autonomic Fluctuations 
Monday,  March  8, 1999, Noon-2 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  1:00 p .m. -2 :00  p.m. 
1 84] Circadian Regulation of Heart Rate Variability 086-1 in 
Primary Pulmonary Hypertension: 
An Unappreciated Risk Marker? 
M. Rosas, J. Kuri, J.A. Hermosillo, A. Bosque, J. Aguirre, J. Sandoval. 
Instituto Nacional de Cardiologia 'lgnacio Chavez' Mexico Ci~ Mexico 
Background: A reduction of heart rate variability (HRV) is now considered as 
an independent risk factor for morbidity, mortality and severity of several car- 
diac diseases. However, the dynamic sympathovagal modulation on HRV in 
patients with severe pulmonary hypertension (PAH) has not been previously 
assessed. 
Methods: 24 hr Holter monitoring (HM) were recorded, analyzed, and 
compared in patients with two distinct forms of severe PAH: Primary pul- 
monary hypertension (PPH; n = 10), and Eisenmenger's syndrome sec- 
ondary to VSD or PDA (ES; n = 12). Both groups had similar age, gender, 
and comparable level of PAH. The HRV time and spectral parameters (mean, 
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SDNN, SDANN, rMSSD, PNN50, LF, HF and LF/HF ratio) were analyzed dur- 
ing three periods: 24 hr; Day (8-22:00), Night (23-07:00), and also at each 
hour of recording (5 min-intervals). 
Results: Frequency parameters of HRV during 24 hr HM were signifi- 
cantly different between the two groups of study. Heart rate circadian rhythm 
was disturbed in both PPH and ES, but the sympathetic tone in PPH was 
higher all 24 hr (p < 0.05). 
Parameter PPH ES p 
Mean (ms) 765.4 ± 39 779.3 ± 53 0.490 
SDNN (ms) 122.8 ± 24 112.3 ± 55 0.560 
MSSD (ms) 26.6 ± 05 32,8 ± 21 0.340 
PNN50 (%) 6.5 ± 04 9.9 ± 09 0,260 
COVR (ms) 15.9 ¢ 02 14.1 ± 06 0,380 
SDANN (ms) 113,8 ± 22 86,7 ± 34 0.038 
LF/HF (day) 5.9 ± 01 2.5 ± 01 0.001 
LF/HF (night) 2.8 ± 01 1,5 2_ 0.8 0,034 
Conclusions: Autonomic cardiac disturbance is clearly present in both 
PPH and ES. The circadian rhythm of HRV is lost mainly due to an increase 
of sympathetic tone. The greater autonomic imbalance in PPH may be an 
important risk marker for the development of heart failure, arrhythmias, and 
sudden death. 
1 851 Heart Rate Variability and Ischemic Responses 
I 
086-1 
to Mental Stress: Results from the 
Psychophysiological Investigation of Myocardial 
Ischemia (PIMI) Study 
D. Sheffield, D.S. Sheps, P.H. Stone, K.E. Fraedland, R.M. Carney, 
K.C. Light, C.G. Coghlan, J.D. Cohen, A.D. Goldberg, C.J. Pepine, 
P.G. Kaufmann, R.P. McMahon. For the PIMI investigators, East Tennessee 
State Universi~ Johnson Ci~ TN and National institutes of Health, 
Washington, DC, USA 
Background: Decreased heart rate variability (HRV) on 24 hour ambulatory 
ECG has been associated with premature death in cardiac patients. The 
possible role of psychological stress in this relationship is unclear. 
Methods: We measured heart rate variability prior to and during a mental 
stress task (Stroop) in 147 cardiac patients (22 women, 125 men) enrolled 
in the PIMI study. All had documented CAD and ECG evidence of ischemia 
during exercise. Forty-seven patients showed radionuclide (ejection fraction 
decrease > 8% or new wall motion abnormality) or ECG evidence of ischemia 
during the Stroop: mental stress-induced ischemia (MSI). 
Results: Spectral analysis of HRV provided evidence of altered auto- 
nomic response in patients showing MSI. At rest, high frequency (HF) power 
and low frequency (LF) power were similar in patients with and without MSI. 
During Stroop, patients with MSI had decreases in HF (p = 0.06) and LF (p 
< 0.05) power compared to patients without MSI. 
Conclusion: These data suggest that ischemic responses to mental 
stress are associated with increased sympathetic activation and/or vagal 
withdrawal. Thus, the increased risk associated with low HRV in cardiac 
patients may be due, in part, to psychological stress and associated changes 
in cardiac autonomic balance. 
1 861 Is There Any Clinical Importance of a 
I 
086-1 
Non-Diagnostic Baroreflex Sensitivity 
Measurement 
Harald Schwacke, Axel Dr6gemLiller, Gregor Siemon, Monika Rameken, 
Jochen Senges, Karlheinz Seidl. Heart Center Ludwigshafen, 
Ludwigshafen, Germany 
Impaired baroreflex sensitivity (BRS) has been demonstrated to be a valu- 
able method for risk stratification in patients {pts) with structural heart dis- 
ease (SHD). Though correctly performed measurement of BRS is often 
non-diagnostic (no correlation between blood pressure and heart rate af- 
ter norphenephrine administration). Aim of this study was to evaluate the 
clinical importance of a non-diagnostic BRS regarding long-term outcome 
of patients (pts) with SHD. In 634 pts (75% male) measurement of BRS 
was performed. Mean age was 62 ± 11 years, ejection fraction 38 ± 15%. 
Organic heart disease was in 82% of pts coronary artery disease, in 14% 
dilative cardiomyopathy, in 4% others. Follow up was 20 ± 11 months. 17% 
of pts had diabetes, 37% hypertension. In 481 lots BRS was diagnostic: in 
338 pts normal (BRS > 3 ms/mmHg) (a) and in 143 pts pathologic (BRS _< 3 
ms/mmHg) (b). In 153 pts BRS was non-diagnostic (c). 
Results: There were no differences in clinical parameters between pts 
with normal, pathologic or non-diagnostic BRS. Total mortality was 4.5%. 
In contrast to pts with normal BRS (mortality 1.5%) mortality in pts with 
pathologic BRS was 7.7% and in pts with non-diagnostic BRS 7.8%. 
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Conclusions: 1. In ¼ of pts with SHD BRS was non-diagnostic. 2. Mortal- 
ity in pts with non-diagnostic BRS was as high as in pts with pathologic BRS 
(7.8% vs 7.7%). 3. A non-diagnostic BRS has the same prognostic impact 
as a pathologic BRS in pts with SHD. 
1086- j Baroreflex Sensitivity and Heart Variability 
3 
1 87 Rate 
in Patients with and Without Sustained T-Wave 
Alternans After an Acute Myocardial Infarction 
Jari M. Tapanainen, Juhani K.E. Airaksinen, Heikki V. Huikuri. Oulu 
University Hospital, Oulu, Finland 
Background: T-wave alternans (TWA) at microvolt level during exercise has 
been shown to be a risk marker of ventricular tachyarrhythmias. We studied 
possible relation of TWA to other arrhythmic risk markers of autonomic 
nervous system, i.e. baroreflex sensitivity (BRS) and traditional and new 
dynamic measures of hear rate variability (HRV). 
Methods: Occurrence of sustained TWA during ergometer exercise 
test, BRS by phenylephrine method, standard deviation of all R-R inter- 
vals (SDNN) and short (c0 and long-term (,8) fractal correlation properties of 
HRV from 24-hour ECG recordings were assessed in a prospective consec- 
utive series of 162 patients after an acute myocardial infarction. QT interval 
dispersion (QTd) and signal-averaged ECG (SAECG) were also analyzed. 
Results: There were no significant differences in either BRS or any of the 
HRV measures between TWA+ and TWA-patients. Neither did SAECG nor 
QTd differ between these groups. 
TWA + (n = 24) TWA - (n = 138) 
BRS 7.2 ± 6.1 8.4 ± 7.2 
SDNN 95.3 ± 22.4 98.9 ± 33.0 
c~ 1.20 ± 0.19 1.26 ± 0.26 
1.30 ± 0.19 -1 .31 ± 0.19 
Conclusions: Presence of TWA during exercise shortly after an acute 
myocardial infarction is not related to BRS, HRV or to other noninvasive 
markers of ventricular tachyarrhythmias. Future follow-up study will reveal 
the predictive value of TWA in arrhythmic risk stratification in relation to other 
arrhythmia risk factors. 
1086-188 i Differences in Heart Rate Between Variability 
i African-Americans and Whites With Coronary 
Artery Disease and Ischemia 
David E. Bush, Lee A. Fleisher, Robed P. McMahon, Carl J. Pepine, Peter 
H. Stone, George Sopke, C. Richard Conti, Pamela Ouyang. For the ACIP 
Investigators, Maryland, USA 
Background: Epidemiologic studies suggest differences in morality from 
myocardial infarction (MI) or cardiac death between blacks (B) and whites 
(W) with similar cardiac risk factors. The Asymptomatic Cardiac Ischemia 
Pilot study enrolled patients with angiographically confirmed coronary artery 
disease (CAD), abnormal stress tests and ischemia on 48 hour ambulatory 
ECG (AECG) recordings. 
Methods: The AECGs were obtained on minimal or no anti-anginal ther- 
apy and analyzed for heart rate variability (HRV). The 366W and 38 B subjects 
were similar with respect to prior MI, diabetes, hyperlipidemia, current smok- 
ing, prior coronary revascularization, and distribution of 1,2 or 3 vessel CAD. 
Hypertension was more common among B than W (55% vs 35%, p = 0.02). 
Results: The groups differed in HRV with AA subjects having higher 
mean square of successive differences (r-MSSD) and high frequency power 
(HF) compared to W (r-MSSD of 60 ± 53.7 msec in B vs 36.2 ± 29.3 in 
W; p = 0.001, and HF power of 558.8 ± 633 in B vs 295.9 ± 375.4 in W; p 
= 0.003). Overall HRV (SDNN) was greater in B vs W (figure), particularly 
during late night and early morning hours (p < 0.001). 
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Conclusion: This study of blacks and whites with similar cardiac dsk fac- 
tors and disease severity shows higher vagal tone and overall HRV (SDNN) 
in blacks. Whether racial differences in HRV are a factor in differential rates 
of CAD morbidity/mortality remains to be determined. 
11086-1891 Alterations of Autonomic Nervous Activity in 
L J Recurrence of Variant Angina 
Masahiro Takusagawa, Sadayoshi Komori, Ken Umetani, Isao Kohno, 
Sohichi Sano, Dongfeng Yin, Riroshi Ijiri, Kohji Tamura. Yamanashi Medica/ 
Universi~ Yamanashi, Japan 
Background: Autonomic activity plays an important role in the trigger mech- 
anism of variant angina. However, alterations of autonomic activity related 
to the recurrence of angina remain unknown. Previous studies have been 
performed using the fast Fourier transform (FFT), but the FFT was insufficient 
to estimate the precise power spectral density from short time series data. 
MemCalc method is a new technique, which is a combination of the maxi- 
mum entropy method for spectral analysis and the non-linear least squares 
method for fitting analysis, and enables us to achieve a reliable analysis of 
the low-frequency component on a minimum interval of 30 seconds. 
Methods: Our study was designed to investigate the relationship be- 
tween autonomic nervous activity and the recurrence of coronary spasm 
using MemCalc method. We analyzed 24-hr Holier monitoring in 18 patients 
(pts) with variant angina (male/female; 17/1, average aged 62 yrs). Of 18 
pts, 9 pts had only one anginal attack (OA group) and 9 pts had more than 
2 attacks (MA group). Heart rate variability was calculated using MemCalc 
method at 30-sec. intervals from 40 min before to 30 min after attack. High- 
frequency (HF: 0.15-0.40 Hz) and low-frequency (LF: 0.04-0.15 Hz)/HF ratio 
were measured as a marker of parasympathetic and sympathetic activity, re- 
spectively. 
Results: 
3-2.5  (rain) Group Baseline Mean (SD), 2 -1 .5  (rnin) Onset 
InHF OA 5,42 (0,48) 5.08 (0.27) • 4.67 (0.27) 1 7.11 (0,30) *t  
(ms 2) MA 5.40 (0.83) 5.54 (0.57) 4.92 (0.59) 1 6.52 (0.37) 1 
InLF/HF OA 1.54 (0.15)' 0.34 (0.23) 1 1.74 (0.21) 1" 1.96 (0.14) .1 
MA 0.68 (0.25) 0.11 (0.35) 1 1.19 (0.33) t 1.02 (0.72) 
• <0.05 vs MA, t <0.05 vs Baseline 
1) In both groups, HF and LF/HF significantly decreased at 2 min. and at 
3 min. before the attack compared to the baseline, respectively. 
2) The baseline LF/HF was significantly lower in MA group than in OA 
group. 
Conclusion: A reduction of sympathetic activity plays a key role in de- 
termining the recurrence of transient ischemic episodes caused by coronary 
spasm in patients with variant angina. 
ORAL  
I 8~ New Mapping Techniques for Ventricular 
Tachycardia 
Monday ,  March  8, 1999, 2:00 p .m. -3 :30  p.m. 
Mor ia l  Convent ion  Center ,  La Lou is iane  A 
2:00 p.m. 
~ T h e  Value of Epicardial Mapping of Ventricular 
Tachycardia from the Coronary Venous System: 
A Prospective Multicenter Study 
Mauricio Arruda, David Wilber, Roger Marinchak, Timothy Talbert, 
Ted Friehling, Thomas Ahem, William Resh, Dusan Kocavic, Michael Belz, 
Kreigh Moulton, Seth Worley, All Massumi, Warren Jackman. University of 
Oklahoma, Oklahoma City, OK, USA 
Background: Some ventricular tachycardias (VT) originate or have a critical 
component of the reentrant circuit located subepicardially. The coronary veins 
course epicardially and can be used for epicardial mapping. This prospective 
multicenter study assessed the value of coronary venous mapping in a large 
series of pts with multiple forms of VT. 
Methods: 68 pts, age 3-80 years, with post-infarction VT (20 pts), id- 
iopathic outflow tract VT (31 pts), and other forms of VT (17 pts) initially 
underwent CS angiography and 1.5-2.5Fr catheters (4, 8, or 16 electrodes) 
were placed in 1 (45 pts) or 2 (23 pts) coronary veins. 34 pts (52%) had a 
prior failed ablation procedure. 
Results: Mapping was obtained along the anterior interventricular vein 
(AIV) in 53 pts, a posterolateral coronary vein (PLV) in 12 pts, the middle 
cardiac vein (MCV) in 17 pts, a lateral coronary vein in 5 pts, and great 
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cardiac vein in 4 pts. Relatively early or earliest activation was recorded 
from the coronary veins, guiding successful endocardial ablation in 6 of 26 
pts (23%) with RVOT V-f, in 2 of 3 pts with LVOT VT, in 5 of 20 pts (25%) 
with post-infarction VT, and in 2 of 17 pts (12%) with other forms of VT. 
Ablation from endocardial sites was not successful in 12 pts (46%) referred 
with RVOT VT. Mapping from the AIV in 7 of 12 pts was suggestive of an 
epicardial focus and ablation was not attempted due to proximity of AIV to 
LAD coronary artery. For the remaining 6 pts, VT was likely deep intramural 
and AIV recordings were helpful to exclude an epicardial origin. In 2 pts 
without structural heart disease, ablation of VT was successfully performed 
from the MCV and anterolateral vein of the left ventricle, respectively. 
Conclusions: Mapping from the AIV identifies or excludes epicardial 
origin of idiopathic outflow tract VT, which often accounts for ablation failure. 
Coronary venous mapping is a helpful adjunct for RF catheter ablation of 
post-infarction and other forms of VT. 
2:15 p.m. 
[ -~6-~ Thermometry Predicts Electrode During Orientation 
Ablation of Ventricular Myocardium with a New Dual 
Thermocouple 8-mm Tip Catheter 
C. Timothy Johnson, Zhong G. Wang, Philip A. Cooke, John G. Kall, David 
J. Wilber. University of Chicago, Chicago IL, USA 
Background: While the orientation of long electrodes relative to the endo- 
cardial surface may influence their thermal properties and subsequent per- 
formance during radiofrequency ablation (RFA), determination of electrode 
orientation in vivo is difficult. We examined the feasibility of using differential 
temperature profiles from two thermocouples placed at opposite ends of a 
new 7 F 8-mm tip catheter (Biosense/Cordis-Webster) to predict electrode 
orientation. 
Methods: We evaluated temperature profiles during percutaneous RFA 
(30-70 W) of normal left ventricles in 7 dogs. Catheter location was assessed 
a nonfluoroscopic imaging system (CARTe). Catheter tip orientation during 
RFA was classified as perpendicular (PD) or parallel (PL) based on imag- 
ing of the electrode-endocardial interface by intracardiac echocardiography 
(ICE) using a 7.5 MHz deflectable probe (Acuson). Continuous tempera- 
ture recordings from both sensors were plotted graphically during ablation 
(Stocker). 
Results: ICE was performed during 37 RFA. Adequate images to assess 
tip orientation were obtained in 35/37 RFA (95%); temperature profiles were 
not available from 2 RFA for technical reasons. Of the remaining 33 lesions, 
electrode orientation was PL in 22 and PD in 11. The maximum temperature 
difference between the two sensors was significantly greater for PD com- 
pared to PL orientation (13 ± 3 vs 5 ± 3 -°C, p < 0.001). The maximum 
temperature difference was _<10 ~C in 21/22 PL RFA, but in only 1/11 PD 
RFA 
Conclusions: Incorporation of dual thermocouples into an 8-mm tip 
catheter may permit in vivo discrimination of catheter tip orientation based on 
differential temperature profiles. The consequences of variable orientation 
on lesion formation requires further investigation. 
2:30 p.m. 
~6~1 Catheter Refractory Multiple Ablation for 
Morphologic VT: Values of Non-Fuoroscopic 
Electroanatomical Mapping 
Koonlawee Nademanee, Erol Kosar, Kiertijai Bhuripanyo, Daniel Reiders, 
Jacklyn Wheeler, John McKenzie, Runjroj Krittayaphong, Mark Schwab. 
Cardiology Division, University of Southern California, Los Angeles, USA 
Background: Patients (Pts) with multiple morphologic VT (MVT) poses a 
therapeutic challenge because it is commonly resistant to anti-arrhythmics 
and ICD. Catheter ablation (CA) guided by conventional mapping technique 
is often ineffective and inadequate because of the hemodynamically compro- 
mised MVI  and changing the V I  foci or their exit sites. We tested values of 
a new non-fuoroscopic electroanatomical mapping (CARTe) in guiding CA 
for Pts with MVT. 
Methods: We studied 24 patients (17 males; mean age = 48) with at least 
2 morphology MVT: 7 right ventricular dysplasia (RVD), 9 post MI, 3 Tetralogy 
of Fallot repair (TET) and 5 cardiomyopathy (COCM). MVT failed to respond 
to antiarrythmic drugs including amiodarone (mean 2.6 drugs) and caused 
multiple ICD discharges in 9 patients. CARTe mapping was performed during 
MVT if it was well tolerated. But mapping of arrhythmogenic areas during 
sinus was done if MVT was hemodynamically compromised. 
Results: CARTe created 3-D replica of the endocardial structure and 
simultaneously corelate them with the intracardiac electrogram; this en- 
ables sites of interests i.e. fractinated potential, concealed entrainment and 
pacemap to be tagged and revisited. CARTe identify macroreentry circuit 
around the surgical patches in all 3 TET Pts with the 2 exit sites from the 
same circuit. Two arrhythmic foci were identified in all 7 RVD, in all 9 post MI 
and 3 COCM. Two Pts had bundle branch reentry. CARTe guided successful 
ablations in 21 Pts yielding MVT non-inducible; the remaining 3 Pts could not 
be mapped adequately and did not have an ablation. Of the 21 Pts whose 
MVT were ablated, 18 (85%) were arrhythmia free with the mean follow-up 
of 11 months. ICD discharges were reduced by 95% 
Conclusions: CARTe represents a major advance in guiding MVT ab- 
lations and deserve further study to determine its role in treating complex 
VT. 
2:45 p.m. 
~-- ]  Linear Lesions for Control of Unmappable 
Ventricular Tachycardia in Ischemic and 
Non-lschemic Cardiomyopathy 
Francis E. Marchlinski, David J. Callans, Charles D. Gottlieb, Erica Zado. 
Allegheny University Hospitals, Philadelphia, PA, USA 
Background: Conventional activation mapping is are difficult to employ in 
pts with poorly tolerated ventdcular tachycardia (VT). 
Methods: We evaluated 9 pts with ischemic cardiomyopathy (ICM), LVEF 
(24 4- 9%), and 7 pts with non-ICM- primadly RV involvement in 4 of the 7 pts. 
All patients had implantable defibdllators (ICD) and drug refractory VT with 
frequent ICD shocks (6 to >30 VT episodes, median 20, during prior month). 
All pts underwent detailed, 98-390 sites per/pt, catheter mapping (bipolar 4 
mm tip to 2 mm ring electrode) during sinus rhythm after determining that 
VT was not mappable. Normal endocardium was defined by amplitude > 1.5 
mV based on 4 RV and 4 LV maps in 6 pts with no structural heart disease. 
Dense scar was defined by amplitude < 0.5 mV. Extent of abnormal and 
densely scarred myocardium was assessed using 3-D color voltage map 
display (CARTe TM Biosense). RF sequential point lesions (1-2 min at 50-60 -0 
or impedance drop of 5-10 Ohms) created linear lesions (LL) extending from 
dense scar to anatomic boundaries or normal endocardium. Site of LL was 
guided by pace mapped 12 lead EKG matching VT. No drug therapy was 
added after ablation. VT recurrence was documented by ICD interrogation. 
Results: RF point lesions applied to LV or RV ranged from 8-86 lesions 
(mean 55) creating a median of 4 LL, average length = 3.9 cm (1.4-9.4 cm). 
Follow up ranged from 3-24 months, median of 7 months. Thirteen of the 
16 pts (81%) have been free of VT; 3 pts having VT at 1, 3, and 7 months 
respectively. Only 1 pt has had frequent VT episodes. 
Conclusions: RF linear endocardial esions extending from dense scar to 
normal myocardium or to anatomic boundary appears to be effective therapy 
for control of frequent, drug refractory, unmappable VT. 
3:00 p.m. 
I 8~ Electroanatomic Mapping of Chronic Porcine 
Anterior Infarction; Correlation With Pathology and 
Intracardiac Echo 
David J. Callans, Jian-Fang Ren, John Michele, Farooq Chaudhry, Francis 
E. Marchlinski, Stephen M. Dillon. Allegheny University of the Health 
Sciences, Philadelphia, PA, USA 
Background: Improved imaging techniques may facilitate catheter ablation 
of ventricular tachycardia (VT) in man. 
Methods: Anterior infarction was produced by LAD embolization in 7 
60-80 lb. male swine. After infarct healing (6-8 weeks), detailed elec- 
troanatomic LV voltage mapping (66-149 points, 4 mm electrode tip, 10-400 
Hz) was done using CARTe (C). Catheter positions were verified with 9 MHz 
LV intracardiac echo (ICE). Endocardial infarct size (calculated as an ellipse) 
was measured by pathology (TTC staining), ICE (akinesis), and C voltage 
mapping. 
Results: Infarct size by path correlated with the area defined by _<1 mV 
bipolar electrograms (EgM) by voltage mapping (Table, r = 0.98, p = 0.0001 ). 
The area of akinesis by ICE correlated with the area defined by <2 mV EgMs 
by C voltage mapping (r = 0.95, p = 0.0016). 
Table. Endocardial infarct size, cm2 
exp path CARTe 1 mV ICE CARTe 2 mV 
1 6.99 7.42 15.10 15.61 
2 3.53 2.35 9.66 9.23 
3 0.08 0.06 0.27 0.43 
4 1.98 1.77 4.49 7.21 
5 1.10 1.13 5.24 5.23 
6 3.14 2.96 8.27 8.25 
7 1.57 1.57 16.12 12.02 
Conclusions: In this model of healed anterior infarction, C voltage imap- 
ping correlated well with ICE and pathologic analysis. C voltage mapping 
may be useful in designing anatomically based VT ablation procedures. 
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~6-~ Comparison of Activation Patterns During Sinus 
Rhythm and Ventricular Tachycardia in 
Postinfarction Patients Using a Non-Contact 
Mapping System 
Frank Bogun, Birgit Bender, Yi-Gang Li, Gerian Gr~nefeld, Graydon Beatty, 
Stefan H. Hohnloser. JW Goethe University, Division of Cardiology, 
Frankfurt, Germany 
Background: Fixed anatomic barriers in postinfarction patients with ventric- 
ular tachycardia (VT) might result in activation patterns which are similar in 
sinus rhythm (SR) and Vll Conventional single catheter mapping techniques 
appear inadequate in assessing precise sequential activation patterns. 
Methods: Using a high resolution non-contact mapping system we sought 
to assess the relationship of activation patterns during VT and during SR. The 
system consists of a 64 wire braid around a 7.5 ml balloon on a 9F catheter 
allowing the reconstruction of 3300 endocardial electrograms superimposed 
on a 3-dimentional computer model creating isopotential maps. 
Results: 4 hemodynamically tolerated VTs (VT cycle length: 431 ± 80 
msec) were mapped in 3 patients (3 men, age 63 5:11 yrs, EF 0.25 ± 0.05). 
Sites with concealed entrainment and isolated diastolic potentials (IDP) were 
identified. The course of activation from the diastolic potentials to the exit 
site of the VT was completely reconstructed in 3/4 VTs using the noncontact 
mapping system. The non-contact mapping system revealed delayed focal 
activation of the exit site in SR occurring 67 ± 30 msec after the onset of the 
QRS complex. From the exit site, the subsequent activation in SR involved 
part of the circuit used by the VT in all 4 VTs. All VTs were successfully 
ablated by a singular lesion delivered at the site with the IDP. 
Conclusion: Sites displaying IDPs during VT in postinfarct patients ap- 
pear to share at least in part a similar activation pattern during sinus rhythm 
and during VT. Fixed anatomical barriers appear to be responsible for this 
finding. These areas which are critical for VT can be localized using a non- 
contact mapping system during SR and during VT. 
POSTER 
Atrial Catheter Mapping 
Monday,  March  8, 1999,  3 :00  p .m. -5 :00  p.m. 
Moda l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour :  4 :00  p .m. -5 :00  p.m. 
1114-146 1 Accurracy of Geometric Using 
I 
Localization 
Non-Contact Multielectrode Mapping Array in the 
Right Atrium 
Alan Kadish, John Hauck, Brian Pederson, Graydon Beatty, 
Chades Gornick. Division of Cardiology, Northwestern Universi~ 250 E. 
Superior, Wesley Pavillion, Suite 520, Chicago, IL 60611, USA 
A novel non-contact mapping system using a muir±electrode balloon array 
(MEA, Endocardial Solutions, Minneapolis, MN) has been shown to be useful 
in mapping endocardial activation. An integral part of the system is the local- 
ization of a roving mapping or ablation catheter using a 5 kHz Iocator signal 
emitted through the tip of the roving catheter sensed by two ring electrodes 
on the MEA.. In three normal mongrel dogs the MEA was positioned in the 
mid right atrial cavity. A multielectrode catheter was positioned at ten sites 
at various distances and orientations to the MEA to determine the ability of 
the non-contact mapping system to correctly predict inter-electrode distance 
(lED) between two different electrodes. Individual IED's as well as a global 
inter-electrode distance from pole 1 through pole 8 were determined at each 
of the 10 locations in each of the three animals. Actual IED's results were 
determined on the catheter by optical micrometer and the accuracy of the 
locater signal was determined by subtracting the measured from actual in- 
ter-electrode distance. When two adjacent electrodes were evaluated, the 
mean difference between a visually measured and computer inter-electrode 
distance was 0.09 5:1.3 mm. The mean absolute value of the difference was 
0.96 5:0.77 mm. The actual catheter distance from pole 1 to 8 was 38.4 ram. 
The Iocator signal computed some of segment lengths for the entire catheter 
was 38.4 ± 4.0 mm. The distance from the balloon center of the roving 
catheter and the vertical distance from the balloon equator did not affect the 
accuracy of distance measurements. In addition, the mean absolute errors 
were similar in sinus rhythm and atrial fibrillation. 
Conclusions: The Iocator system feature of this non-contact mapping 
system provides a location estimate that is accurate within 1.0 mm over 
small distances and within 10% over large distances. Thus, the system 
should have good ability to localize roving catheters and to create three 
dimensional endocardial models using a contoured geometry approach. 
1114-147 j Characterization of the Configuration and 
Dimensions of the HIS Bundle Region Using the 
CARTO System: Defining the HIS Cloud 
Hemal M. Nayak, Joseph C. Pennington, David J. Callans, Chades 
D. Gottlieb, Mary Sokoloski, Francis E. Marchlinski. Allegheny University 
Hospitals, Philadelphia, PA, USA 
Background: The CARTO magnetic mapping system (Biosense, Inc.) can 
accurately establish electroanatomic relationships. To date, the dimensions 
and configuration of the HIS bundle region have been poorly characterized. 
We used the CARTO system to define the maximum dimensions of a region 
from which HIS bundle potentials could be recorded and termed this region 
the HIS Cloud. 
Methods: HIS Clouds were obtained in 15 pts undergoing ablation for 
SVT (10 female; age 53 ± 20 yrs; 12 with normal and 3 with reduced LV 
function by echocardiography). The baseline rhythm was sinus in 14 and 
atrial fibrillation in 1 pt. Electrograms were filtered at 30-500 Hz. Sites with 
a distinct HIS bundle potential were labeled as HIS points. An average of 
19 HIS points per pt were obtained. An average of 15 non-HIS points per 
pt were obtained to circumscdbe the HIS points and delineate the maximal 
extent of the HIS Cloud. 
Results: The HIS bundle region or HIS Cloud best fit the shape of 
an elliptical structure. The HIS Cloud area was then calculated using the 
formula rrab where a = ½ apico-posterior (AP) and b = ~- supero-inferior (SI) 
dimensions of the HIS Cloud. 
AREA (mm 2) AP (mm) SI (mm) 
MEAN ± SD 345.1 • 130.3 23.8±6.1 18.2+4.4 
RANGE 147.2-621.8 15 .5 -32 .2  12.0-24.6 
There was no correlation between the size of the HIS Cloud and age, sex 
and LV function. 
Conclusion; The shape and dimensions of the HIS bundle region can 
be defined by etectroanatomic magnetic mapping. Accurately identifying the 
dimensions of the HIS bundle region may have important implications for 
devising linear ablation strategies for the treatment of atrial fibrillation. 
/ 1114-148/ Three-Dimensional Non-Fluoroscopic 
L J Electroanatomical Mapping of the Right Atrium 
During Coronary Sinus Pacing: Comparison of 
Patients with and Without Atrial Flutter 
Andrea Natale, Mark Richey, Gery F. Tomassoni, Salwa Beheiry, 
Kathleen Rajkovich, Brandon Wides, Debra Nickel, Fabio M. Leonelli. 
University of Kentucky, Lexington KY, USA 
Three-dimensional non-fluoroscopic electroanatomical mapping of the right 
atrium during coronary sinus pacing at 500 msec was compared between 
patients with history of atdal flutter and a control group undergoing ablation. 
32 patients with atrial flutter and 12 control entered the study. In each patient, 
before radio-frequency catheter ablation was performed, complete recon- 
struction of the electroanatomical right atrial activation was obtained during 
coronary sinus pacing at a rate of 500 msec. In the two groups, anatomical 
differences, local and global activation times were compared. In addition, in 
each patient the crista term±nails was identified during pacing by the presence 
of split potentials, In the two groups complete conduction block across the 
crista term±nails during coronary sinus pacing was also compared. Patients 
with atrial flutter had a longer total right atrial activation time (120 ± 21 msec 
vs. 96 ± 11 msec). This was associated with larger dimension of the isthmus 
and of the global right atrial volume (normal isthmus 1.5 + 0.6 cm vs. atrial 
flutter isthmus 2.4 J_ 0.7 cm) (normal volume 57.7 ± 20 cc vs. atrial flutter 
volume 103 ± 21 cc). The number of patients showing a complete block 
across the crista during CS pacing was similar in both groups. However, the 
interval between each component of the split potentials recorded at the site 
of the crista term±nails was longer in the atrial flutter patients (normal 20.5 ± 
11 msec vs. atrial flutter 33.7 ± 14 msec). In conclusion, patients with atrial 
flutter exhibit electroanatomical differences as compared to control subjects, 
which may be responsible for this arrhythmia. 
1114-149 t The Clinical Usefulness of Multielectrode Basket 
J Catheter in Mapping and Ablation of Type I Atrial 
Flutter 
Bernhard Zrenner, Gjin Ndrepepa, Michael Schneider, Martin Karch, 
Isabel Deisenhofer, Claus Schmitt. Deutsches Herzzentrum & 1. Med. 
K/inik, TUM, Munich, Germany 
Background: The construction of three-dimensional activation maps and 
evaluation of ablation-created bidirectional block in inferior vena cava-tricus- 
pidal annulus isthmus (IVC-TAI) in patients (pts) with atrial flutter (AFI) are 
difficult with conventional mapping techniques. 
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Methods: In 28 pts with type I AFI (mean age 61 ± 11.5 years) a 64-elec- 
trode basket catheter (BC) was deployed in the right atrium (RA). The IVC-TAI 
conduction, conduction velocity (CV) in different reentry circuit limbs, distri- 
bution of double potentials (DP) and fragmented activity (FA), location of 
reentry circuit, endocardial activation-surface ECG relations and pestabla- 
lion evaluation of bidirectional block were analyzed. 
Results: Stable bipolar electrograms were recorded in 49 ± 2 of electrode 
pairs. Conduction time in IVC-TAI, septal, roof and lateral reentry circuit limbs, 
accounted for 42 ± 9%, 22 ± 6%, 18 ± 6% and 17 ± 5% of the whole cycle 
length, p < 0.001. CV in IVC-TAI was significantly lower than in lateral or 
septal limbs of the circuit, in counterclockwise or clockwise episodes. DP 
and FA were recorded in 94% and 78% of patients; most frequently, DP and 
FA were recorded in posterior wall, followed by septal and lateral walls. The 
reentry circuit involved IVC-TAI, septal and lateral walls and a part of RA roof, 
anterior to superior vena cava. Activation patterns within the RA and coronary 
sinus correlated closely to surface ECG morphology. Radiofrequency ablation 
was successful in 24 out of 28 pts (86%). Bidirectional IVC°TAI block was 
demonstrated in 26 pts. 
Conclusions: The BC is a useful mapping tool that simplifies arrhythmia 
identification, location of reentry circuits, construction of three-dimensional 
maps and facilitates ablation procedures in patients with AFI. 
1114-150]  Identification of a Gap in Linear Radiofrequency 
Lesions in Humans Using a Noncontact Mapping 
Catheter 
Rajiva Goyal, Hakan Oral, Hung-Fat Tse, Michael Kim, Frank Pelosi, 
Matthew Flemming, Gregory Michaud, Bradley P. Knight, S. 
Adam Strickberger, Fred Morady. University of Michigan Medica/ Center, 
Ann Arbor, M148109, USA 
Background: Ablation of typical atrial flutter (AFL) can be achieved by 
creating a line of block at the isthmus. Complete conduction block is usually 
not achieved after the first attempt. 
Methods: Using a novel noncontact balloon catheter (ESI, Minneapolis, 
MN), high-density endocardial mapping of AFL was performed. The catheter 
consists of 64 wire electrodes. Electrograms from these are used to recon- 
struct electrograms at more than 3300 virtual sites which are superimposed 
on a model of the atrium. Isopotential mapping of the isthmus region was 
performed in 4 pts (age 53 • 11 yrs) undergoing ablation of typical AFL. 
Results: Virtual electrograms in the isthmus region were evaluated before 
and after a linear lesions which did not result in complete block. The site of 
conduction through the linear lesion was identified in all pts using isopotential 
mapping. The mapping catheter with a locater signal at the tip was guided to 
this site and ablation resulted in termination of AFL. Compared to baseline 
the isthmus conduction velocity decreased following the linear lesion (0.72 
0.14 vs. 0.97 + 0.21 m/s, p < 0.05). After ablation, split potentials were 
noted around the linear lesion. However at the site of the gap, identified by 
isopotential mapping, a single electrogram was present in 3 of 4 pts. 
Conclusion: Isopotential mapping with the noncontact mapping system 
described in this study is able to identify and guide ablation to the site of 
residual conduction following an incomplete linear lesion. Virtual electro- 
grams confirm the results of isopotential mapping. 
/ 1114-1 51 Discordant Recovery of Electrophysiologic 
L J Parameters After Conversion of Lone Atrial 
Fibrillation in Humans 
Toshiaki Sate, Hideo Mitamura, Akiko Takeshita, Kaori Shinagawa, 
Byunichiro Miyoshi, Hideaki Kanki, Motoki Hara, Seiji Takatsuki, 
Kyoko Sejima, Satoshi Ogawa. Keio University, Tokyo, Japan 
Background: Even after a successful card±overs±on, recurrence of atrial fib- 
rillation (AF) is not uncommon and often takes place early after conversion. 
This is at least partly explained by delayed recovery of electrical remodeling 
caused by persistent AF. However, there have been no clinical investiga- 
tions how electrically remodeled atria recover after conversion of lone AF of 
relatively long duration in humans. 
Methods: Seven patients (mean age 45) with no structural heart disease 
and persistent AF (median 4months) were subjected to undergo transthoracic 
electrical cardioversion (EC). After resumption of sinus rhythm, ERP was 
determined at basic cycle lengths (CLs) of 600 ms and 400 ms at the right 
atrial appendage (RAA). Stimulus-P interval and P-wave duration were also 
measured from the surface ECG. These electrophysiologic parameters were 
obtained at 30 min and 24 hrs after EC, which were compared to values 
obtained from 11 age-matched control pts with no history of AF (AVNRT7, 
idiopathicVT3, syncope 1) 
Results: As shown in Table, compared to control pts, AF pts had sig- 
nificantly shorter ERP at CL 600 ms at 30 min after EC with loss of rate 
adaptation, which recovered to the control range in 24 hrs. 
In contrast, conduction slowing persisted even at 24 hrs after EC. 
Control PostAF 30 min PostAF 24 hrs 
ERP (me) CL 600 ms 257 221 # 263 
CL 400 ms 231 219 238 
Stimulus-P interval (ms) 21 29 # 28 # 
P-wave duration (ms) 92 126 # 116 # 
#p < 0.05 vs. control 
Conclusion: After conversion of persistent AF, ERPs prolong and gain 
rate adaptation relatively rapidly, reaching the control level within 24 hrs. 
However intraatrial conduction delay sustains for more than 24 hrs, indi- 
cating a discordant recovery process of refractoriness and conduction after 
AF-indueed electrical remodeling. 
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1 ] Long Term Results of Permanent Biventricular 1 1 5-1 52 
Pacing in Refractory Heart Failure: Comparison 
of Patients with Stable Sinus Rhythm and 
Chronic Atrial Fibrillation 
Christophe Leclercq, Christine Alonso, Daniel Gras, Frederic Victor, 
Herv~ le Breton, Dominique Pavin, Philippe Mabo, J. Claude Daubert. 
University Hospital, Rennes, France 
Background: Results of previous studies suggest that permanent biventric- 
ular pacing (BVP) may improve symptoms and exercise tolerance in patients 
with refractory heart failure (RHF), chronic LV systolic dysfunction and broad 
QRS complex The aim of this study was to compare the long term effects of 
transvenous BVP in patients with stable sinus rhythm (SSR) and in patients 
with chronic atrial fibrillation (AF). 
Methods: patients with SSR at baseline (n = 23) received a DDD-biven- 
tricular pacemaker. Patients with AF (n = 7) were implanted with a biventric- 
ular-VVIR device. 5 SSR patients went to chronic AF during the first 4 weeks 
following the implantation and were reprogrammed in the VVIR mode. So 
the comparison was done between 18 SSR patients and 12 AF patients. At 
baseline there were no significant differences between the two groups for 
age (66.5 • 7.9 vs 68.4 ± 6.4 years), etiology (ischemic/idiopathic: 7/11 vs 
3/9), LVEF (21 ± 5 vs 22 ± 4%), symptoms (NYHA class Ill/IV: 12/6 vs 7/5) 
and QRS duration (178 & 24 vs 181 ~- 23 ms). 
Results: 
SSR (n = 18) AF(n = 12) P 
Follow-up time (months) 10.5 ± 7.4 13.8 ± 8 NS 
Death (n/%) 4 (22%) 4 (33%) NS 
NYHA class at baseline 3.3 ± 0.5 3.4 ± 0.5 NS 
1 month 2.1 ± 0.6 2.2 ± 0.7 NS 
End EU. 2.4 ± 0.8 2.4 ± 0.9 NS 
A peak VO2 (%) 32 ± 35 55 ± 25 0.06 
Conclusion: BVP provides significant and sustained improvement in 
symptoms and exercise tolerance in both SSR and AF patients. Improvement 
in exercise tolerance tended to be greater in AF patients. 
[1115-153j  Clinical Evaluation of Transvenous Prospective 
J Biventricular DDD Pacing in Refractory Heart 
Failure: Preliminary Results of the In-Sync 
Multicentre Study 
Christophe Leclercq 1 , Daniel Gras, Roger Chatoor, Henk Oude Luttikhuis, 
Karl-Heinz Tschetiessnig, Anders Kirsten Pedersen, Tony Tang, 
Jean-Claude Deharo, Philippe Mabo. On behalf of the In-Sync Study Group; 
i University Hospital Rennes, France 
Background: Biventricular resynchronization was recently introduced as 
additional treatment o drugs for refractory heart failure (RHF) in patients 
with chronic LV dysfunction and broad QRS complex. This study was aimed 
to assess prospectively the technical feasibility, the safety and the clinical 
effects of this new therapeutic approach. 
Methods: 71 patients, mean age 66, were included. 45 were in NYHA 
class III and 26 in class IV. All patients received diuretics and ACE inhibitors at 
the optimal tolerated dosage. Mean LVEF was 21 • 9% and the mean QRS 
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duration was 177 5:29 ms. The transvenous implantation procedure was 
successful in 82% of patients (n = 58) NYHA class, quality of life (Minnesota 
LHF questionnaire), exercise tolerance (6 min. walking distance) and LVEF 
(echo) were assessed at baseline before implantation (To) and 1, 3, 6 and 
12 months after. 
Results: Results at 3 months follow-up (M3) are shown here: 
To M3 P 
NYHA class (') 3.4 ± 0.5 2.1 ± 0.7 <0.001 
QOL score 55.2 ± 5.3 34 ± 10.4 = 0.004 
6 min. W.D. (m} 299 ± 16 418 ± 20 = 0.03 
LVEF (%) 20.9 ± 2.5 23.9 ± 5.6 NS 
(*) At 3 months follow-up no patient deteriorated, 15°./0 remained in stable condition, 55% 
improved by one class and 30% by two classes. 
Conclusion: Biventricular resynchronization (+DDD pacing) seems to 
be of clinical value in patients with RHF and intraventricular conduction 
block. This new therapeutic approach has now to be validated in randomized 
controlled studies. 
111 5-1541 Patients with Heart Failure and a Congestive 
i 
Permanent Pacemaker Have an Increased Risk of 
"Non-Sudden" Death 
Venkateshwar K. Gottipaty, Steven P. Krelis, Fei Lu, Elizabeth P. Spencer, 
Vladimir Shusterman, Raul Weiss, Susan Brode, Amie White, Kelley 
P. Anderson, B.G. White. For the VEST investigators; University of 
Pittsburgh, Pittsburgh PA, USA 
Background: We hypothesized that patients with dilated cardiomyopathy 
(DCM), congestive heart failure (CHF) and permanent pacemakers would 
have a poorer prognosis than those without pacemakers. 
Methods: Baseline 12-lead electrocardiograms (ECG) from patients en- 
rolled in the VEST trial were examined for the presence of a paced rhythm. 
Matched control patients were selected from the remaining pool of patients, 
Results: There were no significant differences in clinical variables (age, 
sex, ejection fraction, heart rate, croat±nine) between the two groups. Mortality 
due to sudden death was equal (14%, p > 0.8) in the two groups. Non-sudden 
mortality for patients with pacemakers (23%) exceeded that of the controls 
(14%, p = 0.01). The figure shows KM survival curves for all-cause mortality. 
!: 
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Conclusions: Patients with DCM and CHF who have permanent pace- 
makers have a greater mortality due to non-sudden causes than clinically 
similar patients without pacemakers. This may be because need for a pace- 
maker sub-selects a group of patients with worse underlying disease or 
pacing itself results in an increased mortality. 
1115-155 ] Deleterious Right Apical Effect of Ventricular 
Pacing on Regional Systolic and Diastolic Left 
Ventricular Function: A Study with Tissue 
Doppler Imaging 
Pui-Ching Ho, Cheuk-Man Yu, Hung-Fat Tse, Chu-Pak Lau. Division of 
Cardiology, Department of Medicine, Queen Mary Hospital, China 
Background: Right ventricular apical pacing (RVP) induces an abnormal 
cardiac activation sequence which may impair regional and global left ven- 
tricular (LV) function in long term. A new ultrasound technology, Tissue 
Doppler Imaging (TDI) allows high-amplitude, low-velocity signals of regional 
myocardial velocities to be quantified. 
Methods: 11 patients (M:F = 8:3, age = 67 5:13 yrs) with sinus node 
disease were paced randomly in either AAI or DDD (atrioventricular delay = 
100 ms) at 10 beats higher than the lower rate. Cardiac Output was measured 
by pulse Doppler at the aortic outflow tract. Mid and basal septal and lateral 
ventricular wall motions were studied at the four chamber view by TDI. 
Results: a) Activation Sequence: During AAI pacing, LV activation starts 
from mid cavity (67% at mid lateral and 44% at mid septum), with the basal 
septum activated last, but is reversed in DDD pacing, at which 63% starts at 
basal septum, 50% lastly at mid lateral and basal lateral regions, b): Regional 
systolic/diastolic peaks: Peak E and peak A are higher at AAI pacing, indicat- 
ing impaired diastolic function during ventricular pacing, c) Cardiac Output: 
AAI pacing contributes to better cardiac output than DDD pacing. 
Systolic Peak Peak E Peak A Cardiac Output 
At AAI 4.21 cm/s 4.70 cm/s 4.21 crn/s 3.23 L/min 
At DDD 4.02 cm/s 4.11 crn/s 3.83 crrVs 2.59 L]min 
p-value 0.34 0.0t 0.02 0.03 
Conclusion: RVP reverses the normal in LV contraction pattern, which 
is associated with abnormal regional left ventricular relaxation with a conse- 
quent reduction in cardiac output. 
1115-156 / Outcome in Intention to Treat a 
] 
with Biventricular 
J Pacing for Severe Heart Failure. Comparison 
Monoventricular/Biventricular Pacing 
Didier Klug, Moustapha Jarwe, Dominique Lacroix, Pierre Le Franc, 
Philippe Delfaut, Salem Kacet. University of Lille, Lille, France 
Background: biventricular pacing (BIV) is a new pacing mode proposed in 
congestive heart failure and left bundle branch block (LBBB). 
Methods: We implanted chronic pacemaker (PM) with BiV in 16 patients 
(pts) (65 + 9 y.o) in NYHA class Ill-IV and LBBB. In 9 pts BiV was not possible 
at discharge (2 failures of the coronary sinus lead implantation, 7 loss of 
anodic LV stimulation) and PM were programmed to right monoventricular 
pacing (MonoV). In 7 pts, BiV could be maintained at discharge and during 
the follow-up. To evaluate the advantage of BiV, we compared the outcome 
of the pts according to the final pacing mode at discharge (MonoV or BiV). 
Results: the mean ejection fraction (EF) was 24 5: 5%. All pts described 
an initial improvement of the NYHA status. PM implantation induced a sig- 
nificant improvement of the 6mn walk test but without significant difference 
between the two groups (Table 1). 
Table 1 
6 mn walk Before implant At discharge p 
MonoV (n = 9) 84 ± 108 meters 188 ± 163 meters 0.04 
BiV (n = 7) 138 ± 131 meters 233 ± 141 meters 0.007 
p NS NS 
The outcome at a follow-up of 8 ± 4 months is summarized in table 2. 
Tab le  2 
NYHA II III Unstable tV Heart transplant Death 
MonoV (n = 9) 3 1 2 1 2 
BiV (n = 7) 3 2 0 2 0 
Conclusion: / )The significant improvement obtained with the 6 mn walk 
test confirmed the subjective functional improvement described by pts after 
PM implant. 2) We did not observe clear benefit of BiV over MonoV at 
discharge and dudng follow-up. 
I l l l  5-157 1 Biventricular is Also of Benefit in Less Pacing 
Severe Heart Failure 
Roger Chatoor, Elaine McGing, Alethea Cooper, Graham Jackson, 
Cliff Bucknall, Phyllis Holt. The Cardiothoracic Centre, SL Thomas' Hospital 
London, UK 
Biventricular pacing has been proposed for the treatment of heart failure and 
is primarily used in advanced heart failure. We prospectively assessed this 
form of therapy in varying degrees of heart failure, including Class II patients. 
Methods: Inclusion criteria were stable heart failure, continuing symp- 
toms, an EF < 35% and a QRS duration >140 ms. Patients received a 
Medtronic Biventdcular pacing system. They acted as their own controls and 
all tests were carried out at baseline, 1 month post-implant and at 3 months, 
including echocardiographic assessment, cardiopulmonary exercise testing, 
a six minute walk, and the Minnesota questionnaire. 
Parameter Baseline Month t P val Month 3 P val 
Fractional Shortening 10 i 2.6 13 ± 3.8 0.004 15 + 1.8 0.04 
LVIDs (cm) 6.7 ± 0.8 6.3 ± 0.9 0.02 6 ± 0.9 0.003 
Stroke Distance 13 ± 2.4 15 ± 2.2 0.04 15.9 ± 1.7 0.07 
Filling "Hme (ms) 399 ± 101 475 ± 130 0.03 500 ± 192 ns 
VO2 max (ml/m/kg) 16 ± 5.6 19 ± 7.9 0.04 15 ± 4.7 0.06 
Exercise 33me (min) 6.5 ± 2.5 7.8 + 2.5 0.02 7.4 ± 2.6 ns 
6 minute walk (m) 248 ± 107 295 ± 95 0.003 257 ± 110 0.02 
QOL Score 66 ± 16 45 ± 15 0.004 51 ± 14 0.01 
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Results: t2 patients were recruited and followed for 3 months. Mean age 
was 64 ± 10 years, 11 were male. Five were in NYHA Class II and 7 in 
Class Ill/IV. Mean QRS duration was 154 -- 17 ms and mean interventdcular 
conduction time (IVCT) measured at implant was 110 ± 32 ms. 
All parameters improved at 1 month apart from AT which showed a 
positive trend. Improvement in filling time, stroke distance and exercise 
duration were no longer significant at 3 months. IVCT and %age increase in 
FS were correlated (r = 0.51, p = 0.04). 
Conclusion: Despite the inclusion of 5 Class II patients there was signif- 
icant improvement across the entire group suggesting benefit in less severe 
classes of heart failure. IVCT seems to predict improvement. 
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j 1116-1781 High Energy Synchronized External Direct 
Current Card/overs/on With 720 Joules for Atrial 
Fibrillation Refractory to Standard Card/overs/on 
Walid I. Saliba, Nour Juratli, Okan Erdogan, Ralph Augostini, Mina 
K. Chung, Bruce L Wilkoff, Mark J. Niebauer, Gregory A. Kidwell, Frederick 
J. Jaeger, Patrick J. Tchou. The Cleveland Clinic Foundation, Cleveland, 
OH, USA 
Background: Standard external electrical card/overs/on (CV) fails to restore 
sinus rhythm (SR) in 5-30% of patients (pts) with atrial fibrillation (AF). We 
previously reported a novel technique of CV using energies greater than 360 
joules (J) in pts refractory to standard energy CV. This study describes the 
outcome of pts undergoing CV with 720 J over a two year period. 
Methods: 31 pts underwent 44 CVs with 720 J using simultaneous syn- 
chronized shocks from two defibrillator units over 4 patch electrodes. These 
pts had failed an average of 2.1 ± 0.9 shocks at 360 J. There were 25 men 
(81%). The mean age was 60 ± 12 years with a mean weight of 119 4z 24 
kg (body mass index 48.7 ± 4.5 Kg/m2). 66% had evidence of structural 
heart disease. The mean LVEF was 47 ± 11%. Pts were on antiarrhythmic 
medications during 34 (87%) of the 39 attempts. (sotalol 21%, amiodarone 
47%). AF was present for more than 3 months in 59%. 
Results: SR was achieved in 34 out of the 39 attempts (87%). 4 pts 
received more than one shock at 720 J at the same setting. No patient de- 
veloped hemodynamic ompromise or congestive heart failure. One patient 
developed transient bradycardia without AV block. There were no docu- 
mented cerebrovascular accidents within one month post CV. Skin injury 
was limited to the minor skin irritation around patches which is observed 
dudng standard energy CV. Of the 34 successful attempts, 11 pts (33%) 
remained in sinus rhythm over a mean follow-up of 2.3 months. 
Conclusion: 1) External high energy CV is effective in restoring SR in 
pts with AF refractory to standard energy CV. 2) This method is safe and 
does not result in clinical evidence of myocardial impairment. It may be 
used as an alternative to internal CV since it can be done within the same 
setting of the failed standard CV, and obviates the need to withhold protective 
ant/coagulation for internal CV. 
L l l l  6-1 791 Increased at Phase Reversal Voltage Change 
Does Not Lower Defibrillation Threshold for a 95 
t~F Capacitor B/phasic Waveform 
Teresa A. Whitman, David E. Euler, Michael J. Kallek. Angeion Corporation, 
Minneapolis, MN, USA 
Background: Previous studies have shown that truncated exponential b/pha- 
sic waveforms with a high voltage change at phase reversal lower defibril- 
lation thresholds (DFT); however, these results are confounded since the 
duration of phase 1 and/or phase 2 was also changed. The objective of this 
study was to determine if increasing the voltage change at phase reversal 
while holding duration constant would lower the DFT using a b/phasic 95 [LF 
waveform (Control- Phase 1 - 44% tilt plus 1.6 ms extension, Phase 2 - 2.5 
ms). 
Methods: Delivered energy DFTs (4-reversal up/down method) for each 
waveform were measured in pigs (n = 10) using a unipelar lead system (RV 
as anode during Phase 1). A voltage spike was superimposed on the Control 
waveform either at the end of phase 1 (PosVS), the beginning of phase 2 
(NegVS), or both (BiphVS). The voltage spike was a 1 ms discharge from a 
20 p_F capacitor charged to the leading edge voltage of phase 1. 
Results: The addition of a voltage spike added approximately 12% to the 
delivered energy of the control waveform for the same leading edge voltage. 
The DFT (mean ± SD) was higher for PosVS (12.0 ± 4.1 J) compared to the 
Control (11.2 4- 4.3 J, p < 0.05), BiphVS (10.6 ± 4.4 J, p < 0.01 ), or NegVS 
(10.5 9c 4.2 J, p < 0.01); no difference was found between the Control and 
NegVS or BiphVS. 
Conclusion: The addition of a positive voltage spike at the end of the first 
phase increased the delivered energy DFT for a standard 95/~F capacitor 
b/phasic waveform. Increasing the negative voltage change at phase reversal 
while holding duration constant did not significantly lower the DFT. 
I l l l  6-1 80  j Approximate Entropy as an Index for Ventricular 
l 
Fibrillation Stratification. Implications for 
Mechanism 
All Hamzei, Toshihiko Ohara, Moon-Hyoung Lee, Olga Voroshilovsky, 
Peng-Sheng Chen, Hrayr S. Karagueuzian. Cedars-Sinai Medical Center, 
UCLA School of Medicine, Los Angeles, CA, USA 
We previously have shown that reduction of the swine RV mass to near its 
critical mass for ventricular fibrillation (VF) decreases the number of activa- 
tion wave fronts (WFs). We hypothesized that approximate entropy (ApEn), 
a regularity measure suitable for biological time series, can differentiate VFs 
with different number of WFs. Higher ApEn values indicate higher VF com- 
plexity or lower regularity. The isolated RV of five farm pigs were perfused via 
the RCA and the endocardium was optically mapped using voltage-sensitive 
dye (di-4ANNEPS at 5 uM concentration) in two pigs. ApEn was calculated 
from 2 pairs of bipolar electrodes one with t mm (BEg) and the 2nd with 4 cm 
("ECG") interpolar distances. VF was induced by rapid pacing. At baseline, 
the mean RV mass was 37.4 4- 3.1 g, the ApEn of the BEg was 0.68 ± 0.09 
and the number of WFs 5.2 4: 0.44. When the RV mass was reduced to near 
its critical mass for VF, i.e., 32.6 ± 2.9 g (P < 0.03), the ApEn was reduced 
to 0.12 ± 0.1 (P < 0.001) and the number of WFs down to 2.44 ± 0.52 (P < 
0.001), consistent with our previous electrical mapping data. No significant 
changes occurred in the ApEn of the simultaneously recorded ECG (0.36 ± 
0.11 vs 0.23 ± 0.02, P = 0.1). We conclude that when VF is sustained by 2 to 
3 WFs rather than 5 to 6 WFs, the ApEn significantly decreases on the local 
BEg but not on the ECG. The ability to stratify the complexity of VF by ApEn 
computed on a local BEg may be useful in refining detection and therapy 
algorithms for ICDs. 
l l  16-1 J Influence of the Mode of Induction on the 
I 
1 81 
Characteristics of Ventricular Fibrillation 
Taresh Taneja, Jeffrey Goldberger, George Horvath, Nikki Robinson, 
David Johnson, Alan Kadish. Northwestern Universi~ Chicago, IL, USA 
Background: Little information is available on the relationship between the 
mode of induction of ventricular fibrillation (VF) to the VF characteristics. 
Methods: VF was induced in random order by AC current (M1), burst 
pacing at cycle length (CL) of 50 ms (M2), high current $2 at a site remote 
from $1 (M3), programmed electrical stimulation (M4), T wave shock (M5) 
and intersecting wavefronts (M6) in 7 normal dogs and 8 dogs with chronic 
(8 week) myocardial infarction (MI). Using plaque electrode arrays with a 
2.5 mm inter-electrode distance, 112 electrograms were recorded from the 
anterior (infarcted) or lateral (noninfarcted) wall. In most cases a period of 
polymorphic ventricular tachycardia (PMVT) was followed by VE 
Results: There were 4 episodes of PMVT, 62 episodes of PMVT followed 
by VF and 19 episodes of VF. The mean CL was significantly longer in the 
presence of chronic MI (140 ± 15 ms) than in control animals (126 ± 15 ms) 
and during PMVT (138 ± 18 ms) as opposed to VF (129 ± 14 ms). There 
was no significant difference in the CL of VF between anterior and lateral 
walls. Pooled mean ± S.D. CL of PMVT and VF, transition times (ms) from 
PMVT to VF and the number of episodes of VF with no preceding PMVT are 
shown. MI presence did not affect the intermode differences. 
M1 (n = 15) M2 (n = 15) M3 (n = 13) M4 (n = 15) M5 (n = 14) M6 (n = 13) 
PMVT 1395-17 139±17 134±14 1399_18 146i 16" 132 :~ 20 
VF 134 i 15 129-}-14 129± 14 123±11 136±13" 126±14 
Duration 760 ± 378 926 ± 517 644 ± 208 829 :t_ 478 925 ± 260 626 ± 307 
# with No 7 3 3 2 3 1 
PMVT 
• -P < 0.05 vs other modes of induction 
Conclusions: PMV-[ and VF induced by T wave shock has a longer CL 
than VF induced by other methods. These findings suggest that "VF" is not a 
uniform entity and have implications for understanding the pathophysiology 
of induced versus spontaneous VF and for defibrillation threshold testing. 
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111 6-1 82[ Potential Hazards of New Programming a 
J Dual-Chamber Detection Algorithm: Implications 
for Patient Selection and Programming 
Christian Wolpert, Wemer Jung, Susanne Spehl, Burghard Schumacher, 
Bahman Esmailzadeh 1 , Chriatian Schneider 1 , Berndt L0dedtz. Depts. of 
Cardiology; T Cardiovascular Surge~ University of Bonn, Bonn, Germany 
Dual-chamber implantable cardioverter-defibrillators incorporate the atrial 
sensing information into the detection algorithm. This suggests an increase 
in specificity. However, to date, there is no data available, if and to what 
extent ventriculo-atrial sensing adds new possibilities of arrhythmia misin- 
terpretation. New PR-recognition based algorithms dividing the RR-intervals 
into zones of antegrade and retrograde conduction may harbour the risk of 
misclassification in the clinical setting of atrial tachycardias with long PR of 
ventricular tachycardias with long RP intervals. The purpose of this prospec- 
tive study was to assess the incidence of inappropriate device detection in 
order to guide patient selection and device programming. 
Patients and Methods: A total of 34 patients (pts) with a Medtronic 
Jewel AF 7250 were included in the study. A total of 399 supraventricular 
(SVT) (225) and ventricular (174) tachyarrhythmias (VT) were included into 
the analysis. Arrhythmia classification was based on atrioventricular stored 
electrograms. 
Results: A total of 12/399 (3%) episodes (E) were incorrectly classified 
by the device due to failure of the PR-pattern recognition detection algorithm. 
11 sinus tachycardias (ST) with a long PR-interval were misclassified in 2 
pts as VT due to the allocation of the atrial signal to the zone of retrograde 
conduction. One of the two pts had an AV-block I S. The other pt had normal 
AV-conduction at rest and experienced several shocks during a ST with a 
PR/RR cycle length ratio <50% i.e. the limit for antegrade conduction zone 
in the device algorithm. One of six pts with documented R wave oversensing 
received an atrial shock therapy due to imitation of atrial flutter caused by 
double sensing of the R wave in the atrial channel. 
Conclusions: 1. The incidence of clinical failure of the new PR-pattern 
recognition algorithm in 1:1 tachycardia is low with 3%. However, pts with 
AV-block 19 or long PR during sinus tachycardia and overlap of sinus rate 
and VT rate may receive inappropriate therapies. Thus, AV-nodal conduction 
should be assessed by exercise test also in pts without AV-block I ~. 2. 
Although R wave oversensing occurs in 17% of the pts, the algorithm failed 
only in one episode in one pt. Atrial sensitivity should be adjusted in those 
pts. 
I l l l  6-1831 Recurrence of VF Following Out-of-Hospital Low-Energy Biphasic and High-Energy 
Monophasic Defibrillation Shocks 
Bradford E. Gliner, Roger D. White. Hewlett-Packard Heartstream, Seattle, 
WA; Mayo Clinic, Rochester, MN, USA 
Background: Low-energy impedance-compensating biphasic waveform shocks 
defibrillate at higher rates than higher-energy monophasic waveform shocks. 
This study compared the rate at which VF recurs following out-of-hospital 
defibrillation of sudden cardiac arrest patients as a function of waveform use. 
Methods: Automatic external defibrillators (AEDs) with 200-360 J monopha- 
sic damped sine (MDS) (First Medic 510 and 710 AEDs, Physio-Control, 
Redmond, WA) and 150 J impedance-compensating biphasic (ICB) (Fore- 
Runner AED, HP Heartstream, Seattle, WA) waveforms were employed in a 
combined police/paramedic program in Rochester, MN. ECGs from 87 MDS 
and 21 ICB patients were analyzed at post-shock times of 3, 5, 10, 20, and 
60 seconds. Logarithmic curves were then fit to the percentage of patients 
in VF versus the time following MDS and ICB shocks. The derivative with 
respect to time of these curves gave the rate of VF recurrence. 
Results: 
MDS ICB 
% of Patients in VF at time t (sec) 34% log(t) + 20%, 31% log(t) 5%, 
R 2 = 0.94 R 2 = 0.99 
Rate of VF recurrence at time t, %VF/sec (15%/t) (14%/t) 
Conclusion: At all post-shock times, low-energy ICB shocks defibrillated 
at higher rates than high-energy MDS shocks. Moreover, regardless of shock 
success rate, the rate of recurrence of VF was the same following low-energy 
ICB or high-energy MDS waveform defibrillation. 
ORAL 
Atrial Fibrillation: Mechanisms and Predictors 
Monday, March 8, 1999, 4:00 p.m.-5:30 p.m. 
Modal Convention Center, La Louisiane A 
4:00 p.m. 
l -~0-~ Predictors of Atrial Fibrillation in the 
Tachycardia-Bradycardia Syndrome: Results from 
the Pacing and Atrial Tachycardia Trial 
Anne B. Curtis, Arjun Sharma, Robert A, Sorrentino, Douglas Criger, W. 
Eugene Sanders, Jr., Kerry L, Lee, J. Marcus Wharton. The PAC-A-TACH 
Investigators. University of Florida, Gainesvi//e FL; Duke U. Medical Center, 
Durham, NC, USA 
Background: While some studies have suggested that atrial-based pacing 
decreases the incidence of atrial arrhythmias compared to Wl  pacing, there 
are limited prospective data available to confirm this impression, 
Methods: The Pacing and Atrial Tachycardia Trial (PAC-A-TACH) is a 
prospective, randomized multicenter trial of DDDR versus VVIR pacing; for 
the primary prevention of atrial fibrillation (AF) in the tachycardia-brady- 
cardia syndrome. Patients (pts) were enrolled at the time of pacemaker 
implantation for sinus bradycardia or asystole if they had a history of atrial 
tachyarrhythmias Pts were randomized to the DDDR or VVIR mode, with 
sub-randomization to sotalol (or quinidine if not tolerated) vs. no drug. Time 
to first recurrence of an atrial tachyarrhythmia nd number of recurrences 
were documented during 2 yr follow-up. Cox proportional hazards modeling 
was used to determine predictors of AF. Pro-specified variables included 
age, sex, ejection fraction, pacing mode, baseline type and duration of atrial 
tachyarrhythmia, antiarrhythmic drug status, mitral or tricuspid regurgitation, 
and VA Wenckebach point. 
Results: Univariate analysis showed that antiarrhythmic drug status (p 
= 0.0092), baseline atrial flutter (p = 0,0308), and mitral regurgitation (p = 
0.091) were possible predictors of AF. After adjustment, only antiarrhythmic 
drug status and baseline atrial flutter continued to be significant. Pts who 
were on sotalol had a risk ratio for AF that was 0.62 compared to pts on 
no drug. Pts with baseline atdal flutter had 1.47 times the risk for later AF. 
Pacing mode had no impact on the incidence of AF. 
Conclusion: Antiarrhythmic treatment significantly increased the time to 
first episode of AF in pts with techy-brady syndrome, Pts with atrial flutter 
appeared to have a higher risk for later AF than pts whose baseline atrial 
arrhythmia was AF or atrial tachycardia. 
4 :15 p.m. 
[ -820~ Is Atrium Essential Initiate and Sustain the Right to 
Idiopathic Atrial Fibrillation? 
Sabine Ernst, Feifan Ouyang, Riccardo Cappato, Karl H. Kuck. SL Georg 
Hospital, Hamburg, Germany 
Background: The role of the right (RA) and left atrium (LA) in the initiation 
and sustenance of idiopathic atrial fibrillation (AF) in pts without a focal origin 
is unknown. 
Methods: To evaluate the role of the RA in idiopathic AF, 32 of 45 
pts underwent primary RF catheter ablation in the RA. The following 3 linear 
lesions were created: a line severing the isthmus (isthmus line) between vena 
cava inferior (VCI) and tricuspid annulus (TA), an intercaval ine between VCI 
and vena cava superior (VCS), and an anterior line between TA and VCS. 
An intentional gap was left in the superior part of the intercaval ine. 
Results: During the procedure, after achieving complete lesions along 
the isthmus and anterior line, RF current application in the superior part of 
the intercaval ine lead to transient RA isolation in 1 pt. This was associated 
with the abrupt occurrence of sinus rhythm in the RA while the LA continued 
to fibrillate. During follow-up, 4 pts developed either transient (3-7 days) 
or permanent RA isolation. However, all 4 pts had spontaneous episodes 
of sustained AF. The surface ECG then showed the typical pattern of AF 
and simultaneous regular sinus p waves, indicative of LA fibrillation in the 
presence of sinus node activation of the RA. 
Conclusions: Continuous linear lesions in the RA formed by sequential 
RF current applications may lead over time to permanent RA isolation despite 
an intentional gap. In this RA segment, sustained AF no longer occurs. The 
LA mass is nonetheless sufficient enough to sustain AF. This demonstrates 
that the RA may not be essential for the initiation and maintenance of AF. 
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4:30 p.m. 
~20~3-] Observations on the Transition from Intermittent 
Occurrence to Permanence in Patients With Atrial 
Fibrillation 
Sana M. AI-Khatib, William E. Wilkinson, Linda L. Sanders, Elizabeth 
A. McCarthy, Edward L.C. Pritchett. Duke University Medical Center, 
Durham, NC, USA 
Background: The purpose of this study was to determine the proportion 
of patients with intermittently occurring atrial fibrillation at presentation that 
progress to become permanently in atrial fibrillation dudng follow*up, and to 
study the baseline clinical characteristics that predict such a progression. 
Methods: In this retrospective cohort study, we identified 231 patients 
who presented with intermittently occurring atrial fibrillation to a university 
hospital-based clinic from January of 1978 to December of 1997. Patients' 
medical records and electrocardiograms were reviewed and data were col- 
lected up to the date of the last clinic visit. 
Results: By the Kaplan-Meier method, the proportion of patients who 
remained free of transition from atrial fibrillation that occurred intermittently 
to atrial fibrillation that occurred permanently was 0.92 (95% C.I. 0.88-0.96), 
0.88 (95% C.I. 0.83-0.93), 0.83 (95% C.I. 0.77-0.89), and 0.82 (95% C.I. 
0.75-0.88) at one, two, three, and four years respectively. By the Cox pro- 
portional hazards model, among five baseline characteristics (age, gender, 
race, hypertension, and structural heart disease), the only significant predic- 
tor of progression of intermittently occurring to permanently occurring atrial 
fibrillation was age (p = 0.0005). The hazard ratio associated with 10 years 
of advancing age was 1.74 (95% C.I. 1.28-2.38). 
Conclusion: Approximately 18% of patients who presented with atrial fib- 
rillation that occurred intermittently were permanently in atrial fibrillation after 
4 years of follow-up. Age was more important han other clinical variables in 
predicting such a progression. This finding may affect the choice of treatment 
for elderly patients who present with intermittently occurring atrial fibrillation. 
4 :45 p.m. 
~-0~ Increased Body Mass Index and Obstructive Sleep 
Apnea Signs are Risk Factors for Atrial Fibrillation 
Dawn Atwal, John IE Genter, Stephen L. Kopecky, Susan Weston, Kent 
T. Bailey, Stephen C. Hammill. Mayo Clinic, Rochester, MN, USA 
Background: We hypothesized that nocturnal sympathetic surges in re- 
sponse to obstructive sleep apnea (SA) can induce atrial fibrillation (AF) in 
vulnerable (bradycardic-short refractory period) atrial myocardium. 
Methods: 103 patients with normal echocardiograms and a diagnosis of 
AF were matched by age, gender, and geography with 182 controls under- 
going negative General Medical Exams. Treated hypertension was allowed 
in patients. However, left ventricular hypertrophy and all other diseases were 
excluded. Questionnaires designed to elicit signs of SA were sent to patients, 
controls, and their respective sleeping partners, with blinded case-control sta- 
tus. Follow-up of indeterminate responses regarding sleeping pattern was 
made by a physician phone call. SA determination was based on algorithms 
for both sleeper and observer questionnaires. Simple and joint associations 
of SA, body mass index (BMI), and other variables with AF were based on 
conditional logistic regression for matched case-control data. 
Results: BMI, considered as a continuous variable, was strongly associ- 
ated with AF (p = 0.0001, OR 1.15 per unit increase in BMI, 95% CI 1.07 to 
1.23). SA based on sleeper responses was associated with AF (p = 0.055, 
OR 2.10, CI 0.98 to 4.50). When considered jointly, the association of AF 
with BMI remained strong (p = 0.0001, OR 1.15, CI 1.07 to 1.23), while the 
independent association with SA was reduced (p = 0.15, OR 1.83, CI 0.80 to 
4.17), due to the substantial positive association between SA and BMI (p = 
0.0033). 
Conclusions: Two previously undescribed risk factors for AF (increased 
BMI and SA) were uncovered in this study. These findings have mechanistic 
and therapeutic implications regarding a very large public health problern. 
5:00 p.m. 
~5~ Stroke After Discharge from Hospital with a 
Diagnosis of Atrial Fibrillation: A National Survey 
Lars Frost, Gerda Engholm, Soren Johnsen, Henrik Moiler, Steen Husted. 
Department of Cardiology, Amtssygehuset, University Hospital, Aarhus, and 
Centre for Research in Health & Social Statistics, Copenhagen, Denmark 
Background: Atdal fibrillation (AF) is an important risk factor for stroke. We 
estimated risk factors for stroke in patients discharged from hospital with a 
diagnosis of AF. 
Methods: A random sample of 27,202 patients aged 50-89 years with a 
diagnosis of incident AF in the Danish National Hospital Discharge Register 
during the period 1980-t993 was studied. Data on previous or concomitant 
cardiovascular morbidity during the period 1977-1993 was taken from the 
register. Endpeint: First diagnosis of stroke (fatal and nonfatal) recorded in the 
Danish National Hospital Discharge or Death Register after discharge with 
index AF diagnosis. Risk estimates were calculated by Poisson regression 
analysis (multiplicative model) using the Danish population as reference 
population. 
Results: 
Adjusted relative risk (95% CI) of stroke in AF patients 
Age Males Females 
50-59 years 3.3 (2.6-4.3) 6.9 (5.1-9.4) 
60-69 years 2.3 (1.9-2.8) 4.0 (3.3-4.8) 
70-79 years 2.0 (1.7-2.4) 2.8 (2.4-3.2) 
80-89 years 1.5 (1.2-1.8) 2.0 (1.7-2.3) 
Hypertension 1.6 (1.4-1.9) 1.4 (1.3-1 6) 
Diabetes 1.5 (1.3-1.8) 1.7 (1.5-1.9) 
Congestive head failure 1.1 (1.0-1.3) 1.0 (0.9-1.1) 
tsch. heart dis. with M} 1.2 (1.1-1.4) 1.1 (0.9-1.3) 
Isch. heart dis. without MI 1.1 (1.0-1.3) 1.1 (1.0-1.2) 
Peripheral arterioscl. 1.4 (1.1-1.8) 1.2 (1.0-1.6) 
Conclusions: AF patients discharged from hospital have a two-sevenfold 
excess in stroke risk. Stroke risk is further increased in AF patients with 
hypertension, diabetes, ischemic heart disease, congestive heart failure, 
and peripheral arteriosclerosis. 
5:15 p.m. 
~8-2-0~ Downregulation of L-Type Calcium Channel and 
Sarcoplasmic Reticular Ca2+-ATPase mRNA in 
Human Atrial Fibrillation: An Insight into the 
Mechanism of Atrial Electrical Remodeling 
Ling-Ping Lai, Ming-Jai Su, Jiunn-Lee Lin, Fang-Yue Lin, Chang-Her Tsai, 
Shoei K. Stephen Huang. College of Medicine, National Taiwan Universi~ 
TaipeL Taiwan 
Background: Recent studies have demonstrated that atrial electrical re- 
modeling in atdal fibrillation is associated with intracellular catcium overload. 
However, the changes of calcium handling proteins remain unclear. We in- 
vestigated the gene expression of calcium handling genes including L-type 
calcium channel, sarcoplasmic reticular Ca2+-ATPase, ryanodine receptor, 
calsequestrin, and phospholamban in human atrial fibrillation. 
Methods: A total of 25 patients undergoing open heart surgery were 
included (13 with atrial fibrillation for more than 3 months; 12 with atrial 
fibrillation for less than 3 months or no atrial fibrillation). Atrial tissue was 
obtained from the right atrial free wall, right atrial appendage, left atrial 
free wall and left atrial appendage respectively. The mRNA amount of the 
genes was measured by reverse transeription-polymerase chain reaction 
and normalized to the mRNA levels of GAPDH. 
Results: The mRNA of L-type calcium channel and of Ca2÷-ATPase were 
significantly decreased in patients with persistent atrial fibrillation for more 
than 3 months (0.43 i 0.38 Vs 1.19 ± 1.26 for L-type calcium channel; 0.82 
± 0.43 Vs 1.36 ± 0.61 for Ca2÷-ATPase; both p < 0.05). We further demon- 
strated that there was no spatial dispersion of the gene expression among 
the four atdal tissue sampling sites. Age, sex and undedying cardiac disease 
had no significant effects on the gene expression. In contrast, the mRNA 
levels of ryanodine receptor, calsequestrin and phospholamban showed no 
significant change in atrial fibrillation. 
Conclusions: L-type calcium channel and the sarcoplasmic reticular 
Ca2+-ATPase gene were downreguiated in atrial fibrillation. These changes 
may be a consequence of, as well as a contributory factor for, atrial fibrillation. 
ORAL  
Repolarization Dynamics and Risk 
Tuesday,  March  9, 1999, 8:30 a ,m. -10 :00  a.m.  
Mor ia l  Convent ion  Center ,  La Lou is iane  A 
8:30 a.m, 
~ Q T  Dispersion Is not a Predictor of Sudden Cardiac 
Death in Hypertrophic Cardiomyopathy as Assessed 
in an Unselected Patient Population 
Barry J. Maron, Mark J. Leyhe, Thomas E. Gohman, Susan A. Casey, 
Richard S. Crow, Morrison Hedges. Minneapolis Heart Institute Foundation 
and University of Minnesota, Minneapolis, MN, USA 
Background: QT dispersion (QTD) has been cited as a predictor of future 
adverse cardiac events and sudden death in patients (pts) with coronary 
artery disease. 
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Methods: We have assessed the role of this variable for risk stratification 
in a population of pts with hypertrophic ardiomyopathy (HCM) who represent 
a large, unselected cohort free of tertiary center referral bias. QTD (difference 
between longest and shortest QT interval corrected for heart rate) was 
measured on the initial 12-lead ECG in each pt. 
Results: The study group of 254 HCM pts showed greater QTD in com- 
parison to 69 normal controls (85 ± 49 vs. 53 ± 17 ms; p < 0.001). However, 
QTD did not differ significantly within the HCM group when 31 pts who died 
of HCM (87 ± 36 ms) were compared to 223 survivors (85 ± 50 ms; ns) or 
when 16 pts who died suddenly (79 ± 30 ms) were compared to survivors 
(85 ± 50 ms; ns). In addition, corrected QT interval (QTc) was greater in 
HCM than in controls (453 ± 66 vs. 397 ~l- 32 ms; p < 0.001), but QTc in pts 
who died of HCM did not differ from survivors (458 ± 69 vs. 451 ± 66 ms; 
ns). 
Conclusion: In an unselected HCM cohort closely resembling the true 
disease state, QT dispersion (and QTc) on 12-lead ECG did not prove to be 
reliable predictors of subsequent HCM-related death and would not appear 
to be useful in devising risk stratification strategies for sudden cardiac death 
in this disease. 
8:45 a.m. 
~ - ]  QT Dispersion Should Be Adjusted for Age: 
Observations from 1096 Normal Subjects 
Irina Savelieva, A. John Carom, Marek Malik. St. George's Hospital Medical 
School, London, UK 
Background: Although QT dispersion is developing into an important re- 
search and clinical tool, criteria of normality yet have not been established, 
particularly regarding age and gender. 
Methods: Several parameters characterising global (12-lead) and precor- 
dial dispersion of ventricular epolarization were obtained from 1096 healthy 
volunteers (910 men, age 32 ± 11; 186 women, age 35 ± 15). Disper- 
sion of ventricular epolarization was defined as 1) difference between the 
maximum and minimum QT (QTD), QTpeak (QTpD), Tpeak-Tend (TpTeD) 
intervals; and 2) interlead standard deviation (SD) of the QT, QTp and TpTe 
intervals. Measurements were made automatically by QT Guard software 
(Marquetle Medical Systems, Milwaukee, Wl). 
Results: Global QTD and SD QT were significantly higher while precordial 
TpTeD and SD TpTe were significantly lower in men compared to women 
(27.9 ± 16.6 vs 24.8 ± 17.2 and 8.5 ± 4.9 vs 7.6 ± 4.8 ms, p < 0.03; 
24.3 ± 14.3 vs 29.2 ± 15.2 and 9.4 ± 5.4 vs 11.2 ± 5.6 ms, p < 0.001 
resp.). When all the subjects were divided into 3 age groups (17-29, 30-49, 
50-80 yrs), the difference in precordial TpTeD persisted between genders in 
all age groups while the difference in global QTD was only observed in the 
elderly group. Multiple comparisons analysis (Scheffe) revealed than all the 
parameters of dispersion of ventricular epoladzation decreased significantly 
with an increase in age (see table, data presented as mean ± SD). This 
was true for the whole population and male gender. However, in women only 
global QTD and precerdial TpTeD and SD TpTe decreased in elderly group 
while no significant difference was observed regarding other parameters. 
The decrease in dispersion of repolarization was due to an increase in the 
minimum values of QT, QTp and TpTe intervals with small or no changes in 
the maximum values. 
17-29 30-49 50-80 p vs [17-29] 
(n = 561) (n = 415) (n = 117) 
QTD 29.1 ± 17.8 26.5 ± 15.6 21.7-c 13.3 <0.0001 
QTpD 34.7 ± 14.9 32.5 ± 15.6 30.2 ± 14.5 <0.004 
TpTeD 33.8 ± 13.3 30.3 ± 12.1 27.4 ± 10.3 <0.0001 
SD QT 6.8 ± 5.4 8.1 ± 5.6 6.8 ± 3.6 <0.002 
SD QTp 10,5 ± 4.6 9.7 ± 4.8 9.4 ± 4.6 <0.007 
SD TpTe 10.2 ± 3.9 9.3 ~- 3.4 8.7 ± 3.3 <0.0001 
Precordial QTD 22.6 ± 18.3 20.1 ± 15.2 17.4 ± 13.8 <:0.004 
Precordial QTpD 27.6 ± 14.5 24.9± 15.1 24.1 ± 14.1 <0004 
Precordial TpTeD 27.6 ± 10.6 23.0 ± 13.8 20.9 ± 11.4 <0.0001 
Precordial SD QT 8.9 ± 7.3 7.9 ± 5.8 6.9 J: 5.3 <:0004 
Precordial SD QTp 11.0 ± 6.0 9.7 ± 5.7 9.7 ± 5.6 ~0.0009 
Precordial SD TpTe 10.6 ± 5.9 8.9 ± 4.9 8.3 ± 4.7 <0.0001 
Conclusion: QT dispersion strongly depends on gender and age in 
healthy population. Clinical expedence gained in the past with QT dispersion 
measurement in young normal subjects cannot be applied blindly to data 
obtained from cardiac patients. Before using in clinical practice QT dispersion 
should be corrected for gender and age. 
9:00 a.m. 
[ - ~  Assessment of QT Interval and QT Dispersion for 
Prediction of All-Cause and Cardiovascular Mortality 
in American Indians: The Strong Heart Study 
Peter M. Okin, Richard B. Devereux, Barbara V. Howard. Cornel/Medical 
Center, New York, New York, USA 
Background: Both a prolonged QT interval and increased QT interval dis- 
persion (QTD) on the 12-lead ECG have been proposed as surface ECG 
markers of vulnerability to ventricular arrhythmias and as potential predic- 
tors of mortality. However, there remains a paucity of data examining the 
prognostic value of these methods in large populations. 
Methods: The predictive value of QT and QTD were assessed in 1,839 
American Indian participants in Phase I of the Strong Heart Study. ECGs 
were digitally-acquired at 250 Hz; QT intervals were measured by computer 
in all 12 leads and corrected for heart rate (QTc) using Bazett's formula. QTD 
was calculated as the difference between the maximal and minimal QTc. 
Results: After a mean follow-up of 3.7 5:0.9 years, there were 188 
deaths from all causes and 55 cardiovascular deaths. In univariate Cox 
analyses, QTc (x 2 = 55, p < 0.0001) and QTD (x 2 = 11, p = 0.0008) were 
significant predictors of all-cause mortality and of cardiovascular mortality (x 2 
= 13, p = 0.0004, and x 2 = 27, p < 0.0001, respectively). After multivariate 
Cox regression analyses that included age, sex, diabetes, HDL and LDL 
cholesterol, body mass index, diastolic and systolic blood pressure, smoking, 
microalbuminuria, and prevalent coronary heart disease, QTc remained a 
significant predictor of total mortality (x 2 = 16, p = 0.0001), and QTD remained 
significant predictors of cardiovascular death (x 2 = 12, p = 0.0005). In this 
population, a QTc > 460 msec was associated with a 2.6-fold increased 
risk of death (95% confidence interval [CI] 1.8-3.7) and a QTD > 58 msec 
(the upper 95 th percentile in a separate population of normal subjects) was 
associated with a 3.2-fold increased risk of cardiovascular mortality (95% CI 
1.8-5.7). 
Conclusions: In this large, population-based prospective study, pro- 
longed QTc is a powerful and independent predictor of all-cause mortal- 
ity, and increased QTD predicts cardiovascular mortality only, suggesting 
differing roles of these findings in risk stratification by the ECG. 
9:15 a.m. 
~ ls QT Dispersion Altered by Changes in Heart Rate? 
Rupa Subramanian, Alaa Shalaby, Philip Sager. UCLA and West Los 
Angeles VAMC, Los Angeles, CA, USA 
Background: QT dispersion (QTdisp) is being investigated 1o identify pts at 
high risk of developing sudden death. While the QT interval is sensitive to 
changes in heart rate, the relationship between heart rate and QTdisp is not 
well described and cycle lengths changes might alter QTdisp. 
Methods: We determined QTdisp during fixed rate atrial pacing over a 
wide range of cycle lengths (750 ms-350 ms) in 18 patients without conduc- 
tion abnormalities undergoing clinical electrophysiologic study in the drug- 
free state. QT intervals were measured in all leads and QTdisp (QTmax - 
QTmin) and QTc dispersion (QT/(RR) 1/2) were determined. In addition, RV 
repolarization was measured using a monophasic action potential catheter 
to record the APDgo. Data was fit to a curve for each pt and the slope was 
determined. 
80 
~ 7o 
N so 
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Results: Consistent with known physiology, QT duration and APDgo de- 
creased significantly at shorter cycle lengths (p < 0.01). Importantly (see 
graph), there was a major dichotomy between the results for QTdisp and 
QTc disp: QT dispersion remained relatively constant in each patient and did 
not change as a function of the atrial paced rate (P = NS) while QTc disp 
significantly increased (p < 0.05) at shorter cycle lengths. Heart rate-induced 
changes in the QT interval and APD90 were not associated with alterations 
in QTdisp. 
Conclusion: QT dispersion is not altered by isolated changes in heart 
rate and thus rate corrections of QT dispersion do not appear necessary. 
QTc dispersion measurements may be misleading since changes in this 
parameter at different heart rates may largely reflect changes in cycle length 
and not actual alterations in cardiac repoladzation. 
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I~ -~ Dynamics of the QT Interval in Response to Sudden 
Vagal-lnduced Lengthening of the RR Interval 
Agustin Castellanos, Federico Moleiro, Gustavo Lopera, Heikki Huikuri, 
Alberto Inter±an Jr., Robert J. Myerburg. University of Miami School of 
Medicine, MiamL Florida, USA 
Recordings of human action potentials showed that after an abrupt decrease 
in pacing cycle length the first action potential was longer than steady state 
(SS) action potentials. To determine if the uncorrected QT intervals shows a 
similar behavior we studied 28 episodes (ep) of abrupt RR prolongation due 
to transient, vagal induced sudden and paroxysmal AV nodal block detected 
by Holter monitoring in 14 nonmedicated patients (ages: 19 to 46, mean: 
31.5 years) without structural heart diseases. SS QT intervals had durations 
between 340-430 ms (mean: 365). During the time elapsing between SS and 
the first blocked P wave sinus cycle lengths decreased from 40 to 240 ms 
while the PR intervals increased from 0 to 60 ms. With pauses (RR intervals) 
between 1290 and 2160 ms (19 ep) the first post-pause QT intervals were 
similar to the SS QT intervals. With pauses between 2460 and 14600 ms the 
first post-pause QT intervals increased by 20-80 ms. Restitution of SS QT 
intervals always occurred in the second post-pause beat of the resumed 1:1 
AV conduction in the 4 ep where only 2 P waves were blocked and in the 5 
ep developing (between SS and 1:1 conduction) transient high degrees of 
AV block (in which ep the QT intervals remained prolonged while the latter 
persisted). In summary: 1) vagal effects appeared to have been less marked 
in the ventricles than in the AV and sinus nodes; 2) accumulation and a 
type of memory seemed to play an important role in the response of the QT 
intervals to abrupt decreases in ventricular cycle lengths. 
9 :45 a,m.  
[-8--3-~ Microvolt Alternans Is Prevalent in Level T-Wave 
Subjects With Congenital Long QT Syndrome 
Elizabeth S. Kaufman, Eiran Z. Gorodeski, Niuton Koide, Linda M. VerriHi, 
Guhan Rammohan, David S. Rosenbaum. Case Western Reserve 
Universi~ MetroHealth Medical Center, Cleveland, Ohio, USA 
Background: Grossly visible T-wave alternans (TWA) is an important prog- 
nostic sign in congenital Long QT Syndrome (LQTS). Although microvolt 
level TWA is a marker of risk in patients with structural heart disease, its 
prevalence in LQTS is unknown. 
Methods: 68 subjects (32 M, 36 F, age 36 ± 16) with personal or family 
history of LQTS underwent TWA measurement during exercise on a station- 
ary bicycle. We compared the prevalence of TWA in subjects with normal 
versus prolonged (>_0.45 s in males, >_0.46 s in females) QTc on the baseline 
ECG. Abnormal TWA (> 1.9 #V at a threshold H R < 110/min) was considered 
sustained if it lasted > 1 min and persisted at increased HR; it was considered 
present (any TWA) if it lasted >-0.3 min but did not necessarily meet criteria 
for sustained TWA. 63 subjects had diagnostic TWA tests (achieving HR > 
105/min with noise < 1.8 #V and ectopics < 10%) and were included in the 
analysis. 
Results: Both sustained (p < 0.01) and any (p < 0.02) TWA were found 
with higher prevalence among subjects with prolonged QTc. 
Sustained TWA 
Long QT Norman QT 
TWA+ 6 0 
TWA- 21 36 
Any TWA 
Long QT Normal QT 
TWA+ 21 18 
"FVVA - 6 18 
Of subjects with long QTc, 78% had TWA (22% sustained). In contrast, 
among subjects with normal QTc, 50% had TWA (none sustained). 
Conclusion: Microvolt level TWA can be detected in a substantial propor- 
tion of individuals with LQTS. TWA analysis may aid in diagnosing subjects 
at risk for LQTS, a potentially lethal but treatable disorder. 
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[ 1143*146 1 Electrophysiologic and Anti-Arrhythmic Effects 
of KB130 015, A New Thyroid Hormone Receptor 
Blocker, in the Mammalian Heart 
Jiang Xu, Johan Haggblad, Johan Maim, Bo Carlsson, Amir Pelleg. 
Allegheny University of the Health Sciences, Philadelphia, PA and Karo Bio 
AB, Huddinge, Sweden 
Background: Amiodarone is an effective anti-arrhythmic drug, however, its 
use is associated with numerous side effects. 
Methods: The cardiac electrophysiologic effects of KB130 015, an amio- 
darone-like compound with reduced toxicity, (KB; 40 mg/kg/day, i.p., for 20 
days), were determined in guinea-pigs under physiologic conditions, and in 
rabbits subjected to 30 min left anterior descending coronary artery (LAD) 
occlusion followed by 60 min reperfusion. 
Results: In guinea-pigs (n = 12), KB did not affect either sinus cycle 
length (SCL) or atrio-ventricular nodal and atdal refractoriness but prolonged 
sinus node recovery time from 300 ± 39 msec to 396 ± 19 msec (p < 
0.05), ventricular action potential duration at 50% (APDs0) and 90% (APDgo) 
repolarization from 90 ± 4 msec and 115 • 4 msec to 106 ± 4 msec and 132 
± 5 msec, respectively (p < 0.05, each), and ventricular effective refractory 
period, at a paced cycle length of 200 msec and 160 msec from 84 ± 4 
msec and 75 ± msec to 103 ± 4 msec and 99 ± 5 msec, respectively 
(p < 0.05, each). In rabbits (n = 12), prior to LAD occlusion/reperfusion, 
KB prolonged SCL from 188 ± 3 msec to 248 ± 9 msec and ventricular 
APD5o and APD~o from 76 ± 4 msec and 108 ± 3 msec to 105 ± 4 msec 
and 141 ± 7 msec, respectively (p < 0.05, each), In addition, KB treatment 
totally prevented the induction of occlusion and reperfusion arrhythmias: The 
frequency of animals exhibiting these arrhythmias was 6/6 vs. 0/6 in control 
and KB-treated animals, respectively (p < 0.02). 
Conclusion: KB has cardiac electrophysiological characteristics similar 
to those of amiodarone, in particular its ability to prolong ventricular refrac- 
toriness in a rate-independent manner and in inverse relation to the action 
potential duration, and its anti-arrhythmic efficacy. Thus, KB can be viewed 
as a promising new prototypic anti-arrhythmic agent. 
[1143-147~ Protect ion of Atr ial  Dose-dependant 
J Tachycardia-lnduced Electrical Remodeling by 
Mibefradil 
Samir Fareh, Bernard Thibault, Stanley Nattel. Montreal Heart Institute, 
Montreal, Canada 
Atrial fibrillation (AF) causes tachycardia.induced alterations in atrial electro- 
physiology that favor AF induction and maintenance. Although L-type Ca 2+ 
channel blockers reduce some electrophysiologic (EP) changes caused by 
atrial tachycardia (AT), they appear ineffective in preventing AF promotion by 
AT. We have obtained preliminary evidence suggesting that the T-type Ca 2+ 
channel blocker mibefradil (Mib) can prevent EP remodeling and AF promo- 
tion by AT. The present study was designed to determine the concentration 
(Conc) dependance of Mib's remodeling-inhibiting effects. Dogs were atrially 
paced at 400/min for 7 days, with AV block and ventricular pacing (60/min) 
used to control the ventricular esponse, prior to open-chest EP study. Mib (n 
= 8 dogs) or placebo (Pla, n = 10) were given in blinded fashion throughout 
the pacing period. Mib significantly reduced atrial vulnerability (from 41 - 10 
to 9 ± 4% sites at which AF could be induced, p = 0.01), AF duration (from 
414 ± 232 to 3 ± 1 s, p < 0.0001) and refractory period (ERP) heterogeneity 
(from 28 ± 2 to 19 ± 1%, p < 0.01). Mean ERP at a cycle length of 300 
ms was substantially greater (102 ± 7 ms) in Mib dogs vs Pla (76 ± 5 ms, 
p < 0.01). Among Mib dogs, ERP was positively related to Mib Conc (r = 
0.73, p < 0.05); atrial vulnerability and AF duration were negatively related 
to Mib Conc (r = -0.71, r = -0.70 respectively, p = 0.05 for both). Acute 
administration of Mib did not alter ERP or AF duration. 
Conclusions: Mib prevents AT-induced remodeling and AF promotion in 
a Conc-dependant way, suggesting that T-type channels may be important in 
AT-induced remodeling and that T-channel blockers may be useful in treating 
AF. 
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1143-148 1 Effects of Long-Term Electrophysiologic 
Treatment With SR33589B on Rabbit Atrial 
Muscle. Comparison With Amiodarone 
Wei Sun, Jonnalagedda S.M. Sarma, Sean S. Steele, Uma Narasimhan, 
Devi Navamani, Apel Keuroghlian, Bramah N. Singh. Cardiovascular 
Research Laboratories, Section of Cardiology, West Los Angeles VA 
Medical Center, UCLA School of Medicine, Los Angeles, CA, USA 
Background: SR33589B (SR) is a new non-iodinated benzofuran derivative 
of amiodarone (AM). Its electrophysiologic effects on the atrial muscle have 
not been reported. 
Methods: Electrophysiologic effects of 4-week oral administration of SR 
and AM were studied in rabbit atrial muscle in vitro by the standard micro- 
electrode techniques. The animals were divided into 5 treatment groups (n = 
5/group), G1 : vehicle only, G2:50 mg/kg/day AM, G3:50 mg/kg/day SR, G4: 
100 mg/kg/day AM, and G5:100 mg/kg/day SR. 
Results: The results are summarized in the table and figure below. 
APDg0 at ERP at Vmax at 
1 Hz 1 Hz 1 Hz 
G1 59~E1 49 :E3  208±5 
G2 60 :5  1 57 ± 1" 204 ± 5 
G3 60 ± 1 65 ± 2" 203 ± 4 
G4 67--_ 1" 63± 1" 191 ±6 
G5 67±1"  68±2*  187±4 
APDgo = Action potential duration (msec) at 90% repolarization, ERP = Effective refrac- 
tive period. Vmax = Maximum slope of depolarization, volts/sec. " p < 0.01 compared to 
G I .  
i 60 ~ 50 -,~-- c-6 
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Conclusion: The APDg0 of the rabbit atrial muscle has a biphasic re- 
sponse to stimulation frequency with the peak at 3 Hz. Both SR and AM 
equally prolong APD~0, without reverse use dependency over a wide range 
of stimulation rates (1-8 Hz). SR has a tendency to prolong ERP beyond 
APDg0, with possible implications for early after depolarization. Otherwise, 
SR has similar electrophysiologic effects on the atrium as AM., without the 
iodine atoms which were implicated in thyroid dysfunction caused by AM. 
1143-149 [ The Cardiac Ouabain Enhances Glycoside 
I Inducibility of Atrial Tachycardia in Dogs With 
Pacing-Induced Heart Failure 
Guilherme Fenelon, Tom Manders, Bruce S. Stambler. West Roxbury VA 
Medical Center and Harvard Medical School, West Roxbury, MA, USA 
Background: We previously demonstrated that dogs with rapid ventricular 
pacing-induced heart failure (CHF) have inducible atrial tachycardia (AT). 
Responses to Ca 2÷ channel blockers, pacing, mapping and cellular studies 
suggested that AT has a focal mechanism consistent with delayed afterde- 
polarization (DAD) induced triggered activity due to Ca 2+ overload. Because 
blockade of Na+/K ÷ pump by cardiac glycosides increases intracellular Ca 2÷, 
we hypothesized that cardiac glycosides would enhance inducibility of AT in 
CHE 
Methods: Conscious dogs (n = 6) were studied with transvenous, chronic 
right atrial leads at baseline and in CHF after 2-4 weeks of ventricular 
pacing (235 bpm). Non-toxic doses of ouabain (30 l~g/Kg divided into 3 equal 
intravenous boluses every 45 rain) were evaluated in dogs with AT induced 
in CHF by burst pacing but not by extrastimuli (ES). Inducibility of AT was 
assessed at 3 cycle lengths (400, 300, 200 ms) with up to 3 ES before and 
30 min after each ouabain dose. 
Results: At baseline before CHF, inducibility of AT with ES was not en- 
hanced by ouabain (0/6 dogs before and during ouabain 775 ± 35 #g). In 
CHF before ouabain, sustained (>30 rain) AT was induced with ES in 1/6 
dogs. In contrast, among the 5 remaining CHF dogs during ouabain, sus- 
tained AT was induced in 4 dogs with 1-3 ES (240-780 (Lg) and nonsustained 
AT was induced in 1 dog with 1-3 ES (810 ~Lg). In 2/3 dogs, a dose response 
from repetitive responses to sustained AT was observed. AT induced during 
ouabain could not be entrained, terminated with verapamil or flunarizine and 
had similar cycle lengths (126 :E 10 vs t22 ± 9 ms) as AT induced with 
burst pacing before ouabain. At all cycle lengths, the shortest ES coupling 
intervals before and during ouabain were not different. Spontaneous atrial 
arrhythmias were not observed and atrial fibrillation was not induced during 
ouabain. 
Conclusion: At non-toxic doses, ouabain facilitates induction of AT in this 
CHF model. Ouabain's proarrhythmic effect appears related to cellular Ca 2+ 
overload rather than to shortening of atrial refractoriness. 
I1 43-150  J Sotalol  Effects Are Exaggerated 
1 
1 in CHF: Action 
Potential Durationa and Reverse 
Use-Dependence In-Vivo 
Sumeet S. Chugh, Susan B. Johnson, Douglas L. Packer. Mayo Clinic 
Foundation, Rochester MN, USA 
Background: Mechanisms of increased incidence of proarrhylhmia in heart 
failure (CHF) remain unexplained. As reverse use-dependent effects of 
d,l-sotalol have been implicated in torsades de pointes occurrence, we ex- 
amined related action potential duration dynamics in 6 open-chested dogs. 
Methods: In 4 dogs with tachycardia-induced CH F and 2 controls, monopha- 
sic action potential duration at 90% (APD9o) from RV/LV epicardium & en- 
docardium, effective refractory periods (ERPs) and surface QT interval were 
measured at pacing cycle lengths 300-1000 ms. 
Results: Sotalol (1 & 3 mg/kg IV, each over 20 rain) increased APDgo in 
both groups at all cycle lengths, with corresponding increases in ERPs and 
QT interval (p < 0.05). While effects on APDgo were more pronounced at 
longer cycle lengths in both groups, the magnitude of change was significantly 
greater in CHF as shown in fig. (ANOVA, p = 0.05). After sotalol 1 mg/kg, 
APDg0 at cycle length 600 ms increased to 250 ± 18 ms in CHF vs 216 ± 19 
ms in controls (p < 0.05). 
60 
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Conclusions: These exaggerated effects of sotalol may be related to 
K + channel abnormalities inherent in CHF. Sotalol-induced excessive pro- 
longation of APD9o, especially at low heart rates, may explain the increased 
propensity for proarrhythmia in CHE 
1143-151 i Spatiotemporal Organization 
1 
of Ventricular 
Fibrillation Increases During Global Ischemia in 
the Isolated Rabbit Heart 
Jay Chen, Ravi Mandapeti, Omer Berenfeld, Allan Skanes, 
Moussa Mansour, Sanjay Dixit, Faramarz Samie, Jos Jalife. Dept of 
Pharmacology, SUNY Health Science Center at Syracuse, NY, USA 
Background: It is well known that global ischemia modifies the natural 
course of ventricular fibrillation (VF). After a few minutes of its initial onset, 
the VF rate decreases and is thought to show greater organization. However, 
this organization has never been quantified in any detail. 
Methods: High resolution video imaging (~7500 pixels per frame; 240 
frames/sec) in the presence of a voltage sensitive dye and spectral analysis 
was used to quantify the spatial and temporal organization of dominant 
frequency (DF) domains in 5 isolated Langendorff-perfused rabbit hearts. 
About 40% of the epicardial surface of the ventricles was mapped. A protocol 
of no-flow global ischemia followed by reperfusion was utilized. Recordings 
were obtained dudng control VF, 5' ischemia, and 5' reperfusion. DF maps 
were constructed by taking the DF of each pixel during each frame in the 
movie, and then averaging their respective values. 
Results: The ECG appeared to become more organized during ischemia. 
The DF of VF decreased from 13.5 ± 5.3 Hz to 6.5 ± 3.0 Hz (p < 0.05) and 
increased to 15.6 ± 6.1 Hz (p < 0.05) under conditions of control, ischemia, 
and reperfusion, respectively. Concurrently, DF distribution became more 
homogeneous; the density of domains (#domains/total area) changed from 
9.4 ± 3.7 to 3.2 ± 2.4 Hz to 9.0 ± 3.3 Hz (p < 0.05). The % area of the 
largest domain (area of largest domain/total area) increased from 30.1 ± 
11.9 to 76.4 ± 14.0 (p < 0.05) during ischemia and decreased to 27.4 ± 19.2 
(p < 0.05) during reperfusion. 
Conclusions: Spatiotemporal organization of VF paradoxically increases 
during global ischemia. This is the first quantification of organization of VF 
during global ischemia. 
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11144-152t DofeUlide a New Class III Antiarrhythmic Drug 
I I Prevents Atrial Fibrillation in Patients With 
Congestive Heart Failure in Normal Sinus 
Rhythm - Results of the DIAMOND-CHF Study 
Lars Kober. The DIAMOND Study Group, Gentofte University Hospital, 
Hellerup, Denmark 
Background: The Danish Investigations of Arrhythmia and Mortality ON 
Dofetilide in patients (pts) with congestive heart failure (DIAMOND CHF) 
included 1518 pts admitted to the hospital with new or worsening CHF and a 
left ventricular ejection fraction (LVEF) < 35%. 
Methods: Pts were randomly allocated to receive dofetilide (13), a selec- 
tive potassium channel blocker, or placebo (P) in a double blind fashion. At 
baseline, 1090/1518 (72%) lots were in sinus rhythm (SR) and were random- 
ized to D 500 mcg bid or P. Minimum duration of follow up was 12 months 
(median = 18 months). Baseline characteristics were well balanced between 
the two treatment groups. The mean age was 70 years, 73% were male, 67% 
had a history of ischaemic heart disease and 60% of the pts were NYHA 
class Ill/IV. 
Results: Of the 1090 pts in SR at baseline, 46 developed atrial fibdllation 
(AF), 35/534 on P and 11/556 on D (p < 0.001). The number of deaths were 
similar in both treatment groups (221/556 on D and 220/534 on P). 
Conclusions: This study showed that D can reduce the incidence of AF or 
atrial flutter by 70% in pts at risk of developing AF with severe left ventdcular 
dysfunction and CHF. There was no excess mortality in pts treated with D. 
1144-1 I Patients With Longer QT (QTc) 
I 
53 Interval Are More 
Likely to Remain in Sinus Rhythm After One Year 
Treatment on Dofetllide. The EMERALD 
(European and Australian Multicenter Evaluative 
Research on Atrial Fibrillation Dofetilide) Study 
Ronald Lehman, Robed A. Greenbaum, Ternece J. Campbell, Kevin 
S. Channer, Harris W. Dalrymple, J. Herre Kingma, Massimo Santini, 
Kad Theisen, Lauri K. Toivonen. For The EMERALD Study Group; Suite 10 
57-59 Anzac Highway Ashford South Australia, 5035, Australia 
Background: Dofetilide (D) is a new pure class III antiarrhythmic agent with 
a linear relationship between dose and QT interval. The relationship between 
QT interval and clinical efficacy has not been established for class III drugs. 
Method: EMERALD assessed the efficacy and dose relationship of oral 
dofetilide (D) [125, 250, 500 mcg bid] and placebo (P), in 534 patients (pts) 
with atdal fibrillation (AF) in a double blind parallel group design. Pts with a 
QT interval > 500 msec or an increase over 20% from pro dose after first 
oral dose were excluded from the study. 
Results: By day 3,431 pts (81%) regained sinus rhythm (SR), pharma- 
cologically or by DC conversion. D cardioverted significantly more Lots (up to 
29%) in a dose-dependent manner than P (<1%, p < 0.05 at all dose levels). 
At 3, 6, and 12 months, all doses of D maintained significantly more Lots in SR 
than P (p < 0.05 at each time point). D was effective in converting pts with 
AF and maintaining up to 71% in SR at 6 months. The post-cardioversion QT 
interval correlated linearly with the efficacy of D in maintaining SR after 12 
months (p = 0.04). Pts with a QT interval after conversion > 425 msec had a 
31% higher chance of staying in SR, compared to pts with a shorter QT. 
Conclusion: The efficacy of D to maintain sinus rhythm after conversion 
of atrial fibrillation was related to the degree of QT prolongation by D. 
1144-1 54 1 Effect of Ibutilide Atrial Defibrillation Energy on 
Requirement 
Hakan Oral, Joseph J. Souza, Matthew Flemming, Michael H. Kim, 
Frank Pelosi, Hung-Fat Tse, Gregory F. Michaud, Bradley P. Knight, 
Rajiva Goyal, S. Adam Strickberger, Fred Morady. University of Michigan, 
Ann Arbor, MI, USA 
Background: Ibutilide, a class III antiarrhythmic agent that prolongs repo- 
ladzation, has been reported to convert atrial fibrillation (AF) to sinus rhythm 
with an efficacy of 20-50%. The purpose of this study was to determine 
whether ibutilide decreases atrial defibrillation energy requirement (DER) 
and increases the efficacy of transthoracic cardioversion (-rcv) in humans. 
Methods: Eighty-four patients with AF (duration = 157 i 329 days, range 
2 hrs-6 yrs, ejection fraction (EF) = 0.47 4- 0.09, age = 62 ± 14 yrs, and 
left atdal (LA) size = 48 ± 9 ram) were randomized to receive TCV (N = 46) 
with a step-up protocol of 50, 100, 200, and 360J (Group A); or ibutilide (1 
mg over 10 min, N = 38) followed byTCV in 31 patients who remained in AF 
after ibutilide (Group B). If TCV in Group A failed, patients crossed-over to 
Group B. Age, gender, EF, !-A size and duration of AF were not statistically 
different between the two groups, 
Results: Conversion to sinus rhythm occurred in 27 of 46 (59%) and 29 
of 31 (94%) patients in Groups A and B, respectively (P < 0.001). Nineteen 
patients in Group A crossed-over to Group B, and TCV was then successful 
in 18 (95%). The overall efficacy of TCV in restoring sinus rhythm was 94% 
and 59% with and without ibutilide pretreatment, respectively (P < 0.0001). 
Atrial DER without ibutilide pretreatment was 243 + 84J, compared to 197 
92J after pretreatment with ibutilide (P = 0.04). With ibutilide, sustained 
polymorphic ventdcular tachycardia occurred in 3 patients, all of whom had 
an EF of <30%. 
Conclusions: Ibutilide lowers atdal DER and is of great value in facilitating 
transthoracic cardioversion of AF. 
I l l  ] Time Course of Ibutilide Effect on Atrial Rate in 44-1 55 
J 
Patients With Atrial Fibrillation 
Robert,Schwartz, Kevin McTeague, Jonathan Langberg. Emory University 
Section of Cardiac Electrophysiology, Atlanta GA, USA 
Background: Although ibutilide infusion is useful for conversion of atrial 
fibrillation (AF), little is known about the time course of its electrophysiologic 
effects. The purpose of the current study was to quantify the time course and 
magnitude of ibutilide-induced slowing of fibrillatory activity in patients with 
AF. 
Methods: Eleven patients (9 male, age 57 4- 11 years) with persistent AF 
received ibutilide 1 mg IV over 10 minutes and a second dose 10 minutes later 
as needed. A 12-lead ECG was continuously recorded and digitized. QRS 
and T waves were removed from the ECG signal using a template subtraction 
technique and the frequency spectrum of the remaining fibrillatory baseline 
determined using Fourier transformation. A previous study has shown that 
this measurement closely correlates with AF frequency measured directly 
from intraatrial recordings. 
Results: AF decreased rapidly after the onset of ibutilide infusion (t 1/2 
= 2 minutes). Ibutilide-induced slowing of AF was more rapid (t 1/2 = 1.6 
minutes vst 1/2 = 3.8 minutes) and more intense (31 ~ 5% vs 26 ± 4% 
reduction in AF rate, p = 0.02) in patients who converted to sinus rhythm than 
in those who failed to convert. 
.~ ~ 10 
.~ 20 
.= 30 
40 
2 3 4 $ 6 7 8 9 
Time After Start of Ibutilide 
Infusion (minutes) 
Conclusion: Ibutilide-enhanced slowing of AF occurs rapidly and ap- 
proahces steady state well before the end of the 10 minute infusion. The 
speed and intensity of slowing correlate with successful conversion to sinus 
rhythm. These observations suggest that more rapid infusion may enhance 
ibutilide efficacy. 
1144-156]  LOW Dose Superior to Metoprolol Sotalol Is in 
the Prevention of Supraventricular Arrhythmias 
After Cardiac Surgery 
O. Abdulrahman, H.T. Dale, V. Levin, 17 Theman, N. Omoigui, 
C. Hassapoyannes, M. Hallner. SL Luke's Hospital, Bethlehem, PA and 
USC School of Medicine, Columbia, SC, USA 
Objective and Methods: To compare the efficacy and adverse event rate of 
low dose sotalol with those of metoprolol in the prevention of supraventdcular 
arrhythmias (SVA) after cardiac surgery, 191 consecutive patients (pts) (142 
male, 49 female, mean age 64 years) were prospectively enrolled. Eligible 
pts were randomized to receive either metoprolol or sotalol in a double-blind 
fashion within 24-48 hours following extubation. Pts assigned to sotalol ( n 
= 93) received 40 mg of the drug orally Q 12 hours on the first day after 
surgery, then 80 mg Q 12 hours for five days thereafter. Pts assigned to 
metoprolol (n = 98) received 25 mg of the drug orally Q12 hours on the first 
day after surgery, then 50 mg Q 12 hours for five days thereafter. Baseline 
characteristics were not significantly different between the two groups. 
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Results: SVA occurred in 16% of all pts and atrial fibrillation was the most 
common type of arrhythmia. Nine pts (10%) in the sotalol group developed 
SVA compared to 22 patients (22%) in the metoprolol group (p = 0.028; chi 
square). Nonsustained ventdcular tachycardia was recorded in 2 pts in each 
group (2.1% in the sotalol and 2% in the metoprolol group; p = NS). There was 
no torsade de pointe. Bradyarrhythmias occurred in 3 pts receiving sotalol 
(3.2%) [and in 7 pts receiving metoprolol (7.1%); p = NS. 
Conclusion: Low dose sotalol appears to be well tolerated and more 
efficacious than metoprolol in the prevention of SVA following cardiac surgery, 
I1 ] Spectral  Analysis of the Fibr i l latory Act iv i ty  on 1 44-1 57 
the Surface ECG in Patients With Persistent 
Atrial Fibrillation and Its Response to Chronic 
AnUarrhythmic Medication 
Andreas BoUmann, Hans-Dieter Esperer, Kai Sonne, Ines Toepffer, 
Ekaterini Hecht, Daniela Polywka, Jonathan J. Langberg 1 , Helmut U. Klein, 
University Hospital Magdeburg, Germany; iEmory University Hospital, 
Atlanta, GA, USA 
Background: Recently, it was shown that spectral analysis of the fibrillatory 
baseline on the surface ECG accurately reflects the average rate of atrial 
fibrillation (AF). The clinical utility of this technique was explored by correlating 
fibdllatory frequency with the behavior of the arrhythmia and the response 
to ibutilide infusion, The aim of this study was to evaluate the capability 
of this test to monitor changes in atrial rate due to chronic antiarrhythmic 
medication. 
Methods: One minute ECG recordings from an orthogonal lead system 
were analyzed at baseline and after 3 to 5 days in 18 pts with AF lasting 
longer than 3 months. In 9 10ts antiarrhythmic drugs were given empirically 
prior to electrical cardioversion for prophylaxis of AF recurrence (Group I). 
In 9 pts no intervention was performed (Group II). Groups were compara- 
ble with respect to age, gender, heart disease, AF duration and left atrial 
dimension. Determination of peak frequency (f) was performed using a three 
step algorithm (bandpass filtering, QRST averaging and subtraction, discrete 
Fourier transformation of the fibdllatory baseline). 
Results: At baseline mean f measured 7.2 ± 0.5 Hz in Group I and 7.1 + 
0.7 Hz in Group II (p = ns). Frequency was reduced by antiarrhythmic drugs 
(amiodarone n = 5, sotalol n = 3, flecainide n = 1) in all pts by 1.0 ± 0.5 
Hz (range 0.2 to 1.6 Hz, p < 0.001 vs baseline). In contrast, there was no 
significant shift in f in Group II (7.5 ± 0.8 Hz, range 0.1 to 0.5 Hz, p = n.s.). 
Conclusion: Spectral analysis of the fibdllatory activity on the surface 
ECG can be used to monitor response to chmnic antiarrhythmic medication 
in AF. Continued study to determine the role of this test in the management 
of AF seems to be warranted. 
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I11 78 } Use of the Implantable Cardioverter Defibrillator 45-1 
in the Long QT Syndrome 
Mark S. Link, Deborah L Cliff, Craig A. Swygman, Munther K. Homoud, 
Paul J. Wang, N.A. Mark Estes III. New England Medical Center, Boston, 
MA, USA 
Background: Patients with the Long QT Syndrome (LQTS) are at risk of 
sudden death, Despite this risk of sudden death and the increasing use 
of implantable cardioverter defibrillators (ICDs), there is concern about the 
utility of ICDs in this group of patients. 
Methods: Analysis of patients with the LQTS undergoing ICD implanta- 
tion at a single center from 6/90 to 4/98 and comparison with the patients 
undergoing ICD implantation without LQTS. 
Results: In a cohort of 498 patients receiving ICDs, there were 8 with 
the diagnosis of the LQTS. Six patients presented with a cardiac arrest and 
2 with syncope. Patients with the LQTS were more likely female (7 of 8 vs. 
113 of 490), younger (42 + 22 years vs. 61 + 15). The mean left ventdcular 
ejection fraction was higher in the patients with the LQTS (52 ± 8% vs. 33 
± 15%). Defibrillation thresholds were lower in the patients with the LQTS 
(5.0 ± 2.2 joules vs. 10.7 ± 5.5, p = 0.003). R-waves and pacing thresholds 
were similar. With a mean follow-up of 28 ± 57 months, 5 patients have 
had recurrent arrhythmias (ventdcular fibrillation in 4, and syncope with ICD 
discharge in 1) in the LQTS compared to 186 patients with other diagnosis (p 
= ns). No patient with the LQTS died or was unable to be defibrillated. One 
patient had salvos of torsades (17 in a 1 day period) which were converted to 
normal sinus rhythm by the ICD, only to have reinitiation of torsades minutes 
later. 
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Conclusion- ICDs in LQTS patients are 
cohort, salvos of torsades can be seen. The 
torsades and preventing sudden death. 
both feasible and safe. In this 
ICD is effective in terminating 
1145-179 1 Safety of  Cel lular Telephones on Implantable 
Cardloverter Defibrillators 
John A. Chiladakis, Pedkiis Daviouros, Antonis S, Manolis. Patras 
University Hospital, Pio, Patras, Greece 
Background: Cellular telephones may generate electromagnetic interfer- 
ence (EMI) which could potentially interact with normal device operation. We 
determined whether EMI generated by the European Standard Global Sys- 
tem for Mobile Communication (GSM) mobile phones is sensed incorrectly 
and delivers inappropriate therapy. 
Methods: In 19 men, aged 67 i 10 years with > 3 months transve- 
nous pectoral implantable Cardioverter Defibrillators (ICD) (18 prepectoral 
and 2 subpectoral) from 2 different manusfacters (12 Medtronic, 7 CPI) 2 
mobile phones (Motorola) with different levels of power output (2 and 8 W) 
were tested in the standby, the dialing and the receiving mode. All tests 
were performed in activated ICDs during spontaneous cardiac activity and 
continuous VVI pacing ~20 ppm above the patients intrinsic rate to evalu- 
ate possible pacing inhibition. First, the phone was placed at each patient's 
ear and then was moved over the implanted device. The programmer head 
was retained over the device to obtain continuous electrogram and marker 
channel telemetry. After each test the device was interrogated to determine 
possible tachyarrhythmia detection. 
Results: There was no damage, inappropriate shock therapy or repro- 
gramming dudng the tests. In most patients noise detection was noted tem- 
porarily in the intracardiac (fig.) but not in the surface ECG which was not 
sensed by the device (see marker channel) and did not result in spurious 
arrhythmia detection or inhibition during the pacing operation. The noise in- 
teraction was more intense when the phone was placed within 5-10 cm from 
the telemetry wand, and especially during dialing. 
..... : : i ~ " t l  ~ ~ 1 
Conclusions: GSM technology mobile phones do not affect ICD function 
even when they are held in close vicinity of the devices. EMI generated by 
cellular phones does not cause inappropriate ICD therapy. 
l l  I Need for Exercise Testing for Optimal  I 1 45-1 8o The 
Programming of the EGM Width Criterion in 
Patients With an Implantable Defibrillator 
Firat Duru, Mariette Sch(3nbeck, Reto Candinas. University Hospital, Zurich, 
Switzerland 
Background: The Electrogram (EGM) Width Cdtedon, which is the first 
digital signal processing feature used in an implantable cardioverter-defibril- 
lator (ICD), intends to increase ventdcular tachycardia (VT) detection speci- 
ficity by rejecting inappropriately detected supraventricular tachyarrhythmias. 
This study was aimed to evaluate EGM Width measurements during exer- 
cise-induced sinus tachycardia. 
Methods: 21 pts with Medtronic Micro Jewel Model 7223 ICDs were 
included in the study. The EGM Width Criterion was tested under resting 
conditions for baseline measurements. The optimal slew thresholds were 
determined that provided width measurements within a 12 ms range and the 
width thresholds were set to a value 4 ms longer than the widest measured 
sinus rhythm EGM. A modified chronotropic assessment exercise protocol 
was performed with speed increments every minute. EGM Width test was 
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repeatedly performed during exercise-testing in order to detect potential 
inappropriate EGM width measurements leading to false VT confirmation. 
Results: In 7 of the 21 Lots (33%) a minimum of 6 out of 8 sinus beats 
were inappropriately measured as wide complexes at least once during 
exercise-testing, satisfying the EGM Width Criterion for VT confirmation. 11 
other pts had inappropriate wide EGM measurements, but not satisfying the 
criterion. The causes of wide EGM Width measurements were: a) an actual 
increase in EGM Width of 4 ms or more during sinus tachycardia in 10 pts, 
which caused inappropriate VT confirmation in 4 Lots, and b) inappropriate 
detection of baseline irregularities, reaching the slew threshold, as EGM 
onset or offset points in 8 pts, resulting in false VT confirmation in 3 pts. 
Conclusion: The EGM Width Criterion may classify intracardiac elec- 
trograms as wide complexes during sinus tachycardia causing false VT 
confirmation. We recommend to test the criterion during exercise-testing and 
set the thresholds accordingly for optimal ICD function. 
[ 1145-1811 Programming of a Rate Stability ___ 40 ms Can 
Cause Delayed Detection of Ventricular 
Tachycardia: Prospective Analysis of 485 
Spontaneous Ventricular Tachyarrhythmias 
Susanne Spehl, Werner Jung, Christian Woipert, 8urghard Schumacher, 
Rainer Schimpf, Christian Schneider 1 , Bahman Esmailzadeh ~ ,
Bemdt LQdefitz. Depts. of Cardiology; ~ Cardiovascular Surge~ University 
of Bonn, Bonn, Germany 
Better discrimination of supraventricuLar and ventricular tachyarrhythmias 
(VT) in patients with an implantable defibrillator (ICD) can be achieved by 
enhanced detection criteria such as rate stability and sudden onset crile- 
rion. However, preservation of a high sensitivity has to be guaranteed. It is 
known for ventricular tachycardias to be more stable than atrial fibrillation 
with rapid ventdcular response. Yet, there is a high stability described for 
atrial tachycardias and varying cycle lengths (CL) at the onset of ventricular 
tachycardias. Aim of the study was to assess the RR-interval-stability of VT 
for beginning and later course of the episode in order to obtain information 
about stability threshold programming and potential delay of detection. 
Patients and Methods: 485 stored electrograms and RR-intervals of 
42 patients were analysed. Stability was determined for the CL max/min 
of the first 5 tachycardia intervals, all 4 consecutive intervals as a gliding 
window and minimal and maximum CL for the 16-24 detection intervals. The 
tachycardias were divided in groups with slow, medium and fast heart rate. 
Results: 
Tachycardia Stability _< 40 ms 
CL Intervals 1-5 Interval 5-18/24 
460-320 ms 138/230 E 223/230 E 
320-280 ms 91/197 E 181/197 E 
<280 ms 29/58 E 53/58E 
Conclusions: 1. At the onset of VT, cycle length varies significantly more 
than during the later course of the arrhythmia. This can be observed in both 
slow and fast VT. 2. Due to the higher variation a delayed detection can 
occur at the onset of the tachycardia. 3. During the ongoing tachycardia the 
RR-interval-stability is in more than 90% of the episodes _< 40 ms. 
1145-1 1 The Upper Limit of Vulnerability 82 Predicts 
Biphasic Waveform Defibrillation Energy 
Requirements Better Than Monophasic 
J. Jason Sims, Allison W. Miller, Michael R. Ujhelyi. University of GA, 
Medical College of GA, Augusta VA Medical Center, Augusta GA, USA 
Background: Upper limit of vulnerability (ULV) is used as a surrogate of 
defibrillation energy requirements (DER). However, recent data suggests 
that the ULV may not adequately describe a shock's proarrhythmic effects 
since ventricular fibrillation (VF) can be induced at multiple coupling inter- 
vals. Therefore, we determined the predictability of ULV and the area of 
vulnerability (AOV) for DER values. 
Methods: AOV and ULV were determined in swine randomized to receive 
bipbasic shocks (BS) (n = 11) or monophasic shocks (MS) (n = 13). Shocks 
were delivered at 5 coupling intervals (160-240 ms) and 10 shock strengths 
(50-500V) after the last paced beat of an 18 beat 300 ms cycle length drive 
train. AOV, defined by a 2-dimensional grid according to shock strength 
(y-axis) and coupling interval {x-axis), is reported as the number of points in 
the grid that induced VF. ULV was defined as the highest energy shock that 
induced VF regardless of coupling interval. DERso values were measured 
using an up/down method. 
Results: ULV and AOV strongly correlated with DERso values for both BS 
and MS (see figures). However, multiple linear regression analysis revealed 
that BS DER values are best predicted by ULV, while MS DER values are 
best predicted by AOV. 
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Conclusions: Biphasic DER values are best predicted by the ULV due to 
the small AOV and less proarrhythmic activity of BS. MS are more proarrhyth- 
mic and thus DER values are best predicted by accounting for vulnerability at 
multiple coupling intervals (AOV). These data indicate that the defibrillation 
mechanisms for MS and BS may be different. 
1145-183 t Acute Results With a New Single Pass, Right 
Ventricular Defibrillation Lead Capable of Pacing 
and Sensing in the Right Atrium and Ventricle 
Rainer Gradaus, Anja Dorszewski, Andreas. Kleemann, Dieter Hammel 1 , 
Dirk Backer, GQnter Breithardt, Michael Block. 1Department of Cardiology & 
Angio/ogy and Cardiovascular Surgery, Westf~/ische Wi/he/ms-Universit~t 
MOnster, Germany 
Background: In patients (pts) with implantable cardioverter-defibrillator (ICD) 
atrial sensing is desired to avoid inappropriate shocks due to supraventricular 
tachycardias (SVTs). Additionally, many pts with left ventficular dysfunction 
or conduction disease will benefit from dual chamber pacing. However, dual 
chamber pacing requires an additional lead and exposes the pts more fre- 
quently to lead failures. If adequate dual chamber sensing and pacing can 
be achieved by a single pass lead without the need for a separate atrial 
pace/sense lead is unkown. 
Methods: In nine pts, a new single pass, right ventricular defibrillation lead 
(Medtronic, model 14108) with integrated bipolar ventricular and true bipolar 
right atrial pacing and sensing was tested actually. Pacing and sensing in 
the right atrium occurred between an atrial ring and an electrode on a line 
13.5 cm or 15.5 cm proximal to the fight ventdcular tip. In order to enhance 
the contact between these electrodes and the atrial wall, the lead had a 90 g 
curve just distal to the atrial electrodes. In the first 5 pts, the shorter lead 
was used, in the following 4 pts the longer one. Intraoperatively, the lead 
was positioned twice in every patient. Measurements were obtained directly 
after the lead was positioned in the fight ventricle under fluoroscopy without 
optimizing the position of the atrial lead at the lateral wall. In five pts an atrial 
pace/sense lead (model 6940) was finally implanted in combination with a 
DDD-ICD. 
Results: Handling of the lead was easy in 6 pts and complex in 3 pts. 
The optimal of the two measurements were 1.7 ± 1.1 mV for sensing and 0.4 
± 0.2 V at 0.5 ms pulse width for pacing. In 1/4 pts, no acceptable capture 
was achieved with one of the two position using the longer AV-distance lead, 
and in 3/5 pts using the shorter AV-distance lead the pacing threshold was 
high for one position. Values obtained for the chronically implanted atrial lead 
were comparable to the ones of the experimental ead (2.4 ± 1.4 mV versus 
2.1 4- 1.3 mV; 0.8 4- 0.3 V at 0.5 ms versus 0.4 4- 0.2 V at 0.5 ms) 
Conclusions: Acute results with a single pass, fight defibrillation lead 
capable of pacing and sensing in the right atrium and ventricle are promising. 
Further investigations with chronically implanted leads have to be awaited. 
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1 46-1841 Gender-Dependent Relation Between QT 1 Interval 
and Its Components and Cardiac Cycle Length 
in Apparently Normal Population 
Irina Savelieva, Katerina Hnatkova, A. John Carom, Marek Malik. St. 
George's Hospital Medical School, London, UK 
Background: An abnormal bradycardia-sensitive prolongation of ventricular 
repolarization in long QT syndrome is associated with lethal arrhythmias. 
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Methods: Because of high prevalence of this syndrome in women and 
known gender-specific difference in the QT interval and its components, 
the relation between QT, QT peak (QTp), T peak-Tend (TpTe) intervals and 
RR interval was assessed in 1096 normal subjects (910 males, age 32 ± 
11; 186 females, age 35 ± 15). Measurements were made automatically 
using QT Guard software (Marquette Medical Systems, Milwaukee, WI). The 
slopes of linear regressions of QT, QTp and TpTe intervals plotted against 
the corresponding RR interval were computed. 
Results: A strong linear correlation between QT, QTp intervals and car- 
diac cycle length was observed in all subjects (r = 0.81 and 0.79 resp., p < 
0.0001). There was a weak correlation between TpTe and RR intervals (r = 
0.33, p < 0.02). Both the maximum and mean QT/RR and QTp/RR slopes 
were significantly steeper in women compared to men (p < 0.05). This was 
true for all age groups (17-29, 30-49, 50--80). Women demonstrated more 
labile relations between ventricular epolarization and cycle length, i.e. in- 
crease in steepness of QT/RR and QTp/RR and decrease in TpTe/RR with 
age, while in male population the QT/RR, QTp/RR and TpTe/RR relation 
remained stable in all the three age groups. 
Slopes All subjects Males Females 
QT/RR max 0.1463 0.1471 0.1715 
QT/RR mean 0.1410 0.1434 0.1559 
QTp/RR max 0.1292 0.1312 0.1504 
QTp/RR mean 0.1281 0.1318 0.1430 
TpTe/RR max 0.0105 0.0105 0.0091 
TpTe/RR mean 0.0124 0.0115 0.0116 
Conclusion: The gender-related difference in steepness of regression 
slopes in apparently healthy population may indicate gender-specific auto- 
nomic modulations and explain, in part, a higher risk of drug-induced torsades 
de pointes in women. The heart rate-dependent QT interval; variability may 
be more essential for assessment of ventricular epolarisation than QT inter- 
val itself. The terminal part of ventricular epoladzation (TpTe interval) is less 
affected by both the heart rate and autonomic modulations. 
1 46-185 t Circle Maps of Respiratory Sinus Arrhythmia 
I 
1 
Patterns: A New Method to differentiate Cardiac 
Denervation From Vagal Modulations After AV 
Node Modification 
Markus Zarse, Kai Marcus, Michael Schiek, Wolfgang Drepper, 
Peter Hanrath, Christoph Stellbrink. University Hospital Aachen, Germany 
Background: A decrease in time and frequency domain of heart rate vari- 
ability can be seen both after AV nodal modification (NM) and with aging. 
Respiratory sinus arrhythmia (RSA) is an indicator of vagal cardiac inner- 
ration, which decreases with age and after AVNM. Circle maps (CM) are a 
new method for analyzing nonlinear cardiac dynamics underlying the RSA 
pattern. Differences in CM are quantified by the Kulback information (KI), 
increased KI showing decreased vagal innervation. We hypothesized that 
CM can differentiate vagal denervation from modulations in vagal input due 
to destruction of ganglia in fat pads adjacent to the ablation site. 
Methods: 12 young (22 ± 4 years 8 m, 4f) and 11 old (58 ± 11 5 m, 
6f) probands with no cardiopulmenary disease underwent 24 hour holter 
monitoring (H) and a paced breathing (PB) protocol. 10 consecutive patients 
(46 ± 19 years, 7 f, 3 m) underwent H and the same PB protocol before 
and after AVNM. In H high frequency (HF) and low frequency (LF) bands as 
well as LF/HF ratio were analyzed. Amplitudes (A) of RSA were analyzed for 
spontaneous breathing (SB) and PB. CM were obtained and differences in 
cardiac dynamics were analyzed with the Kt. 
Results: 
HF ms 2 LF/HF SB-A ms SB KI PB-A ms PB-A KI 
young 970 -E 83 2.4 4- 0.4 92 4- 37 0.41 4- 0,03 230 ± 90 0.40 4- 0.07 
old 260±104"  3 .6±1.8"  43-}-16" 0.554-0.07* 74±24"  0.564-0.09* 
pre 696 ± 285 1.8 ± 0.6 53 4- 28 0.34 ± 0.08 138 ± 74 0.45 ± 0.08 
post 287 i 125" 2.8 ± 1.3" 39 4- 21+ 0.3 ± 0.08+ 127 4- 86+ 0.47 4- 0.09+ 
• p < 0.05, + p = NS (Compared to young or pre = before NM, post = after NM) 
Conclusions: Conventional frequency domain analysis cannot differen- 
tiate between denervation and vagal modulation. After AVNM HF and LF/HF 
but not SB-KI and PB-KI are altered indicating vagal modulation but not 
cardiac denervation. 
I1 j Exercise-Induced QT-Interval Changes for 
7 
1 46-1 86  
Predicting Improvement in Regional Myocardial 
Blood Flow and Cardiac Output After Coronary 
Angioplasty in Patients With Right Bundle 
Branch Block 
Takuya Watanabe, Takashi Katagiri, Kenichi Harumi. Showa University 
School of Medecine, Tokyo, Japan 
Background: We showed that exercise-induced QT-interval changes are 
even more useful than ST-T changes in evaluating myocardial ischemia in 
patients with RBBB. The purpose of this study was to evaluate whether 
improvements in regional myocardial blood flow (RMBF) in ischemic areas 
and cardiac output (CO) after PTCA can be predicted preoperatively by 
exercise-induced QT-interval changes. 
Methods: The RMBF and CO were quantified with 13N-ammonia PET at 
rest and during exercise in 20 male patients with RBBB and CAD before and 
6 months after PTCA and in 9 healthy male volunteers. 
Results: Before PTCA, exercise-induced shortening of the QT interval 
(422 ± 30 to 380 i 27 ms, p < 0.001) was observed in 13 patients (group 
1) and prolongation or no change (416 4- 36 to 424 ± 32 ms, p = NS) 
was observed in 7 (group 2). The number of regions of critical CAD was 
significantly greater in group 2 than in group 1 (4.0 ± 1.2 vs 2.1 ± 1.2, 
p < 0.01). The RMBF in regions of critical CAD and CO at rest were not 
significantly different between groups 1 and 2, whereas during exercise both 
the parameters were significantly lower in group 2 than in group 1 (both p < 
0.05). Six months after PTCA, no restenosis was observed in each patient. 
The RMBF (mlJmin/g) both at rest and during exercise improved significantly 
in group 1 (0.67 ± 0.04 to 0.71 ± 0.06, p < 0.01; 0.74 i 0.05 to 0.84 ~- 0.08, 
p < 0.0001) but did not improve significantly in group 2 (0.63:5 0.05 to 0.65 
± 0.07, 0.65 -Jc 0.04 to 0.69 ± 0.11; both p = NS). The CO (L./min) both at 
rest and during exercise improved significantly in group 1 (4.4 ± 0.5 to 5.1 ± 
0.5, 6.4 ± 0.7 to 7.4 ~ 0.9; both p < 0.002) but not in group 2 (4.5 ± 0.6 to 
4.8 ± 0.4, 5.7 ± 0.6 to 5.9 ± 0.6; both p = NS). 
Conclusions: Our results suggest that the absence of QT-interval short- 
ening during preoperative exercise may predict a lack of improvements in 
blood flow in ischemic myocardium and CO after PTCA in patients with 
RBBB. 
I1146-1871 Rate-Related in Cardiac Changes Repolarization: 
i QT interval Versus Monophasic Action Potential 
Duration 
Rupa Subramanian, Alaa Shalaby, Philip Sager. UCLA and West Los 
Angeles VAMC, Los Angeles, CA, USA 
Background: While the QT interval is commonly used as a noninvasive 
measure of cardiac repolarization, data comparing the QT interval to a direct 
measurement of cardiac repolarization over a wide range of atrial cycle 
lengths is lacking. This is important since QT determinations are being 
increasingly scrutinized to identity pts at increased risk for developing sudden 
death. 
Methods: The QT interval and the RV monophasic action potential du- 
ration at 90% repolarization APDg0) were determined during steady state 
high right atrial pacing over a wide range of cycle lengths (750 ms-350 ms) 
in 18 patients without conduction abnormalities undergoing cardiac clinical 
electrophysielogic study in the drug-free state. QT intervals were measured 
in all 12 leads and the mean QT interval was calculated. Data was fit to a 
curve for each patient and the slope was determined. 
Results: The relationship between mean QT and APDgo is shown in 
the adjacent figure and demonstrates that over the range of cycle lengths 
examined there is a close correlation (r = 0.74) between these 2 measures 
of repolarization. 
38O 
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Conclusion: The mean QT interval closely correlates with the RV APDgo 
and is an excellent noninvasive measure of cardiac repolarization over a 
wide range of heart rates. 
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1146-188 I Heart Rate Turbulence in Patients With and 
Without Autonomic Dysfunction 
Petra Barthel, Georg Schmidt, Raphael Schneider, Kurt UIm, Marek Maiik ~ ,
Albert Sch0mig. Medizinische Klinik & Deutsches Herzzentrum, Technische 
Universit~t MOnchen, MQnchen, Germany,; ~ St. George's Hospital Medical 
School, London, UK 
Background: Heart Rate Turbulence (HRT) is a phenomenon, described by 
our working group, based on fluctuations of sinus rhythm cycle length after 
single ventricular premature beats (VPBs). HRT is a biphasic reaction and 
can be quantified by two numerical parameters (turbulence onset: TO; and 
turbulence slope: TS). Both parameters are potent risk stratifiere in post-MI 
patients which are independent of each other and other known risk factors. 
We hypothesize that TO and TS reflect specific autonomic regulations. This 
study was performed to investigate whether HRT is affected by autonomic 
dysfunction. 
Methods: In 100 patients (pts) with coronary artery disease, HRT was 
assessed using Holter-ECGs. TO and TS were dichotomized into 'normal' 
and 'abnormal' values using predefined cut-off-points. Pts were divided into 
two groups according to the history of diabetes mellitus (GO: no diabetes, 
GI: diabetes). Univariate and multivariate Cox regression analysis was per- 
formed to test the differences between the two groups. In the multivariate 
analysis, age, history of previous infarction, left ventricular ejection fraction 
(LVEF), mean heart rate, and SDNN were included. Primary endpoint was 
cardiac mortality. 
Results: With the univadate approach, TO was a significant predictor of 
cardiac mortality in GO and G1 (p < 0.05 respectively). TS was a significant 
predictor in GO (p < 0.0001), but not in G1 (p = 0.56). With the multivariate 
approach, we found 3 independent risk parameters (TS p < 0.001, LVEF p 
< 0.05, age p < 0.05) in GO. In G1, LVEF was the only independent variable 
(p < 0.02). 
Conclusion: Our findings support our hypothesis that TS is mediated by 
a autonomic reflex presumably a baroreflex activated by the changes of the 
arterial pressure during and after VPBs. 
1 I The Influence of Cigarette Smoking on Time 
I 
1 46-1 89 
Domain Measures of Heart Rate Variability in 
Healthy Volunteers 
John Frew, Gall Borthwick, James M.M. Neilson, Andrew D. Flapan. 
Departments of Medical Physics and Cardiology, University of Edinburgh, 
Royal Infirma~ Edinburgh, UK 
Background: Upto 50% of deaths from acute myocardial infarction (AMI) are 
sudden and most frequently occur as a result of lethal ventdcular arrhythmias. 
Smoking cigarettes increases the risk of AMI, and in an analysis of the CAST 
study, a marked reduction in arrhythmic death occurred in those who had 
stopped smoking. The role of the autonomic nervous system in the genesis 
of lethal ventricular arrhythmias is well established and decreased heart rate 
variability (HRV) may predict those survivors of AMI at risk of arrhythmic 
death. Nicotine is a powerful partial agonist at parasympathetic ganglia and 
we, therefore, sought to demonstrate the effects of cigarette smoking on 
HRV. 
Methods: Ten healthy male occasional smokers (aged 21-25 years) 
had 24 hour electrocardiographic recordings on 2 separate occasions. On 
one occasion smoking was not allowed, but on the other, individuals were 
encouraged to smoke at least one cigarette per hour. Blood samples were 
taken to measure carboxy-hemoglobin at the end of the recording. 
Results: Mean ± standard deviation 
No Smoking Smoking P 
Carboxyhemoglobin (%) 0.7B ± 0.08 2.63 ± 0.40 0.008 
sNN50 (log counts) 4.104 ± 0.032 3.958 ± 0.043 0.001 
SD 219:5 11 204 ± 7 0.018 
RMSSD 68 ± 7 51 ± 5 0.004 
Conclusions: Smoking is associated with reductions in time domain 
measures of HRV. If smoking causes profound effects on HRV, then further 
studies are required to determine whether smoking predisposes to arrhyth- 
mias through its action on the autonomic nervous system, Alternatively, HRV 
may simply identify patients who continue to smoke and are, therefore, at 
increased risk. 
ORAL  
Atrial Fibrillation: Ablation 
Tuesday,  March  9, 1999, 10:30 a .m. -Noon 
Moda l  Convent ion  Center ,  La Lou is iane  A 
10:30 a.m.  
~-- ]  Primary Ablation of Atrial Fibrillation: Impact of 
Completeness of Right Atrial Ablation Lines on 
Symptomatic Outcome 
Feifan Ouyang, Sabine Ernst, Michael SchlQter, Karl H. Kuck. St. Georg 
Hospital, Hamburg, Germany 
Using the CARTO" mapping system in 32 consecutive pts with idiopathic 
atrial fibrillation (AF), the right atrium (RA) was compartmentalized by 3 RF 
ablation lines: a line severing the isthmus (isthmus line) between vena cava 
inferior (VCI) and tricuspid annulus (TA), an intercaval ine between VCI and 
vena cava superior (VCS), and an anterior line between TA and VCS. An 
intentional gap was left in the superior part of the intercaval line. Cdteda to 
validate line completeness comprised demonstration of bidirectional conduc- 
tion block, change in activation sequence along the posterolateral RA, double 
potentials along ablation lines, and change in the CARTO propagation map. 
Results: Lines were validated in 26 pts (81%). In 15, complete linear le- 
sions (apart from the intended intercaval gap) could be demonstrated. Among 
them, significantly more pts (p = 0.04) reported a symptomatic improvement 
during a mean follow-up of 5.4 ± 2.8 months than did the 11 pts with in- 
complete lines (Figure). Improvement of symptoms correlated with repeated 
ECG and Holter findings demonstrating sinus rhythm, atrial ectopy and/or 
reduced number or duration of AF episodes. LA fibrillation was still inducible 
in 3 of 9 pts with complete RA lines. 
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Conclusions: Complete RA ablation lines are associated with an im- 
proved clinical outcome compared 1o incomplete lines. In primary RA ablation 
of AF, every attempt should be made to achieve completeness of ablation 
lines. LA fibrillation may persist in the presence of complete RA ablation 
lines. 
10:45 a.m.  
~-~- ]  Criteria for a Complete and Trsnsmural Anterior Line 
in Primary Right Atrial Ablation for Idiopathic Atrial 
Fibrillation 
Sabine Ernst, Feifan Ouyang, Riccardo Cappato, Michael Schl~ter, Kad 
H. Kuck. St. Georg Hospital, Hamburg, Germany 
Using the CARTO TM mapping system in 32 consecutive pts with idiopathic 
atrial fibrillation (AF), the right atrium (RA) was compartmentalized by 3 RF 
ablation lines: a line severing the isthmus (isthmus line) between vena cava 
inferior (VCI) and tricuspid annulus (TA), an intercaval ine between VCI and 
vena cava superior (VCS), and an anterior line between TA and VCS. An 
intentional gap was left in the superior part of the intercaval ine. 
Results: In all 32 pts, conduction block along the isthmus line was demon- 
strated during pacing from the coronary sinus and the posterolateral RA wall 
by a distinctive difference in the activation sequence in a posterolaterally 
placed multipolar catheter. Following block in the isthmus, in 14/32 pts com- 
pleteness of the anterior line was also associated with a sudden change 
in the activation sequence from the same multipolar catheter along the the 
pre post ~L~ 
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posterolateral RA wall (Figure). The previously earliest activation recorded 
in the proximal electrodes (pR 1-9) then shifts towards the middle to distal 
electrodes (dR 3--8) of the multipolar catheter, This shows that during pacing 
from the coronary sinus the RA is now activated from infedor posterior wall 
to superior posterior wall. At the same time, the p wave during sinus rhythm 
changes from a monophasic to a biphasic morphology in lead II, reflecting a 
markedly delay in interatrial conduction. 
Conclusions: For primary RF catheter ablation of idiopathic AF, complete 
and transmural lesions along the RA anterior line can be demonstrated by 
a distinctive change in posterolateral RA activation and a biphasic p-wave 
morphology in the surface ECG. 
11:00 a .m.  
~ Local Electrogram Characteristics of Pulmonary 
Vein Foci in Patients With Focal Source of Atrial 
Fibrillation 
Hung-Fat Tse, Chu-Pak Lau, William Kou, Gregory F. Michaud, Bradley 
P. Knight, Rajiva Goyal, S. Adam Strickberger, Fred Morady. The University 
of Hong Kong, Queen Mary Hospital, Hong Kong, China; University of 
Michigan Medical Center, Ann Arbor, MI, USA 
Background: Atrial fibrillation (AF) can be triggered by ectopic foci within 
a pulmonary vein (PV). The purpose of this study was to characterize the 
electrograms (EGM) recording at these PV foci. 
Methods and Results: We studied the characteristics of local EGMs 
inside the PV in 15 patients (pts) (12 M, 3 F; mean age: 41 yrs) with 
structurally normal heart and AF triggered by PV foci. All pts had frequent 
atrial premature beats, runs of nonsustained AF or spontaneous re-initiation 
of AF after defibrillation to allow mapping of the foci. Mapping of the PV was 
performed by transeptal approach and the sites of PV foci were confirmed 
by earliest atrial activation and by successful radiofrequency ablation (RFA). 
14/15 pts had acute successful RFA. The PV loci originated either at the 
ostium (4) or inside (10) the PV: left superior (7) or inferior (1), or right 
superior (6), with a coupling interval of 247 4- 46 ms. The PV loci had more 
fragmented EGMs (73 :~ 12 ms vs 57 4- 14 ms, p < 0.05) and earlier local 
activity (91 4- 24 ms vs 50 4- 18 ms before the ectopic P wave, p < 0.05) than 
other PV sites. A discrete PV spike at the focus was observed during sinus 
rhythm in 9/14 (64%) pts. The ectopic beats that initiated AF were marked by 
either increased fragmentation of the EGM (3) or separation into two EGM 
components (PV and local atdal EGM) (11). Local exit block within the PV 
focus was observed in 6/14 case (27%). RFA resulted in either loss of the 
PV spike (6) or decreased in local EGM amplitude (8). 
Conclusions: Local PV EGM characteristics, including the presence of 
fragmented EGM, PV spike, separation or increasing EGM fragmentation 
in the ectopic beats that initiated AF, and the local exit block are helpful in 
guiding the mapping and RFA of a focal source of AF. 
11:15 a.m. 
~-~ Catheter Ablation of Left Atrial Tract (Marshall) from 
the Coronary Sinus 
Hiroshi Nakagawa, Kagari Matsudaira, Benjamin J. Scherlag, ,Jan V. Pitha, 
William S. Yamanashi, Ralph Lazzara, Warren M. Jackman. Univ of 
Oklahoma, OKC, OK, USA 
Recent studies show the left atrial tract (LAT) within the ligament of Mar- 
shall may be arrhythmogenic (focal atrial fibrillation). The purpose was to 
determine whether the musculature (CSM) lining the coronary sinus (CS) 
provides the LAT-LA connection and allows LAT ablation from CS. Five dogs 
(24-28 kg) underwent a left thoracotomy. Two 20-electrode catheters (2-4-2 
mm spacing) were placed into the CS and along the ligament of Marshall 
(LAT) on the epicardium. During superior LAT pacing, earliest atrial activa- 
tion was recorded at the distal end of CSM (posterolateral CS, arrow in fig 
1. LAT 2. Anterior 3. Post 
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1) in 5/5 dogs, suggesting LAT-CSM connection. Anterior LA pacing allowed 
separation between LA and CSM potentials in CS, which was followed by 
LAT potential (fig 2). A single application of RF current within CS at the distal 
end of CSM (arrow) eliminated LAT conduction during anterior LA pacing (fig 
3) in 2/2 dogs. Histological sections through the ligament of Marshall at the 
level of the posterolateral CS showed LAT joined the CSM. 
Conclusions: 1) LAT connects to CSM at the posterolaterat region, and 
2) RF ablation at this site eliminates LAT conduction and may eliminate focal 
AF in some pts. 
11:30 a.m. 
~8~-]  Right Atrial Mural Swell ing and Its Effect on 
Adjacent Great Vessels from Linear Radiofrequency 
Ablation for Atrial Fibrillation 
Jian-Fang Ren, David Schwartzman, Susan E. Brode, David J. Callans, 
Farooq A. Chaudhry, Francis E. Marchlinski. Allegheny University Hospitals, 
Philadelphia; University of Pittsburgh, Pittsburgh, PA, USA 
We have observed that right atrial (RA) radiofrequency (RF) ablation consis- 
tently causes RA mural swelling and may produce adjacent right pulmonary 
vein (RPV) and aortic (Ao) wall edema in an animal model. To further evaluate 
these effects in man, we measured RA wall thickness (THK) adjacent to the 
lower RPV (THK-I), ascending Ao (THK-II) and Ao root (THK-III) and the RPV 
lumen diameter in 10 pts (age 46-68 yrs) Pre- and immediately Post-ablation 
(4 mm length electrode, thermometry/atrial EKG guided-power) with three RA 
linear lesions (intercaval, septal and medial isthmus) guided by intracardiac 
echocardiographic (9 MHz) imaging and electroanatomic mapping (CARTe). 
RA septal line guided by ICE avoided ablation at RA sites directly contiguous 
to Ao. Results in Table (*p < 0.01, vs. Pre-): 
Wall THK-I THK-II THK-III RPV lumen 
Pre- (mm) 5.4 ± 1.5 6.2 ± 1.7 6.8 ± 1.6 8.0 ± 2.9 
Post- (mm) 9,4 ± 3.1" 7.6 ± 2,2" 8.9 ± 1.8" 6.2 ± 2.9" 
Significantly increased RA wall THK contiguous to Ao root and ascending 
Ao (from intramural and interstitial edema extension, medial septal linear 
lesions), and narrowing of RPV (intercaval posterior lesions) were observed 
immediately post-linear ablation for atrial fibrillation. 
Conclusions: RA linear RF ablation using the techniques applied causes 
swelling of the RA wall. In addition, swelling of non-RA structures contiguous 
to the RF sites was evident. The clinical significance of these effects on the 
adjacent aorta and RPV lumen narrowing needs to be further determined. 
11:45 a.m.  
~8~ Evolution of Right Pulmonary Vein Lumen Narrowing 
After Right Atrial Linear Radiofrequency Ablation 
Jian-Fang Ren, David Schwartzman, Susan E. Brode. Allegheny University 
Hospitals, Philadelphia; University of Pittsburgh, Pittsburgh, PA, USA 
We have observed in a large porcine model that linear radiofrequency (RF) 
ablation in the posterior right atrium (RA) causes immediate swelling of 
the walls of contiguous right superior pulmonary vein (RPV), resulting in a 
decrease in RPV luminal diameter (LD). The purpose of the present study 
was to characterize the magnitude and time course of this phenomenon. 
Methods: In 12 healthy swine, a single intercaval "linear" RF lesion 
was made in RA posterior central smooth wall. Lesion deployment (stan- 
dard ablation electrode, thermometry guided-power titration) was guided by 
intracardiac echocardiography (ICE, 9 MHz) and electroanatomic mapping 
("CARTe"). Using ICE, the RPV contiguous to the RA is imaged (Figure), per- 
mitting precise wall thickness (THK) and LD measurements. In each animal, 
THK and LD were measured Pre- and immediately Post-lesion deployment. 
Animals subsequently underwent repeat measurement at intervals of 1 week, 
and 1,2 and 3 months. Results in Table (*p < 0.05, vs. Pre-): 
Pre- Post- 1 week 1 month 2 month 3 month 
THK (mm) 1.8±0.6 6.1±1.1" 4 .2 t0 .5"  1.8 ± 0.2 2 .5±0.7  2.7:£0.6 
LD (mm) 7,5 ± 1,7 5.0 ± 1.5* 4.5 ± 0.7" 6.3 ± 1,0 5.8 ± 2.5 8.1 ± 3.6 
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Conclusions: Increased RA wall THK and decreased RPV LD began 
acutely after lesion deployment. The magnitude of THK increase and LD 
decrease was maximal early, and had resolved by I month. Alteration in left 
atrial structure by RA linear ablation may require consideration in designing 
clinical protocols for RF ablation. 
ORAL  
Abnormal Repolarization and Ventricular 
Arrhythmias 
Tuesday ,  March  9, 1999,  10 :30  a .m. -Noon 
Mor ia l  Convent ion  Center ,  Room 345 
10:30  a.m. 
[~- ]  Efficacy Limitations of Beta-Blocker in and Therapy 
Long QT Syndrome 
Arthur J. Moss, Wojciech Zareba, W. Jackson Hall, Jennifer L Robinson, 
Jesaia Benhorin, Emanuela Locati Heilbron, Jeffrey Tewbin, Aharon Medina, 
Mark Andrews. University of Rochester Medical Center, Rochester, NY, USA 
Background: Although /3-blockers (BB) are routinely prescribed (Rx) in 
LQTS, principally to prevent syncope and sudden death, there has not been 
a study systematically evaluating the safety and efficacy of BB therapy in this 
disorder. 
Methods: This study involved 310 probands and 169 affected family 
members (AFM) from the Rochester and Israeli portion of the International 
LQTS Registry who had BB Rx for LQTS. Each pt. served as his/her own 
control, with matched durations of at least one-year of risk exposure before 
and after BB (average 6 years), with analysis by intention-to-treat. 
Results: BB were associated with a reduction in the yearly rate of cardiac 
events (syncope, aborted cardiac arrest, or LQTS-related death) in probands 
(from 0.59 ± 1.56 to 0.20 ± 0.44 events/yr; P < 0.001), but not in AFM (from 
0.12 • 0.72 to 0.18 ± 0.93 events/yr., P = NS). Of note, 8.4% of probands 
and 4.1% of AFM had life-threatening or fatal cardiac events after starting 
BB; 14 pts. died after initiation of BB (0.5%/yr.) even though 79% had an 
active prescription for BB at the time of death. The chance of having at least 
one cardiac event within 5 yrs. after starting BB was 37% in probands and 
15% in AFM. 
Conclusion: BB therapy results in a significant reduction in the yearly 
rate of cardiac events in probands. However, life-threatening arrhythmias and 
fatal cardiac events continue to occur after initiation of BB in some probands 
and AFM. These findings indicate the need to identify LQTS pts. who do not 
benefit from BB, for these are the pts. who require further life-saving therapy. 
1 0 :45  a.m. 
~2-]  Sudden in and Patients With the Death Relatives 
Syndrome of Right Bundle Branch Block and ST 
Segment Elevation from V1 to V3 
Pedro Brugada, Josep Brugada 1 , Ramon Brugada 2. Cardiovascular 
Research and Teaching Institute Aalst, Belgium, ~ Hospital Clinic, 
Barcelona, Spain; 2 Baylor College of Medicine, Houston, Texas, USA 
Background: The syndrome (Synd) with an electrocardiographic pattern 
of right bundle branch block, ST segment elevation in leads V1 to V3 and 
sudden death (SD) is caused by mutations in the gene encoding the cardiac 
sodium channel (SCN5A). The inheritance is autosomic dominant. SD may, 
however, occur from a variety of causes in relatives and patients (pts) with 
this Synd. 
Methods: Seventeen Flemish families with this Synd (total of 270 mem- 
bers) were studied. Affected members were recognized by means of ECG, 
ajmaline, flecainide or procainamide IV test. SD (aborted or not) in pts in 
whom tests were not available were classified as related or not to the Synd 
by analysis of the mode of inheritance. Four families (48 members) with the 
Synd were asymptomatic, in 13 families (232 members) at least 1 SD related 
to the Synd occurred (symptomatic families). 
Results: Of the 270 members, 38 were affected. In total, 37 SD's occurred 
(14%). Twenty two SD's (60%) were related to the Synd and all happened in 
symptomatic families. Fifteen SD (40%) were of unclear cause. Two of them 
occurred in one asymptomatic family, and the remaining 13 in 5 symptomatic 
families. Twenty-two of 38 affected pts (58%) suffered SD, which was statis- 
tically higher than the total incidence of SD in non-affected pts (15 in 232 or 
6%, p < 0.0001). 
Conclusiona: In families at high risk of SD because of arrhythmic genetic 
diseases transmitted with an autosomal dominant pattern, the cause of SD 
is related to the genetically determined disease in affected pts. However, 
40% of SD in these families are of unclear cause and probably not related 
to the disease. Accurate classification of the causes of SD is mandatory for 
analysis of genetically determined diseases. 
11:00 a .m.  
[ -8 -3~ Differential Response of QT and QU Intervals to 
Adrenergic Stimulation in Long QT Patients With IKs 
Defects 
Li Zhang, Steven J, Compton, Charles Antzelevitch, Katherine W, Timothy, 
G. Michael Vincent, Jay W. Mason. University of Utah Division of 
Cardiology, and LDS Hospital, Salt Lake City, UT, USA 
Background: There is controversy concerning whether the U wave is part of 
the T wave, and whether the U wave should be included in the QT measure- 
ment. A difference in QT and QU responses to adrenergic stimulation would 
indicate independence of T and U waves. 
Methods: Six LQT1 (age 31 ± 10 years, 3 female) and 6 normal con- 
trols (age 29 ± 6 years, 3 female) were studied. QT and QU intervals were 
measured in lead V2 during atrial pacing at baseline and during isopro- 
terenol infusion (ISO). Within each group, intervals were compared during 
pacing at the same rate for each patient, using the Wiicoxon Matched- Pairs 
Signed-Rank Test. 
Results: The values are shown as mean ± SD in msec. 
LQT1 Patients Normal Controls 
Baseline ISO p Value Baseline ISO p Value 
QT 393 ± 56 442 i 58 <0.0001 338 :~ 30 323 ± 25 <0.05 
QU 565 ± 61 441 ± 58 <0.001 518 i 45 448 ± 39 <0.0001 
Conclusions: The QU interval was markedly shortened by isoproterenol 
in both LQT1 and normal patients, while the QT interval lengthened in LQT1 
but shortened in normals. The differential response of the QT and QU inter- 
vals to isoproterenol in patients with LQT1 suggests that IKs is not involved in 
generation of the U wave. Therefore, the U wave should not be considered 
as part of the T wave. 
11:15 a.m. 
~3-9~ Right Bundle Branch Block ST Segment and 
Elevation in Lead V1-V3: Prevalence in an 
Apparently Healthy Population 
Jean-Sylvain Hermida, Jean-Luc Lemoine, Fad± Bou Aoun, 
Genevi@ve Jarry, Jean-Luc Rey, Jean-Claude Quiret. University Hospital 
and ASMIS center, Amiens, France 
Background: The presence of a specific electrocardiographic (ECG) pattern 
of right bundle branch block (RBBB) and ST-segment elevation (ST-SE) in 
lead V1-V3 has been associated with sudden cardiac death in patient without 
structural heart disease. 
Methods: To assess the prevalence of such ECG abnormalities in asymp- 
tomatic patients, we reviewed systematic 12-lead ECG recordings performed, 
between 1992 and 1998, in a population of 1000 (F = 37%, M = 63%; mean 
age = 39 ± 10 y) apparently healthy working subjects. All subjects should 
have no cardiac history and a normal clinical examination 1o be included. 
ST-SE was defined as an elevation of the J point at least 0.1 mV in lead V1 
to V2-V3. The (saddleback or coved) form of the ST-SE was also collected. 
Analysis of the ECG was achieved by 2 different observers. 
Results: A ST-elevation was observed in 61 subjects (F = 15%, M = 85%, 
mean age = 36 ± 9 y) and more frequently in absence than in presence of 
an apparent RBBB 
ST-SE V1 and V2 ST-SE Vl to V3 
Absence of RBBB 15 34 
Presence of RBBB 3 9 
There was a saddleback ST-SE in 60 subjects. Only one patient exhibited 
the typical coved ECG aspect of the syndrome of RBBB, ST-SE in lead 
V l -V3 and sudden death. During the follow-up (49 zE 30 me), none of the 
subjects died suddenly. 
Conclusion: A saddleback ST-SE is a rare but not an exceptional finding 
as compare to the 1/1000 prevalence of the typical coved ECG pattern of the 
syndrome of RBBB, ST-SE in lead V1-V3 and sudden death in an apparently 
healthy population. 
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11:30 a.m. 
Recording of Torsades de Pointes in Patients With 
Congenital Long QT Syndrome 
Emanuela H. Locati, Wojciech Zareba, Arthur J. Moss, Silvie G. Prion, 
Cado Napelitano, Peter J. Schwartz. University of Perugia and University of 
Pavia, Italy; University of Rochester Medical Center, Rochester, NY, USA 
Background: In acquired long QT syndromes, Torsades-de Pointes (TdP) 
are typically preceded by "shod-long-tong" (SLS) patterns. In congenital 
Long QT Syndrome (LQTS) SLS patterns have been described, even if 
Me~,~d~'. ~ t65 LQTS ~t~e~ts (9~ w~th i~o~ of Trip ec~e~ted ie. 
the LrJ)-)'S Re d~st~. TOF' record~nos were av,~hab)e'm 55.~s )'i~% "~ema3es, 
age 2~ ± 2G y'e~s, QTc 54~ 4- ;'2 insect. 
Results: TdP runs had cycle length (CL) of 240 4- 68 msec and lasted 
_>30 beats in 32 pts (58%). Sequences of onset (_>3 cycles prior to TdP, CL-1, 
CL-2, CL-3) were available in 44 pts (80%), but only 20 pts (45%) showed 
typical SLS pattern. FastTdP runs (n = 38; mean CL 200 4- 31 msec), when 
comp~,u& *,~, s(ow ~P ~ % = ~.7; m~ CL ~Z2 ~ 5?- ~ , ,  "~,~ ~ 
frequ~f, '~ ,  (&~eJ'~ t~O=,~. <>_.?JZ 4~,,,-~.r~ 47. ;3~:~ ~.  ,='{..'~/7, q. < , "Z, '~ ~. 
Fsat runs showed less often SLS patterns than slow runs (34% vs. 67%, p 
< 0.05), with shorter coupling of first TdP beat (CLO, 468 4- 108 vs. 628 4- 
4- 29~8 msec..:o < 0.000")), ar, d smaller CL-1K;L-2 rat~oi~1735 :~3.;~5 vs.273"0 
4- 1.30, p = 0.001). All 17 slow runs were self-terminating, whereas 12/38 
(32%) of fast runs degenerated in ventricular fibrillation (VF). Sequences of 
offset, available in 32 pts, showed progressive TdP rate slowing, the last two 
with the interruptien of reentry circuits as mechanism of cessation for TdE 
preceded by SLS patterns. In contrast fast TdP runs were seldom preceded 
by SLS #atterns< Jested JongeJl and often degenerafed Jn ME suggesting that 
tachycardia-dependent mechanisms associated with adrenergic activation 
may favor fhe genesis of life-threatening TdP in LQTS patients. 
11:45 a.m. 
I~~ Do Congenital and Acquired Long Syndromes QT 
With Torsades de Pointes Have Different Clinical and 
Genetical Patterns? 
Franc~, 'f ";~c~[h,,,, -~.J ?,r,,~i~ ,L,e~r~,", ,{'¢~a a'~ ,£,~t?, -tc/,-zje~ ,,~ca}lk ~ ,
Angelo Carboni 2 , Angelo Finardi 2, Silvia Pnod 3 . ~ Cardiologia Azienda USL 
della Citt& di Bologna; 2 Cardiologia Azienda Ospedaliera di Parma; 
3 Cardiologia e Genetica Molecolare, Fondazione Maugeri, Pavia, Italy 
sades de peintes (TdP), secondary to acquired long QT syndromes (ALQTS), 
should be tested for the presence of the same alterations, in ions channels, 
determ~ne~ '~ the 9e~et~c ~{e~s o~ CLOTS. 
Methods: We analyzed, from the clinical point of view, 7 subjects with 
TdP, in the context of CLQTS (3) and ALQTS (4) and their families and we 
used GS for them and members of the families. 
Results: In CLOTS, the clinical and GS was useful to define the type of 
genetic an<~maly and to stratify AR, in the affected members~ with or witheut 
TdP, identifying the non affected members. In the first family, the affected 
members showed a disorder in chromosome 7, the second family, the mother, 
a non affected member, showed the disorder on chromosome 11. This is a 
higher risk condition for TdP. In the third family, the candidate member is a 
deaf-mute; ~hus i~ shou~ be a recessive dSsorder, where both parer~ts are 
non affected bearers. Conversely, none of the members with ALQTS and 
TdP, showed a GS positive for ions channels pathology. 
(1) In the CLQTS, with and without TdP, clinical evaluation and GS is manda- 
tory to stratify AR. 
(2) In ALQTS, so far, GS seems to be negative. 
(3) Tbe e(~b#bgy of repoi;anYa~i0n cha~nge and" 7dP, in dl~ com'e'x~ =~=m'o- 
1o be mull~faetofia(, including feminine ~endet drugs able to affect {ons 
traphydro~egtca~ promo~rrtg evert~s, ~sc~tTha a~t m~;n}y cce'~cz~rt~a~ 
ipokalemia seem to be the most relevant ones. 
POSTER 
IT ]~ '  Ventricular TachycarOTa: Mappihg and 
Ablation 
Tuesday, March 9, 1999, Noon-2:00 p.m. 
Morial Convention Center, Hall F 
Presentation Hour: 1:00 p.m.-2:00 p.m. 
I 1172-1471 Microwave Radiometric Thermometry as a New 
Method o f  Measu~)ng Tem~>etature at  De~>th 
Sorn~ ~. V~ancj, 3"am~ ~etja~, '(,enneth C~r, ~r~a~ A. '~r~e~Sr~t&, 14~r~ 
Arrhythmfa Center, New England Med[caf Center, Boston, Massachusetts; 
Microwave Medical Systems, Acton, Massachusetts, USA 
Background: Current techniques for measuring catheter tip temperature in 
ablative therapy for cardiac arrhythmias employ thermocouples or thermis- 
tors embedded in the tip electrode. Electrode cooling, however, may interfere 
microwave radiation from the molecular motion of molecules, we propose mi- 
crowave radiometric thermometry as a new technique to monitor temperature 
awa~ #ore the electrode t~ du#u~2 ablative t~e~ 
mometer were inseded in a test tube filled with circulating saline kept at a 
constant temperature of 23.5~C. The test tube was placed in a saline bath 
of 37-°C that was heated in one degree Celsius increments while the tern- 
temperature of the bath reached 70~C. 
from the antenna, the microwave radiometer temperature changed 0.26~C 
and 0.14~C, respectively. The radiometer temperature was highly correlated 
with the warm saline bath temperature (R ~ = 0.9966 for 5 mm away from 
antenna ,  R 2 = 0.9909 for 8 mm away from antenna). 
Conclusions: Microwave radiometric thermemetry can estimate distant 
temperatures consistently by defecting microwave lectromagnetic radiation. 
The microwave radiometer serves as a promising instrument for monitoring 
temperatures away from the catheter electrode tip during ablative therapy for 
cardiac arrhythmias. 
Atenolol and Placebo in Treating Patients With 
Symptomatic Premature Ventricular Contraction 
Rungroj Knttayaphong, Kiertijai Bhuripanyo, Ongkarn flaungratanaamporn, 
"{/¢~irah ?wu~¢atr,.j, '-P-ay-uT r~ ~c~'dc~,  ~1.# r,¢~ r& "C'mdf~n'~r'~ r, ,, 
Koonlawee Nademanee. Division of Cardiology, Her Majesty's Cardiac 
Center, Siriraj Hospital, Thailand; University of Southern California, Los 
Angeles, CA, USA 
Objectives: To determine if catheter ablation (CA) is more effective than 
atenolol (Ate) and placebo (P) in treating severely symptomatic patients 
(Pts) with high density PVCs from the right ventricular outflow tract (RVOT). 
Background: Although PVCs in Pts without head disease is benign, 
many Pts experience disabling symptoms. These Pts pose a therapeutic 
dilemma. While/~-blockers are commonly used, there are no data on their 
efficacy compared to P. And the role of CA compared to ,~-blocker has never 
been studied. 
Methods: Our study consists of two phases: the first phase is a double 
blind study of 20 pts with severely symptomatic PVCs. Mean PVCs were 
21,612 beats/24 hr. 8 and 12 Pts were randomized to Ate (mean dose = 75 
m q) and P, res~pectively. A 24-hr Holter, quality of life (COL) and symptom 
assessment were done at a screening visit and one month after Ate or P. 
The second phase was an open label study that enrolled 10 of the 20 Pts 
from the initial phase to undergo CA after 1 month of Ate treatment. CA 
wc.-r~ ui~ed, ~y. ~¢th~eR. ~z.d. ~&~2~ . .~F'piR~ #.e~,, .~te. ~i¢4;~tiP.L~ati~, %r.
halfJives. Heifer, symptom assessment and COL were done dunng Ate and 
1 moc~th a~ter CA. 
P had no effects (p = 0.018). Both Ate and P improved symptoms but not the 
COL (not significant). CA abolished PVCs in 7 out of 10 Pts and significantly 
reduced symptoms in the remaining 3 Pts. Compared to Ate, CA drastically 
reduced PVCs from the baseline of 12,008 beats/24 hr to 3.5 beats/24 hr (p 
= 0.017) and improved the COL (0.042). 
Conclusions: CA effectively treats symptomatic PVCs. If improved COL 
and is superior to Ate. CA is a safe and viable alternative to drugs if disabling 
symptoms occur in Pts with frequent PVCs. 
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I 1172-149 j Comparison of 8-mm Tip Irrigated Tip 
1 
and 
Catheters for Radiofrequency Ablation of 
Ventricular Myocardium 
Zhong G. Wang, C. Timothy Johnson, Philip A. Cooke, John G. Kall, David 
J. Wilber. University of Chicago, Chicago IL, USA 
Background: Irrigated-tip and 8-mm tip catheters both produce large lesion 
volumes during radiofrequency ablation (RFA) of ventricular myocardium. 
Their performance has not been directly compared. 
Methods: Left ventricular lesion volumes were assessed 5-7 days after 
percutaneous RFA in 19 dogs. Energy (30, 50, 70 W) and duration (30, 
60, and 120 s) were randomly assigned during RFA with either an 8-mm 
dual thermocouple electrode, or a 3.5-mm saline irrigated (1 ml/s) thermo- 
couple electrode catheter. Both catheters had embedded magnetic sensors 
(Biosense/Cordis-Webster) and were positioned at predetermined locations 
by 3-dimensional mapping (CARTO). Maximum tip temperature for both 
catheters was limited to 70 -0 C. 
Results: By multivariable ANOVA, lesion volumes were significantly 
greater with the 8-ram electrode catheter (p = 0.001), independent of ap- 
plied energy (p < 0.001) and duration {p = 0.003): 
Energy x Duration 8-rnm tip Irrigated tip 
3~ W × 3~ s 5-2'2 ~ 428- ,~ = 5- ~ ~.s;,s,~s 
30W × 60s  916 ± 366n =5 394± 176 n =4 
30W x 120s 911 ±229n=5 533±255n=5 
50Wx30s  1137±482n=5 470±158n=4 
50W × 60 s 1634 ± 584 n =4 948 ± 189 n = 6 
50W× 120s 2024 ± 787 n = 5 1611 ± 552n =6 
70 W x 30 s 1280 ± 773 n = 5 1049 ± 301 n = 5 
70W× 60s  1814 ± 608n = 6 1153 ± 448n = 5 
At each power and duration, 8-mm tip lesions had similar depth, but 
greater maximum lateral dimensions and a wider endocardial base. 
Conclusions: The 8-mm electrode may produce larger, more broadly 
based ventricular lesions compared to a 3.5-mm irrigated electrode, and 
merits further clinical evaluation. 
1172-150 I Intracardiac Echocardiographic Quantification of 
Changes in Wall Thickness and Ventricular 
Function Associated With Radiofrequency 
Ablation in Chronic Myocardial Infarction 
Jian-Fang Ren, David J. Callans, John Michele, Francis E. Marchlinski, 
Farooq A. Chaudhry. Allegheny University Hospitals, Philadelphia, PA, USA 
Purpose: To characterize changes in left ventricular (LV) wall thickness (THK) 
and regional function caused by ablation using intracardiac echocardiography 
(ICE) in swine with chronic anterior infarction. 
Methods: ICE (9 MHz catheter positioned within LV) imaging guided 
linear LV ablation at the infarct border zone in 8 swine (36-40 kg) 6-8 weeks 
with LAD infarct. Energy applications (30-50 watts, 120 sec) created 85 
lesions (51 anterior, 10 interventricular septum {IVS} and 24 lateral/posterior 
wall). The wall THK at end-diastole and regional fractional shortening (FS) 
at each site (within 1 cm of the ablation site) (Table) were measured at Pre- 
and 1 minute Post-ablation. 
Results: 
IVS Anterior Lateral/Posterior 
THK (mm) FS (%) THK (ram) FS (%) THK (mm) FS (%) 
Pre 9.2 ± 3.0 32 ± 25 6.8 ± 1 9 40 ± 24 10.7 ± 2.0 49 ± 29 
1' Post" 11 .6±3.8  14±12 8 .5±2.2  29±26 11 .9±2.4  25±20 
"vs Pre: p < 0.003 = 0.06 <0.001 <0.003 <0.0001 <0.02 
At all sites but one with a deeper crater, LV wall THK increased and 
FS decreased (p < 0.0001) at 1' Post-ablation. These changes correlated 
with the autopsy findings of hematoma, edema, and/or coagulative necrosis. 
The LV global ejection fraction was 34 i 15% at baseline without significant 
change through the ablation procedure. Spontaneous contrast was seen 
following 17/85 lesions. 
Conclusion: Radiofrequency application caused increased walt THK and 
decreased FS at the ablation site which can be detected by ICE imaging. This 
may have implications for LV catheter ablation of ventricular tachycardia. 
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11 521 Prevention of Refractory Paroxysmal Atrial 73-1 
Fibrillation With Sequential Biatrial Pacing 
Intisar Mirza, Jas Gill, Cliff Bucknall, Phyllis Holt. Maidstone Hospital Kent; 
Guy's/St. Thomas's Hospital, London, UK 
Background: We investigated the ability of biatrial pacing to prevent the 
recurrence of atrial fibrillation in patients with symptomatic drug resistant 
paroxysmal atrial fibrillation (PAF). 
Methods: Thirteen patients with a history of PAF resistant to 2 or more 
antiarrhythmic drugs (excluding sick sinus syndrome), underwent implanta- 
tion of a right atrial (RA) and a Coronary sinus (CS) (Medtronic 2188) lead. 
RA leads were either atrial appendage or high atrium. CS leads were either 
proximal or distal. Pacing was via Medtronic Thera DR dual-chamber rate- 
CS lead into the Ventdcular port. Interatrial delays were 50 ms sensed/70 
ms paced. Recurrence of PAF was evaluated pre and post pacing (after an 
initial 3 month control period with pacemaker in sensing mode only) and then 
in 3 monthly single/dual site pacing modes (4 possible combinations) using 
patient documentation diaries, twenty-four hour ambulatory ECG monitoring 
and pacemaker diagnostics interrogation. 
Results: Sequential biatrial pacing significantly reduced the number of 
symptomatic episodes of AF per month in all 13 patients when compared 
with the pre-paeing state (t test level of significance 0.001 < P < 0.002). 
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 
Prepacing 15 4 2 8 30 6 9 16 30 4 30 4 30 
(paroxysms per month) 
Biatrial pacing 0 2 1 1 0 0 0 0 4 2 2 1 9 
Conclusion: Biatdal pacing significantly reduces frequency of symp- 
tomatic episodes of atrial fibrillation and should be considered as therapy for 
patients with drug refractory PAF. 
1173-1531 and Pattern of Atrial Time Dependence 
/ 
Fibrillation Recurrences After Single and Dual 
Site Right Atrial Pacing 
Sanjeev Saksena, Atul Prakash, Ryszard Krol, Philippe Delfaut. Eastern 
Heart Institute-At/antic Health System, Passaic, N J, USA 
We analyzed the time dependence and pattern of atrial fibrillation [AF] recur- 
rences after implementation of single & dual site RA pacing in patients [pts] 
with drug-refractory AF. 30 pts with drug-refractory AF underwent insertion of 
dual site RA pacing systems with lead placement at the high RA & coronary 
sinus ostium. They were followed up to 54 (mean 30 J- 12) mos. A pilot 
crossover period (up to 18 mos) with single site & dual site atrial pacing was 
followed by a tong-term dual site pacing phase. 
Results: 29 pts entered the crossover phase & 25 pts continued in the 
long-term phase. The number, time dependence & pattern of symptomatic 
AF recurrences during long-term followup are shown. 
•11 t 1 . 6  
'= 9 .  .~1.4 
t 2 
0.8 R =0.5163 
o 4~ ~0.s 
°3 t 0.4  ~- - .~  ~2 ..~. 0.2 - - "- = 1 
Z 0 Q 
o ~ 1= is =, 30 3~ 4= °" ;; ?, "; =:; ';; ':; 
Time of recurrences (months) Follow-tip (mos) 
13 pts had 1 to 3 AF recurrences. 4 pts had only 1 AF recurrence, all 
within the first 6 mos. Intervals free of AF recurrences increased between 
events in 5 of the remaining 9 pts. 
Conclusions: 1) Symptomatic AF recurrences are most frequent during 
the initial 6 mos after single & dual site RA pacing. 2) The pattern of AF 
recurrences is consistent with a progressive decline with a majority of pts 
becoming arrhythmia-free long-term. This pattern is consistent with reverse 
atrial remodeling on combined atrial pacing & drug therapy. 
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11 73-154 t Clinical for Selection of and Algorithm Pacing 
Defibrillation Therapies in Drug-Refractory Atrial 
Fibrillation 
Sanjeev Saksena, Atul Prakash, Ryszard Krol, Philippe Delfaut, 
Heather ,%roczyn~KL Eastern ~eart )ns~ute-AY~antic Hea)Yn System. 
Passaic, N J, USA 
Dual site RA pacemakers, implantaMe atrial delibri~ators & combined im- 
plantable atrial pacemaker-defibrillators [ICDs] are all being employed in 
patients {ptsl with drug-refractory atrial fibrillation [AF1 but pt selection guide- 
lines for each device are not available. We analyzed the clinical outcome 
of pts with drug-refractory AF treated with dual site RA pacing, & internal 
or external athal defibfl'~Mtion with respect to rhythm contro~ & frequency 
of suste;me~ AT- recurrences. ~Ne com~are~ c~d~c~ c~narac~ef~s~cs o'~.~s 
who achieved rhythm control with dual site RA pacing without the need for 
atrial d e;h~,;,:¢at., k'd~. ,-&~b G ~n..~G- tPJ:q~. (~fc~v~,~r# Gr.~j7 t.. ~ t,~ ¢.Or~.P~ ¢~ r.~.J~4{J:r.e~ 
combined RA pacing & defibrillation therapies (Group 2). 
Results: 25 pts were followed for 2 to 4.5 years. 
Group I Group 2 p 
(n = 15) (n = 10) Group I vs2 
Age (yrs) 70 ± 10 67 ± 10 ns 
Paroxysmal or persistent AE {%) 91 89 ns 
Lone AF (%) 27 20 ns 
Coexistil%qnmarz doa~Far~ta [%'~ E'~ K(Y ns 
Mean preimpiant duration of AP (rues) 48 ± 65 47 ± 41 ns 
Mean A[F free interval before.pacinq ~davs) 12 ± 13 8 ± 8 ns 
LV ejection fraction (%) 49 ± 10 49/_ 7 ns 
Mean LA diameter (mm) 38 ± 5 43 ± 6 0.05 
% pts or oac(n~& c(ass f er3druqs 27 9<2 G.~24 
% pts on beta or calcium blockers 73 70 ns 
Group 2 pts had a mean of 0.77 ± 0.33 AF recurrences per year. 
Conclusions: 1) Pts with drug-refractory AF with heart disease & nor- 
mal to modestly dilated LA can be effectively managed long-term with dual 
site RA pacing alone. 2) Pts with moderate to severe LA dilatation often 
require backup defibrillation to maintain rhythm control with dual site RA 
pacing but frequency of AF recurrences with pacing should determine need 
for ICD insertion in these pts. 3) Dual RA pacing should be employed as 
a prim~ary nonp~mmacd~9~e ~'nerap~ n ~rug-re1~aO.o£~ AF ~/~ or W¢#~at 
backup defibrillation. 
J1173-155 J Failure of Different Rates of Right Atrial 
1 
Appendage Pacing to Suppress Episodes of 
Paroxysmal Atrial Fibrillation 
Kevin J. Ward, Kavan Kamalvand, Nell Sulke, Jennie E. Willett, Phyllis Holt, 
Clifford Bucknall, Jaswinder S. Gill. Cardiothoracic Centre, Guy's & St 
Thoma's%'%~p~q? ,%~rrb~,~,~e~,~-~'~,, ,%,'~rd~,'~P, ,~  P~,, ~ 
Background: It hs been suggested that symptomatic paroxysmal atrial fibril- 
lation (PAF) may be suppressed by pacing the right atrium iRA). The precise 
influence of increasing RA pacing rate on the efficacy of arrhythmia sup- 
pressi©n rem~ims ufi~no'~n. '~an~ e;d~s~bes 6~ '~'~,T- le'm~im ~m~.~rh~l~t 
and therefore previous studies using external Holters and questionnaires to 
Hyllpo't'nes'ls: 'mcreas'mg "RA padmg raXe Wtf~ reduce "fne =red,hence ol ar- 
rhythrria in those (ndMduets grone to frequent, s~fmgtomatic PAP. 
Methods: 18 patients (12 M, mean age 62.7 yrs) with frequent AF, previ- 
ously implanted DDDR mode-switching pacemakers (Medtronic Thera, Vita- 
tron Diamond, Pacesetter Trilogy, CPI Vigor) with suitable internal diagnostic 
and maximum tracking rate was maintained. Diagnostic Holters were reset 
and the lower atrial pacing rate randomly set to either 60, 75 or 90 beats 
per minute (b.p.m.). Each pacing mode was maintained for 2 months. At 
subsequent visits the pacemaker Holler was interrogated in order to assess 
the number and total duration of AF episodes and then reset. Questionnaires 
were c~.rt~ rd~-,~ "a~ b,J ~,mc~ , ¢~¢, £ "~'~t~', ~,,~,.r~ .~r~ , ,,~, ,~,.rtT~(~,, ~f, ~ ,  
study, patients asked to choose the preferred mode. 
Results: Six patients were unable to tolerate pacing at 90 b.p.m due to 
unacceptable symptoms and did not complete this section. These patients 
data. In these patients the amount of paced rhythm (% paced) increased with 
the rise in background pacing rate. The number of mode switch (MS) episodes 
Pacing Rate (b.p.m.) % Paced MS Episodes % AF Exercise Tolerance 
60 1.42 1,83 1.96 2.42 
75 1.92 2,29 2.21 1.79 
90 2.67 1.88 1 83 1.79 
N = 12 sig (P < 0.009) NS NS NS 
did not differ by the background pacing rate, neither did the percentage time 
spent in AF. There was no improvement in exercise tolerance with any of the 
modes and no difference in the symptomatic status or well being. In 50% of 
patient the preferred mode was that prior to study recruitment (table - mean 
rank for each category/. 
Conc~us(on: Thts is the ffrsf s~uay reporf(ng the use of pacemaker Hbf[~rs 
to assess in patients paced at different RA rates, the number and duration of 
episodes of AF. There appears to be no ~alue in pacing the RA appendage 
at higher rates for the suppression of attacks of AF. Indeed one third of 
the patients were unable to tolerate the higher pac#~j rates and in agditien 
battery life will be significantly reduced with no apparent benefit, suggesting 
that this modality of treatment should be abandoned. 
1173-1 }' Activation Effects of Single-Site and Dual-Site 56 
Huabin Sun, Emre O. Velipasaoglu, David E. Wu, Helen A. Kopelen, William 
A. Zoghbi, William H. Spencer III, Direr S. Khoury. BaylorCollege of 
Medicine, Houston, TX, USA 
The mechanism of prevention of atrial fibrillation recurrence by artificial pac- 
ing remains unclear. To compare right atrial iRA) and left atrial (LA) activation 
during single-site and dual-s)te pacing, basket-shaped catheters carrying 64 
electrodes (EPT) were deployed into both the RA and LA of 7 dogs. Basket 
ket electmde-gairs in inferior RA se~tum i,RAS~, and hiclh RA i,HBA~, alone 
as we~l' as both sffes s~mu~t'aneous~y. hferafna, r conabcf~bn t~me was a~fihee' 
as earliest LA activation time, and completion of activation was identified by 
)at~st act)vatio~ t)m& both with r~sp~ct o pacing slime)us. 
Results: Summarized below, pacing at HRA alone led to the greatest 
delay in interatrial conduction (p < 0.001 ) and, as a result, delay in complete 
LA activation (p < 0.001). Activation of both RA and LA was completed 
simultaneously during RAS pacing. Pacing at HRA + RAS resulted in the 
earliest completion of RA activation (p < 0.001), but did not significantly alter 
LA activation compared to RAS alone. 
Pacing Sites(s) IAT ACT iRA) ACT (LA) 
HRA 47 ± 6 67 -4:11 t,  II 87 ± 7 I! 
HRA + RAS 29 ~ 5* 51 ± 7 I] 66 ± 89, 1] 
IAT: interatrial conduction time (ms); ACT: complete activation time (ms). *, t, ~, and §: p 
= NS; II : p = 0.003; ¶: p = 0.013. 
Conclusions: Pacing at RAS shortens interatrial conduction time. Pacing 
at HRA + RAS also shortens RA complete activation time. 
/ 
Tachycardia Trial 
Robert A. Sorrentino, J. Marcus Wharton, Harry DeAntonio, Andrea Natate, 
William Bredine, David Steinhaus, Gall Harley, Kerry L. Lee. The 
Center, Durham, NC, USA 
~'acKgroun~* ~acema~ter syndrome [ i~f  ~s a co((ecdbn ofs~gns anu'symp- 
toms.i# pacemake~ pts caused by JnAqorepdate timie~ of atrial a~d ventricula~ 
depending on the severity of symptoms. 
Methods: The Pacemaker Atrial Tachycardia Trial (PAC-A-TACH) prospec- 
tively randomized pts with symptomatic paroxysmal tachycardia-bradycardia 
syndrome (T6SJ fo OQO-F¢ or V~/f-f:i" pac~hg modes w~l'fi andarrhyfflm~b drug 
(AAD), predominately sotalol, or no AAD. Follow-up was a median of 23.7 
months and pts were clinically assessed at regular intervals. 
Results: Baseline characteristics of the 101 VVI-R pts were: median age 
of 74 yrs, 46% female, 37% CAD, 57% HTN and 56% mean EF. PS occurred 
in 36 VVI-R pts, prompting cross-over of 32 pts to DDD-R. Pre-implantation 
dhd~c~il dnaradtensflcs an0 ednocard~ograldri~c ata d~l not predidt ~ev~lop- 
ment of PS although pts with junctional or atrial bradycardia at implantation 
(p = 0.051), females (p = 0.06) and pts randomized to AAD (p = 0.08) tended 
to be at greater risk. VA conduction was present in only 22/101 VVI-R pts at 
time to develop PS was 35 d and tended to occur earlier with AAD than 
without AAD (34 d vs. 55 d; p = 0.063). 
Conclusion: PS was very common in VVI-R paced TBS pts. PS tended 
to occur earlier with AAD use and in pts with junctional or atrial bradycardia, 
perhaps because pacing was more frequent. Neither VA conduction nor other 
baseline characteristics predicted PS. The high prevalence of PS and inability 
to predict its occurrence in TBS pts warrants a strong consideration of dual 
chamber pacing for most of them. 
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I 1174-1791 Does the Electrical Cardioversion Induce 
I I Intracardiovascular Hyperclottlng State in 
Patients With Atrial Fibrillation? 
Kiyoshi Umemoto, Masatake Fukunami I , Tsuyoshi Shimonagata 1 , 
Kazuaki Kumagai ~ , Takahisa Yamada 1 , Hisakazu Ogita ~ ,
Yoshihisa Asano 1 , Akio Hirata 1 , Nodtake Hoki ~ . Yao Municipal Hospital, 
Osaka; ~ Osaka Prefectural General Hospital, Osaka, Japan 
Background: Electrical cardioversion (ECV) of atrial fibrillation (At) carries a 
sedous risk of major thromboembolism. However, it still remains controversial 
whether thrombus formation would be induced by electrical procedure itself. 
The aim of this study was to determine whether the intracardiovascular 
hyberclotting state would be induced by ECV itself. 
Methods: Plasma D-dimer and thrombin-antithrombin IIIcomplexes (TAT) 
were measured in consecutive 32 patients with paroxysmal atrial fibrillation 
at the end of Af and 24 hours after conversion to sinus rhythm: 13 patients 
with ECV, and the remainig 19 patients with non-electrical (pharmacologic or 
spontaneously) cardioversion (NECV). There were no significant differences 
in baseline parameters such as age, sex, the presence of organic heart 
disease between ECV and NECV. Warfarization for three weeks before 
cardioversion was done in 9 of ECV pts and 4 of NECV pts. 
Results: 
D-dimer (ng/ml) TAT (ng/mI) 
ECV NECV ECV NECV 
End of At 108.6:1:69.0 113.4:1:77.2 3.4 :E 2.3 8.6 ± 11.5 
24 hrs after 139.5:1:83.8 88.5 ± 50.1" 4.0 ~: 3.8 2.8 ± 1:9" 
(mean :E SE, "p < 0.05, vs End of At) 
The D-dimer and TAT values did not change significantly, but tended to 
increase on the contrary after cardioversion in ECV, although these values 
significantly decreased in NECV with dissappearance of At. 
Conclusions: These results indicate that electrical conversion itself would 
parfialy contribute to increase the intracardiovascular clotting. Thus, it was 
reconfirmed that anticoagulation therapy should be done after electrical car- 
dioversion according to the guideline. 
1174-180 1 Pocket Hematomas Following Device 
Implantation 
Gregory F. Michaud, Frank Pelosi Jr., Hung-Fat Tse, Matthew Flemming, 
Hakan Oral, Michael Kim, Bradley P. Knight, Rajiva Goyal, Fred Morady, S. 
Adam Strickberger. University of Michigan Medical Center, Ann Arbor, MI, 
USA 
Background: Anticoagulation with intravenous (IV) heparin following pace- 
maker or defibrillator implantation may lead to an increased incidence of 
pocket hematoma formation. 
Methods: Patients with an indication for postoperative anticoagulation 
were randomized to receive warfarin plus either heparin at 6 hrs (n = 27) 
or heparin at 24 hrs (n = 24) following device implantation (Heparin Group). 
H eparin was administered IV at 1000 units per hour or at a previously 
therapeutic steady state drip rate without a bolus dose. Patients who received 
postoperative warfarin but not IV heparin (Warfarin Group) and patients who 
did not receive anticoagulation (No Anticoag Group) were also followed for 
bleeding complications. 
Results: A total of 193 consecutive patients were followed for bleeding 
complications following pacemaker or defibrillator implantation. 9 patients 
developed pocket hematomas. Pocket hematomas occurred in 4 (15%) of 
the 27 patients randomized to heparin 6 hours postoperatively and in 3 (13%) 
of the 24 patients randomized to heparin 24 hours postoperatively (p = 0.8). 
The risk of bleeding was significantly greater among the 51 patients in the 
Heparin Group (14%) than among the 30 patients in the Warfarin Group (3%) 
or the 112 patients in the No Anticoag Group (1%) (p = 0.001). The only 
stroke, presumed to be thromboembolic, occurred in a patient with chronic 
atrial fibrillation receiving warfarin alone. 
Conclusions: Patients receiving IV heparin after device implantations 
have a significantly higher risk for developing pocket hematomas. Delaying 
IV heparin from 6 to 24 hours does not reduce the incidence of bleeding. 
1 74-1 J Sensing Lead Failure in Implantable Cardioverter 
1 
1 81 
Defibrillators 
Florin T. Degeratu, Robert W. Peters, Stephen R. Shorofsky, Michael 
R. Gold. University of Maryland, Baltimore, MD, USA 
Background: Spurious shocks due to insulation breaks in implantable defib- 
rillator (ICD) sensing leads are well described, but the long-term stability of 
these leads is unknown. 
Methods: We evaluated 252 patients with an abdominal ICD implant 
utilizing either a dedicated bipolar endocardial rate sensing lead (BT 10, n = 
109) or an integrated defibrillation lead (Endotak, n = 143). Lead failure was 
defined prospectively as a documented insulation break with inappropriate 
therapy. 
Results: There were 20 lead failures in the BT 10 group (18%) after 
259-1505 (mean 754) days and 6 lead failures in the Endotak group (4,2%) 
after 410-1203 (mean 785) days. The Kaptan-Meier survival curves demon- 
strate improved survival of the Endotak lead (log-rank test, p < 0.02). 
: ; I  o ~m- ,o  
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Conclusions: Insulation breaks should be suspected when spurious 
shocks occur >6 months post implant. Lead revision should be consid- 
ered at device replacement with the BT 10 lead because of the high failure 
rate. 
11 I Spontaneous and Diaphragmatic 
i 
74-1 82 Provoked 
Myopotential Oversensing in Patients With ICDs: 
Incidence and Relationship to Clinical Variables, 
Sensing Lead Configuration and Sensing 
Algorithms 
Michael O. Sweeney, Kristin E. Ellison, Julie B. Shea. Brigham and 
Women's Hospital, Boston MA, USA 
Background: Ventdcular oversensing (OS) of diaphragmatic myopotentials 
may cause spurious VF detection and inhibition of pacing in pts with ICDs. The 
incidence and relationship to clinical variables, sensing lead configuration and 
sensing algorithms is unknown. 
Methods: 100 consecutive ICD pts (52 CPI Mini/Mini AV, 48 Medtronic 
Jewel/Micro Jewel) underwent provocative respiratory maneuvers (deep in- 
spiration, forced exhalation, valsalva and cough) at rest with maximum ven- 
tricular sensitivity during intrinsic rhythm (IR) and ventricular pacing. 
Results: High-frequency respirophasic noise transients resulting in spu- 
dous VF detection were provoked in 5/100 (5%) pts during IR and 14/100 
(14%) during pacing; all pts with provocable OS during IR had OS during 
pacing. Age, gender, cardiac history, time since implant, R-wave and pac- 
ing threshold were not different between pts with/without provocable OS. 
Provocable OS was similar between integrated vs. true bipolar sensing leads 
and automatic gain control (CPI) vs. auto-adjusting sensitivity (Medtronic) 
sensing algorithms. OS was eliminated by reducing sensitivity in all cases 
when programmable. Spontaneous OS occurred in 4/100 (4%) pts (spurious 
shocks 2 pts, aborted shocks 2 pts) during mean follow-up 13 months; all 
spontaneous episodes occurred during pacing. OS was provocable during 
pacing in 3 of 4 pts with spontaneous OS. 
Conclusions: Provocable OS in ICD pts is common during pacing at 
maximum sensitivity and is unrelated to clinical variables, sensing lead con- 
figuration or device-specific automatic sensing algorithms. In contrast, provo- 
cable OS dudng IR and spontaneous OS resulting in spurious VF detections 
and therapies are relatively less common. 
1174-183 ] Predictors of Low 
1 
Atrial Defibrillation 
Thresholds, Early and Late Recurrences of Atrial 
Fibrillation After Internal Atrial Defibrillation 
Werner Jung, Burghard Schumacher, Heyder Omran, Christian Wolpert, 
Thorsten Lewalter, Susanne Spehl, Bemdt L0dedtz. Department of 
Cardiology, University of Bonn, Bonn, Germany 
Background: To avoid unnecessary internal atrial defibrillation (lAD) at- 
tempts in patients (pts) with persistent AF, it is important o predict low atrial 
defibrillation thresholds (ADFTs) and to predict those pts at high risk for early 
AF relapses (ERAF) and late recurrences of AF (LRAF). 
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Methods: Clinical data (age, gender, body surface area, duration of AF), 
electrophysiologic parameters (average cycle length of the most recent 30 
PP intervals preceding lAD, endocardial site and time to earliest atrial acti- 
vation after lAD, coupling interval of the first atrial premature beat, interatriai 
conduction delay after lAD), and echocardiographic data (ejection fraction, 
left atrial size, left atrial appendage (LAA) area, left atrial appendage area 
assessed by peak emptying velocities (LAAV) were prospectively analyzed 
in 116 pts. 
Results: Successful lAD was achieved in all 116 pts (ADFT 8.6 ± 7,3 J). 
Pts were followed for 7 5= 4 months. Pts with low ADFTs (<10 J) exhibited 
significantly (p < 0.05) longer PP intervals (175 4. 38 ms) as compared to pts 
with high (> 10 J) ADFTs (131 4, 24 ms). E RAF (< 1 month) occurred in 28 pts 
and LRAF (>1 month) in 16 pts. When the interatdal conduction delays and 
first atrial coupling intervals were compared in pts with and without ERAF, 
significant differences (p < 0,05) were found (159 4- 37 ms vs 127 4. 36 ms 
and 378 4- 94 ms vs 721 4- 214 ms). Pts with LRAF had diminished LAAV 
(0.27 4. 0.1 m/s) as compared to pts without AF (0.53 5= 0.21 m/s; p < 0.01). 
Conclusions: Long PP intervals are associated with a low atrial defibrilla- 
tion threshold. Prolonged atrial conduction delays and short atrial premature 
coupling intervals are predictors of early AF relapses. Late AF recurrences 
can be predicted by depressed left atrial appendage function. 
POSTER 
Noninvasive Marker of Atrial 
Electrophysiology 
Tuesday ,  March  9, 1999,  Noon-2 :00  p .m.  
Moda l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour :  1 :00  p .m. -2 :00  p.m. 
[ 1175-178 J Electrocardiographic Markers for the Prediction 
of Paroxysmal Lone Atrial Fibrillation 
George K. Anddkopoulos, Polychronis E. Dilaveris, Dim±trios J. Richter, 
Elias J. Gialafos, Elias K. Karabinos, Mihail N. Zairis, John E. Gialafos. 
State Department of Cardiology, Hippokration Hospital, Athens, Greece 
Maximum P wave duration (Pmax) and P wave dispersion defined as the 
difference between the maximum and the minimum P wave duration (Pdisp) 
in the 12-lead surface electrocardiogram (ECG) have been used as predictors 
of paroxysmal lone atrial fibrillation (PAF). In this study, we introduce the 
variation of P-waves duration (Pvar), defined as the square of the standard 
deviation of P-waves' duration as a new ECG marker for the prediction of 
PAl=. We also focused on the reproducibility of the measurements of all these 
ECG markers. 
Methods: Twelve-lead surface ECG was obtained from 60 patients with 
a history of PAF and from 50 controls (mean age 59 4- 12 and 55 4. 14 years 
respectively). All patients were in sinus rhythm and free of any medication. 
All ECG's were scanned through a flatbed scanner and were magnified and 
measured using common software. P-wave duration was measured in all 12 
leads from two investigators. The mean percentage error (m.p.e.) and the 
correlation coefficient (r) of the two measurements were also calculated. 
Results: 
Pmax Pdisp Pvar 
Patients 122 ± 22 msec 49 ± 15 msec 227 ± 131 msec 2 
Controls 101 ± 10 msec 30 ± 9 msec 104 ± 78 msec 2 
Anova F = 37.2, P < 0.001 F = 63.3, P < 0.0001 F = 47.5, P <- 0.0001 
m.p.e. 17±9 26± 19 15±20 
r r = 0.263, P = 0.006 r = 0.787, P < 0.001 r = 0.947, P < 0.001 
Conclusions: 1) the variation of P-waves duration was found to be 
significantly higher in patients than in controls and could be useful for the 
prediction of PAF. 2) P maximum and P dispersion showed similar efficacy 
for the prediction of PAF but lower reproducibility and higher interobserver 
variability compared to the variation of P waves duration. 
[ 1175-184 J P Wave Duration Predicts the Risk of Early 
Recurrence of Atrial Fibrillation After 
Card±overs±on 
Merritt H. Raitt, Michael Thurman, Kenneth D. Ingram. Portland VA Medical 
Center, Portland Oregon, USA 
Background: The recurrence of atrial fibrillation (AF) is a common problem 
after cardioversion. The ability to predict which patients will have an early 
recurrence after cardioversion could have a significant impact on clinical 
care. Because P wave duration reflects both atrial size and atrial conduction 
velocity we hypothesized that it would predict with the risk of recurrence after 
cardioversion. 
Methods: P wave signal averaging was performed in 19 patients 3.92 
± 6.23 hours after electrical cardioversion of AF using a custom personal 
computer based P triggered system that digitizes ECG at 2000 Hz with 32 bit 
accuracy. P wave duration was measured from the root mean square of three 
unfiltered orthogonal P waves using automated onset and offset criteria. The 
study population was 100% male, 67.7 4. 9.3 years old, 63% had CAD, 63% 
had hypertension, and none were taking antiarrhythmic medications. 
Results: Nine patients had an early (<3 months) recurrence of AF 29 4. 
25 days after card±overs±on and 10 were still in NSR 253 4, 96.82 days after 
cardioversion. P wave duration was significantly longer in patients with an 
early recurrence of AF compared to those that did not (145 4- 16 ms vs. 125 
4- 17 ms, p < 0.01). A cutoff P wave duration of 135 ms had a sensitivity of 
90% and a specificity of 78% for early recurrence. 
Conclusion: In this preliminary study P wave duration measured soon 
after card±overs±on accurately predicted which patients would and would not 
have an early recurrence of AF after cardioversion. P wave signal averaging 
may be useful for identifying patients in whom antiarrhythmic therapy may 
be required to maintain sinus rhythm. 
J l 75-185 ] Changes in Atrial Conduction Following 1 
Cardiopulmonary Bypass - Relationship to the 
Development of Post-Operative Atrial Fibrillation 
William P, Orr, Peter J. Stafford, Steven S.L. Tsui, Ravi Pillai, Yaver Bash±r. 
Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK 
Background: Atrial fibrillation (AF) is common after cardiopulmonary bypass 
(CPB). The mechanism is unclear but may involve slowed intra-atrial conduc- 
tion due to ischaemic injury. Prolongation of pre-operative P-wave duration 
appears to be a weak predictor of post-op AF, but no study has explained 
the changes in atrial conduction following CPB or their relationship to the 
development of AR 
Methods: Signal-averaged P-wave duration was analysed in 97 consec- 
utive patients undergoing first-time CABG with no prior history of AF, using 
a previously validated P-wave selective averaging system. Measurements 
were performed pre-operatively and at day 1, day 5 and week 6 post-oper- 
atively and compared in patients who developed AF (>30 mins or requiring 
treatment). 
Results: AF developed in 31 patients (32%) 
P-wave Pre-op 1 day post-op 5 days post- 6 weeks post- 
duration (SEM) (SEM) op (SEM) op (SEM) 
AF 139 ms ± 2.7 129 ms ± 3.6" 130 rns ± 2.8 131 ms ± 2.8"* 
Non-AF 136 ms ± 1.8 129ms ± 1.6" 127rns ± 1.6 139 ms -E 2.5 
Total 137 ms ± 1.5 129ms ± 1,5" 128ms ± 1.4 136ms± 1.9 
"p < 0.005 of pre-op; "*p < 0.05 of non-AF 
Conclusion: Contrary to expectation, intra-atrial conduction accelerates 
after CPB, indicating that the pro-fibrillatory effects must be mediated by 
shortening of atrial refractoriness to enable re-entry. Moreover, the failure 
of P-wave duration to return to baseline values in patients who developed 
AF suggests that they sustained persistent structural changes of atrial my- 
ocardium, possibly due to ischaemic injury. Further studies are needed to 
evaluate the nature and cause of these alterations in atrial electrophysiology. 
J l f Identification of the Involvement of Sinus Node 
] 
1 75-1 86  
J Dysfunction in Patients With Paroxysmal Atrial 
Fibrillation by Atrial Early Potential 
Takahisa Yamada, Masatake Fukunami, Tsuyoshi Shimonagata, 
Kazuaki Kumagai, Hisakazu Ogita, Yoshihisa Asano, Akio Hirata, 
Nor±take Hoki. Osaka Prefectural General Hospital, Osaka, Japan 
Baackgound: In patients (pts) with paroxysmal atrial fibrillation (Paf), the 
identification of the coexistence of sinus node dysfunction (SND) has ther- 
apeutic implication. To determine whether the involvement of SND in Paf 
pts would be identified by atrial early potential (EP), low amplitude poten- 
tials early in filtered P wave on the signal-averaged ECG, we prospectively 
studied 112 consecutive Paf pts. 
Methods: Signal-averaged ECG was recorded through a band pass filter 
of 40-300 Hz with the P wave-triggering technique. The root mean square 
voltage for the initial 30 msec (EP30) and the duration of initial low amplitude 
signals < 4 ,uV (ED4) of filtered P wave were measured in the vector 
magnitude. The criteria of EP was defined as "EP30 < 3.0/~V and ED4 > 22 
ms". SND was diagnosed using conventional ECG, 24 hour Holter monitoring, 
bedside ECG monitorings for at least 2 days or electrophysiological study. Pts 
were considered to have SND if they had episodes of sinus arrest or sinoatrial 
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block (with a pause > 2 sec), persistent and unexplained sinus bradycardia 
(<40 beats/min), prolonged corrected sinus recovery time (>600 ms) or 
sinoatrial conduction time (> 150 ms). 
Results: Thirty of 112 Paf pts had EP. There were no significant differ- 
ences in age, gender, the presence of organic heart disease or resting heart 
rate between pts with and without EP. Eighteen (60%) of 30 pts with EP had 
SND, while SND was found in only 3 (4%) of the other 82 pts without EP (p < 
0.0001). EP gave a sensitivity of 86%, a specificity of 86% and a predictive 
accuracy of 87% for the detection of SND in Paf pts. 
Conclusion: EP would be useful for the identification of the involvement 
of SND in Paf pts. 
1 I Alterations of Heart Rate Variability After 
I 
1 75-1 87 
Radiofrequency Catheter Ablation of Focal Atrial 
Fibrillation 
Ming-Hsiung Hsieh, Zu-Chi Wen, Ching-Tai Tai, Chin-Feng Tsai, 
Yu-An Ding, Mau-Song Chang, Shih-Ann Chen. Cardiology, Veterans 
General HospitaI-Taipei, Taiwan, China 
Background: Transient sinus bradycardia and hypotension has been re- 
ported as a complication during radiofrequency catheter ablation (RFCA) 
of focal atrial fibrillation (AF) originating from pulmonary veins (PVs). This 
study used heart rate variability (HRV) to evaluate the possible denervation 
of parasympathetic nerve caused by RF energy. 
Methods and Results: Time (SDRR, rMSSD) and frequency (HF, LF/HF) 
domain analysis of HRV was performed by using 24-hour Hotter monitoring 
before and 1 week, 1 month, and 6 months after RFCA of PVs in 30 patients 
with focal AF. Compared with preablation values, a significant increase in 
mean heart rate and LF/HF, and a significant decrease in SDRR, rMSSD and 
HF were noted 1 week after ablation, indicating vagal withdrawal phenomena 
(see table). The reductions of HRV recovered 1 to 6 months after ablation. 
Conclusions: Parasympathetic nerve fibers located in PVs may play an 
important role in changes of heart rate and HRV during or after RFCA of focal 
AF. 
Before 1 week 1 month 6 months 
Mean HR (bpm) 70 + 10 80 ± 12" 72 ± 11 6g ± 8 
SDRR (ms) 106 ± 33 81 ± 26" 109 ± 40 103 ± 32 
rMSSD (ms) 25 ± 8 13 ± 5" 24 ± 13 25 ± 10 
HF (0.15-0.40 Hz) 137 ± 42 79 ± 26* 127 ± 28 132 ± 35 
LF/HF 2.1 ± 0.6 2.4 ± 0.7* 1.9 ± 0.5 2.0 ± 0.5 
HR = heart rate; bpm = beats per minute; SDRR = stand deviation of mean RR inter- 
val; rMSSD = root mean square of differences of successive RR intervals: HF = high 
frequency; LF = low frequency p < 0.05, after vs before RFCA 
1175-1 I Non-lnvasive Assessment of Atrial 
I 
88 
Electrophysiology in AF - Influence of Posture 
Change 
Carl J. Meurling, Katerina Hnatkova, Johan E.P. Waktare, Hiro Negayoshi, 
Thomas Janota, A. John Carom, Marek Malik. St. George's Hospita/ 
Medical School, London, UK 
Autonomic influence on the heart can be estimated non-invasively during 
sinus rhythm, but are currently poorly investigated during atrial fibrillation 
(AF). We sought to detect changes in the fibrillatory rhythm in response to 
increased sympathetic tone. 
Method: Digital Holter (3 channel, 1 kHz sampling, Burdick Inc.) was 
recorded in 23 patients (11 men, mean age 61 yr) with chronic AF before 
and after active postural change. After routine editing, the QRS and T waves 
were separately subtracted using in-house written software, leaving pure 
atrial fibrillatory records. Spectral analysis by autoregressive method was 
performed on 1 sec segments in overlapping windows for 1 period of 100 
sec 5 min prior to postural change, and 3 periods of 30 sec 1 min after the 
change. The summed total spectral power, and that in the 4-10 Hz range 
(corresponding to that found in AF) was calculated and compared before and 
after posture change. 
Results: 3 patients were excluded due to inadequate QRS or T wave 
subtraction, and a further 3 due to baseline noise. After postural change, 
spectral power fell (total power: from 19442 to 8154, 4-10 Hz power: 4031 
to 1764), but became concentrated in the 4-10 Hz range. The ratios of 4-10 
Hz power against total power were evaluated. The values from the period 
preceding postural change (mean 0.18) were compared with 3 following 
segments (mean 0.21,0.24, 0.27 in the first, the second and the third period 
after) using non-parametric paired Wilcoxon test (p = 0.06, 0.05, and 0.07 
respectively). 
Conclusion: Increased sympathetic tone due to active postural change 
causes a shift of spectral power into the frequency band of AF. Clinically 
relevant changes in atrial electrophysiology during AF are detectable non- 
invasively. 
1175-189]  Detect ion of  Concealed Interatrial Conduction 
Delay from Morphology of the "Unfiltered" 
Signal-Averaged P-Wave 
Pyotr G. Platonov 1 , Jonas Carlson, Max P. Ingemansson, Lev V. Chireikin 1 , 
S. Bertil Olsson. Department of Cardiology, Lund Universi~ Lund, Sweden; 
Research Institute of Cardiology, St-Petersburg, Russia 
Objective: To explore interatrial conduction using "unfiltered" signal-aver- 
aged P-wave ECG (PSAECG), compared to conventional filter settings in 
patients with lone paroxysmal atrial fibrillation (PAF). 
Methods: Twenty one pts with lone PAF in a drug-free state were enrolled 
to the study (mean age 51 ± 15 y). Twenty age-matched healthy volunteers 
were included as controls (mean age 45 ± 16 y). ECG was high-pass fil- 
tered at 0,8 Hz to eliminate baseline drift. Using a P-wave trigger principle, 
the P-waves were averaged and combined into a spatial magnitude. P-wave 
limits were defined as the earliest onset and latest offset in any of the three or- 
thogonal leads (X, Y, Z). P-wave duration was compared with conventionally 
filtered (40-300 Hz) PSAECG. 
Results: 1) Two distinct types of spatial magnitude (single- and double- 
peaked) were identified. Double-peaked P-waves (interpeak distance > 30 
ms) were revealed in 11 of 21 PAF patients but only in 2 of 20 controls (p < 
0.05). 2) In double-peaked P-waves, terminal positive phase in lead Z was 
longer (60 ± 18 vs. 40 ± 22 ms, p < 0.05) and had higher amplitude (98 ± 
59 vs. 29 ± 34 ~.V, p < 0.01) than in single-peaked. 3) Duration of the Z lead 
terminal positive phase was longer in PAF group (58 ± 22 vs. 41 ± 27 ms 
respectively, p < 0.05). 4) No differences in filtered P-wave duration were 
noticed between the groups (128 ± 18 vs. 121 ± 12, p = 0.2). 
Conclusions: PSAECG revealed significant differences in P-wave mor- 
phology in patients with lone PAF related to the specific changes in the lead 
Z, while conventional filtered P-wave duration failed to discriminate the two 
groups. These findings may be explained by differences in routs of atrial 
activation in patients with lone PAF, rather than overall conduction slowing, 
although its nature remains to be verified. 
ORAL  
[ -~  Noninvas ive Outcomes  Predictors: 
E lectrophysio logical  and Autonomic  
Tuesday,  March  9, 1999, 2 :00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 222 
2:00 p.m. 
I -84~ T Wave Alternans in Post Myocardial Infarction 
Patients (ACES Pilot Study) 
Stefan H. Hohnloser 1 , Heikki Huikuri, Peter J. Schwartz, Johan Vijgen, 
Roberto F. Pedretti, Samuel Levy, Thomas Klingenheben, Jar± Tapanainen, 
Emilio Vanoli, A. John Camm, Douglas P. Zipes, Richard J. Cohen. ~J.W 
Goethe Univ., Div. of Cardiology, Frankfurt, Germany 
Background: Identification of pts after myocardial infarction (MI) at risk for 
ventricular tachycardia and fibrillation (VT/VF) and death is a major clinical 
problem. Exercise induced microvolt level T wave altemans (TWA) is a 
promising new means for risk stratification. 
Methods and Results: The Alternans Cardiac Electrical Stability (ACES) 
pilot study is a prospective multi-center investigation of the occurrence of 
TWA in post MI pts in order to design a follow-up trial. 448 pts were tested 
during 5-21 days after MI. Pts were 81% male, with mean age of 59 ± 
10 years, and LVEF of 48 ± 11%. TWA was determined to be positive if 
the onset of sustained TWA occurred below a specified heart rate threshold 
(HRT). At HRT of 110 bpm, TWA was positive in 18% of pts, negative in 
55%, indeterminate in 9%, and incomplete (unable to achieve target heart 
rate) in 17%. TWA results were computed for HRT from 90 to 110 bpm. As 
HRT is reduced to 90 bpm, TWA positivity rate is reduced to 5%. LVEF was 
not significantly different in TWA positive and negative pts at any HRT. 184 
pts had an additional TWA test during 28-56 days post MI. The concordance 
between determinate TWA tests obtained in pts studied during both time 
periods was 67% at HRT of 110 bpm. Although not part of the pilot design, 
follow-up data is being collected. 
Conclusions: The occurrence of TWA evolves significantly during the 
immediate post MI period and thus TWA measured after this immediate post 
MI period may be most approphate for risk stratification. Optimal HRT cutoffs 
need to be defined for TWA based risk stratification in this population. 
2:15 p.m. 
Electrocardiography and Electrophysiology Study to 
Predict Arrhythmia Vulnerability 
Michael R. Gold, Daniel M. Bloomfield, Kelley P. Anderson, David J, Wilber, 
Nabil Ei-Shenf, NA M. Estes III, William J. Groh, Elizabeth Kaufman, 
Richard J. Cohen. University of Maryland, Baltimore, MD, USA 
Bac~groun~:'~ wave a?=emans ) '1~)  6uhn9 padmgpre6~c~ affny~m}e vul- 
nerability. To assess the utility of TWA measured noninvasively with exercise, 
we evaluated signal averaged ECG (SAECG), TWA and electrophysiology 
testing (EPS) in 201 patients "m a mu~ticenter trial 
Methods: Pts in sinus rhythm undergoing EPS were studied. "rWA and 
SAECG were interpreted blindly by standard criteria. EPS + was defined 
as the induction of sustained monomorphic ventricular tachycardia (VT). An 
defibrillator discharge. 
Results: The pts were 63% male with a mean age of 56 ± 15 years 
ancb a djec~on ~C~)Dn 0~ ~-~) ~ ')~=)o. ~oronar.v ahe~ d)sease was ~rese~ )n 
48% '~; %t=. "~ "W'~,~ T:,'~:~%'~'~ % *,q~%. '~ "i~.~, ? '~'~'~'~'~.'~ % -'-'-'-'-'-'-'-'-'~%. "~,  Wi,~°'3.'~J 
or indeterminate in 26%. SAECG was positive in 19%, negative in 54%, 
indeterminate or missing in 27%. EP was positive in 23%, negative in 52% 
an~ nD~sp~)~')c }",}F) Dr )%~.~)n 9 ')~) ~%.  %ap~an-~)er ~a~)~)s ~eve~e~ 
TWA and EPS as significant predictors of event-free survival (Table). 
Events Relative Risk P value 
TWA 12 11.0 <0.001 
SAECG 13 1.8 ns 
EPS t7 3.1 <0.01 
Conclusions: We conclude that in this population, the noninvasive as- 
sessment of TWA with exercise is a highly significant predictor of events that 
is superior to SAECG and may be superior to EP. 
2:30 p.m. 
~4-7----~ Heart Rate Turbulence Following Ventricular 
Premature Beats Predicts Mortality After Acute 
Myocardial Infarction 
Geor9 -~c'nm~'~t .. "~ar e~. '~a~, °-, 'Pe~.m 1~attne~ ~ . 1~,a~'nae~ %dnne~6er ~ ,
Kurt UIm ~ , Linda Rolnitzky 3, A. John Carom 2 , J. Thomas Bigger Jr. 3, 
Albert Sch0mig ~ . ~Medizinische Klinik & Deutsches Herzzentrum, 
School, London, UK ; 3Department of Medicine, Columbia Universi~ New 
B~cckg~ocm~: "The ~e~e accavacy ~ cu~en~' used r~sk Wed~c~xs ~s 
modest. Thus, new powerful risk predictors independent of the available 
stratifiers are of considerable practical value• 
Methods: In this study, the fluctuations in sinus rhythm after single ventric- 
ular premature beats (VPBs), termed heart rate turbulence (HRT), recorded 
in Holter-ECGs were quantified by two numerical parameters (turbulence 
omse'T: 3~; an~ "~u~dlence ~lope: "3~. "The me~noO was Oevdroped usm 9 a 
population of 100 patients with CHD and was subsequently blindly applied to 
the population of the MPIP trial (577 survivors of acute myocardial infarction 
(AMI)) and to the placebo population of the EMIAT trial (614 survivors of 
AMI). Median follow-up was 22 months. Primary endpoint was total mortality. 
Multivariate risk stratification was performed using TO and TS together with 
conventional risk factors. 
Results: TS was the strongest univadate nsk stratifier in EMIAT (risk 
r~t~  -~,'P, 35-%- ~ '~3d~ ;~¢"mv~ TM ,~.3~F..Z~, #, -~ 3~.3~$~,) - ~P,~. ,'l"~P ,~P,~m'~t' 
most powerful stratifier in MPIP (risk ratio 3.5, 2.2-5.5, p < 0.0001). In the 
multivariate analysis, LVEF and TS were the only independent variables for 
noKad~ qrea'(cflbn =h ~4F~r~ (g < G.GGri... wh((e (n E~,  "CO. T~,.h(s¢o~ of 
previous infarction, LVEF, and increased mean heart rate were independent 
predictors of mortality (p < 0.001). In both MPIP and EMIAT, the combination 
of TO and TS was the most powerful multivariate risk stratifier: MPIP risk 
r~&,~ 3.2 ~?.7-~.~, ~" < &~6~,~ ", E,~A'F, ~'.~ ,'~[';~ 3.2 ~i'.8~-&& ~- < &gg~,,% 
Conclusion: Heart rate turbulence following VPBs, quantified by TO and 
TS, '~s a new post-m~arcY~on risk s~ra~f~er which is independent ol an(~ stronger 
than other presently dsk predictors. 
2:45 p.m. 
aria inexpensive MarKer of Prognosis in Patients 
with Chronic Congestive Heart Failure 
Venkateshwar K. Gottipaty, Steven P. Krelis, Fei Lu, Elizabeth P. Spencer, 
Vledimir Shusterman, Raul Weiss, Susan Brode, Amie White, Kelley 
P. Anderson, B.G. White, Arthur M. Feldman. For the VEST investigators; 
University of Pittsburgh, Pittsburgh PA, USA 
Background: Patients with dilated cardiomyopathies (DCM) routinely un- 
dergo 12-lead electrocardiographic (ECG) evaluation• Although ECGs are 
inexpendwe and read#y available, their ut#ity in the management of patients 
with DCM has not been defined. We hypothesized that QRS duration (QRSd), 
a measure of cardiac depolarization, might provide a marker of risk in pa- 
tients with DCM and congestive heart failure (CHF). To test this hypothesis 
which assessed the efficacy of Vesnafinone in patients with class fi4V CHF. 
Methods: 3654 ECGs were digitally scanned and QRSd in lead II was 
measuTe~D%nOeb reabe~s, us)no e~ec~rod}c ca3~ers. T-o~ow u~ ba~a were 
regression, and Kaplan-Meier survival analysis. 
Results: The following clinical variables were found to be independent 
rate, and QRSd. Cumulative survival from all-cause mortality decreased 
proportionally with QRSd. The relative nsk of the widest QRSd group was 5 
times greater than the narrowest. 
[ = 
'j \ .  
Conclusion: We conclude that the resting ECG is a powerful yet ac- 
cessible and inexpensive marker of prognosis in patients with DCM and 
CHE 
•] ,  Increased QRS Duration Reduces Survival in 
l~m a Cohor t  o~ ~'7.63 Pat ients 
Helme Silvet, Jatin Amin, Sfiram Padmanabhan, Ramdas G. Pal. Loma 
Linda University and VA Medical Center, Loma Lind& CA, USA 
Background: Increased QRS duration may imply diffuse conduction system 
disease in the LV. We hypothesized that this in patients with LV dysfunc- 
bredycardiac deaths and hence a reduced survival. 
Methods: 2263 consecutive patients with an LV ejection fraction (EF) of 
_<40% were identified from the echo data base. All had simultaneous ECGs. 
The mean EF was 30%, age 70 years and mean follow up 1007 days. The 
QRS duration was computed using QT Guard software (Marquette Medical 
systems) of the digitally stored ECG data on the MUSE system. There were 
688 deaths. Kaplan-Meier curves and log rank tests were used for mortality 
Results: The mean QRS duration was 113 ns. A QRS duration of >_ 110 
ms was associated with a cumulative 6 year mortality of 66% compared to 
EF of <30% and QRS duration > 110 ms had a 6 year mortality of 75% 
compared to 30% for those with EF >_ 30% and QRS duration <110 ms (p < 
0.0001 ). 
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Conclusions: (1) In patients with LV dysfunction, presence of QRS pro- 
longation independently predicts higher mortality. (2) It is speculated that 
QRS prolongation in this patient population may indicate more extensive 
myocardial disease or may predispose to bradycardiac deaths. 
3:15 p.m. 
~ - ]  Repolarisation Characteristics and Sudden Death 
After Myocardial Infarction: A Case Control Study 
Rene Tavemier, Luc Jordaens. Department of Cardiologz University 
Hospital Gent, Belgium 
Background: The prognostic value of the spatial and dynamic repolarisation 
characteristics in the recognition of patients at risk for sudden death after 
myocardial infarction (MI) is unclear. 
Methods: Twelve patients out of 710 consecutive patients disbcharged af- 
ter MI died suddenly (SCD) within two years. They were matched for age, eggg~- 
der and left ventricular ejection fraction to survivors (S). QTc (QTmax/~/RR) 
and QTdispersion (QTd = QTmaximum - QTminimum) were calculated from 
the surface ECG. The QTapex duration was measured automatically on a 24 
hour ECG on an averaged QRST complex calculated over 30 seconds and 
plotted against the mean RR interval of the previous minute. The QTapex/RR 
correlation coefficient (cQTapex), slope (sQTapex) and intercept (iQTapex) 
of the linear QTapex/RR regression line described the rate dependency of 
the QTapex. Measurements were done for the 24 hour, a day and a night 
segment. 
Results: QTc and QTd were comparable for S and SCD (QTc: 464 ± 33 
ms vs. 463 ± 40, p = 0.67; QTd: 74 ~ 15 ms vs. 65 ± 15 ms; p = 0.31). Over 
24 hour cQTapex, sQTapex and iQTapex were not different between S and 
SCD (cQTa24:0.686 ± 0.172 vs. 0.727 ~: 0.197, p = 0.72; sQTa24:193 ± 
76 vs. 231 ± 68, p = 0.26; iQTa24:137 ± 72 vs. 126 ± 46, p = 0.22). The 
same was observed when day and night were analysed separatly. 
Conclusions: QTc, OTd and QT dynamics do not characterize the pa- 
tients with SCD after MI. 
ORAL  
Atrial Defibrillation 
Tuesday,  March  9, 1999,  2:00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  La Lou is iane  A 
2:00 p.m. 
~ H o w  Many Patients Are Possible Candidates for an 
Implantable Stand Alone Atrial Cardioverter? 
Analysis of 694 Patients with Atrial Fibrillation 
Karlheinz Seidl, Axel Dr6gemOller, Harald Schwacke, Gregor Siemon, 
Jochen Senges. HeFzzentrum Ludwigshafen, Cardiology, Germany 
Background: Due to the limited efficacy of antiarrhythmic drugs against 
atrial fibrillation (AF), several nonpharmacological therapeutic options have 
been developed. One of these options is an implantable atrial defibrillator for 
patients (pts) with severe symptoms and infrequent drug refractory episodes 
of AF. The purpose of this study was to evaluate from our AF ciinic, how many 
pts with AF are possible candidates for an implantable atrial defibrillator. 
Methods: From our AF clinic we evaluated the number of possible can- 
didates for an atrial defibrillator using the following predefined criteria: 1.) 
Recurrent persistent AF (_>2 episodes of AF in 3 months), 2.) Long last- 
ing (_>48 hrs) but infrequent episodes (_<2 episodes/week), 3.) Refractory 
to antiarrhythmic drugs (AAD, _>2 ineffective AAD), 4.) Capability of main- 
taining normal sinus rhythm for at least 48 hrs, 5.) No factors increasing 
proarrhythmic risk. 
Results: The study population consisted of 694 consecutive pts with AF 
(72% male, mean age 64 ± 5 yrs, organic heart disease 69%, mean EF 54 
9%). 706 electrical cardioversions were performed in 431 pts. Mean number 
of ineffective AAD was 1.6 ± 1.1.56 of 694 pts (8%) fulfilled the predefined 
criteria as a possible candidate for an atrial defibrillator. 
Conclusion: About 8% of selected pts with AF are possible candidates 
for an atrial defibrillator. 
2 :15 p.m. 
~8-~ Unexpected Intracardiac Abrasion of Implantable 
Silicone Rubber Atrial Defibrillation Leads 
Diane M. Muff, John R. Helland, Xavier Gonzalez./nContro/, Inc. Redmond, 
WA, USA 
Introduction: Cases of abrasion of implantable lead insulation have pre- 
viously been reported to occur in areas of lead entrapment by tissue (e.g. 
between ribs and in the costeclavicular ligament region) and in areas of 
rubbing contact with pacemaker/defibrillator cans or other leads in the pace- 
maker pocket. Our studies in sheep show that abrasion of silicone rubber 
lead insulation can also occur within the heart when multiple leads have rub- 
bing contact with each other; and that such abrasion was eliminated when 
polyurethane encased leads were used. 
Methods: The atrial defibrillation lead system (ADLS) was composed of 
3 transvenous leads: a coronary sinus (CS) lead with its shock coil in the 
coronary sinus/great cardiac vein; a right atrial (RA) lead with its shock coil 
fixed in the right atrium; and a conventional bipolar, right ventricular pacing 
(RV) lead positioned with its tip electrode in the apex of the right ventricle. The 
two ADLS studied were either composed of 3 silicone rubber (SR) insulated 
leads, or 3 polyurethane (PU) encased leads. The SR and PU ADLS were 
implanted in a total of 23 and 25 sheep, respectively, for up to 24 months 
implant duration. A total of 69 SR leads and 75 PU leads were analyzed. 
Results: Lead insulation thinning and breaches due to abrasive wear 
were detected in 69% of the SR leads (after 3 mos. and 6 mos.) in regions 
where leads rubbed against each other inside the heart, particularly on the 
CS and RV leads. Complete insulation breaches occurred in 5 (7%) of the 
SR leads in the study (1 in 3 mos., 4 in 6 mos.). No abrasion was detected in 
any of the 75 PU leads. 
Conclusion: This study showed that abrasion of silicone lead insulation 
can occur for ADLS as early as 3 mos. due to leads contacting and rub- 
bing against each other within the heart. For a comparable ADLS utilizing 
polyurethane leads, no evidence of wear due to abrasion was detected even 
after two years of implant. Manufacturers and clinicians should consider and 
evaluate the potential for intracardiac abrasion of ADLS and similar lead sys- 
tems which utilize leads positioned in the CS and/or leads having RA shock 
electrodes. 
2 :30 p.m. 
~4~-]  Atrial Defibrillation Energy Requirements and 
Activation Wavefronts in the First Four Hours of 
Atrial Fibrillation 
David Keane, Li Zheu, Christopher Houghtaling, Brian McGovem, 
Hasan Garan, Jeremy Ruskin. Cardiac Unit, Massachusetts General 
Hospital, Boston, MA, USA 
Background: For patients with an implantable atrial defibrillator, a number of 
hours may pass from the time of onset of atrial fibrillation through the detection 
of the arrhythmia by the device (programmable sleep mode duration) to the 
elective activation by the patient of the device for shock delivery. While this 
delay may allow some episodes of atrial fibrillation terminate spontaneously, 
recent studies have indicated that atrial fibrillation may be associated with 
electrical remodeling and it is unknown if a delay in therapy incurs an increase 
in atrial defibrillation energy requirements. 
Methods: We performed serial measurements of the endocardial atrial 
defibrillation threshold (ADFT), the right atrial effective refractory period, and 
of the number of epicardial activation wavefronts on isochronal mapping 
(112 electrode high density plaque) of the anterior wall of the right atrium in 
nine goats (60 kg). Measurements were at made at baseline, at 30 minute 
intervals during the first 240 minutes of pace induced atrial fibrillation, and 
subsequently after return to sinus rhythm for 60 minutes. 
Results: The ADFT increased from baseline to 240 minutes of atrial 
fibrillation in 8 of 9 goats. The mean ADFT was 1.57 + 1.2 J at baseline, 3.03 
± 2.2 J (p = 0.04) at 240 minutes, and 2.5 4- 1.2 J (n.s.) after returning to sinus 
rhythm for 60 minutes. The right atrial effective refractory did not shorten over 
the first 240 minutes of atrial fibrillation (160 ± 20 ms at baseline; 163 ± 46 
ms after 240 minutes; 160 ± 27 ms after 60 minutes of returning to sinus 
rhythm). The number of concurrent right atrial activation wavefronts at onset 
of atrial fibrillation (2.75 ± 0.7) did not increase significantly after 240 minutes 
of atrial fibrillation (2.88 ± 1.0, n.s.). 
Conclusion: In this experimental model, allowing atrial fibrillation to per- 
sist for up to four hours may be associated with higher defibrillation energy 
requirements. This upward drift in defibrillation energy requirements is not 
associated with a change in the level of disorganization in right atrial activa- 
tion. 
2:45 p.m. 
~ Atrial Using the Defibrillation Conventional 
Implantable Cardioverter Defibrillator 
Rajaa Kaddaha, Dhiraj D. Narula, Fred Fefer, Frederick A. Ehlert, Jonathan 
S. Steinberg. St. Lukes -Roosevelt Hospital Center and Columbia 
University New York, NY, USA 
Patients (pts) with the implantable cardiovertor defibrillator (ICD) frequently 
have acute or chronic atrial fibrillation (AF). These pts are subject to in- 
tracardiac shocks to terminate ventricular tachyarrhythmias. Deliberate or 
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inadvertent atrial cardioversion may result from these shocks. Therefore, we 
sought to evaluate the shock efficacy for AF and its clinical correlation. We 
AF at baseline, and received 93 ICD shocks for ventricular tachyarrhythmia 
during ICD implantation or testing. Twenty of 28 pts (71%) had AF converted 
to SR with >_ one ICD shock; 50 of 93 shocks (54%) were successful at 
shock, Pts who did not convert were similar in age, gender, duration of AF, 
underlying cardiac disease, left atrial size, number of shocks received, and 
shock waveform, but were more likely to have an EF < 20% (63% vs. 38%, 
p = 0.03), and to have received a lower mean shock energy (22 ± 13 J vs. 
27 ± 9 J, p = 0.07) than pts who converted. Shocks >20 J were more likely 
Conclusion: Internal conversion of AF with conventional ICD occurred 
frequently. It was more likely to occur in patients with better LV function, and 
when using higher shock energy. This information may be useful for plan- 
ning elective cardioversion, as well as for safeguarding against inadvertent 
atrial conversion during ICD implantation or testing in pts not appropriately 
anticoagulated. 
3:00 p.m. 
~4-~ Atrial Overdrive Pacing for Suppression of 
~'l~omaneous ~-an~/h"b,~hdlb~ibn ot'Kthb£~fJrfflbtlbn 
After Transvenous Atrial Defibrillation 
Hung-Fat Tse, Chu-Pak Lau, Gregory M. Ayers. The University of Hong 
Kong, Queen Mary Hospital, Hong Kong, China;/nContro//nc., WA, USA 
IBaekground: Spontaneous early re-initiation of atrial fibrillation ~ERAF) after 
successful transvenous atrial defibrillation (TADF) was frequently observed 
end c~u~ Wgr~an~y ~,rm~ he use o~FADF an~ ~mp~anta~e a~f~e~ deF~ft~a~r 
for cardioversion of AF. 
Methods: We performed TADF in 82 pts with persistent AF, 12 pts patients 
(pts) (11 M, 1 F; mean age: 51 :E 13 yrs) had repeated episodes (:>2) of 
ERAF by atrial premature beat (mean coupling interval: 380 ± 43 ms) after 
successful TADF (mean defibrillation threshold: 310 ± 33 V, 4.2 ± 0.5 J). 
We tested the effect of atrial pacing (AP) after TADF (at cycle length: 500 
ms) or repeated TADF (no pacing) on suppression of ERAF in a randomized 
cross-over fashion. AP at cycle length of 300 ms after TADF was also tested 
in pts who failed both treatments. Finally, pts with persistent ERAF despite 
AP and repeated TADF were given intravenous sotalol (1.5 mg/kg) and 
underwent repeated TADF. 
Results: AP at 500 ms suppressed ERAF in 42% (5/12) pts vs 0% 
with repeated TADF (p < 0.05). There were no significant differences in 
age, AF duration, defibrillation threshold, left atrial size, ejection fraction, 
time of onset ERAF, the coupling interval and cycle length of the preceding 
atrial rhythm of the premature beat that re-initiated AF between pts with or 
without suppression of ERAP by AP (all p > 0.05). In pts with persistent AF 
recurrence despite AP at 500 ms, AP at 300 ms did not prevent ERAF in 
any of them. However, intravenous sotalol was effective in preventing ERAF 
after repeated TADF in 71% (5/7) of these pts. 
Conclusions: 1) AP at high right atrium could prevent AF recurrence in 
42% of pts with significant ERAF after TADF. 2) There is no clinical predictor 
for those who may benefit from AP to prevent ERAF after TADF. 3) AP 
at a shorter cycle length (300 ms) did not appear to be more effective in 
preventing ERAF. 4) In pts with persistent ERAF despite AP, intravenous 
sotalol was effective in suppressing AF in 71% of them. 
3:15 p.m. 
~8~ Low Impedance Temporary Electrode Wires for the 
Treatment of Postoperative Atrial Fibrillation 
Xavier Gonzalez, Darrell O. Wagner, Clif A. Alferness, Kathryn S. Dawson, 
Willis A. racker. InControl Inc. Redmond, WA, USA 
Atrial Fibrillation (AF) is a common complication after cardiac surgery. A new 
treatment for this arrhythmia consists of delivering low energy shocks be- 
tween atrial defibrillation electrodes placed during surgery. We hypothesized 
that low impedance wire electrodes (LIWE) and increased surface area elec- 
trodes (ISAE) would reduce the atrial defibrillation threshold (ADFT) required 
for defibrillation. 
Methods: In each of six sheep a bilateral thoracotomy was performed 
and 3 different models of defibrillation wires were tested: 1) A TADPOLE TM 
heart wire with approximately 15 Ohms impedance, 2) A prototype LIWE with 
<2 Ohm resistance, and 3) A prototype electrode (ISAE) with approximately 
15 Ohms impedance coiled to increase its surface area. Each electrode had 
a 6 cm electrode length for defibrillation and was sutured to the epicardium 
of each atria. AF was induced by 50 Hz stimulation and sustained by super- 
fusing 0.016 mg/min of Betamethacholine, a cholinergic substance. R-wave 
synchronized shocks were delivered using a 160/~F capacitor 6.6 ms bipha- 
sic waveform. ADFT voltage and energy was determined for each electrode 
model delivering shocks in 10 Volt increments until AF was terminated. De- 
livering 20 shocks at ADFT, a percent success (>10 or <90%) was used to 
,~ffY.PJe~ rhR, rt)r~j~pJc~. 
Results: 
TADpole LIWE ISAE 
Pb'~P, zce" #,~'~'~ ¢,t ?'~ 3'~P o%' ± Z~7 t~'~ -~ :£G 
Energy (Joules) 1.2 ± 0.7 0.4 ± 0.2 1.0 ± 0.8 
Impedance (Ohms) 117 ± 9 67 ± 15 114 ± 18 
Repeated measures analysis of variance revealed that low impedance 
wires had a lower ADFT voltage, energy and impedance (p < 0.05) compared 
different (p > 0.05) compared to the TADPOLE heart wires. 
Conclusions: In this animal model, low impedance electrodes had the 
lowest ADFT probably because the energy is not dissipated in the resistance 
of the conductors. Efficacy of atrial defibrillation did not improve using in- 
creased surface area electrodes. In patients, low impedance wire electrodes 
could improve the treatment of postoperative AF using very low energy 
shocks. 
_ P_O_,£TJ~ FI 
Pathophys io logy of Atrial and A-V Nodal  
Conduct ion  
T~o-J3~,~, ~,~c/-~ c3, ~a~a~a~, 3".~3 9.W~.-5".QI3 ~.~.  
Moda l  Convent ion  Center ,  Hal l  F 
Presen~at}o~ Hour :  4:00 p .m. -5 :00 p.m. 
1 1 / New Insights into Atrial Flutter- Studies in a 
1 
202- 52 
Canine Model 
Yasushi Tomita, Kunihiro Matsuo, Celeen Khrestian, 
Jayakumar Sahadevan, Albert L. Waldo. Case Western Reserve Universi~ 
Cleveland, OH, USA 
Background: A line of block, functional or anatomic, in the right atrium (RA) is 
necessary to obtain classical atrial flutter (AFL). We tested the hypothesis that 
the location of the line of block would determine whether the AFL reentrant 
circuit would be a single loop or a figure-of-eight reentry. 
Methods: Simultaneous multisite mapping from 392 sites on both atria 
and the atrial septum was performed in 10 normal dogs before and after cre- 
ating a linear lesion on the RA free wall during the anesthetized, open-chest 
state. The lesion was created using cryoablation (8 dogs) or a surgical inci- 
sion (2 dogs). In the 8 cryolesion dogs, the length of the lesion was extended 
from an initial 1.5 cm until either AFL was induced or the lesion was at least 
3.0 cm long. In the other 2 dogs, the surgical lesion was 3.1 and 3.7 cm 
long, respectively. In 5 dogs, a lesion was created on the crista terminalis 
(group A). In 5 dogs, a lesion was 1.5-2 cm anterior and parallel to the crista 
terminalis (group B). Induction of AFL was attempted with rapid atrial pacing 
before and after creation of lesions. 
Results: In the control state (prelesion), no sustained (>2 min) AFL was 
induced. After making the lesion, sustained AFL was induced in all dogs. In 
group A, the AFL reentrant circuit consisted of the RA free wall anterior to 
the lesion and the atrial septum (single loop reentry). In all instances, the 
length of the block was extended to the superior and inferior vena cava by 
a line of functional block. In group B, the AFL reentrant circuit consisted of 
the RA free wall antedor to the lesion and the atrial septum in 3 dogs (single 
loop), and a figure-of-eight reentry (RA free wall circuit plus the septum - RA 
free wall circuit) in 2 dogs. In the 3 dogs without figure-of-eight reentry, a line 
of functional block extending from the lesion to one of the vena cavae was 
present, thereby preventing figure-of-eight reentry. 
Conclusion: The location of the induced anatomical line of block and its 
functional extension determine whether the AFL reentry circuit is a single 
loop or figure-or-eight. 
1202-1531 of the Atrial Muscle Fibers in the Arrangement 
i Inferior Right Atrial Isthmus. Its Role in Atrial 
Flutter 
Jos6 A. Cabrera, Damian Sanchez-Quintana, Yen Ho, Alfonso Medina, 
Robert H. Anderson. P/no Hospital, Las Palmas, University of Badajoz, 
Spain; National Heart and Lung Institute, London, UK 
Background: It has been reported a typical pattern of anisotropic conduction 
in the inferior right atrial isthmus, which are essential for reentry in common 
atrial flutter. However no close examination has been made of the anatomy 
of this isthmic area in human hearts. 
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Methods and Results: This study was designed to investigate the gross 
morphological features along with the arrangement of the atrial musculature 
in the area bounded by the orifices of the inferior caval vein (ICV), coronary 
sinus (CS) and tricuspid valve (TV) in 28 autopsied specimens of normal 
human hearts. Gross inspection and histological studies revealed marked 
morphological differences in the myocardial structure, permitting distinction 
of three parallel sectors within the area (figure): a membranous ector (MS) 
composed mainly of fibroareolar tissue, a trabecu/ar sector OS) of muscu- 
lar trabeculations and a vestibular sector (VS) composed of smooth muscle 
fibers lacking trapeculations. A uniform pattern of arrangement of the suben- 
docardial atrial fibers and fibrous tissue was found in most of the specimens 
(68%) (figure). The confluence between the trabecular sector and the vestibu- 
lar sector at the medial area of the isthmus constitutes a significant zone of 
intersecting muscle fibers. 
Conclusions: 1) The orientation of the subendocardial atrial fibers in the 
isthmus, revealed a constant overall pattern, consistent with a typical pattern 
of anisotropic conduction in the low right atrium 2) This finding may help to 
understand this crucial area for the reentrant circuit of common type atrial 
flutter 
1202-154[ New into the Initiation Mechanism of Insights 
I Vagally Mediated Atrial Fibrillation 
Dong-Gu Shin, Kenneth R. Laurita, Don W. Wallick, Mark D. Carlson. 
University Hospitals of Cleveland, CWRU, Cleveland, OH, USA 
Background: Previous studies in our laboratory suggested that the right 
atrium is important for initiation of vagally mediated atrial fibrillation (AF). 
In order to determine if block in the right atrium is required for initiation of 
vagally mediated AF, we used a high resolution mapping System (95 bipolar 
electrodes) to map the conduction of atrial premature beats (APB) that initiate 
the arrhythmia. 
Methods: During vagal stimulation (100% increase of sinus cycle length), 
single APBs were delivered from the high right atrium at 5 to 10 ms decre- 
mental coupling intervals (CI) after an 8 beat drive train (basic cycle length 
= 300 ms). We mapped the right atrial free wall during the onset of AF in 
14 dogs. We also recorded electrograms and measured the effective re- 
fractory periods from the high right atrium, right atrial appendage, left atrial 
appendage and posterior left atrium. 
Results: Initiation of AF was CI dependent (table). APBs that initiated 
AF at CI _> 100 ms blocked in the posterior left atrial wall, which had longer 
refractory period than other atrial sites during vagal stimulation. APBs at CI 
< 100 ms always blocked and initiated AF in the right atrium. 
Coupling Interval (ms) 130 120 1 O0 80 60 
AF initiation (dogs) 1/14 5/14 13/14 14/14 7/7 
right atrial block (dogs) 0/1 0/5 6/13 14/t4 7/7 
At longer CIs, APBs that induced AF blocked in the left, but not the right 
atrium. At shorter CIs, APBs that induced AF always blocked in the right 
atrium. 
Conclusion: Right atrial block is not always required for initiation of 
vagally mediated AF. This indicates that the site of AF initiation depends on 
the APB CI and on local refractoriness rather than on the right or left atrium 
per se. 
1202-155J Multisite Mapping of Interatrial Septal Activation 
in Canine 
Huabin Sun, Emre O. Velipasaoglu, David E. Wu, Helen A. Kopelen, William 
A. Zoghbi, William H. Spencer III, Dirar S. Khoury. Bay/or College of 
Medicine, Houston, TX, USA 
To map spread of activation between the right atrium (RA) and left atrium 
(LA), including RA septum (RAS) and LA septum (LAS), basket-shaped 
catheters carrying 64 electrodes (EPT) were deployed into both the RA and 
LA of 11 dogs. Position and orientation of the baskets were determined 
by fluoroscopy and echocardiography. Basket unipolar electrograms were 
simultaneously recorded during sinus rhythm, right ventricular pacing, and 
while pacing RAS or LAS in superior, middle, and inferior regions through the 
basket electrodes. 
Results: During sinus rhythm, wave fronts propagated from superior to 
inferior regions on both RAS and LAS; onset of LAS activation was delayed 
by 17 ± 7 ms compared to RAS. During right ventricular pacing, activation 
of the septum was discordant. One wave front propagated rapidly on RAS 
from inferior to superior regions, whereas two wave fronts emerged on LAS; 
a predominant front in superior region and a localized front in inferior region. 
Onset of LAS activation was delayed by 11 ± 6 ms compared to RAS. While 
pacing RAS or LAS, wave fronts appeared on the other septal aspect in 
superior (Bachmann), inferior, or both regions depending on site of pacing. 
Wave fronts emerged preferentially in superior LAS while pacing RAS. During 
LAS pacing, inferior wave fronts consistently emerged from posterior RAS 
(posterior to coronary sinus ostium). 
Conclusions: 1) Activation of the interatrial septum is discordant. 2) 
Electrical conduits are present between the RA and LA in superior and in 
inferior-posterior septal regions. 
1202-156 ] Maturational Dual Atrioventricular Nodal 
Physiology in the Mouse 
Colin 12 Maguire, Laura M. Bevilacqua, Josef Gehrmann, Charles I. Berul. 
Children's Hospital, Harvard Medical School, Boston, MA, USA 
Dual atrioventricular nodal (AVN) physiology is characterized by the presence 
of discontinuous conduction from the atrium to His bundle during programmed 
atrial extrastimulus testing (A2V2 conduction curves), AVN echo beats, and 
induction of A-V nodal reentry tachycardia (AVNRT). Transvenous in vivo 
electrophysiology studies (EPS) in mice can now be performed. The purpose 
of this study was to characterize maturational A-V node conduction properties 
and determine the frequency of dual AVN physiology and inducible AVNRT 
in intact mice. The in vivo mouse EPS was performed on 50 normal mice. 
Assessment of AVN conduction included: 1) surface ECG and intracardiac 
atrial and ventricular electrograms, 2) decrementat atrial pacing to determine 
the point of Wenckebach block and 2:1 conduction, 3) programmed prema- 
ture atrial extrastimuli to determine A-V effective refractory periods (AVERP), 
construct A2V 2 conduction curves and attempt arrhythmia induction. 
Results: The mean Wenckebach block interval was 73 milliseconds (ms) 
in males and 74 ms in female mice. The 2:1 block pacing cycle length was 
62 ms in males and 64 ms in females. The AVERP1oo was 58 ms in males 
and 56 ms in females. A discontinuous A2V 2 conduction curves was present 
in 22% of all mice, with occasional AVN echo beats, but no inducible AVNRT. 
The frequency of dual AVN physiology increased with chronological age, 
with a "jump" or AVN echo beats in 15% of mice -< 8 weeks, and 60% in 
adult mice > 12 weeks (p < 0.01). No gender differences were evident in 
presence of dual AVN physiology. These data suggest that mice, similar 
to humans, have maturational development of dual AVN physiology, but 
do not have inducible AVNRT. Characterization of murine electrophysiology 
may be of value in studying genetically-manipulated animals with conduction 
abnormalities. Furthermore, extrapolation to humans may help explain the 
relative rarity of AVNRT in the younger pediatric population. 
I 1202-1571 Anisotropic Conduction over the Trabeculated 
I Right Atrial Wall 
Li Zhou, David Keane, Christopher Houghtaling, Brian McGovern, 
Hasan Garan, Jeremy Ruskin. Massachusetts General Hospital, 32 Fruit 
Street, Boston MA, USA 
Background: The optimal location and orientation of linear atrial lesions for 
the catheter maze procedure has yet to be determined and further insights 
into atrial activation patterns are required. In-vitro optical mapping studies of 
the atrial appendage have found atrial activation during atrial fibrillation to be 
three dimensional with epicardial breakthrough patterns. 
Methods: To further study atrial activation over trabeculated muscle we 
performed epicardial isochronal mapping of the anterior right atrial wall in vivo 
during organized (paced) rhythm in 60 kg goats. A 112 electrode epicardial 
plaque (3.8 mm spacing - Prucka) was introduced through a right lateral 
thoracotomy and transvenous endocardial pacing was performed from the 
center of the mapped area at a fixed cycle length (400 ms) and with tightly 
coupled extrastimuli. 
Results: Epicardial conduction velocity was faster parallel to the pre- 
dominant longitudinal axis of the underlying pectinate muscles than that in a 
transverse direction during both constant (1.30 ± 0.66 m/s Vs 0.37 • 0.10 
m/s, p = 0.002) and premature pacing (1.02 ± 0.40 m/s Vs 0.31 ± 0.06 m/s, 
p = 0.0005). The average number (± SD) of epicardial breakthrough activa- 
tions during constant and premature pacing were similar (1.0 (~ 0.6) and 1.1 
(:E 0.5), respectively). During constant and premature pacing, the number of 
breakthrough activations in transverse direction tended to be higher than in 
longitudinal direction (1.2 ± 0.7 m/s Vs 0.8 ± 0.4 m/s, p = 0.17, and 1.3 ± 
0.5 m/s Vs 0.8 • 0.4 m/s, p = 0.10, respectively). 
Conclusion: Right atrial activation over trabeculated muscle appears to 
be similar among individual goats. If this pattern is also present in humans 
then the linear lesions of the catheter maze procedure across trabeculated 
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muscles might be optimally oriented parallel to the direction of the maximal 
c~>n~ucllon ve~o61~ 2 an~ ot~ogona3 ~o'[Y~e Sir ec'~lon 0% br ea'~'lY}r oupY~ ac~}va'fi on. 
1202-1821 Electrophysiological Heterogeneity of 
Atrio-Ventricular Node Cells 
N. Sato, M. Zaniboni, Y. Kawamura ~ , K. Kikuchi ~ , K.W. Spitzer. Nora Eccles 
Harrison Cardiovascular Research and Training Institute, University of Utah, 
Salt Lake City, USA; ~ F/rst Oepartment of Internal Medicine, Asahikawa 
Medical College, Asahikawa, Japan 
Background: Although catheter ablation has been used for the therapy of 
atrioventricular nodal re-entrant tachycardia, the underlying cellular electro- 
physiological mechanisms remain undefined. To approach this problem, we 
have characterized the action potential waveform in single myocytes obtained 
from a~di'[ r~ddft a'momven'mcu'iar node ~;~9-~,) ce'fis dbtaine~ "from (fiWererft 
regions W~h~n Koch's 'mangSe. 
Methods: 64 rabbit AV-N cells were isolated using collagenase and pro- 
tease. ?n ~ach, spon~.aheous action po'[eh'~a~s "~ere reaD, BeG t)s~n 9 'nys'~a'fin- 
permea~itized patch methods. Action potential parameters, celt capacitance 
and input resistance were measured. 
Results: Based on gross morphology, the AV-N cells which we have 
studied could be divided i~to 3 groups; ovoid ceils, ted shaiz~ed cells, and 
upstroke velocity dV/dt of action potentials fell into 4 subgroups: Group I 
(dV/dt < 5 V/s), Group II (dV/dt > 5 but <10 V/s), Group III (dV/dt > 10 
but <15 V/s), and Group IV (dV/dt > 20 V/s). Ovoid cells had the smallest 
(695t~s Whereas rob ~,n%oeb c6/)s'nablhe'}i~hesh 59'~s.'3'ne ad'bon~Dohen'~) 
the maximum diastolic potential was more negative in groups III and IV than 
in groups I and II. A notch in the phase II of the action potential was observed 
in 23% of group Ill cells and 56% of those in group IV, but was not present in 
c-'erlPo,k',~grU~o < ; "~c& q; . 
Conclusions: These results provide further evidence that isolated AV-N 
ce'~s me hele~'ogeneous bo~h 'm "terms ol ~/~r morpho'~092 a~d '~hd~T e'~ec'tre- 
physiological characteristics. Based on the relationship between dV/dt and 
COD6DS"~)DD ",)eSod)~, ce'~$s ~'h 91DUp ~$~ ant~ $~ ma 2 ar~se llbTn ~as'~ co~Suc"f~oD 
tissue whereas those ?n groups ~ ~nd ~ are more ?tkePy to be respondtbPe toe 
slow conduction pathways. 
I I  1202-1831 Left Atr ium Is the Crit ical Area of  Atrial / F='br(lfat='on: Evidence from Reg='onat O(fferences 
in Recovery Course of Tachycardia-lnduced 
Electrical Remodeling 
Shih-Huang Lee, Jun-Jack Cheng, Mau-Song Chang, Shih-Ann Chen. 
Shin-Kong Memorial Hospital, and Veterans General Hosp~taI-TaipeL 
Taiwan, ROC 
Background: Recent studies have shown that prolonged episodes of atrial 
fibrillation (AF) could induce shortening of atrial effective refractory pefiods 
(AERP). It is still unknown whether there are regional differences in time 
course of recovery from tachycardia-induced electrical remodeling of the 
atria. 
Methods: We examined the time course of recovery from tachycar- 
alia-induced electrical remodeling of the atria in 15 dogs after 8 weeks of 
rapid atrial pacing (780 bpm). We determined AERP (basic cycle length 200, 
250 and 350 ms) at the seven atrial sites before pacing, immediately and 
subsequently every 4 hours for 48 hours (Fig) after termination of atrial pac- 
ing. Inducibility of AF was assessed by premature atrial stimulation during 
AERP testing. 
Results: Post-pacing AERP shortening (.l.), maladaptation of AERP, and 
inducible AF (+) were present immediately after termination of atrial pacing, 
but the recovery course varied in different atrial sites. The time with disap- 
pearance of the three events were shown in table (presented as hours after 
termination of pacing). 
Conclusions: Tachycardia-induced shortening and maladaptation of AERP, 
also the inducibility of AF, recovered faster at the right atrium and Bachmann's 
bundle than that at the left atrium. However, all the tachycardia-induced elec- 
trical remodeling recovered completely within 48 hours. 
Site Post-pacing AERP $ Maladaptation of AERP AF (+) 
RAt 12 12 12 
RA2 4 4 4 
RA3 4 4 4 
BB 4 4 4 
LA1 24 28 24 
LA2 24 24 24 
LA3 28 28 28 
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Atrium Should Be Targeted First for Control of 
Fibrillation? 
David Krum, John Hare, Kashef Mughal, Reza Mousavi-Javardi, Jasbir Sra, 
Masood Akhtar, Mohammad R. Jazayeri. Sinai Samaritan/St. Luke's 
Med~bal Center, Milwaukee, Wl, USA 
hypothesis that AF can be ablated with fewer lesions when the left atrial 
tissue is targeted first. 
Methods: Chronic AF developed in 16 dogs following surgical creation 
"off "nffrr~i "~'Jl~ "regLrcgfc~,ffoh "pius <~rg~r~r~',r 9 -r, qJr~ %tdr~i "l.£d'd~ ~ %tl ~'u 
beats per minute. Linear lesions using an epicardial approach were created 
7~ )he ~o))o~m# seq~eoce. ~: Pu)moAa~ ~2dm )so)~)o~ ~PV~, 2: le~ ~/~)  
Appendage (LAA), 3: Right Atrial Appendage (RAA), 4: Superior Vena Cava 
to )~)ehor ~)e~ Cava ISh)C-)~D>, 5: ~Sacbman#s B~nD)~ ~B>, ~." Coronary 
Sinus (CS~. Ab?ation was considered successful if sustained AF I f5 minutes) 
could not be induced in 3 consecutive attempts. These results were compared 
to those obtained using the following alternative lesion sequence: 1: BB, 2: 
Results: AF persisted for an average of 12 ± 5 days prior to ablation. 
In the group where left atrial tissues were targeted first, AF terminated after 
lesions 1,3, and 4 in 1 dog each, and after lesion 6 in 3 dogs, for an overall 
success rate of 38%. Successful abolition of AF occurred after a mean 
of 4.2 ± 2.2 lesions. In contrast, in the alternative lesion sequence, AF was 
successfully ablated in 75% of experiments after a mean of 4.3 ± 1.9 lesions. 
The differences in the number of lesions required and overall success rates 
between the two groups was not statistically significant (p = NS). 
Conclusions: A critical number of linear lesions in both the left and 
right atria are usually needed to abolish AE These data do not support any 
advantage of creating left-sided lesions first. 
1 47J Electrical Isolation of the Left Atrium Using 
] 
203-1 
Right Atrial Radiofrequency Catheter Ablation: 
Description of a New Technique 
David Schwadzman, Eduardo N. Warman, Rahul Mehra, David Fischer, 
Elizabeth P. Spencer. University of Pittsburgh, Pittsburgh, PA, USA 
Background: Left atrial (LA) electrical isolation was first reported as a surgi- 
cal procedure to control atrial fibrillation. We hypothesized that LA isolation 
could also be achieved using right atrial IRA) radiofrequency catheter abla- 
tion. 
Methods: In 8 large (45-70 kg) adult Hanford pigs, radiofrequency energy 
(RF) was applied to the RA aspect of the interatrial septum in 4 predefined 
zones: 1. septal aspect of the crista terrninalis, adjacent to Bachmann's bun- 
dle; 2. limbus of the fossa ovalis: 3. foramen ovale; 4. proximal coronary sinus. 
The procedure was performed utilizing electroanatomical mapping (CARTe) 
and intracardiac echocardiography (9 MHz). RF was applied via a standard 
ablation electrode, inserted percutaneously. RF power titration was guided 
by thermometry. Interatrial conduction times (IACT) were measured during 
sinus rhythm (SR), during fight atrial pacing at cycle lengths (CL) 200-600 
msec, and during decremental right atrial extrastimulation. Final conduction 
characteristics were correlated with postmortem pathological analysis. 
Results: Baseline: IAC was intact during SR (IACT 25 ± 12 msec) and 
during RA pacing at all CL, and there was no significant increase in IACT with 
extrastimuli (AIACT 2 ± 2 msec). After ablation: 1. mln 3 pigs, complete LA 
isolation, with no intrinsic LA rhythm. 2. mln 4 pigs, incomplete LA isolation, 
defined as LA conduction block occurring during RA pacing (CL 250-500 
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msec) but not during SR. IACT during SR in these animals was markedly 
prolonged versus baseline (96 ± 12 msec; p < 0.001). In addition, there 
was a significant increase in IACT with extrastimuli versus baseline (AIACT 
30 ± 10 msec; p < 0.001); 3. In 1 pig, failed isolation, defined as no LA 
conduction block during SR or RA pacing at all CL. In this animal, IACT in 
SR was markedly prolonged versus baseline (110 msec) and there was a 
significant increase in IACT with extrastimuli (~,IACT 42 msec). No animal 
developed AV block. Pathological analysis in animals without complete LA 
isolation revealed inadequate ablation in the coronary sinus. 
Conclusions: Isolation of the LA using RA catheter ablation is feasible. 
1203-148 1 of Atrial Fibrillation After Non-Inducibility 
I Complete Right Atrial Compartmentalization 
Does not Predict Symptomatic Improvement 
Sabine Ernst, Feifan Ouyang, Michael Schlflter, Kad H. Kuck. St. Georg 
Hospital Hamburg, Germany 
Using the CANTO" mapping system in 32 consecutive pts with idiopathic 
atrial fibrillation (AF), the right atdum (RA) was compartmentalized by 3 RF 
ablation lines: a line severing the isthmus (isthmus line) between vena cava 
inferior (VCI) and tricuspid annulus (TA), an intercaval ine between VCI and 
vena cava superior (VCS), and an anterior line between TA and VCS. An 
intentional gap was left in the superior part of the intercaval line. Criteria to 
validate line completeness comprised demonstration of bidirectional conduc- 
tion block, change in activation sequence along the posterolateral RA, double 
potentials along ablation lines, and change in the CANTO propagation map. 
Results: RA ablation lines were validated in 26 pts (81%). In 15, com- 
plete lines (apart from the intended intercaval gap) could be demonstrated. 
Following the ablation procedure, high-rate pacing of the RA was performed 
in 13 of these pts to induce AF. Sustained RA fibrillation could not be induced, 
but in 7 pts (54%) sustained LA fibrillation (activating the RA with 3:1, 2:1 or 
1:1 conduction) was induced, indicating that the RA was a bystander during 
,f~rilkttb'~ ~'~ri?,a ~ ,~lb"w,~ ,to ~ u'fif~r~rc~ ,i~ ,t~" ~yKr~"tb~ffttL ~ o"U~t,'oqWe" 
~as alSserveo,~Se~weer~ t~ese ?- 9t~s ~,3" ~mpro~te~, Z ~e~e ur~c6ar~e~, Z w~rs- 
ened) and the 6 pts in whom AF could not be induced (1 improved, 3 were 
unchanged, 2 worsened; p = 0.57). 
Conclusions: Even in the presence of complete RA ablation lines, LA fib- 
rillation may be still inducible and recurs clinically. Symptomatically, patients 
in whom AF was no longer inducible fared no better than those in whom LA 
fibrillation persisted. 
1 I Microcatheter Ablation Technique Paroxysmal 
1 
203-1 50 in 
Atrial Fibrillation: Results of Clinical Follow up 
in a Pilot Study 
M. Adam, D. Fischetti, G. Pelargonio, A. Ciolli, F. Bellocci, P. Zecchi, 
A.S. Montenero. Istituto di Cardiologia, Universita Cattolica, Rome, Italy 
Linear radiofrequency (RF) ablation (A) was performed in the right atrium of 
24 patients (pts) (mean age 53 ± 11 years) with drugs refractory paroxysmal 
atrial fibrillation (AF) (mean episodes before ablation 16.7/month), using the 
microcatheter technique (Pathfinder, Cardima Inc.). 
Inclusion Criteria: 2 episodes of AF per week since 1 year. "Apparently 
normal heart" and absence of associated non-cardiac disease. An electro- 
physiological (EP) study was performed at baseline conditions to exclude 
any other electrical disease. 
Method: 15 pts (Group A) underwent initial right atrial ablation procedure, 
in which the atrium comparfimentalization was attempted by forming two 
linear lesions (LL): 1) postero-to posteroseptal between the Inferior Vena 
Cava (IVC) and the Superior Vena Cava (SVC); 2) transverse lesion from 
posterior to anterior atrial free wall. In 9 pts (Group B), a further lesion was 
performed, at the isthmus between IVC and Tricuspid Valve. 15 pts of Group 
A underwent RFA in sinus rhythm (SR), 8 pt of Group B in AF and one in SR. 
Results: No major complications were observed for this study. During a 
follow-up period ranging from 1 to 28 months, 5 pts (33%) of Group A had 
no recurrences, 5 pts (33%) had recurrences well-controlled by drugs and 
5 pts (33%) had no benefit. 6 pts (67%) of Group B had no recurrences, 1 
pts (11%) had recurrences well-controlled by drugs and 2 pts (22%) had no 
benefit. The overall number of AF episodes decreased from 257 per month, 
to 125 per month, before and after ablation respectively, in Group A (p = 
0.56) and from 144 to 26 episodes in Group B (p < 0.001). 
Conclusion: Right atrial procedure may improve the outcome of selected 
patients with PAF. The isthmus lesion is mandatory to achieve a further 
success rate. 
1203-151 I for Atrial Fibrillation Surgery Using 
I Intraoperative Radiofrequency Catheter 
Ablation. Results at One Year in Mitral Patients 
Jofio Melo, Pedro Adrag~to, Jose Neves, Moradas Ferreira, 
Regina Ribeiras, Rui Teles, Maria J. Rebocho. Cardiothoracic Surgery and 
Cardiology Departments. Santa Cruz Hospital, Carnaxide, Portugal 
Background: Surgery for atrial fibrillation (AF) is a long operation with high 
potential for bleeding. To overpass these limitations we used radiofrequency 
catheter ablation (RFCA) instead of surgical incisions to treat AF. 
Methods: RFCA was performed using quadripolar catheters with four 
thermosensors. We did the ablation lines to isolate the inflows of the right 
and the left pulmonary veins applying the energy in each catheter pole. 
Maximal power was 50 Watts, preset temperature 70~C and duration of each 
application 30 seconds. A score was used for assessing of results (0 = AF, 
1 = absent AF with no atrial contraction; 2 = absent AF with right atrial 
contraction; 3 = absent AF and bilateral atrial contraction; 4 = normal sinus 
rhythm and bilateral atrial contraction). 
Since 1996, 43 patients (pts) with chronic AF were operated with pul- 
monary veins isolation and concomitant mitral valve surgery. Their mean age 
was 59 (43-74) y.o.. Standard sternotmy (35 pts) or minithoracotomy (8 pts) 
was used. A mean of 31 5:6 RFCA applications taking from 12 to 28 minutes 
were performed. 
Results: There was no early or late mortality, no myocardial infarction 
and blood loss was, on average, 800 ml. No bleeding was due to RFCA. ICU 
stay was below 36 hours. 
Average follow-up is 8 months with maximum of 14 months. At the last 
follow-up scores are: 
Scores %Pts 
0 36 
1 9 
2 6 
5b ^ 
Conclusion: RFCA during surgery is an efficacious, safe and short dura- 
tion procedure, allowing to enlarge the indications for AF surgery. 
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1204-178 1 Repeatability of Activation Patterns on the 
Epicardium During Ventricular Fibrillation in 
Humans 
Gregory P. Walcott, William L. Holman, Jack M. Rogers, Sharon B. Melnick, 
Anthony L. Sims, William M. Smith, Raymond E. Ideker. University of 
Alabama at Birmingham, Birmingham, AL, USA 
Background: Ventricular fibrillation (VF) is commonly described as being 
maintained by reentrant wavefrents or spiral waves. The primary purpose 
of this study was to determine incidence of reentry on the epicardium of 
humans during VF. The secondary purpose was to determine the number of 
repetitive activation patterns on the epicardium during VF and to determine 
the number of times those patterns repeated. We hypothesize that, similar to 
animals, overt reentry in the mapped region would be rare but that repeating 
activation patterns would be much more common. 
Methods: VF was recorded from four patients, age 55 ± 8 years, undergo- 
ing cardio-pulmonary bypass for coronary artery bypass grafting. Recordings 
were made with a 504-electrede (21 × 24) plaque with 2-ram inter-electrode 
spacing. Fibrillation was induced with rapid pacing just as the patient was 
placed on cardio-pulmonary bypass. A total of 13 2-sec epochs of VF were 
analyzed from recordings made from the left ventricular epicardial surfaces. 
Computer analysis of the electrograms was used to determine the total 
number of activation patterns that occurred in the mapped region, the av- 
erage number of times that those patterns repeated, and the incidence of 
wavefronts reentering one or more times. 
Results: The average number of wavefront patterns seen was 16.3 ± 
7.25. The average number of times that each pattern was seen was 73 ± 
2.1. The incidence of wavefronts exhibiting reentry was only 3.8 ± 4%. All 
reentry was shorter than 2 cycles. 
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Conclusions: Though reentry is rare in the mapped region, repetition 
of activation patterns is not. This finding suggests that wavefronts follow 
c(Dm.~e~ 3no.On )'e~i~ve.:Da~erns buhnp~-~-')n'~)umans. 
1 J Relation Between the Cellular Repolarization 204-1 79 
Characteristics and the Critical Mass for Human 
Ventricular Fibrillation 
A. Athill, James J.C. Ong, Lawrence Czer, Alfredo Trento, Carlos Blanche, 
Robert M. Kass, Alan Garfinkel, James N. Weiss, Michael C. Fishbein, 
Hrayr S. Karagueuzian, Peng-Sheng Chen. Cedars-Sinai Medical Center 
and UCLA, Los Angeles, CA, USA 
Background: The minimum amount of mass (critical mass, CM) for main- 
Methods: Native hearts from transplant recipients (6 with coronary artery 
diseases and 2 with cardiomyopathy, 47-75 years old, M/F = 7/1) were 
studied. The RV was immediately excised, and was perfused (n = 6) or su- 
perfused (n = 2) with Tyrode's solution at 36°-C. The action potential duration 
(APD) restitution curve was determined by an S~-$2 method. Programmed 
stimulation and burst pacing were used to induce VF. In three of eight tissues 
10/~M cromakalim, an ATP-sensitive potassium channel opener, was added 
to "~e pef~usale an0 ~e s'fimu)al~on protocd~ repea'~eO. 
Results: At baseline, VF did not occur either spontaneously or during 
rewarming, and could not be induced by aggressive electrical stimulation in 
any tissue. The mean APD9o at CL of 600 ms was 227 ± 49 ms, and the mean 
stope of APDR curve was 0.22 ± O.O& Among 6 tissues perfused, 5 were not 
treated with any antiarrhythmic agent. The weight of these 5 heart samples 
averaged 111 :E 23 gm (range, 85 to 138 gm). However, after cromakalim 
infusion, sustained VF (>30 min in duration) was consistently ~nduced_ As 
Conclusions: CM for VF in diseased human hearts in vitro is >111 gm. 
However, the CM can vary as it can be reduced by shortening the APD and 
increasing the slope of the APD restitution curve. 
II 1204-1801 Right Atrial Activation with Coronary Sinus 
" ' ~ac,hg: zhs,b~'lht'o P'att'erns ofth~'erad',bl" 
Conduction 
Enrique Rodriguez, David J. Callans, Charles D. Gottlieb, Francis 
E. Marchlinski. Allegheny University of the Health Sciences, Philadelphia, 
PA, USA 
Background: Coronary sinus (CS) pacing is used routinely in electrophys- 
iology as a surrogate for endocardial left atrial stimulation. Yet, limited in- 
formation is available regarding right atdal activation when pacing from the 
CS. Magnetic electroanatomical mapping (CARTO'"-Biosense) can charac- 
terize activation as it relates to intracardiac anatomic location and distance. 
Such data during CS pacing may provide insight into patterns of right atrial 
activation, from left atdal foci. 
Methods: Nine patients, age range 43-72, underwent detailed right atrial 
(RA) CARTO mapping during pacing from proximal (7 pts) CS (<5 mm from 
the us) and distal (9 pt) CS (>30 mm from the us). A minimum of 62 RA sites 
(range 62-199, median 125 pts) were mapped per CS site paced with more 
detailed recordings at septal sites. 
Results: During proximal CS pacing, only one RA breakthrough which 
originated near the us of the CS was noted. During distal CS pacing, two 
distinct septal breakthrough wavefronts were documented in 8 of the 9 
patients by discontinuous activation of the septum. The two breakthrough 
wavefronts were separated by intervening sites activated >10 msec later. 
The first breakthrough was at the CS us; the second breakthrough was 
superior to the CS us (1.2-3.8 cm, median 2.2 cm). Activation time to this 
superior site when pacing from proximal versus distal CS was 24 ms vs 14 
ms respectively, p < 0.03, median values. 
Conclusions: RA activation dudng proximal versus distal CS pacing 
distinctly different. The patterns of activation with distal CS pacing suggest 
that there are two well differentiated pathways of preferential conduction 
from left to RA. The exact structural correlate for this superior RA second 
breakthrough will require direct anatomic imaging. However, left to right atrial 
conduction superior to the CS is cleady documented. 
1204-1 1 Prognostic Significance of Increased QT 81 
Dispersion in Ventricular Extrasystoles and in 
Andrzej D~,browski, Ryszard Piotrowicz, El~,bieta Kramarz. Central Clinical 
Hospital Military Medical Academy, Warsaw, Poland 
Background: To date, no informations are available on the comparison of 
prognostic significance of QT dispersion measured in sinus beats (QTd-S) 
and QT dispersion calculated in ventrioular qramature beats (,QTd-V~,. The 
aim of this study was to assess the relation between QTd-S and QTd-V, and 
to compare the value of these two variables for identifying high risk patients 
after myocardial infarction. 
Methods: In 148 postinfarction patients with ventricular premature beats, 
on a routine ECG the QT dispersion, defined as the difference between 
the maKimum a~td the mit~imum QT intewal across the (2-1ead ECG, was 
beat. The relation between QTd-V, QTd-S and the risk of arrhythmic events 
(sustained ventricular tachycardia, ventricular fibrillation or sudden death) 
was explored with use of log-rank test and Cox regression analysis. 
Results: QTd-V was greater than QTd-S (83 ± 33 vs 74 ± 34 ms, p < 
0.001). During follow-up of 35 ± 17 months the arrhythmic events were noted 
in 30 patients. These patients, compared with patients without arrhythmic 
events, had greater values of QTd-V (99 ± 28 vs 76 ± 34 ms, p < 0.001) and 
O'T 0-~ ~*  _~ 3-3 vs 59 ~ 33 ms, p < EDDS). ~mo~p )~ ev~)ua)efJ desc~p)ors, 
the QTd-V >_ 100 ms was the strongest univariate marker of arrhythmic 
events (sensitivity of 50%, specificity of 80%, positive predictive accuracyof 
38% and negative predictive accuracy of 86%). Cox regression analysis 
selected only QTd-V >_ 100 ms and left ventricutar eiection fraction <4(~'A 
as an independent predictors of arrhythmic events; regression coefficients of 
3.56 (p < 0.001) and 2.62 (p < 0.001), respectively. 
Conclusion: In postinfarction patients the Q-Id-V is greater than QTd-S. 
1 204-1 84 ] Relationship Between Total Activation Time and 
Malignant Ventricular Arrhythmias During Acute 
Ischemia 
~,-,h~,7,-~ a  ~j, I r~tb ~,~ ~.~J'~,~,,°,.,~tb~ri~, M,.£-r~'~,, ')~tb~y'~.%mro, 
Dennis L. Rollins, Gregory P. Walcott, William M. Smith, Raymond E. Ideker. 
OhNersffy ot-Plabama t f~rmthgham, Birm~hgham, AL, U~A 
To determine the relationship between total activation time (AT, the time 
required for a single cycle to cross the entire ventricular myocardium) and 
the occurrence of malignant ventdcular arrhythmias during acute ischemia, 
3*dimensional mapping was performed from 398-420 intramural cardiac 
electrodes in 10 dogs. Regional ischemia was created by thrombotic occlu- 
sion of the left circumflex coronary artery (LCX) induced by passing current 
through a wire inserted in the vessel. Preischemic AT of sinus beats from 10 
dogs was 40 :~ 4 ms. AT started to increase near the time of total occlusion 
(total occ). The maximum increase was 27-102 ms (77-242%). Most delayed 
activation was in the myocardium perfused by the LCX. In 9 of 10 animals, 
NSVT developed with peaks of incidence at 1-5 and 20-25 min after total 
occ. The number of NSVT episodes positively correlated with AT duration at 
1-4 min after total occ (r = 0.91 ). In 6 of 10 dogs sustained VT developed (4 
type la with 3 reentry, 1 focal and 2 type Ib, both focal). AT of 10 sinus beats 
before VT (101 ± 28 ms) was significantly longer than AT 1 minute before VT 
in these same dogs (79 ± 15 ms, p < 0.01). In 4 dogs, VT occurred 3-7 min 
after total occ when AT increased to 98-146 ms. AT in the 4 dogs without VT 
was always less than 98 ms. VT in the other 2 dogs occurred 12 and 22 min 
after total occ following rapid increases in ATto 57 and 87 ms respectively, in 
4 of the 6 dogs, VT degenerated into VF. Mean AT of the first 10 beats of the 
VTs in these 4 dogs (162 ± 29 ms) was significantly longer than that in the 
2 dogs in which VT remained stable without degenerating into VF (81 ± 11 
ms, p < 0.01). In conclusion: AT is a sensitive measurement that is positively 
correlated with malignant ventricular arrhythmias. AT may frequently differ- 
entiate between VTs which remain stable and those which progress to VF. 
11204-185] Sinus Node Behavior During Stable and 
Unstable Ventricular Tachycardia With 
Ventriculo-Atrial Dissociation 
Kar-Lai Wong, Reginald T. Ho, Dusan Z. Kocovic, Behzad B. Pavri. Hospital 
of the University of Pennsylvania, Philadelphia, PA, USA 
Background: Sinus node behavior may allow assessment of autonomic 
modulation during ventricular tachycardia (VT). 
Methods: We studied the behavior of the sinus node during ventricular 
tachycardia with ventriculo-atdal dissociation in 23 men and 7 women who 
had a total of 38 episodes of monomorphic VT induced during electrophysi- 
ology study. There were 21 episodes of stable VT (no loss of consciousness, 
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no need for urgent termination) and 17 episodes of unstable VT (requiring 
termination within 20 seconds due to hemodynamic collapse). The sinus 
cycle length (SCL) was measured from the right atrial catheter immediately 
prior to V I  induction, at 10 and 20 s, and the mean SCL for the entire duration 
of the v-r episode was calculated. The percentage change (%A) in SCL was 
calculated. Atrial activation sequence was noted by relative activation of the 
right atrial and His bundle atrial electrograms. Unpaired Student's t test was 
used for comparisons between the two groups. 
Results: (shown as mean values; "-"  sign indicates SCL shortening) 
VT CL SCL pre %~ in SCL %A in SCL Mean 
V'l" Type n (ms) VT (ms) at 10 s at 20 s SCL 
Stable 21 321 699 -10.2 -14.7 606 
Unstable 17 259 824 -3.3 -2.7 800 
p value 0.0002 0.08 0.03 0.004 0.03 
20 s into VT, SCL decreased significantly (p = 0.0002) in patients with 
stable VT, but did not change (p = 0.3) in patients with unstable VT. Seven of 
11 patients with unstable VT compared to 2 of 19 with stable VT developed 
"low-high" atrial activation during VT, p = 0,002. 
Conclusions: (1) Sinus node behavior was different in stable and unsta- 
ble VT, (2) Sinus node accelerated in stable Vl-, but not in unstable VT. (3) 
Mean SCL was shorter in stable VT. (4) Low-high atrial activation was noted 
more frequently during unstable VT. These observations suggest that sympa- 
thetic activation and/or vagal withdrawal accompany stable but not unstable 
VT. In addition to VT cycle length, autonomic modulation may contribute to 
VT stability. 
1204-1861 There Differential Effects of the New Iks Are 
Blocking Agent Chromano1293b in Normal and 
Infarcted Canine Hearts? 
Alexander Bauer, Ruediger Becker, Hans J. Lang 1 , Uwe Gerlech 1 , 
Alexander Hansen, Matthias Mueller, Patricia Kraft, Julia C. Senges, 
Frededk Voss, Kirsten D. Freigang, Wolfgang Schoels. University of 
Heidelberg; ~ Hoechst Marion Rousse/, Medicinal Chemistry, Frankfurt, 
Germany 
We recently demonstrated the positive use dependent effect of chromanol 
293b (CR) on repolarization in intact canine hearts. Several class III anti-arrhyth- 
mic agents exhibit differential use dependent effects on normal and infarcted 
hearts. The effects of CR on repolarization in infarcted hearts are still unde- 
termined. Therefore, 5 mongrel dogs were studied 5 days after left anterior 
descending artery ligation. 6 by 6 needle electrodes (12 mm in length, 4 bipo- 
lar electrodes per needle, interelectrode distance 2.5 ram, distance between 
needles 10 mm) were inserted into the left ventdcular wall perpendicular to 
the left anterior descending artery (LAD). Activation maps were reconstructed 
from local activation times using a multiplexer mapping system. Effective re- 
fractory periods (ERP) were determined in normal (NZ) and infarcted tissue 
as well as in the border zone (BZ) between NZ and IZ at each electrode pair 
of 5 ± 1 randomly selected needle electrodes (extrastimulus technique with 
basic cycle lengths (BCL) of 300, 500 and 850 ms). Relative changes of ERP 
after administration of CR (10 mg/kg) are summarized in the table below (* = 
p < 0.05 300 ms vs 500 or 850 ms respectively; # = p < 0.05 NZ vs IZ, "i" = p 
< 0.05 IZ vs BZ). 
BCL NZ BZ IZ 
850 ms +7 ± 7%# +15 4- 9% +15 4- 8%:1: 
500 ms +9 ± 10%# ÷12 ± 8%# +14 4- 11%# 
300 ms +20 4- 17%*# +34 ± 26%*'i" +46 ± 24%* 
Conclusions: CR exhibited positive use dependent effects on repolar- 
ization in NZ, BZ and IZ. However, the effect on ERP at fast heart rates was 
more pronounced in BZ and IZ than in NZ. Thus, CR seems to be a potent 
antiarrhythmic drug in both normal and infarcted tissue. 
1204-187J Dofetilide Decreases Reentry During 
1 
Functional 
Ventricular Fibrillation 
Jian Huang, Jack M. Rogers, Ramon W. Pedoto, Raymond E. Ideker. 
University of Alabama at Birmingham, Birmingham, AL, USA 
This study quantified the effects of different dofetilide doses on functional 
reentry during ventricular fibrillation (VF). A flexible mapping plaque of 504 
(24 × 21) electrodes spaced 2 mm apart was sewn to the anterior right 
and left ventricular epicardium. Six pigs were studied using two cumulative 
doses of dofetilide (2.5 and 25/xg/kg bolus + 0.9, 9/zg/kg/hr maintenance, 
respectively). VF was induced using 60 Hz alternating current and unipolar 
electrograms were recorded from the plaque for 20s after VF onset. VF 
before and after dofetilide was compared using computer analysis of the 
electrograms to identify individual activation pathways and determine which 
were reentrant. The following parameters were measured (1) the number of 
activation pathways (APs) per s, (2) fraction of pathways that were raentrant 
(Incidence), (3) the mean area cimumscribed by each cycle of reentry (A). 
Data are mean ± SD; * denotes p < 0.05, compared with baseline. 
Dofetilide APs/s Incidence (%) A (mm 2) 
Baseline 32.9 ± 8.9 1.74 ± 3.7 70.4 ± 63.7 
2.5 p+g/kg 33.3 ± 9.5 2.74 ± 11.6 59.9 4- 40.6 
25 p.g/kg 32.9 ± 7.9 0.35 ± 1.9" 99.5 4- 60.9 
Conclusion: Only a small fraction of the APs form reentrant pathways 
at baseline. High dose dofetilide significantly reduces the incidence of func- 
tional reentry even more. The size of the pathways increase, though not 
significantly. 
I1 J PAI-I Gene Polymorphism in Patients With 
1 
204-1 88 
Coronary Artery Disease and Malignant 
Ventricular Arrhythmias 
Anahit Anvari, Zeynep TQrel, Ernst Schuster, Michael Gottsauner-Wolf, 
Kurt Huber. Department of Cardiology, University of Vienna, Austria 
Background: The 4G/5G polymorphism of the plasminogen activator in- 
hibitor I (PAl-I) gene, as a marker for exposure to different levels of PAl-I, 
is involved in the pathogenesis of coronary thrombosis, with greatest risk in 
subjects possessing the 4G/4G genotype. Myocardial is, chemic events, even 
in the absence of acute myocardial infarction, may play an adjunctive role for 
generation of the fatal arrhythmias in patients with coronary artery disease 
(CAD). In this setting PAI-I genotype may be of relevance for development 
of malignant arrhythmias in these patients. 
Methods: In this study the frequency distdbution of the PAI-I gene poly- 
morphism with regard to malignant ventricular arrhythmias in patients with 
CAD was determined. Ninety seven patients with a history of malignant 
ventricular arrhythmias and implantable cardioverter defibrillator (ICD group, 
mean age 63 ± 9 years, 83% male) and 113 patients without a history of 
malignant arrhythmias (control group, mean age 62 ± 10 years, 78% male) 
were included. The patients were comparable with regard to the duration of 
the CAD and left ventricular ejection fraction. 
Results: The difference in the distribution of the PAI-I genotypes between 
the two group was statistically significant (p < 0.01): 
PAI-I genotypes ICD, n = 97 Control, n = 113 
4G/4G (%): 43 (44) 27 (24) 
4G/5G (%): 45 (46) 70 (62) 
5G/5G (%): 9 (9) 16 (14) 
Furthermore, the relative risk for arrhythmias approximated by the ad- 
justed odds ratio was 1.9 per number of 4G allele (95% confidence interval 
f .2 to 2.9, p = 0.004), with greatest risk in the subset of individuals carrying 
4G/AG alleles (odds ratio 3.6, 95% confidence interval 1.4 to 8.9). 
Conclusion: Our results suggest that the PAI-I genotype may be an 
independent risk factor for malignant ventricular arrhythmias in patients with 
CAD. Regarding the potential relevance of this gene in the modulation of 
ventricular arrhythmias, further studies in an independent population are 
needed to confirm these findings. 
L 1204-189 l  Acute Effects of Selective and Non-Selective .J Beta-Receptor Antagonism and Potassium on 
QT Interval In LQT1 Type of Long QT Syndrome 
Heikki Swan, Kirsi Piippo, Matt± Viitasalo, Kimmo Kontula, Laud Toivonen. 
Department of Medicine, Helsinki Universi~ Helsinki, Finland 
Background: Beta-adrenergic blocking agents have been widely used to 
prevent arrhythmias in long QT syndrome (LQTS). We investigated the dif- 
ferences of cardioselective and nonselective beta blockers as well as the 
effects of potassium supplementation on QT interval in LQT1 type LQTS 
(LQT1) patients with cardiac potassium channel defect. 
Methods: QT interval was examined in 12 LQT1 patients (mean age 37 
± 10 years) and their 6 healthy relatives (40 ± 7 years) at baseline, during 
intravenous infusion of beta-l-selective adrenergic blocking agent esmololol 
(3 mg/kg/min), after infusion of non-selective beta-antagonist propranolol (0.1 
mg/kg) and after supplementation with potassium hydrochloride (118-157 
mmol potassium dudng 20 hours). To compare QT intervals at different heart 
rates (HR), cubic root formula (QTfc = QT × (HR/60) 1/3) was used. 
Results: Heart rate of LQT1 patients at baseline was 69 ± 15, during 
esmololol 65 ± 6 (p = NS) and during propranolol 59 ± 8 beats per minute 
(p = 0.06), respectively. Mean serum potassium level in LQT1 patients was 
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raised from 4.1 mmol/I to 4.6 mmol/I after potassium supplementation (p = 
0.005). QTfc-values (ms) are shown in the table. 
Baseline Esmolol Propranolol Potassium 
LQT1 (ms) 460 ± 35 430 5: 24" 439 ± 24 i" 442 ± 181:1: 
Controls (ms) 403 ± 21 385 ± 14" 386 ± 15 1" NA 
Wilcoxon test: compared to baseline *p < 0.001, 1" P < 0.05, :1: P = 0.07. 
Conclusions: The QT interval shortening effect of a non-cardioselective 
beta blocker propranolol does not exceed that of a selective beta blocker 
esmolol in LQT1 patients. Shortening of the QT interval after a modest 
raise in serum potassium level suggests that LQT1 patients are likely to be 
sensitive to changes in serum potassium concentration. 
ORAL 
[ -~ Clinical Results of Permanent Pacing 
Tuesday, March 9, 1999, 4:00 p.m.-5:30 p.m. 
Morial Convention Center, Room 222 
4:00 p.m. 
[ - ~  Effect of Pacing Modality on Quality of Life in 
Patients With the Tachycardia-Bradycardia 
Syndrome 
Edward Keating, Cathy Grill, Gall Harley, Robert A. Sorrentino, Kerry L Lee, 
J. Marcus Wharton. The Pacemaker Atrial Tachycardia Trial Investigators; 
Duke University Medical Center, Durham, NC, USA 
Background: Previously studies suggest a number of potential benefits 
of atrial-based pacing compared to VVI pacing in patients with sick sinus 
syndrome. However, little prospective data is available, and even less is 
known about the impact of pacing modality on the quality of life (QOL) in the 
patient cohort with the tachycardia-bradycardia syndrome (TBS). 
Methods: In the Pacemaker Atrial Tachycardia (PAC-A-TACH) Trial, 202 
patients with TBS were randomized to VVI-R or DDD-R pacing. At the time of 
randomization, patients' quality of life was assessed using the Duke Activity 
Status Index (DASI) and SF-36. This was repeated at 6 month follow-up. 
Rates of cross-over before 6 mo were 45% and 4% in the VVI-R and DDD-R 
modes, respectively. 
Results: By intention-to-treat analysis, there were no significant differ- 
ences at baseline or at 6 mo follow-up in DASI or SF-36 general health, 
health transition, physical function, vitality, mental health, or social function 
scores. Pertinently, median change in general health score for either group 
was 0, with little change in other categories as well. Given the fact that 
cross-over from VVI-R was 45%, primarily due to development of pacemaker 
syndrome, an on-treatment analysis of QOL was performed including only 
those patients in the initially randomized pacing mode at the 6 mo follow-up. 
Although baseline SF-36 general health scores tended to be lower in the 
censored VVI-R group (median 50 vs 67 in the DDD-R, p = 0.06) as were 
social functioning scores (60 vs 75; p = 0.045), there were no significant 
differences at 6 mo follow-up. 
Conclusions: Although DDD-R pacing decreases mortality and pace- 
maker syndrome in TBS patients compared to VVI-R pacing, there is little 
change in the QOL between pacing modalities in the patient cohort able to 
continue VVI-R pacing. 
4:15 p.m. 
F-~ Long-Term Survival Benefit Associated With Dual 
Chamber Pacing 
Peter A. Brady, Win K. Shen, Sharon A. Neubauer, David O. Hodge, David 
L. Hayes. Mayo Clinic, Rochester, MN, USA 
Dual chamber (DC) pacing improves hemodynamics and survival in selected 
patients (Pts) with conduction system disease. Whether the very eldedy also 
benefit from DC pacing, when compared to single chamber (SC) pacing, is 
unknown. To determine this, we compared survival in 465 Pts aged >_ 80 
(mean age 85 ± 4 years, 245 males (53%)) with 617 Pts aged < 80 (mean 
age 74 ± 3 years, 374 males (61%)) who underwent permanent pacemaker 
implantation between 1980 and 1992. Mean follow up was 4.4 5:3.1 years. 
Pts with chronic atrial fibrillation were excluded, Survival (Kaplan-Meier es- 
timates) according to age and pacing mode and the expected survival from 
North Central Control Population (1988) is shown in the table. 
DC pacing was associated with improved survival compared to SC pacing 
in the very elderly. This difference was apparent even after adjusting for 
multiple variables. When survival was compared to expected for age- and 
sex-matched controls, survival following DC pacing was better than expected 
(p = 0.03), but was worse than expected following SC pacing (p = 0.001). 
Age Pacing Mode Survival 
in) 1 yr (%) 3 yr (%) 5 yr (%) P 
>80 
<80 
DC(144) 144(92) 85(78) 51 (61)* 
Expected (%) 90 71 54 * <0,001 
SC(320) 250 (80) 149 (57) 98 (45)* 
Expected (%) 86 68 50 
DC(264) 233 (90) 189 (76) 144 (64)* 
Expected (%) 95 84 73 "0.025 
SC(351) 291 (85) 225 (70) 170 (60)" 
Expected (%) 95 84 74 
Conclusions: DC pacing is associated with a significant survival, advan- 
tage in the very elderly, which is better than expected survival. These findings 
emphasize that older age should not preclude the elderly from the benefits 
of a DC pacemaker. 
4 :30 p.m. 
~ Predictors of Death in VVI-R and DDD-R Paced 
Patients With the Tachycardia-Bradycardia 
Syndrome 
J. Marcus Wharton, Robert A. Sorrentino, Douglas Criger, 
Mohammed Shenasa, Sheldon Brownstein, Thomas Derring, Larry Gering, 
Cathy Grill, Kerry L. Lee. The Pacemaker Atrial Tachycardia Trial 
Investigators; Duke University Medical Center, Durham, NC, USA 
Background: The Pacemaker Atrial Tachycardia (PAC-A-TACH) Trial demon- 
strated a significantly higher mortality with VVI-R, compared to DDD-R, 
pacing in patients with tachycardia-bradycardia syndrome (TBS). Factors 
contributing to this excess mortality are not known. 
Methods: Patients with TBS were randomized to either DDD-R or VVI-R 
pacing modalities and sub-randomized to antiarrhythmic drug therapy (sotalol 
or quinidine) or none. After follow-up of approximately 2 yrs on all patients, the 
trial was stopped due to excess mortality in VVI-R paced patients. Univariate 
analysis of clinical characteristics was performed and variables with a p < 
0.10 were incorporated into a Cox Proportional Hazards model to determine 
predictors of mortality. 
Results: Of 202 pts randomized (101 to VVI-R and 101 to DDD-R), 
cumulative mortality was 21% in VVI-R and 5% in DDD-R (p < 0.001). 
Univariate predictors of mortality included VVI-R pacing mode (p = 0.002), 
history of prior MI (p = 0.005), EF (p = 0.020), left atrial size (p = 0.021), 
duration of tachyarrhythmia > 6 mo (p = 0.023), and prior beta-blocker 
usage (p = 0.026). Antiarrhythmic drug usage did not affect survival. Survival 
modeling revealed that only VVI-R pacing mode (risk ratio 4.3; 95% CI 
1.6-11.4; p = 0.004) and prior MI (risk ratio 3.1; 95% CI 1.4-6.7; p = 0.006) 
were predictive of mortality in these patients. 
Conclusions: VVI-R pacing increased mortality compared to DDD-R 
pacing in patients with tachycardia-bradycardia syndrome, and prior MI inde- 
pendently increased this risk, perhaps due to adverse hemodynamic and/or 
neurohumoral effects of VVI-R pacing which facilitate ischemic events. 
4 :45 p.m. 
~1-~]  Development of Sinus Nodal Disease in Patients 
With AV-block: Implications for Single-Lead 
VDD-Pacing 
U.K.H. Wiegand, F. Bode, R. Schneider, A. Brandes, H. Bonnemeier, 
W. Peters, J. Potratz. Medical University of Luebeck, Germany 
Backround: Before implantation of a VDD-pacemakers, sinus node disease 
must be excluded. However, asynchronised ventricular pacing may also oc- 
cur if sinus node dysfunction is developed later on. Up to now, the probability 
for subsequent development of sinus node disease was not systematically 
investigated in patients with AV-btock and normal preoperative sinus node 
function. 
Methods: 249 patients with intermittent high-degree AV-block and dual 
chamber pacemakers were followed over a mean period of 31 months. Sinus 
node disease and atrial arrhythmias were excluded by preoperative Holter- 
monitoring. Further Holter-ECGs and treadmill exercises were performed 2 
and 12 weeks after implantation followed by 6-months-intervals. Sinus node 
dysfunction was defined as sinus bradycardia below 40 bpm, sino-atrial block 
or sinus arrest as well as subnormal increase of heart rate during exercise. 
Results: Cumulative incidence of sinus nodal disease was 0.7% per year. 
After a mean follow-up of 31 months, sinus bradycardia below 40 bpm was 
present in 1.2% of patients, 0.8% developed an intermittent sino-atrial block 
and 1.6% showed chronotropic incompetence. 1.2% of patients showed two 
or three signs of sinus node dysfunction, but only 0.4% were symptomatic. 
Cumulative incidence of atrial fibrillation was 1.6% per year. 
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Conculsion: In pacemaker recipients with isolated AV-block, the probabil- 
ity of subsequent development of sinus node disease is low. Thus, single-lead 
VDD-pacemakers can be safely implanted in these patients. 
5:00 p.m. 
~8-6-~ Rate-Responsive Pacing Improves Longevity in 
Single and Dual Chamber Pacing 
Ross D. Fletcher, Christopher D. McManus, Pamela E. Karasik, 
Edmund Keung, Steve Singh. VA and Georgetown University Medical 
Centers, Washington DC; VA Medical Center, San Francisco, CA, USA 
Large-scale cardiac registry-surveillance centers afford a unique opportu- 
nity to evaluate long-term survival implications of various pacing modal±ties. 
The VA Cardiac Registry-Surveillance Center in Washington DC and San 
Francisco, CA, established in 1982, have implant histories on more than 
50,000 patients. For this study, patient implants were categorized as single 
or dual-chamber and as rate-responsive or not. Kaplan-Meier curves for sur- 
vival past initial implant were calculated; and log-rank differences measured. 
Comparisons of post-first implant survival for single and dual-chamber 
pacing with and without rate-responsive pacing are as follows: 
N %5-yr survival 
Single 4,277 38.8% ± 0.9% 
Single rate-resp 1,895 55.0% J- 1.5%" 
Dual 5,472 53.1% ± 0.9%* 
Dual rate-resp 2,791 61.5% ± 1.3%* 
* p < 0.0001. 
Conclusions: Rate-responsive pacing improves longevity in single-cham- 
ber pacing to the levels seen with dual-chamber pacing. Rate-responsive 
pacing added to dual-chamber pacemakers further improves longevity in 
dual-chamber pacing to a lesser degree. Age matched controls yield the 
same results. 
5:15 p.m. 
~-~ls  Gender Bias in Selection of Dual Chamber There a 
and Rate Responsive Pacemakers? 
Dhiraj D. Narula, Wael A. Jaber, Alyce J. Widmer, Frederick A. Ehlert, 
Margot E. Vloka, Jonathan S. Steinberg. St.-Luke's-Roosevelt Hospital & 
Columbia Univ., New York, NY and Medtronic Inc., Minneapolis, MN, USA 
Gender bias has been reported to influence decision making, resource utiliza- 
tion and referral for invasive procedures. Whether gender influences selection 
of complex or expensive permanent pacemakers (PPM) is not known. 
Methods: 288,434 (48% female (F)) consecutive US pts with new PPM 
over 5 y were identified from an industrial database. Utilization of dual vs. 
single chamber and of rate responsive vs. non rate-responsive PPM was 
analyzed. 63,673 pts (51% male (M)) with atrial arrhythmia were excluded 
as this may bias choice of PPM. 
Results: F were less likely to receive dual chamber (OR 0.78, 95%CI 
0.77-0.8) or rate responsive (OR 0.71,95%CI 0.7--0.73) PPM (p < 0.0001). 
. . . . . . .  ~ ~ ~ ~ ~ p<0.001 
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This was more marked in older age groups, and persisted in an analysis 
stratified by age and indication for implant (sick sinus, AV block, other). 
Conclusion: Across the age spectrum, but especially in elderly pts, there 
was less utilization of dual chamber and rate responsive pacers in women 
independent of indication. Whether these differences represent legitimate 
clinical needs or gender bias merits further study. 
ORAL 
Molecular Electrophysiology 
Wednesday, March 10, 1999, 8:30 a.m.-10:00 a.m. 
Modal Convention Center, Room 228 
8:30 a.m. 
~68~ Intraatrial Conduction Disturbances in Cx40 
Deficiency Are Associated With an Increased Atrial 
Vulnerability 
Burghard Schumacher, Andreas Hagendortf, Susanne Kirchhoff 1 , 
Klaus Willecke 1 , Berndt L0deritz. Dept. of Cardiology; ~ Institute of Genetics, 
University of Bonn, Bonn, Germany 
Background: In mouse heart, the gap junctional protein Connexin40 (Cx40) 
is expressed in the atrial and ventricular myocardium and the His-Purk- 
inje system. Recently, we demonstrated that Cx40 deficiency in targeted 
mouse mutants is associated with a marked intraatfial conduction distur- 
bance. Conduction delay and conduction block are well known conditions for 
the development of reentrant achyarrhythmias. In this study, we investigated 
the susceptibility of Cx40 deficient mice for atrial tachyarrhythmias by rapid 
atrial stimulation. 
Methods: Thirty mice (10 Cx40 +/÷, 10 Cx40 ÷7 , and 10 Cx40 / mice) 
were initially studied by surface electrogram recordings. Subsequently, they 
were subjected to transesophageal atrial stimulation with a pacing cycle 
length of 25 msec for 10 sec. 
Results: In Cx40 deficient mice, surface electrocardiogram analysis 
showed a significant increase in intraatrial conduction time (23.6 ± 3.2 
msec) as compared to Cx40 +/- (18.2 ± 3.6 msec; p < 0.05) and wild type 
mice (16.8 ± 2.5 msec; p < 05). In 6 of 10 Cx40 -/ -  mice, sustained atrial 
tachyarrhythmias could be induced by atrial burst pacing. One mouse pre- 
sented with a sustained, regular supraventricular tachycardia that could be 
terminated by overdrive pacing and that was reproducibly re-inducible. Thus, 
reentry had be considered as underlying pathophysiologic mechanism. In 5 
Cx40 / mice, atrial burst pacing resulted in an atrial arrhythmia with irregu- 
lar RR intervals and without distinct P waves suggesting atrial fibrillation as 
underlying arrhythmia which has not been observed in these animals before. 
In contrast, no atrial arrhythmias were inducible in heterozygous or wild type 
animals. 
Conclusions: In atrial myocardium, conduction disturbances due to Cx40 
deficiency are associated with an increased atrial vulnerability and might 
contribute to arrhythmogenesis. 
8:45 a.m. 
~ Impaired Atrial/3-Adrenergic Responsiveness 
Contributes to Atrial Stunning 
Ulrich Schotten, Ingo Sabatschus, Christoph Stellbrink, 
Friedrich Schoendube, Peter Hanrath. University Hospital Aachen, Germany 
Atrial stunning is characterized by atrial contractile dysfunction after the 
cessation of atrial fibrillation (AF). Since atrial contractile force in-vivo can 
be increased mainly via the #-adrenergic system we investigated whether 
impaired j~-adrenergic responsiveness contributes to atrial stunning. 
Methods: Right atrial appendages were obtained from patients under- 
going mitral valve repair. 9 patients were in sinus rhythm (SR), whereas t0 
had developed chronic AF. Force of contraction (Foc) of thin isolated muscle 
preparations (17 in AF, 14 in SR) was measured under isometric conditions 
at 1 Hz. 
Results: Basal Foc was reduced by 81% in AF. However, in the presence 
of high extracellular Ca 2+ Foc were the same in AF and SR. Absolute Fec 
in the presence of 1 /~M isoprenaline (Iso) and the relative positive inotropic 
Table: Values are means ± SEM, ECso with 95% confidence intervals. 
Table basal Ca 2+ 12 mM Iso 1 #M Iso/Ca 2+ EC~ 
mN/mm 2 raN/ram 2 mN/mm 2 ratio nM 
SR n = 14 3.1 ± 0.3 7.0 ± 0.5 7.5 ± 0.7 1.1 ± 0.1 3 (1-7) 
AF n = 17 0.6 ± 0.1" 7.2 ± 0.7 4.6 ± 0.6" 0.6 ± 0.1" 25 (13-42) ° 
": p < 0.05 AF versus SR 
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Similary. the pos'ffwe lnduojd~c potency of 1so {F-.Cs~) was reduced 'In AE. as 
shown by the increase in ECho of Iso in AF. 
(IDonc)us)on: I)asa) Foc )s mc)uce(~ )n AF. )-)oweve~ ~)s ¢~)#e~ence )s 
spornshveness cor~lfloUles '~o ~[(la:l ~tundln.g. 
9 :00 a,m, 
~ Atrial Stunning: increased Myocardial 
Na+/Ca2÷-Exchanger but Unchanged SR Ca 2+ 
Transport Protein Expression 
Ulric't, ~o-',,~ ~Jt'(e-~ ,, ,C~1L~e{{~,, ~. e'{e~J~,, ,3i&~n'R-e=, ,{~; ~ u~&~e;, 
Christoph Stellbrink, Friedrich Schoendube, Peter Hanrath. University 
Hospi~{ Aachen, Germany 
Atria;' s~'un~;wcj' IAS) ~s characterized by a~ria'~ coY'~trac~e dys~unc'~oY't aP~er 
the cessation of atrial fibrillation (AF). AS has been suggested to be due to 
alterations of the atrial Ca2+-homeostasis. Therefore, we studied the protein 
expression of the Na+/Ca2+-exchanger and of Ca ~+ transport proteins of the 
sarc-~;~n#'~ -ret~cC(a-n, ~"...,'f,-~4~ '#, 'te.rnr, Rj'~,~Ce'o ~o';, -fi'97{, "~"r~ "a-'p"p~'a-'ge'o 
of patients undergoing mitral valve repair (MVR) or co[chary artery bypass 
graftt surgery (CAB). 9 of 22 patients undergoing MVR and 11 of 26 patients 
undergoing CAB had developed chronic AF, whereas the others were still in 
sinus rhythm (SR). 
Methods: Protein expression of the SAR Ca2+-ATPase (SERCA), phoso 
pholamban (PLB), calsequestrin (CAL) and Na+/Ca2+-exchanger (NCX) were 
meesure~ ush~ ~ ~ecP~ue 1"~&£4> c~mg pr~e:~n~. T,~e derisory, 
of the SAR calcium release channel was determined by 3H-ryanodine radi- 
oligand binding (CRC, fmol/mg protein). 
Results: Values as means 4- SEM. 
Table SERCA PLB CAL CRC NCX 
MVRSRn= 13 22.24-1.5 16.6 ~- 1.5 26.1±2.2 1334-23 3 .6±0.4  
MVIR AF n = 9 24.8:t=1.7 17.6±3.1 26.44-2.2 1244-22 5.44-0.6" 
CAI~ SR n = 15 25.34-1.7 21.44-2.2 39.04-3.7 1274-21 2.64-0.2 
CA[BAF n = 11 22.34-1.9 17.2±2.7 34.44-5.7 1374-23 4.3 4- 0.(~ 
*: p < 0.01 AF versus SR. 
In MRV as well as in CAB patients NCX was increased in AF. In contrast, 
SAR Ca 2÷ transport proteins were unchanged. 
Conclusion: Atrial stunning is not due to changes of the SAR Ca ~+ 
trarns.oor~ .prdtems 'o~t mLdn'~ 'de 0ue 'To increased £;a ~-~ extrusion V~a 'fne 
Na~/Ca 2 *-exchanger. 
9:15 a.m.  
~ ~  Myocardial Expression of Pro-Inflammatory 
Cytokines and Mitogen-Activated Protein Kinases 
During Atrial Fibrillation 
Andreas Goette, Uwe Lendeckel, Thorsten Staack, Marco Amdt, J. 
Christoph Geller, Christof Huth, Siegfried Ansorge, Helmut U. Klein. 
University Hospital Magdeburg, Germany 
Background: Recent animal studies have demonstrated a marked hyper- 
trophy of atrial myocytes and structural abnormalities of the contractile ap- 
paratus during atria~ ~ibr'~llation {AF). The morphologic changes were simi'~ar 
to abr~ormal~ties see~ in h~mar~s vsnt~c~es d~rir~g ~ow-f~ov~ ischemia I"~ber- 
nating myocardium"). Pro-inflammatory cytokines like tumor necrosis factor 
(TNF-(z) and Intedeukin-1/~ (IL-1/~) are factors known to cause myocardial 
dysfunction and fibrosis. The purpose of this study was to determine whether 
TNF-e, IL 1/~, Interleukin 6 ilL-6) and additionally Erk-2, a protein associated 
with intrace~lalaT signalling of cardiac hyperlrophy, are expr~:~sL=~:~ in ht~ma,n 
atrial myocytes during AE 
Methods: Total RNA was isolated from right atrial appendages of 23 pa- 
tients (pts) undergoing open heart surgery for valve replacement or coronary 
artery bypass grafting. 7 pts had chronic AF (> I year), 16 pts were in normal 
sinus rhythm (SR). TNF-c~, IL-1,8, IL-6 and Erk-2 mRNA expression were de- 
during polymerase chain reaction. Erk2-gene expression was quantified by 
using a LightCycler system (Idaho Technologies). 
Results: Mean age, ejection fraction, severity of cardiac and non-cardiac 
dis~-~,:co'-e'o ,we'~e "~r~ "difFErent, ~.f'eqw'e'~, -p'(s ,w/d', ~'r& "w~ro~ ¢,.,'F'. T"tre -thai'a;, 
4.2 -~ ~.~ c/~'t.: :;3 < ~.~3- E~'~.~'~G{t <3~ T~F-=, ~L-"~.~ ,~ ~L-~ .oG~c:~ 
be demonstrated in tissue samples of any patient. Erk-2 expression was 
si(p~iihcan'b~ increase0 )n ~s  ~'tn AT- corn, par eO Wttn .D'~s Yn ~ )~3~ = ~b 'O 
vs. 468 ± 212 U; p < 0.05). The Erk-2 expression correlated with the atrial 
siz-¢ i~T i.~%  ^witiT #E 
Conclusions: Pro-inflammatory cytokines are not expressed in human 
atrial myocytes. Therefore, the cytokine pathway is not responsible for 
{F_.rk-2) seem robe 'involved in the induction of atria] pathology during chronic 
AF in humans. 
9-3Q &m. .  
I 868-5 [ Functional Excitation-Contraction Coupling in the 
Absence of Calcium Induced Calcium Release 
Kiran C.R. Patal, Lesley A. Arberry, John V. Jones ~ , Allan J. Levi. University 
of Bristol; ~ Dept. of Cardiology, Bristol Royal tnfirma~ Bristol, UK 
Background: Until recently, it has been accepted that the only mechanism 
calcium release (CICR). Having b~ocked transmembrane calcium [,Ca) entry 
we were ~22,~e t  sh~w that cellular depo~4sat&~ was stY# able te e~¢::t a~ 
intracellular calcium (Ca~) transient. 
Methods: Guinea-pig venthcular myocytes were dialysed internally with a 
100/~M cAMP (3'5' cyclic adenosine monophosphate) containing pipette so- 
lution and patch clamped at -60 mV, then depolarised in 20 mV increments, 
from -60 to +80 mV. Ca4 transients were measured using the fluorescent 
dye I=I]RA-2.5 rriM nickel (which blocks Ca entry via both the L-type Ca 
channe~ and the sodium-ca~6~um exchange [,with 350 .~  lidoca'me to b~ock 
sodium channels)) was supedused over the cel~s for 10 secs. prior to each 
test depolarisation. In cells held at -60 mV, we switched to 10 mM caffeine 
to measure the sarcoplasmic reticulum (SR) Ca content. 
Results: In the presence of 5 mM Ni, depolarisation was still able to 
elicit Cai release. This release showed a bell shaped voltage dependence, 
peaking at +20 mY, and was able to release 70 4- 7.9% (mean :~ SEM; n = 
6) of total SR content. A prepulse to caffeine before the depolarising pulse 
abolished any voltage activated Ca transient, suggesting that the transient 
was due to Ca release from the SR. this Ca release mechanism was absent 
when the cellular dialysate lacked cAMP. 
Conclusion: we provide evidence that cardiac myocytes possess, in ad- 
dition to CICR~ a second mechanism which is_ able ~ re, le, as.e Ca. f.~o.m.t.b~ 
ihtormatibn about bow myocytes behave under adrenergic stimulation and in 
disease states. 
9:45 a.m.  
in a Mouse Model- of Myotonic Oystrophy 
Samir Saba, Brian A. VanderBrink, Brenda Luciano, Mark J, Aronovitz, 
Charles I. Berul, Sita Reddy, David Housman, Michael E. Mendelsohn, N.A. 
Mark Estes III, Paul J. Wang. Tufts-New England Medical Center, Boston 
MA; Massachusetts Institute of Technology, Boston MA, USA 
Background: A mouse strain lacking functional myotonic dystrophy protein 
kinase (DMPK) has recently been developed. DMPK - / -  mice exhibit mus- 
cular and conduction abnormalities consistent with the disease, however the 
site of abnormal cardiac conduction is unknown. 
Methods: 9 homozygous DMPK - / -  mice and 7 age-matched wild type 
controls underwent in vivo EP studies using an endocardJal 2F catheter. Base- 
line intervals as well as Wenckebach and 2:1 cycle lengths were measured 
1or the atrioventricular {AV) and VA conduction. Effective refractory periods 
/EP, P) and t~ctior~a t, ~e~ractory per;,ods IFRP~, were deteTmi$3ed e,~r;,ng atTia~ 
and ventricular premature stimulation. 
Results: His bundle recordings were obtained on all the studied animals 
(16/16). DMPK-/ -  mice had significantly prolonged PR (48.3 4- 4.6 versus 
40.3 4- 4.1 ms, p = 0.003) and AH (39.8 4- 4.5 versus 31.0 4- 5.6 ms, p 
= O.OO$) intervals compared to wild ~pe (W3") contrc4s. HV i~terva/s were 
very significantly prolonged as well (15.7 4- 1.7 versus 10.4 4- 1.1 ms, p 
< 0.0001). 3/9 DMPK-/ -  and 1/7 WT mice exhibited VA block. Atrial ERP 
was reached before AV node ERP in 2/9 (22%) of the knockout mice and 
5/7 (71%) of the controls. Only one mouse (DMPK-/-) exhibited infrah{sian 
block on premature atrial stimulation. 
ular conduction abnormalities were localized to the supra- and infrahisian 
conduction tissues, a finding similar to the human form of the disease. 
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I1 -146]  Risk of Development of Delayed AM Block After 231 
Slow Pathway Modification in Patients With 
Atrioventricular Nodal Reentrant Tachycardia 
and Preexisting Prolonged AH Interval 
Yi-Gang Li, Frank Bogun, Thomas Klingenheben, Stefan H. Hohnloser. 
Department of Internal Medicine, Division of Cardiology, J.W. Goethe 
Universi~ Frankfurt, Germany 
Background: Incidence and risk factors of delayed AV block (DAVB) in lOtS 
who underwent successful, uncomplicated slew pathway modification (SPM) 
for atrioventricular nodal reentrant achycardia (AVNRT) and preexisting pro- 
longed AH Interval are poorly defined. 
Methods: SPM was performed in 14 patients (60 4- 7 yrs, 2 females) with 
AVNRT and an AH interval of 152 ± 22 ms prior to the ablation procedure. 
Total elimination of the functional slow pathway was assumed if the antegrade 
effective refractory period (ERP) following SPM was longer than the AVNRT 
cycle length. To detect AV conduction disturbances, 24 hour Holter recording 
(HR) was done 1 day prior to SPM, and 1 day, 1 week. as well as 1, 3, 6 
months after the procedure. 
Results: SPM was successful in all pts without immediate higher degree 
AV block. Repeated HR after SPM revealed symptomatic intermittend 2nd 
AV block in 3/14 pts. There were no significant differences in clinical charac- 
teristics or in the AH or HV interval after SPM in pts with or without AV block. 
The ERP (593 ± 237 ms vs 324 ± 102 ms, p < 0.05) and the Wenckebach 
cycle length (653 4- 174 ms vs 396 ± 80 ms, p < 0.05) following SPM were 
longer in pts with a delayed AV block. The incidence of delayed AV block 
was higher in pts with total elimination of the functional slow pathway (3/6 
pts) compared to pts without total elimination (0/8 pts; p < 0.025). 
Conclusions: SPM in pts with AVNRT in the setting of a prolonged AH 
interval is highly effective. However, there is a significant risk of development 
of delayed AV block, particularly when SMP results in total elimination of the 
functional slow pathway. 
I1231-147 I Predictive of RR Interval Distribution Accuracy I Pattern for the Assessment of Dual AVN 
Physiology in Patients With Chronic Atrial 
Fibrillation 
Stelios Rokas, Styliani Gaitanidou, Sofia Chatzidou, Dennis Achtipis, 
Kostas Pamboukas, Stamatis Stamatelopoulos. Alexandra University 
Hospital, Athens, Greece 
Background: Modification of atrioventricular node (AVN) conduction with 
radiofrequency energy delivered at the slow pathway area seems to be an 
effective mode of therapy in patients (pts) with chronic atrial fibrillation (AF) 
and rapid ventricular esponse. Success or failure of this method to control the 
ventricular ate may be associated with the presence or absence respectively 
of dual AVN physiology, a concept that has not been assessed yet in pts with 
chronic AF. In this study we assess the predictive accuracy of a non invasive 
method, the RR interval distribution pattern analysis, for the detection of the 
presence or the absence of dual AVN physiology. 
Methods: Thirty one pts with chronic AF who underwent successful 
external or internal cardioversion were included in this study. The mean age 
was 65 4- 8 years. No severe heart disease was present and all antiarrhythmic 
drugs including digitalis were discontinued. Twenty-four-hours ambulatory, 
ECG recordings were obtained and from the analysis of all 24 h RR intervals. 
heart rate stratified histograms (HRSH) were constructed. The RR distribution 
pattern that derives from the final analysis of HRSH may be unimodal, bimodal 
or trimodal. Few days later and while all the pts maintained sinus rhythm, an 
electrophysiologic study (EPS) was performed in each pt in order to assess 
the presence or the absence of dual AVN phsyiology, using the standard 
criteria. 
Results: Fourteen pts presented a bimodal pattern (B) of RR distribution, 
16 pts demonstrated a unimodal pattern (U) and one pt had a trimodal 
distribution pattern (T). Eleven out of 14 pts with B had dual AVN physiology 
while in 14 out of 16 pts with U the duality was absent. The pt who presented 
the T had 2 "jumps" recorded during the EPS. This pt was finally categorized 
in the pts group with B and dual AVN physiology. The sensitivity of this 
method for the detection of dual AVN physiology is 85.7% and the specificity 
is 82.3% while the predictive accuracy is 83.8%. 
Conclusion: In pts with chronic AF the RR interval distribution pattern is 
highly sensitive and specific for the detection of the presence or the absence 
of dual AVN physiology. This method may be proved useful in the selection 
of pts with chronic AF who require modification of AVN conduction. 
1231-148 ] Efficacy and Safety of Dofetilide in the 
7 
Prevention of Symptomatic Attacks of 
Paroxysmal Supraventricular Tachycardia 
A.M. Wnuk-Woinar, M. Tendera, P. Kulakowski, Ole Graft. 1 st Department of 
Cardiology, Silesian School of Medicine, Katowice, Poland 
Baokgound: The aim of this double-blind, parallel group study was to com- 
pare the efficacy and safety of selective potassium channel blocker dofetilide 
(D) with placebo (P1) and propafenone (P) in long-term (_<26 weeks) pre- 
vention of symptomatic attacks of paroxysmal supraventricular tachycardia 
(pSVT). 
Methods: 122 of 253 adult pts screened during < 6 week P1 run-in period 
who had a documented pSVT were randomized into treatment groups: D 500 
/~g bid (40 pts: 11 M, 29 F; mean age, 50 yr), P 150 Izg tid (41 pts: 14 M, 
27 F; 47 yr), and P1 (41 pts: 13 M, 28 F; 48 yr). A Kaplan-Meier estimate 
was used to analyze the time from steady state (72 hr post 1st dose) to 1st 
attack of pSVT. The hazard ratio of active treatment D and P group vs P1 
was calculated to measure the relative survival. 
Results; No serious adverse events were reported on D. There were no 
proarrhythmic events with D, but 3 with P. 
Group of treatment D P1 P 
Probability of remaining 4weeks 0.7569 0.3953 0.7601 
attack free for: 12 weeks 0.6606 0.1976 0.6113 
26 weeks 0.5480 0.0847 0.5349 
Probability of treatment difference P < 0.001 P < 0.001 
(leg rank test) 
Hazard ratio vs placebo 0.33 0.26 
Median number of attacks 1 5 0.5 
Median duration of therapy (days) 183 182 182 
Serious adverse events n (%) 0 7 (17.1) 7 (17.1 )
Conclusion: D was shown to be substantially more efficacious than P1 
and equally efficacious as P in prevention of pSVT attacks in pts waiting to be 
placed on alternative (RF ablation) therapy. D was safer and better tolerated 
than P in the terms of severity of events reported. 
I1 491 Prospective Study of Diagnostic Pacing 231 -1  Maneuvers During Paroxysmal Supraventricular 
Tachycardia 
Bradley P. Knight, Matthew Flemming, Frank Pelosi, Hakan Oral, Michael 
H. Kim, Hung-Fat Tse, Gregory F. Michaud, Rajiva Goyal, S. 
Adam Strickberger, Fred Morady. Univ of Michigan, Ann Arbor, MI, USA 
This study prospectively determined the usefulness of various diagnostic 
pacing maneuvers during paroxysmal supraventricular tachycardia (SVT). 
Sustained SVT (CL = 336 i 64 ms; VA interval = 108 ± 85 ms) was 
induced in 95 pts (68% female; age = 47 4- 16 yrs; LVEF = 0.60 4- 0.05). 
SVT features, and responses to pacing were characterized. Arrhythmia was 
atrioventricular node reentry (AVNRT) in 53 pts (atypical in 6), orthodromic 
reentrant achycardia (ORT) in 29 pts, and atrial tachycardia (AT) in 13 pts. 
A variable VA relationship following entrainment (Ent) from the RA, a similar 
atrial activation sequence during Ent from the RV as during SVT, and an 
A-A-V response following Ent from the RV were each 100% sensitive and 
100% specific for AT. However, Ent was not possible from the RA in 18% 
of cases and was not possible from the RV in 75% of cases of AT, 14% of 
AVNRT, and 14% of ORT. Inability to entrain from the RV because VA block 
CL was > SVT CL was 42% sensitive and 100% specific for AT. During 
brief rapid RV pacing, dissociation of the RV was 82% sensitive and 69% 
specific for AT, and termination w/o atrial preexcitation was 27% sensitive 
and 100% specific for AVNRT or ORT. Termination or atrial preexcitation with 
PVC's during His-refractoriness was 48% sensitive and 100% specific for 
ORT. Spontaneous termination with AV block excluded AT, but occurred in 
only 32% of cases of ORT and AVNRT. Termination was dependent on a 
short AH interval in 100% of cases of AVNRT, 67% of ORT, and 0% of AT. An 
extranodal response during para-Hisian pacing during SR was 70% sensitive 
and 88% specific for ORE. In conclusion, many maneuvers are highly specific 
for a mechanism of PSVT, but are either insensitive or cannot be applied to a 
high proportion of cases. Performance of multiple pacing maneuvers is often 
required for an accurate diagnosis during SV-I-. 
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I1231-1501 An of With Epidemiology study patients 
Wofff-Parkfnson-Wh(te pattern 
Christos S. Katsouras, John A. Goudevenos, Lampros K. Michalis, 
Georgios F. Grekas, Vasilios K. Giogiakas, Christos S. Stroumbis, Urania 
G. Argyri, Dimitris A. Sideris. Department of Cardiology, Medical School of 
Ioannina, Ioannina 45110, Greece 
Background: Most of our knowledge about the epidemiology of ECF Wolff- 
Parkinson-White (WPW) comes from studies influenced by a bias in patient 
referrals who in the majority are symptomatic. Epidemiologic data about 
asymptomatic WPW however, is sparse. 
Methods: Over a 8 years period (1990-1997) we contucted a prospective 
population-based survey of cases of ECG-WPW. The prevalence was esti- 
mated from a closed geographical area with known population size (340000 
citizens) stratified for age and sex (49%male). ECG-WPW were obtained 
from a widespread pool of ECGs within the health system (GPs, health cen- 
ters, private clinics, all routin and emergency ECGs from the two district 
hospitals). 
Results: During the study period 157 cases (109 males) patients were 
identified. The age, at diagnosis, range from infants to 84 years and the mean 
age was 39 ± 19 years for men and 50 ± 18 years for women (p < 0.01). 
Prevalence (n/1000 residents) in men was 0.62 and in women 0.29.80 (51%) 
subjects had no history of syndrome related syndromes. Asymptomatic sub- 
jects (57 males) were older than symptomatic (mean age 48 ± 19 vs 37 ± 19 
years, p < 0.01). Documented supraventricular tachycardia was recorded in 
28 (18%) while atrial fibrillation in 13 (8%) patients (mean age at first episode 
32 ± 19 and 47 ± 19 years, respectively, p < 0.01). During follow-up (mean 
time, 5 years) no case of sudden cardiac death occurred. Three asymp- 
tomatic reported episodes of dreaf palpitations, 10 symptomatics underwent 
ablation and 6 died (4 neoplasia, 2 myocardial infarction). 
Conclusion: WPW pattern is more common, and diagnosed at a younger 
age in men than in women. About half of patients with ECG-WPW are 
asymptomatic (no gender difference) at diagnosis and tend to remain so 
thereafter. 
J1231 51 j Quantitative Effects of Functional Bundle 
3 
-1 
Branch Block in Patients With A-V Reentry 
Yanfei Yang, Jie Cheng, Parvin Dorostkar, Melvin Scheinman. University of 
California, San Francisco, CA, USA 
We sought to assess the changes in BBB duration on retrograde conduction 
time (AVA) during AV reentry (AVRT). 
Methods: We retrospectively analyzed 198 consecutive pts with AVRT 
and found 80 with single non-decremental pathways (42 left free walI[LFWAP], 
14 right[RFWAP] and 24 septal[SAP]) who developed BBB during AVRT. The 
QRS duration (QRSD) was measured from a simultaneously recorded 12 lead 
ECG. Complete BBB (CBBB) was > 120 ms, incomplete (IBBB) < 120 ms. 
Results: IBBB ipsilateral to a FWAP was observed in 27/56 (48.2%) pts, 
and CBBB was recorded in 35/56 (62.5%). Pts with CBBB had a significantly 
longer AVA (64 ± 17 ms) than those with IBBB (29 ± 10 ms)(p < 0.0001). 
Overlap in AVA between I&CBBB was observed in 8/56 (14.3%) pts with 
FWAP. The mean AVA for pts with SAP (excluding those with fascicular 
block) and CBBB was 20 ± 9 ms, which was similar to that for pts with FWAP 
and ILBBB. 
Graphs: 
FW~P with I /CBaB 
i', I 
s,p:== p,t~,y wlm can 
Conclusion: Use of AVA to separate FWAP from SAP must be interpreted 
in light of QRSD. Transseptal activation of FWAP with ipsilateral CBBB 
appears to be patient specific. FWAP always had AVA >_ 40 ms achievable 
with QRSD of 108-125 ms, but QRSo of 120-125 ms could be associated 
with AVA < 40 ms. The best criterion for separating FWAP from SAP is ~VA 
> 40 ms with QRSo >_ 125 ms. 
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[1232-152] Mortality, Injury, and Remaining Population at 
Risk Related to the Telectronics Accufix Atrial 
Permanent Pacemaker Lead: Management 
implications of Database Results at 3 1/2 Years 
After Lead Recall 
David T. Kawanishi, Jeffrey A. Brinker, Russell C. Reeves, G. Neal Kay, 
Jay Gross, Gary Grunkemeier, JoAnn Fee. For the Physician Advisory 
Committee; Accufix Research/nstitute, Eng/ewood, Colorado, USA 
Background: After the formal recall in November 1994 of the Telectronics 
Accufix series of atrial pacemaker leads due to injury and death from fracture 
of the J-wire, a database was established to tabulate subsequent injuries 
and deaths. An estimated 40,860 devices were implanted. 
Methods: A worldwide registry was established to determine the clinical 
condition of all patients who received the recalled lead; extensive effort was 
made to determine whether injuries or deaths resulted from J-wire fracture or 
lead extraction procedures. A prospective multicenter study (MCS) of serial 
cinefluoroscopy involved a closely monitored subset of patients. 
Results: The reported condition of patients worldwide (WW) and in the 
MCS are as follow: 
WW MCS 
No. of leads reported implanted 31,060 2,558 
Deaths reported (not related to J) 5,618 706 
No. of leads reported extracled 4,366 601 
Total J-wire injuries 38 (0.2%) 2 (0.2%) 
Fatal J-wire injury 6 (0.03%) 1 (0.2%) 
Post recall Major intravascular 
extraction injury (including latal) 113/2732 (4.1%) 19/549 (3.5%) 
Fatal extraction injury 18/2909 (0.6%) 1/549 (0.2%) 
Conclusion: 1. The cumulative rate of injury related to J-wire fracture 
appears to be less than 1%. 2. Approximately 22,000 patients are estimated 
to be still at risk of injury, but this figure will decrease over time, as implants 
have ceased, and 3. This rate of decrease could be accelerated by increased 
lead extractions, if the risk of complications could be reduced. 
1232-153 ] Single Centre Experience of 51 Insertable Loop 
Recorders for Investigation of Unexplained 
Syncope 
Amir Zaidi, Adam P. Fitzpatrick. Manchester Heart Centre, Manchester 
Royal Infirmary, Manchester, UK 
Background: Many patients with recurrent syncope remain undiagnosed 
after initial investigation. It is thought that transient arrhythmias may be the 
underlying cause in many of these patients. Long-term ECG monitoring with 
the insertable loop recorder may provide a means of having ECG recordings 
during symptoms that are sporadic and infrequent over many months. 
Methods: Since November 1997 51 patients (29 male, mean age 45.4 ± 
18.3) with 2 or more episodes of syncope have received an insertable loop 
recorder. All devices have been implanted in the left precordium under local 
anaesthetic. Intravenous sedation was not normally required. All procedures 
were carried out in a clean laboratory by a cardiologist with 1 assistant. 
Mean procedure time was approximately 30 ± 5 minutes. 3 patients have 
developed minor superficial wound infections requiring antibiotics. 2 devices 
have been removed for intractable discomfort. 
Results: Over a mean follow-up of 4.6 ± 3.7 months, 82 recordings 
have been made in 24 (47.1%) patients. Only 3 attempts to make recordings 
have failed. Mean time to first recording was 19.6 ± 23.4 days. Marked 
bradycardia/asystole has been identified in 5 patients all of whom have 
received permanent pacemakers. Vasovagal syncope has been diagnosed 
in a further 4 patients. 2 patients have ventricular bigeminy associated with 
pre-syncope and are making further recordings. The remaining 13 patients 
have sinus rhythm at the time of attacks. 
Conclusions: The insertable loop recorder is a safe and effective means 
of acquiring ECG recordings in patients with sporadic symptoms over tong 
periods. It has a major role in excluding tachy or bradyarrhythmia in patients 
with blackouts. 
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L1232-1541 Clinical and Characteristics of Pathologic a 
Unique Form of Heritable Atrioventricular Node 
Dysfunction 
Redney Graber, Elizabeth A. Sparks, Harry L Graber, Harisios Boudoulas, 
Peter Baker, Charles F. Wooley, Steven D. Nelson. The Ohio State 
Universi~ Columbus, OH, USA 
Background: Heritable disorders of the cardiac conduction system with 
delayed expression, though common, are poorly characterized. 
Methods: We studied 40 affected family members (23 females: 17 
males) with an autosomal dominant heritable cardiac disorder (chromosome 
1 p1-lq1 ) who had permanent pacemakers (PPM) implanted for symptomatic 
high grade atrioventricular (AV) block. 
Results: The median age at PPM was 47 ± 11 yrs. The time from onset of 
phenotypic expression of the heritable cardiac disorder to PPM implant was 8 
± 8.2 yrs. The PR interval recorded from the 12 lead ECG was 245 ± 61 ms. 
(n = 27). None had bundle branch block. Fourteen family members with PPM 
had a parent with a PPM. Electrophysiology testing showed abnormal AV 
node function in 100% (15/15) but normal infranodal conduction (HV interval) 
in 78% (7/9). 27 family members developed atrial fibrillation within 1 ± 5 yrs 
of PPM implant. 19 deaths (9 sudden) have been reported at a median age 
of 57 ± 8 yrs. Autopsies were performed on 6 affected family members with 
PPM. All hearts had marked AV node fibrosis and prominent fatty infiltrate in 
4 of the AV nodes. 
Conclusion: High grade AV block in the heritable (chromosome 1p1-1q1 )
cardiac disorder is primarily due to progressive AV nodal dysfunction. A 
prolonged PR interval is an eady marker of disease. The pattern of AV nodal 
fibrosis and fatty infiltrate may represent apoptosis. 
[ 1232-155 ] Biventricular triggered pacing for the treatment 
of ventricular tachycardia, An in Vivo 
experimental study 
LK. Michalis, A. Karahaliou, C.S. Katsouras, V. Giogiakas, D. Niokou 1 , 
D. Patsiouras, D. Nikas, A. Gel±as, G. Papadopoulos 1 , J. Goudevenos, D. 
A. Sideris. Departments of Cardiology; 1Anaesthesiology, University 
Hospital ofloannina, Ioannina, Greece 
Background: Pacing during the QRS complex is expected to exert an an- 
tiarrythmic effect by reducing inhomogeneity of the ventricular myocardium. 
The aim of the present study was to test the hypothesis that simultaneous 
triggered pacing (VVT) of both ventricles terminates ventricular tachycardia 
(VT) in an experimental model. 
Methods: Eight anaesthetised lambs were used. A combination of eleva- 
tion of systolic blood pressure and ischaemiaJreperfusion was tried in order 
to induce ventricular arrythmias. Blood pressure was elevated either by ob- 
structing the ascending aorta or administrating intravenously metaraminol. 
Ischaemia/reperfusion was achieved by ligating the left anterior descending 
coronary artery for 45 rain and releasing the ligation afterwards. 
Results: In seven experiments VT was observed eight times at a mean 
systolic ventricular pressure of 189.5 ± 15.1 mmHg. VT was terminated on 
starting simultaneous VVT pacing of both ventricles. VVT pacing of only the 
one or the other ventricle failed to stop it. We didn't observe any VT when 
the biventricular VVT pacing was started prior to systolic blood pressure 
elevation or ischaemia induction. In one experiment we failed to induce VT. 
Conclusions: Simultaneous VVT pacing of both ventricles may termi- 
nate v-r initiated by elevation of systolic ventricular pressure and/or is- 
chaemia/reperfusion. 
1232-156 ] Lone Congenital Complete Heart Block - 
Outcomes 1-21 Years After Permanent Pacing 
David J. Heaven, Ann M Ingrain, Arvinder S. Kurbaan, Zahra K. Stack, 
Jane Somerville, Richard Sutton. Royal Brompton Hospital, London, UK 
Background: In light of recent recommendations for prophylactic pacing 
we examined the complications and outcome of patients paced for lone 
congenital complete heart block without structural congenital heart defects 
(LCCHB). 
Methods: Review of all patients paced for LCCHB in a tertiary cardiac 
centre with a Grown Up Congenital Heart unit 1977-1998. 
Results: 38 patients with LCCHB 24 females, 14 males. Mean age at di- 
agnosis 4.8 years (range fetus-16years). Mean age at first pacemaker implant 
19.4 years (3 months-63 years). Indications for pacing were symptoms (26), 
prophylactic (12). At first implant 15 Dual-Chamber and 23 Single-Cham- 
ber ventricular (mostly before 1986 or age below 5years) pacemakers were 
implanted with mean follow-up 9 years (1-21years). 43 pacing procedures 
followed including 15 generator eplacements, 5 generator upgrade& 16 pro- 
cedures required lead revision (2 extractions). Total procedures 2.13/patient, 
one/4.2 years. 33 complications occurred in 17 patients including 8 operative 
complications and 10 pacing system malfunctions requiring reoperation. 4 
patients developed cardiomyopathy with 1 death and ;2 transplants. Atrial 
fibrillation occurred in 5 patients. 4/5 were paced after age 40, 1 initially 
paced VVl and developed pacemaker syndrome, and 1/5 stroked. 1 patient 
developed lead related tricuspid stenosis requiring valve replacement. 
Conclusion: Pacing in patients with LCCHB was associated with impor- 
tant morbidity. Although prophylactic pacing for asymptomatic young adults 
with LCCHB has a role the high complication rate over decades must be 
considered. 
L1 I Technique for Vagal Nerve Stimulation 232-1 57 New 
Jeffrey J. Goldberger, Alan H. Kadish, David Johnson, Xiaoshi Qi. 
Northwestern Universi~ Chicago, IL, USA 
Background: The vagus nerve travels in a neurovascular bundle with the 
carotid artery and internal jugular vein. The present study was designed 
to assess whether transvascular stimulation through the right carotid artery 
(RCA) of the dog can be used to directly stimulate the vagus nerve. 
Methods: In five anesthetized dogs, a steerable electrode catheter was 
positioned under fluoroscopic guidance in the RCA in the mid neck via the 
femoral artery. Multipolar catheters were positioned transvenously through 
the femoral vein in the right atrium, across the tricuspid valve to record a His 
bundle electrogram, and in the right ventricle. 
Results: In all five animals, vagal nerve stimulation was successfully 
achieved with outputs ranging between 10 and 30 mA at a burst cycle length 
of 50 ms. During stimulation from the RCA, sinus cycle length increased from 
473 ± 113 ms at baseline to 894 ± 315 ms (p < 0.025), the AH interval 
increased from 55 ± 14 ms to 77 ± 23 ms (p < 0.03), the atrial effective 
refractory period decreased from 136 ± 8 ms to 126 ± 6 ms (p < 0.01), and 
the systolic blood pressure fell from 135 ± 20 mmHg to 117 ± 20 mmHg (p 
< 0.005). A prolongation of the AV block cycle length (AVBCL in ms) and 
the AV nodal effective refractory period (AVNERP in ms) was also noted with 
stimulation from the RCA (see table); precise measurements were limited by 
either atrial refractoriness or the stimulator. 
Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 
Baseline 
AVNERP < 170 < 165 < 140 252 < 170 
AVBCL <200-200 <250 <:200 220-540 200-210 
RCA stimulation 
AVNERP <160 225 138 560 208 
AVBCL <200-30 300 <200-200 590-690 240-310 
Atrial fibrillation was not induced at baseline in any animal. During stim- 
ulation from the RCA, atrial fibrillation was induced in 3 of 5 animals and 
persisted for the duration of stimulation from the RCA (5 minutes). 
Conclusion: Stimulation of the cardiac branch of the vagus nerve can be 
achieved by positioning a catheter in the blood vessel adjacent to the nerve 
in its neurovascular bundle in the neck. 
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1 78 ] Can Extensive Right Atrial Ablation in Atrial 233-1 
Fibrillation Patients Decrease Atrial 
Defibrillation Thresholds? 
G. Muqtada Chaudhry, S. Dinakar Satti, Tamjeed Arshad, Patricia E. Pacetti, 
Thomas F. Marchese, Sarah Patton, Chades I. Haffajee. St. Elizabeth's 
Medical Center, Tufts University School of Medicine, Boston, MA, USA 
Background: We and others have shown that creation of linear lines of 
block by radiofrequency (RF) ablation in right atrium can reduce relapse of 
atrial fibrillation (AF) in drug refractory patients. Recent advances in atrial 
defibrillators have resulted in increasing use of hybrid therapy with drugs 
and implantable defibrillators. Defibrillation thresholds (DFT) with these de- 
vices, however, are still in the range of 6-8 joules (J), which is above the 
pain threshold and generally not tolerated by most patients. We sought to 
determine whether extensive right atrial ablation similar to catheter based 
maze procedure but limited only to right atrium can lower atrial DFT using 
the optimum defibrillation pathway shown in prior trials. 
Methods: In 9 patients with structurally normal hearts and recurrent AF, 
atrial DFTs were determined between multibolar coronary sinus (+) and lat- 
eral right atrial (-)  catheters using a step up protocol starting at 0.16 J until 
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AF conversion. Linear RF lesions were then placed along crista terminal±s, 
tricuspid valve-inferior vena cava isthmus and posterior right atrial wall be- 
tween inferior vena cava and fossa ovalis. Atrial fibrillation was reinduced with 
rapid atrial pacing after the ablation procedure and atrial DFT determination 
was repeated as preablation. 
Results: Atrial DFT before ablation were 7.21 ± 3.38 (range 0.65-30) J. 
Ablation procedure was accomplished in all the patients without any com- 
plications. After ablation DFT were determined to be 6.80 ± 1.92 (range 
0.65-16) J. There was no statistically significant difference between DFTs 
measured before and after ablation (p = 0.85). 
Conclusions: 1) Extensive right atrial ablation does not result in lowering 
of atrial DFTs. 2) Even with the most optimum pathway, atrial DFTs remain 
high enough to be tolerated by most conscious patients. 
1 79  ] A Single Left Atrial Radiofrequency Ablation 233-1 
Lesion Reduces Atrial Defibrillation Thresholds 
in Sheep 
James B. White, Parwis C. Fotuhi, Gregory P. Walcott, Nipon Chattipakorn, 
Raymond E. Ideker. The University of Alabama at Birmingham, 
Birmingham, AL, USA 
Background: Early post-shock activity is correlated with specific regions of 
the atria following defibrillation-strength shocks. The purpose of this study 
was to create a single linear radiofrequency (RF) lesion in the area of early 
post-shock activity to determine its effect on defibrillation efficacy. 
Methods: A left thoracotomy was performed on six anesthetized sheep 
and a 504 electrode mapping plaque was placed on the left atrium. Defib- 
rillation electrodes were placed in an RV/SVC configuration with distal coil 
as cathode. Atrial fibrillation was induced by burst pacing and maintained by 
infusion of beta-methylcholine (2--42 uL/min). In each animal, 5 atrial defib- 
rillation thresholds (ADFT) were obtained both before and after creating a 
single linear drag-lesion in the left lateral atrial wall. Unipolar electrograms 
were recorded after each shock to determine post-shock activation patterns. 
Results: In each animal, a significant decrease in current, voltage, and 
energy was observed in the ADFT after RF application (see table). Post-shock 
activations recorded from the mapped region before RF treatment were focal 
for 75% of failed shocks. Shock strengths failing to defibrillate before RF 
treatment were successful after RF treatment producing a normal sinus 
rhythm occasionally (30%) proceeded by focal activity. 
Before Lesion After Lesion P AftedBefore 
Leading Edge Voltage 283 :t_ 65 230 ± 66 <0.01 0.81 
Leading Edge Current 7.1 ± 2.2 6.3 ~ 2.4 <0.01 0.89 
Total Energy 4.8 ± 2.3 3.2 h- 2.0 <0.01 0.71 
Conclusions: A single RF lesion in the region of earliest activation re- 
duces the ADFT. RF lesions appear to reduce or alter the substrate necessary 
for the reinitiation of atrial fibrillation following defibriltation strength shocks. 
1233-180/ Clinical Results With New Device for Internal a 
J Atrial Cardioversion of Atrial Fibrillation and 
Combined Dual Chamber Pacing 
Andreas Plewan, Bettina Koller, Eckhard Air L Medizinische K/inik, K/inikum 
rechts der lear, Technische Universit~t MOnchen, Germany 
Introduction: Previous studies showed that internal card±overs±on (i tCV) of 
atrial fibrillation (AF) is leasable. Aim of the present study was to proof the 
safety and efficacy of a new device for intCV of chronic AF with an additional 
option for atrial and ventricular back-up pacing. 
Methods: IntCV of AF (duration of AF: 228 :E 515 days) was performed 
in 50 patients (pts, age: 59 5_ 11 years, 10 pts postcardiothoratic surgery). 
A single lead balloon guided 7.5 french catheter for intCV (EP MedSystem) 
was introduced via the brachial vein (48 pts) or femoral vein (2 pts). The 
distal shock array was placed in the left pulmonary artery, the proximal 
shock array had firm contact to basal atrial tissue. Each array consists 
of five 5 mm ring electrodes with a total surface of 2.5 cm 2. Via a distal 
lumen hemedynamic measurements can be performed. R-wave triggered 
biphasic shocks of 50% tilt were delivered by the new external defibrillator 
(Alert, EP MedSystem) device that incoorporates combined 12 lead surface 
ECG, intraatrial and ventricular EGM online recording and monitoring on 
an integrated LCD monitor. All signals can be stored on disc and printed 
for documentation. The option of atrial (AAI, AOO) stimulation for overdrive 
supression of atrial premature beats after intCV or overdrive of atrial flutter 
and ventricular (WI, VOO) pacing for postshock bradycardia can both be 
performed by the new device. 
Results: 48 Lots (96%) were successfully cardioverted to stable sinus 
rhythm. The energy requirement was 6.7 5_ 4.5 J. A mean of 2.6 ± 2.3 
shocks were delivered per pt Triggering of the card±overs±on shock to the 
internally sensed R-wave waS'accurate in all 139 shock applications. In 7 pts 
atrial pacing was performed post shock for overdrive suppression of atrial 
premature beats. The mean fluroscopy time was 2.2 ± 0.6 minutes. 
Conclusion: IntCV of AF by the means of this new device proofed to 
be save, effective and easily performable. Especially post cardiac surgery 
pts might benefit of routine use of this system with the option of internal 
cardioversion, AAI and VVI pacing and hemodynamic monitoring as with a 
conventional Swan Ganz catheter. 
L1233-181 I Waveform Optimization for Internal Atrial 
Defibrillation: A New Rounded Biphasic 
Trapezoid Shock 
Bakhtiar J. Kidwai, Mark T. Harbinson, J. Desmond Allen, Alistair Mclntyre, 
John Anderson, A.A. Jennifer Adgey. Regional Medical Cardl~91ogy Centre, 
Royal Victoria Hospital, Belfast, UK 
Background: Optimization of the shock waveform aims to conserve battery 
life and reduce patient discomfort. The leading edges of the standard biphasic 
trapezoid waveform (Ventritex HVS-02) were rounded to give reduced peak 
and trough voltages and currents and total delivered energy with less tilt. 
Methods: Sheep (weight 55.2 i 2.2 kg; mean ± SEM), were anaes- 
thetised with pentobarbitone and ventilated with room air. Defibrillation catheters 
were passed to the lateral wall of the right atrium and the coronary sinus. 
Right atrial burst pacing induced episodes of atrial fibrillation (AF). Peak and 
trough currents and voltages, and total delivered energy were determined for 
each shock. 
Three biphasic waveforms were studied: the standard trapezoid (ST), 
rounded leading edge of the first phase - single rounded (SR) and rounded 
first and second phases - double rounded (DR). Efficacies were compared 
in 8 sheep in 4 episodes of AF for each waveform at voltage settings of 
100/-50 V, 150/-70 V and 200/-100 V; 6 msec duration for both phases. 
Results: Peak voltage and peak current of the leading edge of the first 
phase were reduced by more than 25% (p < 0.001) and total delivered 
energy was reduced by >21% (p < 0.001). The success rates of the rounded 
waveforms were similar to the standard trapezoid waveform at the three 
voltage settings (56 ± 13.2% ST, 53 ± 12.0% SR and 59 ± 10.5% DR, p = 
NS at 100/-50 V; 100 ± 0% ST, 84 ± 10.5% SR and 75 :~ 10.6% DR, p = 
NS at 150/-70 V; 88 ± 4.7% ST, 84 ± 6.6% SR and 97 ± 3.1% DR, p = NS, 
rounded vs ST at 200/-100 V). 
The optimum phase duration for the double rounded waveform was shown 
to be 6-10 msec in a further 6 experiments. Phase durations of 1, 2 and 20 
msec were tess effective. 
Conclusion: This double rounded waveform reduces voltage and current 
requirements and delivered energy for internal atrial defibrillation with similar 
efficacy to the standard trapezoid waveform. This may conserve battery life 
and reduce patient discomfort. Clinical studies will assess patient discomfort 
associated with the new waveform. 
1 233-1 82]  Duration and Circadian Variation of Paroxysmal 
Atrial Tachyarrhythmias in Patients With Dual 
Chamber Implantable Defibrillator: Implications 
for Programming of Atrial Therapies 
Christian Wolpert, Werner Jung, Dirk Tenzer, Susanne Spehl, Necmi Demir, 
Burghard Schumacher, Christian Schneider 1 , Bahman Esmailzadeh 1 , 
Berndt L0deritz. Depts. of Cardiology; 1Cardiovascular Surgerz University 
of Bonn, Bonn, Germany 
A new dual-chamber implantable cardioverter-defibrillator (ICD) provides 
additional atrial therapies. Moreover, the activation of the atrial therapies 
can be freely programmed to any time of the day. Little is known about the 
incidence and duration of paroxysmal atrial tachyarrhythmias (AT) in patients 
with an ICD. Because the activation of atrial therapies has not only impact on 
the rhythm, but also on quality of life, the aim of this prospective study was, 
to assess the clinical characteristics as atrial rate, duration and circadian 
variation of AT episodes in ICD-patients to guide device programming. 
Patients and Methods: A total of 225 episodes from 19/34 patients with 
a dual-chamber ICD Medtronic Jewel AF 7250 were included in the analysis. 
Duration and circadian variation of the AT episodes (E) were assessed based 
on the device data log. Only one episode in the same hour was counted. 
Furthermore, the atrial rate of atrial tachyarrhythmias were determined. 
Results: The mean atrial cycle length was >220 ms in 78% of the E. In 
all these E there was a regular atrial activation with Amax PP < 40 ms. The 
duration of the AT episode was <1 min in 64 E, 1-5 min 107 E, 5 min -24 
h in 52 E and >24 h in 4 E. The mean duration was 11 min. The circadian 
variation of AT episodes ehibited a significant peak between noon and 6 p.m. 
(0-6 a.m 11 E, 6 a.m-noon 25 E, noon-6 p.m. 63 E and 6 p.m-12 p.m. 23 E) 
(p < 0.05). 
Conclusions: 1.76% of the AT show regular atrial activity with a rate <270 
bpm. Therefore atrial antitachycardia pacing therapies should be always 
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extensively programmed. 2. The duration of paroxysmal AT is short and 
98.3% of the episodes terminate spontaneously within 24 hrs. Empiric atrial 
shock programming should therefore be avoided. 3. Shock therapy should 
be programmed in patients with persistent AT during the sleep hours to 
reduce pain perception. Most of the paroxysmal episodes, yet, occur in the 
afternoon, so that there would be a therapy delay of >6 hours at least. 
1233-1831 Duration Sinus Pause Predicts of of Risk 
Recurrence of Atrial Fibrillation After Direct 
Current Card±overs±on 
Xiao-Hua Guo, Mark M. Gallagher, Yee-Guan Yap, Jan Poloniecki, 
Marek Malik, A. John Carom. St George's Hospital Medical School London, 
UK 
Background: Atrial Fibrillation (AF) often recurs after Direct Current Car- 
dioversion (DCC). If recurrence could be predicted accurately, antiarrhythmic 
drugs could be targeted at those at highest risk. AF duration influences the 
risk of recurrence but is often unknown. 
Methods: We reviewed the notes of 350 patients randomly selected from 
the 632 who underwent DCC at this centre since 1990. Rhythm strips of good 
quality were available in 59 patients (46 male, age 59 -± 19 years) in whom 
360J restored sinus rhythm. 
Results: The sinus pause after the DCC correlated closely with the 
duration of AF (R = 0.26, P < 0.05, Fig. 1), and negatively with the age of the 
patient (R = -0.4, P < 0.005). The pause was longer in those in whom AF 
recurred by I hour or 30 days post DCC than in those in whom sinus rhythm 
persisted for >30 days. (P < 0.05, Fig. 2). 
M e~n and ~D of  $1 hue pmuB= i f  te l  
OC iho~ ~n AF =rid ~R 0¢OU= 
i -  =.. i',2 
Correlation between sinus pause 
and duration of AF 
o 
Conclusions: A long sinus pause predicts recurrence of AF. This could 
be used to target antiarrhythmic drug therapy after DCC. 
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1234-184]  Inf luence of  Delayed on Activation QT and JT 
Intervals and Dispersion in 724 Survivors of 
Acute Myocardial Infarction 
P. Kirchhof, O. Arslan, L. Eckardt, G. M~nnig, T. Fetsch, G. Breithardt, 
M. Borggrefe, W. Haverkamp. Department of Cardiology, Angiology and 
Institute of Atherosclerosis Research, University of MEmeter, Germany 
QT dispersion has been intensively tested as a risk marker in survivors of 
acute myocardial infarction (MI). Whether delayed activation in the infarcted 
area prolongs QT intervals, or modifies QT dispersion, has never been inves- 
tigated. In 724 survivors of acute Q-wave MI, signal averaged ECG (SAECG) 
and QT dispersion in the standard 12 lead ECG (maximum-minimum) were 
simultaneously recorded 14-21 days after the infarction. Patients were fol- 
lowed for 6 months for serious arrhythmic events (susVT, VF, or sudden 
cardiac death). Late potentials (LP) in the SAECG were assumed to be 
present when an abnormal value in 2 of the 3 criteria QRS duration (>114 
ms), duration of low amplitude signal (>38 ms), and root mean square voltage 
of the last 40 ms (<20 #V) was observed. Positive late potentials correlated 
with arrhythmic events, and with higher dispersion of JT intervals, but not QT 
intervals; higher JT dispersion was almost exclusively associated with long 
QRS duration in the SAECG. High dispersion of QRS durations in 12 lead 
ECG (QRSd), in contrast, correlated with both higher QT and JT dispersion 
(see graphic), but did not relate to arrhythmic events. 
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Conclusions: (1) QT dispersion is not influenced by delayed activation in 
survivors of an acute Q wave infarction. (2) High dispersion of QRS duration, 
although not associated with arrhythmic events, correlates with significantly 
higher QT and JT dispersion. (3) Long QRS duration in the SAECG might 
influence determination of J point, thereby modifying JT dispersion. QT dis- 
pets±on appears not to adequately assess the arrhythmogenic substrate in 
survivors of myocardial infarction. 
I1 [ Wave Alternansand Late Potential as I 234-1 85 T 
Predictors of Ventricular Tachyarrhythmias in 
Patients With Post-Myocardial Infarction 
Takanori Ikeda, Kaoru Sugi, Takao Sakata, Naoki Kondo, Mitsuaki Takami, 
Naoki Tezuka, Takeshi Nakae, Mahito Nora, Yoshihisa Enjoji, 
Tetsu Yamaguchi. Toho University Ohashi Hospital, Tokyo, Japan 
Background: T wave altemans (TWA) and Late potential (LP) have been 
proposed as noninvasive markers of vulnerability to ventricular tachyarrhyth- 
mias (VT) in pts with post-myocardial infarction (PMI). The yield of both 
methods has not been compared with each other. 
Methods: To evaluate the sensitivity and specificity in predicting future 
VT development, TWA and LP tests were sequentially examined in 65 PMI 
pts who were diagnosed by coronary angiography. TWA was analyzed from 
the Frank X, Y, Z leads and the standard V4 lead ECG by means of the 
power spectral method during a supine bicycle exercise test. A positive TWA 
was defined as sustained alternans >1.9/~V with an alternans ratio >3.0. 
LP was analyzed using signal-averaged ECG as the vector magnitude from 
the filtered Frank X, Y, Z leads in the same position as TWA tests. A positive 
LP was defined as two of three items (f-QRS > 114 ms, RMS4o < 20/~V or 
LAS40 > 38 ms). 
Results: TWA was positive in 38 pts (58%), and LP was positive in 18 
pts (28%). VT including ventricular fibrillation occurred in 13 pts (20%) during 
follow-up of 12 :E 5 months. Although TWA had a higher sensitivity (82%) and 
a higher negative predictive value (90%), it had a lower specificity (47%). 
On the contrary, LP had a higher specificity (81%) but a lower sensitivity 
(58%). Combination of TWA and LP had the highest specificity (87%) and 
the highest positive predictive value (61%), and its sensitivity was 64%. 
Conclusion: TWA and LP seem to be independent predictors for VT in 
pts with PMI. Combination of both tests could be identified high risk pts more 
accurately. 
1234-186 j Relationship Between Left Ventricular Function 
1 
and Recovery Time Dispersion in Patients With 
Previous Myocardial Infarction 
Takanao Mine, Hiroki Shimizu, Takanori Inazumi, Tadaaki Iwasaki. Hyogo 
College of Medicine, Nishinomiya, Japan 
Background: Ventricular arrhythmia is associated with inhomogeneous ven- 
tricular repolarization and left ventricular (LV) function. However the relation- 
ship between inhomogeneous ventricular repolarization and LV function is 
unclear. We studied that relationship by recovery time (RT) measured from 
body surface mapping. 
Methods: In 120 patients (pts) with previous myocardial infarction (age 
64 ± 10, M/F: 106/14), RT (i.e., the interval between QRS onset and the time 
of maximum dV/dt in the ST-T segment) was measured from 87 body surface 
unipolar leads. RT dispersion defined as the difference between maximum 
and minimum RT was compared with LV dyskinesis, ejection fraction (EF), LV 
end diastolic volume (EDV) and ventricular tachycardia or fibrillation (VTNF). 
Results: RT dispersion was increased in pts with LV dyskinesis (n = 18), 
decreased EF (EF < 40%, n = 30), increased EDV (>200 ml, n = 15) and 
VTNF (n = 9). (175 ± 36 vs 149 ± 22 ms, p < 0.001,181 ± 35 vs 156 ± 25 
ms, p < 0.001,175 ± 33 vs 153 ± 28 ms, p < 0.05, 203 :E 28 vs 155 ± 30 
ms, p < 0.001, respectively). 
Conclusion: LV dilatation and dysfunction in patients with previous my- 
ocardial infarction lead to inhomogenous ventricular repolarization and may 
provide the electrical substrate of ventricular arrhythmia. 
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I1234-1871 The ECG in Hypertrophic Cardiomyopathy 
i Revisited: Do ECG Voltages Reflect Left 
Hypertrophy? 
Barry J. Maron, Mark J. Leyhe, Thomas E. Gohman, Morrison Hodges, 
Susan A. Casey. Minneapolis Heart Institute Foundation, Minneapolis, MN, 
USA 
Background: The 12-lead ECG has traditionally been part of the non-inva- 
sive diagnostic evaluation of patients (pts) with hypertrophic ardiomyopathy 
(HCM). In particular, magnitude of precordial/standard lead voltages has 
been regarded as indirect evidence of the left ventricular hypertrophy (LVH) 
often so prominent in this disease. 
Methods: We have reassessed this issue in an unselected HCM pt 
population most representative of the true disease state. 
Results: In the 254 HCM pts, maximum R wave and S wave voltages and 
also the sum of all ECG voltages significantly exceeded those in 69 normal 
controls (19 ± 8, 20 ± 8, 190 ± 6 vs. 16 ± 5, 12 ± 4, 142 ± 38 ram; p <.- 
0.001 ). However, when ECG voltages were compared with maximum LV wall 
thicknesses (measured by echo) little or no relationship was evident - i,e., 
maximum R or S wave or the sum of all voltages with correlation coefficients 
of only 0.1-0.2. Of 26 pts with massive LVH (wall thickness _> 30 mm) only 
4 (15%) had marked ECG voltages > 30 mm (ns); of 24 pts with particularly 
tall voltages (_>30 mm), only 4 (20%) had massive LVH (ns). 
Conclusion: ECG voltages in HCM significantly exceed that in normals. 
However, in this unselected HCM pt population greater magnitude of LV 
wall thickening was not reflected in the ECG voltages, even in those pts 
with massive LVH. In HCM, the 12-lead ECG is not a reliable predictor of 
phenotypic (i,e., morphologic) expression of the disease, 
1 881 Involvement of Sympathetic 234-1 Cardiac Nerve 
Dysfunction in Increased QT dispersion in 
Patients With Chronic Heart Failure 
Hisakazu Ogita, Masatake Fukunami, Tsuyoshi Shimonagata, 
Kazuaki Kumagai, Takahisa Yamada, Yoshihiro Asano, Akio Hirata, 
Nor±take Hoki. Osaka Prefectural Hospital, Osaka, Japan 
The pathogenesis of increased QT dispersion (QTd), which might be related 
to malignant ventricular arrhythmia or sudden death, in patients with chronic 
heart failure (CHF) has not been fully elucidated. To elucidate the relationship 
between QTd and the pathophysiology of cardiac sympathetic nerve function, 
measurement of QTd and SPECT using iodine-123-metaiodo-benzylguanidine 
(MIBG) as an analogue of norepinephrine (NE) were performed in 43 patients 
with CHF (left ventricular ejection fraction < 40%). QTd was determined by 
subtracting the shortest QT interval from the longest one measured on the 
standard 12-lead ECG. The regional MIBG washout rate (WR) in left ven- 
tricular anterior, septal, inferior and lateral segments of SPECT images were 
calculated from two scintigrams 20 min and 200 min after isotope injec- 
tion. Dispersion of cardiac MIBG WR (WRd) was determined by subtracting 
the minimum regional WR from the maximum regional WR. There was a 
significant correlation between QTd and WRd (r = 0.40, p = 0.0080) (Fig.). 
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These results suggest that cardiac sympathetic nerve dysfunction such as 
accelerated release of NE from the cardiac nerve terminal might be involved 
in increased QTd which elicits the inhomogeneity of ventricular repoladzation 
and makes the heart more vulnerable to ventricular arrhythmias in patients 
with CHF. 
I1234-1891 ECG Criteria for Total Occlusion of Predicting 
I 
the Proximal Left Anterior Descending Coronary 
Artery in Anterior Wall Acute Myocardial 
Infarction 
Masami Kosuge, Kazuo Kimura, Toshiyuki Ishikawa, Osamu Tochikubo. 
Yokohama City Urafune Hospital, Yokohama, Japan 
Patients with acute myocardial infarction (AMI) caused by art occlusion of the 
LAD proximal to the first septal perforator ($1) and diagonal branch (D1) may 
receive marked benefit from reperfusion therapy because of their extensive 
risk area. We assessed whether admission ECG could predict such patients. 
ST segment deviation on admission 12-lead ECG was measured in 109 pts 
with a first anterior AMI with total occlusion of the LAD confirmed by coronary 
angiography within 12 hrs front symptom onset. Patients were divided into 
2 groups according to the culprit lesion: 33 pts (Gr A) had a total occlusion 
of the LAD proximal to $1 and D1, and 76 pts (Gr B) distal to $1 and/or 
D1. There were no differences between 2 groups in ST segment deviation in 
precordial leads. However, ST elevation in lead aVL (ST 1" aVL) _> 0.5 mm 
and ST depression in tead III (ST $ III) _> 0.5 mm were more common, and 
moreover ST $ III > ST t aVL was much more common in Gr A than in Gr 
B (p < 0.0001). ST $ III > ST ? aVL identified Gr A with a high predictive 
accuracy of 88%, which is better than both that of ST 1" aVL (67%) and ST ,~ 
III (66%) (p = 0.0002). 
ST t aVL >_ 0.5 mm ST J~ III _> 0.5 mm ST ~ III > ST I" aVL 
Gr A (n = 33) 33 (100%)* 32 (97%)* 28 (85%)" 
Gr B (n = 76) 36 (47%) 36 (47%) 5 (7%) 
" p < 0.0001 vs Gr B 
Conclusion: In patients with anterior AMI, ST $ III > ST "~ aVL strongly 
predicts total occlusion of the LAD proximal to the first major septal perforator 
and diagonal branch. 
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F-8-8~ Venous Pooling in Patients With Neurally-Mediated 
Syncope: Evidence for an Impaired Muscle Pump 
Reflex 
Daniel M. Bloomfield, Harold Rivadeneira. Columbia University, College of 
Physicians and Surgeons, New York, N. Y., USA 
Background: In patients (pts) susceptible to neurally-mediated syncope 
(SYNC), pooling of blood in the lower extremities is thought to be the primary 
stimulus that leads to a series of events culminating in SYNC. Little data 
exists, however, about whether the amount or time course of venous pooling 
is different in pts susceptible to SYNC than those who are not susceptible. 
We evaluated venous pooling during tilt table testing in 27 consecutive pts 
referred for evaluation of SYNC. 
Methods: Pts were tilted head-up to 60 ° for 45 min or until SYNC devel- 
oped. The amount of blood pooling the lower extremities was estimated by 
measuring the change in calf circumference (CC) using a mercury-in-silastic 
strain gauge. We measured the total change in CC over the duration of tilt, 
and the number of times during tilt that the calf muscle contracted causing 
a rapid and significant change in CC. This latter measurement provides an 
estimate of how often an individual utilized the muscle pump reflex (MPR) to 
expel blood from the veins in the legs to augment venous return. 
Results: The mean age of the sample was 50 ± 18 years and 44% were 
male. 12/27 (44%) of the pts developed SYNC after 21 ± 9 min of heed-up 
tilt. The change in CC was similar after 1 rain and 5 min of head-up tilt. 
Unexpectedly, the total change in CC was greater for the pts without SYNC 
(5.7 ± 0.5 vs 3.9 ± 0.4%, p < 0.01). Despite this greater total change in CC, 
the MPR was utilized significantly more often in the pts without SYNC (11,9 
± 2.4 vs. 3,3 ± 1.5 times, p < 0.01). Of the pts without SYNC 10/15 utilized 
the muscle pump reflex more than 10 times, compared with only 1/12 pts 
with SYNC. Most of the patients with BYNC (7/12) barely utilized the muscle 
pump reflex at all. 
Conclusion: Pts susceptible to SYNC appear not to utilize the MPR 
during head-up tilt to augment venous return. The lack of use of this reflex 
may result in a greater fall in venous return while head-up thus increasing 
the likelihood of triggering the Bezold-Jarisch reflex. 
10:45 a.m.  
[~The of Heart Rate in Role Variability Analysis 
Diagnosis of Neurocardiogenic Syncope: Do We 
Need Isoproterenol Infusions or Monitoring 
Hemodynamic Profiles in a Tilt Test? 
Chi-Jen Tseng, Chia-Ting Chao, Chung-Peng Liu, Hung-ring Chiang. 
Kaohsiung, Veterans Genera/Hospital, Taiwan, Republic of China 
Background: Head-up tilt test (HUT) with isoproterenol infusion became 
the most useful test to diagnose patients of neurocardiogenic syncope iNS). 
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Recently, many investigators had demonstrated shifts of heart rate variability 
(HRV) in NS patients. However, they could not predict HUT results in a single 
baseline tilting. 
Methods: We carried out power spectral analysis of HRV in 33 NS patients 
during HUT tests. Of which, twenty-six were HUT responders seven were 
HUT non-responders. By analyzing high frequency power (HF, 0.15~0A 
Hz) and tow frequency powers (LF, 0.04~0.15 Hz) in both supine (LFL and 
HFL) and standing positions (LFs and HFs), we tried to obtain an index to 
differentiate HUT responders and non-responders by canonical analysis. 
Results: We could develop a syncope index (SI) as follow: 
k 
sli = ~ w~ivi (1) 
j--1 
where Sli was the i-th SI, Vj isthe j-th variables of insterest, Wjj, the weight of 
j-th variable in i-th SI, k is the number of variables of interest. We expressed 
the SI as 1.148.LFL - 0.8859,HFL + 0.2998*LFs - 0.3099,HFs. Setting 
a cut-off value of SI = -1 ,  we could successfully classify 100% of HUT 
responders and 71.4% of non-responders of syncope patients (figure). 
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Conclusion: By derived SI, we could predict results of HUT in its base- 
line status. There were no need of isoproterenol infusion or hemodynamic 
monitoring. 
11 :00  a .m.  
[ -~-~ Is Recording a Presyncopal Event Adequate in 
Patients Undergoing Prolonged Monitoring for 
Investigation of Syncope? 
Andrew Krahn, George Klein, Raymond Yee, Allan Skanes, Cam Norris. 
Ted Tak/e-Newhouse for the Reveal Investigators; University of Western 
Ontario, London Ontario, Canada 
Background: In patients undergoing monitoring after an episode of syncope, 
there is uncertainty about the significance of the observed rhythm when 
presyncope is the recurrent symptom. 
Methods: Eighty-five patients (age 59 4- 18 yrs, 44 male) with recurrent 
unexplained syncope underwent prolonged monitoring with an implantable 
loop recorder. Patients presented for investigation of syncope, which was 
either recurrent or preceded by at least 2 presyncopal episodes. Patients 
had a mean of 5.1 ± 5.5 syncopal episodes in the previous 12 months, and 
70% of patients had symptoms for over 2 years. 
Results: A symptom-rhythm correlation was obtained in 52 patients dur- 
ing a 12 month follow-up period. Syncope recurred in 12 patients, presyncope 
in 24 and both in 16. An arrhythmia was present in 64% of syncopal events 
(bradycardia in 16, tachycardia in 2) vs 25% for presyncopal events (brady- 
cardia in 7, tachycardia in 3, p = 0.001). An arrhythmia was detected in 9 of 
the 16 patients with both syncope and presyncope (56%), which was present 
in all but one episode of syncope compared to 6 of 9 presyncopal episodes. 
Eight patients had a clinical diagnosis of neurocardiogenic syncope, which 
was associated with bradycardia (HR < 50 bpm) in 5 and slowing without 
marked bradycardia in 3. Patient-related failure to "freeze" the device after 
symptoms occurred on 7 occasions after syncope (20%) compared to 3 after 
presyncope (7%, p = 0.09). 
Conclusion: Syncope is more likely to be associated with an arrhythmia 
than presyncope in patients undergoing extended monitoring. Presyncope is 
a less useful endpoint which is frequently associated with sinus rhythm. 
11 :15  a .m.  
[ -~-~ Usefulness of a Score-System in Predicting the 
Outcome of Electrophysiologic Studies in 
Non-lnvasively Unexplained Syncope 
Karlheinz Seidl, Axel Dr6gem01ter, Harald Schwacke, Monika Rameken, 
Gregor Siemon, Jochen Senges. Heart Center Ludwigshafen, Germany 
Electrophysiologic studies (EPS) have been used to uncover the underlying 
arrhythmic mechanism in patients (pts) with non-invasively unexplained syn- 
cope (S). In 643 consecutive patients with S, an EPS was performed. The 
diagnostic yield of the EPS was 35% (223/643 pts had a positive EPS). Aim 
of this study was to establish a score system which predicts best a positive 
electrophysiologic finding. By the use of a logistic regression model, history 
of injury during S (p < 0.001), ejection fraction _< 40% (p = 0.03), and PR 
interval _> 200 ms (p = 0.001) were independent predictors of an abnormal 
EPS study. These 3 variables were entered into a score system. The max. 
score consisted of 3 points (injury = 1 point, EF < 40% = 1 point, PR interval 
> 200 ms = 1 point) 
Results: 
Score Sensitivity Specificity PPV NPV 
1 54% 75% 54% 75% 
2 24% 97% 79% 70% 
3 9% 99% 100% 67% 
PPV/NPV = positive/negative predictive value 
Conclusion: 1. A predefined score using clinical and easily measur- 
able variables is helpful in predicting a positive EPS result in pts with non- 
invasively unexplained syncope. 2. A score of >_2 predicts a positive EPS 
response in more than 79% of pts with non-invasively unexplained syncope. 
11 :30  a .m.  
~ - ]  Differences in Vasomotor Function in Patients With 
Vasovagal Syncope 
Win K. Shen, Philip A. Low, Douglas Beinbom, David O. Hodge, 
Chris Scott, Stephen C. Hammill. Mayo Clinic, Rochester, MN, USA 
Vasovagal (VV) response, likely caused by variable mechanisms, is a com- 
mon cause of syncope in large heterogeneous population. In this prospective 
study, we hypothesized distinct vasomotor (MBP, TPR) and cardiomotor (HR, 
SV) functions may be present in pts with syncope. Consecutive pts with a 
history of syncope without other causes of syncope underwent a tilt ta- 
ble testing protocol: passive tilt (70 -°, 45 rains) and isoproterenol (Iso) tilt 
(0,05 mcg/kg/min, 70 ~, 10 rains). The sequence of the tests was random- 
ized. Hemodynamics were continuously monitored by photoplesthysmogra- 
phy and impedance cardiography. Comparisons were made between 16 pts 
(Group I, 37 ± 13 yrs) with a negative passive tilt and a positive iso tilt and 
17 pts (Group II, 45 ± 21 yrs) with a positive response to both passive and 
iso tilt. Hemodynamic parameters are shown: 
Hemodynamics Pts Baseline Passive :i: Iso Iso $ 
Supine Tilt Supine Tilt 
Vasomotor 
MBP (mmHg) I 108 ± 16* 122 ± 23** 103 ± 21 97 + 23" 
II 98±9 97±18 90±18 79±18 
TPR I 1370 ± 282 t 753 ± 474* 840 ± 293 599 ± 156 
(dyne.s.cm 3) II 1287 ± 664 1209 ± 455 825 ± 644 590 4- 411 
Cardiomotor 
HR (bpm) I 69:510 77 :E 12" 103±19 113±17 
II 69±11 90±17 111±14 120:1:19 
SV (ml) I 95±15 76114 103±26 118±21 
II 108 ± 39 75±22 108 :E 53 111±52 
t: 1 min after tilt before symptoms developed; *p < 0.05 "*: p < 0.001 
Summary and Conclusions: 1) Distinct hemodynamic profiles, in re- 
sponse to orthostatic and pharmacologic provocation, are present in pts with 
VV syncope. 2) A diminished vasomotor tone at baseline and the inability to 
vasoconstrict during orthostatic stress of group II pts correlate to vasovagal 
response during passive tilt. 3) Responses to the testing dose of ,8-receptor 
agonist were indistinguishable between these 2 groups of pts. 4) The abil- 
ity to differentiate pts of VV syncope may provide insight into syndrome 
mechanisms and therapeutic interventions. 
11 :45  a .m.  
[ -~-~ Patients With Recurrent Unexplained Syncope and 
Nondiagnostic Head-Up Tilt Testing: Need for 
Further Psychomatic Evaluation 
Rodolfo Ventura, Andreas Schuchert, Daniel Zeidler, Henning Kober, 
Ulrich Stuhr 1 , Brigitte Niemann 1 , Wolfram Terres, Thomas Meinertz. Depart. 
of Cardiology, UKE, Hamburg; ~ Department of Psychosomatic, UKE, 
Hamburg, Germany 
Patients with recurrent unexplained syncope and negative head-up tilt test- 
ing are a diagnostic and therapeutic challenge. A psychosomatic/psychiatric 
evaluation was recommended in 41 patients with recurrent unexplained 
sycope and without underlying cardiac disease. A psychosomatic/psychiatric 
evaluation was suggested after negative head-up tilt testing. The evaluation 
was accepted by 23 patients (78% females, 36 & 0 years) and denied by 18 
patients (67% females, 50 i 20 years). 
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Results: A psychosomatic/psychiatric disease was diagnosed in 19 of 
23 patients: 12 patients had depression, 3 panic disorder, 2 general anxi- 
ety disorder and 2 somatization. 4 patients showed a normal psychosocial 
function. 
17 of 19 patients refused further evaluation or treatment so that only 
2 of 19 patients received prescribed psychotherapy and/or antidepressive 
drugs. During the follow up none of 2 patients had a recurrence, while the 
frequence of syncope remained unchanced in the other patient group. (4.6 
~E 5.3, compared to 4.1 ± 4.4 in the 6 months thereafter.) 
Conclusion: in patients with unexplained syncope and negative head-up 
tilt testing, impairment of psychosocial function appears to be frequent. How- 
ever, the acceptance of psychosomatic/psychiatric evaluation and treatement 
by these patients is rarely accepted. 
ORAL 
Atrial Mapping: New Methods 
Wednesday, March 10, 1999, 10:30 a.m.-Noon 
Modal Convention Center, Room 222 
10:30 a.m. 
~~-~ Intracardiac, Phased-Array Ultrasound Imaging of 
Cardiac Structures and Devices: First Application of 
High Resolution Vector Imaging Within the Heart 
Douglas L. Packer, Susan B. Johnson, Michael Curley, Randy Schlesinger, 
Carolyn L. Stevens, James B. Seward. Mayo Foundation, Rochester, MN, 
USA 
Background: Intracardiac echocardiographic imaging of the heart during EP 
procedures has been limited by shallow ultrasound penetration and radial 
format of available single element, rotational imaging devices. 
Methods: Therefore, to test the feasibility of higher resolution imaging, 
a 10 Fr phased-array, variable 5.5-10 MHz vector imaging catheter with a 
4-way deflectable tip was developed and applied in four patients undergoing 
electrophysiologic evaluation. Two had no other organic heart disease, one 
had undergone prior ablation and another had an ischemic cardiomyopathy 
with an EF = 30%. The ability to image general cardiac structures as well as 
16 specific cardiac targets from the right heart was assessed. 
Results: In each patient, all targets including the RA/SVC junction, crista 
terminalis, tricuspid valve isthmus, membranous foramen ovale, pulmonary 
veins and mitral valve support structures were readily imaged from the RA. 
Longitudinal axis images of each cardiac chamber along with the tricuspid, 
mitral, aortic, pulmonic valves, the pericardium, pulmonary veins, and left and 
right atrial appendages were also readily visualized. Average target depth 
was 8,8 ± 1.5 cm with a maximum penetration depth at a 7.5 MHz imaging 
frequency of 13 cm. Image resolution also provided clear visualization of 
6-8 French intracardiac electrophysiology catheter electrodes, and catheter 
tip/endocardial surface contact, without image-disrupting shadowing. Dra- 
matic spontaneous echo contrast and mobile aortic plaque measuring 1 mm 
in size was also seen in the patient with ischemic cardiomyopathy. Color flow 
and Doppler utilities provided a clear indication of trans-valvular blood flow 
obtained in each patient, including in low output states. 
Conclusion: These initial studies demonstrate the utility of intracardiac 
phased-array vector imaging for longitudinal-axis, apex to base, global car- 
diac imaging. The specific high resolution of endocardial structures and 
eleotrophysiologic electrodes suggests additional utility for identifying car- 
diac pathology and visualizing intracardiac catheter procedures. 
10:45 a.m. 
~7~-- ]  Optical Coherence Tomography of Cardiac 
Radiofrequency Catheter Ablation 
David Keane, Parth Patwari, Stephen Boppart, Debra Stamper, Li Zhou, 
Jeremy Ruskin, James Fujimoto, Mark Brezinski. Massachusetts General 
Hospital MA; Massachusetts Institute of Technology MA; King's College PA, 
USA 
The guidance by intracardiac echo of radiofrequency (RF) catheter ablation 
is limited by the resolution of ultrasound imaging systems. The recent intro- 
duction of the catheter maze procedure for the treatment of atrial fibrillation 
has increased our requirements for a reliable method to determine when a 
transmural atrial lesion has been achieved and when a lesion is at risk of 
"popping" or endocardial disruption. 
Optical coherence tomography (OCT) has recently been developed to 
provide in-situ high resolution catheter-based imaging on a micron scale. 
OCT is analogous to B-mode imaging except that it uses light rather than 
sound. Infrared light of 1300 nm wavelength is used to provide back-reflected 
tomographic gray-scale imaging at 4 to 8 frames/s with a resolution of 10 
microns and a tissue depth of up to 3 mm. 
To explore the potential application of OCT to the guidance of RF ablation 
we performed real-time imaging of catheter ablation of atrial and ventricular 
tissue in-vitro. During the delivery of RF current the endocardium and my- 
ocardium were seen to undergo a series of changes in real-time. Among the 
earliest changes was loss of tissue polarization sensitivity which likely results 
from the derangement of the highly ordered collagen and actin-myosin. Next 
the tissue back scattering intensity increased. After a number of seconds the 
endocardial surface developed minor crimping, followed by more extensive 
undulation of the endocardium and myocardium. Subsequently, distortion 
of the myocardial architecture was observed before the lesion was seen in 
real-time to "pop" with endocardial disruption. The images were recorded 
digitally and on VHS video tape. 
It is concluded that OCT has the potential to provide high resolution 
imaging during RF cardiac ablation and may be particularly useful in the 
real-time guidance of linear atrial ablation. 
11:00 a.m.  
I - ~  Intracardiac Echocardiography and Temperature 
Decay for the Guidance of Radiofrequency Catheter 
Ablation 
David Keane, Robed Lamkin, Thomas Aretz, Li Zhou, Brian McGovem, 
Hasan Garan, Jeremy Ruskin. Cardiac Unit, Massachusetts General 
Hospital, Boston, MA, USA 
Background: The success of catheter ablation of cardiac arrhythmias is 
dependent upon the achievement of an adequate myocardial lesion depth. 
Fluoroscopy is conventionally used to guide catheter placement but is limited 
in its ability to determine electrode contact with the endocardium and ex- 
poses the patient and operator to radiation. We hypothesized that 1) phased 
array (longitudinally in plane) intracardiac echo would provide a superior 
assessment of electrode contact and 2) a slow temperature decay upon dis- 
continuation of radiofrequency current (time for temperature to fall by 90% 
after a 10 second test application of radiofrequency current pre-ablation - 
T90) would indicate optimal electrode contact with the underlying heated 
myocardium. 
Methods: Sixty endocardial lesions were created in the right and left atda 
and ventricles in 6 anesthetized goats by the simultaneous delivery of ra- 
diofrequency current through two adjacent electrodes of a 3.7F microcatheter 
with a central thermocouple in the interelectrede space. Catheter placement 
was guided by fluoroscopy. A transvenous, deflectable, phased array, 7.5 
MHz, intracardiac echo transducer in the right atrium or right ventricle was 
used to assess electrode contact. After the procedure, histomorphometry 
was performed on the ablated cardiac lesions. 
Results: Lesion depth was significantly correlated with: intracardiac echo 
assessment of electrode contact (r = 0.56, p = 0.001); temperature decay 
upon radiofrequency current offset (r = 0.48, p = 0.008); impedance fall upon 
radiofrequency current onset (r = 0.37, p = 0.008); bipolar pacing threshold 
pre-ablation (r = -0.56, p = 0.001); bipolar electrogram amplitude pre-ablation 
(r = 0.43, p = 0.02); but not with fluoroscopic assessment of electrode contact 
(r = 0.18, n.s.). 
Conclusion: Both phased array intracardiac echocardiography and tem- 
perature decay provide additional clinically relevant information for the guid- 
ance of cardiac catheter ablation. 
11:15 a.m.  
I8~4- ]  Interatrial Electrical Activation in Man: Correlation of 
Anatomy With Activation Sequence Mapping 
David Schwartzman, William Devine. University of Pittsburgh and Childrens 
Hospital of Pittsburgh, Pittsburgh, PA, USA 
Background:To better discern specific routes of interatrial conduction, we 
correlated interatrial septal (IAS) anatomy with IAS activation mapping. 
Methods: I. Gross and microscopic examination of 8 post-mortem adult 
human heads was performed to locate areas where interatrial septal conduc- 
tion could occur, defined by direct myocardial bddging (DMB) between the 
chambers. Serial 1 millimeter coronal sectioning of the IAS and contiguous 
right (RA) and left (LA) atrial free walls was performed. Histologic specimens 
were processed with hematoxylin and eosin ± trichrome stains. II. In 10 
adults, electroanatomical activation mapping (CARTO, Biosense/Webster) 
of the RA aspect of the IAS was performed during pacing from the LA at a 
cycle length of 300 milliseconds. The procedure was assisted by intracardiac 
echocardiography (9 MHz, Boston Scientific), permitting direct visualization 
of discrete RA septal anatomical sites, including foramen ovale, septal aspect 
of the crista terminatis (CT), coronary sinus (CS) ostium, Iimbus, components 
of the triangle of Koch, and caval orifices. In each patient, the map was com- 
prised of >100 sites. 
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Results: I. In each heart, the dominant loci of DUB were the CT and the 
CS. CT fibers continued across the roof of the IAS to become Bechmann's 
bundle. A portion of the CS in the left posteroseptal space shared a common 
wall with the adjacent LA. Myocardium invested the CS from its ostium to this 
site, thus forming a DUB. In some patients, DUB loci were also identified 
in the limbus, foramen ovale, and/or superior triangle of Koch. I1. In each 
patient, RA septal activation occurred first at the CS ostium. During pacing 
from the LA floor, earliest activation at the ostium preceded activation at the 
CT by >25 milliseconds. During pacing from the LA roof, activation at the 
ostium and CT were essentially simultaneous. Activation of the remainder of 
the septum appeared to be caused by wavefront(s) eminating from one of 
these sites. 
Conclusions: Left-to-right IAS activation mapping appears to proceed 
preferentially via CS and CT, likely due to major DUB at these sites. 
11:30 a.m.  
~ Ablation of Isthmus-Dependent Atrial Flutter Using 
the CARTO TM Non-Fluoroscopic Mapping System 
David J. Callans, Robert F. Coyne, David S. Kleinman, Joseph 
C. Pennington, Kamran Toluie, Manisha Ashar, Charles D. Gottlieb, Francis 
E. Marchlinski. Allegheny University Hospitals, Philadelphia, PA, USA 
Background: Radiofrequency ablation (RFA) cures isthmus-dependent atrial 
flutter (IsDAF) with a success rate of >95%. The previous "gold standard" for 
isthmus block has been reversal in atrial activation sequence using mull±polar 
catheter recordings during coronary sinus (CS) pacing. The present study 
evaluates the CARTO TM non-fluoroscopic mapping system in ablating IsDAF 
and in determining whether isthmus block is present. 
Methods: 45 pts with IsDAF underwent RFA of the isthmus with a 
CARTO TM 4 mm tip ablation catheter. An 8 mm tip ablation catheter was 
used if ablation with the CARTO TM catheter was unsuccessful. Following 
RFA, isthmus block was assessed during CS pacing by both CARTO TM and 
Halo TM mull±polar catheter mapping in 30 pts (Group I) and by CARTO TM alone 
in 15 pts (Group II). 
Results: 27/30 pts, Group I (90%) had isthmus block by both CARTO TM 
and HaloS"; 2/30 pts (7%) had persistent conduction by both CARTO TM and 
Halo'U; 1/30 pt (3%) had apparent isthmus block by CARTO TM but persis- 
tent conduction by HaloT~; 14/15 pts, Group II (93%) had isthmus block by 
CARTO TM and 1/15 (7%) had persistent conduction by CARTO TM following 
RFA. One pt in Group I with isthmus block by both methods subsequently 
had recurrent IsDAF; no pts in Group II had recurrent IsDAF. Overall, 19/45 
pts (42%) required an 8 mm tip catheter to create isthmus block. 
Conclusions: (1) CARTO TM non-fluoroscopic mapping correlates with the 
"gold standard" of multipelar catheter mapping in determining isthmus block 
during CS pacing after RFA. (2) Isthmus block by CARTO TM predicts freedom 
from IsDAF. (3) An 8 mm tip ablation catheter may be necessary to achieve 
isthmus block in selected pts. 
11:45 a.m.  
~ - ]  Initial Experience With the Non-Contact Mapping 
Guided Radiofrequency Ablation of Atrial Flutter 
Michael A.E. Schneider, Bernhard Zrenner, Martin Karch, Gjin Ndrepepa, 
Albert Sch6mig, Claus Schmitt. Deutsches Herzzentrum and 1. Med. Kiln±k, 
TU Muenchen, Germany 
Background: Inserting a non-contact mull±electrode catheter into the right 
atrium enabtes a high resolution mapping of atrial flutter (AFI) activation. 
A non-contact mapping (NCM) guided radiofrequency (RF) ablation is per- 
formed by visualizing the electroanatomical isthmus of atrial flutter and by 
documenting the catheter positioning with corresponding ablation sites. 
Methods: The mathematical reconstruction of 3,300 endocardial elec- 
trograms (ECG) is achieved via a 64 electrode wire braid around a saline 
filled 8 ml balloon. The ECG generates an isopotential map on an anatomi- 
cal computer model of the endocardium where also a 5 kHz signal emitted 
from the ablation catheter's tip is displayed. The NCM documentation of the 
atrial activation during flutter and stimulation manoeuvres was compared to 
conventional recordings by placing multielectrode catheters in the coronary 
sinus and along the crista term±nails. NCM guided RFA was performed in 8 
patients (pt; male 7x, age 65 ± 9 y.). 
Results: The zone of slow conduction and the isthmus region could be 
visualized by NCM in all pt. RF applications were guided by information of 
NCM and AFI was successfully ablated in all Lot using an 8 mm large tip 
electrode (RF applications 21 ± 12 [range 5--39], temperature 51 :E 6-°C, 
power 43 ± 16 watts, time 49 ± 20 seconds). In two pt an activation gap 
within the linear lesions was demonstrated and could be closed by NCM 
targeted RF applications. In all pt a bidirectional activation block was shown 
by conventional multielectrode recording and by NCM during stimulation 
manoeuvres. 
Conclusion: NCM guidance in atrial flutter is promising to enable insights 
into the reentry mechanism, to document the RF application sites and thus, 
to increase the efficacy of RF ablation therapy. 
ORAL  
Atrial Flutter: Mapping and Ablation 
Wednesday ,  March  10, 1999, 2:00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 222 
2:00 p.m. 
~-0~ Anatomy and Dimensions of the Inferior Right Atrial 
Isthmus in Patients With and Without History of 
Common Atrial Flutter 
Jos4 A. Cabrera, Dam±an Sa.nchez-Quintana, Yen Ho, Alfonso Medina, 
Femando Wanguemert, Egon Gross, Robert H. Anderson. Pino Hospital 
Las Palmas, Spain; National Heart and Lung Institute, London, UK 
Background: Although most ablation procedures for therapy of common 
atrial flutter (CAF) target the inferior right atrial isthmus, comparative studies 
of the morphology of this isthmic area are lacking. 
Methods: The inferior isthmus displayed by right atrial angiography was 
compared in 23 patients (pts) (59 ± 15 years; 21 M) with clinically documented 
CAF and in 30 control subjects (53 5:7 years; 16 M). For comparison, we 
studied 20 normal heart specimens from adults. 
Results: When viewed in right anterior oblique projection, the inferior 
isthmus was profiled as the area between the Eustachian valve (EV) and the 
attachment of the septal leaflet of the tricuspid valve (TV). Two specific areas 
were distinguishable in all patients: a pouch-like recess anterior to the EV 
and the smooth vestibule terminating in the hinge of the TV. The table shows 
the dimensions (mm) in the three study groups. 
Post-mortem Controt group Atrial flutter 
Inferior Isthmus 30 ± 4 (19-40) 28 ± 6 (17-38) 37 ± 8 (21-49) 
Posterior recess 17 ± 2 (9-23) 15 ± 4 (7-22) 20 ={_ 7 (12-31) 
Vestibule 12 ± 2 (8-15) 13 ± 4 (6-22) 17 ± 5 (9-30) 
There was no significant difference in the length of the isthmus as found 
in controls and in the specimens. The mean lenght of the isthmus, however, 
was larger in pts with CAF than in the control group (p < 0.01 ). The posterior 
recess was larger in pts with CAF without structural heart disease than in the 
control group (19 • 5 mm vs 15 ± 4 mm, p < 0.05). 
Conclusions: 1.-The dimensions of the inferior isthmus in patients with 
common atrial flutter was significantly different from a control population. 
2.- Enlargment of the isthmic area, in particular its posterior recess, may 
predispose to the development of atrial flutter 
2:15 p.m. 
~2~ Stimulus-An+l : A New Measure for Entrainment 
Mapping for Atrial Flutter 
Kyoko Soejima, William G. Stevenson, Etienne Delacretaz, 
Corinna Brunckhorst, William H. Maisel, Kristin E. Ellison, Peter 
L. Friedman. Brigham and Women's Hospital Boston, MA, USA 
Introduction: Entrainment mapping for atrial flutter (AFL) is limited by 1) 
difficult ECG assessment of p waves to ascertain fusion, and 2) pacing 
artifact obscuring the recording from the stimulation site needed to measure 
the post-pacing interval (PPI). 
Purpose: To evaluate the stimulus- to remote atrial electrogram interval 
(S-An+I), a new entrainment measurement which does not require analysis 
of p-wave morphology or PPI for identifying reentry circuit sites. 
Methods: In computer-simulations, (S-An.0 during resetting was equal 
to the local electrogram to An+l interval (Egn-A n+l ) during pacing at reentry 
60 
:_ r~ 0.90, p< 0.0001 
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circuit sites, but not at bystander sites. At 45 sites, in 10 consecutive patients 
who underwent RF ablation of AFL, the following intervals were measured: 
1) AA cycle length (AACL); 2) during entrainment he stimulus to the 2nd A 
electro oram ~o~'~)n9 "fne s'~)mu')us )~5- ,~;  3,,') buhn9 AT--~_ ~e e')ec'~ro~ram 
at the stimulus site to the 2nd following A electrogram (Egn+p-An+p+~), and 4) 
PPI. 
Results: S-An+~ difference correlated well with PPI-AACL difference (r = 
0.9, p < 0.0001), and identified reentry circuit sites with sensitivity of 97% 
and specificity of 100%. 
ConcLusion: S-A~,,, cact t~e used to ~dead(y cee~t(-y cicc(~(( sites ~(t~t 
entrainment without analysis of p-wave morphology or measuring PPI. 
2 :30  p .m.  
I - ~  Should Complete Reversal of the Depolarization 
Sequence in the Right Lateral Atrium During 
Coronary Sinus Pacing be an Endpoint of Catheter 
Ablation in Common Atrial Flutter? 
Jian CYre~, "%'n/r~'~ ra~ Y.fe %'t ill re u, ~rard ~ ~a~ FO ut~y, "1',i ~d ~ %-~ d t, 
Isabelle Magnin-Poult, Marc Messier, Etienne Allot. University Hospital 
Nancy, France 
Background: Complete reversal of the right lateral atrial depolarization se- 
q uenc-e -~r~ ~.~t~,-~, ~t~ '~S') T.,'uc'rtr u %'z~ 0.~.~, T..r~r=.r',~r6 "~'o "a ~d"dc~- 
minard~ chTehon to  assess com,61eTe cavOthcus, P~l con~udbon h~lOdK ~rC~L,~t~) 
durin~p ahS)a'i)en D3 a~#)a ") "f)'#tler );h~). h~e )nves'i~ale[b a new "~ed)3n)gue "~o 
assess the '~a{{d{t,j ofth(s critedm'~. 
who underwent a AF  ablation procedure, a 24-pole catheter (Orbiter TM, Bard 
Inc) was positioned so that 2 adjacent bipoles were bracketing the target line 
of block (LOB). The distal bipole of the catheter was inserted in the CS and 
used for permanent per procedural pacing. At least 5 bipoles lateral to the line 
of block recorded low right lateral and cavotncuspid isthmus electrograms. 
R~esu'}'~s:'i~e'~ore~?_.'i~ were ohD~a)ne0. Dropress}ve con~}uc~)on ~e'}a, vs were 
obserrve~ "in YI .Datien'ts. W~tn a maxlm~h ~dftt in 'fne dth~il cdliiston wave'tronI 
respectivaly at 1 t, 22 and 33 mm from the LOB in 4, 5 and 2 ~atients dudng 
SC pacing. Thus no CCB was observed despite complete reversal of the 
sequence of depolarization in the right lateral atrium in 28.2% (11/39) of our 
patient population. 
C~]ec'~)~')o~" £)or S'lt)l~'~ sn#~es`[s ~%a1 revetsa~ D'~ 3'~e a`[i)a) be~DD~ai)za'bDn 
sequence 'm Y~e f)9~ ~a'~efa~ a~fium ~s Do'[ a 6e1~rf)'[~ve ci~ei)Dn ~or success- 
ful AF ablation. The atdal activation sequence should be mapped a few 
millir~efers r'rom [he L(...,~ fo assess (.,"~"~. 
2 :45  p .m.  
~9~-~ ) Rad)ofrepuencv Catheter Ablation of Common and 
Reverse Common Atrial Flutter: A New Algorithm to 
Determine Complete Isthmus Conduction Block 
Robe,:( Jat~c~, T~ta~as Eet~ch, L.acs Ec~,a~(, G,3c~(,~c ~ce~t~a~'<~, 
Martin Borggrefe. Department of Cardiology, Institute of Arteriosclerosis 
Rese~,c/,,, /¢,,~X,~er~,,;'y ~ ¢~ZO,~e,,;, Gex-,m, aw~ 
Ratimna'~e: ~om.d~e~e conbuc'boDhS~oc~ oYtne~sh_~mus~e'~ween}Dhehor vena 
cava (IVC) and tricuspid anulus (TA) is a predictor for long-term success if 
radiofrequency catheter ablation (RFA) of common and atrial flutter (AFI) is 
performed. Isthmas block is assumed if the activation sequence in the low 
lateran ~ ,{~." ,~'~{~,V~ ~E E ,'~'A'), ;s" ,~e~ eq -~'e.~ ,r~%" ~,",~ r~,:,n ~ ~,-,m-,q'P~.,3' .~i~,~" ('PCS'~ 
pacirna.'~¢e'qyD0tneslze(~htnaftne~r%%-'CC~'~ cen(3u~ben't~mes can'De usech 
as a surrogate endpoint. 
~t~~ EL 
A: common flutter, B: before ablation, C: after ablation, CT: crista terminalis, ER: eu- 
stachian ridge, T1 : conduction time across the TA-IVC isthmus before ablation, T2: PCS- 
LLRA after ablation or during common flutter 
Methods: RFA of the TA-IVC isthmus was performed in 50 patients (pts) 
with AFI. PCS-LLRA was measured before i t1)  and after i t2)  ablation and 
isthmus block was classified as complete, partial or none based on LLRA 
activation sequence. Then the parameter A = T1 + T2 - CL (AFI cycle 
length) was calculated. 
FFlesults: In ots with complete isthmus block.in = 32), A was 18 ± 15 ms 
(range 0 to 40 ms), in pts with partial (n = 11 ) or no (n = 4) block A was -39  ± 
25 ms (range -100 to -20  ms). In 3 pts T2 could not be measured because 
of AF at the end of the study. 
Conclusion: Complete isthmus conduction block was uniformly associ- 
ate~ wifn a3  ) ÷ '35 - UL > = D~ "5 ) ÷ 32  - [-;)_ ~,~.s <- D )~ ,~)) pz~)-)~,.o.t~ w):t~ 
a partial or no conduction block. ~, = T1 + T2 - CL could assess the degree 
of isthmus conduction block (complete vs. partial or none) with a diagnostic 
accuracy of 100% in our series. 
3:00 p.m. 
~-9~-1  Endocardial Mapping ot Induced Atrial Fibrillation 
Initiated by Premature Atrial Extrastimuli Delivered 
at Different Right Atrial Sites in Patients With 
Recurrent Sustained Atrial Fibrillation 
Atul Prakash, Sanjeev Saksena, Ryszard Krol. Eastern Heart 
Institute-Atlantic Health System, Passaic, N J, USA 
We performed catheter endocardial mapping of sustained atrial fibrillation 
[AF] induced by atrial premature extrastimuli [ES] delivered at 3 different 
~-t~ sitesin pa.tiedts'[ptg] v~ith recurrent sust,alne£1 ~-F. ~ AT- elJlsodesln~ZB 
pts (mean LA diameter 42 ± 5 cm, mean LV ejection fraction 44 4- 11%) 
were studied. Endocardial mapping was performed from multiple RA & LA 
regions. Induction of AF was attempted with high RA ES, coronary sinus 
osEEat ] CSOs? &.mid [nte.ratdat P~p~at ES. .Pfs ~.re  cta,%~,~f'.ieg.(ofD G.r.oj.~ .1' ,=~2.0 
qls], = AF induced usin~hi~q PJk.F_.~ & Gro_tKl.'2_(t0. q_ts3 = AE in@tne..dLwitb. 
c~_dsegtal.ar L,%'tYs ESa ~_ 2~ 9ts ha.d. ALF-LnctizcacL bath. t~m. bLq~. ~ &. C~CIS.. 
ECG morphology, the site of mftia} activation & the return cycle lenglb ~RCL,I 
~.t LA  ~, FIA ~[tes 2= SL2"~.P4:tLLe ntAtrial ~¢.t iyat i.n n ,.nat ~, rCL~ .w.erp J~f~al/v=_7.P~ 
Results: The mean coupling interval for initiating APB was 194 ± 40 
ms in Group 1 & 177 ± 25 ms in Group 2 (p = NS). Group 1 lots (74 AF 
episodes) showed the initial site of activation at the cnsta terminalis (10 pts, 
39 AF episodes), septum or His bundle region (7 pts, 24 AF episodes), or 
simultaneously (_<10 ms) at both septal & crista terminalis sites (4 pts, 11 
egisQdasL Grou0 2 ors. (2Q AF egisQdes~, s.ho.we.d tb.e. im#Jal, site. q[ &td.al 
activation a~ the. (ntoaiatria[ &e,~tJlJ33. i,.~ ~t~, 1.t o=rfi.~'ldP.&~,, C.~5_OS. (,4, r~,%, 6. 
episodes)', distal'CS ('t pt, 2-epiC;odes) or crista termii~alis ('1 pt, I episode; p 
< 0,001 vs Group 1). Pts in both groups with multiple induced AF episodes 
had _> 1 site(s) of initial activation. In the 2 pts with AF induction with both 
high RA ES & CSOs ES, site of first AF beat was in proximity to the region 
of the initiatina. ES. Mean RCL at the initial site of atrial activation for the first 
AFbeat was 215 ± 38 ms for Grou~ i & 202 ± 40 ms tar Grou9 2 (,9 = 0.21. 
Co~ciu, s(or~- 1) The stim~latie~ site in the RA for the ES initiating AF 
significantly influences the eadiest site of a~ivatio.n f~.r the ~ir+< beat of 
induced AT-, suggesting alocal mtra-atnal reentrant medhadism. 2 )~eront  
RA regions can support AF initiation in pts with recurrent AF & heart disease. 
3) Atrial ES prematurity does not differ during AF initiation at different RA 
"~j~.3~%. 
3:15 p.m. 
~-~-~ Influence of Atrial Flutter Ablation on Inter-Atrial 
Septum and Left Atrial Depolarization 
Christian Bal~Qn~ Ant~L~ D& Costa_. Eric BQ.D.~e.f.Qx. PaL&TQub.QUl. Hdg/Ia.t 
~arc/ib/bg(que, Lyon, F~ance 
Background: Previous studies have shown that radiofrequency ablation of 
the right atria( {sthmus between the tricuspid annu(us (TA} and the inferior 
Tm]dtehor]Leads duhrt~]Lew~later~l {'~ht at{'tal,~O..T-~)~,D~&Cirt~.-T~ts;L~lLev~d 
te result from change in the sequence of activation of the inter-atrial septum 
(IAS). Our purpose was to verify this hypothesis by comparing the sequence 
of activation of the IAS and the left atrium (LA) before and after ablation of 
the IVC-TA isthmus during LRA pacing. 
Methods: in 13 pts, LA mapping was performed using a duodecapoLar 
catheter electrode advanced to the far distal coronary sinus (ca). The distal 
pair of electrodes corresponded to the anterior aspect of the LA and the 
proximal pair to the ostium of the CS. A minimum of 7 bipolar endocardial 
recordings were obtained. The IAS was mapped using a duodecapolar right 
atrial catheter electrode with a minimum of 4 bipolar recordings. Conduc- 
tion times were measured during LRA pacing at 600 ms cycle length from 
the pacing artefact to every lead recorded simultaneously before and after 
creation of bi-directional ine of block. 
Results: During LRA pacing, isthmus ablation resulted in a significant 
delay in every LA lead. However, changes were maximal at the posterior 
aspect of the LA (84 4- 20 ms to 131 ± 23 ms, p < 0.0001) and minimal at 
its anterior aspect (143 ± 19 to 160 ± 21 ms, p = 0.0026). Using ANOVA, 
activation times were delayed more significantly at the proximal CS compared 
to distal sites (p = 0.0001). No significant change was discernible in the IAS. 
Conclusion:-Creation of a line of block at theIVC-~FA isthmus delays 
LA activation predominantly at its posterior aspect during LRA pacing, thus 
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explaining P wave morphology changes, but has no effect on depolarization 
of the IAS. 
ORAL  
Supraventricular Tachycardia: Mapping and 
Ablation 
Wednesday ,  March  10, 1999, 4:00 p .m. -5 :00  p.m. 
Moda l  Convent ion  Center ,  Room 222 
4:00 p.m. 
[ -~~ Localization of Accessory Pathways Based on 
Change in Ventriculo-Atrial Interval During 
Entrainment of Orthodromic Reentrant Tachycardia 
Rajiva Goyal, Takashi Tokano, Hakan Oral, Michael Kim, Hung-Fat Tse, 
Frank Pelosi, Matthew Flemming, Gregory Michaud, Bradley P. Knight, S. 
Adam Strickberger, Fred Morady. University of Michigan, Ann Arbor, MI, 
USA 
Background: During orthodromic reentrant tachycardia (ORT), a change in 
the ventriculo-atrial interval (VAI) with development of bundle branch block 
(BBB) can help in accessory pathway (AP) localization. 
Methods: As BBB does not occur predictably, we paced the right ventric- 
ular (RV) apex to simulate left BBB. We postulated that during entrainment of 
ORT by ventricular pacing, there would be a prolongation of the VAI if the AP 
was left-sided. 61 pts (age 39 ± 17) with structurally-normal hearts under- 
going radiofrequency ablation of an AP were enrolled. Quadripolar catheters 
were placed in the right atrium and RV apex. 
Results: VAI was measured during ORT and during entrainment from the 
RV at a cycle length (CL) 20-40 msecs shorter than the tachycardia CL, and 
the change in VAI was compared between locations of AP's. Location of the 
AP was based on the site of successful ablation: left free wall (LFW) in 42, 
right free wall (RFW) in 8, posteroseptal (PS) in 8, and anteropseptal (AS) in 
3. The change in VAI was significantly greater for LFW AP's compared with 
RFW and PS AP's (67 ± 27 vs. 23 ± 23 & 36 ± 23 msec, respectively, p < 
0.01). A change in VAI > 40 msec identified a LFW AP with a sensitivity of 
88% & specificity of 58%. A change in VAI < 25 msec identified a RFW AP 
with a sensitivity of 63% & specificity of 88%. A change in VAI of 25-40 msec 
identified PS AP's with a sensitivity of 25% & specificity of 94%. 
Conclusion: A change in VAI during entrainment of ORT may help in 
localization of an AP when spontaneous left BBB does not occur during ORT. 
4 :15 p.m. 
~90~ Ablation of Slow/Slow Atrioventricular Nodal 
Reentrant Tachycardia: Evidence for Multiple Slow 
Pathways 
Zulu Wang, Kenichiro Otomo, Mauricio Arruda, Mario Gonzalez, 
Nayyar Shah, Hiroshi Nakagawa, Karen Beckman, Ralph Lazzara, Warren 
M. Jackman. University of Oklahoma HSC, Oklahoma Ci~ OK, USA 
Background: Slow/slow (S/S) AV nodal reentrant tachycardia (AVNRT) is 
defined as AVNRT using a slow pathway (SP) for antegrade conduction with 
a retrograde atrial activation sequence typical of retrograde conduction over 
the SP. This tachycardia has been postulated to result from reentry between 
two SP. This study examined evidence from response to SP ablation for the 
use of multiple SP in pts with S/S AVNRT. 
Methods: 54 pts with S/S AVNRT underwent radiofrequency catheter 
ablation. Initial ablation was targeted at retrograde SP in 50 pts and antegrade 
SP in 4 pts. 
Results: Retrograde SP conduction and 1:1 antegrade SP conduction 
were eliminated at one ablation site in 20 pts. In the remaining 34 pts, 
antegrade and retrograde SP conduction were located at different site. In 
5 of these pts, ablation at the first site eliminated the initial tachycardia but 
allowed a second S/S AVNRT (shift in retrograde atrial activation sequence 
and different cycle length), with SP conduction eliminated at 2--4 separate 
sites in the posteroseptal right atrium and coronary sinus. In 18 other pts, 
ablation at the first site eliminated retrograde SP conduction with persistence 
of 1:1 antegrade SP conduction (4 pts then had slow/fast AVNRT). Ablation 
at a second site eliminated or modified antegrade SP conduction in these 18 
pts. In the remaining 11 pts, ablation at the first site eliminated antegrade SP 
conduction with persistence of retrograde SP conduction (fast/slow AVNRT in 
1 pt). Ablation at other site eliminated or modified retrograde SP conduction. 
AVNRT was eliminated in all 53 pts at the end of the procedure. AVNRT 
recurred in 6/54 pts (5 as fast/slow AVNRT and 1 as slow/fast AVNRT) 
compared to only 2/348 pts with slow/fast AVNRT (P = 0.0001). 
Conclusion: These data indicates 1) slow/slow AVNRT utilizes multiple 
anatomically discrete slow pathways; 2) more extensive SP ablation may be 
needed for slow/slow AVNRT to increase success and reduce recurrence of 
other forms of AVNRT. 
4:30 p.m. 
~6-~ Dynamic Patterns of High- and Low-Frequency Atrial 
Activation Potentials Recorded at the Posterior Input 
to the AM Node Using a Split-Tip Electrode Catheter 
and a Long Stabilizing Sheath 
Gaetano Senatore, Feifan Ouyang, Marius Volkmer, Mafthias Antz, 
Joachim Hebe, KarI-Heiz Kuck, Riccardo Cappato. AK, St. Georg, 
Hamburg, Germany 
Antegrade and retrograde patterns of bipolar local activation at the posterior 
input to the atrioventricular (AV) node were investigated in 12 pts with AV 
nodal reentrant tachycardia (AVNRT) through a custom-made 7 F quadripo- 
lar-tip (split-tip) miniaturized electrode ablation catheter (Cordis-Webster). To 
optimize stability, the catheter was advanced to the target region through a 
long sheath. Local activation was assessed in all pts during atrial and ven- 
tricular programmed electrical stimulation and during AVNRT. During sinus 
rhythm, a double potential consisting of a high-frequency (HF) component 
followed by a low-frequency (LF) component was found in all pts in the 
midseptal area of Koch's triangle. During programmed atrial stimulation, con- 
duction through the AV node was associated with non-decremental pattems 
of HF and decremental pattems of LF potentials in all pts; multiple distinct LF 
potentials (up to 5) were recorded in response to atrial extrabeats resulting 
in antegrade jump and AV node echoes or AVNRT. The antegrade AV nodal 
refractory period occurred either before and after LF potential activation. Dur- 
ing retrograde slow pathway conduction, LF potentials were recorded before 
HF potentials. One radiofrequency pulse (range, 1-12) at sites where both 
HF and LF potentials were recorded successfully abolished AVNRT in all pts. 
Conclusions: LF potentials reflect local activation of transitional areas 
involved in slow pathway conduction. Use of split-tip miniaturized electrodes 
and long sheaths increases the local resolution and allows an accurate 
detection of LF-potential dynamic patterns in response to pacing maneuvers 
and during AVNRT. 
4:45 p.m. 
[-9--0-~ Atypical Patterns of Reentry in Patients With 
Atrioventricular Nodal Tachycardia 
Gaetano Senatore, Feifan Ouyang, Nelly Paparella 1 , Michael Schl0ter 1 , 
Paolo Alboni 1 , Karl-Heinz Kuck, Riccardo Cappato. AK St. Georg, 
Hamburg, Germany; ~ Osp. Civile Cento, Cento (Fe), Italy 
Background: Similar or identical His-to-atrium (H-A) intervals during tachy- 
cardia (T) and during ventricular (V) pacing (P) at the T cycle length (H-AP) 
([H-AT]-[H-AP]~0) are suggestive of a lower reentrant circuit turn-around 
located in close proximity to the proximal His bundle and account for most 
patterns observed in the typical slow/fast [s/f] form of atrioventricular nodal 
reentrant achycardia (AVNRT). 
Methods: Out of 219 pts with AVNRT, we investigated the [H-AT]-[H-AP] 
in 29 (13%) pts presenting with an atypical AVNRT (definition: any AVNRT 
with a P-wave clearly separated from the QRS and/or earliest retrograde 
atrium (A) activation recorded at the proximal coronary sinus [CS]). Mode 
and patterns of T induction during pacing from the right A, CS or V were 
also investigated. The H-AT was defined as negative if the first retrograde A 
activation at time of T induction preceded the H deflection of the first T QRS 
complex. 
Results: Of 29 lots with atypical AVNRT, 7 presented with a f/s, 8 with 
a s/s, 8 with a f/s and a s/f, 3 with a s/s and s/f, and 1 with a s/s, f/s 
and s/f form; in 2 more pts, retrograde s pathway emerged at the anterior 
input to the AV node. At time of T induction, the H-AT was negative (-83 
± -28 ms) in 9 and positive (173 ± 76 ms) in 20 pts. H-AP matching 
retrograde A conduction through the slow AVN pathway as during T were 
available in all 9 pts of the former and in 13 pts of the latter group. The 
[H-AT]-[H-AP] was 249 ± 93 ms in pts with negative H-AT and 100 • 55 
ms in pts with positive H-AT at time of T induction. Ablation was achieved 
in all 29 pts with 2 (range, 1-17) radiofrequency pulses delivered at the 
posteroseptal-to-midseptal trio-tricuspid region. 
Conclusions: Atypical AVNRT: 1) accounts for ~ 10% of all AVNRTs 
referred for radiofrequency catheter ablation; 2) is related to a retrograde 
s pathway emerging at the posterior and anterior AV nodal input in ~ 90% 
and ~ 10% of cases, respectively; 3) is associated with antegrade f pathway 
conduction in ~ 50% and s pathway conduction in ~ 50% of cases. During 
retrograde S pathway conduction, H-AT invariably shorter than H-AP are 
suggestive of a lower turn-around of the reentrant circuit away from the 
entrance of the compact node into the His bundle. 
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ORAL 
Metabolic Factors in Cellular 
Electrophysiology 
Wednesday, March 10, 1999, 4:00 p.m.-5:00 p.m. 
Morial Convention Center, Room 228 
4:00 p.m. 
~ Reduced Myofilament Responsiveness Ca 2* 
Underlies Postfibrillatory Contractile Dysfunction 
Christian E. Zaugg, Andr~ Ziegler, V&nia Barbosa, Peter T. Buser. Div. 
Cardiology and Dept. Research, University Hospital Basel, Switzerland 
Background: After resuscitation from cardiac arrest due to ventdcular fibril- 
lation (VF), patients often require hemodynamic support because of postfibril- 
latory contractile dysfunction. The pathogenesis of this dysfunction is unclear. 
We sought to determine whether educed myofilament Ca 2+ responsiveness 
underlies this dysfunction. 
Methods: We compared left ventricular developed pressure (LVDP) and 
amplitudes of intracellular Ca 2+ ([Ca2+]i) transients in isolated perfused rat 
hearts before VF (baseline) and 1.5 or 10 rain after defibrillation. Pac- 
ing-induced VF was sustained for 1.5 or 10 min (n = 8 hearts each) be- 
fore electrical defibrillation was performed. [Ca2+]i was assessed as indo-1 
fluorescence at the interventdcular septum using a flexible fiberoptic light 
guide. 
Results: 
Posffibdllatory values after 1.5-min VF 10-min VF 
LVDP (%) 97 5:2 67 5:10* 
[Ca2+]i amplitude (%) 107 5:4 92 5:14 
Ratio LVDP/[Ca2+]i amplitude 0.91 ± 0,04" 0.62 5: 0.09" 
Mean ± SEM of % baseline, *p < 0.05 vs. baseline 
The ratio LVDP/[Ca2+]i amplitude was reduced after 1.5 and particularly 
after 10 min of VF indicating progressive reduction of myofilament Ca 2÷ 
responsiveness. In addition, postfibrillatory LVDP correlated strongly with 
the ratio LVDP/[Ca2+]i amplitude (linear regression, r = 0.91, p < 0.05). 
Because of the constant perfusion pressure used, VF did not cause ischemia 
in this model (decrease of coronary flow during VF = 12%). 
Conclusion: Similar to myocardial stunning, reduced myofilament Ca 2~ 
responsiveness underlies posffibrillatory contractile dysfunction. The degree 
of this reduction appears to progress during VF and is not dependent upon 
ischemia. 
4:15 p.m. 
~3-~ C~la-Adrenergic Receptor and Protein Kinase C 
Stimulation Suppress Delayed Afterdepolarizations 
in Hypertrophic Cardiomyopathic Hamsters 
Ricardo A. Samson. Department of Pediatrics, University of Arizona, 
Tucson, AZ, USA 
Background: Delayed afferdepolarizations (DAD) and triggered activity are 
postulated to be an arrhythmogenic mechanism in hypertrophic cardiomy- 
opathy (HCM). The hamster with hereditary HCM (BIO 14.6) serves as a 
useful model to study DAD development. We have shown that BIO 14.6 
is more susceptible to the development of DAD. Furthermore, BIO 14.6 is 
known to have enhanced Cqa-adrenergic responsiveness and elevated pro- 
tein kinase C (PKC) activity. Therefore, we sought to characterize the effects 
of Cqa-adrenergic receptor (AR) and PKC stimulation on DAD development 
in BIO 14.6. 
Methods: Standard microelectrode technique was used in superfused 
left ventricular free wall preparations. Baseline DAD were induced by burst 
pacing. Isoprotereno110 7 M or [Ca]o = 4 mM was used in some experiments 
to facilitate DAD induction. 
Results: Compared to baseline, DAD amplitude at a burst pacing CL 150 
ms following ctla-AR stimulation was significantly smaller (8.4 ± 0.4 vs. 4,4 
± 0.6 mV, n = 10, p < 0.05). The longest burst pacing CL to cause a DAD to 
reach threshold and trigger an action potential was significantly shorter with 
Oqa-AR stimulation vs. baseline (85 ± 8.3 vs. 114 5:11.9 ms, n = 10, p < 0.05). 
Sustained triggered activity, seen in 6 of 10 experiments in the baseline, was 
reversed in 5 by ~la-AR sub-type stimulation. Exposure to the specific PKC 
activator phorbol myristate acetate 10 -7 M also produced similar effects. 
No differences were seen when Otlb-AR stimulation was studied or when 4 
c~-phorbol didecanoate, an inactive phorbol ester, was used. 
Conclusions: These results suggest that o~la-AR sub-type stimulation 
and PKC stimulation suppress DAD development in the hamster with HCM. 
4 :30 p.m, 
~3-~ Effect of Aging on NO-Mediated Anti-Adrenergic 
Actions of Adenosine in the Rat Heart In Vivo 
Jiang xu, Eitan Friedman, Amir Pelleg. Allegheny University of the Health 
Sciences, Philadelphia, PA, USA 
Background: We have already shown (Circ Res 81: 1065, 1997; JPET 285: 
299, 1998) that the anti-adrenergic actions of adenosine are significantly 
attenuated in old (24 month old) vs. adult (6 month old) Fisher 344 rats. 
Others have shown that nitrous oxide (NO) mediates the anti-adrenergic 
electrophysiologic actions of adenosine on the sinus and atrio-ventricular 
nodes in vitro. Thus, we hypothesized that the role of NO in the anti-adrenergic 
electrophysiologic action of adenosine is diminished in the aged heart. 
Methods: The negative chronotropic action of adenosine (0.01 /~mol/kg 
to 0.1 /~mol/kg), quantitated as the maximal prolongation of sinus cycle 
length (SCL), was determined under baseline conditions (control) and during 
isoproterenol (ISO) infusion (0.2 ~g/kg/min) in adult (n = 6) and old (n --- 
6) rats before and after the administration of the NO synthase inhibitor 
N °-nitro-L-arginine methyl ester (L-NAME; 30 mg/kg). 
Results: In control, adenosine caused a dose dependent prolongation of 
SCL which was potentiated in the presence of ISO in adult more than in old 
rats; e.g., in control, adenosine (0.05/~mol/kg) prolonged SCL of 191 ± 15 
msec and 214 ± g msec by 69 ± 18 msec and 43 ± 5 msec, and in the 
presence of ISO, by 171 ± 47 msec and 93 ± 15 msec, respectively (p < 
0.05). In the presence of propranolol + atropine, L-NAME did not affect the 
action of adenosine in either old or adult rats. However, in the presence of 
ISO, L-NAME attenuated adenosine's prolongation of SCL in adult (to 110 ± 
32 msec; -36%) much more than in old (to 80 • 19 msec; -14%) rats (p < 
O.O5). 
Conclusion: (i) NO plays a mechanistic role in the anti-adrenergic elec- 
trophysiologic action of adenosine in vivo, and (ii) this mechanism is inhibited 
in old vs. adult rats. These data suggest reduced cardio-protective fficacy of 
adenosine in the aged heart which could be involved in the increased cardiac 
pathologies in elderly patients. 
4 :45 p.m. 
~-~ Upregulation of Catecholamine-Sensitive Focal 
Automaticity from the Ligament of Marshall in a 
Canine Model of Chronic Atrial Fibri l lat ion 
Rahul Doshi, Tsu-Juey Wu, Masaaki Yashima, Young-Hoon Kim, James 
J.C. Ong, Jimin Cao, Payam Yashar, Michael C. Fishbein, Hrayr 
S. Karagueuzian, Peng-Sheng Chen. Cedars-Sinai Medical Center, LA, CA, 
USA 
We hypothesize that the ligament of Marshall (LOM) is the source of atrial 
automatic tachyarrhythmias during adrenergic stimulation, and that this focal 
automaticity may degenerate into atrial fibrillation (AF) in dogs after chronic 
rapid pacing. Computerized mapping studies were performed in isolated-per- 
fused canine LA tissues from normal dogs (N = 9) and from dogs with chronic 
AF induced by 10-41 weeks of rapid pacing (N = 3). Recordings were made 
before and during isoproterenol (ISU) infusion. The LOM was excised during 
ISU infusion in a normal and an AF tissue. Histological sections were stained 
with tyrosine hydroxylase (TH). Before ISU infusion, spontaneous activity 
occurred in only one normal tissue (CL > 1,300 ms). During ISU infusion, 
automatic rhythm was induced in both normal tissues (CL = 5"78 5:172 ms) 
and AF tissues (CL = 255 ± 29 ms, p < 0.05). Mapping studies revealed 
that the origin of spontaneous activity was in the LOM. In the AF tissues (but 
not the normals) we observed the transition from rapid spontaneous activity 
to multiple wavelet AF. Ablation of the LOM terminated the spontaneous 
activity and prevented AF. Immunocytochemical studies of the LOM revealed 
muscle tracts surrounded by TH-positive (sympathetic) nerves. The LOM 
was seen to insert into the inferior LA. We conclude that the LOM is richly 
innervated by sympathetic nerves, and serves as the source of ISU-sensitive 
focal automatic activity. Sensitivity to ISU is increased after chronic rapid 
pacing and may trigger the development of AF. Upregulation of the sensitiv- 
ity to catecholamines and electrical remodeling may both contribute to the 
development of AF after chronic rapid pacing. 
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Role of Cytokines in Heart Failure 
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Morial Convention Center, Hall F 
Presentation Hour: Noon-1:00 p.m. 
~ T h e  Pattern of Tissue in Cytokine Expression 
Murine Models of Myocardial Infarction 
Karen Aitken, Hiroshi Nakamura, Fayez Dawood, Josef Penninger, 
Min Irwin, Wen-Hu Wen, Peter Liu. The Toronto Hospitals, University of 
Toronto, Canada 
Background: We have reported that tissue levels of the tumor necrosis 
factor-c~ (TNF-e) is up regulated in the myocardium in models of rat infarction 
and canine pacing induced heart failure. To determine if this pattern also 
occurs in the novel murine model of myocardial infarction, we determine 
the tissue expression of TNF-<x and compared it to 6 other cytokines in this 
model. 
Methods: Murine infarction model was performed by LAD ligation under 
anesthesia. The hearts were removed at times of 0, t5, 30 minutes and 1, 3 
and 6 hours post infarction. Samples from the central zone of risk and remote 
normal zones were immediately frozen and extracted for RNA. RT-PCR was 
then performed for cytokine expression of IL-lcq IL-2, IL-4, IL-6, TNF-cq 
TNF-~ (lymphotoxin) and interferon gamma (IFN-y). /~-actin was amplified 
from all samples to act as controls. 
Results: The results showed that the normal myocardial expression of 
IL-l<x, IL-2, IL-4, TNF-/3 and IFN-p' are at very low levels, and does not change 
significantly in response to myocardial infarction. In contrast, basal levels of 
TNF-e is detectable at low levels, however, after myocardial infarction, there 
was robust up regulation of TNF-e and IL-6 transcripts immediately following 
infarction, peaking at 1 hour, and decreases slowly after 3 hours. 
Conclusions: Thus myocardial stress responsive cytokines TNF-~ and 
IL-6 are uniquely up regulated immediately following injury, and may regu- 
late other downstream genes orchestrating the phenotypic change seen in 
infarction and failure. 
~ High Serum Levels of Soluble Interleukin 2 
Receptor, Neopterin and/3-2 Microglobulin in 
Idiopathic Dilated Cardiomyopathy: Relation to 
Heart Failure Severity and Autoimmune Features 
Alida L.P. Caforio 1'2, Mirza K. Baig 2, Jonathan H. Goldman 2, Bernard 
E. Souberbielle 2, Angus G. Dalgleish 2, David W. Holt 2, William 
J. McKenna 2 . ¢ Dept of Cardiology, University of Padua, Padua, Italy- 2St. 
George's Hospital Medical School, London, UK 
Background: It is unclear whether high levels of soluble interleukin 2 receptor 
(slL-2R), neopterin and l%2 microglobulin in idiopathic dilated cardiomyopa- 
thy (IDC) reflect congestive heart failure (CHF) severity and/or an active 
autoimmune process. 
Methods: We studied 60 IDC patients, 67 controls with ischemic heart 
failure (IHF) and 34 normals, slL-2R, neopterin and t}-2 microglobulin levels 
in IDC were related to clinical features, serum levels of cardiac-specific 
autoantibodies, HLA and intercellular adhesion molecule-1 expression on 
endomyocardial biopsy. 
Results: Abnormal levels of slL-2R were more frequent in IDC than in 
IHF (35% vs. 16%; p = 0.02) or in normals (35% vs 12%, p = 0.01). The 
frequency of abnormal neopterin and ~-2 microglobulin levels was similar 
among the study groups. IDC patients with abnormal slL-2R had higher levels 
of neopterin than IHF (p = 0.03) or normals (p = 0.009) and higher levels of 
/7-2 microglobulin than normais (p = 0.0001). Abnormal levels of slL-2R in 
IDC were associated with lower peak oxygen consumption (p = 0.008) and 
higher HLA class II expression on cardiac endothelial and interstitial cells (p 
= 0.02), abnormal levels of neopterin and of/~-2 microglobulin with adverse 
prognosis (p = 0.02). Cardiac antibody status or titre was not associated with 
abnormal slL-2R, neopterin or/~-2 microglobulin levels. 
Conclusion: High slL-2R, neopterin or/~-2 microglobulin in IDC correlate 
with CHF severity and adverse prognosis. High slL-2R levels, being more 
common in IDC than in IHF and related to high HLA class II on the my- 
ocardium, may also represent markers of an active cellular immune process 
in IDC. 
~ Reduced Expression on of CD14 
Polymorphnuclear Cells Despite Unchanged 
Leukocyte Apoptosis in Patients With Chronic 
Heart Failure 
Natalie-Viviane Ulrich 1 , Wolf D6cke 1 , Martin M6ckel 2, Ged Baumann 1 . 
l Charite/Campus Charite Mitte; 2 Charite/Campus Virchow-Klinikum 
Humboldt University Berlin,, Germany 
Background: Inflammation processes, partly mediated by polymorphnuctear 
blood cells (PMN) and circulating lymphocytes, play a significant role in the 
pathogenesis of chronic heart failure (CHF). It is unknown if increased apop- 
tosis of cardiomyocytes is reflected by immunological changes of circulating 
blood cells. 
Methods: We examined 14 male patients with chronic heart failure (62.4 
SD10.04 years, ejection fraction 31%, NYHA III) and 7 healthy controls 
(30.56 SD4.16 years). Morning blood was drawn from a peripheral vein 
and leukocytes were separated immediately. Fluorescein isothiocyanate 
(FITC)-Iabeled human annexin V and propidium iodide (PI) were used to de- 
tect early stages of apoptotic cell death in lymphocytes under dye exclusion 
by flow-cytometry. Expression of CD14, CD32, and CD36 were measured 
on PMN to determine their potential scavenger rote for the phagocytosis of 
apoptotic cells. Plasma levels of IL-6 and TNF-o~ were measured also. 
Results: Annexin V binding of PI negative cells was not different between 
patients and healthy controls (1.64% vs 2.10%). CD14 expression was sig- 
nificantly higher in PMN in the control group (2.5 vs 1.87 mean fluorescence 
intensity, p < 0.05). IL-6 and TNF-~ were significantly higher in patients 
(15.7ng/L vs 2.05ng/L, 16.6ng/L vs 7.6ng/L, p < 0.01, respectively) but did 
not correlate with annexin V binding or CD14 expression. CD32 and CD36 
were not different between the groups. 
Conclusion: CHF patients have reduced CD14 expression on PMN and 
therefore less immunological competence. This phenomenon is not mediated 
by IL-6 or TNF-~. 
~ Serum Cytokine Antagonists During Profiles of 
the Acute Decompensation of Advanced Heart 
Failure 
J. Parissis, K. Venetsanou, D. Mentzikof, N. Ziras, K. Merkouris, S. Karas. 
Amalia Fleming Hospital and St. Anargiri Hospital, Athens, Greece 
Background: Previous studies have shown an abnormal cytokine expres- 
sion in patients with advanced congestive heart failure (CHF). However, the 
potential role of cytokine antagonists in the unstable state of decompen- 
sated CHF (dCHF) has not been further investigated. This study investigates 
the kinetics of representative cytokine antagonists, such as soluble Tumor 
Necrosis Factor Receptor I (sTNFRI), soluble Interleukin-6 Receptor (slL-6R) 
and tnterleukin-1 Receptor antagonist (IL-1 ra) during the course of dCHF and 
correlates the findings with the clinical performance of dCHF patients. 
Methods: Serum levels of sTNFRI, slL-6R and IL-lra were measured 
using Elisa assays, in 19 patients with dCHF (Ischemic Heart Failure: 12, 
Dilated Cardiomyopathy: 7; NYHA Ill-IV; LVEF: 22 ± 3%), 23 patients with 
stable chronic CHF (LVEF < 30%) and 15 healthy age-matched controls. Ten 
out of 19 dCHF patients were in low output state (LOS) requiring support with 
iv inotropes. Serum concentrations of soluble receptors in dCHF patients 
were assayed serially at baseline and every 12 hours for a 3-day period of 
hospitalization, as well as one week after their clinical stabilization as follow 
up. 
Results: At baseline and during the observation period, serum levels 
of slL-6R in dCHF patients, did not differ significantly from sCHF group, 
although were significantly higher from those of healthy controls (3.3 ± 1.1, 
vs 1.7 ± 0.3 ng/ml, p < 0.05). Serum concentrations of sTNFRI and IL-lra 
in dCHF patients presented both a transient increase during the observation 
unstable period (max sTNFRh 7.1 -t: 1.1 ng/ml; max IL-lra: 5.6 ± 1.3 ng/ml). 
Peaks of sTNFRI and IL-1 ra in dCHF group were significantly higher than the 
respective levels of sCHF group (sTNFRI: 4.2 ± 0.9 ng/ml, p < 0.01; IL-1 ra: 
3.8 ± 0.5 ng/ml, p < 0.05) and healthy controls (sTNFRI: 1.8 ± 0.1 ng/ml, 
p < 0.001; IL-lra: 2.1 ± 0.3 ng/ml, p < 0.005). Patients with LOS (n = 10) 
exhibited higher levels of sTNFRI and IL-lra than the other dCHF patients 
(n = 9) (p < 0.01 and p < 0.03 respectively). In dCHF group peak of sTNFRI 
significantly correlated with body mass index (r = 0.69, p < 0.01), while 
peak of IL-lra with serum sodium (r = --0.52, p < 0.05), max. furosemide 
dosage (mg/day) (r = 0.59, p < 0.01) and right atrial pressure (r = 0.72, p < 
0.01). 
Conclusions: We have detected a significant release of sTNFRI and 
IL-lra into circulation of patients during the unstable state of dCHR This 
release may affect the clinical performance of dCH F patients and characterize 
the clinical instability of dCHF. 
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~ Elevated Circulating CXC-chemokines, a Levels of 
New Group of Cytokines Involved in the 
Pathogenesis of Congestive Heart Failure 
Jan K. Dam&s, Lars Gullestad, Thor Ueland, Nils O. Solum, 
SveJn Simonsen, Stig S. Froland, P~I Aukrust. Rikshospita/et University 
Hospital, Os/o, Norway 
Background: Persistent immune activation has been implicated in the patho- 
genesis of congestive heart failure (CHF), Chemokines or chemctactic 
cytokines are essensial factors in the recruitment and activation of leuko- 
cytes from the circulation into inflammed tissue, and may play a role in the 
pathogenesis and progression of CHF by recruiting these cells into the fail- 
ing myocardium. We therefore hypothesized that these cytokines would be 
elevated in CHF. 
Methods: Levels of 3 members of the CXC-chemokine family, IL-8, GROe 
and ENA-78 were measured in serum and platelet-free plasma (PFP) by 
enzyme immunoassay in 49 CHF patients and in 21 healthy controls. 
Results: CHF patients had significantly higher levels of IL-8, GROc~ and 
ENA-78 compared with healthy controls (p < 0.05), and this was found 
irrespectivly of ethiology. The highest levels of IL-8 and ENA-78 were found 
in in NYHA class IV. There was a significant inverse correlation between IL*8 
levels and left ventricular ejection fraction. This elevation in CXC-chemokines 
levels was found both in serum and in PFP. Furthermore, platelets from 
CHF patients had decreased intracellular levels of ENA-78 and GROc~, and 
released reduced levels of these chemokines upon stimulation ex vivo with 
trombinreceptor agonist, suggesting chronic platetet activation in vivo. 
Conclusion: This study demonstrates for the first time elevated levels of 
circulating CXC-chemokines in CHF, which may be of importance for progres- 
sion of disease. Moreover, our findings suggets that chronic platelet activation 
in vivo may contribute to increased circulating levels of CXC-chemokines in 
CHE 
~ Removal of Cardiodepressant Factor(s) in Dilated 
Cardiomyopathy by Immunoadsorption 
Alexander Staudt, Peter Bramlage, Wolf V. D~rffel, Verena Stangl, 
Peter Pietsch, Gert Baumann, Stephan B. Felix. Department of Internal 
Medicine, Charite, Humboldt Universi~ Berlin, Germany 
Background: Six patients with dilated cardiomyopathy (DCM) received irn- 
munoadscrption (IA) therapy. During IA, the cardiac index increased from 2.3 
to 2.9 I/min/m 2 (p < 0.05), and systemic vascular resistance decreased from 
1373 to 1028 dyne*s*cm -5 (p < 0.05). The underlying mechanisms of these 
haemodynamic effects as mediated by IA remains unclear. 
Methods: In-vitro experiments were performed to determine the influence 
of factor(s) (> 100 KD) eliminated by IA in DCM patients on the intracellu- 
lar cytoplasmatic calcium transient ([Ca2+]i s,/t - [Ca2+]± dia) and on myocyte 
shortening of isolated, fieldstimulated (1 Hz; 2 ms; 10-30 V) rat cardiac 
myocytes. IA was also performed with the blood of 6 healthy donors (con- 
trols). We investigated the effects of factor(s) (> 100 KD) in the irrigation 
solution (IS) of IA columns on myocyte shortening and on calcium transient 
of myocytes loaded with Ca 2÷ -sensitive fluorescent probe, (Fluo-3AM). IS 
was dialysed (MWCO 100 KD, 1:100, 1:1000) and heated (56-°(3 for 30 min) 
for inactivation of complement. After incubation of cardiac myocytes with IS 
(1:30; 1:20; 1:10; 1:5; 1:2), myocyte shortening and calcium transient were 
analysed by confocal laser scanning microscopy (125 images/sec). 
Results: IS of DCM patients (n = 6) caused immediate and dose-related 
decrease of calcium transient (1:30: 90.3%; 1:2: 60.9% - p < 0.05) and of 
myocyte shortening (1:30: 90.1% 1:2: 75.2%-p < 0.05). In contrast, IS of 
controls (n = 6) did not influence calcium transient and myocyte shortening 
of cardiac myocytes. In IS, different cytokines (e.g., TNF-alpha, interleukin 6, 
8 and 10) were not detectable. 
Conclusion: IA eliminates cardiodepressant factor(s) in DCM. 
POSTER 
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~ B o d y  Wasting in Chronic Heart Failure is 
Associated With Altered Fat and Protein 
Metabolism 
M. Rauchhaus 1 , P.V. Carroll 2, D. Russell-Jones 2, A.J.S. Coats 1 , 
S.D. Anker 1 . 1 Cardiac Medicine, NHLI, London; 2Department of Medicine, 
St. Thomas' Hospital, London, UK 
Background: The precise metabolic alterations in cachectic (c) patients with 
chronic heart failure (CHF) are not known. Therefore we have studied in 8 
male cCHF (weight loss > 7.5% in > 6 months, age 60 ± 5 y, weight 61 ± 
3 kg, mean ± SE) and 6 matched healthy male control subjects (Con, 50 4- 
9 y; 82 4- 3 kg) protein and substrate metabolism the morning following an 
overnight fast. 
Methods: Whole body protein metabolism was assessed using a stable 
isotope technique. Each patient received a primed (1 mg/kg) constant (1 
mg/kg/hr) infusion of 1J3C]-Ieucine for 180 min, following priming of the 
bicarbonate pool with a bolus (0.2 mg/kg) of [1-13C]-bicarbonate. Blood and 
breath samples were taken at baseline and at steady state for the enrichment 
of a-KIC and CO2, in addition to the baseline hormonal and amino acid 
profiles. Resting energy expenditure, and respiratory gas exchange were 
measured at steady state using a metabolic cart. Body composition (lean 
mass: LBM, fat mass: FM) was assessed using DEXA and bioelectrical 
impedance. 
Results: Leucine Ra (a measure of protein breakdown, 2.0 4- 0.1 vs 2.6 
± 0.3 #mol/kgLBM/min, p = 0.048) and plasma leucine concentration (111 
4- 8 vs 137 4- 7/~mol/I, p = 0.03) were lower in cCHF compared to Con, but 
leucine oxidation and NOLD (a measure of protein synthesis) were similar 
in the two groups. Protein and carbohydrate oxidation were similar in cCHF 
and Con. Fat oxidation tended to be higher in cCHF than Con (32 ± 19 vs 
6 4- 1 mg/kgFM/min, p = 0.11). Cachectic CHF with the lowest FM had the 
highest rates of fat oxidation (n = 4) compared with those with less advanced 
fat tissue loss (n = 3.62 4- 32 vs 3 4- 1 mg/kgFM/min, p = 0.09). 
Conclusion: Patients with cardiac cachexia have a decreased rate of 
protein breakdown in the fasting state compared with healthy controls. Protein 
synthesis and oxidation are similar, but cachectic CHF patients show an 
elevated rate of fat oxidation, indicating a reliance on fat as an oxidative fuel. 
Further studies are needed to investigate whether 2 groups of cachectic CHF 
patients exist, differing in their use of fat as energy source. 
~ T h e  Impact of Cachexia on Cardiorespiratory 
Reflex Control in Chronic Heart Failure 
Piotr P. Ponikowski ~'2, Massimo Piepoli 1 , Tuan Peng Chua ~ ,
Waldemar Banasiak 2, Darrel Francis ~ , Stefan D. Anker ~ , Andrew 
J.S. Coats 1 . 1 -Cardiac Medicine, NHL/, London, UK; 2-Cardiology 
Department, Clinical Military Hospital, Wroclaw, Poland 
Background: Upregulated muscle reflexes may contribute to neurohormonal 
imbalance in wasted chronic heart failure (CHF) pts. Thus, we hypothesised 
that pts with cardiac cachexia might exhibit particularly profound abnormali- 
ties in cardiorespiratory reflexes. 
Methods: We investigated 39 CHF pts: 13 with cardiac cachexia (cCHF, 
dry, documented weight loss > 7.5% of previous normal weight in > 6 
months), and 26 non-cachectic pts (ncCHF) matched according to the sever- 
ity of CHF (age: 59 vs 60 y, NYHA: 2.6 vs 2.5, peak VO2:16.2 vs 16.8 
ml/kg/min). We assessed cardiac sympatho-vagal balance (epinephrine [E], 
norepinephrine [NE], heart rate variability [HRV] analysis), baroreflex sensitiv- 
ity (phenylephrine method, [BRS]), and peripheral chemosensitivity (transient 
hypoxic method). 
Results: There was a severely abnormal pattern of cardiorespiratory 
reflex control in cCHF compared with ncCHF The former group exhibited 
impaired autonomic reflex control, characterised by an abnormal profile of 
HRV, and depressed BRS (p = 0.02, vs ncCHF). Pts with cachexia had also 
an increased peripheral chemosensitivity (0.91 vs 0.46 IJmin/%Sa02, p < 
0.001, cCHF vs ncCHF respectively). In the correlation analyses the degree 
of impairment in the reflex control was more closely related to wasting, and 
to the level of neurohormonal activation (expressed by the levels of E and 
NE, and HRV indices) than to conventional markers of the severity of heart 
failure. 
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Conclusions: CHF patients who developed cardiac cachexia demon- 
strate an abnormal reflex control within the cardiovascular and respiratory 
systems. The nature of the link between this phenomenon and hormonal 
changes and the poor prognosis of cachectic CHF patients warrants further 
investigation. 
[ -~~ Persistent Myocardial Apoptosis Contributes to the 
Lack of Gross Left Ventricular Hypertrophy and the 
Rapid Disease Progression in Canine 
Pacing-Induced Heart Failure 
Gordon W. Mee, George Naik, Andrea Konig, Qingping Feng. University of 
Toronto, Toronto; University of Western Ontario, London, Ontario, Canada 
Background: Chronic rapid pacing in the dog induces severe heart failure 
(HF). Despite severe hemodynamic perturbation and intense neurohormonal 
stimulation, LV hypertrophy (LVH) at the whole-organ level does not occur. 
We hypothesized that persistent myocardial apoptosis contributed to the lack 
of gross LVH in this HF model. 
Methods: Apoptosis was assessed by DNA fragmentation analysis and 
in situ TUNEL staining in the LV samples from 12 normal dogs [controls]; 9 
dogs RV-paced (250 beats/min) for 1 week (wk) [early HF]; 14 dogs for 3 
weeks and 10 dogs for 4 weeks [severe HF]. 
Results: Data (means ± SEM) for LV end diastolic pressure (LVEDP, 
mm Hg), plasma norepinephrine level (NE, pg/mL), echocardiographically- 
derived LV mass (g/kg) and apoptosis (cells/103 normal ceils) are shown in 
the table.'p < 0.05, tp < 0.01 versus controls 
LVEDP NE LV mass  Apoptosis 
Controls 10 ± 1 190 ± 25 2.6 ± 0.2 0.29 ± 0.10 
1 wk pacing 23 ± 1" 528 ± 84* 2.7 ± 0.2 2.50:5 0.66 ¢ 
3 wk pacing 26 ~- 2 t 650 ± 78 t 2.6:5 0.2 1.39 :L 0.17" 
4 wk pacing 32 = 3 t 722 ± 68 I 2.7:5 0.1 2.09 ± 0.48 ?
Rapid pacing produced a progressive increase in LVEDP and plasma NE 
level but with no increase in LV mass. The number of apoptotic cells was 
markedly increased after 1 week of pacing and remained increased at severe 
HF with characteristic DNA laddering phenomenon. 
Conclusion: In canine pacing-induced HF, apoptotic cell death occurs 
early and persists in the course of evolving HF. This may contribute to the 
lack of whole-organ LVH and the rapid progression of HF in this model. 
~ Genetic ACE Underexpression Affects Pattern of 
Hypertrophy but Does Not Prevent Cardiac 
Hypertrophy Due to Aorto-Caval Fistula 
Gilbert J. Perry, Tatsuhiko Mori, Chih-Chang Wei, Louis J. Dell'Italia, 
Yiu-Fai Chen. Birmingham VA Medical Center, and University of Alabama in 
Birmingham, AL, USA 
Background: Experimental and clinical evidence suggests that angiotensin 
converting enzyme (ACE) may be an important mediator of cardiac hyper- 
trophy. Pharmacologic ACE inhibition ameliorates failure and remodeling in 
both clinical and experimental heart failure. The effect of genetic variation of 
ACE activity on hypertrophy and CHF is unknown. 
Methods and Results: Heterozygote ACE knockout (+/-) and wildtype 
(+/+) mice were studied 4 weeks after aorto-caval fistula (ACF) or sham 
operation. ACF shunting, assessed by injecting colored microspheres in the 
ascending aorta and measuring % lung uptake, was similar in +/-  and +/+ 
mice (34.4 vs. 32.5%, p = NS). HearVbody weight ratio 4 weeks post-op 
was 74% higher in ACF vs. sham mice, but was not different between +/+ 
and +/-  (2 way ANOVA). There was a trend toward lower echo LV wall 
thickness/diameter ratio in +/-  vs. +/+ ACF (0.28 ± 0.08 vs. 0.34 ± 0.09, p 
< 0.10). Echo stress vs. VCFr curves demonstrated epressed LV function 
in both +/+ and +/-  ACF mice vs. shams, but no difference between ACE 
genotypes (VCF, = 2.67 vs. 2.06, sham vs. ACF, p < 0.001; VCF, = 2.30 
vs. 2.43, +/-  vs +/+, p = 0.38; 2 way ANOVA). LV ACE activity was lower 
in sham +/-  vs. +/+ (22.1 ± 12.3 vs. 39.3 ± 12.5 mU/g). ACF increased LV 
ACE activity in +/+ (111.2 ± 8.1 vs. 24.6 ± 8.8) but not +/-  (24.6 ± 8.8 vs. 
22.1 ± 12.3) mice (p < 0.001 for genotype, fistula vs sham, and interaction 
term, 2 way ANOVA). 
Conclusion: ACE underexpression does not prevent hypertrophy or early 
CHF in response to volume overload from ACF, but may affect the pattern of 
hypertrophy. 
~ Human Cardiac Troponin Function - an in Vitro 
Motility Analysis 
lan F. Purcell, Wu Ring, Steven B. Marston. Cardiac Medicine, National 
Heart and Lung Institute, Imperial College School of Medicine, London, UK 
Background: Differences in human cardiac troponin isoforms and phospho- 
rylation may be seen during development and heart failure but their functional 
effects are unknown. We studied human cardiac troponin function using the 
in vitro motility assay. 
Methods: Functional troponin was isolated from human ventricular my- 
ocardium: 4 normal adults, 2 batches of fetal hearts and 6 adults with end- 
stage heart failure were studied. Calcium dependent troponin regulation of 
actin-tropomyosin filament movement across a layer of heavy meromyosin 
was quantitatively analysed. 
Results: Under relaxing conditions (pCa 9) human cardiac troponin inhib- 
ited filament movement: decrease in fraction of filaments moving from 90% 
to <20% and 40% decrease in velocity. There was no significant difference 
between adult, fetal and failing hearts. Under activating conditions (pCa 5) 
human cardiac troponin did not affect the fraction of moving filaments. At 
pCa 5, mean filament velocity was increased by troponin from normal adult 
hearts by 47 ± 5% (SEM) compared with actin-tropomyosin filaments alone; 
troponin from fetal hearts: 4 ± 6% increase and troponin from failing adult 
hearts: 32 ± 5% increase; (p < 0.01 normal adult v fetal or failing; p < 0.01 
fetal v failing). 
Conclusions: Human cardiac troponin was capable of calcium dependent 
actin-tropomyosin filament regulation in the in vitro motility assay. A large 
functional difference was seen between troponin from normal adult, fetal 
and failing hearts in vitro. These data suggest that changes in troponin 
associated with development and heart failure may significantly alter human 
cardiac function. 
~ Cardiac Troponin T (cTnT) as a Biomarker for 
Monitoring Chronic Doxorubicin (DXR) 
Cardiomypathy 
Eugene H. Herman, Jun Zhang, Steven E. Lipshultz, Nader Rifai, 
Kazuyo Takeda, Zu-Xi Yu, Douglas P. Chadwick, Victor J. Ferrans. FDA, 
Laurel, MD; University of Rochester Medical Center, Rochester, NY," Boston 
Childrens Hospital, Boston, MA; NIH, Bethesda, MD, USA 
Background: Functional methods for evaluating early DXR cardiotoxicity 
are of limited value. The present study seeked to determine whether cTnT, 
a cardiac protein used to diagnose ischemic myocardial injury, also may be 
useful in detecting DXR cardiotoxicity. 
Methods: Spontaneously hypertensive rats (SHR) (5/group) were given 
1 mg/kg DXR weekly. Myocardial tissues and serum samples were collected 
after 2, 4, 6, 8, 10 or 12 weeks of treatment. DXR lesion scores were as- 
sessed semiquantitatively by light microscopy and serum levels of cTnT were 
quantified by an ELtSA method (Enzyum). Myocardial localization of cTnT 
was studied by immuno-histochemical staining and confocal microscopy. 
Results: Increases of cTnT (0.03-0.05 ng/ml) in serum and myocardial 
lesions (lesion scores of 1 or t.5) were noted in 1/5 and 2/5 SHR given 2 
and 4 mg/kg DXR, respectively. All animals receiving 6 mg/kg or more DXR 
had elevations of cTnT in serum and myocardial esions. The average cTnT 
concentrations and the average lesion scores increased with the cumulative 
DXR dose (0.13 vs 0.40 ng/ml cTnT and 1.4 vs 3.0 in SHR given 6 and 
12 mg/kg DXR, respectively). (P < 0.01). Decreased staining for cTnT was 
detected in SHR receiving cumulative doses that caused only minimal his- 
tological alterations (lesion score of 1-1.5). Labeling for cTnT decreased in 
conjunction with increases in the severity of the myocardial lesion scores. 
Conclusion: cTnT is released from DXR-damaged myocytes, and mea- 
surements of serum levels of this protein provide a sensitive means for 
assessing the early cardiotoxicity of DXR. 
~ Regulation of Atrial Contractility in the Human 
Heart 
Monique L. Ogletree-Hughes, Robert W. Stewart, Christine S. Moravec. 
Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: Much is known about the regulation of ventricular (V) contrac- 
tility, while little is known about atrial (A) contractility, which may play a greater 
role in determining cardiac output during the early stages of heart failure. We 
compared A and V muscle removed from non-failing human hearts. We have 
investigated baseline contractile properties at Lmax and correlated these 
with the Ca 2+ regulatory sarcoplasmic reticutum (SR) protein levels. 
Methods: Isometric contractile parameters were recorded at 1.0 Hz and 
37-°C from atrial pectinate and ventricular trabecular muscles removed from 
the same non-failing human hearts. Total left ventricular or atrial heart 
homogenate was used for Western blot analysis of the SR Ca2+-ATPase 
(SERCA), phospholamban (PLB), and calsequestrin (CQ), which were quan- 
tified by immunoblotting. 
Results: Although the amplitude of V contraction is si m liar to A contraction 
(2.28 ± 0.17 vs 2.16 :~ 0.26 g/mm2), the time to peak tension (183 ± 4 ms 
in V and 77 ± 7 ms in A) and time to half relaxation (143 ± 9 ms in V vs 
88 ± 4 ms in A) are signficantly reduced in A. Protein levels of PLB in A are 
signficantly less as compared to V (A = 41% of V; p < 0.05), while protein 
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levels of SERCA and CQ are not different between A and V (SERCA, A = 
90% of V; CQ, A = 99% of V). 
Conclusion: These data demonstrate that non-failing human atrial mus- 
cle contracts faster, but produces the same force as ventricular muscle. The 
faster contraction in A muscle may be caused by differences in the ratio of 
PLB to SERCA. These data suggest the need to study human A vs V muscle 
in heart failure, where the regulation of these SR proteins is known to be 
altered in V muscle, but has not been studied in A muscle. 
• Cellular Hypoxia, Cyclooxygenase-2, Spl : and 
Potential Cofactors in Heart Failure 
Qing Xu 1 , Yan-Shan Ji 2, John F. Schmedtje Jr. 1 . 1 Wake Forest University 
School of Medicine, Winston-Salem, NC; 2 University of Texas Medical 
Branch, Galveston, TX, USA 
Background: Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step 
in prostaglandin synthesis from arachidonic acid and is induced in the fail- 
ing human heart. We have previously shown that COX-2 is transcriptionally 
regulated by hypoxia in human umbilical vein endothelial cells (HUVEC) in 
culture, leading to increased production of PGE2. NF-KB p65 is a transact±- 
vat±on factor that participates in hypoxia-mediated COX-2 expression. Spl 
is a transcription factor known to be important in the regulation of chemokine 
expression in association with NF-KB. Spl also mediates expression of the 
constitutive cyclooxygenase (COX- 1). 
Hypothesis: We hypothesized that Spl is involved in the induction of 
COX-2 in hypoxic HUVEC. 
Results: Hypexia increased Spl content in HUVEC nuclear (but not cy- 
toplasmic) protein by immunoblotting. Furthermore, electrophoretic mobility 
shift assays showed specific binding of HUVEC nuclear protein to the Spl site 
just upstream of the proximal NF-x B element known to specifically enhance 
COX-2 transcription in hypoxia in our previous studies. The Spl DNA-protein 
complexes were supershifted specifically by anti-Spl antibody. Mutation of 
this Spl element abrogated Spl DNA-protein interaction. Overexpression of 
Spl through transfection of HUVEC resulted in increased COX-2 promoter 
activity as measured by the marker luciferase gene expression. 
Conclusion: Spl is most likely another cofactor in the transact±vat±on f 
the COX-2 gene by hypoxia, suggesting a tink between cellular hypoxia and 
the mediators of inflammatory responses associated with heart failure in a 
cell culture model of human vascular endothelium. 
• Dyspnea Threshold is Related to Ventilatory 
Threshold During Exercice in Patients With 
Chronic Heart Failure 
S. Cade, F. Anselme-Martin, F. Raszka, M. Pons, J.-M. Davy, 
P. Messner-Pellenc. Prefaut Ch. Service Central de physiologie clinique, 
Hopital Amaud de Villeneuve, 34295 Montpellier and Services de 
Cardiologie, CHU Montpellier-Nimes, France 
Background: Some groups use the Ventilatory Threshold (VT) to realise 
training program in Chronic Heart Failure (CHF). Cardiopulmonary exercice 
test is necessary to define VT and some authors propose to use the Dys- 
pnea Threshold (DT) defined as the appearance of dyspnea feeling during 
exercice. We therefore study the relation between DT and VT. 
Methods: DT was noted by 2 independants operators on the curve of 
dyspnea score versus time by using visual BORG modified scale and by 
using specific language of dyspnea in CHF during a maximal exercice test 
on cycloergometer, in 19 patients with CHF (NYHA II/111). VT was calculated 
by BEAVER method and by using respiratory equivalents during the same 
test. 
Results: This study did not show a significative difference between DT 
and VT in term of oxygen consumption [VO2 at DT (mean 4- se) = 12.3 ± 
1.1 ml/kg/mn vs at VT = 11.8 ± 0.9 ml/kg/mn; r = 0.92, p < 0.01], heart rate 
[HR at DT = 118 4- 4c/mn vs at VT = 116 ± 4c/mn; r = 0.92, p < 0.01] and 
ventilation [VE at DT = 29.6 ± 2.3L/mn vs at VT = 27.9 4- 1.7L./mn; r = 0.86; 
p < 0.01]. There was a linear correlation between DT and VT [DT VO2 = 
0.530+(0.968"VT VO2), p < 0.01]. 
Conclusion: Ventilatory and dyspnea thresholds are correlated in pa- 
tients with CHF. The DT may be use to define and evaluate exercice training 
program and for follow up. This suggests a relation in dyspnea sensation and 
excessive ventilatory response in CHF to exercice which may be an argu- 
ment to choose the intensity of training program with moderate and tolerable 
dyspnea feeling. 
~ Effects of Chronic Exercise in Patients With 
Chronic Heart Failure on Markers of Oxidative 
Stress 
Josef Niebauer 1,2, Katharine Webb-Peploe 1 , Greg Quinlan 1 , Philip 
S. Tsao 3, John P. Cooke 3, Andrew J.S. Coats 1 . 1NHLI, London, UK; 
2 Herzzentrum, Univ of Leipzig, Germany; 3 Stanford University, USA 
Background: Generation of reactive oxygen species is thought o lead to en- 
dothelial dysfunction; chronic exercise restores impaired endothelial function 
in chronic heart failure (CHF) through a nitric oxide dependent mechanism. 
In this study, we measured plasma nitrite, L-arginine, asymmetrical dimethy- 
larginine (ADMA; an endogenous nitric oxide synthase inhibitor), hypoxan- 
thine (pro-oxidant substrate for xanthine oxidase), and uric acid (putative free 
radical scavenging properties) to assess whether their levels can be altered 
by chronic exercise. 
Methods: 21 patients and 9 controls were randomly assigned to 8 weeks 
of exercise (EX; > 5 d/wk, ergometer training, 30 min/d; calisthenics 9 
min/d) followed by 8 weeks of detraining, and vice versa (cross-over study). 
L-arginine, ADMA, hypoxanthine, and uric acid levels were measured by 
high performance liquid chromatography and nitrite concentrations by Griess 
reaction. 
Results: Maximal exercise time increased in both groups (p < 0.005). 
Uric acid levels were highest in CHF (p < 0.005) but did not change after 
training. However, there was an inverse correlation between uric acid levels 
and maximal exercise time (r = -0.32, p < 0.02). Hypoxanthine levels 
were significantly higher in patients than in controls (p < 0.02), and were 
normalized by chronic exercise. Nitrite levels were significantly lower in CHF 
patients than in healthy controls. Although nitnte levels were highest after 
EX, changes did not reach statistical significance (p = n.s.). There were 
no baseline differences detected for L-arginine and ADMA; levels were not 
altered by exercise. 
Conclusion: Chronic heart failure is associated with increased levels 
of hypoxanthine and decreased levels of nitrite. This imbalance can be 
beneficially modulated by chronic exercise training. Furthermore, uric acid 
levels are elevated in CHF and associated with diminshed exercise capacity, 
reflecting an impairment of oxidative metabolism. 
~ T h e  Effect of Reactive Airways Disease on Peak 
Oxygen Consumption in Congestive Heart Failure 
Pradeep Mehra, Venkat Pasnoori, David Sengstock, Omar Obaidat, Clinton 
A. Brawner, Steven J. Keteyian, Edward F. Philbin, Peter A. McCullough. 
Henry Ford Health System, Detroit, Michigan, USA 
Background: Previous studies have established peak oxygen consumption 
(peak VO2) as an independent predictor of survival in congestive heart 
failure (CHF). The impact of superimposed asthma and chronic obstructive 
pulmonary disease (COPD) on peak VO2 is unknown. 
Methods: Cases, n = 16, were defined as having class I1-111 CHF and 
moderate asthma (13) or COPD (3) documented with reduced FEVjFVC, 
65.4 ± 9.1; but normal lung capacity, 100.5 4: 19.0% of predicted TLC. All 
cases required chronic beta-agonist inhaler therapy and were under the care 
of a pulmonologist. Controls were randomly selected from CHF patients, 
matched by ejection fraction (EF), who had no evidence of lung disease. 
All patients underwent a symptom-limited treadmill protocol. Expired air was 
analyzed using indirect open-circuit spirometry. Ventilatory threshold (VT) 
was derived using the V-slope method. 
This study had adequate (80%) power to find a 30% relative difference in 
peak VO2, with a two-tailed alpha level of 0.05. 
Results: Cases and controls were matched for age 50 4- 13 vs 53 4- 5 
yrs, p = 0.36; gender ratio, p = 0.50; and EF 17 4- 6 vs 20 ± 7%, p = 0.08. 
We found no significant differences in peak VO2 16.8 4- 6.4 vs 16.5 4- 5.8 
ml/kg/min, p = 0.86; VO2 at VT 15.6 4- 5.8 vs 14.1 4- 4.9 ml/kg/min, P = 0.41 ; 
VO2/predicted 63.2 ± 24.9 vs 59.8 4- 18.0%, p = 0.62; minute ventilation 
55.5 ± 20.2 vs 57.0 ± 14.8 IJmin, p = 0.80: or respiratory exchange ratio 1.1 
± 0.1 vs 1.2 4- 0.1, p = 0.09, between cases and controls, respectively. 
Conclusion: Peak VO2 and other cardiopulmonary exercise test variables 
of clinical importance in severe CHF are not affected by the presence of 
co-existent, moderate chronic obstructive airway disease or asthma. 
~ Myocardial Beta Natriuretic Peptide Release After 
Acute Ischaemia in Patients Undergoing Beating 
Heart Coronary Surgery 
Gerald S. Carr-White, Tat W. Koh, Michael Kemp, James Hooper, Anthony 
C. DeSouza, John R. Pepper. Royal Brompton Hospital, London, England 
Background: Plasma Beta Natriuretic Peptide (BNP) levels are used as 
markers of ventricular dysfunction in ischaemic heart disease. Beating heart 
coronary artery surgery allows the effects of prolonged local coronary artery 
occlusion on cardiac and systemic BNP release to be examined. 
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Methods: Twelve consecutive patients aged between 56 and 77 years 
undergoing beating heart coronary surgery with the "Octopus" stabilisation 
system were studied. Paired arterial (A) and coronary sinus (CS) samples 
were taken before a 17 ± 4 minute occlusion of the left anterior descending 
coronary artery and then at t, 5, 10 and 20 minutes after release of the 
snare. In all patients intraoperative transoesophageal echocardiography was 
used to document regiona~ waff motion abnormalities and global ventricular 
function. 
Results: Net cardiac BNP release (coronary sinus concentration > arterial 
concentration} was demonstrated at all t/me po~ts measured. Coronary 
artery occlusion, despite producing hypokinesis of the anterior left ventdcular 
wall in all patients, did not lead to an increase in systemic or coronary sinus 
B3NP levels. 
CS BNP (pmot/1) CS-A BNP (pmol/I) 
I~re occlusion 50.7 4- 55 29.1 ~. 34 
Max, release post occlusion 51.3 4- 55 27.9 4- 32 
Post-pre occlusion 0.5 :E 4.7 2,9 ~: 5.4 
Conclusion: Paired artedal and coronary sinus BNP levels demonstrate 
net myocardial release in patients with coronary artery disease. Acute coro- 
rna.rv artery ocd~us~oq, ~es.dfte pm~udm..o ednocard=ogra, drfic dnan.ges dt m- 
IBNP release. 
[ •  Is Blood Pressure Response to the Valsalva 
~Paneuver PTelbfeo'fo Rburor~ormons, Exercl~se 
Capacity, and Clinical Findings in Heart Failure? 
Hans-Peter Brunner-La Rocca, Daniel Weilenmann, Hans Rickli, 
Wo/fgang Kiowski, Ferenc Follath. Cardiology, Un/versity Hospffal Zur/ch, 
Switzerland 
Background: Recordings during the straining phase of the Valsalva maneu- 
ver (VM) are considered as a useful tool to diagnose heart failure (CHF) and 
they are closely related to left sided filling pressure. Despite that and the 
easily applicable and noninvasive character of this test, little attempts have 
been made to correlate the blood pressure (BP) response to the VM and 
parameters of CHF others than hemodynamic measures. 
Methods: We investigated 45 patients with stable CHF (EF 28 ± 7%). 
Patients were examined clinically, by questionnaire and by spiroergometry. In 
addition, neurohormones (ANP, BNP, norepinephrine (NE)) were measured. 
The BP amplitude ratio (PAR) was calculated between the beginning and the 
end of the VM using the first 3 and the last 2 beats of straining phase. 
Results: Patients in NYHA class 3 (n = 15) had higher PAR than those 
in class 2 (82 ± 20 vs 63 ± 20%, p < 0.01). Patients with PAR > 80% (n = 
17) had higher neurohormons (ANP 291 ± 166 vs 97 ± 49pg/ml, BNP 353 
± 315 vs 89 4- 83pg/ml, p < 0.001; NE 4.2 4- 1.7 vs 3.4 ± 1.5, p = 0.1), 
lower exercise capacity (18.7 ± 4.8 vs 22.9 ± 4.2 ml/kg/min, p < 0.005), and 
more signs of CHF (Score 1-9:3.7 ± 1.4 vs 2.8 ± 1.0, p < 0.05). In addition, 
their quality of life (Minnesota questionnaire) was more compromised (35 5: 
19 vs 18 4- 15, p < 0.005), There was a close correlation between PAR and 
ANP (r = 0.76) and BNP (r = 0.61) while other parameters were less but still 
significantly correlated (r = 0.3 to 0.45). 
Conclusions: Blood pressure response to the VM is related to a broad 
range of clinical and neurohumoral parameters of heart failure. Whether it is 
also related to prognosis remains to be determine. Nevertheless, this easily 
applicable test should be part of the assessment of patients with CHF. 
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J 1048-14J Impaired Cardiac Function in Mice 
I ' Overexpressing Bovine Growth Hormone Gene 
Entela Bollano, Mohammad Bohlooly, Elmir Omerovic, Jan Tomell, 
Vuk Kujacic,/~,ke Hjalmarson, Olle Isaksson, J0rgen Isgaard. Wallenberg 
Laborato~ Sahlgrenska Hospital, Dept of Physiology, Gdteborg Universi~ 
Gdteborg, Sweden 
Growth hormone (GH) has been shown to be involved in cardiac structure 
and function. Our aim was to evaluate the effects of high levels of GH at long 
term, in cardiac structure and function. 
Methods: Female transgenic mice overexpressing bGH eight months old 
(n = 11 ) and aged and sex matched non-transgenics littermates controls (n = 
11) were used. Left ventricular (LV) morphology and function was studied in 
vivo by using two-dimensional guided M-mode and Doppler echocardiogra- 
phy. We examined the animals with 31P magnetic resonance spectroscopy 
to asses the cardiac energy status and levels of cardiomyocytes apoptosis 
were also studied. 
Results: bGh overexpressing mice has significantly high mean body weight 
(BW) compared with non-transgenics (53.2 ± 2.4 vs 34.6 ± 3.7 p < 0.0001 ). 
LV eccentric hypertr~pfty was observe~ ir~ TG mica. LV mass ir~de~ (LV- 
mass/BW) was significantly greater relative to controls despite high BW (4.6 
± 0.7 vs 3.1 ± 0.4 mg/g p < 0.0001). While heart rate was not significantly 
different b.etw~a~n~rD_qz',~ mttlt~J'zar_atrt, qt~.m_d.ero~.~tLat.~zl.c~Lrto..,"~,on- 
t ~ac.tiJ~ty. f(lt'.tbe~h("-~-:l .¢"~v~Lrp,.Y.EEP.~.C-,~3g. mlc#~r~,l~i.ve~tcL~qt ~;OJ.$~. LV- ~.ho~ten!t~ 9. 
fraction was reduced for bGH mice relative to controls (25 ± 3% vs 39.9± 3.1 
.o < ~.~ll.~tect~ontraction dtLV was also decreased in TG mice co . red . to  
controls (0.57 ± 0.09 vs 0.77 ± 0.05 p < 0.01 ). In addition mean velocity of cir- 
cumferential shortening was significantly decreased in bGH overexpressing 
mice relative to controls (4.7 ± 0.8 vs 6.4 ± 1.1, circ/sec p < 0.01). 
Conclusions: Long exposure to high levels of GH impairs systolic cardiac 
function and induce LV hypertrophy. 
' ~ ~  "Cnemdl~me--P..xpresdion|nHuman-End--Stag, e 
Congestive Heart Failure due to ~/ated 
Cardiomyopathy and Ischemic Heart Disease 
Thomas M. Behr, Marinela Berova, Michael Scheloske, Andreas Haslinger, 
r-~e~'a - ~er ,  P"m~r £J'ber(ufiT, m~tuno H~bhan; Uqm~r ~ongratz, 
Karl Theisen, Christiane E. Angermann. University of Munich, Germany 
Background: Chemokines constitute a family of cytokines which induce 
chemotaxis, or directed migration, of leucocyte subsets. Chemokine xpres- 
sion is induced by pro-inflammatory cytokines such as IL-1, IL-6 and TNF-c~, 
which are well known to be involved in the pathogenesis of end-stage conges- 
tive heart failure (CHF). Thus, this study was designed to explore, whether 
chemokine-expression is present in end-stage CHF due to dilated cardiomy- 
opathy (DCM) and ischemic heart disease (IHD). 
Methods: Left ventricular specimens of 24 patients with CHF (DCM: n = 
14; IHD: n = 10) acquired at transplantation were immunohisto-chemically in- 
vestigated (alkaline phosphatase) for presence of macrophage inflammatory 
protein-l~ (MIP-lc0 and regulated on activation normal T-cell expressed and 
secreted (RANTES). As controls served two cadaver hearts. The number of 
positive mononuclear cells (mean 5: standard deviation) is given per 0.1 cen- 
timeter square. In addition, western blots were performed to verity specificity 
of commercially obtained monoclonal antibodies used. 
Results: MIPI-c~ expression was found in 23 of 24 specimens. The 
number of positive cells were 3.5 ± 3.8. RANTES was found in 15 of 24 
specimen, with 0.6 ± 0.5 positive cells. There was a significantly higher 
expression for MIPI-~ in IHD (4.4 ± 2.7) compared to DCM (1.9 ± 1.6). No 
cardiomyocytes, connective tissue or blood vessels were labelled. Cadaver 
hearts were negative. Western blots of control proteins revealed positive 
bands at the appropriate molecular weight (8 kD). 
Conclusion: The chemokines MIPlc~ and RANTES are expressed in 
human end stage CHF, but not in control tissue. IHD may trigger a more 
profound expression compared to DCM. We suggest a potential role for 
these chemokines in the pathophysiological cytokine concert leading to heart 
failure. 
J1048-161 Protein Is Increased in Left Phosphatase Activity 
i Ventricular Myocardium of Explanted Failed 
Human Hearts 
Ramesh C. Gupta, Vinita Singh, Sudhish Mishra, Robert S.D. Higgins, 
Robert H.G. Schwinger 1 , Christine S. Moravec 2, Sidney Goldstein, Hani 
N. Sabbah. Henry Ford Heart & Vascular Institute, Detroit, MI; ZThe 
Cleveland Clinic Foundation, Cleveland, OH, USA; 1 University of Kdln, Kdln, 
Germany 
Background: In contrast to protein kinases, protein phosphatases (PP) 
are responsible for the dephosphorylation of regulatory proteins involved in 
cardiac muscle contraction and relaxation. We previously showed that PP 
activity is increased in LV myocardium of dogs with chronic heart failure (HF). 
Methods: In this study, we examined PP activity in LV myocardium ob- 
tained from 12 explanted failed human hearts and 6 normal donor hearts 
deemed not suitable for transplantation. HF was due to ischemic cardiomy- 
opathy (ICM) in 6 of 12 hearts and to idiopathic dilated cardiomyopathy 
(IDC) in 6. PP activity was measured using 32p-labeled phosphorylase a as 
substrate and was expressed as nmo132p released/min/mg protein. 
Results: PP activity was significantly higher in failed LV tissue of both 
etiologies compared to normal. There was no significant difference in PP 
activity between ICM and IDC. 
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Normal ICM IDC 
PP Activity 16.8 ± 1.5 47.2 ± 3.3" 41.0 ± 2.8* 
"p < 0.05 vs. Normal 
Conclusion: PP activity is increased in LV myocardium of failed human 
hearts. Elevation of PP activity may be a key maladaptation that leads to 
abnormalities of Ca 2+ cycling in I-IF and, consequently, to LV systolic and 
diastolic dysfunction. 
• Sarcoplasmic Reticulum Calcium Cycling 
Proteins in Human Hypertensive Left Ventricular 
Hypertrophy 
Nicholas R. DiPaola, Robert W. Stewart, Christine S. Moravec. C/eve/and 
Clinic Foundation, Cleveland, OH, USA 
Background: The Framingham study demonstrated that left ventricular hy- 
pertrophy (LVH) is an independent risk factor for the development of heart 
failure. Unfortunately, little is known about the molecular changes which 
accompany LVH in humans. Animal models of LVH are characterized by 
alterations in the expression of Ca 2+ cycling proteins in the sarcoplasmic 
reticulum (SR). The present study characterizes the expression of these 
Ca 2+ cycling proteins, including calsequestrin, the SR Ca2+-ATPase and 
phospholamben, in order to determine if molecular changes found in animal 
models are also seen in human LVH. 
Methods: 12 non-failing (NF) hearts from unmatched organ donors were 
used. Six heads demonstrated LVH by echo or ECG prior to harvest, while 
the other 6 sewed as non-hypertrophied controls. LVH was confirmed by the 
presence of ventricular ANF mRNA, using Northern blotting. SR protiens from 
LV heart homogenate were separated via gel electropheresis and quantified 
using immunoblotting techniques, Protein levels in heads with LVH were 
expressed as a percent of controls. Statistical significance was determined 
using the Mann-Whitney test. 
Results: There were no statistically significant differences in levels of 
calsequestrin (102% of control; p = 0.93), the SR Ca 2+ ATPase (110% of 
control; p = 0.61), or phospholamban (91% of control; p = 0.57) between 
hearts with LVH and control hearts. Actin levels also were not different 
between LVH and controls (110% of control; p = 0.82). 
Conclusion: Unlike many animal models of LVH, human hypertensive 
LVH is net accompanied by changes in the proteins which regulate SR Ca 2÷ 
cycling. 
~ l s  Myocardial Exchanger Na*Ca 2+ Gene 
Expression Altered in Chronic Heart Failure? 
Cornelia Piper, Johannes Bilger, Andrea DSrner, Eva-Maria Henrichs, 
Peter Schwimmbeck, Marcus Wiemer, Heinz-Peter Schulthei8, 
Dieter Horstkotte. Dept. of Medicine, University Hospital Benjamin Franklin, 
Free University Berlin, Germany 
Background: Upregulation of the sarcolemmal Na÷Ca 2+ exchanger (EXCH) 
gene expression is one of the characteristics of disturbed myocardial calcium 
homeostasis in end stage heart failure of any etiology. To investigate the 
alteration in EXCH gene expression in less severe stages of myocardial 
dysfunction, we established a quantitative PCR method using an internal 
RNA standard for the determination of the EXCH mRNA copy number in 
small biopsy samples. 
Methods: Right ventricular biopsies from 22 patients with valvular heart 
disease (VHD, ejection fraction EF: 34-77, cardiac index CI 1.8-4.5) and 
18 patients with dilated cardiomyopathy (DCM: EF 24-71, CI 2.6-5.0) were 
analysed. In addition, myocardium from explanted hearts from 13 patients 
with end stage heart failure due to ischemic or dilated cardiomyopathy were 
analysed. Myocardium from 4 individuals without heart disease served as 
controls. 
Results: The average level of EXCH mRNA in controls (22 ± 13 atmol 
per ng total RNA) was not different from those with DCM (23 ± 15 atmol/ng 
total RNA) or those with VHD (21 ± 15 atmol/ng total RNA). No difference of 
the EXCH expression was found in VHD and DCM patients with respect to 
the severity of LV pump function: 
CI > 3.5 (EXCH 20 ± 15 atmol/ng total RNA), CI 3.5-2.4 (EXCH 20 ± 16), 
CI < 2.4 (EXCH 25 4- 13); EF > 50% (EXCH 22 ± 15), EF 30-50 (EXCH 18 
± 13) and EF < 30 (EXCH 24 ± 17). 
However, patients with end stage heart failure (CI < 2.4 plus EF < 30%) 
had a fourfold increase in the EXCH mRNA level (89 ± 19 atmol/ng total 
RNA). 
Conclusion: These data indicate that the switch in EXCH gene expres- 
sion in humans either occurs at a very late stage of heart failure or is due to 
hemodynamic changes during heart explantation. 
~ Function and Expression of Antioxidative Gene 
Enzymes in Human Hearts With End-Stage Heart 
Failure 
Anselm T. B&umer, Xinkang Wang 1 , Markus Flesch, Giora Z. Feuerstein 1 , 
Michael BShm. Klinik III for Innere Medizin der Universit#t zu KS/n, Cologne, 
Germany; ~ Departments of Cardiovascular Pharmacology, SmithKline 
Beecham Pharmaceuticals, King of Prussia, PA, USA 
Background: Myocardial damage due to reactive oxygen species may play 
a pivotal role in the pathogenesis of heart failure. Therefore, we investigated 
the damage due to reactive oxygen species and major intracellular enzy- 
matic pathways involved in the elimination of reactive oxygen species in left 
ventricular myocardium of 10 individuals without heart failure and 12 patients 
with end-stage heart failure. 
Methods and Results: Reactive oxygen species mediated damage was 
determined by tissue levels of products of lipid peroxidation, malondiatde- 
hyde and 4-hydroxyoalkenals, and immunodetection of nitrosylated proteins. 
Enzyme activities, mRNA expression (Northern analysis) and protein lev- 
els (Western blot) of the hydrogen peroxide scavenging enzymes cata- 
lase (CAT) and glutathione peroxidase (GPX), and the superoxide anion 
scavenging enzymes mitochondrial (Mn-SOD) and cytosolic (Cu/Zn-SOD) 
superoxide dismutases were measured. In failing myocardium, there was 
a significant decrease in CAT activity by >30% (6.59 ± 0.52 vs. 4.83 ± 
0.32 U/mg, p < 0.01) despite unchanged mRNA expression and protein 
levels. GPX and Mn-SOD were decreased concerning activity (ns), mRNA 
(ns) and protein levels (ns). Cu/Zn-SOD activity and gene expression was 
similar in both groups investigated. Differences in reactive oxygen species 
mediated damage between non-failing and failing myocardium were not ob- 
served. 
Conclusion: Changes of antioxidative enzymes, i.e. decrease in activ- 
ity and gene expression, were observed. In contrast to GPX and Mn-SOD, 
decreased CAT activity appears to be a posttranslational mechanism. De- 
creased antioxidant activities might shift the intracellular edox balance lead- 
ing to activation of redox sensitive signalling pathways in end-stage failing 
myocardium. 
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~ T h e  Aetiological Importance of Coronary Artery 
Disease in Incident Heart Failure: A Population 
Study 
Kevin F. Fox, Martin R. Cowie, David A. Wood, Andrew J. Coats, J. 
Simon Gibbs, S. Richard Underwood, Rebecca M. Turner, Phillip 
A. Peele-Wilson, George C. Sutton. Imperial College School of Medicine, 
London, UK 
Background: Heart Failure (HF) represents a large and increasing health 
care burden. The importance of coronary artery disease (CAD) in unselected 
new cases of HF has only been described using non-invasive data. New 
treatments for HF due to CAD, including revascularisation for hibernating 
myocardium add to the importance of accurately ascertaining the number of 
HF cases due to CAD. 
Methods: All new HF cases arising in a population of 292 000 in South 
London, UK were identified by in-patient monitoring and from a dedicated 
rapid assessment clinic over a period of 15 months. Cases under 75 years 
(<75), were investigated with coronary angiography. If CAD was present 
myocardial perfusion imaging to determine the aetiological importance of the 
CAD and the presence of viable myocardium was performed. 
Results: 332 cases were identified with 136 aged <75. Angiographic 
data were available on 98 (78% of the 124 cases surviving the initial presen- 
tation of HF). CAD was present in 66/98 (67%) of cases. In assessing the 
aetiological importance of the CAD perfusion data was analysed in addition 
to angiographic and clinical data. In 6 cases (with valve disease) the CAD 
was not of aetiological importance. 
Including cases who died during acute ischaemic episodes, of the 136 
cases aged <75, CAD was the aetiology in 59%. 18/44 cases (41%) not 
allocated to CAD or valve disease on the basis of non-invasive data were 
found to have anatomically significant CAD at angiography. Of these 18 
cases with "unpredicted" CAD, perfusion data was available in 12. In 8/12 
(67%) significant hibernating myocardium was present. 
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Conclusion: CAD is the single most frequent aetiological factor in incident 
heart failure. Non-invasive methods may miss cases due to CAD including 
• Flash Pulmonary Edema: Reoccurrence Despite 
Coronary Revascularization 
R. Keith Kramer, William C. Little. Wake Forest University School of 
~,ledicine. Winston-Salem. NC. USA 
Background: The sudden develqpment of acute (flash] .pulmonary edema 
is considered to be an indication for coronary angiography and revascular- 
ization. 
Methods and Results: We studied 45 patients with flash pulmonary 
edema requiring hospitalization within six hours of the onset of symptoms. 
Twenty required fntubation and ventila]~(on. There were 2Y men and 24 
women, ages 44-84 (mean 68 ± 10 years). Systolic blood pressure (BP) 
on admission was 196 ± 40 mmHg. Left ventricular (LV) ejection fraction 
was greater than 40% in 23 of 45 patients. Thirty-three patients underwent 
coronary angiography; 24 had obstructive coronary artery disease. Sixteen 
were revascularized, 10 surgically and 6 percutaneously. Flash pulmonary 
edema reoccurred in 14 patients within 6 months: in 8 of 24 (33%) who had 
been revascularized and in 6 of 21 (29%) who had not been revascularized 
(p = NS). Systolic BP during reoccurrence of flash pulmonary edema was 
188 ~: 34 mmHg, similar to the initial presentation (p = NS). Of the 8 patients 
who were evaluated, renal artery stenosis was present in 4 patients. 
Conclusion: Patients with flash pulmonary edema frequently have nor- 
mal systolic LV function and coronary artery disease. Flash pulmonary edema 
frequently reoccurs in association with marked systolic hypertension. Coro- 
nary revascularization does not appear to reduce the reoccurrence of flash 
pulmonary edema. This suggests that control of hypertension is important o 
prevent reoccurrence of flash pulmonary edema. 
~ Detection of Myocardial Viability and Prediction of 
Post Revascularization Ejection Fraction in the 
Presence of Severe Left Ventricular Dysfunction 
Binoy K. Singh, Varinder P. Singh, Snehal Ghandi, Aman M. Amanullah, 
Kathleen Galatro, William Van Decker, Alexis B. Sokil, Farooq A. Chaudhry. 
MCP, Hahnemann School of Medicine, Philadelphia, PA 19129, USA 
Background: We have shown that low dose dobutamine stress echocar- 
diography (LDDE) can identify viable myocardium and predict improvement 
in ejection fractions (EF) after coronary bypass surgery (CABG) in patients 
(pts) ischemic cardiomyopathy. However, the ability of LDDE to identify viable 
myocardium and predict post CABG LV EF in pts with CAD and severe LV 
dysfunction has not been determined. 
Methods: Thus, we evaluated 54 pts with CAD and severe LV dysfunction 
(mean LV EF 27%, range 6-40%) who underwent LDDE and CABG. Of these, 
33 (mean age 54 ~ 10 yrs) (28 males) underwent follow-up echocardiography 
(range >_6-15 months). EF at baseline, during optimal contractile reserve, and 
at follow-up were determined offline using a modified Simpson's equation. 
Results: We evaluated 528 segments of which 479 had baseline wall 
motion abnormalities (91%). The sensitivity, specificity, and positive and 
negative predictive value of LDDE in identifying pts with viable myocardium 
were 70%, 75%, 61%, and 81% respectively. The mean LV EF increased to 
38% (p _< 0.001) with LDDE and 36% (p < 0.001) at follow-up. There was 
significant correlation between LDDE EF and post CABG follow-up EF (r = 
0.8) 
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Conclusion: 1) LDDE can identify viable myocardium even in patients 
with CAD and severe LV dysfunction. 2) LDDE can predict improvement in 
EF after CABG even in patients with CAD and severe LV dysfunction. 
~-9~ Influence of PET Viability Studies on Clinical 
Decision Making in CHF Patients 
Martin Allen-Auerbach, Heiko Sch6der, Michael E. Phelps, 
Johannes Czemin. UCLA School of Medicine, Los Angeles, California, USA 
Background: Selected heart failure patients (CHF-patients) with extensive 
areas of viable myocardium exhibit improved survival rates and heart failure 
symptoms following revascularization (CABG), However, the impact of PET 
btc~ I~O~N ~NH%i~etabc~c (F{3G~ m~uc3 ou c~u~ca~ dec~s~(x~ r ak~ ueeds 
to be investigated. 
(HTX) or medical treatment was determined in 110 patients with ischemic 
heart disease (mean age: 63 ± 10 years; mean LVEF: 26 ± 8%) who were 
evaluated for presence of viable myocardium. The LV was divided into 19 
segments. Blood flow and glucose utilization were graded from 3 = severely 
reduced, to 0 = normal. Viability was defined as an FDG-NH3 difference of 
>_1 grade (mismatch) and non-viable myocardium as concordant reduction 
in NH3 and FDG (match). Viability was considered extensive if >5 segments 
(approximately 25% of the LV myocardium) and limited if 1-4 segments were 
involved. 
Results: Thirty-seven patients (34%) had extensive viability, 23 (21%) 
had limited viability, and 50 (45%) had no viable myocardium. Sixty-eight 
percent of the 37 patients with extensive viability, 52% of the 23 patients with 
limited viability, and only 36% of the 50 patients without viability underwent 
CABG (p < 0.05). Patients without viability were medically treated more 
frequently than patients with viability (42% vs. 24% vs. 26%; p < 0.05). More 
importantly, 36% of patients without viability underwent CABG because of 
anginal symptoms. Only patients with extensive viability showed improved 
LVEF after CABG (26 ± 8% vs. 33 • 9%; p = 0.002). 
Conclusion: These findings demonstrate a significant impact of PET 
viability studies on patient management. However, 32% of the patients with 
extensive viability are poor surgical candidates and require medical treatment 
or HTX. Conversely, clinical symptoms such as angina result in CABG even 
in 36% of the patients without viability. 
~ Comparison of Echocardiography and Electron 
Beam Computed Tomography in Differentiating the 
Etiology of Heart Failure 
Thuy Le, John Y. Ko, Matthew J. Budoff. Harbor-UCLA Medical Centerand 
Saint John's Cardiovascular Research Center, Torrance, CA, USA 
Background: The distinction between dilated cardiomyopathy and coro- 
nary-induced heart failure may be clinically difficult, however the distinction 
has important therapeutic and prognostic implications. Incorrect etiology 
based upon wall motion abnormalities by echocardiography has led to un- 
necessary coronary angiography. Coronary calcification (CC) by electron 
beam computed tomography (EBCT) has been shown to correlate well with 
angiographic stenosis. 
Methods: The accuracy of EBCT and echocardiography was compared 
in 111 patients undergoing coronary angiography for the evaluation of heart 
failure. Ischemic etiology was defined by angiography when more than one 
coronary vessel had >_50% diameter stenosis. The presence of CC by EBCT 
or segmental wall motion abnormalities by echocardiography were used as 
evidence of coronary-induced cardiomyopathy. 
Results: 61 of 63 patients (97%) with obstructive coronary artery disease 
had CC by EBCT. This sensitivity was significantly higher compared to 43 of 
63 (73%) with segmental wall motion abnormalities by echocardiography (p 
< 0.001). Of 48 patients without coronary artery disease by angiography, 39 
(81%) had no CC by EBCT and 35 (73%) had no segmental wall motion (only 
global hypokinesis) by echocardiography (p = 0.33). The overall accuracy 
of EBCT to differentiate ischemic from non-ischemic cardiomyopathy was 
90%, significantly higher than two-dimensional echocardiography (70%, p < 
0.001). 
Conclusion: This double blind study demonstrates that the presence of 
CC by EBCT is superior to segmental wall motion abnormalities on echo-car- 
diography in its ability to successfully distinguish ischemic from non-ischemic 
cardiomyopathy. This modality may prove an important diagnostic tool when 
the etiology of the cardiomyopathy is not clinically evident. 
~ Ejection Fraction Changes During Dobutamine 
Stress Echocardiography Predict Functional 
Recovery After Revascularization in Patients With 
Left Ventricular Dysfunction 
Guido Rocchi, Don Poldermans, Riccardo Rambaldi, Jaroslaw D. Kasprzak, 
Wim B. Vletter, Jeroen J. Bax, Abdou EIhendy, Jos R.T.C. Roelandt. 
Thoraxcentre, Erasmus Universi~ Rotterdam, The Netherlands 
Aim: To assess the predictive value of ejection fraction (EF) changes during 
dobutamine stress echocardiography (DSE) for improvement of left ventricle 
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(LV) function after coronary artery bypass grafting (CABG) in pts with LV 
dysfunction. 
Methods: Thirty-five pts underwent DSE. LV EF was calculated at rest, 
low dose dobutamine (10 ,u.g/kg/min) and at peak stress by 2-Dimensional 
bi-plane method. Pre and post CABG rest EF were also calculated by ra- 
dionuclide ventriculography (RNV) in order to evaluate LV function recovery 
independently. The second RNV was performed 8 ± 2 months after CABG. 
Results: Mean pre CABG EF at rest was 33 ± 10% by RNV. After CABG 
EF improvement >5% occurred in 11 pts (Group 1), whereas in 24 pts EF 
remained unchanged or worsened (Group 2). During DSE EF increased 
from rest to low dose more in group 1 than in group 2 (+11.8 • 5.3% vs 
+5.5 ± 7.8%; p = 0.02). The table shows sensitivity and specificity of EF 
improvement at low dose and worsening at peak stress for prediction of EF 
recovery after CABG of >5% by RNV: 
Improvement ofEF at low dose Sens. Spec. 
A EF > 5% 56% 90% 
~. EF > 10% 71% 73% 
~. EF > 5% with peak EF worsening >5% 70% 72% 
~. EF > 10% with peak EF worsening >5% 88% 67% 
Conclusions: In pts with left ventricular dysfunction the degree of ejection 
fraction increase during low dose dobutamine stress echo and the ejection 
fraction worsening at peak stress can be helpful for the selection of pts who 
will benefit from CABG. 
• Analysis of the Interval-Force in Relation the 
Presence of Coronary Artery Disease and/or 
Cardiomyopathy in Atrial Fibrillation 
David I. Silverman, Aftab A. Awan, Ronatd J. Raymond, Steven Walsh, 
Sarah Golden, Arnold M. Katz. UCONN Health Center, Farmington, CT, 
USA 
Background: We tested the hypothesis that cycle length-dependent cardiac 
contractility in atrial fibdllation (AF) is primarily governed by the negative 
interval-force relation, and that there is no difference in this relation between 
normal patients (pts), pts with coronary artery disease (CAD), and pts with 
cardiomyopathy (CMP). 
Methods: We performed 2D guided M-mode echocardiography in 41 
pts, (mean age 69 ± 4 years, range 48-92 yrs; 19 M/11 F), 12 of whom 
had objective evidence of CMP (mean EF 37 ± 7%) in the absence of 
CAD, 11 of whom had documented CAD (mean EF 43 ± 8%), and 16 of 
whom had normal resting systolic function (control, mean EF 58 ± 7%). 
Simultaneous beat-to-beat blood pressure, end-systolic and end-diastolic 
dimension, circumferential velocity of fiber shortening (Vcf), and end-systolic 
wall stress (ESWS), were calculated for all pts. 
Results: All 3 groups demonstrated a significant linear relation be- 
tween beat-to-beat Vcf, and Vcf corrected for afterload (represented as the 
Vcf/ESWS ratio) and preceding cycle length, p = 0.001. There was however 
no difference in the rate of change in either Vcf or Vcf/ESWS ratio from 
beat-to-beat among the 3 groups (Figure). Controls demonstrated greater 
Vcf at any given cycle length compared to CMP patients. 
/ • 
Conclusions: Our data suggest that, for each beat in AF, contractile 
function is decreased after shorter cycle lengths and increased after long 
cycles, but that there is no significant attenuation of this relation in patients 
with CMP or CAD compared to controls. Thus, the negative interval-force 
relation, the predominant determinant of beat-to-beat variation in contractility 
in AF, is preserved in the presence of CAD or left ventdcular dysfunction. 
~ - ~  Peripheral Endothelial Function is Vascular 
Abnormal After Cardiac Transplant in Ischemic but 
not in Nonischemic Cardiomyopathy 
Ayan R. Patel, Jeffrey Kuvin, Marvin A. Konstam, John J. Smith, James 
E. Udelson, Richard D. Patten, Natesa G. Pandian, Richard H. Karas, 
Michael E. Mendelsohn. New England Medical Center, Boston, MA, USA 
Background: Coronary and peripheral vascular endothelial dysfunction (ED) 
is associated with early atherosclerosis and is present in CHF patients with 
both ischemic (IC) and nonischemic (NC) cardiomyopathies. Although core- 
nary ED has been demonstrated in both IC and NC patients following cardiac 
transplantation, the degree to which peripheral ED persists after transplan- 
tation in IC versus NC has not been compared. 
Methods: Brachial artery dilatation during reactive hyperemia and after 
sublingual nitroglycerin was evaluated post-transplant by high-resolution ul- 
trasound in 8 patients with IC and 7 patients with NC. Control data were 
obtained from 5 normal subjects. 
Results: IC and NC subjects were similar in baseline characteristics 
including time since transplant (IC, 34 ± 11 months; NC, 33 • 16); total, LDL, 
and HDL cholesterol levels; lipid-lowering therapy, hypertension, diabetes 
and smoking. Endothelium-independent vasodilation was similar in IC and 
NC. Hyperemic vasodilation was impaired in IC but not in NC: 
25 
~ 2o 
"-.-~ 10 
IC NC Control 
Conclusion: Peripheral endothelial function is impaired after transplant 
in IC patients but not in NC patients. These findings contrast with reported ED 
in CHF and suggest that peripheral endothelial dysfunction may normalize 
after transplant in patients with nonischemic cardiomyopathy. 
• Long-term Survival of Patients With Severe Left 
Ventricular Dysfunction and Multivessel Coronary 
Artery Disease: 5-Year Results of the High Risk 
Myocardial Ischemia Trial 
Eric J. Velazquez, Mitchell W. Krucoff, Robert H. Jones, Suzanne W. Crater, 
Cynthia L. Green, Vic Hasselblad, Eugenia Bastos, Chades B. McCants, 
Robert M. Califf, Christopher M. O'Connor. Duke Clinical Research Institute, 
Durham NC, USA 
Background: The survival benefit of revascularization for ischemic heart 
failure is controversial and undefined. The High Risk Myocardial Ischemia 
Trial (HIRMIT) was a prospective, randomized study and registry series 
evaluating the impact of revascularization on survival in patients with iechemic 
heart failure. 
Methods: We prospectively identified 125 patients with low ejection frac- 
tion (EF), clinical heart failure, evidence of ischemia, and recent rejection 
from PTCA, CABG, or transplantation due to perceived high risk. 23 patients 
accepted randomization to either high-risk CABG (7), PTCA (8), or medical 
therapy (8). Of 102 patients who declined randomization and entered the 
registry, 17 underwent CABG and 20 had PTCA within 30 days. Vital status 
at 5 years was obtained for the entire cohort through the Duke Databank for 
Cardiovascular Disease or the National Death Index. 
Results: The randomized and registry groups did not differ regarding 
baseline or outcome variables and thereby were combined for statistical 
analyses. Median EF for all patients was 21%. The 5-year survival rates (with 
95% CI) were 38.5% (25.2-51.7%) for the revascularization group and 28.8% 
(18.4-39.2%) for the medical cohort (p = 0.26). Survival rates for patients 
receiving CABG were 41.7% (21.9-61.4%), PTCA 32.1% (14.8-49.4%), and 
medical therapy 28.8% (18.4-39.2%) (p = 0.47 across groups). 
Conclusion: HIRMIT is the only known prospective, randomized trial 
of revascularization in ischemic heart failure. HIRMIT shows the feasibility 
and necessity of a larger trial of revascularization versus medical therapy in 
patients with low EF, coronary artery disease, and clinical heart failure. 
1049-10 1 More Severe Disease Does not Coronary Artery 
Result in Worse Left Ventricular Systolic Function 
in Patients With Type 2 Diabetes 
Francois Ledru, Salvatore Battaglia, Fabrice Beverelli, 
Marie-Th~r~s Guillanneuf, Pierre Ducimetiere, Jean-Leon Guerrnonprez, 
Beno~t Diebold, Didier Blanchard. Broussais Hospital, Paris, France 
Background: Non insulin-dependent diabetes mellitus (NIDDM) is asso- 
ciated with increased severity of coronary artery disease (CAD) as well as 
increased incidence of heart failure. Relationship between coronary anatomy 
and left ventricular (LV) systolic function in these patients, as compared to 
non diabetic patients (pts), is not yet known. 
Method: We prospectively recruited 537 pts (61 ± 10 y.o., 82% males) 
free of any previous CABG or PTCA, idiopathic cardiomyopathy or valvular 
heart disease and carefully assessed clinical history and status and med- 
ication intake. CAD severity and LV systolic function were assessed by 2 
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independenl observers 1rum l~e coronary and L'O ang)ograms. A coronary 
(number of coronary segments with >_25% stenosis, adjusted to 15 segments) 
were derived. Angiographic LV ejection fraction (LVEF), end-diastolic (EDV) 
aro' eno'-svs(o{'(i:: E'~'[  va(umes sewe(Y as ~e svs(o((b (undO(On (nob×es. 
Results: Non diabetic and NIDDM pts were similar in terms of age, sex 
ratio, risk factors, clinical status, medication intake except that hypertension 
and hypertriglyceridemia were more frequent in NiDDM pts. Compared to 
n©n d)a'De'i~c p'~S, %'~ '~ 71'~s %ab.orea'~er scores o') £_.,~) - C~') .h~ ~Y ") .D2 "~S 
0.91 ± 0.98 (p = 0.02), ES 5.4 ± 4.0 vs 3.7 ± 3.2 (p = 0.0001 ), occlusion rate 
LVEF62 ± 14% vs 61 ± 14% (p = 0.47), EDV77 ± 23 ml/m2 vs 80 ± 27 
ml/m2 (p = 0.44) and ESV29 ± 16 ml/m2 vs 33 ± 22 ml/m2 (p = 0.07). No 
interaction between any of the CAD scores and LV systolic function indexes, 
NIDDM status and any clinical data were significant. 
Conclusion: Compared to non diabetic patients, NIDDM patients have 
a more severe CAD that does not result in worse indexes of LV systolic 
function. 
~ T h e  Role of Carotid Atheroscterosis in the 
Distinction Between Ischemic and Non-lschemic 
Cardiomyopathy 
Aristidis Androulakis, George Andrikopoulos, Dimitrios Adamopoulos, 
Dimitrios Richter, Konsantinos Tentolouris, Athanasius Trikas, 
Ch~'~r~ 'Or'rso'r)oou, ~')Trf~ios l~ark~Ju, ~T~at~r'~rft A~je]oTzd~ou, 
C~fr~qe~d~os &elarra~')s, .Jt.,'rrn ~rd 'os ,  'P"d,,t~os "TrJU~OLTZ'as. $1E~e and 
University Cardiac Departments, Hippokration Hospital, Athens, Greece 
EBackaround: The distinction between ischemic from dilated cardiom.v.ooa- 
thy (DCM) is sometimes clinically impossible. We examined the prognostic 
accuracy of carotid artery disease in distinguishing coronary" artery disease 
(CAD) or DCM as the cause of clinically undetermined congestive head 
fe ;~ ~C~F~. 
Methods: Forty-three consecutive pts with clinically unexplained CHF 
were enrolled during the last 20 months. Detailed history, clinical and labora- 
tory evaluation were not suggestive of previous myocardial infarction, angina 
mr ceha~n con6~iiens r~)~eb'~o carb~omye.~Da'[n)es. ~on eS"n~.. "~ey "&"nab en- 
larged left ventricles with poor global systolic function and absence of any 
valvular, pericardial, congenital heart disease or cardiac markers of systemic 
c~)sease. ~l).~5~s ~nberwefit car{Ybb scan anb catboat calnehehs~i'hon. 
Results: Demographic, clinical, classical CAD risk factors, ECG and 
no CAD patients. 
DCM (n = 30) CAD (n = 131 P value 
Age (years) 57 ± 11 61 -E 12 NS 
~ex ~ ?#E }' 2279 P 2,> ~ ' < ~q ,981~ 
~mok~ng ?2 7 ~S 
LVEDD (mm) 66.2 ~ 5,8 64.9 ± 4 NS 
Ejection fraction (%) 27 ± 6 26 ± 6 NS 
Carotid Plaques 1 13 <0.001 
Carot)O steno'~)s > 5D% O 6 <D.DD1 
Conclusion: The presence of carotid artery atherosclerosis is extremely 
sensitive {senooitNity = 100%) and spedlic (spedlicity = 97%) to indicate 
severe CAD as the underlying cause of CHF in patients with clinically unde- 
termined left ventdcular dysfunction. 
I1049-121 and Global of the Left Regional Hypoperfusion 
Ventricle fn Congestive Heart Failure 
M. Ciopor, P. Kaufmann, G.K. yon Schulthess, O.M. Hess. University 
Hospital, ZOrich and Inselspital, Bern, Switzerland 
Background: Myocardial hypoperfusion with subendocardiat ischemia plays 
an impodant role in the progression of heart failure (CHF). Thus, regional 
and global coronary flow was determined in patients with severe CHF using 
positron emission tomography (PET). 
Methods: Myocardial blood flow was measured in 25 patients using 
13N-ammonia at rest and during maximal vasodilation with dipyridamole 
(0.57 mg/kg iv.). 10 patients presented with CHF due to dilated cardiomy- 
opathy (DCM, age 55 ± 12), 5 patients with CHF due to coronary artery 
disease (CAD, age 46 ± 17) and 10 served as controls (age 35 ± 17). Re- 
gional coronary flow reserve (CFR = hyperemic flow divided by resting fbw) 
was assessed in 3 planes (apical, midventricular and basal) and 4 regions 
(sept& anterior, lateral and inferior). Patients with CHF had severe LV dys- 
function (ejection fraction 27 ± 8% resp. 22 ± 6%) despite triple therapy with 
ACE-inhibitors, diuretics and digitalis. 
Results: Resting flow was 0.767 ml/g/min in controls, 0.654 ml/g/min in 
DCM and 0.390 ml/g/min in CAD (p < 0.001), respectively. Coronary flow 
increased S~gfi)11can'~)y a11er dipyf)damole 13.OTB m),'~m)n )n con)to)s) but 
CFR was 4.214 in controls, 1.691 in DCM (p < 0.0001) respectively 1.280 
in CAD (p < 0.001 vs. controls). The coefficient of vanation (SD/mean) for 
re~bna(oerrus(bn amount'e¢ fod'. r3f  {h con(rots, d.~rZ lh OCr, K (ns vs. CAOf, 
respectively 0.448 in CAD (p < 0.05 vs. controls). 
Conclusion: There is marked hypoperfusion of the left ventricle in patients 
with CHF, probably due to the increased extravascular resistance and the 
rat e'/)cal)on o1'l~)e su£D')#~n~ a~ef)es. ')-3,vT)opef)us;)on )s e~en more mah{e# ~n 
patients with head failure and CAD due to the obstructions of the coronary 
Thus, reduced myocardial perfusion seems to play a crucial role in the 
symptomatology and pathogenesis of congestive head failure. 
~ Insulin Resistance in Patients With Idiopathic 
Dilated Cardiomyopathy Assessed by 
Fluorodeoxygiucose Positron Emission 
Tomography Imaging: Implications for Metabolic 
Intervention? 
Hans-Marc J. Siebelink, Ad F.M. van den Heuvel. Paul K. Blanksma, Dirk 
J. van Veldhuisen, Willem Vaatburg, Harry J.G.M Crijns. University Hospital 
Groningen, The Netherlands 
Background: insulin resistance may reduce glucose uptake in dysfunctional 
myocardium in patients with idiopathic dilated cardiomyopathy (IDC). There- 
fore myocardial glucose uptake might be influenced by metabolic imaging 
conditions. 
Methods: Myocardial glucose uptake with 18-Fluorodeoxyglucose (FDG) 
pog~lron erfllss~onqomogralbny ~magmg was t~tub~eU ~nq'z consecdtlve'TIX,- 
patients during hyperinsulinemic euglycemic glucose clamp (clamp) and 
compared to 17 IDC-patients who underwent FOG imaging with oral glucose 
loading (load). 
Results: Acje (46 +_ 15 vs 46 +_ 14~ and [eft ve~tricu[~ eiect~en fraction 
(LVEF) (27 ± 10% vs 34 ± 15%) were not statistically different in both 
groups (load and clamp resp.). In load a positive correlation was observed 
between FDG-uptake and LVEF (r = 0.37, p = 0.15), while in clamp a negative 
(FDG= 0.82 LVEF + 30.5) and clamp (FDG= -0.50 LVEF + 76) were 
significantly different by ANOVA (p = 0.031. For patients with LVEF < 30% a 
vs 64.9 ± 19.9 ~mol/min/100 g, p = 0.07, load and clamp resp.). 
metabolic imaging conditions. Difference between load and clamp can be 
explained by insulin resistance predominantly present in IDC-patients with 
lower LVEF. With clamp insulin resistance was cimumvened and preserved 
gliJcose uptake was di~monstrated in d~,stunctibnar myocardium. These re- 
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I1  41 Endothelin is Activated to 080-  1 Pr ior  the 
Renin-Angiotensin-Aldosterone System During 
the Evolution of Congestive Heart Failure 
Horng H. Chen, John S. Schirger, William L. Chau, Gall J. Harry, 
Michihisa Jougasaki, John C. Burnett Jr.. Mayo Clinic, Rochester, MN, USA 
Background: Repeated studies have established a concept that activa- 
tion of sodium retaining and renal vasoconstricting neurohumoral systems 
contribute to the transition from compensated ventricular dysfunction to 
overt congestive heart failure (CHF) resulting in avid sodium retention. Both 
renin-angiotensin-aldosterone system (RAAS) and the endothelin lET) sys- 
tem are sodium retaining, but the temporal activation of each during the 
progression of CHF remains poorly defined. 
Methods: Using a canine model of progressive CHF produced by rapid 
ventricular pacing over 38 days (n = 5), which evolves from compensated 
ventricular dysfunction to overt CHF, we defined the temporal activation of 
the ET and RAAS systems as they relate to the onset of sodium retention 
during the progression of experimental CHF. Ventricular pacing was initiated 
at 180 bpm for 10 days and then increased at 7-day intervals to rates of 200, 
210, 220 and 240 bpm. 
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Results: Sodium retention occurred midway during the fourth week of 
CHF with a decrease of urinary sodium excretion from 67 ± 15 to 22 ± 2 
/~Eq/24 hr (p < 0.05) in association with a selective increase in circulating 
ET from 8.4 ± 0.9to 15.7 ± 2.9 pg/ml (p < 0.05). Both sodium retention and 
ET activation occurred in the absence of increases in plasma angiotensin II 
(ANG II) or aldosterone, with no changes in renal cortical or medullary ANG 
II tissue concentrations. 
Conclusion: We report for the first time that during the progression of 
experimental CHF, sodium retention and ET activation occur prior to RAAS 
activation. These findings underscore a role for ET in contributing to the 
onset of sodium retention in CHF. Additionally, this study suggests that ET 
antagonism could be employed early in the course of CHF since ET activation 
precedes activation of the RAAS. 
• Early, Long-Term Therapy With Bosentan 
Prevents Progressive Left Ventricular Dysfunction 
and Dilation in Dogs With Moderate Heart Failure 
Takayuki Mishima, Mitsuhiro Tanimura, Sidney Goldstein, Hani N. Sabbah. 
Henry Ford Heart & Vascular Institute, Detroit, MI, USA 
Background: Acute administration of bosentan (BOS), a combined endothe- 
lin-1 ETA and ETB receptor antagonist, was shown to improve LV function 
in in patients and dogs with heart failure (HF). In this study, we examined 
the effects of early, long-term therapy with BOS on the progression of LV 
dysfunction and dilation in dogs with moderate HF. 
Methods: LV dysfunction (ejection fraction, EF = 30-40%) was produced 
in 14 dogs by coronary microembolizations. Dogs were randomized to 3 
months therapy with BOS (30 mg/kg Bid, n = 7) or to no therapy at all 
(CONTROL, n = 7). The change (A) in mean aortic pressure (AP), cardiac 
index (CI), LV EF, end-systolic (ESV) and end-diastolic (EDV) volumes, and 
plasma norepinephrine (PNE) between pro- and post-treatment are shown 
in the table. 
Results: In CONTROL dogs, LV EF and CI decreased and LV volumes 
and PNE increased after 3 months of follow-up. BOS increased CI and 
prevented the decline in EF and the increase in EDV, ESV and PNE. 
CONTROL BOS P-value 
Mean AP (mmHg) 1.4 ± 4.0 - 1.0 ± 3.0 0.640 
CI ([/min/m 2) -0.4 ± 0.1 0.7 ± 0.3 0.005 
A LV EF (%) -6 ± 1 5 ± 2 0.001 
b. LV EDV (ml) 13 ± 6 -4 ~- 2 0.020 
A LV ESV (ml) 14 ± 5 -5 • 1 0.003 
A PNE (pg/ml) 118 :E 28 21 ± 59 0.04"7 
Conclusion: In dogs with moderate HF, long-term therapy with BOS 
prevented progressive LV dysfunction and dilation. These results support the 
use of nonselective endothelin-1 receptors blockade in HF. 
• Impaired Intravascular Conversion and Clearance 
of Big Endothelin-1 in Experimental Heart Failure 
Andreas Luchner, Michihisa Jougasaki, Denise Heublein, John C. Burnett 
Jr.. Mayo Clinic, Rochester, MN, USA 
Background: Big Endothelin-1 (Big ET-1) isa 38 amino-acid peptide which is 
converted to Endothelin-1 (ET-1) by Endothelin Converting Enzyme (ECE). 
ET-1 has been shown to be strongly activated in congestive heart failure 
(CHF) and mediates vasoconstriction and cardiac and renal dysfunction. To 
date, ECE-activity and the clearance of Big ET-1 have not been determined 
in CHF, although ECE-inhibition has been advanced as therapeutic strategy 
to antagonize the ET-system in CHF. 
Methods: To assess ECE-activity as well as metabolic clearance of Big 
ET-1 in experimental CHF during steady state conditions, Big ET-1 (50 
ng/kg/min i.v.) was infused into control (n = 5) and CHF dogs (n = 6, 3 weeks 
of rapid ventricular pacing at 245 bpm). ECE-activity was calculated as "Er-I 
/ Big ET-I" as assessed with sensitive and specific radio-immuneassay and 
metabolic clearance rate of Big ET-1 as "infusion rate / ([Big ET-1 infused 1 - 
[Big ET-1 baseline])". 
Results: CHF was characterized by decreased arterial pressure (100 ± 
5 mmHg vs. 139 ± 8, p < 0.01), decreased cardiac output (2.0 ± 0.3 L/rain 
vs. 4.3 ± 0.3, p < 0.01), increased cardiac filling pressures (PCWP 25.3 ± 
3.9 mmHg vs. 3.5 ± 0.8 and RAP 9.9 ± 1.4 vs. -1.6 ± 0.8, both p < 0.01), 
and renal sodium retention (UNaV 3.2 ± 1.1 umol/min vs. 47.1 ± 19.5, p 
< 0.04). While Big ET-1 concentrations at baseline were unchanged (37.0 
± 5.2 pg/ml vs. 38.4 ± 4.7, p = n.s.), Big ET-1 increased markedly greater 
in CHF as compared to control during Big ET-1 infusion (2610 ± 247 pg/ml 
vs. 629 ± 55, p < 0.01). In contrast, the increase of ET-1 during infusion of 
Big ET-1 was attenuated (96.2 ± 13.7 pg/mL vs. 175.9 ± 41.9 in control, p 
= 0.06). Consequently, ECE activity (0.04 ± 0.01 vs. 0.27 ± 0.05, p < 0.01) 
and metabolic clearance rate of Big ET-1 (20.8 ± 2.5 ml/min/kg vs. 87.7 ± 
9.1, p < 0.01) were markedly attenuated in CHF. 
Conclusions: The current studies are the first to demonstrate in-vivo 
regulation of intravascular Big ET-1 clearance and ECE-activity in CHF. The 
finding of an attenuated Big ET-1 clearance and ECE activity suggests that 
ET receptor antagonism rather than ECE inhibition may be the superior 
therapeutic strategy in CHF when attempting to suppress the ET system. 
~ Endothelin Type Receptor-Dependent Signaling A 
Pathways Inhibit/~-Adrenergic Agonist-lnduced 
Apoptosis in Cardiac Myocytes 
Makoto Araki, Koji Hasegawa, Eri Iwai-Kanai, Masatoshi Fujita, 
Tatsuya Sawamura, Satoshi Kaburagi, Shigetake Sasayama. Kyoto 
University, Kyoto, Japan 
Background" Cardiac expression of endothetin-1 (ET-1) is markedly acceler- 
ated in various types of heart failure. However, ET-1 's regulation of apeptosis 
in post-mitotic cell type is unknown. 
Methods: Primary cultured cardiac myocytes from neonatal rats were 
stimulated with a ~-adrenergic agonist (Isoproterenol, Iso) or a membrane- 
permeable cAMP analogue (8-Br-cAMP) for 48 hours. 
Results: Iso and 8-Br-cAMP markedly increased the number of TUNEL- 
positive cells (% TUNEL-positive nuclei > 40%) compared with saline stimula- 
tion (<10%). Apeptosis was also confirmed by DNA fragmentation in agarose 
gels and morphologic features. Administration of 10-rM of ET-1 completely 
blocked Iso-induoed myocardial cell apoptosis. An ETA receptor antagonist 
FR 139317 completely negated ET-I's inhibitory effect of apoptosis while ETB 
receptor antagonist BQ788 was unable to achieve this response. ET-1 also 
inhibited apoptosis induced by 8-Br-cAMP which bypassed Gi, suggesting 
a rote of Gq downstream pathways rather than that of Gi. The apeptotic 
inhibitory effect by ET-1 was neutralized by PD098059 (MEK-l-specific in- 
hibitor) and by Wartmannin (PI3-kinase inhibitor), smilar with the data in other 
cell type. In contrast, ET-I's inhibition of apoptosis was negated by rapamycin 
(p 70 S6-kinase inhibitor) in cardiac myocytes but not in PC12 cells. 
Conclusion: These findings suggest that ET-I's inhibition of myocardial 
cell apeptosis is mediated mainly through ETA-dependent pathways and 
that this inhibition in cardiac myocytes requires multiple signaling pathways 
distinct, in part, from those in other cell type. 
~ Correction of Endothelial in Rats Dysfunction 
With Chronic Myocardial Infarction by Treatment 
With Endothelin Receptor Antagonists 
Johann Bauersachs, Daniela Fraccarollo, Julian Widder, Georg Ertl II. 
Medizinische Kiln±k, Universit~tsklinikum Mannheim, Germany 
Background: Endothelial dysfunction of the vasculature contributes to the el- 
evated peripheral resistance in congestive heart failure, and can be improved 
by treatment with angiotensin converting enzyme inhibitors. The effect of en- 
dothelin (ET) receptor antagonists, which prolong survival in experimental 
chronic myocardial infarction, on endothelial function in heart failure, how- 
ever, has not been elucidated yet. 
Methods: In the present study, dilator responses were determined in 
aortic rings of Wistar rats with experimental heart failure 12 weeks following 
myocardial infarction (HF) and compared to sham-operated animals (SHAM). 
Rats were either treated by gavage with placebo (HF-P, SHAM-P), with the 
ETA-receptor antagonist LU 135252 (30 mg/kg body weight/day, starting on 
the 7th postoperative day, HF-L, SHAM-L) or with the non-selective ET- 
receptor antagonist Bosentan (100 mg/kg/day, HF-B, SHAM-B). Infarct size 
(>45% of left ventricle) was matched between HF-P, HF-L and HF-B. In order 
to exclude acute effects of the study drug, treatment was stopped one day 
before the organ bath studies. 
Results: In HF-P, the concentration-response curve of the endothelium- 
dependent, acetytcholine-induced relaxation (following preconstriction with 
phenylephrine) was significantly shifted to the right and the maximum relax- 
ation was attenuated (ED5o (-log) 6.58 i 0.07, Rrn~ 86 ± 3%) as compared 
to SHAM-P (7.12 ± 0.05, 97 ± 1%). Treatment with LU 135252 as well as 
Bosentan significantly improved acetylcholine-induced relaxation (SHAM-L 
ED5o 7.02 ± 0.09, amax 95 ± t%; HF-L 7.01 ± 0.06, 96 ± 1%, SHAM-B 6.97 
± 0.08, 92 ± 1%, HF-B 6.84 ± 0.06, 94 ± 2%). Endothelium-independent 
relaxations induced by sodium nitroprusside were similar in all groups of rats. 
Conclusion: These results for the first time demonstrate the correction 
of endothelial dysfunction in chronic myocardial infarction by treatment with 
ET-receptor antagonists which may contribute to beneficial effects of these 
drugs in heart failure. 
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1080-1 9 I of Endothelium Nitric Oxide Overexpression 
Restores Relaxation in the Hindlimb Vasculature 
After Myocardial Infarction 
Medical Center and University of Arizona Heart Center, Tucson AZ, USA 
is attenuated in both large and resistance arteries. The mechanisms of this 
Methods: To determine if the attenuated vasorelaxation after MI is due to 
dcwnrec~utation feNOS protein, immunobto~nq and qene t~nsfer of eNOS 
adenoviral vector (1.2 x 109 Pfus) containing cDNA encoding the eNOS 
Rasulta: Five days after infection, overexpression was confirmed by 
immunohistochemical staining and immunoblotting. Recombinant gene ex- 
pression was localized to the vascular endothelial ceils. ENOS protein level 
P < 0.06) and increased two fold (4.3 ± 1.2 intensity units/pg protein, n = 
5) after gene transfer. Acetylcholine (ACh)-stimulated vasorelaxation in the 
hindlimb was decreased (P < 0.05) by 30% after MI and was restored to nor- 
mal in MI rats transfected with eNOS. Addition of 100/zM Ne-nitro-L-arginine 
methyl ester (L-NAME} abolished the difference between sham, MI, and MI 
transfected rats. 
Conclusion: The attenuated NO-mediated vasorelaxation in the hindtimb 
after MI is due to a downregulation of eNOS protein. Overexpression of eNOS 
restores the ACh-mediated vasorelaxation. 
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~ Evidence for a Heart Failure Epidemic: Findings 
from the REACH Study 
Peter A. McCullou~h, Udava Cinqireddy, Edward F.]:'hllbin, W. 
Douglas Weaver. Henry Ford Health System, Detroit, Michigan, USA 
I~ackaround: Sources of e.pidemioloqical idformation on con qestive heart 
failure (CHF) in the U.S. have indicated increases in the frequency of CHF 
real community health system impact of CHF is still largely unknown. 
Methods: The R__e_esource Utilization Among Congestive H_eart Failure 
Study is an epidemiological study with the aim of describing the health sys- 
tem impact of CHF in order to plan for future resource allocation and develop 
population-based care management. We developed and validated an elec- 
tTonic dia~os~ o1 CHF based on clinical e~cot~ers cod,~{ by" physicians 
for CHF and its related ICD-9 groups. 
Results: Since 1989, 26,442 index cases of CHF were identified. The 
mean annual incidence was 5 per 1000 health system pa~ents. The annual 
prevalence rose from 9 to 20/1000 over 9 years, p < 0.0000001. The figure 
below illustrates an incidence-prevalence diversion in absolute cases. 
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Conclusions: We conclude there is an increase in the CHF prevalence 
pool which can be considered a chronic disease epidemic experienced by 
large health systems across the U.S. today. This calls for epidemic resource 
planning and management on the provider, health system, and national level. 
~ Does Patient Race Influence Utilization of Effective 
Medical Therapy for Heart Failure? 
Kishore J. Harjai, Eduardo Nunez, Mehul Shah, Jeff Newman. Ochsner 
Medical Institutions, New Orleans, LA, USA 
Background: Previous studies have shown underutilization of effective treat- 
ment modalities in African-American patients with coronary artery disease. 
We sought to evaluate if a similar bias existed in utilization of medical therapy 
for symptomatic heart failure. 
Methods: In 577 consecutive adult patients discharqed alive from the 
r~ospffar w~th a pnhcFpar dragnos~s offlear( (affure, we compared oiP, charge 
medications between white (n = 385) and non-white patients (n = 192, 
Results: White patients were older (72 vs 66 years), more likely to have 
P-~owo. CAO (46 ,cs 2e%L at~al f~t~d~,~x <S~ vs ~8%~, ~ I~ss ~k~,y t~ 
have systemic hypertension (51 vs 63%). At the time of hospitalization, white 
9at~ents had lower s~to#c (133 vs 145 mm htQ~t and diastolic (75 vs 83 mm 
LV end-diastolic diameter (5.3 vs 5.6 cm). At hospital discharge, the frequen- 
nitrate), digoxin, diuretics, and combination therapy (i.e digoxin + diuretic 
+ vasodilator) were 66, 72, 63, 93, and 50% respectively. After adjustment 
for age, gender, and clinical variables, non-white face was associated with 
1.2-2.7), vasoditators (OR = 1.7; 95% CI = 1.2-2.6), and combination ther- 
apy (OR = 1.9; CI = 1.2-2.8). No significant association was seen between 
race and utilization of digoxin or diuretics. In multivariate analyses of subsets 
of patients with known LV ejection fraction (LVEF; n = 429), and those with 
known LVEF _< 45% (n = 294), patient race showed no significant association 
with utilization of any of the medications. 
Conclusions: Our study does not support the presence of bias against 
African-American patients in the utilization of effective medical therapies for 
symptomatic heart failure. 
~ A  Population Based Study on Congestive Heart 
Failure Admissions in the Largest Italy Region 
Edoardo Gronda, Maria Frigerio, Maunzio Mangiavacchi, Fabrizio Oliva, 
Bruno Andreuzzi, Gabriella Comerio, Marco Paolucci, Rita Ciliberto, 
Pietro Barbier0. Cardiology Department A. De Gasperis, Niguarda, Ca' 
Granda Hospital," i Istituto Di Biometria, Universita di Milano, Italy 
Background: Congestive heart failure (CHF) is a major public health prob- 
lem; no uPdated information is available in Europe about incidence of hospital 
admissions in the whole population. 
Method: The Lombardia Regional Database of hospital records (Sistema 
Informative e Controllo di Qualit& Bureau) provided the requested informa- 
tion: all the CHF cases admitted in all the institutions of the region were 
The available data included: diagnoses and surgical procedures (up to 4), 
date of birth, admission and discharge, outcome, DRG code, discharge unit 
..P-D.ELR, ~ , r  ~rta.ta vr'.htaiP, zf,r.P,,~P.r.tn,b-qFt~ital.dL%ct:lar.~,Jo .lfiL°~3Qd ,lfiLq7. 
Results: 32093 cases (males 16066) in 1996 and 34948 cases in 1997 
"~mdles~i"73^de) w re sdlec~e~.l'~ean ge were~8.h ±'dl Yere Tnd~es and?d'u:6 
± 10.7 in females in 1996 while were 71.8 ± 11.7 in males and 78.3 ± 10.6 in 
females in 1997. The distribution of cases by DRGs is depicted in the table. 
1996 1997 
DRG Proportion of Mortality Proportion of Mortality 
cases cases 
f 2T (CHF~ 56. 7% 7.~% 58.9% 8.~% 
121,122, 123 (AMI) 7.3% 15.0% 6.6% 15.7% 
Others 36.0% 14.9% 34.5% 14.B% 
In 1997 the in hospital mortality was 14.7% in patients (pts) over 80 y.o., 
9.6% in pts between 71 and 80 y.o., 7.4% in pts between 61 and 70 y.o. and 
6.9% in pts under 61 with the exclusion of pediatric cases. The in hospital 
mortality was different between discharge units: 2.8% in pts discharged from 
cardiology units and 10.3% in pts discharged from general medicine units. 
Readmission rate at 1 month was 5.2%. and 14.3% within 1 year. 
Conclusions: CHF mortality differences between hospital units are not 
explained by age and may be related to different incidence of medical condi- 
tions. The readmission rate appears lower than in previous reports. 
~ Natural Clinical Outcomes in Heart History and 
Failure: Report From a Community Hospital-Based 
Registry 
Edward F. Philbin, Thomas A. Rocco Jr, Norman W. Lindenmuth, 
Kathleen Ulrich, Maureen McCall, Paul L. Jenkins. Henry Ford Hospital 
Detroit, MI; Park Ridge Health System, Rochester, NY, USA 
Background: Natural history information is useful to HF specialists, though 
most recent data have come from large clinical trails with selective inclusion 
criteria. We now report trends from a community-based registry. 
Methods: We compiled data on 2,906 unselected patients with confirmed 
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HF admitted to 10 community hospitals in New York State between 1995 and 
1997. Patients were followed for 6 months after their index discharge. 
Results: Patient demographics in our sample were representative of 
other large hospital-based HF cohorts in terms of mean age (76 years), sex 
(56% female) and extent of comorbid illness, in our sample, mean length of 
stay was 7.4 days; mean hospital charges were $7,507. Death rates during 
the index admission and follow-up period are shown in the Table. Despite 
mean NYHA functional class falling from 3.4 in the hospital to 2.2 immediately 
after discharge, 46% of hospital survivors had at least one readmission for 
any cause during the follow-up period and 26% had at least one readmission 
for HE The mean time from discharge to the first readmission was 59 days. 
Overall, 54% of the 2,906 patients died or were rehospitalized within 6 months 
of being admitted for HE 
Cause of Death Index Admission Post-Discharge Cumulative 
Progressive HF 3.7% 7.9% 11.6% 
Other causes 1.7% 8.3% 10 1% 
Total mortality 5.4% 16.4% 21.8% 
Conclusions: In spite of advances in the management of HF, patients 
recently hospitalized for this disorder remain at high risk for death, hospital 
readmission and poor clinical outcome. Thus, discovery and implementation 
of new methods of prevention and treatment should remain a high priority. 
~ W h a t  Are the Major Hospital Determinants of 
Charges for Heart Failure? an Analysis of 
Administrative Data 
Edward F. Philbin, Thomas G. DiSalvo, Paul L. Jenkins. Henry Ford 
Hospital, Detroit, MI; Massachusetts General Hospital, Boston, MA, USA 
Background: Hospital charges are responsible for most of the extraordinarily 
high cost of heart failure (HF) care. 
Methods: We examined data for 43,157 patients who were admitted 
with a primary diagnosis of HF to New York acute care hospitals during 
1995. Hospital characteristics, patient demographics, procedure use, and 
clinical factors including comorbid diagnoses and outcome were examined 
as potential determinants of hospital charges using multiple linear regression. 
Results: Mean patient age was 74 ± 13 years; 57% were female. Mean 
length of stay was 10 ± 14 days and mean total hospital charges were 
$11,507 ± 15,995. The best model for charges, selected when overall r 2 
increased <0.004 upon addition of another independent (predictor) variable, 
had an r 2 = 0.65. The predictors retained in this model and their • coefficients, 
all positive in their association with charges, are shown in the Table. Because 
<1% of patients underwent cardiac surgery, a second model omitting it was 
also derived. The second model had an r 2 = 0.63; its significant predictors 
are also shown in the Table. 
Predictors in Model 1 # Predictors in Model 2 ,~ 
Length of stay 795 Length of stay 804 
Any cardiac surgery 44,506 Mechanical ventilation 6,403 
Mechanical ventilation 7,097 Cardiac catheterization 7,049 
Teaching hospital 3,317 Pacemaker placement 13.540 
Pacemaker placement 12,389 Teaching hospital 3,264 
Patient treated in ICU 2,870 Patient treated in ICU 2,873 
Swan-Ganz catheterization 8,546 
Conclusions: Hospital charges for HF are higher in teaching hospitals 
but are mostly driven by length of stay and high-technology care. Physician 
specialty and patient factors such as age, race, gender, comorbid diagnoses 
and mortality appear to have less influence on charges. 
• Self-Management Practices, Quality Life, of and 
Healthcare Resource Utilization in Patients With 
Chronic Heart Failure 
Christi Denton, Laura Jacobson, Dee Anderson, Andrew L. Smith. Emory 
Universi~ Atlanta, GA, USA 
Background: Heart failure is a significant problem, and patient self-man- 
agement may reduce morbidity and health-care costs. The study aim was to 
determine the relationships among self-management, quality of life (QOL), 
and healthcare resource use in 161 previously diagnosed heart failure (CHF) 
patients referred to a CHF clinic. 
Methods: Clinical data, Minnesota Living with Heart Failure Questionnaire 
(MLHFQ) and knowledge/behavior questionnaire at initial visit; with univariate 
analysis of variables. 
Results: Mean age 54.5 (± 14) years, 42% female, primarily NYHA 
Class Ill or IV. When asked to identity worsening CHF symptoms, 58% did 
not choose any on a list, 32% identified increased dyspnea, and 3% chose 
weight gain >_ 4 pounds. Only 50% weighed daily, but the majority limited 
salt and liquid intake. Mean scores on MLHFQ subscates indicated high 
impairment and poor QOL. 52% had been hospitalized at least once (mean 
2.2 ± 2.2) and 48% had an emergency department (ED) visit during the last 
six months for CHF. Patients who had been hospitalized were less likely to 
recognize symptoms of worsening CHF than non-hospitalized (39% vs 46%, 
p < 0.05), had worse MLHFQ scores (p < 0.05), and more ED visits (p < 
0.001). 
Conclusion: In spite of significant CHF, the majority did not practice 
appropriate self-management at time of referral. CHF hospitalizations were 
associated with inability to recognize significant symptoms, more ED visits, 
and worse quality of life. 
• Predictors of Incident Congestive Heart Failure in 
the Elderly: Relative influence of Age, Gender, 
Race, and Biological Characteristics 
John S. Gottdiener, Alice M. Arnold, Robed J. Marshall, Gerard 
P. Aurigemma, Julius M. Gardin, John C. Rutledge, Vivienne E. Smith, 
Robin E. Boineau. Georgetown University Medical Center, Washington, DC; 
National Institutes of Health/NHLBI/DECA, Bethesda, MD, USA 
Background: The elderly constitute a growing proportion of pts diagnosed 
with congestive heart failure (CHF). 
Methods: To characterize the predictors of incident CHF (determined by 
central clinical adjudication) in community-based elderly, we analyzed data 
from the Cardiovascular Health Study, a multicenter, prospective epidemio- 
logic study of 5,888 participants (ppts) >65 yrs (av 73.5, range 65-100). 
Results: During fotlowup (median 6.3 yrs), 597 ppts developed new 
CHF (rate 19.3/1000 pts. yrs). CHF incidence progressively across age 
groups (e.g. age 64-69:10.6/1000 pt. yrs; age > 80:42.5/1000 pt. yrs, 
p < 0.0001 ANOVA), and was greater in men (26.2/1000 pt. yrs) than 
women (14.6/1000 pt. yrs, p < 0.0001 ), but not greater in African-Americans. 
On multivariate analysis other independent predictors (RR: 95% CL) were 
prevalent coronary heart disease (CHD) (1.6; 1.3-2.0), stroke or TIA at 
baseline (1.5; 1.2-2.0), diabetes (1.8; 1.42.2),-systolic BP (1.1; 1.0-1.2/20 
mm Hg), forced expiratory volume 1 sec (FEV1) (0.6; 0.5-0.7/L), creatinine > 
1.4 mg/dl (1.5; 1.2-1.9), C-reactive protein (CRP) > 7.4 mg/dl (1.9; 1.4-2.6), 
ankle-arm index <0.9 (1.6; 1.3-1/9), atrial fibrillation (AFIB) (1.7; 1.2-2.6), 
ECG LV mass (2.9; 2.0-4.1), ECG ST-abnormality (1.5; 1.1-2.0), internal 
carotid wall thickness (1.2; 1.0-1.5), and LVEF (2.4; 1.7-&4). Population 
attributable risk determined from predictor risk and prevalence was relatively 
high for FEV: (13.2%), prevalent CHD (11.6%), systolic BP > 140 mm Hg 
(11.2%), and CRP (9.4%)-but low for EF (3.6%), or AFIB (1.4%). 
Conclusions: Incidence of CHF is high in the elderly, and related to age, 
gender, clinical and subclinical CHD, systolic BP, and inflammation. Despite 
high RR of EF and AFIB, influence of these on CHF is small because of their 
relatively low population prevalence. 
~ Heart Failure Is Due to Diastolic Dysfunction in 
Women More Often Than in Men 
JoAnn Lindenfeld, K. Suzanne Fiske, Jo DeBuhr, Elizabeth R. Stevens, 
Edward P. Havranek, Frederick R. Abrams. University of Colorado Health 
Sciences and Colorado Foundation for Medical Care, Denver, CO, USA 
Background: The prevalence of heart failure in the United States is similar 
in men and women despite a higher incidence in men. Previous studies have 
suggested that diastolic dysfunction is a more frequent cause of heart failure 
in women than men but the frequency of systolic vs diastolic dysfunction by 
gender in a comparable population is unknown. 
Methods: We reviewed a national sample of 2445 hospital admissions in 
medicate patients randomly selected in proportion to each state's population. 
Results: Of these 2445 admissions 1447 had an ejection fraction known 
or measured during the hospitalization. Diastolic dysfunction was determined 
to be present if the EF was > 40%. Patients with an EF > 40% are shown 
by age group and gender. 
Female Male 
All 285/631 (45.1%) 132/653 {20.2%)* 
Age < 65 years 13/13 (41.9%) 10/77 (13.0%)* 
65-69 33/88 (37.5%) 16/82 (19.5%)" 
70-74 57/123 (46.3%) 31/126 (24.6%)" 
75-79 47/115 (40.9%) 30/124 (24.1%)* 
80-84 57/124 (46.0%) 26/80 (28.9%)" 
>85 78/150 (52.0%) 19/61 (31.0%)" 
*p < 0.001 female vs mate 
Conclusions: In this older population women admitted with a primary 
diagnosis of heart failure have an EF > 40% more than twice as often as 
men. While the prevalence of EF > 40% increases with age in both men 
and women admitted for heart failure, EF > 40% is much more common in 
wo~en even Wnen pa't~en~s are dider Ynan ~5. 
• S, vsto))c and D)asto))c Heart Fa))ure Have Sim))ar 
Impact on Hospital Costs 
Don B. Chomsky, Chris Kelly, Jane Smith, Karen Dahle, John R. Wilson. 
Va~derbilt Universi~ Medical Center.. NashvNe, TN, USA 
Effofls to reduce cosls an6 ~mpro'~e qua~2 o'i care ~or heafi fa}~ure have 
focused almost entirely on the patient with reduced left ventricular systolic 
function. Little is known about the relative economic importance of patients 
with heart failure with preserved LV systolic function. The purpose of this study 
was to characterize costs of care in this population. We reviewed all primary 
DRG 127 discharges at Vanderbilt University Medical Center between 4/95 
an~l z~.}~3"~. O~ 529 '[eta) 6~schar#es, 2~2 .162%) ~nvo~ve~pa~en'~s v~)'lh preserve6 
thcse with preserved vs those with reduced systolic function (3% for both 
g rce~, D$).~-~i~les 6"1 r eab#))Sg)Dn wel'e S))-h~)a r b D/Db~TLOID~DS W~) reabrh)S&DnS 
within 1 month of 8% and 12%, respectively (preserved vs reduced systolic 
furnciior)). ~veraae' ienQln 6T sIavlIE'LJ'b,'I anbt0tlir nosDit:~t COgIS were sire'liar 
between the two groups (p = NS for both comparisons), with annual hospital 
costs exceeding $500,000 for patients with preserved systolic function alone. 
There was also no relationship between severity of systolic dysfunction 
and LOS or costs. In summary, patients with heart failure with preserved 
systolic function have similar hospital costs, readmission rates and inhospitat 
Attempts to reduce costs and improve quality of care in heart failure must 
address both populations. 
~ T h e  Prevalence Correlates and Effects of 
Diastolic Dysfunction in an Urban Population 
TLeresa A. McOonag.h, Steghen O. RobO,, Caroline E. Mornson. Hen~ 
J. Dargie. MRC CRI in Heart Failure, University of Glasgow, Scotland, UK 
function in about 40% of cases. There is ;itt'le population-based work on 
dilas%o~>,c hear% ~X~ure ar~6 ~o ,oub~,sb, e6 ep~bem'~e~,o~c@, studies on ~asto%~c 
dysfunction in the general population. 
Methods: We report the prevalence, correlates and effects of abnormal 
men and women aged 25-74, from North Glasgow. Symptomatic was de- 
fimeb as ettner cari~iac b vs!~noea~160tameb'qv guegbonnalrE)) ±hoqp a,urebc 
therapy. Exercise testing was carried out using the STEEP Protocol and BNP 
was measured using a standard rad~oimmunoassay. LV fitting was measured 
using pulsed wave Doppler echocardiography and pure diastolic dysfunction 
free ~ car($}ovaseu',a~ 5 sease w~'r'/m ?5~s popu l iS t ,  n, an6  a 'L'~F_F > "35% 
(Simpson's Rule). 
Results: Diastolic dysfunction (DD) was present in 1.3% (19), 53% were 
male, 36% were symptomatic The prevalence rose with age to 2.1% of those 
>55 years. 67% of those with DD had hypertension (HT), 51% had evidence 
ot ischaemic heart disease tlHD) and 40% had both HT and iHD. DD was 
BNP concentrations (mean ± SEM) were significantly higher in subjects 
with diastolic dysfunction (16.8 pg/ml 4- 4.) cf those with no ventdcular 
dysfunction (9.8 pg/ml 4- 0.36), either systolic or diastolic (p = 0.02). The four 
year all-cause mortality was 20% for pure DD compared to 4.1% in those 
wi~.h no ventricular dysfunction and 21% in ~t'~se wit~ S~stolic dTsfunc~ion. 
Conclusions: Of all the ventricular dysfunction identified in this population 
13% was diastolic in nature. It appears to be associated with impaired 
circulatory function and an increased mortality. 
~ H i g h  Prevalence of Normal Systolic Function in 
Inner City African Americans With Congestive 
Heart Failure 
Thomas D. Stamos, Hashim Shaltoni. Cook County Hospital I Rush Medical 
CCo))goe. Ch)c@oo. )L. "l.)S~ 
Background: The prevalence of congestive heart failure (CHF) with normal 
We studied the frequency of this entity in a population of African American 
patients. 
Methods: Consecutive African American patients, with signs, symptoms 
and a pnmary diagnosis of CHF by their admitting physician, were included 
'm Yne stu0y wnen preserffln9 to Ine echo lab lor evaluation of EV ~unc.ben. 
Patient interview and exam was performed when data in chart was unclear. 
~'a&,~?ac #e~ct d~se,~se ~'~f'e e~ccidd~d. Echo w~s ce~fe~ed (ordetermfnatfon 
of LV function. 
Results: Normal systolic function was found in 40 of the 67 heart failure 
Dat;~ents studied (,6(3%~. Ch~ ~cte~tst~cs %~ D~'Ae~ts ,N~,th r~m~ an~ ~bn~rm~ 
systolic function (fxn) are shown below. 
HTN CAD Diabetes ETOH Use 
Normal txn 92% 27% 50°/° 52% 
Abnormal fxn 85% 18% 30% 70% 
P value NS 0.05 0.01 0.05 
Corlc/usjoJrJ- The prevaleJ3ce of head f~J.uJ'~ ~J~ .nDzmaJ systolic .fJJs~c- 
tion found in this inner city African American population was higher than 
ex qPz1o~d_ b,-2sff~..d_ t-~. rg&u.i c~ l.& r.pJ'g~s. _ T.his. c~P~ f. ~stoJic~ he.,a&faihEP_ miq~5,t. 
be accountedR)r by the high prevalence ofuncontrolled hypertension in our 
qati.e.nt .qo~ Ca.t.Lc~n ._Th e~&eJi.n d~ cb£.hi.ct~ Ij.c~t . b e~n eP,('Lf oz. r te.t eJemi.~i.~ q~l _v.ft n¢.; 
tlan c~rtsl~tertrt~ t i~ elff£ertet~ reatmeett (~t-tie~a~t t tture patteetts ~tth t~oee~t 
and abnormal LV fxn. 
, ~ E f fec t  ~f_a_ Heart_ F_ailu r_e_ P r_qj] m m _~ n 
• ' .t-ln..sl~ital'~zatin p:e, atP~,.a rLd.Mn ddditv.Piate~ 
Simonetta Scalvini, Maurizio Volterrani, Diego Domenighini, Michele Senni, 
Amerigo Giordano. Sa/vatore Maugeri Foundation/RCCS Cardiac 
Rehabilitation dpt Gussago, Brescia, Italy 
Background: Patients (.ptsl with con(lestive heart failure (CHF~ are 0rone to 
repeat" exacerOat'~bns oft'he=i" caroiac e/sease anGfrierefore need recurrent 
and frequent hospitalizations• There is a progressive increase in mortality 
rate associated with more advanced age and the medical care is associated 
with high socioeconomic burden. We conduced a prospective, randomized 
that on the effect of a three month multidisciplinary intervention after hos- 
pital discharge on morbidity, mortality and functional status in a group of 
unselected pts with CHF. 
~t~'#~cc~t~ ". ~d, ~, ~¢J~ Tt~ "~&% ~%T:, ~tr¢r~"~,cdit~ty ~r~ ~I'I~)T~I J~ 
Institute from July 1994 to January 1996, 160 were identified and randomized 
heart ta~,ure Drogram; while the group I5, controls, unde~Nent conventional 
treatment an~ were f~ee t~ receive ~d, icatiens an~3 ~resc~t~ons ~r~m the~'~ 
physicians. All the pts were followed for one year. 
Results: After one year, mortality was 15% in group A and 20% in 
instabilizations were 51% in group A and 56% in group B. VO2 peak increase 
showed a significant increase in mortality and hospitalizations in group B (p 
< 0.01). 
Conclusion: The present study seems to confirm that a multidisciplinary 
I1081-131 of Failure Analysis Congestive Heart Patient 
Preferences for Treatment Outcomes: Symptoms 
• ~ ~ki~,~i,~& 
Me?ante B. Oates, Eric J. Stanek, David ~2eNofffo, Evan Lob, Wit?tam 
F. McGhan. Philadelphia College of Pharmacy, University of the Sciences in 
Philadelphia; University of Pennsylvania, Philadelphia, PA, USA 
Background: Treatment strategies for congestive heart failure (CHF) may 
have different effects on sy.rnptoms and survival Patient preferences for 
treatment strategies related to different outcomes have not been quantified 
systematicafly. 
Methods: Fifty CHF pts were surveyed by a conjoint analysis technique 
to determine preferences for hypothetical treatment outcomes, and quality 
of life was assessed by Minnesota Living with Heart Failure questionnaire 
(LHFQ). For conjoint analysis, 16 treatment outcome profiles, each with 4 
attributes (tiredness, shortness of breath, depression, and survival) varied 
across 4 seventy levels, were rated by visual analog scale. Attnbute im- 
portance weights 0Ws) were derived by multJpJe linear regression of profile 
~&LL~. LL,'V& q~4a.o.t Lb~, the. ~a..lu.e, a.s,sJ.q$-Le, d.lo% Lbe, q.t to e.acJo_ all rLb.u.te rQ ~o.w\- 1. 
sis. 
50%/dilated 38%, NYHA class Ill-IV 67%, LVEF 24 4- 12%, peak VO2 15.6 
~. 5.7 m L./min/Kg, ACE inhib. 86%, diuretic 88%, diGoxin 90%, #-blocker 
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35%, LHFQ score 50 + 25. Attribute IWs of identified preference segments 
(symptom-sensitive, n = 33; survival-sensitive, n = 17) are presented below: 
Attribute Symptom-sensitive Survival-sensitive P value 
Tiredness 0.30 ± 0.10 0.16 ± 0.09 <0.01 
SOB 0.26 ± 0.08 0.21 ± 0.08 0.07 
Depression 0.26 ± 0.09 0.19 ± 0.09 0.01 
Survival 0.18 ± 0.07 0.43 ± 0.11 <0.01 
There were no significant clinical predictors of preference. 
Conclusions: CHF lots were clustered into symptom-sensitive and sur- 
vival-sensitive segments, suggesting that survival is not as important an 
outcome as symptoms to some pts. Development of new treatment strate- 
gies may be enhanced by acknowledgement of these discrete preference 
groups. 
ORAL 
Alterations in Gone Expression in Heart 
Failure 
Monday, March 8, 1999, 2:00 p.m.-3:30 p.m. 
Morial Convention Center, Room 275 
2:00 p.m. 
I 8~- ]  Induction of Tenascin in Cardiomyocytes by 
Mechanical Strain: Role of Reactive Oxygen Species 
Keiji Yamamoto, Quynh N. Dang, Scott P. Kennedy, Ralph A. Kelly, Richard 
T. Lee. Brigham and Women's Hospital, Boston, MA, USA 
Background: Mechanical overload leads to important changes in cardiac 
structure, and tenascin-C is a prominent extracetlular molecule in actively 
remodeling tissues. 
Methods: We investigated the effects of deformation on the expression 
of tenascin-C in cultured neonatal rat cardiac myocytes. 
Results: Mechanical strain induced tenascin-C mRNA (3.9 ± 0.4 fold, p < 
0.01, n = 12) in an amplitude-dependent manner, but did not induce SPARC 
nor fibronectin. RNase protection demonstrated that mechanical strain in- 
duced all three alternatively spliced isoforms of tenascin-C. Message stability 
for tenascin-C mRNA was not affected by strain; in addition, cycloheximide 
did not inhibit the effect of strain. CP191,166 (0.1 ~M), an angiotensin II 
receptor type 1 antagonist, inhibited the induction of brain natriuretic peptide, 
but not tenascin-C, by strain. Neither calphostin C, genistein, PD98059, nor 
SB203580 inhibited the effect of strain. However, N-acetyl-cysteine (10 mM; 
41% inhibition), an antioxidant, and GdCI3 (10 ,uM, 24% inhibition), a specific 
inhibitor of stretch-sensitive cation channels, partially inhibited tenascin-C 
induction. 
Conclusion: Mechanical strain induces tenascin-C in cardiac myocytes 
through an angiotensin II-independent and protein kinase C-independent 
mechanism; this induction is inhibited by N-acetyl cysteine. These data sug- 
gest that reactive oxygen species may participate in mechanically-induced 
left ventricular emodeling. 
2 :15  p .m.  
~ ]  Co-Regulation of Nkx2-5 and Serum Response 
Factor Transcriptional Activation of the Cardiac 
Sodium-Calcium Exchanger Promoter 
Joachim G. M~ller, Jerry T. Thompson, Mary S. Rackley, Donald R. Menick, 
Terrence X. O'Brien. VAMC-Charleston and the Medical University of South 
Carolina, Charleston, SC, USA 
Background: Our previous studies found the cardiac-specific homeobox 
transcdption factor Nkx2-5 (or CSX) up-regulates during the induction of 
pressure-overload ventricular hypertrophy, paralleling other erstwhile fetal 
gene products that re-express during hypertrophic growth. 
Methods: The regulation of Nkx2-5 and serum response factor (SRF), a 
myogenic transcription factor known to interact with Nkx2-5, were examined 
in primary neonatal rat cardiomyeoytes and the 02012 myoblast cell line. 
Two target cardiac gene promoters (below) containing the Nkx2-5 DNA 
binding element, NKE, and the SRF binding element, CArG, were transiently 
transfected with Nkx2-5 and SRF protein expression vectors. 
Results: Using the 184 bp promoter of the recently described cardiac 
isoform of the Sodium-Calcium Exchanger (NCX184), containing NKE and 
CArG sites, Nkx2-5 increased luciferase reporter activity by 8.9-fold, SRF 
by 11-fold, and Nkx2-5 plus SRF by 56-fold in C2C12 cells, with a similar 
pattern in neonatal rat cardiomyocytes. Mutagenesis of the NKE and CArG 
elements demonstrated the CArG site as being required for this synergistic 
trans-activation. Gel-shift analysis showed Nkx2-5 binding to the NKE and 
SRF to the CArG element, respectively. Also, a 638 bp atrial natriuretic 
factor promoter/reporter construct containing NKE and CArG sites similarly 
trans-activated 30-fold by Nkx2-5, 16-fold by SRF and 60-fold by Nkx2-5 plus 
SRF. 
Conclusion: These data support the key activating role of the cardiac 
transcription factor Nkx2-5 and its interaction with SRF in two active cardiac 
promoters. This suggests a novel mechanism of cardiac transcriptional acti- 
vation dependent on these factors and their interaction with CArG and NKE 
DNA binding elements. 
2 :30  p.m. 
~-]  Exposure to Hypoxia and Angiotensin-II Increases 
the Expression of Mitogen Activated Protein Kinase 
in Cardiomyocytes Isolated from Explanted Failed 
Human Hearts 
Victor G. Sharov, Anastassia Goussev, Robert S.D. Higgins, 
Norman Silverman, Sidney Goldstein, Hani N. Sabbah. Henry Ford Heart & 
Vascular Institute, Detroit, MI, USA 
Background: Mitogen activated protein kinase (MAPK) is an enzyme deemed 
important in promoting cell growth and apoptosis. We showed that expres- 
sion of MAPK is increased in human failed cardiomyocytes (C). Factors that 
trigger this increase in heart failure are not known. We tested the hypothesis 
that exposure of failed human C to hypoxia (HPX) or angiotensin-II (A-II) 
enhances the expression of MAPK. 
Methods" Studies were performed in C isolated from LV myocardium of 
5 explanted failed human hearts and from normal donor hearts (n = 2) for 
whom no suitable recipients were available. Aliquotes of C were exposed 
to normoxia (95% air + 5% CO2 without A-II, baseline), severe HPX (95% 
N2 + 5% 002), or high concentration of A-II (0.2 mg/ml) for 3 hours. The 
percent change relative to baseline conditions in the expression of MAPK 
was evaluated from Western blots. 
Results: The yield of rod shape C with clear cross-striation (>70%) was 
the same before and after exposure to HPX or A-It. Exposure of normal 
C to HPX or to All had no effect on the expression of MAPK. In contrast, 
exposure of C from failed hearts to HPX resulted in a 109 ± 11% increase 
in the expression of MAPK while exposure to A-II resulted in a 108 ± 18% 
increase. 
Conclusion: Compared to normal, C of patients with HF manifest a 
profound increase in the expression of MAPK when exposed to A-II or to 
brief periods of HPX. Accordingly, HPX and elevated A-II in the setting of 
heart failure may be instrumental in promoting C apoptosis. 
2 :45  p.m. 
[ -~- - ]  Effects of M-Creatine Kinase Deletion on In Vivo 
Murine Cardiac Contractile Function and Reserve 
Janet M. Simsic, Shintaro Nemoto, George Cooper IV, Gregg T. Schuyler, 
Gilberto De Freyte, Joanne S. Ingwall, Michael R. Zile. Medical University of 
South Carolina, Charleston SC; Brigham and Women's Hospital, Boston 
MA, USA 
Creafine kinase (CK) maintains a high ATP/ADP ratio and ensures ade- 
quate free energy to perform work. Changes in CK occur in patients with 
myocardial failure, but whether these changes have a pathophysiologic role 
is unclear. In vitro studies in transgenic mice lacking M (MCK / ) or M and 
mitochondrial isoforms (M/MtCK / ) showed function was not impaired in 
isovolumic hearts, but it was not possible to augment workload sufficiently 
to assess contractile reserve. Therefore, contractile function and ability to 
increase work were examined in vivo in age-matched wild C57BL, MCK -/-, 
M/MtCK / mice at baseline and after angiotensin II using LV dimension & 
thickness (echo) and pressure (cath). Blood pressure was increased equally 
in all groups. Fractional shortening vs. wall stress and ability to increase work 
were decreased in MCK / and M/MtCK -/ . 
0.6-] Wi ld±95% 
/ I o MCK-/- I 
g °~ 1 ; -" 
0 0 50 100 1 200 
Stress (g/crn 
O e,a~ldne 1 
• Angk~tensJn I~ zo i 
E 2sl " ~ °=N0.05v= baleline i 
o | i = p< 0.05 vs Wild 
Wild MCK 4" M/MtCK "l" 
Thus, loss of MCK caused a decrease in contractile function and reserve. 
These data support the hypothesis that changes in energetics contribute to 
the limitation in contractile reserve found in the failing myocardium. 
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~ Altered Activation of c-Jun N-terminal KJnassb~ the 
Hypertrophied and Failing Rat Myocardium 
Wataru Hayashida, Yasuki Kihara, Koichi Inagaki, Yoshitaka Iwanaga, 
Background: The c-Ju~ N-term~,na~ kinase (JNK) has been suggeste~ to be 
involved in the regulation of myocardial cell growth, but its regulation in the 
in vivo hypertrophied and failing heart remains unknown. 
Methods: We studied expression and activation of JNK using left ven- 
tricular (LV) myocardium from Dahl salt-sensitive (DS) rats. When compared 
with normotensive control DS rats (fed 0.3%-salt diet, n = 18), hypertensive 
DS rats (fed 8%-salt diet) developed concentric LV hypertrophy (LV/body 
weight: 3.1 vs. 2.3 [mean] g/kg, LV wall thickness: 2.1 vs. 1.5 mm, both p 
< 0.01) with compensated echocardiographic fractional shortening (FS: 59 
vs. 3~,~ e~ ~ wee~s ~_~,~,~;~,  = ~,  ~ ~y m,W~ed L¥ ~;~ata;~ 
and decompensated FS {29 vs. 56%, p < 0.01) at 17 week {HFgroup, n = 
10). The isolated heart preparation from each rat was coronary-perfused for 
15 mi~,. ~itb, either o~ er~k~he~i~-I {ET-1, 10 nM~, ar,~jk~ter~sin |~ {A~L 1 ~M) 
or vehicle alone, and then LV myocardium was harvested for Western blot 
analysis and immunoprecipitation-kinase assay of JNK. 
Results: JNK was activated by ET-1 (3.0-fold increase) and by Ang II 
(217"-,M~" ,iT d~r u~tu~t  flbwe~ce, d~'a" ,'rrd'xlin'a',.,,l~R" autt~,a~tb~r was- ~gn]il z
cantly decreased in the LVH group (ET-1 : 1.9-fold and All: 1.5-fold increase, 
both p < 0.01 vs. the age-matched controls) and was further impaired in the 
HF group (ET-1:1.44old and All: 8 0.8-fold, both p < 0.01), although JNK 
1/2 protein expression in LV myocardium was preserved in the LVH and HF 
groups. 
Conclusions: JNK activation by ET-1 and All is down-regulated in the, 
hypertrophied and failing LV myocardium. This altered JNK activation pre.. 
cedes to the transition from compensated hypertrophy to heart failure and 
may relate to changes in gene expression and myocardial remodeling during 
this period. 
3:15 p.m. 
~ - ]  Dysregulation of the Transforming Growth Factor 
Beta Signaling Pathway in Rats With Chronic Heart 
Failure 
John R. Teerlink, Lian-ru Gao, Carlin S. Long ~ , Joel S. Karliner. UCSFand 
VAMC, San Francisco, CA; r Denver Health Medical Center, Denver, CO, 
USA 
~Back&~round: Transforming,growth factor,.8,(TGF~) is an inlDortant re, pulator 
~'~ carC~ornvocY'~e"nv~DehroD'n._V, extrace'hu'~ar ma'~hx be~osi~on anb'~ro~ast 
function that signals via Smads, a newly elucidated pathway of peptides 
(Smad2/3, effectors; Smad6, inhibitory). We investigated this pathway in a 
ral mode~ of chronic hear[ failuTe (CHF). 
Methods: Rats underwent coronary artery ligation (CHF; LVEDP >_ 15 
rmrn'~cl, ~ ~avs ~fter 3¢Ib or ~nam qper~ihon ~nam,'). ,~x wedKs 'la:ter. "tne~r 
hearts were excised, and myocytes and non-myocytes were isolated from 
the viable myocardium by collagenase digestion. Protein was extracted in 
RIPA buffer, quantified by Bradford assay, and separated by SDS-PAGE 
(15%) electrophorasis. Blots were prepared and probed with commercially 
et?a)yze~ Via d~t~ scam'tzt~j desser tS .  Ftes~ts expressed as re~a~'tve 
~Sens)'h} urh~s, l~ean ~ ~;  ccm;DahSDnS were 7)e#orme6 wYfn l~e tmpa~re{~ 
#test. 
Results: In the non-myocytes, CHF produced increased concentrations 
of TGF,~ (ad)usted for Snarling; Sham B2 ± 2 vs CBF 134 ± 20; p < 0.02) 
and decreased TGF,S3 (Sham 144 ± 4 vs CHF 48 4- 8; p < 0.01), although 
there was marked down.regulation of the inhibitory Smad6 and increased 
production of stimulatory Smad2/3 (Sham 21 4- 4 vs CHF 52 4- 2; p < 0.002). 
In the myocytes, CHF also produced a marked decrease in TGF/~a in the 
context of increased expression of TGF/~ (Sham 12 ± 3 vs CHF 31 4- 7; p 
< 0.01) associated with down-regulation of Smad2/3 (Sham 31 ::E 5 vs CHF 
20 ± 3; p < 0.01) and increased production of Smad6 (Sham 14 4- 2 vs CHF 
22 4- 4; p < 0.05). 
Conclusiona: This data demonstrates for the first time isoform- and ceil- 
specific abnormalities in the regulation of TGF/~ and its signaling elements in 
response to CHF at 6 weeks from MI in the viable non-infarcted tissue. This 
dysregulation has important implications for the pathophysiology of CHF and 
for possible future therapeutic targets. 
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~ Effects of Carvedilol on Renal Function in Patients 
with Heart Failure 
Merete Heitmann, Ulla Davidsen, Knud H. Stokholm, Knud Rasmussen. 
Floskilde County Hospital, Roskilde, Denmark 
The effect of carvedilol on renal hemodynamics in patients with chronic 
~a~lu/e ot ischemic etiology an~ L'4 e)ec--~ion ~raction <5.40, carvedi~ol was 
added to standard (d~uratics, ACE-I, d~gox~n) therapy. Cardiac output {CO 
(I/rain/1.73 m2}} was determined by radion.ucUde venbricutegraphy and effec- 
tive renal plasma flow (ERPF (ml/min/1.73 mZ)) and glomerular filtration rate 
(GFR (milreiS1.73 mZ)) were determined by clearance technique (single 
injection) using r251-hippuran and 5~Cr-EDTA, respectively. Hemodynamic 
were reinvestigated 4 weeks after withdrawal of carvedilol: 
Baseline 4 Months Baseline 4 Months Withdrawal 
(n = 14) (n = 14) (n = 9) (n = 9) (n = 9) 
CO 3.9 ::E 0.2 4.2 ± 0.2 4.0 4- 0.2 4.3 ± 0.3 4.6 4- 0.3 
HR 704-3  56:}-2*** 73±4 594-2*" 71 ±4**  
MAP 954-3  91 ±2*  934-4  92±2 964-2"  
GFR 85±5 834-6  894-5  904-5  94 4- 5"* 
ERPF 3654-22 393±25 3874- 16 407±26 3924- 16 
. 
RVR 173 ± 20 155 ± 15 149 -{: 9 143 ± 12 150 4- 10 
Values are mean :£ SEM. "p < 0.05, "*p < 0.02, ***p = 0.001 
Conclusion: Despite a reduction in renal peffusion pressure, ERPF in- 
creases and renal vascular resistance (RVR = MAP/(ERPF/(1 - hematocrit)), 
(mmHg/I/min/1.73 m2)) decreases during treatment (n = 14). A similar in- 
crease with a subsequent fall after withdrawal was seen in the subgroup (n = 
9), but this did not reach significance. Thus, this study indicates that carvedilol 
possesses a renal vasodilating effect and preserves normal autoregulation 
in the kidneys. 
B l ind  Trfal of Carvedffol and Metoprolo/ 
John E. Sanderson, Skiva Chan, Gabriel Yip, Leata Young, 
Kenneth Raymond, Kam W. Chan, Kam S. Woo. The Chinese University of 
Hong Kong, Hong Kong SAIl, China 
Background: Carvedilol (C) is a non selective /~-blocker with additional 
u-antagonism and antioxidant activities which may be superior to metoprolol 
(M) for the treatment of heart failure. We have compared the effects of C vs M. 
Methods: 51 patients (mean age M: 60 4- 2.3; C: 59 ± 3.0 years) with 
ek~(~(~ stable ~e~O. ~&&~e ~13 42%1, r3c~I, ?_~o& N,TN,r,] 3~o&~ q~ ~t~qi  
thera.p V ~e~e ~a~doml~ aLl~te~ to M (`50 m£~ B.O.~ e( C (,2.5 rag, B.O.~ a~te~ 
a 4 week tttea.~ert 9eetc~!, fee t2 ~eeks t~t&t. STmptoms {QQL (~L[est~r~naire, 
assessed at baseline, 4, 8, and 12 weeks. 
Results: At 12 weeks compared to baseline, both M & C therapv were 
associated with improvement of symptoms (QOL score: M-63%; C-53% p < 
Q .001 ), NYHA c~ass (M: ?_.7 4-,_ (3 .og to 2.1 4- 0.09, p = 0.0001, C. 2.6 4- 0.1 to 2.2 
± 0.12, p = 0.002 rain), ETT (M + 88 ± 136 rain; p = 0.007; C + 63 4-102 rain; 
p = 0.02), LVEF (M: +7 4- 9% p = 0.00f; C: +8 4- 9% p = 0.0013). There were 
no significant differences between M and C. The fall in HR was similar (M: 85 
9:2.5 to 64 4- 2.0 beats/min; C: 83 ± 3 to 65 4- 2 beats/min both p < 0.0001 ). 
Conclusion: Both M & C therapy were associated with a highly significant 
improvement in symptoms, exercise capacity, and LVEF but there were no 
significant differences between M & C. 
II110-101 Effect of Immediate and The on Heart Rate 
i Slow-Release Metoprolol in Patients with Chronic 
Heart Failure 
Bert Andersson, Jan ~,berg. Dept. of Cardiology, Wallenberg Laboratory for 
Cardiovascular Research, Sahlgrenska University Hospital, Gdteborg; 
Clinical Pharmacology, Astra HAssle, M5lndal, Sweden 
Background: Many studies with ,8-blockers in heart failure, including the 
first major beta-blocker trial, the Metoprolol in Dilated Cardiomyo-pathy trial, 
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have used immediate release metoprolol 50 mg three times daily (CT 50 
tid) as maintenance dose. A controlled release (CR) preparation has then 
been developed. The aim of this study was to compare CT 50 tid, with CR 
100 mg once daily (od) and 200 mg od regarding effects on heart rate, 
pharmacokinetics and tolerability. 
Methods: Fifteen patients already on chronic treatment with metoprolol 
for heart failure were included (mean age 64 ± 9.9 years). Patients were 
randomized to a three-week cross-over study comparing CT 50 tid, CR 100 
od, and CR 200 od. Investigations with 24 hour holter monitor, sub-maximal 
exercise test (70 Watt), and blood sampling was performed. 
Results: Peak plasma concentrations in the three groups were 298 ± 
183 (CT 50 lid), 133 ± 113 (CR 100 od), and 306 ± 215 (CR 200 od) nmol/L. 
The average heart rate was 68 ± 10, 69 ± 9.3, 63 ± 6.4, respectively, and the 
total number of heart beats during 24 hous was 97920, 99360, and 90720, 
respectively. The maximal heart rate during exercise was 95 ± 16 (CT 50 
tid), 102 ± 14 (CR 100 od), and 90 ± 12 (CR 200 od). A more even 24-hour 
effect with a more favourable trough/peak ratio was observed with the CR 
formulations od compared to CT tid. All treatment regiments were equally 
well tolerated. 
Conclusion: Metoprolol CR 200 od was associated with a more effective 
suppression of heart rate dudng exercise and over 24 hours as compared to 
CT 50 tid, without higher peak plasma concentration. On average, patients 
with CT 50 experienced 7000 more heart beats during each 24 hour period 
as compared to CR 200 od. Thus, using the slow-release preparation, a more 
even ,8-blocking effect is achieved without causing tolerability problems. CR 
200 od is the target dose in the ongoing survival study MERIT in heart failure. 
• ~-Blockers for Chagas's Heart Disease: The 
Reduction in Heart Rate may not be Associated to 
Improvement in Left Ventricuiar Ejection Fraction 
and Remodeling Process 
Humberto Freitas, Gustavo Salatino, Paulo Chizzola, Joyceli Costa, 
AIfredo Mansur, Josd F. Ramires, Edimar Bocchi. Heart Institute, S&o Paulo, 
Brazil 
Background: fl-blockers may reduce mortality and symptoms in heart failure 
(CHF) due to ischemic and idiopathic dilated cardiomyopathy. However, it is 
not clear for CHF due to Chagas's disease specially to specific involved mech- 
anisms including autonomic disorders, immunological, myocarditis, vascular 
reactivity, and presence of the parasite. 
Methods: We investigated in 16 pts with severe CHF due to Chagas' 
heart disease the effects of carvedilol on clinical status (NYHA), heart rate, 
LV remodeling process by echo (LV end diastolic diameter, LVEDD), LV 
ejection fraction (MUGA) (EF), maximal oxygen consumption (VO2), and 
serum norepinephrine (NOR). The initial dose was 6.25 mg and progressively 
increased to 50 mg per day. The pts were evaluated 6 months after beginning 
carvedilol. The mean age of pts was 46 ± 8 years, 13 males, and were 
receiving digoxin, diurectics, and ACE inhibitors. 
Results: (Table 1) Two pts died during the initial phase of administration 
and 1 pt due to ventricular sustained tachycardia. 
LVEDD EF Heart Rate NOR VO2 NYHA 
Pre 70.42 ~- 8.81 0.21±0.06 77.71±13.08 442:E295 15±7.6 111-6,11-1 
6m 74.57±6.77 0.23±0.10 62.28±7.69 489~:211 16±4.7 11-3,1-3,1V-1 
p = 0.04 0.32 0.012 0.55 0.77 
Conclusion: Despite of the reduction in heart rate and improvement in 
functional class, the carvedilol may not be effective to improve LV function 
and prevent progression of remodeling process in selected cases of CHF 
due to chagasic cardiomyopathy. 
• Chronic Moxonidine Therapy Produces Sustained 
Reduction of Plasma Norepinephrine in Patients 
with Heart Failure 
Kenneth Dickstein, Cord Manhenke, Torbjorn Aarsland, John McNay, 
Curtis Wiltse, Theressa Wright. Cardiology Division, Central Hospital in 
Flogaland, Stavanger, Norway 
Background: Plasma norepinephdne (PNE) has been shown to be an im- 
portant predictor of mortality and morbidity in patients with CHF. Moxonidine 
selectively stimulates imidazoline receptors which centrally inhibit sympa- 
thetic outflow and potently reduce NE release, with an acute vasodilator 
response in CHF patients. 
Methods: This single-center study evaluated 25 patients (mean :1: SD 
age 69 ± 7 years, 20 males) with symptomatic CHF (NYHA II-III, mean EF 
28 ± 7%) stabilized on chronic therapy with diuretics and ACE inhibitors. 
Patients were randomized in a double-blind protocol to 12 weeks of oral 
therapy with placebo (n = 9) or a new formulation of moxonidine 0.9 mg bid 
(n = 16). Systemic arterial blood pressure was recorded by ambulatory blood 
pressure monitoring and cardiac rhythm was assessed by Holter recordings. 
Exercise performance was evaluated using an endurance, treadmill protocol. 
Tolerance and safety were evaluated by quality-ofqife assessment and a daily 
self-administered electronic diary. 
Results: All patients completed the trial and reached the target dose 
without drug related serious adverse events. Apart from dry mouth and 
drowsiness, the side-effect profile of moxonidine was not significantly different 
from placebo. PNE was substantially reduced after 6 weeks at the maximum 
dose (0.9 mg BID) by 68% from baseline vs placebo (p < 0.006). Supine heart 
rate was reduced by 6.5 bpm (p < 0.01). The heart rate response to exercise 
and both resting and ambulatory systolic and diastolic blood pressures were 
unaffected. Systolic pulmonary arterial pressures as assessed by Doppler 
were reduced (p < 0.05). A reduction in ventricular arrhythmia during chronic 
therapy was observed. 
Conclusions: Twelve week therapy with a new formulation of moxonidine 
in CHF is well-tolerated with substantial and sustained reductions in PNE. 
Trials designed to evaluate the efficacy of long-term moxonidine therapy on 
morbidity and mortality are warranted. 
• Early Morning Sympathovagal Balance is 
Improved by Aldosterone Blockade in Chronic 
Heart Failure 
K. Meng Yee, Stuart D. Pringle ~ ,Allan D. Struthers. Departments of Clinical 
Pharmacology; 1 Cardiology, Ninewells Hospital and Medical School, 
Dundee, UK 
Background: In chronic heart failure (CHF), aldosterone escapes suppres- 
sion from ACE inhibition 3-6 months after initiation of treatment. Recent 
evidence from animal models suggest that aldosterone may have detrimen- 
tal autonomic modulating properties and pro-arrhythmic effects on the head. 
We therefore evaluated the effects of aldosterone blockade on the diurnal 
variation of heart rate variability (HRV) in CHF patients. 
Methods: Twenty-eight patients (age 63 ± 9 yrs) with NYHA II-lV CHF on 
optimal therapy (including diuretics and ACE inhibitors) received spironolac- 
tone 50 mg daily and placebo for 4 weeks each in a double-blind cross-over 
fashion. All patients were in sinus rhythm without bundle branch block. 24 hr 
HRV was assessed by power spectral analysis at the end of each treatment 
phase. 
Results: Mean 24 hr Low Frequency/High Frequency (LF/HF) ratio, a 
measure of sympathovagal balance is significantly improved by spironolac- 
tone therapy compared to placebo (4.40 ± 3.10 vs 4.98 -t- 3.54; p < 0.002). 
The impact of spironolactone therapy is greatest during the morning hours 
(0600-1000 hrs) when endogenous aldosterone is also high: 
0600-1000 hr Placebo Spiro p-value 
RR int 785 ± 154 821 ~: 161 0.014 
LF in.u) 71 + 18 67± 16 NS 
HF in.u) 20 ± 14 27 :E 18 0.001 
LF/HF 5.62 ± 4.01 4,01 ± 2.76 0.002 
Conclusion: The study confirms that aldosterone blockade improves 
HRV in CHF. This effect is greatest during the morning hours when ACTH-in- 
duced aldosterone secretion is maximal. Treatment with anti-aldosterone 
agents in addition to ACE inhibitors may potentially reduce arrhythmic events 
and sudden death in CHF. 
~ Results of a Multidose Phase I Trial with Tumor 
Necrosis Factor Receptor (p75) Fusion Protein 
(Etanercept) in Patients with Heart Failure 
Biykem Bozkud, Guillermo Torre-Amione, Ozlem Z. Soran, Arthur 
M. Feldman, Consuelo Bloech, Marshelle Warren, Douglas L Mann. Bay/or 
College of Medicine, Houston TX; University of Pittsburgh, Pittsburgh, PA; 
Immunex Corporation, Seattle, WA; Baylor College of Medicine, Houston, 
TX, USA 
Background: Recent studies have suggested that tumor necrosis factor 
(TNF) may play a role in the pathogenesis of heart failure. An earlier single 
dose phase I study demonstrated that etanercept, a soluble TNF antagonist, 
was well tolerated and suppressed circulating levels of biologically active 
TNF for up to 14 days in patients with moderate heart failure (HF). In order to 
evaluate the safety of repeated doses of etanercept, we conducted a larger 
phase I study at two different institutions. 
Methods: 47 Class Ill-IV HF patients were treated for 3 months with 
biweekly subcutaneous etanercept 5 mg/m2 (n = 16), etanercept 12 mg/m2 
(n = 15) or placebo (n = 16) in a double-blinded and randomized study. 
Results: Baseline demographics were comparable in all 3 treatment 
groups. Doses of 5 and 12 mg/m 2 for 3 months were well tolerated in HF 
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patients. Adverse events were consistent with this population an equally 
distributed amongst the treatment groups. For the patients who received 5 
and 12 mg/m 2 etanercept, there was an improvement in NYHA class for 50% 
of the patients. The physical dimension quality of life (MLWHF) improved in 
both etanercept groups compared to baseline. 
Conclusion: Etanercept, dosed for 3 months, was well tolerated in pa- 
tients with moderate HF, and resulted in a trend toward overall improvements 
in NYHA classification and quality of life. These changes appeared more 
consistent in the 12 mg/m 2 dose group. These results suggest that a large 
multicenter, randomized placebo controlled trial is warranted using the higher 
dose of etanercept. 
• Clinical Benefits of Low Serum Digoxin 
Concentrations in Heart Failure 
Kirkwood F. Adams, Jr., Mihai Gheorghiade, Barry F. Uretsky, J. 
Herbert Patterson, Todd A. Schwartz, James B. Young. University of North 
Carolina, Chapel Hill, NC; Cleveland Clinic Foundation, Cleveland OH, USA 
Background: We studied the relationship between trough serum, digoxin 
concentration (SDC) and clinical outcomes in patients with symptomatic left 
ventricular systolic dysfunction who continued or withdrew from digoxin. 
Methods: The study analyzed results from two randomized, double-blind, 
placebo-controlled clinical trials: Prospective Randomized Study of Ventricu- 
lar Function and Efficacy of Digoxin (PROVED) and Randomized Assessment 
of Digoxin and Inhibitors of Angiotensin-Converting Enzyme (RADIANCE). 
The primary study analysis determined risk for worsening heart failure and the 
change in left ventricular ejection fraction and treadmill exercise time in rela- 
tion to the randomization SDC. These same endpoints were also considered 
in a categorical analysis defined as patients who discontinued digoxin versus 
patients who continued on digoxin and had low (0.5-0.9 ng/mL), moderate 
(0.9 < SDC <_ 1.2 ng/mL), or high SDC (>1.2 ng/mL) at randomization. 
Results: Multiple regression analysis failed to find a relationship between 
randomization SDC and any study endpoint (all p > 0.40). Multivariate Cox 
analysis, which adjusted for left ventricular ejection fraction, cardiothoracic 
ratio, and heart failure score, found that the risk of worsening heart failure was 
significantly less (all p _< 0.02) for patients who continued digoxin compared 
to patients withdrawn from digoxin, regardless of whether their SDC was 
in the low, moderate, or high group. The change in left ventricular ejection 
fraction and treadmill exercise time was similar in all three SDC groups that 
continued digoxin and was significantly greater in all these groups compared 
to patients who discontinued digoxin (all p _< 0.005 and p < 0.03 respectively). 
Conclusion: In patients with severe, symptomatic systolic dysfunction, 
evidence of beneficial effects of digoxin on common clinical endpoints was 
similar in patients with low, moderate, and high SDC. 
~ T h e  Effects of Hydralazine on the Prevention of 
Nitrate Tolerance in Patients with Chronic Heart 
Failure 
Hideki Watanabe, Masaaki Kakihana, Sadanori Ohtsuka, Iwao Yamaguchi, 
Yasuro Sugishita. KINU Medical Association HospttaL Mitsukaido; 
University of Tsukuba, Tsukuba, Japan 
Background: Reduced cGMP production due to increased superoxide has 
been proposed to be responsible for nitrate tolerance, and we have previously 
reported preventive ffects of antioxidants on nitrate tolerace. This study was 
designed to investigate the preventive effect of hydralazine with antioxidant 
properties on nitrate tolerance in patients with chronic heart failure. 
Methods: Twenty patients with chronic heart failure were randomized to 
receive either hydralazine (10 mg t.i.d, hydralazine group, n = 10) or placebo 
(placebo group, n = 10). The vasodilator esponse to nitroglycerin (NTG) was 
determined with forearm plethysmography as the change in venous volume 
(VV) before and 5 minutes after sublingual administration of 0.3 mg NTG. At 
the same time, venous blood samples were taken to measure the platelet 
cGMP levels. Plethysmography and blood sampling were performed serially 
at baseline (Day 0), 7 days after taking of hydralazine or placebo (Day 7), and 
7 days after continuous application of a 20 rag/24 hr NTG tape concomitant 
with hydralazine or placebo (Day 14). 
Results: There were no differences in VV and platelet cGMP between the 
two groups on day 0 or day 7. The response of venous volume (%VV) and 
platelet cGMP (%cGMP) after sublingual NTG were not significantly different 
between the two groups on day 0 (%VV: 31 ± 15 vs 32 ± 13; %cGMP: 42:5 
18 vs 40 ± 16, hydralazine group vs placebo group) and on day 7 (%VV: 30 
± 12 vs 31 ± 10; %cGMP: 40 ~L 14 vs 41 J~ 15, hydralazine group vs placebo 
group). On day 14, %VV (14 ~ 8) and %cGMP (12 ± 4) were significantly 
lower in the placebo group than on days 0 and 7 (p < 0.05 by ANOVA). 
However, %VV and %cGMP in the hydralazine group were approximately 
the same on day 14 as those on days 0 and 7 (%VV: 28 = 14; %cGMP: 38 
±10.  
Conclusion: Hydralazine may be potentially useful for the prevention of 
nitrate tolerance in patients with chronic heart failure. 
• Cardiac, Renal and Endocrine Effects of Three 
Month Treatment of Chronic Heart Failure with the 
Vasopeptidase Inhibitor, Omapatrilat 
Dougal McClean, Hamid Ikram, lain Melton, lan Crozier, Amanda Garlick, 
Mark Richards, Gary Nicholls, Michael Hume. Cardiology Department, 
Christchurch Hospital, New Zealand 
Background: Omapatrilat is a combined inhibitor of neutral endopeptidase 
and angiotensin converting enzyme. The purpose of this study was to eval- 
uate the effects of this drug on clinical status, indices of left ventricular and 
renal function and neurohormonal changes in chronic heart failure. 
Methods: The study was a randomised, double blind single centre study 
in 42 patients with NYHA Class II-IV, EF _< 40%. Patients were randomised 
to 2.5, 5, 10, 20 or 40 mg once daily. Data for all doses was combined. Clinical 
status assessment, echocardiography and digital applantion tonometry were 
performed at baseline and after 3 months of chronic therapy. 
Results: 
HR EF Vcfc o SP DP 
B 68.5 25.4 0.46 16444 135 83 
3 mths 65.7 ~ 31.1" 0.51 12350*' 116"* 72"* 
ANP BNP EPI NEPI ET Uvo I UNa 
B 66.0 47.8 148 2419 2.43 1797 112 
3 mths 64.4 39.3"* 101"* 2318 2.33 2148" 135"* 
Patient and Physician clinical assessment of heart failure status at 3 months = signifi- 
cantly improved** (Wilcoxon Test) B = Baseline; Vcfc = Rate corrected velocity of fibre 
shortening (circ/sec), ~r = wall stress (mmHg/cm 2), SP = systolic pressure (mmHg), DP 
= diastolic pressure, NEPI norepinephrine (pmol/L), ET = endothelin {pmol/L), Uvo I = 
urinary volume (mls/24 hr), UNa = Urinary sodium (mEq/24 hr). "P < 05, **P < 01. 
Conclusion: Long term Omapatrilat treatment resulted in improved clin- 
ical status and cardiac function by aftertoad reduction, diuresis, natriuresis 
and improved neuroendocrime status. There was a trend for the higher doses 
to have a greater effect in some variables. 
• Long-Term Beneficial Hemodynamic and 
Neurohormonal Effects of Vasopeptidase 
Inhibition with Omapatrilat in Heart Failure 
Hamid Ikram, Dougal R. McClean, Sukh Mehta, J. Thomas Heywood, 
Michel F. Rousseau, Alan L. Niederman, Rafael F. Sequeira, Eckart Fleck, 
Steven N. Singh, Benoit Coutu, R. Bran(It, Michel Komajda, Catherine 
C. Bryson, Chunlin Qian, James J. Hanyok. For the Omapatrilat 
Hemodynamic Study Group; Christchurch Hospital, Christchurch, New 
Zealand 
Background: Omapatrilat is a potent inhibitor of two vasopeptidases, neutral 
endopeptidase (NEP) and angiotensin converting enzyme (ACE). This study 
assessed the effects of omapatrilat added to background therapy in patients 
(pts) with heart failure (HF). 
Methods: This was a randomized, double-blind, multLcenter study in 369 
pts with HF: NYHA Class II-IV, EF ~ 40%, PCWP >_ 15 mmHg, cardiac index 
(CI) _< 3.0 L/min/m 2 . Hemodynamics and neurohormones were measured at 
baseline, day 1, and 12 wks of once-daily omapatrilat 2.5, 5 or 10 mg (first 
190 pts, Panel 1) or 2.5, 20 or 40 mg (last 179 pts, Panel 2). 
Results: 
Mean pulmonary capillary wedge pressure (PCWP, mmHg) 
2.5 mg 5 mg 10 mg 2.5 mg 20 mg 40 mg 
Baseline 21.6 23.3 22.8 22.4 22.2 22.2 
Day 1, peak (4 hrs) 17.8 18.1 15.0" 17.7 12.9" 13.4" 
Wk 12, trough (24 hrs) 19.4 18.6 18.0 19~0 18.1 18.2 
Wk 12, peak (4 hrs) 15.3 146 14.1 17.1 14.4" 14.0" 
*p < 0.05 vs. 2.5 mg, which is a dose with primarily ACE inhibition 
Heart rate tended to decrease, EF improved (from 23 to 25% with 2.5 mg, 
22 to 27% with 40 mg), CI was unchanged, and dose-related decreases in 
arterial pressure were seen. Incidence of death, hospitalization or co-inter- 
vention for HF was 34% with 2.5 mg and 19% with 40 mg. In substudy, 
plasma level of brain natriuretic peptide (BNP), prognostic factor in HF, was 
lower at wk 12 trough than at baseline in the 40 mg group (42 pmol/L vs. 54), 
though NEP inhibition was shown by trough to peak increases in BNP. 
Conclusion: Omapatrilat produced sustained benefit in heart failure and 
warrants evaluation as replacement for ACE inhibitors in this setting. 
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~ Dofetilide Heart Failure in Patients with Improves 
Atrial Fibrillation and Left Ventricular Dysfunction: 
A Diamond Subanalysis 
Lars Kober. The DIAMOND Study Group; Gentofte University Hospital, 
Hellerup, Denmark 
Background: The two Danish Investigations of Arrhythmia and Mortality 
ON Dofetilide (DIAMOND CHF and DIAMOND MI) included 3028 patients 
(pts) with severe congestive heart failure (CHF) or recent (within 7 days) 
myocardial infarction (MI) and wall motion index < 1.2, corresponding to a left 
ventricular ejection fraction (LVEF) _< 35%, at high risk of sudden unexpected 
cardiac death (SUCD) who were randomly allocated to receive dofetitide (D) 
or placebo (P). 
Methods: Among the total population, 506 pts (17%) had concomitant 
atrial fibrillation or flutter (AF/AFI), allowing the efficacy and safety of D in 
AF/AFI to be assessed in pts with severe underlying structural heart disease. 
Pts were followed for up to 3 years (median 17 months) for hospitalization 
with CHF which was pre-defined as an episode of increasing symptoms of 
CHF requiring hospitalization and an intensification of medication. 
Results: Pts were well balanced across treatment groups; the mean age 
was 72 years (range 36-92), 389 (77%) were male, 292 (58%) had a history 
of ischaemic heart disease and 115 (23%) had LVEF < 25%. There were 
73/249 pts hospitalized with worsening CHF on D and 102/257 pts on P. The 
risk reduction was 0.67 with 95% confidence limits 0.50--0.91 (p < 0.009). 
There was no excess mortality on D (111 deaths on D, 116 deaths on P) and 
there were 4 cases of torsade de pointes on D (1.6%) in these pts with severe 
CHF or recent MI at high risk of SUCD. This safety profile is consistent with 
the overall results from DIAMOND CHF and MI studies. 
Conclusion: D has no adverse effect on mortality and is effective in 
delaying the progression of heart failure in pts with AF/AFI with severely 
impaired left ventricular function, 
POSTER 
~ - ~  Cardiac Transplantation: Transplant 
Arteriopathy 
Monday ,  March  8, 1999, 3:00 p .m, -5 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  3 :00 p .m. -4 :00  p.m. 
• Transplant Coronary Artery Comparative Disease: 
Value of Dobutamine Stress Echocardiography, 
Intracoronary Ultrasound, Endothelial Function and 
Flow Reserve 
Vidya Ponnathpur, Kwame Akosah, Charles Cannan, Anthony Minisi, 
Daniel Kirchberg, P.K. Mohanty. McGuire VAMC/Med Coil of Virginia, 
Richmond, VA; Gundersen Lutheran Hospital, LaCrosse, WI, USA 
Background: The diagnosis of transplant coronary artery disease (CAD) is 
challenging. The contribution of Dobutamine stress echocardiography (DSE) 
and intracoronary ultrasound (ICUS) for the evaluation of CAD in transplanted 
patients is evolving. 
Objective: The purpose of this study was to determine the mechanistic 
basis for inducible wall motion abnormalities (WMA) in transplant patients 
with apparently normal coronary ANGLO. 
Methods: Nine consecutive heart transplant patients who had normal 
angiograms were studied. Endothelial independent flow by adenosine and 
nipride as well as endothelial dependent flow by acetylcholine (ACH) were 
assessed. In addition, 5 patients underwent ICUS of the left anterior descend- 
ing. The following were measured: coronary flow reserve (CFR), coronary 
blood flow (CBF), vessel diameter by quantitative angiography (QCA) and 
intimal plaques. There results were compared with WMA on DSE. 
Results: Four of 5 with ICUS had severe plaque in the proximal or mid 
segments. All 4 had abnormal DSE. The other patient had moderate distal 
plaque and negative DSE. All 3 patients who failed to dilate with ACH had 
abnormal DSE. Two of these who had ICUS showed severe plaque. All but 
one with abnormal ICUS had normal CBF in response to ACH and normal 
CFR. There was poor correlation of CFR and CBF with either ICUS or DSE. 
Conclusions: (1) WMA by DSE correlates with intimal plaques by ICUS in 
patients with normal angiograms. (2) The pathomechanism of inducible WMA 
in the setting of normal angiograms related to factors other than alteration 
in CFR or CBF. (3) The extent to which endothelial dysfunction relates to 
dobutamine induced WMA remains to be determined. 
[ -~-~ Microvascular Hemostasis, Anticoagulation, 
Fibrinolysis and Endothelial Activation in the First 
Month Post-Transplant Are Associated with 
Outcome in Cardiac Transplant Recipients 
Carlos A. Labarrere, David R. Nelson, Douglas Pitts, Philip C. Kirlin, 
Harold Halbrook. Clarian Health Partners, Inc., Indianapolis, IN, USA 
Background: The presence of myocardial fibrin, depletion of vascular an- 
tithrombin and arteriolar tissue plasminogen activator and expression of 
arteriolar endothelial activation markers intercellular adhesion molecule-1 
(ICAM-1) and HLA-DR following cardiac transplantation is assOCiated with 
subsequent allograft outcome. We asked whether microvascular changes 
detected only during the first month post-transplant were adequate to identify 
patients at risk of developing coronary artery disease (CAD) and graft failure. 
Methods: We prospectively studied 141 cardiac allograft recipients with 
serial endomyocardiat biopsies obtained dudng the first month post-trans- 
plant (2.3 • 0.1/patient) and serial coronary angiograms (3.3 ± 0.2/patient). 
Biopsies were studied for the presence of fibrin, depletion of tissue plasmino- 
gen activator and vascular antithrombin and presence of arteriolar endothelial 
activation markers ICAM-1 and HLA-DR. 
Results: AIIografts that showed the presence of immunohistochemically- 
detected myocardial fibrin, depletion of vascular antithrombin and artedo- 
lar tissue plasminogen activator and expression of arteriolar ICAM-1 and 
HLA-DR in endomyocardial biopsies obtained during the first month post- 
transplant (n = 36) developed more CAD (72% vs. 48%, p = 0.01), developed 
CAD earlier (19.2 ± 2.6 me. vs. 41,1 ± 3.0 me., p < 0.001), failed more (42% 
vs. 18%, p = 0.006) and failed earlier (34.3 • 3.7 me. vs. 52.0 ± 3.2 me., p 
< 0.001) than allografts that did not show all these changes (n = 105). 
Conclusion: The concomitant finding of abnormalities in hemostasis, 
anticoagulation, fibrinolysis and endothelial activation within the microvas- 
culature of cardiac allografts during the first month post-transplant identifies 
patients at risk of developing CAD and graft failure. 
~ Impact of Myocardial Endothelin Expression on 
Functional and Morphological Coronary Alterations 
During Follow-Up in Cardiac Transplant Recipients 
Michael Weis, Stephen M. Wildhirt, Costas Schulze, Wolf P. Wolf, 
Gabriele Rieder, Ute Wilbert-Lampen, Rainer M. Arendt, Georg Enders, 
Peter 0berfuhr, Wolfgang von Scheidt. Klinikum Grosshadern, University of 
Munich, Germany 
Background: Endothelin (ET) opposes the effects of NO and plays a signif- 
icant role as a modulator of coronary vascular reactivity in the early stages 
of arteriosclerosis. ET may be important as an participant in and marker for 
cardiac allograft vasculopathy. 
Methods: We investigated the impact of myocardial ET and eNOS-gene 
(RT-PCR) and protein expression (immunohistochemistry) as well as ET and 
nitrite/nitrate-plasma levels (aorta and coronary sinus; RIA, Griess) on de- 
velopment of morphological and functional coronary changes in 42 cardiac 
transplant recipients (CTr) early (1 month) and 12 months after HTx. Epicar- 
dial (QCA) and microvascular (ic Doppler) endothelium-dependent (acetyl- 
choline) and endothelium-independent (adenosine) vasomotor-function was 
studied sequentially. IVUS was performed to determine intimal hyperplasia. 
Results: Aortic ET levels I months after HTx were significantly enhanced 
compared to nontransplanted subjects and did not change significantly over 
time. Significant ET uptake by the heart (aortic-coronary sinus plasma level 
>1 fmol/ml) was noticed in the majority of CTr (p < 0.001). Endothelium- 
dependent flow increase during follow-up was inversely correlated to eady 
aortic ET-levels (r = -0.38; p < 0.05). CTr with newly developed intimal 
thickening and epicardial endothelial dysfunction during follow-up had an 
increased ET mRNA expression score at baseline compared to patients with 
no functional and morphological changes over time (p < 0.03). The most 
striking immunostaining for ET was consistently seen in the microvascular 
smooth muscle cells. Importantly, eNOS-mRNA expression and nitrate/nitrite 
levels at baseline were comparable in CTr with and without development of 
intimal thickening and/or endothelial dysfunction during follow-up. 
Conclusion: Coronary endothelial vasomotor dysfunction as well as mor- 
phological coronary alterations during follow-up after HTx are at least in part 
induced by early myocardial activation of the ET-pathway. 
~ Attenuation of Myocardial Injury and Endothelial 
During Reperfusion by Endothelin A and B 
Receptor Antagonists 
G~tbor Szab6, Levente Fazekas 1 , Susanne B~hrle, Damian MacDonald 
Christian F. Vahl, Siegfried Hagl. University of Heidelberg, Heidelberg, 
Germany; 1Semmelweis Universi~ Budapest, Hungary 
The aim of the present study was to investigate the effects of ET antagomsm 
on myocardial and endothelial function during reperfusion after reversible 
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hypothermic ischemia in a rat heart transplantation model. Intraabdominal 
heterotopic transplantation was performed in Lewis rats. After one hour of 
ischemic preservation, reperfusion was started after application of either 
saline vehicle (control, n = 12), ET-A receptor antagonist BQ123 (n = 12), 
or ET-B receptor antagonist BQ788 (n = 12). Myocardial blood flow (MBF) 
was assessed by the hydrogen-clearance method. An implanted balloon 
was used to obtain pressure-volume relations of the transplanted head. Left 
ventricular pressure (LVP), its first derivative (dP/dt), end-diastolic pressure 
(LVEDP), isovolumic relaxation constant (TE) and MBF were measured after 
60 minutes and 24 hours of reperfusion. Endothelium-dependent vasodi- 
latation to acetylcholine (ACH) and endothelium-independent vasodilatation 
to sodium nitroprusside (SNP) were also determined. After one hour, MBF 
was significantly higher in the BQ123 and BQ788 groups in comparison to 
control (2.8 4- 0.3 and 3.2 4- 0.6, respectively, vs. 1.9 4- 0.2 ml/min/g, p < 
0.05). The treatment groups showed a better recovery of systolic function 
and myocardial relaxation (maximal LVP: 143 4- 15 and 171 4- 17 vs. 95 4- 7 
mmHg, p < 0.05, maximal dP/dt: 6767 4- 649 and 7789 ± 763 vs. 3312 ± 274 
mmHg/s, p < 0.05, TE: 6.9 4- 1.9 and 6.1 ± 0.5 vs. 12.2 4- 1.5 ms, p < 0.05, 
at an intraventricular volume of 110 #1). There were no significant differences 
between the two treatment groups. LVEDP was similar in all groups. After 
24 hours, there was no difference between the groups in basal MBF, LVP, 
dP/dt, TE, LVEDP and the response of MBF to SNP. However, ACH led to a 
significantly higher increase in MBF in the BQ123 and BQ788 groups (+51 
4- 7% and +53 4- 6% vs. +37 ± 7%, p < 0.05). Thus, 1) both subtypes of 
ET-A and ET-B receptors contribute to ischemic injury during early reper- 
fusion after heart transplantation, 2) ET-A and ET-B receptor antagonists 
have a persisting beneficial effect against reperfusion induced graft coronary 
endothelial dysfunction. 
• Immunohistochemical Characterization of Coronary 
Thrombus in AIIograft Vascular Disease 
Eloisa Arbustini, Barbara Dal Betlo, Patrizia Morbini, Sabrina Filippone, 
Antonello Gavazzi, Carlo Campana, Giuseppe Specchia, Marie Vigan6. 
IRCCS-Policlinico San Matteo, Pavia, Italy 
Background: AIIograft vascular disease (AVD) is a major cause of late 
failure of transplanted heads; its progression is munch faster than sponta- 
neous atherosclerosis. The pathologic hallmarks of AVD are: lack of coronary 
wall remodelling, concentric neointimal proliferation of smooth muscle cells, 
inflammation and mural thrombosis. This study was aimed at immunohisto- 
chemically characterizing coronary thrombosis in a consecutive series of 48 
cardiac allografts failed with a follow-up _> 2 months. 
Methods: Four major and 4 minor branches of the epicardial coronary tree 
were obtained from 48 heads at autopsy (n = 42) and at retransplantation (n 
= 6) from 48 patients (2 females and 46 males) after a mean post-transplant 
follow-up of 38 4- 34 mos. We obtained an average of 70 segments distributed 
in 140 sections (Hematoxylin-eosin and Movat stains) for each graft. For the 
immunohistochemical characterization of thrombi we used anti4ibrinogen 
(Biogenex), anti-CD41a (gpllb-Illa) and anti-CD61a (gpllla) (Immunotech) 
antibodies. 
Results: Coronary thrombi were found in 30 of 48 heads (62.5%), in 30 
of 37 AVD affected (81.1%) and in 17 of 18 AVD failed heads (94.4%). Of 
the overall 384 coronary branches, 83 had thrombus: 39 mural recent, 26 
mural organized-reabsorbed, 10 occlusive recent, 8 occlusive organized. Im.. 
munoreactions showed that recent mural thrombi were platelet-rich (CD614- 
and CD41a+) and only partially constituted of fibrinogen; organized thrombi 
were fibrinogen-rich and platelet poor. 
CD41a CD61 Fibrinogen 
mural recent +++ +++ +/- 
mural occlusive +/- +/- ++ 
organized mural +++ ++ +++ 
organized occlusive +/- +/- +++ 
Conclusions: Thrombi are very frequent and diffuse along the coronary 
tree in AVD-affected heads. Recent mural thrombi are largely composed of 
platelets, while recent occlusive thrombi are constituted of both platelets and 
fibrinogen. 
•]  Effects of Soluble Cell Adhesion Molecules and 
Proinflammatory Cytokines on Coronary Vasomotor 
Function in Chronic Rejection After Heart 
Transplantation in Humans 
Stephen M Wildhid, Michael Weis, Costas Schulze, Nicole Conrad, 
Sinan Pehlivanli, Hermann Reichenspurner, Wolfgang v. Scheidt, 
Bruno Reichart. Depts. of Cardiac Surgery and Cardiology, 
Ludwig-Maximilians-Universi~ Munich, Germany 
Background: The major limiting factor of long-term survival after heart trans- 
plantation (HTx) is the progressive development of transplant coronary artery 
disease (TxCAD) as a result of chronic rejection. Early vasomotor dysfunction 
precedes and predicts the development of TxCAD. P-Selectin is expressed 
on the surface of activated thrombocytes by thrombin and has been linked to 
the progression of native atherosclerosis. In addition, it is known that TNF-c~ 
mediates P-Selectin expression. 
Methods: The present study investigated a possible association between 
changes in endothelium dependent (acetylcholine (Ach); 30 /~g/min) and 
endothelium independent (adenosine; 160 llg/min) coronary flow velocity 
reserve (CFVR; doppler flowire), expression of coronary sinus (CS) soluble 
adhesion molecules (P-Selectin, ICAM; ngJml) and transcardiac (Aorta vs 
CS) expression/activation of proinflammatory Cytokines (TNF-c~, TNF-Rp55 
and Rp75) in 45 human cardiac transplant recipients 1, 6 and 12 months 
(Me) after HTx. 
Results: Both, ICAM and P-Selectin in the CS were highly expressed 1 
Me after RTx and decreased over time (ICAM: 1 Me: 286 ± 28; 6 Me: 195 
± 11, p = 0.005 vs 1 Me; 12 Me: 192 ± 10, p = 0.002 vs 1 Me; P-Selectin: 
1 Mo:78±9;6Mo:65±6,  p=0.03vs  1 Me; 12 Me: 47 ± 3, p=0.008 
vs 1 Me). CS P-Selectin levels were associated with impaired CFVR 12 Me 
after HTx (r = 0.50, p = 0.05). TNF-~ remained at high levels throughout he 
first year (1 Me: 19.5 ± 2.3; 6 Me: 21.5 ± 4.8; 12 Me: 24.3 ± 4.1, p = n.s.). 
A transcardiac production of TNF-o~ was noted after 12 Me (Aorta: 17.4 ± 
3.7 vs CS: 24.3 ± 4.1, p = 0.02). An inverse correlation was found between 
CFVR to Ach and CS TNF-e levels (r = 0.37, p = 0.03) and TNF-Rp55 (r = 
0.39, p = 0.02) 12 Me after HTx. In addition, P-Selectin was associated with 
TNF-~ levels 12 Me after Htx (r = 0.62, p = 0.01). 
Conclusions: The present data suggest that P-Selectin alters endothe- 
lium dependent CFVR in the coronary microvasculature, a mechanism which 
is triggered by the proinflammatory cytokine TNF-e. Thus, P-Selectin may 
play a critical role in the development of endothelial dysfunction and in the 
process of chronic rejection within the coronary circulation. 
• Coronary Endothelial Dysfunction Predicts 
Progression of AIIograft Vasculopathy After Heart 
Transplantation 
Steven M. Hollenberg, Durand E. Burns, Markus Scherer, Lloyd W. Klein, 
Nina Oberoi, Magdy Ahmed, Sahar Ahmad, Maria Rosa Costanzo, Joseph 
E. Parrillo. Flush Medical College, Chicago, IL, USA 
Background: Endothelial dysfunction may be an early marker for cardiac 
allograft vasculopathy (CAV) in odhotopic heart transplant (OHT) recipi- 
ents. We have previously shown that coronary endothelial function can be 
measured comprehensively using the novel technique of simultaneous intra- 
coronary ultrasound (IVUS) and Doppler flow wire measurements. We report 
serial studies of endothelial function and CAV using these techniques in a 
cohort of patients after OHT. 
Methods: 24 patients have been studied yearly beginning at OHT (9 
twice, 10 thrice, and 5 4 times). At each study, sequential intracoronary 
infusions of adenosine (Aden, 32 ,~g bolus), acetylcholine (Ach, 54 t~g over 
2 min) and nitroglycerin (NTG, 200 t~g bolus) were given into the LAD; IVUS 
images and Doppler velocity were recorded continuously. Average intimal 
index (11) was calculated by morphometric analysis of 10 equally spaced 
segments from IVUS pullback. 
Results: None of the patients had angiographic evidence of CAV. II 
increased most during the first year after OHT. Endothelial-dependent epi- 
cardial responses to Ach correlated significantly with progression of II over 
the course of the next year (r = 0.33, p = 0.04), and microvascular responses 
to Ach correlated even more strongly with progression of II (r = 0.40, p = 
0.02). No correlation was seen between change in II and Aden flow reserve 
or NTG area responses. 
Conclusions: Endothelial dysfunction predicted the progression of coro- 
nary intimal thickening over the next year in OHT patients; microvascular 
responses to Ach were the strongest predictors. This suggests that serial 
measurements of endothelial function may provide important prognostic in- 
formation about subsequent development of CAV after OHT. 
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~ ]  Intermittent Large Dose to Nitrates Added Standard 
Therapy, Improves Left Ventricular Function and 
Exercise Capacity in Patients With Chronic Heart 
Failure 
Uri EIkayam, Janet V. Johnson, Avraham Shotan, Syed Bokhari, 
Alejandro Solodky, Menahem Canetti, Omar R. Wani, Ilyas S. Karaatp. 
University of Southern California School of Medicine, Los Angeles, CA, USA 
Background: Organic nitrates are widely used in the treatment of chronic 
heart failure (CHF). No information, however, is available regarding their 
effect in patients (pts) already treated with standard therapy including angio- 
tensin converting enzyme (ACE) inhibitors. 
Methods: We studied in a randomized, double blind, crossover design, 
the effect of intermittent, high dose (50-10 mg q 12 h/daily) transdermal 
nitroglycerin (TNTG) vs placebo on maximal exercise time (ET), echocar- 
diographic left ventricular (LV) dimensions, incidence of CHF worsening and 
quality of life in 29 pts with CHF class II-Ill. 
Results: Change in ET 4 h post patch application from baseline was: 
1 Month 2 Months 3 Months 
TNTG 38 4- 35 sec 76 ~ 28 sec" 111 4- 34 sec" 
Placebo 12 ~- 20 sec 5 4- 26 sec 19 5- 28 sec 
'p < 0.05 
Changes from baseline in ET at 8 h, LV end diastolic (ED) and end systolic 
(ES) dimensions and fractional shortening (FS) after 3 mo. were: 
ET 6 h (sec) LVED (%) LVES (%) FS (%) 
TNTG 87 ± 28" 2.1 4- 0.1" -3.2 ± 1.3" 25 ± 11" 
Placebo 23 ± 36 -1.0 ± 1.3 0.6 ± 1.7 5 4- 7 
No difference was found between the two groups in the incidence of 
symptomatic CHF worsening or change in quality of life. 
Conclusions: Use of high dose nitrates results in a significant improve- 
ment in exercise tolerance, LV size and systolic function in pts with CHF 
already treated with standard therapy including ACE inhibitors. These find- 
ings support a role for organic nitrates as an adjunctive therapy to ACE 
inhibitors in pts with CHF. 
4 :15  p.m. 
[ ~  Nesiritide (Human B-Type Peptide) Natriuretic 
Improves Symptoms and Hemodynamics in NYHA 
Class III and IV Heart Failure 
William T. Abraham 1 , Allen D. Johnson 2, Lynne Wagoner, Michael 
M. Givertz, Darlene P. Horton. ~ University of Colorado Health Sciences 
Center, Denver CO; 2Scripps Clinic and Research Foundation, La Jolla, CA, 
USA 
Background: Plasma b-type natriuretic peptide (BNP) levels correlate with 
severity of chronic heart failure (HF). In controlled studies, infusions of ne- 
siritide (exogenous BNP) improve symptoms and hemodynamics, reduce 
neurohormones, and increase diuresis in patients with acutely decompen- 
sated HE Comparative efficacy of nesiritide in moderate (NYHA Class III) 
and severe (NYHA Class IV) HF patients has not been described previously. 
Methods: From a randomized, double-blind, placebo-controlled study of 
127 subjects, 124 with a history of NYHA Class III or IV HF received either 
placebo (P) or 0.015 or 0.03/~g/kg/min esiritide. After 6 hours of infusion, 
global symptoms, dyspnea, and hemodynamics were assessed. 
Endpoint NYHA Class Ill NYHA Class IV 
p 0.015 0.03 P 0.015 0.03 
(n = 25) (n = 24) (n = 18) (n = 15) (n = 19) (n = 23) 
Symptoms 
global 20% 68%* 54%* 7% 50% 59%* 
dyspnea 12% 68%" 54%* 13% 44%" 50%* 
PWP +2% 25%" -33%** +20% -15%** 36%** 
CI -1% +14% +32%*' -6% +19%** +27%- 
"p < 0.05, vs. placebo [WUcoxon 1]; "'p < 0.05 vs. placebo [pairwise contrast] 
Results: Median baseline BNP levels were 790 and 942 pg/ml in the 
NYHA Class III and IV patients, respectively. Percent (%) of subjects experi- 
encing symptom improvement and the mean % change in pulmonary wedge 
pressure (PWP) and cardiac index (CI) are presented in the table. 
Conclusions: Nesiritide produces rapid symptom improvement and dose- 
related improvement in hemodynamics in patients with acutely decompen- 
sated heart failure, regardless of baseline disease severity. 
4 :30  p.m. 
[ ~  High Dose ACE-Inhibitor Strategy Is More Effective 
Than Low Dose in Diabetic Patients With Congestive 
Heart Failure 
Lars Ryden, Paul Armstrong, John G.F. Cleland, John Horowitz, 
Barry Massie, Milton Packer, Philip A. Poole-Wilson. For the ATLAS 
investigators; Karolinska Institutet, Stockholm, Sweden; Columbia 
University, New York, USA 
Introduction: The number of patients (pts) with Diabetes Mellitus (DM), and 
in particular non-insulin dependant (type 2) diabetes, is increasing rapidly and 
coronary artery disease accounts for considerable disability and a majority 
of deaths in such patients (pts.) DM will become an increasingly common 
predisposing factor for congestive heart failure (CHF) and because of the 
severity and frequency of this combination, and its impact on health care 
resources, improved knowledge of the handling of CHF in DM pts is important. 
Material/Methods: The ATLAS trial compared high (32.5-35.0 mg) and 
low (2.5-5.0 mg) doses of the ACE-inhibitor lisinopril (L) over a median 
period of 46 months in pts with CHF, NYHA class ll-IV. The total cohort was 
3,164 pts of whom 611 had DM (defined as on anti-diabetic treatment at 
randomisation). ATLAS therefore comprises the largest diabetic CHF cohort 
in a prospective, randomised clinical trial to date. 
Results: The mean age of DM-pts was 65 ± 9 years and 78% were males. 
Corresponding figures for pts without DM were 63 ± 11 and 80% respec- 
tively. The aetiology of CHF was similar among DM-pat (71% ischaemic, 23% 
dilated cardiomyopathy and 5% other). Total mortality was 299/611 (49%) in 
DM compared with 1084/2553 (42%) in non-diabetics and the combined end- 
point of death + hospitalisation was greater (88% vs 80%). The interaction 
between the presence of DM and L-dose was not significant for mortality (p = 
0.502) or mortality + hospitalisation (p = 0.275) indicating that the comparison 
between a high and low dose L-strategy was independent of the presence 
of DM. Comparing high and low dose treatments in DM and non-DM pts 
the relative risk reduction in mortality was 14% vs 6% and the relative risk 
reduction in mortality + hospitalisation was 5% vs 13%. Tolerability of high 
dose L was similar to low dose in both the DM and non-DM groups. 
Conclusion: Diabetic patients with heart failure have considerable mor- 
tality and morbidity. High doses of lisinopril are well tolerated and improve 
the prognosis more than low doses in these patients. 
4 :45  p.m. 
~ ]  Eplerenone, a Novel Selective Aldosterone Receptor 
Antagonist (SARA): Dose Finding Study in Patients 
With Heart Failure 
Bertram Pitt, Barbara Roniker. For the Eplerenone Heart Failure 
Investigators; University of Michigan School of Medicine, Ann Arbor, MI, 
USA 
Eplerenone (EPL) is a new highly selective aldosterone receptor antagonist 
(SARA) in development for the treatment of hypertension and heart failure 
(HF). To detect a pharmacologically effective and safe dose of eplerenone 
(EPL) 321 patients with stable NYHA Class II-IV HF, mean age 61 years, and 
an LVEF _< 40% maintained on standard therapy, including an angiotensin 
converting enzyme inhibitor (ACE-I), diuretic, ±digoxin, were randomized to 
EPL 25 mg daily, EPL 25 mg twice daily, EPL 50 mg; daily, EPL 100 mg daily, 
spironolactone (SP) 25 mg daily as a positive control, or placebo. Patients 
were followed for 12 weeks for determination of changes in neurohormones 
including BNP, urinary aldosterone, plasma renin and testosterone as well 
as serum K ÷, blood pressure, heart rate, and NYHA class. At the end of 
12 weeks, the dose of EPL was doubled and the patients were followed an 
additional 4 weeks for safety evaluation. 
At 12 weeks patients on EPL and SP had a significant decrease in BNP, 
and an increase in urinary aldosterone and renin in comparison to placebo 
(p < 0.05) beginning at a dose of EPL 50 mg daily. There was a clinically 
important increase in the incidence of hyperkalemia (K + > 6.0 mEq/L) on 
EPL 100 mg; daily (12.0%) compared to SP (8.7%). In male patients there 
was a significant increase in total testosterone, on SP compared to EPL (p 
_< 0.02) likely due to positive feedback in response to blockade of androgen 
receptors. There was no significant change in NYHA class or body weight in 
patients treated with SP or EPL as compared to placebo. 
In conclusion, EPL appears pharmacologically similar to SP with the 
exception of a lack of an effect on serum testosterone. A dosing strategy of 
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EPL 50 mg daily appears pharmacologically effective and safe in patients 
with HF maintained on standard therapy including an ACE-I. 
5 :00  p.m. 
[ -8~- ]  A Randomized Trial Evaluating Tolerability of 
Candesartan for Patients With Congestive Heart 
Failure and Intolerance to Angiotensin Converting 
Enzyme Inhibitors 
Christopher B. Granger, George Ertl, Jerzy Kuch, John McMurray, 
Jean-Lucien Rouleau, Karl Swedberg, James B. Young, Salim Yusuf, 
Peter Held, Marc A. Pfeffer. On behaff of SPICE Investigators; Duke Clinical 
Research Institute, Durham, NC, USA 
Background: Many patients with congestive heart failure (CHF) are currently 
not receiving the benefits of angiotensin converting enzyme inhibitors (ACE-I) 
because of discontinuation due to intolerance. 
Methods: To determine the tolerability of the angiotensin II receptor an- 
tagonist candesartan in patients with CHF and left ventricular ejection fraction 
< 35% and ACE-I intolerance, we randomized patients 2:1 to candesartan (n 
= 179) (titrated to 16 mg per day) versus placebo (n = 91) in a double-blind 
trial involving 97 centers in 7 countries for a 12 wk treatment period. ACE-I 
intolerance was due to cough in 67%, hypotension in 15%, and renal failure 
in 11% of patients. Median age was 67 yrs, 71% had ischemic etiology, and 
41% were NYHA class Ill. 
Results: Study drug was continued for 12 weeks in 82.7% of candesartan 
versus 86.8% of placebo-assigned patients: there was no significant differ- 
ence in discontinuation rate between the treatments (difference of 4.1%; 
95% CI, -4.8, 13%). Of patients who tolerated candesartan, 78% tolerated 
the target dose of 16 mg. Clinical events were not statistically significantly 
different between treatments. 
Placebo (n = 91) Candesartan (n = 179) 
Death 3 (3.3%) 6 (3.4%) 
Hospitalization for CHF 11 (12.1%) 15 (8.4%) 
Conclusion: This pilot study shows that patients with ACE inhibitor intol- 
erance can tolerate candesartan and can be enrolled in clinical trials. This 
ACE inhibitor intolerant population, therefore, will be included in the CHARM 
trial which will investigate whether candesartan results in improved clinical 
outcomes. 
5 :15  p.m. 
~5~]  Long-Term Effects of Heart Rate Reduction in 
Patients with Heart Failure: Comparison With 
Chronic/3-Adrenergic Blockade 
Toshiro Shinke, Hideyuki Takaoka, Motoshi Takeuchi, Katsuya Hate, 
Yoshiyuki Yokota, Mitsuhiro Yekoyama. First Department of Internal 
Medicine, Kobe University School of Medicine, Kobe, Japan 
Background: Reduction in heart rate (HR) is one of the clinical features 
of patients with heart failure that have been graced with beneficial effect of 
chronic beta-adrenergic blockade on impaired left ventricular (LV) function 
and malevolent natural history. We previously reported HR reduction induced 
by specific bradycardic agent decreased myocardial oxygen consumption to 
the similar extent with acute/~-blockade. The aim of this study was to examine 
whether HR reduction itself might have long-term benefit on LV function in 
comparison with chronic ,8-blockade. 
Methods: This was an open label, prospective trial in which 17 men with 
LV dysfunction (53 ± 17 y.o. 13 with idiopathic dilated cardiomyopathy and 
4 with old myocardial infarction) were enrolled. Echocardiographic examina- 
tion, New York Heart Association (NYHA) functional class, symptom limited 
maximum exercise test and plasma concentration of norepinephrine (PNE) 
were assessed before and after 4 and 12 weeks of therapy with metoprelol 
(n = 9, 86 4- 28 mg/day p.o.) or specific bradycardic agent, ULFS 49 having 
no negative inotropic action (n = 8, 6.9 { 2.5 mg/day p.o.), in addition to 
standard therapy. 
Results: Metoprolol and ULFS 49 decreased HR comparably (74, 67, 
63 bpm and 75, 62, 64 bpm for pre, 4 W, 12 W). In metoprolol group, 
EDV'~~ MetoproIol 
2O0 # 
ULFS 
1 so Metoprolol 
(mi) 
Pre 4W 12W 
#: p<0.05 vs Pre, 't: p<0.05 vs Metoprolol. 
ejection fraction (LVEF) gradually increased (26%, 28%, 33% for pre, 4 W, 
12 W) accompanied by decreases in LV end-diastolic (EDV) and end-systolic 
volume (ESV). Contrary, in ULFS 49 group, LVEF increased early after 
treatment (26%, 35%, 36% for pre, 4W, 12W) with increase in EDV. In both 
groups, NYHA class and the duration of the exercise test improved to the 
similar extent, while PNE remained unchanged. 
Conclusion: Long-term bradycardic intervention improves LV function 
earlier than fl-blockade which is accompanied by a relief of symptom; how- 
ever, it does not exert a regression of LV remodeling. 
POSTER 
Predictors of Outcome in Heart Failure 
Tuesday, March 9, 1999, 9:00 a.m.-11:00 a.m. 
Modal Convention Center, Hall F 
Presentation Hour: 9:00 a.m.-10:00 a.m. 
[ - ~  Prognostic Value of Central Chemoreflex 
Sensitivity in Patients With Chronic Heart Failure 
Darrel P. Francis, Tuan Peng Chua, Jonathan Chambers, 
Mathias Rauchhaus, Maria D.J. Marinho, Stefan D. Anker, Piotr Ponikowski, 
Andrew J.S. Coats. National Heart Lung Institute, London, UK 
Background: In chronic heart failure (CHF), central chemereflex sensitivity 
is increased, which may contribute to symptoms of breathlessness and to 
resting and exercise hyperventilation. However its prognostic significance is 
unknown. 
Methods: Eighty-seven CHF patients were studied with age 59 :~ 9 y 
(mean ± sd), LVEF 28 ~ 14%, NYHA h II:llhlV = 14:43:27:5. Patients re- 
breathed from a 6L bag initially filled with 7% CO2 and 93% oxygen. Rising 
end-tidal pOe2 was measured by mass spectrometer (Amis, DK), and ven- 
tilation was measured by heated pneumotachograph. Central chemoreflex 
sensitivity (cCRS) was determined from the slope of the regression line re- 
lating ventilation to Poe2. Patients also underwent standard treadmill testing 
for peak oxygen uptake (peak Me2). 
Results: Subjects attained peak VO2 of 18.4 ± 6.6 ml/kg/min, cCRS 
was 3.0 ~E 1.8 L/min/mmHg. During a median follow-up of 23 months, 19 
patients died. cCRS was a significant univariate prognostic predictor by Cox 
proportional-hazards analysis (p <: 0.0001). Dichotomising the patients into 
groups of high ('H') and low ('L') cCRS, using the median cCRS value as a 
cut-off, revealed a clear mortality difference (see Fig). 
Finally, bivariate Cox proportional-hazards mortality analysis showed that 
cCRS had prognostic value (p < 0.05) independent of peak VO2 (p < 0.03). 
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Conclusion: Enhanced central chemoreflex sensitivity assessment pro- 
vides prognostic information independent of peak VO2. We speculate that 
this is because it may be a marker of neurohumoral derangements rather 
than hemodynamic limitations. 
• Angiotensin Converting Enzyme Genotype Predicts 
Prognosis in Patients With Congestive Heart 
Failure 
Dennis M. McNamara, Richard Holubkov, Karen Janosko, Amy Palmer, Jue 
J. Wang, Mary Trost, Ren J. Alvarez, Jr., Warren D. Rosenblum, Guy 
A. MacGowan, Sdnivas Murali, Arthur M. Feldman. University of Pittsburgh 
Medical Center, PA, USA 
Background: Previous studies have shown that the deletion allele (D) of the 
angiotensin converting enzyme (ACE) gene is associated with higher levels 
of plasma ACE activity No previous prospective studies have evaluated 
its role predicting subsequent prognosis in patients with CHF from systolic 
dysfuntion. 
Methods: DNA was isolated from 260 patients with CHF and LVEF < 
0.45 (195 M, 65 F), referred to the Heart Failure Service of the University 
of Pittsburgh. ACE genotyping was performed (DD, II, or ID) and death or 
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transplants were noted over a median follow-up of 17 months (range 6 to 
28). Patients with the II genotype had a significantly better transplant free 
survival than who were ID or DD (see Figure below: Kaplan-Meier ordered 
survival curves, P = 0.0034). 
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Conclusions: Patients with the II genotype had a significantly better 
transplant free survival than patients who DD or ID. This study suggests 
that ACE genotyping may have an important role in predicting subsequent 
prognosis in patients with congestive heart failure. 
• VenUlatory and Chronotropic Responses to 
Exercise: Better Predictors of Heart Failure 
Mortality than Peak VO2 
Mark A. Robbins, Gary Francis, Claire E. Snader, Kathy Hoercher, 
James Young, Michael S. Lauer. Cleveland Clinic Foundation, Cleveland, 
OH, USA 
Background: An abnormally low chronotropic response and an abnormally 
high ventilatory response (VE/Vco2) to exercise are common in patients with 
severe heart failure, but their relative prognostic impacts have not been well 
explored. 
Methods: Consecutive heart failure patients referred for metabolic stress 
testing who were not on beta-blockers or inotropes (n = 510, 71% male, 
ejection fraction 21 ± 8%, 67% with CAD) were followed for 1.5 years. 
The chronotropic response index (CRI), a previously described measure 
of exercise heart rate which accounts for age and functional capacity was 
calculated while VENco2 was directly measured. CRI and peak Vo2 were 
considered abnormal if in the lowest 25%ile (<0.52 and <14 ml/kg/min), 
while VENco2 was considered abnormal if in the highest 25%ile (>44.6). 
Results: There were 75 deaths. In univadate analyses, predictors of 
death included low peak Vo2 (relative risk [RR] 2.96, 95% CI 1.89-4.67, 
P < 0.0001), low CRI (RR 2.96, 95% CI 1.88-4.66, P < 0.0001), and 
high VENco2 (RR 3.95, 95% CI 2.51-6.22, P < 0.0001). In multivariable 
analyses adjusting for age, gender, ejection fraction, and presence of CAD, 
independent predictors of death were low CRI (adjusted RR 2.06, 95% CI 
1.24-3.42, P = 0.005), high VeNco2 (adjusted RR 2.20, 95% Ct 1.31-3.69, P 
= 0.003), and ejection fraction (P = 0.007), butpeak Vo2 no Iongerpredicted 
death (adjusted RR 1.26, 95% CI 0.69-2.28, P > 0.4). 
Conclusions: Ventilatory and chronotropic responses to exercise ate 
powerful and independent predictors of heart failure mortality. 
~ Do We Really Need Expensive Tests to Accurately 
Predict Prognosis in Patients With Heart Failure? 
Prakash C. Deedwania, Khawar M. Gul, Ronna Mallios, Donna Hudson. 
VAMC/UCSF School of Medicine, San Francisco, USA 
Although the predictive value of numerous diagnostic parameters in pts wilh 
CHF has been studied in clinical trials, little is known about the prognostic 
value of routinely available parameters such as clinical symptoms (Sx), vital 
signs, and biochemical tests in consecutive, unselected pts treated in clinical 
setting. We examined the predictive value of 71 vadables, derived from clini- 
cal Hx, vital signs, physical findings, LVEF, RVEF, echo parameters, exercise 
capacity, and Holter data, in 575 CHF pts followed at our hospital from 1992 
to 1997. Mean age was 69 ± 10 yrs, average duration of CHF 37 mos, 
mean NYHA 2.4, mean LVEF 38 ± 16; 64% had ischemic cardiomyopathy; 
79% were on ACE inhibitors, 65% on other vasedilators, 92% on diuretics, 
and 62% on digoxin. Of 575 pts, 174 (30%) had cardiac death during the 
5-yr period. Statistical significance was assessed using student's t-test for 
continuous variables, Mann Whitney rank sums test for ranked data, and chi- 
square for categorical variables. Evaluation of various predictors revealed 
higher HR as the most significant predictor of death (85 ± 1 vs 78 ± 1 bpm, p 
< 0.0001). Other significant predictors in order of importance were worsening 
PND, progression of symptoms, number of blocks at dyspnea, higher BUN, 
higher creatinine, higher K ÷ (all p < 0.001). LVEF, RVEF, echo dimensions, 
exercise capacity, and Holter data were not significant predictors of outcome. 
Multivadate discriminant analysis revealed 1" BUN, ~ HR, and worsening 
symptoms as the most powerful predictors of cardiac death. 
Conclusion: In unselected consecutive CHF pts, higher HR, worsening 
Sx, and poor renal function are the most important predictors of cardiac 
death. These data indicate that routine clinical parameters provide reliable 
prognostic information; data from additional expensive diagnostic tests add 
little to improve their predictive value. 
~--~5- ]  Effect of Right Bundle Branch Block on Survival in 
2263 Patients With an Ejection Fraction _< 40% 
Jatin Amin, Sriram Padmanabhan, Helme Silvet, Remdas G. PaL Loma 
Linda University and VA Medical Center, Loma Lind& CA, USA 
Background: Right bundle branch block (RBBB) on the surface ECG is 
considered to be a benign abnormality and may be found in up to 2% of normal 
individuals. We hypothesized that RBBB in patients with LV dysfunction may 
imply right ventricular disease or pulmonary hypertension and may portend 
a reduced survival. 
Methods: 2263 consecutive patients with an LV ejection fraction (EF) 
of _<40% were identified from the echo data base. All had simultaneous 
ECGs. The mean EF was 30%, age 70 years and mean follow up 1007 days. 
There were 688 deaths. Kaplan-Meier curve and log rank tests were used 
for mortality analysis. 
Results: RBBB was present in 256 patients and was associated with 
a cumulative 7 year mortality (shown in figures) of 75% compared to 45% 
for those without RBBB (p < 0.003). This was independent of EF which 
independently affected mortality as well (p < 0.0001). Patients with an EF of 
<30% and RBBB had a 5 year mortality of 85% compared to 40% for those 
with EF >_ 30% and no RBBB (p < 0.0001). 
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Conclusions: (1) In patients with LV dysfunction, presence of RBBB 
independently predicts higher mortality. (2) It is speculated that RBBB in 
this patient population may indicate right ventricular disease or pulmonary 
hypertension. 
• Prognostic Value of Frequent Episodes of 
Non-Sustained Ventricular Tachycardia in Patients 
With Congestive Heart Failure. The Italian Network 
Congestive Heart Failure (IN-CHF) Database 
Claudio Fresco, Alessandro Proclemer, Maria C. Albanese, Donata Lucca I , 
Aldo P. Maggioni 1 , Marco GorinP, Anna L. Cuzzato, Paolo M Fioretti. On 
behaff of In-CHF Invesigators; Istituto di Cardiologia, Az. Osp. SMM, Udine; 
i Centro Studi ANMCO, Firenze, Italia 
Background: It is not certain if Non Sustained Ventricular Tachycardia 
(NSVT) is a predictor of total mortality and/or sudden death in patients with 
Congestive Heart Failure (CHF). The GESICA study (randomized clinical 
trial) found a strong association between NSVT and mortality, while our na- 
tional database ("real world") could not confirm it. Aim of this study was to see 
if a reclassification of the patients with respect to the frequency of episodes 
of NSVT during 24-hour Holter monitoring could improve the predictivity of 
NSVT. 
Patients and Methods: From the IN-CHF database we selected 1012 
patients with CHF who underwent 24-hour Holter Monitoring (HM) at the 
admission visit to evaluate the impact of frequent episodes of NSVT on 1 
year mortality. NSVT was defined as a run of three or more ectopic beats 
lasting less than 30 seconds. 
Results: The etiology of CHF was ischemic in 456 pts (45.1%). Males 
were 790 (78.1%), and 272 pts were older than 70 years (26.9%). Advanced 
(Ill-IV) NYHA class was present in 296 pts (29.2%) and ejection fraction 
was lower than 30% in 368 pts (36.4%). NSVT was recorded in 272 patients 
(26.9%). One year mortality was 13.8% (99/740) in patients without NSVT, 
18.6% (35/188) in those with 1-3 episodes and 21.4% (18/84) in those 
with >3 runs of NSVT (p < 0.01). After multivariate adjustment, age (OR 
1.025 95%CI 1.01-1.04 per year), NYHA class (111 and IV) (OR 2.06 95%CI 
1.39--3.04) and systolic blood pressure (OR 0.99 950/CI 0.98-0.999 per 
mmHg), were independent predictors of 1 year mortality, while the presence 
of frequent NSVT lost its predictivity (OR 1.40 95%/CI 0.77-2.56). 
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monitoring is not a predictor of one year mortality in patients with congestive 
heart failure. 
~ D o e s  Spherical Left Ventricular Shape Imply Worse 
Prognosis in Dilated Cardiomyopathy? 
Kishcca J. Hari~ 6tavi Edug~jat~, Teasel Tuc~c~t~ Ed~acdo ~une~, Natesa: 
G. Pandian ~ . Ochsner Medical Institutions, New Orleans, LA; ~ Tufts New 
Background: The left ventricle (LV) tends to become spheroid in patients with 
dilated cardiomyopathy. The prognostic significance of spherical distortion of 
LV shape is not well studied. 
Methods: In 115 patients (67 ± 16 years; male 60%; coronary artery 
disease 42%) with LV ejection fraction (LVEF) < 30% and NYHA Class Ill or 
IV heart failure requiring hospitalization, we assessed LV shape in the apical 
4-chamber view using the eccentricity index (El) (El = I/T, where L = longest 
distance from mitral annular plane to LV apex; T = transverse diameter of the 
LV, measured at midpoint of L). Et was determined on end-diastolic (E/D} and 
end-,,~s~'ofk; (E(-S~ frames. ~ f~f~ ~a'#ients cf~h~a#'¢ f~r f 7 ~c ~E mon~s 
to determine the incidence of death and the composite endpoint of death or 
emergent heart transplantation. We sought to correlate EID and EIS (divided 
into quartiles) with clinical outcome. 
Results: Complete follow-up was available in 112 (97%) patients. Death 
during follow-up occurred in 32 (29%) patients, while emergent heart trans- 
plantation was performed in eight (7%). There was no difference in EID (1.58 
± 0.2"2,~s ^ ~'.5@± ~ZS,V= ~ P3~ uq-g--~,~' i'.@t ± 5t2,~ ,s^ P.53± ,2~"~, ~ = 
0.11) between patients who died versus those who survived. Kaplan-Meier 
analysis shewed no difference in the incidence of death between quartiles 
of patients based on EID or EIS. In Cox regression analysis, after adjusting 
for age, gender, race, LVEF (_<20% vs >20%), and coronary artery dis- 
ease, niether EID nor EIS were significantly associated with death. Similar 
results were seen for the composite end-point of death or emergent heart 
transplantat~. 
Conolusions: Left ventricular shape does not appear to relate to tong- 
term outcome in patients with moderate to severe left ventricular systolic 
dysfunction and symptomatic heart failure. 
[ - ~  IS Atrial Fibrillation an Independent Predictor of 
1-Year Mortality and Hospitalization in Patients 
With Congestive Heart Failure? Data from Italian 
Network on Congestive Heart Failure (IN-CHF) 
Aldo P. Maggioni, Ermanno Angelini, Gerardc Ansalone, Luciano De Blase, 
Marc~ ~-,.eo?i~;, f'~ ,"a','~ '¢~;, ~ho ~'~e~; 'P~i~ra~r~,  'ai~g; ~ ~,~_~;./'.3;', ~-.f,~F, 
IN-CHF t r~t ig~.  Af',?/¢~,O F{eseatc¢~ Cer~,  Ffr_,,ter~ce,/l~d(¢ 
Baclkground: Atrial fibrillation {AF) has been associated with increased mor- 
tality and morbidity in several reports, although recent studies suggest that 
AF rma.v nohonaer~oe an'~mDoha~.Dre~or "r.Droclnos~s once co~oun~mq 
f act(ors'nave ~een ha~en )n'~e acco~n3. 
Methods: We prospectively studied 2757 patients, enrolled in the CHF 
trained clinicians using an ad-hoc software. Univariate and multivariate anal- 
ysis were performed to test the association between AF and 1-year mortality 
and hospitalization rates. 
Results: The etiology of CHF was ischemic in 1329 pts (48.2%), dilated 
cardiomiopathy in 1003 pts (36.4% other in 425 pts (15.4%). Males were 
2143 (77.7%) and 800 pts (29.0%) were 70 years or older. Advanced (Ill-IV) 
NYHA class was present in 831 pts (30.1%) and ejection fraction was _<40% 
in 78.4% of the pts. AF was recorded in 518 pts (18.8%). Pts with AF were 
significantly older than pts without AF, in higher NYHA class, with higher heart 
rate. The ischemic etiology was significantly less frequent in pts with AF. One 
year mortality was 14.7% (328/2239) in pts without AF and 20.7% (107/518) 
in those with AF (p < 0.001). No significant difference was found between 
pts with and without AF in the rate of hospital admission at 1-year follow-up 
(24.7% vs 23.1%, p = 0.420). After adjusted analysis AF was associated 
neither with 1-year mortality (OR 1.24, 95% CI 0.95-1.61) nor with hospital 
admission rate (OR 1.06, 95% CI 0.83-1.35). 
Conclusions: The prevalence of AF in a large population of outpatients 
f011cwed Oy card(otoujists who gcact~ce in cammuni~ h~sq(tals was t8.8%. 
AF identifies a subgroup of pts at higher risk of 1-year death. After adjusted 
analysis, when the role of confounding factors was taken into account, AF 
was not co~firmed to be an ~,nde~ndent dete~{nant of #rogaosis. 
~ )  ~ '~a ' )~h33~'~>. ' )~E~a~)~a3.as .a~-~b~>~ >) 
the Level of Left Ventricular Function: Results from 
a Cohort of 2263 Patients With an Ejection Fraction 
of <40% 
Jatin Amin, Sriram Padmanabhan, Helme Silvet, Ramdas G. Pal. Loma 
Linda University and VA Medical Center, Loma Lind& CA, USA 
Background: Epidemiological data suggests a probable association be- 
tween atnal fibrillation (AF) and increased mortality, However, its impact on 
mortalit,~ in those with LV d~sfunctJon and the interaction between, the two is 
not very clear, 
Methods: 2263 consecutive patients with an LV ejection fraction (EF) 
of _<40% were identified from the echo data base. All had simultaneous 
ECGs, The mean EF was 30%, age 70 years and mean follow up 1007 days. 
There were 688 deaths. Kaplan-Meier curve and log rank tests were used 
for mortality analysis. 
Results: AF was present in 513 patients and was associated with a 
cumulative 7 year mortality (shown in figures) of 72% compared to 41% for 
those without AF (p = 0.002), This was independent of EF and age. in 50% 
of patients with an EF of <30%, presence of AF had no effect on the 5 year 
m~af~.,  and marshal effec ~' on Z" ~e"ar meda~. Ot  P,e ~ &~ed, ~ thane 
with EF of >_30%, presence of AF markedly increased the mortality (63% vs 
31%, p < 0.005). 
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Conclusions"/1) ~n patients with LV dysfunction, presence ol A~: inde- 
pendently predicts higher mortality. (2) The impact on mortality is seen mostly 
in the subset of patients with better EF, 
1140-1 0 1 Value of Over Time Prognostic Changes in 
! 
Exercise Capacity and Echocardiographic 
Variables in Patients With Chronic Heart Failure 
Viorel G. Florea, Michael Y. Henein, Stefan D, Anker, Darrel P, Francis, 
Jonathan S. Chambers, Derek G, Gibson, Andrew J.S. Coats. National 
Heart and Lung Institute and Royal Brompton & Harefield NHS Trust, 
London, UK 
Backqround: Measurements of peak oxygen consumption (VO~I and left 
ventricutar e~ectien fraction (LVEF~ have become accepted methods to pre- 
dict survival in patients with chronic heart failure (CHF). The prognostic im- 
Methods: Sixty-two patients with CHF (58 men, mean age 60 ± 10 
years; mean peak VO2 18.2 ± 6.9 mFkg/min, mean LVEF38,9 ± 15.8%) 
underwent treadmill exercise test and echocardiographic examination at 
baseline and after 19 ± 15 months. After the second examination all patients 
were followed-up for a mean of 17 months (interquartile range 9-30 months). 
Results: During the follow-up period 19 (30%) patients died and 3 
(4.8%) underwent heart transplantation. Of measurements taken at a sin- 
gle time-point exercise duration, peak VO2, vantilatory response to exemise 
(VENCO2), left atrial diameter and LVEF were found by Cox proportional- 
hazard analysis to predict the outcome in these patients (all p < 0.05). Of 
parameters measured as changes over time only delta peak VO2 per year 
(p = 0.026) predicted non-transplanted survival (independent of changes 
in LVEF and VENCO2). In Kaplan-Meier survival analysis patients with in- 
creased peak VO2 over time (n = 28) showed a better prognosis at 2 years 
(cumulative survival 75% [95% confidence interval: 56-95%] than those with 
a decrease in peak VO2 (n = 34, survival 50% [95% confidence interval: 
3t~8%]). 
Conclusion: Although single estimates ofpeak VO2, VEJVCO2 and LVEF 
have significant prognostic importance in patients with CHF, when monitoring 
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~ Survival in Cardiac Amyloidosis: Role of Exercise 
Capacity 
Athanasios G. Tdkas 1 , Loukianos Rallidis 2, Costas A. Tentolouris 1 , 
Costas Stratos 1 , Christodoulos C. Stefanadis ~ , Pavlos K. Toutouzas ~ ,
Petros Nihoyannopoulos 2. Cardiology Departments; ~ University of Athens, 
Greece; 2Hammersmith Hospital, London, UK 
Background: To examine the association between exercise capacity (EC) 
and incidence of cardiac death in patients (pts) with primary systemic amy- 
Ioidosis (PSA), we studied 42 consecutive pts (age 50.5 ± 11.4 years) with 
biopsy proven PSA [(22 with 2D-echocardiographic features of cardiac in- 
volvement (Group I) and 20 without (Group II)]. Each subject underwent a 
complete 2D-echocardiographic and Doppler study followed by cardiopul- 
monary exercise testing (CPX) using a modified Bruce protocol. Left atrial 
diameter, left ventricular dimensions, septal (IVS) and posterior wall (PW) 
thickness, fractional shortening (FS), peak velocities of early (E) and late (A) 
diastolic filling of left ventricle were measured and their E/A ratio was calcu- 
lated. EC was assessed by peak oxygen consumption (VO2 max - ml/kg/min). 
Results: During a successive follow-up of 18 months, ten patients (24%) 
died, 9 of Group I and one of Group I1. All deaths were judged to be the 
results of cardiac complications. Multivariate stepwise analysis revealed that 
VO2 max was the most significant independent predictive factor of survival (p 
= 0.02) in comparison to echo-Doppler findings. Kaplan-Meier estimates of 
survival showed that pts with a VO2max > 15 ml/kg/min had a better survival 
than those with VO2max < 15 ml/kg/min (Figure, p = 0.01). 
~ ' , 
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Conclusion: Among the many factors important during evaluation, EC is 
a strong independent predictor of survival in these patients. 
Baseline Relative Lymphocyte Concentration: ~ 
A Powerful Prognostic Indicator in Advanced 
Heart Failure 
Jalal K. Ghali, Regina Nye, Anne Cropp. Louisiana State University Medical 
Center, Shreveport LA, USA 
The correlation of several clinical characteristics and laboratory values with 
prognosis is well established in heart failure. Recently, baseline relative 
lymphocytes concentration (RLC) was proposed to play such a role. In 
PRAISE-1 a total of 1153 class III and IV heart failure patiens, predominantly 
male (76%), mean age 64, mean LVEF 20.7% on digoxin, diuretics and 
ACE inhibitors were randomized to amlodipine or placebo. A total of 158 
patients (14%) had RLC < 16% and 994 (86%) had RLC > 16%. One 
patient did not have lymph count. Cox proportional hazards analysis was 
used to examine the correlation of several baseline variables to combined 
mortality and cardiovascular morbidity as well as to total mortality. Stepwise 
regression using a Cox proportional hazards model showed the following 
baseline variables; NYHA, etiology, LVEF, cardiothoracic ratio (CTR) and 
RLC as predictors of prognosis. Similar results were obtained for mortality 
and for the combined endpoint of morbidity and mortality. 
Variables RR (95% CI) p-value 
RLC 1.51 (1.27, 1.81 ) <0.001 
CTR 1.38 (1.16, 1.63) <0.001 
Etiology 1.41 (1.16, 1.68) <0.001 
NYHA 1.52 (1.29, 1.79) <0.001 
LVEF 1.37 (1.17, 1.60) <0.001 
s0.8:l > , , z  
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Conclusion: 1) Baseline RLC is a powerful predictor of prognosis 2) 
This finding may have relevance in designing future trials, listing for cardiac 
transplantation and potentially in management. 
1140-13 I High Level of Plasma BNP at Discharge is an 
J 
Independent Risk Factor for Mortality and 
Morbidity in Patients With Congestive Heart 
Failure 
Keiko Maeda, Takayoshi Tsutamoto, Atsuyuki Wada, Naoko Mabuchi, 
Masaru Hayashi, Masato Ohnishi, Masahide Sawaki, Masanod Fuji±, 
Masahiko Kinoshita. Shiga University of Medical Science, Otsu, Japan 
To evaluate whether repetitive measurements of plasma brain natriuratic 
peptide (BNP) levels before and after treatment for congestive heart failure 
(CHF) are useful for predicting mortality and morbidity in CHF patients, we 
measured plasma levels of atrial natriuretic peptide (ANP), BNP, endothelin 
(ET)-I and norepinephrine (NE) both at admission and at discharge in 103 
patients with severe CHF on admission to our hospital (NYHA class Ill-IV, 
mean left ventricular ejection fraction (EF) = 35%) Physicians who were blind 
to the plasma neurohumoral factors until study completion treated patients 
using standard drugs and doses such as digitalis, diuretics, ACE inhibitors, 
and beta-blockers. Patients were monitored for a mean follow-up period of 
19 months. Plasma levels of neurohumoral factors and EF were measured at 
admission and discharge. The end points, which were judged independently 
by researchers, were cardiac death or recurrent admission for severe CHF 
at NYHA class Ill-IV. Plasma ANP, BNP, ET-1, and NE and EF at discharge 
were significantly improved compared with the value at admission (ANP:204 
vs. 72 pg/ml; BNP:760 vs. 221 pg/ml; ET-1:4.34 vs. 2.57 pg/ml; NE:823 
vs. 371 pg/ml; EF:35 vs. 40%; p < 0.0001). Twenty-seven patients had 
recurrent admission or died. Cox proportional hazard analysis was performed 
to determined independent significant predictors of NYHA functional class, 
EF, plasma ANP, BNP, ET-1 and NE at admission and discharge, age and 
gender. By univariate analysis, ANP, BNP, EF and NYHA class on discharge 
showed significant relations with high mortality and morbidity. By stepwise 
multivariate analysis, only a high BNP on discharge (p < 0.0001) showed 
an independent significant relation with a high cardiac event rate in patients 
with CHF. These findings indicate that high plasma BNP levels at discharge 
are an independent risk factor for mortality and morbidity of CHF patients, 
suggesting that titration of the drug and doses of ACE inhibitore and/or 
beta-blockers to decrease the plasma BNP could have a beneficial outcome 
in CHF patients. 
I 1 1 4 0 - 1 4  j Usefulness of Brain Natriuretic Peptide for i 
Predicting An Association of Diastolic Restriction 
in Patients With Chronic Heart Failure: A Doppler 
Echocardiographic Study 
Keiko Matsukida, Akira Kisanuki, Masahiko Saigo, Satoshi Abe, 
Ryuichiro Arian, Yutaka Otsuji, Shinichi Arima, Shoichiro Nakao, Chuwa Tel. 
Kagoshima University Kagoshima, Japan 
Background: The relationship between the brain natriuretic peptide (BNP) 
and left ventricular (LV) diastology has not been fully studied. 
Methods: We measured BNP in 42 patients (25 with dilated cardiomy- 
opathy and 17 with ischemic cardiomyopathy) with chronic heart failure (HF). 
We also measured LV dimension, fractional shortening (%FS), the ratio of 
eady transmitral flow velocity (FV) to atrial FV (E/A), mitral deceleration time 
(DT) and the ratio of pulmonary venous FV in systole to that in diastole (S/D) 
with Doppler echocardiography. NYHA class, quality-of-life (QOL) score and 
6-minute walk test were assessed. Patients with F_J'A _> 1.0 and DT < 150 
msec were considered to have diastolic restriction. 
Results: The patients were divided into 3 groups according to the BNP 
value, G-I (BNP < 74 pg/ml), G-II (75-149) and G-Ill (150<). There were 
no differences in the %FS among the 3 groups. There were significant 
differences in the E/A, DT, S/D and NYHA class in G-Ill compared to G-I 
and G-II. No differences in the QOL score or walk distance were observed 
between G-I and G-II. The sensitivity of BNP > 150 for identifying diastolic 
HF was 89% (17/19) with a specificity of 83% (19/23). 
G-I(n= 12) G-II (n= 9) G-Ill (n = 21} 
LVDd (mm) 59 ± 4 67 ± 6* 64 ± 7 
%FS 20±5 14±7 17±7 
E/A 0.7 ± 0.4 0.7 ± 0.6 2.0 ± 2.1*t 
DT (msec) 223 :L 77 215 ± 67 151 ± 67 .1 
S/D 1.5 ± 0.4 1.6 ± 0.6 0.8 ± 0.4 *t 
NYHA class 2.2 ± 0.4 2.3 ± 0.5 3.0 ± 0.6 .1 
*p < 0.06 vs G-I, "~p < 0.05 vs G-II, Dd = diastolic dimension. 
Conclusion: BNP _> 150 pg/ml predicts the presence of diastolic restric- 
tion in patients with chronic HF. 
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• Superiority of Brain Natriuretic in Peptide 
Assessing Efficacy of Therapy to Improve 
Symptoms of Congestive Heart Failure in the 
Outpatient Setting 
Sharc~ M. SaadOer(3, Homej H. Che~, Trac~" L. ~tevens, Ooucjlas 
Jr.. Mayo Foundation, Rochester, MN, USA 
Background: New York Heart Association (NYHA) classification is used as a 
measure of efficacy of therapy in the management of congestive heart failure 
(CHF) based upon its correlation with survival despite subjectivity of the 
classifications. Left ventricular ejection fraction (LVEF) is also used to assess 
efficacy of therapy because of its sensitivity in the detection of ventricular 
dysfunction despite high cost and lack of strong correlation to survival in 
treatment trials. The cardiac hormone BNP which is increased in the plasma 
in humans with CHF is a sensitive and specific serum marker for detecting 
systolic and diastolic dysfunction. It is also a prognostic marker for survival 
in patients with CHF and following myocardial infarction. 
Methods: The current study investigated the role of BNP as compared to 
other natriuretic peptides [ANP and N-terminal ANP (N-ANP)] and LVEF by 
echo~card~oeraT~y m cbrreSa'hn9 W~ ~"~,  c'~ssgfflca~o~n m.~s'~en'~s un6er - 
going treatment for CHF in the outpatient setting (Visit 1 ). We also assessed 
at a 6-12 month follow-up visit (Visit 2) which parameter would correlate with 
NYHA classification during medical therapy. 
n = 2Tano'~; n = fSJ. At ,;,Isff 1', oni~] 6-~F~was iho~penoerr@ assooiafeo'wi~ 
NYHA class in a multivariate model while ANP, N-ANP and LVEF were not. 
BNP was also the most sensitive and specific marker for NYHA class when 
comt:areQ' to A~P, ~-AtTP and LVEF ~b~ F:.OC ana/Tsfs. At V~sft 2, 42 garments 
were assessed, 10 of which improved (Ill-IV to I-Ill and 32 had no change 
(maim'~a~ne~ lsss]. ~r~!v ~qP ane not ~'N'r','lh-~-~l~r or'E~,,-~-}lnt]epeneerit!v 
Conclusion: These studies demonstrate that in the outpatient manage- 
ment of CHF, BNP is an objective serum marker correlating to NYHA classi- 
fication. "¢,Je conc~o6e Yna't ~,~F' co~6 a)6 ~ o~5)ec'fi'~e~y assess)n~ '~e ~m~sd~ 
~ N-terminal proANP Is a Marker of Clinical Relevant 
Diastolic Dysfunction 
Bert Andersson, Christian Hall. Dept. of Cardiology, Sahlgrenska University 
Hospital, GSteborg, Sweden; Department Group for Clinical Medicine, 
University of Oslo, Rikshospitalet. Oslo, Norway 
Background: The frequency of diastolic heart failure has been considered as 
com~non as  s v's'~dilC 'nesft "rahure. Xt~noudn/oncp'[erm iprognosls 'is Tegar~e6 
as better than in systolic heart failure, no prognostic marker has yet been 
identified in diastolic heart fsilure. We studied pmgr~osis nd s'tmp'[oms in 
diastolic heart failure in relation to the atrial peptide N-terminal proANE As 
the c~t~rc~4v~'in~, ~, ~ ' ,~ ,  ~J~A~,t,'P ,;~ ;~,~,~r~ ~ , ~  ~ ~e~,r& 
fillin~eress~reslrhs~De~%Ce cod~6 re.oreserhl~e 6eo~ee 5]'~eafl'r~imre. 
Methods: From a group of patients with idiopathic heart failure from the 
western part of Sweden (n = 293), 60 patients were identified with normal 
systole 1uric'Con JE? 2 ~,~%) an6 w'ffn O't~eT concordfisHt ~henS 0I t~S'tu~e6 
left ventricular function, in accordance with diastolic heart failure. N-terminal 
proANP was analyzed and was related to 7-year survival. 
Results: Patients with N-terminal proANP > 1200 pmol/L had significantly 
worse pro(3nosis than patients with Cower concentrations. In a multivariate 
analysis, N-terminal proANP was the only independent predictor of survival: 
RR 2.7t ~5% Ct t.32-5.5~, p = &~7.  A ~,~rger propo'rt~o~ o,~ p~t~ts  Wtt~ 
high concentrations of N-terminal proANP suffered from death or hospital- 
ization during follow-up (67% vs. 33%, p = 0.028). Further, they tended to 
mg vs. 55 ± 42 rag, p = 0.015). 
CC, onc)u~on: Patients W~h d~asto))c heart ~,fi~)ure an~ h~0n concentration 
of N .to rmin-a!.p rgA~,LP.,h~ -sight. ef.sli~ic~lly.impo ~-ant-~.~,m_.-e~nt£ #At ~.i ~ 
creased mortality and symptoms. We postulate that increased concentration 
of N-terminal proANP might be one of few markers of diastolic heart failure 
of clinical relevance. 
~ A n  Algorithm for Biochemical Diagnostic 
Screening of Cardiac Function; Assessment of 
Left Ventricular Function by B-type Natriuretic 
Peptide Levels 
Tom Suzuki, Kazuhide Yamaoki, Osamu Nakajima, Tsutomu Yamazaki, 
Yoshiharu Yamada, Hisashi Akioka, Yoshio Yazaki. The University of Tokyo, 
Tokyo, and Nissei Hospital, Osaka, Japan 
function in the clinic is lacking, and still too often the diagnosis of cardiac 
dysfunction is overlooked. To establish a rationale for accurate screening of 
cardiac function by cost-effective and non-specialized means is important 
We have focused our studies on biochemical testing given its optimal role 
in diagnostic screening. The present study was done with the objective 
to determine the use of B-type natriuretic peptide (BNP) levels, a most 
sensitive biochemical marker reflective of cardiac function, to detect cardiac 
dysfunction in asymptomatic patients. 
Methods: 294 consenting asymptomatic patients were examined for 
raised BNP levels and presence of cardiac dysfunction. Patient charac- 
teristics, physical examination, chest X-ray, electrocardiogram and serum 
creatinine levels were examined in all patients, Patients with raised BNP 
levels (> 18.4 pg/ml) were further subjected to echocardiographic examina- 
tion of systolic (ejection fraction and fractional shortening, EF and FS) and 
diastolic rE-wave to A-wave ratio, E/A) functions. Complementing factors of 
BNP levels were also examined to attest to reliaNe detection. 
Results: BNP levels in elevated patients showed significant correlation 
with echocardiographic parameters of the systolic and diastolic functions (EF 
r = -0.51, FS r = -0.50, E/A r = 0.42, p < 0.01). Moderate correlation 
with the CTR on chest X-ray was also seen (r = 0.23, p < 0.01). Multiple 
regression analysis showed numerous echocardiographic and hemodynamic 
.oarame~ers m~6mo ~ose o~ sys~o~ an6 6~as~o'~c~u~c~onm a66~on ~o~e~ 
ventricular wall thickness, blood pressure and serum creatinine levels to be 
significantly associated with raised BNP levels. 
Conclusions: BNP levels accurately reflect cardiac dysfunction, both 
for ¢~ean'faiibre, aoJi~nct use wit~ esta6~ls~eo'olagnos~b methoo~ ['e.g. echo- 
cardiography) should prove useful in the clinic. A diagnostic algorithm with 
BNP levels is proposed. 
Fibrillation in Patients With Congestive Heart 
Failure 
TakaNsa Yamada, Masatake Fukunami, TsqvosN Sh(mon~ata. 
Kazuaki Kumagai, Hisakazu Ogita, Yoshihisa Asano, Akin Hirata, 
Noritake Hoki. Osaka Prefectural General Hospital, Osaka, Japan 
Background: Paroxysmal atrial fibrillation (Pal) could cause the deterioration 
of congestive heart failure (CHF). Although atrial natriuretic peptide (ANP) 
has been reported to have prognostic significance in patients (pts) with CHF, 
no information is available on the relation between ANP and the development 
of Paf in CHF pts. To clarify the prognostic significance of ANP as a predictor 
of the development of Paf in CHF pts, we prospectively studied 75 pts 
without the history, of Paf, whose LV ei.ection fraction (RI-EF) measured by 
raoibnucfib'e ang~bgrapCly was <,4'~g 12"6" ± to"%). 
Methods and Results: Plasma level of ANP, renin activity, aldosterone 
and norepinephrine were measured at the entry. During a follow-up period 
of 21 ± 9 months, 10 of 75 ,ots developed Paf attacks documented on the 
ECG. ANP concentration was siclnificantlv hicIher in pts with than without Paf 
~everopmenf (T.~.Z ± ,¢r.,£ vs 5-,¢ ~ d'~..4" pg?Cn~ p = 5t~'rr', wr~rre dlere were 
no significant differences in age, gender, plasma levels of renin, aldosterone 
or norepinephrine, LV end-diastolic dimension, left atrial dimension, RI-EF 
or fhe tOld(counts or atda¢ premature beats fn Hoffer reon~'odng at t~e enfry 
between them. ]-he development of Pal was significantly more frequently 
observed in pts with than without elevated ANP level > 60 pg/ml (32% [8/25] 
vs 4% [2/50], log-rank test, p = 0.001). 
Pal- free ratio 
~ ANF < 60 a~.~mt 
.8 ~ t 
.6 ) ANF > g~ ~ml .  
"# t 
.2 , , , (day,s) 
0 200 400 600 800 
Conclusion: In CHF pts, ANP might also provide prognostic information 
about the development of Paf. 
rrl 
..4 
11 
c- 
ill 
I.H 
- J  
m 
l-- 
i l l  
"1" 
194A ABSTRACI 'S  - Heart Failure JACC February 1999 
• Comparison of Amino-terminal Pro-Brain 
Natriuretic Peptide and "Big" Endothelin 1 as 
Prognostic Indicators After Myocardial Infarction 
A. Mark Richards, D.J. Webb, T.G, Yandle, N,R. Johnston, M.G. Nicholls, 
J.M. Elliott, H. Ikram, J.G. Lainchbury, R.W, Troughton, J. Turner. 
Christchurch School of Medicine, Christchurch, New Zealand and University 
Department of Medicine, Western Genera/Hospital, Edinburgh, Scotland 
Background: We hypothesised plasma levels of cardiac peptides (BNP and 
N-terminal BNP) and endothelin (ET~ and "Big" ETa) provide independent 
prediction of cardiovascular prognosis after MI. 
Methods: A series of 290 patients with acute MI had blood samples taken 
(24-96 hours after onset of infarction) for assay of BNP, N-BNP, ET1 and 
"Big" ET~. Radionuetide ventriculography was conducted in the same time 
window. 
Results: Over 22 months, rates of death and heart failure (HF) were t l  
and 26%, Levels of all four neurohormonal factors and LV systolic volume 
were greater, and LVEF less in those who died or incurred HF than in ethers 
(P < 0.001 for all), The relative risk ratios (95% CI) for death in those with 
hormone levels above compared with below the median fell between 2.5 
(1.2-5.2) and 9.1 (2,6-29) (least for ET~ and greatest for N-BNP; P = 0.011 
and P < 0.0001 respectively). For HF the corresponding results were 2.2 
(1-4.6) and 12.5 (3-52) (P = 0.043 and P < 0.0001). Of the four peptides, 
N-BNP had greatest sensitivity, specificity, positive and negative predictive 
values for both death (81, 66, 24 and 96% respectively) and HF (85, 76, 28 
and 98%). Multivariate analysis (Cox proportional hazards) indicated both 
"Big" ET1 and N-BNP were predictive of death and HF independent of age 
and LVEF. 
Conclusion: N-BNP and "Big" ET~ are independent predictors of death or 
HF over 2 years post-MI with N-BNP the more powerful individual predictor. 
ORAL  
[ -~  Exercise Performance and Training in Heart 
Failure 
Tuesday,  March  9, 1999, 10:30 a .m. -Noon 
Moda l  Convent ion  Center ,  Room 228 
1 0:30 a.m. 
~-- ]  Alleviation of Dyspnea in Patients With Heart Failure 
via Selective Leg Muscle Training 
Ainat Beniaminovitz, Marie Cordisco, Celine Sese, Donna Mancini. 
Columbia Presbyterian Medical Center, NY, NY, USA 
Background: Dyspnea is a frequent limiting symptom in patients with heart 
failure. According to the "muscle hypothesis", this sensation may primarily 
originate from changes which occur in the leg musculature rather that the 
lung. 
Methods: To investigate whether dyspnea can be alleviated by selective 
changes in leg muscle function, we performed isolated lower limb training 
in 9 patients with severe CHF. Eight patients learned relaxation techniques 
and thus served as an active control group. Exercise training consisted of 3 
months of low level bicycle and treadmill exercise such that minute ventilation 
was less than 25 L/min. Leg calisthenics were also performed. Maximal 
and submaximal exercise performance, respiratory and quadriceps muscle 
strength and endurance, quality of life and dyspnea scales were measured 
before and after training. Metabolic stress testing (VO2), pulmonary function 
tests, and isokinetic strength testing (Cybex) was performed. 
Results: In the active control group, no changes in leg muscle function, 
pulmonary function, maximal and submaximal exercise performance, and 
quality of life questionnaires were observed In the trained group, increase in 
the peak torque of leg flexors (Pre: 39 4- 15; Post: 50 ± 13 ff-lbs; p < 0.002) 
and in the fatigue ratio indicating improved strength and endurance of the leg 
muscles was observed. Maximal inspiratory and expiratory mouth pressures 
and maximum voluntary ventilation (Pre: 95 4- 21; Post 91 ± 19 I.Jmin) were 
unchanged. Peak VO2 was unchanged (Pre: 12.3 ± 2.5; Post: 12.9 ± 2.9 
ml/kg/min) but the duration of exercise at 70% peak VO2 increased (Pre: 
11.5 ± 3.1; Post: 21.5 ± 5.4 min; p < 0.003). Level of perceived dyspnea 
during the submaximal testing was decreased (Pre: 6 ± 2; Post: 4 ± 2; p 
< 0.02). Minnesota Living with Heart Failure, 02 cost diagram and Guyatt 
dyspnea scales were all improved with training (all p < 0.05). 
Conclusion: Improvement of limb muscle function alleviates dyspnea 
and improves submaximal performance in patients with CHF. 
10:45 a.m. 
~-~- ]  Plasma Leptin Levels Are Related to Fatigue in 
Patients With Chronic Heart Failure 
Francisco Leyva 1 , Stefan D. Anker ~ , Philip A. Poole-Wilson, Andrew 
J.S. Coats ~ . ~ Department of Cardiac Medicine, ICSM at NHLI, London, UK 
Background: Fatigue, an important symptom in patients with chronic heart 
failure (CHF), correlates weakly with haemodynamic measures and responds 
poorly to treatment. CHF is a hypercatabolic, hyperleptinaemic state in which 
plasma leptin levels are positively related to energy expenditure. We consid- 
ered that in CHF, plasma leptin levels might also relate to muscle strength 
and fatigue. 
Methods: Male patients with CHF due to coronary heart disease In = 19, 
aged 63.2 4- 2.1 yrs, mean ± SEM, body mass index (BMI) 25.7 4- 0.9 kg/m 2, 
radionuclide LVEF 23 ± 3.0%] underwent measurement of fasting plasma 
leptin [radioimmunoassay, 7.1 (-0.82, +0.93) ng/ml)], a symptom limited 
exercise test, and measurement of isometric quadriceps muscle strength 
and fatigue as well as body fat and lean tissue composition (dual energy 
X-ray absorptiometry, total fat = 19.2 ± 1.7 kg, total lean tissue = 52.1 4- 
1.8 kg). Muscle fatigue was expressed as % of baseline quadriceps muscle 
strength (20 min protocol). 
Results: In univariate analysis, plasma leptin concentrations did not cor- 
relate with skeletal muscle strength at baseline. Strong correlations, however, 
emerged between plasma leptin levels and exercise time to exhaustion (r 
= -0.54, p = 0.02) and skeletal muscle strength at 5 mins (r = -0.58, p = 
0.009), 10 mins (r = -0.79, p < 0.001), 15 mins (r = -0.55, p = 0.017) and 
20 mins (r = -0.59, p = 0.016). In multivariate analyses, fasting plasma leptin 
emerged as a significant predictor of muscle fatigue at all time points (all p < 
0.05), independently of total body fat. 
Conclusions: In CHF, plasma teptin levels are related to measures of 
general fatigue as well a quadriceps muscle fatigue. This relationship, which 
is independent of adiposity, implicates leptin in the fatigue experienced by 
patients with CHF. 
11:00 a.m.  
~4~3- ]  Exercise Training Reduces the Expression of 
Inducible Nitric Oxide Synthase in Skeletal Muscle 
Biopsies of Patients With Chronic Heart Failure 
Rainer Hambrecht, Volker Adams, Jiangtao Yu, Nina Schoene, 
Stephan Gieten, Claudia Walther, Gerhard Schuler. University of Leipzig, 
Heart Center, Leipzig, Germany 
Background: Increased expression of inducible nitric oxide synthase (iNOS) 
have been described in skeletal muscle (SM) of patients (pts) with chronic 
heart failure (CHF). Functional work capacity in these pts was inversely 
correlated to the extent of iNOS expression. The present study was designed 
to determine the effect of aerobic exercise training (ET) on iNOS expression 
in SM of pts with CHF. 
Methods: Pts (n = 17) were randomized to either a training group (T) par- 
ticipating in a moderate exercise training program (60% of VO2max) in addi- 
tion to standard mediacal treatment or to a physically inactive control group 
(C). At study begin (B) and after 6 months (E), pts underwent symtom-limited 
bicycle ergospirometry as well as percutaneous needle biopsies of the vastus 
tateralis muscle. Expression of iNOS was quantified by immunohistochem- 
istry (% iNOS positive tissue area) and confirmed by reverse-transcriptase 
polymerase chain reaction. 
Results: Six months of moderate ET lead to a significant increase in 
VO2max by 18% (from 18.5 ± 3.5 to 21.8 4- 3.6; p < 0.01 vs. C). At B 
expression of iNOS was comparable between T and C (3.9 4- 1.6 vs. 3.4 
4- 1.9%). A significant reduction (-26%) in iNOS expression was observed 
after 6 months of ET (from 3.9 4- 1.6 to 2.9 4- 1.2%, p < 0.01 vs. C). Changes 
in VO2max were inversely correlated to changes in iNOS expression (r = 
-0.6, p < 0.01). 
Conclusion: Moderate aerobic ET leads to a significant reduction in iNOS 
expression in the skeletal musculature of pts with CHF. A decreased local 
production of nitric oxide by iNOS may significantly contribute to improved 
functional work capacity, possibly by decreased inhibition of aerobic enzymes 
in the skeletal muscle. 
11:15 a.m. 
l - ~  Increased Body Mass Index Is Associated With 
Attenuated Ventilatory During Exercise in Chronic 
Heart Failure 
w. Sham±m, D. Francis, M. Yousufuddin, J, Chambers, M. Rauchhaus, 
M. Cicoira, F.R. Am±n, A.J.S. Coats. Royal Brompton Hospital & National 
Heart and Lung Institute, London, UK 
Background: Patients with chronic heart failure manifest an inappropriate in- 
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crease in their hyperpneic response to exercise (VE/VCO2 slope). Increased 
body mass index may restrict the ventilatory response to exercise, but this 
relationship has not been well character±sod. 
Methods: We analysed data from 142 consecutive patients with chronic 
heart failure, who underwent cardiopulmonary exercise testing. Patients were 
aged 60 ± 11 years (mean ± SD), and had mean left ventricular ejection 
fraction 27.7 ± 13.9%, peak oxygen uptake 16.9 ± 5.7 ml/min/kg. Exercise 
testing was performed using modified Bruce protocol, with continuous on-line 
respiratory gas analysis. The slope of the relationship between ventilation 
(VE) and CO2 production (VCO2) was determined by computerised graphical 
analysis. 
Results: The subjects had body mass index (BMI) of 26,6 ± 4.4 kg/m2 
(mean ± SD), and VENCO2 slope values of 38.4 ~ 12.5. The correlation 
between BMI and VENCO2 slope was 0.28 (p < 0.0008). When the patients 
were divided into categories according to BMI (<22, 22-30, >30), there were 
differences between the mean VE/VCO2 slopes of each group, which was 
significant (by ANOVA) for each pair of comparisons, as shown in figure. 
vr=nK:o'z ,dora 
BMI<22 BM122-30 BMI>30 
Conclusion: Patients with normal or mildly increased BMI show relatively 
more hyperpneic response to exercise. In contrast, patients with marked 
obesity (BMI > 30) demonstrate a mild hyperpneic response to exercise. 
11:30 a.m. 
~ - ~  Exercise Capacity in Heart Failure Patients During 
• an Hypoxia-Altitude Simulation Test 
Piergiuseppe Agostoni, Gala Cattadori, Marco Guazzi, Maurizio Bussotti, 
Cristina Conca, Mass±me Lomanto, Giancarlo Marenzi, Maurizio D. Guazzi. 
Istituto di Cardiologia, Centro Cardiologico, Fondazione Monzino, Universita 
di M#ano, Milan, Italy 
Background: It is unknown whether heart failure patients can safely reach 
altitude and whether their working capacity reduces at altitude. 
Methods: We studied 14 normals and 38 heart failure subjects: peak VO2 
> 20 ml/min/kg 12 patients, peak VO2 20-15 ml/min/kg = 14 and peak VO2 
< 15 ml/min/kg = 12 (class A, B and C, respectively). All subjects performed 
in random order 5 cardiopulmonary exercise tests (ciclo-ergometer, person- 
alized ramp protocol) with atmospheric PO2 equal to the one present at 92, 
1000, 1500, 2000 and 3000 rots. 
Results: All subjects completed the trial; no test was interrupted because 
of arrhythmia, angina or ECG evidence of transient ischemia. As the simu- 
lated altitude increased, maximal workload progressively reduced: at 3000 
mrs maximal workload was reduced by ~8%*, ~15%', ~15%', ~32%" (* = p 
0.01 vs. 92 mts), in normals and class A, B and C patients, respectively. Peak 
VO2 showed a similar behavior. This allowed as to prepare a drawing from 
which it is possible to predict the maximal workload at altitude by knowing 
the workload reached at sea level. 
[re~ctlon as % of workload Mt sea leve~ 
Is,~,,.,d Qc,.,.., ~+B A...,, c I 
Conclusion: Patients with heart failure can safely ascend to altitude but 
they should be instructed to limit their exercise activity in a proportion related 
to altitude and their exercise capacity at sea level. 
11:45 a.m. 
[ - ~  The Impact Feasibility an Program and of Exercise in 
Elderly Patients With Heart Failure 
Stephen S. Gottlieb, Gretchen Zietowski, Lynette Alves, Robert McCarter, 
Catherine Krichten, Michael L. Fisher, Ronald Freudenberger, 
Shawn Robinson. University of Maryland School of Medicine and VA 
Medical Health Care System, Baltimore, MD, USA 
Exercise (exer) programs have been shown to improve maximal exercise in 
pts with heart failure, but the feasibility of such a program in elderly patients 
& effects on activities of daily living are unknown. We therefore randomized 
36 elderly patients (age 65 ± 9 yrs) with CHF (ejection fraction = 24%; 12 
NYHA class II & 24 class III pts) to a supervised 6 month exercise program 
or usual care. The following parameters were obtained at baseline & at 6 
months: maximal exercise duration (DUR) and peak VO2, Functional Status 
Assessment-Intermediate Activity (FSA) and Minnesota Living With Heart 
Failure (Minn) Questionnaires, and daily energy expenditure assessed by 
Caltrac accelerometer & doubly labeled water (DLW) technique. 
73 patients initially agreed to participate. Of these, 37 later declined 
(concerns about time & transportation & fear of exer). Of patients who enrolled 
in exer, 6 dropped out because of inability to exer, non-compliance, or death. 
Of the patients who remained, exer led to improved maximal exer, but daily 
activity, as indicated by questionnaires, and daily energy expenditure did not 
change, where " = p < 0.05 v. Pre, Cont = control (n = 12), Exer = exercise 
(n = 11): 
VO2 Dur Caltrac DLW Minn FSA 
Cont Pro 14 ,2±3.0  9 .8±4.8  3954±743 3961±t699 44+20 75±14 
Post 14,5 ± 4.3 10.2 ± 5.6 3966 ± 743 2404 ± 152 23 ± 13 69 ± 26 
Exer Pre 13 .8±1.8  12 .9±3,2  3986±393 2098±478 16±21 73±15 
Post 16 .6±2,6"  18.5±2.9+ 4177±904 2033±251 19118 73±13 
Eldedy, sick patients with CHF can safely enroll in an exercise program 
with improvement in maximal exercise. However, most elderly CHF patients 
will not participate in such exercise programs. Furthermore, improvement 
in maximal exercise may not translate to improvements in activities of daily 
living. 
POSTER 
Right Ventr icular  and Pu lmonary  Dynamics  
in Heart Fai lure 
Tuesday,  March  9, 1999, Noon-2 :00  p.m. 
Moda l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  Noon-1 :00  p.m. 
I -1 -1~ Effect of Left Ventricular Filling Pressure as 
Measured by Pulmonary Capillary Wedge Pressure 
on Right Ventricular Function in Patients With 
Congestive Heart Failure 
Fatima Franco, Michael A. Solomon, Eduardo Fernandez, Clyde W. Yancy, 
Ronald M. Peshock. University of Texas Southwestern Medical Center, 
Dallas, TX, USA 
Background: Right ventricular ejection fraction (RVEF) and left ventricular 
filling pressure, as measured by the PCWP, correlate strongly with survival 
and functional capacity in patients with congestive heart failure. However, 
the dependence of RV function on PCWP is not well described. Magnetic 
resonance imaging (MRI) is a highly accurate, quantitative method for as- 
sessment of RV function. We asked (1) what is the effect of PCWP on RVEF 
and (2) To what extend does reducing PCWP improve RVEF? 
Methods and Results: Patients [n = 46, age 52 ± 13 years, NYHA class 
II (11/46), class III (27/46) and IV (8/46)], underwent MRI and right heart 
catheterization (RHC) within 24 hours of each other. MRI mean LVEF was 
0.33 ± 0.12 and mean RVEF was 0.36 ± 0.11. RVEF and PCWP correlated 
strongly (r = -0.85). Severely or moderately depressed RVEF predicted 
PCWP > 16 mmHg in all cases. The correlation between RVEF and PCWP 
was significantly stronger than between LVEF and PCWP (r RVEF = --0.85 MS. 
r LVEF = --0.52, p < 0.001). Fourteen of 46 patients received IV diuretics and 
vasodilators with follow-up RHC and MRI. RVEF remained highly correlated 
with PCWP (r = -0.90) and in patients who responded to therapy RVEF 
improved significantly (0.27 ± 0.06 at baseline to 0.44 ± 0.04 post treatment, 
p < 0.0001). 
Conclusions: RV function by MRI correlates strongly with PCWP. Severely 
or moderately depressed RVEF identifies patients with increased LV filling 
pressure, who may benefit from intensive medical management. A success- 
ful response to medical treatment (PCWP _< 16 mmHg) was associated with 
dramatic improvement in RVEF. RV function is highly dependent on PCWP 
and therefore RVEF is not an independent prognostic indicator in patients 
with congestive heart failure. 
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• Right Ventricular Ejection Fraction in Idiopathic 
Dilated Cardiomyopathy Compared to Ischemic Left 
Ventricular Dysfunction. Data from an 
Angiographic Study 
Luigi La Vecchia, Mar±emma Paccanaro, Leonardo Varotto, Carlo Bonanno, 
Manuela Martini, Maudzio Sartori, Renato Ometto, Mario Vincenzi. 
Department of Cardiology, S. Bortolo Hospital, Vicenza, Italy 
Background: Radionuclide studies suggest that nght ventncular (RV) ejec- 
tion fraction (EF) is more often impaired in idiopathic dilated cardiomyopathy 
(IDC) compared to ischemic left ventricular dysfunction (ILVD). However, it 
is unknown whether this is a consequence of pulmonary hypertension or 
biventricular involvment in IDC. 
Methods: Hemodynamic data, left ventricular (LV) and RV angiograms 
were analyzed in 82 patients (pts) with LVEF < 45%. IDC was diagnosed in 
48 (normal coronary arteries, biopsy negative for myocarditis); ILVD in 34 (of 
these, 82% had multivessel disease and 68% had a critical right coronary 
artery lesion). RV dysfunction was defined as a RVEF < 35% (mean - 3 
standard deviations of controls). 
Results: LVEF was 31 ± 9% in IDC pts and 32 ± 7% in ILVD pts. LV 
and RV volumes were comparable in the 2 groups, so that the ratio of LV/RV 
end-distolic volume (relative LV dilatation) was also similar (1.25 ± 0.4 and 
1.3 ± 0.5). Mean pulmonary pressure was 27 ± 12 in IDC and 25 ± 11 mmHg 
in ILVD (p = 0.44), while LV end-diastolic pressure was 18 ± 7 vs 17.3 ± 8 
mmHg (p = 0.68). RVEF was significantly lower in IDC compared to ILVD pts 
(34 ± 11% vs 44 ± 11%, p < 0.0001). RV dysfunction was present in 58% of 
IDC vs 15% of ILVD (p < 0.0001). 
Conclusions: IDC is associated with RV dysfunction more often than 
ILVD. This finding is independent of the entity of pulmonary hypertension. 
These data suggest that IDC is a biventricular disease more often than 
suspected and that biventricular involvment is a distinguishing feature of this 
disease. 
• Doppler Echocardiographic Evaluation of Right 
Ventricular Function During Graded Nitric Oxide 
Inhalation in Heart Failure 
Karl Dujardin, Johan Vanhaecke, Johan Van Cleemput, Walter Droogne, 
Frans Van de Werf, Stefan Janssens. Cardiac Unit, University Hospitals 
Gasthuisberg, University of Leuven, Belgium 
Inhaled nitric oxide (NO) is a selective pulmonary vasodilator in patients with 
left ventricular dysfunction, but the effects on right ventricular (RV) function 
are unknown. Ten patients (all men, age 54 ± 14 years) with NYHA II or 
III congestive heart failure (CHF) inhaled incremental doses of NO (20 and 
80 ppm) mixed with room air via nasal prongs and were evaluated using 
simultaneous Doppler echocardiography and pulmonary artery (PA) catheter 
monitoring. Doppler time intervals of the right heart cycle were combined in 
a previously defined ratio: the sum of isovolumic relaxation and contraction 
time (ICT + IRT) divided by ejection time (ET). 
Baseline NO 20 ppm NO 80 ppm 
MBP (mmHg) 81 ± 8 80 ± 8 77 ± 13 
CO (I/rain) 4.85 ± 2.13 5.16 ± 1.94 4.91 ± 2.30 
MPAP (mmHg) 29 ± 9 23 ± 10" 27 ± 10" 
PCWP (mmHg) 17 ± 8 15 ± 7* 17 ± 6 
TPG (mmHg) 11 ± 6 8 :L 5* 8 ± 6" 
PVR (dynes/sec. cm 5 213 ± 160 136 ± 88 ' 126 ± 108" 
RVEF (%) 30 ± 13 31 ± 15 29 ± 10 
ICT + IRT (msec) 165 ± 52 142 ± 44" 155 ± 99" 
ET (msec) 261 ± 36 266 ± 36 269 ± 32 
(ICT + IRT)/ET 0.63 ± 0.55 0.48 ± 0.23" 0.21 2: 0.22" 
CO, cardiac output; MBP, mean blood pressure; MPAP, mean PA pressure; PCWP, pul- 
monary capillary wedge pressure; PVR, pulmonary vascular resistance; RVEF, RV ejec- 
tion fraction; TPG, transpulmonary pressure gradient. *P < 0.05 versus baseline. 
Conclusion: In CHF with moderately elevated PCWP, NO selectively 
lowers PVR with improved RV performance, suggesting a potential role in 
the management of CHF. 
~ T h e  Evaluation of the Coupling Between Right 
Ventricular Function and Pulmonary Artery 
Pressure Allows Improved Prognostic Assessment 
in Congestive Heart Failure 
Stefano Ghio, France Recusani, Corinna Inserra, Luigia Bucci, 
Catherine Ktersy, Claudia Raineri, Carlo Campana, Alessandra Repetto, 
Antonello Gavazzi, Luigi Tavazzi. Dept. of Cardiology, IRCCS Policlinico S. 
Matteo, Pavia, Italy 
Background: A reduced right ventricular ejection fraction (RVEF) is an 
indicator of poor prognosis in pts with advanced congestive heart failure 
(CHF). It is well known however that RV function is inversely related to 
the level of pulmonary artery pressure (PAP). This study was designed to 
elucidate as to whether the evaluation of the coupling between RVEF and 
PAP may improve prognostic assessment in such pts. 
Methods and Results: The case series consisted of 144 pts (108 males) 
with symptomatic CHF despite optimized medical therapy. At right heart 
catheterization, the mean PAP was 30 ± 10 mmHg and the RVEF was 27 
± 13%. In the whole population an inverse relation was obsewed between 
the two parameters (r = -0.71, p < 0.001). Dunng a follow-up period of 
12 ± 7 months 27 pts died and 15 underwent heart transplantation. At the 
univahate analysis a mean PAP > 20 mmHg and a RVEF _< 25% were 
significantly associated to the occurrence of events. Using these values to 
draw coordinates on the scatterplot, the population was subdivided into 4 
groups. At the Cox survival analysis the pts in the "low pressure - low RVEF" 
group had the worse prognosis. The hazard ratio indicated a risk of these 
pts 16 times larger than that of the pts in the "low pressure - good RVEF" 
group (95% CI: 3-79, p < 0.001), 5.8 times larger than that of the pts in the 
"high pressure - good RVEF" group (95% CI: 1.3-26, p = 0.02) and 3.5 times 
larger than that of the pts in the "high pressure - low RVEF" group (95% CI: 
0.85-15, p = 0.09). 
Conclusion: A low RVEF despite normal pulmonary artery pressure 
indicates very poor short-term prognosis in pts with congestive heart failure. 
• Right and Left Ventricutar Interaction in Chronic 
Heart Failure: Contribution of External Forces to 
Determine Hemodynamic Response During 
Nitroprusside Infusion 
Soccorso Capomolla, Oreste Febo, Angelo Caporotondi, Cristina Opasich, 
Giorgio Riccardi, Franco Cobelli. "Salvatore Maugeri" Foundation Institute 
of Medical Care and research Montescano (Pavia), Italy 
Background: Diastolic right ventricular volume can influence diastolic left 
ventricular volume. In physiologic condition this interaction is insignificant; 
however in chronic heart failure (CHF) volume overload modifies ventricular 
interaction and increases right ventricular filling pressure which enhances 
the external force and heart chambers interdependence. 
Objective: To evaluate the relations between external forces, ventricular 
interaction and its clinical importance in patients with CHF. 
Methods: Right heart catheterization and transthoracic echo-Doppler 
were simultaneously performed - at baseline and after nitroprusside infusion 
(NTP)- in 164 consecutive patients with CHF (LVEF 25 ± 7%) and pul- 
monary wedge pressure (PWP) >_ 18 mmHg. The following parameters were 
considered: left ventdcular ejection fraction (LVEF), left ventricular end-dias- 
tolic volume (LVEDV), right atrial (RAP), mean arterial pulmonary (mPAP), 
pulmonary wedge pressure (PWP) and cardiac index (CI). Accordingly to 
baseline RAP patients were divided in three groups: G1 (RAP _< 5 mmHg); 
G2 (5 < RAP < 10) and G3 (RAP ~ 10 mmHg): 
Results: 
NTP A RAP ± mPAP A PWP ALVEDV ALVEF ~CI 
changes mmHg mmHg mmHg ml % I/min/m2 
G1 50 pts --2 :c 1 12 i 7 12 ± 6 -42 ± 35 +4 ± 3 +.4 ± 0.36 
G2 57 pts -4±2 -13 i7  11 ±7 -37±30 +4±4 +.66±0.43 
G3 57 pts -613"  11 ±7 -5±3"  +10 ± 33" +5=4 +.98 i 0.33 
"p < 0.001 
Conclusions: In pts with normal or moderately increase of right atrial 
pressure, concordant reduction of right and left atrial pressure induced by 
NTP infusion were associated with LVEDV reduction. Despite in patients 
with have baseline high right atrial pressure, decrease of right atrial pressure 
after NTP infusion was accompanied by LVEDV increase with concomitant 
increase of cardiac output. Baseline High right atrial pressure identified pts 
with operating ventricular interaction. 
• Pulmonary Haemodynamics and Exercise Gas 
Exchange in Secondary Pulmonary Hypertension 
Due to Chronic Heart Failure or Connective Tissue 
Disease 
Alan A. Smith, Peter Cowburn, David Raeside ~ , Matthew Parker, 
Andrew PeacOCk ~ , John G.F. Cletand. Clinical Research Initiative in Heart 
Failure, University of Glasgow, Glasgow; t Department of Respiratory 
Medicine, Western Infirmary, Glasgow, UK 
Background: Secondary pulmonary hypertension can result from a variety 
of card±o-respiratory disease states, and may be related to the abnormalities 
of metabolic gas exchange seen in these patient groups during exercise. 
We investigated the relationship between pulmonary haemodynamics at rest 
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and metabolic gas exchange during exercise, in patients with chronic heart 
failure (CHF) and patients with connective tissue disease (CTD). 
Methods: Pulmonary haemodynamics were measured in the supine po- 
sition at rest, by Swan-Ganz catheter±sat±on, in 14 patients with CHF (NYHA 
II/111), and 12 patients with CTD. All subjects also performed a symptom 
limited maximal exercise test with measurement of metabolic gas exchange. 
Results: 6 patients in each group demonstrated pulmonary hypertension 
at rest (mean pulmonary artery pressure (mPAP) _> 20 mmHg). In patients 
with CHF, there was a direct relationship between the slope of ventilation 
to carbon dioxide production during exercise (VEVCO2) and mPAP at rest 
(VEVCO2 = 25.3 + 0.49 mPAP, r = 0.71 ; P < 0.01), and an inverse relationship 
between peak exercise oxygen consumption (VO2Jkg) and resting mPAP 
(VO2/kg = 20.6 -- 0.24 mPAP, r = -0.64; P < 0.05). The correlations were 
remarkably similar in patients with CTD, both for VEVCO2 (VEVCO2 = 27.0 
+ 0.44 mPAP, r = 0.77; P < 0.01) and peak exercise VO2/kg (VO2/kg = 20.6 -- 
0.22 mPAP, r = -0.58; P < 0.05). 
Conclusions: Pulmonary hypertension relates to increased ventilatory 
demand and reduced aerobic capacity in patients with CHF and CTD, and 
this relationship appears, at least in part, to be independent of the aetiology 
of pulmonary hypertension. 
~-~-~ Evidence of Early Reverse Remodeling of the Right 
Ventricle in Congestive Heart Failure After 
Intensive Medical Therapy Targeted to Reduce 
Afterload 
Fatima Franco, Michael A. Solomon, Roddy McColl, Clyde W. Yancy, 
Ronald M. Peshock. University of Texas, Southwestern Medical Center, 
Dallas, EUA, USA 
Background: Aftedoad reduction has been shown to improve symptoms 
and survival in patients with congestive heart failure (CHF) and is associated 
with reversal of maladaptive left ventricular emodeling. However, the specific 
effects of afterload reduction on right ventricular (RV) geometry are unknown. 
We hypothesize that in patients with congestive heart failure a decrease in 
RV afterload results in early reverse remodeling and improvement of RV 
function. 
Methods and Results: Using cine magnetic resonance imaging we mea- 
sured RV volumes, mass, aid segmental radius of curvature before and after 
treatment in 14 CHF patients (53 ± 9 yrs, NYHA class Ill-IV; PCWP 33 ± 7 
mmHg) and in 13 age-sex matched controls. Myocardial tagging was used 
to measure RV longitudinal and radial shortening. Compared to controls all 
patients demonstrated increased radius of curvature and depressed short- 
ening prior to therapy. Nine of 14 patients responded to treatment (PCWP 
decreased from 31 ± 2 to 12 ~ 4 mmHg, p < 0.001; RVEF increased from 
0.27 ± 0.06 to 0.44 ± 0.04 (p < 0.0001); transverse radius of curvature 
decreased from 4.7 ± 0.8 to 4.0 ± 0.8 cm (p < 0.05), free wall longitudinal 
shortening increased from 7 ± 4% to 17 ± 2.4% (p < 0.02); and mid-free 
wall radial shortening increased from 7 ± 5% to 36 ± 7% (p < 0.0001). Five 
patients who did not respond to treatment showed no change in RV geometry 
or function. 
Conclusions: RV geometry is altered in patients with advanced heart 
failure and severely increased left ventricular filling pressures. Afterioad 
reduction rapidly restores RV geometry and increases longitudinal and radial 
shortening resulting in dramatic improvement of RV function. This may be 
an important mechanism responsible for the early symptomatic improvement 
observed in patients responding to afterload reduction. 
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~ "Expanded" Cardiac AIIograft Transplantation Can 
Help Maximize Donor Resources 
Srinivas Mural±, Kenneth McCurry, Rene J. Alvarez, Jr., Guy A. MaeGowan, 
Dennis M. McNamara, Warren D. Rosenbtum, Robert L. Kormos. University 
of Pittsburgh Health Systems, Pittsburgh, PA, USA 
Cardiac transplantation (CTX) is limited by donor availability. Up to 20% of 
CTX candidates die annually because of a lack of timely availability of a 
donor allograff. Utilizing cardiac allografts that are not considered optimal 
("Expanded" donor, E) may help maximize donor resources. We evaluated 
our one year experience with E donor CTX (n = 13) and compared it to 
our experience with optimal (conventional, C) donor CTX (n = 31) done 
concurrently. E donor allografts were initially deemed unsuitable by all the 
CTX programs in our OPO. Reasons included older donor age, presence of 
coronary artery disease, presence of left ventricular dysfunction and need for 
significant inotropic support. E donor CTX were significantly (p < 0.05) older 
(63 J,- 5 vs 52 ± 8 yrs), had a lesser proportion of UNOS status I (62% vs 81%), 
higher proportion of pdor CTX recipients (31% vs 0%) and lesser proportion 
of pts on mechanical support (0% vs 29%). There were no differences 
between E and C donor CTX in gender and race distribution, etiology of 
heart failure, incidence of diabetes, history of previous thoracotomy, and 
pre-CTX creatinine or bilirubin. E donor age was older (41 ± 5 vs 34 ± 4 
yrs, p < 0.05), but ischemic time was similar to C donor CTX. One E donor 
recipient had single vessel coronary bypass at the time of CTX and another 
had single vessel coronary angioplasty 1 week after CTX. One month and 
one year actuarial survival was comparable in the 2 groups (E, 100% and 
93% vs C, 96% and 90% respectively). 
Conclusions: Carefully selected E donor allograft CTX has a short-term 
outcome comparable to C donor CTX. Since E donor CTX can help maximize 
donor resources, long-term outcomes with this approach needs prospective, 
mull±center valuation. 
~ Acute Volume Load in Patients After Heart 
Transplantation-Hemodynamic Effects and 
Endothelin Response 
Marian S. Petrasko 1 , Jan Horak 2, Michael Zelizko 2, Jaroslav Hubacek 2. 
Department of Cardiology, Brown University School of Medicine, 
Providence, RI, USA; 2Department of Cardiology, Institute for Clinical and 
Experimental Medicine, Prague, Czech Republic 
Background: This study aimed to investigate hemodynamic changes and 
endothelin levels during acute volume load in order to better understand 
etiology of right ventricular (RV) diastolic dysfunction described earlier in 
patients after heart transplantation (HTX). 
Methods: 14 HTX patients and 5 control subjects (C) were studied at 
rest and after 1000 ml bolus of normal saline. In HTX pressures in right 
atrium (RAP), RV, pulmonary artery (PAP), pulmonary capillary wedge pres- 
sure (PCWP) and cardiac output (CO) were measured and systemic (SVR) 
and pulmonary vascular resistance (PVR) were calculated. In both groups 
forearm blood flow (FBF) were measured using venous occlusion plethys- 
mography and local peripheral resistance (LPR) and venous compliance 
(VC) were calculated. Endothelin (E) levels were measured. 
Results: Volume load produced and increase in CO (from 5.53 to 6.50 
I/min), RAP (from 3 to 5 mmHg), PCW (from 7 to 11 mmHg), PAP (from 16 to 
21 mmHg), while PVR (1.59 to 1.62 units) and SVR (from 19.7 to 16.2 units) 
did not notably change. VC significantly decreased in HTX patients (0.0523 to 
0.0251 ml/mmHg with 20 mmHg occlusion and 0.0279 to 0.0215 ml/mmHg 
with 40 mmHg occlusion) while in C did not (0.0440 to 0.0337 ml/mmHg 
with 20 mmHg occlusion and 0.0345 to 0.0257 ml/mmHg with 40 mmHg). 
There were no significant changes in FBF and LPR. Endothelin levels did not 
change significantly in HTX (from 2.16 to 2.57 fmol/I); nor in C (from 5.28 to 
6.58 fmol/I). 
Conclusion: The above hemodynamic changes in HTX are most likely 
caused by active venous constriction, which presumably serves to increase 
cardiac output via Frank-Starling mechanism. Venoconstriction is unlikely to 
be mediated via endothelin effect. 
~ Microvascular Perturbations in Human Cardiac 
AIIografts: Is This Vascular Rejection? 
Carlos A. Labarrere, David R. Nelson, Douglas Pills, Philip C. Kirlin, 
Harold Halbrook. C/arian Health Partners, inc., Indianapolis, IN, USA 
Background: The presence of cellular infiltrates defines cellular rejection, 
but what defines vascular rejection still remains debated. 
Methods: We prospectively studied 141 cardiac allograft recipients with 
serial endomyocardial biopsies (5.5 ± 0.1/patient) obtained during the first 
three months post-transplant that were studied for the presence of fib- 
rin, depletion of tissue plasminogen activator and vascular antithrombin 
and presence of arteriolar endothelial activation markers intercellular ad- 
hesion molecule-1 (ICAM-1) and HLA-DR and serial coronary angiograms 
(3.3 ± 0.2/patient) to evaluate coronary artery disease (CAD). Cellular in- 
filtrates were evaluated using light microscopy and immunohistochemistry 
for macrophages and T-lymphocytes. Immunohistochemically-detected mi- 
crovascular fibrin, depletion of arteriolar tissue plasminogen activator, deple- 
tion of vascular antithrombin, and presence of arteriolar endothelial activation 
markers ICAM-1 and HLA-DR were considered as representing vascular re- 
jection. 
Results: AIIografts without vascular rejection (35 of 141,25%) developed 
significantly less CAD (23% vs. 64%, p < 0.001), showed less disease 
progression (9% vs 36%, p = 0,002) and had less graft failure (9% vs. 29%, 
p = 0.01) than allografts with vascular rejection. In contrast, allografts with 
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cellular rejection (92 of 141, 65%) did not have more CAD (58% vs. 47%, p 
= 0.29) CAD progression (32% vs. 25%, p = 0.44) or failure (26% vs. 20%, p 
= 0.54) than allografts without cellular rejection. 
Conclusion: Immunohistochemically defined vascular changes consid- 
ered as representing vascular rejection, but not the presence of cellular in- 
filtrates, detected eady after transplantation are associated with subsequent 
CAD and graft failure. 
11169-11 I Brain Death Associated Neural and Humoral 
Changes Are not Responsible for Cardiac 
Dysfunction in the Potential Organ Donor 
G&bor Szabb, Christian Sebening, Thilo Hacked, Sergei Melnitschuk, 
Susanne B&hde, Christian F. Vahl, Siegfded Hagl. University of Heidelberg, 
Heidelberg, Germany 
Although hemodynamic instability and cardiac dysfunction after brain death 
(BD) are reported in the potential organ donor, the underlying mechanisms, 
e.g. neure-humoral changes, myocardial injury and altered loading condi- 
tions, have not been differentiated in clinical and experimental settings. In 
the present study, a load-independent analysis of cardiac function was per- 
formed focussing on the influence of BD associated neural and humoral 
factors. In a canine in situ cross.circulated heart model, BD was induced by 
inflation of a subdural ballon catheter. Pre- and aftedoad and coronary per- 
fusion pressure were kept identical in all hearts throughout the experiment. 
In group H (humoral factors), the heads of healthy dogs were perfused with 
blood from BD support dogs (n = 6). In group N (neural factors), the heads 
of BD dogs were perfused with blood from healthy support dogs (n = 6). 
In group H + N (humoral and neural factors), the heads of BD dogs were 
perfused parabiotically in situ with the animals' own blood (n = 6). Myocardial 
contractility was assessed by the slope of the end-systolic pressure-volume 
relationship (Emax). Induction of BD led to a significant ('p < 0.05 vs. base- 
line) hyperdynamic response in all groups with the highest peak in group H 
+ N followed by group H and group N (see figure). 
l e  4 -  
A f te r  the initial hyperynamic phase, cardiac function returned to baseline 
within 15 minutes and remained stable in all groups for the 2-hou r observation 
period when loading conditions and perfusion pressure are kept constant. 
Thus, both neural and humoral factors contribute to the initial hyperdynamic 
reaction after BD which only in combination cause a maximal hemody- 
namic effect. Furthermore, poor cardiac function in the potential donor may 
rather reflect altered loading conditions and impaired coronary perfusion than 
neuro-humorally mediated direct myocardial injury. 
~ Chronic Disease Does not Recur Chagas's Heart 
Up to 13-Years Follow-Up After Heart 
Transplantation 
Edimar Bocchi, Giovanni Bellotti, Femando Bacal, Noedir Stolf, 
Adib Jatene, Jos~ A.F. Ramires. Heart Institute, S~o Paulo, Brazil 
Background: Chagasic chronic heart disease may develop after a long-term 
latency period after initial infection with T. cruzi. Transplantation centers 
have been hesitant to accept patients with Chagas's heart disease due to 
possibility of reactivation of acute T. cruzi infection and the development of 
chronic chagasic cardiomyopathy in long-term follow-up. 
Methods: We studied in a mean follow-up of 1210:5 1100 days (from 
6 to 154 months) 28 pts, 26 male, mean age 37:5 12 years, submitted 
to heart transplantation for treatment of Chagas's heart disease. K cruzi 
infection, cardiac function and LV diameters were evaluated by sequential 
echocardiogram, endomyocardial biopsy, detection of T. cruzi in blood and 
tissues, and serologic tests. The chronic immunosuppression was based on 
triple therapy with cyclosporine, azathioprine, and steroids. 
Results: The survival rate rate at 1,2, 6 and 12 years was 67%, 63%, 55% 
and 37%. Parasitemia was detected in 50% of pts, and acute reactivation 
of Chagas's disease with symptoms or myocarditis in 25% of pts. Treatment 
with benznidazole was successfull in all episodes. The reactivation episodes 
repeated in 13%. The mean late LV ejection fraction was 76:5 5% and 
endomyocardial biopsies did not show chronic chagasic myocarditis. The 
causes of death were neoplasia (5 pts), rejection (3 pts), infection (1 pt), 
early graft failure and surgical complications (3 pts), and restrictive CHF (1 
pt). 
Conclusion: Chronic chagasic cardiomyopathy seems not recur on long- 
term follow-up after heart transplantation despite of frequent parasitemias. 
Heart transplantation for Chagas's heart may be associated with long-term 
survival with preserved allograft function. 
I l l  69-131 and the Conduction in the Rejection System i Human Cardiac Transplantation 
Vittorio Calzolari, Annalisa Angelini, Cdstina Basso, Ugolino Livi, 
Lino Rossi, Gaetano Thiene. Dept. Pathology, University of Padua, italy 
Background: There are only very few histological studies on the cardiac 
conduction system in the human transplanted head. The severity of the 
conduction system involvement during acute rejection has been variably 
reported but always with scarce clinical correlates. 
Methods: Histology by serial sections of the recipient and donor si- 
nus nodes and specialized atrioventricular (AV) junction was performed and 
compared with working myocardium. Acute rejection was scored from 0 to 4 
(absent to severe). ECG tracings, immediately prior to death, were reviewed 
for clinico-pathologic orrelation. 19 transplanted heart specimens were stud- 
ied: 10 with "acute" (4 early, mean survival 50 days; 6 late, mean 875 days); 
3 with "chronic" (mean 1562 days) and 6 without rejection (infection, trauma, 
acute graft failure; mean 214 days). Five heads from non transplanted, non 
cardiac patients served as control. 
Results: In hearts with acute rejection the mean score was 3.5 ± 0.4 in 
the working myocardium; 3.1:5 0.7 in the donor sinus node; 2.9 + 0.9 in 
the AV node; 2.1:5 1.0 in the His bundle; 3.0:5 0.9 in the bundle branches; 
vasculitis involved the donor sinus node artery in 7 and the AV node artery 
in 5. In heads with chronic rejection obstructive graft vasculopathy, besides 
subepicardial coronary trunks, involved the donor sinus node artery in all 
and the AV node artery only in one. Of 16 available ECG, 15 (93%) showed 
incomplete or complete right bundle branch block; a first degree AV block 
was observed in three cases with early acute rejection and two of them had 
sudden fatal cardiac arrest. 
Conclusions: Acute rejection does involve the conduction system with 
an equal severity as observed in the working myocardium, with the exception 
of the His bundle. During acute rejection, the sudden appearance of a first 
degree AV block might suggest a severe involvement of the conduction 
system with impending cardiac arrest. 
I l l  69-141 Echo of Left Ventricular Improved Diagnosis i End-Diastolic Stiffness in Patients With 
Transplant Rejection 
Jing Ping Sun, Yong Xu, Vanda Huang, Jill A. Odabashian, Helga 
P. Lombardo, William J. Stewart, James B. Young, Mado J. Garcia, James 
D. Thomas, Brian P. Griffin. The Cleveland Clinic Foundation, OH, USA 
Cardiac transplant rejection causes diffuse cellular infiltration and interstitial 
edema, which may cause left ventricular diastolic dysfunction. 
Purpose: to evaluate the changes in myocardial function by pulsed 
Doppler in patients with heart transplantation. 
Methods: Echocardiographic studies were performed on the same day as 
were the endomyocardial biopsies in 241 pts. Pulsed Doppler was performed 
in each patient for measuring mitral inflow early (E) and atrial (A) filling 
velocities, pulmonary venous systolic (S), diastolic (D), and atrial reversal 
velocities (ARV). 
Results: Patients were classified according to the histologic results of 
acute rejection in no rejection group (167 patients, 128 male, 54:5 11 years 
old), and with rejection group (74 pts; 54 male, 49:5 13 years old). 
E A ARV NARV 
cm/sec crn/sec cm/sec ratio 
No rejection 71 -E 21 48 i 18 11 ± 4 4.6 :~ 2.1 
Rejection 77 -E 21 42 • 13 14 ± 9 3.5 • 1.8 
p value 0.06 0.005 0.002 0.001 
Because A goes down and ARV goes up with the severity of rejection: 
A/ARV ratio may be a useful index: 4.6 ± 2.1 in 29 pts with mild rejection, 4.0 
:5 1.7 in 32 lots with moderate rejection, and 3.3:5 1.8 in 13 pts with severe 
rejection. That late diastolic forward velocity into left ventricle is decreased 
and atrial reversal velocity into pulmonary veins is increased in the cardiac 
recipients with acute transplant rejection suggests increased late diastolic LV 
stiffness. 
Conclusions: Because end-diastolic stiffness is increased, the ratio of 
mitral A velocity to pulmonary vein ARV may provide a useful clinical tool in 
patients with transplant rejection. 
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I •  Disturbances in Bone and Mineral Metabolism in 
Patients With Chronic Heart Failure 
Christiane Werner, Tanja Assure, Julia Sytsch, Peter 0berfuhr 1, Christiane 
E. Angerrnann, Karl Theisen, Roland G~irtner, Hans U. Stempfle. Depts. of 
Medicine; ~ Cardiac Surgery, University of Munich, Germany 
Background: The loss of bone mass is an important complication after heart 
transplantation (HTx). Recent studies demonstrated already a reduced bone 
mineral density (BMD) in patients with chronic heart failure awaiting HTx. 
The purpose of our study was to investigate BMD and parameters of bone 
metabolism to evaluate the risk of bone disease before HTx. 
Methods: We studied 92 patients (85 male, mean age 53 ± 16; 7 fe- 
male mean age 51 ± 12, EF 24 ~ 11%) with an end-stage heart disease. 
Bone mineral density was measured at the lumbar spine and femoral neck 
using dual-energy-X-ray-absorptiometry (Lunar expert). Fractures were as- 
sessed by X-rays of chest, thoracic and lumbar spine. Biochemical parame- 
ters included gonadal hormones, urinary and serum parameters of calcium 
metabolism, renal function, markers of bone formation (Osteocalcin, Oc; 
carboxyterminal propeptide of type 1 procollagen, PICP) and bone resorp- 
tion (Pyridinoline, PYD; Deoxypyridinoline, DPD; cross-linked aminoterminal 
telopeptide, NTX). 
Results: Impaired BMD (T-score > 75% and < 90%, defined as os- 
teopenia) was seen in 39% of the patients at lumbar spine and in 27% at 
femoral neck. 18% of the patients had an osteoporosis (T-score ~- 75%), 
No fractures were found. 21 male patients showed a gonadal dysfunction. 
Elevated parathyreoid hormone was assessed in 45 patients. 13 patients 
had a reduced 25OHVitD3. Renal function was impaired in 52%. Resorption 
markers (PYD, DPD) were significantly increased. 
Conclusion.' Approximately two thirds of patients listed for HTx show 
decreased BMD of lumbar spine and femoral neck. Bone markers indicate 
increased bone resorption due to a secondary hyperparathyreodism and 
gonadal dysfunction as main reasons for bone loss. Therefore prevention 
therapy for osteoporosis seems necessary in patients with severe chronic 
heart failure. 
~ Time to Harvest: A Critical Determinant of 
Outcome in Heart Transplantation With Older 
AIIografts 
Robert L. Scott, Tamer Sayin, Krishnaveni Srigiri, Debra Rose, 
GJnny McBride, Metin Ozenci, Myung H. Park, Mandeep R. Mehra. Ochsner 
Medical Institutions, New Orleans, LA, USA 
Background: An advanced donor allograft age (>40 years) in heart trans- 
plantation represents an independent risk factor for short and long term 
mortality. No previous investigation has comprehensively elucidated clinical 
predictors of adverse outcome, in particular "time to harvest" (TTH, from 
declaration of brain death to cross clamping) within the population of aged 
allografl recipients. 
Methods: We therefore studied a consecutive cohort of 23 heart trans- 
plant recipients (donor age > 40 years) between 1995-1997, and evaluated 
the independent influence of 35 donor and 35 recipient characteristics on the 
primary outcome variable of survival. 
Results: (selected variables only) 
Outcome n survival Ischemic donor donor TTH 
(months) time (minutes) age smoking ~ (hours) 
Alive 10 30-E9 177±46 56±10 22±24 17±9 
Dead 11 7±11 # 152±23 52±13 16 zE 29 23 ± 9"" 
"pack years; #p < O001; "'p = 0.05 
Regression analysis identified a significant inverse correlation between 
time to harvest and survival time (r = 0.4, p = 0.07). Furthermore, time 
to harvest > 17 hours was selected as the single independent predictor of 
survival in a Cox (proportional hazards) model. When TTH was <17 hours, 
long term survival was 73% compared to a 20% 2 year surviva~ in the 
presence of a TTH >17 hours (p < 0.01). History of heavy smoking in 
the donor and recipient, performing donor coronary angiography, and post 
transplant allograft rejection were not significant predictors. 
Conclusions: This is the first investigation to identify time to harvest, a 
hitherto unexamined predictive variable, as an independent predictor of post 
transplant survival in aged allografls. These findings suggest that attempts 
targeted at reduction of time to harvest might allow us to successfully exploit 
the aged donor pool in this era of donor scarcity. 
~ Redo Heart Transplants Have Increased Incidence 
of Transplant Coronary Artery Disease: Impact on 
Long-Term Survival 
Jon A. Kobashigawa, Thomas K. Ro, Kim Einhom, Jaime D. Modguchi, 
Michele A. Hamilton, Antoine Hage, Nobuyuki Kawata, Judith D. Cassem, 
Hillel Laks. UCLA Medical Center, Los Angeles, CA, USA 
Redo heart transplant patients (2HT pts) are known to have worse outcome 
compared to pts who undergo primary heart transplant (1HT). However, a 
recent study reports that 2HT pts do not have an increased incidence of 
transplant coronary artery disease (TCAD). Conversely, there is concern 
that pts who initially develop TCAD and undergo 2HT are at higher risk for 
developing TCAD in the 2 nd donor heart. We reviewed the post transplant 
course of 27 pts at our institution who underwent 2HT due to TCAD in their 
lS~ donor heart and compared them to 260 1HT patients transplanted during 
the same time period for survival and the development of TCAD. Five-year 
freedom from TCAD in 2HT pts was lower than in 1 HT pts (see graph). In 
addition, 5-year actuarial survival was lower in 2HT Lots vs. 1HT pts. In 2HT 
pts, 67% of deaths were due to complications of TCAD in the 2 nd donor heart. 
Actuarial Freedom from TCAD Act-retrial Survival 
coo o'   , 
• • ' ' 
Conclusion: Pts who undergo 2HT due to TCAD in their 1 st donor heart 
appear to have a higher tendency to develop TCAD in their 2 nd donor heart, 
which appears to impact survival. This should be considered when evaluating 
pts for 2HT. 
~ T h e  Role Lipids and Fibrinogen in Coronary of 
Vasomotor Dysfunction After Cardiac 
Transplantation 
Michael Weis, Sinan Pehlivanli, Bruno M Meiser, Joachim Thiery, 
Wolfgang von Scheidt. Klinikum Grosshadern, University of Munich, 
Germany 
Background: Several reports suggest an impact of elevated lipid-levels on 
the development of morphological manifestations of cardiac allograft vascu- 
Iopathy (CAV). CAV is primarily initiated by repetitive coronary endothelial 
injuries leading to coronary vasomotor dysfunction. Whether an elevated 
lipid-state or high fibrinogen levels are associated with functional coronary 
alterations after HTx remains an open question and was analyzed in this 
study. 
Methods: We tested the impact of fibdnogen, Lp(a), LDL-C, HDL-C, and 
triglyceride-levels (determined at time of the study) on coronary vasomotor 
function in 90 patients 32 ± 24 months after HTx. Vasomotor response in 
the coronary microcirculation was determined endothelium-dependent with 
acetylcholine (ACh 30 ~g/min;ic.over 5 rain) and endothelium-independent 
with adenosine (ADO 160 j:,g/min;ic.over 5 min) using intracoronary Doppler- 
Flowire. Epicardial diameter changes in response to ACh and ADO were 
measured using quantitative angiography at proximal and distal segments. 
Results: Using single or multiple regression analysis none of the tested 
parameters was significantly associated to coronary vasomotor dysfunction. 
A trend was observed for an inverse correlation of Lp(a) and LDL-C to distal 
epicardial endothelial response (r = -0.19; p = 0.06 and r = -0.15; p = 0.08, 
respectively). In addition, microvascular endothelial dysfunction was weakly 
associated with elevated fibrinogen levels (r = -0.14; p = 0.09). 
Conclusion: Our results suggest that after heart transplantation the lipid- 
or fibrinogen-state is of minor importance for changes in the coronary en- 
dothelial vasomotor function. This is in contrast to the nontransplant athero- 
sclerotic setting, supporting the concept that coronary functional alterations 
after HTx are primarily immune mediated. 
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~ Carvedilol Reduces QT Interval Dispersion in 
Patients With Chronic Heart Failure 
Nigel Jepson, Ahmad Farshid, Cheryl Friend, Roger Allan, Warren Walsh. 
Department of Cardiology, Prince of Wales Hospital, Sydney, Australia 
Background:/~-edrenergic blocking agents improve left ventricular (LV) func- 
tion in patients with chronic heart failure (CHF), however their effect on mor- 
tality remains unclear. Data has suggested carvedilol can reduce mortality 
from both sudden death and progressive pump failure in patients with poor 
LV function. 
Methods: This study assessed the effect of carvedilol therapy on QT 
dispersion (predictor of susceptibility to ventricular arrhythmias) in 35 patients 
(27 male, mean age 55) with CHF (28 IHD, 7 DCMP) and mean ejection 
fraction 34%. All received conventional therapy for CHI c. QT dispersion (QTd) 
and the derived values, QTcd and QTd ratio were determined pre-treatment 
and at least 4 weeks (mean 22) after cavedilol introduction (25 mg BD in 
68%). 
Results: Carvedilol resulted in a significant reduction in QTd (107 ± 20 
vs 86 ± 19 ms, P < 0.01), QTcd (122 ± 18 vs 92 ± 18 ms 1/2, P < 0.005) 
and QTd ratio (14 ± 2 vs 10 ± 2%, P < 0.005). Heart rate was also reduced 
(82 ± 14 vs 71 ± 12 bpm, P < 0.01). QTcr,ax however, was not altered by 
carvedilol (542 ± 34 vs 551 ± 42 ms 1/2, P = NS) while QTcmin increased (420 
± 31 vs 454 ± 41 ms 1/2, P < 0.05). 
Conclusions: Carvedilol therapy in a heterogenous patient group with 
CHF was associated with a significant reduction in interiead QT variability. 
This favourable influence on ventricular repolarization may confer protec- 
tion against ventricular arrhythmias and contribute to the survival benefits 
reported with carvedilol treatment in CHF. 
~ Withdrawal of Chronic Beta Blockade in Heart 
Failure Patients Does not Influence Exercise 
Hemodynamics 
Eugene Wolfel, Brian Lowes, William Abraham, Robert Roden, 
Alistar Robertson, JoAnn Lindenfeld, Edward M. Gilbert, Michael R. Bristow. 
University of Colorado Health Sciences Center, Denver, CO; University of 
Utah Medical Center, Salt Lake Ci~ UT, USA 
Background: Although #-adrenergic blockers have been shown to improve 
resting ventricular function in head failure patients, exercise capacity has 
not increased. The pharmacological effects of these drugs, especially on 
exercise heart rate, may be responsible for the lack of improvement in 
exercise capacity. 
Methods: 28 patients (54 ± 3 yrs) with nonischemic cardiomyopathy 
were randomly assigned to placebo (P), (n = 9), metoprolol (M), 50 mg BID 
(n = 9) and carvediolol (C), 25 mg BID (n = 10). Baseline LVEF = 23.2 ± 2% 
and peak VO2 was 16.9 (P), 15.4 (M), and 16.9 (C) ml/kg/min prior to drug 
administration. Hemodynamic exercise testing was performed prior to drug 
administration (0), after 6 months of drug therapy, on drug (1), and 48 hrs 
after withdrawal of drug (2). 
Results: Both M and C patients had a significant increase in resting LVEF 
after 6 months of therapy, with no improvement in the P group. There were no 
significant increases in peak VO2 in any of the subject groups at 6 months, 
either at #1 or #2 testing periods. Peak exercise heart rate decreased in both 
M and C at #1, and upon withdrawal of drug, heart rate returned to pre-drug 
values in M with incomplete recovery of heart rate in C. Exercise cardiac 
output remained unchanged compared to baseline (0) at all testing periods 
in both M and C groups, with stroke volume compensating for the changes in 
heart rate. There were no changes observed in intracardiac filling pressures 
or mixed venous 02 saturation during exercise in either M or C at either 
periods #1 or #2. 
Conclusion: Peak exercise capacity and exercise hemodynamics remain 
unchanged after 6 months of therapy with either M or C in chronic heart failure 
patients despite acute withdrawal of drug effect There may be incomplete 
withdrawal of receptor blocking effects at 48 hrs. with C suggested by only 
partial recovery in exercise heart rate. 
• Withdrawal of the Inotropic Agent Vesnarinone is 
not Associated With an Adverse Outcome: 
Substudy Results from the VesT Trial 
Ozlern Soran, James Young, B.G White, Arthur M. Feldman. University of 
Pittsburgh Medical Center, PA; Cleveland Clinic Foundation, OH, USA 
Background: The use of inotropic agents has been controversial. One aspect 
of this controversy has been the concern that withdrawal of an inotropic agent 
might worsen symptoms in an otherwise compensated patient. The VesT 
study assessed the efficacy of either 30 mg or 60 mg of the inotropic agent 
vesnarinone (V) in the therapy of patients with CHF when compared with 
placebo. At the conclusion of the study, patients were withdrawn from study 
drug because of a significant increase in mortality in patients randomized 
to 60 mg V, providing an opportunity to test the hypothesis that inotropic 
withdrawal might be harmful. 
Methods: At the termination of the VesT, 1,140 patients at 109 study sites 
were enrolled in the withdrawal sub-study from a total of 2,638 patients alive 
at the completion of the trial. Each study center assessed the dates for any 
hospitalizations, death, transplant, or enrollment into another investigational 
study for each study patient dudng 6-months. 
Results: Of the 1,140 pts, 1.5% underwent cardiac transplantation, 12.7% 
were enrolled in another clinical trial, 9.3% died, and 1.5% were lost to 
follow-up. A small number of patients (26) were re-treated with V. The patients 
in the withdrawal sub-study were younger than those in the original VesT 
population, were less likely to have ischemic heart disesase, were more 
likely to be NYHA Class III versus NYHA Class IV and had higher mean 
ejection fractions. There were no statistically significant differences between 
deaths in the group of patients withdrawn from placebo and those withdrawn 
from either 30 or 60 mg V. Similarly, withdrawal from V did not affect the 
incidence of the combined end-point of either death or worsening heart 
failure when compared with patients withdrawn from placebo. Furthermore, 
withdrawal from vesnarinone did not increase the risk of being hospitalized 
for worsening heart failure during the 6-month study period. 
Conclusion: The data from this study suggests that withdrawal from ves- 
narinone was not associated with an adverse outcome. While the results 
cannot be generalized to other inotropic agents, these results are in con- 
trast with previous anecdotal data. Furthermore, the results raise concems 
regarding enrolling "survivors" of large multi-center studies in subsequent 
clinical trials. 
• Dobutamine-lnduced Hypersensitivity 
Myocarditis: A Potential Mechanism to Explain the 
Increased Mortality With Chronic Intravenous 
Infusion 
Charles Y. Lui, Jared R. Younger, Richard Sobonya, Bernardo deLa 
Guardia, Francisco A. Arabia, David A. Ar-zouman, Bruce Toporoff, 
Venki Paramesh, Gulshan K. Sethi, Jack G. Copeland. University of 
Arizona, Tucson, AZ USA 
Background: Dobutamine (D) therapy has been reported to cause peripheral 
eosinophilia (E) and hypersensitivity myocarditis (HM). 
Methods: We routinely perform histological examination on all explanted 
hearts after orthotopic heart transplantation (OHT). From 1985 to 97, 27/429 
(6.3%) of the explanted hearts were diagnosed hypersensitivity myocarditis 
(HM). The medical records were reviewed; each HM case was subsequently 
matched with a non-HM, Dobutamine-treated transplant patient (control) from 
the same cohort. 
Results: None of the HM cases were clinically diagnosed. The mean age 
of HM pts was 53 ± 8 yr, 21/27 were male and all of them had been receiving 
intravenous D therapy for decompensated CHF at the time of OHT. No other 
medication was identified that was common to these two groups of lots. The 
mean cumulative dose of D received by 26/27 HM pts was 399 ± 70 mg/kg 
vs 239 ± 39 mg/kg by the control group, P < 0.03. Sixteen of these 26 (62%) 
HM pts developed E vs 6/26 (23%) of the control, P = 0.005. However, atthe 
onset of E, neither the cumulative dose nor the duration of D adminstered 
were significantly different between these 26 HM and control pts (199 -- 53 
mg/kg vs 134 ± 28 mg/kg, P = 0.29; 18 ± 4 days vs 14 ± 3 days, P = 0.49). 
The majority of pts from either group received Dobutrex (dobutamine sodium 
bisulfite) and only a few patients intermittently received dobutamine sodium 
metabisulfite. 
Conclusion: Prolonged infusion of dobutamine, either with sodium bisul- 
rite or metabisulfite as preservative, can induce hypersensitivity myocarditis 
which is often associated with peripheral eosinophilia. 
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• Predictors of Oral Anticoagulant Utilization in 
Congestive Heart Failure: A Survey on 6428 
Outpatients of the italian Network-Congestive 
Heart Failure (IN-CHF) 
Steiano Urbinali, Bruno AIoisi, Giuseppe Castiglioni, Luisa Areal±, Gianna 
P. Gambarati, Marco Gorini, Donata Lucci, Aide P. Maggioni, 
Giuseppe Pinelli. On the behalf of IN-CHF Investigators; Bellaria Hospital, 
Bologna; ANMCO Research Center, Florence, Italy 
Background: In pts with congestive heart failure (CHF) the use of oral 
ardt=coagdlan'ts ~I~AT.,g)is ila.') usudlly lndlcs~ted 'in ,dls witn 8;iPlal "fibrillation 
(AF) or left ventricular thrombosis (LVT), (b) acceptable, but of uncertain 
efficacy, in those with severe left ventricular dysfunction or dilatation, and (c) 
nor~')n6)ca~e~')~) ~,se'~ed~ 7,'}s ,~/)9) £.~7- ~nf) s:)n~s/)-)~'Dn'). 
Aims: To evaluate: (a) the appropriateness of the use of OACs in a large 
population oi OUtDIS ~/)YD C~,/~) ~e preh~c~ors a sod~a~ef) ~ ~b ~b~)r use. 
Patients: Between 1995-97, 6428 pts from 133 cardiologic centers of the 
IN-CHF were enrolled (_>70 yrs 33%, m 74%, NYHA Ill-IV 30%, EF < 30% 
21%, CHD 41%, DCM 31%, AF 22%); among them 1672 pts (26%) assumed 
C#,Cs a~d ZZT4 9is <35%~ ae, t(9(ete(et dru%s. 
Results: OACs were used in 52% of pts with AF and in 48% with LVT, 
in 33% of pts with EF < 30% and in 33% with LVdD > 7 cm, finally in 11% 
tre rema(h(h~ qfs w((h CHFan(Y s(hus nfl~.hm. (n ~he mu(t'(Vanafe ana(vs(s fhe 
predictors of the use of OACs were: AF (95% CI 4.7-6.7, OR 5.5), LVT (CI 
2.7-6.1, OR 4.1), EF < 30% vs >40% (CI 1.7-2.8, OR 2.2), valvular etiology 
vs DCM (CI 1.8-2.6, OR 2.2), CHD vs DCM (1.3-1.8, OR 1.5), LVdD > 7 
cm (CI 1.2-1.8, OR 1.4), NYHA ill-IV (CI 1.0-1.4, OR 1.2). OACs were less 
used in pts with hypertensive etiology vs DCM (CI 0.4-0.7, OR 0.5) and in 
ttose acLeo'>_£0"vrs (,L,q'ctc,z--(J'~.u"H~(Z4[. 
Conclusions: (1) According to the guidelines, OACs are used in one-half 
of pts with accepted indication, in one-third of pts with acceptable indication, 
and in 11% of pts without indication. (2) Hypertensive etiology and age 
>__70 v rs are associated with sicLnificantlv lower use of OACs. (.3) Further 
irrq,~emerit~(~en gtr~e.dles are necessa.rv "for ednand~n 9 'tne use o~ ~JA~S 
according to the evidence-based recommendations. 
• Herbal, Megavitamin and Nutritional Supplement 
(Naturoceutical) Use is Very Common in Heart 
Failure Patient Populations 
[Denise O. Hermanr), Johannes J. Kuioer, RalDh ShabetaL 
[Denise Carethers, David J. Shaw, Barry H. GreenbeLa. Universitv of 
Califomia at San Diego Medical Center, San Diego, CA, USA 
Background & Methods: Consumer demand for herbal, megavitamin and 
ru~'n~'ronar sup.0rement's ~s escaraf/nq, The 0revarence ornafuroceuf~bar(h~bh- 
~ose-#J~am)n, m~ner~. 'nef~a'~ or e~er nenhee6 sure, omen1) use'qv.Da'ben'~s 
(pts) with chronic heart failure (HF) is unknown. We therefore surveyed pa- 
tients (pts) enrolled in specialized HF clinics at a University (Univ), Veteran's 
Administration (VA) and a Private institution (Priv). A total of 293 (94%) of 
usage were sought. 
Results: Forty-four percent (128/293) of survey respondents affirmed 
naturoceutical use. Over 75% of users took two or more supplements (mean 
4.4, range 1-28, median 3). Clinic location was the strongest predictor of 
naturoceutk~a~ usage (p < 0.001 by X2); reported by 53%, 40% and 27% of 
pts in Priv, Univ, and VA clinics respectively. There was no difference in age, 
gender, exercise capacity, ejection fraction or quality of life between users 
and non-users. Correcting for clinic site, only race (white vs. non-white) was 
an independent predictor of naturoceutical consumption (p < 0.02). While 
4t% of pts ascribed health benefits to their naturoceutical intake (95%CI = 
33 to 50%), only 5% (95%CI = 1 to 9%) attributed adverse effects to these 
agents. One patient in three reported that their physicians were unaware of 
their use of naturoceuticats. Fewer than 25% of pts (95% CI = 18 to 33%) 
knew whether an adverse interaction with their prescribed medications was 
possible. 
Conclusions: 1) Naturoceutical use is extremely common in pts with HF 
and physicians may be unaware of this practice. 2) HF pts should be specifi- 
cally queried about use of these products. 3) Naturoceutical consumption is a 
previously unrecognized factor that may affect outcome in HF management 
(and clinical trials?). 4) Objective information regarding the risk/benefit ratio 
of naturoceufical agents in heart failure patient populations is clearly needed 
for physicians and patients alike. 
1 41 Amlodipine Improves Mortality and Function in a I 1 99-1 
Murine Model of Myocarditis-Dilated 
Cardiomyopathy: The Role of Microvascular 
Blood Flow 
Geoffrey] Pu~ey, M~chaei J. So~e, Fayez Dawned, Wen-Hu Wen, 
Michael Dodd, Peter Liu. University of Toronto, Canada 
Background: The PRAISE-1 thai suggested that amlodipine (Am) may ben- 
efit dilated cardiomyopathy, but mechanism is not clear. 
Methods: To determine if amlodipine has impact on mortality, ventricular 
"tundt~on an0 rd~crovascu}arl~oo~ flow in a m~e} 6t ~li]a~P-d .card~myq~.&tbM 
we performed a 2 × 2 study randomizing 125 DBA/2 mice to infection with 
EMC virus or sham, and to Amlodipine (Am Rx) or placebo. The LV function 
~as ~e~e~)neb )>2 ~anDenC~DY~ ~>~epara))D)> ~ByS}D)')C pxessuz~ ~y~, m)$~), 
developed P (DVP, mmHg), positive dP/dt (mmHg/sec)], and microvascular 
~)OW ~))) y~)cro~)) an5 ~t)a)))ur;) au?iDra~Jograpby. 
Results: 
infection - - + + 
SysP 88±9 96±9 4629 80±3"  
DVP 83 ± 9 90 ± 8 44 4- 10 75 ± 3" 
+dP/d,* .5 ~,9,9 2- .£.9,9 4.~D ~ 774 3722 -~ 825 5 t~? :~ 2@S F 
(mean ± SEM, p < 0.05 vs. untreated controls) 
The pathologica~ score also improved with am~odipine treatment. In a 
separate study, the mortality in the placebo group was 80% at 28 days 
vs. 57%" in Am Rx group. Microvasculature shown by Microfil improved 
slajl+ficantIV with Am FTx. Furthermore. ~antitatfi/e autQradk~jai~v, wJtt~ 
thallium-201 demonstrated that the tissue flow was 2278 ± 104 in untreated 
vs. 2727 ::E 103* counts/high power field in the Am Rx. 
Conclusions: Amtodipine improves mortality, ventricular function and 
p.athology+ in this model of dilated cardiomyp~athy, This mav be related to 
]m, Drovemen't "m'SIood "flow aZt'fne rri~crovascdlar'level. 
I1 J Continuous Administration of Prostacycin 
I 
1 99-1 5 
Analogue Improves Vascular Remodeling and 
Survival in Pulmonary Hypertensive Rats 
Yasushi Numaguchi, Takahito Tom±do, Mitsunori Harada, Hideo Matsui, 
Yukio Toki Taka.vuki Ito Ke0ii Okumura. Na.gqva Universi~. Naoqv& J~oan 
~thougli prost~cyclih (PLql2)' ao('nlhJ~;ti'atibn ~mproves Ibng-ti)rm effects ~h 
patients with pulmonary hypertension (PH), the effects of continuous supply 
of PGI2 on regulatory mechanism remain unknown. To evaluate the effects of 
P"GCZ a(Yrnfhfsfraf+0n +h [he course or F~H, we measurecr femi?,orar reo,,urafo~ 
(Da~em 0'i m3h'~A o'} ~P~3~ s vnlnase anO reee, D~or as we'b as ~DtJ~rnenar>, 
vascular remodeling and survival in monocrotaline-treated PH rats. 
Methods: 1. Male Sprague-Dawley rats (170~190 g) were divided into 4 
groups: BPS (beraprost sodium, PGI2 analogue, 30/~g/kg, PC, daily), MCT 
(rrru-wo~qrut~rr~, 6"¢,T~,g" ?P, ~n~'e ,'~e,."~b~r t¢~ errtry)', 6'PS ÷ ,t,l'CT, a,~ 
Control (n = 16 each). At day 7, 14, 21, and 28, rats were measured both 
ventricles, lung and body weight, mRNA expression levels were quantified 
by the competitive PCR method. Vascular remodeling was evaluated by 
the percentage of muscularisation in pulmonary arterioles (<200 /~m in 
diameter). 2. The survival rate was evaluated in MCT and BPS + MCT 
groups for a 17-week period. (n = 18 each) 
Results: 1. In MCT-treated rats, BPS administration reduced right ven- 
tricular hypertrophy and muscular±sat±on in pulmonary arterioles to a greater 
extent han MCT alone. 2. Rats of MCT group died before 6 weeks, whereas 
22% of BPS-treated rats survived (Kaplan-Meier method. Mean survivah 36.4 
and 96.3 days for MCT and MCT + BPS, p < 0.0001) Data at day 28 are 
shown below. 
Control BPS MCT MCT + BPS 
RV/IVS + LV 0.27 ± 0.05 0.28 ± 0.05 0.68 ~- 0.08"* 0.42 ± 0.07* 
Muscular±sat±on (%) 8 ± 0.2 8 ± 0.3 78 ± 0.8"" 35 ± 0.6" 
PGI 2 synthase 248 ± 9 242 ± 8 648 ± 10"" 447 ± 9" 
PGI 2 receptor 12 ± 0.5 11 ± 0.3 9 ± 0.6 6 ± 0.5" 
"P < 0,05, +'P < 0.01 vs Control. Data: mean ± SEM. RV; right ventricle, WS; intraven- 
tricu]ar septum, LV; left ventricle, mRNA levels: attomole/#L 
Conclusion: BPS administration improved pulmonary vascular remodel- 
ing and survival with suppressing mRNA expression. 
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~ A C E  Inhibition Limits Apoptosis in 
Cardiomyopathic Hamsters, and Improves 
Remodeling and Scar Tissue Material Properties 
Samuel A, Wickline, Qingyan Zhu, Glenn Davison, Christopher S, Hall, 
Michael J. Scott. Barnes-Jewish Hospital at Washington University School 
of Medicine, St. Louis, MO, USA 
Background: Cardiomyopathic hearts manifest substantial myocyte apopto- 
sis that may contdbute to eventual failure. However, whether treatment with 
ACE inhibitors effectively ameliorates apoptosis and ventdcular emodeling, 
while preserving tissue architecture and microscopic matedal properties, 
remains unknown for this condition. 
Methods: TO-2 cardiomyopathic Syrian hamsters were treated ad lib with 
either 2 g/liter captopril in ddnking water (n = 6) or placebo (n = 6) through 4 
months of age. Alterations in cardiac matedal properties were charactedzed 
with acoustic microscopy (50 MHz) on 2 mm thick cross-sections of hearts for 
computation of quantitative ultrasonic integrated backscatter (IB), previously 
validated as an index of local material properties. Myocyte apoptosis was 
determined in the TO-2 hamsters in matched histologic sections and in 6 
additional control hamsters by the end labelling TdT method (ApopTag Plus 
kit, Oncor), and expressed as # apoptotic cells per 1000 myocytes. Collagen 
and calcium content were determined biochemically. 
Results: Captopdl treatment reduced LV mass by 23% (p < 0.0005), 
along with a comparable reduction in the total amount of LV collagen. The 
IB from the scar tissue elements themselves was reduced 2.4-fold (or 3.8 
decibels; p < 0.0005) by captopril, indicative of altered density and/or elas- 
ticity of the scars. Apoptosis was virtually absent from 4 month-old control 
animal hearts. Treatment of T0-2 hamsters resulted in a marked diminution 
in myocyte apoptosis from 97.5 ± 38.8 to 45.5 ± 26.0 cells/1000: a 53% 
decline (p < 0.005). Scar tissue calcification was also reduced after captopril 
(37%; p < 0.001). 
Conclusion: Apoptosis, cardiac remodeling, and tissue material proper- 
ties are dramatically affected by treatment with captopril in cardiomyopathic 
conditions. Thus, evaluation of specific therapies to prevent cardiomyocyte 
apoptosis appears justified. 
~ Unique Renal and Systemic Hemodynamic 
Actions of a New Natriuretic Peptide in 
Experimental Heart Failure 
Ondrej Lisy, John G, Lainchbury, John C, Burnett, Jr,, Mayo Clinic, 
Rochester, MN, USA 
Background: Clinical trials have reported that the maintenance of glomeru- 
lar filtration rate (GFR) is the most important determinant of survival in CHF. 
To identify agents which could have unique renal actions in CHF, the current 
study characterized the renal and cardiovascular actions of a new natri- 
uretic peptide, Dendreaspis natduretic peptide (DNP), which is structurally 
related to ANP, BNP and CNP and which is present in canine plasma and 
myocardium. We hypothesized that DNP possesses GFR enhancing and 
systemic vasodilatory actions in mild and overt CHF which are not observed 
under normal conditions. 
Methods: Three groups of anesthetized dogs were studied: normals (n 
= 6), mild CHF (n = 7) and overt CHF (n = 7). CHF was produced by rapid 
ventdcular pacing for 10 days (mild CHF - 180 bpm; overt CHF - 245 bpm). 
Intravenous DNP was infused at 10 and 50 ng/kg/min in all dogs. 
p < 0.05 vs. Baseline, t < 0.05 vs DNP-10 ng/kg clearance. 
Results: In normals with DNP, GFR was unchanged with an increase in 
UNaV (63 ± 29 to 174 ± 48" and 232 • 69" mEq/min). PCWP (5.8 + 0.3 to 
4.3 ± 0.3* and 3.5 ± 0.2"1 mmHg) and CO decreased (3.9 ± 0.2 to 3.3 ± 
0.2" and 2.5 ± 0.1 *t I/min) and SVR increased (36 ± 2 to 39 ± 3 and 46 ± 
5" mmHg/I/min). In marked contrast, DNP increased GFR in mild and overt 
CHF (mild CHF: 27 ± 4 to 44 :E 8" and 36 ± 3"; overt CHF: 22 ± 1 to 30 ± 3 
and 32 ± 4" ml/min) with a significant but attenuated natriuresis. PCWP was 
reduced (mild CHF: 13.3 ± 1.8 to 10.8 ± 2.4" and 9.9 J: 1.9"; overt CHF: 
26.7 ± 2.1 to 23.0 ± 2.0" and 21.6 ± 1.5" mm/Hg). In contrast to normals, 
CO was maintained and SVR was reduced (mild CHF: 41 ± 3to 37 i 3" and 
38 ± 3; overt CHF: 41 ± 4 to 35 ± 3* and 38 ± 3 mmHgA/min). 
Conclusion: DNP is a new natriuretic peptide which in mild and severe 
CHF uniquely enhances GFR in association with systemic vasodilatalion. 
These findings suppert a possible role for DNP in the treatment of CHF. 
~ T h e  Effect of Chronic Nocturnal Oxygen on Sleep 
Disordered Breathing Associated With 
Congestive Heart Failure (CHF) 
Joseph b Blackshear, Joseph Kaplan, Cynthia G. Day±son. Mayo Clinic 
Jacksonville, Jacksonville, FL, USA 
Background: Cheyne-Stokes respirations (CSR) occur in approximately 
one-third of patients with CHF. Oxygen (02) is acutely effective in reducing 
CSR, but whether it is effective chronically with other salutary effects on CHF 
is unknown. 
Methods: We evaluated chronic nocturnal 02, two liters/min versus air, 
both by nasal cannula, in 27 patient with CHF due to LV systolic dysfunction 
in a double-blind 3 month crossover trial. 
Results: Patients with (n = 18) vs. without CSR (n = 9) were older (75 
± 9 vs 65 ± 11 years, p = 0.03), had lower ejection fractions (23 ± 8% 
vs 31 ± 9%, p = 0.03), had more disordered breathing events per sleep 
hour, (DBE), 35 ± 26 vs 17 ± 17, p = 0.02, and had lower sleep efficiency 
(hours sleep/time in bed, 58 ± 16% vs 72 ± 13%, p = 0.03), and borderline 
differences in 6-minute walk time, number of arousals per hour of sleep = 
arousal index, and quality of life scores. 
After three months on nocturnal 02, polysomnography performed on 
blinded therapy was associated with overnight mean 02 saturation of 97 ± 
1% versus air 93 ± 3% (p < 0.0001), while arousal index declined from 42 ± 
23 to 27 ± 17/hr (n = 21, p = 0.005), and DBE from 29 ± 24 to 11 ± 10 (n = 
21, p = 0.002). For CHF patients with CSR treated with 02, the A DBE with 
02, -26 ± 27 (n = 14, p = 0.003). For non-CSR treated with 02, A arousal 
index was -7.6 ± 12.8 (n = 7, p = ns), and ~ DBE was -6  ± 5.9 (n = 7, p = 
0.04). No significant changes in ejection fraction, 6 minute walk time, quality 
of life scores or neurohumoral markers of CHF were noted. 
Conclusion: 
(1) The presence of CSR in CHF is associated with poor sleep quality. 
(2) Chronic nocturnal 02 results in improved sleep quality and a reduction 
in periodic breathing in patients with CHF and CSR. 
(3) Nocturnal 02 does not affect usual measures of CHF status. 
• Sequential Evaluation of Big Endothelin Plasma 
Concentration in Patients With Advanced Heart 
Failure: Effects of Therapy 
Rudolf Berger, Bernhard Fray, Bdgitte Stanek, Richard Pacher. Dpt. of 
Cardiology, Dpt. of Experimental Endocrinology, Uni~ of Vienna, Austria 
Background: The aim of this study was to analyze the prognostic value of 
sequential measurements of big endothelin (ET) on survival in patients (pts) 
considered for heart transplantation (HTx). 
Methods: 321 pts with advanced heart failure (NYHA Ill-IV, LVEDD 72 
± 10 mm, LVEF 16 ± 7%, CI 2.2 ± 0.6 L/min/m2) were treated with a 
combination therapy of high dose angiotensin converting enzyme inhibitor 
(ACE I), digitalis and diuretics. Pts were stratified according to therapy at 
the end of observation per±ode: Group A included 123 pts with high dose 
ACE I only, group B included 108 pts with additional #-blockade and group 
C included 90 pts with chronic i.v. bridging therapy. Pts were followed for 19 
± 11 (range 6-36) months. Big ET plasma levels were evaluated at time of 
first presentation and after 3 and 6 months. 
Results: 61 (19%) pts underwent HTx, 16/123 pts in group A, 2/108 pts 
in group B and 43/90 pts in group C (P < 0.001). 44 (14%) pts died, 19/123 
pts in group A, 4/108 pts in group B, and 21/90 pts in group C (P < 0.001). 
At baseline, big ET plasma levels were 3.3 ± 2.1 in group A, 3.2 ± 2.2 in 
group B and 6.5 ± 3.7 fmol/ml in group C (P < 0.001). After 3 (6) months of 
therapy, big ET plasma levels were 3.2 ± 1.9 (3.2 ± 2) in group A, 2.5 ± 1.1 
(2.3 ± 1) in group B and 5.5 ± 2.7 (5 ± 2.9) fmoVml in group C (P < 0.001). 
Big ET plasma levels decreased only in group B after 3 months (P < 0.01) 
and after 6 months (P < 0.001). In group C, big ET plasma levels decreased 
only in pts who were successfully stabilized (6.3 ± 3.2 vs. 4.4 ± 2.2 vs. 3.5 
± 1.5 fmoVml, baseline vs. 3 months vs. 6 months, P < 0.001), but not in pts 
who underwent HTX (5.7 ± 2.7 vs. 5.9 ± 2.8 vs. 7.3 ± 3.3 fmol/ml, P = n.s.) 
or in pts who died (8.5 ± 5.1 vs. 6.4 ± 2.5 vs. 7.3 ± 3 fmol/ml, P = n.s.). 
Conclusion: 1) Big ET plasma levels were higher in pts on chronic (.v. 
bridging therapy. 2) Big ET plasma levels decreased in pts treated with 
#-blockade and in pts on i.v. bridging therapy who were successfully stabi- 
lized. 
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~ T h e  Benchmark CounterpulsaUon Outcomes 
Registry: Results in 5335 Patients 
James J. Ferguson, Marc Cohen, Robert Freedman, Geoffrey M Graeber, 
Robert R. Cuffey Jr, Michael F. Miller, Debra L. Joseph. Texas Heart 
Institute, Houston, TX; Allegheny University/Hahnemann Hospital, 
Philadelphia, PA; St. Francis Cabrini Hospital, Alexandria, LA; West Virginia 
Universi~ Morgantown, WV; Datascope, Fairfield, N J, USA 
Background: The Benchmark Counterpulsation Outcomes Registry is an 
ongoing, large-scale prospective registry established in January 1997 to 
track the use of intra-aortic balloon counterpulsation (IABC). There are 100 
participating institutions electronically submitting demographic, clinical and 
outcome data on all patients treated with IABC. 
Objective: To describe the use, complications and outcomes of IABC in 
current US practice. 
Results: As of September, 1998, a total of 5335 patients (66% men, 34% 
women; mean age 66 years) have been enrolled; current enrollment is ap- 
proximately 225 patients/month. The indications for IABC include support in 
the cath lab (23%), cardiogenic shock (16%), weaning from cardiopulmonary 
bypass (15%), refractory unstable angina (14%), mechanical AMI complica- 
tions (6%), refractory ventricular failure (6%), high risk general surgery (4%), 
and refractory arrhythmias (2%). 78% were 40 cc balloons and 21% were 34 
cc balloons; 75% used a sheath for insertion, while 25% used a sheathless 
technique; 63% were inserted in the catheterization laboratory, 21% were in- 
serted in the operating room, 11% were inserted in intensive care units, and 
4% were inserted at other locations. The mean duration of IABC was 64.8 
hours. The incidence of severe bleeding (0.6%), limb ischemia (3.3% total; 
1.3% major), and unsuccessful IABC (2.5%) were low. In-hospital mortality 
was 20% (11% with the balloon in place). 
Conclusions: In the current practice of IABC, the incidence of balloon- 
related complications is low, although in-hospital mortality in these critically 
ill patients is high. 
~ - ~  Cardiomyoplasty: Compromised Right Ventricular 
Function Is Dependent on Latissimus Dorsi Muscle 
Stimulation 
Abul Kashem, William P. Santamore, Bang Yu Chiang, A. David Slater, 
Laman A. Gray. University of Louisville, Louisville, KY, USA 
Background: Although cardiomyoplasty (CMP) is somewhat believed to 
compromise fight heart function due to constraint effect, we hypothesized 
continuous volume infusion might impair right heart diastolic function in CMP 
and could be reversed by latissimus dorsi muscle (LDM) stimulation. 
Methods: A posterior cardiomyoplasty procedure was performed in dogs 
(n = 8), using left LDM after vascular delay. LDM was conditioned for 9 weeks 
by intermittent (n = 5) and continuous stimulation (n = 3). 10 weeks later, 
left jugular vein was cannulated using 7 Fr. Catheter sheath and continuous 
rapid volume of 3.0 L Lactated Ringer's saline solution were infused. Data 
were taken before, during and after volume infusion with CMP off and on. 
Results: RVEDP and peak systolic RVP were significantly increased 
during and after volume infusion compared to pre-infusion (p < 0.05). LDM 
stimulation reduced the RVEDP (p < 0.01) and increased cardiac output with 
high increases of RVP. 
Before infusion During infusion After infusion 
RVEDP Peak RVP RVEDP Peak RVP RVEDP Peak RVP 
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg) (mmHg) 
ST Beats* 2.59 35.97" 7.15 ¢ 46.82" 7.27 ~- 55.29* 
± 0.57 ± 1.78 ± 1.65 ± 1.57 ± 0.61 ± 2.43 
NS Beats 2.66 31.40 8.89 ~ 27.05 9.06 ~ 29.27 
± 0.56 ± 7.90 ± 1.88 ± 3.56 ± 1.00 ± 1 51 
"C -0.07 21.24 -0.74 23.12 - 1.79 26.02 
± 0.05 ± 1.24 ± 0.27 ± 0.95 ± 0.62 ± 1.11 
%C -2.88 94.03 -8.43 103.29 16.32 90.27 
±1.89 ±4.11 ±2.50 ±12.75 ±3.83 ±3.32 
*p < 0.05; ST vs NS. ST: stimulated beats; NS: Non-stimulated beats; "C: absolute 
changes; %C: percent changes; ~ : p < 0.05 when compared to pre and post infusion; ~ :
p < 0.01 ST vs. NS. 
Conclusion: CMP may reduce right ventricular compliance and restrict 
diastolic filling in response to rapid volume loading. LDM stimulation caused 
moderate decrease of RVEDP with myocardial left and right systolic hemo- 
dynamic assistance. 
• Early Versus Medium Term Effects of Partial Left 
Ventriculectomy on Left Ventricular Function: 
An Invasive Study 
Milutin Miri6, Zoran Popovi6, Sini,~a Gradinac, Aleksandar D. Popovi6, 
Aleksandar N. Ne,~kovi6, Milovan Boji6. Dedinje Cardiovascular Institute, 
Belgrade, Yugoslavia 
While partial left ventficulectomy (PLV) reduces left ventricular (LV) volumes 
and increases EF, the duration of this effect is not known. We report medium 
term effects of PLV on LV function in 15 concecutive patients with end- 
stage heart failure due to non-ischemic dilated cardiomyopathy. Right heart 
catheterization and ventriculography were performed preoperatively, 2 weeks 
after PLV, and at 6-months follow-up. 
Results: Compared to preoperative values, both early and at follow-up 
LV end-diastolic (EDV) and end-systolic volume indexes (ESV) decreased 
(EDV from 166 + 30 to 100 ± 22 and 102 4- 15 ml/m 2, p < 0.001 vs. pre 
for both; ESV from 127 ± 25 to 60 ± 15 and 63 ± 12 ml/m 2, p < 0.001 
vs. pre for both), whereas EF and LV systolic major-to-minor axis ratio (L/D 
ratio) increased (EF from 24 4- 7 to 40 ± 11 and 38 4- 8% p < 0.001 vs. 
pre for both; L/D ratio from 1.44 ± 0.17 to 1.93 ± 0.32 1.86 ± 0.28, p < 
0.001 vs. pre for both). There was no change in variables between early and 
follow-up study, and no loss of early EF increase. However, while pulmonary 
capillary pressure decreased early from 20 ± 10 to 15 ± 5 mmHg (p = 0.04), 
it increased to 19 :E 8 mmHg at follow-up (p = NS vs. pre). 
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Conclusion: PLV leads to reduction of LV volumes and stable improve- 
ment in EF and LV geometry during medium-term follow-up. 
~ Intermediate-Term Results of Partial Left 
Ventriculectomy 
R. Vijayanagar, Mark Weston, Stephen Mester, Jog/Nareddy, 
Narendra Sastry, Gary Chan. Tampa Genera/Hospital, and The Heart 
/nstitute, Hudson, Florida, USA 
Purpose: To evaluate the outcome of partial left ventdculectomy (PLV) for 
the treatment of patients with end stage heart disease (ESHD). 
Methods: 29 ESHD patients (19 males, 10 females; mean + SD age 
62 4- 13 years) underwent PLV in the period 9/96-1/98. All 29 patients had 
cardiomegaly. Eighteen (18) patients were considered ineligible for heart 
transplantation (HT) due to medical contrainclications. Cardiomyopathy was 
diagnosed in 25 patients and ischemic heart disease was present in 14 pa- 
tients. Left ventficular end-diastolic diameter (LVED) was 7.6 ± 0.9 cm, and 
ejection fraction was 15 ± 6% prior to surgery. Mitral regurgitation was present 
in 28 patients, and severe tricuspid regurgitation was documented in 1 individ- 
ual. During PLV, the resected ventricular mass was 55 ± 22 grams with mean 
dimensions of 9.2 cm × 5.6 crn. The follow-up duration was 18 ± 4 months. 
Results: Postoperatively, ejection fraction increased by 23 ± 6%, and 
LVED decreased by 2.2 ± 0.8 cm. Low output syndrome and renal insuffi- 
ciency were common after PLV. Seven (7) deaths occurred within 30 days 
postoperatively. Kaplan-Meier survival rates at 3, 6, 12 and 18 months after 
PLV were 69%, 44%, 41% and 37%, respectively. Of the 11 patients initially 
considered HT candidates, one had received a heart allograft. PLV resulted in 
a significantly higher initial increase in ejection fraction in patients considered 
non-candidates for HT (25 ± 6% vs 19+%, p = 0.03). However, 14 (74%) 
of the 19 deaths observed in the entire follow-up period occurred in patients 
who were considered non-candidates for HT. The 12-month survival rates for 
HT candidates and non-candidates were 64% and 28%, respectively. The 10 
survivors remained in NYHA functional class II. 
Conclusion: Despite initial encouraging experience with PLV, the in- 
termediate-term outcome of PLV in ESHD patients who have medical con- 
traindications to HT is disappointing. The results for HT candidates, however, 
are considerably better. PLV may be a useful bridging procedure for ESHD 
patients awaiting suitable HT allograft donors. 
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~ L e s s  Spherical Smaller Ventricle, Increased Wall 
Thickness and Mitral Competence Account for 
Benefits After Partial Left Ventriculectomy 
A.T. Kawaguchi, L.O. Bocchino, T. Ujiie, S. Shimura, A.R. Mustafa, 
R.J.V. Batista. Tokai Universi~ Japan; Vilera Batista Heart Foundation, 
Curitiba, Brazil 
Background: Mechanism of action of partial left ventriculectomy (PLV) re- 
mains unclear despite apparent benefits in some and deterioration in others. 
Methods: In 22 patients undergoing PLV and transventricular mitral an- 
nuloplasty, transesophageal Doppler-Echocardiography were repeated intra- 
operatively (TEE) and perioperatively through transthoracic window (3-1E). 
Results: TEE 4-chamber view showed that left ventricutar (LV) short-axis 
(S) decreased more than long-axis (L), reducing sphericity of LV after PLY 
more in end-systole (S-L/S) than in end-diastole (D-L/S). LV dimensions 
decreased more in end-systole than in end-diastole in all axes, increasing 
fractional shortening (FS, %) and ejection fraction (EF, %), preserving total 
stroke volume (SV, ml) from a nearly halved end-diastolic volume (EDV, 
ml). TTE showed posterior wall thickness (PW, mm) increased after surgery, 
reflecting reduced wall stress after PLV as in the excised wall thickness that 
doubled without stress (17 ± 6 mm). While mitral regurgitation (MR, 0: none, 
1 : mild, 2: moderate) was eliminated in all, early ventricular filling (E, cm/sec) 
and atrial kick (A, cm/sec) were unchanged, indicating preserved LV diastolic 
property (A/E). 
S-I.JS D-L/S FS EF SV EDV MR A E A/E 
PRE 1.97 1.92 16 28.2 70.7 399 1.92 75 117 0.81 
POST 2.95 2.42 24 37.1 70.5 203 0.00 76 121 0.84 
PValue 0.0001 0.004 0.0003 <0.001 0.440 0.0001 <0.0001 0.205 0.925 0.182 
Conclusion: PLV with mitral annuloplasty improved systolic performance 
and preserved diastolic characteristics, thereby increasing forward SV from 
a much smaller and less spherical LV with a thicker wall. 
~ Save Me the Money: A Cost Comparison of 
Inpatient vs. Outpatient Care of Left Ventricular 
Assist Device Patients 
Dawn M. Christensen, Patricia A. Frazier, Eric R. Messner, Walter E. Pae 
Jr., David H Silber, Benjamin Sun, John P. Boehmer. The Milton S. Hersey 
Medical Center, Hershey, PA, USA 
Mechanical ventricular assist devices (VAD) have expanded the options to 
heart transplant candidates and the healthcare community. However, with this 
advanced technology, medical costs have the potential for escalating. Out- 
patient care may markedly reduce the cost of managing the VAD supported 
patient. A total of 12 patients with VADs awaiting heart transplantation at our 
institution were transferred to an assisted living facility. A sample of seven of 
these patients were compared to five similar patients awaiting transplant at 
our university health center. The mean stay and average cost per day were 
compared. Currently there are four private apartments available on a monthly 
basis with a cost of $9860 per month (30 days). This fixed cost is incurred 
regardless of whether there are 0 or 4 patients. Therefore, patient cost per 
day decreases as the number of patients staying at the outpatient facility 
increases. The average patient cost per day at the outpatient facility came to 
$1357.00 per day not including laboratory or professional fees. The average 
patient cost per day for patients who were required to stay in house due to 
insurance regulations was $3441.00 not including laboratory or professional 
fees. Therefore, an average daily savings of $2084.00 was realized. The 
calculated average total savings for the 7 patients housed at the outpatient 
facility for a total of 705 patient days was $1,469,220. This analysis does 
not include professional fees and laboratory costs due to inability to obtain 
records. All but one of the patients were eventually transplanted. Two corn- 
plications occurred at the outpatient facility, one being a ddveline infection, 
the other a device failure. Both patients were transported to and arrived at 
the hospital in stable condition. One death occurred as a result of the device 
failure. Results suggest that outpatient care for VAD supported patients can 
significantly reduce the costs of these cardiac transplant candidates without 
increasing their risk for serious complications. 
Recovery-Directed Left Ventricular Assist Device - ~ 
A New Concept 
Fujio Miyawaki, Takayuki Tsuji. National Cardiovascular Center Research 
Institute, Osaka, Japan 
Background: To promote recovery from potentially reversible myocardial 
failure such as postcardiotomy cardiac failure, we developed a new LVAD 
(RDLVAD) and evaluated its efficacy by comparison with an ordinary LVAD. 
Methods: RDLVAD consists of a valved apical conduit, a compliant af- 
tedoad-controlling chamber (ACC) and a pump (Fig. 1 ). Unlike the ordinary 
LVAD (the control group device), which sucks the blood from LV, RDLVAD 
(the RD group device) allows LV to eject blood preferentially through the 
valved conduit into the ACC because the blood pressure in the ACC can 
be controlled at much lower levels than the aortic pressure. In each of 5 
miniature pigs with ischemia-induced heart failure, flow and pressure mea- 
surements were made while maintaining the LVAD pump flow and arterial 
pressure equal between groups. A centrifugal LVAD pump was used in this 
study. 
Results: Fig. 2 shows substantial differences between the aortic and left 
ventricular pressures, and no ejection through the aortic valve in the RD 
group However, in the control group, some ejection through the aortic valve 
against the aortic pressure, which resulted in higher LV work, was likely to 
occur although the LV blood was sucked vigorously. Then, 1) the RD group 
diastolic-to-systolic pressure time index ratio (DPTI/SPTI) increased by 5 
times and LVEDP fell by 30% (P < 0.05). 2) RDLVAD allowed full left ventdc- 
ular relaxation. 3) In one control group pig, which was able to achieve almost 
no ejection through the aortic valve, echocardiography revealed restricted 
left ventricular relaxation. 
• [ Pump Flow . 118 'L/rain) 
• va lve  ~ ~ ' F,g.l 
/ ~  ~¢o- I t ' . _ tt • Aortic Root Flow 
~ L J . - - .  -k--.L -k--llJ-..- ..'kJ~-.....k,~ [ 0 (mmHg) 
Pump RD group Control group F ig .  2 
Conc lus ion :  RDLVAD may promote cardiac recovery by ensur ing  less 
LV work, greater blood supply over demand to the coronary circulation, and 
full ventricular relaxation. 
ORAL  
~5~ Cardiac Transplantation: Predicting and 
Preventing Complications 
Tuesday,  March  9, 1999, 4:00 p .m. -5 :30  p.m. 
Mor ia l  Convent ion  Center ,  Room 262 
4:00 p.m. 
~ g s e  of Daclizumab Decreases the Frequency of 
Early AIIograft Rejection in De-Novo Heart 
Transplant Recipients 
Ainat Beniaminovitz, Mary Donovan, Silviu Itescu, Elizabeth Burke, 
Niloo Edwards, Mehmet Oz, Donna Mancini. Columbia Presbyterian 
Medical Center, New York, New York, USA 
Background: Induction therapy using a monoclonal antibody to the IL2 
receptor (Daclizumab) has been shown to decrease rejection frequency and 
improve survival in renal allograft recipients. 
Methods: To investigate whether rejection frequency would also be de- 
creased in cardiac allograff recipients, 34 de-nero non-sensitized patients 
were randomly assigned to induction therapy with Daclizumab. administered 
at a dose of 1 mg/kg within 24 hrs of transplant and q 2 wks for total of 
5 doses. All patients were treated with cyclosporine, prednisone and my- 
cophenolate mofetil. Duration of inotropic support post transplant, hospital 
stay, survival, rejection and infection frequency were monitored. 
Results: Thirty-four patients were enrolled of which 17 patients received 
Daclizumab. Recipient and donor age, gender, ischemic time, and recipient- 
donor CMV mismatch were similar in both groups (p = NS). Overall survival 
of the 34 patients was 91%. All 3 deaths occurred in the control group (C). 
In the Daclizumab group (D), duration of inotropic support was less (C: 11 ± 
7; D: 5 • 2 days; P < 0.001), as was hospital stay post transplant (C: 19 ± 
8; D: 13 ± 4 days; p < 0.05). Thirteen ISHLT grade 1B or greater rejection 
episodes (5-3A) occurred in the control group vs 5 episodes (no 3A) in the 
Daclizumab group. None of the Daclizumab patients required rescue therapy 
vs 4 in the control group. By Kaplan Meier and log rank analysis, time to 
first rejection episode was later in the Daclizumab than the control group (p 
< 0.001). Seven hospital re-admissions (3 for CMV) occurred in the control 
group vs 3 (1 for CMV) in the Daclizumab group. 
Conclusion: Early post transplant, Dactizumab therapy decreases sever- 
ity of and increases time to allograft rejection in de novo non-sensitized car- 
diac allograft recipients. Length of hospital stay and inotropic support is also 
significantly reduced in the Daclizumab group. 
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~ Pravastatin Confers Superior Survival After Cardiac 
Transplantation when Compared to Simvastatin 
Anne M. Keogh, Peter S. Macdonald, Christina Aboyoun, Julia A. Mundy, 
Dermot McCaffrey, Philtip M. Spraft. St Vincent's Hospital, Sydney, NSW, 
Australia 
Background: Pravastatin has been reported to reduce rejection and mortality 
after cardiac transplantation. 
Methods: To determine if outcomes on pravastatin differ from simvastatin, 
87 cardiac transplant recipients received pravastatin (20 rag) or simvastatin 
(10 mg), on an alternating transplant basis, given from Day 2. Dosage was 
targetted to 40 mg and 20 rag/day respectively. 78 patients have completed 
12 month follow up on mean pravastatin dose 36 ± 8 mg (n = 40) or 
simvastatin 18 ± 6 mg/day (n = 38). 
Results: There were no significant differences in lineadsed rejection or 
infection rates, creatinine, liver function tests, immunosuppressant doses, 
total cholesterol, triglycerides, LDL or HDL cholesterol between the two 
groups at baseline, 3, 6 or 12 months. Actuarial survival on pravastatin at 12 
months was 95.3% and on simvastatin 78.7% (p < 0.05 Gehan) with only 
1 immunosuppression-related eath on pravastatin and 6 on simvastatin. 
Rhabdomyotysis occurred only on simvastatin (n = 3) and headache only on 
pravastatin (n = 2). The proportion of patients with hemodynamic compro- 
mise, or requiring OKT3, cytolytics, FK506 or total lymphoid irradiation for 
recurrent rejection was 25% on pravastatin vs 47% on simvastatin. 
Conclusion: One year survival of heart transplant recipients on pravas- 
tatin was significantly superior to that on simvastatin (95.2% versus 78.7%), 
by a Iowedng of 'mmunosuppression related' deaths. This effect appeared 
independent of lipid levels achieved. The proportion of patients experienc- 
ing serious or recurrent rejection was halved on pravastatin and there were 
no episodes of rhabdomyolysis despite concomitant use of cyclosporine. 
Pravastatin appears to have a special life protective effect after cardiac 
transplantation, without oxicity. 
4 :30 p.m, 
~55~]  A Prospective Randomized Trial of the 
Immunomodulatory Role of Simvastatin and 
Pravastatin on Cardiac AIIograft Rejection 
Mandeep R. Mehra, Krishnamoorthy Vivekananthan, Patricia A. Uber, 
Helen deGruiter, Charanjit Kapoor, Sergio Sol±s, Carl Lay±e, Richard Milan±. 
Ochsner Medical Institutions, New Orleans, LA, USA 
Background: HMG CoA reductase inhibitors inhibit natural cell killer cytotox- 
±city, T Cell proliferation and monocyte chemotaxis in transplant recipients. 
The relationship of lipid lowering magnitude and immunomodulation has not 
been previously delineated. 
Methods: To compare and contrast the immunomodulatory effect of 
Simavastatin and Pravastatin on clinical and subclinical indices of allograft 
rejection, we investigated a prospective cohort of 49 heart transplant recipi- 
ents that were randomly assigned to either Simvastatin (10 mg qd, n = 26) 
or Pravastatin (20 mg qd, n = 23) within 6 weeks of transplant, and treated 
for 1 year. Episodes of treated rejections, rejection (Rej) with hemodynamic 
compromise (HC), noncellular rejections, and mean biopsy rejection score 
were examined in both groups. 
Results: 
Group Rej Score Treated Rej Rej with HC Noncellar Rej 
Pravastatin 0.74 ± 0.6 8.3% 16.7% 0% 
Simvastatin 0.78 ± 0.6 13% 6.7% 6.7% 
No significant differences in rejection indices were found (all p = ns). 
Regression analysis revealed no significant correlation between percent 
lipid change and mean biopsy score (r = 0.2, p = ns). A parallel group of 37 
untreated heart transplant recipients had a mean biopsy rejection score of 
0.96 ± 0.7, p < 0.05 compared with the Simvastatin and Pravastatin groups. 
No rejection deaths, nor significant transaminase elevations or myopathy 
requiring drug withdrawal were noted. Simvastatin more effectively lowered 
total cholesterol ( -  19% vs -9%, p = 0.08), LDL cholesterol (-23% vs - 11%, 
p = 0.02), but not triglycerides (8% vs 6%, p = ns) than Pravastatin. 
Inferences: Simvastatin and Pravastatin provide equivalent immunomod- 
ulation in synergy with cyclosporine based immunosuppression. This impor- 
tant immunomodulatory property is independent of the lipid lowering effects 
of these agents. 
4:45 p.m. 
[ ~  Cytomegalovirus Antigenemia After Cardiac 
Transplantation Is Associated With Endothelial 
Dysfunction 
Mihai Croitoru, Jose G. Diez, Clay P. Haas, Richard D. Fish, James 
J. Ferguson, Bran±slav Radovancevic. St. Luke's Episcopal Hospital/Texas 
Heart Institute and Baylor College of Medicine, Houston, Texas, USA 
Background: Cardiac transplant patients have been shown to have impaired 
endothelial function. We tested the hypothesis that active cytomegalovirus 
(CMV) replication after transplantation, manifested as CMV antigenemia 
(CMVag), is associated with endothelial dysfunction. 
Method: Twenty orthotopic heart transplant patients (16 men, 4 women) 
were evaluated. Mean age was 54.2 years (21-68 y). Mean duration since 
transplant was 48 months (9-144 months). Flow-mediated diameter increase 
(FDI) and nitroglycerin-mediated iameter increase (NDI) were assessed by 
duplex ultrasonography of the brachial artery, using the reactive hyperemia 
technique. CMVag was considered positive if patients had a positive blood 
culture or quantitative pcr assay after transplantation. 
Results: Five patients had at least one episode of CMVag. None had 
active antigenemia at the time of the study. The average FDI was 10.49% (± 
2.59%) in non-CMVag patients, compared to 1.25% (± 5.74%) in the CMVag. 
This was statistically significant (p = 0.02). When compared to healthy con- 
trois, all CMVag patients had impaired endothelium-dependent vasodilatation 
(defined as FDI < 8%), compared with only 4 of the 15 non-CMVag patients. 
Nitroglycerin-mediated (endothelium-independent) vasodilatation was simi- 
lar in the two groups. Only CMVag status and serum cyclosporine trough 
levels were independent predictors of endothelial dysfunction. Transplant in- 
dication, age, gender, atherosclerosis risk factors, history of rejection, biopsy 
scores, medications were not. 
Conclusion: CMV antigenemia after cardiac transplantation is associated 
with endothelial dysfunction, as assessed noninvasively with the reactive 
hyperemia technique. 
5:00 p.m. 
~ Methylene-Tetrahydrofolate Reductase 
Polymorphism and Ailograft Vascular Disease After 
Heart Transplantation 
Klaus Pethig, Andrea Hoffmann 1 , Bernd Heublein, Thorsten Wittwer, 
Axel Haverich. Dep. of Thoracic and Cardiovascular Surge~ Hannover 
Medical School; 1GBF-Laboratories Braunschweig, Germany 
Background: Recently plasma homocysteine (HCY) levels have been sug- 
gested to be a risk factor in native coronary artery as well as in cardiac 
allograft vascular disease (CAVD). 
Methods: As plasma levels are partially under genetic control, we inves- 
tigated the influence of the Methylenetetrahydrofolate Reductase (MTHFR) 
polymorphism on HCY levels and development of CAVD in heart transplant 
(HTX) recipients. Genotyping and assessment of fasting HCY levels were 
performed in a cohort of 146 HTX recipients (1-12 years post HTX, 121 male, 
mean age 46.2 i 11.3 years) and correlated to the onset and progression 
of CAVD as assessed by serial angiography (3.7 ± 1.3 examinations per 
patient). 
Results: Allelic frequencies were 38.4% for MTHFR-CC, 52.7% for the 
CT, and 8.9% for the TT genotype. The highest HCY levels with 19.4 ± 7.8 
#mol/L were observed in the TT-group as compared to 18.9 ± 7.0/~mol/L in 
CC and CT-genotypes (p = 0.8). Actuarial freedom from CAVD did not differ 
significantly between the genotypes. However patients positive for CAVD (as 
defined by a luminal obstruction >_50% in one of the major coronary arteries) 
presented with higher HCY levels than CAVD negative individuals (21.9 ± 
10.4 vs 18.3 ± 6.9 #mol/L, p = 0.04). 
Conclusions: There is some evidence that plasma HCY might be in- 
volved in development of CAVD. However polymorphism of the MTHFR gene 
could not be shown to be related to severity of allograft vascular disease. 
5:15 p.m. 
[855~ Diagnostic and Prognostic Value of Combined 
Dobutamine Stress Echocardiography and 
Myocardial Scintigraphy After Heart Transplantation: 
Comparison With Intravascular Ultrasound and 
Angiography 
Christoph H. Spes, Andreas Tausig 1 , Volker Klauss, Andres R. Tammen, 
Johannes Rieber, Susanne D. Schnaack, Peter Knesewitsch 1 , 
Bruno Reichart, Karl The±sen, Klaus Hahn 1 , Harald Mudra, Chdstiane 
E. Angermann. Depts. of Cardiology (Klinikum Innenstadt); 1Nuclear 
Medicine, University of Munich, Germany 
Background: Dobutamine stress echocardiography (DSE) is a reliable non- 
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invasive method for assessment of cardiac allograft vasculopathy (CAV), but 
is restricted to patients (P) with adequate image quality. In this study, DSE 
and myocardial scintigraphy (MS) were performed simultaneously and com- 
pared to coronary angiography (CA), intravascular ultrasound (IVUS) and 
clinical outcome. 
Methods: 97 DSE-MS studies (5-40 l~g/kg/min) were done in 77 (76 ± 
39 months after heart transplantation) (HTX). Tc-99m-MIBI (250 MBq) was 
injected at peak stress and after 3 h (650 MBq) for the rest study. SPECT-data 
were acquired 1 h after Tc injection. Regional wall motion abnormalities or 
abnormal MS were regarded as markers of CAV. 60 CA and 26 IVUS studies 
were performed. By CA any luminal irregularities were defined as CAV. By 
combined CA-IVUS, CAV was defined as mean IVUS grade >3.0 (6-grade 
scale) and/or abnormal CA. Cardiac events (death, reHTX, PTCA, heart 
failure) were registered at follow-up. 
Results: In 10 of 97 DSE-MS the image quality was not adequate for 
analysis of DSE. DSE and MS were concordant in 58 of 87 tests (67%). 
Sensitivity (specificity) to detect angiographic CAV was 80% (56%) for DSE, 
69% (50%) for MS, and 95% (39%) for combined DSE-MS. Sensitivity to 
detect CAV defined by CA and IVUS was 76% (DSE), 61% (MS), and 87% 
(DSE-MS); Specificity was low (50%/25%/25%), but only 4 P had both normal 
CA and IVUS findings. All 6 events occurring at follow-up were detected by 
DSE-MS and DSE, 5 by MS. 1 event was not predicted by CA. No event 
occurred after a normal DSE-MS. 
Conclusion: Combined DSE-MS is a feasible approach for noninvasive 
assessment of CAV also in P with poor echocardiographic images. DSE-MS 
has a high sensitivity to detect P with CAV and is useful to identify P at risk 
for subsequent events. By noninvasive screening with DSE-MS unnecessary 
routine angiography and potential side effects (e.g. of contrast agents in P 
with impaired renal function) may be avoided. 
ORAL  
in Heart Failure Novel Mechanisms 
Tuesday,  March  9, 1999, 4:00 p .m. -5 :30  p.m. 
Mor ia l  Convent ion  Center ,  Room 275 
4:00 p.m. 
~ Estrogen Prevents Fas-Ligand Production. Evidence 
for a Apoptosis-Protective Effect from a 
Population-Based Study 
Andreas V. Sigel, Hans-Wemer Hense I , Sabine Laberer, GQnter 
A.J. Riegger, Her±bert Schunkert. Klinik und Poliklinik for Innere Medizin II, 
Universit&t Regensburg; Institut fDr Epidemiologie, Universit~t MDnster, 
Germany 
Background: The prevalence of systolic heart failure is only half in women 
as compared to men. The mechanisms responsible for this apparent gender 
related dimorphism in cardiac function are incompletely understood. Herein, 
we investigated the association between estrogen status and Fas-ligand, 
a circulating peptide that has been shown to induce myocyte cell death 
(apoptosis) and that is elevated in serum of end-stage congestive heart 
failure patients. 
Methods: The 646 subjects of this study, aged 52-67, have been partici- 
pating in the MONICA (Multinational Monitoring of Trends and Determinants 
in Cardiovascular Disease), Augsburg, baseline survey of 1984-1985 and 
its follow-up examinations in 1987-1988 and t994. Plasma was stored at 
80°C and measurements were carried out in duplicates using commercially 
available ELISA kits for 17fl-estradiol and Fas-ligand. 
Results: Overall, Fas levels were significantly lower in women as com- 
pared to men (6104 vs. 6446 pg/mi, p < 0.05). In addition, pre-menopausal 
women displayed signifcantly lower levels of Fas-ligand than post-menopausal 
women without estrogen replacement therapy (5508 vs. 6590 pg/ml, p < 
0.05)). Next, estrogen replacement herapy (ERT) was associated with sig- 
nificant lower Fas levels in post-menopausal women (5889 vs. 6539 pg/ml 
without ERT, p < 0.01). Further, multivariate analysis indicates an inverse 
relationship between plasma levels of Fas-ligand and female gender. In ad- 
dition to the inverse association with female gender (-271 pg/ml, p ~ 0.05), 
multivariate analysis revealed that Fas levels were positively associated with 
both age (+95 pg/ml per year, p < 0.05) and diabetes mellitus (+1523 pg/ml, 
p < 0.05). 
Conclusion: The data demonstrate for the first time an inverse associ- 
ation between the estrogen and Fas-ligand levels. Further, given the impli- 
cations of Fas for cardiac myocyte death on one hand and the cardiopro- 
tective effects of estrogen replacement herapy on the other hand, one may 
speculate this protection may be partially mediated through decreased Fas 
production. Further prospective controlled trials should address the potential 
interaction of estrogen replacement herapy and apoptosis regulating factors. 
4 :15 p.m. 
~ Soluble and Surface-Bound P-Selectin Reveal 
Heightened Platelet Activity in Patients With 
Decompensated Heart Failure: Is Aspirin Therapy 
Enough? 
Christopher M O'Connor, Paul A. Gurbel 1 , Victor L. Serebruany 1 . Duke 
University Medical Center, Durham, NC; t Center for Thrombosis Research, 
Sinai Hospital Baltimore, MD, USA 
Background: Selectins may participate in the pathogenesis of congestive 
heart failure (CHF) by modulating platelet-leukocyte-endothelial interactions 
in the deteriorating myocardium. P-selectin is an important marker of piatelet 
activation and may be up-regulated in patients with CHF. However, no data 
are available on the simultaneous determination of plasma levels and platelet 
expression of P-select±n, nor are the effects of antecedent aspirin use on 
P-selectin in patients with CHF known. We sought to prospectively compare 
platelet and soluble P-selectin in patients with CHF and in healthy controls. 
Methods and Results: Matched soluble levels by ELISA, and platelet- 
bound expression by whole blood flow cytometry of P-selectin were prospec- 
tively determined in twenty-two patients with decompensated CHF and com- 
pared with fourteen healthy controls. Twelve patients were aspirin-free and 
ten patients were using aspirin (81-500 mg/daily). Patients with CHF exhib- 
ited significantly elevated soluble P-selectin (186.6 ± 82.7 ng/ml, p = 0.017) 
and more than two-told increased expression of platelet-bound P-selectin 
(9.58 ± 7.16% positive platelets, p = 0.021) compared to the P-selectin 
profile (102.6 ± 29.0 ng/ml plasma, and 4.06 ± 1.21% positive platelets, 
respectively) in controls. Aspirin therapy did not affect the P-selectin profile 
in patients with CHIC. 
Conclusions: Despite antecedent aspirin therapy and intedndividual vari- 
ability of the P-selectin profile, soluble and platelet P-selectin were elevated 
in the majority of patients with severe CHF, suggesting persistent platelet 
activation. The present data provide evidence that more potent adjunctive 
antiplatelet regimens deserve further study in the heart failure population. 
4:30 p.m. 
I~ -6~ Endothelial Cell dysfunction and Elevation of 
Circulating Smooth Muscle Cell chemoattractants & 
Mitogens in Congestive Heart Failure Patients: 
Potential Role of cxv~3 Integrin 
Shaker A. Mousa, Porur E. Somasundaram, Bong Hee Sung, 
William Lorelli, Jeff Bozarth, Michael F. Wilson. DuPont Pharmaceuticals 
Co., Wilmington, DE," State University of New York, Buffalo, NY, USA 
Background: The present study was undertaken to determine the plasma 
smooth muscle mitogens, plasma soluble endothelial cell adhesion molecule 
markers (s-VCAM-I, s-ICAM-1), platelet derived growth factor (PDGF), and 
pro-inflammatory markers (TNF-~, IL-6) in CHF patients. 
Methods: Patients hospitalized with class III or IV congestive heart failure 
(CHF) were included in the study. Blood samples were taken from 34 CHF 
patients within 24 hours of admission for the quantitation of the above pa- 
rameters using a sensitive and specific ELISA. Additionally, the role of ~,v/~3 
integrin antagonist on in vitro human smooth muscle cell chemotaxis induced 
by plasma from CHF subjects was examined. 
Results: Using an improved quantitative method for smooth muscle 
chemotaxis, a significant increase (P < 0.01) in the circulating plasma levels 
of smooth muscle mitogenic stimuli in plasma from patients with CHF as com- 
pared to that from healthy subjects was demonstrated. A significant increase 
(P < 0.01) in plasma levels of PDGF, TNF-o~ and IL-6 were demonstrated in 
CHF patients. A selective c~vfi3 small molecule antagonists, monoclonal an- 
tibodies LM609 or c7E3 demonstrated maximal inhibition of smooth muscle 
chemotaxis toward vitronectin, osteopontin or plasma from CHF patients. A 
significant elevation (2-3 fold) of s-VCAM-1 and s-ICAM-1 in plasma from 
CHF versus normal was demonstrated. 
Conclusion: This data suggests a compromised endothelial cell function 
in CHF patients as evident from the elevation in s-VCAM-1 and s-ICAM-1 
and the potential implication of the c~vfl3 integrin in pathological processes 
involving smooth muscle chemotaxis in CHF patients. 
4 :45 p.m. 
~ B o d y  Small Bowel and Impedance, Permeability 
Immune Activation in Chronic Heart Failure 
Veronika Koloczek 1-2 Math±as Rauchhaus t , Michel Kemp 1 , 
Ingvar Bjarnanson 1 , lan S. Menzies ~ , Roger Crane ~ , Juergen Holtz 2, Philip 
A. Poole-Wilson 1 . Andew J.S. Coats 1 , Stefan D. Anker 1 . ~Cardiac 
Medicine, NHLi London, UK; 2 pathophysiology Martin Luther University 
Halle, Germany 
Background: It has been suggested that endotoxin (LPS) triggers immune 
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activation in patients with chronic heart failure (CHF). Venous congestion 
occurs in CHF and may cause altered bowel wall permeability (BWP) that 
could contribute to LPS uptake into the circulation. 
Methods: In 19 CHF patients (age 67 ± 2 y, mean ± SE, clinically 
edematous: 10) and 7 healthy controls (age 70 & 2 y) we measured plasma 
levels of LPS and tumor necrosis factor-c~ (TNF) and assessed total body 
water content (TBW) with body impedance (BI, TANITA TBF-305). We also 
assessed small intestine BWP (sugar absorption technique using melibiose, 
D-xylose, 3-Om-D-glucose, and L-rhamnose). 
Results: Patients with severe edema had highest LPS (0.65 ± 0.08 
EU/ml, ANOVA p = 0.0022) and TNF (8.6 ± 1.4 pg/ml, p = 0.0026) levels, but 
lowest BI (239 ± 37 ~, p < 0.0001) compared to controls and non-edematous 
CHF patients - the latter did not differ significantly. 
TBW was highest in edematous patients (p < 0.05). BI correlated with 
TNF (r = -0.54, p = 0.009) and LPS (r = -0.45, p = 0.037, n = 26). However, 
these findings could not be explained by alterations of small intestine BWP 
as measured with the sugar test. Urinary sugar appearance levels and 
the melibiose/rhamnose absorption ratio did not differ significantly between 
groups. 
Conclusion: This study confirms that LPS levels are raised in edematous 
CHF patients who also show significant immune activation. Body impedance 
correlated strongly and inversely with LPS and TNF. This study does not 
exclude abnormal permeability in the large intestine. 
5:00 p.m. 
~ Enhanced Hepatocyte Growth Factor Secretion from 
the Infarct Region May Prevent Ventricular 
Remodeling in Patients After Acute Myocardial 
Infarction 
Satoshi Yasuda, Yoichi Goto, Takeshi Baba, Toru Satoh, Hitoshi Sumida, 
Shunichi Miyazaki, Hiroshi Nonogi. National Cardiovascular Center, Japan 
Background: Hepatocyte growth factor (HGF) is a novel, multifunctional 
growth factor implicated in angiogenesis, wound healing and promotion of cell 
survival. Recent animal studies have demonstrated that HGF system exists 
in the heart, which is activated by myocardial ischemia and reperfusion. We 
hypothesized that HGF may play a cardioprotective role in the human infarct 
heart. 
Methods: We studied 20 patients with acute myocardial infarction (MI), 
who underwent coronary reperfusion therapy on admission. Approximately 
4 weeks alter, left ventricular (LV) catheterization was repeated to determine 
LV ejection fraction (EF), end-diastolic volume index (EDVI) and pressure 
(EDP). Levels of HGF and brain natriuretic peptide (BNP) were measured 
by collecting blood samples from cardiac veins in MI and non-MI regions. 
The ratio of the HGF level in the MI region to that in the non-MI region (= 
MI/non-MI ratio) was calculated in each patient as an index of the MI-related 
HGF secretion. The MI/non-MI ratio for BNP was also calculated. 
Results: The MI/non-MI ratio for HGF correlated inversely with LVEDP (r 
= -0.659, P < 0.001 ) and LVEDVI (r = -0.799, P < 0.001 ), and positively with 
LVEF (r = 0.722, P < 0.001). These correlations were completely opposite 
in direction to those between the MI/non-MI ratio for BNP and LVEDP (r = 
0.647, P < 0.005), LVEDVI (r = 0.722, P < 0.001) and LVEF (r = -0.799, P 
< 0.001). These findings indicated that cardiac HGF acts in contrast to BNP, 
a biochemical marker for the development of LV remodeling. 
Conclusions: An enhanced secretion of cardiac HGF from the MI region 
is associated with attenuation of ventricular enlargement and improvement 
in cardiac function. The HGF system may modulate the process of post-MI 
ventricular remodeling and thereby have an important clinical implication. 
5:15 p.m. 
~-6~- ]  Ang iotensin-Converting Inhibitors Restore Enzyme 
Hepatocyte Growth Factor Production in Patients 
With Congestive Heart Failure 
Satoshi Yasuda, Yoichi Cote, Hitoshi Sumida, Takeshi Baba, Teruo Noguchi, 
Hireshi NonogL National Cardiovascular Center, Osaka, Japan 
Background: Endothelium-dependent vasodilation is impaired in patients 
(pts) with congestive heart failure (CHF). For vascular endothelium, hepato- 
cyte growth factor (HGF) is a most potent and specific growth factor, which 
acts protectively against endothelial dysfunction. HGF production is down- 
regulated with angiotensin II (Ang II) in vitro. We hypothesized that HGF 
production is impaired due to increased Ang II in pts with CHF, and if so, the 
impaired production should be restored with angiotensin-converting enzyme 
inhibitors (ACE-I). 
Methods: We studied 8 pts with CHF due to previous anterior myocardial 
infarction in whom left ventricuLar ejection fraction was 35 ± 9% (mean ± 
SD). Before and approximately 4 weeks after ACE-I therapy, blood samples 
were collected to measure levels of HGF, Ang II, and brain natriuretic peptide 
(BNP) regarded as a biochemical marker for severity of CHF. We also studied 
5 control subjects (No CHF, No ACEq). 
Results: In control subjects, heparin (5000 unit iv) increased HGF pro- 
duction to 48 ± 5 fold. In pts with CHF, HGF response to heparin was 
significantly attenuated (25 ± 7 fold, P < 0.05 vs control) despite similar 
HGF levels at baseline (= before heparin). Therapy with ACE-I for CHF pts 
decreased levels of Ang II (from 71 ± 20 to 27 ± 11 pg/mL, P < 0.05) and 
BNP (from 288 ± 95 to 140 ± 46 pg/mL, P < 0.05), and restored HGF 
production in response to heparin by 46 ± 7 fold, comparable to the control 
response. 
Conclusions: Impaired HGF production was restored with therapy with 
ACE-I due to Ang II inhibition. This novel effect of ACE-I may contribute to 
the functional improvement in pts with CHF and thereby have an important 
clinical implication. 
ORAL  
Mechanical Interventions in Heart Failure 
Wednesday ,  March  10, 1999, 8:30 a .m, -10 :00  a.m.  
Moda l  Convent ion  Center ,  Room 265 
8:30 a.m. 
[~- ]  Passive Ventricular Constraint With the Acorn 
Prosthetic Jacket Prevents Progressive Left 
Ventricular Dilation and Improves Ejection Fraction 
in Dogs With Moderate Heart Failure 
Hani N. Sabbah, Pervaiz A. Chaudhry, Gaetano Paone, Takayuki Mishima, 
Clif Alferness. Henry Ford Heart and Vascular Institute, Detroit, MI, USA 
Background: Preventing progressive LV dysfunction and dilation is a key 
goal that defines therapeutic success in heart failure (HF). We examined 
the concept that passive mechanical constraint of the cardiac ventricles 
with a surgically placed prosthetic jacket (Acorn Cardiovascular, Inc., figure) 
prevents progressive LV dilation and preserves LV systolic function in HF. 
Methods: Studies were performed in 12 dogs with moderate HF (LV ejec- 
tion fraction, EF = 30--40%) produced by multiple intracoronary microem- 
bolizations. Six dogs underwent a mid-sternotomy and pericardiotomy with 
surgical placement of the Acorn jacket (a preformed-knitted polyester mesh), 
snugly around the ventricles and anchored at the AV groove. Six untreated 
dogs served as controls. LV end-diastolic pressure (EDP), end-systolic (ESV) 
and end-diastolic (EDV) volumes and EF were measured before (PRE) and 
3 months after surgery (POST). 
Results: In controls, LV EF decreased and LV volumes increased after 
3 months of follow-up; whereas in dogs treated with the Acorn jacket, EF 
increased and LV volumes decreased after 3 months (" = p < 0.05). 
Control (untreated) Acorn Wrap 
PRE POST PRE POST 
EDP (mmHg) 14~-2 17±6 15± 1 13±2 
ESV (ml) 43 ± 3 60 J_ 7 * 45 ± 3 36 ± 3* 
EDV (ml) 67 • 5 83 ± 8" 68 ± 4 61 ± 4" 
EF (%) 36 ± 1 28 ± 2* 34 ± 1 41 ± 1" 
Conclusion: Passive ventricular constraint with the Acorn jacket prevents 
progressive LV dilation and improves LV EF in dogs with moderate HF. 
8:45 a.m.  
~ Epicardial Patch on Against Acute Infarct Protects 
Late Ventricular Dilation and Preserves Function 
Bruno K. Podesser 1 , Ravin Day±doff, Franz R. Eberli, Mohit Jain, Carl 
S. Apstein 1 . Dept. of CT Surgery, AKH Wien, Vienna, Austria; Boston 
University, Boston MA, USA 
Background: Ventricular dilation post MI is considered to be a progressive 
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process which induces hypertrophy and finally leads to heart failure. Me- 
chanical fixation of infarcted myocardium or scarr tissue could theoretically 
prevent dilation. We tested whether an epicardial vicryl mesh fixed on the 
area of infarction (AOI) after coronary ligation is able to protect against late 
ventricular dilation and to stabilize function. 
Methods: Fifteen adult White New Zealand rabbits received myocardial 
infarction by coronary ligation, in 8 a vicryl mesh with the size of the AOI 
was sutured on the infarct (p), 7 served as control MIs (mi). One rabbit in 
each group died. Five additional rabbits represented an age matched control 
group (c). Cardiac output (CO) was recorded prior and post infarction by a 
flow probe around the ascending aorta. Rabbits were followed over a period 
of 6 months by TTE before sacrifice. 
Results: There were no differences between p, mi and c hearts with 
respect to body weight, CO prior (267 ± 10 vs 240 ± 20 ml/min, ns) and post 
coronary ligation (199 ± 6 vs 203 ± 20 ml/min, ns) nor in infarct size (41 ± 6 
vs 34 ± 7% of left ventricutar mass) and in the AOI (38 ± 6 vs 36 ± 3 sqmm). 
TEE 4 weeks post infarction showed a significant increase in diastolic (1.78 
± 0.08 vs 1.85 ± 0.03 vs 155 ± 0.06 mm, p < 0.01) and systolic (1.26 i 
0.06 vs 1.37 ± 0.04 vs 1.05 ± 0.05 mm, p < 0.004) dimensions in p and rni 
hearts compared to c. Decrease in fractional shortening (FS) did not reach 
significant difference between the three groups (28.7 ± 2.6 vs 26.2 ± 2 vs 
32.6 ± 1.5%, ns). Six months post boths infarct groups had further dilated 
but diastolic dilation was more pronounced in mi (1.92 ± 0.07 vs 2.04 ± 0.06 
vs 1.8 ± 0.05 mm, p < 0.05 between mi and c). Systolic dimension increased 
less in p than mi (1.35 ± 0.05 vs 1.49 ± 0.04 mm, p < 0.01). Accordingly, 
FS was reduced in mi hearts compared to c (27.3 ± 1.7 vs 34.4 ± 2%, p < 
0.05), but not in p (30.8 ± 1.5%, ns vs c). 
Conclusion: These results indicate that mechanical fixation of an acutely 
infarcted area protects against late ventdcular dilation and preserves function. 
9:00 a.m. 
~-0~ Passive Ventricular Containment in the Treatment of 
Experimental Dilated Cardiomyopathy 
Jai Raman, John Power, Brian Buxton, Clif AIferness. Austin & Repatriation 
Medical Centre, Heidelberg Victoria, Australia 
Background: Heart failure (HF) is a clinical problem of increasing magnitude 
and few satisfactory therapeutic options. Dilated myopathy (DCM) is associ- 
ated with a progressive decline in cardiac function, and worsening HF. Our 
hypothesis was to arrest this decline by mechanically containing the dilating 
heart. 
Methods: Twelve adult merino sheep (52 ± 4kg) were studied. A Tran- 
sonic 20A cardiac output (CO) flow probe was implanted around the main 
pulmonary artery through a minimal access thoracotomy. The sheep were 
paced into early heart failure using right ventricular pacing for 21 days at a 
rate which resulted in an initial decrease in CO by 10%. A polyester jacket 
(Acorn Cardiovascular Inc, St Paul, MN) was placed around the ventricles 
through a lower, partial sternotomy. The jacket was wrapped around the 
ventricles to ensure a snug fit and its base secured around the A-V groove. 
Animals were then randomized to either jacket retention (wrap) or removal 
(sham). Pacing was continued thereafter at a higher rate to further reduce CO 
by 10%. Hemodynamic and echocardiographic parameters were monitored 
at surgery and termination of pacing. 
Results: At termination of pacing, significant findings were improve- 
ment in left ventricular fractional shortening (p = 0.007), lower mitral re- 
gurgitation (p = 0.006), smaller left ventricular long-axis area (p = 0.01) 
and better contractility measured by [dp/dt]/P (p = 0.008), in the wrap 
group. Animals were euthenased at 6 to 13 weeks after jacket implantation. 
Histopathology revealed no significant reaction to the jacket except for mild 
adhesions and no constriction of epicardial coronary arteries. 
Conclusions: Passive ventricular containment reduced the deleterious 
consequences of DCM and arrested the progression of HF. The implanted 
polyester jacket was well tolerated. This device may have significant ther- 
apeutic application in patients with progressive DCM and HF, after longer 
implant data in experimental animals. 
9:15 a.m. 
[~-~ Time Course of Left Ventricular Regression Mass 
Following Left Ventricular Assist Device 
Implantation 
Donna R. Zwas, Marco R. Di Tullio, Margaret Flannery, Katherine 
A. Catanese, Shin Takuma, All Fard, Henry D. Wu, Shunichi Homma, 
Daniel Burkhoff. Columbia Universi~ New York, NY, USA 
Background: Left ventricular assist device (LVAD) implantation induces re- 
gression of left ventricular hypertrophy in some patients with end-stage heart 
failure (HF). Reduction of LV mass (LVM) is an indicator of reverse ventricular 
remodeling, and may identify patients in whom the LVAD has a beneficial 
effect on the myocardium. 
Methods: To study the time course of LVM regression, we performed 
serial transthoracic echocardiography, per±operatively and at 2 and 4 weeks 
after surgery, in 7 patients who underwent LVAD implantation. Five patients 
had idiopathic dilated cardiomyopathy (DCM) and 2 patients had ischemic 
cardiomyopathy (IC). LVM was calculated by a modified Simpson's formula 
that uses multiple short axis measurements and the measurement of ven- 
tricular height in apical 4-chamber view. 
Results: A significant reduction in LVM was seen in the entire group at 2 
weeks and persisted at 4 weeks. LVM reduction was significantly greater in 
patients with DCM than in patients with IC (25% vs. 6%; p < 0.05): 
Group Baseline 2 Weeks 4 Weeks 
Pooled 220 ± 60 185 ± 55" 177 ± 59* 
ICM 221 ± 65 195 ± 55 207 ± 70 
DCM 220 ± 67 181 ± 61" 165 ± 59" 
All values in grams; * = p < 0.05 
Conclusions: 1) LVM regression begins rapidly after LVAD implantation. 
2) Different regression patterns occur in DCM and IC patients. 3) Echocardio- 
graphic LVM determination may help identify reverse ventricular remodeling 
in individual patients. 
9 :30 a.m. 
~ - ~  Factors Influencing Functional Recovery on 
Ventricular Assist Device Support in End-Stage 
Heart Failure: Lessons From the "Bridge" to 
Transplantation Experience 
Srinivas Mural±, Steve Winowich, Kenneth McCurry, Ren@ J. Alvarez Jr., 
Guy A. MacGowan, Dennis M McNamara, Warren D. Rosenblum, Robert 
L. Kormos. University of Pittsburgh, Pittsburgh, PA, USA 
Electric and pneumatically powered ventricuiar assist devices (VAD) are uti- 
lized either for isolated left ventricular (L) or for biventricular (BI) supped, 
in select pts with end-stage heart failure (HF) as a "bridge" to transplanta- 
tion. Although functional capacity improves on VAD support, the factors that 
determine the extent of improvement have not been previously studied. We 
evaluated maximal exercise capacity after 30 days of VAD support in 15 
pts receiving a pneumatic device (THORATEC LVAD, n = 9; BIVAD, n = 6) 
and 19 pts receiving an electric device (NOVACOR LVAD). All pts under- 
went supervised rehabilitation after VAD placement. Peak exercise oxygen 
consumption (VO2 max, ml/min/kg) for the entire population (13.4 ± 4.9); 
for THORATEC LVAD pts (14.3 ± 5); for THORATEC BIVAD pts (12.5 ± 5); 
and for NOVACOR LVAD pts (13.4 ± 4.8) were similar. Pts were arbitrarily 
divided into 2 groups; VO2 max _< 15 (10.9 ± 2; Group I, n = 25) and > 
15 (20.4 ± 3.6; Group II, n = 9). Group I was significantly (p < 0.05) older 
(52 ± 10 vs 38 ± 14 yrs), and had longer UNOS status I waiting times (30 
± 29vs 13 ± 9 days) prior to VAD insertion. There were no differences in 
gender ratio, etiology of HF, type of VAD inserted or right ventricular fractional 
area change measured from echocardiograms obtained within 7 days of VAD 
insertion (LVAD pts only) between groups. 
Conclusions: 1 ) Functional capacity improves in HF pts after VAD inser- 
tion irrespective of the type of device and whether one or both ventricles are 
supported. 2) The extent of functional improvement is greater in younger pts 
and those who undergo VAD insertion earlier in the course of their end-stage 
HE These observations have important implications regarding clinical design 
of future trials comparing VAD support to medical therapy in severe HE 
9:45 a.m.  
I~ - ]  Poor Outcome With Left Ventricular Assist Devices 
as Bridge to Transplant Following Myocardial 
Infarction With Cardiogenic Shock 
John I% Boehmer, Waiter E. Pae, David Silber, Dawn Chdstenson, Benjamin 
C. Sun. The Milton S. Hershey Medical Center, Hershey, PA, USA 
Background: Mortality remains high for patients with cardiogenic shock 
(CS) complicating acute myocardial infarction (AMI). When revascularization 
is not feasible or fails to improve hemodynamics, patients may be considered 
for heart transplantation. Left ventricular assist devices (LVAD's) have been 
used with varying results. 
Methods: 14 consecutive patients with AMI complicated by CS underwent 
placement of a pneumatic LVAD with intention to bridge to transplant. 
Results: Eight patients received a Pierce-Donachy (P-D) LVAD and six 
patients received a TCI HeartMate (TCI) LVAD. The AMI involved acute 
occlusion of the proximal left anterior descending or left main coronary artery 
in thirteen patients. The results are listed in the table below. One patient 
is clinically stable 6 months after LVAD implantation and continues to await 
heart transplantation. Stroke and muir±system organ failure (MOF) were the 
most common causes of death. 
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P-D TCI All 
Successf~ ~r~d~e 1 (13%) I (20%) 2 (15%) 
Stroke 6 (75%) 4 (60%) 10 (77%) 
Device infection 0 (0%) 1 (20%) 1 (8%) 
Cause of death Stroke 4 (50%) 2 (40%) 6 (46%) 
MOF 2 (25%) 1 (20%) 3 (23%) 
Other 1 (13%) 1 (20%) 2 (15%) 
Conclusion: The use of the LVAD as a bridge to heart transplantation 
following AMI is associated with a high mortality. The incidence of stroke 
is unacceptably high and may limit our ability to support such patients with 
LVAD's alone. 
POSTER 
~ - ~  Sympathetic Activation Experimental in 
Heart Failure 
Wednesday ,  March  10, 1999,  9 :00  a .m. -11 :00  a.m. 
Mor ia l  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour :  9 :00  a .m. -10 :00  a.m. 
~ Effects of Cardiac Function and Metoprolol on 
Remodeling in Postinfarct Failing Rats 
Elmir Omerovic, Entela Bollano, Vuk Kujacic, Michael Fu, ,&.ke Hjalmarsson, 
Finn Waagstein. Wallenberg Laboratory, Sahlgrenska University Hospital, 
GOteborg, Sweden 
Background: ~-blockade has been shown to improve left ventricular (LV) 
function in the patients with heart failure (HF) due to ischemic heart disease. 
However, conflicting data exists about effects of/%blockade on postinfarct 
cardiac remodeling. 
Methods: Male Sprague-Dawley rats (200-250 g) were used. Myocardial 
infarction (MI) was induced by ligation of the left coronary artery resulting in 
infarction of LV anterolateral wall. Three different groups were studied: MI 
rats treated with metoprolot (Mete, n = 17), MI rats untreated (Placebo, n 
= 12), and sham operated rats (Sham, n = 12). Three weeks after infarc- 
tion the rats were randomized for 6 weeks (w) treatment with metoprolol 1 
mg/kg/h (delivered by implanted osmotic minipumps). Cardiac function and 
morphology were evaluated before and after the treatment using transtho- 
racal echocardiography. Only rats with large MI (>1/3 LV) were selected for 
the study. 
Results: 
The values represent the mean of the difference before and after the treatment 
BW HR EF LVDd LVDs EDV ESV 
g blmin % mm mm ml ml 
Sham +149 -13  -16  +0.8 +0,9 +1,0 +0.11 
Mete  +128 -58  TM -5  # -0 .2  TM -0 .4  TM +1.3" +0.15 
P lacebo  +150 +9 -2  ~ +1.9 # +2.1 +2.5 # +0,19 
"p < 0.05 v placebo; #p < 0.05 v sham; BW = body weight; HR = heart rate/beat per mip; 
EF = ejection fraction; LVDd = LV diameter in diastole; LVDs = LV diameter in systole; 
EDV = end diastolic volume; ESV = end systolic volume 
Conclusions: Long-term selective ,8~ -blockade with metoprolol decreases 
EDV and LV dimesions without effect on LV function in the rats with chronic 
MI. 
~ Potentiation of the Responsiveness /3-Adrenergic 
in Failing Human Myocardium by Dantrolene 
Sodium 
Jiangyong Min, Achim Meissner, Nils Haake ~ , Stephan Hid ~ ,
RLidiger Simon. Department of Cardiology; ~ Department of Cardiovascular 
Surgery, University of Kiel, Germany 
Background: Dysregulation of the intracellular Ca2+-homeostasis with ab- 
normal diastolic Ca 2+ handling are hallmarks of the failing myocardium. 
Dantrolene sodium (D) has been shown to modulate the function of the sar- 
coplasmic reticulum (SR) and to inhibit diastolic Ca 2+ oscillations in animal 
models. This study investigated the effects of D on intracellular CaZ+-handling 
and contractile force in failing human myocardium. 
Methods and Results: Muscle strips from human left ventricular my- 
ocardium were obtained from patients undergoing heart transplantation tot 
end-stage heart failure caused by ischemic (n = 12) and dilated (n = 3) 
cardiomyopathy. Isometric force and free intracellular Ca 2+ concentrations 
([Ca2*]i) were determined in isolated, electrically stimulated trabeculae (Ca 2+ 
Pn~t?c~tor. zequod~n'i. ?soproterendr ¢ose-cesponse cccv~s ~ere peff'onTred" 
separately in a control group (n = 8), after addition of dantrolene (10/~M; n = 
8) or after addition of verapamit it  #M; n = 7). 
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Diastolic [Ca2+]i was  reduced from 0.38 ± 0.03 to 0.33 ± 0.02 /~M in 
the dantrolene (p < 0.05) and from 0.39 ± 0.04 to 0.38 i 0.03 /~M in the 
verapamil group. 
Conclusion: D potentiates the f~-adrenergic responsiveness in failing 
human myocardium. This effect is not accompanied by an additional increase 
in [Ca2+]i but might be related to an improvement of the diastolic Ca 2÷ 
homeostasis. 
~ Dantrolene Sodium Restores the Altered 
Force-Frequency Relationship in Failing Human 
Myocardium 
Jiangyong Min, Achim Meissner, Nils Haake 1 , Stephan Hirt 1 , 
RQdiger Simon. Department of Cardiology; ~ Department of Cardiovascular 
Surgery, University of Kiet, Germany 
Background: Failing human myocardium is characterized by a negative 
force-frequency relationship which might be related to alterations of the in- 
tracellular Ca 2+ homeostasis. Dantrolene sodium (D) interferes with Ca 2+ 
induced Ca 2+ release from the sarcoplamic reticulum (SR) and modulates di- 
astolic Ca 2+ oscillations in animal models. This study investigated the effects 
of D on the force-frequency relationship and intracellular Ca 2+ homeostasis 
in failing human myocardium. 
Methods and Results: Muscle strips from human left ventricular my- 
ocardium were obtained from patients undergoing heart transplantation for 
end-stage heart failure caused by ischemic (n = 12) or dilated (n = 3) car- 
diomyopathy. Isometric force and intracellular CaZ+-concentrations ([Ca2+]i) 
were determined in isolated, electrically stimulated trabeculae (Ca 2+-indicatOr 
aequorin). Force-frequency analyses were performed separately in a control 
group (n = 8), after addition of dantrolene (10/~M; n = 8) or after addition of 
verapamil (1 ~M; n = 7). 
-- '~-- cor, lroi I ~ Control 
• . . . .  ; 
~8 0, 
~6 **  **  ~ 0,6 
4 ~_ 0, with ~mg 
2 J , . 0,2 . . . . . . .  
0,33 033 2 3 0,33 0.33 1 2 3 st ~lat ion kequercy 0dz) ~twulati~ rectu~cy IHZ) 
Diastolic tension (mN/mm 2) Diastolic [Ca2+]j (,~M) 
0.33 Hz 3 Hz 0.33 Hz 3 Hz 
Control 5.12 ± 0.13 10.2 ± 0.18"" 0.39 ± 0.03 0.64 ± 0.04'* 
Dantro]ene 5.63 ± 0.16 8.45 ± 0.23 TM 0.37 ± 0.02 0.52 ± 0.16 TM 
Verapamil 5.48 ± 0.20 11.4 ± 0.26"  0,38 ~- 0,02 0.57 ± 0.05"* 
"p < 0.05, "*p < 0.01 3 Hz VS 0.33 Hz in each group; #p < 0.05 dantrolene vs control at 
3 Hz 
Conclusion: The negative force-frequency relationship in failing my- 
ocardium can be partly restored by dantrolene sodium. In parallel, both 
systolic and diastolic Ca 2÷ handling appears to be improved. 
~ 7 ~  Ventricular Gene and Augmented Expression 
Secretion of Adrenomedullin in Experimental 
Congestive Heart Failure 
Michihisa Jougasaki, Andreas Luchner, John A. Schirger, Margaret 
M. Redfield, John C. Burnett Jr.. Mayo Clinic, Rochester, MN, USA 
Background: Adrenomedullin (ADM) is a newly discovered natriuretic and 
vasorelaxing peptide with inotropic actions. Although plasma ADM is in- 
creased in human congestive heart failure (CHF), no studies to date have 
established whether cardiac production of ADM is increased in CHF. The 
present study was designed to investigate cardiac ADM gene expression 
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and secretion in the presence and absence of experimental CHF which was 
produced by rapid ventricular pacing in the dog for 4 weeks. 
Methods: We first developed 293 bp canine specific ADM probe for North- 
em blot analysis and in situ hybridization using reverse transcription-poly- 
merase chain reaction with highly conserved pdmers for mammalian ADM. 
ADM gene expression, myocardial and circulating ADM as well as cardiac 
secretion of ADM were investigated by using methods of radioimmunoassay, 
Northern blot analysis and in situ hybddization. 
Results: ADM mRNA was present in the heart by Northern blot analysis 
and was localized to atrial and ventdcular myocytes by in situ hybridization in 
normal dogs. Ventricular ADM mRNA was markedly increased in association 
with an increase in plasma (5.5 ± 0.5 to 16.8 ± 3.3 pg/ml, p < 0.05) and 
ventricular tissue ADM (111 ± 25 to 305 i 49 pg/g, p < 0.05) in CHF. Plasma 
sampling was also obtained from aorta and anterior interventricular vein, and 
revealed a significant step-up in plasma ADM between aorta (15.6 ± 0.4 
pg/ml) and anterior interventricular vein (17.7 4- 0.4 pg/ml, p < 0.05) in CHF 
consistent with left ventricular secretion. 
Conclusion: The present study demonstrates ADM synthesis in normal 
canine atrial and ventricutar myocytes with increased ventricular production 
and secretion in CHF in association with increases in ventricular and cir- 
culating ADM concentrations. This study provides evidence that ventricular 
production of ADM is increased in CHF representing an additional myocardial 
gene product activated in the failing heart, 
~ T h e  Transition From Pressure Compensated 
Overload Hypertrophy Is Characterized by an 
Increase in the Interstitial Norepinephrine to 
Adenosine Concentration Ratio 
Mojca Lorbar, Eugene S. Chung, Theo E. Meyer. University of 
Massachusetts Medica/ Center, Worcester, MA, USA 
Background: Increased sympathetic activity plays a key role in the progres- 
sion of heart failure. Attenuation of sympathetic tone, such as with adenosine 
A1 receptor activation, may be an important cardioprotective mechanism 
dudng the course of pressure ovedoad hypertrophy (POH). 
Methods: This study was designed to investigate the balance between 
interstitial norepinephrine (NE) and adenosine (ADO) levels as the heart pro- 
gresses from compensated (C-POH) to the decompensated state (D-POH). 
POH was induced in rats by abdominal aortic banding. Based on the lung 
weight, animals were defined as C-POH (<2SD of sham control) end D-POH 
(>2SD of sham control). Epicardial surface transudates were collected from 
isolated inverted heart for NE and ADO determinations. 
Results: 
sham C-POH D-POH 
Lung weight (g) 1.947 ± 0.050 1 .g70 ± 0.048 4.205 ± 0.399"1" 
NE (ng/ml) 0.340 ± 0.125 0.450 ± 0.121 0.957 ± 0.298 "+, 
ADO (nmoVmf) 0.261 ± 0.053 0.390 ± 0.065" 0.267 ± 0.044 
NE/ADO 1.962 ± 0.764 2.156 ± 0.924 3.479 ± 1.662"1' 
* p < 0.05 vs. sham; 1" p < 0.05 vs. C-POH 
Conclusion: In C-POH, the ratio of interstitial NE/ADO levels remains 
unchanged as compared to sham. However, in D-POH elevated interstitial 
NE levels are not accompanied by further elevation of ADO levels, leading 
to an increase in the interstitial NE/ADO ratio. This may render the pressure 
overloaded heart more vulnerable to the detrimental effects of increased 
sympathetic activity. 
~ Effects Changes Adrenergic Activity of in Cardiac 
on Gene Expression in the Intact Failing Human 
Heart 
Brian D. Lowes, E. Michael Gilbert, William T. Abraham, Wayne A. Minobe, 
Patti Larrabee, Robert L Reden, Michael R. Bristow. University of Utah 
Health Sciences Canter, University of Colorado Health Sciences Center, 
USA 
In order to investigate how chronically elevated adrenergic activity con- 
tributes to progressive myocardial dysfunction, we measured changes in RV 
endomyocardial biopsy gene expression as measured by quantitative RT- 
PCR performed at baseline and after six months of treatment with placebo or 
/~-blockade, and compared these changes to changes in cardiac adrenergic 
drive as measured by coronary sinus (CS) norepinaphrine (NE) levels. All 28 
subjects had idiopathic dilated cardiomyopathy (IDC) with ejection fractions 
<40% (average 21 ± 2, with RVEFs of 31 ± 3). Gene expression measure- 
ments (in molecules mRNA x 105/ug RNA) included/~1 adrenergic receptor 
(/~+AR), /~2-adrenergic receptor (/~2AR), SR Ca 2+ ATPase (SRCA), atrial 
natriuretic peptide (ANP), ~x-myosin heavy chain (c~-MyHC) and ~-MyHC. 
Relationships of changes in the expression of the various genes to changes 
in adrenergic activity were assessed by linear aggression as shown in the 
table: 
CS NE vs: /~1AR ~2AR SRCA ANP e-MyHC /~-MyHC 
r -0.002 -0.18 -0,20 -0.23 0.07 0.46 
p 0.99 0.36 0.34 0.24 0.72 0.01 
When ,6ARs, SCRA & ANP data were normalized to total MyHC gene 
expression,/~IAR and SRCA were increased relative to CS NE change (r = 
-0.57, p = 0.002 for ,61AR; r = -0.43, p = 0.03 for SRCA). There was no 
significant statistical interaction between subjects treated with placebo vs. 
fl-blockade. 
Conclusions: Expression of ,6-MyHC may be under adrenergic control 
in the failing human heart. An adrenergically mediated increase in/~-MyHC 
expression could potentially decrease contractile function, as could relative 
reduction in the expression of/3~AR & SRCA. 
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~ Congestive Heart Failure and Depression: 
Frequency and Impact of Depression on Functional 
Status 
Christine Skotzko, Cathy Krichten, Gretchen Zietowski, Lynnette Alves, 
Michael Fisher, Stephen S. Gottlieb. University of Maryland School of 
Medicine & VAMHCS, Baltimore, MD, USA 
Background: Symptoms of depression can mimic constitutional symptoms of 
congestive heart failure (CHF). We screened individuals with CHF for depres- 
sion, and examined the physiologic and functional status of the depressed 
and non-depressed individuals to determine if there were any differences 
between the groups. 
Methods: 34 adults with CHF completed the Center for Epidemiologic 
Studies Depression Scale and the Medical Outcome Study Short Form 36. 
Participants underwent cardiopulmonary exercise (CPX) testing to measure 
maximal oxygen consumption (MV02, ml/kg/min) and respiratory quotient 
(RQ). Doubly labeled water (EE, kcal) and Caltrac Accelerometer (CT, kcal) 
assessment of energy expenditure were also performed. 
Results: Of the 34 individuals evaluated, 15 scored in the depressed 
range (44%) and 19 did not. The two groups did not differ significantly 
in age, left ventricular election fraction, MV02 or assessment of energy 
expenditure. RQ was significantly lower for the depressed group. There were 
no discernible differences in quality of life measures, with the exception of 
social functioning, where the depressed individuals had greater limitations (p 
< 0.01 ). 
Age MV02 RQ EE CT 
Depressed 64 ± 11 14.1 ± 3.4 0.96 ± 0.09 1655 ± 309 3969 ± 805 
Non-Oep 67 ± 7 14.4 4- 2.3 1.05 ± 0.11 1674 ± 354 4048 ± 801 
P value 0.4 0.8 <0.05 0.9 0.8 
Conclusion: Depression was common in the cohort of CHF patients ex- 
amined. No physiologic or functional differences between depressed and 
non-depressed individuals were seen. Depressed individuals did demon- 
strate significantly decreased effort in CPX testing and limited social func- 
tioning. These results suggest that depressed CHF patients are not more ill, 
but less motivated. 
• Patient Motivation and Reaction to Participating in 
Clinical Heart Failure Trials 
Rita Yuval, Klari Uziel, Amnon Merdler, Basheer Karkabi, Nader Khader, 
David A. Halon, Basil S. Lewis. Lady Davis Carmel Medical Center, 
Technion-IIT, Haifa, Israel 
Background: The motivation, reaction and perception of patients partici- 
pating in randomized placebo-controlled heart failure trials has gained little 
attention, even in the era of GCP. 
Methods: An anonymous questionnaire was completed by 54 pts (age 
64 ± 10yr; 48 m, 6f; NYHA class II in 29%, III in 65%, IV in 6%) who had 
participated in 4 outpatient rials of new pharmacotherapeutic agents for heart 
failure. Replies analyzed by descriptive statistics, association tests, analysis 
of variance. 
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Results: Patients were motivated to participate in trials for different rea- 
sine: 33 <61%( eKOected Oettec ~tt<]w-u~, tt <20%~ hettet c.~ce, ~t (tF% I 
cl~me~ a desire ~o he~ salience, 1 uncaP, Bin. ,~u~d,~ec'(~ve m,orovemen% was 
reported by 43/52 (82%) pts during the trial; most (37/50, 74%) pts ascribed 
this to better follow-up, only 8 (16%) to altered medication, 5 (10%) to in- 
creased motivation. The possibility of placebo therapy was of no concern to 
The greatest inconvenience was travel to the medical center (29 pts, 62%), 6 
(20%) p~s complained ol need for additional m~dication, 4 (13%) time spent 
at each visit, I (3°1o) extra blood tests. All but I pt expressed a desire to 
klnow 'fne resdlis o'i'fne "i£1~i an~i li~Tilc9 ",Cb"I=P?~i irlieres~ "re DaI~id!Di~le 'In "I~ure 
sludies. 
Conclusions: 1. Pt motivation to participate in heart failure trials was 
b~Bsed ~n > ~,~% e~ CaSes oT~ ey, pe~a~of~ o~ beY~e~ ca~e o~ ~A~w-u~. 2
Subjective improvement was reported by more than three quarters of pts, 
mostly due to better follow-up. 3. Placebo therapy was usually not a cause 
for concern. 
[ -~~ Quality of Life in Heart Failure and Other 
Conditions 
Russell C. Davis, F.D. Richard Hobbs, Joyce E. Kenkre, Andrea K. Roalfe, 
Sandy McLeod, Rachel Hare, Michael K. Davies. University of Birmingham, 
EBirmiooham, UK 
Introduction: Heart failure (HF) is common and has poor prognosis. Treat- 
ment improves symptoms and prognosis, but many patients remain disabled. 
[De.spite its hNh prevalence, there have been few studies of the in]pact of HF 
cn quality of tile, especially in the community & in the old. 
Methods: The 'Heart of England' study is a large, community based study 
cf HF. Patients are assessed clinically and with ECG and echocardio~raphy, 
and on this basis a diagnosis of heart failure or not is made. Patients also fill 
in Yne ,~no~ Form ~t'6'Rea'Ptn ,~urvey I~F-~3'6)., a s'not{ se'~-aCmilri~s~ered ques- 
tbnnaire with 36 ~lems wNch measure eight multi41em variables: physical 
functioning (PF), role limitations due to physical problems (RP), role )imita- 
tions due to emotional problems (RM), social functioning (SF), mental health 
(MH), energy and vitality (El, pain (P), and general perception of health 
(HP). We compare results in patients with HF with a random population 
Results: The health perceptions of 2600 patients aged 45 and older, 
those in 200 patients with HF, subdivided by NYHA class (on treatment). The 
~r~D~ s~ows ~e ~'esuT~s ~or eac~ o~ ~ne B meas o~ %ea~ ~n ea~ ~ass, as 
Conclusions: Patients with HF have statistically significant impairment 
of all aspects of health, net simply physical functioning. However, patients 
with HF who improve to NYHA class 1 on treatment have health perceptions 
similar to random controls. 
• Change in Radial Pulse Wave Contour With 
Glyceryl Trinitrate as a Method to Assess Severity 
of Left Ventricular Failure 
Katzuo Uebaba, Michael F. O'Rourke, Anne Keogh, Peter Macdonald, 
Andrew Sindone. Cardiology Department, St Vincent's Hospital, Sydney, 
NSW, Australia 
Background: In cardiac failure, dicrotism of the arterial pulse is attributable 
to early return of wave reflection from peripheral sites causing premature 
aortic valve closure and shortening of left ventricular ejection duration tED). 
Reduction of wave reflection with nitroglycenne is a strategy for treatment 
of cardiac failure. WE, explored the possibility that the magnitude of glyceryl 
trinitrate (GTN) effect might provide a method for assessing severity of left 
ventricular failure. 
Methods: Of 196 patients undergoing right heart catheterisation for 
assessment of cardiac failure at a heart transplant centre, 50 in regu- 
lar heart rhythm had simultaneous radial artery pressure wave measure- 
ment by tonometry, using SphygmoCor ~, together with measurement of 
pulmonary artery pressure and cardiac output (Swan-Ganz thermedilution 
catt~ete<~, tix he(ore ~(xd a~er ~m~n~s~t~or~ ~' GT(~ (~'/~n(~ave~,~us (r~- 
~:~on ~1.0-~..O.ag]~.¢r6m). Age range was ~2-"/~, mean 5'3 years. 
Results: In the whole group, cardiac index (CI) and stroke volume, index 
(SVI) increased from 2.3 ± 0.7 to 2.6 ± 0.6 (p < 0.0003, paired-t), and 28.5 
± 9.0 to 33.2 ± 7.7 (p < 0.0002, paired-t) respectively with GTN. The change 
r = 0.52, p < 0.001). Changes in ejection duration were likewise inversely 
related to inilial 01 and SVI {r = 0.51, p < 0.0001 and r = 0.51, p < 0.01). 
Increase in SVI after GTN was directly related to increase in ED (r = 0.56, p 
< "O 7d05" L
Conclusion: In patients with cardiac failure, increase in ED after GTN ad- 
ministration correlates with severity of LV failure, is associated with increase 
m s'{~.~ke v~urr~, an~ ~s ex;DF, cab~e on ~he bas'~s e~ ~c~on ~n p~p,~e~a~ 
wave reflection. 
• Radial Artery Pulse Wave Analysis for Assessment 
of Left Ventricular Failure 
Katzuo Uebaba, Michael F. O'Rourke, Anne Keogh, Peter Macdonald, 
Andrew Sindone. Cardiology Department, St Vincent's Hospital Sydney, 
NSW, Australia 
cardiac failure, and is attributable to eady wave reflection from peripheral 
sites causing premature aortic valve closure. The purpose of this study was 
to quantify pulse wave analysis by relatin~left ventricular ei ection duration 
~LFJ'~,  , n~.~J ,,cojL ~m,  t h,..m a'u;~ f ~J,'~,~, ,~ ~,~ ,  h,J~P, ~?p; '~  ~ ,.e, r,,~ ,,;nv.~'¢~ 
inc~ices ol LV dysfunction. 
Methods: The study was conducted in a group of 196 patients, aged 
?_'2-~?., m~a~ 5i  "yea~s, ' #,~,h cC, inica~ cardiac t~~C,~r~ ~eler~e~ far ~ssessme~t 
at a heart transplant unit. Results are presented for 159 patients with regular 
su, r,ed b'J aI:~anatk~, ~.m-vzx,~m~ anab~sed b'J S~h'/cJn",~--~r ® , ,Nere ra~ate~ 
to previously determined echocardiographic measurements, and to cardiac 
output, mean pulmonary artery and capillary wedge pressures, and derived 
indices, determined simultaneously by thermodilution and conventional pres- 
sure measurement at right heart catheterisation. 
~e~e-d~: rh ~e wCro~ gr~op', e~ecdrbrT ~br~dbrr w~ £nve~¢y- F~¢~tee" 
to heart rate (as in normal subjects). Between heart rate 55--120/min the 
regress~on'ime was'~ower'{~.Td~ower, p <"u?O-5[~or'tne "]~)7~ pafled~s compare(~ 
to a group of 90 normal control subjects. The regression line was lowest (p 
< 0.05~ ;'R the 9~ ~tmnts w)th card)at ~z~x ~C~ < 28  Um~z'~ than ?n t~ 
"b~ wltn~g~ >_~L'~.'m'tne ~n6~e group d¢~5'-J p~ber l rs~ was r~eb'[o'£.9 
stroke work index (r = 0.63, p < 0.00001), stroke volume index (r = 0.71, p 
< 0.00001) and fractional shortening (r = 0.54, p < 0.00001), and inversely 
related to LV end-diastolic and end-systolic diameter (r = 0.40, p < 0.00001 ; 
r = 0.52, p < 0.00001) end to mean pulmonary capillary wedge pressure 
(r = 0.36, p < 0.00001) and pulmonary vascular resistance (r = 0.48, p < 
0.00001). 
Conclusion: in patients with regular rhythm, analysis of the radial pulse 
waveform provides a useful, simple screening procedure for presence and 
severity of LV dysfunction in patients with cardiac failure. 
F•8---• Night Heart Rate Trends Correlate With Changes in 
Heart Failure 
Vssant Padmanabhan, Karen A. Stone, Michael F. O'Toole, R. 
Andrew Rauh, Nancy J. Schwabauer, Elaine L. Enger, Walter H. Olson, 
Richard M. Powell. Midwest Heart Research Foundation, IL; Medtronic Inc., 
MN, USA 
Background: Autonomic imbalance is a hallmark of heart failure. Heart 
rate is a noninvesive measure of autonomic function. We hypothesized that 
improvements in heart failure status over several months would be correlated 
with trends of heart rate. 
Methods: Ten patients admitted to the hospital due to new or recent 
exacerbation of heart failure (EF < 35%, NYHA Class III or IV) were enrolled 
into the study at the time of discharge. Following discharge, the following 
data were collected at 7 follow-ups condu4cted over 16 weeks: a) 2 channels 
of 24 hour ECG Holter, b) NYHA Class, and c) distance walked in 6 min. ECG 
data were processed to calculate day heart rate, night heart rate (NHR), and 
day-night difference. Trends of these heart rate measures were compared to 
the trends of NYHA Class and 6 minute walk distance, for each patient. 
Results: 4 patients with improvements of at least 1 NYHA Class had a 
decreasing trend in NHR. 2/3 patients with exacerbations of at least 1 NYHA 
Class had an increasing trend (figure). 3 patients with minimal changes 
in NYHA Class had minimal changes in NHR. In all, trends of NHR were 
correlated with trends of NYHA Class (r = 0.83, p = 0.0004) as well as trends 
of 6 minute walk distance (r = 0.87, p = 0.0001). 
I 
'-r 
m 
-4 
,71 
J> 
F 
c 
::1o 
m 
i i i  
rr" 
..I 
l -  
Oc 
w 
"i" 
212A ABSTRACTS - Heart  Fai lure JACC February 1999 
110 Ill l IV 
= U]ll Improvement 
90 I I I I  
80 [[ 
i ' °  %~ 
= os Ital d ischarge 
2 4 e a le  12 14 1~ 
Time (weeks) 
Conclusion: Long term (16 weeks) trends of night heart rate were strongly 
correlated with NYHA Class and 6 minute walk distance, and may be useful 
in monitoring progression of clinical heart failure 
• Hypothermia: A New Indicator of Imminent Death in 
Congestive Heart Failure 
H. Siddiqui, S. Patel, B.N. Lal, M. Naghavi, Ward Casscells. UT-Houston, 
6431-Fannin, Houston, TX 77030, USA 
Numerous predictors of mortality in patients (pts) with CHF have been de- 
scribed, but the strong predictors apply to few pts and prognosis for a specific 
pt remains difficult. This hampers the selection of pts for heart transplantation 
or LV assist device implantation. We cared for apt whose temperature (T) 
fell from 97~F to 91.7~F two hrs prior to death despite maintenance of normal 
BP and mentation. We found no published precedent. We therefore reviewed 
pure CHF deaths from 1996 to present. There were 180 deaths recorded in 
which CHF was a major diagnosis but after excluding T confounders (sepsis, 
thyroid disease, acute stroke, ETOH intoxication, exposure to cold or to heat- 
ing blankets, etc.) there were 43 pts who died of progressive CHE 24 were 
hypothermic (mean T = 95.2-°F) within 24 hrs of death. The remaining 19 did 
not have hypothermia. Survivors with CHF did not develop hypethermia. 
Hypothermia Normothermia Survivors 
N 25 27 9 
Age 74 73.6 74 
M:F 8:16 14:13 4:5 
8 P 112/61 141/90 120/73 
T (°F) 95.2 96.7 98 
HR 89 60 83 
Cr (mg/dl) 1.9 2 1.6 
Na (meq/dl) 137 139 137 
LVEF 32.8 47.4 42.6 
RVEF 4, $ $ N 
Compared to pts dying with normothermia or survivors, CHF/Hypothermic 
pts were no different in age, sex, creatinine (Cr) or serum sodium (Na), but had 
slightly lower BP, LVEF, and RVEE A drop in T appears to be an independent 
predictor of imminent mortality. It may be due to excess vasoconstriction 
causing tissue death or hepatic congestion or a hypothalamic effect. In CHF 
pts, a drop in core T may suggest the need for LV assistance or other urgent 
intervention. 
~ Critical Event Pathways for Progression Heart of 
Failure and Mortality: Insights From the ATLAS 
Study 
John G.F. Cleland, Philip A. Peele-Wilson, Milton Packer, Paul 
W. Armstrong, John D. Horowitz, Barry M. Massie, Lars Ryd@n. For the 
ATLAS Study Investigators; West Medical Building Glasgow University, 
Scotland, UK 
Background: Chronic heart failure (HF) is associated with high morbidity 
and mortality, but previous reports give little information on the sequence 
of events that could give insight into progression of the disease. In the 
ATLAS (Assessment of Treatment with Lisinopril and Survival) study 3,164 
patients (pats) with chronic HF were randomised to either lisinopril 2.5-5.0 
or 32.5-35.0 rug/day and followed for (median) 46 months. 
Methods: We evaluated the timing and sequence of the following out- 
comes: hospitalisation for a) supraventricular tachycardia (SVT), b) HF, c) 
myocardial infarction (MI), d) any cardiac ischaemic event, e) stroke/transient 
ischaemic attack (TIA), f) other cardiovascular (CVS), g) non-CVS events, 
h) death. This was performed for the whole population and repeated for the 
random±seal rms and for pats with/without ischaemic heart disease. 
Results: For the whole population, the first recorded event* was death in 
10.3% pats, hospitalisation for SVT in 3.0%, hospital±sat±on forHF in 17.1%, 
hospital±sat±on for any cardiac ischaemic event in 8.9%, hospitalisation for 
stroke/TIA in 2.2%, other CVS hospitalisations in 16. t9% and non-CVS hos.. 
pitalisations in 29.5%. The first recorded CVS event" was death in 12.4% 
pats, hospital±sat±on for SVT in 4.0%, hospital±sat±on for HF in 23.8%, hos.. 
pitalisation for any cardiac ischaemic event in 11.2%, for strokeFFIA in 2.6% 
and other CVS hospitalisations in 22.7%. Mortality among pats who had 
been hospitalised (all-cause) at least once was 46.9% vs 31.3% in those 
who had not. Mortality among pats who had at least one CVS hospital±sat±on 
was 51.0% vs 30.1% in those who had not. In 49.6% of cases death was 
preceded by hospital±sat±on forHF, in 8.8% by a validated MI, in 18.4% by an 
ischaemic event and in 5.8% by a stroke/TIA. 
*Patients may have fallen into more than one category and therefore be 
counted more than once 
• Pulmonary Function Changes with Progressing 
Heart Failure - Increasing Lung Restriction with 
Decreasing Functional Capacity 
Sebastian Helbig, Haralampos Kriatselis, Konrad G6hl, Dean MacCarter, 
Peter Richter, Martin Gottwik. Nuremberg General Hospital, Klinikum 
N#rnberg - Department of Cardiology, Nuremberg, Germany 
Background: Dyspnea is the central symptom of relevant heart failure. 
Which parameters do reflect increasing heart failure at rest and at exercise 
and could serve as an objective tool in follow up assessment? 
Methods: 389 subjects (56 i 14a; 109f) were subdivided into 4 groups 
according to their 02 uptake capacity (FC). 95 with normal 02 uptake (FC 1, 
Functional capacity > 90% of predicted VO2 max), 106 with mild to moderate 
compromised FC (FC 2, VO2 pk 75-90%), 95 moderate to heavy reduced 
FC (FC 3, pkVO2 60-75%) and 90 with heavy reduced FC (FC 4, pk VO2 
< 60%). Amongst the groups there were no significant differences regarding 
age and bsa. All patients were symptom limited exercise tested on a treadmill 
with breath by breath gas exchange analysis. 
Results: 
FVC% VT pk-re ml petCO2 pk V'T/RR pk VCO2NT pk VE 100W 
FC1 97±13 1360±599 41±6 61117 1 .11±0.22 28±3 
FC2 89±16 1222 ± 472 40±5 58±13 1.05 ± 0.23 34___7 
FC3 82±14 976±385 36±5 53±11 0 .98±0.23  38±8 
FC4 76±15 761±430 35±7 44&11 0 .84±0.20  42±22 
FC 1/FC 2, FC 1/FC 3, FC 1/FC 4, FC 2/FC 3, FC 2/FC 4, FC 3/FC 4 all p < 0.05 
Conclusion: Patients with decreasing functional capacity showed a sig- 
nificantly reduced forced vital capacity FVC and tidal volume VT at unchanged 
respiratory frequency RR. Endtidal CO2 was significantly reduced with in- 
creasing FC class, whereas the respiratory equivalents were increased. VT/ 
RR and VCO2/VT at peak exercise produced a significant decrease at in- 
creasing FC class. The same workload required an increasing respiratory 
work (Minute ventilation VE at 100W workload) with progressing heart failure. 
Simple parameters like VT/RR or VCO2/VT could proof useful for more 
precise monitoring and grading of heart failure. 
l l  I Trends of Patient Physical Activity for Heart 
I 
228-1 0 
Failure Monitoring 
Michael F. O'Toote, R. Andrew Rauh, Nancy J. Schwabauer, Elaine 
L. Enger, Vasant Padmanabhan, Karen A. Stone, Walter H. OIson, Richard 
M. Powell. Midwest Heart Research Foundation, ILl Medtronic Inc., MN, 
USA 
Background: Limitation of physical activity is an important symptom of 
clinical heart failure. We hypothesized that changes in heart failure status 
over time would be correlated with trends in patient activities. 
Methods: An accelerometer based pacemaker was modified (Exact de- 
vice) to sample activity signals at 0.5 Hz and store an 80 second average for 7 
days. Ten patients admitted to the hospital due to new or recent exacerbation 
of heart failure (EF < 35%, NYHA Class Ill or IV) were enrolled into the study 
at the time of discharge. Following discharge, 7 follow-ups were performed 
over 16 weeks. At each follow-up, NYHA Class, distance walked in 6 min, 
and 7 day activity data were collected. Activity data were then processed to 
compute patient activity (hrs/day). The trend of patient activity was compared 
to the trend of NYHA Class and 6 minute walk distance, for each patient. 
Results: Activity trends were of 3 types: 4 pts had improvements, 3 pts 
had improvements & exacerbations, and 3 pts had minimal changes in NYHA 
Class. Figure shows decreasing activities with exacerbation of heart failure 
,:o01 ~,~, ,~ .... 
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and increasing activities with improvement in a patient. In all, trends of activity 
were correlated with trends of NYHA Class (r = 0.89, p = 0.0001) and trends 
of 6 rain walk distance (r = 0,87, p = 0.0001). 
Conclusion: Trends of patient physical activity correlated strongly with 
NYHA Class and 6 minute walk distance. Activity trends collected using 
implantable devices may be useful for heart failure monitoring and drug 
management. 
• Reliability of the 6-Minute Walk Test in CHF 
Patients 
Catherine Demers, Robert S. McKelvie, Danny Pericak, Salim Yusuf. For 
the RESOLVD Investigators; McMaster University, Hamilton, Canada 
Background: The 6-minute walk test (6 MWT) is commonly used in clinical 
tdals to assess prognosis and to follow changes of functional capacity. The 
reliability of this test has not been previously evaluated in a large cohort 
of CHF patients. The RESOLVD pilot study, a multicenter andomized con- 
trolled trial comparing the effects of candesartan, enalapdl, and metoprolol 
on functional capacity, cardiac function, and neurohormenes, provided the 
opportunity to assess the reliability of the 6 MWT in CHF patients. 
Methods: Following a screening test, the 6 MWT was performed in du- 
plicate (tl, t2) at baseline, 17 and 43 weeks and averaged (Table). A stan- 
dardized method was used in all 60 participating centers to perform the 6 
MWT. 
Results: A total of 768 CHF patients (65% NYHA-FC II; 32% NYHA-FC 
III) were enrolled, age 63 ± 11 (mean ± SD) yrs, 83% were men, and baseline 
LVEF determined by RNA was 0.27 ± 0.10. 
Table. 6-Minute Walk Test Characteristics 
Baseline 17 weeks 43 weeks 
(mean - SD) (mean :k SD) mean ± SD) 
Distance (m) 381 ± 84 387 ± 94 387 ± 103 
Days between tl and t2 2.6 ± 1.6 3.7 = 3.0 3.1 =: 3.4 
Using a random-effects ANOVA, the overall reliability coefficient for the 6 
MW'F, when repeated twice at each assessment, was 0.92. 
Conclusion: To our knowledge, this is the first report on a large number 
of CHF patients on the reliability of the 6 MWT. We demonstrated that, when 
performed twice at each assessment, the 6 MWT is highly reproducible. 
These results support the use of the 6 MWT as a reproducible measure of 
functional capacity of CHF patients in clinical trials. 
I1228-12 I QT Interval Dynamicity for Risk Stratification in 
Idiopathic Dilated Cardiomyopathy 
Laurent Fauchier, Dominique Babuty, Philippe Poret, Marie 
Laurence Autret, David Tena-Carbi, Pierre Cosnay, Jean Paul Fauchier. 
Cardiology B Department, Trousseau University Hospital Tours, France 
Background: QT dispersion has shown to be a poor predictor of cardiac 
death in patients with idiopathic dilated cardiomyopathy (IDC). QT interval 
dynamicity has been proposed as another tool for assessment of the risk of 
cardiac events or ventdcular arrhythmias. This study assessed the useful- 
ness of several parameters of QT interval dynamicity for dsk stratification of 
patients with IDC. 
Methods: We performed 24-h ECG recording in 95 patients with IDC who 
were in sinus rhythm (WHO criteria; mean age 50 years; range 18-70; 72 
men; left ventricular ejection fraction 35 ± 12%) and in 60 healthy subjects. 
The QT intervals (QT end and QT apex) were measured automatically with 
a validated computerized Holter system (Elatec, Ela medical, France). The 
rate dependence of repolarization was evaluated over 24 hours, during a 
daytime pedod (9AM-9PM) and during a nighttime period (11PM-6AM) with 
measurement of QT/RR slopes. 
Results: QTc durations (end, apex, 24 hours, day and night) were sig- 
nificantly increased in patients with IDC compared to control subjects (p < 
0.001). QT end/RR slopes were significantly increased in patients with IDC 
(p < 0.001) whereas QT apex/RR slopes were not different from control 
subjects. With a follow-up of 54 ± 39 months, 15 patients died (10 progres- 
sive CHF, 5 sudden deaths) and 11 underwent heart transplantation. Among 
QTc durations and QT/RR slopes, using multivariate analysis (proportional 
hazards model), the only independent predictor of cardiac events (cardiac 
death or heart transplantation) was an increased QT end/RR slope during 
the daytime period (p = 0.02). For this parameter, a cutoff level of 0.22 dis- 
tinguished 2 groups of patients with significantly different survival curves of 
cardiac events (p = 0.008). 
Conclusion: This study is the first to suggest that QT dynamicity provides 
a risk stratification in patients with IDC. Among the several parameters of 
QT interval dynamicity, increased QT end/RR slope during the daytime is the 
most powerful predictor of cardiac events in these patients. 
1 I Beat-by-Beat QT Variability Is Markedly Sensitive 228-1 3 
to Respiration in Patients With Heart Failure 
Mitsunori Fujimura, Hiroshi Takaki 1 , Yoshio Yasumura, Masaru Sugimachi I , 
Kenji Sunagawa~. Department of Cardiology, National Cardiovascular 
Center; I Department of Cardiovascular Dynamics, National Cardiovascular 
Center Research institute, Osaka, Japan 
Background: Although numerous studies have shown the role of repolar- 
ization abnormality in the pathogenesis of the lethal ventricular arrhythmia, 
significance of temporal QT vadability (QTV) has not been fully understood. 
We investigated the lability of QTV to respiration in patients with chronic heart 
failure (CHF). 
Methods: We examined 41 patients with CHF (LVEF 37 ± 11%, is- 
chemic 23, idiopathic 18) and age-matched 9 volunteers. Surface ECGs 
were recorded for 3-min under spontaneous breathing and control breathing 
at 10/rain. We measured the beat-by-beat QT interval by a cross-correlation 
technique and compared successive changes in RR (ARR), QT (~,QT) and 
QTI (~QT/~RR) between the 2 groups. 
Results: In CHF, both ~QT and AQTI were greater than those of normals 
(AQT (msec): 0.77 ± 0.18 vs. 1.37 ± 0.84, p < 0.05, QTI 0.05 ± 0.02 vs. 
0.20 ± 0.16, p = 0.01). In normals, control breathing increased both ARR and 
AQT by 30%, thereby QTI remained unaffected. In contrast, in CHF, control 
breathing increased ARR only by 10% but ~QT by 40%, and thus markedly 
increased QTI (+49%). The ratio of QTI under control breathing to that under 
spontaneous breathing correlated inversely with ejection fraction (r = -0.53, 
p < 0.001), indicating that the larger QTV is, the worse ventricular function 
is. 
Conclusion: QTV was larger in CHF patients. The fact that control breath- 
ing increased QTV, not in normals, but in CHF suggests that QTV is decoupled 
with HRV in patients with depressed LV function. This lability of repolarization 
may serve as the substrate for serious ventricular arrhythmia. 
ORAL  
Mechan ism o f  Agents Interfering With the 
Renin-Angiotensin System 
Wednesday ,  March  10, 1999, 10:30 a .m. -Noon 
Mor ia l  Convent ion  Center ,  Room 345 
10:30 a.m.  
~~-]  Vascular Reactivity to Angiotensin II in Heart Failure 
Patients on Chronic 
Angiotensin-Converting-Enzyme Inhibition 
Valentin Barbulescu, Ulrich P. Jorde, Adam Hammer, Vana Suryadevara, 
Edmund H. Sonnenblick, Thierry H. LeJemtel. Albert Einstein Co#ege of 
Medicine, New York, USA 
Background: Increased vascular reactivity (VR) to angiotensin II (All) due 
to upregulation of AT II-type-l-receptors after treatment with ACE-inhibitors 
(ACEI) has been reported in the hypertensive rat. Whether this occurs in 
heart failure (HF) lots is unknown. We assessed the VR to All in as a function 
of the degree of ACEI in 38 HF pts (NYHA class I1-111, LVEF < 45%) on 
chronic full dose ACEI. 
Methods: Increasing doses of i.v. AI and All were administered until SBP 
increased by >20 mmHg. HR and BP were monitored noninvasively beat 
per beat (Collins Pilot). VR was assessed as the amount of All needed to 
provoke a rise of SBP > 12 mmHg (= 2 standard deviations of SBP vadation 
at rest). The degree ACEI was defined as the presser response (PR) to 100 
ng/kg AI. 
Results: Reduced PR to AI (i.e. high degree ACE-inhibition), was not 
accompanied by increased VR to All. VR tended to be inversely correlated 
with degree of ACE-inhibition (R = -0.42, P 0.008). 
Degree of ACE-inhibit ion (PR to AI) and vascular  
reactivity to Al l  
,~0 ~ ~ ]  IPR  to AI in mmHg 
20 . . . 
~ ~ ~ ~ T- ~ N ~ ~ N N N N P. N N N N 
18 pls according to PR to AI 
B lack  bars: PR to 100 ng/kg AL Open bars:  Amount  Al l  needed to raise SBP. 
Conclusion: ACE-inhibition does not induce increased vascular reactivity 
to All in heart failure patients. 
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~8~]  Non ACE Dependent Angiotensin II Generation in 
Resistance Arteries from Patients With Chronic 
Heart Failure 
Mark C. Petrie I , Neal Padmanabhan 2, John M.C. Connell 2, John 
J .V. McMurray ~ . 1MRC CRI in Heart Failure, University of Glasgow; 
2 Department of Medicine and Therapeutics, Western Infirmary, Glasgow, 
UK 
Background: We have sought to demonstrate non angiotensin converting 
enzyme (ACE) dependent angiotensin II generating pathways in resistance 
artedes from patients with chronic heart failure (CHF). 
Methods: Resistance arteries were dissected from gluteal biopsies and 
studied using wire myography. Concentration response curves to angiotensin 
I (AI) were constructed in the presence of 1) vehicle 2) chymostatin (CH) [an 
inhibitor of chymase], 3) enalaprilat (E) and 4) the combination of CH and E. 
Results: AI responses were inhibited by CH (p = 0.044) and there was 
a trend with E alone (p = 0.075). The combination of CH and E gave a 
significantly greater inhibition of AI responses than either alone (p = 0.003). 
Qualitatively and quantitatively similar findings were found in identical re- 
sistance arteries and in left internal mammary arteries from patients with 
coronary heart disease and normal left ventricular function. 
Resul ts ;  
15 
• A 10 
AI + Vehicle 
• ->= / . . . .  A I+E 
~' -~-  AI+ CH+ E 
11 -10 -9 -8 -7 -6 -5 
Angiotens in  I ( log M) 
Conclusion: Non-ACE dependent angiotensin II generating pathways 
exist in the resistance arteries of patients with CHF and may have important 
treatment implications. 
11:00 a.m. 
-] The Detrimental Effect Aspirin of Combined and 
Angiotensin Converting Enzyme Inhibitor Therapy 
on Readmission Rates in Heart Failure 
Kishore J. Harjai, Eduardo Nunez, Tansel Turgut, Jeff Newman. Ochsner 
Medical Institutions, New Orleans, LA, USA 
Background: An adverse interaction between aspirin and ACE-inhibitors is 
suspected in patients with heart failure (HF). The effect of combined therapy 
with these agents on early readmission rates following hospitalization for HF 
has not been well studied. 
Methods: In 514 consecutive patients (54% male, 70 ± 15 years, CAD 
40%) discharged alive with a pdncipal diagnosis of HF, we examined the 
incidence and number of HF readmissions within 30 days after discharge. 
Patients were classified into 3 groups based on the use of ACE-inhibitors 
and aspirin at discharge: ACE-inhibitor without aspirin (group I, n = 162), 
ACE-inhibitor with aspirin (group II, n = 182), and no ACE inhibitor (group HI, 
n = 170). 
Results: One or more readmissions for HF occurred following 67 (13%) 
hospitalizations; the mean number of readmissions for HF was 0.14 ~_ 0.37. 
A comparison of the 3 groups is shown below. 
Group I Group II Group III 
> 1 Readmission, %* 9.9 16.5 12.4 
No. of readmissions ¶ 0.10 ± 0.30 0.19 ± 0.44 0.13 ± 0,35 
"p = 0 .07  for g roup  I Vs  II; 'lip = 0 .03  for  g roup  I Vs  II 
After adjusting for age, gender, CAD, and clinical differences between 
groups, the incidence of readmission in group II was significantly higher than 
group I (adjusted odds ratio, OR = 2.6; 95% CI = 1.2-4.9), and marginally 
higher than Gr III (OR=1.7; 95% CI = 0.9-3.4). Similar results were seen in 
subset analyses of patients with known LV ejection fraction (n = 341), and 
those with LV ejection fraction < 45% (n = 218). 
Conclusions: In patients with symptomatic heart failure, combined ther- 
apy with aspirin and ACE-inhibitors is associated with a greater incidence of 
eady readmissions than use of ACE-inhibitors alone. 
11:15 a.m. 
[ - ~  Aspirin and Angiotensin Converting Enzyme 
Inhibitors in 445 Patients With Moderate Congestive 
Heart Failure 
Valerie Aumegeat, Pascal de Groote, Thibaud Meurice, Alain Millaire, 
G(~rard Ducloux, Jean-Marc Lablanche. University of Lille, France 
Background: There are controversial results concerning the negative inter- 
action between aspirin and angiotensin converting enzyme inhibitors (ACEI) 
in patients (pts) with congestive heart failure (CHF). Most of the previous 
studies are multicenter studies. 
Methods: We report our retrospective experience in 445 consecutive pts 
with CHF from the same institution. The mean age was 52.4 ± t l  .4 years, 65 
pts were women, 304 pts were in NYHA class 1/11 and 141 in class Ill/IV, 190 
pts had ischemic cardiomyopathy, the mean left ventricular ejection fraction 
was 29.6 ± 9.8%. Most of the pts were taking ACEI (417 pts, 93.7%), 157 
pts aspirin, 168 pts anticoagulants and 22 pts aspirin and anticoagulants. 
Results: During a median follow-up period of 757 days (range 2-2325 
days), there were 99 cardiac deaths (CD), 6 non-CD, 57 transplantations 
of whom 7 were UNOS1 and 8 pts were lost to follow-up. The event-free 
survival rate from CD and UNOS t was similar in the 2 subgroups of pts 
Aspirin/No aspirin (Fig). 
365 730 1095 1460 1825 2190 2555 
S~iva l  Time (Days) 
t No  asp i r in  * Asp i r in  
In multivariate analysis, aspirin was not related to survival, whatever the 
model studied (ischemic/non-ischemic, ACEI ±, anticoagulants ±, dose of 
aspirin..). 
Conclusion: In this population of pts with stable CHF, aspirin has no 
negative interaction with ACEI. 
11:30 a.m. 
~ Plasma Aldesterene Levels Do not Predict Degree of 
Angiotensin-Converting-Enzyme Inhibition in Heart 
Failure Patients 
Ulrich P. Jorde, Vane Suryadevara, Adam Hammer, Valentin Barbulescu, 
Janet Piscitelli, Edmund H. Sonnenblick, Thierry H. LeJemtel. A/bert 
Einstein College of Medicine, New York, USA 
Background: Plasma Aldo levels are elevated in heart failure (HF) and can 
be reduced with ACEI. However, during prolonged ACEI therapy, aldo levels 
have been reported to rise again, which may be related to the ACE-escape 
phenomenon. We examined whether the degree of ACEI actually correlates 
with aldo levels in 31 HF pts (LVEF < 45%, NYHA class I1-111) on currently rec- 
ommended full dose ACEI (Monopril40QD, Lisinopril40QD, Enalapdl20BID, 
Captopdl50TID), diuretic and digoxin. 
Methods: Degree of ACE inhibition was assessed as pressor response 
(PR) to 100 ng/kg i.v. angiotensin I (AI). Aldo was measured by solid phase 
RIA (Diagnostics Products Corp) 
Results: PR to AI and aldo levels are illustrated in the figure below: 
Relat ionsh ip  o f  Degree  AC E - inh ib i t ion  and  A ldo  
leve l  
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There was no statistical correlation between degree of ACE-inhibition and 
aldo levels (R = 0.2, P 0.2) 
Conclusion: Aldo levels do not predict degree of ACE-inhibition in heart 
failure. Elevated aldo levels during prolonged ACE-inhibition may not reflect 
attenuated ACE-inhibition. 
JAC(C ]~ebm~ ] 999 . # J~o~ #CE'~ - J~ ,~- ,~2~ 22., ~, 4 
11:45 a.m. 
~ '  ~ngfofensi'n Converting ~'nzyme ~.4CE',~ Gene 
Polymorphism Does not Account for the Variable 
Level of ACE Inhibition (ACE-I) Observed in Heart 
Failure During Chronic ACE Inhibition Therapy 
Valerdt~n~aPothescu,'O~h~n~-'. 3or~e,'t~ahe T~i~vao. ~a~e"#are~a. 
H. Lc,~.c~,e(. d,v~ec~ E¢~,s,~ech C,"d,.@,~je ,3(Me<#,c4~:~, , '~,, O'SA 
Backc j~6~ A ~j~'~';s lb~:~'mt~'rp'h'ism ";'n &'he 'hu'm'a'n 9e'ne ";o'~ .'h~ ACE. ap- 
patients (pts) having the highest levels. Whether ACE liD polymerphism af- 
fects the level of ACE-I during chronic therapy in pts with CHF is unknown. 
Accordingly, the level of ACEq as assessed by the p~essor esgo~se to in- 
cremental doses of AI and the ACE gene I/D polymorphism were determined 
in 32 pts treated for an average of 12 months on full dose of ACE inhibitors. 
Methods: The pressure response was assessed by non-invasive beat to 
beat reading of the SBP (Collins) after iv administration of incremental doses 
(10, 100, and 200 ng/kg) of Angiotensin I (AI). Genomic DNA was extracted 
from whole blood with the phenol/chloroform method. PCR amplification of 
intron 16 with opt/m/seal primers was used to determine the ACE genotype. 
Results: The PR to AI challenge was extremely variable ranging from 
-9  to 93 mmHg. 54% of pts were homozygous for D allele and 43% were 
heterozygous {;or I and [3 alleles. The dose-pressure response curve of pts 
with different ACEG genotype is depicted in figure. 
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Conclusion: The degree of ACE-I in CHF pts on chronic ACE-I therapy 
is no(' d~eren~ (n Ot's. w(~t~ OO vs. ((7 gbeno~ge.. 
ORAL  
Novel Approaches to Altering Gene 
Expression in Heart Failure 
Wednesday ,  March  10, 1999, 2:00 p .m. -3 :30  9.m.  
Mor ia l  Convent ion  Center ,  Room 265 
2:00 p.m. 
~-~ Influence of Fetal Cardiomyocyte Transplantation on 
the Progression of Heart Failure 
Jonmhan Leor, Sharon Abou~a~ia-Etzion, Israe~ M. Ba~bash, Maya Rovner, 
Yosef Granot, Alexander Battler. Cardiology Department, Ben Gurion 
Universi~ Beer Sheva, Israel 
Methods: To investigate the influence of fetal cardiomyocyte (CM) trans- 
plard~ ~[3~HPj on'E~" remo~]di%q ant] "~un~on'T~howmq ex"~ens~ve hv*l!, we s~-  
jected rats to permanent LAD coronary occlusion. Rats were randomized to 
= 11 ) 7-10 days after MI. Echocardiography was performed before TRP and 
55 :b 3 days after TRP to assess LV remodeling and f~nct;~n. Transp~antad 
CMs were identified by oc -actin immunohistochemistry staining. 
Results: Following transplantation, there was no mortality among CM- 
TRIP rats vs. 3 of 11 control rats. Alfa-aetin staining identified transplanted 
fetal CMs in 8 of 9 CM-TRP heads and was positive in 1 of 8 control heads (p 
= 0.003). There was a s~gnif[cant LV dilatation in control but not in CM injected 
rats (table). While cardiac output (CO) and stroke volume (SV) increased in 
CM-TRP rats after TRP, it deteriorated in control rats: 
Before TRP After TRP p = 
LV ~a;ea £,'~& ~3 .'3% ~_ %~ cm %Aq ± ~.~ c~ ~-~ 
COCM(ml /min)  50~:7  x 10 3 74±8 x 10 3 0.04 
COControl  72±7 x 10 3 65±105x 10 3 0.6 
SV CM (rnl) 0.20 ± 0.03 x 103 0.30 ± 0.03 × 10 -3  0.05 
SV Control0,23 ±0.02  x 10 3 0 .20±0.02  x 10 3 0.34 
Conclusions: Transplantation of fetal cardiomyocytes after extensive MI 
remodeffng and augmentation of cardiac function. 
2:15 p.m. 
~ ~ressmn dr ~,benmhrus_'SecP-~xers ~A~.ae/o ~,~ 
Indicating Ar~tomical Vector Bar£jp~rs 
Haiti Wang, Karin Eizema ~ , Jos Lamers ~ . Dept. of Cardiology, Univ. Hospital 
Benjamin Franklin, Freie Univ. Berlin, Germany; ~ Dept. of Biochemistry, 
Erasmus Univ. Rotterdam, The Nether(ands 
Background: Adenoviral vectors have particularly high efficacy for most 
cardiovascular cell types. Whereas they almost selectively reach the liver 
after iv injection in mice, re-targeting to the myocardium requires specific 
measures (injection into coronaries or temporarily clamped aortic root). This 
is unexpected since cardiac myocytes are easily transfected in cell culture. 
Known determinants of adenovirus entry in cell culture are the coxsackie- 
adenovirus-receptor CAR and integrins ~v#3 and c~v~5. Other determinants 
of vector targeting in vivo are less well understood and were the subject of 
this study. 
Methods: Expression of CAR, c~v/~3, ~v/% in the organs of several species 
was studied by quantitative RT-PCR and Nodhern analysis as described 
(Biechem J 1998;331:577) and correlated to data on vector targeting in these 
species. Vectors used are described (PNAS 1998;95:9003) and express 
Results: Highly vanable expression of CAR was observed in different 
injection in the left ventricle, ev~3, c~v/~5 expression patterns were variable, 
but g)rfil'~ar m '~)ver an~ m,vocarS)um, so fnal '['ne #ross ¢J)~erence o~ vector 
targeting into these organs does not correlate with neither CAR or integrin 
receptor expression. 
Conclusion: Differential targeting of adenoviral vectors into liver and my- 
ocardium is not explained by corresponding expression of known adenovirus 
~.'~.~,~, %'~. '~Wi:~%~ .~,  '~,~% ~.'b ~v,'~.'bvh~t'~', ~ '~,~ %.% ~*~'~ ~ ~; "~ 
endothelium) which need to be fudher defined. 
2:30 p.m. 
~-7 Adenovirus-based Ant/sense Phospholamban as 
Potential Gene Therapy Approach for Improvement 
of Diastolic Dysfunction 
Kafin Eizema, ~a~el Bezstaros~i, Sonia Schneider-Hasp ~ ,Wo~tgang 
C. Poller 1 , Jos M.J. Lamers. Department of Biochemistry, Cardiovascular 
Research Institute COEUR, Erasmus University Rotterdam, Rotterdam, The 
Netherlands ; I Dept. of Cardiology and Pneumology, Free University Berlin, 
Berlin, Germany 
Background: Reduced SERCA2a gene expression is believed to contribute 
to the diastolic dysfunction in the failing head. A gene therapy approach 
directed towards improving the diasto~'ic function of the failing heart could 
be the restoration of Ca 2÷ pump activity. Since phospholamban (PL) is an 
endogenous inhibitor of the sarcoplasmic reticulum Ca 2+ pump we devel- 
head tissue specific and strongly upregulated during hypedrophy and failure. 
system in which hypertrophy, upregulation of ANF and downregulation of 
(ET-1). The effects of infection with PL-antisense and control sense encoding 
viruses on the e~d~geno~s ~eve~s of PL mRNA ar',d prote~r~ and Ca 2* pump 
activity are studied in cell homogenates. 
Results: Using the CMV promoter based viruses (CMVPLAS and CMV- 
PLS (sense control)), a marked (50%) decrease in endogenous Pt_ mRNAis 
observed already 24 hr after the start of infection. Likewise a decrease (up 
to 80% after 72 hr) in PL protein is detected starting 48 hr after the stad of 
infection. As expected the sensitivity of the Ca 2+ pump to Ca 2+ is elevated 
in cells infected with the CMVPLAS. Incubation with the control sense virus 
does not have any effect on the PL content of the cells. 
Infections of cardiomyocytes with the ANFPLAS viruses results also in 
virus infection is currently tested. 
Conclusion: Ant/sense downregulation of PL is feasible using adenovirus 
vectors in cardiomyocytes, resulting in a marked decrease of PL mRNA and 
protein and improvement of the Ca 2+ pump activity 
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~-~- ]  An Adenovirus Minivector With High Cloning 
Capacity Suitable for Expression of SERCA and 
Phospholamban-Antisense-mRNA to Improve 
Cardiac Myocyte Function In Vitro and In Vivo 
Wolfgang Poller, Christoph Schmidt 1 , Anja Haack ~ , Henry Fechner, 
Haili Wang, Hans Brackmann ~ , Kadn Eizema 2, Jos Lamers 2 . Dept. of 
Cardiology, Univ. Hospital Benjamin Franklin, Freie Univ. Berlin.; ~ Inst. of 
Haematology, Univ. of Bonn, Germany; 2Dept. of Biochemist~ Erasmus 
Univ. Rotterdam, The Netherlands 
Background: Disturbed SERCA and phospholamban PL expression con- 
tribute to decreased contractile function in the failing head. A gone therapy ap- 
proach directed towards improving the contractile function of the failing heart 
is restoration of normal Ca 2+ pump activity. This can possibly be achieved by 
transfedng the SERCA gone in conjunction with PL-antisense-mRNA, since 
PL is a negative regulator of SERCA. 
Methods: We have previously shown, that adenoviral PL-antisense vec- 
tors dnven by a CMV promotor downregulate endogenous PL-mRNA and 
-protein by 50% and 80%, respectively, in cardiac myocyte cultures. The vec- 
tor used in those studies had no capacity to package an additional SERCA 
expression cassette. Therefore, we developed new minivector (Ad5 min) 
containing the basepairs 1-436 and 35705-35935 of wildtype adenovirus 5 
(inverted terminal repeats, packaging signal) inserted in a pUC19 derivate. 
Cloning sites for Pacl, Ascl, Clal are used to insert a SERCA+PL-antisense 
expression cassette under the control of a CMV or an inducible ANF pro- 
motor The minivector genomes are amplified by using a Cre-lox helper virus 
system. 
Results: The SERCA/PLas vectors are produced in titers sufficient for 
cell culture studies revealing adequate expression of SERCA-sense and 
PL-antisense mRNA, with resulting changes at the protein levels, compara- 
ble with conventional adenoviral vectors, and without adverse interactions 
between the two expression cassettes. 
Conclusion: The new high capacity vector system is promising for the 
joint expression of multiple transgenes and the combination of two or more 
gone therapeutic strategies complementing each other. 
3 :00 p.m. 
~ ~-blocker-related Improvement in Ventricular 
Function is Associated With Increased Gone 
Expression of SR Ca 2+ ATPase 
Brian D. Lowes, Edward M. Gilbert, William 12 Abraham, Wayne A. Minobe, 
Robed L Reden, Michael R. Bristow. University of Utah Health Sciences 
Center, Salt Lake Ci~ Utah; University of Colorado Health Sciences Center, 
Denver, CO, USA 
In idiopathic dilated cardiomyopathy (IDC) we have previously reported that 
improved left or right ventdcular function which occurs spontaneously or in re- 
sponse to ,8-adrenergic blocker therapy is associated with an upregulation in 
c~- and downregulation in ,8-myosin heavy chain (MyHC) gene expression. In 
the current study we identified changes in gone expression exclusively asso- 
ciated with improved ventricular function in subjects treated with ,8-blockade, 
i.e. not present in subjects treated with placebo. As previously described, 
favorable changes in MyHC isoforms occurred in 33 IDC subjects treated 
randomly for 6 months with placebo or ,8-blockade. However, as shown in the 
table below, an increase in SR calcium ATPase (SRCA) expression occurred 
only in ventricles demonstrating improved function on ,8-blockade: Data are 
expressed as mean ± S.E.M. in molecules SRCA mRNA x 105/#g total 
RNA (absolute SRCA expression) or expression normalized to total MyHC 
(SRCNMyHC): 
Group Absolute SRCA Expression SRCA/MyHC Expression 
LVEF ~ _> 5 (n) LVEF/', < 5 (n) LVEF ~ >_ 5 LVEF ~ < 5 
Placebo - 1.0 (4) 14,9 (9) -0 .03 0.08 
n = 13 ± 6.0 + 8.3 ± 0,07 ± 0.06 
,8-blocker "7.5 (14) -9.1 (6) 0.06" -0 .07 
n = 20 ± 4.0 ± 7.8 ± 0.03 ± 0.06 
*p < 0.05 vs. LVEF A < 5; LVEF ~ is in EF units. 
Summary: In IDC subjects treated with ,8-blockade, improved entricular 
function is accompanied by an increase in SRCA gone expression. These 
changes in SRCA do not occur in subjects treated with placebo who exhibit 
spontaneous improvement in LVEE 
3:15 p.m. 
~-~ U-74, A 21 Aminosteroid-Lazaroid Selectively 
Inhibits the Transcription of iNOS in Cultured Endo- 
and Myocardial Cells 
Ronald J.P. Bronsaer ~ , Pieter A. Doevendans 1 , Rien van der Zee. rDept, of 
Cardiology, Cardiovascular Research Institute Maastricht, and RdG 
Hospital, Delft, The Netherlands 
Introduction Myocardial NO production is increased in patients with heart 
failure, due to increased inducible NOS (iNOS) expression. High NO levels 
lead to myecyte injury and reduced contractility. Cytokines like interleukin-l,6 
(IL-1,8) can be used to activate the iNOS gone. Potentially, selective inhibition 
of iNOS activity could preserve cardiac function. It is known that 21-aminos- 
tereid-lazaroids are devoid of glucocorticoid actions, therefore we studied 
the effects of a 21-aminosteroid lazaroid (U-74) on the expression of iNOS 
in cultured rat endocardial and neonatal ventricular myocytes. 
Methods: Cells were cultured in coloudess medium and treated with 
10-9M IL-1,8 in the absence or presence of U-74 (10-9M), 30 minutes after 
cytokine stimulation the NO production was assessed chemically using the 
Gde,8-reaction. In identical experiments the expression of iNOS at the RNA 
and protein level was studied by RT-PCR and Western analysis. 
Results: The NO production, induced by IL-1,8 showed a maximal peak 
after 40 min of 20 /~M NO~. The rise in NO could be blocked completely 
by coincubation with U-74, while baseline NO levels were unchanged. West- 
ern analysis, using polyclonal antibodies directed against either iNOS or 
ecNOS revealed that U-74 did not influence eoNOS protein levels, but a 
marked reduction of iNOS was found. RT-PCR showed that U-74 inhibited 
the transcription of the iNOS gone completely. 
Conclusion: U-74, a 21-aminosteroid-lazaroid inhibits the transcription 
of cytokine induced iNOS but not ecNOS in cultured endo- and myocardial 
cells. 
ORAL  
Oxidative Stress in Heart Failure 
Wednesday ,  March  10, 1999, 2:00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 262 
2:00 p.m. 
1-~ AIIopurinol Improves Endothelial Dysfunction in 
Patients With Chronic Heart Failure 
Colin A.J. Farquharson, Robed Butler, Allan D. Struthers. Department of 
Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical 
School, Dundee, United Kingdom 
Background: There is evidence to suggest that increased oxidative stress in 
chronic heart failure contributes to endothelial dysfunction. Xanthine oxidase 
is a key free radical generating system in the vasculature, and therefore 
the xanthine oxidase inhibitor allopudnol may produce beneficial effects on 
endothelial function in patients with heart failure. 
Methods: We performed a randomised, placebo controlled, double-blind 
cross-over study on 11 patients with NYHA Class I1-111 chronic heart failure 
(mean age 67 ± 5.5 years) comparing 300mg allopurinol daily (1 month) 
vs placebo. Endothelial function was assessed by bilateral forearm venous 
occlusion plethysmography using endothelial-dependant (acetylcholine) and 
endothelial-independant (sodium nitroprusside and verapamil) vasodilators, 
as well as endothelial-dependant (N-monomethyI-L-arginine) and endothe- 
lial-independant (noradrenaline) vasoconstrictors. 
Results: AIIopurinol significantly increased the forearm blood flow re- 
sponse to acetylcholine (percentage change in forearm blood flow (mean ± 
SEM) : 181 ± 19% vs 120 zlz 22% allopurinol vs placebo; p = 0.003). There 
were no significant differences in the forearm blood flow changes between 
the placebo and allopurinol treatment arms with regards to sodium nitreprus- 
side, verapamil, noradrenaline or N-monomethyI-L-arginine. There were no 
significant changes in blood pressure during both study visits. 
Conclusion: These data suggest that allopurinol improves endothelial 
dysfunction in patients with chronic heart failure, possibly by reducing free 
radical generation and thus increasing nitdc oxide bioavailability. AIIopuri- 
nol may therefore provide a cost-effective therapeutic strategy in reducing 
oxidative stress in heart failure. 
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~ Do Serum Urate Levels in Heart Failure Reflect 
Chronic Vascular Inflammation? 
Francisco Leyva 1 , Stefan D. Anker ~ , lan F. Godstand 2, Mauro Teixeira 3, 
Paul G. Hellewell 3, P.A. Poole-Wilson ~ , A.J.S. Coats 1 . ~Department of
Cardiac Medicine," 2Department of Appfied Pharmacology, ICSM at NHLI; 
3 Wynn Institute of Metabolic Medicine, St Mary's Hospital, London, UK 
Background: Chronic heart failure (CHF) is associated with hyperuricemia 
and elevations in circulating markers of cellular activation. Activation of xan- 
thine oxidase causes leukocyte and endothelial cell activation. Associations 
could therefore be expected between serum urate level, as a marker of in- 
creased xanthine oxidase activity, and markers of cellular activation. We have 
explored these associations in CHF, taking into account the hyperuricaemic 
effects of diuretic therapy and insulin resistance. 
Methods: Circulating urate and measures of cellular activation were 
measured in 39 male patients with CHF and 16 healthy controls. All patients 
also underwent an intravenous glucose tolerance test for measurement of 
insulin sensitivity. 
Results: Compared to controls, patients with CHF had significantly higher 
levels of circulating urate, interleukin (IL)-6, soluble tumour necrosis factor 
receptor (sTNFR)-I, soluble intercellular adhesion molecule-1 (slCAM-1), 
(all p < 0.001), E-selectin and sTNFR2 (both p < 0.05). In patients with 
CHF, serum urate levels correlated with circulating sTNFR1 (r = 0.74), IL-6 
(r = 0.66), sTNFR2 (r = 0.63), TNFc~ (r = 0.60) (all p < 0.001), slCAM-1 (r 
= 0.41, p < 0.01). In stepwise regression analyses, serum urate emerged 
as the strongest predictor of slCAM-1, IL-6, TNF, sTNFR1 and sTNFR2, 
independently of diuretic dose, age, body mass index, alcohol intake, serum 
creatinine, plasma insulin and glucose, and insulin sensitivity. 
Conclusions: In patients with CHF, serum urate levels are strongly related 
to circulating markers of cellular activation. This is consistent with a role for 
increased endothelial xanthine oxidase activity in the cellular activation in 
patients with CHF. 
2 :30  p,m. 
~8-~ Serum Urate Is Related to Circulating Matrix 
Metalloproteinases in Chronic Heart Failure 
Callum S. Wingrove 1 , Edmund D. Garr 1 , Stefan D. Anker 2, Andrew 
J.S. Coats 2 , Francisco Leyva 2. Wynn Institute of Metabolic Medicine, St 
Mary's Hospital; 2 Department of Cardiac Medicine, ICSM at NHLI, London, 
UK 
Background: Hyperuricemia is a marker of poor prognosis in patients with 
chronic heart failure (CH F). Free radicals released by xanthine oxidase, which 
generates urate, have been linked to activation of MMPs and atheromatous 
plaque rupture. We sought to determine whether serum urate concentration 
is related to serum MMP concentration or activation in patients with CHF. 
Methods: MMP levels were measured in 20 male patients with CHF due 
to coronary heart disease (age 64.5 ± 11.1 yrs, mean - SD) and 20 healthy 
age-and sex-matched controls using zymography. MMP-2 and MMP-9 were 
identified by zymography and metal ion dependence was confirmed by inhibi- 
tion using EDTA. Laser densitometry was employed for MMP quantification. 
MMP levels are given as percentage of controls ± SEM. 
Results: Compared to healthy controls, patients with CHF had lower 
serum MMP-9 levels (34% ± 8%, P < 0.001). No group differences emerged 
in circulating MMP-2 levels. A significant correlation between concentrations 
of MMP-2 and urate (r = 0.56, P = 0.01) was observed in CHF but not controls 
(r = 0.08, NS). There was no relationship between urate and MMP-9 (r = 0.06, 
NS). No relationship was found between serum urate and activation of serum 
MMP. 
Conclusions: CHF is associated with a dramatic decrease in circulating 
MMP-9, possibly reflecting impaired vascular turnover. The correlation be- 
tween MMP-2 and urate in this study may indicate a relationship between 
MMP-2 production and oxidative damage to thevasculature in CHE 
2 :45  p.m. 
~-~ Cytotoxic Aldehydes in Patients With Congestive 
Heart Failure 
Susanna Mak, Eduardo R. Azevedo, Peter P. Liu, Denis C. Lehotay, Gary 
E. Newton. Mount Sinai Hospital Toronto, Canada 
Background: Free radical-mediated lipid peroxidation may be involved in 
the pathcphysiology of CHIE Aldehyde products of lipid peroxidation have 
cytotoxic effects which may impair cardiac function. Our purpose was to de- 
scribe the relationship between aldehydes and impaired cardiac contractility 
in humans with CHE 
Methods: Eight CHF patients (LVEF 25 + 3%) and 8 subjects with normal 
LV function (LVEF 59 ± 3%) were studied. A micromanometer-tipped catheter 
was inserted to measure LV contractility (+dP/dt). Coronary sinus (CS) and 
PA catheters were also inserted. Total aldehydes were measured in arterial 
and CS blood using a gas chromatography mass spectrometry method. 
Results: The CHF group had elevated total aldehydes in arterial plasma 
as compared to the normal LV group (9.3 + 0.8 vs 6.6 ± 0.3 ,~mol/L, p < 
0.05). A positive transcardiac gradient for aldehydes was not consistently 
observed in either group. In CHF patients there was an inverse relationship 
between arterial aldehydes and both +dP/dt (r = -0.76, p < 0.05, figure) and 
cardiac output (r = -0.69, p < 0.05). Similar relationships were not found in 
the normal LV group. 
1coo 
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Conclusion: These data demonstrate that impairment of cardiac con- 
tractility in patients with CHF is related to elevated circulating aldehydes. 
This observation suggests a role for these products of oxidative injury in the 
pathophysiology of ventricular dysfunction in patients with CHF. 
3 :00  p.m. 
~-~ Augmentation of Cardiac Production of Nitric Oxide 
in Patients With Chronic Heart Failure 
Masashi Fujita, Shinsuke Nanto, Tomoki Ohara, Takakazu Morozumi, 
Hiroyuki Nakayama, Junichi Kotani, Tetsuya Watanabe, Nobuaki Inoshiro, 
Mayu Nishio, Seiki Nagata, Masafumi Kitakaze 1 , Koichi Node 1 , 
Tsunehiko Kuzuya 1 , Masatsugu Hori 1 . Kansai Rosai Hospital, Amagasaki; 
i The First Department of Medicine, Osaka University School of Medicine, 
Suita, Japan 
Backgrounds: Nitric oxide (NO) is believed to be cardioprotective. NO in the 
systemic venous blood is reported to increase in patients with chronic heart 
failure (CHF), however, there is no clear consensus whether NO prOduction 
from the failing heart increases or decreases. 
Purpose and Methods: To answer this question, we measured cardiac 
NO levels and the amount of NO production in patients with CHF (n = 16). 
We sampled blood from coronary sinus (CS) and Aorta (Ao) simultaneously. 
We measured the levels of end-product of NO (nitrate + nitrite) in these blood 
samples, and we obtained cardiac NO levels by calculating the differences 
between NO levels in CS and Ao. We measured coronary blood flow (CBF) 
using Doppler flow wire. We also measured the same parameters in patients 
without CHF (n = 22). 
Results: Both cardiac NO levels (4.78 ~ 2.96 in patients with CHF vs. 
2.01 4- 3.55 nmol/ml in patients without CHF, p < 0.02) and the amount of NO 
production (845,3 ± 598.8 in patients with CHF vs. 297.5 ± 422.4 nmol/min 
in patients without CHF, p < 0.005) were significantly increased in patients 
with CHF. 
Conclusion: We suggest that cardiac nitric oxide production is enhanced 
in failing hearts in patients with chronic heart failure. Increases in NO pro- 
duction may contribute to pathophysiology in chronic heart failure. 
3 :15  p .m.  
~ Nitric Oxide Induces Apoptotic Death of 
Cardiomyocytes Via Cyclic GMP Pathway 
Takashi Shimojo, Michiaki Hiroe, Shigeru Ishiyama, Hiroshi Ito, 
Toshio Nishikawa, Fumiaki Marumo. Tokyo Medical and Dental University 
and Tokyo Women's Medical College, Tokyo, Japan 
Background: We have reported that excess amounts of nitric oxide (NO) 
produced by inducible NO synthase are involved in the development of 
myocardial damage in myooarditis rats. In this study, we examined whether 
NO induced cell death via apoptosis in cardiomyocytes. 
Methods: Cultured rat neonatal cardiomyocytes were exposed to SNAP 
as a NO donor, or 8-bromo-cyclic GMP (cGMP). DNA fragmentation was 
confirmed by electron microscopy, and TUNEL method. 
Results: Exogenously supplied SNAP or 8-bromo-cGMP induced car- 
diomyocyte apoptosis in a dose- and time-dependent manner. Electron mi- 
croscopy demonstrated typical features of apoptosis in cardiomyocytes. The 
incidence of apoptosis was enhanced by co-treatment with SNAP and za- 
prinast, a selective cGMP-phosphodiesterase inhibitor. SNAP-induced car- 
diomyocytes apoptosis was completely blocked by a PKG inhibitor or a 
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soluble guanylate cyclase inhibitor. Apoptotic cardiomyocyte death induced 
by SNAP was suppressed by hemoglobin and was completely blocked by 
ZVAD-FMK, a caspase inhibitor. 
Conclusion: These results show that NO-mediated apoptosis of car- 
diomyocytes is cGMP dependent and that the caspase family is involved in 
this process. 
ORAL 
Intravascular Ultrasound and Cardiac 
Transplantation 
Wednesday, March 10, 1999, 4:00 p.m.-5:00 p.m. 
Modal Convention Center, Room 271 
4:00 p.m. 
~-0~ Prognostic Intravascular Ultrasound After Impact of 
Heart Transplantation: A Multivariable Analysis in a 
Large Patient Cohort 
Volker Klauss, Klaus Pethig ~ , Helen Kalies, Elke Pichlmayer, 
Bernd Heublein ~ , Johannes Rieber, Christoph H. Spes, Bruno Re/chart, 
Uwe Siebert, Axel Haverich ~ ,Harald Mudra. DpL of Cardiology, Klinikum 
Innenstadt, University of Munich; ~ Hannover Medical School, Germany 
Background: Previous studies have shown that cardiac allograft vasculopa- 
thy (CAV) as assessed by intravascular ultrasound (IVUS) may predict car- 
diac events in patients (pts) after heart transplantation (HTx). These results 
were in part limited by the statistical approach (bivariate analysis) or by the 
number of patients included. We therefore sought to evaluate the prognostic 
impact of IVUS-parameters in a large patient cohort using a multivariable 
Cox analysis. 
Methods: 203 pts (47 5:12 years) were studied by IVUS 0.1 to 12 years af- 
ter HTx at 2 transplant centers. IVUS-parameters (maximal intimal thickness, 
mean and maximal intimal index) and coronary angiography (presence of an- 
giographic CAV) as well as clinical characteristics and risk factors for CAV 
in the first year post-HTx were related to cardiac events (cardiac death, my- 
ocardial infarction, revascularization procedures and retransplantation due 
to CAV). Only variables with a p-value _< 0.2 in the bivariate screening were 
included in the Cox analysis. 
Results: During a follow-up periode of 2.9 5:1.2 years (range, 0.3 to 
6.0), 37 events occurred. Bivariate analysis revealed age of donor and 
recipient, recipient sex, graft ischemic time, cholesterol level, elevated blood 
pressure, body mass index (BMI), dose of azathioprine and time interval 
after HTx to IVUS as significant covariables. By multivariable analysis, only 
the presence of angiographic CAV (risk ratio [RR] 18.2; 95% confidence 
interval [CI], 6.5-50.7), maximal intimal index > 30% by IVUS (RR 12.0; 95% 
CI, 3.4-42.2) and BMI (RR 5.6; 95% CI, 2.2-14.4) (all p < 0.0005) were 
independent predictors of cardiac events. 
Conclusion: This multivariable analysis demonstrates that IVUS provides 
additional prognostic information to angiographic findings. This is important 
in particular in pts with a normal coronary angiogram. Among all clinical 
parameters, BMI has an independent prognostic impact. With improved dsk 
stratification, surveillance schedules may be individualized. This may also 
help to reduce costs and the need of invasive procedures in low-risk sub- 
groups. 
4:15 p.m. 
~ Coronary Artery Thickening During InUmal the First 
Year of Cardiac Transplantation Predicts Late 
Clinical Outcome: A Serial IVUS Study 
Samir R. Kapadia, Khaled M. Ziada, Navdeep Boparai, Luba Platt, 
Velkan Ozduran, Timothy D. Crowe, James B. Young, Robed E. Hobbs, 
Steven E. Nissen, E. Murat Tuzcu. The Cleveland Clinic Foundation, 
Cleveland OH, USA 
Background: The impact of allograft vasculopathy developing in the first 
year of cardiac transplantation, detected by serial intravascular ultrasound 
examinations (IVUS), on long-term clinical outcome remains unknown. 
Methods: The study cohort consisted of 100 patients who underwent 
multivessel IVUS examination 1.0 ± 0.5 months after cardiac transplantation, 
which was repeated 12.0 5:1.0 months later. One year images were analyzed 
to identify sites with disease, defined as a lesion with an intimal thickness 
0.5 mm. For each diseased site, the identical location (whether diseased or 
not) was compared with the one month IVUS examination to determine the 
extent and severity of progression. A total of 755 paired sites in 217 arteries 
were analyzed. An adverse clinical outcome was prospectively defined as 
either death, heart failure requiring hospitalization or myocardial infarction 
with new wall motion abnormality. 
Results: Thirty-six patients (36%) developed new lesions of allograff vas- 
culopathy defined as an increase in intimal thickness of >_ 0.5 mm at one 
or more paired sites. The composite adverse clinical outcome rate in these 
patients was 25% during 43 months follow-up. On the other hand, patients 
without rapid progression had an adverse outcome rate of 11% (p = 0.03). 
Furthermore, the event-free survival by Kaplan-Meier analysis was worse 
in patients rapidly progressive intimal thickening (p = 0.06). Using multivari- 
ate analysis, adjusting for donor and recipient age, gender, hypertension, 
diabetes, immunosuppression dose, body weight, lipid values and ischemic 
time, patients with rapidly progressive intimal thickening suffered a worse 
clinical outcome (relative risk = 3.1, 95% confidence interval from 1.1 to 8.8, 
p = 0.03). 
Conclusion: Rapidly progressive intimal thickening in the first year after 
transplantation is a powerful predictor of significant adverse events (death, 
MI and CHF) in subsequent years. Accordingly, such patients may constitute 
a subset who should be targeted for more aggressive therapy. 
4:30 p.m. 
~-8~3-~ Remodeling Does Not Prevent Lumen Loss Early in 
Stages of Transplant Vasculopathy: A Serial 
Intravascular Ultrasound Study 
Khaled M. Ziada, Samir Kapadia, Timothy D. Crowe, $teven R. Steinhubl, 
Simon Homer, Steven E. Nissen, E. Murat Tuzcu. The Cleveland Clinic 
Foundation, Cleveland, OH, USA 
Background: In autopsy studies of atherosclerotic oronary arteries, emod- 
eling compensated for disease progression preventing lumen loss until cross 
sectional area narrowing exceeded 40%. This threshold has not been vali- 
dated in vivo and has not been examined in cardiac allograft vasculopathy. 
Methods: In 49 patients, intravascular ultrasound imaging was performed 
in 107 coronaries at 4 weeks, 1 year, and 2 years after cardiac transplantation. 
Planimetric measurements at matched sites included lumen area (LA), vessel 
area (VA), and max. plaque thickness (Pmax). Plaque area (PA = VA - LA) 
and cross sectional area narrowing [(PA + VA) * 100] were calculated. 
Vasculopathy lesions were defined as sites with no disease at 4 weeks and 
Pmax > 0.5 mm at 2 years. 
Results: AIIograft vasculopathy lesions were identified in 96 of 285 sites. 
During the 1 st year following transplantation, plaque area increased (1.3 ± 
1.4 to 3.6 5:2.6 mm ~; p < 0,0001 ) but vessel area remained unchanged (16.0 
J: 5.4 to 16.4 5:5.1 mm 2, p = 0.29), resulting in cross sectional narrowing 
of 22.0 5: 15.2%. Despite this modest cross sectional narrowing there was a 
significant reduction in the lumen area (14.7 5:4.9 to 12.7 5:4.7 mm 2, p < 
0.0001). 
Conclusions: The previously reported threshold of 40% cross sectional 
area narrowing beyond which lumen loss starts has not been validated 
in this study population. Early and serial ultrasound imaging allowed the 
identification of significant lumen loss in very early stages of disease. The 
remodeling response to rapidly progressive allograft vasculopathy may be 
different from that observed with native coronary atherosclerosis. 
4:45 p,m. 
[ -9 -0~ Different Patterns of Coronary Artery Remodeling 
After Heart Transplantation. A Serial Study With 
Intravascular Ultrasound and Three-Dimensional 
Vessel Reconstruction 
Johannes Rieber, Volker Klauss, Christof Weber, Francesco Prati 1 , 
Christoph H. Spes, Christiane E. Angermann, Bruno Reichart, Karl Theisen, 
Harald Mudra. Dpt. of Cardiology. Klinikum Innenstadt, University of Munich, 
Germany; IS. Camille Hospital, Rome, Italy 
Background: The progression of transplant coronary artery disease (Tx- 
CAD) remains the limiting factor after heart tranplantation (HTx). The mech- 
anisms of coronary artery remodeling during the progression of TxCAD are 
not yet fully understood. 
Methods: In 50 patients (pts) with angiographically normal coronary ar- 
teries (LAD = 38, LCx = 10, RCA = 2), serial intravascular ultrasound studies 
were performed immediately (19 pts, group I) and beyond the first year after 
HTx (group II, 31 pts) and t2 months thereafter in each group with a motorized 
pullback system. Up to 400 precisely matched sites per patient (200 #m step- 
ping, frame rate 5/s) were analyzed using an interactive three-dimensional 
analysis software package (TomTec"). Total vessel volume (VV), luminal 
volume (LV) and intima volume (IV) were compared between the baseline 
(A) and follow-up (B) study. 
Results (see table): Although mean vessel volumes did not change in 
group I, the pattern of remodeling was very heterogeneous, revealing an 
enlargement remodeling in 42% and shrinkage in 58% of the vessels. In 
group II, 70% of the pts showed a homogeneous vessel shrinkage. 
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Group I Group ]1 
A B p A B p 
W (ram 3) 466.9 437.2 as 559.8 526.5 <0.05 
LV (mm 3) 426.7 390.2 ns 488,8 435.2 <0.001 
IV (mm 3) 40.8 47.2 ns 71.0 91.3 <0.05 
Conclusion: By serial volumetric studies, heterogeneous pattems of 
coronary artery remodeling were observed, depending on the time since 
HTx. In pts late after HTx, the ability for compensatory enlargement of 
coronary vessels seems to decrease. The pattern of remodeling may have 
an important clinical and prognostic impact. 
ORAL  
Ventricular Assist Devices 
Wednesday ,  March  10, 1999, 4 :00 p .m. -5 :00  p.m. 
Moda l  Convent ion  Center ,  Room 210 
4:00 p.m. 
I - ~  Hypertension During Support With Ventricular 
Assist Devices: Incidence, Risk Factors and 
Management 
Robert L. Kormos, Srinivas Mural±, Eileen A. Stanford, Kenneth R. McCurry, 
Steven Winowich, Bartley P. Griffith. University of Pittsburgh, Pittsburgh, 
Pennsylvania, USA 
Background: Ventdcular assist devices (VAD) are being considered as an 
alternative to cardiac transplantation (CTX), yet no information exists on late 
adverse events other than thromboembolism or infection. The incidence, 
dsk factors, implications and management of hypertension (HTN) in VAD 
recipients is undefined. 
Methods and Results: Among 100 patients (PTS) receiving a VAD as a 
bridge to CTX, 56 were supported for greater than 30 days (mean-65 days). 
The overall incidence of HTN after LVAD implant was 64% in the total group 
(NOVACOR LVAD = 34, Thoratec LVAD = 13, and THORATEC BiVAD = 9) 
despite being present in the past medical history in only 10 to 20%. When 
present, the average onset of HTN was within 7-10 days of support and if 
present, HTN required drug therapy 70-80% of the time during VAD support. 
HTN was more frequent in PTS on the NOVACOR vs THORATEC (74% vs 
48%: p < 0.05) and in PTS with idiopathic vs ischemic etiology (75% vs 50%: 
p < 0.05). Patients age, renal function, gender, smoking or diabetes history, 
peak exercise 02 consumption, and incidence of neurological events were 
similar in PTS with and without HTN. HTN was successfully managed with 
either ACE-inhibitor or direct acting vasodilator in 72%, with the addition of 
a second agent (calcium blocker) in 18%. Three agents (addition of alpha 
or beta receptor blocker) were required in only 10%. Clinical outcome was 
independent of presence of HTN. 
Conclusion: 1) HTN, a previously unreported problem in VAD PTS, is 
frequently seen in those supported over 30 days. 2) Incidence is related to 
type of VAD and etiology of heart failure. 3) Pre-implant risk factors do not 
play a role in the incidence of HTN 4) Single anti-hypertensive regimens are 
often adequate in managing VAD HTN but a smaller minority have new onset 
persistent HTN. These findings have implications for the design of VAD's for 
chronic support. 
4 :15 p.m. 
~ Reversal Subendocardial Metallothionein of 
Expression and Myocyte Diameter After Prolonged 
Left Ventricular Assist Device Support 
Hideo A. Baba 1 , Chdstof Schmid 2, Christian August I , Kurt W. Schmid 1 , 
Tonny D.T. Tjan 2, Mario C. Deng 2 . 1Institute of Pathology; 2Department of 
Cardiothoracic Surge~ M(Jnster University Hospital, MDnster' 
Germany 
Background: Dudng left ventricutar assist device (LVAD) support reverse 
remodelling takes place. The role of metallothionein (MT), a highly con- 
served molecule inducible by proinflammatory cytokines with a potential role 
in oxygen free radical scavenging in ischemic myocardium has not been 
examined. 
Methods: Seventeen patients with end-stage heart failure (9 dilated car- 
diomyopathy, 6 ischemic heart disease, 1 myocarditis, 1 congenital heart 
disease, mean age 41 ~ 10 y, mean duration of support 139 d i 92, range 
14-309 d) who underwent successful LVAD implantation (15 × Novacor, 
2 × TCI Heartmate) as a bridge to transplantation were studied. Forma- 
lin-fixed, paraffin-embedded left ventricular free wall myocardial specimens 
were harvested at LVAD implantation (preLVAD) and transplantation (postL- 
VAD) and analyzed with regard to MT expression by immunohistochemistry 
(monoclonal antibody E9, Dako, semiquantitative score) and myocyte di- 
ameters (MYOD) by morphometry with the aid of an image analyzer. Both 
parameters were analyzed with respect to subendocardial, midmyocardial 
and subepicardial sections. 
Results: MT expression was detected in cardiomyocytes, small vessels, 
and fibroblasts. PreLVAD, MT and MYOD correlated positively (r = 0.43, P = 
0.001). Compared to preLVAD, MT expression and MYOD were significantly 
lower postLVAD (p = 0.006 and P = 0.3, resp). This difference was mainly 
explained by reduction in subendocardial MT and MYOD (p = 0.008 and 
0.05, resp). Furthermore, MT regression correlated with time after LVAD 
implantation (P = 0.001) and ability to exercise on the 75 watt level for 15 
rain (P = 0.03). 
Conclusions: In endstage heart failure, subendocardial left ventricular 
MT expression correlates positively with MYOD and inversely with time after 
LVAD implantation and ability to exercise. These data support a thophysio- 
logical role of MT in endstage cardiomyopathy. 
4 :30 p.m. 
~ Resting Myocardial Blood Flow and Metabolism 
Predicts Improved Native Cardiac Output and the 
Ability to Exercise with Weaning in Patients with the 
TCI Heartmate Left Ventricular Assist Device 
Simon Maybaum, Shilpi Epstein, Ainat Beniaminovitz, Mehmet Oz, 
Steven Bargmann, Donna Mancini. Co/umhia-Presbyterian Medical Center, 
New York, New York, USA 
Background: Reverse remodeling of the left ventricle has been demon- 
stratod in some patients supported by a left ventricular assist device (LVAD). 
We sought to determine the effect of resting myocardial blood flow (MBF) 
and myocardial oxygen consumption (MVO2) on native myocardial function 
and the ability to exercise with the device weaned. 
Methods: Nine patients with CHF on LVAD support for 12 wks were stud- 
ied with PET to assess MBF and MVO2. Exercise testing with hemodynamic 
and echocardiographic monitoring was performed with full LVAD support in 
auto mode and was attempted with the device weaned to a fixed rate of 20 
cycles/min. Native left ventdcular output (LVO) was calculated by subtracting 
LVAD flow from Fick cardiac output. 
Results: 
Normal MBF (n = 4) Low MBF (n = 5) 
0.6 ± 0.1 ml/g/min 0.2 ± 0.1 ml/g./min* 
Etiology of CHF 4 DCM 3 CAD, 2 DCM 
LVEDD (cm) 5.4 ± 1.4 3.1 ± 0.21" 
Peak VO2 (ml/kg/min) 15.6 ± 4.3 11.7 ± 2.1 
Peak LVO (l/rain) 6.3 ± 1.3 0.4 ± 0.3" 
% exercised @ 20/rain 100% 0% ° 
LVEDD = left ventricular end diastolic diameter, "p < 0.02 between groups MVO2 in the 
normal MBF group (n = 2) was normal vs significantly decreased in the low MBF group 
(n = 2). 
Conclusion; Normal MBF and MVO2 predicts improved native LV output 
on exercise in auto mode and the ability to exercise with the device weaned. 
Normal MBF was only seen in partially loaded ventricles. Partial loading of 
the LV may be important in the assessment of myocardial recovery and for 
hemodynamic stability in the event of device failure. 
4 :45 p.m. 
[ - ~  Platelet GP lib/Ilia Inhibitor Attenuates Complement 
C3a Generation and Granulocyte-Platelet 
Conjugation Product LTC4 During MAD Circulation 
Dan L. Serna, Ledford L. Powell, Bryan O. King, Hongphuc Ha, 
Scott Webster, John C. Chen. UC Irvine Medical Center, Orange, California, 
USA 
Background: Preliminary evidence suggests complement activation may 
mediate formation of granulocyte-platelet (GRAN-PLT) conjugates during in 
vivoventricutar assist device (VAD) use which may, in turn, cause VAD asso- 
ciated thromboembolic events including stroke. Leukotriene C4 (LTC4) is pro- 
duced by granulocyte-platelet conjugates. Platelets, moreover, are thought 
to regulate complement by the release of C1 esterase inhibitor C1 INH) from 
intracellular granules by an energy-consuming receptor-mediated process. 
Preservation of platelet function using a GP lib/Ilia inhibitor may attenuate 
GRAN-PLT conjugation by attenuation of complement. 
Methods: Ten in vitro non-pulsatile centrifugal VAD circuits were simu- 
lated for 4 days using 450 ml of fresh human whole blood. A highly selective 
inhibitor of platelet GPIIb/llla (Aggrastat) was added to the final five VAD 
experiments. The first five VAD experiments were conducted without Aggra- 
star. Temperature, ACT, cardiac index, pH, pCO2, pC2, Ca, and glucose were 
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maintained at physiologic values. We examined C3a generation by ELISA in 
all circuits throughout circulation. LTC4 production was measured by ELISA 
in 3 circuits with and 3 without Aggrastat during circulation. 
Results: LTC4 levels in the Aggrastat group declined to 23% mean normal 
by 72 hrs of VAD circulation vs. 127% mean normal in the control group. C3a 
generation rose to 33 times mean normal in the untreated group and 22 times 
mean normal in the group treated with Aggrastat. 
Conclusions: Production of LTC4 in this in vitro VAD circuit suggests 
granulocyte-platelet conjugation occurs during in vitro VAD circulation. Atten- 
uation of C3a generation and LTC4 generation by Aggrastat after prolonged 
in vitroVAD circulation suggests platelet GP lib/Ilia protection correlates with 
reduced complement activation and granulocyte-platelet conjugation after 
prolonged VAD circulation. This may represent preservation of platelet regu- 
lation of complement. GP lib/Ilia inhibition may provide a means of reducing 
granulocyte-platelet conjugation during VAD use. 
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I1 011-20 1 Role of in the Modulation of Redox Peroxynitrite 
i 
State and Oxidative Stress in Bovine Coronary 
Artery 
Kevin M. Mohazzab-H, Michael S. Wolin. Department of Physiology, New 
York Medical College, Valhalla, NY 
Background: Nitric oxide (NO) and peroxynitrite (ONOO-) are known to be 
reversible and irreversible inhibitors of mitochondrial respiration, respectively. 
We have previously shown that NADH-oxidase is the major site of superoxide 
anion (O~-) production in the endothelium-removed calf coronary artery (CA). 
Aim: The purpose of this study was to examine the effect of NO pretreat- 
ment on the redox state and the levels of O,~- production in CA. 
Methods: Isolated endothelium-removed arterial rings were prepared 
from the left anterior descending or the circumflex coronary artery of calf 
hearts. These rings were exposed to ~50 nM NO gas for 2 minutes under 
aerobic conditions prior to measuring oxygen consumption (using Clark-type 
oxygen electrodes), lactate formation (using YSI lactate analyzer), and O~- 
changes (using lucigenin-elicited chemiluminescence (CL)). 
Results: Exposure of CA to 50 nM NO for 2 min caused both a decrease 
in respiration and subsequent increase in lactate release from CA by 33% 
and 150%, respectively (p < 0.05, n = 5-11) which was not observed in the 
presence of the intracellular scavenger of O~ nron (10 raM), implicating 
a role for ONOO . Lactate levels under these conditions were similar to 
vessels that were exposed to 10 min of hypoxia (~10 Torr of oxygen) (p < 
0.05, n = 9). NO exposure also caused an increase in O,~- generation by 
45% (p < 0.05, n = 34) which was markedly potentiated in the presence of 
10 mM lactate (p < 0,05, n = 34) and inhibited in the presence of intracellular 
0~- scavenger Firon (10 mM)(p < 0.05, n = 11). 
Conclusions: These data suggest that inhibition of mitochondrial respi- 
ration by ONOO causes an increase in anaerobic glycolysis associated with 
lactate formation and elevated O~- production, which is presumably caused 
by increasing the availability of cytosolic NADH for NADH oxidase. 
~ Mechanism of on Cholesteryl Action of Probucol 
Ester Transfer Protein (CETP) mRNA in a CHO 
Cell Line That Had Been Stably Transfected With a 
Human CETP Gene 
Jiafu Ou, Keijire Saku, Shiro Jimi, Bo Zhang, Henry J. Pownall, 
Kikuo Arakawa. Fukuoka Universi~ Fukuoka, Japan; Baylor College of 
Medicine, Houston TX, USA 
Background: Probucol is associated with a significant reduction of plasma 
HDL-C levels. The mechanism of probucol's HDL-Iowering effect and its 
effects on CETP and cholesterol metabolism in cells are still unclear. 
Methods: CHO cell line that had been stably transfected with a human 
CETP gene (hCETP-CHO) were used. 
Results: After this cell line was incubated with probucol (5, 10 and 50 #M) 
for 24 hr, mean intracellular probucol concentrations reached 0.47, 0.67, and 
1.52/~g/mg cell protein, respectively. Northern blot analysis showed that cel- 
lular CETP mRNA was increased by probucol in a dose-dependent manner 
(137%, 162%, and 221%, respectively). The specific CET activity in the cul- 
ture medium also increased in a dose-dependent manner. Intracellular total 
cholesterol levels were decreased to 87.5%, 74.9%, and 52.5% of the con- 
trol, respectively. Probucol had no effects on HMG-CoA reductase activity or 
cholesterol synthesis from [+4C] acetate. However, [14C]-incorporated choles- 
terol secretion into the culture medium from hCETP-CHO was increased to 
181%, 256% and 354% of the control, respectively. 
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Conclusion: Teatment with probucol increased the CETP mRNA level 
and specific CET activity in the hCETP-CHO cell line, and probucol pro- 
moted cholesterol efflux from hCETP-CHO, which resulted in a decrease in 
intracellular cholesterol levels, 
I1 ] Increase Angiotensin II Type 1 Receptor 01 1 -22  Lack of in 
Protein After Acute Ischemia-Reperfusion in 
Isolated Working Rat Hearts 
Y~ Xu, Jason Dyck, Darryl W. O'Brien, William R. Ford, Alexander 
S. Clanachan, Gary D. Lopaschuk, Bodh I. Jugdutt. University of Alberta, 
Edmonton, Alberta, Canada 
Background: Angiotensin II (Angll) type 1 receptor (AT1) expression in- 
creases immediately after ischemia-reperfusion (IR) in isolated non-working 
rat hearts (25 min. global ischemia and 30 min. reperfusion) using autora- 
diography. Whether AT+ receptor protein synthesis also increases is not 
established. 
Methods: We assessed AT1 protein by Western blots of tissue from 
isolated working rat hearts using antibody specific for AT1 receptor. Groups 
of hearts (n = 6) were subjected to 30 min. of ischemia followed by 45 
min. of reperfusion and exposed to no drug (controls), Iosartan (Los, AT1 
antagonist), PD (PD 123,319, Angll type 2 receptor or AT2 antagonist), CHA 
(N 6 -cyclohexyladenosine, adenosine A1 receptor agonist), enalaprilat (an 
angiotensin-converting-enzyme inhibitor), PD + Los, Angll, and Angll + Los. 
Results: Significant cardioprotection with recovery of mechanical function 
after IR was only found in working hearts with CHA and PD. Although 
qualitative differences were apparent in AT~ protein content, no detectable 
quantitative differences in AT~ protein content between the groups were 
found. 
CON . - l - -  
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Conclusion: The short time interval after IR may be insufficient o show 
differences in AT1 protein synthesis even when AT~ mRNA expression is 
increased. 
~ In Vivo Aortic Uptake of MDA2, an 
Oxidation-Specific Monoclonal Antibody, Highly 
Correlates With Atherosclerosis Burden 
Sotirios Tsimikas, Wulf Palinski, Joseph L. Witztum. University of California, 
San Diego, La Jolla, CA, USA 
Background: Quantitation of atherosclerosis in animal models is traditionally 
performed by image analysis of Sudan-stained lesions or by volumetric 
analysis of a small number of aortic cross-sections. We here describe a 
novel technique that quantitates atherosclerosis. 
Methods: Atherosclerosis was measured by determining the activity of 
12SI.MDA2, a monoclonal antibody (MAb) to malondialdehyde-lysine pitopes 
(e.g. in oxidized LDL). The aortic uptake of 12SI-MDA2 was evaluated 24 hours 
pest I.V. injection in 11 LDL-receptor deficient (WHHL) and 2 NZW rabbits, 
as well as 16 LDL-receptor negative and 8 apoE-deficient mice. As a control, 
12Sl+Halb, an isotyped irrelevant MAb which binds to human albumin, was 
injected into 5 WHHL and 2 NZW rabbits, and 6 LDL-receptor deficient mice 
and 8 apeE-deficient mice. The rabbits were on regular chow and the mice 
on chow supplemented with 1.25% cholesterol. Aortic autoradiography was 
performed and the mean uptake of MAbs was measured as the % of the 
injected dose (%ID). Results were compared to the % surface area of Sudan 
positive lesions. 
Results: The blood clearance of both MAbs was similar. The aortic uptake 
of both MAbs was minimal in NZW rabbits. The aortic uptake of 1251-MDA2 
was 2.6X higher in WHHL rabbits (P < 0.001) and 1.6X higher in mice (P < 
0.001) than 1251.Halb. Highly significant correlations were noted between 1) 
the %ID of 12~I.MDA2 and the % area in rabbits (r = 0.83, P < 0.001) and mice 
(r = 0.90, P < 0.001), 2) the %ID of 12SI-MDA2 and the aortic weight (which 
reflects lesion volume) in rabbits (r = 0.95, P < 0.001) and mice (r = 0.82, P 
< 0.001), and 3) the aortic weight with the % area in rabbits (r = 0.80, P < 
0.002) and mice (r = 0.89, P < 0.001). Interestingly, 12SI-Halb had weaker but 
significant correlations with the same parameters as 12SI-MDA2, suggesting 
that some of the uptake of MAbs is due to increased permeability of lesions 
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and binding to macrophage Fc receptors. Autoradiography confirmed that 
MDA2 accurately reflects the lesions in their entirety. 
Conclusion: In vivo uptake of 1251-MDA2 highly correlates with athero- 
sclerosis and at the same time provides a measure of the presence of 
oxidized lipids. This technique may complement traditional methods of ath- 
erosclerosis quantitation and be particularly useful for assessing changes in 
lesions rich in oxidized LDL, 
1011-241 Differential Effect of Local Paclitaxel Release a 
i from a Biodegradable Stent Coating on Vascular 
Smooth Muscle Cells and Endothelial Cells in a 
Coculture Model 
Iris Haehnel, Utrike Pfeifer, Ansgar Resch, Robert Herrmann, 
Albert Sch~mig, Eckhard AIt. L Med. Klinik, Klinikum rechts der Isar, and 
Deutsches Herzzentrum, Technische Universit~t MOnchen, Germany 
Background: Paclitaxel (P) exerts a pronounced antiproliferative ffect by 
irreversibly interacting with the cellular microtubular system, affecting there- 
fore migration and proliferation. P was integrated in a recently described 
biodegradable polylactic acid stent coating (PLA, 30 kDa) for a sustained 
release. This study was designed to show the impact of locally released 
paclitaxel on VSMC and EC in a coculture model, simulating in vitro the 
conditions of both cell types interacting via the internal lamina elastica. 
Methods: Human VSMC and EC cocultures were done on collagen- 
coated PTFE membranes. 12.5 #g PLA ± paclitaxel (0.2 to 3.2 nmol) was 
deposited on the membrane. Both cell types were seeded on each side 
at a density of 25,000 cells/cm 2. After the haVSMC reached confluency 
in the control sample, the membranes were fixed and embedded in epoxy 
resin. Eight l~m-sections were cut and the number of cells of each cell type 
was counted on both sides of the membrane in at least 12 different areas 
(diameter of visual field 200 ,u.m; mean :E SD). 
~ l~l°°J T ~ p<0.ool 
50 i~  = ,~>!:~;, 
cot/rod paclitaxel paelitaxel 
1.6 nmol 3.2 nmol 
Conclusion: Despite strong antiproliferative ffects of P released from the 
biodegradable stent coating on haVSMC, endothelial growth was significantly 
less affected. This could be important for the clinical application of a paclitaxel 
impregnated stent, since the rapidity of reendothelialization after stenting is 
also relevant to the extent of the in-stent neointimal formation. 
1011-25 I Detection of Different Formation of Superoxide 
I Radicals by Nitroglycerin in Contrast to 
Pentaerithrityl tetranitrate 
Eberhard Bassenge, Serguey Dikalov, Bruno Fink. Institute of Applied 
Physiology, University of Freiburg, Germany 
Background: To date it was not possible to detect nitrate-induced increases 
in reactive oxygen species (ROS) formation in rive. The measurements are 
difficult to perform due to the strong competition of ascorbate and thiols 
for ROS on one hand and simultaneous ascorbate-induced destruction of 
paramagnetic spin-traps/ROS edducts on the other hand. The aim of the 
study was to monitor directly a GTN- or PETN-induced formation of ROS in 
blood in vivo by means of electron spin resonance (ESR). 
Methods: 20 mg/kg of our newly-developed ESR spin trap carboxy proxyl 
C5HzO3N1 (CBPX), which forms a paramagnetic spin adduct CBPX/ROS 
resistant to ascorbate and thiols (in concentration present in blood), and 130 
/zg/kg of GTN or PETN were infused IV. into anaesthetized rabbits. Blood 
probes 200 ~1 were obtained from a carotis 5 and 10 rain after GTN or PETN 
infusions. 
Results: Triplet ESR signals with g± = 2.002 and g~ = 2,008 correspond- 
ing to the paramagnetic CBPX/ROS spin adduct were detected in blood, 
Concentrations of CBPX/ROS adduct in blood measured 5 and 10 rain after 
infusions of GTN or PETN were 9.3 • 0.8 and 7.1 ± 0.6nM for GTN and 2.8 
or 3.0 ± 0.2 nM for PETN, basal concentrations were 2.4 ± O,3nM (data are 
mean ± SEM, n = 5). 
Conclusion: In rive infusions of nitroglycerin in rabbits in therapeutic 
doses increased significantly the formation of superoxide radicals in the vas- 
culature and blood in contrast to pentaerithrityl tetranitrate which caused 
minimal increases. Thus, formation of the unwanted side-product peroxyni- 
trite (a strong oxidant formed from GTN-derived NO and from simultaneous 
superoxide production) eliciting vascular dysfunction with GTN was not de- 
tected when PETN was used. 
I1 I Adenoviral Gene Transfer to Mouse Carotid 
I 
01 1 ~26
Arteries: Limited Role of Antigen-Specific 
Immunity in Elimination of Transgene Expression 
Ramtin Agah, Giuseppe Vassali, Ruth Linnemann, David Dichek. Unit,, of 
Calif. San Francisco, 350 Parnassus Ave., Suite 709 San Francisco, CA, 
USA 
Background: Adenoviral vectors (Ad) are useful tools for delivering trans- 
genes to the artery wall. However, Ad produce only transient recombinant 
gene expression. The brief duration of gene expression is thought to be due 
primarily to an immune response to foreign transgenes and Ad proteins. To 
test this hypothesis, we developed a murine model of arterial gene transfer 
and determined the duration of transgene expression in both immune-com- 
petent and immune-deficient mice. 
Results: Ad encoding a/~-gatactosidase (~-gal) reporter gene were in- 
fused in carotid arteries of adult CD-1 and C57BL/6 mice. Maximal gene 
expression (measured as/~-gal activity in artery extracts) was obtained at 
viral concentrations of 1-5 x 10 l° pfu/ml. Histochemical staining revealed 
/~-gal expression predominantly in endothelium, in approximately 10% of lu- 
minal endothelial cells. As expected, expression was present at 3-7d, but 
was undetectable at 14d. The/~-gal vector was then infused in arteries of 
ROSA-26 mice (which are transgenic for and therefore tolerant of ~-gal). 
Expression was again elevated at 3d and fell to background levels at 14d. 
Finally, the vector was infused in arteries of RAG2 / mice (which are in- 
capable of mounting antigen-specific immune responses). /~-gal expression 
was present both at 3d and 14d in RAG2 / arteries. Surprisingly, however, 
the level of expression of ~-gal in the 14d RAG2 /- arteries was only 10% of 
the 3d levels. 
Conclusions: Ad gene transfer to mouse arteries is feasible and repro- 
ducible. Although antigen-specific immunity contributes to the elimination of 
transgene expression, neither transgene tolerance nor the absence of anti- 
gen-specific immunity ensures stable gene expression. Hence, it is appropri- 
ate to investigate factors other then the immune system that may contribute 
to the stability of Ad gene expression. 
New 
Orleans 
March  7 -10  
I1011-28 1 Atorvastatin Gene Downregulates AT1 -Receptor 
Expression and Cell Proliferation in Vascular 
Smooth Muscle Cells 
Sven Wassmann, Georg Nickenig, Michael B6hm. K/in&/11 for Innere 
Medizin, University of Cologne, Cologne, Germany 
Background: HMG-CoA reductase inhibitors (statins) effectively lower plasma 
cholesterol levels. In addition, it has been reported that these drugs exert 
direct cholesterol-independent effects on vascular cells. In order to further 
elucidate the molecular mechanisms involved in the beneficial effects of 
statins on cardiovascular diseases, the effects of atorvastatin (ator) on cell 
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proliferation and ATe-receptor gene expression in vascular smooth muscle 
cells (VSMC) were investigated.. 
Methods: VSMC were isolated from rat aortas and cultured. Cells were 
incubated with 1 #mol/I ator. ATl-receptor mRNA was assessed by North- 
ern Blot Analysis after 0-24 h of incubation. In addition, ATl-receptor den- 
sity after 24 h of incubation and ATl-receptor binding were measured with 
1251-angiotensin II radioligand binding assays. The effect on cell proliferation 
was assessed by 3H-thymidine- and BrdU-incorporation following a 24 h 
incubation with ator and/or angiotensin II. 
Results: Atorvastatin did not specifically bind to the AT1 -receptor. AT~ -receptor 
mRNA was downregulated to max. 54 5: 2.4% of control levels after 4 h of 
incubation with ator. In analogy, ATe-receptor density was decreased to 59 5: 
16.3% of control levels (B-max 1424 5:474 vs 823 5: 235; no change in KD). 
After 24 h of incubation with ator, DNA synthesis of VSMC was reduced to 
61 ± 6.6% of control levels. In addition, ator attenuated angiotensin-induced 
cell proliferation by 30 5: 10.7%. 
Conclusions: Atorvastatiminduced ownregulation of ATe-receptor gene 
expression and cell proliferation demonstrate that statins exert direct effects 
on vascular cells which are independent of plasma cholesterol levels. This 
may contribute to the beneficial effects of these drugs on cardiovascular dis- 
eases, since proliferation of VSMC and AT1 -receptor regulation play a major 
role in the pathogenesis of atherosclerosis, hypertension, and restenosis 
after PTCA. 
~ Simvastatin Increases Nitric Oxide Induced 
Coronary Vasodilation and Nitric Oxide 
Production in Canine Coronary Microvessels 
Seema Mital, Xiaoping Zhang, Robert Bernstein, James Liao, Thomas 
H. Hintze. Columbia-Presbyterian Medical Center, New York, NY; New York 
Medical College, Valhalla, NY; Brigham Women's Hospital, Boston, MA, 
USA 
Background: Statin drugs can reverse endothelial dysfunction in both coro- 
nary and peripheral vasculature of hypercholesterolemic subjects before 
regression of vessel atherosclerosis. We proposed that the beneficial effects 
of statins are in part secondary to improvement in endothelial function and 
enhanced nitric oxide (NO) production. 
Methods: Mongrel dogs (n = 4) were chronically instrumented to measure 
systemic hemodynamics and coronary blood flow (CBF) before and after 14 
days of Simvastatin (20 mg/kg). Coronary microvessels (CM) were isolated 
to measure baseline and stimulated NO production. 
Results: With the heart rate controlled (150 bpm), veratrine - a stimulator 
of reflex NO mediated coronary vasodilation, caused a dose-dependent 
increase in CBF (27 5:2 to 57 ± 10 ml/min) and decrease in coronary 
resistance (3.8 ± 0.3 to 1.4 5:0.2 mmHg/ml/min) (p < 0.05 from baseline). 
After Simvastatin, the dose-response curve to veratrine was shifted to the 
left - CBF increased from 33 5:2 to 81 ± 7 ml/min and coronary resistance 
decreased from 3.2 5:0.1 to 1 ± 0.1 mmHg/ml/min (p < 0.05 from control). 
Baseline NO production was higher in CM from treated dogs (72 5:6 vs 110 
± 14 pmol/mg, p < 0.05). Also, NO production in response to Acetylcholine, 
bradykinin, A23187 and ramiprilat was greater in CM of simvastatin treated 
dogs (p < 0.05). For instance, ramiprilat (10 8M) increased NO production 
to 140 5:18 pmol/mg in CM from normal dogs and to 219 ± 28 pmol/mg in 
CM from simvastatin treated dogs (p < 0.05). 
Conclusion: Endothelial dependent coronary vasodilation is enhanced in 
normal dogs after short duration administration of simvastatin. This appears 
to be secondary to increased NO production in CM and may be an important 
therapeutic action of statin drugs. 
~ Reduced in the Arterial Wall Phosphatase Activity 
Following Balloon Injury 
Paul Dimayuga, Jenny Zhu, Sanjay Kaul, Prediman K. Shah, Bojan Cercek. 
Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, 
California, USA 
Arterial wall injury is associated with increased transcription factor activation 
and smooth muscle cell (SMC) proliferation. As protein phosphorylation is 
a critical step in transcription factor activation we investigated the activity 
of cytosolic phosphatases (phosphotyrosine phosphatase [PTP] and ser- 
ine/threonine phosphatases [PP2A, 2B, 2C]) 6 hours after balloon injury of 
femoral arteries in rats. Rats were untreated, treated with phosphatase stimu- 
lator octreotide (Oct) or with Oct and phosphatase inhibitor okadaic acid (CA) 
(n = 15). Balloon injury (Table) resulted in decreased PP2A activity without 
significant change in PP2B, PP2C or PTP activity. Treatment with octreotide 
increased PTP activity and prevented the injury induced reduction of PP2A 
activity, which was associated with reduced AP-I and NF-KB binding at 6 
hours (57 ± 3% and 43 5:11% of control respectively) and SMC proliferation 
3 days after injury, (43% reduction in PCNA activity compared to untreated 
rats). The effects of octreotide were prevented by addition of okadaic acid, 
AP-1 and NF-KB binding 81 ± 9% and 114 5: 25% of control respectively. 
Table: Phosphatase activity 6 hr post injury: (activity in control uninjured 
arteries = 100%) 
PP2A PTP 
Untreated 54 ± 241 73 ± 29 
+ Oct 88 5:252 149 ± 442 
Oct + CA 54 5:83 91 + 3 
1 p < 0.05 vS. uninjured control; 2p < 0.05 vs. 6 hr post injury untreated; 3p < 0.05 vs. 6 
hr post injury + Oct; 
Conclusion: Reduced activity of serine/threonine phosphatase PP2A 
following arterial wall balloon injury leads to increased AP-1 and NF-~:B 
binding. 
~ Biphasic Pattern of Cell Turnover During 
Atherogenesis in Man and APOE*3 Leiden Mice 
Esther Lutgens, Ebo D. de Muinck, Mark Kockx 1 , Pieter J. Doevendans, 
Hein J. Wellens, Mat J. Daemen 2 . 2Cardiology and Pathology, University 
Hospital Maastricht; ~ Pathology, The Netherlands; AZ Middelheim, 
Antwerp, Belgium 
Background: Cell turnover during all stages of atherogenesis in man has 
not been described nor compared with transgenic APOE*3 Leiden mice. 
Methods: Lesions were classied according to the AHA classification. 
APOE*3 Leiden mice (n = 6) were fed high fat/cholesterol for 6 months. 
Lesions (n = 135) were stained 5-Bromodeoxyuridine and TUNEL. Human 
aortas were obtained at autopsy (n = 7) or vascular surgery (n = 8). Lesions 
(n = 80) were stained MIB 1 and TUNEL. All data are mean 5: SEM. 
Results: atherogenesis in APOE*3 Leiden mice: Lesions were type 0-5, 
there were no ruptured plaques (type 6). In all lesions DNA synthesis was 
increased compared to non diseased (ND) segments. It peaked in type 2 
(8.6 5: 0.8% vs. 1.0 4- 0.2% ND; p < 0.05) and declined to 5.8 5: 0.7% in 
type 5 (p < 0.05). Apoptosis was only elevated in type 4 and 5 (1.3 5: 0.1% 
and 1.2 4- 0.2% vs. 0.04 4- 0.04% in ND; p < 0.05). Atherogenesis in man: 
In type 2-6 DNA synthesis was increased compared to ND segments. DNA 
synthesis peaked in type 2 (3.0 5: 0.5% vs. 0.02 5: 0.02% in ND; p < 0.05), 
declined to 0.7 5: 0.2% (p < 0.05) in type 5 and peaked again in type 6 (1.7 5: 
0.1%). In type 2 DNA synthesis occurred in the foam cell rich area (98.6%), 
in type 5 in the shoulder (68.1%) and in type 6 under the rupture (52.7%). 
Apeptosis was only elevated in type 4-6 (0.8 5:0.1%, 0.8 ± 0.1% and 1.1 ± 
0.1% vs. 0.0 5: 0.0% in ND; p < 0.05). In type 4 and 5 it occurred in the lipid 
core (90.5% and 54.2%) and in type 6 in the lipid core and under the rupture 
(31.8% and 34.6%). In man and mice proliferation and apeptosis occurred 
predominantly in macrophage foam cells. 
Conclusions: DNA synthesis is an early event in atherogenesis in man 
and APOE*3 Leiden mice, while in man it shows a second peak in ruptured 
plaques. Apoptosis only occurs in advanced lesions. 
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~ Regional and Highly Myocardial Efficient Gene 
Transfer by Selective Pressure-regulated 
Retroinfusion of Coronary Veins 
Peter Boekstegers, Georges yon Degenfeld, Daniel Heinrich, 
Gerhard Steinbeck, Hugo Katus 1 , Wolfgang Franz 1 . Int Med I, University 
Hospital Grof3hadem, Munich; w Int Med IL University of Ldbeck, Germany 
Background: An important prerequisite for myocardial gene therapy is an 
efficient local gene delivery system. Regional myocardial drug delivery has 
been successfully performed by pressure-regulated retroinfusion, a clinically 
applicable method (JACC 1998;31 ;1525--33). In the present study a modified 
retroinfusion technique was used to prolong contact of viral vectors with the 
myocardium to increase transfection and gene expression rates. 
Methods: Replication-deficient adenoviral vector with the luciferase or 
,8-galctosidase reporter gene under control of the RSV-promotor (2.5 x 109 
pfu in 25 ml) was delivered in a pig model: (A) continuous antegrade delivery 
into the LAD during ischemia (2 x 10 min), (B) retrograde delivery into the 
anterior interventricular vein during ischemia (2 x 10 min) and (C) antegrade 
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and retrograde delivery without ischemia (2 × 10 mini. Luciferase activity 
and ,8-galactosidase expression was studied in 9 probes of the LAD region 
and in control probes (CX) 7 days after gene delivery. 
Results: Antegrade transcatheter delivery (A) slightly increased luciferase 
activity in the LAD region (260 4- 114 LU/mg protein, n = 5) compared to the 
control region (110 ± 88). In contrast gene delivery by retroinfusion during 
ischemia (B) resulted in a highly significant increase of luciferase activity 
(39.302 + 15.741 LU/mg protein, n = 5) in the LAD region compared to the 
control region (79 ± 55). Using a combination of retrograde and antegrade 
delivery (C) similar levels of luciferase activity (50.059 ::1: 9803, n = 5) were 
reached in the LAD region without ischemia. Alter retroinfusion (B and C) 
#-galactosidase expression was observed in 30-50% of the cardiomyocytes 
in the LAD region but not in the CX region. 
Conclusion: Gene delivery by retroinfusion with and without ischemia 
was highly efficient for selective regional myocardial gene transfer. 
I 1012-76 t Oxidant Stress Stimulates the Activity of the 
Endothelin-1 Promoter in Cultivated Endothelial 
Cells 
Jan K~hler, Jdrn Weckm011er, Sabine Mendel, Ralf Kdster, 
Clemens Mittmann 1 , Hans-Dieter Orzechowski 2 , Martin Paul 2, 
Thomas M0nzel, Thomas Meinertz. Dept. of Cardiology; ~ Dept. of 
University Bedin, Germany 
associated with increased endothelin-1 levels. Therefore we investigated 
the effect of oxygen derived radicals on endothelin-1 promoter activity and 
ando~e))n-~ mmabo))sm. 
Methods: Cultivated endothelial cells were incubated with xanthine/xanthine 
lase. Furthermore, the effect ot-hydrogen peroxide was ihvestigated~ E-n- 
dothelin (ET)-I promoter activity was investigated in bovine endothelial cells 
using a luciferase construct including the first 132 bp of the ET-1 promoter, 
the cac~ce~tcatio~ f ec~k~the~in- 1-mRNA ar~l El'- f was de~ecmir~ed with a 
pre-pro-ET-1 probe by means of northern blot and by radioimmunoassay. 
Results: ET-1 promoter activity was increased bE stimulation with xan- 
tri,ne/xanth,ne ox,~ase "('z rfil~ an~l-O.l to "I-U n~O'/rfil) up to 'F'z'r61~ drthe 
baseline level. This effect was time- and dose de0endent, the maximum 
activation was observed at a concentration of I mU/ml xanthine oxidase, the 
mutase (SOD) and catalase. The incubation with xanthine/xanthine oxidase 
~i3g~s ~fi~b~ was't~me- an~5 0ose b~e-penbeTh as w~e~. nCU~"~T~ Wil~ ~y0tt~g~n 
under comparable conditions. 
Conclusion: The data indicate that oxidant stress induced by xan- 
thine/xanthine oxidase increases the activity of the endothetin-l-promotor, 
t,~,~ ,~ i '~ j  t~ ~ev~%~ '~L~,~A ,~ 's .  ~; / . '~  ~,~" c~ a c',,~ u
ture model the in vitro concentration of ET-1 is decreased, either by oxidative 
degradation of denaturation of the peptide. Whether the increased synthesis 
of endothelin-1 induced by oxidant stress is relevant in vivo remains to be 
determined. 
~ Cotransfection of FosB and JunB Genes Induces 
Hypertrophy in Cultured Pulmonary Arterial 
Smooth Muscle Cells 
LingZhi Zhang, ChuanYi Lu, Abraham Rothman. University of California 
San Diego Medical Center, San Diego CA, USA 
Background: The cntical cellular signals associated with pulmonary arterial 
smooth muscle cell (PASMC) hypertrophy are unknown. We have previously 
shown that an increase in FosB expression alone does not induce hyper- 
trophy; however, inhibition of FosB expression results in a diminution of 
thrombin-induced hypertrophy by 58%. Our aim in this study was to investi- 
gate whether cotransfection of fosB with each of 3 jun family members leads 
to PASMC hypertrophy. 
Methods: E1 region-deleted recombinant advenoviral vectors carrying 
either sense or antisense fosB cDNAs or junB cDNAs (termed Ad.S.fosB, 
Ad.A.fosB, Ad.S.junB and Ad.A.junB, respectively), or sense c-jun cDNA 
and junD cDNA (Ad.S.c-jun and Ad.S.junD), were constructed. PASMCs 
were maintained in Dulbecco's modified Eagle's minimum essential medium 
(DMEM) containing 10% fetal bovine serum (FBS) and antibiotics. At 60-70% 
confluence, cells were switched to medium containing 0.25% FBS and incu- 
bated for 48 hours to make the cells quiescent. Cells were divided into the 
following groups: 1) control (maintainted in serum deprivation), 2) thrombin (1 
unit/ml, positive control for hypertrophy), 3)-9) cotransfection of Ad.S.fosB or 
Ad.A.fosB with each Ad.S.junB, Ad.S.junD, Ad.S.c-jun or Ad.A.junB. PASMC 
growth was assessed by daily cell number count, determination of [3H]leucine 
incorporation (new protein synthesis) and quantitation of total cellular protein. 
Results: Adenovirus-mediated cotransfection of a) Ad.S.fosB and Ad.S. 
c-jun, b) Ad.S.fosB and Ad.S.junD, c) Ad.S.fosB and Ad.A.junB or d) Ad.A. 
fosB and Ad.S.junB did not induce a change in new protein synthesis or total 
protein/cell in quiescent PASMCs; however, cotransfection of Ad.S.fosB and 
Ad.S.junB induced an increase in new protein synthesis of 49% at 72 hours 
(p < 0.01, compared to controls), and an increase in total protein/cell of 15% 
at 48 hours (p < 0.05) and 34% at 72 hours (p < 0.01). 
Conclusion: Adenovirus-mediated cotransfection of Ad.S.fosB and Ad. 
S.junB induces hypertrophy of quiescent PASMCs. The upstream and down- 
stream signals in this process remain to be determined. 
I 1012-78 1 Smooth Muscle Cell Phenotype Modulation in 
Balloon Injured Rat Carotid Arteries as Monitored 
by Smoothelin Expression 
Philipp Wende, Jdrg Kreuzer, Lisa Watson, Stephanie Denger, 
Wolfgang K0bler, Lothar Jahn. Department of Cardiology, University of 
Heidelberg, Bergheimerstr. 58, 69115 Heidelberg, Germany 
Background: Restenosis is the major obstacle hindering the suCCessful, 
long-term outcome of balloon angioplasty. A better understanding of the 
cellular mechanisms involved ma~ lead to new therapeutical aQl~roaches. 
Neointima formation foJIowing endothelial balloon iniuty is the result of ~he- 
notype modulation and proliferation of smooth muscle cells (SMC) of the 
Methods: To charactenze the time dependent phenotype modulation of 
SMC, a rat balloon injury model of restenosis was assessed with immuno- 
h~st~chem~ca~ tec~n~ques, us'rag monoc~onal an~~odies recogn'~zmg smooth 
muscle myosin heavy chain (SmMHC), desmin and smcothelin, a novel 
tra:dKet -spe-dffrc "turlne dfftetet~,aXe~ TJnend[ype dt ~'~f~. ~a'~s were sacffi:,ce(] 
1, 3, 5, 7, 14, 28 and 56 days after endothelial balloon injury (n = 5). 
Results: Neointima formation could be seen from day 7 onwards. In early 
neointima formation (days 7 and 14), the number of smoothelin positive cells 
it~ the media was decrease4 campared w~t~ t~e uc~ic~j~ced cantrols. Smoot'he- 
lin staining was absent in the neointima, but many SMC were SmMHC- and 
desmin-Dositive. Using immunocvtochemical labelinp with ki-67 antibody we 
6brained a pr61[terative prdfile ot the vessels. -SMC were also ]ound to be 
Qroliferatinq.at this earl~ staa~e. An uQ-reajation of smoothelin exQressien in 
both the media and neointima was observed with a peak at days 28 and 56, 
SmMHC or desmin. The time-dependent initial down-regulation and subse- 
~,onc3u,~mn: ~o'/"/owlng "t)~hoon /ifl}ury, %'1~, m "-oo~zn ~'ne me~m an0 "the 
fectively used to monitor SMC dedifferentiafion in the neointima and media, 
in rive. The findings support the pivotal rote of SMC phenotype modulation 
in neointima formation and restenosis. 
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I1 I Intravenous of C Acutely 3-67 01 Administration Vitamin Improves Endothelium-Dependent Dilation in 
Brachial Artery in Vasospastic Angina 
Bonpei Takase, Akira Hamabe, Hirokuni Etsuda, Akimi Uehata, 
Toshihiko Nishioka, Ryoji Kuhara, Takashi Akima, Yoshihiro Matsushima, 
Kimio Satomura, Fumitaka Ohsuzu, Akira Kurita. National Defense Medical 
College and Self Defense Force Central Hospital Saitama and Tokyo, Japan 
Endothelial dysfunction in coronary artery contributes to the pathogenesis of 
vasospastic angina (VSA), and increased oxygen-derived free radicals have 
been implicated as this mechanism. We investigated whether endothelial 
dysfunction exists in the penpheral artery in patients (pts) with VSA, and also 
examined the effect of vitamin C (VlTC), an antioxidant, on endothelium- 
dependent vasodilation. Using high resolution ultrasound, flow-mediated di- 
lation (FMD, endothelium-dependent vasodilation) and sublingual glyceryl 
trinitrate induced dilation (0.3 mg, GTN-D, endothelium-independent vasodi- 
lation) were measured in the brachial artery. FMD and GTN-D were measured 
before and after intravenous administration of VITC 1 g in 12 pts with VSA (6 
male, age 65 ± 6 years); 4 hypertensive, 3 hypercholesterolemics, 2 diabet- 
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ics and 5 smokers. As a control, FMD and GTN-D were obtained in 12 normal 
subjects who matched an age, sex and coronary risk factors with VSA pts. 
In VSA pts, FMD was significantly impaired compared to NL (0.3 ± 1.6% vs 
7.2 ± 3.0%, p < 0.01), and was significantly augmented by VlTC (from 0.3 ± 
1.6% to 3.2 ± 1.6%, p < 0.05). However, it was still significantly lower than 
NL (p < 0.01). GTN-D was not significantly different (VSA pts, 9.3 ± 6.1% 
vs. NL, 10.2 ± 5.4%) and it was not affected by VlTC. In conclusions; 1) 
FMD in brachial artery is impaired in VSA pts, and 2) acute administration of 
the antioxidant, VITC, partially reverses this endothelial dysfunction. These 
findings support that systemic inactivation of nitric oxide by oxidative stress 
exists in VSA pts and antioxidant herapy can be useful in this population. 
~ Vitamin Improves the Coronary C Vasodilator 
Reserve in Asymptomatic Smokers 
Philipp A. Kaufmann, Tomaso Gnecchi-Ruscone, Paolo G. Camici. MRC 
Cyclotron Unit, Hammersmith Hospital, Imperial College School of 
Medicine, London, UK 
Background: Coronary endothelial function and vasomotion are impaired in 
smokers without coronary disease and this is thought to be due to increased 
oxidative stress. To test this hypothesis, we measured the coronary vasodila- 
tor reserve (CVR) in smokers and controls before and after administration of 
the antioxidant vitamin C (Vit C). 
Methods: Myocardial blood flow (MBF, ml/min/g) at baseline (B) and 
during iv adenosine (Ado; 0.14 mg/kg/min) was measured in 8 healthy 
males (GR1) and 11 age-matched asymptomatic male smokers (GR2) us- 
ing positron emission tomography and oxygen-15 labeled water. Thereafter, 
B- and Ado-MBF were repeated after 3 g of Vit C, infused iv over 10 min- 
utes. CVR was calculated as Ado-/B-MBF after correcting B-MBF for the 
rate-pressure product, an index of cardiac work. 
Results: Heart rate and mean arterial blood pressure were similar in both 
groups at rest and during Ado before and after Vit C. 
Before Vit C After Vit C 
B-MBF Ado-MBF CVR 1 B -MBF Ado-MBF CVR 2 
Controls 1.32-{-0.22 3.99±0.82 3,07:1:0.61 1.44±0.34 4.17±0.45 3.08±102 
Smokers 1.31 ±0.14 3.58±0.33 2.74±0.33 1.370.17 4.24±0.51" 3.13±0.49" 
('p < 005 vs baseline) 
Conclusion: The finding that Vit C improves CVR in smokers provides 
evidence that increased oxidative stress contributes to coronary endothelial 
dysfunction in individuals with this habit. 
~ l n  Vivo Human Vasomotor to Coronary Response 
the Selective B1 Kinin Receptor Agonist 
Des-Argg-Bradykinin 
Eduardo Aptecar, Philippe Garot, Patrick Dupouy, Emmanuel Teiger, 
Said Sediame, Christophe Benvenuti, Jean-Marc Pernes, Alain Castaigne, 
Daniel Loisance, Jean-Luc Dubois-Rand& Henri Mondor University 
Hospital, Creteil, France 
Background: Coronary B~ receptors to kinins seem to be constitutive and 
to mediate endothelium-dependent relaxation when up-regulated under in- 
flammatory or traumatic conditions. In humans, the effects of selective B~ 
stimulation on coronary arteries vasomotion (CAV) are unknown. 
Purpose: To assess the in vivo effects on human native and transplanted 
CAV induced by B~ selective agonist des-Argg-Bradykinin (DBK). 
Methods: 9 control subjects and 10 transplant patients (HTX) were in- 
cluded, all with angiographically normal coronary arteries, and without any 
clinical or biological marker of infection or inflammatory disease. Quantitative 
angiography of 3 segments of the left coronary artery, and coronary blood 
flow velocity (CBFV) (Doppler wire) were assessed at baseline, after intra- 
coronary acetylcholine (ACh) (50/~g bolus) and increasing doses of DBK: 
0.04, 0.4, 4.9, 49 and 145/~g/min, 5 min each. DBK doses were chosen on 
the basis of previous in vivo animal studies. The response to Ach was used 
as the marker of endothelial function. 
Results: ACh induced epicardial vasodilation in control subjects (8 ± 
12%, p < 0.01) and constriction in HTX -7  ± 9%, p < 0.05) whereas CBFV 
increased similarly in both groups (64 ± 30 and 72 ± 29%, both p < 0.001 ). 
DBK at the doses of 49 and 145 #g/min induced significant and similar 
epicardial vasoconstriction in both groups: -6  ± 9 and -7  ± 12% in control 
subjects (both p < 0.01) and -8  ± 8 and -9  ± 11% in HTX (both p < 0.0001), 
whereas CBFV did not change. With lower doses of DBK, no effect on CAV 
was observed. 
Conclusion: B~ receptors to kinins exist in human coronary arteries. 
Their selective stimulation induces epicardial vasoconstriction whatever the 
endothelial function is, suggesting that their predominant effect is on smooth 
muscle cells. 
~ Effects of Hyperoxia on Flow-Related Endothelial 
Function and Hemodynamics in Patients With 
Heart Failure 
Paul G. Silance, Niloufar Mojdehian, Jean L. Vandenbossche. CHU St 
Pierre, Brussels, Belgium 
Hyperoxia is a vasoconstrictor factor and may produce detrimental hemody- 
namic effects especially in patients with heart failure. The underlying mech- 
anisms responsible for the oxygen effects on the peripheral circulation are 
controversial. Arterial oxygen reactivity could be mediated either directly by 
the vascular smooth muscle or through endothelial cells. 
The aim of the study was to evaluate the effects of hyporoxia on the 
hemodynamic and vascular function of patients with heart failure. 
We studied hemodynamic variables and vascular function in 11 patients 
with chronic congestive heart failure (NYHA functional class II and III), Pa- 
tients were submitted to two separate evaluations, in one they inhaled room 
air and in the other 100% oxygen (delivered by a nonrebreathing face mask 
for 20 minutes). Using high resolution ultrasound we measured brachial arte- 
rial dilation in response to reactive hyperemia (endothelium dependent flow 
mediated dilation [FMD]) and following sublingual glyceryl trinitrate (GTN, 
400 #g) (endothelial-independent dilation). Stroke volume and cardiac out- 
put were measured by Doppler echocardiography. 
Hyperoxia reduced significantly cardiac index (from 2.4 ± 0.2 to 2 ± 0.3 
L./min.m 2, p < 0.01) and stroke volume index (from 28.5 ± 4.8 to 24.1 
3.6 ml/beat/min.m 2 , p < 0.05) and increased significantly systemic vascular 
resistance (from 1678 ± 185 to 2098 :E 331 dynes.s/cm s, p < 0.05). After 
100% oxygen, FMD significantly decreased from 6.8 ± 1.8 to 2.1 ± 15% (p 
< 0.01) but GTN responses were preserved (t9.7 ~: 3.5% room air vs 18 ± 
4.9 at 100% oxygen, NS). 
Conclusion: In heart failure, hyperoxia shows a detrimental effect on car- 
diac output, stroke volume and systemic vascular resistance. The deleterious 
effect of hyperoxia on vascular function could be mediated by endothelial 
dysfunction. 
• Aging, a Risk Factor, Markedly Cardiovascular 
Increases Expression of Endothelin-1 In Vivo 
Independent of Blood Pressure and Endothelin-1 
Clearance 
Matthias Barton, Thomas Lattmann, Sidney Shaw I , Thomas F. L0scher. 
Cardiology, University Hospital ZOrich, Cardiovascular Research, Institute of 
Physiology, University of ZOrich; ~ Clinical Research, University Hospital 
Bern, Switzerland 
Backgroud: Endothelin-1 (ET-1), a potent vasoconstrictor and mitogen in the 
vasculature and kidney, has been implicated in the pathogenesis of vascular 
and renal disease. The kidney was used to determine whether aging, an 
independent cardiovascular dsk factor, affects ET-1 protein expression in 
vivo and to cladfy the role of blood pressure and ET-1 clearance. 
Methods: Mean arterial blood pressure (MAP) and clearance of radio- 
labeled 1251ET-1 were measured in adult and old male (3 months and 24 
months) and female Wistar rats (6 months and 33 months). Renal cortex 
and medulla were separated, ET-1 protein was extracted using RIA/HPLC 
methods and related to tissue weight (pg/g). 
Results: Adult and old rats were normotensive (MAP male: 90 ± 3 vs. 
92 ± 4 mmHg, n.s.; female: 84 ± 3 vs. 92 ± 7 mmHg, n.s.) and clearance 
of 12SlET-1 was unaffected by aging (n.s.). In male rats, tissue ET-1 protein 
content increased by 230% in the medulla (from 59 ± 5 to 136 • 10 pg/g) 
and by 440% in the cortex (from 32 ± 4 to 143 ± 15 pg/g). In old female rats, 
ET-1 protein increased by 330% in the medulla (from 34 ± 5 to 114 ± 21) 
and by 530% in the cortex (from 54 ± 7 to 287 ± 38 pg/g). All data are p < 
0.05 adult vs. old. 
Conclusion: This is the first study demonstrating that in aging rats (1) a 
marked upregulation of ET-1 protein expression occurs in vivo independently 
of blood pressure and (2) that clearance of ET-1 is not attenuated by aging. 
These data provide further evidence suggesting that activation of ~e ET-1 
pathway is independent of blood pressure. Increased local production of 
ET-1 during the physiological aging process may promote the structural 
changes observed in the vasculature and kidney thereby further accelerating 
the development of vascular and renal disease. 
~ l s  Remodeling Among Major Coronary Different 
Artery Branches? 
Allen Jeremias, Heike Huegel, David P. Lee, Peter J, Fitzgerald, Paul 
G. Yock, Alan C. Yeung. Stanford University Medical Center, Stanford, CA, 
USA 
Background: Coronary artery remodeling has been studied using least dis- 
eased neighboring segments as control. This method however does not allow 
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studying of site specific determinants of remodeling. Our aim is to determine 
if the degree of remodeling is influenced by vessel size or location. 
Methods: We studied 30 patients pre-intervention using intravascular 
ultrasound (IVUS) and measured vessel area (VA), lumen area (LA) and 
plaque area (PA = VA-LA) during motorized pullback at I mm intervals. The 
difference in remodeling was investigated in 14 LAD, 6 LCX, 10 RCA and 18 
left main (LM) coronary arteries. 
Results: A total of 946 cross sections were measured and 658 were 
included in the analysis (LAD = 224, LCX = 94, RCA = 281, LM = 59); 288 
were excluded with a PA < 5 mm 2. There was no significant difference in 
remodeling index (measured by VA/LA) between the LAD and LCX. However, 
both arteries remodeled better than either the RCA or the LM (figure). VA 
was significantly larger for the RCA and LM as compared to the LAD and 
LCX (figure) indicating an inverse relationship between remodeling and VA. 
Linear regression analysis showed a significant correlation between those 
parameters (R = 0.22, p < 0.001). PA was similar in all vessels (LAD: 9.0 + 
3.38, LCX: 8.29 ~E 2.65, RCA: 9.06 :E 3.6, LM: 8.81 ± 2.8). 
Remodeling Index 
- I  1 . . . . .  
J . 
LAD LCX RCA LM 
tt~mt N,*4 N=~II N,,al 
Ve=mel Area 
a 
LAD LCX ItCA LM 
Conclusion: These results suggest that vascular remodeling is increased 
in smaller vessels independent of plaque size. This increased ability to 
remodel is most likely due to increased shear stress at the surface of the 
endothelium. 
101 3-73 1 of Vascular Extracellular Increase Superoxide 
i Dismutase by Pravastatin Treatment 
Tsuyoshi Toyokawa, Hiromi Tasaki, Kazuhito Yamashita, Yoshitaka Nagai, 
Yasuhide Nakashima. Univ. Occup. Environ. Health. Kitakyushu; Tetsuo 
Adachi, Gifu Pharmaceutical Univ. Gifu, Japan 
Background: HMG-CoA reductase inhibitor has been revealed to improve 
the prognosis of ischemic heart disease. Although endothelial-dependent 
vasodilatation is recognized to be a key event for this improvement, its 
mechanism is still controversial. Therefore, this study was attempted to elu- 
cidate the change of extracellular superoxide dismutase (EC-SOD) according 
to the reduction of cholesterol with pravastatin. 
Methods: Thirty hypercholesterolemic patients were treated with pravas- 
tatin (10-20 rag/day) for 12-60 weeks. EC-SOD, tipids in plasma and lipopro- 
tein fractions and apolipoprotein were measured every 12 weeks. EC-SOD in 
plasma was determined by ELISA (anti human EC-SOD) at basal and at post- 
heparin (100 unit/kg b.w.) intravenous injection. The values (post-heparin 
minus basal) was defined as heparin-releesable EC-SOD from endothelium. 
Results: LDL cholesterol significantly decreased from 150.3 42.0 to 135.4 
± 45.8 (mg/dl) with pravastatin (p = 0.03 by student t-test). The % change 
of haparin-releasable EC-SOD was well cor-retated with % change of LDL. 
cholesterol or apo. B. 
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Conclusion: Vascular EC-SOD can disproportion superoxide, resulting 
in keeping the bioavailability of nitdc oxide. This study suggests that the 
increase of heparin-releasable EC-SOD pravastatin treatment might be one 
mechanism for the improvement of endotheiium-dependent vasodUatation. 
1 1013774 1 Testosterone Enhances Brachial Artery Reactivity 
in Men With Coronary Artery Disease 
Giampiero Patrizi, Paul J.L. Ong, William C.F. Chong, Christopher 
S. Hayward, Carolyn M. Webb, Peter Collins. National Heart & Lung 
Institute, Imperial Co#ege School of Medicine, Royal Brompton Hospital 
London, United Kingdom 
Background: Testosterone (T) is assumed to be a risk factor for coronary 
artery disease (CAD) since men have a greater incidence of CAD than women 
of similar age. However, our group has shown that physiological doses of 
male hormone increase coronary blood flow in men with CAD. 
Methods: We conducted a double-blind, crossover study to evaluate the 
effect of acute administration of T on brachial artery reactivity in men with 
angiographically proven CAD. After withdrawal of antianginal therapy for 
4 days, patients (pts) underwent a vascular reactivity study using external 
ultrasound. Brachial artery diameter was measured at baseline and at 1,2, 3 
and 5 minutes after reactive hyperemia. The test was performed 60 minutes 
after the i.v. administration of T (2.3 mg in 10 min) or placebo (P; 1 ml 60% 
ethanol in 10 min) given in a random order. A week later, the treatment was 
crossed over and the procedure repeated. 
16, p=0.015 
o:i 
01 
P T 
Results: Results from 11 male pts (mean ± SD; aged 58 :E 8 years) show 
that the flow-mediated changes in brachial artery diameter between baseline 
and 1 min hyperemic response were significantly greater after the injection of 
T compared to P (5.21 + 0.71 mm and 5.56 ~- 0.7 mm vs 5.31 + 0.5 mm and 
5.47 ± 0.46 mm; T vs P respectively). Percentage increases from baseline 
at 1 rain were 6.86 ± 3.7% vs. 3.16 ± 1.9%; T vs P respectively (p = 0.015) 
(figure). Blood pressure and heart rate did not change throughout he study. 
Conclusion: These data show that acute administration of T enhances 
endothelium-dependent flow-mediated vascular relaxation in men with CAD. 
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1014-1101 Test-Retest of Measurements of Left Reliabil ity 
Ventricular Mass in Single Patients: 
The Reproducibility Echocardiographic Study 
(RES) 
Giovanni de Simone 1 , M. Lorenza Muiesan 2 , Antonello Ganau 3 , 
Carlo Longhini 4, Paolo Verdecchia s , Vittorio Palmieri ~ ,
Enrico Agabiti-Rosei ~ , Giuseppe Mancia 6 . On behalf of the Working Group 
on Heart and Hypertension of Italian Society of Hypertension. Universities 
of r Naples; 2Brescia; 3 Sassari; 4 Ferrara; 5 R. Silvestrini Hospital, Perugia; 
6 University of Milan, Italy 
Background: The ability of M-mode echocardiography to detect serial changes 
in LV mass (LVM) in single patients is still debated, due to method variability. 
A multicenter trial was designed to address the issue of the clinical reliability 
of single-patients repeated measurements of LVM 
Methods: Two M-mode tracings (3 consecutive cycles) were recorded in 
the same session and 3-10 days apart (5 • 2 days) in 261 subjects (45 ± 
13 years, 24.7 ± 3.6 kg/m 2, 50% hypertensive, 50% women) in 16 Centers 
in Italy and read by two observers in each center. Studies were classified by 
a 3-order quality-score (1 = poor, 2 = sufficient, 3 = optimal). 
Results: Average quality-score was 2.08 :E 0.71 (21% poor, 50% suffi- 
cient, 29% optimal). Range of LVM was 56--419g (170 ± 61g). Same day, 
90% interval of agreement (IoA) between tracings 1 and 2 was --28 to 19g 
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for reader I ( -  15 to 10% of 1st tracing, single-measure intraclass correlation 
[ICCr] = 0.977) and -23 to 22g for reader 2 (-17 to 10%, [ICCr] = 0.978). 
For day-to-day, test-retest variability (average 3 cycles) 90%1oA was -25 to 
33g for reader 1 (-18 to 17%, ICCr = 0.958) and -25 to 27g for reader 2 
(-13 to 14%, ICCr = 0.964). In reader 1, test-retest variability was -11 to 
12% at 80%1oA and -9  to 10% at 75%1oA, whereas in reader 2 it was -9  
to 10%, and -8  to 8%, respectively. No relation was found with age, BMI, 
weight, and time between studies. No regression to the mean was identified. 
Conclusion: Thus, serial measurements of LVM in single patients are 
associated to technical variability that needs to be taken into account for 
clinical applicability. The probability of chance is minimized when changes in 
LVM exceed 18% of the initial value, but even differences of 10-12% might 
have clinical relevance. 
1 j Change of Left Ventricular Geometric Pattern 
] 
01 4-1 1 1 
After One Year of Antihypertensive Treatment: 
The LIFE Study 
Bj6rn Dahl6f, Kristian Wachtell, Richard B. Devereux, Jens Rokkedal, 
Vasilious Papademetriou, Markku S. Nieminen, Gunnar Smith. Sahlgrenska 
Hospital-Ostra, Sweden; The New York Hospital-Come# Medical Center, 
Ny USA 
Background: Hypertensive patients left ventricular (LV) hypertrophy have 
different types of abnormal LV geometry. It remains unclear what impact 
antihypertensive treatment has on LV geometry change. 
Methods: Echocardiograms with 2-D and M-mode were recorded at 
baseline in 500 unmedicated patients with stage I-III hypertension and LVH 
determined by ECG (Cornell voltage duration _> 2,440 mm × msec or modified 
Sokolow Lyon: SV1 + RV5/RV6 > 38 mm) after 14 days of placebo treatment. 
A follow-up echocardiogram was done after 1 year of blinded treatment with 
either Iosartan or atenolol, and in some cases supplemented with thiazide 
and calcium antagonist in Order to reach target blood pressures (BP) of 
140/90 mmHg. 
Results: Prevalence of concentric hypertrophy (CH) decreased from 26 
to 7%, eccentric hypertrophy (EH) from 44 to 37%, concentric remodeling 
(CR) from 10 to 9% and normal geometry (N) increased from 20 to 47% A 
shift towards lover LV mass and relative wall thickness (RWT) was found (e.g. 
67% CB shifted to N, whereas only 9% N shifted to CR. 31% CH shifted to EH, 
whereas only 5% EH shifted to CH). Baseline systolic BP was reduced from 
172 ± 21 to 148 - 19 mmHg, diastolic BP from 95 i 11 to 84 ± 10 mmHg. 
RWT was reduced from 0.41 ± 0.07 to 0.38 ± 0.06. LV mass was reduced 
from 231 ± 54 to 207 ~ 49 g (all p < 0.001) Furthermore multiple regression 
analysis showed that stroke volume reduction was an independent predictor 
of LV mass reduction (8 = 0.38, p < 0.001) and change in BP did not enter 
into the model. 
Conclusion: Antihypertensive control reduces LV mass and decreases 
the prevalence of LV hypertrophy and CR. Control of stroke volume strongly 
potentiates the effect of BP reduction on LV mass reduction independently 
of the BP reduction per se. 
I1014-11  / Ventricular Mass and 
] 
2 Relationship Between Left J Day or Nighttime Blood Pressure in 649 Patients 
With Treated Essential Hypertension 
Luc H. Missault, Marc L. De Buyzere, Daniel A. Duprez, Denis L. Clement. 
University Hospital Gent, Belgium 
Background: Controversy exists regarding the relative influence of daytime 
vs. nighttime blood pressure (BP) on left ventricular mass (LVM). We eval- 
uated (Spearman rank) correlations between echocardiographic parameters 
of LVM and both day- and nighttime ambulatory BP in 649 patients with 
treated essential hypertension. 
Results: 
SD LVD PWD LVM 
Office SBP 0.12"" 0.10" 0.07 0.14"'" 
Office DBP 0.07 0.04 0.04 0.07 
24 hr SBP 0.23*** 0.05 0.16-" 0.19-* 
24 hr DBP 0.16"** -0.01 0.10"* 0.11" 
day SBP 0.21 **" 0,05 0,15"* 0.17"- 
day DBP 0.14*** -0.01 0.07 0.08" 
night SBP 0.22"- 0.05 0.15"** 0.19"** 
time DBP 0.16"*" 0.01 0.11" 0.13"** 
* = p < o.o5;** = p < O.Ol;*"" = p < 0.0Ol; 
SD = septum diastole; PWD = posterior wall; LVD = left ventricular in- 
ternal diameter. In treated HT, the septum is thicker than the posterior wall. 
Measured wall thickness correlates better with BP than calculated LVM does 
because no relation exists between BP and LVD. Wall thickness correlates 
better with ambulatory than with office BP, better with SBP than with DBP and 
better with nighttime than with daytime BP. However both day- and nighttime 
pressure influence wall thickness so that the best overal correlation is found 
with 24 hr SBP. 
Conclusion: In this largest single study on the relationship between 
BP and LVM, nighttime BP correlates better with LVM than daytime BP, 
in accordance with the finding that "dippers" have better prognosis than 
"non-dippers". 
1 3| Left Ventricular Mass in Normotensive Black 
/ 
01 4-1 1 J 
Patients With a Hypertensive Response to 
Stress Testing 
Sameer Sofat, Kyung S. Kim, Bernice Jackson, Charles L. Curry. Howard 
University Hospital, Washington DC, USA 
Objective: To determine the relation between left ventricular (LV) mass and 
an exaggerated BP response to exercise stress testing in black patients with 
no history of hypertension. 
Background: Left ventricular hypertrophy is an early manifestation of 
end organ damage caused by hypertension and is associated with increased 
mortality. Thus, eady identification of patients at increased risk for the devel- 
opment of LV hypertrophy would be clinically useful. 
Methods: Retrospective study in which 69 normotensive black patients 
(34 male and 35 female) who underwent exercise stress testing were anal- 
ysed. 2D echocardiography was utilized to determine LV mass. Nineteen 
patients had a hypertensive response to stress testing. Patients were divided 
into 2 groups based on the presence or absence of increased LV mass (LV 
mass index > 150g/m2 in males and > 120g/m2 in females). Hypertensive 
response to exercise stress testing was defined as a > 10 mmHg increase 
in systolic BP per met. 
Results: Increased LV mass was associated with a hypertensive re- 
sponse to exercise (p = 0.0002), increased left atrial size (p = 0.005) and 
inversely associated with exercise duration (p = 0.04). Increased LV mass 
was also positively associated with the systolic BP achieved at peak exercise 
(OR 1.07, 95% CI: 1.02-1.14, p = 0.029) and to the difference between rest 
and peak systolic BP (OR 1.05, 95% CI: 1.01-1.10, p = 0.03). 
Conclusion: In black patients with no history of hypertension we found 
a positive association between increased LV mass, increased LA size and a 
hypertensive response to exercise. In addition, there is an inverse relation- 
ship between LV mass and exercise duration. Hypertensive responders who 
do not have LV hypertrophy may warrant careful observation for possible 
development of this disorder. Further studies are needed to determine the 
benefit of therapy in patients with a hypertensive response and increased LV 
mass. 
1 I Brain Peptide as an Early Marker 
I 
01 4-1 1 4 Natriuretic of 
Cardiac Dysfunction and LV Remodeling in 
Newly Found Hypertensives 
Willem F. Terpstra, Johan F. May, Dirk Jan van Veldhuisen, 
Frans Boomsma, Andries J. Smit, Pieter A. de Graeft, Harry J.GM. Crijns. 
Groningen Hypertension Service, Academic Hospital Groningen and 
Academic Hospital Rotterdam, The Netherlands 
Background: Plasma Atrial Natriuretic Peptide (ANP) and Brain Natriuretic 
Peptide (BNP) have emerged as markers for the detection of LV dysfunction 
and remodeling. The purpose of this study was to determine the relation- 
ship between these natriuretic peptides and cardiac endorgan damage in 
previously untreated, elderly hypertensives. 
Methods: From a population survey 178 previously untreated elderly hy- 
pertensives (4 × systolic blood pressure > 160 mmHg and/or diastolic blood 
pressure > 95 mmHg), aged 60 to 75 years with 53% male were included. 
Exclusion criteria: heart failure, angina pectoris, diabetes mellitus and ar- 
rhythmias. LV function and geometry were measured by echocardiography 
Results: ANP and BNP were both related to left ventricular mass index 
(r = 0.2; p <: 0.05 and r = 0.2; p < 0.05 respectively). Multivariate regression 
analysis using the backward method identified LVMI as an independent 
determinant for ANP. For BNP, besides LVMI, Early to Atdal velocity ratio 
of transmitral Doppler flow (E/A) and IsoVolumetric Relaxation Time were 
identified as independent determinants (Stand. Beta: 0.15, 0.16 and 0.17 
resp; P < 0.05). 
Conclusion: Increase of ANP is related to LV mass enlargement, whereas 
an increase of BNP is not only related to LV mass enlargement but also with 
diastolic dysfunction. For the detection of hypertensive patients prone to 
heart failure BNP seems a promising marker. 
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I1014-11 5 1 Diastolic Left Ventricular Dysfunction Precedes 
J Remodeling in Newly Found Elderly 
Hypertensives 
Willem F, Terpstra, Robbert Meerwaldt, Johan F. May, Andries J. Stair, 
Pieter A. de Graeff, Harry J,G.M. Cdjns. Academic Hospital Groningen and 
Groningen Hypertension Service, The Netherlands 
Background: Diastolic function is influenced by hypertension. Little is known 
about diastolic function in hypertensives without left ventricular remodeling. 
The purpose of this study was to compare diastolic function in a group of 
newly found elderly hypertensives having normal left ventricular geometry 
with a group of matched normotensive controls. 
Methods: From a population survey we measured left ventricular ge- 
ometry with 2D mode echocardiography in 183 newly found hypertensive 
patients, between 60 and 75 years of age. Hypertensive patients with Left 
Ventricular Mass Index (LVMI) < 125 g/m2 and Relative Wall Thickness < 
0.45 were considered to have normal geometry. A total of 49 hypertensive 
patients had normal geometry (prevalence 27%) and were compared to a 
group of sex-, age-, and weight-matched normotensive controls. Diastolic 
function was measured with pulsed Doppler echocardiography in the stan- 
dard apical view with sampling volume placed between the tips of the mitral 
valve leaflets. Peak velocity of Early filling (E) and Atrial filling (A), Deceler- 
ation Time of Early filling (E-DT) and Atrial filling (A-DT) and IsoVolumetric 
Relaxation Time (IVRT) were measured. Early to Atrial filling (E/A) ratio was 
calculated. 
Results: See table. 
Mean ± SD Nomlotensives (n = 45) Hypertensives (n = 49) 
LVMI (g/m 2) 76± 11 106± 12 '1' 
F_.JA Ratio 0.94 ± 0.20 0.79 5:0.21 • 
A (m/sec) 0.69 ± 0.11 0,77 ± 0.17 ~ 
E (rNsec) 0,63 ± 0.09 0.59 ± 0.15 NS 
EDT (msec) 198 ± 26 223 ± 43 ° 
ADT (msec) 92 ± 8 99 :E 11 • 
WRT (msec) 88 ± 9 103 ± ~4 ,L 
~P < 0.05 e,p < 0.01 ~'P < 0.001 (Independent T-test) 
Conclusions: In the absence of disturbed left ventricular geometry elderly 
hypertensives have higher left ventricular mass index and marked diastolic 
dysfunction compared to normotensives. The latter is mainly due to delayed 
relaxation of the left ventricle associated with an increased atrial contribution 
to filling, potentially predisposing for atrial fibrillation. 
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[ 1015-11 6 ) Depressed Coronary Disease Patients Derive 
More Improvement in Quality of Life from 
Coronary Revascularization 
Chen Y. Tung, Lai Choi Lain, Nancy Clapp-Channing, Redford Williams, 
Daniel B. Mark. Duke Clinical Research Institute, Durham, NC, USA 
Background: Depression has been shown to be an independent predictor 
of coronary disease outcomes. However, whether depressed patients derive 
similar quality of life (QOL) benefit from coronary revascularization is unclear. 
Methods: We prospectively studied 812 patients with cath-proven coro- 
nary disease treated with either PTCA or CABG. Baseline depressive symp- 
toms were assessed using the Center for Epidemiological Studies - Depres- 
sion scale (CES-D: depressed > 16). QOL as measured by Duke Activity 
Status Index (DASh range 0-58) and SF-36 (range: 0-100) were obtained 
at baseline and one year. 
Results: 
PTCA (n = 396) CABG (n = 416) 
CES-D DASt* SF-36" DASr SF-36" 
Base 1Yr Base 1Yr Base 1Yr Base 1Yr 
<16 29 29 67 68 27 29 63 69 
16 17 21 43 52 13 21 40 54 
"Mean values presented, P values for improvement of QOL from baseline to 1 year for 
depressed vs. non-depressed patients are < 0,03. 
Conclusion: Patients who are depressed prior to coronary revasculariza- 
tion have lower baseline QOL but derive significantly greater improvement 
in QOL after 1 year than non- depressed patients. However, despite the 
improvement, depressed patients continued to have lower QOL at 1 year. 
I1 5-1 J A View of the Bridge: The Effectiveness of 
I 
Ol 1 7 
Interventions to Improve Cardiovascular Care 
Daniel B. Stryer, Carolyn Clancy. Agency for Health Care Policy and 
Research, Rockv/Ife, MD, USA 
Background: Interventions to bridge the gap between knowledge and prac- 
tice have proliferated recently. Systematic assessment of their effectiveness 
has received far less attention, however. This study assesses the published 
literature of interventions to improve cardiovascular care to identify tech- 
niques of successful quality improvement projects. 
Methods: Citations were obtained through a MEDLINE search using 
terms including "quality of health care," "intervention" and "cardiovascular 
diseases" and review of references from related articles. Studies were se- 
lected if they were in English and evaluated the effects of interventions 
intended to alter provider behavior. Extracted data included: publication year, 
intervention(s), technique for control and result Categorization of interven- 
tions was based on a published taxonomy (Oxman, 1995). 
Results: Inclusion criteria were met by 53 publications, including 31 pub- 
lished after 1992. Overall, 66% reported successful interventions to improve 
practice or outcomes. Since 1992, interventions have been more success- 
ful than those published eadier (80% vs. 45%, p < 0.01). However, since 
1992, 55% of the studies used a pre/post design, only one of which was 
negative, Of the randomized, quasi-randomized or crossover studies, 64% 
were positive. The most common interventions were report cards and distri- 
bution of educational material. There was no association, however, between 
practice improvement and intervention type. Also, for the 40% of studies re- 
porting use of a combination of interventions, no association existed between 
improvement and intervention number. 
Conclusion: The bridge from knowledge to practice is not yet complete. 
Despite an increasing number of studies and success, additional well con- 
trolled studies are needed to identify consistently successful strategies to 
improve cardiovascular care. 
I1 / Costs Over 8 Years in the Emory Angioplasty vs 
7 
01 5-1 1 8 
Surgery Trial 
William S. Weintraub, Edmund R. Becker, Patrick D. Mauldin, Andrzej 
S. Kosinski. Emory Universi~ Atlanta, GA, USA 
Background: In the EAST trial 392 patients with multivessel coronary artery 
disease were randomized between 1987 and 1990 to coronary surgery 
(CABG) or PTCA. At 3 years there was no difference in the primary endpoint, 
the composite of death, a large reversible thallium defect or a Q wave MI. 
There were more additional revascularization procedures in the PTCA arm. 
Methods: Hospital charges were assessed from the UB92 version of 
the hospital bill and reduced to costs by departmental cost to charge ratios. 
All physician charges for each episode of care were summed to estimate 
professional costs. Costs were inflated to 1997 dollars using the Medicare 
inflation rate. Costs are available for the initial hospitalization and follow-up 
CABG or PTCA on 366 patients. 
Results: The initial total hospital cost was $27,793 zE 21,236 with PTCA 
vs $41,785 ± 11,526 with CABG (p < 0.0001). Over the follow-up period, 
the costs converged (see figure), due to more additional revascularization 
procedures after PTCA, such that by 3 years there was no longer a significant 
difference in cost. At 8 years, total cost was $44,491:5 27,462 with PTCA vs 
$46,337 i 15,056 with CABG (p = 0.42). 
5O 
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Conclusion: While medical care and costs have changed dramatically 
during the follow-up period for EAST, this study suggests that additional 
procedures negate the initial cost advantage of PTCA, For patients requir- 
ing revascularization, cost should not guide the choice between PTCA and 
CABG. 
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1015-119]  Local  Bed Capacity is Associated With 
Probability of Readmission: A Study of 6,752 
Coronary Artery Bypass Surgeries in New 
England 
Paul D. McGrath, David E. Wennberg, F. L. Lucas, Andrea E. Siewers. Div 
of Health Services Research, Maine Medical Center, Portland, ME, USA 
Background: Readmission after hospitalization for CABG may be related to 
patient characteristics and quality of care. Local hospital bed capacity may 
also influence readmissions by lowering the threshold to readmit. 
Methods: We used Medicare Part A data to identify all patients who 
underwent CABG in New England during 1994-95 and their subsequent 
admissions. The 166 Hospital Service Areas (HSAs) were categorized into 
tertiles based on hospital beds per capita. Cox proportional hazards models 
estimated the relative risk of readmission associated with local bed capacity 
controlling for patient and CABG admission characteristics. 
Results: Overall, 33% of patients were readmitted at least once during the 
six months following their CABG admission. Controlling for patient/hospital 
characteristics, patients living in HSAs with higher bed capacity were more 
likely to be readmitted than patients from low capacity HSAs, relative hazard 
= 1.18 (95% CI 1.05-1.34). 
Readmission Following CABG 
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Conclusion: Readmission rates following CABG are driven in part by the 
capacity/bed availability of a patient's local health care system. This is an 
important limitation in the use of readmission as an indicator of quality. 
1 01 5-1 ] Does Transoperative Right 20 Heart Catheterization 
Reduce Cardiac Complications After Noncardiac 
Surgery? 
Luis E. Rohde, Lee Goldman, Cadsi A. Polanczyk, E. Fran Cook, Thomas 
H. Lee. Brigham & Women's Hospital, Boston MA; University of San 
Francisco, San Francisco, CA, USA 
Background: Few prospective studies have evaluated whether patients 
managed with dght heart catheterization (RHC) during non-cardiac surgeries 
have reduced complication rates. 
Methods: From 4315 consecutive patients who underwent elective major 
non-cardiac procedures, 220 matched pairs who were managed periepera- 
tively with and without RHC were studied. To control for treatment selection 
bias, patients were matched on the propensity for use of RHC and type of 
surgical procedures, using multivariate logistic regression. A reviewer blinded 
to preoperative data classified the occurrence of major postoperative cardiac 
events. 
Results: Major cardiac events occurred in 48 (11%) patients. The propen- 
sity for use of RHC was similar between cases and controls (0.174 vs. 0.175; 
p = 0.97). In paired analysis, there was no significant difference (all p > 
0.10) in baseline clinical charactedstics between cases and controls with 
regard to age, cardiovascular risk factors, previous cardiovascular morbidity, 
medications, functional status and preoperative laboratory profile. Patients 
managed perioperatively with RHC were at increased risk for major postop- 
erative cardiac events (OR 2.3, 95%CI 1.2-4.6) and congestive heart failure 
(OR 2.1,95%CI 1.1-4.0). Although there was no difference in transoperative 
hypotensive or hypertensive episodes between cases and controls, patients 
managed with RHC had higher maximal perioperative heart rate (94 ± 18 vs. 
87 ± 16 bpm; p < 0.01) and net intravenous fluid intake (3.2 ± 3.0 vs. 2.0 ± 
1.2 L; p < 0.01) than patients without RHC. 
Conclusion: We were unable to demonstrate evidence of benefit as- 
sociated with use of perioperative RHC in this population. Because of the 
morbidity and the high costs associated with RHC, the impact of this inter- 
vention in transoperative care should be evaluated in randomized trials. 
[ 1015-121 ] Estimation of Operating Room Costs for 
Coronary Artery Bypass Graft Surgery 
Timothy J. Bell, Saif S. Rathore, Kevin P. Weinfurt, Kevin A. Schulman. 
Clinical Economics Research Unit, Georgetown University Medical Center, 
Washington, De, USA 
Background: Operating room costs and factors influencing operating room 
utilization remain poody characterized for coronary artery bypass graft (CABG) 
surgery, we compare the results of time-and-motion and procedure-based 
evaluations of CABG operating room costs. 
Methods: We evaluated 180 patients who underwent CABG at a private 
academic health center between July 1996 and May 1997. Time-and-motion 
(HOUR) and procedure (PROC) cost models were developed to calculate 
operating room costs due to labor, materials (supply) and perfusion. Physician 
labor costs were calculated houdy and on a procedure basis for the HOUR 
and PROC models respectively. Supply costs for both HOUR and PROC 
evaluations were based on average CABG supply costs. Peffusion costs 
in both models were a fixed fee per case. Operating room costs from both 
models were compared by t-test and regression analysis for association with 
number of vessels grafted, 
Results: Median CABG operating room costs were $4,167 (25th--75th: 
$3,791--$4,532) by the HOUR model and $5,803 (25th--75th: $5,267--$6,326) 
by the PROC model. Paired t-test analysis indicated costs varied significantly 
by model (HOUR: ~ = $4,195 vs PROC: Y = $5,289, p < 0.0001 ). Further, total 
OR costs were significantly correlated (p < 0.0001) with number of vessels 
grafted. Incremental vessel costs were $303 (HOUR) and $398 (PROC). 
Conclusion: Estimates of coronary artery bypass graft costs vaded sig- 
nificantly between two estimation models. Further efforts should focus on 
development of a consistent framework for assessing operating room costs. 
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1040-20 ] Dose Vitamin E Decreases Arterial Wave High J 
Reflection and Improves Ventricular/Vascular 
Coupling 
Sherry Jouei, Shailesh J. Patel, Wilmer W. Nichols, Cad J. Pepine, Jawahar 
L. Mehta. University of Florida, Gainesville, Florida, USA 
Background: Early return of wave reflection from peripheral reflecting sites 
augments systolic pressure and increases left ventricular afterload. Such 
changes are attributable to arterial stiffening and increased pulse wave ve- 
locity (PWV). The aim of this study was to determine if high dose vitamin E 
(Vit E) influences central systolic arterial wave reflection and alters artedal 
blood pressure. 
Methods: High-fidelity carotid artery pressure waveforms were recorded 
noninvasively by applanation tonometry and the extent of systolic wave 
reflection estimated by the augmentation index (defined as the amplitude 
of the pressure wave above its systolic shoulder to the pulse pressure) 
in 26 individuals; 12 were healthy volunteers and 14 were patients with 
coronary artery disease without heart failure. Thirteen individuals received 
Vit E (800 IU/day) for 4 weeks and the other 13 received placebo (randomized 
double-blind). 
Results: The Vit E group included three healthy subjects and 10 patients 
while the placebo group included nine healthy subjects and four patients. 
There was no difference in age between the two groups (53 ± 19 vs 48 i 16 
yrs., p = NS). Vitamin E influenced a decrease in augmentation index from 
0.19 ± 0.1 to 0.09 ± 0.05 (p < 0.05) indicating decreased wave reflection 
from the pedphery. This change in wave reflection was associated with a 
decrease in systolic pressure from 141 ± 20 to 129 ± 11 mmHg (p _< 0.01). 
The placebo group did not show these benefits. 
Conclusions: High dose vitamin E for 4 weeks reduces systolic arterial 
wave reflection and decreases systolic pressure. These changes are likely 
due to increased arterial compliance and decreased PWV. 
[ 1040-21 i Midkine (MK) Plays a Crucial Role in Neointimal 
i i Formation 
Mitsuru Hodba, Kenji Kadomatsu, Takashi Muramatsu, Makoto Hirai, 
Hidehiko Saito. Nagoya University School of Medicine, Japan 
Background: MK is a heparin-binding rowth/differentiation factor which was 
found as a product of a retinoic acid-responsive gene. MK exerts mitogenic 
activity on some ceil lines, enhances plasminogen activator activity on bovine 
endothelial cells, and has been implicated in tissue repair, In the present study 
we examined the profile of the MK expression in rat carotid artedes following 
balloon injury, and analized vascular remodeling with neointimal formation in 
normal and MK-deficient mice. 
Methods: After rat carotid arteries were injured with Fogarty 2 F balloon 
catheter, they were harvested at 3 hours, 3 days, 7 days and 14 days. MK 
expression was evaluated by RT-PCR, competitive PCR, Western blotting, 
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and immunohistochemistry. The arteries of mice were completely ligated 
just proximal of the carotid bifurcation to disrupt blood flow. After 14 days 
morphometric analysis of arterial sections was performed. To further comfirm 
the MK's role in neointimal function, MK protein and saline (as the controls) 
were continuously infused by the use of osmotic pump into MK-KO mice. 
Results: MK expression was induced, reaching a maximum around 7 
days, following balloon injury in the rat carotid arteries. MK protein was 
localized in the neointima. The similar expression mode was observed in 
the mouse carotid arteries following ligation. The neointimal formation was 
dramatically supressed in MK-KO mice, as compared to that in wild-type 
mice. Moreover, the continuous infusion of MK protein into MK-KO mice 
increased both the frequency and degree of the neointimal formation. 
Conclusion: MK is a crucial molecule in the neointimal formation. 
~ Endothelin-1 Induces Protein Mitogen-Activated 
Kinases in Smooth Muscle Cells Through a 
Radical Sensitive Mechanism 
J6rg Kreuzer, Jianwei Fei, Martina Werle, Lisa Watson, Lothar Jahn, 
Christiane Viedt. Medizinische Klinik Iit, Universit~t Heidelberg, Germany 
Background: Endothelin (ET-1) has been proposed to contribute to plaque 
rupture in coronary heart disease. As activation and inflammatory response 
of vascular smooth muscle cells (SMC) has been implicated in plaque desta- 
bilization the effect of ET-1 on activation of SMC was studied. Induction of 
a number of proinflammatory genes is mediated through mitogen activated 
protein (MAP) kinases. Therefore in the present study the effect of ET-1 
on MAP kinases c-Jun amino terminal kinase (JNK) and extracellular signal 
regulated kinase (ERK) in SMC was investigated. 
Methods: Rat VSMC were exposed to ET-1 for different imes at concen- 
tration from 10 6-10-1° M. MAP kinase activity was quantitated by West- 
ern blotting, immunocomplex kinase assay and translocation of kinases as- 
sessed by immunocytochemistry. 
Results: Treatment of rat VSMC with ET-1 resulted in an activation of 
JNK and ERK with a maximum stimulation at a concentration of 10 - 7 M. In 
response to ET-1, ERK showed the fastest response with a peak activation 
at 5 minutes. The activity of JNK increased 15 min after addition of ET-1 
and went back to baseline at 60 min. ET-1 Receptor antagonist BQ 123 
prevented activation of MAP-Kinases. Addition of tyrosine kinase inhibitor 
genestein inhibited activation of ERK and JNK. ET-t mediated activation of 
JNK but not ERK was sensitive to the radical scavenger N-acetylcysteine 
indicating a role of oxygen radicals for activation of JNK. Activity of both 
kinases was decreased by wortman~n and PD97059, an inhibitor of MAP 
kinasekinase. 
Conclusion: The data indicate a differential, ET-1 dependent mechanism 
of MAP-Kinase activation. Whereas JNK was preferentially activated through 
oxygen radicals, ERK activation appeared to be independent of radical for- 
mation. Activation of MAP-kinases in SMC may be one of the underlying 
mechanisms of plaque destabilization by ET-1- 
10•4•-2--• Characterization of Retinoblastoma Control Initial Element and Sp3 Protein in Smooth Muscle 
Differentiat ion 
Li Fan, Keith L. March. Krannert Institute of Cardiology and Roudebush 
VAMC, Indianapolis, IN, USA 
We have previously shown that conditionally transformed vascular SMC 
(TsT-SMC) from transgenic mice expressing a temperature-sensitive mutant 
SV40 T antigen (TAg) under control of the mouse SM alpha-actin promoter 
possess the capability of differentiation upon TAg inactivation and release of 
RB protein. We hypothesize that RB control element (RCE) within the smooth 
muscle myosin heavy chain (SM-MHC) promoter and its DNA-protein com- 
plex may be associated with smooth muscle differentiation. A putative RCE 
was identified located from -65 and -60 bp relative to SM-MHC transcrip- 
tion start site, within sequences identified as necessary for full transcription. 
Electrophoretic mobility shift analysis (EMSA) using a radiolabeled SM-MHC 
RCE probe indicated three specific DNA-protein complexes in TsT-SMC 
extracts. A rapidly migrating, major complex at 33~C was significantly dimin- 
ished and a more slowly migrating complex become predominant upon TAg 
inactivation at 39.5-°C. These complexes were competed with 50-fold excess 
molar of unlabeled RCE probe. Transient transfection of 175 nt 5' SM-MHC 
promoter-luciferase plasmid paralleled with immunoblotting analysis of RB 
demonstrated that the RCE-containing promoter activity increased at 39.5 
C was accompanied by increase in expression of RB protein and shift in 
complex pattern. Sp3, rather than RB, was identified as one of complex 
components. Moreover, RCE complexes were also found in vivo in smooth 
muscle extracts; SP3 protein was decreased while SM-MHC gene expres- 
sion was increased during mouse SM development. These data suggest that 
RCE may be an important element for SM-specific transcription; Sp3 may, 
as found previously, act as a represser for the gene expression; pRB might, 
via mediating Sp3 function, regulates SM differentiation in vivo and in vitro. 
• Cyclic Adenosine Monophosphate Is a More 
Potent Inhibitor of Human Vascular Smooth 
Muscle Cells Than Cyicic Guanosine 
Monophosphate mdash; An In Vitro Comparison 
of Anti-Proliferative SignaI-Transduction 
Alexander S. Sasse, Juergen v. Dahl, Peter Hanrath. University Clinic 
RWTH Aachen, Germany 
Background: Intracellular signal transduction of multiple receptors and sub- 
stances in vascular smooth muscle cells (VSMC) are in part mediated through 
the activation of adenosine- and guanosine-cyclases resulting in an increase 
of cellular cyclic adenosine-monophosphate (cAMP) or cyclic guanosine 
monophosphate (cGMP). This signal transduction is also involved in the 
activation of protein kinases and the regulation of cellular proliferation. 
Methods: Cells were cultivated by explantation from human lilac artery 
and aorta, VSMC were identified by immunohistochemistry. Proliferation was 
assessed by determination of bromodeoxyuridine (pyrimidine analogue) in- 
corporation in DNA (BrdU), by cell number and through a tetrazolium-for- 
mazan assay measuring mitochondrial dehydrogenase activity (XTT). 
Results: The cyclic monophosphate analogues 8-Br-cGMP and Dibu- 
tyryl-cAMP (DB-cAMP) as well as the phosphodiesterase inhibitor isobutyl- 
methyl-xanthine (IBMX) were incubated over different periods of time with 
proliferating human VSMC. DB-cAMP decreased growth to 35.6% (1.0 mM, 
p < 0.001), 8-Br-cGMP to 49.1% (1.0 mM, p < 0.001) and IBMX to 34.2% 
(1.0 mM, p < 0.001). Results from other methods (BrdU, cell count) parallel 
the presented results. 
OD 
1.0 VSMC-proliferation (XTT) 
t and DB-cAMP in mM 
0.5 ~ ~_ ! 
0,0 ~ ~ - mM 
0 0.5 1 
Conclusion: Cyclic monophosphates result in a time- and close-depen- 
dent growth inhibitory effect on human VSMC in vitro, while cAMP is more ef- 
fective than cGMP. These pathways of receptor-mediated signal transduction 
might allow the treatment of hyperproliferative VSMC reactions in processes 
such as post-interventional restenosis and post-transplant vasculopathy. 
• cAMP-Dependent Phosphorylation Increases PN 
200-110 Binding to DHP Receptor During 
Membrane Depolarization 
Kaoru One, Masafumi Yano, Takeshi Yamamoto, Takayuki Hisaoka, 
Taketo Tanigawa, Michihiro Kohno, Tomoko Ohkusa, Masunori Matsuzaki. 
Second Department of Internal Medicine, Yamaguchi Universi~ Japan 
Background: In cardiac muscle, excitation-contraction (E-C) coupling is ini- 
tiated when depolarization permits calcium to enter the myoplasm through 
voltage-dependent calcium channels (DHP receptor) in the sarcolemma. 
Several evidences have suggested that the channel gating of DHP recep- 
tor may be augmented by a cAMP-dependent phosphorylation, however it is 
unclear whether this phosphorylation effect is modified by the degree of depo- 
larization. The objective of this study is to assess the depolarization-induced 
change in the binding of a specific ligand, PN 200-110 to DHP receptor with 
or without cAMP-dependent phosphorytation. 
Methods and Results: The microsomal fraction of canine cardiac muscle 
enriched in diads were isolated. T-tubule in diads (n = 6) was first polarized 
by incubating the diads (0.4 mg/ml) with 5 mM ATP in a solution of 150 mM 
K gluconate, 5 mM MgCI2, 20 mM imidazol, 15 mM NaCI (pH 7.1), 1 mM 
EGTA-Ca buffer (5 t~M free [Ca2+]), and 0.5 nM [3H]PN 200-110. Then, using 
filtration method, T-tubule was chemically depolarized by a replacement of 
the solution from 150 mM K gluconate to 150 mM Na gluconate. By the 
depoladzation of T-tubule, the number of [3H]PN 200-110 binding (nmol/mg) 
was increased from 99 ± 5 to 107 i 2, p < 0.05. In the presence of 5 mM 
cAMP together with 10 units cAMP dependent protein kinase, the difference 
in the [3H]PN 200-110 binding between polarization and depolarization was 
significantly increased by 15% (p < 0.05). Ten mM Monensin (membrane 
ionophore), which inhibits polarization and also the following depolarization, 
abandoned the enhancement of the [3H]PN 200-110 binding by cAMP. 
Conclusion: The cAMP-dependent phosphorylation on DHP receptor 
is more effectively operated during deporarization than during polarization, 
which may contribute to the increase in carcium transient during action 
potential phase. 
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~ Vascular Endothelial Growth Factor-C Fails to 
Induce Fibrovascular Growth 
James J. Jang, Hoai-Ky V. Ho, John P. Cooke. Stanford University School of 
Medicine, Stanford, CA, USA 
Background: Vascular endothelial growth factor-C (VEGF-C) has been pro- 
posed as a selective inducer of lymphangiogenesis, which may be mediated 
by an increase in nitric oxide (NO) production, similar to VEGF induced anglo- 
genesis. Asymmetric dimethylarginine (ADMA), an endogenous competitive 
antagonist of NO synthase, is known to be elevated in known vascular dis- 
orders associated with atherosclerosis and may now have implications in 
lymphatic disorders. 
Methods: To study the effects of ADMA on VEGF-C, we used a disc an- 
giogenesis system (DAS). The DAS consisted of a synthetic polyvinyl alcohol 
disc which was implanted subcutaneously in normal female C57BL/6J mice. 
Inside the center of the disc, we placed (a) control (PBS), (b) ADMA (100 
mmol), (c) VEGF-C (20/~g), and (d) VEGF-C (20/~g) + ADMA (100 retool) in- 
side a pellet which was coated with a copolymer to allow a controlled release 
of the agent. After 14 days, the disc was extracted and sectioned to character- 
ize and measure for growth. Using basic immunohistochemistry techniques, 
we used a CD31 antibody to stain for both blood and lymphatic vessels. To 
distinguish blood from lymphatic vessels we injected luconyl blue dye into 
the carotid artery prior to euthanizing the mice. Vessel growth occurred cen- 
tripetally into the disc and was quantitated through morphometric analysis. 
Results: 
Pellet Agent Fibrovascular Growth Area (mm2) 
Control (PBS) 12.2 ± 3.6 
ADMA (100 mmol) 4.3 ± 1.2 (p < 0.007) 
VEGF-C (20 ,~g) 11.2 ± 0.2 (NS) 
VEGF-C (20 ~4g) + ADMA (100 mmol) 6.0 ± 0.5 (p < 0.01) 
Conclusion: VEGF-C does not increase fibrovascular growth or reverse 
the anti-angiogenic effects of ADMA in an in vivo disc angiogenesis assay. 
~ Chronic Receptor Antagonism EndotheUa 
Preserves Coronary Endothelial Function In Vivo 
in Experimental Hypercholesterolemia 
Patricia J.M. Best, David Hasdai, David R. Holmes, Jr., Amir Lerman. Mayo 
Clinic and Foundation, Rochester, MN, USA 
Endothelin-1 (ET) alters vascular tone via stimulation of the ETA and ETB re- 
ceptors. Experimental hypercholesterolemia is associated with impaired coro- 
nary endothelial function and elevated ET. This study tested the hypothesis 
that chronic ET receptor antagonism preserves coronary endothelial func- 
tion in experimental hyperchotesterotemia. Acetylcholine (10-s-10 4 M) was 
serial infused into the coronary artery in 3 groups of pigs at baseline and 
after 12 weeks high-cholesterol diet (HC). Group 1 received no additional 
drug therapy, Group 2 received RO 48-5694, an ETA/ATB receptor antago- 
nist, and Group 3 received ABT-627, an ETA receptor antagonist. Percent 
change in coronary artery diameter (~CAD) and coronary blood flow (~,CBF) 
were calculated based on quantitative coronary angiography and intracoro- 
nary Doppler. At 12 weeks, total cholesterol was significantly and similarly 
increased in all groups (Group 1, baseline: 77 ~E 4 mg/dL, 12 weeks: 444 + 48 
mg/dL). 
Coronary vascular measurements with infusion of acetylcholine 10 4M after 12 weeks 
high-cholesterol diet 
Measurement Group 1 Group 2 Group 3 
(No Drug (ETA/ET B Receptor (ET A Receptor 
Therapy) Antagonist) Antagonist) 
% ~. CBF -41.6 ± 10.7 -4.7 ± 11.9" 11.4 ± 7.4" 
% ~. CAD -13.2 ± 5.1 -5.1 ± 1.9" -3.8 ± 3.8" 
*p < 0.05 vs. Group 1 
The table demonstrates that chronic ET receptor antagonism preserves 
coronary endothelial function in hypercholesterolemia n vivo. 
Conclusion: This study supports the rote for ET in the pathogenesis 
of endothelial dysfunction. Moreover, ET receptor antagonism may have a 
therapeutic role in hypercholesterolemia. 
~ T h e  ETA Receptor Antagonist LU 135252 Prevents 
the Progression of Established Pulmonary 
Hypertension Induced by Monocrotaline in Rats 
Jocelyn Dupuis, Stephane Prie. Montreal Heart Institute, Montreal, Quebec, 
Canada 
Background: An imbalance between the nitric oxide (NO) and endothe- 
lin systems may contribute to the development of pulmonary hypertension 
(PH). We evaluated the effect of the specific ETA receptor antagonist LU 
135252 (LU) in rats with established monocrotaline (MCT)-induced PH and 
the involvement of NO in the control of pulmonary vascular tone. 
Methods and Results: Two weeks after MCT, rats developed PH with a 
right ventricular pressure (RVP) of 42.3 + 8.5 vs. 28.2 ± 4.1 mmHg for con- 
trols (mean ~ SD, p < 0.05). Daily oral therapy with LU (50 mg/kg) or saline 
was started 2 weeks post-MCT injection for 20 days. LU non-significantly 
increased the survival rate from 41.7% to 66.7%. The surviving MCT + saline 
rats showed severe PH (RVP of 82.5 i 8.9 mmHg) and RV hypertrophy with 
a right-to-left ventricle + septum weight ratio of 69.6 i 10.2%, which were 
improved by LU to 53.5 i 11.1 mmHg and 53.7 ~ 9.9% respectively (p < 
0.01). The lungs were isolated to obtain pressure-flow curves: pulmonary 
vascular compliance was reduced by PH and unaffected by LU therapy. After 
the NO synthase inhibitor L-NNA (10 4 M), compliance was further reduced 
although much less in the LU-treated group (p < 0.01). 
Conclusion: In this model of established PH, ETA antagonist herapy has 
a favorable effect on survival and pulmonary hemodynamics and reduces 
the dependency on NO for the attenuation of reduced pulmonary vascular 
compliance. 
~ Advanced Glycation End Products Inhibit the 
Stimulation of Nitric Oxide Synthase by Histamine 
in a Human Endothelial Cell Model 
Albert Ferro, Biao Xu. Department of Clinical Pharmacology, King's College 
London, St Thomas' Campus, London, England 
Background: Advanced gtycation end products (AGEs) accumulate in dia- 
betes, and may be responsible for many of the vascular abnormalities seen 
in this condition. The aim of the present study was to determine whether 
AGEs affect nitric oxide synthase (NOS) activity, in isolated human vascular 
endothelial cells. 
Methods: AGE-medified bovine serum albumin (AGE-BSA) was pre- 
pared by incubating glucose 50 mM in phosphate-buffered saline (PBS) with 
bovine serum albumin (BSA) 2 g/L and EDTA 1 raM, for 12 weeks at 37-°C, 
under sterile conditions, followed by dialysis against PBS. Confluent human 
umbilical vein endothelial cells (HUVEC) at passage 3 were incubated in 
PBS containing AGE-BSA 200 mg/L, native BSA 200 mg/L or vehicle, for 
20 min, in the presence or absence of an anti-AGE antiserum (anti-AGE) at 
1:750 dilution. Histamine f 0 ~M or vehicle was added for a further 20 min. 
[3H]L-citrulline was isolated from extracts by ion-exchange chromatography 
and counted. All experiments were done in quadruplicate, and results are 
shown as mean • SEM. 
Results: Basal [3 H]L-citrutline production was 360 ± 29 dpm/#g protein (n 
= 11). This was unchanged when cells were incubated with AGE-BSA either 
alone or in the presence of anti-AGE. Histamine increased [3H]L-citrulline 
production by 32.7 + 4.1% above basal (P < 0.001), and this increase 
was abolished by co-incubation with AGE-BSA. In the combined presence 
of AGE-BSA and anti-AGE, the increase in [SH]L-citrulline production by 
histamine was restored (24.6 ± 5.9% above basal, P < 0.001). Native BSA 
had no effect on the response to histamine. 
Conclusions: AGE-BSA prevents stimulation of NOS by histamine in HU- 
VEC. Such an effect on stimulated endothelial NOS activity may explain our 
recent observation that AGE-BSA inhibits endothelium-dependent relaxation 
to acetylcholine, in rabbit aortic rings in vitro. 
~ Raloxifene Relaxes Rabbit and Human Acutely 
Coronary Arteries In Vitro by an 
Endothelium-Dependent Mechanism 
Gemma A. Figtree, Ying-qing Lu, Carolyn M. Webb, Peter Collins. Imperial 
College School of Medicine at National Heart & Lung Institute, London, UK 
Selective estrogen receptor modulators (SERMs) have tissue specificity with 
regard to estrogenic actions, and appear to share the beneficial effect of estro- 
gen on bone and tipids, but are not associated with an increased risk of breast 
or uterine carcinoma. The effects of SERMs on the coronary vasculature is 
unknown. We therefore investigated the effects of the SERM Raloxifene (R) 
on isolated rabbit and human coronary arteries (CA). Epicardial CA rings of 
male and female rabbits and male humans were suspended in organ baths 
for measurement of changes in isometric tension. The endothelium (endo) 
was denuded in alternate rings. R induced significant relaxation of CAs from 
rabbits precontracted by PGF2,, (3 ~M) (mean + SEM; 18 + 5", 37 + 7"", 
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78 ± 6"'*, 94 ± 5"" %, -7, -6.5, -6, -5.5 togM respectively; "P < 0.05, "'P 
< 0.01, *"P < 0.001; n = 11-13), and from human males precontracted by 
U46619 (30 nM) (18:1: 5, 37 ± 13, 46 ± 14", 53 ± 12"* %; n = 8). R-induced 
relaxation in dngs with endo was significantly greater than in rings without 
endo in both rabbits (14 ± 2", 42 ± 7"-, 75 ± 7-* %; -6.5, -6, -5.5 IogM 
respectively; n = 9-11) and humans (5 ± 3, 7 ± 4", 13 ± 3- %; -6.5, -6, 
-5.5 IogM respectively; n = 6 = 8). L-NAME significantly reduced R-induced 
relaxation in rings with endo from rabbits (18 ± 9", 53 :E 9" %; -6.5, -6  IogM 
respectively; n = 9-11 ). BaCI also significantly inhibited R-induced relaxation 
in rabbit rings with endo (40 ± 10"* %; -6  IogM; n = 3), but not in rings 
without endo (n = 6). ICI 182,780 significantly inhibited R-induced relaxation 
in rabbit rings with endo (14 ± 4", 36 ± 5"", 65 ± 11"%; -6.5, -6, -5.5 
respectively; n = 6), but not in rings without endo (n = 6-8). There was no 
difference between relaxation in rings from male and female rabbits. Calcium 
(Ca ++) concentration-dependent contraction curves (4, 3.5, 3, 2.5, 2 - IogM 
Ca ÷+) in K + depolarization medium were shifted to the right compared with 
control (25 ± 5, 43 ± 6, 63 ± 5, 86 ± 3, 100 ± 0 % maximum contraction; 
n = 11) after incubation with R (-6 IogM) (2 ± 2, 4 ± 3"", 12 ± 6"", 32 ± 
6"'*, 57 ± 8""%; n = 7) and R (-6.5 IogM) (9 ± 3, 20 ± 5", 40 ± 8", 67 ± 
10", 84 ± 9%; n = 9) in dngs without endo. We have demonstrated the R 
induces significant endo-dependent relaxation in isolated rabbit and human 
CA. This appears to be mediated by a NO and estrogen receptor-dependent 
mechanism. At higher doses R may directly affect calcium conductance in 
the vascular myocyte. 
I1 J Asymmetric Dimethylarginine Inhibits Basic 041 ~31 Fibroblast Growth Factor Induced Angiogenesis 
James J. Jang, Hoai-Ky V. Ho, John P. Cooke, Stanford University School of 
Medicine, Stanford, CA, USA 
Background: Induced angiogenesis by basic fibreblast growth factor (bFGF) 
has been shown to be mediated through a nitdc oxide (NO) synthase path- 
way. Asymmetric dimethylarginine (ADMA), an endogenous competitive an- 
tagonist of NO synthase has been found to be elevated in many disorders 
associated with atheroscleresis. We hypothesized that ADMA may be an 
endogenous anti-angiogenic factor. 
Methods: To study the effects of ADMA on bFGF induced angiogenesis, 
we used a disc angiogenesis system (DAS), The DAS consisted of a synthetic 
polyvinyl alcohol disc which was implanted subcutaneously in normal female 
C57BL/6J mice. Inside the center of the disc, we placed control (PBS), ADMA 
(10 mmol, 100 mmol), bFGF (20/zg), and bFGF (20 #g) + ADMA (100 mmol) 
inside a pellet which was coated with a copolymer to allow a controlled 
release of the agent. After 14 days, the disc was extracted and sectioned to 
charectedze and measure for growth. Vascular growth occurred centripetally 
into the disc and was quantitafed through morphometdc analysis. 
Results: 
Pellet Agent Fibrovascular Growth Area (ram 2) 
Control (PBS) 12.2 ± 3.6 
ADMA (10 mmol) 7.2 :I: 1.6 (p < 0.04) 
ADMA (100 mmol) 4.3 ± 1.2 (p < 0.007) 
bFGF (20/~g) 23.3 ± 4.0* 
bFGF (20/~g) + ADMA (100 mmol) 12.3 ~- 4.0* (p < 0.006) 
Conclusion: By competitively inhibiting NO synthase, ADMA significantly 
blocks fibrovascular growth even in the presence of bFGF. In disorders as- 
sociated with atherosclerosis, elevated ADMA may have a significant impact 
in the induction of native or therapeutic angiogenesis, 
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11042-671 The Effects of Short Term Passive Smoke 
i Exposure on Endothelium-Dependent and 
Independent Vasodilation 
Masahiko Kato, Philip Roberts-Thomson, William G. Haynes, Bradley 
G. Phillips, Virend K. Somers. University of Iowa Hospitals, Iowa Ci~ 1,4, 
USA 
Background: Little is known about the mechanisms mediating the deleteri- 
ous effects of passive smoke exposure. We tested the hypothesis that acute 
exposure to sidesfream (passive) smoke impairs endothelium-dependent 
vasodilation in healthy nonsmokers. 
Methods: We studied 12 healthy nonsmokers (age 27 ± 5 years, 9 males 
and 3 females). We obtained measurements of BP, HR, and bilateral forearm 
blood flow (FBF). Each subjects was studied twice, following a randomized, 
placebo controlled design. Effects of passive smoke were studied on one day 
and effects of vehicle (room air) on a separate day. Acetylcholine (ACh) and 
sodium nifroprusside (SNP) were infused into the left brachial artery before 
and after 15 minutes of exposure to either passive smoke (CO concentration 
20 and 40 ppm) or vehicle (room air). The order of ACh and SNP, and smoke 
or vehicle was randomized between subjects. 
Results: Smoke exposure increased carboxyhemoglobin from 0.5 ± 0.1% 
to 1.0 ± 0.1% in the passive smoke session (p = 0.002). Neither passive 
smoke nor vehicle changed baseline measurements of HR, BP and forearm 
vascular resistance (FVR). The vasodilatory responses to each of ACh and 
SNP were very similar both before and after exposure to passive smoke and 
before and after vehicle. Figure shows % change in ratio of left to right FVR. 
0 .~% change L/R FVR 
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Conclusion: Passive smoke does not alter responses to intra-arterial 
infusion of either ACh or SNP. Acute short-term exposure to passive smoke 
does not acutely impair endothelium-dependent or endothelium-independent 
vasodilation in healthy nonsmokers. 
J 1042-68 l Vascular K+ATP Channels, Nitric Oxide and 
Human Forearm Reactive Hyperemia 
Alan J. Bank, Ronald T. Sih, Kathleen Mullen, Paul Lee. University of 
Minnesota, Minneapolis, MN, USA 
The contribution of vascular ATP-dependent potassium (K+ATP) channels 
to human reactive hyperemia and their interaction with nitric oxide have not 
been well characterized. Reactive hyperemic blood flow responses follow- 
ing 5 minutes of cuff occlusion were measured using strain-gauge plethys- 
mography in 22 normal human subjects age 42:1:2 years. Measurements 
were obtained at baseline and following intra-arterial administration of the 
K+ATP channel closer glibenclamide, the nitric oxide (NO) synthase inhibitor 
L-N-monomethyl arginine (L-NMMA), or both drugs simultaneously. Gliben- 
clam±de (100 mg/min) did not change basal flow (2.7 :E 0.3 to 2.7 ± 0.3 
ml/min/dt) but significantly (p < 0.01) decreased hyperemic flow (18.2 ± 1.3 
1o 14.8 ± 1.3 ml/dl) and excess flow (5.3 ± 1.2 to 1.3 ± 1.3 ml/dl). L-NMMA 
(8 mmol/min) significantly (p < 0.05) decreased basal flow (3.3 ± 0.5 to 2.5 
± 0.3) and hyperemic flow (21.2 ± 1.8 to 18.9 ± 1.9) and tended to decrease 
excess flow (6.1 ± 2.2 to 3.9 :I: 2.5). Combined drug infusion significantly (p 
< 0.01 ) decreased basal flow (3.3 ± 0.5 to 2.5 ± 0.3), hyperemic flow (21.6 ± 
2.2 to 18.0 ± 2.4) and excess flow (6.3 ± 1.6 to 1.6 :E 1.6) with reductions in 
hyperemic and excess flow similar to those following glibenclamide infusion 
alone. 
Conclusion: Forearm vascular K+ATP channels are closed at baseline. 
They open and contribute to reactive hyperemic vasodilation. The addition 
of NO inhibition to K+ATP channel blockade does not result in additive or 
synergistic inhibition of reactive hyperemia. 
J 1042-69 I Studies of Brachial Artery Flow-Mediated 
Vasodilation Using a Continuous Echo-Tracking 
Ultrasound Technique 
Alan J. Bank, Daniel R. Kaiser, Shailesh Shetty, Scott M Rajala. University 
of Minnesota, Minneapolis, MN, USA 
Non-invasive measurement of endothelial function in humans has been per- 
formed using external ultrasound techniques. However, the time course and 
detailed characteristics of the vasodilator esponse to increased blood flow 
have not been fully described. We have utilized an echo wall-tracking sys- 
tem (PIE Medical) to continuously record the brachial artery diameter for an 
80-second period starting 10 seconds prior to the release of a forearm cuff 
inflated to supra-systolic pressure for 5 minutes. A stereotactic device was 
used to hold a 7.5 MHz transducer. We studied 9 normal human subjects 
(mean age 38.7 ± 11.4, range 28-61). A typical response is shown. Average 
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baseline diameter was 4.02 ± 0.20 mm. Percent diameter increase was 5.44 
± 0.68. The peak vasodilator response occurred at 39.5 ± 2.9 seconds. The 
30-second area (starting at initial dilation) under the diameter vs. time curve 
was 262 ± 36 mm*s. Reproducibility studies performed 10 minutes apart 
showed the following differences (p = NS) in mean ± sem values: baseline 
diameter 0.045 ± 0.023 mm (1.1% of mean), percent diameter increase 
-0.051 ± 0.026 (0.9% of mean), time to peak -2.3 ± 1.1 sec (5.8% of 
mean), and 30 second area 8.4 ± 4.2 mm*s (3.2% of mean). 
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Conclusion: We describe a new technique for measuring brachial artery 
flow-mediated vasodilation which provides high reproducibility, continuous 
tracking of vessel diameter, and detailed characteristics of the vasodilator 
response. 
[ 1042-701 Coronary Vasomotion and Stenting 
Willibald Maier, Adrian K0ng, Lazar Mandinov, Bernhard Meier, Otto 
M. Hess. Cardiology, University Hospital Bern, Switzerland 
Purpose: About half of all PTCA cases are completed by stenting for me- 
chanical stabilization of the dilated vessel segment. The purpose of the study 
was, therefore, to evaluate the effect of stenting on coronary vasomotion 
during dynamic exercise. 
Methods: Biplane quantitative coronary angiography was performed in 
26 patients with coronary artery disease at rest and during bicycle exercise. 
Twelve patients had single vessel disease with stable angina pectoris (con- 
trois) and 14 patients had undergone coronary stenting 9 ± 3 months prior 
to the examination. Patients with restenosis were excluded. Minimal luminal 
area, stent area, as well as proximal and distal (normal) vessel segment area 
were determined in all patients. 
Results: In controls, stenosis vasoconstriction ( 15 ± 5%, p < 0.001) 
occurred during exercise, whereas the normal segment showed vasodilation 
(+13 ~ 3%). Stented vessel segments showed no change of cross-sectional 
area (CSA) during exercise, but coronary vasomotion of the proximal (+9 ± 
2, p < 0.005) and distal (+12 ± 3%, p < 0.005) segments was preserved. 
Nitroglycerin induced maximal vasodilation of stenotic and normal segments. 
16[ 
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Conclusions: The loss of local coronary vasomotion induced by stenting 
is accompanied by an adequate vasomotor reponse of the proximal and 
distal vessel segment. Thus, exercise-induced stenosis vasoconstriction is 
abolished by stenting, but the loss of vasomotion is limited to the length of 
the implanted stent and is not propagated to the adjacent vessel segments. 
11042-711 Debunking the Yuppie Habit: Cigars and 
Endothelial Function 
Minerva Santc-Tomas, Francisco Lopez-Jimenez, Harry R. Aldrich, 
Gervasio A. Lamas, Eric H. Lieberman. Mount Sinai Medica/Center, Miami 
Beach, Florida, USA 
Cigar smoking has become a fast growing trend particularly among teenagers 
and young adults. The purpose of this study was to determine whether cigar 
smoking, like cigarette smoking, affects flow-mediated vasodilation in healthy, 
non-smoking young adults. 
Methods: Healthy, non-smoking and normotensive young adults were 
assigned to either a cigar smoking group (n = 12) or a control group (n = 10). 
High-resolution ultrasonography was used to measure endothelium-depen- 
dent, flow-mediated vasodilation as percent diameter increase in the brachial 
artery diameter during post-occlusion hyperemia. Endothelial-independent 
vasodilation using sublingual nitroglycerin was measured ten minutes follow- 
ing hyperemia. All participants had a baseline study in the morning and a 
follow up study within 2 hours. In study subjects, hyperemia was measured 
immediately following cigar smoking. 
Results: Participants were 32 ± 3 years of age, 79% male. Baseline 
percent diameter increase in the brachial artery following reactive hyperemia 
and nitroglycerin was similar in both groups (7% vs. 10%, p = 0.3 and 22% 
vs. 23%, p = 0.7, respectively). Follow-up studies revealed a 2% diameter 
increase with hyperemia after cigar smoking in study patients and a 10% 
increase in controls, p = 0.05. Values following nitroglycerin, however, were 
similar in both groups, 25% vs. 19%, p = 0.3. 
Conclusion: Cigar smoking acutely impairs endothelium-dependent, flow- 
mediated brachial artery dilation but has no effect on endothelium-indepen- 
dent vasodilation. These results suggest that cigars are not an innocuous 
alternative to cigarette smoking. 
~ C a n  Magnesium Sulfate Suppress 
Acetylcholine-lnduced Coronary Spasm in 
Patients With Vasospastic Angina? 
H. Teragawa, M. Kato, H.Y. Fukuda, H. Hirao, T. Yamada, Y. Muraoka, 
T. Yamagata, H. Matsuura, G. Kajiyama. First Dept. of Internal Medicine, 
Hiroshima University Hiroshima, Japan 
Previous studies have indicated that deficiency of magnesium (Mg) is related 
to the mechanism of coronary spasm. However, little is known about whether 
Mg can prevent coronary spasm. We examined whether Mg suppressed 
acetylcholine (ACH)-induced coronary spasm in patients with vasospastic 
angina (VSA). 
Methods: Coronary spasm was induced by intracoronary infusion of 
ACH (30 #g/min or 100/~g/min over 2 min) in 19 patients (pts) with VSA. Ten 
minutes after spontaneous relief of coronary spasm, magnesium sulfate (0.27 
mmoi/kg body weight) was intravenously infused in 14 pts and 5% glucose 
was infused over 20 minutes as a control in 5 pts. Then, intracoronary infusion 
of ACH was repeated. The luminal diameter of epicardiat coronary arteries 
was assessed by quantitative angiography. 
Results: Serum total Mg increased from 0.83 ± 0.01 to 2.38 ± 0.06 
mmol/I (p = 0.001 ) and ionized Mg increased from 0.48 ± 0.06 to 1.24 ± 0.29 
mmol/I (p = 0.001) after Mg infusion. Chest symptoms were less frequent 
after Mg infusion (before: 9 of 14 pts; after: 3 of 14 pts, p = 0.0219). At the 
26 spastic sites, the change in diameter induced by ACH decreased from 
-66.3 ± 16.3% at baseline to -42.4 ± 28.1% after Mg infusion (p = 0.0206), 
while the values did not change in 7 spastic sites in the 5 control pts (-55.6 
± 6.4% at baseline, -65.2 ± 25.4% after 5% glucose, p = 0.1886). 
Conclusions: These results suggest that Mg may suppress ACH-induced 
coronary spasm in patients with VSA, although this effect is modest. 
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1 I Counterbalances the Action the 
I 
043-73  Vitamin E of  
i Phosphatase InhibitorCyclosporine A (CsA) on 
the Na÷-K + Pump 
Mahidi Mardini, Susie Mihailidou, Helge Rasmussen. Cardiology 
Department Royal North Shore Hospital St Leonards Sydney, Australia 
Background: The balance between effects of protein kinases and protein 
phosphatases determines the phosphorylation state of the membrane Na+-K ÷ 
pump. Phosphorylation in turn determines function. We previously found that 
in vivo treatment with the phosphatase inhibitor CsA inhbits the Na +-K + pump 
of rabbit cardiac myocytes. As vitamin E (Vit E) can cause inhibition of protein 
kinases we wished to examine if treatment with Vit E can counterbalance 
the effect of the phosphatase inhibitor CsA to induce pump inhibition. This 
effect of Vit E might be important for treatment of the CsA toxicity common in 
clinical practice. 
Methods: We studied 3 groups of rabbits: an untreated control group, a 
group treated with 10 mg/kg/day CsA s.c. and a group treated with both CsA 
and 500 IU Vit E by oral gavage. Rabbits were killed after 7 days and single 
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ventricular myocytes were isolated. The myecytes were voltage clamped 
with wide-tipped patch pipettes filled with solutions which included 10 mM 
Na +, a concentration near physiological intracellular levels. Pump current 
(Ip), a result of the 3:2 Na÷:K ÷ exchange ratio, was identified from the shift 
in holding current induced by pump blockade with 100 #M ouabain. Ip is 
reported normalized for membrane capacitance and hence cell size. 
Results: Mean Ip of myocytes isolated from control rabbits was 0.33 ± 
0.03 pAJpF (n = 11) while mean Ip of myocytes from rabbits treated with CsA 
was 0.19 ~ 0.03 pNpF (n = 11). The difference was statistically significant. 
Mean Ip of myocytes treated with both CsA and Vii E was 0.37 4- 0.05 pA/pF 
(n = 12). This was significantly greater than mean Ip of myocytes treated with 
CsA only. 
Conclusion: Na+-K + pump inhibition induced in vivo by treatment with 
CsA can be abolished by cotraatment with Vit E. 
~ T h e  Effects of Cyclosporine-A on Apoptosis and 
p53 Expression in Human Cardiomyocytes 
Hong Song, Koichi Seta, John V. Conte Jr., Chiming Wei. University of 
Maryland, Baltimore, MD, USA 
Background: Cyclosporine-A (CsA) is the most widely used immunosup- 
pressant drug in heart, lung and kidney transplantation. However, the effects 
of CsA are limited by a significant cytotoxic action. Cellular apoptosis is 
being suggested as a possible mediator of CsA toxicity. To date, regarding 
the effects of CsA on apoptosis and apoptosis-related genes expression in 
cardiomyocytes remain unclear. Therefore, the present study was designed 
to investigate the effects of CsA on cardiomyocytes apoptosis and p53 ex- 
pression. 
Methods: Human cardiac atrial tissue was obtained from open-heart 
surgery (n = 6). The cardiac tissue was minced and incubated in the special 
tissue culture system for 24 hours in the absence or presence of CsA (10 6 
M). To detect he DNA fragmentation, TUNEL study was performed. The p53 
level in cardiomyocytes was determined by immunohistochemical staining 
(IHCS). An average of 1000 nuclei was analyzed for both TUNEL and p53 
IHCS studies. 
Results: TUNEL and IHCS studies demonstrated that CsA increases 
apoptosis and p53 expression in human cardiomyocytes. The results of 
TUNEL and p53 staining are shown in the table. 
Control (n = 6) CsA (n = 6) 
TUNEL (%) 7.3 ± t .9 33.4 ± 3.4" 
p53 (%) 6.3 rE 1.8 35.0 ± 3.6" 
Mean ± SE; "p < 0.001 vs Control. 
Conclusion: This data indicated that CsA induces apoptosis in human 
cardiomyocyles through p53-dependent pathway. Therefore, apoptosis may 
be a mediator of cellular toxicity of CsA. 
~ Induction Early AfterdepolarisaUons of  and 
Torsade de Pointes by Macrolid-Antibiotics in the 
Isolated Rabbit Heart 
Lars Eckardt, Thomas Cron, Robert Johna, Paulus Kirchhof, 
Martin Borggrefe, G0nter Breithardt, Wilhelm Haverkamp. Dept. of 
Cardiology and Inst. of Arteriosclerosis Research, University of MOnster, 
Germany 
Background: Intravenous administration of macrolid-antibiotics, which block 
the outward time-dependent potassium current, may cause life-threatening 
arrhythmias uch as Torsade de Pointes (TDP). To investigate the underlying 
mechanism and to compare different macrolid-antibiotics we studied the 
dose-dependent proarrhythmic effects of erythromycin (E) and clarithromycin 
(C) in a recently developed model of acquired TDP. 
Methods: Conditions that are clinically known to be associated with TDP 
such as bradycardia and hypokalemia were simulated in either sinus-driven 
or AV-blocked isolated rabbit hearts. E and C were infused in the presence 
of normal and low potassium. TDP was defined as a polymorphic ventricular 
tachyarrhythmia of more than 5 beats arising form abnormal T/U-complexes 
with a changing ventricular axis and spontaneous termination. 
Results: E and C led to a dose-dependent increase in QT-interval and 
monophasic action potential (MAP) duration. In sinus-driven hearts (n = 13) 
no arryhthmias occurred irrespective of drug dose and potassium concentra- 
tion. In AV-blocked hearts (n = 14), no arrhythmias occurred with 30 #M or 
50/~M E and C. In 4 out of 9 hearts 100/~M E led to repetitive episodes of 
TDP in the presence of low potassium whereas 2 out of 5 C-perfused hearts 
developed TDP. All hypokalemic and bradycardic hearts demonstrated ven- 
tricular salves (less than 5 ectopics) and TDP when treated with 150 #M E 
or C. Endo- and occasionally epicardial MAPs demonstrated early afterde- 
polarizations (EAD) that corresponded to markedly pronounced T/U waves 
and the initiation of TDP. 
Conclusion: (1) Clinically relevant doses of macrolid antibiotics can in- 
duce TDP in rabbit hearts. (2) E and C have a similar proarrhythmic potential. 
(3) EADs which are more prominent in endocardial sites are the most likely 
underlying mechanism. 
~ N O  Mediated Positive Inotropic Effect in Isolated 
Myocytes 
David Sarkar, Patrick Vallance, Sian Harding. National Heart and Lung 
Institute, Imperial College, London, UK 
Background: The effect of nitric oxide (NO) donors on myocyte contractile 
function remains controversial with studies reporting both positive and neg- 
ative inotropic effects. To investigate further we exposed isolated guinea pig 
and human myocytes to a range of NO donors at physiologically relevant 
concentrations. 
Methods: Guinea pig and human myocytes were prepared by enzymatic 
digestion. Paced contractile amplitude was recorded at 37°-C using an edge 
detection system, sampling at a frequency of 100 Hz. 
Results: On a background of low dose isoproterenol (0.3 nM) the con- 
tractile responses to 1-100 #M S-nitrosoglutathione (GSNO), S-nitroso-N- 
acetyl penicillamine (SNAP), glyceryl trinitrate (GTN) and Papanoate were 
recorded. Compared with isoproterenol alone 10 /~M of NO donor signifi- 
cantly increased contraction amplitude: GSNO 72 ± 9% (mean ± SEM, p 
< 0.001, n = 6); SNAP 116 -- 23% (p < 0.01, n = 7)) and papanoate 90 
± t1% (p < 0.001, n = 6). GTN at 1-100 #M had no effect. The positive 
inotropic responses were rapid, sustained and reversible. Exposing cells to 
100 #M 1 H-[1,2,4]oxadiazolo [4,3-alpha]quinoxalin-l-one (ODQ), a soluble 
guanylyl cyclase inhibitor, did not abolish the positive response to GSNO, 
whilst the cGMP analogue 8Br-cGMP did not mimic it. The positive effect 
was unchanged in the presence of thapsigargin but reversibly inhibited by 
the free NO scavenger oxyhaemaglobin. Preliminary studies in ventricular 
myocytes from failing human hearts showed a similar increased contraction 
with GSNO (n = 3 patients). 
Conclusion: Isolated guinea pig myocytes showed a marked positive 
inotropic effect with certain NO donors including GSNO. This was mediated 
by free NO via a mechanism independent of soluble guanylyl cyclase. The 
positive inotropic effect of GSNO coupled with its vasodilating and antiplatelet 
properties makes it of therapeutic interest. 
• Ticlopidine Hypoxia-lnduced Collagen Inhibits 
Types I and Ill Expression in Cardiac Fibroblasts 
Chang-Fu Peng, Eckhard P. Kromer, G0nter A.J. Riegger, 
Heribert Schunkert, Andreas V. Sigel. Klinik und Poliklinik f(Jr Inhere Medizin 
II, Universit&t Regensburg, Germany 
Background: Ticlopidine serves as an important tool to prevent subacute 
stent thrombosis via inhibition of platelet aggregation. In addition, we have 
recently shown that ticlopidine significantly decreases the proliferation and 
transforming growth factor beta 1-induced collagen types I and III mRNA 
expression in cardiac fibroblasts. However, its effects on cardiac fibroblasts 
during hypoxia, which is responsible for the remodeling process in the heart, 
is yet unknown. 
Methods: For this purpose we used a new cell culture model of hy- 
poxia and reoxygenation. Rat cardiac fibroblasts were cultured in 2% 02 
for 24 hours to produce hypoxic conditions and then exposed to 20% 02 
for additional 12 hours to simulate reoxygenation. Drug treatment started 
2 hours prior to hypoxia either with 50 ,~M ticlopidine or vehicle for the 
entire duration of hypoxia and reoxygenation. We investigated protein pro- 
duction by 3H-phenylalanine incorporation and Western blot, RNA synthesis 
by 3H-Uridine incorporation, DNA synthesis by 3H-thymidine incorporation 
and mRNA expression by Northern blot. 
Results: In this cetl culture model hypoxia showed a significant decrease 
of DNA synthesis by 60% (p < 0.05) and RNA synthesis by 23% (p < 0.05). 
Protein synthesis, however, remained unchanged. In addition, reoxygenation 
further decreased both DNA- and RNA synthesis, whereas protein synthesis 
was stimulated by 66% (p < 0.05). Next, collagen types I and III mRNA 
expression increased by 43% (p < 0.05) and 93% (p < 0.05), respectively, 
during hypoxia. However, ticlopidine administration during hypoxia prevented 
from hypoxia-induced collagen type I mRNA induction by 49% (p < 0.05). 
Finally, northern hybridization also displayed a significant protection form 
collagen type III mRNA expression by 78% (p < 0.05). 
Conclusion: We, therefore, conclude that ticlopidine significantly inhibits 
hypoxia-induced collagen types I and III mRNA expression in cardiac fibrob- 
last. The change of collagen mRNA expression may reflect a direct effect of 
ticlopidine on cardiac fibroblasts, which represent the cellular source for car- 
diac matrix protein production. Given the fact that collagen type I represents 
the major extracellular matrix protein in the heart, ticlopidine may represent 
a powerful tool to prevent extracellular remodeling during ischemic periods 
in vivo. 
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• C~OSO((C CaIc{um (s (ncreased in Patients W{th 
Left Ventricular Hypertrophy 
Peter A. Brady, Jose R. Lopez, Nancy Linares, Andr~ Terzic. Venezuela and 
Mayo Clinic, Rochester, MN, USA 
Despite advances i~ ~herap~ m~rtality from ee, d-sta~e conges~ve heart fail- 
ure (CHF) remains high. Therefore, understanding of the cellular mechanisms 
of eady heart failure, prior to the onset of overt CHF, is important. Cardiomy- 
ocyte hypertrophy (CH) is a frequent finding in early CHF and is believed to 
lea~ ~D 6)as~DS]c bys'~un~)on a b mcT~ase6 hs~n o'~ suOben beach, c~mmon 
in I:atfen/s with CHF. However, the cellular alterations associated with CH 
are incompletely understood. Evidence from patients with end-stage CHF 
suggests that increased intracellular calcium ([Ca2+],) may play an impor- 
tant role. However, it is unknown whether increased {Ca2+]i in such patients 
is secondary to membrane depolarization or cell damage, or whether it is 
due to CH. To resolve this, we measured [Ca2+]i and membrane potential 
simultaneously using double-barreled Ca2+-selective microelectrodes, in 14 
patients with CH due to aortic stenosis, and 16 patients with mdral stenosis 
without CH, who served as controls. No patients had CHF or were taking 
medications known to affect [Ca2+]~. Cardiomyocytes which were damaged, 
or in which resting membrane potential was abnormal, were excluded from 
anaiy ~s~ ,~K-~a r,, "~-'~1 t 'P~ [~,~'-~' ,va~3 " @Ei' 2- ,~  ,'a'~1' ~'P = 4'~" ;l'p p'~1 ~'a'~" ,~ittv ;~  
pertrephied cells versus 106 :t: 2 nM (n = 48) in controls (p < 0.0001). Levels 
of [Ca2+]i correlated with increasing ventricular mass (coefficient 0.94). 
Conclusion." Cardiomyocyte hypertrophy is associated with significant 
increase in [Ca2+]i which correlates with ventricular mass. Such an increase 
in (~)as'~6~¢)T.;a~-~'~}~ cod~b unbefJ~e)m.I)~i)reb ven'~hctI~ar rC,}axal)on anb artn.-~n- 
further study. 
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I 1044-110] The Effects of Nifedipine on Systemic 
Sympathetic Activity 
John D. Parker, Eduardo R. Azevedo, Gary E. Newton, May Chan, Corey 
B. Toal. University of Toronto and Bayer Inc, Toronto, Ontario, Canada 
B~a,~;c~,v~. • 7 ,~,~ff~,,t,~ , ~,~,'~,;,~ ,l~;~v~,~ , i~  ~,~"~ 'av~ @.a',,.v,.jn~,;i~',,.~ 
on the sympathetic nervous system remain poorly understood. 
Methods: 40 pts with stable CAD were randomized to receive Nifedipine 
(Nit) GITS (n = 15, 60 mg daily), Nit capsule (n = 16, 10 mg TID) or placebo 
(n = 9) for 7-10 days. All pts were receiving #-blockers. On the final day, 
femoral and pulmonary pressures were measured prior to, and for 6 hours 
after, the 8 AM dose. Total body norepinephdne spillover (TBNESP) was 
measured from artedal plasma using radiotracer methods. 
Results: Pulmonary pressures were unchanged. Cardiac output and HR 
were significantly increased after Nit capsule. Nit capsule also caused a 
marked fall in MAP (-20 4- 4 mmHg) which was greater than that observed 
with GITS or placebo. The peak change in TBNESP from time 0 was sig- 
nificantly greater after Nit capsule than that observed with GITS or placebo. 
The effect of Nit treatment on TBNESP varied as a function of time. With Nit 
GITS it occurred later. 
P2" 
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Conclusions: Nif administration, particularly in short-acting formulation, 
is associated with increases in sympathetic activity dudng chronic therapy. 
1 "{ I Ang(otens(n Convert(n~ 3 Enzyme inhibit{on 044-  
Improves Endothelial Dysfunction in Chronic 
Cigarette Smokers 
Robert Butler, Andrew D. Mords, Allan D. Struthers. Ninewe//s Hospital and 
Medical School, Dundee, UK 
Background: ACE inhibitors have been shown to improve mortality in heart 
failure and left ventricular dysfunction and improve endothelial dysfunction 
in subjects with coronary artery disease, diabetes and in hypedipidaemia. 
~J~are~e smo~qp causes enbo~e~aJ ~vs'~unChDn, '~now seems a;D, Dro, Dh- 
ate to examine whether ACE inh(bitors im~reve endothelial dysfunction (n 
smokers. 
Methods: We treated 23 subjects (mean age 38 + 12 years) for eight 
weeks with 20 mg of lisinopril in a randomised, placebo controlled, double 
blind, cross over study. Endothe/ial funct/on was assessed by venous occlu- 
sion plethysmography using intra-artedal infusions of endothelial-dependent 
(acetylcholine) and independent (sodium nitroprusside) vasodilatore and en- 
dothelial-dependent (L-NMMA) vasoconstrictor. 
Findings: Forearm vascular response: Lisinopdl significantly increased 
the forearm blood flow response to acetyleholine (3.12 4, 1.76 vs. 2.58 4. 
1.21 ml/100 mls/min lisinopril vs. placebo; p = 0.02, 95% CI 0.09, 1.06); 
1.87 vs. 3.92 4, 1.85 mV100 mls/min lisinopril vs. placebo; p = 0.84, 95% 
CI -0.50, 0.61). The vasoconstrictor response demonstrated a significant 
improvement o monomethyI-L-arginine (L-NMMA) (0.77 4. 0.27 vs. 0.95 4- 
0.19 ml/100 mls/min lisinopril vs. placebo; p < 0.001, 95% CI -0.09, -0.27). 
,~. ~..,~-~. ~= %q~, .  
Interpretation: These results indicate for the first time that ACE inhibition 
improves endothelial dysfunction in cigarette smokers. Usinopdl may cause 
less ang II induced superoxide radicals which can inactivate NO or because 
of changes in bradykinin metabolism. ACE inhibitors may have beneficial 
anti-atherosclerotic effects in at risk patients with endothelial dysfunction 
who are unable, or unwilling, to stop cigarette smoking. 
1 I Contribution of Bradykinin to the Vasodilator 
I 
044-1 1 2 
Effects of Enalapril and Losartan in Patients 
With Heart Failure 
Andrew P. Davie, John J. McMurray, MRC Clinical Research Initiative in 
Heart Failure, University of Glasgow, Glasgow, UK 
Background: Angiotensin converting enzyme inhibitors (ACEI) have been 
shown to potentiate the effects of exogenous bradykinin (BK) by inhibition 
of its breakdown. Despite this there is no data on whether inhibition of 
endogenous BK breakdown actually contributes to the effects of ACEI, or 
indeed other inhibitors of the renin-angiotensin-system such as angiotensin 
Methods: 12 patients with congestive heart failure (CHF) (11 male, 1 
female, ages 59 to 81 years) were randomised to double-blind crossover 
treatment with either enalapri110 mg bd followed by Iosartan 25 mg rod each 
for 5 weeks, or the reverse. At the end of each treatment period, forearm 
blood flow was measured by venous occlusion plethysmography during an 
intra-brachial infusion of BK before and after an intra-brachial infusion of 
Hoe-140, a potent, selective and long-acting BK antagonist (5 nmol/min for 
30 rnins). 
Results: 
EnaLapdl Losartan 
Vasodilatation to BK 357 ± 67% 230 :~ 46% 
Vasoconstriction to Hoe-140 4 ~: 2% -4  4- 6% 
Hoe-140 
Conclusion: Inhibition of endogenous BK breakdown does not contribute 
to the effects of ACEI or A2A in the forearm of patients with CHF, despite the 
marked effects of ACEI compared with A2A on exogenous BK breakdown. 
1 044-113 1 Effect of Chronic 
I 
The Blood Pressure Lowering 
Dietary L-Arginine Supplementation in Newly 
Diagnosed Hypertensives Is Associated With 
improved Endothelial-Mediated VasodilaUon 
Giuseppe MC. Rosano, Giuseppe German6, Filippo Leonardo, 
Gala Panina, Francesco Pelliccia, Paolo Pagnotta, Elena Cerquetani, 
Barbara Sposato, Massimo Volpe, Sergio L. Chierchia. /stituto H. San 
Raffaele, University "La Sapienza", Roma; /RCCS Neuromed, /ta/y 
Background: Dietary L-Arginine supplementation reduces blood pressure in 
newly diagnosed untreated hypertensives. Aim of the present study was to 
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evaluate whether the hypotensive effect of oral L-Arginine is related to the 
improvement of endothelial function. 
Methods: Fourteen untreated hypertensives pts (age: 56 ± 8 yrs) un- 
derwent 24-hour blood pressure monitoring and evaluation of endothelium 
dependent flow-mediated vasodilation of the brachial artery using high res- 
olution ultrasound. The diameter of the brachial artery and blood flow were 
measured at rest, during reactive hyperemia (FMV) and in response to nitro- 
glycerine (GTN). After a baseline evaluation of FMV, pts were randomized 
to receive either oral L-Arginine (2 g, tds) or oral placebo (P, tds) for 1 week 
according to a cross-over double-blind protocol. 
Results: Resting systolic blood pressure was significantly reduced by 
L-Arginine but was not affected by P (165 • 20 vs 148 ± 18 vs 158 zE 28 
mm Hg, L-Arginine vs baseline vs P, p < 0.05). Similarly, 24 hour systolic 
and diastolic blood pressure loads were significantly reduced by L-Arginine 
as compared to P (131 ± 10 vs 139 ± 10 mm Hg, p < 0.05; 85 ± 7 vs 90 
± 6 mm Hg, p < 0.01, respectively). FMV was not affected by P, while was 
significantly improved by L-Arginine (5.4 z~ 2.8 vs 1.8 i 2.1%, p < 0.05). A 
greater degree of GTN-induced vasodilation was observed after L-Arginine 
as compared to P (18.2 ± 6.7 vs 15.6 ± 5.5%, p < 0.05). A significant linear 
correlation was found between the degree of blood pressure load reduction 
and the improvement in FMV after L-Arginine (r = 0.62, p < 0.01). 
Conclusion: The hypotensive effect of L-Arginine in newly diagnosed 
borderline hypertensives seems to be related to the degree of improvement 
of endothelium dependent flow-mediated vasodilation. 
I1 044-114 / and 
1 
Digoxin Impairs Endothelium-Dependent 
J -Independent Relaxations in Isolated Arteries 
Matthias R. Schulze, Claus-GLinther Konnerth, Katrin PI6tze, Utz Kappert, 
Steffen Pfeiffer, Rolf HenSge. Heart and Circulation Center Dresden, 
University of Dresden, Germany 
Background: Digoxin (DIG) is widely used in treatment of patients with 
moderate to severe congestive heart failure (CHF). High DIG-concentrations 
(10 6 M) constrict isolated arteries. It is not known whether DIG in therapeutic 
concentrations (3"10 -9 M) alters endothelium-dependent or -independent 
relaxations in isolated arteries. 
Methods: Ring preparations of pig coronary arteries (PCA) and hu- 
man internal thoracic arteries (ITA; obtained dudng surgery) were mounted 
into organ baths and were preconstricted with prostaglandine F2~ (10 -5 
to 3 x 10 6 M) or norepinephrine (10 6 M). Rings (n = 5-10) were sub- 
sequently exposed to endothelium-independent vasodilator nitroglycerine 
(NTG; 10-9-10 -6 a). In ITA we used endothelium-dependent vasodilator 
acetylcholine (Ach; 10-8-10 -s M), and respectively in PCA substance P (SP; 
10 TM-10 9 M). Relaxations to different substances are analysed in the ab- 
sence (-DIG) and presence of DIG (+DIG) in percentage of preconstriction. 
Results: In PCA DIG impairs significantly (p < 0.05) relaxations to NTG 
and SP, in ITA only relaxations to NTG are significantly reduced. Table 
summarizes maximal relaxations for agonists (mean -~ SEM, "p < 0.05). 
PCA {TA 
-DIG +DIG --DIG +DIG 
NTG 98.7 ± 2.3 92.0 ± 6.1+ 93,1 ± 10.3 81 9 ± 19.8" 
ACh 67,3 ± 19.5 66.0 ± 17,9 
SP 100 65.8 ± 26.2" 
Conclusions: 1. DIG impairs endothelium-independent and -dependent 
relaxations in PCA, and endothelium-independent relaxations in ITA. 2. Fur- 
ther investigations are needed to evaluate whether these findings have ther- 
apeutic consequences in treatment of patients with CHF. 
1044-115l  Effects of Nicotine Gum 
I 
Acute on Coronary 
i Artery Dimensions in Patients With Coronary 
Artery Disease 
Alain Nitenberg, Isabelle Antony. H6pital Louis Mourier, /NSERM U.426, 
Colombes, France 
Background: Smoking cessation rate, that is an important prevention mea- 
sure in patients with coronary artery disease, may be improved by nicotine 
replacement herapy. However, anti-smoking compounds may have coronary 
adverse effects. 
Methods: In this study, coronary cross-sectional area (CSA) before and 
at the peak of plasma nicotine concentration have been measured on 32 
coronary artery stenoses and 32 adjacent apparently normal coronary seg- 
ments using quantitative coronary angiography in 17 heavy smokers (12 
males and 5 females, 55 ± 9 year old). Control measurements were made 
at baseline (Base 1) and after sympathetic stimulation by a cold presser test 
(CPT 1). Measures were repeated 30 min after chewing 4 mg nicotine gum 
(Base 2 and CPT 2). 
Results: Heart rate was not modified after nicotine gum, but blood pres- 
sure was mildly increased. CSA of coronary artery stenoses and of apparently 
normal segments were reduced during CPT either before or after nicotine 
gum. However, there was no differences in CSA of coronary artery stenoses 
and normal segments between Base 1 and 2, and between CPT 1 and 2. 
2-" 
= z.o 
3,0 StellO~S (mean+~.qEM) 
p<0.CO 
p<O.O001 vs Ba! 
Base 1 CPT 1 Base 2 CPT 2 
10+0 NormaISc~men~Imean~F~ 
9.5~ F NS ------~ 
1 ",x vs Base /  [ "x.p<O.O00 
+01 1 
6.01 + NS- -  
S~¢ ] CPT I Base 2 cPr  2 
Conclusion: These results show that nicotine gum did not reduce CSA 
of coronary stenoses and normal segments at baseline, and did not increase 
the response to sympathetic stimulation evoked by the CPT. 
POSTER 
Hypertens ion,  Left Ventr icular  Hypertrophy, 
and the ECG 
Sunday,  March  7, 1999, 3:00 p .m. -5 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  3:00 p .m. -4 :00  p.m. 
I1 1 Performance of Classical ECG Criteria for LVH in 045-1 1 6 J Black Individuals 
Fran(~ois Perret 1.2, Christian Jaggy ~ , Pascal Bovet 2,3, Michel Abel 3, 
Fred Paccaud 2, Lukas Kappenberger ~ . 1Division of Cardio/ogy, University 
Hospital Lausanne; 2 University Institute of Social and Preventive Medicine, 
Lausanne, Switzerland; 3Ministry of Hea/th, Seyche//es, USA 
Background: The applicability of classical ECG criteria for left ventricular 
hypertrophy (LVH) criteria to black individuals remains to be demonstrated. 
Methods: Digitized twelve-lead ECG tracings were obtained from 334 
randomly selected black individuals. LVM was calculated with M-mode echo- 
cardiography and indexed to body size. Sensitivity, specificity and accuracy 
were calculated for each of nine classical ECG criteria set at their tradi- 
tional partition value (TPV). Sensitivity was re-estimated for partition values 
yielding 95% or 90% specificity in our collective. Finally, a new "weighted 
time-voltage" criterion (~FFV criterion) was defined using a stepwise multiple 
linear regression and was thereafter tested as the others. 
Results: 
Sens. Spec. Accur. Sens. at Sens. at 
Criterion at TPV at TPV at TPV 95% sp 90% sp 
Sokolow-Lyon voltage 61 68 67 16 23 
Cornell voltage 23 90 84 19 23 
Gubner- Ungerleider voltage 19 95 88 19 35 
RaVL voltage 10 97 89 16 35 
Lewis voltage 39 87 83 23 32 
12-lead QRS sum 42 78 74 19 32 
Sokolow-Lyon product 58 73 72 19 26 
Cornell producl 32 89 84 26 32 
Gubner-Ungerleider product 39 91 86 19 42 
New WTV-criterion 32 95 89 32 45 
Conclusions: Several classical ECG criteria for LVH appear to have 
inadequate performance in black individuals when used at their traditional 
partition values. At a standardized specificity of 90%, the Gubner-Ungerleider 
product and the new WTV-criterion appear to perform best with sensitivity 
exceeding 40%. 
1045-1 7 1 Relation of ECG Left Ventricular Hypertrophy 
I 
1 to 
Obesity in Hypertensive Patients: The LIFE 
Study 
Peter M. Okin, Sverker Jern, Richard B Devereux, Stevo Julius, Sverre 
E. Kjeldsen, Bj6rn Dahl6f. Come//Meclica/Center, New York, NY, USA 
Background: Obesity appears to limit the sensitivity of ECG voltage criteria 
for left vantricuJar hypertrophy (LVH), perhaps due to the attenuating effects 
JACC February 1999 ABSTRACTS - Hypertension, Vascular Disease, and Prevention 237A 
of increased body mass (BM) on precordial voltages. However, obesity can 
be associated with an increased prevalence of anatomic LVH, making ECG 
criteda with greater accuracy in obese patients a clinical priority. 
Methods: The Losartan I_ntervention For Endpoint Reduction in Hy- 
pertension (LIFE) trial used Cornell voltage-duration product (CP) [RaVL + 
Sv3]*[QRS duration] > 2,440 mm.msec) and/or Sokolow-Lyon (SL) voltage 
(Svl + Rvs-s > 38 ram) ECG LVH criteria to screen for patients at high risk 
of morbid events. Clinical information and BM index (BMI) were available 
in 8,417 patients. Obesity was defined by a BMI >_ 31.0 kg/m 2 in men and 
>32.2 kg/m 2 in women, and was present in 1,573 participants (18.7%). 
Results: Obesity had significant but different effects on ECG LVH by SL 
and CP criteria. Obesity was associated with significantly lower SL (25 ± 9 
vs 31 ± 11 mm, p < 0.001) and a lower prevalence of LVH by SL (10.9% vs 
25.8%, p < 0.001). In contrast, obese patienls had higher mean CP (2613 
± 923 vs 2487 ± 1048 mm.msec, p = 0.006) and a significantly higher 
prevalence of LVH by CP criteria (75.1% vs 64.1%, p < 0.001). Differences 
in SL and CP between nonobese and obese patients remained significant 
after adjusting for differences in sex, age, and blood pressure using analysis 
of covariance (p < 0.001). Moreover, obesity remained a strong positive 
predictor of the presence of LVH by CP (x 2 = 74, p < 0.0001) and a strong 
negative predictor of ECG LVH by SL (x 2 = 142, p < 0.0001) after controlling 
for these covariates using logistic regression analysis. 
Conclusions: ECG LVH cdteria in LIFE are strongly related to obesity. 
The significantly lower prevalence of SL in obese patients suggests that SL 
criteda may underestimate the presence of LVH in the presence of obesity. In 
contrast, ECG LVH using CP criteria may provide a more accurate measure 
of LVH in obese patients. 
I1045-1181 Relation of Echocardiographic Left Ventricular 1 
Mass and Hypertrophy to Electrocardiographic 
Left Ventricular Hypertrophy in Hypertensive 
Patients: The LIFE Echocardiographic Substudy 
Peter M. Okin, Sverker Jern, Richard B. Devereux, Kristian Wachtell, 
Stevo Julius, Sverre E. Kjeldsen, Bj6rn Dahl6f. Cornel/Medical Center, NY, 
NY, USA 
Background: The Losartan Intervention For Endpoint Reduction in Hyper- 
tension (LIFE) trial used left ventricular hypertrophy (LVH) on a screening 
ECG to identify patients at high risk of morbid events. An echocardiographic 
(Echo) substudy was performed in over 800 subjects. 
Methods: Additional baseline ECGs and echocardiograms were obtained 
prior to randomization to Iosartan or atenolol in 875 patients who were 
grouped according to the presence or absence of ECG LVH by Cornell volt- 
age-duration product (CP) [aavL + Sv3]*[QRS duration] > 2,440 mm-msec) 
and/or Sokolow-Lyon (SL) voltage (Svl + Rv5-s > 38 mm). Echocardio- 
graphic LV mass indexed to body surface area (LVMI) > 104 g/m 2 in women 
and >116 g/m 2 in men was used to define echocardiographic LVH (Echo 
LVH). 
Results: Because of regression to the mean, not all patients met screen- 
ing criteria on their baseline ECGs. Compared to those with no ECG LVH at 
baseline by either criteria, patients with persistent ECG LVH had higher LVM 
and LVMI, and a higher prevalence of Echo LVH; the presence of both ECG 
criteria was associated with the highest values (p < 0.001 by ANOVA or x2): 
Variable CP -/SL- CP -/SL+ CP+/SL- CP+/SL+ 
(n = 219) (n = 159) (n = 395) (n = 102) 
LVM (g) 217 ± 47 228 ± 46 238 ± 67 270 -E 66 
LVMI (g/m 2) 114 ± 21 121 ± 21 126 ± 33 141 -E 30 
Echo LVH (%) 54.3 61.6 77.2 86.3 
Conclusions: Persistent ECG LVH between screening and LIFE study 
baseline identifies patients with greater LVM and LVMI, and a higher preva- 
lence of Echo LVH, suggesting that these patients may be at higher risk of 
subsequent events. 
L1045-119/ of Criteria for Comparison Electrocardiographic J Left Ventricular Hypertrophy in Young 
Hypertensive Black Men 
Wendy S. Post, Roger S. Blumenthal, Gary Gerstenblith; Anne R. Capdotti, 
Martha N. Hill, James L. Weiss. Johns Hopkins Universi~ Baltimore, MD, 
USA 
Background: Standard electrocardiographic (ECG) criteria have a relatively 
high specificity for the detection of left ventricular hypertrophy (LVH) in the 
general population. However, ECG-LVH criteria may have lower specificity in 
blacks, due to higher voltages for the same LV mass. 
Methods: We performed ECG's and echocardiograms in 223 men young 
black inner city men participating in a randomized study evaluating the 
effectiveness of a nurse-community health worker-physician team approach 
to control hypertension. LV mass was measured using the 2-D area-length 
method and indexed to height 2.7. Echo-LVH was defined as LV mass index 
> 50 g./m 2-7. 
Results: Sensitivities (sn) and specificities (sp) for LVH using standard 
criteria follows: 
sn = 66% sp = 55% for Sokolow-Lyon (SV1 + RV5 or RV6 >_ 35 ram); 
sn = 59% sp = 72% for Romhilt-Estes-score >_ 5; 
sn = 29% sp = 94% for Cornell Voltage (RavL + SV3 >_ 28 ram); 
sn = 26% sp = 94% for Cornell Voltage-duration product 
[(RavL + SV3) × QRS-duration _> 264.7 #V-sec]. 
To compare sensitivities, thresholds for the diagnosis of LVH were varied 
to obtain a specificity of 92%. The Sokolow-Lyon method threshold needed to 
be increased from 35 to 49 ram. The Romhilt-Estes method required 6 points 
instead of 5. The Comell Voltage threshold was slightly decreased from 28 
to 27.5 mm, and the Cometl voltage-duration threshold was decreased to 
260 uV-sec. At a specificity of 92% the sensitivities for diagnosing LVH were 
similar between the four criteria (28-34%). 
Conclusions: Standard Cornell criteria have the best specificity for diag- 
nosing LVH in young black men with hypertension. However, using thresholds 
which produce a specificity of >90%, all four methods have similar but low 
sensitivity. Criteria for LVH may need to be adjusted in this population to 
improve specificity. 
1045-1201 Autonomic Modulation of Heart Rate and Blood 
| 
J Pressure in Offspring of Hypertensive Subjects 
G. Piccirillo, E. Viola, M. Nocco, M. Durante, S. Tarantini, A. Moise, 
V. Madgliano. I Clinica Medica, Un. "La Sapienza", Roma, Italy 
Predominant sympathetic ardiovascular modulation in the hyperkinetic phase 
of arterial hypertension has been well described. Less information is avail- 
able on nauroautonomic ontrol in persons with a family history of arterial 
hypertension. The aim of this study was to assess autonomic nervous system 
control in normotensive subjects with a family history of arterial hypertension. 
For this purpose we obtained short-term recordings for spectral analysis of 
RR intervals and arterial pressure variabilities and baroreflex sensitivity (BS) 
at baseline (rest) and during tilt test (tilt) in 61 normotensive subjects with 
hypertensive parents (HP), 30 normotensive subjects with non-hypertensive 
parents (NHP) and 21 hypertensive subjects (HS). The three groups had 
similar ages, sex, salt intake and weight. HP had higher diastolic blood pres- 
sures (73.7 ± 0.9 ± vs 70.00 ± 1.6, p < 0.05), left ventricular mass index 
(114.1 ± 2.9 vs 194.1 ± 2.2, p < 0.05) and QTc dispersion (48.8 ± 2.3 vs 
40.55 ± 2.0, p < 0.05) than NHP. They also had higher spectral densities 
of low frequency (LF) expressed in normalized units (NU), both for RR (63.0 
± 2.03 vs 54.28 ± 2.8, p < 0.05) and systolic pressure variabilities (79.8 
± 1.5 vs 70.9 ± 3.1, p < 0.05); and a greater ratio of LF to high-frequency 
(HF) powers of RR variability (0.61 ± 0.09 vs 0.27 ± 0.13, p < 0.05). These 
spectral indexes of RR were significantly higher in HP also after tilt. 
The HS had significantly lower BS than both normotensive groups (7.5 
± 1.0 vs 13.2 ± 0.7 ms/mm Hg, p < 0.05 and vs 13.5 ± 1.2 ms/mm Hg, p 
< 0.05). No difference was observed between the two normotensive groups 
for BS. Our spectral data indicate that HP have more prominent sympathetic 
modulation at rest and after tilt than NHP. The spectral indexes of sympathetic 
modulation showed that HP responded better to tilt, hence they had greater 
BS than the HS. In HP, good BS could be the mechanism that buffers the 
tendency for pressures to increase. In conclusion, the neuroautonomic profile 
characterized by increased sinus and vascular sympathetic modulation with 
normal BS could be considered as an intermediate phenotype for arterial 
hypertension. 
1045-121 / Do Non-lschemic Patients With Hypertensive 
J Left Ventricular Hypertrophy Have Late 
Potentials or Complex Ventricular Arrhythmias? 
The LIFE Study 
Kristian Wachtell, Michael H. Olsen, Jergen K. Kanters, 
Vasilious Papademetriou, Richard B. Devereux, Hans Ibsen, 
Jens Rokkedal. Glostrup University Hospital, Denmark; The New York 
Hospital, Come# Medical Center, NY, USA 
Background: Hypertensive patients with left ventricular (LV) hypertrophy 
have a higher prevalence of LV arrhythmias and greater incidence of sudden 
cardiac death sudden cardiac death. It remains unclear whether the increased 
sudden cardiac death is due to an association of arrhythmias with LVH in 
the absence of overt myocardial ischemia or sensitization by LVH to morbid 
arrhythmias. 
Methods: Echocardiograms with 2-D and M-mode were obtained in 45 
unmedicated patients with stage I-Ill hypertension and LVH determined by 
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ECG (Cornell voltage duration >_ 2,440 mm × msec or Solokow-Lyon voltage: 
SV1 + RV5/RV6 > 38 mm) after 14 days of placebo treatment. No patient had 
history of ischemic heart disease and all patients had a bicycle exercise ECG, 
24-hour ECG-monitoring and Signal Averaged ECG performed. A subgroup 
of 20 patients also had dobutamine-atropine stress echocardiogram (DASE) 
performed. Two of 45 patients with ischemia on exercise ECG were excluded. 
Results: No patients showed signs of ischemia on DASE. LV mass index 
(mean ± SD) for men 127 ± 31 g/m 2 and women 111 ± 29 g/m 2. Only 1 of 
43 (2%) had significant late potentials. Heart rate variability showed SDNN = 
134 ± 38 msec (normal: 121 ± 32 msec) Patients had 248 ± 68 premature 
ventricular complexes (PVC). 2 patients had PVC couplets PVC. No patient 
had non-sustained ventricular tachycardia. 
Conclusion: In this hypertensive population with LV hypertrophy and 
no overt epicardial and microvascular coronary disease we found no late 
potentials, normal heart rate variability and no ventricular arrhythmias. Thus, 
LV hypertrophy per se does not contribute to ventricutar arrhythmogenesis, 
but may reduce the ability to tolerate ventricular tachyarrhythmias. 
ORAL  
Hypertension: Clinical Aspects 
Monday,  March  8, 1999, 10:30 a .m. -Noon 
Moria l  Convent ion  Center ,  Room 275 
10:30 a.m. 
~-~-~ Non Drug Therapy of Hypertension: Persistence of 
Effect After Discontinuation of Intervention 
John B. Kostis, Clifton R. Lacy, Alan C. Wilson, Celeste Cardona, Nora 
M. Cosgrove, Daniel M. Shindler. UMDNJ-Robert Wood Johnson Medical 
School, New Brunswick, N J, USA 
Non-pharmacologic intervention has been found useful in controlling blood 
pressure. However, information is needed on the persistence of the effect 
after the end of intervention and discontinuation of contact with health profes- 
sionals. Trial of Nonpharmecologic Interventions in the Elderly (TONE) was 
a 4 center clinical trial that demonstrated that sodium reduction (sodium), 
weight loss (weight) and their combination (Na-Wt) provide a feasible, effec- 
tive and safe means for non-pharmacologic therapy of hypertension in older 
persons. The medications of TONE participants aged 60 and above with hy- 
pertension controlled on 1 or 2 drugs were discontinued after 90 ± 14 days 
of intensive dietary intervention as above or attention control (control). Of 
the 223 TONE participants who completed the 30 months study in 1 clinical 
center, 222 were contacted 8.4 months (6-13 months) after the end of the 
study. The percentage of participants whose blood pressure was controlled 
without medication (controlled off meds), weight and 24 hour sodium excre- 
tion at randomization (RND), at the end of the study (END) and at follow-up 
after last study contact (FU) are presented below. 
% Controlled off Weight (Ibs.) 24 H Sodium 
Meds (mEq) 
RND END FU RND END FU RND END FU 
Control 0 35.5 25.8 167 163 164 146 147 146 
Weight 0 46.4 32.1 202 188 190 153 161 118 
Sodium 0 47.8 40.6 180 173 176 145 102 86 
Na-Wt. 0 51,7 44.8 198 191 195 162 136 116 
The beneficial effect of intensive dietary intervention followed by extended 
routine maintenance visits appears to persist even after discontinuation cf 
intervention. 
10:45 a.m. 
[ ~  Effects of Hormonal Replacement Therapy on Left 
Ventricular Mass in Hypertensive Postmenopausal 
Women. A Randomized Double Blind Placebo 
Controlled Study 
Rosario Rossi, Rosella Molinari, Nicola Muia Jr, Annadele Castelli, 
Giorgia Odgliani, Anna Andria, Maria G. Modena. Department of Cardiology 
II, Policlinico Hospital, University of Modena, Italy 
Background: Epidemiological studies indicate that left ventricular hypertro- 
phy (LVH) represents the most important independent risk for coronary and 
cerebro-vascular disease in women 
Methods: In a randomized double blind placebo controlled study we in- 
vestigated the effects of transdermal 17/~-estradiol (100 #g/24 hours) plus 
oral norethisterone acetate (2.5 mg/die) (HRT) in modifying left ventricular 
mass index (LVMI). The study group consisted of 192 mild to moderate hyper- 
tensive non-hysterectomized women. Patients were divided intwo Groups: 
Group I (n = 97) receiving HRT and Group II (n = 95) receiving placebo and all 
women were under the same dosage of ACE-inhibitors. LVMI was calculated 
by echocardiograms at baseline and after 6, 12 and 18 months of therapy. 
LVH was defined as LVMI > 110 g/m 2. 
120 
115 
110 
105 
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months mont l~ 
Results: LVMI showed a significant decrease in both groups; however 
the reduction was significantly greater (p < 0.01) in the HRT group (Figure). 
In group I the percentage of patients with LVH was 46% at baseline and 
17.2% after 18 months (p < 0.0001) while in group II it was 48% vs 31.5% (p 
< 0.05). 
Conclusion: HRT associated with standard therapy may reduce LVMI in 
hypertensive postmenopausal women. 
11:00 a.m.  
~ ~  Effect of Sildenafil on Blood Pressure in Men With 
Erectile Dysfunction Taking Concomitant 
Antihypertensive Medications 
Randall Zusman, Mike Collins. For the Si/denafil Study Group: 
Massachusetts Genera/Hospital, Boston, MA, USA; Pfizer Ltd, Sandwich, 
UK 
Background: Oral sildenafil, a selective inhibitor of phosphodiesterase type 
5, is effective in restoring erectile function in response to sexual stimulation 
in patients with erectile dysfunction (ED). This subanalysis of data from 5 
double-blind, placebo-controlled studies (N = 2098) assessed the effect of 
sildenafil on systolic (SBP) and diastolic blood pressure (DBP) in men with 
ED taking various antihypertensive medications. 
Methods: Men with ED (mean age 58 yr) received sildenafil (25-200 mg) 
or placebo for 12 or 24 weeks. BP data were collected at baseline and at 
the final visit; the men were instructed to take a dose of study medication at 
home on the day of the final visit, prior to their arrival at the clinic. Adverse 
events (AEs) were recorded throughout he studies. 
Results: BP data for men taking or not taking anti-HTNs were as follows: 
Mean change from baseline in SBP/DEIP (mm Hg) 
Anti-HTN Class Placebo Sildenafil 
Diuretics 1,1/0.6 -2.0/ 1.5 
Beta blockers 3.2/1,1 -4,4/-2.4 
Alpha blockers -2.6/-0.9 3,0/-3.3 
ACE inhibitors 1.0/0.8 3,0/-1.9 
Calcium channel 
blockers -0.3/0,5 5.0/-2.5 
No Anti-HTN 0.4/0,9 2,7/-1.8 
The incidences of AEs related to BP changes (eg, dizziness, hypotension, 
syncope) were comparable in patients taking anti-HTNs and in those not 
taking anti-HTNs for both the sildenafil and placebo treatment groups. 
Conclusion: Overall, treatment with sildenafil had no significant effect on 
BP in men with ED, including those who were taking concomitant anti-HTN 
medications. 
11:15 a.m.  
~ Problems Casual Blood Pressure Measurement With 
in a University Hospital Cardiovascular Clinic 
Clarence E. Grim, Sharmila S. Thadani, Srijaya Bandi. Medical College of 
Wisconsin, Milwaukee Wl, USA 
Background: Blood pressure (BP) measurement is being delegated to less 
well trained staff most of whom have not undergone any standardized training 
and certification of knowledge and performance. Our assessment of current 
equipment and practices was stimulated by several serious errors in BP by 
our clinic staff. 
Methods: Equipment: We randomly selected 44 BP devices (26 aneroid 
(A) and 18 mercury (Hg)) from 60 clinic rooms. Each was tested for inflation 
system integrity (leaks) and accuracy at BP levels used to stage hypertension 
(JNC VI: 80, 86, 90, 100, 110, 120, 130, 140, 160, and 180 mm Hg) and the 
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date of last calibration was sought on the device. Measurement accuracy: 
We compared the "casual" (C) BP in 78 patients (P), taken in the routine 
fashion by clinic staff, to the "true" (T) BP taken by certified (Shared Care 
Method) observers using AHA guidelines. 
Results: Equipment: None of the A and 18% of the Hg had ever been 
checked for accuracy, 16% of the devices did not zero, 25% of the A and 
18% Hg devices were out of calibration, and 75% of devices failed the leak 
test. Overall, over 75% of the BP devices used in our clinics should have 
been removed from use by an informed staff. Accuracy: In 22 P the T DBP 
was between 85-95: in 7 the C BP was >5 mm too high and in 5 it was >5 
mm too low. In another 22 P the true SBP was 140-160: in 9 the C BP was 
>-5 mm too high and in 4 it was >-5 mm too low. When all readings were 
considered the casual DBP was > ± 5 mm in 21% and >_ -5  mm in 24% and 
45% of DBPs were in error. For C SBP, 30% were > ± 5 mm, 33% _> -5  mm 
below the T SBP and 63% of SBP were inaccurate. 
Conclusion: These results document serious errors in BP measurement 
in a Cardiovascular Clinic. The proven benefits of the detection and treatment 
of HBP can only be transferred to the population by accurate and reliable 
BP measurements. We have implemented a QA program to improve these 
problems. 
11:30 a.m. 
I~ -1  Cocaine Use is Strongly Associated With Left 
Ventricular Hypertrophy in Young, Hypertensive 
African-American Men 
Carlos S. Ince, Jr., Martha N. Hill, Cheryl R. Dennison, James L. Weiss, 
Gary Gerstenblith, Roger S. Blumenthal, Wendy S. Post. The Johns 
Hopkins University, Baltimore, Maryland, USA 
Background: Left ventricular hypertrophy (LVH) is a potent predictor of 
adverse cardiovascular events in hypertension (HTN). Regular alcohol use is 
associated with HTN. Acute cocaine ingestion can result in vasoconstriction, 
increased affedoad, and transient HTN. The relationship between substance 
use and LVH, however, is inconclusive. 
Methods: Baseline demographics, substance use behavior, and 2D 
echocardiographic data were collected on 278 young, inner-city African- 
American men with HTN, ages 21 to 54. Alcohol and cocaine use were 
measured using a self-reported questionnaire and urine toxicology (for co- 
caine). Echocardiographic left ventdcular mass (LVM) was calculated using 
the 5/6 area-length formula and indexed to height 2'7 (LVMI). LVH was defined 
as LVMI > 50 g/m 2"7. Logistic and linear regression models were used to 
define the relationship between substance use and LVH. 
Results: Over 52% reported regular use or tested positive for cocaine, 
while 64% had alcohol CAGE scores > 2 of 4. Baseline demographics of 
regular cocaine users were similar to controls, while those with positive CAGE 
scores had lower BMI than controls. Cocaine users had a higher unadjusted 
LVMI than non-users (47.8 vs. 43.8 g/m 2-7, p = 0.024), which remained 
significant after adjusting for age, BMI, systolic blood pressure, and use of 
antihypertensive medication (p = 0.028). Cocaine use was associated with 
LVH, in a similar logistic regression model (OR 1.75, p = 0.045). There was 
no relationship between reported alcohol intake (CAGE scores or average 
alcohol quantity consumed per week) and LVH. 
Conclusions: Regular cocaine use is associated with, and may be an 
important etiologic factor in, the development of LVH in this population. 
11:45 a .m.  
~--~ Association Between Hypertension, Lipids and 
Lipoproteins in Women 
David Ashton, David Wood. National Heart & Lung Institute, Imperial 
College School of Medicine, University of London and Kiran Nanchaha/, 
Department of Medical Statistics, London School of Hygiene & Tropical 
Medicine, London 
Background: The aim of this cross-sectional occupational cohort study was 
to examine the relationship between hypertension and serum lipids, tipopro- 
teins and other CHD risk factors in a large cohort of UK women. 
Methods: The subjects for this study were 14077 female employees, aged 
30-64 years, who underwent screening between 1988 and 1991. Main out- 
come measures were systolic blood pressure (SBP), diastolic blood pressure 
(DBP), serum total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-choles- 
terol (LDL-C), triglycerides, apolipoprotein A1 (ape A1 ), apolipoprotein B (ape 
B) Lp(a), fasting blood glucose (FBG) and body mass index (BMI). Hyperten- 
sion was defined as SBP >_ 140 mmHg and/or DBP >- 90 mmHg, or already 
on treatment for hypertension. 
Results: Subjects were divided in four groups: those currently being 
treated for hypertension but who remained hypertensive (Group 1, n = 291); 
women who were hypertensive but not on treatment (Group 2, n = 1742); 
normotensive women on treatment (Group 3, n = 228); and untreated nor- 
motensive women (Group 4 n = 11725). Women in Groups 1 & 2, had a 
significantly more atherogenic risk profile when compared with women in 
Group 4. Mean TC, BMI, TC/HDL-C ratio, LDL-C, triglycerides, ape B and 
FBG were all significantly higher and HDL-C significantly lower (all p < 
0.0001). There was no significant difference in mean ape A1 or Lp(a). Those 
in Group 1 also had a higher risk lipid profile than those in Group 2. Those in 
Group 3 had a significantly less atherogenic profile than those in Groups 1 & 
2. 
Conclusions: Both untreated and inadequately treated hypertension at- 
tract a considerable metabolic penalty. These data underscore the fact that 
the degree of blood pressure control and the specific drugs used in its man- 
agement, may each have a major impact on the lipid and lipoprotein profile. 
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~ Differential Regulation of the Expression of the 
PAl-1 Gene by TGF-/3 and Gemfibrozil in Human 
Arterial Smooth Muscle Cells 
Thomas K. Nordt, Steffen Lutzi, Karlheinz Peter, Burton E. Sobel, 
Christoph Bode. University of Heidelberg, Germany; University of Vermont, 
Burlington, VT, USA 
Background: Human atherosclerotic lesions exhibit increased expression 
of plasminogen activator inhibitor type 1 (PAl-l). Recently, we could identify 
TGF-# as a potent agonist of increased PAl-1 expression and we could 
demonstrate direct and specific inhibition of TGF-#-induced PAl-1 synthesis 
by gemfibrozil (G). 
Methods and Results: To characterize mechanisms by which G modifies 
PAl-1 synthesis, human aortic smooth muscle cells were incubated with 0 
or I ng/ml TGF-~ and 0, 500, or 700 ,~M G, respectively. The PAl-1 gene 
was expressed as two species of PAl-1 mRNA, a 2.2 and 3.2 kb form, and 
quantified by Northern blotting. TGF-,6 increased the 2.2 kb form by 133 
± 17% (± SEM, p = 0.019) and the 3.2 kb form by 23 4- 3% (p = ns). In 
contrast, G predominantly affected the 3.2 kb PAl-1 mRNA by decreasing its 
expression by 74 ± 10% (p = 0.024) under basal conditions and by 87 ± 
3% (p = 0.042) after TGF-,~ induction. Half-life studies using the transcription 
inhibitor actinomycin D showed a reduction of the half-life of 3.2 kb PAl-1 
mRNA as underlying mechanism. After the removal of TGF-/~, its stimulatory 
effect on PAl-1 expression lasted 12 h, whereas the inhibitory effect of 
G decayed after 4 h under control conditions and after 8 h with TGF-# 
induction. Corresponding results were obtained in human coronary smooth 
muscle cells. Other fibrates such as fenofibrate were much less effective 
than G in this setting. 
Conclusion: These data demonstrate the differential regulation of the 
expression of the PAl-1 gene by TGF-# and by G, the specific action of G 
in comparison with other fibrates, and the relevance for PAl-1 expression in 
human coronary smooth muscle cells. 
~ Endothelial Dysfunction After Acute Chlamydia 
Pneumoniae Infection in ApoE-Knock-Out Mice 
Petru Liuba 1 , Erkki J. Pesonen 1 , Anders Forslid 1 , Kenneth Person 1 , 
Torkel Wadstr6m 1 , Ilari Paakkari 2 , P&ivi Karnani 2, Li Liang 2, t University of 
Lund, Lund, Sweden; 2University of Helsinki, Helsinki, Finland 
Background: Endothelial cell damage is the first step in atherogenesis. En- 
dothelial cell damage impairs the release of nitdc oxide (NO) and changes the 
function of coronary arteries. Infections and especially Chlamydia pneumo- 
niae (Cpn) infections are potential risk factors for atherosclerosis. However, 
their role as endothelial cell damaging factor is not firmly established. Ape 
E-knock-out mice are susceptible to atherosclerosis and therefore serve as 
an appropriate model for testing the connection between Cpn infection and 
atherosclerosis.. 
Methods: 10 ape E-ko mice on a regular diet were included in the study. 
Five were infected at 7 weeks of age with Cpn intranasally, and sacrificed 
2 weeks after. The arterial smooth muscle tone was measured with a force- 
displacement ransducer connected to a Grass polygraph (Model 7D, Grass 
Instrument Co., USA). The ascending aorta rings were first contracted with 
noradrenaline. The cumulative relaxation concentration-response curves to 
methacholine were then constructed in the absence and presence of L-NAME 
(NG-nitro-L-arginine methyl ester), an NO synthase inhibitor, and diclofenac, 
a cyclo-exygenase inhibitor. 
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Results: In the presence of L-NAME the aorta rings from infected mice 
showed significantly less endothelium mediated relaxation (maximal relax- 
ation remained below 20%) compared to controls (relaxation 70%). The 
combination of L-NAME with diclofenac did not increase the inhibitory ef- 
fect in the infected mice and diclofenac alone did not modify relaxation to 
methacholine. 
Conclusion: Acute Cpn infection inhibits relaxation of contracted arteries 
which is associated with decreased NO production. Prostaglandines do not 
seem to play an important role at least at this early stage. Cpn infection is a 
risk factor for coronary heart disease. 
~ D o e s  Affinity Affect Vascular Tissue the 
Protection Induced by Angiotensin Converting 
Enzyme Inhibitors? 
Yiping Sun, Boqing Zhu, Amanda E.M. Browne, Richard E. Sievers, Tony 
M. Chou, Prakash C. Deedwania, Kanu Chatterjee, Kdshnankutty Sudhir, 
William W. Parmley. University of California San Francisco, CA, USA 
The renin-angiotensin system plays a role in the process of atherogenesis. 
Interference with this system may have potential vasculoprotective effects. 
The difference in tissue affinity of various angiotensin converting enzyme 
inhibitors. (ACE-Is) may influence the degree of their vascular protection. 
To evaluate the effects of tissue affinity of ACE-Is on atherogenesis and 
vascular function, the present study was designed to compare the vasculo- 
protective effects of captopdl (low affinity) and quinapril (high affinity). Thirty 
New Zealand male rabbits (average 3.55 ± 0.04 kg) were randomized into 
3 groups: placebo, captopril (average 13.2 ± 1.4 mg/d) and quinapril (1.0 
± 0.2 mg/d) in drinking water while receiving a 0.5% cholesterol diet for 
14 weeks. Serum lipids, plasma angiotensin II (Angll) levels and percent 
of atherosclerotic lesions (planimetry) were measured. Another 10 rabbits 
on a regular diet served as a normal control to compare aortic endothelial 
reactivity. Mean ± SEM, "p < 0.001 by one-way ANOVA. 
Groups Chol (mg/dl) HDL (mg/dl)" Aorta (%)" "Ach-relax (%) 
Placebo 1935 ± 288 9 ± 1 35 ± 3 22 ± 3 
Captopril 1805 ± 226 11 ± 1 19 ± 2 30 ± 4 
Quinapril 1910 ~: 129 21 ± 3 21 ± 3 31 ± 5 
"Ach-relax: Acetylcholine (at dose 10 7 M) induced relaxation 
Both captopril and quinapril significantly attenuated aortic atherogenesis 
without obvious lipid changes (both p < 0.001 compared with the placebo). 
Both ACE-Is improved the vascular endothelial dependent relaxation to 
acetylcholine impaired by high lipid diet (38 • 4% vs. 22 ± 3% in nor- 
mal control and placebo, p = 0.004), but only quinapril blocked the ACE 
efficiently [Angll changes (after - before): 8 • 6, -2  ± 8 and -44 ± 10 
pg/ml in placebo, captopril and quinapril group, p = 0.002]. There was a 
negative correlation between aortic atherogenesis and Ach-relax (r -0.516, 
p = 0.005). It is concluded that both ACE-Is with different issue affinities exert 
similar vascular protection in this animal model. 
• Trapidil Inhibits Monocyte Chemoattractant 
Protein-1 (MCP-1) and Macrophage Accumulation 
After Balloon Arterial Injury in Rabbits 
Michael Poon, Jason R. Cohen, John T. Fallon, Mark B. Taubman. Mount 
Sinai School of Medicine, New York, New York, USA 
Background: Trapidil (triazolopyrimidine) is an anti-platelet agent and PDGF 
inhibitor, which has been found to attenuate restenosis after PTCA. MCP-1 
is a PDGF-inducible monocyte chemoattractant abundant in atherosolerotic 
plaques and the injured arterial wall. We hypothesized that trapidil would 
inhibit MCP-1 expression and monocyte accumulation in arterial injury. 
Methods: New Zealand white rabbits were fed a 2% cholesterol, 6% 
peanut oil, rabbit chow diet for one month prior to balloon dilatation of the 
femoral arteries. Trapidil was administered subcutaneously (60 mg/kg/d) 
one day prior to arterial injury with a 4 Fr embolectomy catheter (3, 60 
sec 4 atm inflations) and subsequently for 7 days. Six days after injury, 
the animals were euthanized, the femoral arteries were perfusion fixed and 
paraffin embedded. Sections were stained with antibodies against rabbit 
MCP-1 and macrophages (RAM-11). The absolute areas of MCP-t and 
RAM-11 staining in the intima and media of the section most narrowed by 
plaque for each control (n = 31) or trapidil-treated (n = 22) vessel was 
determined by computerized morphometry. Whole blood was collected at the 
time of sacrifice for assessment of monocyte number and function. 
Results: Trapidil reduced the mean area of macrophage accumulation 
in the intima and media by 75% (p < 0.004) and the mean area of MCP-1 
expression by 75% (p < 0.016). Trapidil had no effect on the number of 
circulating monocytes or their ability to adhere to cultured endothelial cells. 
Trapidil decreased the intimat area by 31% at day 7 (p < 0.04). 
Conclusion: Trapidil reduces MCP-1 and macrophage accumulation af- 
ter artedal injury. This may be an important component of its activity in 
attenuating restenosis. 
~ Endothelin-1 Potentiates Human Vascular Smooth 
Muscle Cell Growth Mainly Through ET-A 
Receptor 
Zhihong Yang, Nazmi Krasnici, Thomas F. L0scher. Cardiovascular 
Research, Physiology Institute, University ZOrich-lrchel; Cardiology, 
University Hospital ZDrich, Switzerland 
Background: Endothelin-1 (ET-1) is the most potent vasoconstrictor peptide. 
However, its mitogenic effects on vascular smooth muscle cells (SMC) remain 
controversial. In this study we investigated the role of ET-1 in human SMC 
growth and interaction with other growth factors such as ptatelet-derived 
growth factor (PDGF). 
Methods: SMC were cultured from human aorta and cell proliferation was 
assayed by 3H-thymidine incorporation. Activation of cell cycle regulatory 
kinase such as cyclin-dependent kinase 2 (Cdk2), expression of the Cdk 
inhibitor (KIP1) and hyperphosphorylation of the tumor suppressor gene 
(pRb) were analysed by immunoblotting. 
Results: ET-1 (10 -9 to 10 -6 M) did not stimulate 3H-thymidine incorpo- 
ration, while the growth factor PDGF-BB (0.01 to 5 ng/ml) concentration- 
dependently enhanced cell growth up to 43-fold; n = 3). The inability of ET-1 
on cell growth was further confirmed by the fact that PDGF-BB (5 ng/ml), 
but not ET-1 (10 --7 or 10 -6 M), activated Cdk2, downregulated KIP1 and 
hyperphosphorylated pRb. Interestingly, a low concentration of PDGF-BB (1 
ng/ml) stimulated 3H-thymidine incorporation (8.7-fold), which was markedly 
potentiated by ET-1 (10 -9 to 10 -7 M) up to 71.8-fold (n = 3; p < 0.001) in a 
concentration dependent manner. 88% of the potentiating effect was blocked 
by the ET-A receptor antagonist LU 135252 (10 -s M) and completely blocked 
by the ET-A/B receptor antagonist bosentan (10 -5 M; n = 3). 
Conclusion: ET-1 itself has no mitogenic effects on human SMC, but 
markedly potentiates the effects of other growth factors mainly through ET-A 
receptor activation. This may represents a noval function of ET-1 in vivo for 
pathogenesis of structural vascular changes. 
• Phosphorylation of 8 and 18 in Cytokeratin 
Human Vascular Smooth Muscle Cells Is Related 
to Apoptosis and Cell Stress 
Harald Bar, Florian Bea, Erwin Blessing, Lisa Watson, Philipp Wende, 
J6rg Kreuzer, Lothar Jahn. Department of Cardiology, Universit~t 
Heidelberg, Gemnany 
Background: Expression of cytokeratins (CK) is considered a hallmark of 
the state of epithelial differentiation. Cytokeratins also occur in certain mes- 
enchymal vascular smooth muscle cells (VSMC), inferring an association 
with a modulated, less differentiated phenotype. CK posttranslational mod- 
ification has recently been shown to occur in epithelial cells under cellular 
stress, mitosis or induced apoptosis. 
Methods: Tissue samples of human vessels were evaluated by im- 
munofluorescence microscopy applying mono- and polyclonal antibodies 
specific for cytokeratin 8/18 and distinct known phosphorylation sites, as 
well as Ki-67-antigen as a proliferation marker. The TUNEL-technique was 
applied to detect apoptosis. 
Results: Although all samples examined contained cytokeratins, phos- 
phorylation patterns were found to be diverse. The C-terminal serine 431 
of cytokeratin 8 was phosphorylated in the vast majority of CK-express- 
ing VSMC of clinically symptomatic coronary artery lesions. Only a subset 
of these cells demonstrated phosphorylation of CK18Ser-33 or, to an even 
lesser extent, CK8Ser-73. In contrast, chronically occluded peripheral esions 
exhibited little or no phosphorylation, corresponding to a negative TUNEL- 
staining in these samples. 
Conclusion: A high incidence of TUNEL-pesitive nuclei in areas with 
abundant CK phosphorylation in VSMC of atherosclerctic lesions suggest a 
specific functional response to cell stress and a relation to apoptosis. These 
data provide insight into mechanisms of VSMC modulation associated with 
the development of atheroscterotic lesions. 
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I1 i' Coronary Arteriaf Remoaeling at the of 07"3-2"6 S~es Focal Vasospasm in Variant Angina 
Che©3'~'nan 'Lee, %aon0 -"~r~ OO'X '~ af)',. "~.v e on 0 -'~) ~O)')p. Dae-boon# ~tm. 
Hoo~n-'K~ T~atK. bae-'Kwan ~on.g, ~eung-bun.g ~'ah~. De..oattmerir dr ~e6)dme. 
University of U/san, Asan Medical Center, Seoul, Korea 
Little data are available about remodeling patterns according to the angina 
syndromes. Using intravascular ultrasound, remodeling patterns of 27 spasm 
sites (SS) from 24 vanant angina (VA) patients were compared with those of 
10 non-spasm sites (NSS) in the same artery, 9 non-spasm related arteries 
(NSA) from the same patients and 27 lesion-matched sites from 24 stable 
angina (SA) patients. The vessels' cross-sectional area (CSA), lumen area 
and plaque area were calculated at the lesion and reference sites. The lesion 
sites were compared to the distal reference sites: constrictive remodeling was 
defimed ashes]on < r~rerence a~ehal%%~.~oronarv s.oasm sites were an.. 
giographically documented by ergonovine provocation test before the study. 
Ather,3~c(e~,3(~c/es,}3ns we<e o~se~ve,~ ( a(t oo<o~&¢y spasm s~tes. ~e~ecer~ce 
CSA was not different among the groups. However, constrictive remodeling 
was more common at the SS in VA (70.4%, 19/27) than at the NSS in the 
same artery (20%, 2/10), NSA in VA (22.2%, 2/9) or lesion-matched sites in 
SA (22.2%, 6/27) (p < 0.05). 
Variant Angina Stable 
CSA, mm 2 SS NSS NSA Angir~a 
Reference EEM 15.0 ± 5.6 12.4 ± 3.2 11.7 ± 4.4 13.7 ± 4.4 
Reference Lumen 9.8 ± 4.7 7.9 ~ 2.5 7.8 ± 2.6 9.0 ± 3.1 
Lesi~nJ-umen %7"o ~:2x~ "b.~ =~,z7.:, 1~,7b ~c ~,.b ~.~, ~-27~ 
EEM: external elastic membrane, R: remodeling, "p < 0.05 
~onc)u~ons: Coronary s~asm s~e shows more ~re~uent constnc~ve 
remodeling compared to the non-spasm sites in VA or the control sites in SA, 
indi~ca'fing't'na'= remo6e'hn 9 process ~sphmaf)~2 a~,ec't e0 ~y ~,ecal '~ac'tors ra'fner 
tham' o v s vgtemtc'raCtors. 
• Earlier Pressure Wave Reflection as a Marker of 
Atherosclerosis: Assessment by Portable 
Applanation Tonometry 
A. Gana~, P.S. Saba, L. Petrette, R. Fadda, C. Lo~ghir~i ~ , R. Pini ~, 
G. IFlealdi. Clinical Medicine. Sassari: ~' Internal Medicine, Ferrara: 
and promotes development of aortic plaques, two mechanisms able to en- 
hance pressure wave reflection. Thus, amplitude and/or timing of the reflected 
pro#ress~on ol A3~. 
Objective: To investigate relations of ATS with arterial pressure wave 
Methods: We studied 56 healthy subjects (N; 49% male; 45 ± 20 years) 
and 174 subjects with one major nsk factor (hypertension, hypercholes- 
terc~emia~ e< d(a~etesl~ (~ o( them were uaco~p((cated (R-U:. 48% ma(e~ 
47 ± 16 years) and 26 had a documented history of coronary or peripheral 
t ime- ,we~,a , '~ 'ck , '~'$  4;',M"F ~' a,-t,d, #'Ee~,'~s" w~'e  assessexq ~}" ~,~',~'as~'~.~-a#~?,t 
Two pressure transducers were positioned over the right carotid and femoral 
of the 2 pressure waves; m/s). Carotid pressure waveforms was digitally 
= 1 mmHg), interfaced with a laptop PC through A/D acquisition board. A 
dedicated software allowed central pressure waveform analysis. After the 
in fl~',d~n, rp, xo~,: ~ (~',q; wa.&,~&¢~t,~'~,-d ,-Lq,r~u:~-t,,ff.: q~¢,~ r~. ~d#~n (.( 5 rde~ ~m q.K.c~: a_~: 
RPW on the incident wave, both amplitude and timing of RPW were estimated 
respectively as augmentation index [AI = (peak systolic pressure - pressure 
at IP)/pulse pressure; %)] and transit time (TT; time interval between IP and 
foot of carotid pulse). 
Results: (means adjusted by age, gender and systolic blood pressure) 
IMT (mm) Plaque (%) PWV (m/s) AI (%) ~ (ms) 
N 0.59±0.13 16 7.8±2.2 12±21 131 ±41 
R-U 0.63±0.14 41" 8.4±2.7 17±20 115±38" 
R-C 0.74±0.13 *'1" 79 **:~ 8.2±3.1 26±13-*  94±24 **$ 
* = p < 0.05,'" = p < 0.01vs N; ? = p < 0.05, $ = p < 0.01 vs R-U 
Conclusion: Augmentation index increases in patients with complicated 
ATS..while IT  shortens in #araltel with the dev£1opment of ~laq.ues andevQ- 
lution from silent to complicated ATS. Thus, eadier pressure wave reflection 
as assessed by portable applanation tonometry, a relatively simple and low 
I1 I Increased Prevalence of Prothrombin Mutated 
I 
073-28  
Allele G20210A in Patients With Familial Acute 
Coronary Syndromes 
Francesco Burzotta ~ , Felicita Andreotti 1 , Katia Paciaroni 2, 
Patrizia Chiusolo 2 , Alessandro Manzoli ~ , Ida Casore~li 2 , Valeno De 
Stefano 2 , Giovanni Leone 2, Attilio Maseri ~ . ~Cardiology," 2Hematology, 
Catholic University, Rome. Italy 
cently identified as a new risk factor for venous thrombosis and juvenile 
~schem~c stroke, b~ ~.s ro~e ~n ~.he pat.hogenes~s ol coronary "th~'ombosis 
is debated. We investigated the possible association between acute coro- 
nary syndromes, family history of myocardial infarction and this prothrombin 
polymorphism. 
Methods: The genotype at the 20210 locus of the prothrombin gene was 
determined in 94 patients (pts) with acute coronary syndromes (77 with acute 
myocardial infarction and 17 with unstable angina) <65 yrs of age, and in 
166 healthy control subjects, matched for age and sex. 
Results: The frequency of the heterozygous genotype for the mutated 
allele (G/A) was 6.3% (6 of 94) in pts and 2.4% (4 of 166) in controls (odds 
~4 dr ~T), s~gnff~cadtly greater fr~an 'm contrdls ~o0ds ratio: 4.37, "95% UI: 
1.03-18.27). 
Conclusions: The A20210 allele of the prothrombin gene is significantly 
that this genetic variant may play a role in the pathogenesis of coronary 
t#rom22os~s, l:~zrth@r ?after st~d~s are needed t~ c~n~#m t#is (;'~d;'n~. 
I 1  073-291 Peripheral Vascular Endothelial Dysfunction Is Associated With Stress-Induced 
"Echocardiographically Silent" Ischemia-Like ST 
Segment Depression in Patients With Normal 
Coronary Arteries 
@bnfia @brelbs, ~6en" 9&rga, Eabaro& P"acett[; I~Ul~l" f al&nbo, ~qer 
Carlo Rossi, Eugenio Picano. Institute of Clinical Physiology, Pisa; Regional 
Background: In patients with normal coronary arteries a normal-hyperkinetic 
left ventricular contraction Pattern is often found durinq stress inpresence of 
transient ischemic-like ST segment depression. 
A='m: To determlhe endothe(ium dependent vasodffator function fn the 
brachial arte~ of patients with a~aina pectoris and anaio.graphicall3 nor- 
mal coronary arteries and different electrocardiographic response during a 
echocardiographically negative vasodflator stress. 
Methods: Twenty-five patients with chest pain syndrome and angiegraph- 
icaily normal coronary arteries underwent'nig'n dose (up'to 0.B4 mgTKg) dlpyfl- 
damole echocardiography est. Endothelium dependent vasodilation was as- 
sessed by measuring the change in brachial artery diameter in response to 
hyperemic flow by vascular ultrasound. 
Results: All patients had a negative stress test by echo criteria. On the 
basis of the associated ECG response, 2 groups were identified: I. (n = 14), 
without and I1. (ri = 11 ), with ischemic-like (> 0.15 mV ST segment depression) 
E-CG~ c#~ rge~ abrrn~ ~'ztes~. d '~rc~ ~ ~rr~y~ d6w r r re~Y va~rc~(~t~T wa~- 
decreased in patients with stress-induced ischemic-like ECG changes (I = 
14.1 ± 2.4% vs II = 1.3 ± 2.0%,.p < 0.00!L 
Conclusion: Endothelial dysfunction is the physiological hallmark of 
echocardiographically silent stress-induced ST segment depression in pa- 
tients with angiographically normal coronary arteries. 
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t 1 0 7 3 - 3 0 1  The Reduction of Vascular Extracellular 
Superoxide Dismutase in the Patient With 
Restenosis After Percutaneous Transluminal 
Coronary Angioplasty (PTCA) 
Yoshitaka Nagai, Hiromi Tasaki, Kazuhito Yamashita, Tsuyoshi Toyokawa, 
Masahiro Okazaki, Akira Yashiro, Yasuhide Nakashima. Univ. Occup. 
Environ. Health, Kitakyushu, Tetsuo Adachi; Gifu Pharmaceutical Univ. Gifu, 
Japan 
Background: The inhibitory effect of nitric oxide against atherosclerosis 
is inactivated with superoxide, which is disproportioned with extracellular 
superoxide dismutase (EC-SOD). Thus, we attempted to study whether the 
low level of EC-SOD would participate as the risk factor for restenosis after 
PTCA. 
Methods: In the successive patients who underwent PTCA, 59 subjects 
(39 male/20 female) with successful PTCA (residual stenosis < 50%) were 
enrolled in the study. Since heparin can release EC-SOD from endothelium, 
endothelium-bound EC-SOD was calculated as the difference of the serum 
level before and after heparin administration. Moreover, serum NOx level was 
measured with Griess method. Other 23 coronary risk factors, including of 
lipide, hypertension, dabetes mellitus etc.) were also compared in the groups 
with or without restenosis. 
Results: Based on the presence (+) or absence (-)  of restenosis (steno- 
sis > 50%) in follow-up CAG, subjects were divided into 34 patients in (-)  
group and 25 patients in (+) group. In the comparison between both groups, 
no significant difference were recognized in risk factors except EC-SOD 
value. The level of heparin-releasable EC-SOD in (+) group (117.7 ± 39.6 
ng/ml) was significantly lower than that in (-)  group (148.9 ± 42.2 ng/ml, p = 
0.0056). In NOx, there was no difference between both groups. 
Conclusion: The decrease of EC-SOD, a protective factor against su- 
peroxide, might be a new risk factor for restenosis after PTCA. 
1073-31 I Effect of Active and Passive Wave 
I 
Smoking on 
J 
Reflection as Measured from the High-Fidelity 
Aortic Pressure Waveform 
Charalambos Vlachopoulos, Christodoulos Stefanadis, Dorothea Tsekoura, 
Pavlos Toutouzas. Hippokration Hospital, Athens Medical School, Athens, 
Greece 
Background: We have previously shown that active (A) and passive (P) 
smoking (S) deteriorate function the human aorta (Circulation 1997; 95." 
31-8 & Ann Intern Med 1998; 128: 426-34). However, wave reflection along 
the arterial bed, a major deteminant of cardiac aftedoad and an important 
index of arterial stiffening, has not been studied. 
Methods: High-fidelity pressure waveforms of the thoracic aorta were 
obtained before and for 20 min. after the initiation of AS (standard cigarette, 
1.0 mg nicotine, 10 pts), PS (exposure to 30 p.p.m. CO, 10 pts), or sham 
S (10 pts) with an intravascular catheter-tip micromanometer (Millar Instr.) 
during diagnostic catheterization. In all pts, an inflection point (Pi) defined 
by computer algorithm (4 th derivative), divided aortic pressure waveform into 
early and late systolic phase (fig.). Augmentation index was defined as: 
~P/PP (fig.). 
ResultS: Systolic and diastolic pressures increased with both AS and PS 
(AS: systollcfrom 125 :~ 14 to 138 - 15 and diastolicfrom 74 ~ 12 to 83 • 13 
mmHg, peak at min. 5; PS: systolic from 126 ± 14 to 137 ± 12 and diastolic 
from 74 ± 8 to 80 ± 7 mmHg, peak at min. 4, P < 0.001 for all). Augmentation 
index increased with both AS and PS (AS: from 0.28 ± 0.12 to 0.33 ± 0.12, 
peak: min. 5 and PS: from 0.29 ± 0.12 to 0.33 ~E 0.14, peak: min. 4, P < 0.05 
for both) indicating increased wave reflection in the periphery. In contrast, no 
changes were observed with sham S. 
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Conclusions: Wave reflection is increased with active and passive smok- 
ing indicating increased left ventricular afterload and arterial stiffening. This 
effect may be involved in the deleterious effect of smoking on cardiac perfor- 
mance and on the functional and structural integrity of the arteries. 
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• Current Management of Type A Thoracic Aortic 
Dissection - Results from the Interventional 
Registry of Aortic Dissection (IRAD) 
C.A. Nienaber, D. Bruckman, E. Isselbacher, A. Evangelista, R. Fattori, 
T. Suzuki, J.K. Oh, U. Sechtem, J. Robles Marcos, H. Deutsch, D. Gilon, 
L. Pate, D. Karavite, K. Eagle. Univ. of Hamburg, Germany; Univ. of 
Michigan Health System, Coordinating Center for IRAD Investigators, USA 
Background: Early death in the course of thoracic aortic dissection is fre- 
quent; according to the IRAD registry of 225 consecutive type A dissections 
30-day mortality of 64 patients with type A dissection (28%) not sent for 
surgery was 53%. Nonetheless, the complex temporal relation between di- 
agnosis and surgery in type A dissection is unsettled. Thus, one purpose of 
IRAD was to analyze the impact of potential delays in the interval from onset 
of symptoms to definitive treatment. 
Methods and Results: Of the remainder of 162 out of all 225 consecutive 
patients subjected to surgery for type A dissection 56% presented within 
6 hours, and 83% within 24 hours of symptom onset. After diagnosis by 
tomographic imaging modalities 121 patients (74%) underwent undelayed 
surgery within 12 hours of presentation, while 41 (26%) were noted to have a 
delay of >24-144 hours from clinical presentation to surgical repair; delays 
were due to the need for confirmatory imaging in 54%, angiography in 
25%, or unavailable physician and/or operating theater in 17%, After surgery 
81% of patients with delay to treatment were discharged home (n.s. versus 
undelayed surgery within 4 hours of diagnosis) while death occurred in 19% 
of these patients (n.s.) from either aortic rupture in 13%, neurological events 
in 37%, or other reasons. Interestingly, death was not directly associated with 
surgical delay (p = 0.37), although 43% of delays were physician-related, as 
long as surgery was performed within 6 days. A stepwise logistic regression 
model identified only age, gender and management (medical vs. surgical) 
significant predictors of death. 
Conclusions: Although in one quarter of patients with confirmed type 
A dissection surgical repair is delayed and performed between 24 hours 
to 6 days after presentation, this unintendedly deferred treatment was not 
associated with elevated mortality. Thus, once a hospital is reached for 
diagnosis of type A dissection a positive selection bias for survival is likely, 
however, does not justify a myth of hemodynamic stability. 
1074-68 1 Acute Aortic Dissection: Modern Clinical 
Spectrum - Results from the International 
Registry for Aortic Dissection (IRAD) 
Peter G. Hagan, Christoph A. Nienaber, Sugata Das, Arturo Evangelista, 
Rosella Faftori, Toru Suzuki, Jae K. Oh, Udo Sechtem, Jose 
Robles Marcos, Hans-Joseph Deutsch, Dan Gilon, David Bruckman, 
Dean Karavite, Pamela Russman, Rajendra H. Mehta, Linda Pape, William 
F. Armstrong, G. Michael Deeb, Eric Isselbacher, Kim A. Eagle. University of 
Michigan Health System, (Coordinating Center for IRAD Investigators), USA 
Background: IRAD was established to assess the impact of recent advances 
in management upon the care of acute aortic dissection (AoD). 
Methods: All patients (pts) at 12 international referral centers with AoD 
(symptom onset within 14 days) were enrolled in 1996-7. 
Results: 375 pts (mean age 63 years, 66% male, 60% Type A, 60% 
transferred) were enrolled. By history, 84% had abrupt onset of pain, more 
often sharp than tearing. Prior hypertension was common (71%). Syncope 
occurred in 9.6% of all pts. Aortic regurgitation was described in only 44% of 
Type A AoD. Pulse deficit was noted infrequently (< 10%) in all pts. Ischemia 
on EKG occurred in less than 20%. Widening of the mediastinum on CXR 
was absent in 38% of pts. Interposition (75%), composite (20.3%), and 
homografts (4.7%), were used in pts treated surgically. Due to advanced 
age, comorbidity and patient refusal of surgery, 29.4% of pts with Type A 
AoD were treated medically with highest mortality, as shown: 
ALL PATIENTS TYPE A TYPE B 
MANAGEMENT SURGICAL MEDICAL SURGICAL MEDICAL 
N (%) 375 159 (70.7%) 66 (29.3%) 28 (18.7%) 122 (81.3%) 
Deaths 104 (27.7%) 40 (25.2%) 38 (57.6%) 12 (42.9%) 14 (11.5%) 
Conclusion: Abrupt onset of pain, syncope and absence of mediastinal 
widening are more common than expected. In hospital mortality remains high 
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in AoD, especially for pts with Type A AoD not receiving surgery. Since clinical 
presentation is o~en not classical, a high index of suspicion is necessary. 
1074-691 Determinants of of Aortic Dilatation Progression 
in Marfan Syndrome 
Aleksandar M. Lazarevic, Satoshi Nakatani, Kunio Miyatake. National 
f..Ca}'~)o~ascu)a~ ~e,~fe~. S~ta. O.ajDar~ 
FProeressive aortic dilatation, which is associated with aortic re~urclitation and 
dissection, has prognostic significance in patients with Marian syndrome. 
Tne purpose dt trim s'[udy was to ~een'~#y ,Wd~dn pa~ents were a~ 'hig'n ~'i~K o~ 
progressior~. 
Methods: We studied 43 patients with Marian syndrome (age 22 4- 14 
years, 23 males) who underwent serial echocardiographic evaluation with the 
mean follow-up period of 5.0 4- 3.2 years. Aortic diameters, left ventdcular 
diastolic (Dd) and systolic (Ds) diameters, fractional shortening (FS), and the 
~evedty (f to 4} of aortic (,ARt and mitral re~urc~itation (MRt were assessed. 
Results: Aortic diameters increased with time. Mean annual increases 
were 0.4 4- 6.3 mm at the annulus, 1.5 4- 1.2 mm at the sinuses of Valsalva, 
©.7 4- D.6 mm at the su~raaort)c h~oe and [}.4 4- ~).4 mm at t'ne .~ro:<~ma'~ 
&s-~-eq%.i~ ~ q.t'~, ~,'~"~i~ ~ 3"~. ,-,=3.~', ~ ~,~,e  ;~,~ ,l,~e ~,~,~ ~ '~,~.,--~ 
in the sinuses of Valsalva diameter; rapid (R, >1.5 mm/year, 11 patients) or 
IR were older than those in group S (32 4- 17 vs 19 4- 12 years, p = 0.01). 
Tfiere were no stattsSbafry s(gn~tbam" oi#'erences th heart rate (~ 4- Y vs. 7"Z 
4- 8 bpm} en~ boc~y suri~a area (1.73 ± 2.3 ~s. 1.50 4- 0.30 m2}, b~t systolic 
(127 4- 16 vs. 113 ± 13 mm Hg, p < 0.05) and diastolic (72 4- 6 vs. 64 ~ 8 
mm Hg, p < 0.01) blood pressures were higher in group R. 
Data~ent~ Dd(mm) Ds(mm) FS(%) AR MR 
R 51~6 33±4 35.7±5.7 2.3=1.3 1.2~1.6 
S 47±7 30±5 36.0±3.5 0,5±0,9 0.6±1.0 
pvalue 0.11 0.16 0,86 <0,001 0.15 
Aortic dissection occurred more frequently in group R (5 patients, 45%) 
than in group S (2 patients, 6%, p = 0.01). 
Conclusions: 1) Aortic diameters increased with time with the most 
remarkable increase at the sinuses of Valsalva. 2) Left ventricular size and 
function appeared not to relate to the progression. 3) Martan patients at old 
age, with high blood pressure, and with significant aortic regurgitation were 
at high risk of progression. 
1074-701 Between Aortic Dissection and Atrial Relationship 
i Septal Aneurysm: A Transesophageal 
Echocardiographic Case Control Study 
Pierre Massabuau, Michel Galinier, Jo~lle Fourcade, Bruno Dongay, 
Serge Boveda, Philippe Cabrol, Jean M. Fauvel, Jean P. Bounhoure. 
Cardilogic Department, Rangueil Hospital, Toulouse, France 
Aortic dissection (AD) and atrial septal aneurysm (ASA) are thought to be 
associated with connective tissue disorder. Our study was designed to evalu- 
ate if there is a relation between AD and ASA. Transesophageal echography 
was used to determine the frequency and the characteristics of ASA in pa- 
tients with AD and in controls (C). AD group consisted in 122 consecutive 
patients (91 men - 31 women) with acute AD diagnosed by transesophageal 
echography; the age range was 18 to 83 years (mean 65), there was 75 type 
A and 47 type B dissection. C group consisted in 244 age and sex-matched 
control subjects randomly chosen among 312 patients explored for other 
indications than supra-ventricular tachyarrhythmia, valvular, aortic, embolic 
or congenital disease. Transesophageal echographic criterias of ASA were: 
base > 15 mm and excursion _> 10 mm into right or left atrium or sum of 
bilateral mouvement. ASA was found in 28 patients (22.9%) of AD group and 
in 13 patients (5.3%) of C group: p < 0.0001. Mean age and male/female 
ratio of patients with ASA were not significantly different in AD and C groups: 
respectively 67.5 vs 65 years and 2.1 vs 2.2. In AD group, ASA was present 
in 20/75 patients (26.7%) of type A and in 8/47 patients (17%) of type B. An 
exclusive one side protrusion of ASA was observed in 7 patients (25%) of 
AD, right side: 3, left side: 4; and in 7 patients (53.8%) of C, right side: 5, 
left side: 2. Mobile ASA with bilateral excursion was observed in 21 patients 
(75%) of AD and in 6 patients (46.2%) of C. In AD group, this kind of mobile 
ASA was more frequently associated with type A: 17/21 (81%) than with type 
B: 4/21 (19%). 
Conclusion: prevalence of ASA appears significantly higher in AD than 
in C, it might reflect the presence of tissue disorder in some cases of AD. 
• Transesophageel Echocardiography Could 
Evaluate the Stage of 3"akayasu's Arteritis with 
Aortic Aneurysm 
Yoichi Nakamura 1, Hiroshi Matsuo 2 , Hiroshi Sato 2 , Chikao Yutani 2 . 1Kousei 
Hospital, Okayama; 2National Cardiovascular Center, Osaka, Japan 
Background: Takayasu's arteritis occasionally involves aneurysm. Modali- 
otfihTrQmmatr61q. ¢¢~ confirmed'Tile possl~(@ oT'al'&gnosls o~'lfirr~mmatOry 
lesions and their stacles by transesgphaaeal echoi{TE-~. ). 
Methods: Autopsied aortae were used. After fixation with 10% buffered 
~orma~ideYlyde, ~ne aolffic wa'ti o~ 9 pa'fien'[s V,/l'~ 3a'Kayasu':s a~er~s were 
resected. Sgecimens were ewtuated ~n a~ajassinaj w~ter with the same d~s- 
tance between the specimen and TEE transducer (AIoka-SSD-2200 system, 
5.0-MHz, electric sector scanning). Echo gain was set as 52, the number 
at which the normal left ventricle was delineated in degassing water. After 
imaging by ultrasound, observed areas were re-evaluated by histology. As 
controls, atheroscler~tic aneun~sm with/without mural thrombi and normal 
aortic wall were compared with the same technique. 
Results: Takayasu's arteritis was divided into 2 groups according echo° 
.gra~)'n'Jc~mages: '2images snowed a t'nJc'Kenedin~Jma-medla .TI-'IQ) complex 
images showed single thickened homogeneous and eohogenic layers (6.4 
t)c aneurysms were differentiated in 6 samples with mural thromb} in wh~ch 
itnages were ectlogenib and showed' heterogeneous thii~ iayers ('t.6 -~ ~.~ 
ram} ar~ 2 sam#as w~thc~ m~ra~ th'~om~, images of wb~h had 8cce#~ic 
sonolucent zones in the I-M complex. Normal control aortae were visualized 
for the I-M complex (1.9 ± 0.3 mm). 
Conclusion: TEE can determine the pathogeneses of aneurysm and 
stage of inflammation in Takayasu's arteritis. 
• Effect of Beta Blocker Therapy on Clinical 
Outcome in Patients With Marfans Syndrome: 
Meta-Anaiysis of Data from 802 Patients 
Deborah R. Gersony, Mary Ann McLaughlin, Henry S. Sacks, 
Valentin Fuster, Welton M. Gersony. Columbia Presbyterian Medical Center, 
New York; Mount Sinai Medical Center, New York, USA 
Background: Several recent studies have reported a decreased rate of aortic 
dilatation in patients with Marians syndrome when treated with beta-blocker 
therapy. While such reports might imply a benefit in over-aU mortality and 
morbidity secondary to cardiovascular complications, no studies have evalu- 
ated beta-blocker therapy in terms of clinical outcome. To assess the effect 
of beta-blockade, we have carried out a meta-analysis of reported clinical 
outcome of Marfans patients. 
Methods: A systematic review was completed of MEDLINE, 1975 to June 
1998, of peer-reviewed publications and abstracts from national and inter- 
national meetings. Endpoints included aortic dissection or rupture, cardiac 
surgery and death. Data were combined according to the Yusuf and Peto 
method. 
Results: Sixteen studies which reported relevant outcomes were consid- 
ered for inclusion in the study, however, ten studies were excluded because 
of incomplete or redundant data. Of the reports included, 5 were non-ran- 
domized follow-up studies and 1 was a prospective randomized trial. These 
6 studies were compatible in terms of exclusion and inclusion criteria. A 
total of 802 patients were analyzed. Of these patients, 433 were treated 
with beta-blocker therapy, and 369 were not treated. 96 of the 433 treated 
patients reach an endpoint, while 74 of the 369 untreated patients reached a 
designated endpoint. Treated patients were more likely to reach an endpoint, 
with an odds ratio of 1.54 (confidence interval 1.08-2.14; p < 0.05). 
Conclusions: The results of this meta-analysis showed fewer cardiovas- 
cular complications in the control group, however, the design of the primary 
studies may limit the strength of this finding. Nevertheless, there was no 
evidence that beta blocker therapy had clinical benefit. Therefore, additional 
randomized trials which include clinical outcomes are needed before this 
therapy can be recommended for Marfans syndrome. 
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~ A i r  Force/Texas Coronary Atherosclerosis 
Prevention Study: Lipid Modification and Risk 
Associated With Non-Lipid Risk Factors 
John R. Downs, Polly A. Beere, Michael Clearfield, Stephen Weis, 
Edwin Whitney, Deborah R. Shapiro, William B. Kruyer, Douglas J. Watson, 
Antonio M. Gotto. Wilford Hall Medical Center, San Antonio, TX; University 
of North Texas Health Science Center, Fort Worth, TX, USA 
Background: The Air Force/Texas Coronary Atherosclerosis Prevention 
Study (AFCAPS/TexCAPS), a randomized, double-blind placebo-controlled 
primary prevention trial, demonstrated that, in a cohort with no evidence 
of clinical atherosclerotic disease, chronic treatment with Iovastatin (Lova) 
20-40 mg daily reduced the incidence of first acute major coronary events 
(AMCEs): sudden cardiac death, fatal and nonfatal MI or unstable angina by 
37%, p < 0.001. The cohort included 6605 men and women (15%) charac- 
terized by average LDL-C levels (150 ~E 17) mg/dL and low HDL-C (37 ± 6 
mg/dL). 
Methods: A pre-specified exploratory Cox model confirmed the following 
to significantly affect AMCE outcome: smoking (TOB), hypertension (HTN), 
age, family history of coronary artery disease (Hx CAD), gender and baseline 
LDL-C and HDL-C. 
Results: 
AMCE Rates 1 by Treatment and Non-Lipid CHD Risk Factors 
Risk Fac~r TOB HTN OlderAge 2 Hx CAD Male Sex 
Placebo + 18.66 16.54 13.72 13.57 11.95 
- 9.84 9.23 8.16 10.33 4.92 
Lova + 7.76 10.22 9.46 9.75 7.57 
6.67 5.85 4.32 6.29 2.65 
1 per 1000 PYR; 2 > median by gender (men > 57 years; women > 62 years) 
Conclusion: Treatment decreased LDL-C by 25%, increased HDL-C by 
6%; CHD risk reduction with Iovastatin was independent of risk factors such 
as gender, age, family Hx, HTN and smoking. 
• Large, Dose Dependent Effects of Simvastatin 40 
and 80 mg/day in Combined Hyperlipidemia 
D.B. Hunninghake, D. Plotkin, M. Stepanavage, H. Bays, M.H. Davidson, 
C.A. Dujovne, L.M. Keilson, S.G. Korenman, D.G. Robertson, E.A. Stein, 
S.R. Weiss, M. Mercuri. Heart Disease prevention Clinic, Minneapolis, MN, 
the Simvastatin in Combined Hyperlipidemia Research Group, USA 
Aim: to assess the lipid altering efficacy and safety of simvastatin (S) 40- 
and 80-mg/day in patients with combined hyperlipidemia (CHL; LDL-C > 130 
mg/dL and TG: 300-700 mg/dL). 
Methods: 130 patients (age; 53 :E 10, women: 48%, type 2 diabetes 
mellitus: 16%) with CHL were recruited into a multicenter, double-blind, 
placebo-controlled, 3 period, 6 week, balanced cross-over study. Patients 
were randomized to one of 6 treatment sequences including placebo and S 
40 and 80 mg/day. 
Results: The baseline values (mg/dL) and lipid changes (% change 
from baseline) are summarized below. Treatment with simvastatin was well 
tolerated. 
LDL-Cholesterol- Triglycerides # HDL-Cholesterol 
N Base A N Base A N Base 
Pbo 119 156 2.1NS 120 389 -3.5 NS 120 39.0 3.3" 
S-40 120 156 -28.9** 120 389 -27.8"" 120 38.9 13.1'" 
S-80 119 156 -35.5"* 121 391 -33.0** 121 38.9 15.7'* 
~by ultracentrifugation. #Median baseline and % change reported. All between treat- 
ment comparisons were statistically significant at p < 0.05. Within treatment compar- 
isons: NSnot significant; "p = 0.002; **p < 0.001. 
Conclusions: Simvastatin is an effective treatment for CHL and exerts 
a beneficial effect across the lipoprotein profile. As observed before with 
statins, there was a smaller effect on LDL-C than in patients with normal TG. 
The reduction in TG was large, close dependent and similar in magnitude to 
LDL-C. The effect on HDL-C was substantial and dose dependent. 
~ Simvastatin and Atorvastatin Have Different 
Effects on HDL Cholesterol and Apolipoprotein 
A-I 
J.R. Crouse III 1 , J. Frohlich 2, L. Ose 3, D. Kush 4, M. Wu 4, M. Mercuri 4. 
1 Wake Forest University School of Medicine, Winston-Salem; 4Merck 
Research Laboratories, Rahway, USA; 2St. Paul Hospital Vancouver, 
Canada; 3National University Hospital Oslo, Norway 
Background: A independent relationship between HDL cholesterol and CAD 
was observed in epidemiologic studies and suggested by interventional tdals. 
Therefore, the effects of statins on HDL-C may contribute to the reductions 
in coronary events observed with simvastatin (S), pravastatin and Iovastatin. 
Methods: 842 patients (41% women) with high cholesterol were ran- 
demised at 49 centers in 19 countries to compare the 12 week efficacy of 
atorvastatin (A) 20 mg or 40 mg, or S 40 mg or 80 mg. 
Results: Mean percent changes in plasma lipids produced by S and A. 
are shown in the table ['p: < 0.05, ,"" < 0.01, "" < 0.001 versus corresponding 
dose of S erA; ~ median and non-parametric test] 
LDL-C TG ~ HDL-C ape A-I 
Drug (mg) N A (SE) ~, (SE) ~ (SE) ~. (SE) 
S 40 202 -42.8 (0.8) -23.0 (1 6) &7 (0.6)** 6.3 (0.9) 
A 20 210 -44.9 (0.9)" -23.4 (1.4) 4.2 (0.8) 5.4 (1.0) 
S 80 214 -48.9 (0.7) -25.3 (1.7) 6.5 (0.7)** 5.7 (1.0)"" 
A40 216 -51.1 (0.8)* -29.6 (1.4)" 3.1 (0.8) -0.3(0.9) 
Conclusions: There were small differences between A and S in LDL-C 
and triglyceride level changes relative to the substantial reductions produced 
by all four treatments. However, both doses of S produced approximately 
twice the increase in HDL-C observed with A, and apolipoprotein A-I (the 
principal protein of HDL-C) did not increase at all in the A 40 mg group. The 
mechanisms underlying the difference are unknown, and deserve further 
investigation. 
• Therapy With Statin Agents but not LDL or HDL 
Levels Is Associated With Future Survival at 
Coronary Artery Disease Diagnosis, ,Especially in 
the Presence of High C-Reactive Protein 
Benjamin D. Home, Joseph B. Muhlestein, John F. Cadquist, Troy 
E. Madsen, Tami L. Bait, Marlene J. Egger, Megan Morris, Chad 
R. Peterson, Scott C. Gardner, Jeffrey L. Anderson. LDS Hospital and 
University o1 Utah, Salt Lake City Utah, USA 
Background: Hyperlipidemia is a strong risk factor for predicting initial core- 
naP/artery disease (CAD) diagnosis, but the value of lipid levels, drawn at 
angiography, to guide therapy and predict future events, is unclear. Hence, 
we evaluated the predictive value of LDL, HDL and statin use, as well as 
C-reactive protein (CRP), a marker of inflammation, for survival in 975 con- 
secutive consenting patients diagnosed angiographically with CAD (stenosis 
> 70%). 
Methods: Blood was sampled just prior to angiography and patients were 
followed-up (flu) to assess survival (mean 2.7 years [y] f/u, maximum 4.0 y 
f/u). Total cholesterol (TC), HDL, and triglyceride levels were determined 
enzymatically; LDL was calculated from those values; CRP was measured 
by high-sensitivity FPIA. 
Results: Patients averaged 65 zE 11 y of age; 77% were males; 105 died 
after a mean 1.1 y f/u (range: 0-3.5 y f/u). Cox survival analyses, assessing 
16 baseline and laboratory factors, revealed no independent associations 
with mortality of TC, LDL, HDL, or triglycerides. However, statin prescription 
at discharge (hazard ratio [HR] = 0.39, p = 0.048), CRP (HR/quartile = 1.55, 
p = 0.003), as well as age (HR = 1.07/y), ejection fraction (HR = 0.97/%), and 
diabetes (HR = 2.39) (all, p < 0.002-0.0001) were independent predictors in 
multiple variable Cox regression. Statins reduced the death rate by 69% in 
patients whose CRP was in the 4 ~h quartile vs. 42% in the lSt--3rd quartiles. 
Conclusion: At diagnosis of CAD, CRP, a measure of inflammation, but 
not lipid measurements, is of prognostic value for future mortality. Initiation 
of statin therapy reduced mortality in angiographically-proven CAD patients 
by more than half and appears to be recommended in patients regardless of 
presenting lipid levels, especially in patients with inftamation (elevated CRP). 
• Relation of Ape E Genotype to Response to 
Lipid-Lowering Therapy and Progression of 
Coronary Artery Disease 
Christie M. Ballantyne, J. Alan Herd, Laura L. Ferlic, J. Kay Dunn, Antonio 
M. Gotto, Jr.. Baylor College of Medicine, Houston, TX, USA 
Background: Ape E genotype can influence binding and clearance of lipopro- 
reins and has been reported to affect LDL-C levels and response to diet Rx, 
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but its impact on response to lipid-lowering drug Rx and CAD progression 
has not been well studied. 
Methods: In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), 
which randomized 429 pls with mildly to moderately elevated LDL-C ( t 15-190 
mg/dl) to fluvastatin (FL) or placebo (PL), apo E genotype was studied in 328 
pts to determine its relation to baseline LDL-C, Z~LDL-C, and 2.5-yr CAD pro- 
gression (n = 293) measured by within-pt per-lesion b, MLD and categorical 
assessment of pts (progressor, regressor, or mixed). 
Results: LDL-C at wk 0 did not differ among genotype groups (2/3 + 2/4, 
3/3, 3/4 + 4/4). However, for 12-wk ALDL-C there was a significant interaction 
between genotype group and treatment (p = 0.02); LDL-C reduction with FL 
was significantly greater in 3/3 than in 3/4 + 4/4 pts (p = 0.03"). Neither AMLD 
nor categorical progression differed significantly among genotypes. 
Conclusion: Apo E genotype was associated with response to lipid-low- 
ering Rx with FL for LDL-C reduction but not CAD progression. 
Genotype Rx n 
LDL-C, %Z~LDL-C ~,MLD, mm (2.5- 
mg/dl (wk O; (wk 12-wk O; yr; least squares 
mean ± SD) mean ~: SD) mean ± SE) 
2]3 + 2/4 FL 14 140.9 ± 26.5 -28.9 5:17.9 -0,002 ± 0,065 
PL 14 132.9:5 20.5 +0.3 ± 12 .1  -0.045:5 0.068 
3/3 FL 103 149.2 ± 23,3 -28.6 ± 11.5" -0.058 ± 0.026 
PL 101 142.3:5 24,0 +3.7 ± 16 ,6  -0.135:5 0.024 
3/4 + 4/4 FL 51 143.9:5 21.8 -22.7:5 12 .7  -0.048 ± 0.035 
PL 45 143.8 ~ 19.2 +0.4 ± 10.5 -0.140 ± 0.037 
1075-78 1 The Effects o f  Extended-Release Crystalline and 
Niacin, Niaspan, on HDL Lipoprotein-Mediated 
Cellular Cholesterol Efflux as Compared to 
Placebo 
John M. Morgan, David M. Capuzzi, Margaret de la Uera-Moya, 
Mason Chang, George Rothblat. Thomas Jefferson University and 
Allegheny Universi~ Philadelphia, PA, USA 
Background: A pilot study was conducted to determine the effect of niacin 
therapy on the serum HDL levels and on the ability of such serum to mediate 
cholesterol efflux from cells in culture. 
Methods: The serum specimens were obtained from patients participating 
in a clinical trial in which patients were maintained on placebo, 1500 rag/day 
of crystalline niacin or 1500 mg/day of extended-release niacin, Niaspan. 
Ten patients from each group were selected for evaluation, and serum was 
obtained prior to treatment and after 12 weeks of therapy. Cholesterol efflux 
potential for each specimen was determined using a standardized cell culture 
system in which Fu5AH hepatoma cells labeled with [3H] cholesterol served 
as the cholesterol donors. Efflux is expressed as the % of the cell cholesterol 
released to 5% serum in 4 h. Statistical significance was determined using a 
paired t-test. 
Results: The table below demonstrates a significant increase in the HDL 
cholesterol paralleled by an increase in efflux in the niacin and Niaspan 
groups, but no significant change in the placebo group. A linear regression of 
% change in HDL cholesterol and efflux demonstrated a significant correlation 
for both niacin and Niaspan, r = 0.63 and 0.67, respectively. No correlation 
was observed between efflux and LDL cholesterol. 
HDL HDL Efflux Efflux % change 
(mg/dL) (% change} Baseline (% change) 
Placebo 50 ± 8 1 4- 5 33.4:5 3.7 33.7 ± 3.9 1 NS 
Niacin 45:5 14 52 ± 30 30.7 ± 4.7 34.2 ± 5.2 11 p = 0.04 
Niaspan 51 ± 12 38 5:27 32.3 ± 3.6 36.8:5 3.7 14 p = 0.005 
Conclusion: This pilot study suggests that niacin's beneficial effect on 
HDL cholesterol evels translates into enhanced efflux of cellular cholesterol. 
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] 1076-110 t Hypertension Following Myocardial Infarction 
Causes Increased Eccentric Hypertrophy, 
Dilation, and Interstitial Fibrosis 
Mohit Jain, Bruno K. Podessor, Ronglih Liao, Soeun Ngoy, Cad S. Apstein, 
Franz R. Ebedi. Boston University School of Medicine, Boston, MA, USA 
Background: Hypertension (HTN) following myocardial infarction (MI) is as- 
sociated with an increase in mortality, yet it is uncertain whether HTN post-MI 
increases compensatory hypertrophy (LVH) or causes further deleterious 
remodeling. 
Methods: Male, Dahl salt-sensitive (SS) and salt-resistant (SR) rats un- 
derwent coronary Ugation or sham operation. Post-operation, 4 weeks of 
high-salt diet resulted in HTN (>175 mmHg systolic BP) in all SS rats and 
non-HTN in SR rats. Diastolic pressure-volume relationships (PV) were es- 
tablished in isolated, red-cell perfused, isovolumic paced hearts. Four groups 
were studied: Sham (n = 8), Sham + HTN (n = 8), MI (n = 12), and MI + HTN 
(n = 12). 
Results: Infarct size was similar in MI and MI + HTN animals (48 ~ 4% vs 
46 ± 3%, p = ns). HTN induced concentric LVH in Sham + HTN rats (HW/BW 
vs Sham 5.5 ± 0.2 vs 4.4 ± 0.1 rag/g, p < 0.05) with a leftward shift in the 
PV curve (Fig A). In contrast, HTN resulted in eccentric LVH and LV dilation 
in MI + HTN rats (HW/BW vs MI 6.0 ± 0.2 vs 5.3 ± 0.2 rag/g, p < 0.05) and 
a consequent rightward shift in the PV curve. Furthermore, HTN resulted in 
an increase in developed pressure in sham rats but not in MI+HTN animals 
(Fig B). There was no significant increase in septal fibrosis following HTN or 
MI. HTN following MI, however, caused an increase in septal fibrosis relative 
to MI rats (1.3 i 0.1% vs 0.8 ± 0.1%, p < 0.05). 
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Conclusion: HTN following large MI causes no increase in contractile 
function, but increases eccentric hypertrophy, LV dilation and interstitial fi- 
brosis. Therefore, HTN in post-MI hearts aggravates deleterious post-MI 
remodeling, which may contribute to the worse prognosis of hypertension 
patients post-MI. 
1076-111 / Insulin Levels and Left Ventricular Mass in 
J 
Obese Hypertensives 
Rafael Kuperstein, Zion Sasson. Mount Sinai Hospital Toronto, Ontario, 
Canada 
Background: Obesity and hypertension are associated with LV hypertrophy 
and with a state of insulin resistance. Both are thought to contribute to 
myocardial hypertrophy through potentially independent mechanisms. We 
studied the association between insulin and glucose metabolism with LV 
mass in a group of obese, non-diabetic, hypertensive individuals. 
Methods: Twenty one consecutive, obese, non-diabetic, hypertensive 
individuals (9 male), age 55 • 12 years; with normal LV function and free 
of associated coronary or valvular heart disease were studied. Body mass 
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index (BMI) was 32.8 ± 4.9 kg/m 2, fasting glucose 5.4 ± 0.8 mmot/I, Sys- 
tolic Blood Pressure (BP) 148 ± 11 mmHg, diastolic BP 97 ± 4 mmHg 
and mean BP 114 ± 6 mmHg. LV mass (ASE criteria) corrected for Height 
(LVM/Ht) was 119 ± 12 g/m. After a washout period of 4 to 6 weeks off 
all antihypertensive and cardioactive therapy, a three hour Intravenous Glu- 
cose Tolerance Test (IVGTT) was performed with serial insulin and glucose 
measurements. 
Results: Measures of insulin and glucose correlated well with LVM/Ht in 
univariate analysis. Insulin integration over 180 minutes of IGTT (r = 0.55, p 
= 0.009), baseline insulin (r = 0.44, p = 0.04), insulin level at 90 minutes (r 
= 0.54, p = 0.015), peak glucose levels (r = 0.53, p = 0.013). No significant 
correlation was found with systolic, diastolic and mean blood pressure, age, 
gender or BMI. Using multivariate linear regression analysis only insulin 
integration area (p = 0.0071 ) and peak glucose (p = 0.0099) correlated with 
LVM/Height. 
Conclusions: Left ventricular mass in obese, non-diabetic hypertensive 
individuals is strongly associated with circulating glucose and insulin levels, 
independent of body mass and level of blood pressure. 
/1076-112/  Potential Role of Brain Natriuretic Peptide as a L J Screening Test for Cardiac Remodelling in 
Hypertensive Patients 
P. Bettencourt, A. Ferreira, T. Sousa, L. Ribeiro, F. Brand~.o, J. Polonia, 
M Cerqueira-Gomes, L. Martins. Faculdade Medicina, Hospital S Jo&o, 
Porto, Portugal 
Background: Hypertension is a major cardiovascular risk factor. Cardiac 
remodelling in this population represents additional risk. Brain Natriuretic 
Peptide (BNP) is produced by ventricular myocytes by increased pressure 
and stretch. We hypothesis that BNP could be a useful marker of cardiac 
remodelling in hypertensive patients. 
Methods: We studied 36 consecutive community mild to moderate hy- 
pertensive patients and 11 well matched normotensive controls with respect 
to clinical characteristics, BNP, creatinine and echocardiography parameters 
(M-mode, 2D and transmitral pulsed Doppler) related to left ventricular mass 
and diastolic function. Diastolic dysfunction was considered when: E/A ratio 
< 1, deceleration time > 240 ms, isovolumic relaxation time > 110 ms - at 
least two of them or E/A ratio > 2, deceleration time < 150 ms, isovolumic 
relaxation time < 70 ms - at least two of them. 
Results: BNP levels were significantly higher in hypertensive patients 
than in controls [36.54 (IQR: 38.61) vs 10.30 (IQR: 13.20) pg/ml, p < 0.0001] 
and it was correlated with left ventricular mass index. Hypertensive patients 
with impairment of diastolic filling had significantly higher BNP concentra- 
tions than patients with no abnormalities on echocardiography [61.16 (45.38) 
vs. 31.27 (18.10) pg/ml; p = 0.001]. Multivariate analysis showed that only 
diastolic dysfunction and LVMI were significantly and independently related 
with BNP concentrations in this population. 
Conclusions: Impairment of diastolic function and LVMI are related to 
BNP levels, thus giving insight that this peptide can play a role in the screening 
of ventricular remodelling in hypertensive patients. 
/ 1076-113 ~ Regression of Left Ventricular Hypertrophy in 
L J Hypertensive Patients Treated With Indapamide 
SR 1.5 Versus Enalapril 20: Results of L.I.V.E. 
Study 
Philippe Gosse ~ , Olivier Dubourg 1 , Pascal Gueret 1 , Desmond J. Sheridan 2, 
Carlos Calvo-Gomez 2, Jean-P. Degaute 2, Yuri Karpov 2, Pete de Leeuw 2, 
2 2 Woifgang Motz 2, Jose-L Palma-Gamitz , Achille Pessina , Faiez Zannad 2, 
Agnes de Cord~3e ~ , Sylvie Barrandon ~ , Claude Chastang 1 , David Guez ~ .
For Central Echocardiogram Evaluation Commitee (CEEC); ~ HSspital, St 
Andre, Bordeaux, France; For European Coordination Group; 2St Mary'S 
Hospital, London, UK 
Background: LVH is a powerful risk factor. Relative efficacy of antihyperfen- 
sire drugs on LVH regression is questionable. We need comparative studies 
with large groups (>200 pts). 
Methods: LI.V.E. is a European, multicentric (93 centers), randomized, 
double-blind, controlled study aimed at evaluating the superiority of inda- 
pamide SR 1.5 (IDP) over enalapril 20 (ENL) in reducing left ventricular 
mass index (LVMI) over 12 months in hypertensive patients (sSBP > 160 
and < 210 mm Hg) with LVH (LVMI, females: > 100 males; > 120 g/m2):. 
after checking equivalence in blood pressure reduction. A blind randomized 
reading was performed at the end of study by an independent CEEC with 
3 readers. A covariance analysis on LVMI reduction, adjusted on baseline, 
was performed on the per protocol set treated for at least 3 months. 
Results: Between Nov. 94 and Feb. 97, 505 patients were randomized. 
Mean duration of monotherapy was 9 ± 4 months for the 411 analyzed 
patients. Both groups were similar at inclusion (55 years, 56% male, 96% 
caucasian; sSBP: 172/sDBP: 101 mmHg, LVMI: 141 g/m2). Reduction in 
sSBP/sDBP was statistically equivalent (P < 0.001) in both groups: IDP 
( -25 ± 16/ -13  ± 10 mmHg) and ENL ( -25  ± 17/ -  12 ± 10 mmHg). 
Change in echocardiographic data 
IDP SR 1.5 ENL 20 Between groups 
Mean ± SD N = 205; /=(1) N = 206; FO) AIDP-ENL CI ,0(2) 
LVMIg/m 2 -8.4:L31 <0.001 -1.9::t_28 NS -4.3 [ 6.6;-0.0] <0.05 
PWTd mm 0.2 ~ 1.1 <0.01 -0.2 ~ 1.1 <0.05 -0.0 [-0.2; 0.2] NS 
IVSTd mm -0.2 • 1.3 <0.05 0.0 ± 1.2 NS -0.2 [-0.4; 0.1] NS 
LVlDd mm -0.9 :~ 4.2 .<0.01 -0.2 ± 3.9 NS -0.5 [-1.20; 0.2[ NS 
(1)Within groups: two-sided Stuent t-test paired; (2) Between groups: one-sided (for LVMI) 
or two-sided (other data) Student t-test (90% CI for LVMI, 95% CI for other data), adjusted 
for baseline values; /VSTd: inten/entricular septum thickness, diastole; PWTd: posterior 
wall thickness, diastole; LVIDd: left ventricular internal diameter; diastole; ,~ difference 
between treatments. 
Conclusion: Indapamide SR 1.5 was significantly superior to enalapri120 
in reducing LVMI in hypertensive patients (blind reading) with similar blood 
pressures reductions. 
1076-11 I Effect of Verapamil on Exercise Tolerance and 
I 
4 
Doppler-Echographic Left Ventricular Diastolic 
Filling Parameters in Hypertensive Patients 
Laurent Macle, Jean-Lucien Rouleau, Serge Lepage. Centre Universitaire 
de Sante de L'Estrie, Sherbrooke, Quebec, Canada 
Background: Many trials have shown improvement of diastolic parameters 
and regression of left ventricular hypertrophy with blood pressure lower- 
ing therapy. However, few of them demonstrated objective improvement in 
exercise tolerance associated with modulation of diastolic function. 
Methods: Twenty patients (12 women, 8 men, mean age 61 ± 10 yrs) with 
essential hypertension and exercise intolerance attributed to diastolic heart 
failure were randomised prospectively in a placebo-controlled cross-over 
short term trial of isoptin SR 240 mg vs placebo to evaluate the effect of 
verapamil therapy on exercise tolerance and left ventricular diastolic filling 
indices. Exercise testing and echographic evaluations were done twice at 
baseline to ensure reproducibility and repeated after 1 week of placebo and 
verapamil. Echo-doppler parameters of diastolic function analysed were peak 
early (E) and atrial (A) velocity, E/A ratio, E/A ratio during valsalva maneuver, 
deceleration time and isovolumetric relaxation time (IVRT). 
Results: All patients were limited on treadmill testing because of dysp- 
nea. Doppler indices of left ventricular filling done at baseline demonstrated 
diastolic dysfunction in all patients and were highly reproducible. With ve- 
rapamil there was a marked decrease in both systolic and diastolic blood 
pressure after 1 week of treatment while no change was noted with placebo. 
Left ventdcuiar filling indices significantly improved with verapamJl (p < 0.001 
for peak early velocity and E/A during valsalva maneuver; p < 0.05 for IVRT) 
while no effect occurred in the placebo group. Total duration time on exercise 
testing increased by 19% with verapamil compared to baseline values (532 
± 187 sec vs 447 ± 140 sec; p < 0.001); while in the placebo group, the 
increase did not exceed the predefined reproducibility value. 
Conclusion: Verapamil improves left ventricular diastolic parameters in 
hypertensive patients which translates into improved exercise tolerance. 
l 1076-115 J Effects of Aging on the Left Ventricle in 1 Hypertension: Influence of Gender 
A. Ganau, C. Spanu, M.J. Roman 1 , P.S. Saba, D.J. Slotwiner 1 , P. Sanna, 
G. Realdi, R.B. Devereux I . Clinical Medicine, University of Sassan,/ta/y; 
Cornell Medical Center, New York, USA 
Background: Senescence of the human myocardium is characterized at 
the structural level by myocyte loss and compensatory hypertrophy of the 
remaining myocytes. This phenomenon is more evident in men than in 
women. 
Objective: To investigate whether gender influences the effects of aging 
on LV geometry and function in hypertensive subjects. 
Methods: Echocardiography was performed in 430 healthy normoten- 
sires (H; 72% male) and 372 untreated uncomplicated hypertensives (H; 
67% male). Wemeasured LV diastolic diameter, septal and posterior wall 
thickness, relative wall thickness (RWT), mass index (LVMI, g./m27), circum- 
ferential wall stress (~e, Kdynes/cm2), endocardial and midwall fractional 
shortening (FSe, FSrn; as % of the value predicted from FS-,~c relationships 
in N). N and H men and women were divided in 3 age groups: 540, 41 to 64, 
>_65 years. 
Results: In N, both systolic blood pressure (SBP) and RWT increased 
with age similarly in men and women, LVMI increased only in elderly women, 
and LV systolic function did not change with age, irrespective of sex. 
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Hypertensive men Hypertensive women 
_<40 41 to 64 >65 years _<40 41 to 64 _<65 years 
Number 68 165 18 32 60 29 
SBP 146±17 1505:20 169±145§ 150±17 158±20 + 174±275§" 
LVMI 48 ± 24 47 ± 14 50 ± 20 48 ± 14 44 ± 13 45 ± 9 + 
RWT 0.37 ± 0.06 0.39±07 ¢ 0.38 • 0.06 0.37 ± 0.06 0.38 ± 0.06 0.39 ± 0.06 
,~c 189±37 189±44 218:t:73 t'~ 193±41 192±44 221 ± 67~ 
FSe% 102±10 104±11 108±19 104±10 111± 11 t• 115±16 ~:" 
FSm% 94±12 96±13 98±19 96±13 101±12 102±15 
/ = P < 0.05, :1: = P < 0.01 vs _< 40; ~ = p < 0.05, § = p < 0.01 vs 41-64; * = p - 0.05 vs 
H men of the same age 
When H were compared with N of same age and gender, in the younger 
H groups the increase in LVMI due to hypertension was larger in women than 
in men, blunting the physiological gender-related difference in LVMI. 
Conclusion: In H of both sex, aging does not affect LV geometry, but 
increased~rc increasedac suggests inadequate LV hypertrophy in elderly 
hypertensives. Larger LV hypertrophic response in elderly N and young H 
women as well as higher FSe in elderly H women, compared with men of 
the same age, suggest better LV adaptation to aging and hypertension in 
women. 
POSTER 
~ 0 ~  Quality, Costs, and Outcomes 
Monday,  March  8, 1999, Noon-2 :00  p.m. 
Moda l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  Noon- l :00  p.m. 
11077-1161 The Kansas City Cardiomyopathy Questionnaire, 
i i a New Quality of Life Measure for Heart Failure Is 
Reliable and Responsive to Clinical Change 
c. Patrick Green, Chades B. Porter, Dennis R. Bresnahan, Brent Bliven, 
John A. Spertus. University of Missouri-Kansas City/Mid-America Heart 
Institute, Kansas Ci~ Missouri, USA 
Background: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 
new, self-administered, 24-item questionnaire that quantifies, in a disease 
specific fashion, physical limitation, symptoms, quality of life, social interfer- 
ence, and disease knowledge. Before being used, it must be demonstrated 
to be reproducible in stable patients and sensitive to clinical change. 
Methods: A cohort of 55 patients with an ejection fraction < 40% and 
decompensated CBF requiring admission to the hospital were administered 
the KCCQ, in addition to the Minnesota Living with Heart Failure Question- 
naire (LIhFE) and the Short Form 36 (SF-36). A second cohort of 56 stable 
patients who had not experienced any recent change in their heart failure 
symptoms were administered these same questionnaires to demonstrate the 
instrument's test-retest reliability. All patients were then readministered the 
questionnaires 3 months later. 35 of the unstable patients (10 failed to return 
final instrument; response rate = 78%) returned the follow-up questionnaires 
(60% men, mean age 68 years, mean baseline NYRA class = 3.3). All scales 
of the KCHFQ, except the treatment satisfaction scale improved dramatically 
(mean change = 15-39 points; p < 0.0001 for all). When compared with the 
SF-36 and the LIhFE, the KCCQ was dramatically more sensitive to clinical 
change. Of 56 stable patients, 38 remained stable by predefined criteria and 
returned questionnaires for analysis (Response rate = 90%; 68% men, mean 
EF = 24%). No important changes in scores were observed in the KCCQ 
(mean change = 0.8-4.4). 
Conclusion: The KCCQ is reliable in stable patients and responsive to 
clinical change. It may serve as an endpoint in clinical trials, an aid in patient 
management and as a marker of health care quality. It is more sensitive and 
provides a broader range of information than existing instruments. 
I 1 077-11 7 J Secular Trends in the Management of 
Congestive Heart Failure by Primary Care 
Physicians and Cardiovascular Specialists 
Peter A. McCullough, Udaya Cingireddy, Edward F. Philbin, W. 
Douglas Weaver. Henry Ford Hea/th System, Detroit, Michigan, USA 
Background: Previous studies have indicated that the majority of chronic 
congestive heart failure (CHF) care management is undertaken by primary 
care physicians (PCP's) in the U.S. The influence of managed care systems 
with the "gatekeeper" paradigm is expected to limit subspecialist involvement 
over time. 
Methods: The Resource Utilization Among Congestive Heart Failure 
Study is an epidemiological study with the aim of describing the health 
system impact of CHF in order to plan for future resource allocation and 
develop population-based care management. We identified 26,442 CHF 
patients over 9 years based on clinic, emergency department, and inpatient 
encounters coded by physicians for CHF and it's related ICD-9 groups within 
a vertically-integrated health system. 
Results: Overall, from 1989 to 1997, patients throughout their course 
were treated by PCP's alone, 76.7%; PCP-cardiologist co-managed, 11.7%; 
and treated by cardiologists alone, 11.6%. However, we observed increasing 
cardiologist involvement in CHF index encounters over time (p < 0.0001 for 
trend): 
Co-managed 
C~diologist Alone 
1989 1990 1991 1992 1993 1994 1995 1999 1997 1999 
Conclusions: In the U.S., while the majority of CHF care is delivered 
by PCP's, there are clear secular trends towards increasing cardiovascular 
specialist involvement in primary and consultative care, especially early in 
the individual course of CHF. 
1 077-11 8 1 Efficiency and Cost Saving of Seven Day Per 
Week Exercise Testing Utilizing 
Electrocardiography Technologists 
Donna E. Mooney, Gis A. Smith, Laura Nebo, Louanne L Davey, Madeen 
E. Irwin, Mano P. Senaratne. Division of Cardiac Sciences, Grey Nuns 
Hospital, Edmonton, Alberta,, Canada 
Background: In most centres exercise tests (ET) are done by trained per- 
sonnel Monday-Friday (8 am-4 pm). ECG technologists (ECGT) are available 
for extended hours and days. This project was undertaken to determine the 
feasibility and safety of using ECGTto do ET and thus improve the efficiency 
of the service. 
Methods: ECGT were trained in ET and provided the service after hours, 
weekends and statutory holidays. Safety and cost-effectiveness of this strat- 
egy was analyzed. All ET were done with physician attendance. 
Results: There were 810 patients (age 58.4 ± 0.4 years; range 16-88; 
508-Male, 302-Female; Bruce protocol in 99.5%). The indications for ET 
were; diagnostic-61%, post myocardial infarction (MI) < 8 weeks-t8%, post 
MI > 8 weeks-4%, angina-7%, other-10%. There were no deaths and only 8 
(0.1%) had complications related to the ET; 6 patients had prolonged chest 
pain (>5 minutes post ET) and 2 non-sustained VT. Based on the results of 
the ET during extended hours, clinical management decisions were made 
resulting in 158 bed days (Cdn. $189,600.00) saved on inpatienls. In those 
presenting to the emergency room 15 bed days (Cdn. $18,000.00) were 
saved, as unnecessary admissions were avoided. 
Conclusions: This review demonstrates the feasibility and safety of utiliz- 
ing ECGT for ET thus extending the hours of service. This resulted in efficient 
patient management, leading to timely discharge and a considerable cost- 
saving. 
1077-119 ] Assessing Quality of Care for Patients With 
Coronary Artery Disease Across Managed Care 
Plans 
Karen P, Alexander, Erie D. Peterson, Hope E. Buell, Nancy E. Sinreich, 
Daniel B. Mark, Elizabeth R. DeLong. Duke University Medical Center, 
Durham, NC, USA 
Background: In managed care, existing quality measures focus on health 
maintenance, rather than on care of chronic diseases (ie, CAD). In addition, 
many aspects of care delivery are best assessed from the pt perspective. 
Methods: The Managed Health Care Association, a collaboration of 
health plans and consumers, developed and tested a coronary disease- 
specific instrument for quality assessment using pt surveys. 4,502 CAD pts 
from 9 health plans were identified by ICD-9 codes, and surveyed on their 
cardiac care (63% completed surveys). Demographics, risk factors, diagnosis 
and treatment strategies, and quality of life were collected. Clinical variables 
were used to adjust for disease sevedty across plans after validation by chart 
review. 
Results: Significant variability exists in pt case-mix across plans (ie, de- 
mographics and cardiac risk factors). After adjustment for differences, plans 
varied in their use of cardiologists (32-82%), and in their frequency of cardi- 
ologist visits (mean 2.3 visits/yr, range 1.5-3.0). Use of pdmary physicians 
also vaded (mean 5.8 visits/yr, range 4.1-7.5). Secondary prevention advice 
vaded across plans for smoking cessation (47%-89%), exercise (42-73%), 
and weight loss (48-76%). In pts with documented CAD, use of potentially 
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beneficial medications varied: aspirin (79--95%), ACE inhibitors (18-33%), 
calcium blockers (31-51%), and beta-blockers (29-58%). 
Conclusions: This study was a voluntary collaboration between man- 
aged care and consumers to monitor quality of care for cardiac pt5. Further 
explanation is needed for the considerable variability found in cardiac care 
across participating managed care plans. 
L1077o120/ The of Case Mix Importance Payer on Hospital 
J Costs: Don't Contract Without It 
Eric L. Eisenstein, Lawrence H. Muhlbaier, Charles F. Bethaa, Eric 
D. Peterson, William H. Oehlert, Judith A. Stafford, Daniel B. Mark. Duke 
University Medical Center, Durham. NC, USA 
Background: Hospitals are negotiating increasingly competitive managed 
care contracts, often without considering differences in the relative dsk of 
patients enrolled in specific health care plans. 
Methods: To help one hospital assess how much they should charge an 
insurer for CABG surgery, we developed an economic model using clinical 
and economic data from 574 CABG patients without valvular surgery or 
coronary angiography treated during fiscal year 1996. 
Results: Average patient costs were $18,853. Actual payer group costs 
(Act) ranged from $17,115 to $21,969 (p < 0.006). Although Medicare 
(M-Care) patients were older, payer group (Pay) C had more patients with 
diabetes, emergency room admissions (ER Ad), and patients with myocardial 
infarction as the reason for admission (MI Ad). After adjusting for patient mix, 
there were no differences in estimated costs (Est) among payer groups (p < 
0.577). 
Conclusion: Differences in patient mix accounted for most of the dif- 
ferences in average costs of care among payers. Hospitals should adjust 
managed care contract prices to account for patient mix differences among 
health care plans. 
Pay A Pay B Pay C M-Care Pay D Prob < 
Age 58.1 54.1 55.4 71.3 56.2 0.000 
Diab 28.0% 19.3% 47.2% 28.3% 21.3% 0.017 
ER Ad 20.0% 10.8% 44.4% 16.1% 24.1% 0.000 
MI Ad 12.0% 7.2% 22.2% 6.8% 10.2% 0.032 
Act(S) 17,510 17,970 21,969 19,429 17,115 0.000 
Est ($) 17,653 17,651 19,423 19,289 18,113 0.000 
1 077-121 ] Determinants  of  Satisfaction Across Managed 
Care Plans 
Karen P. Alexander, Eric D. Peterson, Hope E. Buell, Nancy C. Sinreich, 
Daniel B. Mark, Elizabeth R. DeLong. Duke University Medical Center, 
Durham, NC, USA 
Background: Pt satisfaction is an important metric of overall health care 
quality, but may be influenced by variables unrelated to the actual medical 
care given. 
Methods: The Managed Health Care Association, a cooperative effort 
between managed care and consumers, developed and tested a tool to 
measure quality of care and satisfaction of pts with coronary artery disease 
(CAD). 4,502 pts from 9 health plans were identified by ICD-9 codes for 
CAD and surveyed regarding satisfaction with their primary physician and 
cardiologist. Pts rated satisfaction on a 5-point scale (poor to excellent) 
for 'appointment waiting time', 'availability of urgent care', 'competence of 
physician', 'explanation of care', and 'overall quality'. We investigated factors 
associated with higher satisfaction (very good or excellent for 'overall quality'). 
Results: Across managed care plans, pt satisfaction ranged from 61-83% 
for primary physicians and from 74-89% for cardiologists. The strongest 
predictor of overall satisfaction with primary physician and cardiologist was 
explanation of care and treatment by the physician. Satisfaction was also 
influenced by pt race, gender, health status, and mental health. In contrast, 
pt age, education, employment, marital status, and comorbidities were not 
predictive. Interestingly, a major determinate of satisfaction with primary 
physicians was whether pts received secondary prevention education and 
concurrent care by a cardiologist. 
Conclusions: This study highlights the importance of considering pt 
characteristics when assessing metrics of satisfaction. It also highlights the 
importance of communication between pt and physician regarding the plan 
of care as this is a strong determinant of subsequent pt satisfaction. 
ORAL  
Cardiac Interventions: Outcomes and Costs 
Monday,  March  8, 1999, 2:00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 262 
2:00 p.m. 
~-~ Performance of Invasive Cardiac Procedures, Not 
On-Site Availability, Is Associated With Decreased 
Mortality in Acute Myocardial Infarction 
Carisi A. Polanczyk, Michelle Cobum, Edward F. Philbin, Thomas G. Di 
Salvo. Massachusetts General Hospital, Boston, MA, USA 
Background: Previous studies have shown a strong correlation between 
performance and on-site availability of cardiac catheterization (CATH) or 
angioplasty (PTCA). However, it is not known if patients with acute myocardial 
infarction (AMI) admitted to hospitals with on-site CATH and PTCA have 
better outcomes. 
Methods: We analyzed administrative data on all 54,484 patients admit- 
ted with AMI to 248 New York State hospitals from 1993-1995. Previously 
validated multivariate mortality risk adjustment models incorporating demo- 
graphics, clinical characteristics, comorbidities, and hospital characteristics 
were applied to adjust for case-mix across institutions. 
Results: Overall, 26% of patients underwent CATH and 8% underwent 
PTCA. Shown in the table are odds ratios (95% CI) of adjusted in-hospital 
mortality stratified by quartiles of predicted mortality for patients admitted to 
hospitals with on-site invasive cardiac procedure availability and for patients 
who underwent procedures. 
Mortality On-Site CATH On-Site PTCA 
(%) CATH performed PTCA performed 
<3.5 0.9 (0.7-1.2) 0.2 (0.1-0.4) 1.1 (0.8-1.4) 0.4 (0.2-0.7) 
3.5-7.3 1.1 (0.9-1.3) 0.2 (0.1-0.8) 0.9 (0.8--1.1) 0.4 (0.2-0.5) 
7.3-14.7 1.0 (0.9-1.1) 0.2 (0.1-0.8) 1.0 (0.9-1.1) 0.3 (0.2-0.4) 
>14.7 1.0 (0.9-1.1) 0.4 (0.3--0.6) 1.0 (0.9-1.0) 0.5 (0.3-0.6) 
Conclusions: There is no difference in mortality after myocardial in- 
farction in patients admitted to hospitals with and without on-site cardiac 
catheterization and angioplasty. 
2 :15 p.m. 
~ Triage of Patients for Short-Term Observation After 
Elective Coronary Angioplasty 
Karel T. Koch, Jan J. Piek, Martin H. Pdns, Robbed J. de Winter, Carl 
E. Schotborgh, Kada Mulder, Kong I. Lie, Jan G.P. Tijssen. Academic 
Medical Center, Amsterdam, The Netherlands 
Background: Early discharge after PTCA may add to the comfort of patients 
(pts) but may be complicated by unattended subacute occlusion of the treated 
vessel away from monitoring and angioplasty facilities. 
Objective: To assess the appropriateness of triage of pts for short-term 
observation after elective PTCA and to identify factors associated with the 
necessity to prolong the observation period. 
Methods: A total of 1015 consecutive pts scheduled for elective PTCA 
were prospectively included for short-term observation. Braunwald Ill-unsta- 
ble patients were excluded. There were no angiographic exclusion cdteda. 
Pts were discharged from the interventional center when considered stable 
during 4 hours observation after PTCA. Prolonged observation was at the 
operator's discretion. Complications were defined as death, CABG, early 
re-PTCA and MI. Outcome measures were the necessity for prolonged ob- 
servation (>4 hours) and the occurrence of complications. Predictors for 
prolonged observation and complications were assessed by univanate and 
multivariate analysis. 
Results: Two pts died, including 1 of 6 patients who underwent emer- 
gency CABG. A total of 922 pts (90.6%) were triaged to short-term observa- 
tion and had a uncomplicated 3 days follow-up. Observation was prolonged 
in 87 pts (8.5%), 40 pts a complication. Multivariate preprocedural predictors 
of prolonged observation were ostial lesion location (Odds Ratio [OR] 1.6; 
95%CI 1.2-2.5), PTCA of more than one coronary lesion (OR 1.8; 95%CI 
1.1-23) and PTCA of a restenotis (OR 1.7; 95%CI 1.0-2.7). independent 
predictors of complications were acute closure (OR 9.7; 95%CI 4.4-21.4), 
sidebranch occlusion (OR 8.9; 95%CI 3.4-23.7), no angiographic success 
(OR 5.1; g5%CI 2.4-11.0), female sex (OR 3.1; 95%CI 1.7-5.7), any un- 
planned stent (OR 2.8; 95%Ci 1.4-5.9) and ostial lesion (OR 2.2; 95%CI 
t .O-4.7). 
Conclusions: A 4 hour observation period is safe after elective PTCA. 
Since procedural variables are the strongest predictors of postprocedural 
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complications, the immediate procedural result allows effective triage of 
patients to short-term, or prolonged observation in order to anticipate com- 
plications, irrespective of 'adverse' clinical or morphologic characteristics. 
2:30 p.m. 
r -8 -0~ Abciximab Associated With Higher Total Costs at 
Six Months 
Shelby D. Ogilvie-Reed, German Larrain, Warren K. Laskey. University of 
Maryland Medical System, Baltimore, MD, USA 
Background: Analyses based on trials to assess the efficacy of abciximab in 
high risk patients have shown that lower rates of ischemic events and repeat 
revascularizations can offset the additional cost of abciximab at six months. 
Analyses based on data collected during routine medical care may reveal 
dissimilar results due to differences in patient selection, treatment patterns 
and effectiveness. 
Methods: Medical records were abstracted for 101 patients who were 
treated with abciximab and 232 patients who were not while undergoing 
a procedure from July 1995 through December 1996. Cost data for the 
initial hospitalization and subseqent hospitalizations over six months were 
collected. Angiographic films were reviewed and target lesions were assigned 
an ACC/AHA morphology score. A multivariable linear regression model was 
constructed to examine the independent effect of abciximab on the log of 
total costs in 1998 dollars while controlling for age, sex, morphology score, 
cardiac dsk factors (DM, HTN, CHF, and hyperlipidemia), the indication for 
the procedure (acute MI, post-infarction angina, unstable angina, other) and 
whether the patient underwent coronary stenting. 
Results: Abciximab-treated patients had costs that were 34.7% higher 
controlling for demographics and cardiac risk factors. Other factors found to 
be associated with total costs include patients undergoing the procedure to 
treat an acute MI (43.8% higher), stenting (19.8% higher) and patients with 
CHF (34.8% higher) or DM (19.3% higher). 
Conclusion: Abciximab was associated with higher costs at six-months 
when controlling for multiple risk factors. 
2:45 p.m. 
~4-]  Reducing Costs and Improving Outcomes of 
Percutaneous Transluminal Coronary Interventions 
Mauro Moscucci, Eva Kline-Rogers, Dean Karavite, Eric R. Bates, 
Steve Werns, David WM. Muller, Kim A. Eagle. University of Michigan 
Medical Center, Ann Arbor, MI, USA 
Methods to decrease costs of PTCA include attempts to reduce complica- 
tions, appropriate use of new devices (ND) and competitive bidding (CB) for 
supplies. It is however difficult to determine if the results of these interven- 
tions are secondary to a change in case mix or to the intervention, and their 
impact on outcomes. Risk adjustment models for costs and outcomes might 
provide a valid tool for such assessment. 
Methods: Data were collected from 1832 procedures between 7/1/94 
and 12/3/96. Hospital costs were estimated using the Transitional System 
Incorporated method. The database was divided into a pre-intervention set 
(1032 cases) (PRE), and a post intervention set (800 cases) (POST) char* 
acterized by implementation of CB for cath lab supplies, by a reduction in 
the use of post procedure heparin and by implementation of early arterial 
sheaths removal. A risk adjustment model for hospital cost was developed 
on the PRE set, and predicted costs during POST were calculated. 
Results: Multivariate analysis identified lesion complexity, age, number 
of diseased vessels, CHF, acute MI, renal failure and recent cardiac arrest 
as independent predictors of higher costs. POST was characterized by a 
significant increase in case complexity and of new technology utilization (ND 
40% vs 20% and abciximab 12.9% vs 3.7, p < 0.01 ). Despite these changes, 
the observed cost per case was $985 lower when compared to PRE and 
$1495 lower when compared to the predicted cost. In addition, POST was 
characterized by a 24% reduction in the incidence of a combined endpoint 
(Death, Q-wave MI, CABG). 
Conclusion: Despite an increase in case complexity, cost reductions can 
still be achieved through competitive bidding for supplies, and a reduction of 
complications by increased utilization of new technology. 
3:00 p.m. 
~~-]  High Variability in "Normal" on Coronary Rates 
Angiography Among Hospitals 
Zoltan G. Turi. For the Angiographic Evaluation of Cardiac Catheterization 
Study Group; Wayne State University School of Medicine, Detroit, MI, USA 
Background: Coronary angiography has a traditionally predicted normal 
rate of 10 to 20%. The actual severity of disease in cardiac catheterization 
practices across a spectrum of hospitals and cathetedzers is not known. 
Methods: Films (n = 778) were analyzed from 5 hospitals, varying from 
small community to large teaching institutions. Readers were blinded to 
institution, catheterizer, and patient. Three different definitions of "normal" 
were used: no irregularity (NI); mild disease only (MD: no stenosis _> 50%); 
and less than severe disease (LSD: no stenosis _> 70%). The graph below 
shows MD and 3 vessel disease rates. 
1 2 ~ 4 s 
H 0$plta~ 
Results: NI rates varied from 13 to 28%, MD rates from 32 to 41%, and 
LSD from 40 to 49%. Controlling for age and gender did not alter the observed 
variability, No adjustment was made for indications for cardiac catheterization 
and patients with prior coronary bypass were excluded. Individual catheter- 
izers had an MD rate of 39.0 ± 9.8% (range 18--56%). 
Conclusion: "Normal" rates on coronary angiography show substantial 
variation. Although higher than expected, these rates may be more repre- 
sentative of true catheterization practices. 
3:15 p.m. 
~0-8~ Readmission Following Coronary Artery Bypass 
Graft Surgery in New England: Magnitude and 
Variability Across Institutions 
Andrea E. Siewers, Paul D. McGrath, F.L. Lucas, David E. Wennberg. Div. 
of Health Services Research, Maine Medical Center, Portland, ME, USA 
Background: Admission after coronary artery bypass grafting (CABG) is 
frequently used by hospitals as a performance measure. Often hospitals 
only have access to their own data and cannot capture readmissions to 
other hospitals. We assessed the magnitude of the underascartainment of 
readmission and its variability across institutions. 
Methods: Using 1994-1995 Part A Medicare data for New England, 
we calculated 30-day readmission rates following CABG for 23 hospitals 
performing at least 100 CABGs in a year. Crude estimates are presented; 
adjustment for patient characteristics, comorbidity, and length-of-stay gave 
similar results. Rates were calculated for readmission to any hospital and 
only to the CABG center (index hospital). Center variability is described using 
the interquartile range and coefficient of variation. 
Results: Of 6386 CABG patients, 1022 experienced 1127 readmissions. 
Only 46% of readmissions (range 25%-70%) involved either admission or 
transfer to the index CABG hospital. 
People (N = 6386) Readmits (N = 1127) 
Ever To Index Percent To Index 
Overall 1022 (16%) 493 (8%) 524 (46%) 
Across 23 Centers 
Mean 16% 8% 48% 
I nterquarlile Range 14%-19% 6%-11% 37%-58% 
Coefficient of variation 24 38 27 
Conclusions: Half of post-CABG 30-day readmissions are not to the 
hospital where the CABG was performed with considerable variability across 
centers. Disproportionate ascertainment of post-CABG admissions is an 
important obstacle to the use of readmissions as a quality indicator, 
ORAL 
Vascular Biology: Basic Mechanisms 
Monday, March 8, 1999, 2:00 p.m.-3:30 p.m. 
Modal Convention Center, Room 207 
2:00 p.m. 
~ Protein Kinase Hypoxie-lnduced C& Mediates 
Non-apoptotic Cell Death in Endothelial Cells: Roles 
of Heat Shock Proteins 
Yukitaka Shizukuda, Anthony J. Ware. Albert Einstein College of 
Medicine/Montefiore Medical Center, Bronx, NY, USA 
Background: We have previously reported that the activity of protein kinase 
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C,5 (PKC,~) is down-regulated by hypexia in human endothelial cell lines (EC) 
and that such down-regulation enhances EC survival during hypoxia. This 
study investigated whether the decrease in PKC$ in hypoxia either prevents 
EC apeptosis or enhances expression of heat shock proteins (HSP), which 
protect vadous cell types from hypoxia-mediated injuries. 
Methods: To investigate the role of PKC8 in hypoxia-induced EC injury, 
PKC,~ was stably overexpressed in EC (EC-$). Both EC and EC-,~ were 
exposed to either 48 h hypoxia or normoxia. EC death was assessed by 
trypan blue exclusion. Apoptoals was assessed by both TUNEL and DNA 
laddering assays. Expression of HSP was analyzed by immunoblotting. 
Results: EC death was higher in EC-~ compared to vector controls (13.2 
± 1.2% vs. 4.1 4- 0.4%, P < 0.05, values are mean ± S.E.) following 48 h 
hypexia; however, apoptosis was seen in only a small proportion of either 
EC-$ or controls (1.6 ± 0.3% vs. 1.1 ± 0.1%, P = N.S.) by TUNEL assay. 
DNA ladders were not seen in either group at 48 h hypoxia. Immunoblot 
analyses demonstrated the expression of HSP 70 and 90 did not change 
during 24 h hypoxia in either EC-~ or controls. 
Conclusions: Suppression of PKC3 during hypoxia enhances EC survival 
by preventing non-apoptotic cell death, but this effect is not mediated by 
modulation of HSP 70 or 90. Modification of individual PKC isoenymes 
may have therapeutic potential in preventing hypoxia induced endothelial 
injury. 
2:15 p.m. 
( -~-~ Efficacy of the Prophylactic Use of Vascular 
Endothelial Growth Factor (VEGF121) in Animal 
Models of Hindlimb Ischemia - A Functional 
Assessment 
Luis Henrique W, Gowdak 1 , Lioubov Poliakova I , Xiaotong Wang 1 , 
Kenneth Fishbein 1 , Richard Spencer I , Imre Kovesdi 2, Mark Talan ~ ,
Maudzio Capogrossi ~ . r Gerontology Research Center, National Institute on 
Aging, National Institutes of Health, Baltimore, MD; 2GenVec, Inc, Rockville, 
MD, USA 
Purpose: To perform a functional assessment of the efficacy of adenovirus- 
mediated VEGF~21 (Ad.VEGF121) gene transfer to a normoperfused hindlimb 
in enhancing blood flow to skeletal muscles following the induction of is- 
chemia. 
Methods: Rabbits (n = 48) and rats (n = 22) received intramuscular in- 
jections of Ad.VEGF12~, Ad.Null or saline along the projection of the dght 
femoral artery (RFA) in the thigh. Four weeks (rabbits) or 2 weeks (rats) after 
treatment, hindlimb ischemia was induced by removal of the RFA. Tissue 
perfusion (TP) was assessed in rabbits by determining the calf blood pres- 
sure ratio (BPR) between ischemic/non-ischemic limbs and by measuring 
the regional blood flow (RBF) to the gastrocnemius muscle with radioac- 
rive microspheres. In rats, TP was assessed by the bioenergetic profile of 
the gastrocnemius muscle using the 3~ p magnetic resonance spectroscopy 
technique. 
Results: In the first 4 weeks affer surgery, BPR showed a faster restora- 
tion of blood flow in animals treated with Ad.VEGF~2~ than in controls. At 
week 4, BPR (mean + SE) was 0.48 ± 0.10, 0.13 4- 0.03 and 0.19 J:: 
0.05 for Ad.VEGF121, Ad.Null and saline groups, respectively (p < 0.001). 
RBF (ml/min/100 g, mean 4- SE) was higher at day 1 after surgery in ani- 
mals treated with Ad.VEGF12~ than in controls (Ad.VEGFt2~ = 5.69 4- 0.81, 
Ad.Null = 2.97 4- 1.00 and saline = 2.78 4- 0.87, p < 0.001). RBF remained 
higher in the Ad.VEGF121-group until week 4 (p < 0.001 vs. controls). The 
bioenergetic profile of the gastrocnemius muscle at day 1 after surgery was 
markedly improved in Ad.VEGF~21-treated rats than in controls (p < 0.001). 
This improvement persisted at days 7 and 14 after surgery. 
Conclusion: These results support the hypothesis that local administra- 
tion of Ad.VEGF121 can induce angiogenesis in normally perfused skeletal 
muscles and that the newly formed blood vessels preserve blood flow to the 
treated tissue upon the induction of ischemia. 
2 :30 p.m. 
~-0-~ Bacterial Lipopolysaccharide Induces Alkaline 
Phosphatase Activity in Bovine Calcifying Vascular 
Cells: Possible Role in Vascular Calcification 
Jignesh Patel, Farhed Parhami, Linda L. Demer. Division of Cardiology, 
UCLA School of Medicine, Los Angeles, CA, USA 
Background: Chronic bacterial infection (with chlamydia pneumoniae, for 
example) may contribute to atherogenesis. Arterial calcification is a com- 
mon feature of atherosclerosis. We have previously reported that alkaline 
phosphatase (ALP) activity is a marker for differentiation and calcification 
of calcifying vascular cell (CVC) cultures. We have also shown that human 
monocytes can be activated by bacterial lipopolysaccharide (LPS) to induce 
differentiation of CVC through the production of TNFc~. 
Aim: To determine whether bacterial elements may promote differentia- 
tion of CVCs directly through the production of TNFc~, we examined the effect 
of bactedal LPS on CVC differentiation and TNFe production. 
Methods: Conditioned media was prepared from LPS stimulated CVC. 
This media was used to treat new CVC cultures. TNFoL was quantified in the 
conditioned media by ELISA, and total cellular ALP activity was determined 
in the conditioned-media treated CVC. 
Results: Compared to conditioned media from untreated cells, condi- 
tioned media from LPS treated cells induced ALP activity in CVC in a dose 
dependent manner, 44 fold with 1 p.g/ml LPS and 75 fold with 4#g/ml LPS. 
However, there was no significant detection of TNF, in the conditioned media 
at either concentration of LPS. 
Conclusion: Bacterial LPS can therefore stimulate ALP activity in CVC 
by a mechanism independent of TNFc~ production. Furthermore, CVC are 
induced by LPS to produce a secretory factor which acts in an autocrine 
manner to stimulate ALP activity. We hypothesize that bacterial LPS might 
therefore contribute to calcification of atheromatous lesions and may be a 
response to chronic infection within the plaque. 
2:45 p.m. 
Developmentally Regulated Endothelial Cell Locus: ~ 
A Novel Angiogenic Protein 
James J. Jang, Hoai-Ky V. Ho, Kalyani Penta, Thomas Quertermous, John 
P. Cooke. Stanford University School of Medicine, Stanford, CA, USA 
Background: Developmentally regulated endothelial cell locus (Del-1) is a 
novel extracellular matrix protein expressed in an endothelial cell restricted 
pattern during embryologic vascular development. Dell has been shown 
to promote adhesion and migration of endothelial cells through ~v,83 and 
c~5,81 integrin interactions, which may in turn be an activating mechanism for 
angiogenesis. 
Methods: To study the effects of Del-1 as an angiogenic protein, we 
used a disc angiogenesis system (DAS). The DAS consisted of a synthetic 
polyvinyl alcohol disc which was implanted subcutaneously in normal female 
C57BL/6J mice. Inside the center of the disc, we placed either control (PBS) 
or Del-1 (0.2 mol) inside a pellet which was coated with a copolymer to 
allow a controlled release of the agent. After 14 days, the disc was extracted 
and sectioned to charactedze and measure for growth. Vascular growth oc- 
curred centripetally into the disc and was quantitated through morphometric 
analysis. 
Results: 
Pellet Agent  Fibrovascular Growth Area (mm 2) 
Control (PBS) 12.2 ± 3.6 
Del-1 (0.2 tool} 22.7 ± 1.7 (p < 0.005) 
Conclusion: Del-1 enhances angiogenesis in an in vivo disc angiogen- 
esis assay. Therefore, Del-1 may have a role in angiogenesis, as well as 
embryonic vasculogenesis. 
3:00 p.m. 
~8-0-~ Rapamycin Inhibits Vascular Endothelial Cell 
Proliferation Via Induction of a Cyclin-Dependent 
Kinase Inhibitor 
Ji Sun, Hong Jun Chen, Steven O. Marx, Allan Schwartz, Andrew R. Marks, 
LeRoy E. Rabbani. Columbia Universi~ New York, NY, USA 
Background: Rapamycin, a potent antiproliferative macrolide antibiotic, in- 
hibits human smooth muscle cell (SMC) proliferation and migration by de- 
laying phosphorylation of the retinoblastoma protein and upregulating the 
cyclin-dependent kinase inhibitor p27 kip1. In order to establish the tissue 
specificity of rapamycin, we sought to determine whether rapamycin inhibits 
endothelial cell proliferation in a similar manner. 
Methods: The effects of a one week treatment with rapamycin on coronary 
artery endothelial cell (CAEC), bovine artery endothelial cell (BAEC), human 
umbilical vein endothelial cell (HUVEC), and human smooth muscle cell 
(HSMC) proliferation were assayed in vitro using a Coulter counter. 
Results: 
Inhibition of Cell Growth 
Rapamycin 0.1 nM 1 nM 10 nM 100 nM 
CAEC 18%" 43%* 50% ° 47%* 
Cell BAEC 9%** 42%* 47%" 42%* 
Type H UVEC 19%" 36%" 44%* 45%" 
HSMC 28%* 43%* 50%* 53%" 
"n = 6, p < 0.001 compared to control; "n = 6, p < 0.05 compared to controt 
Rapamycin significantly inhibited proliferation of all three types of en- 
dothelial cells. Inhibition of both SMC and endothelial cell proliferation was 
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associated with a 2-4 fold induction of p27 protein levels, determined by 
immunoblot analysis. 
Conclusion: Taken together, these data suggest that both SMC and 
endothelial cell proliferation are inhibited by rapamycin-mediated induction 
of p27 kip1 . 
3:15 p.m. 
[ -80~ Intracranial Arteries of Human Fetuses Are More 
Resistant to Oxidative Damage and 
Hypercholesterolemia-lnduced Fatty Streak 
Formation Than Extracranial Arteries 
Claudio Napoli 1,2, Francesco P. D'Armiento 2, Joseph L. Witztum 1 , 
Filomena de Nigris 2, Oswald Quehenberger 1 , Wulf Palinski 1 . I Department 
of Medicine, University of California, La Jolla, San Diego, CA, USA; 
2Departments of Medicine and Pathology, Federico II University of Naples, 
Italy 
Background: Atherosclerotic lesions in intracranial arteries occur later and 
are less extensive than in extracranial arteries. 
Aim: To investigate potential mechanisms responsible for this difference, 
in particular the atherogenic response to hypercholesterolemia and LDL 
oxidation, we compared the extent of fatty streak formation and lesion com- 
position in intracranial arteries of human fetuses from normo- and hyperc- 
holesterolemic mothers to those in extracranial arteries. 
Methods: Lesions were quantitated by computer-assisted image anal- 
ysis of 30 Sudan stained sections each from the middle cerebral, basi- 
lar, and common carotid arteries and the abdominal aorta of human fe- 
tuses (spontaneous abortions and prematurely newborns who died within 
12 hours of birth; fetal age 6.2 ± 1.3 months) from 43 hypercholesterolemic 
and 34 normocholesterolemic mothers. Radical scavengers were also mea- 
sured. 
Results: Lesion numbers and sizes were dramatically greater in the ab- 
dominal aorta (area of the largest lesion per section: 66.5 ± 10.9 × 103 mm 2) 
and the carotid (11.6 ± 5.3 × 103 mm 2 ) than in the basilar and middle cerebral 
artery (0.4 ± 0.1 and 0.8 ± 0.2 × 10 mm, respectively; P < 0.0001). Hyperc- 
holesterolemia resulted in a significant increase of lesion size in extracranial, 
but only a marginal increase in intracranial arteries. Immunocytochemistry 
did not indicate that lesions of intracranial arteries contained relatively less 
OxLDL or macrophages than similar size lesions of extracranial arteries. 
However, activities of Mn-superoxide dismutase (Mn-SOD), but not of Zn- 
SOD, catalase, or glutathione peroxidase were significantly higher in both 
intracraniat arteries. Fetal erythrocytes contained significantly greater Mn- 
SOD activity than those of newborns and adults, and showed a significant 
negative correlation with the size of fetal fatty streaks. 
Conclusions: Exposure to hypercholesterolemia during fetal develop- 
ment results in extensive formation of fatty streaks in extracranial but not 
intracranial arteries. The fact that such a difference in lesion formation oc- 
curs in the absence of many other atherogenic risk factors found later in 
life suggests that differences in the atherogenic response to hypercholes- 
terolemia are an important contributor to the slower onset of the disease 
in intracranial vessels in adults. Fetal arteries may allow elucidation of the 
mechanisms responsible. These mechanisms are likely to include a better 
protection of intracranial arteries against free-radical mediated atherogenic 
processes. 
POSTER 
Vascular Biology and Thrombosis 
Monday,  March  8, 1999, 3 :00 p .m. -5 :00  p.m. 
Moda l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  3 :00 p .m. -4 :00  p.m. 
~ Comparative Efficacy of Different Platelet 
GPUb/Illa Receptor Antagonists on Tissue Factor 
(TF)-Induced Plateiet-Mediated Clot Strength 
Using Thromboelastography (TEG) 
Shaker A. Mousa, Mark Forsythe. DuPont Pharmaceuticals Co., 
Cardiovascular Division, Wilmington, DE, USA 
Background: The role of the platelet GPIIb/llla as the final common path- 
way for platelet aggregation regardless of the platelet activator is well docu- 
mented. Additionally, platelet surface membrane is known to be an essential 
for the assembly of pro-coagulant activities. Hence, the present study was un- 
dertaken to determine the anti-clotting effect of various classes of GPllb/llla 
antagonists using TF-mediated TEG. 
Methods: Blood clotting strength was measured using TEG under condi- 
tions of platelet activation accelerated by TF and shear. Under these condi- 
tions, platelets significantly enhance clot strength by eight fold. 
Results: All GPIIb/llla antagonists with high affinity and slow dissociation 
rates from resting platelets such as XV459 (active form of DMP754 or Roxi- 
fiban), DMPS02, XV454 and c7E3 (ReoPro) demonstrated a potent inhibitory 
effects on clot strength (IC50 = 50-70 nM). In contrast, GPIIb/llla antagonists 
with relatively higher affinity for activated~ lower affinity for resting platelets 
and relatively faster dissociation rates such as DMP728 and others antago- 
nists with such binding kinetic profiles have a much lower efficacy in altering 
the strength of TF-mediated clot formation. 
IC50 (uM) ± SD 
DMP754 DMP728 C7E3 XT199 
*PI, Agg. 0.05 ± 0.01 0.05 ± 0.01 0.10 ± 0.02 >0.50 
TF-Clotting 0.07 ± 0.02 >-0.50 0.07 ± 0.01 >0.50 
• Platelet aggregation (PI. Agg.) -induced by TRAP at 10 uM 
Under the same conditions ~v#3 antagonist such as XT199 was without 
any significant effects on TF induced platelet-mediated clotting. 
Conclusion: This data indicated a differential efficacy among different 
GPIIb/llla antagonists in inhibiting platelet-mediated clotting in spite of their 
equivalent platelet anti-aggregatory potency. 
~ Tissue Factor Expression is Increased by bFGF 
Infusion in Rabbits 
Deiphine Corseaux, Thibaud Meurice, Isabetle Six, Michael D. Ezekowitz, 
Christophe Bauters, Brigitte Jude. Cardiologic Hospital, Lille, France; Yale 
University New Haven, USA 
Background: Growth factors promote vascular repair and angiogenesis, and 
can induce in vitro tissue factor (TF), a potent agent of thrombogenesis and 
probably of angiogenesis, in macrophages, endothelial cells (EC) and smooth 
muscle cells (SMC). The objective was to evatuate in vivo modifications of 
TF expression induced by bFGF in vascular cells in normal or hyperlipemic 
rabbits. 
Methods: 12 rabbits were randomized to receive a normal diet (Grl, n 
= 6), or a diet containing 2% cholesterol for 6 weeks (Gr2, n = 6), followed 
during 3 weeks by daily infusions of bFGF (2.5 /~g) (Grl + bFGF, Gr2 + 
bFGF). TF activity (amidolytic assay) was evaluated in mononuclear cells 
from arterial blood after incubation with (+E) or without (-E) endotoxin. TF 
was detected in abdominal aorta sections using an anti rabbit TF monoclonal 
antibody (AP-1). 
Results: bFGF induced a strong expression in monocytes (see table), 
and in SMC and EC in normal rabbits. In hypercholesterolemic rabbits, only 
an increase response of monocytes to endotoxin was observed, with or 
without bFGF. 
Conclusion: In this model, bFGF induced a significant increase in TF 
expression in monocytes and vascular cells. Hypercholesterolemia induced 
no or little changes in TF expression, and partially blunted the effect of bFGF. 
This suggests that bFGF can increase the thrombogenicity of vascular cells, 
and that this effect can be modulated by lipids. 
Grl Grl + bFGF Gr2 Gr2 + bFGF 
-E  74±41 164:1=57 32~12 19~: 5" 
+E 80 i 45 148 ± 46 89 ± 15 184 ± 25 § 
*p < 0.05 vs Gr2, §p < 0,05 vs Grl + bFGF 
• Plasminogen (PAl-1) Activator Inhibitor-1 
Promotes Vascular Thrombosis in Mice Following 
Photochemical Injury 
Daniel 11 Eitzman, Randal J. Westnck, David Ginsburg. Internal Medicine, 
Division of Cardiology, University of Michtgan Medical Center, Ann Arbor MI, 
USA 
Background: Acute vascular thrombosis results from activation of the co- 
agulation cascade and platelets while the fibrinolytic system is involved in 
subsequent thrombolysis. However, epidemiological data indicates that plas- 
minogen activator inhibitor-1 (PAl-l), an important regulator of the fibrinolytic 
system, plays an important role in the formation of occlusive arterial and 
venous thrombosis. The aim of the present study was to determine whether 
PAl-1 contributes to occlusive arterial and venous thrombus formation fol- 
lowing vascular injury and to determine the contribution of platelet PAI-I. 
Methods and Results: We have utilized a murine model of thrombosis 
that involves a photochemical reaction between a photosensitizer dye, Rose 
Bengal, and transmural green light. To determine whether PAl-1 plays a role 
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in the development of occlusive arterial thrombosis, the common carotid ar- 
teries of 16 wild-type and 8 PAl-1 deficient mice were injured while blood 
flow was continuously monitored. 16/16 wild-type mice developed occlusive 
thrombus an average of 54.0 4- 3.5 minutes following Rose Bengal injection 
and light exposure. In contrast, only 2/8 PAl-1 deficient mice developed oc- 
clusive thrombus during the 90 minute observation period (p < 0.05). Injury 
to an atherosclerotic plaque at the carotid bifurcation in atherosclerotic-prone 
mice deficient in apolipeprotein E resulted in a time to thrombosis of 43.8 4- 
5.1 minutes. In mice deficient in both apolipoprotein E and PAl-1 the time to 
occlusion at this site was prolonged to 65.2 4- 6.6 minutes (p < 0.05). Injury 
to the internal jugular vein produced occlusive thrombosis in all mice with an 
average time to occlusion of 39.7 ± 2 minutes in wild-type mice and 56.7 4- 
5.4 minutes in PAl-1 deficient mice (p < 0.05). To determine the source of 
PAl-1 affecting thrombosis, bone marrow transplantation was performed be- 
tween PAl-1 deficient and wild-type mice. Following replacement of wild-type 
platelets with PAl-1 deficient platelets, the time to occlusion was prolonged 
from 54.0 4- 3.5 to 85 4- 3 minutes (p < 0.05). 
Conclusions: These studies demonstrate that PAl-1 is an important 
regulator in the development of occlusive arterial and venous thrombosis in 
normal and diseased vessels and that platelet PAl-1 plays a major role. 
~ Antithrombotic Effects of A New ZD-2486, Orally 
Active lib/Ilia Receptor Antagonist 
Merce Roque, Eduardo Acampado, James H. Chesebro, Valentin Fuster, 
Juan J. Badimon. Mount Sinai School of Medicine, New York, USA 
Background: Platelet activation and thrombosis play a key role in the onset 
of acute coronary events. Glycoprotein lib/Ilia receptor complex is the final 
modulator of platelet aggregation and thrombosis. Recent trials demonstrated 
the effectiveness of these agents and suggested the need for long-term 
treatment, triggering the development of orally active agents. 
Methods: We compared the antithrombotic effects of ZD-2486 (ZD, 
Zeneca) versus heparin, using the ex-vivo Badimon perfusion chamber in 
a canine model. Thrombus formation was analyzed by deposition of autol- 
ogous In-platelets (PD) and I-fibrinogen (FgD) after 5-minute perfusions at 
low (212 -s) and high (1690 s) shear rate conditions (LSR, HSR). Dog tunica 
media, mimicking arterial disruption, served as thrombogenic substrate. The 
study included two different approaches: a) an i.v. dose-response study and 
b) after one-week oral administration. Appropriate oral dosing was extrapo- 
lated from the i.v. study. Platelet aggregation and haematological parameters 
were monitored. 
Results: 
HSR LSR 
Treatment Route PD" FgD" PD" FgD* 
UFR 100 i.v. 214 ± 21 626 ± 63 24 ± 3 182 ± 23 
ZD 0.3 mg/Kg i.v. 274±26 340--.32 25±3 118±12 
ZD 0.4 mg/Kg i.v. 187±25 219±33 11±1 107±8 
ZD 0.5 mg/Kg i.v. 98±14 136±18 22±3 136±18 
ZD 1 mg/Kg i.v. 36 ± 8 103 ± 7 11 ± 1 85 ± 4 
ZD 1 mg/Kg oral 264-8 244±38 17±4 180±13 
Data expressed as X ± SEM, i.v dose mg/kg bolus + mg/Kg/h; oral mglKg/day; PD 106 
platelets/cm2; FgD 1012 molecs/cm2; "p < 0.00t ANOVA. 
Conclusions: ZD reduced thrombus formation following iv or oral admin- 
istration especially at HSR, typical of mildly stenosed coronaries. By allowing 
oral treatment after initial iv dosing, ZD seems to be a promising agent in the 
acute and long-term treatment of coronary syndromes. 
~ D o e s  Abciximab Inhibit the Expression of PAC-1 
on Newly Released GP lib-Ilia Receptors? 
M. Greg Treuth, Anand Ramanathan, John Isaac, Tom Chow, David Wu, 
Scott Simon, Neal S. Kleiman. Baylor College of Medicine, Houston, TX, 
USA 
Background: Following platelet activation platelets degranulate, release 
GP lib-Ilia receptors, and bind fibrinogen resulting in platelet aggregation. 
Abciximab prevents platelet aggregation by blocking fibrinogen binding to the 
lib-Ilia receptor but its effect on the activated lib-Ilia fibrinogen binding site 
is unclear. 
Methods: Using whole blood flow cytometry, we studied the effects of 
abciximab (A) on the release and activation of the GP lib-Ilia receptor with 
monoclonal antibodies directed at GP lib (CD41) and the activation-depen- 
dent fibrinogen binding site (PAC-1). Blood was collected before and one 
hour after A, and stimulated with varying concentrations of ADP and 6-mer 
thrombin activating peptide (TRAP). 
Results: A blocked lib-Ilia receptors and PAC-1 by 85% and 90%, respec- 
tively. However, fluorescence of both receptors increased after stimulation 
despite the presence of A. Increases in receptor expression (MFU) were: 
Change in CD41 Change in PAC-1 
Pre A Post A P Pre A Post A P 
5 #M ADP 8.2±1.1 9 .5±0.9 NS 16,2 = 1.9 4 .0±0.8  0.001 
20 #M ADP 7.8:{_1.0 10.1±1.1 NS 17.7±1.8 4 .8±0.9  0.001 
5 ~M TRAP 9.8 ± 1.0 8.1-{-0.9 NS 17.0±2.3 5.5 ± 1.0 0.001 
20 #M TRAP 18,3±1.1 18.4±1.6 NS 1A9 ± 2.2 5.5±1.1 0.01 
While A did not alter the release of lib-Ilia receptors following stimulation, 
expression of PAC-1 binding sites on newly released receptors was blunted 
with A. 
Conclusion: After abciximab the total number of lib-Ilia receptors can 
increase significantly upon platelet activation, while the number of effective 
lib-Ilia receptors does not. Furthermore, tests directed at measuring lib-Ilia 
blockade using antibodies directed at the lib-Ilia receptor alone may under- 
estimate the true effect of abciximab on platelet-fibrinogen binding. 
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~ Vascular Hypertrophy and Distensibility of the 
Carotid Arteries in Patients with Hypertension. 
ICARUS, A Life Substudy 
Michael H. Olsen, Eigil Fossum, Elsa Hjerkinn, Kristian Waehtell, 
Aud Haieggen, Shawna Nesbitt, Ulrik Andersen, Hans Ibsen, 
Sverre Kjeldsen, Stevo Julius. Glostrup University Hospital, Denmark," 
Ullevaal University Hospital, Norway 
Objectives: To investigate the relative importance of insulin resistance ver- 
sus blood pressure on vascular hypertrophy and carotid distensibility in 
patients with left ventricular hypertrophy determined by electrocardiogram. 
Methods: In 99 unmedicated patients, mean age 67, with stage I1-111 hy- 
pertension we measured resting blood pressure, whole body glucose uptake 
using clamp technique, minimal forearm vascular resistance using plethys- 
mography, intima-media thickness and wall distensibility of the common 
carotid arteries using ultrasound. 
Results: 
Simple linear lntima-media Minimal fore* Distensibility 
Regression analyses thickness of the arm vascular of the common 
carotid arteries resistance*" carotid arteries 
R P R P R P 
Age 0.30 <.0.01 NS NS 
Systolic blood pressure 0.22 <0.05 0.48 <0.01 0.36 <0.001 
Body mass index -0.29 <0.01 NS NS 
Fasting insulin -0.21 <0.05 -0.30 0,08 NS 
Glucose uptake index 0,29 <0,01 NS 0.50* <0.05 
*Only in untreated, non-diabetic patients (n: 21) "Only in males 
Conclusions: Vascular hypertrophy and decreased distensibility of the 
common carotid arteries is associated with increased systolic blood pressure 
in elderly patients with essential hypertension and left ventricular hypertrophy 
determined by electrocardiography. 
Insulin does not seem to be a significant vascular growth factor in this 
group of patients, but insulin resistance is associated with decreased disten- 
sibility of the common carotid arteries in the subgroup of untreated hyperten- 
sive, non-diabetic patients. 
~ T h e  of Apoptosis, Migration Role Proliferation and 
as Regulators of Intimal Cell Density in Human 
Carotid Arteries 
Gerhard Bauriedel, Randolph Hutter, Daniela Lambrecht, Frauke Verrel, 
Attain Parzhuber, Ulrich Welsch, Berndt LQderitz. Dept. of Cardiology, 
University of Bonn, Bonn; Dept. of Surgery, University of Munich, Munich, 
Germany 
Background: Programmed cell death (apoptosis), proliferation and migra- 
tion of plaque cells are considered to be involved in human carotid lesion 
formation. In this study, we sought to quantify the cell density effectors apop- 
tosis (detected by TUNEL test), proliferation (MIB1; expression of the cell 
cycle-related antigen Ki-67) and migration (expression of the chemeattractant 
PDGF), as well as to evaluate their relation. 
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Methods: We analyzed 44 high-grade human carotid plaques removed 
by surgery. Detection of PDGF (Oncogene Science) and Ki-67 (Dako) was 
performed by immunohistochemistry, using the APAAP technique. For evalu- 
ation of apeptosis, TdT mediated dUTP nick end (TUNEL) labeling was used. 
Signals were quantified by histomorphometric analysis. 
Results: Intimal cell density ranged from 284 to 1792 cells/ram 2 and av- 
eraged 933 ± 309 cells/ram 2 (x ± SD; n = 44 lesions). Apeptosis identified by 
nucleus-bound TUNEL signals was found with 82 ± 65 cells/ram 2, confirmed 
by additional transmission electron microscopic analysis. Mean expression 
of PDGF amounted to 257 ± 195 positive cells/ram 2 and that of Ki-67 to 4 ± 
4 cells/ram 2, indicating a proliferative activity below 1%. Interestingly, i ntimal 
cell density showed a significant positive correlation with PDGF (r = 0.39, p 
= 0.008), but neither with Ki-67 (r = 0.17, p = 0.33) nor with TUNEL labeling 
(r = -0.16, p = 0.30). In addition, TUNEL labeling correlated inversely with 
Ki-67 (r = -0.42, p = 0.019) and positively with PDGF expression (r = 0.36, 
p = 0.025), whereas expression of PDGF and that of Ki-67 did not correlate 
(r = -0.14, p = 0.45). 
Conclusion: Our data indicate that predominantly migratory, but not pro- 
liferative events contribute to intimal cell accumulation, Conversely, carotid 
lesions with elevated PDGF expression reveal a high level of apoptosis. 
Thus, apeptosis and decreased proliferation may be important regulatory de- 
terminants that control intimal cell homeostasis by prevention of exuberant, 
migration-induced cellularity. 
• Relationship Between Intima-Media Complex of 
Common Carotid Artery, Leptin Serum Levels and 
Insulin Activity in Obese and Non-Obese Subjects 
M. Ciccone, F. Morisco, A. Maiorano, O, Rossi, G. De Pergola 1 , 
R. Giorgino 1 , P. Rizzon. Institute of Cardiology; ~ lnstitute of Endocrinology, 
Bail Universi~ Italy 
Background: Obesity is an independent cardiovascular risk factor and plays 
an important role in the genesis of early atherosclerosis. Leptin is a recently 
discovered protein, produced by white adipose cells, and its serum levels 
are directly proportional to total fat-mass. The aim of the present study was 
to investigate the relationship between the intima-media complex (IMT) of 
common carotid artery and serum levels of leptin. 
Methods: The study was carded out in 120 healthy subjects (52 males e 
68 females), with age ranging between 18 and 45 years and a wide range of 
Body Mass Index (BMI). Fasting glycemia, total cholesterol, LDL-cholesterol, 
HDL-cholesterol, triglycerids and blood concentration of leptin (by RIA) and 
insulin (by RIA) were measured. IMT was obtained by high definition vascular 
echography. 
Results: Common carotid IMT showed a positive correlation with leptin (p 
< 0.001 in males, p < 0.005 in females) and age (p < 0.005 in both males and 
females) and a negative correlation with insulin sensitivity (measured using 
insulin tolerance test and expressed in KITT) in both sexes (p < 0.05). IMT 
showed also a direct relationship with total cholesterol and LDL-cholesterol 
levels in men (p < 0.05 and p < 0.05 respectively) and with arterial blood 
pressure in women (p < 0.05). 
By using a model of multiple regression statistical analysis to evaluate 
the independent contribution of different variables: leptin, age, KITT, smok- 
ing, arterial blood pressure, fasting glycemia, tryglicerides, total cholesterol, 
LDL-cholesterol and HDL-cholesterol on common carotid artery IMT, the cor- 
relation between leptin and IMT was maintained both in men (p < 0.01) and 
in women (p < 0.05). 
Conclusion: This study shows an independent relationship between 
serum levels of leptin and IMT of common carotid artery. Since leptin is 
a marker of body fat accumulation and IMT is considered an early sign 
of asymptomatic atherosclerosis our results suggest that leptin can play 
a significant role in increasing adipose tissue mass and in progression of 
atherosclerosis. 
~ Association Between Mitral Annulus Calcification 
and Carotid Atherosclerotic Disease 
Yehuda Adler, Amen Koren, Noam Fink, David Tanne, Renato Fusman, 
Abid Assali, Avigdor Zelikovski, Alex Sagie. Dept of Cardiology, The 
Sheingarten Echocardiography Unit, and Oept of Vascular Surgery, Rabin 
Medical Center, Beilinson Campus, Petah Tiqva; Sackler School of 
Medicine, Tel Aviv University, Tel Aviv, Israel 
Background: It has been established that mitral annulus calcification (MAC) 
is an independent predictor of stroke, though a causative relationship was 
not proven, and that carotid artery atherosclerotic disease (CAAD) is also 
associated with stroke. Therefore we sought if whether there is an association 
between the presence of MAC and CAAD. 
Methods: Of the 805 pts in whom the diagnosis of MAC was made by 
I-FE between 1995 and 1997, 133 pts (60 males, 73 females; mean age 
74.3 ± 8 yrs, range 47-89 yrs) underwent carotid artery duplex ultrasound 
and comprised the study group. They were compared with 129 age- and 
sex-matched pts without MAC who underwent carotid artery duplex ultra- 
sound during the same period for the same indications. MAC was defined 
by a dense localized, highly reflective area at the base of the posterior mitral 
leaflet. MAC was considered severe when the thickness was _> 5 mm on 2-D 
echo. Carotid artery stenosis was graded as follows: 0% 20%, 40%, 60%, 
80% and 100%. 
Results: Severe MAC was found in 48 pts. Compared with the controls, 
the MAC group showed a significantly higher prevalence of carotid stenosis 
> 40%, (45% vs. 29%; p = 0.004), which was associated with >2-vessel 
disease (23% vs. 10%; p = 0.004) and bilateral CAAD (18% vs. 9%; p = 
0.04); significant differences were also found for the severe MAC subgroup 
for carotid stenosis _> 40% in rates of CAAD (60% vs. 29%, p = 0.0001), 
and >_ 2-vessel disease (31% vs. 10%, p = 0.001), in addition to bilateral 
carotid artery stenosis (23% vs 9%, p = 0.017), and even bilateral proximal 
internal carotid artery stenosis (21% vs. 8%, p = 0.015). On multivariate 
analysis, MAC and age, but not traditional risk factors, were the only inde- 
pendent predictors of carotid atherosclerotic disease (p = 0.008 and 0.03, 
respectively). 
Conclusions: There is a significant association between the presence of 
MAC and CAAD. MAC may be an important marker for atherosclerotic dis- 
ease of the carotid arteries. This association may explain the high prevalence 
of stroke in pts with MAC, 
• Effects of Intensive Lipid-Lowering Therapy on 
the Characteristics of Carotid Atherosclerotic 
Plaques by MRI 
Xue-Qiao Zhao, Chun Yuan, Ellen Hues Frechette, Kenneth R. Maravilia, B. 
Greg Brown. University of Washington, Seattle, WA, USA 
Background: The effects of intensive lipid-towering therapy on the character- 
istics of carotid atherosclerotic plaques in CAD patients (pts) were examined 
using high-resolution magnetic resonance imaging (MRI) with flow suppres- 
sion. 
Methods: Eight CAD pts who have been receiving intensive lipid-lowering 
treatment (niacin 2.5 grn/day, Iovastatin 40 mg/day, and colestipo120 gm/day) 
for 10 years, with mean LDL level < 100 mg/dl, in the Familial Atherosclerosis 
Treatment Follow-up Study were selected as treated group. Eight CAD pts 
who matched to the treated pts for age ± 3 yrs, baseline LDL ± 5 mg/dl 
and triglyceddes ± 50 mg/dl, but never treated with lipid-lowering drugs 
were selected as controls. Thirty-two carotid arteries in these 16 pts were 
examined using MRI. Images per artery with 3 mm section thickness that 
covered approximately 4-cm portions of the common carotid, bifurcation, and 
internal and external carotid artedes were obtained using time of flight, T1, 
proton-density and T2 weightings, and were analyzed blinded to pt treatment. 
For each carotid artery, lumen (LA) and plaque areas (PA) were measured 
by planimetry from an image that showed most plaque. Carotid plaque 
components such as fibrous tissue (FT), calcium (CAL) and lipid deposits 
(LD) were identified based on previous studies using signal intensity from 4 
different weightings, and planimetered for area. Proportions of each plaque 
component were calculated. 
Results: 
LDL HDL LA mm 2 PA mm 2 % FT % CAL % LD 
Treated 84" 51" 55 ± 33 58 ± 19 83 101 11 
Controls 158 37 44 ± 20 64 ± 18 77 2 17 
*: p < 0.001; t: p < 0.05, compared to matched controls. 
Conclusions: MRI can identify the principal tissue components of carotid 
atherosclerotic plaque. By MRI, prolonged intensive lipid-lowering therapy 
is associated with increased calcium and with a decreased lipid-to-fibrous 
tissue ratio. These characteristics predict greater plaque stability in treated 
patients. 
~ Protection Against Shear-Dependent Arterial 
Thrombosis by Local Expression of Human 
Tissue Factor Pathway inhibitor in Balloon-Injured 
Porcine Carotid Arteries 
Pierre Zoldhelyi, Janice McNatt, Hamath S. Shelat, James T. Willerson. 
Texas Heart Institute and Department of Medicine, University of 
Texas-Houston Medical School, Houston, TX, USA 
We recently demonstrated the feasibility of human tissue factor pathway 
inhibitor (TFPI) transduction of normal and atherosclerotic arteries. We now 
investigated whether local gene transfer of human TFPI may be protective 
against thrombosis caused by arterial injury and shear stress. Transfemoral 
carotid balloon angioplasty was performed in 16 Yorkshire pigs (5 inflations 
to 7 atm) followed by local instillation of 3 x 10 l° pfu of an adenoviral 
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vector encoding TFPI (Ad.TFPI, N = 8) or no foreign gene (Ad.RR, N = 
8). Five days later pigs were anesthetized and carotid flow was measured 
in the injured artedal segment by Doppler flow probe. In Ad.RR treated 
pigs carotid cyclic flow variations (CFV) were observed, respectively, in 4/8 
and 7/8 animals at baseline and after creation of a 40% stenosis by an 
external constrictor; 8/8 arteries occluded at a 70% stenosis. In contrast, of 
the Ad.TFPI treated pigs only 1/8 showed CFV at baseline and 40% stenosis 
and only 3/8 occluded at a 70% stenosis. Mean carotid flow was 1.6 ± 3 and 
3.3 :E 3.7 kHz, respectively, at 40% and 70% stenosis in Ad.RR treated pigs, 
but 8.9 ± 2.1 and 3.3 ± 3.7 kHz in pigs treated with Ad.TFPI (respectively, 
p = 0.0001 and p = 0.026 for the comparison at 40 and 70% stenosis). 
Moreover, none of the 5/8 Ad.TFPI pigs open at 70% stenosis showed 
any flow disturbance during an incremental epinephrine infusion up to 38 
~g/min. There were no differences between mean activated coagulation 
times, prothrombin times, activated partial thromboplastin times, bleeding 
times, and ptatelet aggregation to ADP, thrombin, and collagen between the 
groups and between measurements before and five days after surgery. These 
data suggest that local gene transfer of TFPI prevents thrombus formation 
after severe balloon injury in the presence shear stress and an epinephrine 
challenge and without causing systemic hemostatic impairment. 
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~ Aspirin 325 mg, Single Dose, Increases 
Venoconstriction to Norepinephrine in Normal 
Subjects 
T. Nancy Dzeka, Peter Kuzminski, lan D. Callow, J. Malcolm O. Arnold. 
London Health Sciences Centre, University of Western Ontario, London, 
Ontario, Canada 
Background: There is controversy with regard to the physiological and 
clinical significance of inhibition of vascular prostaglandin synthesis versus 
platelet thremboxane A2 synthesis by the antithrombotic doses of aspirin 
(ASA) widely used in patients with ischemic heart disease. We hypothesized 
that if ASA significantly altered vascular prostaglandin synthesis, of which 
prostacyclin is believed to be the major product, this would result in significant 
increases in venoconstriction induced by norepinephrine (NE). 
Methods: Venoconstriction to cumulative doses of NE (0.125-256 ng/min) 
was studied in 8 young healthy volunteers (25 ± 1 years) at least 90 minutes 
after a single 325 mg dose of ASA or placebo using a hand vein tonometry 
technique. Baseline catecholamine levels were measured on the study day. 
Antiplatelet activity of the dose of ASA was confirmed in 3 subjects. 
Results: A single dose of ASA with confirmed antiplatelet activity caused 
an increase in venoconstriction induced by NE as evidenced by a significant 
shift to the left (p < 0.05) of the NE dose-response curve. The NEEDso 
(50% constriction dose) was significantly decreased with ASA compared to 
placebo (1.24 ± 0.13 vs 1.87 ± 0.15, log ng/min, p < 0.01). Baseline plasma 
NE levels were the same on both days (placebo: 840 ± 175 vs ASA: 1073 ± 
300 pmol/L, p = n.s.). 
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Conclusion: The results show that the inhibition of vascular prostaglandin 
synthesis by an antithrombotic dose of aspirin (325 mg) can significantly 
increase venous responsiveness to NE. This may have clinical relevance for 
patients with heart failure and increased sympathetic activity, and the efficacy 
of angiotensin converting enzyme inhibitors with concomitant ASA use. 
~ T h e  Prevalence of Aspirin Resistance in Cardiac 
Patients as Measured by Platelet Aggregation and 
the PFA-100 ® 
Emilio D. Poggio, Kandice Kottke-Marchant, Patricia A. Welsh, Linda 
M. Brooks, Lanz R. Dela Rosa, Eric J. Topoi. The Cleveland Clinic 
Foundation, Cleveland, Ohio, USA 
Background: This study was designed to determine the prevalence of as- 
pidn resistance among cardiac patients (pts), and to examine differences 
in detection between platelet aggregation and PFA-100 ® testing methodolo- 
gies. The long term goals are to determine if aspirin resistant (AR) pts have a 
worse cardiovascular outcome compared to an aspirin sensitive (AS) group. 
Methods: Pts who had taken 325 mg of aspirin for at least seven days 
and who received no other antiaggregant drugs were enrolled (n = 113). 
Blood was drawn into 3.8% sodium citrate and analyzed by two different 
methods for assessing AR. Maximal platelet aggregation was measured by 
optical aggregation using ADP (1,2, 5 and 10 ~M) and 0.5 mg/ml arachidonic 
acid (hA) agonists and by a newer, more rapid technique (PFA-100 ®) using 
collagen/epinephrine and collagen/ADP cartridges with measurement of the 
time to aperture occlusion (closure time, CT). For the aggregometer method, 
aspirin resistance was defined as _>70% aggregation when induced by 10 
/~M ADP and _>20% platelet aggregation with AA. For the PFA-100 ® method, 
aspirin resistance was defined as normal CT with the collagen epinephrine 
cartridge, 
Results: 9/113 (8%) pts were AR by aggregation with 75/113 (66.4%) AS, 
and 29/113 (25.6%) that met one criteria or the other. Of the 9 AR pts, 5/9 
(56%) were also AR by PFA-IO0 ®, By PFA-100 ®, 14/113 pts (12.4%) were 
AR, with 6/14 (42.8%) confirmed by aggregation. In comparing the 9 AR pts 
to the 75 AS pts, the AR pts displayed greater aggregation to 5 #M ADP 
(67.4 ± 16% vs. 46.0 :E 10%, p < 0.0001 ), greater sensitivity to ADP-induced 
aggregation with less ADP resulting in 40% aggregation (2.36 ± 0.9/~M vs. 
5.17 ± 4.1 #M, p < 0.04) and more intact platelet function with the PFA-100 ®, 
as shown by a lower total blood volume to CT (533.0 ± 192 ml vs. 685.9 ± 
103 ml, p = 0.0003). 
Conclusions: These data show that at least 8% to 12% of pts taking as- 
pirin do not achieve the therapeutic benefit of platelet inhibition. Furthermore, 
there was a concordance of 56% between aggregation and the PFA-100 ® in 
detection of AR, with a suggestion that the PFA-100 ® may be more sensitive 
to AR than aggregation. Further characterization of the patient population and 
cardiovascular outcome as well as more definitive comparisons between the 
two methodologies are warranted. 
~ Evidence Platelet Response to for Variable 
Low-Dose ASA in Patients with Coronary Artery 
Disease 
Hugo Stiegler, Yuriko Fischer, Christoph Niederau, Frank C. Schoebel 1 , 
Markus Borries 1 , Bodo E. Strauer 1 , Matthias Leschke ~ , Hans Reinauer. 
Department of Clinical Pathology, ~ Department of Cardiology, 
Heinrich-Heine-University Ddsseldorf,, Germany 
Background: ASA is standard therapy for secondary prevention of my- 
ocardial infarction (MI). In europe low-dose ASA therapy with 100 mg/qd is 
used, but individual dosage is discussed. To detect an individual response to 
chronic low-dose ASA therapy we used the PFA-100 ~ in-vitro bleeding test 
system (DADE-Behring). 
Methods: PFA-100 ® provides a quantitative measurement of platelet- 
dependent primary hemostasis in citrated whole blood by inducing a platelet 
thrombus that occludes an aperture of a membrane coated either with colla- 
gen (col) and epinephrine (epi) or col and ADP. The time required to obtain 
occlusion of the aperture is referred to as "closure time" (CT). We recruited 
29 male patients with angiographically documented coronary artery disease 
(CAD) and history of MI (n = 29, Age: 46-67) taking low-dose ASA (100 
mg/qd) for at least 2 years daily and determined the col/epi CT, col/ADP CT 
as well as the platelet count. Data were compared to reference values found 
in healthy subjects without ASA intake. 
Results: In patients with ASA therapy 3 groups could be differentiated 
by col/epi CT. Group A consisted of 12 patients with a CT above 300 sec. 
Group B included 10 patients with a CT between 200 and 300 sec. Group C 
consisted of 7 patients all with a CT below 150 sec indicating an inadequate 
platelet inhibition by low-dose ASA. No difference could be detected for the 
col/epi CT. 
Conclusions: In patients with CAD and chronic low-dose ASA therapy 
variable platelet responses to low-dose ASA could be observed by PFA. 
Therefore it may be able to identify patients not responding adequately to 
standard low-dose ASA therapy. These data support the need for individual 
dosage. 
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~ A Randomized Comparison of Cilostazol Versus 
Ticlopidine Therapy After Elective Coronary Stent 
Placement 
Seong-Wock Park, Hyo-Jung Lee, Cheol Whan Lee, Jae-Joong Kim, 
Hoon-Ki Park, Myeong-Ki Hong, Seung-Jung Park. Department of 
Medicine, University of U/san, Asan Medical Center, Seou/, Korea 
Objective: Cilostazol is a potent antiplatelet agent with less serious adverse 
effects. The aim of this study was to evaluate the efficacy of cilostazol for 
prevention of stent thrombosis, as compared with ticlopidine. 
Methods and Results: Two hundred and forty patients with elective 
stent placement were randomized to receive aspirin plus cilostazol (n = 120) 
or aspirin plus ticlopidine (n = 120) for 1 month. Clinical and laboratory 
evaluation was performed at regular interval. There were no differences of 
baseline characteristics between the two groups. During the first 30 days 
alter stent placement, overall clinical events were similar between the two 
groups (1.7% vs 2.5%, p = NS): stent thrombosis (1.7% vs 0.8%, p = NS}, 
myocardial infarction (f.7% vs 0.8%, p = NS), severe leucopenia (0% vs 
0.8%, p = NS) and cerebral hemorrhage (0% vs 0.8%, p = NS). Adverse side 
effects led to the drug withdrawal in 4 patients of cilostazol group (3.3%) and 
in 2 patients of ticlopidine group (1.7%, p = NS). There was no death during 
the follow-up period. 
Conclusions: Aspirin plus cilostazol is an effective antithrombetic regi- 
men with comparable results to aspirin plus ticlopidine alter elective coronary 
stenting. 
~ Low-Shear Platelet Adhesion is Inhibited GP by 
lib/ilia Antagonist Tirofiban in Diabetes Mellitus 
Izabella Lipinska, DaLi Feng, Travis Matheney, Joanne Keough, Geoffrey 
H. Toiler. Institute for Prevention of Cardiovascular Disease, BIDMC, 
Harvard Medical School, Boston, MA, USA 
Background: Glycoprotein (GP) lib/Ilia receptor blocking agents have been 
shown to reduce cardiovascular events in acute coronary syndromes. Al- 
though these agents are powerful inhibitors of platelet aggregation, their role 
in low-shear platelet adhesion is not well characterized. Since subjects with 
diabetes mellitus (DM) have increased thromboembolic complications, we 
determined the effect of a GP lib/Ilia receptor blocker (Tirofiban, Merck&Co., 
Inc.) on low-shear platelet adhesion in DM patients and healthy subjects. 
Methods and Results: Low-shear platelet adhesion was studied in 19 pa- 
tients with DM and 20 healthy controls following the addition of Tirofiban (final 
conc. 10 -B M) or saline to platelet-rich plasma using a modified Hele-Shaw 
flow chamber system. Platelet-rich plasma was perfused over a fibrenectin- 
coated slide at a shear rate of 25 s -~ , and the number of adherent platelets 
was determined alter 8 min. There was no significant difference in adhesion 
between DM and control subjects, but the number of adhered platelets was 
significantly reduced by Tirofiban in both groups. 
Subjects Saline "Nrofiban Reduction p 
Controls 47 ± 6 10 ± 4 75% <0.0001 
DM 46 ± 7 13 ± 3 64% <0.0001 
Conclusion: Since low-shear states may occur distal to stenoses, our 
data suggest that GP IIb/lllb receptor blockers such as Tirofiban may achieve 
their antithrombotic effect in part through inhibition of low-shear platelet 
adhesion. 
~ Incidence Thrombocytopenia Complicating of 
Treatment With Glycoprotein lib/Ilia Receptor 
Inhibitors 
James C. Blankenship, Francis J. Menapace, S. Lee Demko. Geisinger 
Medical Center, Danville, PA, USA 
Background: Thrombocytopenia occurring with glycoprotein (GP) lib/Ilia 
receptor inhibitor therapy has not been characterized. 
Methods: The incidence of thrombocytopenia (<90,000-100,000 platelets) 
and severe thrombocytopenia (<50,000 platelets) in 9 multi-center studies of 
N <100,000 <50,000 
All GP lib/Ilia drugs 13,485 3.2% 0.6% 
Heparin 11,461 2.8% 0.3% 
p = 0.05 p = 0.03 
Abciximab 1338 54% 1.0% 
Other GP lib/Ilia drugs 12,147 3.0% 0.35% 
p < 0.0001 p < 0.0001 
1-day infusion GP lib/Ilia 4365 2.7% 0.6% 
2-3 day infusion GP lib/Ilia g120 3.5% 0.7% 
p = 0.02 p = 0.06 
intravenous GP lib/Ilia receptor inhibitors was determined. Outcomes were 
available for 18 patients with severe thrembocytopenia. 
Results are presented in the table. There were no maior bleeding com- 
plications in 18 patients with severe thrombocytopenia. 
Conclusions: Thrombocytopenia may occur more frequently with abcix- 
imab than with other GP lib/Ilia receptor inhibitor drugs or heparin alone. 
Duration of GP IIb/llta infusion does not affect incidence of thrombocytope- 
nia. Severe thrombocytopenia with GP lib/Ilia receptor inhibitor drugs may 
be well tolerated. 
• Investigation of the Novel P2T Receptor 
Antagonist AR-C69931 MX on Ex Vivo Adenosine 
Diphosphate-lnduced Platelet Aggregation and 
Bleeding Time in Healthy Volunteers 
M.A. Nassim ~ , J.B. Sanderson 2, C. Clarke 3, R. Blackshaw 1 , J.J. Gardner 1 , 
P. McCormack 1 , G. Kennedy 1 , N. Yeates 1 , L Rudc42 , F. Butt 3 . i Clinical 
Pharmacology Unit, Astra Chamwood, L oughborough; 21nveresk Clinical 
Research, Edinburgh, 3 Medeval, Manchester, UK 
Background: AR-C69931MX (2-trifluorepropylthio, N-(2-(methylthio)ethyl- 
#,y-dichloromethylene ATP), is a new intravenous P2T receptor antagonist 
with a rapid onset/offset of action. It inhibits adenosine diphosphate-induced 
platelet aggregation (APA) and arterial thrombosis in animals with a minimal 
effect on bleeding time (BT). Here we describe the first investigation of 
AR-C69931MX in man. 
Methods: Healthy volunteers (male and female) received AR-C69931MX 
or placebo in an ovedapping incremental series of 4-step 1 hr iv infusions 
over the dose range 10-4000 ng.kg- 1 .min -~ with a 19 hour extension of the 
fourth step. APA, BT and pharmacokinetic (PK) measurements were made 
at baseline, during and alter the infusion. 
Results: AR-C69931 MX produced dose-related inhibition of ex vivo APA. 
Reversal of inhibition of APA after AR-C69931MX was rapid and complete 
within 20 min from the highest dose with no rebound APA. At doses that 
abolished APA, BT increased only 3.2 fold in males and 2.9 fold in females. 
AR-C69931MX was well tolerated with only minor increases in petechial or 
bruising reactions. Parent compound exhibited dose linearity with no de- 
tectable PK sex differences. Plasma clearance was rapid (50 L.h ~ ) with low 
variability (14%). Short half-life (mean 2.6 min) resulted in rapid attainment 
of AR-C69931MX steady state concentrations in all subjects. 
Conclusion: The separation between inhibition of APA and BT may 
translate into a reduced risk of bleeding without compromising anti-thrombotic 
activity. AR-C69931MX is now being evaluated as a novel, anti-thrombotic 
agent for intravenous use in acute coronary syndromes. 
• Early Clinical Evaluation of rNAPc2, A Novel 
Inhibitor of Blood Coagulation Factor Vlla/Tissue 
Factor (fVIla/TF) 
George P. Vlasuk, Annette Bradbury, Peter W. Bergum, William E. Rote. 
Corvas International Inc. San Diego, CA, USA 
Background: Recombinant nematode anticoagulant protein c2 (rNAPc2) is 
a small protein anticoagulant originally isolated from hematophagous hook- 
worms that targets factor fVIlaJrF, which serves as the initiating enzymatic 
complex in the blood coagulation cascade. To prepare for phase II dose- 
ranging efficacy studies, a Phase I study of rNAPc2 in healthy volunteers 
was initiated at Covance Clinical Research Unit in Madison, Wl. The pri- 
mary objective of this study was to determine the pharmacokinetic (PK), 
anticoagulant and safety profile of rNAPc2 when administered as repeat s.c. 
injections to normal healthy male volunteers over a period of 5 days at 48-h 
intervals. 
Methods: Three treatment groups each consisting of 6 subjects were 
used, with 4 subjects receiving rNAPc2 and 2 subjects receiving placebo in a 
randomized, double-blinded fashion. The protocol called for treatment groups 
1, 2, and 3 to receive rNAPc2 (or placebo) at the respective dose levels of 
1.5 l~g/kg, 3.0 /~g/kg, and 5.0 p.g/kg. Safety and tolerance were assessed 
clinically by examination and by measurement of clinical laboratory tests. The 
anticoagulant effects were assessed by measurement of prothrombin time 
(PT) and activated partial thromboptastin time (aPTT). The pharmacokinetic 
profiles were evaluated using the plasma rNAPc2 levels. 
Results: The study was uneventful in all dose groups and the drug was 
safe and well tolerated with no drug-related serious adverse events. The 
PK/anticoagulant profile of rNAPc2 in this study was remarkably predictable 
based on the results from a previous single dose Phase la study in normal 
volunteers and confirmed the prolonged half-life of the drug of >50 hrs. 
Maximal PT elevations in dose group 3 reached ~40 sec following the 3rd 
administration with no significant effects on aPTT or template bleeding time. 
Conclusions: The combined results from this and the previous Phase 1 
study have defined the anticoagulant and safety profile of rNAPc2 necessary 
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to move forward into Phase II efficacy studies in the prevention and treatment 
of thrombotic disease. 
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~ LCATOklahoma: A Novel GC Deletion in the LCAT 
Gene Associated with a Dominant Effect on 
HDL-C 
Attan Kasid 1 , Haydn Pritchard 2, Michael Miller 1 . 1University of Maryland 
School of Medicine, Baltimore, MD, USA; 2 University of British Columbia, 
Vancouver, Canada 
Background: LCAT deficient heterozygotes generally exhibit mild reductions 
in HDL-C. We investigated the molecular defect in the LCAT gene in a family 
with low HDL-C. The proband is a 53 year old woman from Oklahoma City 
(HDL = 09 mg/dL) and 50 year old sister of San Antonio, Texas (HDL = 16 
mg/dL). 
Methods: Proteoliposome assay revealed reduced LCAT activity in the 
proband (5 nmol/ml/h; normal 24.6 + 3.6 nmol/ml/h) and cholesterol ester- 
ification rate (54.2 nmol/ml/h; normal 123 ± 32 nmol/ml/h), consistent with 
LCAT deficiency. 
Results: Following sequencing of genomic DNA, a 2-base pair deletion 
was identified at codon 256 of the LCAT gene. This results in conversion of 
Arg --, Leu and premature truncation of amino acid 260. As shown in the 
Table, the 4 affected heterozygotes studied revealed significant reduction in 
HDL-C and ape A-I compared to unaffected biologic family members (n = 4). 
Lipid and Lipoprotein Levels in L CAT Deficient and Control Subjects 
Group Age TC HDL-C Ape A-I TG LDL-C Ape B 
mutation 52±21 158±27 t9:1:8 87±29 195±70 96±26 135±19 
nomutation 65±17 217233 44±8 143±12 137±66 148±36 134~-14 
p value NS 0.003 0.003 0.012 NS 0.03 NS 
Conclusions: The marked reduction in HDL-C among the proband and 
her sister suggests a dominant effect of the mutation on HDL-C. These 
findings extend the recent report of LCATFin, where Gly 23° Arg resulted in 
markedly diminished LCAT activity (ATVB 1998; 18: 591) and suggest an 
important role of this region in regulating LCAT activity. 
• Apolipoprotein E Polymorphism Influences the 
Remnant Like Particle-Cholesterol Metabolism 
Takehiko Watanabe, Genshi Egusa, Hisayoshi Mochizuki, 
Masamichi Okubo, Michio Yamakido. Second Department of Internal 
Medicine, Hiroshima University School of Medicine, Hiroshima, Japan 
Background: Apolipoprotein E (apoE) polymorphism is an important ge- 
netic factor associated with lipid metabolism. Recently remnant like particle- 
cholesterol (RLP-C) has been denoted as a new risk factor of coronary artery 
disease. However, an association of apoE polymorphism and the RLP°C 
metabolism are not elucidated. 
Method: The apoE phenotypes were determined on serum samples 
by using isoelectric focusing followed by immunoblotting. The RLP wera 
measured by using an immunoaffinity gel mixture of anti-ape A-I and anti-ape 
B-100 monoclonal antibodies. The unbound fraction was referred to as RLP. 
Results: We examined 516 non-diabetic Japanese-Americans (male/ 
female 212/304, age 61.5 ± 0.7 years old, BMI 23.0 ± 0.2 kg/m2). Serum 
RLP-C levels in subjects with E4-3 (n = 89) were significantly higher than with 
E3-3 (n = 368) after adjustment for gender, age and BMI. (12.2 ± 0.9 vs 7.3 
± 0.4 mg/dl, p < 0.0001), respectively. In addition, serum LDL-cholesterot 
(LDL-C) and triglyceride (TG) levels in subjects with E4-3 were significantly 
higher than with E3-3 (146.5 ± 3.7 vs 135.7 :t: 1.8 mg/dl, p < 0.01, 191.9 ± 
10.9 vs 138.8 ± 5.4 mg/dl, p < 0.0001) and serum HDL-chotesterot (HDL-C) 
were significantly lower than with E3-3 (50.0 ± 1.5 vs 55.2:1:0.8 mg/dl, P < 
0.005). Although LDL-C level in subjects with E3-2 (n = 47) were significantly 
lower than with E3-3 (117.5 ± 4.7 vs 135.7 ± 1.7 mg/dl, p < 0.0005), no 
differences were observed in serum RLP-C, TG, and HDL-C levels between 
the subjects with E3-2 and E3-3. 
Conclusion: Compared to subjects with E3-3, both RLP-C and LDL-C 
levels were higher in subjects with E4-3. Although RLP-C levels were identical 
between subjects with E3-3 and E3°2, LDL-C levels were higher in subjects 
with E3-3. Thus atherogenic impact was higher in subjects with E4-3, followed 
by those with E3-3 and E3-2. 
• Immunolocalization of Oxidized 
Phosphatidylcholine and Apolipoprotein B in 
Association with Inflammatory Processes in 
Human Coronary Atheroscierosis 
Yoshiaki Tsukamoto, Makiko Ueda, Allard C. van der Wal, Chris M. van der 
Lees, Hiroyuki Itabe, Tatsuya Takano, Anton E. Becker. Academic Medical 
Center, Amsterdam, The Netherlands; Osaka City University Medical 
School, Osaka, Japan 
Background: Coronary atheroscterosis has many features of a chronic in- 
flammatory response. In vitro studies have suggested that oxidized low 
density lipoprotein (ox-LDL) plays a key role in the genesis of these inflam- 
matory processes. To elucidate the role of ox-LDL in the development of 
coronary atherosclerosis in humans, we immunohistochemically studied the 
presence of oxidized phosphatidylcholine (ox-PC) and apolipoprotein B (ape 
B) in coronary arterial segments, in relation to inflammatory cells. 
Methods: We studied 228 coronary artery segments, obtained at autopsy 
from patients under 40-year-old. These coronary segments were character- 
ized histologically as normal with diffuse intimal thickening (DIT), hypercellu- 
lar lesions (HL) composed of smooth muscle cells (SMCs) without inflamma- 
tory cells (SMC-rich HL), hypercellular lesions with abundant inflammatory 
cells (HL with inflammatory cells), and an atheromatous plaque containing a 
lipid-core (AP). Antibodies were used against SMCs, macrophages (M~s), T 
lymphocyles, ape B and ox-PC. For the identification of cell types which stain 
for ox-PC or ape B, immunodouble (ox-PC/apo B) and triple (SMC/M~/ox-PC) 
stainings were used. 
Results: Normal arteries with DIT and SMC-rich HL revealed no staining 
positivity for ox-PC or ape B. In contrast, HL with inflammatory cells as well as 
AP, showed distinct positivity for ox-PC in M~-dedved foam cells. In the many 
of M~-derived foam cells, ox-PC staining colocalized with ape B staining. 
Conclusion: These results strongly suggests that ox-LDL plays a crucial 
role in the progression of inflammatory processes at early stages of coronary 
atherogenesis in humans. 
~ Reactive Oxygen Species Generated During LDL 
Oxidation Activate the Cell Death Effector CPP32 
and Contribute to DNA Fragmentation and 
Apoptosis of Human Endothelial Cells 
Claudio Napoli, Oswald Quehenberger, Filomena de Nigris, Joseph 
L. Witzlum, Wulf Palinski. Department of Medicine, University of California, 
La Jolla, San Diego, CA, USA 
Background: To investigate the mechanisms by which the degree of LDL 
oxidation influences apoptosis in human cells. 
Methods: Human endothelial umbilical vein cells (HUVEC) were incu- 
bated with 10 mg/ml LDL that had been extensively oxidized by incubation 
with 5 mM CuSO4 Cu-LDL) for 18 h, or mildly by incubation with 2 mM 
xanthine + 0.1 U/ml xanthine exidase (X/XO-LDL) for 6 he, in the absence 
or presence of 20 mM vitamin E, 330 U/ml superoxide dismutase (SOD), 
1000 U/ml catalase, or SOD + catalase. The degree of oxidation of Cu-and 
X/XO-LDL was assessed by TBARS and electrophoresis and DNA fragmen- 
tation by analysis of transmission electron micrographs. 
Results: Cu-LDL and X/XO-LDL caused significant increases in DNA 
fragmentation proportional to the degree of oxidation (230 ~ 28% and 155 
± 18% of control cells, respectively), disruption of cytoplasmic organelles, 
and loss of membrane integrity. Addition of either vitamin E or combined 
SOD + catalase significantly reduced DNA fragmentation (to approx. 125% 
for Cu-LDL and 102% for X/XO-LDL). Incubation of HUVEC with Cu-LDL, 
but not X/XO-LDL, significantly increased activity of CPP32-1ike proteases 
(135 + 11%). Addition of 80 mM of the CPP32 protease-specific inhibitor 
AC-DEVD-CHO completely prevented apoptosis induced by both forms of 
oxidized LDL. Incubation of HUVEC with Cu-LDL or X/XO-LDL for 6 h did not 
alter mRNA levels of CPP32, showing the lack of a transcriptional effect. In 
contrast, both forms of oxidized LDL stimulated the proteolytic cleavage of 
CPP32 into its active subunit CPP32-P17. This did not occur in the presence 
of vitamin E, or SOD + catalase. 
Conclusion: Our results demonstrate that oxLDL contributes to apoptosis 
(via oxygen radical-mediated processes and activation of the cell death 
effector CPP32) and that apoptosis is dependent on the degree of LDL 
oxidation in human cells. 
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1 10/ Evaluation of Novel Amino-Acid 
1 
1 06-1 Functional J Altering Angiotensin II Type 1 Receptor Gene 
Variants in Essential Hypertension 
Simon G. Megarry, Alistair S. Hall, Stephen G. Ball, Anthony J. Balmforth. 
Institute for Cardiovascular Research, University of Leeds, Leeds, UK 
Background: The angiotensin II type 1 (AT1) receptor is central to blood 
pressure regulation by angiotensin II (Ang II). In-vitro studies demonstrate 
that substitution of a single amino-acid can profoundly alter AT1 receptor 
function. We investigated patients with essential hypertension for the occur- 
rence of amino-acid altering AT~ receptor gene variants affecting receptor 
function. Such mutations might interfere with blood pressure control or the 
response to AT1 antagonists. 
Methods: The coding region of the AT1 gene was amplified using PCR 
for 200 patients with essential hypertension. Mutations were detected using 
dye terminator cycle sequencing of both sense and antisense strands for 
all patients. AT1 variants were expressed in a human cell-line facilitating 
functional assessment. Ligand binding of Ang II, Iosartan, EXP3174, and 
telmisartan was assessed in competition with 0.1 nM [~251-Sar~-Ile6]-Ang I1. 
Agonist stimulated receptor internalisation was studied with 3H-Ang I1. Signal 
transduction was investigated by measuring intracellular calcium mobilisation 
and inositol phosphate production. 
Results: Two new variants in the AT1 receptor gene were found. These 
result in single amino acid substitutions at positions alanine 244 serine and 
isoleucine 290 valine in transmembrane helices VI and VII of the receptor. 
The ICs0 (S.E.M.) values (nM) in competitive binding studies were as follows 
(n = 3): 
Ligands Wildtype receptor Ala244Ser Ile290Val 
Ang II (high) 1.8 (0.4) 2.2 (0.4) 3.6 (0.4) 
(low) 17 (4) 25 (6,6) 36 (3) 
Losartan 19.3 (3.4) 18 (0.9) 32 (7.5) 
EXP 3174 6.0 (0.2) 5.1 (0.1) 7.4 (1.0) 
Tetmisartan 7.3 (0.5) 5.6 (0.2) 9.1 (0.1) 
Ang II stimulated receptor intemalisation, intracellular calcium mobilisation 
and inositol phosphate production were the same for all three receptors. 
Conclusion: We found two novel amino-acid altering mutations in the 
AT1 receptor gene of patients with essential hypertension. They do not 
substantially alter receptor function or AT1 antagonist binding. However, at 
present, we cannot rule out subtle functional effects. 
11 11 I Determination of the Onset of 06-1 Genetic Early J Myocardial Infarction 
Yuan He, Yoshifumi Tomita, Yoshiki Kusama, Kazuo Munakata, 
Hiroshi Kishida, Hirokazu Hayakawa. Nippon Medical School, Tokyo, Japan 
Background: Recently, it has been reported that genetic factors such as 
angiotensin converting enzyme (ACE) gene D/I polymorphism and endothe- 
lial constitutional nitric oxide synthase (ecNOS) gene intron 4 polymorphism 
play a significant role in the onset of myocardial infarction (MI) in addition 
to conventional coronary risk factors. However, correlation between these 
polymorphisms and conventional coronary risk factors in term of the risk of 
early onset of MI has not been thoroughly investigated. 
Methods: We analyzed the relationship with the onset age of MI in 73 
male Japanese patients (55.2 ± 10.8 years). Patients were divided into two 
groups according to the age of onset; the younger group (YG; n = 28, _<50 
years. 44.1 ± 5.7 years) and the older group (OG; n = 45, >50 years, 62.1 ± 
6.7 years). The po~ymorphisms of ecNOS and ACE genes were determined 
by polymerase chain reaction method after extraction of genomic DNA from 
peripheral leukocytes. The polymorphism of ecNOS gene was detected out 
composing of 27-base pair (bp) in intron 4 with 4-times repeated a allele and 
with 5 times repeated b allele. The poiymorphism of ACE gene was detected 
out composing of 287-bp in intron 16 with insertion (I allele) and deletion (D 
allele). 
Results: The incidence of a allele of ecNOS gene in YG was significantly 
higher than that of OG (0.21:0.08, p = 0.02) and the incidence of O allele of 
ACE gene in YG tended to be higher than that of OG (0.41:0.28, p = 0.09). 
Conventional coronary risk factors including hypertension, diabetes mellitus, 
and smoking were equally distributed in two groups but the incidence of hy- 
pedipidemia (HL) in YG was significantly higher than that of OG (p = 0.0008). 
There were no significant differences of the serum level of HDL-cholesterol, 
triglyceride, and LP(a). However, the serum values of total cholesterol, LDL 
and VLDL in YG were significantly higher than these of OG. Stepwise mul- 
tivariate regression analysis, using those two gene polymorphisms and the 
conventional coronary risk factors, revealed HL, D allele and a allele to be 
significant independent factors to predict the age of MI onset (F = 19.57, 
7.51, and 4.77, respectively; p < 0.0001). 
Conclusion: These data suggest that ecNOS gene intron 4 a/b polymor- 
phism and ACE gene polymorphism may be associated with the early onset 
of MI. 
~ 1106-1121 Efficient Retrovirus-Mediated Gene Transfer Into 
J the Healing Rat Heart After Myocardial 
Cryoinjury 
Jonghoe Byun, Duk-Kyung Kim, Jeoung-Eun Huh, Sun-Jin Park, 
Jung-Eun Jang, Yeon-Lim Suh, Francois-Loic Cosset, Jung-Don Seo, 
Won-Ro Lee. Cardiovascular Institute, Samsung Medical Center, 
Sungkyunkwan Universi~ Seoul, Korea; Universite Claude-Bernard Lyon- 1, 
V#1eurbanne Cedex, France 
Efficient and stable introduction of therapeutic DNA into injured myocardium 
would allow the development of genetic treatment o improve cardiac function, 
amplify healing, and induce angiogenesis. Myocardial necrosis caused by 
coronary occlusion induces healing process which is heralded by the acute 
proliferative response of connective tissue cells. Healing myocardium might 
be an ideal target for the delivery of foreign genes by retroviruS which requires 
cell division for efficient infection. The present study was undertaken to 
investigate gene transfer into the fibroblast-rich tissue of wound repair of the 
heart using the high titer retroviruses (107/ml) produced from TE-FLYA cells. 
When cardiac fibroblasts from adult rat (8 wk) were transduced in vitro by the 
retroviruses harboring nlsLacZ reporter, 90% of the cells were lacZ-positive. 
With two rounds of infection, the efficiency reached upto 94%. To translate this 
result into in vivo situation, we forced part of rat myocardium to proliferate 
by performing myocardial cryoinjury. Cell proliferation index in the cardiac 
granulation tissue appeared maximal on 3 days after cryoinjury as determined 
by the 3H-thymidine incorporation assay. Based on this observation, 250/~1 
of retrovirus per rat was injected into the injured region of beating heart 3 
days post-injury and the rats (n = 8) were sacrificed 7 days after injection. 
When the hearts were microsectioned and analyzed by X-gal staining and 
H&E staining, t4.4% of the cells in the reparative tissue were LacZ-positive. 
The transduced cells were myofibroblasts and endothelial cells, while cardiac 
myocytes in the periphery of the injury and in the uninjured area were not 
transduced. These findings suggesl that efficient retrovirus-mediated gene 
transfer to healing rat heart could be accomplished in vivo, which might open 
the way for retroviral gene therapy in myocardial infarction. 
1106-113 t Gene Structure and of Expression 
Phospholemman in Mouse 
Roberta C. Bogaev, Yvonne M Kobayashi, J. Paul Mounsey, J. 
Randall Moorman= Larry R. Jones, Amy L. Tucker. University of Virginia 
Health Sciences Center, Charlottesville, VA; indiana University School of 
Medicine, Indianapolis,/IV, USA 
Background: Phospholemman (PLM) is a 72 amino acid sarcotemmat protein 
that is a major substrate for phosphorylation in response to adrenergic stimu- 
lation. PLM is thought to play an important role in muscle contractility and cell 
volume regulation through its actions as a channel or channel regulator. 
Methods: The murine PLM cDNA and gene were isolated using a probe 
corresponding to the coding region of the canine PLM cDNA. A 32p-labeled 
mouse PLM cDNA probe was hybridized to mouse RNA tissue blots and to 
RNA blots from developing mouse embryos. RNA encoding PLM cDNA was 
injected into Xenopus oocytes and currents were measured with two-micro- 
electrode voltage clamps. 
Results: The mouse cDNA showed close conservation to PLM sequences 
from other species in amino acid sequence, tissue distribution, and electro- 
physiologic properties. The developing mouse embryo shows an increase 
in PLM at day 15. The PLM genomic clone contained the entire coding re- 
gion, interrupted by 5 introns. The 5' untranslated region contained 4 areas 
of (CT)n or (GT)n dinucleotide repeats. The mouse cDNA has evidence of 
alternative splicing in the 5' and 3' non-coding regions. The mouse PLM is 
the only species cloned to date that diverges at a potential phosphorylation 
site, encoding serine-69 rather than threonine-69. 
Conclusion: The coding region of PLM is highly conserved among mam- 
malian species. Several lines of evidence indicate that PLM is important in 
cardiac physiology: its high expression in heart, it is a major substrate for 
phosphorylation, and its phosphorylation parallels increases in cardiac con- 
tractility. The unique properties of the PLM gene of alternative splicing and 
dinucleotide repeats may serve as regulatory mechanisms. 
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I I 106-1  ~ Transcription and Transregulation 
7 
1 4 of the Human 
Sarcomeric Creatine Kinase Gene 
Reema Chugh, Wenning Qin, Arnold W. Strauss. Washington University in 
SL Louis, MO, USA 
We are studying the regulation of the human sarcomeric mitechondrial cre- 
aline kinasa (sMtCK) gene, a nuclear gene which is expressed only in the 
heart and skeletal muscle and plays a key role in cardiac energy transduction. 
Our previous work in transgenic mice shows that -921 to +6 base pairs (bp) 
of the 5'-flanking domain of this gene expressed human growth hormone 
reporter gene at a high level in the heart and skeletal muscle while -485 
to +6 sequence did not activate reporter gene expression to a detectable 
level. To further determine the sequence which is necessary to activate tran- 
scription in the heart and skeletal muscle, we linked each of the following 
sequences between -921 to -760 or -921 to -486, to either the minimal 
sMtCk promoter (-80 to +6) or the thymidine kinase promoter. Transfection 
of these constructs into cardiomyocytes an C2C12 cells showed that the 
-921 to -485 region had two to four fold activity over the -921 to -760 
bp constructs and 150 fold over basic CAT. We then linked the -760 to 
-485 bp region to the minimal sMtCK promoter and to the thymidine kinase 
promoter. Transfection of these constructs into cardiomyocytes and C2C12 
cells showed that the -760 to -485 bp region had maximum activity (2-fold 
over -921 to -485 bp constructs, 27 fold over minimal sMtCK promoter and 
280 fold over basic CAT in cardiomyocytes; 2.7 fold over -921 to -485 bp 
constructs, 21 fold over minimal sMtCK promoter and 200 fold over basic 
CAT in C2C12 cells), on chloramphenicol ecetyl-transferase reporter assay. 
Our data indicate that the -760 to -486 region has an important role in 
directing tissue-specific expression and is necessary to activate transcription 
of the human sMtCK gene to the oxidative and highly metabolically active 
heart tissues. Understanding the transcriptional regulation during cardiac 
myogenesis is essential for defining mechanisms resulting in inadequate 
myocardial energy supply and function which occur in pediatdc and adult 
cardiovascular disease such as hypoxia accompanying cyanotic congenital 
heart disease and hypertrophy caused by chronic hypertension or ventdcular 
outflow obstruction and end-stage congestive heart failure. 
I l l  06-11 5 1 of the Activator Polymorphism Plasminogen 
Inhibitor-1 Gene is not Associated with an 
Increased Risk of Coronary Artery Disease or 
Myocardial Infarction in a Caucasian Population 
Joseph B. Muhlestein, Jess±ca Habashi, John F. Cadquist, Tam± L. Bair, Sid 
P. Elmer, Brant P. Davis, Jeffrey L. Anderson. LDS Hospital, University of 
Utah, Salt Lake City, Utah, USA 
Background: Plasminogen activator inhibitor-1 (PAl-l) plays a central role in 
modulating intravascular thrombosis and thrombolysis. Impaired fibrinolytic 
function, including high levels of PAl-l, has been associated with premature 
or progressive coronary heart disease (CAD) and myocardial infarction (MI). 
A. common deletion polymorphism of PAl-1 (4G) has been correlated with 
increased PAl-1 levels and proposed as a risk factor for CAD/MI in preliminary 
small studies. We prospectively tested this hypothesis in an angiographically 
defined cohort. 
Methods: Blood was drawn from 1353 consecutive consenting pts un- 
dergoing coronary angiography. The 4G and 5G alleles were amplified using 
allele-specific primers. Amplified products were visualized by staining with 
ethidium bromide after electrephoresis in 1.5% agarose. 
Results: Age averaged 63.5 (SD 1t.7) y, 70% were male, 28% had a 
history of MI, 66% had severe CAD (>_70% stenosis), and 23% had no CAD 
or MI. Overall, the frequency of the 4G allele was 54.2%, and 78% of pts were 
4G carriers. Genotype distributions were: 4G/4G = 30.1%, 4G/5G = 47.9%, 
and 5G/5G = 21.8%. Carriage of 4G was not associated with CAD (Odds 
Ratio [OR] = 1.08) or MI (OR = 1.11) nor was a 4G/4G homozygosity (CAD 
OR = 1.07, MI OR = 0.98). In multivariate analyses, common risk factors 
predictive of CAD were (in order): sex, age, smoking, diabetes, cholesterol, 
hypertension; for MI, they were sex, smoking, cholesterol. Genotype did not 
enter as a multivariate predictor. 
Conclusion: A common PAl-1 polymorphism (4G) was not importantly 
associated (i.e., OR > 1.5) with angiographic CAD or history of MI in a 
caucasian population of primarily Anglo-Scandinavian descent. However, a 
smaller overall risk, perhaps in association with other factors, cannot be 
excluded. 
POSTER 
Cardiac Cel lu lar  B io logy II 
Monday ,  March  8, 1999,  3:00 p .m. -5 :00  p.m. 
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  3:00 p .m. -4 :00  p.m. 
[ 11 07-11 6 ] Effect of  Chronic  Act ivat ion of Ang iotens in  II, 
Endothelin and Catecholamines in the Absence 
of Cardiac Volume or Pressure Overload on Left 
Ventricular Mass in Vivo 
Ondrej Lisy, John C. Bumett, Jr., Michihisa Jougasaki, Margaret 
M. Redfield. Mayo Clinic, Rochester, MN, USA 
Background: Myocardial hypertrophy is mediated by both mechanical and 
humoral stimuli. Pro-hypertrophic humoral factors include angiotensin II (All), 
endothelin (ET), and nor-epinephdne (NE). In vivo, these humoral mediators 
are usually activated in conditions associated with LV dilatation or pressure 
overload. Chronic thoracic inferior vena cava constriction (TIVCC) is a unique 
model of reduced venous return associated with activation of All, ET and 
NE in the absence of LV volume or pressure overload thus eliminating the 
mechanical stimulus for hypertrophy. We sought to determine if such intense 
"neurohumoral storm" is associated with LV hypertrophy in the absence of 
LV dilatation or pressure overload. 
Methods: Circulating levels of All, ET and NE, mean arterial pressure 
(MAP), and LV end-diastolic dimension (by echo, LVEDd) were measured 
in conscious dogs 10 days after TIVCC (n = 7) or SHAM operation (n = 6). 
LV mass was determined at autopsy and was indexed to their pre-operative 
body weight (LVMi) as TIVCC dogs had ascities. 
Results: "p < 0.05 vs SHAM 
All (pg/ml) ET (pg/ml) NE (pg/ml) 
TIVCC 168.4 ± 54.7* 15.2 + 2.5* 638.6 + 135.5* 
SHAM 11.3 + 2.0 3.4 + 0.8 170.8 + 12.4 
MAP (mmHg) LVEDd (cm) LVMi (g/kg) 
TIVCC 122 + 15 3.48 ± 0.22* 3.53 + 0.20" 
SHAM 127 + 8 4.08 ± 0.15 4.50 plusmn; 0.23 
Ejection fraction was similar in SHAM and TIVCC. In TIVCC, LVMi was 
reduced reflecting myocyte atrophy and/or loss. 
Conclusion: These data uniquelly demonstrate that even intense activa- 
tion of these mitogenic factors does not stimulate LV hypertrophy in vivo in 
the absence of concomitant hemodynamic stress. 
I 1 1  07-1171 Nitric Oxide but not Brain Natriuretic Peptide i Blunts the Inotropic Response to/3-Adrenergic 
Stimulation in the Anesthetized Dog 
Eugenia L. Hahn, Margaret M. Redfield. Mayo Clinic, Rochester, MN, USA 
Background: Previous studies have demonstrated that Nitric oxide (NO) 
mediates vagal inhibition of the inotropic response to #-adrenergic stimulation 
and the ,8-adrenergic hyporesponsiveness seen in heart failure. Nitric oxide 
and the natriuretic peptides (NP) are activated in heart failure and share the 
second messenger cGMP via activation of soluble (for NO) or particulate 
(for NP) guanylate cyclase receptors. As the presence of myocardial NP 
receptors has been documented, we hypothesized that increased myocardial 
concentrations of brain natriuretic peptide (BNP) would, like NO, blunt the 
inotropic response to/~-stimulation with dobutamine (DOB). 
Methods: In five anesthetized dogs, the inotropic response to intra- 
venous dobutamine (DOB, 5-10 ug.kg 1 min-1) was assessed during in- 
traooronary infusion of: saline, BNP (25 ng.kg -1 min 1), sodium nitroprus- 
side (SNP, 4 ug/min), and finally during saline again (as a time control). The 
inotropic response was quantified as % increase in peak +dP/dt with each 
DOB infusion, all assessed at constant heart rate (atrial pacing). 
m 
r ns * 
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Results: Neither intracoronary BNP nor intracoronary SNP altered load- 
ing conditions prior to DOB infusion. Only SNP attenuated the positive in- 
otropic response to dobutamine (figure; *p < 0.05). 
Conclusion: These findings raise the possibility that the myocardial ef- 
fects of substances which stimulate cGMP may differ in accordance with 
which form of guanylate cyclase they activate. As BNP is being developed 
for the therapy of heart failure, these findings have clinical relevance. 
1107-118 I TNF Enhances IL-1 Stimulated NO Production in J Cardiac Myocytes Through MAP Kinase 
Mediated NF-~B Activation 
I-long Kan, Zirong Xie, Mitchell S. Finkel. Section of Cardiology, West 
Virginia University School of Medicine Morgantown, WV 26506-9157, USA 
The pro-inflammatory cytokines, tumor necrosis factor o~ (TNF) and intedeukin-1 
(IL-t) are elaborated in a vadety of clinical and experimental conditions rang- 
ing from sepsis to ischemia and congestive heart failure. We and others have 
proposed that these cytokines may contribute to myocardial dysfunction in 
patients and animal models. Basic mechanisms underlying myocardial ef- 
fects of cytokines are unclear, but may involve nitric oxide (NO). We have 
previously reported that IL-1 alone induced NO production in neonatal rat 
cardiac myocytes (CM). The effects of TNF on inducible NO synthase (iNOS) 
have not previously been reported. Unlike IL-1, TNF alone failed to enhance 
NO production in CM However, the addition of TNF to IL-1 significantly en- 
hanced NO production above IL-1 alone (4.78 ± 0,9 vs. 8.64 ± 0.2 umol/1.25 
× 10 s cells/48 hrs; p _< 0.05; n = 12). TNF enhanced IL-1 induced iNOS 
mRNA expression, as well as iNOS protein synthesis. TNF enhancement 
of IL-1 induced NO 2 production was blocked by PD98059, a selective MAP 
kinase kinase inhibitor (8,64 ± 0.9 vs. 3.4 ± 0.8 umol/1.25 × 105 cells/48 
hrs; p _< 0.05; n = 12). Calphostin C (Cal C), a protein kinase C inhibitor 
had no effect, TNF increased MAP kinase activity was associated with an 
increase in IL-l-stimulated NF-~B activity. PD98059 but not Cal C inhibited 
TNF-increased MAP kinase activity and NF-~B activity, as well, We con- 
clude that TNF enhances IL-l-induced NO production in CM through MAP 
kinase-mediated activation of NF-xB. 
1107-119 I Estrogen Receptor-Mediated Gender-Specific 
J Vascular Effects of 17/3-Estradiol 
Martin E. Beyer, Georg Yu, Hartmut Hanke 1 , Hans Martin Hoffmeister. 
Medical Hospital, Dept. 1 III, University of TObingen; Medical Hospital, Dept. 
II, University of UIm, Germany 
Background: The cardioprotective effects of estrogen may be explained in 
part by vasodilative effects. The rapid onset of vasodilation after administra- 
tion of 17/~-estradiol (17/~-E) is not typical for an action mediated by estrogen 
receptors (ER). To study the role of ER on 17/~-E-induced hemodynamic 
effects we examined the gender-specific action of 17/~-E without and with 
pretreatment with the selective ER antagonist ICI 182780 (ICI). 
Methods: The gender-specific effects of i.v. 200 ng/kg 17/~-E without 
and with ER-blockade (1 mg/kg ICI) vs. NaCI-controls were compared in 
open-chest rats. The gender-specific ER-density of the vessel wall was 
determined by immunohistochemical staining. 
Results: 
Female rats Male rats 
17,8-E ICI + 17 ~-E NaCI 17~-E ICI + 17fl-E NaCI 
CO 167± 10 t 133±4" 108±5 145±5 t 123 ± 4" 111±1 
EF 127 J: 3 t 125±31 98±3 115 ±3" 107 :E 4 102±2 
TPR 71 ± 4 t 81 :I: 21" 96 ± 4 80 ± 2 t 87 ± 3* 94 ± 1 
Means ± SEM in % of preinfusion values; * = p < 0.01, i" = p < 0.001. 
The acute 17/~-E-induced vasodilation with consequent increase of the 
cardiac output and of the ejection fraction is more pronounced in female than 
in male rats. ER-blockade with ICI reduces these effects in both gender. There 
is no gender-specific difference of ER-density neither in the endothelium 
(ER-positive cells: 78 ± 10% in females vs. 69 ± 11% in males) nor in the 
media (12 ± 4% vs. 21 ± 6%) of the aorta. 
Conclusion: The 17/~-E-induced vascular effects are more pronounced 
in females than in males and can be attenuated in both gender by the ER 
antagonist ICI. These gender-specific vascular effect of 17/%E cannot be 
explained by gender-specific differences of the ER-density from the vessels. 
I1 / Surgical Oophorectomy with and Without  
1 
1 07-1 20 
Hysterectomy, Hormone Therapy and CAD in 
Women: The NHLBI-Sponsored WISE 
C. Noel Bairey Merz, Tanya Kenkre, Vera Bittner, Jannet Lewis, 
Glenn Braunstein, T. Keta Hodgson, Sarah Berga, Barry L. Sharaf, Sheryl 
F. Kelsey. Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Background: Surgical oophorectomy (O) with and without hysterectomy (H) 
increases the risk of CAD in women, but the impact of hormone therapy (HT) 
on CAD likelihood in this setting is unknown. 
Methods: We evaluated 120 women in the Women's Isohemic Syndrome 
Evaluation (WISE) study who underwent coronary angiography for suspected 
ischemia and complete reproductive history categorization. 
Results: Overall, 72/120 (60%) of the women had undergone H, and 
49/72 (68%) had also undergone uni/bilateral O. The surgical O with and 
without H group reported a greater history of HT use compared to the group 
without surgery (73% vs 39%, p < 0.001), a higher proportion of current HT 
use (54% vs 18%, p < 0.008), an eadier age of onset of HT (43 + 11 vs 51 
± 11 yrs, p < 0.001), and a longer duration of HT use (12 ± 11 vs 4 ± 4 yrs, 
respectively, p < 0.0001). There was a graded direct relationship between 
historical HT use and O/H status (Table). 
Historical HT Use 
BSO and H USO and H H alone No surgery 
90% 67% 50% 39% 
BS = bilateral, US = unilateral, p = 0.001 for trend across groups. 
Multivariate analysis demonstrated that age and absence of H were sig- 
nificant predictors of CAD, defined as >_50% stenosis >1 epicardial coronary 
artery (both p < 0.05). 
Conclusions: Surgical O with and without H are associated with a higher 
prevalence, eadier onset, and longer duration of HT use in women with sus- 
pected ischemia. These women have a lower prevalence of CAD, suggesting 
that HT modulates the increased risk of CAD associated with surgical O with 
and without H. 
11 21 I Vasopressin Modulates Sympathetic Nerve 
1 
07-1 
Activitiy in Various Models of Hypertension 
Frank Muders, Dietmar Eisner, Udo Bahner, Miklos Palkovits 1 . University of 
Regensburg, Germany; I Semmelweis Medical Universi~ Hungary 
Background: Central vasopressin (ADH) plays an important role in the con- 
trol of blood pressure and heart rate in hypertension. ADH stimulates sympa- 
thetic outflow via the locus coeruleus (LC) which receives vasopressinergic 
innervation from the hypothalamus, and microinjection of AVP in the LC 
produces an increase in blood pressure and heart rate. 
Methods: In order to investigate the functional status of ADH in the 
LC we determined the ADH content in the LC (micrepunch technique) in 5 
different models of hypertension (SHR, DOCA salt, Angiotensin II infusions 
using osmotic minipumps [7.2 nmol AII/h i.p.], 1 clip 1 kidney [1C1K], 1 clip 2 
kidney [1C2K]) in the rat, 
Results: Elevated blood pressure levels (tail cuff method) were compa- 
rable in all models used (160 ± 13 mmHg). In comparison to controls (53 ± 9 
pg/mg protein) ADH was significantly elevated in the LC of rats with genetic 
hypertension (SHR; +60%; p < 0.05) and in the 1C2K model (+172%; p 
< 0.001), whereas in All induced hypertensive- and DOCA-rats ADH was 
significantly suppressed in the LC (-39.2% and -44.8% vs CTRL; p < 0.05, 
respectively). In rats with 1C1K induced hypedension ADH was unchanged, 
Conclusions: In the two models (SHR and 1C2K), which are both charac- 
terized by elevated sympathetic nerve activity, high endogenous ADH were 
demonstrated in the LC. In the other models (All, DOCA, 1C1K) rats showed 
unaltered or suppressed ADH content in the LC probable due to the high 
circulating levels of All. In these rats, low AVP levels in the LC may reduce 
sympathetic outflow and counteract to a further increase of blood pressure. 
Our results support the hypothesis that central vasopressin modulates sym- 
pathetic nerve activity via the locus coeruleus. 
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ORAL 
~-~ Infection and Atherosclerosis 
Monday,  March  8, 1999, 4 :00 p .m. -5 :30  p.rn. 
Moda l  Convent ion  Center ,  Room 262 
4:00 p.m. 
[81~ Host Variability in Cytomegalovirus Mediated 
Induction of Interferon 3' by CD8 T Lymphocytes: 
A Possible Role of the Immune System in Conveying 
Resistance or Sensitivity to the Effects of Infection 
on the Pathogenesis of Atherosclerosis 
Fareeha Khan, Monica Panelli, Francesco Marincola, Stephan E. Epstein. 
NHLBI, NIH, Bethesda, & Washington Hospital Center, Washington, DC, 
USA 
Cytomegalovirus (CMV) has been implicated in the pathogenesis of ath- 
erosclerosis, but data suggest there is considerable variability in host sus- 
ceptibility. The cellular immune response is crucial in host defense against 
intracellular pathogens. We tested the concept that different individuals have 
different cellular immune responses to CMV by measuring, in 4 healthy blood 
donors, the IFNy response of CD8 T lymphocytes to CMV antigens (Ag). 
CD8 T cells were isolated from peripheral blood cells and exposed to CMV 
infected HEL299 cells 3X at weekly intervals. These stimulated CD8 T cells 
responded to CMV Ag by releasing IFNy in the supematant (Fig 1 ); specificity 
was demonstrated by the fact that considerably less IFNy was released in 
response to Flu peptide. Negligible amounts of IFNy were produced by CD8 
cells stimulated by non infected HEL299 cells (control). Biologic activity of the 
CD8 response to CMV Ag was demonstrated by the finding that treatment 
of CMV-infected HEL299 cells with supernatant containing IFN7' inhibited 
replication of CMV. Importantly, we found a quantitative variation in the IFN 
y response among the 4 individuals (Fig 1). 
i ' 
Local release of IFNx can, through multiple mechanisms, modulate both 
host response to pathogen and pathogen activity. Our results, by demon- 
strating individual variability in the immune response to CMV infection, are 
therefore compatible with the concept that individuals will also vary in their 
susceptibility or resistance to CMV-mediated contribution to atherosclerosis. 
4 :15 p,m. 
~17~ Chlamydia Pneumonia-Induced Transactivation of 
Cytomegalovirus: Potential Synergy of Infectious 
Agents in the Pathogenesis of Atherosclerosis 
Chad Wanishsawed, Yi Fu Zhou, Stephen E. Epstein. NHLBI, NIH, 
Bethesda, MD; Washington Hospital Center, DC. USA 
Background: Both cytomegalovirus (CMV) and chlamydia pneumonia, ex- 
tremely common human pathogens, have been identified in atherosclerotic 
vessels, and epidemiologic studies have found an association of each of 
these infectious agents with atherosclerosis. CMV is believed to exist in 
host tissues in a latent state, with periodic reactivation causing changes 
predisposing to atherosclerosis. 
Methods and Results: The present study was designed to determine 
if chlamydia infection stimulates the expression of CMV genes, an effect 
that could augment any role CMV has in the pathogenesis of atheroscle- 
rosis. Transactivation of the CMV major immediate eady promoter (MIEP) 
is essential for viral gene expression and viral replication. We transfected 
Hela cells with a construct containing a reporter gene (CAT) controlled by 
the MIEP. The cells were then infected with chlamydia at 102-106 infectious 
units (IFU) per ml at various times before assay of MIEP activity (72 hr after 
transfection). Peak transactivation occurred 6 hr after infection at 104 IFU; 
chlamydia increased MIEP activity in a dose-response manner; maximal 
increase was over 2-fold. 
Conclusion: These results suggest that chlamydia infection may activate 
CMV and increase CMV gene expression. Thus, if these infectious agents 
do indeed contribute to atherogenesis, their co-presence may synergistically 
contribute to this disease process. 
4 :30 p.m. 
~-~ HMG-Co A reductase Inhibitors Are Modifying the 
Inflammatory Response of Human Macrophages 
Infected by Chlamydia Pneumoniae 
H. Kothe 1 , J. Rupp 1 , K. Dalhoff 1 , M. Maass 2, H. Katus 1 . ~Department of 
Medicine II; 21nstitut of Microbiology, Medical University of LObeck, Germany 
Background:The clinical benefits of CSE-Inhibitors in patients with coronary 
heart disease are not strictly related to their lipid-lowenng effects. Chlamydia 
pneumoniae (CWL) has been associated with the development of athero- 
sclerosis. The purpose of this study was to determine whether there is an 
influence of the CSE Inhibitor Cerivastatin (Cer) on the infection and inflam- 
matory response of human macrophages. 
Methods: Alveolar macrophages (AM) were collected from 6 healthy male 
volunteers. CWL were grown on HEP-2 monolayers and incubated with AM 
for 48-96 h. The rate of infection was determined by immunofluorescence. 
MCP-1, IL-8 and TNF-c~ were quantified by commercially available ELISAs. 
The release of oxygen radicals was determined by ferricytochrome microplate 
assay. 
Results: Cer treated AMs showed a reduced infection rate as compared 
to AM + CWL without Cer. The infected AMs showed an increased production 
of MCP-1 (AM + CWL: 2643 pg/mt vs. AM: 1573 pg/ml). Incubation with Cer 
resulted in a significantly lower MCP-1 production (AM + CWL + Cer after 
48 h: 1724 pg/ml, p < 0.05). The IL-8 production of infected AMs was also 
significantly suppressed by Cer. The release of TNF-e was not significantly 
altered by Cer treatment. The oxidative response of AMs was increased in 
response to C. pneumoniae (AM + CWL: 0.98 nmol 02 radicals vs. AM: 0.63 
nmol 02 radicals). Car treated AMs had a 1.3-fold lowered release of oxygen 
radicals (AM + CWL: 0.98 nmol 02 radicals). 
Conclusions: In addition to the lipid lowering effects HMG-CoA-Reduc- 
tase Inhibitors have an influence on the inflammatory response of human 
macrophages. These findings could be relevant the therapeutic effects of the 
CSE-inhibitors in patients with normal levels of cholesterol. 
4 :45 p.m. 
I~ - ]  Endotoxemia - A Potential Pathophysiological Link 
m the Association of Smoking, Chronic Infection 
and Atherosclerosis 
Christian J. Wiedermann, Stefan Kiechl, Stefan Dunzendorfer, 
Peter Schratzberger, Georg Egger, Frieddch Oberhollenzer, Johann Willeit. 
Dept. Internal Med. and Neurology, University of Innsbruck, Austria; 
Department of Internal Medicine, Federal Hospital Bruneck, Italy 
Background: The possibility of an infectious risk factor in atherogenesis and 
cardiovascular disease has stimulated renewed research interest, but the 
nature of such process remains obscure. Focus of the current study was on 
the significance of bacterial endotoxin, which shows a variety of pro-athero- 
genic properties and may occur at high concentration in the circulation of 
infected subjects. 
Methods: We measured plasma endotoxin levels (LAL assay) in a ran- 
dom population of 516 men and women 50 to 79 years old at the 1990 
baseline evaluation (Bruneck Study). Endpoints of this prospective survey 
were incident (early) atherosclerosis in the carotid arteries as assessed with 
high-resolution Duplex ultrasound (five-year follow-up rate, 98%) and incident 
cardiovascular disease (follow-up rate, 100%). 
Results: Median endotoxin concentration amounted to 14.3 pg/mL with 
a range of 6.0 to 209.2 pg/mL. Subjects with levels beyond 50 pg/mL (90th 
percentile) faced a three-fold risk of incident atherosclerosis (OR (95% CI) 
2.9 (1.4-6.3); P < 0.01). The risk associated with high endotoxin was most 
pronounced in subjects with chronic infections and in current and ex-smokers. 
Notably, smokers with tow endotoxin levels and non-smokers did not differ in 
their atherosclerosis risk, whereas smokers with high levels almost invariably 
developed new lesions. All findings emerged as independent of vascular risk 
factors. Similar results were obtained for incident cardiovascular disease. 
Conclusion: The current study yields first epidemiologic evidence that 
endotoxemia constitutes (1) a strong risk factor of early atherogenesis in 
subjects with chronic or recurrent bacterial infections and (2) a promising 
pathophysiological ink in the association between cigarette smoking and 
atherosclerotic disease. 
5:00 p.m. 
~ Chlamydia Pneumoniae and Helicobacter Pylori  in 
Human Coronary Atherosclerosis 
Gerhard Bauriedel, Randolph Hutter, Berndt L0deritz. Dept. of Cardiology, 
University of Bonn, Bonn, Germany 
Background: Bacterial pathogens such as Chlamydia pneumoniae (C) and 
Helicobacter pytori (H) have been associated with human atherosclerosis. 
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However, their intralesional presence and the specific mechanisms by which 
they may affect intimal micrcecology, are still incompletely understood. 
Methods: Coronary atherectomy samples obtained from patients with 
unstable (n = 31) and stable angina (n = 21) were immunohistochemically 
examined for the presence of C and H (Medac Inc., Dako Inc.; mesenchymal 
cells infected with C, and tissue biopsies from H diseased gastric mucosa, 
resp., as positive controls), with special regard on intimal predilection sites 
and a potential microbial prevalence (C, H) in one of the two patient groups. 
Results: Immunoreaction for C was positive in 32/51 (63%), that for H 
in 13/39 (33%) coronary plaques. C-signals were detected in necrotic areas 
(in 40% of the lesions exhibiting the respective feature), pericellular ma- 
trix (40%), neovascularization (29%), thrombi (20%) fissured areas (19%) 
and foam cell-rich zones (13%). No signals were found in intimal hyperpla- 
sia, inflammatory infiltrates, and in undiseased, non-implanted bypass grafts 
(negative controls). Additional electron microscopic analysis shows C ele- 
mentary bodies within foam cells/macrophages. More often, these bodies 
were found close to apoptotic or necrotic smooth muscle cells (SMCs), but 
not with viable SMCs or with intact extracellular matrix. Most interestingly, 
26/31 lesions associated with unstable angina, but only 6/20 lesions with 
stable angina presented C signals (84% vs. 30%, p < 0.001). In contrast, 
H-signals were exclusively found in neovascularizations (44%), necrotic ar- 
eas (17%), infiltrates (10%), fissured zones (7%) and thrombi (6%), without 
difference between stable and unstable angina (35% vs. 32%). 
Conclusion: Our data show the presence of Chlamydia pneumoniae and 
Helicobecter pylori, the first pathogen more prevalent with unstable angina. 
Indeed, its co-localization with intimal cells undergoing cell death and its 
intralesional distribution pattern point to a pathogenic role of Chlamydia 
pneumoniae in predisposing to coronary plaque rupture. The predilection 
sites of Helicobacter pylori may solely reflect the exposure to blood flow. 
5:15 p.m. 
~-- ]  Estradiol Restores Endothelial Cell Fas Ligand 
Expression in Hypercholesterolemic Rabbit: 
immune Modulation as a Potential Mechanism for 
Anti-Atherogenesis 
Pernille Holm, Shu-hua Xu, Nell Tripman, Tong Li, Marianne Kearney, 
Douglas W. Losordo. Novo Nordisk, Mdl~v, Denmark; Division of 
Cardiology, St. Elizabeth's Medical Center, Boston, MA, USA 
Background: 1) Inflammatory cell infiltration into the artedal wall occurs 
during atherogenesis; 2) Fas ligand (FasL) expression by endothelial cells 
has recently been shown to be essential for preventing transmigration of 
inflammatory cells into the vessel wall; 3) Estrogen (Estr) is known to sus- 
tain or restore certain aspects of endothelial function, such as nitric oxide 
production, but its effects on FasL expression are unknown. Accordingly, 
we performed a series of experiments to determine if Estr influences FasL 
expression by vascular endothelial cells (EC). 
Methods: A well characterized cholesterol (Chol)-fed rabbit model was 
used in which the diet of each animal is adjusted to achieve equivalent 
levels of serum Chol, despite estrogen replacement in half the population. 
All animals were ovariectomized 1 wk. after beginning Chol feeding. After 
surgery 58 rabbits were divided into 4 groups: placebo (n = 16); 17/~-Estradiol 
(50 #g/kg IM every 3 days) (n = 15); LNAME (160 #g/ml drinking water) (n 
= 13); Estradiol + LNAME (n = 14). After 4 wk. arteries were harvested and 
FasL expression was determined by Western analysis and normalized to 
expression of a-tubulin. 
Results: FasL expression was suppressed by Chol feeding compared 
to control fed animals. Estradiol treatment restored FasL expression toward 
normal levels, increasing expression from 0.24 ± 0.15 (placebo) (arbitrary 
units) to 0.49 + 0.10 (Estr alone) (p 0.01). The addition of LNAME alone to 
the diet did not change FasL expression (0.28 + 0.21, p = NS vs. placebo), 
however, the addition of LNAME to estradiol treatment abrogated the Estr 
mediated restoration of EC FasL expression (0.26 + 0.15, p < 0.02 vs. Estr 
alone, p = NS vs. placebo). 
Conclusions: 1) Hypercholesterolemia suppresses FasL expression by 
vascular endothelial cells; 2) Estradiol restores EC FasL expression despite 
persistent hypercholesterolemia; 3) Estrogen induced restoration of FasL is 
mediated via mechanism involving nitric oxide. 
ORAL 
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Modal Convention Center, Room 207 
4:00 p.m. 
~-]  Significance ofMethylenet~rahyd~folate 
Reductase Gene Polymorphism as a Risk Factor for 
Early Myocardial Infarction 
C). Aras, S, G01e~ 1, E. Akar, K. C)mQdfi 1 , F. Avcu, D. OraP, N. Akar. Pediatric 
Molecular genetics; 1 Cardiology Departments, Ankara Universi~ Turkey 
Hyperhomocysteinemia due to nutritional and genetic factors is emerging as 
a prevalent risk factor for coronary atherosclerosis and for arteriel and venous 
thromboembolism. Homozygotes for the cytosine to thymine substitution at 
nucleotide 677 of the methylene tetrahydrofolate reductase (MTHFR) gene 
has been reported to be associated with higher plasma homocysteine lev- 
els. Myocardial infaction (MI) in the young usually occurs in the presence of 
coronary atherosclerosis and thrombosis. However, the contribution of throm- 
bosis to athero-thrombotic disease is thought to be particularly important in 
the young. We investigated whether MTHFR gene polymorphism influences 
risk for MI in young men. Sixty-seven patients (all men, mean age: 39.6 ± 5.9 
years) who had documented MI before age 45 and demographically similar 
control subjects (all men, mean age: 38.6 ± 8.4 years) were studied. We ob- 
served that T allele was significantly more prevalent in patients with early MI 
than in control subjects (p 0.05). The T/-F genotype was also more common 
in patients with early MI but the level of difference was not significant. The 
relative risk for early MI associated with each T allele was 1.42 (95% CI, 0.83 
to 2.41 ). 
C/C CfT T/T T allele 
Controls, n (%) 41 (63) 20 (31) 4 (6) 0.21 
(n = 65) 
Early MI, n (%) 34 (51) 23 (34) 10 (15) 0.32 
(n = 67) 
p value 0.23 0.75 0.5 0.05 
Odds ratio 1.42 
(95% CI) (0.83-2.41) 
In conclusion, our data suggests an association between T allele of 
MTHFR gene and occurance of MI in subjects younger than 45 year-old. 
4:15 p.m. 
~-~A Novel Polymorphism in the Gene Coding for the 
/31-Receptor Associated With Survival in Patients 
With Heart Failure 
Malin B<Srjesson, Yvonne Magnusson, Bert Andersson. Wallenberg 
Laboratory, Dept. of Cardiology, Sahlgrenska University Hospital, Gdteborg, 
Sweden 
Background: The adrenergic nervous system is of major importance in con- 
gestive heart failure. Polymorphisms of the f12- and #3-adrenergic (,BAR) 
genes have been reported to be associated with asthma, obesity and dia- 
betes. No polymorphism has previously been identified in the ,81AR gene. 
The aim of this study was to find possibly mutations in this gene and to relate 
such findings to morbidity and prognosis in heart failure. 
Methods: Genomic DNA was extracted from blood leucocytes from con- 
trols (n = 77) and patients with congestive heart failure (n = 182). The 
fragment corresponding to nucleotide position 1-794 of the #IAR gene was 
amplified with PCR and analyzed by automated dideoxy sequencing. The 
patients were investigated by echocardiography and were followed regarding 
symptoms and survival for 5 years. 
Results: We identified a point mutation at nucleotide position 145 in the 
/~1AR gene. This missense mutation predicted an amino acid substitution of 
serine (AA~ by glycine (AAG) at position 49 (Ser49Gly), in the N-terminal 
region of the recepor protein. The allele frequency of the mutation was 0.13 
in controls and 0.18 in patients (NS). At the time of 2-years follow-up, 42% 
of the patients with the wildtype genotype and 13% of the patients with 
the mutated genotype had been hospitalized due to a cardiac disorder (p = 
0.007). Patients without mutation had significantly worse prognosis compared 
to those with the mutation, RR 2.34 (95% CI 1.30-4.20), (p = 0.003). In a 
mulivariate analysis, the risk ratio was 2.03 (95% CI 0.99-4.16), p = 0.05. 
Conclusion: We identified a novel missense mution in the ,81AR gene that 
was associated with a decreased mortality risk in patients with congestive 
heart failure. These data suggest that the Ser49Gly mutation might cause an 
altered receptor function, resulting in myocardial protection in patients with 
heart failure. 
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4:30 p.m. 
~T~-~ percutaneous Endocardial Gene Therapy: In Vivo 
Gene Transfer and Expression 
Timothy A. Sanborn, Norman Tarazona, Ezra Deutsch, Leonard Lee, 
Nell Hackett, Tarek EI-Sawy, Ronald G. Crystal, Todd K. Rosengart. New 
York Presbyterian Hospital, Cornell University Medical College, New York, 
NY, USA 
Direct epicardial administration of angiogens (angiogenic proteins and genes) 
by an open surgical approach has been shown to stimulate the development 
of new collaterals on angiography and improvement in myocardial perfusion 
and function in ischemJc myocardium. To evaluate the feasibility of percu- 
taneous endocardial gene therapy, a left ventricular catheter system was 
evaluated to determine whether a less invasive approach is reproducible, 
safe and effective. 
Methods: 1) Under fluoroscopic guidance, intramyocardial delivery of 
marker agents (Hypaque plus tissue dye) 4, 5 and 6 mm from the endocardial 
surface to all regions of porcine myocarcardium (septal, anterior, lateral, and 
inferior walls) was performed. Feasibility was examined on cJnefluoroscopy 
and on post mortem examination. 2) Replication-deficient adenovirus ex- 
pressing the gene for ,6-galactosidase (Ad~gal) or control (AdNull) was ad- 
ministered in similar fashion and gene expression measured 48 hours later 
using quantitative nzymatic and histochemical analysis for ,6-galactosidase. 
Results: In 3 animals, cinefluoroscopy and gross pathology contrast/tissue 
dye administration in 8/13 (62%) attempts with regional localization in all 8 
successful endomyocardial injections. In 3 subsequent animals, adminis- 
tration of a mixture of 30% Hypaque and Ad,~gal resulted in endomyocar- 
dial delivery in 30/31 (97%) injections on cinefluoroscopy. #-galactosidase 
was detected histochemically and quantitative analysis demonstrated levels 
of 103 units/mg protein over background. No arrhythmias, perforations, or 
hemodynamic compromise occurred. 
Conclusion: The feasibility of percutaneous fluoroscopically guided, ade- 
noviral-mediated endocardiat gene therapy with a marker gene,/~-galactosidase, 
has been demonstrated in porcine myocardium. The clinical utility of percu- 
taneous endocardial angiogenesis needs to be examined as it may benefit 
those patients that may not be candidates for conventional angioplasty or 
bypass surgery. 
4:45 p,m. 
~4-~ Mitochondrial DNA Defects Associated With Dilated 
Cardiomyopathy 
Eloisa Arbustini, Marta Diegoli, Maurizia Grasso, Barbara Dal Bello, 
Patdzia Morbini, Nadia Banchieri, Omella Bellini, A. Pilotto, Filippe Magani, 
Carlo Campana, Antonello Gavazzi. IRCCS Policlinico S. Matteo, Pavia, 
Italy 
Background: Mitochondrial (mt) DNA defects, both deletions and tRNA point 
mutations, have been associated with cardiomyopathyes. 
Methods: To determine the prevalence of pathologic mtDNA mutations 
and to assess associated defects of mitochonddal enzyme activity, we inves- 
tigated a large series of patients with dilated cardiomyopathy (DCM), using 
electron and immunoelectron microscopy to select cases for molecular study. 
Results: Of 690 endomyocardial biopsies from DCM patients, 100 (79 
males, 21 females; 16 to 65 years, mean 44.3 ~ 12.9) had uitrastructurat 
evidence of mitochondrial abnormalities analogous to those observed in 
skeletal muscle of patients with mitochondrial myopathies (giant organelles, 
with abnormal cristae, inclusion bodies, etc.); 20 of 100 (20%) had 10 tRNA, 
5 rRNA and 4 missense heteroplasmic mtDNA mutations that were not found 
in 111 normal controls. In all cases, the amount of mutant was higher in heart 
than in blood. These 20 patients constitute a small subset of the overall DCM 
group (2.9%%). In hearts of patients that later underwent transplantation, 
cytochrome c oxidase (Cox) activity was significantly lower in hearts with 
mutations, than in those without, and than in controls (p = 0.0008). Immu- 
noelectron microscopy with anti cytochrome c antibodies showed decreased 
and disomogeneous stain in mitochondda, of patients with mutations. 
Conclusion: Pathologic mtDNA mutations are associated with decrease 
cytochrome c immunoreactivity, ultrastructurally abnormal mitochondria and 
decreased Cox activity in a small subgroup (2.9%) of not-otherwise defined, 
idiopatic DCMs. 
5:00 p.m. 
~5-]  Platelet GPIIla Receptor PL A Polymorphism and 
Cardiovascular Disease: The Framingham Heart 
Study 
DaLi Feng ~ , Martin G. Larson 2, Klaus Lindpaintner 3, Christopher 
J. O'Donnell 2, Izabella Lipinska 1 , Patrice A. Sutherland 2 , Daniel Levy 2, 
Geoffrey H. Tofler ~ . Institute for Prevention of Cardiovascular Disease; 
1Beth Israel Deaconess Medical Center," 2NHLBI'S Framingham Heart 
Study, Framingham, MA; 3Brigham & Women's Hospital, Boston, USA 
Background: The platelet GPIIb/llla receptor plays a pivotal role in platelet 
aggregation. Recent data from some but not all studies suggest the PL A2 
polymorphism of GPIIla may be associated with an increased risk for car- 
diovascular disease. We studied subjects from the Framingham Heart Study 
to determine if the PL A2 allele is associated with an increase in prevalent 
cardiovascular disease (CVD). 
Methods and Results: We determined genotype and phenotype data 
in 3195 subjects enrolled into the study. The PL A polymorphism was de- 
termined by PCR-based restriction fragment length polymorphism analysis. 
Allele frequencies of PL '~ and PL A2 were 0.85 and 0.15 respectively. There 
were no significant differences in genotype distribution among subjects with 
or without CVD, p = 0.58. When we looked separately at unstable angina, 
myocardial infarction, or ischemic stroke these individuals tended to have a 
higher proportion of PL A2 allele (32.1%) than those without CVD, but this was 
not statistically significant. 
PLA genatype (number and %) 
Subjects Number PL A1/PL A1 PL A2 Carrier 
CVD 514 362 (70.4%) 152 (29.6%) 
No CVD 2681 1942 (72.4%) 739 (27.6%) 
Conclusion: In the Framingham Heart Study, the PL A2 genotype was not 
significantly associated with increase in cardiovascular disease. 
5:15 p.m. 
~-1 Novel Missense Mutations in the Cardiac ~-Myosin 
Heavy Chain Gene in Hypertrophic Cardiomyopathy; 
Genotype-Phenotype Relationship 
Ole Havndrup, Henning Bundgaard, Paal Skytt Andersen, Lars 
Allan Larsen, Michael Christiansen, Jens Vuust, Keld Kjeldsen. National 
University Hospital and Statens Serum Institut, Copenhagen, Denmark 
Background: In the Copenhagen clinical and molecular genetic study of 
Danish families with hypertrophic cardiomyopathy (HCM) assessment of 
specific mutations in the seven known genes involved in HCM are performed 
and the genotype--phenotype relationship is described. 
Methods: Fifty unrelated families with HCM were evaluated non-inva- 
sively and molecular geneticically by PCR/SSCP analysis of exons 3-23 of 
the cardiac/%myosin heavy chain gene (MYH7), followed by sequencing of 
heterozygotes. 
Results: Five novel MYH7 missense mutations were found in six out 
of the fifty families, i.e. Arglg°Thr, Leu39°Val, Leu6°~Val, ArgS94Cys and, 
Glu846GIn. The previously described Val6°6Met was found in one additional 
family. The overall penetrance of HCM phenotype at the age of 40 years was 
83%. Echocardiographic findings in the genetically affected adults versus 
the unaffected adults in these families are shown in table (Diastolic, systolic, 
septal and posterior wall dimensions are shown, results are mean ± SD). 
Mutation Age (y) LVEDD LVESD IVS LWPW 
Yes (N = 24) 47±16 48 i6mm 32 JL 7 mm 16 =.5 mm 10±2ram 
No (N = 31) 39±14 50±6mm 35mm±5mm 10±3mm 9~+2mm 
p value ns ns ns p < 0.01 p < 0.05 
Conclusion: MYH 7 gene missense mutations were present in 14% of 
these Danish HCM families, and the observed genotypes were generally 
associated with marked septal hypertrophy and a high degree of penetrance 
at the age of 40 years. No left ventricular dysfunction was present in any of 
the phenotypically affected. 
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4:00 p.m. 
~4-~ Simplified Coronary Risk Stratification for Clinical 
Use 
Jenni'~er [3. ~obinson. )owa Heart Cen~er, Des Moine& ~owa, USA 
from drug therapy remains a challenging clinical issue. Graphs to estimate 
10-year CHD risk for men and women were developed from the Score Sheets 
derived from recently updated Framingham data. 
Methods: Graphs for each gender were generated by assigning the 
corresponding 10-year CHD risk from the Framingham total cholesterol Score 
Shee~,~ ~ ~.,-~.,"J~, ?.r~/: -'~,r~ ~-,f~. ~qj,~ ~.~J~J',~:,f . G¢~z,~,. ,~J~. ~ i [e~d~ f~. ~nj~ 
clinic patients ages 30-74 yearn were then compared to NCEP guidelines. 
Results: Estimates of 10-year CHD nsk from the graphs had a 99.99% 
corre(atior~ w~(:h the .Score Shee~:s. (~ patieris w~h LOL-C >_ t60 raged(, NCEP 
= 70)]. In moderate risk patients (13% to <20% 10-year CHD risk), NCEP 
candidates for drug therapy. In low risk patients (<13% 10 year CHD risk), 
NCEP guidelines identified 63.5% of women (n = 74) and 50.0% of men (n = 
present in less than 30% of low risk women and men; and in 37% and 12% 
of moderate risk women and men, respectively. 
L lO-yr CHD Risk 
[ ]  Low 
munnnn   
mmNmm~m~.,... • High k ~  
30- 35-40- 45-50 55-60-65- 70- 30- 35~40- 45-50-55-60-65- 70- 
Conclusions: Graphic estimates of lO-year CHD risk based on Fram- 
ing-ham data may more accurately identify primary prevention patients as 
4:15 p.m. 
I ~  Randomized Trial of Cholesterol-Lowering Therapy 
and Antioxidant Vitamin Supplementation in over 
20,000 Higher-Risk Patients 
Rory Collins. MRC/BHF Heart Protection Study Collaborative Group; 
Coordination: Clinical Trial Service Unit, Un&ers~ty of Oxford, UK 
Background: ~n observational studies, lower blood cholesterol levels and 
higher antiomdant vitamin intakes are associated with tower Clio risks. 
Methods: Men and women aged 40 to 80 were eligible for the Heart 
Proteclion 91udy p~o'~ided lhe't had a h';story o{ occlt~sive vascular disease 
or diabetes mellitus; blood total cholesterol ±3.5 mmol/I (135 mg/dl); and no 
clear indications for, or contraindications to, study treatments in the view of 
their own doctors. Following Run-in on active treatment, participants were 
design, vitam{ns (800 mg E, 250 mg C and 20 mg beta-carotene daily) or 
plac.-e~,.~. 
Results: Between July 1994 and May 1997 in 69 United Kingdom hospi- 
tats, 15,454 men and 5082 women were randomized, with 9515 aged over 
65. Non-fasting total cholesterol was <5.5 mmol/I (213 mg/dl) in 7882 par- 
ticJt:ants, and COL. cholesterol <3.0 retool//(tt6 m@'dl( ~rt 6888. O~a~nostic 
low cholesterol), 4869 other CHD history, 3288 cerebrovascular disease, 
6748 peripheral vascular disease and 5963 diabetes mellitus. During mean 
were seen in muscle symptoms, other possible side-effects, or elevated liver 
enzymes (ALl" > 3x upper limit ef normal [U LN]: 36 simvastatin vs 27 placebo) 
or rmus(~le enzymes "~C~ > g'bx 'OL't~: ~,~ VS ^ ~.). ~,}|oc~|on "~o S}mva~-'~'~,)n'nas 
red~Jced total and LDL cho)estero) by about 1.6--1.7 mmo))) 162-66 rag)d)) 
and 1.2-1.3 mmolA (46-50 mg/dl) respectively; and allocation te vitamins has 
incrreased ,[hasma Vl~arrhn ~ 'bV ~DOL~ "1~ rTL~ITI. ;~,nrlu~l ev-er~ T'dl~es are "C~L)OLI~ 
2.5% non-fatal MI or fatal CHD, 1.2% stroke, and 2.2% all-cause mortality. 
Conclusion: In this large study among a wide range of patients at risk 
of (B)--)D. :~be t~emrnent re~)mens are we))4o)erateO and ~DroSuce subs'~an~a~ 
effects on blood lipids and vitamins. It should, therefore, provide reliable 
evidence about the effects of these treatments on cause-specific mortality 
and major morbidity in several different categories for whom uncertainty 
remains about the balance of benefits and risks. 
4 :30  p.m. 
~-]  Predicting Risk of First Acute Major Coronary 
Events (AMCEs) in the Air Force/Texas Coronary 
Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) 
Michael Clearfield, Stephen Weis, Douglas J. Watson, John R. Cook, Polly 
University of North Texas Health Science Center, Fort Worth, TX, USA 
Background: AFCAPS/-IexCAPS, a randomized double-blind placebo-con- 
trolled pnmary prevention trial, included 6605 men and women (15%) without 
evidence of atherosclerotic disease who had average LDL (150 ± 17 rag/alL) 
and Jow HDJ_ /37 ± 6 mq/dL). LovastatJn ~Lo~a) 2D-40 m~ daJJF 7educBd LDL 
(25%), increased HDL (6%) and reduced (37%; p < 0.001) the incidence of 
first AMCEs: sudden cardiac death, fatal/nonfatal MI or unstable angina. 
Methods: gl~ ana@ses were inlention-to-treaf. Logis/Jc regression mode;s 
regression model stratified by study site and sex estimated relative risk with 
Results: Baseline HDL, LDL/HDL, TC/HDL and apolipoprotein AI (as- 
sociated with HDL), apolipoprotein B (associated with atherogenic interme- 
B/A1, were each significant predictors of AMCE. After 1 year of treatment, 
apolipoproteins A1, B and the ratio of B/AI were predictive of subsequent risk 
(AMCEs occurring after year 1). When current NCEP guidelines are applied 
to this cohort, both those who would be eligible for pharmacologic lipid mod- 
ification (Rx), and those who would not (no Rx), benefited from treatment. 
Rates per 1000 person years: Rx: Lova 1%/yr, Placebo 1.87%1yr RR 0.53, 
95% CI: 0.33, 0.84; no Rx: Lova 0.62%/yr, Placebo 0.93%/yr RR 0.67, 95% 
CI: 0.51, 0.88. 
Conclusion: As expected, NCEP Rx criteria predicted those who were at 
greater risk for AMCEs. Predictability of the Framingham Risk Model in this 
pNmary" pre~'err¢~on cohort ~r?? aFso be assesse~i 
4:45 p.m. 
Cardiovascular Risk: A POSCH Report 
Henry Buchwald, James R. Boen, Phuong A. Nguyen, Stanley E. Williams, 
John P. Malts. University of Minnesota, Minneapolis, MN, USA 
Background: The relationship of cardiovascular (CV) risk to LDL and HDL 
cholesterol is proven. Starting with the 1990 report of the Program on the 
Surgical Control of the Hyperlipidemias (POSCH), which used partial ileal 
bypass as the intervention modality, several clinical trials have demonstrated 
that decreasing LDL and increasing HDL cholesterol is associated with signif- 
icant differences in CV endpoints. It has been difficult, however, to determine 
that lipid modification is quantifiably correlated with clinical benefits. 
Using Cox regression analyses, we studied the relationship of clinical 
endpoints Io plasm~ lipide "{or" (1) actual val~es, all "~isits 1o 5 yTsl (2) actual 
differences, all visits to 5 yrs; (3) % differences, all visits to 5 yrs; (4) actual 
difference, baseline to 5 yrs; (5) % difference, baseline to 5 yrs; and (6) ratio 
ot baseline to 5 yrs. Endpoints submitted to analysis included alheroscterotic 
infarction (MI); overall mortality; and ACHD mortality. 
and two groups combined were variable, but consistantly confirmed the 
previously-reported reductions in CV risk in the intervention group. The lipid 
findings for the regression analysis of gender, age, and the ratio of LDL/HDL 
cholesterol for the e(~o~nt a( ACHO marta#t{f or defiaRe nonfatal MI in the 
for every unit decrease in the LDL/HDL ratio there was an approximate 20% 
decrease in relative dsk. 
~nabysle oY'J'~ oil m ~ m ~ slit nal es; ~-33L)h'~'L~ 
p-Value Hazard Ratio 
Actual Val ue~ (811 visit&l O.O001 1.196 
KctLJal 'L~ff~rences/all'VlSlt~ I" ~ 0U'IZZ" £. T'bW 
Percentage Differences (art visits) 0.OO01 t .007 
Actual Difference (baseline to 5 yrs) 0.0006 1.192 
.P~ r.cP.eJ~a~p _/"~iffP*e__ nee ~_h~.~eli n.e .to 5 yr.%t 0 eDD~ 1 DO8 
Ratio Baseline to 5 Yrs. 0.0269 0.740 
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be predictably and statistically significantly correlated with certain changes 
in lipid parameters. 
5 :00 p.m. 
l - ~  Are Cholesterol-Lowering Drugs Antiarrhythmic in 
High Risk Patients? 
Johan De Suffer, Rene Tavernier, Jareslaw Kazmierczak, Marc De Buyzere, 
Luc Jerdaens, Denis Clement. University Hospital, Ghent, Belgium 
Background: In secondary prevention cholesterol-lowering drugs (CLD) re- 
duce total and coronary mortality. The effect of CLD in patients with coronary 
artery disease (CAD) and life-threatening arrhythmias (ventricular tachcardia, 
VT and fibrillation, VF) is however less clear, 
Methods: We studied the recurrence of VT and VF in 78 consecutive 
patients (age 86 ± 9 years, 73 male, ejection fraction 33 ± 13%) with CAD 
and V-I or VF who were treated with an implantable cardioverter defibrillator 
(ICD). At discharge 25 (32%) patients were on CLD (14 statins, 11 fibrates). 
Results: After a mean follow-up of 476 ± 330 days, 31 (40%) patients had 
recurrences of VT or VF which were treated by the ICD, 11 patients died and 
14 other patients were hospitalised for cardiac reasons. In univariate analysis 
age > 65 (p = 0.82), female sex (p = 0.64), ejection fraction < 35% (p = O99), 
treatment with amiodarone (p = 0.37), sotalol (p = 0.20) and ACE-inhibitors 
(p = 0.08) did not predict the recurrence of VT or VF. In contrast, in resp uni- 
and multivariate analysis the following parameters predicted recurrences of 
VT/VF: VT as presenting arrhythmia before implantation (81% v 36%, p = 
0.0002, p = 0.01), treatment with CLD (16% v 43%, p = 0.02, p = 0.02) 
and #-blockers (35% v 62%, p = 0,04, p = 0.07). Kaplan-Meier plots for the 
arrhythmia free survival for patients with and without CLD are shown in the 
figure. 
100~ ~ statine~brates (n=25) 
°=°°2  
~5] ~ no stalines/flbrale s (n=53} 
0 
0 250 500 750 1000 1250 
days 
Conclusions: Already after 1 year, CLD are associated with a reduction 
of recurrences the occurrence of malignant ventricular arrhythmias in patients 
with CAD treated with an ICD. 
5:15 p.m. 
~ - ~  Similar Reduct ion in Thrombotic Risk With 
Pravastatin Therapy in Hyperlipidemic Men and 
Women, A Prospective Study 
George Dangas, John A. Ambrose, Donald A. Smith, Allen H. Unger, 
Raghuraman Vidhun, John H. Shao, Perwaiz Meraj, Alice Zervoudakis, 
David D'Agate, Dmitriy Feldman, John T. Fallon, Juan J. Badimon. 
Cardiovascular Institute, Mount Sinai School of Medicine, New York, USA 
Cholesterol (C) lowering trials on prevention of coronary heart disease (CHD) 
have included mostly men (M). The benefit rendered during LDL-C may be in 
part due to improved thrombotic profile. CHD risk in women (W) in association 
to HDL-C, LDL-C and thrombosis is unclear. 
Methods: We prospectively studied changes in thrombogenicity over 6 
months (mo) of therapy with pravastatin and AHA step I diet in 28 M and 29 
W (93% postmenopausal) with untreated, fasting LDL-C > 145 mg/dl and 
triglycerides < 275 mg/dl. Systemic hemostatic markers were measured at 0, 
3, 6 mo. M vs W differed (p < 0.05) in age (62 ± 2 vs 69 =E 2 y) and HDL-C (39 
± 2 vs 55 ± 2 mg/dl); p = NS for body mass index, CHD, risk factors, aspirin 
use, Lp(a), and homocysteine. Thrombosis under dynamic flow conditions in 
an experimental Badimon perfusion chamber, was performed by planimetry 
of the cross-sectional thrombus area (TA,/~m 2 × 103) upon a standardized 
injured vascular substrate. 
Results: LDL-C was reduced within 1 month by 30% (188 ± 123 mg/dl) 
equally in M and W. Baseline TA and hemostatic markers were similar in M 
vs W, except prothrombin fragment F1.2 (1.4 ± 0.3 vs 2.4 ~ 0.3 nmol/L, p < 
0.05); F1.2 at 6 months was 1.5 ± 0.2 vs 1.6 ± 0.2 nmol/L, p = NS. Trends at 
3 mo and significant changes at 6 mo occurred in both M and W in tPA, PAl-l, 
and TA (table). Nonsignificant changes occurred in factor Vlla, fibrinopeptide 
A, and d-dimer in both M and W. 
tPA ng/ml PAl-1 ng/ml F1, 2 nmol/L TA ~m 2 × 10 3 
Men -1.4 4- 0.4* -11.5 4- 2.3* 0.0 ± 0.3 -2,9 ± 0.9* 
Women -1.5 4- 0.4" -7.0 ± 2.2" -0.8 • 0.3** -4,0 ± 13' 
"p < 0.05 6-month vs baseline change; "p = 0.07 women vs men 
Conclusions: Despite higher HDL-C, W had higher baseline thrombin 
generation than M. Pravestatin abolished that difference and improved fib- 
rinolytic markers related to endothelial function in both M and W. W with 
high LDL-C, despite higher HDL-C, appear to have comparable thrombotic 
risk to M. Therapy with pravastatin decreases blood thrombogenicity in both 
genders. 
ORAL  
Vitamins, Hormones, and Clinical 
Cardiovascular Responsiveness 
Tuesday,  March  9, 1999, 8:30 a .m. -10 :00  a.m.  
Moda l  Convent ion  Center ,  Room 228 
8:30 a.m.  
~-- ]  o~-Tocopherol Levels Are Associated With Platelet 
Release of Nitric Oxide Oxide 
Jane E. Freedman, Liquing Li, Joseph A. Vita, John F. Keaney, Jr.. 
Georgetown University Medical Center, Washington, D.C.. Boston Medical 
Center, Boston, MA, USA 
Background: Clinical studies indicate that vitamin E (a-tocopherol) exerts 
a beneficial effect on cardiovascular disease. Unstable coronary disease, 
caused by platelet activation and thrombosis, is also associated with de- 
creased release of platelet-derived nitric oxide (NO), which can be inhibit 
platelet recruitment and thrombus formation. However, the cause of this de- 
crease and the rote of ~-tocopherol in platelet-NO production in vivo are 
unknown. 
Methods: We examined plasma c~-tocopherot concentration in 87 con- 
secutive patients undergoing coronary angiography. Platelet-dedved NO pro- 
duction was measured using an NO-selective microelectrode adapted for use 
in a platelet aggregometer. 
Results: a-Tocopherol levels were 21.6 i 3,2 /~M and 12,2 + 12 /~M 
in patients in the highest quartile and lower three quartiles of platelet NO 
production, respectively (P < 0.01). Platelet NO production correlated with 
plasma a-tocopherol concentration (R = 0.5; P < 0.01) and this effect was 
independent of aspirin and nitrate treatment. To determine the mechanism 
for this association, megakaryocytes were loaded with physiological con- 
centrations of u-tocopherol and NO synthase (eNOS), and protein levels 
were determined by Western analysis, Incubation of megakarycoytes with 
c~-tocopherol led to an 84% increase in eNOS protein (P < 0.05, n = 5). 
Conclusions: This data suggests that, in patients with cardiovascular 
disease, ~-tocopherol evels are associated with platelet-derived NO release 
and that this association may be due to an a-tocopherol-dependent increase 
in eNOS. These observations suggest a potential mechanism for the benefi- 
cial effect of c~-tocopherol in patients with cardiovascular disease. 
8:45 a.m.  
[83~ High Dose B Vitamin Supplementation Does Not 
Normalize Hyperhomocystenemia in 30-50% of 
Patients With Abnormal Homocysteine Metabolism; 
Implications for Screening and Repeat Testing 
Seth J. Worley, Joann L Tuzi. Lancaster Heart Foundation, Lancaster, PA, 
USA 
Background: Adult patients with hyperhomocystenemia re said to respond 
to vitamin supplementation with pyridoxine, folate and B12. 
Methods: We treated 303 patients with vascular disease and an elevation 
in either the fasting homocycteine (>10.6 umol/L) or post methionine load 
homocysteine (>28 umol/L) with high dose folate (5 rag/day), pyridoxine 
(100-260 mg/day) end B12 (250-500 mcg/day). Patients were re-tested 
after _>2 months of therapy. All patients had repeat homocysteine levels 
drawn post methionine load. Of the 303 treated patients, 167 had repeat 
fasting homocysteine levels drawn, 
Results: With vitamin supplementation the mean fasting homocysteine 
levels decreased from 12.8 umoVL to 9,71 umol/L, with 33% remaining above 
10.5 umol/L. The mean post methionine toad homocysteine levels decreased 
from 40.09 umol/L to 29,98 umol/L with 49.5% remaining above 28 umol/L. 
Conclusion: A significant percentage of patients with abnormal homo- 
cysteine metabolism fail to respond adequately to vitamin therapy, The avail- 
ability of new therapies which may help normalize homocysteine levels (i.e. 
trimethylglycine) supports the practice of re-testing patients who have been 
treated with high dose vitamin supplementation. 
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9:00 a.m. 
~-~- ]  Antioxidant Therapy With Vitamin E Does not 
Improve Fibrinolysis in Postmenopausal Women 
Kwang K. Koh, William H. Schenke, Londa Hathaway, Rita Mincemoyer, 
Richard O. Cannon II1. NHLBI, NIH, Bethesda, MD, USA 
Background: We have previously shown that oral conjugated equine estro- 
gen (CEE) reduces plasminogen activator inhibitor {PAl-l) antigen levels in 
postrnenopausa~ women, an e'liec~ assodm~ed WPth propoff~ona'[e increases 
in dr~(a,~<~ ~, ~-~, :~ (~ c.x~ss-((~.~ ~g,  (O-,"~;';~x} q . ,3~( (~e '~(tb, ~.~,- 
hanc,a~ 1' ;~,~s~s,  ~.~,'a~s~, e ,~z~ ~,~b~-~s~'~ ~ (LOL I "~i'P~ 
lares the synthesis and re}ease of PAl-1 from endothe~ia~ cells in culture and 
because vitamin E protects LDL from oxidation, we reasoned that vitamin E 
may reduce the synthesis of PAl- 1 and potentiate the fibrinolytic effect of C EE. 
Methods: We administered CEE 0.625 mg per day, vitamin E 800 IU per 
day, and their combination, each for 6 weeks to 28 healthy postmenopausal 
women in a randomized, double-blind, 3-period crossover study. 
FResults: CEE alone lowered PAl-1 levels relative to re,sDective, Dretreat- 
ment values. (mean :5 SD; 23.9 =E 21.3 to 16.8 -- 15.9 ng/mL, P = 0.016), 
with a trend towards this effect when CEE was combined with vitamin E (26.4 
27~ fo ]'¢£3" ± ] '~Z ng/mr, F = ~.u'V)~ ~lbwever, wt'arnih ~T a~bne had' no 
use of a dose and duration of vitamin E therapy we had previously found to 
protec'i LI3L o'~ ~os~meno;~ausa~ women 1tom ox"lda'f}on, 
CDonc)us~on: ~hese data s~o..oest ))at an~)ox;ban~ t))ar.~;es may nc, t
reduce PAl-1 levels, and that CEE has a primary effect on the enhancement 
of fibrinolytic potential in healthy postmenopausal women. 
9:30 a.m. 
~ Effect of Estrogen + Progestin on Progression of 
Carotid Atherosclerosis in Post-Menopausal Women 
With Documented Heart Disease: HERS B-mode 
Substudy 
Robert P. Byington, Curt O. Furberg~ Ward Riley, William Applegate, 
Alarn 'Rer(~, ~avK~ '~erfl%dron, ~ond~<~ 'Runfimdn~lKe, "lv3aureen 'LOWe .rv. '#~Z[Ke 
Forest University School of Medicine, Winston-Salem, NC, USA 
Bac~cff~umct: T~e He~ ~q,d E~ceue~peeGesti~ Re,~-~eme~t St~.~dy (HERS} 
was a randomized, masked, p~acebo-control~ed, mu~ticenter~ secondary pre- 
vention trial designed to determine the effects of hormone therapy on fa- 
tal/ronfala( coronaw, events (n Z76"3 .Oos¢-meneeausa¢ women wli'~ ~oc~- 
merfi~e~ 'nea~ d=sease wno were "rdhowe(~ "for an averasle dr ~-h ,,'ears."]'ne 
trial has previously reported that although there was no overall significant 
treatment effect, there were more events in the hormone group in the first 
year and fewer in years 4 and 5. As part of the trial, a B-mode ultrasound 
substudy was also conducted in 455 of these women to determine the effects 
of hormone therapy on the progression of carotid atherosclerosis. 
Methods: Women assigned to active treatment received 0.625 mg of 
conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate. 
Women participating in the ultrasound substudy underwent carotid B-mode 
examinations at baseline and at the final trial visits. A central reading center 
is reading the scans in a blinded fashion. The 4.1 year change in mean 
maximum intimal-medial thickness in 8 carotid walls is the primary outcome 
measure for the substudy. 
Results: Examination of the baseline characteristics of the women partici- 
pating in the substudy indicates that they are similar to all women participating 
in the overall trial. Specifically: 
Overall Trial Substudy 
M e,~,e ,~='." 3,.~. ,'2 ~ ~:',~ ,..~ ~.~ ) ,~,:~,,.Y 
Conclusion: The ultrasound results of the HERS substudy will be pre- 
sented and, in light of the clinical findings, may add to our understanding of 
the effect of hormone therapy on atherosclerosis. 
9:45 a.m. 
~ f  Effec*,s c~ Estrogen ~ VR~m~ E o~ N,~tr=,¢ O~de 
Bioactivity and Markers of Inflammation in 
Postmenopausal Women 
Kwang K. Koh, Amen Blum, William H. Schenke, Londa Hathaway, 
Rita Mincemoyer, Julio A. Panza, Richard O. Cannon II1. NHLBI, N/H, 
Bethesda, MO, USA 
Background: Atherosclerosis in humans is associated with inflammation. 
Therapies that increase nitric oxide (NO) bioactivity may reduce synthesis of 
proinflammatory proteins within the vessel wall by inhibiting transcriptional 
activation of target genes. 
Methods: As estrogen and vitamin E therapies improve endothelial NO 
bioactivity, we administered conjugated equine estrogen (CEE) 0.625 mg 
daily, vitamin E 800 IU daily, and the combination, each for 6 weeks to 28 post- 
menopausal women in a randomized, double-blind, 3-period crossover study. 
Brachial artery flow-mediated dilation (FMD) following forearm ischemia (a 
bioassay for endothelial NO), and serum levels of inflammatory cell adhesion 
molecules E-selectin, intercellular adhesion molecule (ICAM-1 I.. and vascu- 
Car ceil' adhesion mofecuCe f~,CAtVI'-IJ were measured before and" after each 
therapy. 
Results: All therapies improved FMD (all P < 0.001) and to a similar 
degree (P = 0.267 by ANOVA), but not the dilator response to nitroglycerin 
(all P > 0.235). However, only therapies including CEE significantly reduced 
levels of cell adhesion molecules. 
CEE Vitamin E CEE/Vitamin E 
E=~eLectie - 13 _+_15"_ ~" ÷3 J,-_.~B_ -2fl +17~ "* 
~C'~M-'~" -/~:~' ]?'" -~:t:'z2^ -/-~:' ] 9 ^ * 
VCAM-1 -6 4- 21- -3  £ 14 2 4- 21 
D~( I  .r~.~'r:~ $D)'= ?4; O~'~'igu-il~'n-re~%,"¢~.'dve-pre~luaxt'ne~vaiL~e~ * = F< ,I.u'~'] "" = F' 
(P < 0.001 by ANOVA). 
~o/~c)us)on: 7herap~es ~hat "~mprove endothel~a~ T~D may not have corn- 
anti-inflammatory mechanism for estrogen in postmenopausal women. 
ORAL 
~8~ Risk Factor Assessment: Age, Race, Gender 
Tuesday, March 9, 1999, 8:30 a.m.-10:00 a.m. 
MorJal Convention Center, Boom 207 
8:30 a.m. 
~ AtrJaJ FJbrJJ/atJon Prevalence Jn the Genera/ 
Population and in High-risk Groups 
Russell C. Davis, F.D. Richard Hobbs, Joyce E. Kenkre, Robed 
Background: Atrial fibrillation (AFt is the commonest cardiac arrhythmia, 
and is associated with high risk of embolic stroke, which can be reduced 
by about two-thirds by anticoagulation with warfarin. To have an impact on 
incidence of strokes in the population as a whole, patients need first to be 
identified, and there is interest in screening for AF. Screening may be most 
cost-effective if targeted on patients at high risk of the condition. We have 
therefore looked at AF prevalence in the general population, and in those 
thought to be at risk. 
Methods: The 'Heart of England' study is a large epidemiological study 
of heart failure, using clinical assessment, ECG and echocardiography. The 
prevalence of AF and associated risk factors on echo has been analysed 
in patients in the following groups: Random population sample, aged 45+; 
existing diagnosis of heart failure (made by GP); previous MI; hypertension; 
angina; diabetes. 
Results: The table details the prevalence of AF in the patient groups. 
Other associated risk factors for embolic stroke (mitral valve disease, left 
atrial enlargement or impaired LV function) are listed, as well as the proportion 
anticoagulated with warfarin at the time of screening. 
AF Echo abnormalities On warfarin 
in pts with AF 
Population aged 45+ 43/2552 (1 7%) 29/43 (67%) 9/43 (21%) 
of which: 
45-54 1/858 (0.1%) 1/1 (100%) 1/1 (100%) 
55-64 7/785 (0.9%) 2/7 (29%) 1/7 (14%) 
65-74 9/615 (1.5%) 6/9 (67%) 4/9 (44%) 
75-84 21/253 (8.3%) 18/21 (86%) 3/21 (14%) 
85+ 5/4f (12.2%j 215 (40%j 0[5 
Clinical heart failure 106/457 (23%) 96/106 (92%) 40/106 (38%) 
Previous MI 9/184 (4.9%) 7/9 (78%) 3/9 (33%) 
Hypertension 9/263 (3.4%) 4/9 (44%) 2/9 (22%) 
Angina 10/205 (4.9%) 8/10 (80%) 3/10 (30%) 
Diabetes 5/135 (3.7%) 4/5 (80%) 3/5 (60%) 
Conclusions: The prevalence of AF in the population sample was 1.7% 
and in the high-risk groups overall was 11.6%, and these patients had other 
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embolic risk factors more frequently also. Targeting a screening programme 
on patients in these groups would identity many of those at highest risk of 
embolic stroke. 
8:45 a,m.  
[ - ~  Effect of Race and Gender on Physician 
Recommendation for Cardiac Catheterization 
Kevin A. Schulman, Jesse A. Bedin, William Harless, Bernard J. Gersh, 
John M. Eisenberg, Jose J. Escarse. Georgetown University Medical 
Center, Washington, DC, University of Pennsylvania School of Medicine, 
Philadelphia, PA, Interactive Drama, Bethesda, MD and RAND Health 
Program, Santa Monica, CA, USA 
Background: Epidemiologic studies have reported differences in access to 
cardiovascular procedures by patient race and gender. However, the role of 
physician decision-making leading to this finding has not been determined. 
Methods: Physicians were randomized to view a video of one of eight 
patient actors varying by race (black/white), gender (male/female) and age 
(55,'70 years old) presenting with identical angina symptoms, coronary risk 
factors and thallium exercise stress test results. After viewing the patient 
actor, physicians provided chest pain estimates, recommendations for fu- 
ture cardiac evaluation and subjective perceptions of the patient actor. The 
survey instrument was administered to 720 physicians at two national meet- 
ings of primary care professional societies. Multivariate logistic regression 
analysis was used to assess the effect of race and gender on physician 
recommendations, adjusting for other experimental factors. 
Results: Patient race and gender were significant predictors of referral 
for cardiac catheterization with women (OR: 0.6, p = 0.02) and blacks less 
likely to be referred (OR: 0.6, p = 0.02). Analysis of race by gender interaction 
found that black females (OR: 0.4, p = 0.004) were less likely to be referred 
for cardiac catheterization than white males (OR: 1.00). Additional analyses 
also found that older black females (OR: 0.2, 95% Ch 0.1,0.6) had the lowest 
rate of cardiac cathetedzation referral. 
Conclusions: Patient race and gender influence physician management 
of chest pain. These findings are most striking for black women, and old black 
women in particular. Our findings suggest that physician decision making is 
an important factor in explaining differences by patient race and gender in 
the treatment of coronary artery disease. 
9:00 a.m.  
[~~- -~ Sex Dif ferences in Mortal i ty Short-Term After 
Myocardial Infarction: A New Perspective 
Viola Vaccadno, Lod Parsons, Nathan Every, Paul Frederick, Harlan 
M. Krumholz. University of Washington School of Medicine, Seattle, WA; 
Yale University School of Medicine, New Haven, CT, USA 
Background: It is commonly held that MI in women has a worse short-term 
prognosis. Studies have suggested distinct pathophysiologic mechanisms of 
MI in younger women as opposed to older women and men. We hypothesized 
that younger, but not older, women have a higher short-term mortality than 
men.  
Methods: We analyzed data from 384,878 patients enrolled in the Na- 
tional Registry of Myocardial Infarction-2 (NRMI-2) from June 1994 through 
January 1998. Patients transferred to or from other hospitals and patients < 
30 or >_ 90 years were excluded. 
Results: The odds of hospital mortality were higher in women than men 
up to age 75 but not thereafter (P < 0.001 for the age-sex interaction) both 
before and after adjusting for medical history, admission data, treatments, 
time to hospital arrival, and hospital characteristics (see table below). 
Age Group Crude Adjusted 
OR 95% CI OR 95% CI 
<50 2.17 (1.95-2.41) 1.74 (1.61-1.87) 
50--54 1.86 (1.66-2.08) 1.47 (1.39-1.54) 
55-59 1.73 (1.58-1.89) 1.37 (1.32-1.43) 
60-64 1.38 (1.29-1.49) 1.28 (1.24-1.32) 
65-69 1.28 (1.21-1.36) 1.20 (1.17-1.23) 
70-74 1.19 (1.13-1.24) 1.12 (1.09-1.15) 
75-79 1.05 (1.00-1.09) 1.05 (1.02-1.07) 
80--84 0.98 (0.94-1.03) 0.98 (0.95-1.01) 
85-89 0.94 (0.89-0.99) 0.91 (0.88-0.95) 
In the adjusted data the excess odds of death for women relative to men 
increased of 7% for every 5 years of younger age (95% CI, 6-8%). 
Conclusion: A higher short-term mortality after MI in women relative to 
men is found only when the MI occurs before age 75. Younger female MI 
patients represent a high-risk group deserving special study. 
9:15 a.m.  
~--~ Determination of Menopausal Status in Women: 
The NHLBI-sponsored WISE Study 
C. Noel Bairey Merz, Tanya Kenkre, Vera Bittner, Jannet Lewis, 
Glenn Braunstein, T, Keta Hodgson, Sarah Berg& Diana L, Pakstis, Barry 
L Sharaf, Sheryl F. Kelsey, George Sopko. Cedars-Sinai Medical Center, 
Los Angeles, CA, USA 
Background: Accurate determination of menopausal (M) and hormonal ther- 
apy (HT) status is key to cardiovascular research in women. Due to the 
heterogenous HT regimens available, the accurate determination of hormal 
status in women using HT is also relevant. 
Methods: M status was assessed by detailed questionnaire in 149 par- 
ticipants of the Women's Ischemia Syndrome Evaluation (WISE) and blood 
hormones (FSH, LH, estradiol [E2], bioavailable estradiol, estrone [El], and 
progesterone) were measured in close proximity. Algodthms for M status 
based on historical data alone, and historical plus blood hormone level data 
were compared. 
Results: The mean age of the group was 60 + 12 (range 32-85) yrs. 
Using historical data alone, 65 (44%) were postmenopausal without current 
HT use, and 57 (38%) used current PIT. Historical plus blood hormone level 
classification was discordant to history alone in 7/87 (8%) of participants not 
using HT. Among 49 participants using HT who were postmenopausal by 
history, only 12 (24%) had a FSH > 40 mlU/ml, a common postmenopausal 
trial entry criteria. Furthermore, 33/57 (57%) of participants reporting current 
HT use had E2 levels < 50 pg/ml, and 25 (43%) had E1 levels < 150 pg/ml. 
Among participants not using HT, E2 levels were >_50 pg/ml and E~ levels 
were >_150 pg/ml in 1/65 (2%) (both p < 0.001 compared to HT group). 
Conclusions: In WISE, misclassification of M and HT status occurs when 
data are obtained by questionnaire and may result in misleading associations 
with cardiovascular measures. 
9 :30 a.m. 
[ - ~  Improvement in Treatment Quality Indicators for 
Elderly Patients With Acute Myocardial Infarction: 
The Cooperative Cardiovascular Project in Maryland 
and the District of Columbia 
William J. Oetgen, Alan K. Berger, Daniel W. Edris, Mariana I. Lesher, 
Joyce Jones, Mary Schuster, Gall Karge, Jeffrey A. Breall, 
Matthew Fitzgerald, Gaetano F. Molinari. Georgetown University 
Washington DC and Delmarva Foundation for Medical Care, Inc., Easton, 
MD, USA 
Background: The Cooperative Cardiovascular Project (CCP) is a Health 
Care Financing Administration and Peer Review Organization collaboration 
to improve the quality of care provided to Medicare beneficiaries with acute 
myocardial infarction (AMI). 
Methods: Eight treatment quality indicators for myocardial infarction were 
identified. Baseline measurements were made of the rates of compliance with 
these indicators for samples of Medicare beneficiaries hospitalized with AMI 
in 1995 and 1996. Initial measurement data was presented to each of 45 
acute care hospitals in the region. Hospitals developed quality improvement 
programs for the care of AMI patients. Remeasurements of compliance rates 
for indicators were made in 1997. 
Results: Baseline data represent evaluation of 3,688 patients with con- 
firmed AMI. Remeasurement data represent evaluation of 1,622 patients 
with AMI. Statistically significant improvement (p _< 0.05) occurred in five of 
the eight quality indicators: reperfusion (62% vs. 73%), thrombolytics (58% 
vs. 74%), aspirin during stay (87% vs. 93%), aspirin at discharge (77% vs. 
85%), and avoidance of calcium channel blockers in patients with low ejection 
fractions (81% vs. 92%). Improvement rends which were not statistically sig- 
nificant were recorded in two indicators: beta blockers at discharge (58% vs. 
69%) and ACE inhibitors in patients with tow ejection fraction (64% vs. 71%). 
A non-significant degradation in quality was noted in the smoking cessation 
counseling indicator (43% vs. 40%). 
Conclusion: The CCP in Maryland and the District of Columbia has 
demonstrated measurable improvement in the quality of care provided to 
Medicare beneficiaries with AMI. 
9:45 a.m. 
I~ - ]  Prediction of Recurrent Cardiovascular Disease: 
The Framingham Heart Study Experience 
Peter W. F. Wilson, Ralph B. D'Agostino, Halit Silbershatz, William 
B. Kannel, Philip A. Wolf. Framingham Heart Study, NHLBI and Boston 
University USA 
Background: Risk factor assessment to estimate the relative odds of initial 
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cardiovascular disease (CVD) events has been studied in several settings, 
but I e,~s~  ~'~z>~ ,~,.;¢..at~j ~.~,#~,-~-~ o: ~,~z-¢~,~-~ b~,~.~,~s,~. 
Methods: Framingham Heart Study participants (379 men and 216 
women) who had survived more than 30 days after an initial CVD event 
[myocardial infarction (MI), stroke, or intermittent claudication] and attended 
curre~ car~ovasc01ar ~lseasei['R~Cq'u-'~!, tr6Ke, or'C,q'u be~tn'l occurred m 
411 persons during the 1970-1992 follow up. Risk of RCVD up to four years 
after baseline was estimated with generalized estimating equation methods, 
including the variables gender, age, systolic pressure, diabetes, cholesterol, 
smoking, history of specific heart diseases, and interaction terms between 
sex an~ age, smokin~ dmbe'~es, and sys'~o~cpressure. 
increments were age (10 years, OR = 1.87 women,  OR = 1.19 men, P < 
0.001), systolic pressure (10 mm Hg; OR = 1.20 women, OR = 1.03 men, P < 
0.001), diabetes (OR = 2.45 women,  OR = 1.57 men, P < 0.001 ), cholesterol 
(10 mQj'dL, OFt = t.03 both sexes, P = 0.05), cigarettes/day (n = tO, OFt = 
1.32 women, OR = 1.05 men, P = 0.03), previous MI (OR = 1.36 both sexes, 
P = 0.04), previous stroke (OR = 1.62 both sexes, P = 0.02), and previous 
CHF (OR = 2.89 both sexes, P = 0.003). 
highly associated with risk for recurrent disease, history of specific events 
altered prognosis, and it was possible to develop a simple algorithm and 
score sheet to estimate risk for recurrent cardiovascular disease. 
POSTER 
Tuesday, h~arch 9, ~999, 9:DO a.m.-~$:OD a.m. 
Morial Convention Center, Hall F 
P r e .~,~,,~,,~,o~ ~J.,,;" 3,.'~;~ , J~. -,~.r~$, ~.,,n. 
~ Effects of Sex and Age on Atherosclerosis and 
Autoimmunity in ApoE-Deficient Mice 
Hosl~(<a(, S(ockho(m, ~wede<~; 2 (~serm L/4GG, Pads, Fcance 
Backz2n>~n~: Es17ccjens and ~rnrnDn~'~ a~2ains'; if~i cc, D::d p::a~. ~ )c,::e ~n 
atherogenesis in apoE knockout (E o) mice. We assessed the development 
of atherosclerotic lesions and cellular immune response to modified LDL 
in me,~ ~,'~' ,~';'~,~ E~ ,'~'ce ~,~- ~v;,e, ~,~ ~',~e ~'~c, ~~', , ' , ?~, -a~ ~,~ 
atheroscleros';s-re~ated ce~u~a~ immunity. 
Methods: Animals were studied after 16 or 48 weeks of normocholes- 
terol diet. Aortic lesions, lymphocyte populations, and the cellular immune 
Results: Atherosclerotic lesions were larger and more advanced in young 
female than in age-matched male E ° mice (26.5 ± 1.3 vs 9.2 ± 0.9 #m 2, 
p < 0.001). In older mice, no significant difference in lesion size or maturity 
was discerned between males and females. In spleen cell cultures of young 
females, addition of 17#-estradiol induced a proliferative T-cell response to 
oxidized LDL, while no such effect was seen in males (Figure). 
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ence of increasing concentration of estrogens. = Females. 
In similar cultures from old E e mice, T-cells from female animals were 
activated by oxidized LDL even in the absence of exogenous estrogens. 
Q3onc~u~ons:These dam showir0~oortant sex d]ferences)n t~e 0eve/oD- 
ment of atherosclerosis that may be related to sex differences in the cellular 
immune responses to the atherosclerosis-related autoantigen, oxidized LDL. 
I1 I Estrogen Treatment Prior to and I 1 32-21 Shor t  Term 
Effectively Blunts the Vascular Injury Response 
Tatsuhiko Meri, Joan Durand, Yiu-Fai Chen, J. Anthony Thompson, 
Suzanne Oparil. Vascular Biology and Hypertension Program, University of 
A(abama a( Birm/noham. ~t)'m~h~ham..AL. LfSA 
Background: Previous studies from our laboratory have shown that estrogen 
treatment initiated 3 days prior to injury and maintained throughout the period 
of observation blunts the neointimal response to vascular injury in ovariec- 
tomized female rats. The current study was designed to test the hypothesis 
~a'~ s~no~-~[erm es~[rogen ~rea~men'~ adrfimistered immediately prior to anc~ 
Methods: Ovanectomized female Sprague-Dawley rats were randomly 
divided into six groups with the following time windows of 17,6-estradiol 
treatment (20 ,~g/kg/day s.c.). (1) from 3 days before to 3 days after balloon 
in(ury ( -3  O to 3 Dl, (2 } -3Dto70, (3}-30to14D, (4}OatoSO, (5}  
7 D to 14 D, or (6) no treatment. Two weeks after balloon injury of the right 
common carotid artery, rats were killed and carotid arteries were evaluated 
for neointimal thickening using morphometric analysis. 
3~es~s: 
Group Intima/media ratio (%) 
-3  D to 3 D (n = 5) 67.7 ± 8 .7"  {p = 0.0074) 
-3  D to 7 D (n = 4} 56.1 ± 7.3"* (p = 0.0032) 
-3  Dto  14 D (n = 5) 60.9 ± 9,1"* (p = 0.0032) 
0 D to 3 D (n = 6) 77.7 =E 11.0" (p = 0.0177) 
7 D to 14 D (n = 7) 136.2 ± 12.7 (p = 0.9887) 
i~tgp~.tm~nh(0.= 4~, 1AP~Z ~17.  2_ 
Means ± SEM Differences were considered significant if*p < 0.05, or **p < 0.01. 
Conclusion: Short term systemic estrogen treatment prior to and follow- 
ing balloon injury effectively blunted the vascular injury response in ovanec- 
continuous estrogen administration in blunting the injury response has im- 
portant clinical implications for the potential use of estrogen in the prevention 
and treatment of vascular disease in humans. 
I ~ I ~acreased Proti~cat~an o# Medlar Muscle 
| 
32-22 Smaottt 
/ 
Cells After Adherence and Chemotaxis of 
Monocy-tes and CD4*-t~mphocytes tnto an in 
Vitro Modell of the Human Coronary Artery  
W~fga~g Koer~ ~ , Vinzenz Horn, bach ~ . ~ Oepartment of Interna~ Mect~cine II
(Cardiology); 2Department of Medical Microbiology, University of UIm, 
Germany 
~ackground: An(mm" modeCs o(pastang(op¢~s~y res(enas(s cfo poodypre~(ct 
the outcome of human restenosis. Transfilter co-culture (TCC)-units mimic 
the inner parts of human arteries and allow in vitro investigations with human 
coronary tissue. 
Methods: The central part of the units is a polycarbonate membrane 
with 5 m pores (corresponding to the internal elastic membrane) that sep- 
arates an upper chamber with human coronary endothelial cells (HCAEC) 
.'tr~m .~ '.~.wp, r .drLarCLr~,r .~(tn '.~lmao .¢~r~ar~ .mP, d~ ~x~.d.fo .ca~,du~ nd,'lL~ 
(HCMSMC). Through the pores of the membrane cells have direct contact to 
each other. The expression of adhesion molecules was increased by tumor 
necrosis factor- (TNF-, 6 hrs, 20 ng/mL), controls were not stimulated. Human 
monocytes (MC) and human CD4÷-Iymphocytes (CD4÷-LC) were added to 
the endothelial side of the TCC-units. After 30 min, 1, 2, 3, and 24 hrs the 
filters of the TCC-units were fixed. Cell divisions of co-cultured HCMSMC 
were analysed by measuring the uptake of Bromodeoxyuridine (BrdU). 
Results: MC were able to adhere to the endothelial surface, enter the 
"subendothelial space" and pass through the pores of the membrane to 
the other side. CD4+-LC only attached to the endothelial surface of the 
TCC-units. Adding of CD4÷-LC with prior TNF-c~ stimulus significanty (p 
< 0.001) increased HCMSMC proliferation to more than 90%, adding of 
CD4÷-LC alone had no stimulatory effect. MC caused a significant increase 
of HCMSMC proliferation (p < 0.001) with (plus 165%) and without (plus 
Conclusion: This is the first reported experience about an in vitro modell 
for investigations of the reactive proliferation of human coronary smooth 
muscle cells after adherence and chemotaxis of blood derived leucocytes. 
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~ Increase Metalloproteinase-2 and -9 Activity of 
During Flow Induced Remodeling is Regulated at 
the Post-Trancriptional Level 
D. de Kleijn, E. Velema, A. Schoneveld, J. van der Zanden, M. Post, 
C. Borst Lab. of Experimental Cardiology, Utrecht, The Netherlands; 
Angiogenesis Center, Harvard Medical School Boston MA, USA 
Background: Arteries structurally adapt to changes in blood flow through 
matrix remodeling. The degradation of collagen, one of the major components 
of the extracellular matrix, by matrix metalloproteinases (MMP) is probably 
involved in this process. 
Methods: To study the relation between flow, arterial adaptation and 
MMP2 and 9 expression and activity, we increased or decreased the blood 
flow in rabbit carotid and femoral arteries by arterio-venous hunting (AV) 
or partial ligation (LIG). Arteries were collected at 2, 7 and 21 days, were 
analyzed for MMP activity by zymography. Flow and diameter changes were 
determined at follow up by transit time measurements and extravascular ul- 
trasound. MMP-2 and -9 mRNA levels were determined by semi-quantitative 
PCR. 
Results: 
Relative change in MMP activity and diameter 
2 dAY 7 dAV 21 dAV 2 dLIG 7 dLIG 21 dOG 
MMP2 act 18±6" 3±4 19 J_ 13 2-E5 16±15 27±7* 
MMP9 act 13±6" 4±5 0±5 14±10 49~30 18±10 
Diam. 25±4" 29±5* 42~E4 16±8 33±7* 383:1" 
N = 48 arteries, " = P < 0.05. relative change in %, data are mean ± sem 
After AV shunting, significant arterial enlargement was found in the arteries 
at day 2 and after partial tigation at day 7. Similary, 2 days after AV and 21 
days after partial ligation, we found an increase in MMP-2 and -9 activity. In 
contrast, no correlation was found between MMP-2 and -9 mRNA levels and 
activity (MMP-2: r = 0.10, p = 0.54; MMP-9: r = 0.27, p = 0.12) 
Conclusions: During flow induced remodeling, the increase of MMP-2 
and -9 activity is regulated at the post-transciptional evel. 
~ Testosterone Male and Rat Relaxes Female 
Coronary Arteries In-Vitro Via an Endothelium 
Independent Mechanism 
Katherine M. English, Richard P. Steeds, Alyn H. Morice, Kevin S. Channer. 
Royal Hallamshire Hospital Sheffield and University of Hull, UK 
Background: Administration of testosterone has been shown to improve 
angina threshold in men, but the mechanism of this action remains unclear. 
This study was performed to examine the effects of testosterone on rat 
coronary arteries in-vitro. 
Methods: Left anterior descending arteries were removed from male and 
female adult Wistar rats. The endothelium was removed from half the vessels 
by rubbing gently with a human hair. Vessels were mounted on a wire myo- 
graph (Cambustion Ltd, UK), pre-tensioned to an equivalent arterial pressure 
of 100 mmHg, and active tension recordings made. Endothelium denudation 
was demonstrated by the abolition of dilatation to 10 M Acetylcholine. Viable 
vessels were pre-contracted with 100 M Prostaglandin-F-2-. Concentration- 
response curves were constructed to 1 × 10 9-1 x 10 -3 M testosterone 
dissolved in water (Sigma UK). Control experiments were performed in half 
the vessels in each group using equivalent concentrations of the vehicle 
molecule, -propyl-cyclo-dextrin (Sigma, UK), dissolved in water. 
Results: Testosterone caused a significant dose dependent dilatation in 
all groups of vessels, when compared with controls (n = 8 in each group). 
The shape of the curve was similar in all groups. Maximal dilatation (Mean 
SEM) (expressed as % of maximal contraction) was as follows; ME+ 103.7% 
± 5%, CME+ 3.0% ± 0.9% (p < 0.0001), ME 109.4% ± 9.5%, CME 3.9% ± 
1.4% (p < 0.0001), FE+ 101.7% - 13.5%, CFE+ 3.6% 0.9% (p < 0.0001), FE 
106.1% ± 8.6%, CFE 8.1% ± 3.9% (p = 0.005). (E = endothelium denuded, 
E+ = endothelium intact, C = control, M = male, F = female) 
Conclusion: Testosterone causes dose-dependent relaxation in supra- 
physiological doses, of both male and female rat coronary arteries in-vitro by 
a mechanism which is independent of the endcthelium 
~ Testosterone Causes Dilatation of Rat Coronary 
Arteries by a Novel Non-Genomic Mechanism 
Katherine M. English, Richard P. Steeds, T. Hugh Jones, Alyn H. Morice, 
Kevin S. Channer. Royal Hallamshire Hospital Sheffield and University of 
Hull, UK 
Background: Steroid hormones classically act by binding to an intracellular 
receptor to affect gene expression. Testosterone induces a dose-dependent 
relaxation of rat coronary arteries in vitro. These experiments were performed 
to determine whether this action is mediated via a genomic effect. 
Methods: Left anterior descending coronary arteries were removed from 
adult male Wistar rats. Vessels were mounted on a wire myograph (Cam- 
bustion, UK), pre-tensioned to an equivalent arterial pressure of 100 mmHg, 
and active tension recordings made. Vessels were pre-incubated with 10 M 
Flutamide, a pure non-steroidal anti androgen, or ethanol control for thirty 
minutes, before being pre-contracted with 100 ibM Prostaglandin-F-2-. Dose 
response curves were constructed to Testosterone (1 × 10 9 to 1 × 10 -3  M) 
dissolved in water (Sigma, UK) 
Results: Testosterone induced an acute dose dependent relaxation of 
rat coronary arteries within sixty seconds. Maximal vasodilatory response 
was seen by five minutes. Dose response curves were not altered by pre 
incubation with Flutamide. Maximal dilatation (as a % of maximal contraction) 
(expressed as mean (95%CI)) was 109.1 (93.2-124.9)% in Flutamide treated 
vessels versus 91.3 (76.2-106.4)% in ethanol treated controls, p = 0.076. 
Conclusions: Testosterone causes acute dilatation of rat coronary arter- 
ies within 60 seconds, whereas even the quickest genomic effects are seen at 
around forty minutes. Furthermore the vasodilatory properties of testosterone 
are unaffected by the classic anti-androgen Flutamide. We conclude that this 
action of testosterone is mediated by a novel non-genomic mechanism. 
POSTER 
~ ~  Pharmacologic Modification of Vascular 
Biology: Basic Studies 
Tuesday ,  March  9, 1999,  9 :00  a .m. -11 :00  a.m. 
Mor ia l  Convent ion  Center ,  Hall  F 
P resentat ion  Hour :  9 :00  a .m. -10 :00  a.m. 
~ Assessment Biological of Retinoic of the Effects 
Acid in Cell Cultures in Vitro and in Vivo After 
Local Delivery in the Rabbit Carotid Artery 
Christian Herdeg, Dorothea I. Axel, Andreas Blattner, Martin Oberhoff, 
Andreas Baumbach, Stephen Schroeder, Karl R. Karsch. University of 
Tuebingen, Tuebingen, Germany 
Background and Methods: Retinoids regulate a variety of biological pro- 
cesses and play an important role in the homeostasis of cell differentiation 
and proliferation. Therefore the effects of all-trans-retinoic-acid (atRA) on 
human arterial smooth muscle cell (haSMC) and endothelial cell (haEC) 
growth, differentiation and extracellular matrix formation were evaluated. 
Furthermore, the potential efficacy of locally-delivered atRA in preventing 
restenosis was analyzed in a rabbit angioplasty model. After induction of a 
fibromuscular plaque in the right carotid arteries of 50 New Zealand rabbits, 
15 animals underwent balloon dilatation and subsequent local atRA delivery 
(10 ml, 10 ~mol/I) with the double balloon. 15 animals served as control 
with angioplasty only, 10 animals were treated with local delivery of vehicle. 
Vessels were excised 7 and 28 days after intervention. 
Results: BRDU-ELISA, M'IT-tests and cell counting showed that atRA 
inhibited haSMC-growth significantly after non-stop treatment with 10-9-10 -5 
M and after 24 h-incubation with 10 8-10 5 M atRA. Additional stimulation by 
PDGF, bFGF or TGF-1 did not attenuate the effects. After local atRA delivery 
in vivo, the extent of stenesis increased slightly from 18.6 ± 8.6% (1 week) to 
21.6 ± 8.3% 4 weeks after intervention compared to 31.6 ± 18.8% in balloon- 
dilated animals. Immunozytochemistry revealed an inhomogenous staining 
pattern after local atRA delivery in the a-actin- and BRDU-stained histologies 
indicating potential effects of atRA on cell proliferation and differentiation. 
Conclusions: AtRA is a potent inhibitor of haSMC proliferation in vitro, 
even in the presence of growth factors, and also in rive. Thus, local atRA 
delivery might be a promising strategy for the prevention of restenosis. 
~ Unique Effects of 7E3 Shear-Induced Inhibiting on 
von Willebrand Factor-Dependent Platelet 
Activation and P-Selectin Expression 
Shinya Goto, Min Lee, Hiroyuki Sakai, Jay-Jong Kim, Noriko Ichikawa, 
Minako Yoshida, Mami Goto, Miyuki One, Shunnosuke Handa. Tokai 
University School of Medicine, Isehara, Japan 
Background: Anti-GP lib/Ilia agents is revealed to be effective for preventing 
acute coronary occlusion after interventional treatment. Clinical efficiency of 
the several anti-GP lib/Ilia agents are not the same although there anti-GP 
IIb/tlla effects are similar. We have attempted to clarify the effects of various 
anti-GP lib/Ilia agents on von Willebrand factor (vWF)-dependent platelet 
activation occurring under shear. 
Methods: Platelet-rich plasma obtained from ten normal donors were 
exposed to the shear rate of 10,800 s 1 for 6 min, by optically modified 
cone-plate viscometer, in the presence or absence of various anti-GP lib/Ilia 
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agents. Specific monoclonal antibody against P-selectin (WGA1) directly 
labeled with FITC was added to the mixture prepared before and after 
exposing platelets to the shear field. Number of FITC-IgG molecules bound 
on platelet surface, corresponding to the number of P-selectin molecules, 
was measured by quantitative flow cytometry. 
Results: Number of FITC-anti-P-selectin antibody molecules bound on 
platelet surface increased after exposing platelets to a relatively high shear 
rate of 10,800 s -1 . This antibody binding reflect increased surface expression 
of P-selectin, not reflecting increased non specific binding of IgG molecules 
after platelet activation, since FITC-anti-thyroglobulin binding to platelet did 
not change even after shearing. Anti-GP lib/Ilia agents, including RGD pep- 
tide (1 mM) and monoclonal antibody LJ-CP8 (50 /~g/ml), did not inhibit 
shear-induced P-selectin expression. On the other hand, 7E3 (50 p.g/ml) 
completely inhibited vWF-mediated P-selectin expression and microparticle 
release occurring under shear. 
Conclusion: Our results suggest that 7E3 have unique inhibiting effects 
on vWF mediated platelet activation. This specific character of 7E3 may have 
relevant role for effective inhibition of acute coronary thrombosis. 
~ T h e  F(ab')2 Fragment of 7E3, the Parent Antibody 
of Abciximab, Blocks GPIIb/llla-Mediated 
Thrombosis in Rats 
Marian T. Nakada, Patricia M. Sassoli, J. Luis Guerrero, Mark A. Nedelman, 
Susan H. Tam, Robert E. Jordan. Centocor, Malvern, PA, USA 
Abciximab (c7E3 Fab, ReoPro) blocks GPIIb/llla and ev,83, and is an effec- 
tive therapy for the prevention of adverse events associated with treatment 
of acute coronary syndromes. Abciximab is efficacious in humans and non- 
human primates and the bivalent fragment, marine 7E3 F(ab')2 has been 
shown to block platelet aggregation (PLT AGG) in dogs. No form of 7E3 has 
previously been shown to be effective in rodent species. 
Objective: The purpose of this study was to determine if 7E3 F(ab)2 is 
effectively anti-thrombotic in rats. 
Results: 7E3 F(ab')2 bound to rat GPIIb/llla (Kd = 7/~g/ml) and o~v~3 (Kd 
= 9 #g/ml) with equivalent affinity that was ~ 30-fold weaker than for human 
platelets. Abciximab had an even weaker affinity for rat GPIIb/llla (Kd = 480 
/~g/ml). 7E3 F(ab')2 blocked in vitro rat PLT AGG with an ICs0 = 15 ± 5 
g/ml. IV injection of rats (n = 6) with 4 mg/kg 7E3 F(ab')2 completely blocked 
ex vivo PLT AGG for up to 6 hrs, whereas 20 mg/kg of aboiximab (n = 11) 
was ineffective at 1 hr. 7E3 F(ab)2 (4 mg/kg i.v.) also prevented thrombus 
formation in response to a rat abdominal aorta double crush injury; 6/9 
vessels occluded (<25% of post-stenotic flow) within 120 minutes in control 
rats compared to 0/8 in 7E3 F(ab')2 treated rats. In vitro mixing experiments 
combining 7E3 F(ab)2-1abeled and unlabeled rat PLTs (n = 2) indicated that 
7E3 F(ab')2 redistributed to unlabeled PLTs in 2 hrs. Ex vivo, 7E3 F(ab')2 
was detected on PLTs by FACS at 1 hr, 6 hrs, and at days 1,2, 3 and 4 after 
a single 4 mg/kg injection (n = 4). A single, unimodal peak was observed at 
each time, suggesting that redistribution had occurred, a pattern that also 
occurs with abciximab in humans. 
Conclusion: These data provide the first evidence that 7E3 F(ab')2 in- 
teracts with rat GPIIb/llla and c~v/~3 and effectively blocks in vivo thrombus 
formation. This suggests that 7E3 F(ab)2 may be a useful agent to study 
the effects of GPIIb/llla and c~v/~3 blockade in a wide variety of rat models of 
disease. 
• Long-term Treatment Prevents Nitrate Ramipril 
Tolerance by an Antioxidant Mechanism 
Philippe Unger, David Fontaine, Stephane Baldassarre, Nicolas Preumont, 
Jeanine Fontaine, Guy Berkenboom. Cardiology Department, Erasme 
Hospital, Brussels, Belgium 
Background: Prevention of nitrate tolerance with ACE inhibitors has been 
related to inhibition of neurohormonal activation. 
Methods: To assess an interaction at the vascular level, 4 groups of rats 
were treated; group 1 (Ram) with ramipril 1 mg/kg/day p.o. for 6 weeks; group 
2 (Ram + HOE) with ramipril 1 mg/kg/day for 4 weeks and the last 2 weeks, 
a cotreatment ramipril + HOE140 (a bradykinin B 2 antagonist 500 pg/kg/day, 
Groups (n) pD 2 (NTG-) pD 2 (NTG+) AUC (NTG-) AUC (NTG+) 
Ram (7) 7.9 ± 0.1 7.9 ± 0.2 418:5 18 444 ± 35 
Ram + HOE (6) 7.9±0.3 7.1±0.4" 400±49 632±70* 
Losart (12) 7.7 ± 0.1 7.3 ± 0.3 484 ± 31 572 ± 63* 
Control (10} 7.8 ± 0.1 6.7 ± 0.1"* 457 ± 16 673 ± 35"* 
mean ± SEM; n = number of rats studied; pD 2 = log NTG concentration evoking a half 
maximal relaxation; AUC = area undereurve; *P < 0.05, **P < 0.01 vs NTG. Endothelium 
removal abolished the protective ffects of Ram and Losart. Superoxide anion (02) levels 
(assessed by lucigenin chemiluminescence) increased after NTG incubation in control 
group but not in Ram group. 
s.c.); group 3 (Losart) with Iosartan 2 mg/kg/day p.o. for 6 weeks (a dose 
equipotent to that of ramipril); group 4 served as control. Rings of thoracic 
aorta were studied in organ baths. After 30 rain nitroglycerin incubation 
(10 /~M, NTG÷) or physiological solution (NTG), relaxations to NTG were 
determined on phenylephrine-contracted rings. 
Results are presented in the table. 
Conclusion: Ramipril counteracts the NTG-induced increase in 02 pro- 
duction. The mechanism is endothelium-dependent, mainly through B 2 kinin 
receptors, but involves also blockade of angiotensin II formation. 
POSTER 
Clinical Pharmacology: Syncope, 
Arrhythmias, and Pulmonary Hypertension 
Tuesday,  March  9, 1999, 9:00 a .m. -11 :00  a,m.  
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  9:00 a .m. -10 :00  a.m.  
~ Randomized Placebo Control Assessment of 
Midodrine in the Treatment of Neurocardiogenic 
Syncope 
Andrea Natale, Salwa Beheiry, Gery F. Tomassoni, Fable M. Leonelli, 
Ennio Pisano, Raffaele Fanelli, Leandro Zimmerman, You He Kim. 
University of Kentucky, Lexington KY, USA; Casa Sollievo della Sofferenza, 
Italy; Hospital Moinhos DeVento, Porto Alegre, Brazil; Asan Medical Center, 
Seoul, South Korea 
We prospectively assessed in a randomized placebo control study the ef- 
ficacy of Midodrine in the management of patients with Neurocardiogenic 
Syncope. Patients included in the study had at least monthly occurrences of 
syncope and a positive tilt table test. A total of 61 patients were randomly 
allocated to either treatment with Midodrine or to fluid therapy and counsel- 
ing. Midodrine was given starting at a dose of 5 mg three times a day, and 
when required increased up to a dose of 15 mg three times a day. Midodrine 
was given during the day-time every 6 hours. 31 patients were assigned to 
treatment with Midodrine, whereas the remaining 30 patients were advised to 
increase their fluid intake and were instructed to recognize their prodromes 
and abort the progression to syncope. Patients were followed up for at least 
6 months. At the end of the study time, each patient assessed the response 
to treatment on a scale from 0 to 6 (no response to excellent response). 14 
patients given Midodrine became asymptomatic while on 5 mg 3 times a day. 
7 patients required 10 mg 3 times a day, and 5 required 15 mg 3 times a 
day. Two patients reported improvement although they continued to expe- 
rience symptoms. One patient had to discontinue Midodnne due to severe 
side effects and additional 6 patients experienced minor side effects that did 
not require drug discontinuation. Of the 30 patients in the placebo group, 4 
experienced no reccurrence of symptoms during the 6 months follow up and 
8 had improvement. The remaining 18 patients did not report any benefits. 
In conclusion, Midodrine appeared to provide a significant benefit in patients 
with neurocardiogenic syncope. To prevent recurrence of symptoms close 
adjustments were required in about one third of the patients. 
~ Effect Preventing Syncopal Spells of Etilefrine in 
m Patients With Recurrent Vasovagal Syncope: 
A Double-Blind, Randomized Trial 
France Giada, Antonio Raviele, Michele Brignole, Richard Sutton, 
Paolo Alboni, Paolo Giani, Carlo Menozzi, Angel Moya. For VASIS 
Investigators; Division of Cardiology, Hospital Umberto I, Mestre-Venice, 
Italy 
Background: The Vasovagal Syncope Intemational Study (VASIS) is a multi- 
center, randomized, placebo-controlled trial designed to evaluate the efficacy 
of etilefdne, a alpha-agonist agent, for long-term therapy of patients with re- 
current vasovagal syncope. 
Methods: One hundred twenty six patients with recurrent vasovagal 
syncope (at least 3 episodes in the last 2 years) and a positive head-up 
tilt test were randomly assigned to placebo (63 patients) or etilefdne (63 
patients) at a dosage of 25 mg tid and were followed-up for 1 year or until 
syncope recurred. The primary end-point of the study was the first recurrence 
of syncope. 
Results: There were no differences between the 2 groups in the base- 
line characteristcs. During the follow-up the etilefrine group had a similar 
incidence of first syncopal recurrence as the placebo group both at the in- 
tention to treat analysis (24% vs 24%) and at on treatment analysis (26% 
vs 24%). Also the time to first syncopal recurrence did not significantly differ 
between the 2 groups (median, 106 days in the etilefdne arm and 112 days 
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in the placebo arm). No statistical difference was observed in the number of 
patients who had at least one presyncope during the follow-up (41% in the 
etilefrine arm vs 51% in the placebo arm) and the total number of presyncopal 
episodes (80 in the etilefrine arm vs 90 in the placebo arm). 
Conclusions: Oral etilefrine is not superior to placebo in preventing 
episodes of vasovagal syncope. Randomized controlled trials are today 
mandatory to assess the real efficacy of any proposed therapy for patients 
with vasovagal syncope. 
• Outpatient Initiation of Antiarrhythmic Therapy 
With Flecainide, Propafenone and Sotalol in 
Patients With Atrial Fibrillation 
Andrea Natale, Gery F. Tomassoni, Salwa Beheiry, Kathleen Rajkovich, 
Brandon Wides, Debra Nickell, Fabio M. Leonelli. University of Kentucky, 
Lexington KY, USA 
We prospectively assessed whether outpatient initiation of Propafenone, 
Flecainide and Sotalol under a strict observation protocol is safe and feasible. 
A total of 159 patients entered the study. 54 received Propafenone to a 
maximum dose of 300 mg TID, 58 patients received Flecainide, which was 
started at a dose of 50 mg BID to be increased to 100 mg. BID within two 
days. Sotalol was given to 47 patients starting at a dose of 80 mg BID to a 
maximum of 160 mg BID. Patients were monitored by obtaining 12 lead ECG 
every two days until two days after the maximum dose was given. The drug 
was discontinued in case of QTc prolongation or severe bradycardia. Drug 
therapy was instituted while the patient was in atrial fibrillation in 29 patients. 
10 of them were given Propafenone and 12 Flecainide. Sotalol was initiated 
during atrial fibrillation in 7 patients. No patient older than 60 years was given 
sotalol on outpatient basis if in atrial fibrillation. No significant pro-arrhythmic 
effects were observed in the group given Propafenone. Among the 12 patients 
receiving Flecainide while in atrial fibrillation increased ventricular response 
associated with worsening of symptoms was observed in 7 of them and 
required the discontinuation of the drug in 2 patients. 2 patients on sotalol 
showed QTc prolongation. Significant bradycardia was observed exclusively 
in the group given sotalol and occurred in 24 of the 31 subjects older than 
60 years. Bradycardia required discontinuation of the drug in 16% of these 
patients. In conclusion, outpatient initiation of sotalol and 1C drugs is safe if 
performed in appropriate monitoring conditions. Patients older than 60 years 
of age had a higher risk of pro-arrhythmia while given Sotalol. Initiation of 
Ftecainide during atrial fibrillation was associated with a significant incidence 
of increased ventricular response. 
• Safety, Pharmacodynamics and Pharmacokinetics 
of an Accelerated Sotalol Dose Titration Regimen 
in Healthy Volunteers 
Jean 17 Barbey, Mark E. Sale, Raymond L. Woosley. Georgetown UniversiCy 
Medical Center, Washington DC, USA 
Background: It is recommended that therapy with sotalol be initiated in a 
monitored setting at 80 mg q12 hrs for 2-3 days, followed by graded titration 
to 120-160 mg q12 hrs for 2-3 days before safety and efficacy can be 
ascertained and patients discharged. An accelerated dose titration regimen 
that would shorten hospital stay safely is desirable, but has not been formally 
evaluated. 
Methods: Healthy middle aged males and females received sotalol in a 
double blind, 2 way crossover, study with a 2 week washout to evaluate an 
accelerated dosing regimen: placebo q6 hrs 4 doses, followed by sotalol 80 
mg q6 hrs 4 doses, then sotalol 160 mg q12 hrs 9 doses, compared to the 
traditional regimen: placebo alternating with sotalol 80 mg q6 hrs 8 doses 
followed by sotalol 160 mg q12 hrs 9 doses. QT, RR intervals and plasma 
concentrations were assessed at specific times throughout the study and 
during washout in a similar fashion for both regimens. 
Results: 34 subjects completed both regimens. The target prolongation 
of QTc (90% of the value achieved at steady-state) was achieved 17 hours 
sooner with the accelerated regimen (P = 0.002). There were no cardio- 
vascular adverse events during either loading phases. At no time during 
the accelerated dose titration did plasma concentrations, QT or RR interval 
prolongation exceed the values achieved at steady state. The relationship 
between plasma concentration and QTc was linear and independent of the 
regimen. 
Conclusion: An accelerated titration regimen for sotalol can shorten the 
time to attain dosages required to effectively control arrhythmias without 
excessive QT prolongation and increased risk of torsades de pointes. 
• Effects of Iloprost Inhalation on Exercise Capacity 
and Gas Exchange in Patients With Primary 
Pulmonary Hypertension 
Christian F. Opitz, Roland Wensel, Ralf Ewert, Saodra Burger, Franz 
X. Kleber. Charit, Humboldt University Berlin, Deutsches Herzzentrum and 
Unfallkrankenhaus Berlin, Germany 
Background: Continuous infusion of prostacyclin has been shown to im- 
prove exercise capacity and survival in patients with primary pulmonary 
hypertension (PPH). Inhalation of itoprost, a stable analogon of prostacyclin, 
is considered to be a possible alternative therapy for PPH, selectively acting 
in the pulmonary vascular bed by ventilation matched alveolar deposition of 
the drug. We investigated the acute effects of iloprost inhalation on exercise 
capacity and gas exchange in patients with PPH. 
Methods and Results: In 11 patients with PPH we performed serial 
spiroergometric exercise testing prior to and after inhalation of 17 g iloprost. 
Patients had marked pulmonary hypertension (mean PAP 86 mmHg) and 
inhalation resulted in a decrease in pulmonary vascular resistance (1509 vs. 
1175 dyne s cm 5, p < 0.05). Arterial blood gases remained unchanged 
(paO2 69.3 vs. 66.8 mmHg; paCO2 29.6 vs. 28.8 mmHg). Spiroergometry 
revealed a significant increase in exercise duration (379 vs. 438 sec) and 
peak oxygen uptake (12.8 vs. 14.2 ml/kg/min) and a decrease in the VE vs. 
VCO2 slope (58 vs. 51.4). 
Conclusions: Our data show that iloprost inhalation exerts pulmonary 
vasodilation and positive effects on symptoms and exercise capacity in pa- 
tients with PPH. It suggests that itoprost inhalation is a suitable treatment for 
PPH, Whether these effects are maintained during chronic treatment and are 
paralleled by improvement in prognosis remains to be determined. 
i 
11134-31 I Is Continuous Intravenous Prostacyclin Infusion 
Effective in Secondary Pulmonary Hypertension? 
Srinivas Mural±, Kimbedy Bollinger, Mary Trost, Tammy Tokarczyk, 
Amy Palmer, Ren J. Alvarez Jr., Guy A. MacGowan, Dennis M. McNamara, 
Warren D. Rosenblum, Arthur M. Feldman. University of Pittsburgh Health 
Systems, Pittsburgh, PA, USA 
Chronic continuous infusions of intravenous prostacyclin (PC) improve symp- 
toms, hemodynamics, functional capacity and possibly survival in pts with 
primary (P) pulmonary hypertension (PH). Whether PC is similarly effective 
in secondary (S) PH has not been prospectively evaluated. Effects of chronic 
PC therapy were evaluated in 18 SPH pts (mean age 53 ± 11 yrs; 11 females, 
7 males, Causes of SPH included portal hypertension (n = 5), sarcoidosis 
(n = 1), congenital heart disease (n = 1) and connective tissue disease (n = 
11). The mean PC dose was 22 ± 14 ng/kg/min (range 6-56) and the mean 
duration of therapy 7 i 3 months (range 1-12). Baseline (B) and data on PC 
therapy are shown. 
PAM PVR CO TRV NYHA Class 
(mmHg) (Wood Units) (I/min) (m/sec) II Ill IV 
B 50±9 14±5 4±1.3 4.2±0.5 0% 44% 56% 
PC 45~-9 * 10±3" 4.8 ± 1.5" 4±0.4 + 28% 60% 12% 
"p < 0.05, +p = 0.06, PC vs B; PAM = pulmonary artery mean pressure; PVR = pulmonary 
vascular esistance; CO = cardiac outpul; TRV = doppler echocardiograrn derived tricus- 
pid regurgitation velocity. 
PC infusion improved hemodynamics, and functional status and trended 
to lower TRV. During followup, 5 pts (28%) underwent transplantation (3 
hepatic, 2 pulmonary), and 4 pts (22%) died. 
Conclusions: Our preliminary observations suggest that as in PPH, 
chronic PC infusion has favorable effects in SPH. Mutticenter, prospective, 
randomized trials are needed to further evaluate the effects of PC therapy in 
SPH. 
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~ Effects of Cholesterol Treatment Lowering on 
Coronary Vascular Remodeling and Endothelial 
Function 
Shuichi Hamasaki, Stuart T. Higano, Jassim AI Suwaldi, James L. Velianou, 
Nelson Araulo, Amir Lerman. Mayo Clinic, Rochester, MN, USA 
Vascular remodeling has been described in the early stages of native ath- 
erosclerosis. The aim of our study was to evaluate the impact of cholesterol 
lowering on coronary remodeling and endothelial function in patients with 
hypercholesterolemia (HC). A total of 372 segments derived from 101 pa- 
tients were analyzed to evaluate vessel area, lumen area, and plaque area. 
Patients were divided into three groups based on the total cholesterol (TC) 
levels: group I: n = 25, patients with a history of HC adequately treated (TC 
< 240 mg/dl); group I1: n = 26, patients with HC not adequately controlled 
(TC > 240 mg/dl); group IIh n = 50, patients without HC. Vessel area and 
lumen area in both groups I and III were significantly greater than that in 
group II (vessel area: 11.9 ~ 0.5, 10.6 ± 0.4, and 11.8 ~ 0.4 mm ~, both 
p < 0.05; lumen area: 8.3 • 0.4, 6.9 ± 0.3, and 8.9 ± 0.3 mm 2, both p 
< 0.01). However, plaque area in both groups I and II were similar. Acetyl- 
choline-induced percent increase in coronary blood flow in both groups I and 
III were significantly greater than that in group II (70.5 ± 20.1, 22.8 ± 13.7, 
and 68.6 ± 14.8°/o, both p < 0.05). Thus, the effect of cholesterol iowedng 
on enlargement in lumen area may result not from a decrease in plaque area 
but rather an increase in vessel area reflecting vascular remodeling. Addi- 
tionally, this adaptive process may occur in association with an improvement 
of endothelial function in the coronary microvessels. 
• Endothelium-Dependent Response in 
Hypercholesterolemic Coronary Artery Disease 
Patients Under the Effects of Simvastatin and 
Enalapril, Either Separately or Combined 
Ricardo J. Esper, Rogelio Machado, Jorge Vilario, Daniel Suarez, 
Jos Cacharrn, Marta Kura. Cardiology Services, Hospital M/l/tar Central, 
Buenos Aires; Hospital A. Gutierrez, Venado Tuerto, Argentina 
Backgroud: Endothelial dysfunction is an early event in atherosclerotic dis- 
ease that preceeds clinical manifestations and complications. To assess 
the endothelium-dependent and -independent vasodilation in hypercholes.- 
terolemic coronary patients (pts) under the effects of Simvastatin (S) and 
Enalapril (E) either separately or combined, a double-blind, cross-over study 
was performed. 
Methods: 38 pts were separated in 2 groups. Group I (18 pts, 3 c2 , mean 
age 62.6 ± 6.0 years) received S 10 mg/d for 8 weeks (w) and S + E 5 
mg/d for another 8 w. Group II (20 pts, 3 9,  mean age 63.8 ± 5.8 years) 
received E 5 mg/d for 8 w and E + S 10 mg/d for another 8 w. All of them 
underwent measurements of brachial Artery Diameter (AD) before and after 
active post-ischemic hyperemia, with high resolution ultrasound at basal 
conditions (Control) and under the effects of the drugs at the end of 8 w and 
16w. 
Results: Cholesterol and LDL-C decreased significantly under the effects 
of S and E. Mean AD (mm) before ischemia was 5.24 ~ 1.25 in Group I and 
4.83 t 0.99 in Group II iNS). Mean percentage of post-ischemic increased 
in AD were as follows: 
Group h Control 8 w (S)% 16 w (S + E)% NTG% 
4.4* 7'.6* 8.6" 17.5-17-18" 
Group II: Control 8 w (E)% 16 w (E + S)% NTG% 
4.3* 5.8" 9.1" 21-21-22" 
NTG is endothelium-independent vasodilation under nitroglycerine ffects in each of the 
3 opportunities. *p < 0.0001 vs pre-ischemic AD; tp < 0.005 vs Control; lp < 0.05 vs 8 
w; §p < 0.005 vs 8 w. 
Conclusions: S significantly increased the post-ischemic vasodilating 
response either alone (3.2%) or after E was given (3.3%). E showed similar 
effects when given alone (1.5%), yet less accentuated when given after 
S (1%). Both drugs improve vasodilation and additive effects seem to be 
present. 
~ l s  There a Benefit to Lowering Low-Density 
Lipoprotein Below 100 mg/dl in Patients With 
Coronary Artery Disease? 
Michael Shechter, Michaal Sharir, James Forrester, C. Noal Balrey Merz. 
Cedars-Sinai Medical Center, Los Angeles, CA, USA 
A central issue in lipid lowering therapy is whether there is any benefit 
from lowering low-density lipoprotein cholesterol (LDL-C) levels below the 
National Cholesterol Education Program (NCEP) target of 100 rag/hi. Conse- 
quently, we assessed prospectively flow-mediated endothelium-dependent 
(ED) and endothelium-independent (El) brachial artery vasoreactivity (BRT) 
in 44 stable CAD patients (36 men, 8 women, mean age 66 ± 10 years) 
on lipid lowering therapy. BRT was measured using 10 MHz ultrasound 1:30 
minutes (rain) following 3 min of blood pressure cuff arterial occlusion and 
after sublingual nitroglycerin (NTG) administration. 
Results: Flow mediated % diameter change at 1:30 min (%D1:30) was 
negatively associated with baseline LDL-C (r = 0.39, p = 0.05). Patients were 
then divided into two groups < and >_ LDL-C level of 100 mg/dl. 
%D1:30 %DNTG LDL-C T-Chol 
100 mg/dl (n = 28) 12 ± 13" 16 ± 10" 75 - 15 150 ± 19 
100 mg/dl (n = 16) 3 ± 11 10 :E 9* 106 zE 26 177 ± 46 
p value 0.03 0.05 0.0001 0.01 
%DNT G = % diameter change from baseline following NTG; T-Chol = total cholesterol 
and LDL-C in mg/dl; p 0.00001 vs basefine. 
There were no significant group differences in baseline brachial artery 
diameter, age, body mass index, blood pressure, triglycerides, glucose and 
fibrinogen between the two groups. 
Conclusion: In CAD patients on lipid Iowedng therapy, ED and El BRT are 
significantly greater when treatment reduces LDL-C < 100 mg/dl, suggesting 
there may be additional benefit to lowering LDL-C < the current NCEP 
guidelines. 
~ Cardiovascular Risk and Lipoprotein(a): Age 
Gender and LDL-C Interaction 
JoAnne Micale Foody, John A. Milberg, Dennis L. Sprecher. The Cleveland 
Clinic Foundation, Cleveland, Ohio, USA 
Background: Lp(a) has been associated with increased CAD risk in men 
and this effect may be mediated by LDL-C. Little data exists in women. 
Methods and Results: The association of Lp(a) (> 30 mg/dl) with CAD 
was examined in 1130 outpatients (391 females, 739 males). Multivariable 
odds ratios were determined (Table). In men < 55, CAD increased from 41% 
to 63% as Lp(a) rose from < 5 mg/dl to > 41 mg/dl (p = 0.003). No increase 
was observed in men > 55 years (OR = 0.93). CAD increased from 24 to 
33% (OR 1.38) in women < 55, and from 45% to 67% (OR 2.25) in women 
> 55. In men, a trend was observed for the effect of high Lp(a) vs. low Lp(a) 
when LDL was below the median value of 158 mg/dL (OR 1.2, CI 0.62.4) vs. 
above the median (OR 2.1, CI 1.14.2). No trend was observed in women. 
Multivariable Lp(a)/CAD Odds Ratios (95% CI} by Gender and Age 
Group Males Females 
Total Population 1.54 (t .0-2.3} 1.87 (1.1-3,1 ) 
<55 Yrs 2.37 (1.3--4.3) 1.38 (0.6-3.4) 
>55 Yrs 0.93 (0.5-1.7) 2.25 (1.2-4.3) 
Conclusions: Elevated Lp(a) was associated with an increased risk of 
CAD in men < 55 years, and in all women. In women, the effect was greatest 
in those above the age of 55 years. We detected no association in the older 
men. While high levels of LDL increased the association between Lp(a) and 
CAD risk in men, no similar trend was observed in women. Lp(a) is influenced 
by both gender and age and predicts more sehous CAD risk in older women 
and younger men. 
~ The Bezafibrate Infarction Prevention (BIP) Study, 
Israel: HDL Subclasses (HDL2 HDLj, LpAI 
LpAI:Ajj), in CHD Patients Compared to Healthy 
Individuals 
Eran Graft 1,2, Sara Schwartz 2, Shoshana Schwartz 2, Mona Boaz 2, 
Daniel Brunner z . For the BIP Study group, ~ TeI-Aviv E. Sourasky Med. 
Center; 2Institute of Physiol. Hygiene, E. Wolfson Med. Center, Holon, Israel 
Background: HDL is an heterogeneous family of particles. The present study 
was aimed at pointing out which of the HDL subtractions better reflects the 
differences in HDL level between the study subgroups. 
Methods: Selective precipitation fractionates HDL-C (HDL) into HDL-C2 
HDL-Cj, (HDL23). Electroimmunoassay separates HDL to particles contain- 
ing apoAj only (LpA1), and those containing both apoAi and apoAIq (LpAl:Ait). 
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CHD patients, 547 men (M) and 51 women (W) aged 45-74 y, were studied 
at their pre-randomization visit for the BIP Study. Healthy control (Con) in- 
dividuals, 750 M and 753 W, were studied in the Tel Aviv-Heidelberg Three 
Generations Offspring Study. 
Results: The ratios of mean values of healthy controls to those of the 
CHD patients are presented in the following graph: 
• --e-- lUlml 
n, ,  
Conclusions: The parameters best distinguishing CHD from healthy 
subjects are in decreasing order: HDL2; HDL; HDL3 and LpAi, (MI patients 
had lower HDL2 and LPA= mean values than those with angina pectoris). All 
the differences between patients and controls were higher in W. Thus, low 
HDL and apoA~ levels as dsk for CHD can be attributed to a lower proportion 
of its HDL2 and LpAi subfractions, respectively. 
• Triglycerides, HDL-c and Diabetes: Prediction of 
Post-Coronary Artery Bypass Grafting Survival in 
Women 
Dennis L. Sprecher, Gregory L. Pearee, Delos M. Cosgrove, Bruce W. Lytle, 
Floyd D. Loop. Departments of Cardiology, Thoracic and Cardiovascular 
Surgery The Cleveland Clinic Foundation, Cleveland Ohio, USA 
Background: Metabolic determinants of mortality post-CABG in women, 
among traditional surgical variables including use of arterial conduits, LV 
function and extent of disease have not been clearly defined. 
Methods: We performed a prospective (follow-up) observational study 
on 1374 women who underwent CABG surgery between 1982 and 1992. 
Recording baseline lipid and lipoprotein values (HDL-c beginning in 1988), 
history of diabetes mellitus (DM) and hypertension (HTN), extent of disease 
and use of internal mammary arteries, we examined which variables best 
explained total survival. These results were compared to 4996 men during 
the same period of time. 
Results: Five and ten year survival for women was 88% and 70%, 
respectively. In women the hazard ratio (HR) for TG 1.22 (p = 0.0005), 
DM was 1.90 (p = 0.0001), HTN 1.37 (p = 0.03), age 1.03 (p = 0.0001), 
IMA use 0.68 (p = 0.004), LVF 1.23 (p = 0.006), and total cholesterol (TC) 
0.82 (p = 0.005). The TG effect became relevant 3 years post-CABG, and 
progressively grew in predictive value over the follow-up period. In a model 
exclusive of TG, HDL was of significance in women, HR = 0.89, (p = 0.01) 
and was predictive of mortality in the first post-op year, and was constant 
over the follow-up period. In contrast, TG and TC were not significant in men, 
while the other variables were of similar significance in both genders. 
Conclusion: TG and HDL-c baseline values, along with the presence of 
diabetes at the time of surgery, are primary determinants for long term total 
mortality after CABG in women. Baseline TG levels showed progressively 
increasing predictive value beginning at 3 years after CABG. HDL-c values 
are predictive immediately after surgery and continue to be predictive through 
follow-up. 
~ Nonesterified Fatty (NEFAs) Acids and 
Triglyceride Levels Are the Predictors of Blood 
Pressure Elevation 
Kazuko Masuo, Hiroshi Mikami, Mikiko Itoh, Toshio Ogihara, Michael 
L. Tuck ~ . Osaka University Medical School, Suita Ci~ Osaka, Japan; 
1Sepulveda VA Medical Center, Sepulveda, CA, USA 
Background: Resistance to the vasodilator action of insulin may contribute 
to the increased neurovascular tone and blood pressure (BP) in obese 
hypertensive subjects. Recently, it has been reported that nonesterified fatty 
acids (NEFAs) were elevated in obese hypertensive subjects and NEFAs 
participated in resistance to the vascular effects of insulin. Thus, we observed 
the changes in BP levels, NEFAs, lipid fractions, sympathetic activity and 
insulin level in a longitudinal study of 10 yrs. 
Methods: In 662, young (<50 yrs), non-obese (BMI < 26 kg/m2), nor- 
motensive men (NT), BMI, BP, fasting blood glucose, plasma insulin (INS), 
norepinephrine (NE), total cholesterol (Tch), triglyceride (TG), HDL-, VLDL-, 
LDL-ch, NEFA were measured every year for 10 yrs after an overnight fast. 
BMI in the subjects did not change for 10 yrs. 
Results: BP elevation (BP-E) was defined as 10% or more elevation of 
mean BP when compared with BP at entry. BP-E was noted in 28% of NT. 
At entry period, fasting blood glucose (99 mg/dl, 91, P < 0.01), plasma NE 
(297 pg/ml, 228, P < 0.05), NEFA (184 mg/dl, 113, P < 0.01) and TG (147 
mg/dl, 103, P < 0.05) in NT with BP-E were greater than those in NT without 
BP-E, although fasting plasma INS (8.6/~U/ml, 8.1, NS), Tch (179 mg/dl, 168 
mg/dl, NS), VLDL-, LDL-and HDL-ch in NT with BP-E was similar to that in 
NT without BP-E. The increments (A) in mean BP (P < 0.01), NE (P < 0.01), 
INS (P < 0.01), NEFA (P < 0.05), and TG (P < 0.01) were greater in NT with 
BP-E than without BP-E. At entry and year 10, mean BP levels correlated 
with NE (P < 0.05, P <: 0.01), NEFA (P < 0.05, P < 0.05), TG (P < 0.05, P < 
0.01), but did not with INS (NS, P < 0.05). The %~.mean BP correlated with 
%~.NE (P < 0.05) and %ANEFA (P < 0.05). The %AINS correlated with 
%ANEFA. 
Conclusions: These results demonstrate that NEFAs and TG as well as 
sympathetic hyperactivity appear to precede BP elevation even in non-obese, 
normotensive subjects. 
~ Influence of Nonlipid and Lipid Risk Factors on 
Coronary Artery Disease Progression 
Christie M. Ballantyne, J. Alan Herd, Laura L. Ferlic, J. Kay Dunn, Evan 
A. Stein, Antonio M. Gotto, Jr.. Baylor College of Medicine, Houston, TX, 
USA 
Background: Efforts to improve coronary artery disease (CAD) risk factor 
assessment include increasing interest in measuring nontraditional risk fac- 
tors to determine how to treat patients with CAD. However, because of the 
paucity of prospective clinical trial data, it remains unclear whether these 
risk factors have prognostic value in patients already documented to have 
CAD. 
Methods: In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), 
which randomized 429 patients with mildly to moderately elevated LDL-C 
(115-190 to fluvastatin or placebo, we examined whether baseline levels 
of homocysteine, fibrinogen, factor VII, factor VIII, intercellular adhesion 
molecule 1 (ICAM-1), E-selectin, and insulin levels, in addition to lipids and 
apolipoproteins, were predictors of 2.5-yr CAD progression assessed by 
mean within-patient per-lesion change in minimum lumen diameter (,~MLD) 
with hierarchical multivariate modeling. We also examined whether these 
factors were predictors of categorical assessment of patients as progressors, 
or stable. 
Results: None of the additional risk factors tested was significantly asso- 
ciated with either mean ~,MLD or categorical progression. The only baseline 
predictors of AMLD were ape A-I and ape C-III:B levels and treatment. Also, 
there was no significant treatment interaction between the additional risk 
factors and response to fluvastatin. 
Conclusion: Nonlipid risk factors at baseline did not provide additional 
information beyond that of apolipoproteins in predicting progression of CAD, 
and no significant treatment interaction was observed between the nonlipid 
risk factors measured and the response to fluvastatin treatment, which sig- 
nificantly slowed progression of CAD. More prospective clinical trial data in 
patients with documented CAD are required to determine whether measuring 
these nonlipid factors will be useful in guiding therapy. 
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/ 1136-1101 Serum Activity of C-C Chemokines in 
L J Hypertensive Patients With or Without 
Significant Hyperlipidemia 
John Parissis, Dimitrios Mentzikof, Koula Venetsanou, Kostas Merkouris, 
Spilios Karas. First Department Of Cardiology, Amalia Fleming Hospital, 
Athens, Greece 
Background: The activation of monocytes with infiltration into the vessel 
wall is an early event in atherogenesis. C-C chemokines may play a role in 
the recruitment and activation of monosytes/macrophages in this disorder. 
This study investigates the differences in serum activity of representative 
C-C chemokines, such as macrophage chemoattractant protein-1 (MCP-1) 
and macrophage inflammatory protein-la (MIP-Ia), between hypertensive 
patients with significant hyperlipidemia and hypertensive patients without 
this condition. 
Methods: Serum levels of MCP-1 and MIP-la were determined by high 
sensitive Elisa assays in 38 patients (29 men and 9 women) with moderate 
hypertension and 15 age-matched healthy controls. Patients (n = 18) with 
total cholesterol (TC) > 240 mg/dl and LDL-C >_ 160 mg/dl were classified 
as group A, while patients (n = 20) with values less than the above, as group 
B. All patients did not receive any medications before blood sampling for 
measurements of serum C-C chemokines. 
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Results: Data (mean ± SD) are shown in the table: 
Pts Age SBP DBP TC* LDL-C* MCP-I** MIP-la*** 
(yrs) (mmHg) (mmHg) (mg/dl) (mg/dl) (pg/ml)  (pg/ml) 
Group A 58.2 172 103 261.2 169.9 198.4 24.3 
(n = 18) ± 6.3 ± 6.1 ± 4.8 ± 11.7 ± 7.9 ± 29.3 iz 4.1 
Group B 56.7 170 105 218 138.3 150.7 19.8 
(n =20) ±7.1 ±6.8 ±4.2 ±12.3 ±8.7 ±33.2 ±3.9 
Controls 54.3 125 88 208.5 133.2 116.2 15.4 
(n = 15) ±5.9 ±4.3 ±3.8 ±14.8 ±9.1 ±24.3 ±3.1 
*p group A vs B < 0.01, "'p group A vs B < 0.01, p group A vs controls < 0.001, p group 
B vs controls < 0.05, ***p group A vs B < 0.05, p group A vs controls < 0.005, p group B 
vs controls < 0.05 
in group A, MCP-1 and MIP- la values were significantly correlated with 
LDL-C (r = 0.49, p < 0.05 and r = 0.56, p < 0.01, respectively). No correlation 
was found between smoking and C-C chemokine serum activity in two groups 
of patients. 
Conclusions: MCP-1 and MIP- la serum levels are elevated in hyper- 
tensive patients, especially in those with significant hyperlipidemia. This 
elevation way reflect the initiation and progression of inflammatory athero- 
sclerotic process triggered by arterial hypertension and its coexistence with 
hyperlipidemia. 
~ Polymorphism Angiotensin Converting of 
Enzyme Gene Affects Unfavorably Transforming 
Growth Factor and Von Willebrand Factor in 
Hypertensive Patients 
Thomas Makris, Panagiota Krespi, Antonios Hatzizacharias, 
George Stavroulakis, Caterina Haida, Emmanuel Chronakis, 
Filippos Triposkiadis, Michael Kyriakidis. Cardiology Dept., 2nd Reg. BTC, 
Haemost. Lab., LAIKO Hospital, Greece 
Background: Transforming growth factor (TGF) has been implicated in dra- 
matic structural disorders in pathologies such as atherosclerosis and hyper- 
tension. Moreover, von Willebrand factor (vWF) is the best available marker 
of endothelial cell dysfunction. This study examined the possible association 
between angiotensin converting enzyme (ACE) gene potymorphism, TGF#2 
and vWF in untreated hypertensive patients (pts). 
Methods: The I/D polymorphism of ACE gene was determined in 104 
hypertensives aged 56 ± 12 yrs. Forty-two pts had DD genotype (Group 
A), 30 pts had ID genotype (Group B) and 32 pts had II genotype (Group 
C). The TGF and vWF levels were determined (ELISA method) in the whole 
population. The three groups are matched for age, sex and body mass index. 
Results: TGFt~2 levels were significantly higher in group A than B and 
C (39.2 ± 5 vs. 35.8 ± 4.6 vs. 36.5 ± 3.6 pg/ml, p < 0.01 and p < 0.05 
respectively), vWF levels were significantly higher in group A than B and C 
(141.4 ± 44.8 vs. 104.6 ± 25.8 vs. 110.2 ± 24%, P < 0.001, respectively). 
Conclusions: Our findings suggest that DD genotype of ACE gene poly- 
morphism affects TGFt~2 and vWF levels unfavorably and may be through this 
mechanism enhances the risk of cardiovascular events in the hypertensives. 
1136-112]  Angiotensin Converting Enzyme (ACE) I 
Insertion/Deletion Polymorphism in Chilean 
Normotensive Population: Effects on Plasma 
ACE Activity, Left Ventricular Mass and Cardiac 
Fibrogenesis 
Jorge Jalil, Samuel Cordova, Ann M. Piddo, Jeanette Vega, 
Gast6n Chamorro, Sergio Lavandero, Perla Fat]ndez, Maria P. Ocaranza, 
Roberto Jalil, Liliana Jadue, Patricia Lastra. P Universidad CatSlica de 
Chile, Departaments of Cardiovascular Diseases, Public Health and 
Nephrology; Universidad de Chile, Faculty of Chemical Sciences; 
Panamerican Health Organization and Valparaiso Health Serw'ce, Chile 
Background: The prevalence of the different alleles of the ACE gene inser- 
tion/deletion (I/D) polymorphism, its effect on plasma ACE activity, on cardiac 
mass and also on cardiac fibrogenesis have been assessed, independently 
of hypertension. 
Methods: 117 healthy normotensive Chilean subjects from a popula- 
tion-based study (CARMEN study), age 45 to 60 years, non obese and 
nondiabetic were evaluated. ACE I/D genotypes were determined in DNA 
from circulating leukocytes by polymerase chain reaction, plasma ACE ac- 
tivity by fluorimetry, and LV mass by echocardiogram. Additionaly, plasma 
procollagen type III aminoterminal peptide (PIIIP, a marker for cardiac fibre- 
genesis) was measured in subjects with II genotype and in subjects with the 
DD genotype (by radioimmuneassay). 
Results: The frequencies of the I and D alleles were 0.57 and 0.43, 
respectively. Plasma ACE activity was lower in subjects with the II genotype 
compared 1o those with the ID and DD genotype (12.6 vs 16.5 ± 2.6 and 
17.6 4- 4 U/ml, respectively, p < 0.05). Among the 3 genotypes there was 
no difference in LV dimensions neither in LV mass. No correlation between 
plasma ACE activity and LV mass was observed. PIIIP levels were similar in 
subjects with II (n = 21) and DD in = 19) genotypes (0.57 ± 0.12 vs 0.59 ± 
0.13 U/mL, respectively). 
Conclusion: In this population the D allele in the ACE gene determines 
higher plasma ACE activity. The D allele is not associated to increased LV 
mass nor to increased cardiac fibrogenesis. Fondecyt 1961065. 
I 1136-113 1 Recent Weight Gain in Patients With Newly 
Diagnosed Obstructive Sleep Apnea 
Bradley G. Phillips, Catherine A. Pesek, Masahiko Kate, 
Krzysztof Narkiewicz, Virend K. Somers. University of/owa,/owa City;, Iowa 
Background: Obesity, a major risk factor for cardiovascular diseases, is also 
common in patients with obstructive sleep apnea (OSA). Weight gain in OSA 
worsens sleep apnea and increases the risk for cardiovascular disorders. 
Whether patients with obstructive sleep apnea are predisposed to recent 
weight gain, as compared to similarly obese subjects without sleep apnea, is 
not known. 
Methods: We compared one year weight histories in 32 male and female 
patients newly diagnosed with OSA, and never treated. We also studied 21 
controls, matched for gender, age, body mass index, and percent body fat. 
Controls were proven to be free of sleep disordered breathing by overnight 
polysomnography. 
Results: Male patients with OSA i n = 21 ) had significant one year weight 
gain (4.1 ± 1.2 kg) over the year preceding diagnosis compared to similarly 
obese control subjects (n = 10), in whom average weight fell by 0.83 + 2.3 kg 
(p < 0.05). Female patients (n = 11) with OSA had an 8.8 ± 2.6 kg one year 
weight gain compared to controls (n = 11) who had a 0.7 ± 2.4 kg history of 
one year weight gain (p < 0.05). 
Conclusions: Patients with OSA are susceptible to increasing obesity in 
the period preceding the diagnosis of OSA. These findings have important 
implications for the pathogenesis of OSA and for cardiovascular risk in OSA. 
I1  36-1  I Effects of Sodium Sensitivity and Blood 1 1 4 
Pressure on Left Ventricular Mass 
Bashar A. Shala, S. George Chrysant, Leslie A. Miller, Andrew J. Bush, Jay 
M Sullivan. Division of Cardiology, University of Tennessee, Memphis, 
Tennessee, USA 
Background: To determine the effects of salt sensitivity and blood pressure 
on the development of left ventricular hypertrophy (LVH). 
Methods: We studied a total of 75 subjects for a period of one year. 
Sixty patients were salt resistant and fifteen were salt sensitive. Twenty-six 
patients were borderline hypertensives and forty-nine were normotensives. 
Left ventricular mass (LVM) was measured by M-Mode echocardiography 
using the Penn formula. Measurements were obtained at baseline, 6 months, 
and 12 months. All patients remained on an ad lib diet. 
Results: LVM increased significantly in all borderline hypertensive pa- 
tients (112.2 ± 5.5 to 118.8 ± 5.3, p = 0.005) from baseline to 12 months. 
This increase was also significant in borderline hypertensive salt resistant 
patients (110.2 ± 3.1 to 125.1 ± 4.1, p = 0.004). However, this trend was 
not noted in the borderline hypertensive salt sensitive group (122.7 ± 7.3 1o 
128.4 ± 7.3, p = 0.58) whose LVM was higher compared to the salt resistant 
patients at baseline (p = 0.12). There was no significant increase in LVM 
in normotensive patients over the same period of time (p = 0.27). When 
normotensives were analyzed according to salt sensitivity, there was no sig- 
nificant difference in LVM in either the resistant or sensitive subgroups (p = 
0.20 v p = 0.71, respectively). When salt sensitive patients were combined, 
regardless of blood pressure status, no significant LVM change was noted. 
This same trend was noted for salt resistant patients regardless of blood 
pressure status (p = 0.80). Similarly, gender and race had no effect. 
Conclusion: We concluded that hypertension by itself, regardless of 
salt sensitivity status, was the major factor in the increase of LVM and 
development of LVH over time. 
1136-11  5 ] E f fec t  of Cardiac Long-Term Hypertension on 
and Neurobehavioral Function in Elderly 
Subjects 
Tomio Hamada, Taishiro Chikamori, Takashi Furuno, Hiromi See, 
Yoshinori Do±. Koch± Medical School, Koch±, Japan 
Purpose and Methods: To evaluate the time course of cardiac function and 
neurobehavioral function in elderly subjects with hypertension (HT) com- 
pared to normotension (NT), 22 subjects (19 men and 3 women; mean age 
of 75 years, 68 to 84 years) underwent echocardiography, exercise testing, 
the visuospatial cognitive performance (VCP) score which represent neu- 
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robehavioral function, and laboratory examinations once and again after 5 
years of follow-up. 
Results: All subjects kept moderate level of regular physical activity dur- 
ing this pedod, and laboratory findings did not show any difference between 
the studies. Maximal oxygen consumption at the follow-up study was 22 
± 4 ml/min/kg; 17 subjects (77%) achieved _> 100% of their age-predicted 
VO2 max. While 2 subjects newly developed hypertension during 5 years, 
24-hour ambulatory blood pressure monitoring did not show any differences 
between HT and NT subjects with anti-hypertensive medication (134 / 78 vs 
123 /68 mmHg). In echocardiographic findings, the calculated LV mass was 
significantly greater in HT than in NT subjects at the initial stage (229 ± 50 vs 
191 ± 31 g, p = 0.05) and the follow-up studies (237 ± 61 vs 188 ± 25 g, p = 
0.03). However, left ventricular ejection fraction did not show any significant 
difference between the subjects (HT 77 ± 7 vs N T 80 ± 7%; at baseline, and 
HT 72 ± 9 vs NT 74 ± 7%; at follow-up). The VCP score was significantly 
lower in HT than in NT subjects (2356 ± 171 vs 2149 ± 206; p = 0.04) in the 
follow-up study. 
Conclusion: Even in eldedy subjects who appear physically well, neu- 
robehavioral deterioration may be caused by hypertension. It is necessary to 
control blood pressure not only to prevent cardiovascular events, but also to 
preserve normal neurobehavioral function. 
POSTER 
Metabol ic  and Behaviora l  Risk Factors 
Tuesday,  March  9, 1999, 9:00 a .m. -11 :00  a.m.  
Mor ia l  Convent ion  Center ,  Hall F 
P resentat ion  Hour:  9:00 a .m, -10 :00  a.m.  
1137-116J The Bezafibrate Infarction Prevention (BIP) 
Study: CHD and Cancer Deaths in 9050 Male 
Coronary Patients During 5.1 Years. Significance 
of Trends in Terti les of  Lipids and Fibrinogen 
Levels 
Eran Graft 1,2, Sara Schwartz 1 , Shoshana Schwartz ~ , Daniel Brunner ~ . For 
the B/P Study Group; l /nstitute of Physio/ogica/ Hygiene, Wo/fson Medical 
Center; 2 Te/-Aviv Sourasky Medica/ Center, Department of C/inica/ 
Biochemistry,/srae/ 
Background: CHD and cancer morbidity and mortality are correlated with 
cholesterol levels. The aim of the study was to assess the relationships 
between serum lipids, lipopreteins, apelipoproteins and plasma fibrinoger~ 
levels and mortality from CHD or cancer, in a large cohort of male Pts with 
established CHD, aged 45-74 years, over 5.1 years. 
Methods: In the prerandomization phase of the BIP Study, 12573 male 
coronary Pts were examined. We assessed the age- standardized CHD and 
cancer mortality per 1000 Pts in tertiles of baseline lipids and fibrinogen 
values, and calculated the significance of trends. 
Results: Mortality rates/1000 Pts, in tertiles of the measured analytes, 
and the significance of trends, are summadzed in the following table: 
CHD mortality/1000 Pts Cancer mortality/lOOO Pts 
Tertiles I n I1 p Value I n ill p Value 
Chol 11.0 11.0 14.6 <0.001 1 4.4 3.4 3.0 <0.004 ,[ 
LDL 10.5 12.7 12.7 <0.01 1" 4.3 3.5 2.9 <0.004 ,[ 
HDL 14.8 12.1 11.1 <0.001 $ 4.2 3.4 3.2 <0.034 ,. 
Trig 10.0 11.4 16.0 NS 3.8 3.8 3.3 NS 
Chol/HDL 9.5 11.2 16.4 <0.001 '~ 3.7 3.4 4.0 NS 
ApoA I 12.8 10.6 8.7 <0.029 ~ 5.3 3.2 2.0 <0.001 ~L 
ApoB 9.0 10.0 14.0 NS I" 3.6 3.2 3.8 NS 
Fib. 7.7 11.9 19.4 <0.001 T 1.4 3.6 4.7 <0.001 
Conclusions: In the studied population, the trends in CHD mortality are 
significant except of the trends in Trig and apoB, while in cancer mortality 
the trends are significant in Chol, LDL, HDL, apoAp and fibdnogen levels. 
Whereas the mechanisms of the involvement of the lipids and fibrinogen in 
CHD were intensively investigated, the mechanisms of their involvement in 
cancer morbidity and mortality are not yet known. 
/ 11 37-11 7 t The Impact of Impaired Glucose Tolerance and 
L / Diabetes Mellitus on Large Artery Structure and 
Function: The Strong Heart Study 
Mary J. Roman, Richard B. Devereux, Richard R. Fabsitz, Thomas Welty, 
Elisa T. Lee, Dawn Fishman, Barbara V. Howard. Come//University Meal±ca; 
College, New York, NY, USA 
Background: Although diabetes (DM) is a well-established risk factor for 
vascular disease, the presence and extent of vascular disease in impaired 
glucose tolerance (IGT) are less well known. 
Methods: Carotid artery structure (wall thickness [IMT], diastolic diameter, 
atherosclerosis [discrete plaque]) and function (stiffness index [beta]) were 
compared in 827 participants in the Phase 3 Family Study of the Strong Heart 
Study of cardiovascular disease in American Indians. 58.4% had normal 
glucose tolerance [NL; age = 36 ± 14; 47% men], 13.4% had IGT (age = 41 
± 14; 38% men), and 28.2% had DM (age = 51 ± 14; 38% men). 
Results: In compadson to NL and IGT, DM was associated with sig- 
nificant increases in carotid artery IMT, diameter, presence and extent of 
plaque (number of involved segments), and beta. All differences remained 
significant after controlling for age, blood pressure and serum cholesterol. 
In contrast, IGT was similar to NL in IMT, diameter, presence (15% in both 
vs. 50% in DM) and extent of plaque. Only beta was significantly increased 
in IGT. Multivariate correlates of atherosclerosis were age, DM (both p < 
0.0005), the presence of hypertension and serum cholesterol (both p < 
0.05). 
Conclusion: DM causes large artery hypertrophy, atherosclerosis, and 
stiffening, all of which may contribute to its association with cardiovascular 
events. IGT is characterized only by arterial stiffening, independent of ele- 
vated blood pressure, which may be an early manifestation of DM-related 
vasculopathy. 
1 18J Is Carot id Ar tery  Int imaI-Medial  Thickness a 
] 
1 37-1 
Marker of Diffuse Atherosclerosis? 
Mary J. Roman, Richard B. Devereux, Richard R. Fabsitz, 
M. Susan Crawford, Elisa T. Lee, Dawn Fishman, Barbara V. Howard. 
Come//University Medica/ Co//ege, New York, NY, USA 
Background: Intimal-medial thickness of the common carotid artery (CCA- 
IMT) is related to cardiovascular (CV) risk factors and morbidity and has 
been postulated to be a marker of diffuse or early atherosclerosis. 
Methods: To examine the validity of this assumption, we related CCA-IMT 
measured in a plaque-free area to CV risk factors and the presence of 
discrete plaque in the extra-crenial carotid arteries (focal thickening > 50% 
of the surrounding IMT) in 1,284 initial participants in Phase 3 of the Strong 
Heart Study, a longitudinal study of CV disease in American Indians (age 48 
± 17; 43% men). 
Results: In univariate analyses, CCA-IMT was most strongly related to 
age (r = 0.59), pulse pressure (r = 0.35), arterial stiffness (beta; r = 0.32) and 
fasting glucose (r = 0.25), all p < 0.01. In multivariate analyses, age, glucose 
(both p < 0.001) pulse pressure and beta (both p < 0.05) were independently 
related to IMT, whereas the presence of plaque was not (p = 0.22). When 
IMT _> 1.0 mm was examined as a marker of diffuse atherosclerosis, only 
age, but not other CV risk factors or presence of plaque (p = 0.53), were 
independently associated. 
Conclusions: Although CCA-IMT, determined as a discrete measure- 
ment (rather than a scoring system which may incorporate plaque) is related 
to C'V risk factors, it is not associated with the presence of discrete athero- 
sclerosis independent of age. This finding has implications for the use of 
CCA-IMF as a measure of atherosclerosis in clinical research. 
1137-11 9 /  Factor  VII and Factor Xll Plasma Levels Are 
J Elevated in Healthy Offspring of Men With 
Premature Myocardial Infraction 
Thomas Makris, Panagiota Krespi, Antonios Hatzizacharias, 
Emmanuel Chronakis, Catedna Tsoukala, Fitippos Triboskiadis, 
Michael Kyriakidis. Cardiology Dept., 2nd Reg. BTC, Haemost. Lab., Laiko 
Hospital, Greece 
Background: A family history of premature myocardial infraction (PMI) con- 
sists an independent cardiovascular risk factor (F) while elevated FVII and 
FXII plasma levels are associated with increased cardiovascular mortility 
and mortality. Aim of the study was to determine FVII and FXII plasma levels 
in healthy offspring of men with PMI (<55 yrs) and to compare these find- 
ings, with those of healthy offspring without a family history of cardiovascular 
disease (CVD). 
Methods: Sixty eight (32 M, 36 F) mean age (MA) 18.2 ± 2.75 yrs and 
Body Mass Index (BMI) 22.5 ± 3.3 healthy offspring of men with PMI (group 
A) and 32 (15 M, 17 F) MA 18.45 5:2.46 and BM121.8 ± 3.6 healthy offspring 
without family history of CVD, diabetes mellitus or hypertension were studied. 
Fasting FVII and FXII plasma levels were determined in the whole population 
(ELISA method). 
Results: The results are shown below (p < 0.0001 p < 0.01): 
FVII % FXII % 
Group A 163.6 4- 36.9 82 ± 21 
Group B 106.2 ± 31.9 72 ~- 17 
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Conclusions: Our results suggest that fasting FVII and FXII plasma levels 
are significantly increased in healthy offspring of men with PMI compared 
with those of healthy offspring without a family history of CVD. This finding 
may be another mechanism which enhances the cardiovascular risk. 
I i "  i'Et~ i' t'o Change $"mo¢i'ng ~'ehavfor fn 
] 
~7-  t~offva~i'o n 
Patients With Coronary Artery Disease in 
Europe: The Euroaspire Survey 
Doden F.M. van Berkel, Dirk De Bacquer' David A. Wood. On behalf of the 
Euroaspire Working Group; Heartcenter, University Hospital Rotterdam, 
The Netherlands; National Heart Lung institute, London, UK 
Background: The aim of this study was to register smoking behavior and 
change smoking behavior after a coronary event. 
Methods: Euroaspire is a survey on secondary prevention in patients 
with CAD in nine European countries. Patients were included with previous 
admission for CABG, PTCA, myocardial infarction or ischemia. Data were 
collected from records of 4863 patients of whom 73% were interviewed 1.6 
:E 0.7 years following their hospitalization. 
Results: Pre-event smoking behavior was known in 82% patients of 
whom 34% were current smokers. In only 35% of the pre-event smokers 
smoking status was recorded after the event. At interview, 560 patients (59%) 
had stopped stuck{no after the coronary event. They had less often a history 
of CA/], were mostl~ found in the myoca~iat infarction group and had (ess 
cffen received an advice to stop smoking or had looked for additior~a( he(p 
than persistent smokers. Furthermore, almost all quitters had tried to stop by 
to'm~ a~s'fir~er~ce. ~t>% ~ '~he per~)s~e~'~ smv~ers h~0 ma~e a~ a~emp~ o s~op 
i~n'fne pas'L 'oUt more o1'ten 'or re~uc'~lon or filch[me re~lacemer~t "~nerapy. 
Conclusion: 34% of the patients smoked pre-event. After a cardiac event 
who were more often chronic CAD patients, showed their motivation to try to 
~a~erits ]s a~'~se~. 
[1137-121 Polymorphism of Angiotensin Converting 
Enzyme ~Tene Kd~ct~s Ohdworadiy  ~35nhogen 
Plasma Levels in Healthy Offspring of Men With 
Premature Coronary Artery Disease 
Thomas ~akns, I-~anag~b~a Kresp~ Anfombs Ratm~'achanas, 
George Stavroulakis, George Anastasiadis, Emanuel Chronakis, 
Chrisostomos Economou, Filippos Triposkiadis, Michael Kyriakidis. 
Cardiology Dept., Laiko Hospital, Greece 
Background: The homogygote deletion (DD) genotype of the Angiotensin 
Converting Enzyme (ACE) gene has been shown to be associated with 
increased risk for coronary artery disease (CAD). Several large studies have 
found slightly higher plasma fibrinogen (F) levels in those with family history 
of CAD. This study examined the possible association between ACE gene 
polymorphism and F plasma levels in healthy offspring of men with premature 
myocardial infarction (PMI). 
Methods: The VD polymorphism of ACE gone was determined in 68 (32 
M and 36 F) healthy offspring of men with PMI aged 18 ± 3 yrs. Twenty-nine 
(44%) had DD genotype (Group A), 27 (40%) had ID genotype (Group B) 
and 12 (16%) had II genotype (Group C). The throe groups are matched for 
age, sex and BMI. Plasma F levels were determined in the whole population 
(ELISA method). 
Results: Plasma F levels were significantly higher in group A than in 
group B or C (345 ± 42 vs. 281 ± 34 vs. 267 ± 25 mg/dl, p ± 0.0001, 
respectively). No significant difference was found between group B and C. 
It is of interest that the incidence of DD genotype was higher in the study 
population. 
Conclusions: These findings suggest that DD genotype of ACE gene 
polymorphism is associated with significantly increased levels of plasma F in 
healthy offspring of men with PMI, indicating another possible mechanism of 
increased cardiovascular risk in this population. 
ORAL  
Clinical Vascular Pathophysiology: 
Endothelium 
Tuesday,  March  9, 1999, 10:30 a .m. -Noon 
Mor ia l  Convent ion  Center ,  Room 207 
1 0:30 a.m.  
[ -~- ]  Endothelial Function and Vitamin C 
Wiifiba~d Maier, Adrian KOng, Lazar Mandinov, Bernhard Meier, Otto 
M. Hess. Cardiology, University Hospital Bern, Switzerland 
ment with various anitoxidants. To evaluate the effect of vitamin C on coronary 
vasomotion, bicycle exercise was used for unmasking endothelial dysfunc- 
tion in patients with coronary artery disease. 
Methods: Vasomotion of angiographicalty normal vessel segments was 
examined in 2 groups of patients with coronary artery disease. The first 
group consisted of 8 patients who received increasing doses of vitamin C 
(10, 20, 50, 100 mg i.c, = dose finding study). Group 2 consisted of 14 
patients who performed exercise during coronary angiography before and 
after administration of 50 mg i.c. vitamin C. At the end of the study, 1.6 mg s.l. 
nitroglycerin was administered. A total of 24 segments (mean cross-sectional 
area, CSA} were evaJuated by quantitat}ve coronary angiograohy. 
Results: In group t (dose finding study} no effect of vitamin C on coronary 
vasomotion was found. In group 2, bicycle exercise was associated with 
vasodilation (+20 ± 3%, p < 0.005 versus baseline exercise). Vasodilation 
3O 
10 
Exercise Exercise NTG 
Conclusions: Vitamin C has no acute effect on coronary vasomotion 
under resting conditions. However, physiologic stress testing after vitamin C 
is associated with an improvement in the vasedilatory response to exercise. 
This suggests that the ant±oxidant effect of vitamin C becomes prominent 
during high flow situations when endothelial dysfunction is unmasked. 
10:45 a.m.  
~83-~ The Effects of Vitamin E on Chronic and Acute 
Endothelial Dysfunction in Smokers 
Thomas Neunteufl, Ute Priglinger, Sandra Heher, Manfrod Zehetgruber' 
Kurt Huber' Gerald Maurer, Franz Weidinger 1 , Karam Kostner. Depts. of 
Cardiology, University of Vienna; 1 University of Innsbruck, Austria 
Background: Endothelial dysfunction in chronic smokers as well as transient 
impairment of endothelial function after acute cigarette smoking have been 
described. Whether chronic and/or acute impairment of endothelium-depen- 
dent, flow-mediated vasodilation (FMD) in the brachial artery can be restored 
and/or preserved by the ant±oxidant vitamin E is unknown. 
Methods: Twenty-two healthy male smokers (mean ± SD, 23 ± 9 
cigarettes per day) were randomized to receive 6001U vitamin E per day 
(n = 11, age 28 ± 6 y) or placebo (n = 11, age 27 ± 6 y) for 4 weeks. FMD 
and endothelium-independent nitroglycerin-induced ilation (NMD) were as- 
sessed in the brachial artery using high resolution ultrasound (7.5 MHz) at 
baseline and after 4 weeks of treatment. Subjects stopped smoking 2 hours 
prior to the examinations. At the end of the treatment period a third scan was 
obtained 15 minutes after smoking a cigarette (0.6 mg nicotine, 7 mg tare) to 
estimate transient impairment of FMD. 
Results: FMD at baseline was similar in both study groups and did not 
change significantly after therapy for 4 weeks. After acute smoking FMD was 
preserved in the vitamin E but not in the placebo group (6.3 ± 3.3 vs 2.8 ± 
3.5%, p = 0.025). Longitudinal changes of FMD after acute smoking were 
significantly different between the vitamin E and the placebo group (-0.6 ± 
2.8 vs -4.4 ± 1.4%, p = 0.0008) and inversely related to the decrease of 
thiobarbituric acid-reactive substances (ATBARS) as an index of oxidative 
stress reduction (r = -0.62, p = 0.005). NMD did not differ between study 
groups at baseline and after 4 weeks of therapy. 
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Conclusion: These results demonstrate that vitamin E can preserve en- 
dothelial function after acute smoking but cannot restore chronic endothelial 
dysfunction within 4 weeks in healthy male smokers. 
11:00 a.m. 
[ -8 -~~ The Effects of Withdrawal of Chronic Estrogen 
Therapy on Brachial Artery Vasoreactivity in Women 
with Coronary Artery Disease 
Diane Z. Greiner, Bradley E. Person±us, Thomas C. Andrews. Wilford Hall 
Medical Center, Lackland Air Force Base, Texas; University of Texas 
Southwestern Medical Center, Dallas, Texas, USA 
Background: The aim of this study was to determine the effects of withdrawal 
of estrogen on vascular reactivity in chronically supplemented females with 
coronary artery disease. 
Methods: We recruited forty postmenopausal women with a history of 
coronary artery disease who had been receiving chronic estrogen replace- 
ment with conjugated estrogens, with the average duration of therapy 17 
years. During estrogen therapy, measurement of brachial artery diameter 
and blood flow were performed with high-resolution ultrasonography under 
baseline conditions, during hyperemia, and after sublingual nitroglycerin ad- 
ministration. Estrogen therapy was discontinued for 3 weeks, and brachial 
ultrasonography was repeated under identical experimental conditions. 
Results: After withdrawal of estrogen, the percent change in brachial 
artery diameter (compared with baseline) declined by 24% during reactive 
hyperemia (p = 0.117) and increased by 18% after nitroglycerin administration 
(p = 0.154). After estrogen withdrawal, there was a 64% increase in brachial 
artery flow during reactive hyperemia (p < 0.001). After adjustment for these 
differences in hyperemic flow, we found a 42% deterioration in flow-mediated 
vasodilation after estrogen withdrawal (p = 0.03). 
Conclusion: This study suggests that withdrawal of oral estrogen therapy 
is associated with a deterioration in endothelial function in postmenopausal 
women with coronary artery disease. Our data also suggest that withdrawal 
of estrogen results in enhanced hyperemic flow. 
11:15 a,m.  
~ - ]  Purple Grape Improves Juice Flow-Mediated 
Vasodilation in Patients with Coronary Artery 
Disease 
James H. Stein, Jon G. Keevil, Susan Aeschlimann, John D. Folts. 
University of Wisconsin Medical School, Madison, Wl, USA 
Background: Flavonoids in red wine and purple grape juice are potent anti- 
oxidants and platelet inhibitors that induce endothelium-dependent vasodila- 
tion, in vitro. We determined the effect of grape juice on endothelial function, 
measured by flow-mediated vasodilation (FMD) of the brachial artery, in 
patients with coronary artery disease. 
Methods: Fifteen adults with angiographically documented coronary 
artery disease (mean ± SD age 62.5 ± 12.7 years, 12 males) ingested 
7 cc/kg/day of grape juice (Welch's 100% Concorde) for 14 days. FMD was 
measured using high-resolution brachial artery ultrasonography (7.5 mHz, 
Hewlett-Packard, Andover, MA). Images were stored digitally and analyzed 
in triplicate using proprietary software (MedArchive Viewer 1.5a, Secure 
Archive, Longmont, CO). 
Results: At baseline, FMD was impaired (2.1 i 2.9%). After ingestion of 
grape juice, FMD increased to 6.4 ± 4.7% (p = 0.003). In a linear regression 
model that included age, baseline tipids, and use of lipid-lowering and ant±ox- 
idant therapies, the grape juice effect on FMD remained significant (mean A 
FMD 4.2 ± 3.6%, p < 0.001). 
Effect of Purple Grape Juice on 
Flow-Mediated Vasodilation 
10.o sn  
~.o mean 
00 . . - . 
5'0 ] PI~ po~ 
Conclusions: Short-term ingestion of grape juice improves FMD in pa- 
tients with coronary artery disease. Improved endothelial function may be a 
mechanism by which flavonoids and grape products reduce coronary events, 
independent of alcohol content. 
11:30 a.m.  
83~3~-5~ Relation of Inflammation to Vascular Function in 
Patients with Coronary Heart Disease 
Juha Sinisalo, Johanna Paronen, Kimmo J. Mattila, Martti T. Syrj&l~i, 
Georg AIfthan, Timo Palosuo, Markku S. Nieminen, Out± Vaarala. Helsinki 
University Central Hospital and National Public Health institute, Helsinki, 
Finland 
Background: Endothelium plays a pivotal role in the regulation of vascular 
relaxation. Inflammation may in turn induce endothelial dysfunction and thus 
increase the risk of atherothrombosis. 
Methods: We investigated 31 men with angiographically verified coro- 
nary heart disease, aged 57.7 ± 5.3 years, in regard to endothelium- 
dependent, acetylcholine-induced, and to endothelium-independent, sodium 
nitroprusside-induced vasodilatation in the forearm vasculature by strain- 
gauge plethysmography. Logistic regression analysis served to determine 
the relation between forearm vascular function and the inflammatory factors 
measured, concentration of C-reactive protein, subtypes of peripheral blood 
T-lymphocytes, and other factors affecting endothelial function (body weight, 
lipoprotein and glucose levels). 
Results: Concentration of C-reactive protein was an independent deter- 
minant of endothelium-dependent vascular function (p < 0.001 for acetyl- 
choline 3 #g/min, p = 0.01 for acetylcholine 15 ,~zg/min). Other determinants 
of endothelium-dependent vascular dysfunction were CD8-1ymphocytes ex- 
pressing ICAM-1 (p = 0.001), antibodies to oxidized low-density lipoprotein 
(p < 0.001), and body weight (p = 0.007). 
Conclusions: The present data showed an association between inflam- 
matory nsk factors linked to atherothrombosis and endothelial dysfunction 
in coronary heart disease patients. It is possible that endothelial dysfunction 
in coronary heart disease patients is related to the chronic inflammation or 
infection coexisting with atherosclerosis. 
11:45 a.m.  
~6~ Quinapril Restores Endothelial Dysfunction in 
Patients With Essential Hypertension Through 
Independent Mechanisms on Plasma Bradykinin 
Increases and Blood Pressure Reductions 
Akimi Uehata, Bonpei Takase, Toshihiko Nishioka, Katsuhiro Kitamura, 
Isojima Kazushige. Self Defense Forces Central Hospital and National 
Defense Medical College, Tokyo, Japan 
Background: Recent study has shown that Quinapdl (QPL), an ACE in- 
hibitor with high tissue-binding affinity, improved coronary endothelial func- 
tion in CAD patients (Pts). However, the precise mechanisms are unknown. 
We investigated whether QPL improves endothelial function in Pts with es- 
sential hypertension (EHT) by inhibition of bradykinin (BK) breakdown or by 
reductions in blood pressure (BP). 
Methods: We studied 16 EHT Pts treated with QPL (20 mg/day) and com- 
pared with 10 Pts treated with nitrendipine (10 mg/day). We used high resolu- 
tion ultrasound to measure flow-mediated dilation (FMD), and NTG-induced 
dilation (NTG-D) of the brachiat artery. FMD and NTG-D were evaluated 
before and after 12 weeks of each study drug. Since tissue BK levels can not 
be measured, plasma levels of BK were measured at the time of the study 
by RIA. 
Results: 
Quinapril Nitrendipine 
Before After Before After 
FMD (%) 1.9 ± 2.7 6.7 ± 3.6 TM 2.0 =L 2.9 2.0 ± 3.6 
BK (pg/ml) 10.4 ± 3.1 12.7±3.7" 11.4 ± 1.7 12.0 ± 4.9 
BPs reduction (mmHg) -19 ± 18"* -18 ± 20"* 
(* p < 6.05, "" p < 0.01 vs. Before. # p < 00.1 v& Nifrendipine. mean ± SD) 
Before the treatment FMD was impaired in both groups, while NTG-D was 
intact. Although the degree of reductions in BP was similar, only QPL group 
showed improved FMD. Plasma levels of BK increased significantly only in 
QPL group. However, the increases in plasma BK levels did not correlate 
with the increases in FMD (r = 0.14). 
Conclusion: Endothelial dysfunction in EHT Pts was restored only by 
QPL. Since reductions in BP and increase in plasma BK did not modulate 
this beneficial effect, inhibition of a local ACE by QPL might play an important 
role in the amelioration of FMD 
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Tuesoa, y, £vfarch 9", I~ ,  l'0":3ffa.m.-~bon 
Morial Convention Center, Room 222 
10:30 a.m. 
[ l~-0~ Improvement in Walking Distance and Quality of Life 
ih P'erl[0herafKn'ert~al'Oi~ease z)y a ~ i , th t ibna£ 
Product Designed to Enhance Nitric Oxide Activity 
Andrew J. Maxwell, Barbara Anderson. Cooke Pharma, Belmont, CA, USA 
Background: We investigated the clinical effects of a food bar enriched 
with L-arginine and a combination of other nutdents known to enhance the 
synthesis or activity of endothelium-derived nitric oxide in individuals with 
claudication from atherosclerotic peripheral arterial disease (PAD). 
Methods: Using a double-blind placebo-controlled design, 41 individuals 
with symptomatic PAD were randomized to consume either 1 active bar and 1 
placebo; (A1), 2 active bars; (A2), or 2 placebo bars/day (P) for 2 weeks. Each 
active bar contains 4g of L-arginine as well as antioxidant vitamins, niacin 
and isoflavenoids. Pain-free and total walking distances were determined by 
treadmill-testing before and after intervention utilizing the Gardner Protocol. 
Quality of life was measured using the SF-36 Questionnaire. 
Results: Before treatment here were no differences in demographics, 
walking distances or SF-36 scores between the three groups. After treatment 
pain-free walking distance increased 66% in A2 (p < 0.05 vs. P), 21% in A1 
and 18% in P (NS). Total walking distance increased 20% in A2 (p < 0.05 
vs. pre-treatment). A1 ; 15% and P; 4%, (NS vs. pre-treatment). The physical 
functioning composite score of the SF-36 also improved from 58 ± 20 to 
70 ± 20 (p < 0.05 vs. pre-treatment). Laboratory values were unaffected. 
The bars were well tolerated and no significant adverse side-effects were 
reported. 
P(N =14) AI(N= 13) A2 (N = 12) p value 
~, Pain-Free 
Walking Distance (m) 19 ± 38 14 -- 67 100 ± 156" 0.05 
A Total 
Walking Distance (m) 7 J_ 38 28 ± 77 69 :E 108" NS 
• p < 0.05 vs. pre-treatment by paired t-testing 
Conclusion: This form of dietary management may have a role in patients 
with PAD. 
10 :45  a .m.  
J -~-~ Beraprost Sodium, an Effective Treatment for 
Peripheral Arterial Disease: Results of BERCl 2, a 
Randomized, Placebo-Controlled, Double-Blind 
Study 
Bruno Besse, Michel Lievre, Sophie Morand, Fran~oise Dellatolas, 
Jean-Noel Fiessinger, Jean-Pierre Boissel. Hoechst Marion Roussel 
France, Paris; Service de Pharmacologie Clinique, EA643, Lyon, France 
Background: Beraprost sodium (BPS) is an orally stable prostacyclin ana- 
logue which leads to platelet aggregation inhibition and vasodilatation. This 
dual activity makes BPS a very interesting drug in intermittent claudication. 
Methods: After a 4-week placebo (P) run-in phase, patients with stable 
stage II arterial disease were randomized to BPS 40/_zg t.i.d, or P over a period 
of 6 months. The main outcomes were percentage changes from baseline 
at month 6 in pain-free walking distance (ICD), absolute walking distance 
(ACD) evaluated by standardized treadmill and percentage of responders 
(ICD improvement more than 50% and at least in one earlier test in the 
absence of any cv events). Walking distances were compared with the 
Wilcoxon test applied on ratio to baseline and the percentage of responders 
using Fisher's exact test on the ITT population. 
Results: A total of 422 pts (209 BPS, 213 P) were included. 74 pts (32 
BPS, 42 P) prematurely discontinued the treatment. At Month 6, there was a 
significant higher increase in ICD and ACD in the BPS group than in the P 
group and a significantly higher rate of responders free of CV event compared 
to P. 
Improvement a  Month 6 BPS (N = 209) P (N = 213) p-value 
ICD (geometric mean increase, %) 81.5 52.5 0.001 
ACD (geometric mean increase, %) 60.1 35.0 0.004 
Cardiovascular events N (%) 10 (4.8) 19 (8.9) 0.123 
Responders % 43.5 33.3 0.036 
QOL is significantly improved in BPS group compared to P (p = 0.049). 
The most frequent adverse events with BPS were headaches and flushes. 
At the end of the 6 months, patients were proposed to go on with BPS 
tolerability of BPS. Moreover, ICD increased by 130% at Month 12 (n = 131) 
andlSy 178~o at+Mbntfi Z4+(n = 46). 
Conclusion: BPS is a safe and effective treatment for stage II arterial 
disease. It improves QOL, increases walking distances with a significantly 
higher rate of responders free of CV event compared to P after 6-month 
treatment 
,4,~.L,'19 a'., ~. 
[~-~ Phase 2 Trial of a Novel Prostacyclin Analogue, 
UT-15, in Patients With Severe Intermittent 
Claudication 
Emile R. Mohler, Bruce Klugherz, Robert Goldman, Alfred P. Fishman, 
Michael Wade 1 , Chandra M. Sehgal. University of Pennsylvania School of 
Medicine, Philadelphia, PA; ~ United Therapeutics Corp, Research Triangle 
Park, NC, USA 
Background: Prostacyclin is a vasodilator and inhibitor of platelet aggre- 
gation produced by the endothelium. Because of these properties, several 
prostacyclin analogues are being evaluated in patients with peripheral artedal 
occlusive disease. The safety and efficacy of a novel, long-acting prostacyclin 
analogue, UT-15, were studied in patients with severe intermittent claudica- 
lion. 
Methods: Seven patients with stable intermittent claudication considered 
Fontaine classes lib-Ill were admitted to the hospital for intravenous infu- 
sion of UT-15. A symptom-limited dose-escalation protocol beginning with 
placebo and then increasing doses of drug (60 minutes at each dose step) 
was begun, followed by a 2 hour maintenance phase at the maximum welt- 
tolerated infusion rate. Lower limb blood flow hemodynamic measurements 
were assessed serially with ultrasound, segmental arteriat pressures and 
pulse volume-recording amplitudes. 
Results: Common side effects at peak dose included headache and 
nausea. No serious adverse events occurred during hospitalization. The 
optimum infusion rate was 10 ng/kg/min in most patients. The mean (&: 
SEM) tower limb blood flow velocity, of all patients combined, increased by 
33 + 10% (p = 0.016) without significant change in blood pressure or heart 
rate. Arterial blood flow in the ankle became apparent during maintenance 
infusion in 2 of 4 patients without ultrasound detectable blood flow at baseline. 
Conclusion: UT-15 is a well-tolerated drug that increases arterial blood 
flow velocity in patients with severe intermittent claudication. A phase 3 study 
is planned to determine clinical efficacy. 
11:15 a .m.  
[ -8 -4~ Analysis of Efficacy and Costs of Severe Intermittent 
Claudication Treatment With PGEI i.v. infusion: 
A Short Term vs Long Term Protocol 
Marco Bucci, Maria R. Cesarone 1 , Maria T. De Sanctis 1 , Domenico Di 
Ctemente, Piero lacobitti, Lucrezia Incandela ~ , Giuseppe Laurora ~ ,
Amleto Nepa, Francesca Spitaleri, Marco Zimarino, Andrew N. Nicolaides 2, 
Gianni Belcaro ~ , Giuseppe Martines. Medical Therapy, University of Chieti; 
I Angiology Center, "Pierangeli" Clinic, Pescara, Italy; 2St Mary's Hospital, 
London, UK 
Backgound: Prostaglandins E~ (PGE1) are more and more used in the 
medical treatment of severe intermittent claudication, but their therapeutic 
protocols are generally too long for patients (pts.) and too expensive for the 
community. 
Methods: To confirm PGEI's efficacy and safety and to analyze the costs 
of the different treatment protocols, we suggested a new "short term protocol" 
(STP) compared with the classic "long term protocol" (LTP) in a randomized 
20-week study including 109 pts., divided into 2 groups clinically [average 
total walking distance (TWD) of 65 4- 8 in (range 20-109)], age (62 ± 8 yrs) 
and sex (M = 60.4%) matched. LTP (PGE1 60 /~g/die, 5 days each week, 
for 4 weeks and then twice a week for other 4 weeks) was performed in 55 
pts. The remaining 54 pts. were treated with STP (60/~g BID for two days 
alone every 4 weeks for 12 weeks). Treadmill tests were performed at the 
inclusion, at the beginning of each phase and at the end of 20 m week. In both 
groups similar training plan was used, with reduction in risk factors levels. 
Results: Intention-to-treat analysis indicated an increase in TWD at 4 th 
week (101.5% in STP vs 78.3% in LTP, p < 0.05), at 8 rh week (260.9% 
STP vs 107.3% LTP, p < 0.05) and at 20th week (351% STP vs 242% 
LTP, p < 0.02), without serious drug-related side effects and with local, mild 
adverse reactions in 7% of the LTP treated subjects vs 5% of the STP ones. 
The analysis of costs showed significant difference between the treatment 
protocols: total LTP cost $ 6600 vs $1900 (= 28%) of STP; the amount to 
improve 1 meter the basal TWD was $ 42 with LTP vs $ 8.5 with STP (p < 
0.02) and to improve 100% the TWD was $ 2700 with LTP vs $ 550 with STP 
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(p < 0.02). In both protocols, the amount of PGE1 (infusion and operative 
costs included) was about 25% of total treatment costs. 
Conclusions: In any case, PGE1 treatment shows good efficacy and 
tolerability. However, STP appears very safe and easier to do than LTP. With 
STP less time is spent in in-hospital infusion, less time is made away with 
job and more time can be spent in the exercise program. Thus, STP is more 
pleasing for pts, speeds up rehabilitation and, reducing costs, may be used 
in a larger number of not-specialized units. 
11:30 a.m.  
~-~ Serum Hepatocyte Growth Factor as a Possible 
Indicator of Atherosclerosis in Patients With 
Peripheral Arterial Disease 
Yuji Matsumoto, Yuji Yoshitomi, Shunichi Kojima, Miehiko Yano, 
Toshihiko Sugi, Masao Saotome, Michiko Endo, Morio Kuramochi. Tohsei 
National Hospital, Shizuoka, Japan 
Background: Hepatocyte growth factor (HGF) is a multifunctional factor im- 
plicated in tissue regeneration, wound healing, and angiogenesis. However, 
its pathophysiological significance has not been established in patients with 
peripheral arterial disease. 
Methods: We measured serum HGF concentrations in 38 patients wilh 
peripheral arterial disease. After blood sampling, 36 patients underwent 
arteriography. We also measured 40 normal subjects who remained free of 
vascular disease, renal failure, or hepatic failure, Serum HGF concentrations 
via peripheral venous access were measured by ELISA. 
Results: Patients with peripheral arterial disease showed elevated serum 
HGF concentrations compared with normal subjects (0.46 ± 0.26 versus 
0.19 ± 0.04 ng/ml, p < 0.001). Risk factors, such as hypertension, diabetes 
mellitus, hypercholesterolemia, and smoking, and vascular complications 
did not affect the serum HGF concentrations. However, the serum HGF 
concentrations were higher in patients with critical ischemia than in those 
with intermittent claudication (0.56 4- 0.37 ng/ml, n = 16 versus, 0.39 J: 0.12 
ng/ml, n = 22, p < 0.05). Moreover, the serum HGF concentrations in patients 
with collaterals differed from those in patients without collaterals (0.52 ± 0.31 
ng/ml, n = 23 versus 0.35 ::E 0.10 ng/ml, n = 13, p = 0.01). 
Conclusions: Our data demonstrate that circulating HGF increases in 
patients with peripheral arterial disease, and correlates with severity of symp- 
toms and collateral circulation. HGF may serve as a marker for underlying 
atheroscterosis of peripheral arteries and that higher levels correlate with 
greater extent of disease. 
11:45 a.m. 
~-0~ Value of Exercise Treadmill Testing for the 
Assessment of Functional Capacity Following 
Percutaneous Revascularization 
Guenter Rauh, Peter Vale, William Irwin, Claudia Diehl, Kenneth Rosenfield, 
Robert M. Schainfeld. St. Elizabeth's Medical Center, Boston, MA, USA 
Introduction: Percutaneous revaseularization procedures (PR) are used to 
improve exercise performance of patients with peripheral arterial disease 
(PAD). The increase in the ankle-brachial index (ABI) of greater than 0.1 
is the accepted objective basis for defining "hemodynamic success". While 
non-invasive vascular tests, such as the ABI accurately diagnose PAD, none 
correlate well with the degree of exercise impairment in pts with claudication. 
It was the purpose of this study to evaluate the role of exercise testing to 
assess functional outcome after PR. 
Methods: We studied 42 pts with severe claudication (25 males, 17 
females, mean age 58 years, ranging from 41 to 79 years) who were treated 
with PTA/stent in the lilac (n = 23) and PTA in the SFA (n = 19) arteries. In all 
42 pts technical success was achieved based on the angiographic result ancl 
significant hemodynamic improvement. Baseline ABI and graded treadmill 
exercise testing were performed in all pts, pre and post-revasculanzation. 
Results: 42 pts (100%) had clinical success after PR as defined by an 
improved absolute claudication distances (ACD) with an average increase 
of 181 m ranging from 41 m to 210 m. In 35 pts (83.3%) an ABI increase of 
0.10 (0.11 to 0.39) was documented post-PTA. The 7 pts (16.7%) with <0.1 
ABI increase was following successful lilac stenting. 
Conclusion: 1) In pts with claudication who have undergone successful 
revascularization, the lack of an ABI increase of >0.1 may not be associated 
with clinical failure. 2) Technical successful revascularizations resulted in an 
objective improvement in the physiological status of all pts, despite a lack 
of hemodynamie improvement in some. 3) Therefore, a graded treadmill 
exercise test may be a more accurate instrument to assess the results of 
percutaneous revascularization as compared to ABIs. 
POSTER 
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11161-112 1 Apoptolysis: A Novel Mechanism for Plaque 
Ulceration and Rupture 
Philip F. Binkley, Nicanor Motdovan, Gregory M. Eaton, Arthur Strauch, 
Pascal Goldschmidt-Clermont. Ohio State University Medical Center, 
Columbus, Ohio, USA 
Although atheroscterotic plaque rupture is believed to be an antecedent to 
acute arterial thrombosis, the mechanism for this acute rupture remains in- 
completely defined. We examined the progressive histomorphometric hanges 
characteristic of the arterial vasculature in the rapid pacing model of ven- 
tricular failure to isolate mechanisms of lesion formation which are not de- 
pendent on lipid loading. Canines undergoing rapid ventricular pacing for 
four weeks were found to develop neointimal proliferation identical to that 
seen in artherosclerotic vessels and which were not seen in sham controls. 
TUNEL staining was diffusely and intensely positive for apoptosis throughout 
the entire neointima of the paced canine, but was not seen in sham controls, 
Co-labeling of alpha-actin showed that the apoptotic cells were of vascular 
smooth muscle origin, and positive for pur alpha/pur beta, a putative tran- 
srepressor of alpha actin typically expressed only in non-muscle cells. In 
this non-ischemic model of ventricular failure, neointimal esions are formed 
which are identical to those observed in atherosclerosis and are comprised 
of pheotypically transformed vascular smooth muscle cells which are syn- 
chronized to enter into a phase of apoptosis promoting destruction of the 
superficial neointimal ayer. This process of "apoptolysis" constitutes a novel 
mechanism by which plaques destabilize, ulcerate, and ultimately initiate 
arterial thrombotic occlusion. 
1161-113 ] Cytotoxic Effect of Adherent Monocytes on 
7 
Aortic Smooth Muscle Cells: An In Vitro Model of 
the Medial Degeneration in Vasculopathies 
Thomas P. Archer, Pascal J. Goldschmidt-Clermont, Clay B. Marsh, Nieanor 
I. Moldovan. Ohio State University Medical Certer, Columbus, OH, 43210, 
USA 
Background: The mechanism of medial degeneration thai is associated 
with, or even precedes, the neointima formation in vasculopathies like ath- 
erosclerosis and coronary allograft vasculopathy, is poorly understood. In 
vivo data points toward a process where monocytes/macrophages directly 
or indirectly damage the smooth muscle cells (SMC) of the media. 
Methods: We coincubated human aortic SMC with purified mononuclear 
cell preparations derived from human peripheral blood, further ennched in 
monocytes (MC) by FC receptor binding to human IgG. SMC were plated 
either on plastic, glass or rat tail collagen I (pretreated with immobilized IgG), 
at subconfluency. MC were added to the plated SMC and allowed to interact 
overnight with or without phytohemaglutinin (PHA), to optimize the interaction 
between cell types, and/or cycloheximide (CH). CH is believed to promote 
Fas-mediated apoptosis. 
Results: In these conditions, we observed a cytotoxic effect of MC on 
SMC, resulting in 30% apoptosis as detected morphologically and with An- 
nexin V (AV)/Propidium Iodide (PI) assay, and analyzed by fluorescence 
microscopy, as well as flow cytometry. This is in contrast o only 7% apopto- 
sis in the absence of these conditions. 
Conclusion: We conclude that SMC killing by MC is consistent with 
a process of "suicidal cytotoxicity" where apoptotic MC induce death of 
sensitized SMC, perhaps by Fas ligand. 
I l l  61-1141 ICAM-1 Precedes Up-Regulation the Remodelling of Collateral Arteries (Arteriogenesis) 
Dimitri Scholz ~ , Britta Engelhardt 2, Alexandra BONer, Wolfgang Schaper. 
Dept. of Experimental Cardiology: IDepartment of Thoracic and 
Cardiovascular Surgery; 2Dept. of Molecular Cell Biology, 
Max-Planck-lnstitute, Bad Nauheim, ER. Germany 
Background: In previous studies we have shown that monocytes play a 
key role in the initiation of the arterial remodelling. Endothelial ICAM-1 is 
known to adhere to/12-integrins on the monocyte membrane. Therefore, we 
investigated the participation of ICAM-1 in arteriogenesis. 
Material: 8 New Zealand rabbits, 9 C57BL/6J (wild type) mice, 4 ICAM-1 
- / -  mice, 
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Methods: In rabbits and mice one femoral artery was occluded. Four 
rdlce were ~rea~e~ every "routtn ~av v/Nn "tne 'e/odKm9 an~l:l~A'tv~-~ a 'toody 
YN1-1.74. Development of the collateral arteries in mice was monitored by 
infrared thermography comparing the occluded vs. non-eccluded leg. Hind 
limbs were perfusion fixed with formaldehyde and filled with gelatine-BaSe4 
[or angrography. Co~?a~era~ vessels were harvested under a stereom'rcroscope 
and s*,udi~ using imm~r~of~,uorescence, ~igh~- and e~ectror~ m~,crescopy. 
Results: In rabbits monocyte accumulation around growing collateral ar- 
teries was found in the same time window as the expression of ICAM-t: 
12-48 h after occlusion of the femoral artery. In mice the temperature dif- 
ference between operated and non-operated leg, was 2-3~C immediately 
after occlusion, then time-dependently decreased in control, but not in the 
ICAM-1 - / -  and YN1-1.74 treated group, that correlated with the stunted 
development of the collateral arteries in these groups. 
Conclusion: ICAM-1 plays a significant role in collateral remodelling 
confirming the hypothesis that arteriogenesis takes place in an environment 
of inflammation. 
1161-115]  Acetylsalicylic Acid Inhibits the 
J Cytokine-lnduced Up-Regulation of 
Pro-Inflammatory Adhesion Molecules on 
Vascular Endothelial Cells 
M. Wede, M. Raffery, P. Salbach, T.J. Dengler. Department of Cardiology, 
University of Heidelberg, Germany 
The protective effect of acetylsalicylic acid (ASS) in coronary artery disease 
has been attributed to the inhibition of platetet aggregation. Recent data 
now indicate an inhibitory effect of ASS on the activation of the transcription 
factor NFKB. It was hypothesized that ASS might be able to influence the 
expression of NFKB-regulated adhesion molecules on vascular cells. In this 
study we investigated in vitro the effect of ASS on the cytokine-induced ex- 
pression of adhesion molecules intracellular adhesion molecule-1 (ICAM-1), 
vascular adhesion molecule-1 (VCAM-1) and E-selectin (ELAM) on human 
umbilical endothelial cells. Antigen expression was quantified by flow cytom- 
etry. ASS (1 mM) almost completely attenuated the tumornecosis factor-e 
(TNF-c~), lipopolysaccaride (LPS) and intedeukin-4 (IL-4) induced expression 
of ICAM-1 after 24 hours. Moreover the up-regulation of VCAM-1 through 
IL-4 and ELAM through TNF-c~ was significantly inhibited by ASS (1 mM) 
after 24 hours. 
Cytokine Target anigen Mean fluorescence (expression) 
basal + cytokine + cytokine/ASS 
TNF-c~ ICAM-1 7.1 30.3 11.7 
( 10 U/ml) 
LPS ICAM-1 23.2 72.6 29.4 
(10 U/ml) 
IL-4 ICAM-1 27.8 50.4 29.9 
(250 U/ml) 
IL-4 VCAM-1 10.6 55.5 24.8 
(250 U/ml) 
TNF-ct ELAM 1.7 4.1 1.9 
(10 U/mb) 
This data show a significant reduction of cytokine-induced expression of 
pro-inflammatory cell surface molecules on endothelial cells by ASS. This 
effect may be mediated by NF,:B inhibition. Hence reduction of inflammatory 
processes in the vessel wall could potentiate the protective effect of ASS in 
coronary artery disease. 
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1162-20 [ Muscarinic and Function in Bradykinin Receptor 
' the Human Coronary Circulation. What Predicts 
Physiologic Coronary Vasomotion? 
Abhiram Prasad, William H. Schenke, Gloria Zalos, Arshed A. Quyyumi. 
NHLBI, N/H, Bethesda, MD, USA 
Atherosclerosis impairs coronary vascular responses to acetylcholine (ACH) 
and to physiologic stress. We investigated whether coronary reactivity during 
pacing is better predicted by muscarinic or bradykinin (BK) B2 receptor 
agonists, and whether isk factors depress responses 1o both agonists. In 62 
patients with atherosclerosis or its risks and 9 normal controls, we measured 
e,61cardla~l E:) dlameTer and ~qo,61er YIOW vdlOdl}y an(3 CglcLd~ted vaScdla.r 
resistance (CVR) during infusions of ACH (30 #g/min), BK (62.5 ng/min, 
4 #g/min), nitroprusside (NTP 40 lzg/min), and cardiac pacing (150 bpm). 
Microvascular dilation with ACH, measured as $ in CVR, in controls (63%5) 
was greater compared to par'rents wrth hypertension (53%,L P < 0.05~, 
hypercho~,estero~emia (3'3% ~., P < ~.02) and those w;th multiple risk factors 
(38%¢, P < 0.01). However, dilation with 4/~g/min BK (65%¢, 56%$, 67°/o$, 
and 64%¢ in CVR, respectively, P = NS), and with NTP was similar in all 
groups. Similarly, there was no correlation between E diameter changes with 
ACH and BK; segments that constncted and those that dilated with ACH had 
similar dilation with BK (13% and 11% dilation, respectively P = NS). During 
pacing, 20 E segments constricted and 30 dilated. BK-mediated E dilation 
was depressed in constricting compared to dilating segments (P < 0.01), 
whereas ACH-mediated responses were similar (P = NS). Pacing-induced 
microvascular dilation did not correlate with either ACH or BK responses. 
Thus, 1) coronary ACH and BK responses are not correlated, suggesting that 
injury of endothelial receptors and/or signalling pathways is heterogenous 
in AT, 2) E reactivity during physiologic stress correlates with BK and not 
ACH responses, indicating that BK may play a role in vasomotion during 
stress and that BK and not ACH may be a better probe to test E physiologic 
endothelial function. 
~ T h e  Importance of Changes in Conduit and 
Peripheral Arteries for Coronary Flow Reserve in 
Patients With Hypertension. A LIFE Substudy 
Michael H. Olsen, Christian Meyer, Kristian Wachtell, Jens D. Hove, 
Harriet Dige-Petersen, Jens Rokkedal, Birger Hesse, Hans Ibsen. Glostrup 
University Hospital & RigshospitaL Denmark 
Objectives: To investigate the relation between changes in vascular structure 
as well as endothelial function in conduit and peripheral artedes and coronary 
flow reserve (CFR) in patients included in the LIFE study with hypertension 
and left ventricutar hypertrophy (LVH). 
Methods: In 30 patients with essential hypertension and LVH and 15 
age matched normotensive subjects we measured CFR by positron emis- 
sion tomography. In the patients we also measured ambulatory blood pres- 
sure, minimal forearm vascular resistance by plethysmography, intima-media 
transversal area of the common carotid arteries and flow-mediated vasodi- 
latation of the brachial artery by ultrasound. 
Results: CFR was reduced in hypertensive patients compared to nor- 
motensive subjects (2.23 ± 0.76 v. 3.33 :E 1.16, P < 0.001). 
Simple linear Mean Minimal fore- Intima-media Flow-mediated 
regression ambulatory arm vascular transversalarea vasodilatation 
systolic blood resistance of the carotid in the brachial 
pressure in males arteries artery 
R P R P R P R P 
CFR -.0.57 <0.001 -0.46 <0.05 -0.37 <0.05 0.50 <0.01 
In multiple regression analyses CFR was correlated negatively to mean 
ambulatory systolic blood pressure (/~ = -0.44) and positively to flow-medi- 
ated vasodilatation (fl = 0.36) (adR 2 = 0.43, P < 0.001). 
Conclusion: CFR was reduced in patients with hypertension and LVH and 
appeared to be related to vascular hypertrophy as well as endothelial function 
in conduit and peripheral arteries indicating the presence of a common 
vascular dysfunction in the coronary and non-coronary circulation. 
~ l s  Isolated Office Hypertension Innocent? A Study 
of the Flow-Related Endothelial Function 
Paul G. Silance, Niloufar Mojdehian, Jean L. Vandenbossche, CHU St 
Pierre, Brussels, Belgium 
It remains controversial whether isolated office hypertension (IOH), so-called 
white-coat hypertension, is a benign clinical condition or if it carries an 
increased risk of cardiovascular morbidity. 
Endothelial dysfunction probably represents the earliest marker of ath- 
erosclerosis, preceding clinically apparent vascular disease. The aim of our 
of study was to assess the endothelial function in patients with IOH. 
We studied vascular function in 14 patients with IOH, 26 patients with 
sustained arterial hypertension and 14 normotensive subjects who served as 
controls (C). Resting brachial artery diameters, age, lipid and glucose levels 
were similar in all groups. 
Clinic and 24-hour ambulatory blood pressure were measured. IOH was 
defined as high blood pressure levels in the clinic (> 140/90 mmHg) and mean 
daytime ambulatory blood pressure < 135/85 mmHg. Using high resolution 
ultrasound we measured brechial arterial dilation in response to reactive 
hyperemia (endothelium dependent flow mediated dilation [FMD] and fol- 
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lowing sublingual glyceryl tdnitrate (GTN, 400/~g) (endothelial-independent 
dilation). 
We found no significant differences in FMD between the IOH and the 
control group (9.1 ± 1.4% and 10.4 ± 2.4% respectively, p = NS), whereas 
FMD was significantly impaired in subjects with sustained hypertension (6.2 
± 2.1%, p < 0.01 vs IOH and C). 
GTN responses were similar in the three groups. 
In conclusion, our data suggest that IOH, in contrast with sustained hy- 
pertension, is not associated with endothelial dysfunction. IOH per se seems 
to carry a low atherogenic risk. 
~ Contribution of Vasoactive Prostanoids to 
Vascular Tone in Healthy Subjects, Hypertensive 
Patients and Hypercholesterolemic Patients 
Wassim Choucair, Crescence M. Kilcoyne, Richard O. Cannon III, Julio 
A. Panza. Cardiology Branch, NHLBI, NIH, Bethesda, MD, USA 
Background: The endothelium modulates vascular homeostasis through 
the release of different factors, including vasoactive prostanoids. These sub- 
stances may regulate vascular tone and other vascular processes. The aims 
of this study were to assess the contribution of vasoactive prostanoids to 
vascular tone in normal humans and to determine whether this regulatory 
activity is dysfunctional in conditions associated with premature atheroscle- 
rosis, such as essential hypertension and hypercholesterolemia. 
Methods: To this end, we investigated the effect of cyclooxygenase 
inhibition with increasing doses of aspirin (ASA; infused at 1, 3, and 10 
mg/min, each dose for 10 min) on resting vascular tone in 16 healthy subjects 
(age: 50 ± 7 years, 10 men and 6 women), 12 hypertensive (age: 52 ± 5 
years, 6 men and 6 women), and 13 hypercholesterolemic patients (age: 52 
± 4 years, 7 men and 6 women). ASA was infused into the brachial artery, and 
forearm blood flow (FBF) was measured by strain gauge plethysmography 
(values are mean ± SD). 
Result==: At the highest dose, ASA decreased resting FBF in healthy 
subjects from 3.0 ± 0.9 to 2.3 ± 0.7 ml/min/dl, or a 23% reduction {p == 
0.002); in hypertensive patients from 3.0 ± 0.9 to 2.3 ± 0.8 ml/min/dl, or a 
23% reduction (p = 0.008); and in hypercholesterolemic patients from 2,9 ~: 
0.6 to 2.1 ± 0.6 ml/min/dl, or a 26% reduction (p = 0.0003). The hemodynamic 
effect of ASA was not significantly different between healthy subjects, and 
hypertensive or hypercholesterolemic patients. 
Conclusions: These findings suggest that vasodilator prostanoids de- 
rived from cyclooxygenase metabolism play a role in the maintenance of 
resting microvascular tone in humans. This physiologic process does not 
seem to be altered in patients with essential hypertension or in those with 
hypercholesterolemia. 
~ In-Vivo Endothelial Function of the Radial Artery 
Coronary Bypass Conduit 
M AI-Bustami, M. Amrani, A. Chester, C. Ilsley, M. Yacoub. Harefie/d 
Hospital, Harefield, UK 
Background: The use of the Radial Artery (RA) as coronary artery bypass 
conduit continues to increase. However its in-vivo endothelial function has 
not been defined. 
Methods and Results: Between January 1998 and July 1998, 60 con- 
secutive patients underwent Coronary Artery Bypass grafting with both the 
RA and pedicled left internal mammary artery (LIMA) used as bypass con- 
duits. To evaluate the early in-vivo flow-mediated endothelium-dependent 
vasodilatory response of the RA, 36 patients (36 Males) underwent angiog- 
raphy within three weeks of surgery. Angiograms were obtained under basal 
conditions, dudng atrial pacing and after intragraft glyceryl trinitrate (GTN); 
GTN administration followed the completion of pacing in all grafts. The study 
was completed in twenty six patients, (the RA was occluded in three, one 
patient had chronic atrial fibrillation, in two patients the RA could not be 
selectively engaged; the remainder four felt unable to undergo the pacing 
sequence.) The LIMA grafts were all patent. Quantitative Coronary Angiog- 
raphy (QCA) of the mean diameters ± SD expressed in mm of 67 RA and of 
66 LIMA segments are tabled below: 
Graft Baseline Pacing Post-GTN P value 
RA 1.9 ± 0.90 2.11 ± 0.93 2.08 ± 1,12 0.0101 
LIMA 2.45 ± 0.69 2.641 ± 0.75 2.71 ± 77 <0.0001 
Conclusion: In-vivo flow-mediated dilation of the RA is comparable to that 
of pedicled LIMA, these results could have implications for the performance 
of the RA as a Coronary bypass graft. 
~ Glucose Does not Influence Large Tolerance 
Vessel Endothelial Function or Carotid Artery 
Distensibility: The Whitehall II Study 
Michael J. Mullen, Harry Hemingway, Mia Taylor, Gillian Oakley, 
Martin Shipley, Eric Brunner, Ann E. Donald, Meena Kumari 
Michael Marmot, John E. Deanfield. University College London, UK 
Background: Insulin resistance and mild glucose intolerance are associated 
with an increased risk of coronary artery disease. This may reflect the direct 
pathogenic effects of hyperglycemia or impaired insulin stimulated synthesis 
of nitric oxide. Alternatively the enhanced risk might be mediated by the 
associated conditions of hypertension and dyslipidemia as part of a 'metabolic 
syndrome'. 
Methods: In a population based cohort of civil servants (age 45-65) we 
selected individuals from the highest (n = 55) and lowest quintile (n = 54) 
of glucose tolerance (2 hour post 75 g OGTT) who were not in the adverse 
quintile for either blood pressure, waist hip ratio, triglycerides or high-density 
lipoprotein. Brachial artery endothelium-dependent flow-mediated dilation 
(FMD) and carotid artery distensibility (CD) were assessed using established 
non-invasive high-resolution ultrasound techniques. 
Results: Baseline characteristics, except glucose tolerance (p < 0.001), 
were well matched between the 2 groups. Mean ± SD FMD was 4.71 + 3.11% 
and 4.37 ± 3.38% in glucose tolerant and intolerant subjects respectively (P 
= 0.6). Similarly there were no significant differences in CD between the 2 
groups (0.11 ± 0.04%/mmHg vs 0.10 ± 0.03%/mmHg, P = 0.3). On multiple 
regression analysis FMD was significantly associated with age (/~ = -0.21, P 
= 0.024) and blood pressure (# = -0.25, P = 0.008), but not with any measure 
of carbohydrate metabolism. CD was associated with age (# = -0.22, P = 
0.021), blood pressure (# = -0.28, P = 0.004), fasting insulin levels (,6 = 
-0.30, P = 0.001) and triglyceride levels (,8 = -0.25, P = 0.009) but not 
glucose tolerance. 
Conclusions: These data suggest that glucose tolerance per se is not 
associated with early abnormalities of vascular structure or function. In con- 
trast, recognized risk factors such as blood pressure and dyslipidemia were 
associated with impaired FMD and CD. The potential for modification of 
these factors is well established and likely to have a greater impact on the 
progression of vascular disease than insulin sensitization. 
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• Higher Quit Rate in Smokers Who Were Smoking 
Given Ultrasound Photographs of Their Own 
Atherosclerotic Plaques 
Fran~:ois Perret 1,2, Pascal Bovet 2,3, Jacques Cornuz 2, Jessy Quilindo 3, 
Fred Paccaud 2, Lukas Kappenberger 1 . ~Division of Cardiology, University 
2 Hospital, Lausanne; University Institute of Social and Preventive Medicine, 
Lausanne, Switzerland; 3Ministry of Health, Seychelles, USA 
Background: We examined if making smokers aware that they had devel- 
oped peripheral atherosclerotic plaques would help them quit smoking. 
Methods: The study included 153 consecutive smokers participating in 
a population-based health survey in which high resolution B-mode ultra- 
sonography of the carotid and femoral arteries was randomly performed to 
approximately half of the participants. All smokers received 10-minute quit 
smoking counseling by a physician. In addition, smokers who underwent 
ultrasound and had atherosclerotic plaques demonstrated were shown and 
given two photographs with one of their atherosclerotic plaques outlined 
together with a relevant explanation. Smoking habits were reassessed 6 
months later by telephone. 
Results: 79 smokers did not undergo ultrasonography (Group A) 20 
smokers had ultrasonography but no demonstrated plaque (Group B) and 
54 smokers had ultrasonography with at least one demonstrated plaque 
o o o (Group C). The quit smoking rates were respectively 6.3%; 5.0 '/o and 22.2 '/o 
in Groups A, B and C (P[x2]: 0.012). Multivariate analysis indicated that 
intervention Group C (OR = 6.3; 95%CI = 1.8-22) and white-collar job (3.5; 
1.1-11) were significantly associated with the quit smoking rate while age 
and sex were not. 
Conclusions: Providing smokers with objective evidence for a detrimen- 
tal effect of smoking on their own person seems to be a strong incentive to 
stop smoking. Quit smoking rates obtained with this intervention appear 1o 
exceed those usually reported in a primary prevention setting. 
JACC PebruaO,  )99~ )x.~.S'Y~AE"YS - ~yper~ens}on, ~asca)ar D)scase, anb Pzevenbon 2~ )A 
1163-27 / Treatment of Ha}ts )-)y~erhomocystl, e) inemia 
Atherosclerotic Plaque Progression 
John C. Peterson, J. David Spence. Univ of Western Ontario, London, 
Ont&~'; C,~,"a ~ 
Background: An elevated plasma homocyst(e)ine [H(e)~ level is a significant 
independent risk factor in the development of premature vascular disease, 
and is present in 30% of such patients. A plasma H(e) level of >14 ~mol/L 
confers an odds ratio for vascular disease of 4.8 (p < 0.001). By enhancing 
the action of methy~tetrahy~ro~c~ate {MTHFR}, an enzyme invo}ved in H{e} 
met~Pb"~di~', i~'~ -a ~ ,~'~'~,, ~'~u"~,~'~, ,~.~ c@.U'~,~'~, ,'~"~, ,%~'~,y c,~'P 
normalized in 98% of patients in 12 weeks. 
Purpose: To determine the effect of treatment with long-term H(e)-Iowering 
thenapy {~L-f~ {%@,a~.e 4- pyndoy~ne, ~ coba~,amm~ on ~e ra~,e o'~ preeress~on 
Methods: Patient records consecutive women and men, aged 36 to 8t 
years, who attended an outpatient premature atherosclerosis clinic at London 
Health Sciences Centre (London, Canada), between January 1990 and De- 
cember 1997, were systematically screened for study eligibility. Inclusion cd- 
teria were a fasting plasma H(e) level > 14 #mol/L prior to HLT initiation, and 
_>2 yearly serial 2-dimensional carotid doppler ultrasound (2-D CDUS) mea- 
lipid-lowering therapy after commencing HLT. A sample size of 24 patients 
was estimated on the basis of an anticipated carotid artery atherosclerotic 
plaque progression rate in untreated hyper-homocyst(e)inemic patients of 
with 95% statistical power and a two-sided ~-Ievel of 1%. 
Results: Thirt~v-eLaht y.uerhomocyst.(e./inemic .patients /20 women, 18 
mert who me( the stuot etr~bfi'~ crffenb were gros~.ec~e(v foYowed wfth 
yearly serial 2-D CDUS measurements for 4.5 ± 1.5 years (mean ± SD). 
~-" ~ ~p=0 
~ o.~ 
<0 0002 (2) 0.4 
O" o.2 +029±0.06 - 0.05 ± 0.04 
cm2/year cm2/year 
o 
pre-HLT post-HLT 
Conclusion: This study is the first to assess and support the hypothe- 
sis that long-term HLT may halt, and thus significantly reduce, the rate of 
atherosc~eros~s prDgress'~on ~n pa'fien~s w~'~ ~2peT~omoc~s~ e)~nem~a. 
~ '  Ffcotamide,  xlr~ /~n ' t~rom~oxa~e ~gen¢, R~d~rces 
Cardiovascular Events in Diabetics With 
Peripheral Vascular Diseases: A Cumulative 
Analysis on 518 Patients 
M Milani. Scientific Services Novartis Farm& Italy 
Study Aim: Picotamide is an antiplatelet drug that inhibits platelet throm- 
boxane A2 synthesis and antagonises thromboxane A2 receptors. Three 
double-blind, placebo-controlled randomised trials, carried out in type 2 dia- 
betic patients with peripheral vascular diseases have been recently published 
(Btr 3. £;fln ~narmasd~, l^~'eE,; ~'[r~e 3W~c~; ~h~e~as l^ V'd"~}. "k~m ~'tf i~ i~,v~- 
sentation was to evaluate the effects of picotamide in comparison to placebo 
on major cardiovascular events by means of a cumulative analysis of these 
studies. 
Patients and Methods: These trials enrolled a total of 518 patients with 
type 2 diabetes mellitus, followed for a minimum of 1.5 to a maximum of 6 
with picotamide and 248 with the corresponding placebo. Each trial evaluated 
the o~curre,ace of rosier <de~t~, acute myocardial in(arction, stroke, ampu~- 
tion) and minor (TIA, CABG, worsening of vasculopathy and angina pectoris) 
validated by an independent review committee. Patients were given either 
picotamide (300 mg t.i.d} or the corresponding placebo Jn each trial 
Results: In comparison with placebo-treated patients, the incidence of 
moor and minor events were s(qn(f(can#v tower ~n gicotam~de groc/p ~t7 
events vs. 42; risk reduction:-BO°/o; p < 0.0£431; X 2 test~. T~eye weTe 21 
in placebo group and in 8 patients in picotamide (-72% risk reduction) (p < 
O.©9- 
Conclusion: This cumulative analysis showed that picotamide, in com- 
parison to placebo, significantly reduced the risk ofcardiovascular events in 
• Betaxo}o}, A New. Long-Act}n9 Beta-B}oc)cer, 
Suppresses Intraoperative Myocardial Ischemia 
During Vascular Surgery in Patients With 
Preol~erative Ischemia and Coronar~ Arter~ 
Disease 
Prakash C. Oeed~vania, Endque Carbajat, James Oaktey. VAMC/O'CSF 
School of Medicine, San Francisco, USA 
Although beta-blockade is recommended in pts with CAD to prevent periop- 
erat}ve coronary events duhng vascu)ar surgery, }i~t)e information ~s avai}ab~e 
,~,~nw ~,~'~, ,~ ~,%~,~ ,~ &~v~,~'~,~,~ ,~'~A, ~%=~ ~v ; ,~ ,~ '~ h~'~.  
Accordingly, we prospectively evaluated the antiischemic effects of betaxolol 
(a long-acting, cardioselective beta-blocker) in pt~ with CAD undergoing ma- 
}or "~asc~ar s~9'~ca~ r~.e~ure~. 13~ tb~e 19~, co~sec~,~ve ~,s eva~ua~,e~, 5~ 
~s ~it~ ~,~-~-o%~,L~'{,~, h~',~"~'~ CA~_~ '~ ~'~a'~.~e ~ ,~;,~ ,~ i~ ~ ; .w,~',~a~,~ 
were enrolled in the study and started on betaxolol (10-20 rag) given for 
at least 10-14 days preoperatively, All 58 pts underwent 48-hr ambulatory 
ECG monitoring at baseline and during vascular surgery, intraoperative and 
in the immediate postopera~ve period. The mean ± SD values for number 
of ischemic events, total duration (rain) per 48 hours, and average duration 
(min) per event are shown in the table: 
,~'~t'~"~" 7L,~.~n "~ ~,~"~ 
of Events Duration Duration 
Baseline 2.6 ± 3 90 ± 140 22 ± 24 
Betaxolol 0.2 ± 0.6 9.5 ± 23 2.2 ± 7 
betaxolol is highly effective in suppressing myocardial ischemia during the 
intraoperative and immediate postoperative period. Future studies should 
examine relative benefits of medical therapy with long-acting beta-blockers 
such as betaxolel in reducing the risk of coronary events in patients under- 
going major vascular surgical procedures. 
1 I Lack of Long-Term Beneficial Effects of Ascorbic 1 63-30  
Acid on Endothelial Vasomotor Dysfunction in 
Patients With Insulin-Dependent Diabetes Mellitus 
J. Lekakis, E. Anastasiou, C, Papamichael, M, Alevizaki, J, Megas, 
K. Stamatelopoulos, A. Voutsas, A. Cimponedu, A. Souvatzoglou, 
S. Stamatelopeulos. Alexandra University Hospital, Athens, Greece 
Backround: Studies in animal models of diabetes and humans have found 
that endothelial dysfunction can be prevented by treatment with antioxidants; 
stuoies examm~hg ~t~e ~bng-ferm e~ecr:s o(ora[ascor15k: ac~b'supp~emenfa~bn 
on endothelial function in patients with diabetes are lacking. 
Methods: Seventeen patients (pts) with insulin-dependent diabetes reel- 
titus (IDDM) (5 men, 12 women, age 34.5 ± 8.4 years) participated in a 
randomized, double blind, crossover trial. IDDM pts were randomly assigned 
to ascorbic acid (1 gr every 12 hrs) for 4 weeks, followed by placebo (8 
lots), or to the opposite sequence of treatment (9 pts). There was a 4 week 
washout period between the alternate medications. At the end of the 4 week 
treatment with ascorbic acid or placebo, high resolution ultrasound imaging 
of the nght brachial artery was performed to evaluate arterial dilatation dur- 
administration (endothelium-independent dilatation). 
Results: Blood pressure, heart rate, glucose, hemoglobin Alc, choles- 
terol, triglycerides, HDL and LDL cholesterol, creatinine and uric acid were 
similar at the end of the treatment penod with ascorbic acid and placebo (ns). 
Baseline artery diameter and degree of hyperemia were also comparable 
3.2% after placebo and 4.4 ± 3.6% after treatment with ascorbic acid (ns). 
NRrate-induced dRatat{on ~as 18 -t-._ 7.2% after p~cebo and ~£.6 -t-__ 5.6% 
after ascorbic acid (ns). 
for 4 weeks did not enhance endothelium-dependent vasodilatien in IDDM 
pts. Higher doses of ascerbic acid may be required to revere endothe/Ja~ 
vasomotor dysfunction in IDDM pts. 
in Biological Males 
T. Meredith. Heart and Chest Research Centre, Monash University and 
Monash Medical Centre, Melbourne, Australia 
Studies have shown that estrogen improves both the lipid profile and vascular 
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reactivity in postmenopausal females. Long-term estrogen therapy (E) also 
appears to have a beneficial effect on vascular hemodynamics and compli- 
ance in postmenopausal women. Whether estrogen has a similar effect in 
males is unknown. Therefore, we compared the effects of E on BP, HR and 
arterial stiffness in 21 male to female transsexuals (TX) with 20 age-matched 
healthy males (M). Systemic arterial compliance (SAC) was assessed using 
the 'area method' by the simultaneous measurement of aortic flow and driving 
pressure. Mean SAC was similar in TX and M (0.66 ± 0.06 vs 0.58 ± 0.05 
acu, respectively, mean ± SE, P = 0.34). These results did not differ after the 
exclusion of TX with risk factors or vascular disease. Heart rate (67 ± 2 vs 
64 ± 3 beats/min, P = 0.41), SBP (119 ± 3 vs 119 + 2 mmHg, P = 0.95) and 
pulse pressure (55 ± 3 vs 50 ± 2 mmHg, P = 0.13) were also similar between 
the two groups. Although DBP (64 ± 2 vs 69 ± 2 mmHg, P = 0.06) and the 
MAP (64 ± 2 vs 89 ± 2 mmHg, P = 0.09) were lower in the TX compared 
with the M, these differences did not reach significance. Serum testosterone 
(3") levels (an index of estrogen therapy) were markedly suppressed in the 
TX compared with the M (0.8 ± 0.5 vs 25.3 ± 12.6 nmol/L, mean ± SD P < 
0.0001). Univariate analysis revealed that the best predictors of SAC were 
the pulse pressure (re = -0.41, P = 0.02) and the SBP (re = -0.35, P = 0.02). 
On multivariate analysis, the best combination of predictors of SAC were the 
pulse pressure, T and LDL levels (R 2 = 0.29, P = 0.01). 
Conclusion: Despite evidence of improved endothelium-dependent va- 
sedilation and the lipid profile with long-term estrogen, we did not observe 
changes in arterial stiffness in biological males, suggesting that the effect of 
estrogens may not be mediated via alteration in arterial compliance. 
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~ Tolerance and Responses to Tamoxifen and 
Toremifene in Male Patients With Coronary Artery 
Disease 
Sarah C. Clarke 1 , Peter M. Schofield 1 , David J. Grainger 2, James 
C. Metcalfe 2, He±de L. Kirschenlohr 2, Andrew A. Grace t2 . lPapworth 
Hospital, Cambridge; 2University of Cambridge, UK 
Background: Tamoxifen (TMX) has a major cardiovascular protective effect 
when used as adjunct therapy for breast cancer. There have been no corre- 
sponding studies of TMX or other triphenylathylenes (TPE), e.g. toremifene 
(]'OR) in patients with coronary artery disease (CAD). 
Study Design: 6 groups of 17 male patients with angiographically proven 
CAD were randemised to receive 20 m~da~ TMX or 15,30,60 or 120 maJda~( 
TOR or placebo for 90 days. Blood samples were prepared at day -7, 0, 
9, 30, 60 and 90 of treatment. Responses reported for the single TMX dose 
and the pooled TOR doses are the means of values for days 30, 60 and 90 
compared with baseline (mean values for days -7  and 0). Students t tests 
of significance are comparisons with the placebo group. 
Results: The only adverse responses were moderate increases (up to 
272 ±u/L) in SGPT in 6 patients receiving 120 mg/day TOR, 1 patient re- 
ceiving 60 rag/day TOR and 2 patients receiving 20 mg/day TMX. 65% of 
the patients were treated with a statin. There were no significant differences 
in any responses to the TPEs between those patients who had been on 
long-term statin treatment (>3 months) and patients not treated with statins. 
TMX caused a significant decrease in total cholesterol (-11.7 ± 1.7%; p 
= 0.019) compared with the placebo group but not in LDL or triglycerides, 
whereas TOR caused no significant decreases in these lipids greater than the 
decreases in the placebo group. TMX but not TOR caused a significant de- 
crease in HDL (-10.4 ± 3.3%; p = 0.007). There was a significant decrease 
in monocyte count in response to both TPEs and reductions in neutrophil 
count were close to significance. There were significant, dose-dependent 
decreases in fibdnogen and alkaline phosphatase in response to TOR and 
similar responses to TMX. Both TPEs caused increases in oestrogen, FSH 
and testosterone. 
Conclusion: The TPEs appear to be safe to evaluate for secondary 
protection against CAD in men and cause a potentially beneficial profile of 
responses except for the HDL reduction in response to TMX. 
• Purple Grape Juice Protects LDL from Oxidation 
in Coronary Artery Disease Patients Taking 
Vitamin E 
Jon G. Keevil, Don Wiebe, John D. Felts. University of Wisconsin, Madison, 
WI, USA 
Background: Oxidation of LDL cholesterol is thought to enhance the pro- 
gression of atherosclerosis. Flavonoids in red wine and purple grape juice 
protect LDL from oxidation in vitro. We determined the effect of purple grape 
juice on ex vivo LDL oxidation in patients with known coronary artery disease 
(CAD). 
Methods: Fourteen patients with angiographically documented CAD 
(mean - SD age 64 ± 13, 11 males, 11 taking vitamin E) ingested 7-10 
mi/kg/day of purple grape juice for 14 days. LDL was isolated from blood 
drawn at baseline and after grape juice, using sequential ultracentrifugation 
and dialysis. CUCl2 (5 ~mol/L final concentration) was added to LDL to initi- 
ate oxidation. The rate of formation of conjugated dienes was monitored at 
the UV wavelength of 234 nm every 3 minutes for 5 hours. Lag time was 
read as the intersection of the baseline diene level and the maximum slope 
of diene production. Baseline and post-grape juice values were compared 
with the paired T-Test 
Results: At baseline, lag time was 87 + 29 minutes. After drinking purple 
grape juice for two weeks, lag time was 117 ± 23 minutes (p < 0.02). The 11 
of 14 patients taking vitamin E showed a similar increase in lag times from 
86 4- 33 to 121 ± 24 minutes (p < 0.02). 
LDL Oxidation Lag Time 
~1,50 
E 6o f- 
-J 0 
Baseline After GJ 
Conclusions: Even while taking vitamin E, purple grape juice, ingested 
for 14 days, protected LDL from oxidation. This represents one of the mech- 
anisms by which daily intake of purple grape juice or other flavonoid sources 
may limit the progression of CAD. 
~ A Nutritional Product Designed to Enhance Nitric 
Oxide Activity Restores Endothelium-Dependent 
Function in Hypercholesterolemia 
Andrew J. Maxwell, Barbara Anderson. Cooke Pharma, Belmont, CA, USA 
Background: We investigated the vascular and biochemical effects of a food 
bar enriched with L-arginine and a combination of other nutrients known to 
enhance the synthesis or activity of endothelium-derived nitric oxide. 
Methods: Using a single-blind dose-rssponse design, 41 individuals with 
Each bar contains 4 g of L-arginine as well as antioxidant vitamins, niacin 
and isoflavenoids. Flow-mediated (endothelium-dependent) and nitroglyc- 
erin-mediated (endothelium-independent) vasodilation of the brachial artery 
was measured using high-resolution ultrasonography before and after inter- 
vention. 
Results: Before 2 or 3 bar/day intervention, mean serum arginine level 
was 33 ± 4 /~M and flow-mediated vasodilation was 5 ± 1% (SE). After 
therapy, trough serum arginine level increased to 43 ± 4/~M (p < 0.0005). 
Concomitant with this increase, flow-mediated vasedilation improved to 17 
± 2% (p < 0.0001). Nitroglycerin-mediated vasodilation also increased (19 
± 2% before, 24 ± 2% after, p < 05). The effects of 2 bars/day was equal 
to that of 3 bars/day. The effect of the intervention was greater in females 
than males and was independent of the degree of initial dysfunction. The 
intervention also lowered total serum cholesterol (269 ± 32 before, 253 ± 
41 after, p < 0.05). Other lipid values as well as serum chemistries and 
hematology were unaffected except for a decline in uric acid levels (5.0 ± 
2 mg/dl before, 4.3 ± 2 after p < 0.0001) and a rise in blood urea nitrogen 
(15 ± 1 mg/dl before, 19 ± I after). The bars were well tolerated and no 
significant adverse side-effects were reported. 
Conclueion: This intervention may have a role in the dietary management 
of individuals with hypercholesterolemia. 
I 1164-701 Hyperlipidemia in Postmenopausal Women: What 
f J Is the Role of Estrogen Replacement Therapy? 
Rachel M. Warner, Thomas A. Pearson, Stephanie Kafonek, Henry Chu. 
University of Rochester School of Medicine and Dentistry, Rochester, NY; 
Parke-Davis/Wamer Lambert Co., Morris Plains, N J, USA 
Estrogen replacement therapy (ERT) in post-menopausal women is known 
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to improve 'h!5~£] prdfiles, 'nowever 'tne e~erit 'to Wrildn E~"i increases lne 
likelihood of achieving adequate control of serum lipid levels is not known. 
To study this, 2099 post-menopausal women enrolled in the Lipid Treat- 
ment Assessment Program (L-TAP) were surveyed for use of lipid-lowering 
theraw. ~n(~'r__T~ana'r'as~ho~(ii~ogroCe(h qrod(~s were measurec~'{h e~cd qa- 
tient. Clinical success was defined as the proportion of women who achieved 
their respective LDL-C goal for each dsk group (0-1 nsk factors, 2+ risk fac- 
tors, or coroner2 'neat[ d~sease )£,~'D)) as spedfi~e6 '~y'~'ne ~a'6ona'~ £_,'no'JeS- 
terol Education Project (NCEP) .guidelines. 
The use of ERT positively predicted patients' success in achieving their 
LDL-(D far.pet. Dvera& 37.5% otpost-menopausa) women achieved NCEP 
specified LDL-C targets; 48.5% of those women on ERT and 31.3% of those 
wom~n no~ on ~" i  );o =~oh'.). 
Proportion el patients achieving LDL-C target: n(%) 
0-1 RF 2+ RF CHD Total 
Patients on ERT 
total 200 (76.6) 136 (39.1) 32 (21.3) 368 (48.5) 
statins 143 (79.4) 101 (42.3) 27 (20.5) 271 (49.2) 
non-drug'~berapy #~ 172.7> 14 ~24.1) 2 ~ 22.2,'} E.414&1) 
Patients not on ERT 
total 138 (58.5) 245 (32.3) 36 (10.4) 419 (31.3) 
statins 114 (66.7) 207 (36.3) 33 (11.3) 354 (34.2) 
non-drug therapy 15 ~34.9) 16 It6.2) O (0) 31 116.1) 
Success in reaching LDL-C target was significantly greater across all 
risk groups for women on ERT. Moreover, this was true for subgroups on 
non-drug therapy and on HMG-CoA reductase inhibitor (statin) therapy. 
Among post-menopausal women being treated for hyperlipidemia, a much 
higher 9,:,~:)3,:'(,k~o.  tte~s¢ ~¢v~ are ~ E~T ~e.4,~ $(CEP LOL-C ~ar,;~J~. 
These findings suggest that ERT should be considered as a therapeutic 
intervention for hyperlipidemia in post-menopausal women at all levels of 
risk and in the setting of either non-drug therapy or aggressive lipid-lowering 
pharmacotherapy. 
~ ) Re)at)on Between Plasma Le.~t)n and )nsu))n 
Metabolism 
Fran~sco Leyva t z 'ran rr. ~o[~s']an0 "~, AnYnDn.,2 5. ~roD[~'ler ! .
Department of Cardiac Medicine, Royal Brompton Hospita# 2 Wynn 
Institute of Metabolic Medicine, St Mary's Hospital; 3 Department of 
Endccnh(~'oe~y. (C~K~, Eerier'on, C(~ 
Background: Hyperleptinemia is an independent risk factor for coronary 
heart disease and is present in patients with chronic heart failure. Hyper- 
leptimerd~a ~s acom, ponedt dr 'the msdim res~gtance s.vnbrome. 'msdim '=s 
known to increase leptin production. We sought to determine which aspect 
of insulin metabolism is more closely related to plasmaleptin levels. 
Methods: Measures of glucose and insulin metabolism were assessed 
in two groups of 23 healthy men with 'high' [6.56 (-0.34, +0.36) ng/ml, 
mean ± asymmeV~cal ~£:M) and '~o~/ I3.B1 ~-D.16. +D.1B) ng)ml) plasma 
leptin levels, matched for age, body mass index (BMI) and centrality of body 
fat [sub.scapular-to-triceps, ubscaputar-to-biceps sk/nfoid ratiosl. Modeliincj 
analysis of cjlucose, insulin and C-9eptide levels during the iv. cjlucose tol- 
erance test (IVGTT) was used to assess insulin metabolism, including a 
measure of the aensit)vffy of the pancreas to g}~cose (~,>. 
Results: Subjects with 'high' plasma leptin levels had a higher IVGTT 
increme~(e( (~s~((e, a.re~s (9 = ,3.(3G2~, ~,[ s(m(,~r (VGTT ~(c(c~se a~d C-9~9- 
tide incremental areas to those with 'tow' leptin levels. No significant group 
differences emerged amongst measures of insulin metabolism, except for 
q~2i, which was higher in subjects with 'high' plasma leptin levels (p = 0.021) 
Plasma leptin correlated with fasting insulin (r = 0.45, p < 0.001), IVGTT 
incre~e~f~J, ~#sJ,J(#, ~J:.,=..~ <r. = ~.5.~, 9. < (L.G'L t,~ ~cL ~2, /r. = ~.~,  9. < (LG U,. 
In multivariate analysis, only/VGTT incremental insulin area (standardised 
coefficient, SC = 0.48, p = 0.003) and fasting insulin (SC = 0.32, p = 0.49) 
emerged as predictors of plasma leptin levels, independently of BMI (SC = 
0.04, ns), ~2i (SO = 0.05, rls) and insulin sensitivity [SC = 0.03, ns). 
Conclusion: In healthy men, plasma leptin concentrations are positively 
related to plasma insulin concentrations and the sensitivity of the pancreas 
to glucose. Further investigations are needed to determine whether drugs 
which modi~ ¢'2~ cause a(temations (n le~t{n metab~sm. 
~ Randomized Trial of Cholesterol-Lowering 
Therapy and Ant/oxidant Vitamin 
Supplementation in 6,000 People With Diabetes 
Mellitus 
Rory Collins. MRC/BHF Heart Protection Study Collaborative Group; 
Coordination: Clinical Tale(Service Unit, Univers(ty of Oxford, UK 
Background: In observational studies, people with diabetes mellRus are at 
increased hsk d~ card~ovascdlar d~sease, and lower dh01esterol levels and 
higher ant/oxidant vitamin intakes are associated with lower risks of coronary 
heart disease (CHD). 
Methods: Men and women aged 40 to 80 were eligible for the Heart 
sire vascular disease; blood cholesterol >_ 3.5 mmol/~ (135 mg/dl); and no 
clear indications for, or contraindications to, study treatments in the view of 
"fn~r own boc~ers. ~-e'Im~m~ ~n:~r~ pn ~c))ve ~.r~,~me.e), p,e~p,e.o~s we~'e 
randomly allocated simvastatin ~40 m,9 daily,) or pJecebo ex)d J, ~ fx3cto.rj.t3J 
design, vitamins (600 mg E, 250 mg C and 20 mg beta-carotene daily) or 
~D)~cebo. 
Results: Between July t994 and May 1997 in 69 UK hospitals, 5963 
Of these, 4665 (79°/°) had non-insulin dependent diabetes (NIDDM) and 
462 (8%) insulin dependent diabetes (IDDM), with the rest showing mixed 
features. 2913 (49%) had no history of occlusive disease, while 1968 (33%) 
reported CHD and a further 1082 (18%) other occlusive vascular disease. 
At baseline in participants with NIDDM and with IDDM, mean non-fasting 
blood total cholesterol was 5.7 mmol/I /,2.20 mg/dl~, and 5.5 mmoUI (2.1.4 
mg/~l) respectively; HDL-cholasterol 1.0 mmol/I (39 rag/all) and 1.4 mmoVI 
(54 mg/dl); tdglyceride 2.4 mmol/I (215 mg/dl) and 1.2 mmol,'l (110 mg/dl); 
and glycosylated haemoglobin 7.0% and 7.9%. During a mean follow-up of 
months, allocation to simvastatin had reduced total cholesterol by 1.6-1.7 
mmol/I (62-66 mg/dl). No significant differences have been seen among 
patients with diabetes in elevated liver enzymes (ALT > 3x upper limit normal 
[ULN]: 13 simvastatin vs 8 placebo), muscle enzymes (CK > 10xULN: 2 vs 1) 
or other possible side-effects. Annual event rates among those with diabetes 
are about 2.7% non-fatal MI or fatal CHD and 2.2% all-cause mortality. 
the effects of cholesterol-lowering therapy and ant/oxidant vitamin supple- 
mentation on CHD in a range of people with diabetes mellitus. 
1 J Is Plasma LDL-Cholesterol Level Correlated With 
I 
1 64-73 
fmgpeni'e~st~e P'affl@m/s .~ 
Joachim F.M. MOiler, I.-W. Franz. K/inik Wehrawa/d der BfA, Todtmoos, 
Germant{ 
Objective: It is established that LDL-cholasterol can lead to an endothelial 
dysfunction and it is of interest o speculate if LDL-cholesterot might influence 
this mechanism. 
Design and Methods: One thousand two hundred thirty-nine patients 
(508 female&.631 males, mean aq.e 50.1 ± 8.6_ v, ears~, underwent a 24 h BP 
monmtbnhg (,;<ld"H"~)' ana'an exercise test (bLr tb IIXJ watts)" on the same cli~y; 
additionally, casual blood pressure (CBP) readings were obtained. Accord- 
ing to ABPM, 569 patients were hypedensives, 488 were normotensives. 
182 patients were not accepted for analysis as they could not be properly 
classified. Within 48 h LDL-cholesterol was measured. 
Results: For the who~e sample there was a significant corre~affon between 
plasma LDL-cholasterol and diastolic BP during exercise (dExBP; 75 watts, 
r = 0.12, p < 0.001), with dCBP (r = 0.09, p < 0.001) and with dABPM 
~a'~t~," r = 6"66", p" < 6".6"?)'. 7,~i~ a-s- ~'-o i 'r~ k,'-r sys%~';c ~P ~s'EK6~F'." • = 
0.10, p < 0.001; sCBP: r = 0.14, p < 0.001 and sABPM: r = 0.08, p < 0.01) 
These correlations were stronger in the group of normotensives (dExBP: r = 
0.08, p = 0.08; dCBP: r = 0.13, p < 0.01; sExBP: r = 0.13, p < 0.01; sCBP: 
r = 0.13, p < 0.01 except diastolic and systolic ABPM: p = n.s.) but weaker 
and not significant in the group of hypertensives (except sCBP: r = 0.11, p < 
0.01). 
Conclusions: Our results in a great sample of patients support the hy- 
pothesis that LDL-cholesterol might influence bloodpressure regulationprob- 
ably via endothelial dysfunction and up-regulation of ATl-gene expression. 
This mechanism might be especially important for initiating hypertension 
and increase of BP in the early stage before vascular demages have been 
manifested. 
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1165-1161 Absence of of II Down-Regulation Angiotensin 
I Type 1 Receptor in Isolated Diastolic Heart 
Failure Due to Hypertension: Key to Benefits of 
Receptor Antagonist 
Kazuhiro Yamamoto, Tohru Masuyama, Yasushi Sakata, Reiko Doi, 
Keiko Ono, Hiroya Kondo, Tsunehiko Kuzuya, Takeshi Miwa, 
Masatsugu Hod. Osaka Univ. Med. Sch., Suit& Japan 
Background: Effects of angiotensin II type 1 receptor (AT1) antagonist are 
not consistent in heart failure. Recent studies have demonstrated down-reg- 
ulation of AT1 in dilated cardiemyopathy (DCM) which may attenuate effects 
of AT1 antagonist in some pts with DCM. Isolated diastolic heart failure (DF) 
has different etiology from DCM. Gene expression of AT1 and effects of AT1 
antagonist in DF remain unclear because of lack in animal model. We have 
developed a rat model of DF, where hypertension (HTN) results in elevated 
LV end-diastolic pressure (EDP) without systolic dysfunction. 
Methods: Dahl salt sensitive rats fed on 8% NaCI since 7 wks old were 
divided into the no treatment group (n = 8) and the group treated with AT1 
antagonist (TCV-116, Candesartan Cilexetil, CC group, n = 7). In the CC 
group, CC was orally given at 1 mg/kg/day from 8 wks old when HTN was 
present. In both groups, hemodynamic study was followed by the harvest of 
the LV to assess the amount of mRNA for angiotensin converting enzyme 
(ACE) and AT 1. 
Results: In the no treatment group, ACE mRNA was increased by 4.1 -fold 
and AT1 mRNA was not changed as compared with age-matched Dahl 
salt sensitive rats fed on normal chew without HTN. Aortic pressure or LV 
end-diastolic diameter was not different between the no treatment and CC 
groups. However, LV mass index and EDP were significantly lower in the CC 
group than in the no treatment group (3.8 • 0.4 vs 4.7 4- 0.6 mg/g, 6 :E 3 vs 
17 :J: 5 mmHg, p < 0.05 respectively). ACE mRNA was decreased by 34% 
in the CC group as compared with the no treatment group. 
Conclusions: A non-depressor dose of AT1 antagonist prevented tran- 
sition to DF in HTN with reduced expression of ACE. This may be partly 
explained by the absence of down-regulation of AT1 in DE 
1165-117j  1 1/3-Hydroxysteroid Dehydrogenase Deficiency 
Regulates Endothelins, Angiotensins and Nitric 
Oxide: A Novel Mechanism in Hypertension? 
Frank Ruschitzka, Sidney Shaw, Georg Noll, Thomas F. L0scher. 
Cardiology, Cardiovascular Research and Institute of Physiology, University 
ZOrich, Switzerland 
Background: Mineralocorticoid receptors have no intrinsic specifity for al- 
dosterone over cortisol and derive specifity from co-expression of the enzyme 
11/~ -hydroxysteroid ehydrogenase (11 fl HSD). In patients with liquorice-induced 
and Iow-renin essential hypertension 11f HSD activity is decreased and 
hence cortisol occupies the mineralocorticoid receptor subsequently causing 
sodium retention and hypertension. 
Methods: To evaluate the potential importance of endothelial factors 
in 11/~ HSD deficiency normotensive Wistar-Kyoto rats received liquorice- 
derived glycyrrhetinic acid that inhibits 11 fl HSD activity in a dose-dependent 
manner (50 mg/kg bodyweight i.p. for one week; saline in the controls; n 
= 7). Endothelium-dependent and -independent function were assessed as 
response to acetylcholine (ACh, 0.01-300 #mol/L) and sodium nitroprus- 
side (SNP, 0.01-300 t~mel/L) in isolated aortic rings. In addition, vascular 
reactivity to endothelin-1 (ET-1; 0.01-300 nmol/L), bigET-1 (1-300 nmol/L), 
the angiotensins (0.1 mmol/L), norepinephrine (NE; 0.1-30 mmol/L) and 
potassium chloride (KCL 100 mmol/L) were tested. 
Results: Blood pressure increased significantly in rats treated with gly- 
cyrrhetinic acid (157 vs 127 mmHg in the controls; p < 0.01). Whereas 
contractions of isolated aortic rings to ET-1, bigET-1 and the angiotensins 
were enhanced in glycyrrhetinic acid treated rats (p < 0.01 vs controls), re- 
ponses to KCL and NE remained unaltered. Most interestingly, ET-1 plasma 
levels were significantly decreased (5.4 vs. 8.1 pg/ml; p < 0.01). In addi- 
tion, ACh-induced endothelial nitric oxide release was blunted (p < 0.05 vs 
controls) and completely blocked by NO-synthase inhibitor L-NAME, while 
responses to SNP remained unchanged. 
Conclusions: These data show for the first time that decreased 11~' 
HSD activity results in a marked potentiation of contractile responses to 
endothelins and angiotensins with a blunted bioavailability of endothelial 
nitric oxide and may thus contribute to the development of hypertension in 
patients with 11/~ HSD deficiency. 
I1 8 1 Angiotensin II Receptor Blockade Does not 1 65-1 1 
Suppress Compensatory Hypertrophy but 
Prevents Excess Hypertrophy Contributing to 
Transition to Heart Failure in Hypertensive Rats 
Yasushi Sakata, Tohru Masuyama, Kazuhiro Yamamoto, Reiko Doi, 
Hiroya Kondo, Keiko Ono, Tsunehiko Kuzuya, Takeshi Miwa, 
Masatsugu Hori. Osaka Univ. Medical School, Suit& Japan 
Background: Angietensin II type I receptor (AT1-R) antagonist may prevent 
the transition from compensated hypertrophy to isolated diastolic failure 
(DF). We attempted to clarify the mechanism by studying effects of AT1-R 
antagonist (Candesartan Cilexetil, CC: 1 mg]kg/day) on the serial changes 
in LV geometry and function in hypertensive rats. 
Methods: Dahl salt sensitive rats were placed on 8% NaCI diet with or 
without oral administration of AT1-R antagonist (group CC (+), n = 12; group 
CC (-), n = 9). The rats fed on 0.3% NaCI diet were defined as control 
rats (group N, n = 8). LV mass corrected for body weight (LV mass/wt), 
LV end-diastolic pressure (EDP) and transmittal flow velocity (E/A) were 
evaluated in each group. 
Results: Hemodynamic data were: 
Group LV mass/wt {10 3) E/A LVEDP 
(7 wks) (13 wks) (19 wks) (13 wks) (19 wks) (mmHg) 
N 2.4 ± 0.4 2.3 ± 0.2 2.4 ± 0.3 2.4 ± 0.9 2.6 ± 1.0 9 ± 3 
CC( - )  2 .5±0.5  3.6 ± 0.5 *# 4.8 ± 0.6 "#$ 1.0 ± 0.3" 3.1 ±2.05 18±5"  
CC (+) 2.7 ± 0.2 3.4 ~ 0.5 TM 3.7 ± 1.0 "#t 1.0 + 0.4" 1.4 -~ 1.2 t 9 ± 3 
(Expressed as mean value SD; *p < 0.05 vs N, tp < 0.05 vs CC (-) ,  #p < 0.05 vs 7w, 
Sp < 0.05 vs 13w). 
LV hypertrophy progressed without changes in fractional shortening in 
CC (-), resulting in elevated EDP and symptoms of heart failure. LV filling 
dynamics presented restrictive pattern that is observed at end stage of 
heart failure. In CC (+), hypertrophy developed as adaptive compensation. 
However hypertrophy and LV filling abnormality did not further progress and 
EDP was not elevated. 
Conclusion: ATt-R blockade does not suppress compensatory hypertro- 
phy but prevents excess hypertrophy contributing to transition to heart failure 
in hypertensive rats. Thus AT1-R blockade may be an effective therapy for 
isolated diastolic heart failure in hypertension. 
11165-1191 Greater Extent and Duration of Antagonism of 
Irbesartan on Angiotensin II Pressor Response 
and Radioligand Binding in Man Compared to 
Losartan and Valsartan 
Gustav G. Belz, Raunhild Butzer, Susan Kober t , Christian Mang, 
Ernst Mutschler I . Center for Cardiovascular Pharmacology, Mainz; 
Institute of Pharmacology, University of Frankfurt, Frankfurt, Germany 
Background: This double-blind, randomized, three-period cross-over study 
evaluated the antagonistic properties of 150 mg irbesartan (IRB), 80 mg val- 
sartan (VAL) and 50 mg Iosartan (LOS) in man from responses to exogenous 
angiotensin II (ANG II) and a radioreceptor assay (RRA). 
Methods: 18 healthy male volunteers completed the study. ANG II chal- 
lenges and RRA were performed before and up to 47 h after single (day 
1) and multiple (day 8) oral doses of the antagonists. The right-ward shift 
(DR-l) of the ANG II dose-effect curves (diastolic blood pressure) was used 
as a measure of in vivo effects. Receptor occupancy in vitro was assessed 
by rat lung RRA. 
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Results: All study drugs clearly antagonized the effects to ANG II chal- 
lenges in vivo (DR-I) and in vitro (RRA). DR-1 for IRB was significantly 
greater than for LOS and VAL at most time points, indicating a greater extent 
and duration of the inhibitory effect of IRB. In vivo findings were supported 
by in vitro RRA data: the percentage of receptor occupancy for IRB was 
significantly greater than LOS and VAL at all time points. (see figures) 
Conclusions: Of the three drugs (tested at recommended therapeutic 
doses), IRB showed the greatest extent and longest duration of ANG II an- 
tagonism in man. This was maintained up to two days post-dose, indicationg 
superior ANG II antagonistic effects for IRB. This may have implications for 
the use of IRB in clinical practice. 
I1 I Production of Nitric Oxide Increases 1 65-1 20 Cardiac i 
Due to Chronic Treatment With an Angiotensin 
Converting Enzyme Inhibitor, Cilazapril, in 
Patients With Essential Hypertension 
Masashi Fujita, Shinsuke Nanto, Tomoki Ohara, Takakazu Morozumi, 
Seiki Nagata, Masafumi Kitakaze 1 , Masatsugu Hori 1 . Kansai Rosai 
Hospital, Amagasaki; 1The 1st Dept, of Med., Osaka Univ. School of Med., 
Suita, Japan 
Backgrounds and Purpose: Systemic hypertension is believed to attenuate 
endothelial-dependent vasodilation, which may cause marked cardiovascular 
complications. Angiotensin-converting enzyme (ACE) inhibitors (ACEI) are 
reported to be cardioprotective, partially due to augmentation of nitric oxide 
(NO) production by inhibiting degradation of bradykinin. However, it is not 
certain if ACE inhibitors increase cardiac NO levels in patients with essential 
hypertension. To test this idea, we measured the cardiac NO levels in patients 
with essential hypertension. 
Methods: Twenty-two patients were derided into two groups: the ACEI 
group (Group A) consisted with 7 patients with administration of an ACE 
inhibitor, cilazapril (1 mg/day), and the control group (Group C) consisted 
with 15 patients without administration of ACE inhibitors. We sampled blood 
from coronary sinus (CS) and Aorta (Ao) simultaneously, and measured the 
levels of the end-product of NO (nitrate + nitrite) in these blood samples. 
Additionally, we measured coronary blood flow (CBF) using Doppler flow 
wire in rest and maximal pacing. We obtained the cardiac NO levels by 
calculating the differences between NO levels in CS and Ao, and also the 
amount of NO production by CBF times the cardiac NO levels. 
Results: At rest, both cardiac NO levels (3.03 ± 1.54 in Group A vs. 1.53 
± 4.13 nmol/ml in Group C, ns) and the amount of NO production (404.7 
± 335.0 in Group A vs. 247.2 ± 459.6 nmol/min in Group C, ns) were not 
significantly different. However, during maximal cardiac pacing, both cardiac 
NO levels (3.96 ± 1.88 in Group A vs. 0.50 ± 2.81 nmol/ml in Group C, p < 
0.01 ) and the amount of NO production (391.3 ± 478.7 in Group A vs. 27.80 
± 392.6 nmol/min in Group C, p < (0.05) increased in Group A compared 
with Group C. 
Conclusion: We suggest that cilazapdl increases cardiac production 
of NO in patients with essential hypertension. The enhancement of NO 
production may explain the cardioprotective ffects of ACE inhibitors seen in 
clinical settings. 
1 65- I  Polymorphism of Angiotensin Converting 
I 
1 12 1 
Enzyme Gene Is Associated With Hemostatic 
Parameters Disturbances in Patients With 
Essential Hypertension 
Thomas Makris, Panagiota Krespi, Antonios Hatzizachadas, 
George Stavroulakis, George Anastasiadis, Caterina Tsoukala, 
Caterina Panayotopoulou, Michael Kyriakidis. Cardiology Dept., 2nd Reg. 
BTC, Haemost. Lab., LAIKO Hospital, Greece 
Background: The deletion (D) allele of the insertion/deletion (I/D) polymor- 
phism of the angiotensin converting enzyme (ACE) gene has been implicated 
in the pathogenesis of a variety of cardiovascular disorders. This study ex- 
amined the possible association of the ACE gene polymorphism with the 
fibrinogen (F), fibrinogen degradation products (FDP), D-dimer, piasminogen 
activator inhibitor-1 (PAl-l) levels in untreated hypertensive patients (pts). 
Methods: The I/D polymorphism of ACE gene was determined in 104 
hypertensives aged 56 ± 12 yrs. Forty-two pts had DD genotype (Group 
A), 30 pts had ID genotype (Group B) and 32 pts had II genotype (Group 
C). The three groups are matched for age, sex and body mass index. The 
F, FDP, D-dimer and PAl-1 levels were determined (ELISA method) in the 
whole population. 
Results: F, FDP, D-dimer and PAl-1 levels were significantly higher in 
group A than B and C (342 ± 54 vs. 295 ± 49 vs. 298 4- 33 mg/dl, p < 0.001, 
429 ± 167 vs. 263 ± 39 vs. 262 ± 64 ng/ml, p < 0.0001, 371 ± 74 vs. 244 
± 85 vs. 233 ± 88 ng/ml, p < 0.0001, 13 ± 8 vs. 9.13 ± 6.6 vs. 8.84 ± 3.2 
IU/ml, p < 0.05 and p < 0.01 respectively). 
Conclusions: Our findings suggest that the DD genotype of the ACE 
gene polymorphism is associated with significantly increased levels of F, 
FDP, D-dimer and PAl-1 in pts with EH, supporting the idea that ACE gene 
polymorphism plays a crucial role in he hemostatic balance of hypertensives. 
POSTER 
Percutaneous  Coronary Intervent ions 
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~ R i s k  Adjustment Models for Adverse Outcomes 
and Benchmarking in Interventional Cardiology: 
A Report from the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium (BMC2) 
Mauro Moscucci, James L. Chambers, Samir A. Dabbous, Kim A. Eagle, 
Dean Karavite, Eva Kline-Rogers, Philip Kraft, Ann MaxwelI-Eward, William 
L. Meengs, Michael J. O'Donnell, Kidt Patel, David Share, Zoltan Turi. 
University of Michigan Coordinating Center for the BMC2 Group, Ann Arbor, 
MI, USA 
The recent development of risk adjustment models for PTCA mortality and 
for major complications has provided a tool for measuring influence of case 
mix on outcomes. However, widespread applications and validation of these 
tools are lacking. The objective of this study was to test the performance 
of two recently proposed dsk adjustment models for PTCA mortality and for 
major complications on a large multicenter quality-controlled atabase. 
Methods: Clinical, procedural and outcome variables were prospectively 
collected from a consortium of 9 hospitals. The present analysis pertains to 
3178 audited consecutive procedures from 6 of the 9 hospitals. Predicted 
mortality and the predicted incidence of a combined endpoint including death, 
emergency CABG and Q-wave MI was calculated using two models devel- 
oped at the Cleveland Clinic. Model performance was assessed using ROC 
Curve analysis. 
Results: Both models performed well and had good discrimination (ROC 
area 0.82 and 0.69). The lower incidence of the combined endpoint might 
reflect improved outcomes secondary to a high use of stents in this series. 
Outcome Observed Predicted ROC area 
Death 1.64% 1,54% 0.82 
Combined 3.24% 4,55% 0.69 
Conclusion: Risk adjustment models for mortality and for major compli- 
cations after PTCA perform well when applied to large multicenter patients 
populations other than the one used for their development, and provide a 
valid tool for quality assessment and for benchmarking. 
• Prioritizing of Patients on the Waiting List for 
PTCA 
Karel T. Koch, Jan J. Piek, Robbed J. de Winter, Kong I. Lie, Jan 
G.P. Tijssen. Academic Medic.a~ Center, Amsterdam, The Netherlands 
Background: Waiting times for resource-intensive cardiovascular proce- 
dures may be the result of financial restrictions in health care systems that 
operate under limited budgets. Management of waiting times for coronary 
revasculansation includes an appropdate selection of the patients in order to 
minimize the risk of the occurrence of cardiac events dudng the waiting time. 
Objective: To assess the adequacy of prioritizing of patients (pts) on a 
waiting list for coronary angioplasty (PTCA). 
Patients and Methods: At the time of acceptance for PTCA, pts were 
classified according to three waiting-time categories: 1) urgent, i.e. PTCA 
to be performed <1 week; 2) semi-urgent i.e. PTCA < 6 weeks; 3) elective 
waiting list. Pdodtizing depended upon anginal status, the results of non- 
invasive tests and angiographic findings. Pts with unstable angina treated 
with heparin and/or i.v. nitrates were not included. Clinical events dudng the 
waiting time were defined as death, myocardial infarction or any admission 
for (unstable) angina. Clinical and angiographic predictors for events were 
evaluated by a Cox proportional regression analysis. 
Results: A total of 917 consecutive pts were included: 265 in the urgent 
group, 380 in the semi-urgent group and 270 in elective group. The mean 
waiting times were 7 ± 4.9, 34 ..L 22.1 and 71 ± 37.0 days respectively. There 
were no deaths on the waiting list, 2 pts (0.2%) had a myocardial infarction 
and 31 pts (3.4%) were admitted for unstable angina. The incidence of 
events was 0.19, 0.53 and 0.24 per waiting year in the urgent, semi-urgent 
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and elective groups respectively. The cumulative probability of events was 
equal in the semi-urgent and elective group at an average waiting time of 34 
and 71 days respectively. Regression analysis identified recent onset angina 
(Hazard Ratio 3.5; 95%CI 1.5-8.1), previous coronary bypass surgery (HR 
5.2; 95%CI 1.9-14.8) and smoking (HR 2.5; 95%CI 1.2-5.6) as independent 
risk factors. 
Conclusion: The incidence of events on the waiting list for PTCA is 
low when patients are prioritized on clinical acuity. Predictors for events 
during the waiting time were recent onset angina, previous bypass surgery 
and smoking. Priority assignment can be used to achieve equality of the 
event-risk among urgency categories. 
~ A  New Composite Outcome Measure Coronary for 
Intervention 
Meri A. Todd, Anne R, Newman, Dominic L. Raco, William B. Hillegass. 
Vanderbilt University Medical Center, Nashville, TN, USA 
The efficacy of percutaneous coronary interventions (PCI) is typically eval- 
uated with a composite endpoint summing the incidence of death, MI, and 
revaseularization. Since most events during and after PCI are nonfatal, a 
more complete measure of patient outcome would appropriately weight non- 
fatal morbid events. Cardiologists (n = 35) were surveyed with a standard 
time trade-off method to evaluate morbidity from nonfatal events. Respon- 
dents were asked the proportion of their remaining estimated survival they 
would forgo to avoid the events below. They were instructed to assess the 
quality-of-life impact of these events independent of survival, which was held 
constant for each event. Utilities were calculated; 0 represents death and 1.0 
perfect health. Median utilities and 25%-75% ranges are shown: 
Event Median 25°/~75% Event Median 25%-75% 
Minor bleeding 1.0O0 0.993--1.000 Class II angina 0.967 0.893-1.000 
Major bleeding 1 .000  0.990-1.000 Urgent CABG 0.933 0.900-0.988 
CK 500* 1.000 9.993--1.000 QWMI 0.920 0.780.-0.983 
Elective PCI 0.993 0.980-1.000 Minor CVA 0.867 0.867-0.965 
CK 8001. 0.987 0.953-.1.000 Class III angina 0.840 0.33.3--0.920 
Urgent PCI 0.987 0.933-0.997 Major CVA 0.007 0.000-0.200 
Elective CABG 9.967 0.922-0.997 Death 0.000 0.000-0.000 
* Non - Q-wave MI, CK 500; 'Non - Q-wave MI, CK 800 
These utilities can be applied to event rates from trials, registries, or 
individual practices to calculate a single composite outcome measure and a 
confidence interval. Coupled with cost and validated risk-stratification tools, 
this measure can be used to perform cost-effectiveness analyses or assess 
individual operator performance. Inclusion of multiple endpoints using these 
utility values more accurately assesses the low-volume operator. 
• Queuing for During Severe Coronary Angiography 
Supply-Demand Mismatch in a US Public 
Hospital: Analysis of a Waiting List Registry 
Salvatore Rosanio, Monica Tocchi, Barry F. Uretsky, David L. Ware, 
Christopher R. deFilippi, George A. Stouffer, Marshall S. Runge. University 
of Texas Medical Branch, Galveston, TX, USA 
Long waiting times for coronary revascularization have been associated with 
increased risk of adverse cardiac events (AE). Mortality rates of 0.4% to 2.2% 
have been reported in CABG candidates, and AE may occur in up to 23% of 
pts awaiting routine PTCA. However, data on the risk of AE in pts awaiting 
coronary angiography (CA) are lacking. Between Jan. '92 and Jul. '94, due to 
a high demand for service, an outpatient waiting list (WL) for non-urgent CA 
was instituted at one US public tertiary hospital. To enable pts to be followed 
while on the WL, all cases were entered into a registry consisting of a modular 
database. Patient queuing was based on referral date, and triage guidelines 
for prioritization were not used. Among 381 WL Lots, 32 (8.4%) developed 
AE before the scheduled CA, including 4 (1%) deaths, and 28 unplanned 
hospitalizations (3 for myocardial infarction, 21 for unstable angina and 4 for 
heart failure). Occurrence of AE prompted expediting the procedure, with a 
waiting time of 29 ~ 31 clays for pts with AE vs. 61 • 54 days (p < 0.05) for 
those without AE. Mean length of hospital stay was significantly increased in 
pts with AE compared to those without (7 i 4 vs. 2 • 1 days, p < 0.01). In a 
multivariable Cox proportional hazard model, significant (p < 0.05) predictors 
of AE were: a strongly positive noninvasive stress test (;ST within 3 min of 
exercise, $ST > 2 mm, or positive echo or nuclear imaging: OR: 3.21, 95% 
CI, 1.07--8.22); increasing age (OR: 1.28; 95% CI, 1.03-3.86); and treatment 
with _>2 anti-ischemic medications (OR: 2.14; 95% CI, 1.23-6.84). 
Conclusion: Although overall survival is high, the unexpectedly high 
morbidity rate in our WL registry suggests that queuing for CA may increase 
social and economic burden and potentially enhance the risk for a poor 
prognosis. Identifying patients at high and low risk by using clinical predictors 
may help patient triage in health care systems with limited cardiovascular 
facilities. 
~ Cost Effectiveness of Targeting Patients for 
Platelet Inhibition in High Risk Angioplasty 
William S. Weintraub, Elizabeth M. Mahoney. Emery University. Atlanta, GA, 
USA 
Background: While platelet inhibition has been shown to decrease event 
rates after high risk angioplasty, the selection of appropriate patients for 
platelet inhibition is unknown. 
Methods: 4,867 patients undergoing 5,946 angioplasty procedures be- 
tween 1993 and 1995 were studied. Determinants of the composite events 
(4.40%) death, MI, CABG and acute closure were determined by stepwise 
logistic regression. The model was thoroughly validated. Tie model was used 
to predict the percent probability of events (ER) in each patient, and prob- 
ability cutoffs for therapy (% Rx) from 0 (t00% Rx) to 100% (0% Rx) were 
considered. Survival with (median 12.19 years) and without (median 13.33 
years) events was determined in 21,535 patients undergoing angioplasty 
between 1980 and 1996. Charges from the UB92 were reduced to cost by 
departmental cost to charge ratios. Therapy was assumed to cost $1000 and 
prevent 40% of events. Cost effectiveness compared to no treatment was 
measured in cost/event prevented (CEA), Cost (in $) per life year saved (CE 
1), Cost per life year saved, 3% discounted (CE 2), and cost per life year 
saved, 3% discounted, events reduce utility to 0.80 for 1 year (CE 3). 
Results: 
Cutoff % Rx ER Cost CEA CE 1 CE 2 CE 3 
0 100% 2.64 11 ,286  40,572 35,636 83,383 59,116 
3% 51,8% 3.21 10 ,895  27,205 23,883 55,883 39,619 
5% 24.4% 3.30 10,638 8,013 5,343 12,501 8,863 
Conclusions: While targeted anti-platelet herapy is cost-effective, treat- 
ing all patients may not be. Cost-effectiveness is sensitive to changes in the 
cutoff for therapy, with an appropriate cutoff of approximately a 3% to 5% 
probability of an event. 
1 0 I Relationship Between Site Volume and Patient 1 66-1 1 
Interventional Procedure Failure in 55 Cath Labs 
Using the OEP TM Database 
Edmund R. Becket, Steven D. Culler, April Simon, LuAnn M. Green, 
Sameer Mehta, William Weintraub. Emory Universi~ Atlanta, GA.; 
Co/umbia/HCA, Nashville, TN, USA 
Background: Interventional procedure failure and levels of volume were 
analyzed for 21,548 (interventional) patient encounters at 55 Cath Labs. 
Methods: Data were analyzed from the OEP" (Operational Effectiveness 
Program) Database covering all procedures during the period 1/97 thru 6/98. 
Results: The table shows mean failure rates, significance levels, and 
patient counts by volume classes for PTCA, arthrectomy, and coronary stent 
patients. While sites performing >2000 interventional procedures per year 
show the lowest levels of failure, sites with <300 procedures have lower 
failure rates than those for sites with 301-500, 501-1000, and 1000-2000 
volume levels. All procedure volume differences are statistically significant. 
PTCA **" Arthrectomy *" Corstent -* 
SffeVolume F~lure Count Failure Count Failure Count 
Levels % % % 
<300 12.7 480 2.56 39 2.60 961 
301-500 14.6 673 5.56 54 3.46 1,650 
501-1000 12.9 2,927 4.81 478 3.05 5,893 
1001-2000 14.4 2,146 4.58 307 2.95 4,818 
>2000 10.5 342 1.72 58 2.77 722 
**p < 0.01; ***p < 0.0Ol 
Conclusions: While physician volume levels have been shown to be 
important predictors of a patient's interventional success, site volume levels 
have less correlation with interventional success for individual procedures. 
1166-1 1 I Shorter Hospital Stays Angioplasty 1 for Patients 
who Receive Abciximab 
Maureen J. Lage, Beth L. Barber, Lee Bowman, Daniel Ball, Mohan Bala. 
Miami Universi~ Oxford, OH, USA 
Background: This retrospective study examines the effect of abciximab 
treatment in a naturalistic setting on hospital length of stay (LOS) for patients 
undergoing angioplasty. 
Methods: Hospital billing data for PTCAs performed over a fifteen month 
period (October 1, 1995 to December 31, 1996) was obtained from HCIA's 
Clinical Database. Results are reported for 13,238 patients, 1,956 of whom 
received abciximab. Multivariate analysis was used to control for a wide range 
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of factors (patient demographics, comorbidities, admission and discharge 
information, hospital characteristics) which may influence LOS. The first 
stage of the analysis utilizes a probit regression to determine the factors 
which lead to an increased likelihood of patients receiving abciximab. In the 
second stage of the analysis, a negative binomial model is estimated for 
patient's LOS, while controlling for unobserved factors which are correlated 
with the patient's likelihood of receiving abciximab. 
Results: Patients in poorer health were more likely to receive abciximab. 
After controlling for high risk indications and selection bias, results indicate 
that angioplasty patients who are given abciximab have a significantly shorter 
LOS (0.89 days). In a sub-group analysis of angioplasty patients who had 
an acute myocardial infarction (n = 4,693), patients receiving abciximab (n = 
1,093) were found to have significantly shorter hospital stays (0.54 days). 
Conclusion: Results of this study indicate that there are potential eco- 
nomic benefits for hospitals administering abciximab. Given that hospital 
length of stay has been found to be one of the most important determinants 
of total health care costs, these results imply cost offsets for patients receiving 
abciximab. 
ORAL  
Hypertension: Pathophysiologic Aspects 
Tuesday ,  March  9, 1999,  2 :00  p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 207 
2 :00  p.m. 
[85~ Ca rdiorespiratory Fitness Exercise Attenuates 
Blood Pressure and Left Ventricular Hypertrophy in 
Normotensive and Hypertensive Women 
Peter Kokkinos, Vasilios Papademetriou, Andreas Pittaras, John Colleran, 
Charles Dotson, David Dietrich, David Jocob, Ross Fletcher. Veterans 
Affairs & Georgetown University Medical Centers Washington, DC, USA 
Background: An abnormal rise in exercise blood pressure (BP) is associated 
with increased risk for hypertension and left ventdcular hypertrophy (LVH). 
Exercise BP may reflect the hemodynamic load during daily activities. We 
reported lower exercise BP in hypertensives following aerobic training. Thus, 
increased fitness may attenuate LVH by attenuating the hemodynamic load. 
Methods: We assessed cardiac structure (echo) and exercise tolerance 
in 556 middle-aged women (age = 53 ± 13), to determine relationships 
between LV structure and exercise parameters. All were free of heart disease 
and antihypertensive medication, but 33% were hypertensive. Three fitness 
groups were formed: Low (n = 138), Moderate (n = 231) and High (n = 187), 
based on exercise time and adjusted for age. 
Results: Group differences were noted in LVMI and exercise BP (Table). 
The strongest predictor of LVMI was SBP at 6 minutes of exercise (SBP-6) 
for low (R 2 = 0.33); moderate (R 2 = 0 .30)  and high fit women (R 2 = 0.23). 
HTN (n = 188) No HTN (n = 368) ALL (n = 556) 
LVMI SBP-6 LVMI SBP-6 LVMI SBP-6 
Low 143±341 189 zE 22 110±30 160±19 126±36" 171+25 
Mod 128±35 189-E 21 105±26 155±20 113 zE 31 166±25 
High 117±34 172 ± 21 t 99~23 t 148± 16 t 103 zE 25 153 ± 20 t 
*Differences among groups (p < 0.01 ); tfrom other groups (p < 0.01) 
Conclusions: 1) High cardiorespiratory fitness is associated with lower 
LVMI and exercise BP in women; 2) The lower LVMI observed in moderate 
and high fit women is partly due to the lower exercise BP in these groups. 
2 :15  p.m. 
l -~ ls  a High Pulse Pressure in Hypertension Associated 
With Altered Left Ventricular Structure or Function? 
Icilma V. Fergus, Vittorio Palmied, Michael H. Alderman, Dawn Fishman, 
Richard B. Devereux. Comell Medical Center and Albert Einstein College of 
Medicine, New York, NY, USA 
Objective: To assess whether high Pulse Pressure (PP) is associated with 
altered Left Ventricular (LV) structure or function, which might contribute to 
the prognostic value of high PP in Hypertension. 
Background: A high PP in untreated hypertensives has been previously 
documented to be independently predictive of coronary artery disease events 
particularly myocardial infarction. A high PP is associated with increased 
arterial stiffness; however, it is unknown whether high PP is also associated 
with abnormal LV structure or function. 
Methods: A total of 474 hypertensive patients (ages 18-82 years) was 
selected from an urban employed population. The patients were further 
subdivided into groups based on PP, PP1 < = 46 mmHg, PP2 47-62 mmHg, 
PP3 > = 63 mmHg. (PP1 n = 118, PP2 n = 199 and PP3 n = 157). Structural 
and functional echocardiographic LV findings were compared among the 
groups. 
Results: There was no significant difference among the groups in body 
mass index. When adjusted for age and sex, the PP3 group had a higher LV 
Mass than PP1 patients, (204.9 gms ± 77.24 Vs 185.5 gms i 52.03, p = 
0.009) and higher LV Mass Index (108.13 gms/M 2 ± 35.17 Vs 96.41 gms/M 2 
-4- 25.50, p = 0.018). There was no difference in LV relative wall thickness 
(RWT), midwall shortening (MWS), fractional shortening (FS) or contractility 
indices. 
Conclusion: Untreated hypertensive patients with a high PP have a 
significantly higher LV mass independent of age and sex compared with 
patients who have a low PP. However, there are no associated LV functional 
differences among the groups. Thus, the prognostic significance of high PP 
in hypertension may be mediated in part by higher LV mass in addition to the 
known increase in arterial stiffness. 
2 :30  p,m. 
[ -~-~ Chronic Hyperinsulinemia Impairs Heart Rate 
Variability in Obese and Hypertensive Subjects 
Michel Galinier. Jo~lle Fourcade, Nicolas Ley, Sophie Solera, 
Marie-Laure Solera, Serge Boveda, Philippe Cabrol, Pierre Massabuau, 
Jean-Marie Fauvel, Pierre Valdiguie, Jean-Paul Bounhoure. Rangueil 
University Hospital, Toulouse, France 
Bakground: During insulin resistance sympathetic nerve activity is increased. 
However insulin resistance is a common feature of obesity and essential hy- 
pertension, it is unclear if chronic hyperinsulinemia per se contributes to 
sympathetic overactivation. The aim of this study was to explor the relation- 
ships between chronic hypednsulinemia (HI) and heart rate variability (HRV), 
a non-intensive tool to assess autonomic function, in obese and hypertensive 
patients (pts). 
Methods: 24 hours Holter ECG for HRV time and frequency domain 
analysis was performed in 77 pts, mean age 53 ± 10 years, 52 men and 
25 women, free of diabetes, without beta-blockers, divided in four groups 
according to three parameters, body mass index (BMI > 27kg/m ~ in man 
and >25 kg/m 2 in woman defined obesity), arterial pressure and insulinemia 
(fasting insulinemia > 25 mUI/L defined hyperinsulinemia): 27 pts obese, 
hypertensive, with HI; 28 pts obese, hypertensive, without HI; 12 pts non 
obese, hypertensive without HI; 10 pts obese, normotensive, without HI. 
Results: In comparison with the three other groups, patients with hyperin- 
sulinemia showed a significant decrease {p < 0.05) of SDNN and the power 
of total spectrum (0.01-1 Hz) band, which are indexes of global HRV, and a 
significant decrease (p < 0.005) of SD and the normalized power of the low 
frequency (0.04-0.15 Hz) band, both indexes reflecting sympathetic modula- 
tion of HRV. In contrast, no significant difference was observed between the 
four groups for indexes of HRV reflecting parasympathetic tone. These rela- 
tions were independent of mean RR Fasting insulinemia was significantly (p 
< 0.0001 ) related with HRV in time domain (SDNN: r = -0.43; SD: r = -0.49) 
and spectral domain (total spectrum: r = -0.49; low frequency: r = -0.52). 
Conclusion: Chronic hyperinsulinemia ppears to be an important deter- 
minant of HRV, particularly for the indexes reflecting sympathetic influence, 
independent of obesity and hypertension. 
2 :45  p.m. 
~ Arrhythmia Risk in Hypertensive Patients With Mild 
Left Ventricular Hypertrophy. Fiction or Facts? 
Kostas T. Gatzoulis, Grigoris K. Vyssoulis, Theodoros Apostolopoulos, 
Polychronis Delaveris, Skevos K. Sideris, Artemisia J. Theopistou, John 
E. Gialafos, Pavlos K. Toutouzas. Cardiology Division, Hippokration General 
Hospital, Athens, Greece 
Background: Electrocardiographic (ECG) and echocardiographic markers 
of severe left ventricular hypertrophy (LVH) are associated with ventricular 
arrhythmias (VA) and sudden cardiac death in hypertensive (HTN) patients 
(pts). Nevertheless, it is unknown, whether milder forms of LVH, most com- 
monly seen in ambulatory HTN pts, carry such a risk. 
Methods: 2 HTN groups were prospectively studied. GR-A pts (n:35) had 
no LVH (LVMI: 112 i 22 g/m 2) while the 65 GR-B pts had mild LVH (LVMI: 
156 ± 24 g/m2). All pts were studied at Baseline with physical examination, 
12 lead ECG, echocardiography, 24 hour ECG and signal averaged ECG 
(SAECG). Mean long term clinical follow-up: 40 ± 5 months. 
Results: GR-B pts were older (56.3 ± 10 vs 50 ± 15 years) with thicker 
intraventricular septum (12.4 ± 1 vs 10.6 + 2 mm), higher systolic blood pres- 
sure off antihypertensives (171 ± 21 vs 155 ± 31 mmHg), larger body mass 
index and body surface area. Despite the above, none of the ECG markers 
differed between the two groups. Similarly, all arrhythmia data analyzed on 
24 hour ECG and SAECG showed no significant differences. During the long 
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term follow-up, under antihypertensive treatment, SBP control was achieved 
in both groups with significant reduction of the LVMI among the GR-B pts. 
No significant morbidity (pro or syncope, sustained ventricular tachycardia) 
or mortality was observed in any of the 100 pts. 
Conclusions: Mild, echocardiographically detected LVH, which is com- 
monly detected in HTN pts, is not associated with serious VA or life threat- 
ening events. Early forms of LVH in ambulatory HTN pts do not result in 
wordssome arrhythmogenic changes and can be easily reversed with anti- 
hypertensive therapy. 
3:00 p.m. 
~ A B P M  and Ergometry in the Assessment of Blood 
Pressure in Normotensive and Hypertensive 
Patients 
Joachim F.M. MOiler, I.-W. Franz. Klinik Wehrawald der BfA, Todtmoos, 
Germany 
Objective: 24 h BP monitoring (ABPM) can exactly distinguish between 
normotensive and hypertensive blood pressure (BP) whereas ergometry 
(increased BP response) can also predict future hypertension even when 
casual BP is still normotensive. However, it is unknown if patients who are 
normal in ABPM can also reveal an increased exercise BP (ExBP) and 
whether an increased body mass index (BMI) may play a major role in this 
process. 
Design and Methods: A total of 1137 patients underwent ABPM (Space- 
Labs 90 207) and were classified by their mean daytime BP into hypertensives 
(HYP, >135/>85 mmHg, n = 525) and normotensivas (NORM, <135/<85 
mmHg, n = 468). 144 patients could not be properly classified. Thereafter 
HYP and NORM were divided into three groups with regard to their BMI. All 
the patients underwent a comprehensive lifestyle modification program for 4 
wee'Ks and an exerd~se '(ast ~5£~'to 10~3 watts) beloTe ar~ aTt~r~a~s. 
Results: 
Normal weight Overweight Obesity 
BMI < 25 BMt 25-30 BMI > 30 
Before After Before After Before After 
BMI HYP 23.24-1.4 22.7±1.2 27.54-1.3 25.94-1.2 33.24-3.1 30.94-3.1 
ExBP HYP 224.24-20/ 196.4±20/223.5{22/ 191.85:22/227.1+23/ 19424-23/ 
100W 116.94-9 99.54-10 117.44-12 99.04-10 121.44-12 101.24-10 
96,04-15 94.64-11 104.94-14 95.14-10 113.14-14 98.6±10 
Daytime BP HYP 147.9--10/96.3:1:7 146.84-9195,8±6 147.8±11/95.44-7 
Ace HYP 51.84-7 n= 104 51.4±7 n = 239 50.5=:8 n= 182 
"~yr~) n "-P~O"RCa "4"uh :£ru n =~ru'~ *¢~?~'=?~ = D~, "4"or :£1"u~ =*T'/'u 
Conclusion: Only NOR (by ABPM) with normal body weight also have 
a normal response of BP during exercise. In NOR ExBP was significantly 
(,9 < Q,001.~, and 9&tho[o~calb~ increased with increasinc& BMI. but could be 
normalised by weight reduction. Increased body weight seems to have an 
important effect on ExBP even in NOR (by ABPM) and can be assessed, at 
a very early stage of hypertension by BP measurement during exercise. At 
this stage body weight reduction can normalise ExBP. 
3:15 p.m. 
[ - ~  Blood Pressure Response to Subjects Exercise in 
With High-Normal Blood Pressure 
Nobuyuki Miyai, Mikio Arita, Ikuharu Mirioka, Kazuhisa Miyashita, 
Ichiro Nishio, Sintaro Takeda. Wakayama Medical University;, Wakayama, 
Japan 
Background: As hypertension is a major health problem in Japan, the early 
detection and treatment of hypertension is a topic of paramount importance. 
To determine whether blood pressure (BP) response to exercise in subjects 
with high-normal BP may be useful in detecting persons who are prone to 
developing hypertension in late years. 
Methods: The subjects for this study were 289 normotensive men (age: 
41.9 4- 5.7 years old, mean 4- SD, normal BP; 191 men, high-normal BP; 
98 men). A graded uninterrupted exercise test on the bicycle ergometer up 
to exhaustion was performed in all subjects. BP was measured in 1-min 
intervals by a Colin STEP-780B automated BP monitor. The increase in 
systolic (S)BP from rest to the workload corresponding to 60% of relative 
heart rate was calculated in each subjects (ASBP). Following the exercise 
test, the resting BP were measured every one year for 5 years in all subjects. 
Stepwise logistic regression analysis was performed for future hypertension. 
Results: 1) After 5 years, 5.2% (stage 1; 4.2%, stage 2; 2.1%) of normal 
BP and 33.7% (stage 1; 28.6%, stage 2; 5.2%) of high-normal BP were 
shown to be hypertension. 2) High-Normal BP were divided into two groups 
with (HT, n = 33) or without (NT, n = 65) hypertension after 5 years. ~SBP in 
HT was significantly higher than that in NT (HT; 69.3 4- 18.9, NT; 54.7 d: 20.0 
mmHg, p < 0.01). 3) The subjects were divided into 2 groups according to 
the pressure response to exercise; L: less than 25th percentile (%ile), H: 75th 
%lie more. 52% of H showed hypertension, while only 12% of L (p < 0.01). 
4) Stepwise logistic regression showed that ASBP was the best predictor for 
future hypertension. 
Conclusions: These data suggest that exaggerated blood pressure re- 
sponse to exercise may be a valid prognostic test to indicate the likelihood 
of future hypertension in the subjects with high-normal BP. 
POSTER 
Coronary Artery Disease: Vascular 
Mechanisms 
Tuesday,  March  9, 1999,  3:00 p .m. -5 :00  p.m. 
Mortal  Convent ion  Center ,  Hal l  F 
P resentat ion  Hour:  3 :00 p .m. -4 :00  p.m. 
~ Relationship Between C-Reactive Protein and 
5-Year Clinical Outcome in a Subset of Patients 
from the Bypass Angioplasty Revascularization 
investigation (BARI) 
Kevin E. Kip, Katherine M. Detre, Alice K. Jacobs, Martial G. Bourassa, 
Norma M Keller, E. Magnus Ohman, Leonard Schwartz, George Sopko, 
MeJvJJo WeJ,ss, George G. KJee. U/]JversJty of PJ#..~bufgb, Mayo CJJnJc, USA 
Background: Emerging evidence suggests that the acute phase reactant, 
C-reactive protein (CRP), is associated with risk of myocardial infarction (MI) 
and cardiac mortality. This marker of underlying systemic inflammation has 
received limited attention in patients (pts) with multivassel coronary disease 
(MVD) undergoing revascularization. 
Methods: From BARI, 164 pts with MVD at 6 of 17 clinical sites had 
characteristics and clinical outcomes in 40 pts with CRP concentrations in 
the upper quartile (>1.7 rag/all) were compared with the remaining 124 pts 
Results: Baseline medical history was similar between pts with measured 
CRP (n = 164) and all ether BARI randomized pts (n = 1665). Compared to 
q < (£.<./tZ:. (~ ~qetZas(- s{~.#~'4~c~¢qc<~K(~adCKcT~(~e~se w s (ess qcev~(enc' 
in pts with high CRP (17% vs. 40%, p < 0.01). At five year follow-up, pts 
W~'n "d~g'n "ease'hne £,'i~'~ "nae'rh g~er rates o~ care~ac t~ea'tn '~,.~.~o ~s. 'h .~'~o, p 
= 0.05) and Q-wave MI (17.7% vs. 5.6%, p = 0.02). In addition, despite the 
low prevalence of proximal LAD disease in pts with high CRP, multivariate 
analysis revealed that pts with both proximal LAD disease and hitch CRP 
had substantially elevated 5-year risk of cardiac deattVMI (relative risk 4.92), 
and the interaction between CRP and proximal LAD disease was statistically 
significant (p = 0.02). 
Conclusions: Among MVD pts undergoing initial revascularization, base- 
line CRP concentration is a marker of poor long-term clinical outcome. This 
was most striking among pts with proximal LAD disease and requires further 
investigation. 
~ T h e  Plasminogen Activator inhibitor-1 Gone 
4G/5G Polymorphism and Cardiovascular 
Disease: The Framingham Heart Study 
DaLi Feng 1 , Geoffrey H. Tofler ~ , Martin G. Larson 2, Christopher 
J. O'Donnell 2, Izabella Lipinska ~ , Patrice A. Suthedand 2, Daniel Levy 2, 
Klaus Lindpaintner 3. Institute for Prevention of Cardiovascular Disease, 
Beth Israel Deaconess Medical Center; 2 NHLBI's Framingham Heart Study, 
Framingham, MA; 3Brigham & Women's Hospital, Boston, USA 
Background: Elevated levels of plasminogen activator inhibitor (PAl-l) have 
been associated with increased cardiovascular risk. More recently, a 4G/5G 
polymorphism in the promoter region of PAl-1 gone has been identified, 
which modifies PAl-1 levels. To determine the relation between the 4G/5G 
polymorphism and cardiovascular disease (CVD), we studied subjects from 
the Framingham Heart Study. 
Methods and Results: Genotype and prevalent cardiovascular disease 
were evaluated in 3177 subjects enrolled in the study. The allele frequencies 
of 4G and 5G were 0.53 and 0.47 respectively. There were no significant 
differences in genotype distribution among subjects with or without cardiovas- 
cular disease, p = 0.83. Similar results were obtained for men and women, p 
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= 0.76 and 0.63 respectively. When we looked specifically at unstable angina, 
myocardial infarction, or ischemic stroke there was also no difference. 
Subjects (number) Genotype (number and %) 
4G/4G 4G/5G 5G/5G 
CVD (n = 511) 149 (29%) 256 (50%) 106 (21%) 
No CVD (n = 2666) 738 (28%) 1344 (50%) 584 (22%) 
Conclusion: In the Framingham Heart Study, although the 4G/5G poly- 
morphism significantly modified PAl-1 antigen levels, this polymorphism was 
not associated with prevalent cardiovascular disease. 
• Augmentation of Reactivity of Platelets in Acute 
Coronary Syndromes Is Associated With 
Increased cx Granule Degranulation but not 
Increased Glycoprotein lib-Ilia Activation 
Michael B. Holmes, Burton E. Sobel, Diantha B. Howard, David 
J. Schneider. The University of Vermont, Burlington, Vermont, USA 
Background: Because increased platelet reactivity appears to presage acute 
coronary syndromes we sought to determine the extent to which specific 
components of platelet activation, particularly glycoprotein lib-Ilia activation 
and e granule degranulation, differ in healthy volunteers and patients with 
acute coronary syndromes. 
Methods: Platelel activation was characterized with flow cytometry in 
whole blood anticoagulated with corn trypsin inhibitor (a specific inhibitor of 
factor Xlla without effect on other coagulation factors) in response to ADP. 
Glycoprotein lib-Ilia activation was determined by fibrinogen binding and c~ 
granule degranulation was determined by P-selectin expression. 
Results: On average, 78% of platelets bind fibrinogen in response to 1 
~M ADP while only 25% express P-selectin. Patients with acute coronary 
syndromes (on aspirin) had significantly increased P-selectin expression in 
response to ADP compared with that in healthy subjects taking aspirin (for 
1 ,~M ADP 41% versus 25%, p < 0.001 by ANOVA contrast statement). 
No difference in fibrinogen binding between patients and healthy volunteers 
was observed. Daily ingestion of 325 mg of aspirin had no effect on either 
P-selectin expression or fibrinogen binding in healthy subjects. 
Conclusions: Analysis of platelet reactivity with flow cytometry defined 
activation with respect to specific components of the process and should 
facilitate optimal titration of antiplatelet herapy and hence development of 
highly targeted antiplatelet drugs. Increased platelet reactivity in patients with 
acute coronary syndromes appears to be a reflection of increased propensity 
for degranulation but not glycoprotein lib-Ilia activation. 
~ F  Vlla and F1 + 2 in Unstable Angina Pectoris: 
Heparin Therapy, Haemostatic Activation and 
Recurrent Ischaemia 
R. Amersey, P.J. Stubbs, M. AI Obaidi, A. Adam±, H. Phillipou, D. Lane, 
M. Noble. Char±rig Cross Hospital, Imperial College, London, UK 
Background: The heterogeneous pathophysiology of UAP includes coronary 
thrombosis. Evidence regarding haemostatic activation following cessation 
of anti-thrombotic therapy for UAP continues to grow. Generation of activated 
Factor VII (F Vlla) is a key initiating event during extrinsic pathway activation. 
We examined peripheral venous levels of F Vlla and the prothombin fragment 
F1 + 2 by ELISA in UAP, the effect of unfractionated i.v. heparin therapy on 
F Vlla and F1 + 2 and their relationship to early recurrent ischaemia. 
Methods: Consecutive patients (n = 102) presenting with chest pain to 
our CCU were studied on admission (baseline) prior to any therapy, during 
standardised AP'I-I" adjusted heparin therapy for UAP (18 to 24 hours post 
admission) and 12 hours following cessation of heparin. 
Results: UAP (n = 54) is characterised by elevated F Vlla on admission 
(mean 4- SE; 1.05 4- 0.3 ng/ml) compared to non cardiac chest pain controls 
(0.32 4- 0.05, p = 0.02). This is associated with raised and correlating F1 + 2 
(mean 4- SE; 45.8 4- 4.0 ng/ml, p < 0.05: rs = 0.33, p = 0.04). 
F Vlla and F1 ÷ 2 During and Following Heparin Therapy 
Heparin Post heparin Therapy 
F Vlla ng/ml 0.37 ± 0.04" 0.42 ± 0.05 
F1 + 2 nglml 38.18 ± 2.9" 47.51 ± 4.5" 
"p < 0.o5 vs admission, "p < 005 vs heparin 
14 patients needed either early revascularisation, sufferred refractory 
ischaemia or AMI at 30 days. There were no differences in F Vlla or F1 + 2 
in this patient group at any time point. 
Conclusions: Activation of the extrinsic pathway of coagulation on ad- 
mission in UAP is detectable. F Vlla and F1 + 2 are suppressed with heparin 
with a rebound in F1 + 2 following discontinuation of treatment. F Vlla does 
not rise. This is the first study to show the effect of heparin on F Vlla in vivo. 
F Vlla and F1 + 2 do not predict early recurrent events. 
1191-241 Flow Characteristics of the Internal Mammary 
I Artery After Minimal Invasive Bypass: Change 
from Systemic to Coronary Circulation 
Gerd P. Meyer, Bernd Laudenberg, Dirk Hausmann, Andreas M0gge, 
Jochen Cremer 1 , Wolf Rafflenbeul, Helmut Drexler. Div of Cardiology; 
Cardiovascular Surgery, Hannover Medical School, Germany 
Background: Little is known about flow characteristics of the left internal 
mammary artery (LIMA) directly before and soon after minimal invasive 
bypass surgery before complete remodeling of the LIMA can be expected. 
Transthoracic doppler (TD) was used to evaluate LIMA-flow pattern. 
Methods: 29 patients (Pt) were examined the day before and 3-8 days 
after MIDCAB to the LAD using a 10 MHZ transducer (HDI 3000, ATL). In 
10/29 Pt intravascular doppler (FW) was performed simultaneously (0.014 
inch Doppler wire). In 9/29 Pt LIMA-flow was obtained in two intercostal 
spaces (ICS). Systolic-, diastolic-peak velocity (SPV, DPV) was measured. 
Change in SPV and DPV between ICS = DPV/SPV-ratio. 
Results: 1. SPV decreased, and DPV increased postoperatively ('p < 
0.01) [Fig.]. 2. Post-operative SPV and DPV correlated well between TD and 
FW (~r = 0.96; °r = 0.95); trend to higher DPV in TD (p = n.s.) [Tab.]. 
.- I I  
LIMA pre- L IMA post - 
MIDCAB I MIDCAB 
preop (TD) n = 29 postop (TD) n = 29 postop (FW) n = 10 
SPV (cm/sec) 103 ± 24 43 J_ 14" 42 ± 11 # 
DPV (cm/sec) 18 ± 7 41 ± 15" 31 ± 113 
3. DPV/SPV-ratio increased from 2nd (0.9 4- 0.26) 1o 3rd ICS (1.2 4- 0.3); 
p < 0.01. 
Conclusions: The LIMA showes an early postoperative adjustment from 
'systemic' to 'coronary' circulation when used as a bypass graft. Diastolic 
flow increases in the course of the LIMA-graft. 
~ Serum Cholesterol Level Vasomotor and 
Responses of Coronary Stenoses to 
Acetylcholine in Patients With Stable Angina 
Dimitris Tousoulis, Diana Gorog, Tom Crake, Homeyra Homaei, 
Nabeel Ahmed, Graham J. Davies. Cardiology Unit, Hammersmith Hospital 
Imperial College School of Medicine, London, UK 
Background: Endothelial dysfunction which characterizes atherosclerosis 
is the major mechanism of acetylcholine (Ach) (an endothelium dependent 
dilator) induced coronary artery vasoconstriction. The purpose of this study 
was to examine the relationship between coronary segments and stenoses 
vasomotion in response to Ach and serum cholesterol level. 
Methods: Intracoronary Ach was infused at 10 7, 10-6 10 5 M, followed 
by intracoronary bolus administration of isosorbide dinitrate (ISDN) in 18 
patients. Fasting serum cholesterol level was measured before the study, 
and computerized angiography was used to assess the diameter changes. 
Results: The % change from baseline was: 
Proximal S Distal S Coronary stenoses 
Saline -0 .2  ± 0,5% 0.2 ± 0.6% 2,3 5: 0.9% 
Ach 10 -7 M -0 .7  ± 0.7% -2 .6  ± 1.2% -5 ,5  ± 2.0%" 
Ach 10 s M 3.6 ± 1.0% + -8,1 ± 2.3%" -11.9 ± 2.4%* 
Ach 10 -5 M -7 .3  ± 1.6%" 13.5 ± 3,8%' -19.6 ± 3.0%" 
ISDN 10.9 ± 1.9%" 27.1 4- 40%" 18.4 -+. 3.0%" 
• = p < 0.01 vs saline, + = p < 0.05 vs saline, S = segments 
A significant correlation was found between cholesterol level and the 
vasomotor responses of stenoses to 10 s M acetylcholine (r = 0.32, p < 
0.05). No significant correlation was found between cholesterol serum level 
and the vasomotor responses of angiographically normal proximal (r = 0.10) 
or distal (r = 0.13) segments 1o maximum acetylcholine concentration. 
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Conclusions: In response to Ach there was a dose-dependent constric- 
tion in proximal and distal segments and at the site of coronary stenoses. 
Cholesterol level correlates with the vasomotor esponse of coronary stenoses 
to intracoronary acotylcholine and hypercholesterolaemia is associated with 
increased basal vasomotor tone. These findings are consistent with a direct 
effect of cholesterol on endothelium derived relaxing factor or on the vascular 
smooth muscle cell contractile mechanism. 
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1192-261 Natriuretic Relaxes Isolated Dendroaspis Peptide I 
Human Arteries and Veins 
Patricia JM. Best, John Burnett, Jr., Stephanie H. Wilson, 
Darcy Richardson, Amir Lerman. Mayo Clinic and Foundation, Rochester, 
MN, USA 
Background: Dendroaspis Natduretic Peptide (DNP) which is structurally 
similar to atrial natriuretic peptide, brain natriuretic peptide, and C-type na- 
tduretic peptide was recently isolated from the venom of the green mamba 
and identified as a circulating peptide in humans. Based upon the vasoactive 
properties of the known natduretic peptides, we examined the vasoactive 
properties of DNP in human arteries and veins in vitro. 
Methods and Results: Rings of human internal mammary artery (n = 
9) and saphenous vein (n = 9) with endothelium intact were suspended in 
an organ bath. The rings were precontracted with 10 7 M endothelin-1 and 
response to cumulative concentrations of DNP (10-7-10 10 M) were ob- 
tained. Additionally, both arteries (n = 6) and veins (n = 6) were preincubated 
with 60 mM KCI and 10 7 M endothelin-1 before relaxation with cumulative 
concentrations of DNP (10-7-10 lO M). DNP caused a dose-dependent re- 
laxation in both the human arteries and veins. Maximal relaxation, however, 
was greater in arteries (maximal relaxation of arteries: 84 ~ 4%, veins: 34 
± 6%, p < 0.0001) as compared to veins. KCL significantly attenuated DNP 
vasorelaxation (maximal relaxation of arteries: 16 ± 8%, veins: 8 ± 8%, p < 
0.0001 compared to vessels without KCL). 
Conclusions: DNP is a newly identified natriuretic peptide which is a 
potent vasorelaxing factor in human arteries and veins and acts as a potent 
hyperpoladzing factor. 
I l l  92-271 Simvastatin in Vitro and Small Improves Large i Vessel Endothelial Function Independent of Lipid 
Lowering Effects 
Stephanie H. Wilson, Patricia J.M. Best, David R. Holmes Jr, Amir Lerman. 
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, 
USA 
Background: The benefits from the HMGCoA reductase inhibitors may occur 
independent of lipid lowering. We aimed to determine the effects of simvas- 
tatin on endothelial function in experimental hypercholesterolemia (HC), in 
the absence of cholesterol lowering. 
Methods: Pigs were randomized to 3 experimental groups (each n = 6): 
normal diet (N), high cholesterol (HC) diet, and HC diet with simvastatin (HC 
+ S) (40-80 mg/day) for 12 weeks. In vitro analysis of coronary epicardial 
and arteriolar (<500 /~m) vasorelaxation to bradykinin (10 11-10-e M), an 
endothelium-dependent vasodilator, was performed. 
Results: Total and LDL cholesterol were not significantly different be- 
tween the HC vs HC + S groups, although levels were significantly increased 
compared to normal controls 
i~ ] Response of coro~at7 arterio4es to I~dykinin 
41 4O "0 -a -7 
1~ Response of epican~i81 vessels to ~-ady)d nin '®' ~-~~ 
l a  • . 
=i 
an~n ~e,0w~r=n~ 
The significantly attenuated epicardial and arteriolar vasorelaxation in the 
HC pigs as compared to the N pigs (p < 0.05) was reversed in the HC + S 
treated group (p < 0.05) despite no change in lipid values. 
Conclusion: Simvastatin improves endothelial function in coronary epi- 
cardial vessels and arterioles, independent of lipid lowering effects. These 
alterations may play a role in the reduction in cardiac events with treatment 
with HMGCoA reductase inhibitors. 
J l I Coronary Vascular Dysfunction Associated With 1 92-28  
Direct Current Shock Injury 
Christine L. Oltman, Craig B. Clark, Neal L. Kane, L. Ray Davies, Richard 
E. Kerber, Kevin C. Dellsperger. VAMC and Univ. of Iowa, Iowa Ci~ IA 
52242, USA 
Background: Direct current (DC) shocks for cardioversion or defibrillation 
can cause myocardial injury. 
Purpose: To determine coronary conduit and microvascular reactivity 
following DC shocks. 
Methods: 9 mongrel dogs (18-23 kg) were anesthetized. In each of 5 
dogs, three 20 J monophasic DC shocks were delivered to the epicardium us- 
ing hand-held paddles. In 4 dogs, paddles cradled the heart, but no shocks 
were delivered (sham). Hearts were immediately removed and placed in 
cold krebs buffer. Epicardial coronary artery rings and microvessels were 
dissected and cleaned. All studies were performed in warmed (37 ~ C), oxy- 
genated (20% 02, 75% N2 and 5% CO2) Krebs buffer. Tension development 
of epicardial arteries was measured after preconstdction with PGF2a. Internal 
diameter measurements were recorded with video microscopy of microves- 
sels (112.1 ± 6.8 #m) mounted onto glass pipettes, pressurized (distending 
pressure 20 mmHg, no flow) and preconstricted with endothelin. After con- 
striction (30-50% of resting diameter), cumulative doses of acetylcholine 
(Ach, 10 l°-10 -4 M), bradykinin (Brady, 10 14-10-6 M) or sodium nitro- 
prusside (SNP, 10 1°-10-4 M) were added to the baths. 
Results: Maximal relaxation: mean i SEM. *p < 0.05 vs sham. 
Conduit Rings Microvessels 
Sham 20 J x 3 Sham 20 J x 3 
Ach 87,6 ± 19.1 65.5 ± 2.6" 103.4 ~- 4.2 68.7 ± 3,4" 
Brady 99.2 ~: 16.6 89.8 ~: 5,6 99.9 ± 7.3 103.7 ± 8.9 
SNP 118.0 ± 16.3 135,3 ~- 7.1 94.5 ± 2.3 97,1 ::c. 2.7 
Ach induced dilation was attenuated in conduit arteries and arterioles 
from hearts which had received three 20 J DC shocks. Responses to Brady 
and SNP were not altered by the shocks. 
Conclusion: DC shocks cause endothelial dysfunction in canine coronary 
conduit arteries and microvessels. 
j 1192-291 The Balance Between Nitric Oxide and Free 
Radicals Affects the Coronary Vasodilator 
Reserve 
Philipp A. Kaufmann, Tomaso Gnecchi-Ruscone, Thomas F. Lascher, Paolo 
G Camici. Hammersmith Hospital Imperial College School of Medicine, 
London, UK; University Hospital, Zurich, Switzerland 
Background: The action of nitric oxide (NO) on the coronary vasculature is 
partially antagonized by simultaneously produced free radicals. We studied 
how changes in this balance affect the function of coronary resistive vessels 
assessed by measuring the coronary vasodilator eserve (CVR). 
Methods: Using positron emission tomography with oxygen-15 labeled 
water, myocardial blood flow (MBF, ml/min/g) was measured in 39 healthy 
male volunteers at rest (R) and during iv adenosine (Ado; 0.14 mg/kg/min). 
Both measurements were repeated 15 minutes later during an iv infusion of: 
A -saline (n = 12); B -  3 mg/kg NG-Mono-methyI-L-arginine (L-NMMA), an 
inhibitor of NO synthase (n = 9); C - 3 mg/kg L-NMMA coinfused with 3 g 
of the free radical scavenger vitamin C (vit C; n = 9); D - 3 g vii C alone 
(n = 9). CVR was calculated as Ado-/R-MBF after correcting R-MBF for the 
rate-pressure product. 
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Results: Heart rate and mean arterial blood pressure were similar in all 
4 groups at R and during Ado, both before and dudng the infusions. CVR 
increased in group C (+36%, *p < 0.05) compared to baseline. 
saline LNMMA LNMMA + vit C vit C 
CVR 1 2.96 ± 0.77 2.91 ± 0.77 2.63 + 0.61 2.91 ± 0.82 
CVR 2 2.96 ± 0.57 2.97 ± 0.74 3.35 ± 0.94* 3.22 ± 0.92 
Conclusion: No reduction of MBF or CVR was observed during LNMMA 
infusion. Coinfusion of LNMMA and vit C increased significantly Ado-MBF 
and CVR, suggesting a shift of the balance in favor of the vasodilator NO. 
1 j Pyruvate Prevents Oxidative 1 92-30  Stress 
Olaf Sommer, Eberhard Bassenge. institute of Applied Physiology, 
University of Freiburg, Germany 
Background: Vascular impairment induced by hyper-cholesterolnemia or 
ischemia is partially due to excessive formation of oxygen radicals (SOD) as 
a consequence of enhanced NADH-oxidase activity (NADHox). The aim of 
the study was to analyze a) NADH-oxidase activities in heart, liver and aorta 
and cardiovascular effects induced by pyruvate (Py) in isolated heads from 
cholesterol-fed (Chol) guinea pigs, b) the effects of Py on ischemic-induced 
cardiovascular SOD formation. 
Methods: Cardiovascular responses were measured in isolated perfused 
hearts. NADHox was assayed measuring chemiluminescence of tissue ho- 
mogenates. SOD formation was quantified by electron spin resonance using 
1-hydroxy-3carboxy-pyrrolidine (CPH) as radical scavenger. 
Results: Py significantly improved the impaired cardiovascular function 
(left ventricular pressure +28 ± 5%, contractility +30 ± 8%) in Chol hearts. 
In tissue homogenates Py as well as hydralazine (inhibitor of NADHox) 
significantly decreased NADHox as compared to Chol (0,05 mM pyruvate: 
-35 ± 3%, -16 ± 2%, -33 ± 4% in liver, heart and aorta, respectively; 
0.5 mM pyruvate: -73 ± 10%, -58 • 9%, -74 :~ 5% in liver, heart and 
aorta, respectively). Py diminishes significantly and dose-dependently the 
ischemic-induced SOD formation (control: +175 + 6%, Py 5 raM: +105%) 
Conclusion: Pyruvate provides protection against ischemia or a choles- 
terol-mediated decrease in cardiovascular function, induced by excessive 
superoxide radicals formed as a consequence of enhanced NADH-oxidase 
activity. 
POSTER 
Vascular Disease Peripheral 
Tuesday, March 9, 1999, 3:00 p.m.-5:00 p.m. 
Modal Convention Center, Hall F 
Presentation Hour: 3:00 p.m.-4:00 p.m. 
New 
Or leans  
March 7-10 
I1 1 Artery Stentin9 Improves Renal Function in 1 93-68  Renal 
Patients With Atheroscierotic Renovascular 
Disease 
Paul Watson, Peter Hadjipetrou, Stephen Cox, Thomas Piemonte, 
Andrew Eisenhauer. Lahey Clinic Medical Center, Burlington, MA, USA 
Background: The long term effect of renal artery stenting on stabilizing or 
improving renal function in patients with renal impairment and atherosclerotic 
renovascular disease has not been established. 
Methods: Patients with chronic, mild to moderate renal failure (docu- 
mented by serial serum craatinine (Cr)) and bilateral renal artery stenosis, 
or unilateral stenosis with a solitary kidney underwent stent deployment and 
were prospectively followed. Benefit on renal function over time was as- 
sessed by comparing the slopes of the plots of the reciprocal of serum Cr vs 
time prior to and following stent deployment. 
Results: 25 patients (14 M, age 71 ± 7 yr) underwent uncomplicated stent 
deployment in 48 stenosed renal arteries. Mean serum creatinine pre-stenting 
was 2.1 ± 0.6 mg/dL. Follow-up (>6 rathe) is available for 20 patients. By 
using the slope of plots of the reciprocal of serum Cr vs time as a dynamic 
measure of renal function, renal function improved or stabilized in all but 
one patient (95%) a mean of 21 ± 10 months post stenting, The mean 
of the slopes of renal function pre and post stent deployment measured 
-0.0088 and +0.0053 dl_/mg/month respectively - representing a significant 
improvement in renal function over time (p < 0.001 paired t-test). Patient 
survival at 21 ± 10 months was 84%. 
I/Serum Cr slopes : dl/mg/month 
O.02S 3 
0.02 -~ Pre stent o.0ts t 
0.01 
°.°0~ 1 
• 0.oos "l 
-0.01 -~ 
-0.015 -~ 
-0.02 -~ Post stent 
-0.02S J 
Conclusion: Endovascular stenting of stenosed renal artedes in selected 
patients with mild to moderate renal failure secondary to chronic ischemia 
stabilizes or improves renal function based on the serial assessment of renal 
function. 
I1 I Treatment of  Pseudoaneurysm of the Femoral 1 93-69  
Artery by Direct Thrombin Injection - Acute 
Results and Follow-Up 
Horst Sievert, Wolfgang Pfeil, Attila Baser, Andreas Fach, Hartmut Merle, 
Hans Spies, Roland Ensslen, Rainer Sch~der, Detlef Scherer. 
Cardiovascular Center Bethanien CCB, Frankfurt, Germany 
Background: Pseudoaneurysms of the femoral artery occurdng after catheter- 
ization can be treated with ultrasound guided manual compression. However, 
this may be painful and time consuming. Recurrence, rupture, skin necrosis 
and other complications may occur. 
Methods: In 9 patients (age 76 ~: 4 years), a pseudoaneurysm of the 
femoral artery 1 to 30 days after PTCA (n = 7) or PTA (n = 2) was treated with 
local injection of thrombin. The maximum diameter of the aneurysm ranged 
from 2.1 to 5 cm, mean 3.5 ± 1.2 cm. 
Results: Under ultrasound guidance, 0.15 to 1.5 ml thrombin solution 
were slowly injected into the aneurysm. In all cases this led to immediate 
thrombus formation within the aneurysm. 2 patients expedenced mild fever 
(<38.5~C). No other complications occurred. Follow-up duplex studies up to 
51 months revealed no recurrence. 
Conclusion: latrogenic pseudoaneurysms of the femoral artery can be 
treated by direct thrombin injection. Because of potential dsks of this treat- 
ment, results of larger studies should be awaited before recommending 
wide-scale use. 
~ 4G/5G Plasminogen Acitvator Inhibitor-1 Gene 
Polymorphism is Associated With Peripheral 
Arterial Disease 
Claire S. Philipp, Harland Austin, John B. Kostis, W. Craig Hooper. 
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New 
Jersey; Centers for Disease Control and Prevention, Atlanta, Georgia, USA 
Background: The 4G allele of the 4G/5G polymorphism of the plasminogen 
activator inhibitor (PAl-l) gene has previously been associated with an in- 
creased risk of coronary artery disease in some studies. Our objective was to 
examine the relationship of the 4G/5G PAl-1 gene polymorphism to periph- 
eral arterial disease (PAD), defined by an ankle brechial systolic pressure 
index (ABI) < 0.85. 
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Methods: The 4G/5G insertion/deletion polymorphism in the promotor 
region of the PAl-1 gone was determined by polymerase chain reaction 
analysis in 34 white participants in the Arterial Disease Multiple Intervention 
Trial (mean age 65.6 ± 7.8) and 83 white age matched controls (mean age 
68.4 ± 6.8). 
Results: 
Genotype + PAD (%) Controls (%) Odds Ratio (96% CI) 
5G/5G 5 (14.7) 27 (32.5) 1.0 (referant) 
4G/5G 20 (58.8) 33 (39.8) 3.3 (1.1,10.8) 
4G/4G 9 (26.5) 23 (27.7) 2.1 (0.61, 7.8) 
Additional analysis assuming a dominant effect of the 4G allele (4G/5G 
and 4G/4G vs. 5G/5G) showed an odds ratio of 2.8 (1.0, 8.9). 
Conclusion: Our data suggest that the 4G/4G and 4G/5G genotypes 
of the PAl gone are associated with an increased risk of peripheral arterial 
disease among whites. 
• Abnormal Free and Total Tissue Factor Pathway 
Inhibitor, and Tissue Factor in Peripheral Artery 
Disease 
Grog Lip, Jean Amiral, Charles McCollum, Andrew Blann. Haemostasis, 
Thrombosis and Vascular Biology Unit, University Department of Medicine, 
City Hospital, Birmingham B18 7QH, UK 
Background: Plasma tissue factor (TF), arising from monocytes and the 
endothelium, is one of the major initiators of coagulation and is raised is 
various cardiovascular diseases. Its activity is regulated by Tissue Factor 
Pathway Inhibitor (TFPI), and alteration in levels of TF and/or TFPI may 
relate to thrombogenesis. 
Aim & Methods: To investigate abnormalities in free and total TFPI in 
patients with peripheral artery disease (PAD), we studied 42 patients (mean 
age 57, 35 men) with objectively (ABPI/Doppler) proven PAD and from 42 
age and sex matched healthy controls. TF (American Diagnostics, pg/mL), 
free TFPI (ng/mL) and total TFPI (ng/mL) (both Diagnostica Stago) were 
measured in citrated plasma. 
Results: 
TF Free TFPI Total TFPI 
Controls 159 ± 61 7.3 ± 1.5 51 9:15 
Patients 276 ± 124 8,0 4- 3.0 42 9:11 
P value <0.001 0,18 0.0059 
Data mean (SD). Uncorrected P values derived from t testing. Tissue 
factor was raised in the patients with PAD. There was no difference in levels 
of free TFPI between the groups but levels of total TFPI were lower in the 
patients. In the controls, 85% of the TFPI was bound, but in patients this 
was only 80% (p = 0.0066). Within the controls, levels of free and total TFPI 
correlated strongly (Pearson r = 0.493, p < 0.001 ) but in the patients this was 
poor (r = 0.154, p = 0.338), suggesting loss of haemostasis in the patients. 
Conclusion: We suggest that reduced levels of total TFPI permit the 
increased levels of TF to rise. This may contribute to the process of athero- 
genesis and the increased risk of thrombosis in patients with cardiovascular 
disease. 
• Angiographic Prevalence and Clinical Predictors 
of Left Subclavian Stenosis in Patients 
Undergoing Diagnostic Cardiac Catheterization 
JoAnna L. English, Daniel J. Donovan, Steven A. Guidera, Edgar S. Carell. 
Wilford Hall Medical Center, Lackland Air Force Base, TX, USA 
Background: This study was designed to determine the angiographic preva- 
lence and clinical predictors of proximal left subclavian artery stenosis in 
patients referred for coronary angiography. The sensitivity and specificity of 
bilateral arm blood pressure differentials in predicting stenosis were also 
determined. 
Methods: The angiographic prevalence of proximal eft subclavian steno- 
sis was determined in 492 subjects undergoing diagnostic cardiac catheteri- 
zation. Bilateral manual arm blood pressures and patient characteristics were 
recorded prospectively. 
Results: Seventeen subjects (3.5%) in the overall population and 9 sub- 
jects (5.3%) with potential surgical coronary disease had proximal subclavian 
stenosis. Pro-catheterization evidence of peripheral vascular disease (PVD) 
was the only predictor of subclavian stenosis in the overall population (p 
< 0.001, OR 7.9, 95% CI 2.6-24.3) and in patients with potential surgical 
coronary disease (p = 0.04, OR 5.4, 95% CI 1.1-27.2). A manual arm blood 
pressure differential of >20 mmHg had a sensitivity of 35% and a specificity 
of 94% for predicting left subclavian stenosis; a differential of >10 mmHg 
had a sensitivity of 65% and a specificity of 85% for predicting stenosis. 
Conclusions: Proximal left subclavian stenosis is not uncommon in pa- 
tients with coronary artery disease. A bilateral arm blood pressure differential 
is a poor screening method for subclavian stenosis. Left subclavian angiog- 
raphy should be routinely performed in patients requiring coronary bypass 
surgery in whom either an arm blood pressure differential of >10 mmHg 
exists or in whom other clinical evidence of PVD exists. 
~ Intimal Hyperplasia and Vascular Remodeling 
Contribute to Lumen Area Change Following 
Balloon Angioplasty of the Femoropopliteal 
Artery: An Intravascular Ultrasound Study 
E.J. Gussenhoven, J.A. van Essen, J. Honkoop, A. van Seyen, J. Seelen, 
W. van Lankeren. Erasmus University Medical Center Rotterdam, Sorbo 
Heart Foundation, IClN, The Netherlands 
Background: Intimal hyperplasia and vascular shrinkage are considered 
responsible for lumen area (LA) reduction following coronary intervention. 
This intravascular ultrasound (IVUS) study aimed to assess the changes 
seen at follow-up in lumen, plaque (PLA) and vessel area (VA) after balloon 
angioplasty (PTA) of the femoropopliteal artery. 
Methods: Patients (n = 20) were studied with IVUS immediately after PTA 
and at follow-up (mean 17 4- 11 months). Corresponding IVUS cross-sections 
derived from the most stenctic site at follow-up, the adjacent treated sites 
and the reference sites not subjected to PTA, were analyzed for change in 
LA, PLA and VA and to seek the relation with calcified lesion, dissection and 
media rupture. 
Results: Cross-sections at the most stenotic site (n = 20) showed a 
significant LA decrease (43%), PLA increase (13%) and VA decrease (9%). 
In cross-sections derived from the treated sites (n = 168) the extent of LA 
decrease was smaller (15%, p < 0.001) and solely caused by PLA increase 
(15%, p < 0.001) i.e. intimal hyperplasia. At the reference sites (n = 77) LA 
decreased slightly (3%); PLA increase (15%, p < 0.001) was compensated 
by increase in VA (6%, p < 0.001). A significant larger amount of intimal 
hyperplasia was seen in IVUS cross-sections showing hard lesion and media 
rupture (both p < 0.05). No relation was found between dissection and the 
changes in LA, PLA and VA. 
Conclusions: At follow-up lumen narrowing at the most stenotic site was 
caused by plaque growth and vessel shrinkage. Both the treated and refer- 
ence sites showed a significant PLA increase: the type of vascular remodeling 
determined LA change. The extent of intimal hyperplasia was significantly 
larger in IVUS cross-sections with hard lesion or media rupture. Dissection 
did not provoke intimal hyperplasia nor influenced vascular remodeling. 
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[ 1194-112/j Lipid Profile Improvement With Long-Term 
Weight Loss in Morbidly Obese Patients 
Alan C. Wilson, Robert E. Brolin, Lisa B. Bradley, Abel E. Moreyra. 
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N J, USA 
Background: Obesity has long been recognized as a risk factor for ischemic 
heart disease. However not all obese individuals have abnormal ipid profiles. 
We studied prospectively the effect of sustained weight loss in improving 
abnormal lipid profiles after gastric restriction surgery for morbid obesity. 
Methods: Of 651 consecutive patients undergoing, 228 (35%) had in- 
creased levels of total cholesterol (TC > 220 mg/dL), triglycerides (TG > 250 
mg/dL), or both preoperatively. HDL-cholesterol levels were low (HDL < 35 
mg/dL) in 45 (20%) of these hyperlipidemic patients. Our study group was 91 
patients (19 men and 72 women) who had been followed for 2 years or more 
(mean 47.8 ± 24.7 months). Lipid profiles (TC/HDL, < 4.5 is desirable), body 
weight and calorie/fat intake were measured. Comparisons between groups 
were made using t-test and ANOVA. 
Results: After the surgery, the mean excess weight loss was 55 ± 25%. 
The BMI decrease was maintained well over the years. 
PreOp Year 1 Year 2 Year 3 Year 4 Year 5 
BMI 47=8 33±7 33±8 33+7 33:£7  34 :57  
TC/HDL 5.9 ~ 2.1 4.3 ± 1.2 4.0 4- 1.3 4.1 ± 1.1 4.0 i 1.1 3.9 ± 1.3 
A striking improvement was noted in the lipid profile, as a result of both 
increases in HDL and decreases in non-HDL cholesterol. 
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Conclusion: Despite the undoubted variations in hyperlipidemic geno- 
type among the patients, gastric restriction surgery appears to result in 
sustained improvements in lipid profile. This is the first report of long-term 
lipid follow-up after this type of procedure. 
1194-113J Massive Cholesterol Lowering Acutely Improves 
I 
Myocardial Vascular Responsiveness in Familial 
Hypercholesterolemia 
Tiziana Sampietro, Gianmario Sambuceti, Danilo Neglia, Oreste Sorace, 
Assuero Giorgetti, Mauro Bertoli, Alfredo Ciardi, Alberto Bionda, 
Oberdan Parodi. CNR Institute of Cfinica/ Physiology, Pisa; Institute of/I 
Medical C/inic, University of Pisa, /ta/y 
Background: Our previous work showed a regulatory role of plasma choles- 
terol (CH) on vascular functionality with regard to endothelial adhesiveness 
and cutaneous microcirculatory blood flow. 
Methods and Results: To answer the question of whether a massive 
CH removal by selective (dextran sulphate columns) LDL apheresis (plasma 
treated = 2.5-3 times the patient plasma volume) would acutely affect the 
reactivity of coronary circulation, we studied myocardial perfusion in 7 (6 
M, 1 F) consenting heterozygous familial hypercholesterolemic (FH) patients 
(age 47.4 :t: 6.3) with (all but one) coronary artery disease undergoing 
apheresis therapy from 6 to 24 months. Soon before and immediately after 
apheresis, myocardial blood flows (ml/min/g), at rest (MBFres0 and after 
adenosine stimulation (MBFade), were assessed with 13N- ammonia and 
positron emission tomography. The mean lipid values before apheresis were: 
CH = 297 4- 61 mg/dL; LDL-CH = 221 4- 40 mg/dL; Apo B = 169 4- 19 reg./alL; 
HDL-CH = 43 4- 18 mg/dL; triglyceride (TG) = 115 4- 32 mg/dL; Lipoprotein 
(a) (Lpa) = 37 mg/dL median (range 17 to 115 mg/dL). After apheresis, 
mean per cent reductions of CH, LDL-CH, Apo B, HDL-CH and Lpa were 77, 
91.5, 87, 6, 64% and 89%. Baseline soluble endothelial eukocytes adhesion 
molecule (sELAM-1) and soluble intercellular adhesion molecule (slCAM-1) 
were 42 4- 21 ng/ml and 363.3 + 60 ng/ml respectively; after apheresis they 
were significantly (P < 0.003 and P < 0.0001, respectively) reduced. MBFres 
before (0.71 4- 0.06) and after apheresis (0.86 ± 0.25) did not change. After 
apheresis the MBFade showed a significant (p < 0.05) increase being 1.31 
± 0.2 before and 2.05 ± 0.8 after, while the rate pressure product was 
unmodified. 
Conclusion: These results, in absence of changes in clinical chemical 
and biocompatibility parameters, tumor necrosis factor alpha, interleukin 
6 and acute-phase reactant proteins, demonstrate a direct role for CH in 
regulating coronary vascular responsiveness, at least in FH patients, and 
suggest that "aggressive" LDL apheresis may be a useful tool to acutely 
reverse coronary vasculature dysfunction 
11 94-114 ] Elevated Gender Fibrinogen Negates Advantage 
for Cardiovascular Risk 
JoAnne Micale Foody, Gregory L. Pearce, Fredric J. Pashkow, Dennis 
L. Sprecher. The Cleveland Clinic Foundation, Cleveland Ohio, USA 
Background: Fibrinogen has been identified in several large clinical epi- 
demiological studies as an independent predictor of CAD and Ml. However, 
the effects of fibrinogen in women have not been clearly delineated. 
Methods: In this series of high risk patients (N = 286 F, N = 495 M), 
risk-adjusted odds ratios for self-reported and clinically confirmed CAD were 
calculated for each 50 mg/dL increase in fibrinogen using logistic regression 
techniques. 
Results: Odds ratios were uniformly higher in women for both CAD (F: 
1.23, p = 0.02; M = NS) and MI (F:1.29; p = 0.005; M: 1.15; p = 0.04). Separate 
logistic regression models were developed for patients with fibrinogen at or 
above 395 mg/dL and those with fibrinogen levels less than 395 mg/dL. For 
the 180 patients with complete data and fibrinogen levels of at least 395, only 
age was a significant predictor of CAD (p = 0.009). Gender did not show a 
significant relationship (p = 0/19). However for those with fibrinogen < 395 
mg/dL, age (p = 0.0001), gender (p = 0.0001), smoking (p = 0.0001), DM (p 
= 0.02) and fibrinogen (p = 0.003) were significantly related to CAD. 
Conclusions: These results demonstrate for the first time the differential 
effects of gender and elevated fibrinogen in the prediction of CAD and MI. 
Elevated fibrinogen is a more powerful predictor of both CAD and MI in 
women. Furthermore, elevated fibrinogen in women is an ominous risk factor 
that negates their typical gender advantage. 
1 J Lipid and Lipoprotein Abnormalities With 1 94-1 1 5 
Indinavir in Human Immunodeficiency Virus 
Infect ion 
Judith Hsia, Gary L. Simon, David M Parenti, Richard A. Muesing, Afsoon 
D. Roberts, Alan G. Wasserman. George Washington Universi~ 
Washington, DC, USA 
Background: Anti-retroviral drug regimens commonly include protease in- 
hibitors. Elevated lipid levels have been reported with the protease inhibitor 
ritonavir; this study evaluated lipid effects of indinavir. 
Methods: Lipids including Lp(a) were measured in 18 human immunod- 
eficiency virus (HIV)-seropositive, anti-retroviral naive patients and repeated 
after 48 weeks (30 weeks for Lp(a)) on indinavir. Patients were also receiving 
either zidovodine with epivir or stavudine wtih didanosine. 
Results: 
Pre-lndinavir On Indinavir p 
Total cholesterol 170 ± 9 mg/dl 211 5:12 mg/dl <0.0001 
Triglycerides 116 • 12 158 5:29 <0.0001 
HDL-cholesterol 38 5:2 39 5:4 NS 
LDL-cholesterol 109 5:8 141 5:12 > 0.0007 
Lp(a) 6.5 5:1.4 9.6 5:2.0 0.07 
Mean CD4 concentration was 379 :E 157/mm2 (mean 4- SD); mean 
plasma HIV RNA concentration was 62816 4- 54377 copies/ml. Abnormali- 
ties in body fat distribution have been reported by others, suggesting insulin 
resistance with attendant changes in carbohydrate and lipid metabolism. 
Homology has also been reported between the catalytic site of protease in- 
hibitors and the LDL-lipoprotein receptor-like protein, a hepatic scavenger of 
circulating lipids, raising the possibility that protease inhibitors competitively 
bind lipoproteins. Current anti-retroviral regimens have lengthened survival 
in HIV infection, thus accelerated atherosclerosis may be a relevant clinical 
concem. 
Conclusion: Treatment with the protease inhibitor, indinavir, raises total 
cholesterol, triglycerides, LDL and may raise Lp(a). 
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~ Genetic Polymorphism of Renin-Angiotensin 
System and Left Ventricular Hypertrophy in 
Endurance Athletes 
Jouko Karjalainen, Urho M. Kujala, Anu Stolt, Matti M~ntysaari, 
Matti Viitasalo, Katariina Kainulainen, Kimmo Kontula. Helsinki University 
Hospital, Helsinki, Fin/and 
Background: Physiological left ventricular (LV) hypertrophy is a feature of 
the athlete's heart. However, similarly training athletes develop LV mass 
to different extents. As polymorphisms in genes encoding components of 
the renin-angiotensin system have been suggested to influence myocardial 
hypertrophy, we studied whether LV mass in athletes is associated with these 
pctymorphisms. 
Methods: We measured LV mass by echocardiography, and blood pres- 
sure levels in 50 male and 30 female elite endurance athletes aged 25 
4- 4 (mean 4- SD) years. DNA samples were prepared for genotyping of 
angiotensinogen (AGT) gene M235T polymorphism, angiotensin-convertase 
enzyme (ACE) gene I/D polymorphism, and angiotensin II type 1 receptor 
(AT1) gene Al166C polymorphism. 
Results: The AGT gene M235T genotypes were significantly associated 
with LV mass independently of blood pressure in both sexes (P = 0.0036 
for pooled data). TT homozygotes had greater mass compared with MM 
homozygotes in both men (147 ± 12 g/m vs 132 4- 15 g/m, P = 0.032) and 
women (121 4- 12 g/m vs 101 + 13 g/m, P = 0.019). AGT gene polymorphism 
explained 12% of the variability in LV mass in men and 28% in women. The 
ACE and AT1 gene polymorphisms were not associated with LV mass. 
Conclusions: AGT gene M235T pctymorphism is associated with the 
variability in LV hypertrophy induced by endurance training, with athletes 
homozygous for the T allele having the largest hearts. 
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1195-75 Paracrine Effects of Stretch on Expression of 
Immediate-Early Genes and Atrial Natriuretic 
Peptide in Cardiomyocytes 
Annemieke JET. van Wamel, Cindy Ruwhof, Lizet J.M. van der Valk. Peter 
I. Schrier, Arnoud van der Laarse. Leiden University Medical Center, 
Netherlands 
Background: Stretch of myocardial tissue, induced by left ventricular over- 
load, initiates growth in this tissue. We investigated the paracrine mech- 
anisms between different cell types in the myocardium in relation to the 
molecular signalling mechanisms of cardiac hypertrophy. 
Methods: Neonatal rat heart myocytes, fibroblasts, endothelial cells and 
aortic smooth muscle ceils (SMCs) were stretched by 15% for O-60 min. 
Stationary myocytes were incubated for 30 min with conditioned medium 
(CM) obtained after stretch of myocytes, fibroblasts, endothelial cells and 
SMCs. Changes in gene expression in the stationary myocytes was studied 
by Northern blot with probes of Immediate-Early genes (c-fos, c-junand ffa-I) 
and atrial natriuretic peptide (ANP). 
Results: Stationary myocytes incubated with CM from 15-60 min stretched 
myocytes showed diminished c-fos and ffa-1 expression and increased c-jun 
and ANP expression. If incubated with CM from 15-60 min stretched fibrob- 
lasts, c-jun expression showed no changes, but the c-fos, fra-1 and ANP 
expression had increased. If incubated with CM from 15-60 min stretched 
endothelial cells, myocytes showed diminished expression of c-fos, c-jun 
and fra-1 but and an increased expression of ANP. If incubated with CM from 
1 MO min stretched aortic SMCs, expression of c-fos, fra-I, c-jun and ANP 
in myocytes had increased. 
Conclusion: Passively stretched myocytes, fibroblasts, endothelial cells 
and SMCs appear to secrete factors that induce early changes in gene 
expression of stationary myocytes. The gene expression responses in sta- 
tionary myocytes, upon incubation with stretch-conditioned medium, are cell- 
type dependent. This suggests the existence of a complex of stretch-induced 
paracrine signalling pathways between different cell types in the myocardium. 
This paracrine signalling may represent a mechanism involved in cardiac hy- 
pertrophy. 
i 1195 76 Oncogenic Ras Induces Premature Senescence in Primary Vascular Endothelial Cells: In Vitro Model 
for Cardiovascular Aging 
loakim Spyridopoulos, Nicole M. Principe, Douglas W. Losordo. University 
of Tuebingen, Germany; St. Elizabeth’s Medical Centec Boston, MA, USA 
Abstract: Advancing age is known to be an independent risk factor for 
atherosclerosis. This includes increased complication rates following acute 
myocardial infarction and coronary interventions as well as impaired angio- 
genesis, all of which depend partly or largely on the functional integrity of the 
endothelium. Accordingly, the study of aging endothelial cells is desirable, 
but is hindered by practical constraints. 
Methods: Bovine aortic endothelial cells were isolated and maintained 
throughout the experiments in growth medium (DMEM supplemented with 
10% fetal calf serum and antibiotics). Adenoviral constructs were used lo 
overexpress Ras61 L, ~16, ~21, c-myc, E2F1, and CMV as a control vector. 
Results: In our model, Ras infected cells presented all characteristics of 
senescent cells 4 days post-infection, including positive staining for senes- 
cence associated @-galactosidase, inhibition of proliferation, abrogation of 
DNA synthesis and lack of AP-1 DNA binding activity upon serum stim- 
ulation, Control vector infected cells showed none of the above. We also 
found that although Ras-induced Gl-arrest is mimicked by over expression 
p21c’P’hvaf1, changes in cell morphology seen in Ras infected cells were not 
duplicated by the cdk inhibitor. Finally, Ras infected endothelial cells were 
E-fold more susceptible to tumor necrosis factor alpha induced apoptosis 
when compared to control cells, consistent with the known susceptibility of 
senescent endothelium for cytotoxic stimuli. 
Conclusion: Over expression of active (oncognenic) Ras induces a 
senescent phenotype in primary endothelial cells. This approach represents 
a novel in-vitro model for cardiovascular aging. Ongoing studies will further 
characterize the downstream targets of Ras which mediate the growth in- 
hibition and morphologic changes induced in (Ras) senescent endothelial 
cells. 
1195-77 Decorin Antagonizes Transforming Growth 
Factor-&-Induced Effects in Cardiac Fibroblasts: 
Evidence for a New Anti-Fibrotic Therapeutic 
Principal 
Andreas V. Sigel, Chang-Fu Peng, Gtinter A.J. Riegger, Heribert Schunkert. 
Klinik und foliklinik flir lnnere Medizin Il. lJniversitz% Ffegensburg, Germany 
Background: Decorin is a small proteoglycan with ubiquitous tissue distri- 
bution and the ability to bind extracellular matrix proteins like collagen type 
I and growth factors like transforming growth factor beta 1 (TGF-fi,). These 
binding properties imply an important biological role of decorin in the struc- 
tural organization and assembly of the extracellular matrix in the heart, We 
hypothesized that this affinity of decorin modulates the biological activity of 
TGF-,f~ thereby resulting in decreased collagen production by adult rabbit 
cardiac fibroblasts. 
Methods: We, therefore, investigated the effect of decorin on DNA-(3H- 
thymidine incorporation), RNA-(sH-uridine incorporation), protein synthesis 
(3H-phenylalanine incorporation and western immuno blot) and mRNA ex- 
pression (northern hybridization) in cardiac fibroblasts, which represent the 
cellular source of extracellular matrix in the heart. Rabbit cardiac fibrob- 
lasts were grown until subconfluent in DMEM supplemented with 10% FBS, 
serum-deprived for 12 hours and then stimulated with 12 nglml TGF-0, in 
the presence of increasing concentrations of decorin. 
Results: Decorin (~5 wg/ml) reversed the well known anti-mitogenic 
effect of TGF-#I,. In fact decorin even stimulated DNA synthesis rn the pres- 
ence of 12 ngiml TGF-p, (350%, p < 0.05). In adddion, TGF$,-induced 
RNA synthesis was decreased by decorin (70%, p < 0.05), suggesting a sig- 
nificant decrease in transcription by 43% (p < 0.05). Next, IO @ml decorin 
decreased protein synthesis by 89% (p c 0.05) suggesting unchanged trans- 
lation. Further, western immuno blots and northern hybridization revealed that 
decorin decreased collagen type I protein production by 60% (p < 0.05) and 
collagen type I mRNA expression by 20% (p < 0.05) in TGF-PI strmulated 
cells. 
Conclusion: Our results indicate a novel regulatory mechanism in the 
modulation of the cardiac extracellular matrix. In addition we show for the 
first time the possibility of antagonizing TGF-@t-induced cardiac effects us- 
ing an endogenous inhibitor. Further, given that decorin is synthesized by 
cardiac fibroblasts, stimulation of endogenous decorin production may offer 
a therapeutical target in conditions that involve myocardial fibrosis. 
1 1195-78 ] Mitogen Activated Protein Kinase is Required for 
ANF’s Anti-Hypertrophic Action in Neonatal Rat 
Ventricular Cardiomyocytes 
Michael Silberbach, Travis Gorenc, Ray E. Hershberger, Charles T. Roberts 
Jr.. tOregon Health Sciences Universit): Port/and, OR, USA 
Atrial natnuretic factor (ANF) expression is induced in the afterload stressed 
ventricle, and sudden death due to hypertrophic cardiomyopathy appears 
to occur in knockout mice lacking the ANF receptor. These data suggest 
that autocrine/paracrine ventricular ANF may antagonize the hypertrophic 
response. We hypothesized that ANF actions involve the mitogen actrvated 
protein kinase (MAPK) cascade. In serum starved neonatal rat ventricular 
myocytes (NRVMCs), ANF induced a rapid B-fold increase In ERK kinase 
activity and caused ERK nuclear translocation. This ANF effect was selectrve 
because ANF treatment failed to phosphorylate MAPK family members p36 
and JNK. ANF-induced ERK activation and nuclear translocation was pre- 
vented by the MEK inhibitor PD098059. (PD). To determine if ANF inhibited 
phenylephrine (PE)-induced hypertrophy, and if this effect required ERK ac- 
tivation, cross-sectional area (CSA) determined by computer was estimated 
in NRVMCs transfected with pCMV/p-Gal and then treated with ANF (1 JIM), 
PD (10 @M), and PE (1 HIM) for 46 hours. Three separate identical experi- 
ments were performed in duplicate and at least 90 cells were measured in 
each group. 
In control cells CSA was 277 f 62 /Am* (mean f SD). ANF or PD alone 
had no effect. ANF inhibited PE-induced hypertrophy by 50%. PD had only a 
small inhibitory effect on PE-induced hypertrophy, but abolished ANF’s inhi- 
bition of PE-induced increases in CSA. These data establish the obligatory 
role of ERK actrvatron in ANF’s anti-hypertrophic action and suggest novel 
therapeutic strategies that take advantage of cGMP-mediated pathways in 
the cardiomyocyte that may function as the heart’s natural defenses against 
maladaptive hypertrophy. 
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I1 0 J Activation of the Signaling Pathway by 
1 
1 95-1 1 JaldSTAT 
Blocking G Protein-Coupled Receptor Kinases in 
Cardiomyocytes 
Jorn Carlsen, Tue E. Chdstoffersen, Juliane Theilade, Stig Hauns~, Seren 
P. Sheikh. Department of Cardiology, The Heart Center, H:S Rigshospita/et 
and The Cardiovascular Research Institute, Copenhagen University, 
Denmark 
Background: The angiotensin II receptor (AT1) couples to heterotrimeric 
G proteins (Gc~ and G#V), and activates the Jak (Janus tyrosine kinase) 
and STAT kinases (Signal Transducers and Activators of Transcription). Here 
we ask whether G protein-coupled Receptor Kinases (GRK's) play a role in 
activation of this signaling system? 
Methods: Primary cell cultures were prepared from the ventricles of 
neonatal 1-2 days old Wistar rats. Overexpression of two different G#y 
sequestering proteins, #ARKct and transducin, was achieved either by tran- 
sient transfection using calcium phosphate precipitation or by infection with 
adenovirus containing the gene for #ARKct (kindly provided by Walter J. 
Koch). Immunoprecipitation was performed with phosphotyrosine and STAT- 
antibodies. 
Results: ,6ARKct potently enhanced both the basal and the Angiotensin 
II stimulated Jak/STAT activation. In addition, flARKct also increased the 
transcription of hBNP (human Brain Natriuretic Peptide), a marker of hyper- 
trophic response. Furthermore,/~ARKct reduced phosphorylation of the AT1 
receptor by 3-4 fold. 
Conclusion: We suggest, that/~ARKct blocks recruitment of GRK's re- 
sulting in enhanced Jak/STAT and hBNP activation. Thus, GRK's may play 
a role in myocardial hypertrophy. 
1 ] Myostatin, A Transforming Growth Factor-~3 
] 
1 95-1 1 1 
Superfamily Gene, is Expressed in Heart Muscle 
Mddula Sharma 1 , Kenneth G. Matthews ~ , Gerard P. Devlin 2, John 
V. Conaglen 2, Wayne G. Seiners 1 , Peter J. Fowke 1 , Selwyn P. Stuart ~ ,
Ravi Kambadur 1 , James J. Bass 1 . 1AgRescarch Ruakura, Hamilton; 
2 Waikato Academic Division, University of Auckland, Hamilton, New 
Zealand 
Background: Myostatin is a secreted growth and differentiation factor (GDF-8) 
that belongs to the TGF-,~ superfamily. Targeted disruption of the myostatin 
gene in mice, and a mutation in the third exon of the myostatin gene in double 
muscled Belgian Blue cattle, results in skeletal muscle hyperptasia. Previous 
published reports have shown myostatin expression only in skeletal muscle, 
with a significantly lower level of myostatin mRNA reported in adipose tissue. 
Methods: We used PCR to identify myostatin mRNA and Western blot- 
ting with anti-myostatin antibodies to identify myostatin protein. Immunecy- 
tochemistry (ICC) was used to localize the myostatin. 
Results: Myostatin mRNA and protein were detected in both fetal and 
adult heart muscle, where ICC localized myosfatin protein to Purkinje fibres 
and cardiomyocytes. Sequence analysis reveals that the Belgian Blue cardiac 
myostatin cDNA sequence contains an 11 nucleotide deletion which causes 
a frameshiff, eliminating virtually all of the mature, active region of the protein. 
Conclusion: Double muscled cattle have a relatively small heart which 
expresses the defective myostatin gene. Myostatin may therefore be required 
for normal development of the heart. 
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I1 6 1 Cost Analysis Model Low Weight 1 96-1 1 of Molecular 
Heparin vs. Unfractionated Heparin for 
Antithrombotic Therapy in Patients Undergoing 
TEE Guided Cardioversion from Atrial Fibrillation 
R. Daniel Murray, Susan E. Jasper, Ariel Goodman, Edmund R. necker, 
Steven D. Culler, William S. Weintraub, Jeffery Olin, Joseph F. Malouf, Allan 
L Klein. The Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: Patients with atrial fibrillation (AF) of >2 day's duration requir- 
ing early cardioversion (CV) are often hospitalized for antithrombotic therapy 
(AT) for 2 to 5 days with IV unfractionated heparin (UFH) plus initiated oral 
warfarin. Cardioversion follows a therapeutic PTT and a negative TEE for 
thrombus. Self-administered low molecular weight heparin (LMWH) and war- 
farin will obviate the need for hospitalization and PTT monitoring, and thus 
potentially lower costs for these patients. 
Methods: We present a cost analysis model to show the potential sav- 
ings with LMWH vs. UFH for patients in AF undergoing TEE guided CV. 
We used ESSENCE Tdal costs of LMWH at $69/day, and UFH with equip- 
ment/monitors was estimated at $35/day. Estimated total pharmaceutical 
costs were $276 for LMWH and $140 for UFH. Assuming a 4-day period to 
achieve therapeutic INn on warfadn, hospitalization costs were estimated at 
$800 for LMWH including instructional time and matedals for home care, and 
$3200 for UFH. Sensitivity analyses for differences in stroke and bleeding 
rates were also evaluated. 
Results: Assuming equivalency in stroke and bleeding rates, LMWH may 
lower costs from $3340/patient o $1076/pafient; a 68% savings. 
Conclusions: Because of the relatively low costs associated with home 
treatment, low molecular weight heparin may markedly lower treatment costs 
over unfractionated heparin for AF patients requidng early TEE guided CV. 
Utility analysis may show even greater advantages of LMWH for these same 
reasons. 
I1 96-1 I Comparative Cost-Effectiveness of the lib/Ilia 
] 
1 1 7 
Glycoprotein Blockade Agents in Percutaneous 
Coronary Intervention 
Anne R. Newman, Dominic L. Race, William B. Hiltegass. Vanderbilt 
University Medical Center, Nashville, TN, USA 
The disparate costs and clinical results with eptifibatide (EP), tirofiban (TI), 
and abciximab (AX) in percutaneous intervention (PCI) motivates a com- 
parative cost-effectiveness analysis. A model was constructed to calculate 
incremental cost, life-years (LY) and quality-adjusted life-years (QALY) saved 
for EP, TI, and AX. Baseline assumptions included 30 day event rates (death, 
MI, bleeding, urgent revascularization) from IMPACT II (EP), RESTORE (TI), 
EPIC&EPILOG (AX); costs were obtained from the EPIC economic substudy; 
and all patients were assumed to be discharged an average of 12 hours after 
completion of drug infusion. Drug costs were based on the total mg and 
duration of infusion in each trial. Quality adjustment factors were from a time 
trade-off model. A secondary model included correction for the effect of MI 
on long-term survival (MI+). The results are shown: 
Drug LY/patient Incremental $ $/LY 
MI MI- MI+ MI- MI+ MI- MI+ 
AX 0.053 0.137 $661 $661 $12.5k $4.8k 
EP 0.076 0.096 $243 $249 $3.2k $2.5k 
TI -0.012 0.017 $1,483 $1,483 -$128k $89.7k 
Drug QALY/patient Incremental $ $/QALY 
AX 0.083 0.165 $661 $661 $7.9k $4.0k 
EP 0.094 0.112 $243 $243 $2.6k $2.2k 
TI 0002 0.029 $1,483 $1,483 $667k $51 .lk 
While AX yields the highest QALYs saved, EP has the lowest $/QALYs 
due to its low acquisition cost at the IMPACT II dose of 130/0.5. EP would 
be less cost-effective than AX if the 180/2.0 dose does not improve efficacy. 
While TI has low efficacy and cost-effectiveness based on RESTORE, PCI 
subset data from PRISM-PLUS appears more promising. 
I1196-118 I Treatment in Non-Insulin Antihyperglycemic 
I Dependent Diabetics With Coronary Disease: 
Increased Metformin-Associated Mortality over a 
5 Year Follow-Up 
Enrique Z. Fisman, Alexander Tenenbaum, Michal Bendedy, Uri Goldbourt, 
Solomon Behar, Michael Metro. Cardiac Rehabilitation Institute and Neufeld 
Cardiac Research Institute, Sheba Medical Center, Te/-Hashomer, Israel 
Background: Mortality rates are considerably higher in coronary patients 
with non-insulin dependent diabetes mellitus (NIDDM) than in those who are 
nondiabetios. The relationship between different ypes of anti-hyperglycemic 
pharmacological therapy and mortality rate in this NIDDM population is un- 
certain. We aimed to examine survival in diabetics with IHD using various 
types of oral antidiabetic drugs over a 5 year follow-up period. 
Methods: The study comprised 11440 patients with previous myocardial 
infarction and/or anginal syndrome, aged 45-74 years, screened but not 
included in the bezafibrate infarction prevention study. Among them, 9045 
were nondiabetics and 2395, diabetics. Diabetics were divided into 4 groups 
on the basis of their therapeutic regimen at screening: diet alone (n = 990), 
sulphonylureas (n = 1041), mefformin (n = 78) and a combination of a 
sulphonylurea and metformin (n = 266). 
Results: All NIDDM groups were similar with regard to age, gender, 
hypertension, smoking, heart failure, angina and prior myocardial infarction. 
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Crude mortality rate was lower in the nondiabefic group (11.21% vs. 21.8%; p 
< 0.001 ). In the diabetic group, mortality was 18.5% for patients on diet alone, 
22.5% for those on sulphonylureas, 25.6% for patients on mefformin, and 
31.6% for the combined sulphonylureaJmefformin group (p < 0.01). When 
analyzing age-adjusted mortality rate and actuarial survival curves, the lowest 
mortality was found in patients on diet alone and the highest in patients on 
metformin (alone or in combination with sulphonylureas). After adjustment 
for variables connected with long-term prognosis, the use of metformin was 
associated with increased relative risk (RR) for all-cause mortality of 1.42 
(95% CI 1.10-1.85), whereas the use of sulphonylureas alone was not [RR 
1.11 (95% CI 0.90-1.36)]. 
Conclusions: NIDDM patients with IHD using mefformin, alone or in 
combination with eulphonylureas, exhibited a significantly increased mortal- 
ity. Until the results of problem-oriented prospective studies on oral control 
of NIDDM in coronary patients will be available, alternative therapeutic ap- 
proaches should be investigated in this population. 
1 96-119 ] Impact of Clinical Judgment on Number of 
1 
1 
Patients Requiring Lipid-Lowering Therapy 
Based on Adult Treatment Panel II Guidelines 
and New National Health and Nutrition 
Examination Survey III Data 
Terry A. Jacobson, Godfrey G. Griffiths, Cristina Varas, Jeffrey R. Schein, 
Christie M. Ballantyne. Baylor College of Medicine, Houston TX, USA 
Background: In 1993, an estimated 12.7 million Americans needed drug 
therapy to lower LDL-C based on ATP II guidelines and NHANES III data for 
1988-91. 
Methods: We reexamined the prevalence of elevated LDL-C in US adults 
using updated (1988-94) NHAN ES data and estimated how many Americans 
require drug therapy on the basis of ATP II. ATP II recommends clinical 
judgment to decide whether to initiate drug therapy in pts with LDL-C above 
goal on diet but below the initiation level for drug therapy: CHD lots with 
LDL-C 100-130 mg/dl, pie without CHD who have >2 risk factors (RF) and 
LDL-C 130-160 mg/dl, and middle-aged or older pts without CHD who have 
<2 RF and LDL-C 160-190 mg/dl. Since ATP II was published, clinical trial 
evidence for the benefit of statin therapy on CHD morbidity and mortality in 1 g 
and 2 ~° prevention, including pts with milder LDL-C elevations, has informed 
evidence-based clinical judgment. 
Results: Based on updated NHANES III data for 1988-94, 55.7 million 
Americans need diet therapy. Estimates for drug therapy, based on a 10% 
LDL-C with diet, depend on clinical judgment for initiation of drug therapy 
in pts with milder LDL-C elevations (Table). Although a large number of pts 
need drug therapy with inclusion of pts with milder LDL-C elevations, an 
estimated 86% of these pts can reach ATP II goal with <30% ~. LDL-C, which 
can be obtained with any of the statins. 
Conclusion: With the increase in pts needing drug therapy by applying 
clinical judgment as defined in ATP II, cost-effective treatment is required to 
ensure appropriate treatment for the most pts. 
Clinical judgment <2 RF >2 RF CHD Total 
Conservative 1,559,589 5,527,793 3,317,201 t0,404,583 
Aggressive 4,119,555 17,491,186 6,774,395 28,385,136 
1 20] Pharmacologic Management of 1 96-1 Cardiovascular 
Disease in a United States Insured Population 
Stephen J. Boccuzzi, Nittaya Suppapenya, Christine Peverly, Robert 
S. Epstein. Merck-Medco Managed Care, L.L.C., Montvale, N J, USA 
Few studies have described the utilization patterns of CV drugs in large 
populations. To evaluate this issue a convenience sample (N = 1.6 M lives) 
from a large geographically diverse administrative claims dataset (N = 55 
M lives) was analyzed. Twenty-two percent (N = 357,674) of this cohort 
received at least one CV drug in 1997. The mean age was 62; 52% were 
female; 46% _> 65 years of age. The distribution of CV drugs alone and in 
combination was as follows: 33% diuretics (DIUR), 30% hypolipidemics (HL), 
30% calcium channel blockers (CCB), 29% ACE inhibitors (ACEI), and 24% 
beta blockers (BB), Males received ACEI, nitrates, and HL more frequently, 
while females received DIUR more often. Fifty-three percent of this cohort 
received two or more classes of CV agents. The most frequent combina- 
tions included: ACEI/DIUR, CCB/DIUR, ACEI/HL, BB/DIUR, CCB/ACEI, and 
CCB/HL. Combination therapy with HL was observed in 71% of this cohort. 
Initiation of CV drug therapy in the first 6 months of 1997 was observed 
in 13% of the study population (N = 47,766). The overall persistency rate 
at 6 months was 58%. Persistency rates for patients taking a single CV 
agent were as follows: All antagonists (71%), ACEI (6.5%), HL (62%), CCB 
(54%), BB (46%), DIUR (37%). For those patients persistent at 6 months, 
persistence increased with the number of agents used: for users of 1,2, 3, 4 
and 5 drugs, persistence was 48%, 78%, 84%, 88% and 91%, respectively. 
This study provides useful insights into issues regarding pharmacologic 
management of CV disease in a large US population and suggests that 
additional evaluation of patient and provider factors is needed. 
L l l  96-121 ] Does Stroke in the Setting of Thrombolytics for 
Myocardial Infarction Alter Subsequent 
Management of Coronary Disease? 
Chen Y. Tung, Christopher B. Granger, Kenneth W. Mahaffey, J. 
David Knight, Robert M. Califf, Daniel B. Mark. For the GUSTO I 
investigators; Duke Clinical Research Institute, Durham, NC, USA 
Background: An increasing number of patients have both coronary disease 
and stroke. However, the effect of stroke on the subsequent management of 
coronary disease is unclear. 
Methods: We studied 229 US GUSTO I stroke patients and 2406 random 
US GUSTO I patients who were discharged alive from the index acute MI 
hospitalization. Resource use data out to 1 year were prospectively collected 
as part of the Economics and Quality of Life substudy of GUSTO I. 
Results: Stroke survivors were less likely to undergo cath (13% vs. 20%, 
p = 0.02) and PTCA (5% vs. 12%, p = 0.001), but had similar rates of 
CABG (5% vs. 7%, p = ns). Both disabled and non-disabled had lower rates 
of cath and PTCA than no stroke patients. For cath the rates were 13%, 
14% and 20% respectively. For PTCA the rates were 3%, 7% and 12%. 
No differences in CABG rates were noted (5%, 5%, and 7%). Independent 
predictors of invasive cardiac procedures were age, stroke occurrence and 
history of angina. 
Conclusion: Acute MI patients who survive a stroke are more likely to 
be treated medically for their coronary disease. This is true even in stroke 
survivors who were not disabled at discharge. These results indicate that 
among survivors, stroke alters the management of their coronary disease, 
which is likely to affect the long-term prognosis of these patients. 
ORAL  
Lipids and Diet 
Tuesday,  March  9, 1999, 4 :00 p .m. -5 :30  p.m. 
Moda l  Convent ion  Center ,  Room 345 
4:00 p.m. 
m-8-~-] The Direct Effect of Components of the 
Mediterranean Diet on Endothelial Function: Olive 
Oil, Vitamins and Fish 
Robert A. Vogel, Mary C. Corretti, Amy B. Fisher, Gary D. Plotnick. 
University of Maryland Hospital, Baltimore, MD, USA 
Background: Cardiovascular disease incidence is low in populations eating 
a Mediterranean diet, rich in olive oil, high antioxidant fruits and vegetables, 
and fish. The direct vascular biological impact of these food groups has not 
been compared. 
Methods: We assessed the direct, short-term effects of 3 single meals 
(50 g olive oil + bread, 50 g olive oil + bread + vitamins C [1 g] and E [800 
IU], 450 g salmon [50 g fat]) on endothelial function, measured as brachial 
artery flow-mediated vasodilation (FMV), before and 3 hours postprandial in 
12 healthy ncrmocholesferolemic individuals. 
Results: The salmon meal raised triglycerides less than the 2 olive oil + 
bread meals (32% vs. 59%) 3 hours postprandial compared with baseline. 
The olive oil + bread meal significantly reduced FMV by 40% (13.9 ± 5.9% 
to 8.3 + 4.2%, p < 0.05). The addition of vitamins C and E to the olive 
oil + bread meal eliminated this impairment, resulting in an insignificant 2% 
increase in FMV. The equal high-fat salmon meal resulted in an insignificant 
10% reduction in FMV (13.2 ± 4.4% to 11.9 ± 3.4%). 
Conclusions: Our observations on the direct effects of components of 
the Mediterranean diet on endothelial function suggest that the beneficial 
components of this diet are fish and antioxidant fruits and vegetables, but not 
olive oil. 
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[86~ Unfiltered Coffee Raises Plasma Homocysteine 
Levels in Healthy Volunteers 
Marina J. Grubben 1 , Godfried H. Boers 1 , Roelinka Broekhuizen 2, Romy de 
Jong 2, Leonie van Rijt 2, Eke de Ruijter 2, Henk J. Blom 1 , Fekko 
M. Nagengast 1 , Martijn B. Katan ~,2 . 2Agricultural University Wageningen; 
~ Academic Hospital Nijmegen, The Netherlands 
Background: An elevated plasma homocysteine level is an independent 
risk factor for cardiovascular disease. Epidemiologic studes have reported 
an association between coffee consumption and homocysteine. We therefore 
studied the effect of unfiltered coffee on plasma homocysteine in a controlled 
cross-over trial. 
Methods: Sixty-four healthy volunteers (31 men, 33 women; age 43 ± 
11 yrs) were randomly assigned to two groups. One group (n = 30) drank 1 
litre of unfiltered cafetiere ("French Press") coffee daily for two weeks. Such 
coffee is rich in the cholesterol-raising diterpenes kahweol and cafestol. The 
other group (n = 34) recieved a combination of water, milk, broth, tee and 
chocolate-drinks. After a wash-out period of 8 weeks both groups recieved 
the reverse treatment for another 2 weeks. At the end of each intervention 
period fasting blood samples were collected. 
Results: Drinking one litre of unfiltered coffee significantly raised plasma 
homocysteine levels as well as plasma lipids (Table). 
Change in Mean 95% CI P-value 
Homocysteine (umot/I) +1.23 0.53-1.92 = 0.001 
Cholesterol (mmol/I) +0.48 0.32-0.63 <0.0001 
Triglycerides (mmol/I) +0.36 0.20-0.53 <0.0001 
CI = confidence interval 
Conclusion: Unfiltered coffee increases the total plasma homocysteine 
concentration in volunteers with normal initial levels. The rise in homocysteine 
caused by six large cups of unfiltered coffee per day might raise CVD risk by 
10% if elevated homocysteine is a causal factor; the latter is still uncertain. 
It is unclear whether the effect is caused by the cholesterol-raising lipids 
kahweol and cafestol present exclusively in unfiltered coffee or by factors 
that are also present in regular coffee. 
4:30 p.m. 
~3~ Randomized Trial Comparing a High-Fat, Low 
Carbohydrate Diet to the National Cholesterol 
Education Program Step II Diet 
Y. Wady Aude, Francisco Lopez-Jimenez, Gervasio A. Lamas, 
Marie Almon, Melinda Ha, nsen, Gerardo Rojas, Eric H. Lieberman, 
Gregory Russell, Roy Heilbron, Arthur S. Agatston. Mount Sinai Medical 
Center, Miami Beach, FL, USA 
Low-fat diets modestly decrease weight and LDL cholesterol but have an un- 
desired effect on HDL cholesterol. Carbohydrate (CHO) restricted, relatively 
high-fat diets (HFD) have been recommended as an option to lose weight 
but their clinical efficacy and safety are controversial. 
Design: To test the effect of the HFD on weight and serum tipids, we 
randomized 42 overweight patients (BMI ~. 27) to a 3-month trial of either the 
National Cholesterol Education Program Step II diet (NCEPD) or to a HFD. 
The HFD consisted of 3 phases: I) 10% CHO, 28% protein and 62% fat, II) 
27% CHO, 30% protein and 43% fat, and III) 33% CHO, 28% protein and 
39% fat. In the HFD, fat was predominantly mono- and poly-unsaturated and 
CHO With a low glycemic index were used. Dietary counseling was given 
every 2 weeks. Physical activity remained unchanged throughout he study. 
Results: Patients were 64.3% female and 45.9 ± 10 years old. Baseline 
weight was 98.4 kg ± 19 (70-160) and the baseline serum cholesterol was 
208 ± 42 mg/dl. 
Difference from baseline: HFD NCEPD P value t
Weight (kg) -6.1 ::t_ 4.1 " -3.6 -E 4.1" 0.05 
Total cholesterol (mg/dl) 10.7 i 27 -12.8 ± f 3* 0.75 
LDL (mg/dl) -0.06 ± 26 -7.0 -E 14 * 0.32 
HDL (mg/dl) -0,9 ± 10 -4.8 ~- 7 * 0.17 
Triglycerides (mg/dl) 48.4 ± 95 * -5.3 J: 43 0.03 
LDL/HDL ratio 0.003 ± 0.5 +0.09 ± 0.4 0.55 
P value < 0.05 when pre-post values were compared within a diet. P value t refers to 
between groups comparison of differences from baseline. 
Conclusions: The HFD is more effective than the NCEPD with respect 
to weight loss and triglycerides reduction. This occurs without a detrimental 
effect on HDL and LDL cholesterol levels. 
4 :45  p .m.  
[~-~ Dietary Treatment in Dyslipidemia: Do Dieticians Do 
It Better? A Prospective, Randomized Clinical Trial 
Y. Henkin, I. Shai, R. Zuk, D. Brickner, I. Zuilli, S. Shani, B. Gold. Soroka 
Medical Center and Ben-Gurion Universi~ Beer-Sheva, Israel 
Background: The NCEP guidelines recommend that initial counseling on the 
Step I diet be provided by the treating physician, with referral to a certified 
dietician in patients who fail to reach their target goals. The appropriateness 
and cost-benefit value of this strategy is unclear. 
Objectives: To evaluate the incremental benefit of a detailed dietary 
assessment and counseling (provided by a dietician) to that of a more general 
counseling provided by a general physician. 
Methods: After initial evaluation of risk factors, baseline lipoproteins 
and dietary history, 142 dyslipidemic individuals were examined by one of 
the participating physicians and received general counseling concerning 
life-style and dietary modifications. Seventy participants were then randomly 
assigned to receive additional counseling sessions by a certified dietician. 
Reevaluation was performed at 6 weeks, 3 months and every 3 months 
thereafter for the first year. 
Results: Baseline characteristics and lipoprotein levels were similar in 
those that received (group II) and those that did not receive (group I) coun- 
seling by a dietician. At three months, the LDL cholesterol (LDLc) levels 
decreased by 6.6 ± 1.4% in group I and by 11.4 ± 1.3% in group II (p < 
0.01 for the difference between groups). However, on long-term follow-up 
the initial reductions in LDLc gradually diminished in both groups, the dif- 
ference becoming insignificant at 12 months (-3.2 ± 1.6% for group I and 
-6.7 ± 1.3% in group II, p = 0.09). No significant differences between the 
groups were seen in the other lipoprotein or lifestyle changes. At three and 12 
months respectively, 23% and 21% of group I and 35% and 29% of group II 
had reached their target NCEP therapeutic goals using dietary modifications 
alone. 
Conclusions: The initially greater LDLc reduction after counseling by a 
dietician was attenuated on long-term follow-up. Although our results support 
the current guideline recommendations, more emphasis should be given to 
long-term maintenance of the initial beneficial effects. 
5:00 p.m. 
Effect of Avocado-Enriched Diets on Serum Lipids: 
860-~ A Meta-Analysis 
Francisco Lopez-Jimenez, Murray A. Miffleman. Mount Sinai Medical 
Center, Miami Beach, FL; Beth Israel-Deaconess Medical Center and 
Harvard School of Public Health, Boston, MA, USA 
Low-fat diets (LFD) are the cornerstone of the management of hyperlipidemia 
and obesity. However, it has been suggested that diets rich in monounsat- 
urated fats may also have a favorable effect on lipid I profile. Sources of 
monounsaturated fats are scarce and research has focused on olive oil. Av- 
ocado, a rich source of oleic acid and other monounsaturated fats has been 
studied in a few trials. 
Methods: All controlled trials published from 1966 to 1997 were analyzed. 
Five studies comparing avocado-enriched diets (AED) with isocaloric, LFD 
and fulfilling pre-specified inclusion criteria were included. Authors of the 
studies were contacted to avoid publication bias. Results were tested for 
homogeinicity and combined using fixed and random effect methods. 
Results: The studies included 126 patients, 70% women. All but one 
study had a cross-over design. The dose of avocado varied from 130 g/d to 
300 g/d, the equivalent of one medium piece. Weighted changes in serum 
lipids (mg/dl) with AED were: 
3. (AED - LFD) Delta; (Baseline Follow up) in AED 
Mean (95% CI) Mean (95% CI) 
Total cholesterol -7.66 (-2.6, -12.7) • -19.96 (-15.3. -24.4)* 
LDL cholesterol -9.24 ( 4.4, -14.1)* -15.55 (-9.9, -21,2)" 
HDL cholesterol +7.86 (+5.4, +10.3)" +1.35 (-4.8, +7.5) 
Triglycerides +3,20 (-8.8, +15,2) -001  (-5.9, +5.9) 
• p < 0.05 
Conclusions: This data suggests that AED effectively decrease total 
cholesterol, and LDL cholesterol, without detrimental effect on HDL. A large 
randomized controlled trial is required to evaluate the short and long-term 
effect of avocado consumption on the lipid profile. 
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5:15 p.m. 
[ -~- -6-~ Uee of  L ip id-Lower ing Medicat ions in Patients With 
Coronary Disease 1990-1996: The National 
Ambulatory Medical Care Survey 
Paul D. Taylor, Pamela L. Russman, David Bruckman, Seema S. Sonned, 
James B. Froehlich. University of Michigan Medical Center, Ann Arbor, MI, 
USA 
Background: Lipid-lowering (LL) medications have been shown to benefit 
patients with coronary disease. We studied whether gender, age, race, geo- 
graphic location, or physician specialty predicted use of LL in the ambulatory 
care setting. 
Methods: The National Ambulatory Medical Care Survey (NAMCS) en- 
compases 248,126 patient encounters from 1990-1996. Two groups of pa- 
tients were analyzed by logistic regression for the current study: (1) patients 
with a cardiac visit reason (CVR), such as chest pain, and (2) patients given 
a diagnosis of cardiac disease (CD) by their care provider. Only those fac- 
tors predictive of LL use in both patient groups are reported as significant 
predictors. 
Results: Gender, age, and geographic location did not significantly predict 
LL use in cardiac patients. Physician specialty (cardiologist (CARD) vs. other 
internist (Other)) and patient race (caucasian (Cauc.) vs. African-American 
(hA)) predicted LL use: 
Cohort CARD Other p Cauc. AA p Total 
CVR (n = 5935) 10% 6% <0,001 8% 4% 0,004 8% 
CD (n = 5588) 17% 11% <0.001 14% 7% <0,001 14% 
Conclusion: Use of LL drugs was low among patients with suspected car- 
diac disease in this national survey of ambulatory care providers. It was lower 
for black patients, and higher for patients of cardiologists. These data argue 
for significant opportunity to improve utilization of LL drugs for secondary 
prevention of CAD. 
ORAL 
Clinical Hypertension: Renin-Angiotensin 
Axis 
Wednesday, March 10, 1999, 8:30 a.m.-10:00 a.m. 
Morial Convention Center, Room 275 
8:30 a.m. 
[~2-~ Angiotensin II Receptor Blockade in Normal 
Subjects: A Direct Comparison of Three AT1 
Receptor Antagonists 
Michel Bumier, Lucia Mazzolai, Marc Maillard, Julien Rossat, 
J,',rg Nussberger, Hans R. Brunner. Division of Hypertension, Lausanne, 
Switzerland 
Background: The use of angiotensin II (AOg II) AT1 receptor antagonists 
for the treatment of hypertension is rapidly increasing. Yet, information on 
the relative efficacy of the antagonists to block the renin-angiotensin system 
(RAS) in humans is lacking. 
Methods: Ang II receptor blockade induced by three antagonists was 
evaluated in normal subjects in a double-blind, placebo-controlled, random- 
ized, four-way crossover study. Subjects received the single official starting 
dose of each compound: Iosartan 50 rag, valsartan 80 rag, irbesartan 150 
mg and placebo. Blockade of the RAS was assessed 4, 24, and 30 h after 
drug intake by three methods: the inhibition of blood pressure (BP) response 
to exogenous Ang II, an in vitro receptor assay and plasma Ang II levels, 
Results: At 4 h, Iosartan caused a 43% blockade of the Ang II-induced 
BP increase, valsartan 51%, and irbesartan 68% (p < 0.01 irbesartan vs 
Iosartan and valsartan). The effect of the antagonists declined with time but 
only irbesartan sustained a significant blockade vs placebo at 30 h. Identical 
results were obtained with the in vitro assay. At 4 h, a greater increase in 
plasma Ang II levels was observed with irbesartan (p < 0.05 vs Iosartan and 
valsartan). 
Conclusions: This study demonstrates that 150 mg irbesartan induces 
a greater and longer lasting Ang II receptor blockade than 80 mg valsartan 
and 50 mg Iosartan in normal subjects. The degree of Ang II blockade with 
higher doses of these three compounds is unknown. 
8:45 a.m.  
F8-7-2-~ Responsiveness to Angiotensin II (A II) Predicts Left 
Ventricular (LV) Mass in Hypertensive Subjects 
R.E. Schmieder, C. Delles, J. Jacob±, A. Fdedrich, M.P. Schlaich. 
Department of Medicine IV, University of Erlangen-NOrnberg, Germany 
Background: We have previously shown that both concentration of A II 
related to sodium excretion and responsiveness to infusions of A II are 
correlated with LV hypertrophy in hypertensive subjects. In the current study, 
we examined whether hyperresponsiveness to A II predicts changes of LV 
mass after 12 months of follow-up. 
Methods: We enrolled 16 male normotensive and 22 mild hypertensive 
subjects (age: 28 ± 3 years). LV mass was determined by 2-D guided 
M-mode schocardiography (at baseline 214 ± 29 vs 253 ± 48 g in normoten- 
sire and hypertensive subjects, respectively). Responsiveness to A II was 
determined by infusion with A II (3.0 ng/kg/min) and subsequent measure- 
ment of changes in mean arterial pressure, glomerular filtration rate (GFR) 
(steady state clearance technique with inulin) and aldosterone secretion 
(radioimmunoassay). 
Results: In the entire study population, changes of GFR due to A II 
infusion were correlated with LV mass (r = 0.48; p = 0.003). Most excitingly, 
the increase of GFR in response to A II was also correlated with changes 
of LV mass over the follow-up period (r = 0.39; p = 0.02). This correlation 
was seen even more markedly in hypertensive subjects (r = 0.57; p = 0.006). 
Accordingly, we found a correlation between the increase of aldosterone 
secretion and LV mass (r = 0.43; p < 0.05), and, moreover, the increase of 
aldosterone secretion was correlated with the change of LV mass over the 
follow-up period, too (r = 0.41; p = 0.01). Including blood pressure (BP) as a 
cofactor in the statistical analysis did not affect these results. 
Conclusion: In this prospective study, we found that hyperresponsive- 
ness to A II is related with LV mass at follow-up independent of BP. Moreover, 
in these young hypertensive subjects with early structural cardiac adaptation, 
hyberresponsiveness to A II is related with the change of LV mass over the 
follow-up period. 
9:00 a.m. 
~-- ]  Smooth  Muscle Cell Hypert rophy in Subcutaneous 
Small Resistance Arteries of Patients With 
Renovascular Hypertension 
Damiano Rizzoni, Enzo Ported, Alfonso Piccoli, Maudzo Castellano, 
Giorgio Bettoni, Giancado Pasini, Michael J. Mulvany 1 , Enrico 
Agabiti Rose±. Chair of Semeiotica and Metodologia Medica, Department of 
Medical Sciences, University of Brescia, Italy; ~ Department of 
Pharmacology, University of Aarhus, Denmark 
Background: Vascular structural alterations in small resistance arteries of 
patients with essential hypertension are mostly characterized by inward eu- 
trophic remodelling. However, experimental models of hypertension with high 
circulating renin are characterized by the presence of smooth muscle cell 
hypertrophy. The aim of our study was to investigate at the cellular level 
the structural characteristics of subcutaneous small resistance arteries of 
normotensive subjects (NT) and of patients with renovascular hypertension 
(RVH) by an unbiased, highly advanced stereological principle (the "disec- 
tor"). 
Methods: Fifteen RVH, 8 NT and 8 patients with essential hypertension 
(EH) have been included in the study. A biopsy of subcutaneous fat was 
taken from all subjects. Small arteries were dissected and mounted on a 
micromyograph and the media]lumen ratio (M/L) was calculated. The cell 
volume (CV), the number of cell per segment length (NC), the cell length 
(LEN) and the number of cell layers (CL) were measured by the "disector" 
method. 
Table 
BP ID (~m) M/L (%) CV NC CL 
(turn Hg) (,u.m3*10 -3) (/zm -1 ) 
NT 128/79±8/7 306:t:83 6.2:1:1.8 2.04 ~ 0.31 10.0±4.304.8721.75 
RVH 164/105 :E 14/6"** 230 2 76" 12.1 2 5.0 "# 3.03 + 0.83** 9.08 :t: 4.46 4.75 + 1.44 
EH 160/104± 13/8"** 264281 9.1 23.5" 2.2620.45 7.88±3.58 4.41±1.14 
Results: The results are summarized in the Table (" = p < 0.05, "" = p 
< 0.01, "-p < 0.001 vs. NT, # = p < 0.05 vs EH). The M/L and the CV was 
significantly greater in RVH and in EH compared with NT, and was greater 
in RVH than in EH. No difference in NC was observed between groups. In 
conclusion, an inward hypertrophic remodelling, as evaluated by a direct, 
unbiased method, was observed in small resistance arteries of RVH but not 
of EH. 
Conclusion: For the first time our data demonstrate that a pronounced 
activation of the renin-angiotensin-aldosterone system is associated to vas- 
cular smooth muscle cell hypertrophy also in human hypertension. 
JACC February 1999 ABSTRACTS - Hypertension, Vascular Disease, and Prevention 299A 
9:15 a.m.  
F8-~-4--] I rbesartan Reduces QT Disperelon in Hypertensives 
Pitt O. Lim 1 , Madeen Nys 2, Abdul A,O, Naas 1 , Allan D, Struthers 1 , 
Mary Osbakken 3, Thomas M. MacDonald 1 . ~Hypertension Research 
Centre, Department of Clinical Pharmacology and Therapeutics, Universi~/ 
of Dundee, Ninawells Hospital and Medical School, Dundee DD1 9SY, UK; 
2Statistician, BM$, Waterloo, Belgium; 3 BMS, Princeton N J, USA 
Background: AT1 receptor antagonists have direct effects on the autonomic 
nervous system and the myocardium, We hypothesized that irbesartan would 
reduce QT dispersion to a greater degree compared with amlodipine, a highly 
selective vasodilator. 
Method: ECGs were obtained from a multinational, multicenter, random- 
ized double-blind parallel group study which compared the antihypertensive 
efficacy of irbesartan and amlodipine in elderly subjects with mild to mod- 
erate hypertension. Subjects were treated for 6 months with either drug, 
Hydrochlorothiazide and atenolol were added after 12 weeks if BP remained 
uncontrolled. 
Results: 188 subjects were randomized, We analyzed 104 patients who 
had complete ECGs at baseline and after 6 months of treatment, The base- 
line characteristics between treatments were similar apart from a slight im- 
balance in DBP [irbesartan (n = 53) 99.2 (3.6) mmHg vs amlodipine (n = 
51) 100,8 (3,8) mmHg, p = 0.03]. There were no significant differences in 
blood pressure normalization (DBP < 90 mmHg) between treatments at 6 
months, We found a significant reduction in QT indices in the irbesartan 
group [QTc dispersion, mean -11,4 (sd 34,5) ms, QTc max -12.8 (35,6) ms, 
p < 0,05]. Amlodipine did not significantly reduce QT dispersion, but there 
was a correlation between the change in QT indices and changes in systolic 
BP. 
Conclusion: Irbesartan improved QT dispersion independently of its BP 
lowering effect. This favourable effect of irbesartan may be important in 
preventing sudden cardiac death in at risk hypertensive subjects. 
9:30 a.m. 
~-8-72---~ Valsertan (Diovan®): Effect on Microalbuminuria in 
Patients With Type II Diabetes and Nephropathy 
N. Muirhead 1 , R. Cheung 2, W. Rodger 1 , R. Lewanczuk 3 , E. Pecher 4 , 
F. Botteri '~, P. Oddou-Stock 4 . ~London, Ontario; 2Windsor, Ontario; 
3 Edmonton, Alberta, Canada; 4 Novartis, Base/, Switzerland 
Background: Microalbuminuria is considered an independent predictor of 
subsequent progression of nephropathy. ACE inhibitors have been found to 
attenuate the progression of nephropathy in hypertensive and normotensive 
subjects with both type I and type II diabetes. 
Methods: A randomised double-blind placebo controlled trial was per- 
formed to assess the effects of valsartan over 12 months on urinary mi- 
crealbumin excretion in normotensive and treated hypertensive patients with 
type II diabetes and nephropathy. A total of 122 patients were randomised to 
valsartan 80 mg o.d. (n = 31), valsartan 160 mg o.d. (n = 31), captopril 25 
mg t.i.d. (n = 29) or placebo (n = 31 ). 
Results: At endpoint a decrease in micrealbumin excretion rate was ob- 
served in both valsartan groups (geometric mean of the ratio endpoint/loaseline 
for valsartan 80 mg: 0.72 and valsartan 160 mg: 0.79) and in the captopril 
group (0.73) whereas there was an increase on placebo (1.18). The treat- 
ment difference was statistically significant for valsartan 80 mg (p = 0.018) 
and captopril (p = 0.009) compared to placebo. One patient treated with 
valsartan 80 mg progressed to clinical proteinuria compared with no patients 
on valsartan 160 mg, 1 patient on captopril and 3 on placebo. 
The mean change from baseline for HbAlc was -0.13% for valsartan 80 
rag, -0.64% for valsartan 160 mg with a slight increase with captopril and 
placebo (0.16% and 0.47% respectively). 
Mean changes in diastolic'systolic blood pressure at 12 months were 
-5.4/-3.4, -4.7/0.6, -3.3/0.2 and -0.7/4.2 mmHg for valsartan 80 rag, 
valsartan 160 mg, captopdl 25 mg and placebo respectively. 
A total of 80.6% of the patients in the valsartan 80 mg group had an AE 
whereas 87.1%, 96.6% and 82.8% reported an AE in the valsartan 160 rag, 
captopril 25 mg (tid) and placebo respectively. 
Conclusion: Valsartan is effective in reducing microalbumin excretion in 
patients with type II diabetes and nephropathy and is well tolerated in this 
patient populafion. 
9:45 a.m. 
[ - ~  Effects of Candesartan Cilexetil in Patients With 
Severe Systemic Hypertension 
Suzanne Opadl, Eric L. Michelson. University of Alabarna at Birmingham, 
Birmingham, AL; Astra Pharmaceutica/s, Wayne, PA; for the Candesartan 
Cilexetil Study Investigators, USA 
Efficacy and tolerability of the potent angiotensin II receptor blocker can- 
desartan cilexetil (CAND) were evaluated in 217 adult patients (68% male, 
41% black) with severe systemic hypertension (JNC Vh Stage 3) on back- 
ground therapy with hydrochlorothiazide (HCTZ) in a 4-week, mulficenter, 
randomized, double-blind, placebo-controlled study. Patients with sitting di- 
astolic blood pressure (SDBP) >__ 110 mmHg were treated with HCTZ 12.5 mg 
once daily (QD) for 1 week. Those with SDBP > 95 mmHg after HCTZ run-in 
were randomized (2: 1) to CAND 8 mg once daily (n = 141) or placebo (n = 
76), plus HCTZ 12.5 mg QD. After 1-week of double-blind treatment, patients 
with SDBP > 90 mmHg were uptitrated to CAND 16 mg QD or matching 
placebo, plus HCTZ 12.5 mg QD; 84% required uptitration. Higher CAND or 
HCTZ doses were not evaluated. Primary efficacy measure was change from 
randomization in trough (24 ± 3 h post dose) SDBP at double-blind week 4. 
Results: 
Mean BP (mmHg) Pre-HCTZ Random- Double- Adjusted 
Systolic/Diastolic Run-In ization blind, Wk 4 Mean ~ BP 
CAND 8, 16 mg 166,2/112.6 156.2/105.0 144.0/95.8 -11.3"/-9.1 ° 
Placebo 164.1/111.4 156.5/105.6 153.0/102.2 -4.1/-3.1 
"p < 0.001 CAND 8, 16 mg vs Placebo 
Overall, 53% of patients on CAND responded (SDBP < 90 mmHg or 
> 10 mmHg) compared with 29% on placebo. BP was controlled (SDBP < 
90 mmHg) in 32% of patients on CAND at the end of double-blind week 4 
versus 16% in the placebo group. A trend toward greater BP reductions was 
observed in patients with higher baseline BP. Tolerability and safety were 
similar in the CAND and placebo groups. 
Conclusion: Candesartan 8 to 16 mg once daily is effective, well toler- 
ated, and safe for lowering systolic and diastolic BP when added to HCTZ 
12.5 mg in patients with severe hypertension inadequately controlled on 
HCTZ. 
POSTER 
Clinical Vascular Pathophysiology 
Wednesday, March 10, 1999, 9:00 a.m.-11:00 a.m. 
Morial Convention Center, Hall F 
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• Comparison of the Assessment of Brachlal Artery  
Flow-Mediated Artery Vasodilation Using Upper 
and Lower Arm Occlusion in Subjects With and 
Without Risk Factors 
Robert A. Vogel, Mary C. Corretti, Amy B. Fisher, Gary D. Plotnick. 
University of Maryland Hospita/, Baltimore, MD, USA 
Background: The assessment of endothelial function as brachial artery flow- 
mediated vasodilation (FMV) is performed using 5 minutes of either upper 
arm (UA) or lower arm (LA) blood pressure cuff occlusion to provide a hyper- 
emic stimulus. These techniques have not been systematically compared. 
Methods: We assessed FMV using both UA and LA occlusion (random 
order) in 20 subjects, 10 without risk factors and 10 with cholesterol >200 
mg/dl, blood pressure > 140/90 mmHg, or active cigarette smoking. Using 
7.5-11 MHz ultrasound, hyperemic blood flow was measured immediately 
after cuff release and FMV was measured 1 minute later. 
Results: In both normal and risk factor subjects, immediate hyperemia 
compared with baseline flow was higher with UA compared with LA occlusion 
(530 =1: 152% vs, 383 + 61% and 583 ± 153% vs. 309 ± 409%, respectively, 
both p < 0.01). FMV was also greater using UA compared with LA occlusion 
in both normal and risk factor subjects (13.4 ± 5.3% vs. 5.6 ± 3.4% and 7.9 
± 3.6% vs. 3.9 ± 2.2%, respectively, both p < 0.01). The normal and risk 
factor groups were statistically different using the UA technique (p < 0.01), 
but not by the LA technique. 
Conclusions: Brachial artery FMV obtained using UA compared with LA 
occlusion is higher due to the increase hyperemia induced and separates 
subjects with and without coronary risk factors better. 
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1220-21 I Correlation Between Coronary Artery 
Calcification and Impaired Peripheral Endothelial 
Function 
Steven J. Class, Bhushan Bhamb, Stuart Rich. Steven M. Hollenberg. 
Section of Cardiology, Rush Medical College, Chicago,/L, USA 
Background: Elevations in coronary artery calcification (CAC) scores de- 
tected by electron beam computed tomography (EBCT) correlate with the 
extent of atherosclerosis and are predictive of subsequent coronary events. 
Arterial endothelial function can be assessed by measuring the brachial 
artery vasodilatory response to hyperemia. We evaluated the correlation 
between endothelial dysfunction and the degree of coronary calcification in 
asymptomatie patients with a spectrum of risks for atherosclerosis. 
Methods: We studied 69 asymptomatic patients presenting for EBCT 
of the coronary arteries. High-resolution ultrasound was used to measure 
brachial artery diameter before and after wrist occlusion to induce reactive 
hyperemia. Studies were analyzed by 2 investigators blinded to the CAC 
score; results are expressed as% change. 
Results: Brachial artery vasoreactivity correlated negatively with CAC 
score (r = -0.47, p < 0.001 ). Patients were prospectively divided by presence 
or absence of significant coronary calcification into groups with low (<100; 
n = 53) and high (>100; n = 16) CAC scores. As expected, there was a 
significant difference in CAC scores between groups (12 vs 477, p < 0.001). 
There was no difference between groups in the following known cardiac 
risk factors: age (49.8 vs 53, p = NS), blood pressure (systolic 126 vs 128, 
diastolic 76 vs 79 mm Hg, p = NS), or total cholesterol (210 vs 231 mg/dl, p 
= NS). Diabetes was present in only 5/69 patients; 4/5 had low CAC scores. 
Brachial artery vasoreactivity was significantly decreased in patients with 
high CAC scores (% increase, 8.43 ± 3.11% vs 4.13 ± 1.95%, p < 0.00t). 
Conclusions: In this population of asymptomatic patients, elevations in 
CAC scores correlated with impaired endothelial function. High CAC scores 
have previously been shown to predict subsequent cardiac events in asymp- 
tomatic subjects. Endothelial dysfunction accompanies even mild atheroscle- 
rosis and may play a role both in its mechanism of development and in the 
propensity for future cardiac events. 
11220-22 J Intracoronary Radiation Increases Thrombosis 
i i Rate With Decreased Luminal Thrombi and 
Thrombus Area 
Yoram Vodovotz, Balram Bhargava, Sara D. Collins, Rosanna C. Chan, 
Roe Waksman. Washington Hospital Center, Washington DC, USA 
Background: Intracoronary Radiation (IR) using either ~ or y emitters in 
doses of 10-25 Gy reduces intimal area (IA) and IA corrected for medial 
fracture length (IA/FL) in animal models, and restenosis in clinical trials. 
Previous studies suggested the possibility of increased thrombosis rate (TR) 
in irradiated porcine arteries. 
Methods: Porcine coronaries were subjected to balloon injury (BI) fol- 
lowed by IR with doses of 0-18 Gy of either ,8 or V radiation. Tissue sections 
were perfusion-fixed, stained by Verhoeff*von Giesson, and analyzed by 
computer-assisted hislomorphometry. 
Results: The overall TR increased in a dose-dependent fashion from 
0-18 Gy (Fig. 1). Lumen thrombus (LT), as opposed to mural thrembi (MT) 
decreased (Fig. 1). Thrombus area (TA) also decreased with increasing 
radiation dose, which corresponded to decreased IA as has been reported 
previously (Fig. 2). Furthermore, LT present after IR was less organized 
consisting of mostly fibrin strands. 
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Conclusions: These data suggest that IR induces thrombosis, but without 
lumen compromise. Strategies for reducing TR may further decrease IA while 
increasing the safety of IR therapy. 
,I 1220-231 Temperature Heterogeneity in Human Carotid 
Atherosclerotic Plaques and the Associated 
Features 
Basit Malik, Cho C. Kuo, Thomas Grayston, Ward Casscells, James 
T. Willerson. University of Texas, Medical school Houston, TX, USA 
Most myocardial infarctions and sudden cardiac deaths result from the ero- 
sion or rupture of atherosclerotic plaques. Though we can document arterial 
narrowing angiographically, the features of atherosclerotic plaques associ- 
ated with erosion (inflammation with endothelial denudation) and rupture 
(large cholesterol pool and inflammatory cells beneath the thin fibrous cap) 
is determined by direct inspection and histopathology. We have recently 
reported thermal heterogeneity (0.5 to 4-°C) in living human atherectomy 
specimens. The surface temperaure (T) varied inversely with the depth of 
celt clusters as the warmer regions characterized by superficial inflammation 
and by a thin fibrous cap with a high density of cells, most of which are 
macrophages (M). Here we report that in a larger series of patients (N = 88), 
the T is correlated (r = 0.66, p = 0.0001) with the density of M. In contrast the 
T is inversely related to the density of smooth muscle cells (r = -0.41, p = 
0.0001 ) as identified by HAM-56 corroborated by electron microscopy. There 
was a 0.6-°C drop in T, when human plaques were incubated ex vivo for 5 
hours in 1 mg/ml Indomethacin suggesting role of inflammation in heat gen- 
eration in atherosclerotic plaques. We also report here that the mean T was 
inversely related to patient age but there was no relation to sex, symptoms, 
cholesterol level, body T, lesion color or aspirin use. There was no associa- 
tion of T maps in living human atherosclerotic plaques with immunoreactive 
staining for Chlamydia pneumoniae, using genus-specific monoclonal anti- 
body CF-2. The positive specimens averaged 1.6-°C in T heterogeneity Vs 
1.8-~C for plaques without evidence of Chlamydia pneumoniae. 
Conclusion: Macrophage activity is mainly responsible for the plaque 
heat and is not predictable by color of the lesion, or by clinical variables 
(except age) and appears not to be related with Chlamydia pneumoniae 
infection. 
1220-241 Baseline of Cell Levels Adhesion Molecules 
i P-selectin and ICAM-1 Predict 5 Year Survival in 
Patients With Coronary Artery Disease 
Bernhard R. Winkelmann, Markus Nauck 1 , Michael Hoffmann ~ ,
Georg Matheis, Jochen Senges, Winfded MArz 1 . Herzzentrum 
Ludwigshafen, Kardiologie, Ludwigshafen; ~ Klinische Chorale, Albert 
Ludwigs-Universit#t. Freiburg, Germany 
Background: Cell adhesion molecules are markers of endothelial dysfunc- 
tion. Increased circulating plasmas levels of the soluble forms of these 
molecules have been reported in overt and subclinical coronary artery dis- 
ease. 
Methods: We measured baseline plasma levels of intercellular adhesion 
molecule-1 (ICAM-1, CD54), vascular cell adhesion molecule-1 (VCAM-1, 
CD106), E-(CD62E) and P-Selectin (CD62P) and determined 5 year survival 
in a cohort of 283 consecutive stable male patients scheduled for elec- 
tive coronary angiography, angioplasty or cardiac surgery (coronary bypass 
and/or valve replacement surgery). Coronary artery disease was present in 
85% of the cohort. Patients with acute coronary syndromes or any other 
acute disease were excluded. 
Results: After 5 years 42 (15%) patients had died. Baseline plasma levels 
of circulating soluble cell adhesion molecules stratified by survivor status at 
5 year follow-up (5YR FUP) were as follows: 
5YR FUP ICAM-I" P-Serectin* VCAM-I* E-Selectie* 
Dead (n = 42) 273 ± 100 105 ~ 34 721 ~: 346 32 ± 13 
Alive (n = 241) 233 ± 66 92 ± 36 645 i 247 37 ± 16 
p value'* 0.02 0.03 0.30 0.07 
" mg/dL, "" non-parametric Wilcoxon Rank Sum Test values are mean ± SD 
In conclusion, increased plasma levels of ICAM-1 and P-Selectin in 
stable patients at baseline were markers of premature death. It is hypothe- 
sized that cell adhesion molecules may serve as early markers of endothelial 
dysfunction indicating the severity and extent of coronary atherosclerosis. 
• Lipid Lowering Therapy Does Not Effect the Acute 
Fibrinolytic Capacity of Hypercholesterolemic 
Patients 
David E. Newby, Robert A. Wright, Peter Bloomfield, Christopher A. Ludlam, 
Nicholas A. Boon, Keith A.A. Fox, David J. Webb. University of Edinburgh, 
Edinburgh, UK 
Background: Endothelial dysfunction, demonstrated by impaired endothe- 
lium-dependent vasodilatation, is found in patients with hypercholesterolemia. 
We examined the effects of lipid lowering therapy on substance P induced 
tissue plasminogen activator (t-PA) release in vivo in patients with hyperc- 
holesterolemia. 
Methods: Blood flow and plasma fibdnolytic factors were measured in 
both forearms of 8 patients with hypercholesterolemia (>296 mg/dL) in 
the absence of co-existing cardiovascular disease. Patients received uni- 
lateral brachial artery infusions of the endothelium-dependent vasodilator, 
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substance P (2-8 pmol/min), and the endothelium-independent vasodila- 
tor, sodium nitroprusside (2-8 /~g/min). Measurements were made on 3 
occasions: at baseline and after 6 weeks of placebo or pravastatin 40 mg 
daily. Placebo/pravastatin was administered in a double blind, randomised, 
crossover design. 
Results: Sodium nitroprusside and substance P caused dose-dependent 
increases in forearm blood flow (p < 0.001). In addition, substance P caused 
dose-dependent increases in plasma t-PA antigen (p < 0.001) and activity 
(p < 0.001) release but had no effect on plasminogen activator inhibitor 
type 1. Blood flow and t-PA responses were reproducible with no significant 
differences between placebo and baseline. During pravastatin therapy, serum 
cholesterol fell by 22% from 308 ± 13 to 242 ± 14 mg/dL (p = 0.002), but 
there were no significant changes in basal or substance P induced t-PA 
release. 
Conclusions: Lipid lowering therapy causes no demonstrable effect on 
acute substance P induced t-PA release in vivo in hypercholesterolemic 
patients. This suggests that hypercholesterolemia does not impair the acute 
endogenous fibrinolytic capacity in man. 
~ Elucidation of Mechanisms for Responsible 
Normalization by Troglitazone of Plasma Activity 
of PAl-1 
Thomas K. Nordt, Christoph GSggetmann, Karlheinz Peter, Christoph Bode, 
Burton E. Sobel. University of Heidelberg, Germany; University of Vermont, 
Burlington VT, USA 
Background: Troglita zone (T) is a novel oral antidiabetic drug that has been 
shown to have beneficial effects on endogenous fibrinolysis: T normalizes 
increased plasma activity of plasminogen activator inhibitor type-1 (PAl-l) in 
women with the polycystic ovary syndrome characterized by hyperinsuline- 
mia and accelerated atherogenesis. However, mechanisms contributing to 
the normalization of plasma activity of PAl-1 have not yet been elucidated. 
Methods and Results: Vascular and liver (Hep G2) cells were studied. 
3 ug/ml T alone increased PAl-1 accumulation in conditioned media of Hep 
G2 cells by 23% (p = 0.001) within 24 h. Induction was dependent on 
the concentration of T but not on insulin (up to 100 nM). The specificity 
of the effect was confirmed by the unaltered levels of total protein in cell 
lysates and by the lack of an effect of T on expression of urokinase-type 
plasminogen activator. By contrast, in human aortic smooth muscle cells, 3 
ug/ml T inhibited basal PAl-1 expression by 23% (p = 0.037) and inhibited 
TGF-~ induced PAl-1 expression by 34% (p = 0.026). Insulin did not affect the 
results. The expression of tissue-type plasminogen activator was inhibited 
by 38% (p = 0.002). In human umbilical vein endothelial cells, the inhibition 
of PAl-1 expression was 32% (p < 0.001). 
Conclusion: T appears to reduce the activity of PAl-1 in plasma in 
patients with hyperinsulinemia both directly by decreasing PAl-1 elaboration 
from vessel walls and indirectly by reducing hyperinsulinemia and hence 
the stimulatory effects of insulin on hepatic synthesis of PAl-1. Thus, T may 
be beneficial in the treatment of accelerated atherogenesis secondary to 
reduced fibrinolysis in hypednsulinemic diseases such as diabetes mellitus. 
~ Beneficial Effects of Endothelial Troglitazone on 
Dysfunction of Coronary Artery 
Tatsuaki Murakami, Sumio Mizuno, Bunji Kaku, Masateru Ohnaka, Fukui 
Cardiovascular Center, Fukui, Japan 
Background: The relation between insulin resistance and coronary artery 
disease has great clinical attention, but remains to be pathophysiologically 
investigated. This study aimed to estimate clinical impacts of troglitazone on 
vasomotion of coronary artery. 
Methods: Nine diabetic patients troglitazone who underwent coronary 
angiography and flow-dynamic examinations were enrolled into this study 
of troglitazone. We administered troglitazone (400 mg per day) for more 
than four months in the diabetic patients (T-group). Nine diabetic patients 
treated with diet or glibenclamide, served as control subjects into this study 
(C-group). We measured endothelium-dependent response to acetylcholine 
(0.5-50/~g) into the study (normal or minimally diseased) left coronary artery. 
Reactive changes in coronary artery diameter (DE: maximal reactive diam- 
eter - baseline diameter / baseline diameter) and coronary blood flow (FE: 
maximal hyperemic flow - baseline flow / baseline flow) were quantified by 
coronary angiography and intracoronary doppler-tipped guidewire. Changes 
in the reactive changes from the baseline through the follow-up point were 
compared between the two study groups. 
Results: T-group manifested good compliance to the treatment and signif- 
icant improvements in glycemic and lipidemic variables. DE were significantly 
improved in T-group but not in C-group (T-group vs C-group: from 0.6:2 3.6% 
to 7.0 ± 5.7%, p = 0.01, vs, from 1.3 ± 2.3% to 1.4 ± 2.4%, n.s.). FE were 
also significantly improved in T-group but not in C-group (T-group vs C-group: 
from 48 ± 20% to 108 ± 53%, p < 0.01, vs, from 45 ± 20% to 39 ± 23%, n.s.). 
Conclusion: These findings suggest that troglitazone restores endothe- 
lium-dependent vasomotion of coronary artery and may have beneficial po- 
tentials for management of coronary artery disease. 
• Hyperglycemia, but not Hyperinsulinemia 
Increases the Risk of Premature Death in Patients 
With Coronary Artery Disease 
Bernhard R. Winkelmann, Markus Nauck 1 , Michael Hoffmann 1 , 
Georg Matheis, Jochen Senges, Winfried M~rz 1 . Herzzentrum 
Ludwigshafen, Kardiologie, Luclwigshafen; ~ Klinische Chemie, Albert 
Ludwigs-Universit~t, Freiburg, Germany 
Background: The role of hyperinsulinemia as a coronary risk factor in non- 
diabetics is controversial. 
Methods: We studied 5 yr survival in a cohort of 283 consecutive male pa- 
tients with elective coronary angiography enrolled in a risk factor prevalence 
study. 85% had coronary artery disease. Diabetic phenotype was evaluated 
with an oral glucose load. 
Results: Total mortality at 5 yr follow-up (FUP) was 5%, 16% and 20% 
for 1, 2 and 3-vessel disease, respectively, and it was twice (23%) as high in 
diabetics as in individuals with a normal or impaired GT (12%) at baseline (p 
= 0.03). Baseline fasting insulin (mU/L) and glucose (mg/dL) by GT status of 
patients who died (D:) or were alive (A:) at 5 year follow-up: 
Normal Impaired Diabetic GT" HX dia. p value 
No of Patients 143 84 44 30 
5 Yr Mortality 13% 11% 24% 21% 0.03 
D: Glucose 80 i10  86±12 106±24 121±47 0.005 
A: Glucose 81±10 86±10 101±25 135±33 0.0001 
D: Insulin 11 ± 5 13 ± 5 14 ±8 14 ± 5 0.37 
A: Insulin 12 ± 6 16 ± 10 18 ± 9 13 ± 7 0,0008 
• diabetes detected at baseline by glucose tolerance test (GT)(WHO criteria); HX dia = 
history of diabetes; mean ~: SD or frequency. 
Conclusion: Hyperinsulinemia in impaired GT (i.e. without hyperglycemia) 
did not increase mortality, while hyperinsulinemia plus hyperglycemia (i.e. di- 
abetics of recent onset) did. Thus fasting hyperglycemia, but not fasting 
hyperinsulinemia by itself was associated with increased mortality. Fasting 
plasma insulin in non-diabetics is not a risk factor for premature death. 
~ Sudden Coronary Death as the First Manifestation 
of Ischemic Heart Disease in Persons Under Age 
Fifty: Can Extent of Calcification Predict Presence 
of Plaque Rupture? 
Axel Schmermund, Robert S. Schwartz, Michael Adamzik, 
Giuseppe Sangiorgi, Eric A. Pfeifer, Allen P. Burke, Andrew Farb, 
Renu Virmani. Mayo Clinic and Foundation, Rochester, MN, Armed Forces 
Institute of Pathology, Washington DC, USA 
Background: The visualization of preclinical coronary atherosclerotic dis- 
ease during life can identify individuals at high risk of coronary events. Elec- 
tron-beam computed tomography (EBCT), by quantifying coronary calcium, 
may also be able to define the extent of coronary atheroscterosis. The value 
of this approach has been questioned for subjects under age 50 because of 
generally less extensive atherosclerosis and calcification. 
Methods: Coronary arteries obtained at autopsy of 28 victims of sudden 
coronary death (SCD) under age 50 with no prior manifestation of ischemic 
heart disease and of 16 age*matched subjects dying of non-cardiac causes 
out of hospital were examined. Representative sections of the complete 
major arteries were cut in 3 -  to 5-mm intervals to yield a total of 1,357 
histologic sections and analyzed using digitized planimetry. 
Results: The fraction of sections in categories of cross-sectional area 
stenosis <25%, 25 -- < 50%, 50 < 75%, and >_ 75% was 4%, 14%, 
33%, and 50%, respectively, in SCD-cases and 43%, 30%, 21%, and 6%, 
respectively, in controls (p < 0.001 ). Total plaque area per patient, normalized 
to the number of histologic sections, was 5.1 + 2.1 mm 2 in SCD-cases and 
2.0 ± 0.9 mm 2 in controls (p < 0.001). Total normalized calcium area per 
patient was 0.18 ± 0.19 mm 2 in SCD-cases and 0.02 ± 0.05 mm 2 in controls 
(p < 0.001). Prevalence and amount of calcification were associated with 
plaque rupture in 52 sections (univariate analysis). In multivariate analysis, 
only plaque and lipid core areas were independent predictors of plaque 
rupture. 
Conclusion: Although in young victims of SCD, there was little coronary 
calcification relative to the extent of plaque formation, the extent of both ath- 
erosclerosis and calcification was substantially greater than in age-matched 
controls. Quantification of calcium in selected individuals may thus be of value 
to identify those who likely benefit most from targeted primary prevention. 
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• Effect of Abciximab (C7e3) on Thrombus 
Architecture in Patients With Acute Myocardial 
Infarction Undergoing Primary Angioplasty 
J.P. Collet 1 , C. Lesty 1 , J. Soria 2, C. Soria 2, Z. Mishal 2, D. Thomas 1 , 
G. Montalescot 1 . r H&pitai Pitie Salp~tri~re; eHotel Dieu, Paris, France 
Background: Disaggregation of platelet aggregates is thought to be respon- 
sible for the efficacy of c7E3 in dissolving occlusive coronary thrombi. We 
have investigated whether this effect might influence platelet-rich clot (PRC) 
properties in 24 patients admitted for AMI. 
Methods: All patients received aspirin and in a double-blind fashion either 
a bolus of c7E3 (n = 14) or placebo (n = 10) before primary PTCA. Then a 12 
hours continuous infusion of c-7E3 (or placebo) was started. Viscoelasticity 
(G' in dyne/cm 2) and morphological (S.ag in/~m 2, mean platelet aggregates 
surface) indexes of PRC were studied before and after the bolus infusion. G' 
reflected the mechanical impact of activated platelets on the fibrin meshwork. 
Results: A positive and significant correlation was observed between G' 
and Sag before infusion in both groups (r = 0.78, p = 0.03). C7E3 strongly pre- 
vented activated platelets interactions with fibrin after bolus infusion in treated 
patients. Moreover, G' decrease after c7E3 bolus infusion was clearly related 
to inhibition of platelet aggregate formation within the clot. No correlation was 
observed between the TIMI score before the bolus infusion and the throm- 
bus properties. However, larger aggregates and stiffer clots were observed 
in patients with spontaneous repertusion. 
Placebo (n = 10) Reopro (n = 14) P value 
G' before botus 1537 ~ 889 a 1820 i 1246 c NS 
G' after bolus 1861 -E 974 b 702 :E 532 <:1 p < 0.001 
S.ag before bolus 2777 :~ 1040 e 2129 5:1533 g NS 
S.ag after bolus 2701 5:798 f 664 ± 510 h P < 0.001 
a, b: p = 0.2; c, d: p < 0.001 ;e, f: p = 0.87; g, h: p < 0.05 
Conclusion: These results highlight he poorly effective platelet blockade 
by aspirin during AMI and the relevance of the combination of c7E3 and 
aspidn. These modifications of PRC architecture in AMI patients may prevent 
thrombus growth and facilitate spontaneous repertusion or revascularization 
procedures. 
~ B o t h  Atenolol and Blunt the Propanolol 
Fibrinolytic Response to Exercise but not Resting 
Fibrinolytic Potential 
Bo Fernhall, Linda M. Szymanski, Patrick A. Gorman, Gary Kamimori. The 
George Washington University Medical Center; Waiter Reed Army 
Research Institute, Washington, DC, USA 
Background: Beta-blockade may attenuate fibrinolytic markers, whereas 
exercise produces an increased fibrinolytic response. This was a randomized, 
double blind, placebo controlled trial of the hemostatic response to exercise 
comparing the effects of atenolol and propanolol on fibrinolytic markers and 
coagulation activation. 
Methods: Twelve healthy men were given a placebo (P), atenolol (A), or 
propanolol (PO) for 3 days, with a minimum 7 day washout period between 
treatments. Blood was collected at rest and after a maximal exercise test 
on day 3, and analyzed for tissue plaminogen activator (t-PA) activity and 
antigen, and its specific inhibitor PAl-1 activity and antigen, prothrombin 
fragment 1.2 and catecholamines. 
Results: Maximal oxygen uptake was not altered by beta blockade. Rest- 
ing levels of the fibrinolytic markers were unchanged by beta blockade, t-PA 
antigen increased with exercise (140%-173%) but the increase was not dif- 
ferent among treatments. PAl-1 antigen was unaffected by exercise and beta 
blockade, t-PA activity increased significantly more with exercise (p < 0.05) 
during P (1.9 to 7.97 IU/ml; 319%) compared with A (1.94 to 6.32 IU/ml; 
226%) and PO (1.96 to 6.56 IU/ml; 235%). PAl-1 activity decreased to a 
greater extent in P (12.47 to 4.35 AU/ml; 64%) compared to A (13.97 to 7.99 
AU/ml; 42%) and PO (10.3 to 6.79 AU/ml; 34%) (p < 0.05). Prothrombin 
fragment 1.2 was not affected by beta blockade nor exercise. Maximal cate- 
cholamine levels were similar in the P and PO conditions but both P and PO 
were higher than A (p < 0.05). 
Conclusion: Both atenolol and propanolol blunt the fibrinolytic response 
to exercise, but do not affect prothrombin fragment 1.2 nor resting fibrinolytic 
measures. These results cannot be explained by differences in exercise 
intensity or circulating catecholamine levels. 
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11221-11 0 / Effect of Smoking on Arterial Wave Reflection in 
L J 
Young Adult Males 
Krishna Prasad, Addan Raybould, Mick Jubb I , lan B. Wilkinson 2, David 
J. Webb 2, Michael J. Wodd 1 , Hugh E. Montgomery 3, Michael P. Frenneaux, 
John R. Cockcroft. Dept of Cardiology,, UWCM, Cardiff; r RAMC, Millbank; 
2 Dept of Clinical Pharmacology, Univ of Edinburgh; 3 UCL, London, UK 
Background: Smoking impairs endothelial function and arterial compliance. 
Pulse wave analysis (PWA) uses the principle of applanation tonometry to 
record peripheral pressure waveforms from which the corresponding central 
waveforms are generated and central pressures determined non-lnvasively. 
Augmentation index (AIx) represents the contribution of wave reflection to 
central pressures, and is a measure of arterial stiffness. We performed PWA 
on 142 young male healthy army recruits at entry and compared the effect of 
smoking habits on the central pressures. 
Methods: All subjects were free of clinical cardiac or vascular disease. AIx 
was determined by PWA at the radial artery (SphygmoCor System). Height, 
weight, smoking habits and medications if any were documented. Subjects 
were grouped into non-smokers and chronic smokers (>_10 cigarettes/day 
for >12 months). Those who did not fulfil this criterion were defined as 
occasional smokers (n = 18). 
Results: All subjects were normotensive. The mean age was 19 =E 2 
years and mean AIx was -6  + 15%. Smokers, (n = 58) had a higher AIx ( -2 
± 15% Vs -12 ± 13%; p < 0.001) but similar brachial artery systolic blood 
pressures (122 4- 13 Vs 120 + 13 mm Hg) compared with non-smokers (n = 
66). A Greater proportion of smokers (n = 25; 43%) had positive augmentation 
than non-smokers (n = 11; 17%) (Chi Sq = 10.5; p-0.001). The groups did 
not differ in terms of age, height, weight or other parameters. 
Conclusion: Smoking increases central aortic pressure & augmentation 
index suggesting increased arterial stiffness, even in young adults. PWA 
detects differences in arterial stiffness and may be helpful in monitoring 
response to therapy or change in risk factor status. 
1221-11 I Hormone Replacement Therapy and Levels of 1 
Soluble Adhesion Molecules in Postmenopaueal 
Women 
Martina BrOckmann 1, Thomas yon Hoist 2, Birgitt Salbach 2, 
Wolfgang K0bler ~ , Peter B. Salbach 1 . ~Dept. of Cardiology & 
2 Gynaecology, University of Heidelberg, Heidelberg, Germany 
Background: Elevated levels of circulating adhesion molecules (CAM) are 
markers for endothelial dysfunction. Postmenopausal hormone replacement 
therapy (HRT) improves endothelial function and is associated with a reduc- 
tion in the incidence of cardiovascular events. The aim of this study was 
to compare the influence of transdermal versus oral HRT on markers of 
endothelial function in healthy postmenopausal women. 
Methods: Healthy postmenopausal women were treated with transdermal 
(td) HRT (delivery rate 50 p.g 17~-estradiol/24 h, n = 20) or with 2 mg oral 17/~ 
estradiol (orHRT, n = 20) for 6 months (Mo). Levels of soluble vascular cell 
adhesion molecule-1 (sVCAM-1), soluble (s) P-, sE-selectin, and estradiol 
were measured by ELISA, results were compared by students t test (paired 
two tailed p values). 
Results: Both therapy regimens induced significant changes in estra- 
diol values (tdHRT: 10.15 4- 4.88 pg/ml / 27.6 =E 15 pg/ml, 0 / 6 months 
respectively; oral therapy: 9.25 =E 6.94 pg/ml / 120.89 + 73 pg/ml; 0 / 6 
Mo respectively). After 6 months of orHRT there were marked reductions in 
sVCAM-1 (-17%, p = 0.0009) and sE-selectin (-12.5%, p = 0.0002) levels. 
Transdermal application of 50/~g 17/~ estradiol lead to similar reductions in 
sE-selectin (-16.31%, p = 0.005) and sVCAM-1 (-18.75, p = 0.008) serum 
values. Levels of sP-selectin remained unchanged in both groups. 
Conclusion: HRT regulates sCAM levels in vivo and may represent a new 
mechanism by which HRT modulates progression of cardiovascular disease. 
In addition transdermal application of 50/~g 17/~ estradiol/24 h may have 
equal positive effects on endothelial dysfunction compared to oral therapy 
regimen. 
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1221-1121 Combination of Chronic Mental Stress and Sleep 
Derivation Attenuates Vasodilation of Brachial 
Artery and Reduces Intracellular Magnesium in 
Humans 
Bonpei Takase, Akimi Uehafa, Takashi Akima, Takanori Tahara, 
Koh Arakawa, Toshio Shibuya, Kimio Satomura, Toshihiko Nishioka, 
Fumitaka Ohsuzu, Akira Kurita. Serf Defense Force Central Hospital and 
National Defense Medical College, Tokyo and Saitarna, Japan 
Chronic mental and physical stress has been suggested as a tdgger for 
cardiovascular events. Also, the reduction of intracellular magnesium (Mg) 
causes ~),=~,.~c~.~P.~,'.~-~ ~ )z-P_.~ p~=: ,~: , -~ .~ ~,.,~r.d~,~,~ " z~ 
investigate if chronic stress (CS) affects endothelial function and intracellular 
Mg in humans, flow-mediated vasodilation (FMD, endothelium-dependent va- 
sod±lotion) and sublingual glyceryl tdnitrate induced dilation (0.3 mg, GTN-D, 
endothelium-independent vasodilation) were measured in the brachial artery 
in 11 healthy male college students (Stds) aged 21 ± 1 years by using high 
resolution ultrasound before and immediately after 4 week-study of preparing 
for a final term examination (exam). Erythrocyte Mg (RBC-Mg) was simulta- 
neously measured. All Stds had chronic sleep derivation for 4 weeks when 
sleep lasted <80% of that in ordinary day as well as Stds were pushed to 
study hard to pass the exam. This condition was considered as CS. There 
were 4 smokers in Stds. Results in table. 
FMD (%) GTN-D (%) RBC-Mg (rng/dl) 
Before CS 7.5:5 3.5 13,4 ± 3.1 5.4:5 0.3 
In CS 4.1 ± 1.8" 7.5 ± 3.8" 5.2 4- 0.2" 
(Mean :5 SD; * p < 0.05 vs before CS) 
Although FMD and GTN-D were normal values in CS phase, CS de- 
creast,,'~Z,,ExT,,;",.c_.,=~,:C,'~.~,h~, t'~=J'..dr~d~. ,t4t ~,~q~'T((,.~,.~.ff~, "¢0rm~ 
lated with that of RBC-Mg (r = 0.68, p < 0.05), but not GTN-D. In conclusions: 
CS attenuates the endothelial function and the sensitivity of the vascular 
smooth musc(e to GTN. The (ormer is poss(b(y assoc(ated w(th t~ reduct(on 
of intracellular Mg. These findings might provide a novel insight into the role 
of CS in development of cardiovascular events. 
1221-113 J Effect of Sildenafil (Viagra) on Coronary 
1 
Blood 
Flow and Hemodynamics During Exercise 
Jay H. Traverse, S. Ruisheng Du, Melanie Crampton, Shauna Voss, 
Paul Undstrom, Robert J. Boche. University of Minnesota; the Minneapolis 
Heart Institute, Minneapolis, MN, USA 
Background: Sildenafil (SIL) selectively inhibits cGMP phosphodiesterase 
Type 5 enhancing the effect of nitric oxide on cGMP levels in the corpus 
cavernosum resulting in increased blood flow. However, the interaction of 
SIL and the heart and its potential to improve coronary blood flow (CBF) is 
not krown. Because rnanv ~. a((en~s us(nq G~L have unfed~inq coronar~ arter~ 
disease, we examined its effect on CBF during exercise with and without the 
preserve ,3~ a co~'o~ary artery stenosis. 
Methods: We measured CBF and hemodynamics in 5 dogs chronically 
instrumented with a flow probe and hydraulic occluder placed on the LAD 
during treadmill exercise (4 MPH, 10 -° grade) before and after the administra- 
tion cf SIC <5Q m(~ ge I. RecJional rnyocarctia/btoocl flow was determined with 
micrcsgt~eres in 3 doqs duNn~ the same level of exercise following inflation 
of th~ oc~ut~erT.o cr~ahe a~en~.  
Results: There were no significant changes in hemodynamics observed 
with SIL during control exercise. During exercise with a stenosis, CBF tended 
to improve with SiL and was accompanied by a small increase in subendo- 
cardial blood flow as ENDO / EPI increased from 0.28 to 0.34. 
MAP HR LV EDP DCP CBF 
(rnmHg) (beat/min) (mmHg) (mmHg) (mmHg) (ml/min) 
Control- EX 132+11 193±7 156+10 11±6 118+7 67:511 
S IL -  EX 121:56 205±6 145±7 6±4 113+6 71:514 
Con-S"?~'l(~ "C'Z"o ~:'Pu ~(~ 5:% ~ff,~ ±~,  ~ 5~ ~ ~='q ~&±-~ 
SIL-STEN 120:511 203,:57 145±15 7 :54  53:59 50:511 
MAP = Mean arterial pressure, DCP = Distal coronary pressure (LAD) 
Conclusions: These findings demonstrate that in the normal heart SIL is 
well tolerated and results in no adverse effects on CBF or hemodynamics. 
In the presence of a coronary stenosis, SIL may actually improve blood flow 
and potentially ameliorate subendooardial ischemia. 
1221 J Correction of Endothelial Dysfunction in Chronic 
] 
1 4 
Heart Failure: Additive Effects of Oral L-Arginine 
Supplementation and Exercise Training 
Stephan Gielen, Rainer Hambrecht, Lutz Hilbrich, Sandra Erbs, 
Eduard Fiehn, Nina Schoene, Gerhard Schuler. Heart Center, University of 
LeJpzig, Leipzig, Germany 
Background: Endothelial dysfunction (ED) in patients with chronic heart 
failure (CHF) can be corrected by both regular physical exercise (PE) and 
supplementation with L-arginine (L-A). The aim of this study was (1) to assess 
the bioavailability of oral L-A and (2) to analyse if L-A has additive effects to 
~'E--. 
Methods: 40 patients (pts.) with severe CHF (left ventricular ejection 
fraction 19 ± 9%) were randomised to an L-A group (L-A 3g-2g-3g), a 
training group with daily handgrip exercise (T), an L-arginine plus training 
group (L-A+T), or an inactive control group (C). In L-A-treated pts. a 24-hour 
serum profile of L-A-levels was determined at the beginning (B) and after four 
weeks (E). The internal radial artery diameter (ID) was determined at B and 
E in response to brachial arterial administration of acetylcholine (ACh) (7.5, 
15, 30 p.g,'min) and nitroglycerine (NTG) (0.2 mg/min) with a high-resolution 
10 MHz A-mode echo tracking system. 
Results: (1) Oral L-A at 8g/day increased the average serum levels of 
L-A from 14.1 ± 3.1 to 23.6 ± 3.9 #g/mL. (2) At B, the mean vasodilation in 
response to ACh, 30/~g/min was 2.54 ± 0.09% (p = NS between groups). At 
E, ID increased by 6.6 ± 0.8% after ACh 30/~g/min in L-arg. (p < 0.001 vs. 
C), by 6.5 ± 0.8% in T (p < 0.001 vs. C), and by 9.1 ± 0.2% in L-arg.+T (p 
< 0.01 vs. C, L-A and T). Vasodilation after NTG was similar in all groups at 
B and E. 
Conclusion: Oral L-arginine and regular physical exercise improve en- 
dothelium-dependent vasodilation (EDD) to a similar extent. Both interven- 
tions tqgether,seem to cr~)duce additive effects with re~oect o EDD. 
I1221-115~ PET Assessment of Myocardial Blood Flow 
q 
Before and After Hormone Replacement Therapy 
in Postmenopausal Women 
Claire Duvemoy, Judith Rattenhuber, Vanadin Seifert-Klauss, Frank Bengel, 
Christian Meyer, Markus Schwaiger. Veterans Affairs Medical Center and 
University of Michigan Medical Center, Ann Arbor, Michigan, USA; Technical 
University of Munich, Munich, Germany 
Background: Estrogen restores endothelium-dependent vasodilation in re- 
sponse to acetylcholine in postmenopausal women, and has a direct, en- 
dothelium independent vasodilatory effect on coronary arteries. Combined 
hormone replacement herapy (HRT) does not, however, improve endothe- 
tium-dependent vasoditation. 
Methods: To determine whether coronary microcirculation can be affected 
by short-term hormone replacement herapy, we performed positron emission 
tomq.graphy [PE'0 in 2 groups of women without Drevious HRT: 9rou, D I /n 
= ~tlJ I 'ha0 "] or more fidK ~actors ~or coronary 'near[ disease ~i'~r'L/); group 
II (n = 8) had documented CHD and previous MI. Group II was older (54 
± 4 vs. 59 Jc 5 yrs, p = 0.03) and had lower total cholesterol levels at 
baseline because of lipid-lowering therapy (244 ± 31 vs. 203 ± 40 mg/dl, p = 
0.03). Pts underwent baseline dynamic PET with N-13 ammonia at rest and 
dudng maximal adenosine-induced hyperernia to assess rnyocardia~ blood 
flow (MBF). Each then began taking HR'T (conjugated equine estrogen and 
medroxv, Qroo~esterone acetate'b, and returned tor tollow-uD. PET 46 ± 12 days 
~'(er. 
Results: 
Baseline Follow-up 
Rest StressM Flow Rest Stress Flow 
MBF BF Reserve MBF MBF Reserve 
Group I 90 ± 26 288 ~- 64 3.5 ± 1,4 91 ± 25 273 ± 52 3.3 + 1.4 
Group II 88 ± 31 243 ± 92 2.9 ± 1.3 81 ± 28 224 ~- 50 3.0 ± 1.1 
p NS for all baseline vs. follow-up values; MBF in ml/min/100 g 
Stress MBF and flow reserve (FR) were slightly higher in Group I pts. 
Mean resting and stress MBF values were not significantly changed from 
baseline, and resulted in similar FR values at baseline and during HRT for 
both groups. 
Conclusions: Short-term HRT in postmenopausal women does not im- 
prove MBF or FR. Combined cyclical HRT may not exert measurable effects 
on coronary microcirculation. Progesterone may attenuate estrogen effects 
on the coronaries, which may be largely endothelium-dependent. 
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~ T h e  Combination of Blood and Agitated Saline 
Contrast Enhances the Doppler 
Echocardiographic Assessment of Tricuspid 
Regurgitation Flow and Estimation of Pulmonary 
Artery Pressure in Patients With Emphysema 
Tomoo Nagai, Shaul Atar, Huai Luo, Zab Mohsenifar, Robert J. Siegel. 
Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Background: The use of echo-contrast, which augments ultrasound signal, 
has been reported to be helpful for the Doppler assessment of tricuspid 
regurgitation (TR) in patients (pts) with poor-quality TR signals. The aim of 
this study is to evaluate the usefulness of contrast enhancement achieved 
by the combination of pts' blood and agitated saline for the evaluation of TR 
flow in pts with emphysema. 
Methods: In 23 pts with emphysema, 74 -L 14 years old, 13 males, con- 
tinuous wave Doppler measurement was performed with contrast injections. 
We used 2 contrast techniques: 1) saline + blood contrast, the combination 
of 1 ml of blood withdrawn from the pts and 8 ml of saline agitated with 1 
ml of air, 2) saline contrast," 9 ml of saline agitated with 1 ml of air. Trans- 
tricuspid valve flow was recorded on the S-VHS videotape and evaluated 
by an independent reviewer. Qualification of TR signal, which was assessed 
semi-quantitatively according to the envelope shape and the signal intensity, 
was performed at the baseline as follows; none (n = 13), poor (n = 7), fair (n 
= 3), good (n = 0), and repeated at each contrast injection. 
Results: Saline + blood contrast achieved a better Doppler envelope 
than agitated saline in 26% of pts (6/23), and improved 38% of cases (3/8) 
which did not have signal enhancement with saline contrast. In 5 pts (23%, 
4/5 with no TR signal), either saline contrast or saline + blood contrast did 
not improve the TR signal. The peak TR velocities and numbers of pts with 
high-quality TR signals are below. 
Baseline Saline Saline + blood. 
peak TR velocity (cm/sec) 273 ± 26 299 ± 39" 322 ± 45" 
pts with TR signal (_>fair) 3/23 (13%) 11/23 (48%)* 17/23 (74%)#. 
(mean ~ SD; " vs baseline, "" vs saline, P < 0.05; # vs saline, p = 0.06). 
Conclusions: Use of the combination of blood and agitated saline con- 
trast improved TR flow signal quality and detected higher peak TR velocities 
than the conventional contrast. This simple method may increase the sen- 
sitivity and specificity to estimate pulmonary artery pressure in patients with 
pulmonary disease and poor-quality TR Doppler signals. 
~ Noninvasive Differentation Primary Pulmonary of 
Hypertension and Chronic Pulmonary 
Thromboembolism Using Transthoracic 
Echocardiography 
Shahin Keramati, Alit Raisinghani, Ehtisham Mahmud, William Auger, 
Daniel Blanchard, Anthony N. DeMaria. UCSD, San Dtego, California, USA 
Although both primary pulmonary hypertension (PPH) and chronic pulmonary 
thromboembolism (CPTE) produce marked elevation of pulmonary artery 
pressure, these entities differ markedly in etiology, level of pulmonary vas- 
cular obstruction, and therapy. However, PPH and CPTE often manifest 
indistinguishable clinical presentations. We analyzed the echocardiograms 
in a group of pts with these two disorders and similar PA pressure to deter- 
mine if the differential pathophysiology produces distinctive alterations in RV 
size and structure which may be of diagnostic value. 
Methods: We retrospectively reviewed the echocardiograms of 24 pts: 
12 with PPH and 12 pts with CPTE. All patients had elevated mean PA 
pressure confirmed by right heart cath. Measured indices on echo included 
right ventricular wall thickness (RVT), LV eccentricity index of 2 orthogonal 
diameters in short axis (E-I), RV elongation index (RVe-I) and mitral E/A ratio. 
Elongation index was defined as the ratio of the RV length (valve apparatus 
to apical endocardium) to width (measured at mid ventricular level) in the 
apical 4 chamber view. 
Results: 
Age (yrs) PA x (mmHg) RV (ram) RVe-I E-I MV-E/A 
PPH 48.9 56±9 13.3~:1.5 1.3±0.25 1.7::c0.23 0.81±0.26 
CPTE 45.7 54±12 12.5±09 1.6±0.20 1.6±0.35 0.88±0.38 
Pvaiue NS NS NS 0.008" NS NS 
The increase in RV width was greater in PPH than CPTE even though 
mean PA pressures were similar. Using a cutoff of 1.4, RVe-I had a sensitivity 
= 83.3% and specificity = 75% for successfully detecting PPH. 
Conclusion: Our study shows differences in right ventricular geometry 
in patients with PPH and CPTE independent of PA pressures. Although the 
mechanisms of these differences are not clear, they may reflect differences of 
RV systolic wall stress associated with proximal versus distal PA obstruction. 
These findings may be of value in distinguishing PPH from CPTE in the 
clinical setting. 
• Asian Americans Are at Very Low Risk of 
Pulmonary Embolism and/or Deep Venous 
Thrombosis 
Arthur L. Klatsky, Mary Anne Armstrong, Jacqueline Poggi. Kaiser 
Permanente Medical Care Program, Oakland, CA, USA 
Sparse data from U.S. population studies suggest a slightly higher preva- 
lence of pulmonary embolism (PE) and deep venous thrombosis (DVT) in 
non-whites than in whites, but this has not been evident in data from the 
Pacific region (CA, OR, & WA). We prospectively studied PE/DVT hos- 
pitalizations in 128,934 persons in relation to traits determined at health 
examinations in 1978-1985. Through 1994, 303 persons were subsequently 
hospitalized for PE or DVT (206 persons for PE first). Cox proportional haz- 
ards models with 9 covadates were used. In multivariate models the following 
RR's (95% confidence intervals) were found for PE/DVT combined: Black/ 
White = 1.1 (0.4-1.4); Hispanic/White = 0.7 (0.3-1.5); Asian/White = 0.2 
(0.1-0.5; p = 0.002). The lower risk of Asians was present in each sex and 
for persons first hospitalized for either PE or DVT. Covariates with significant 
positive relationships to risk were age, male sex, body mass index, and a 
composite coronary disease risk/symptom variable; covariates not signifi- 
cantly related were education, madtal status, smoking, and alcohol. These 
data suggest that Asians have very low risk of PE/DVT, which may explain 
U.S. geographic variations in white/nonwhite dsk differences. Possible ex- 
planations include the existence of genetic (or other) protective traits for PE/ 
DVT in Asians. 
• Intrapulmonary Artery Lesions in Chronic 
Obstructive Pulmonary Disease: Evidence by 
Transesophageal Echocardiography 
Aldo Russo, Massimo N. De Luca, Antonella Lombardo, Carlo Vigna, 
Vincenzo De Rito, Vito D'Alessandro, Francesco Loperfido. Cardiology 
Institute, Catholic Universi~ Rome; Cardiology Department, "Casa Sollievo 
della Sofferenza °Hospital, S. Giovanni Rotondo, Italy 
Background: Thrombi of central pulmonary arteries have been observed in 
patients with primary pulmonary hypertension. We hypothesized that simi- 
lar lesions may also develop in patients with chronic obstructive pulmonary 
disease (COPD), in whom pulmonary hypertension, hypoxemia, and a pro- 
thrombotic state might promote abnormalities of the arterial wall. 
Methods and Results: We examined by transesophageal echocardio- 
graphy 25 patients with COPD and 27 control patients with left-sided cardiac 
diseases, without history of pulmonary embolism. Echo-lucent lesions pro- 
truding (type 1) or wall-adherent (type 2) were found in the great pulmonary 
arteries in 12 COPD and 2 control patients (48% vs 7.4%, p < 0.01). Type 
1 and 2 lesions were located in 3 (t2%) and 9 (36%) COPD patients (vs 
control group, p:NS and <0.01, respectively). No difference was observed 
in FEV1/FVC ratio, PaO2, hematocrit value and pulmonary systolic pres- 
sure (51 i 23 vs 38 i 18 mmHg, p:NS) between patients with and without 
intrapulmonary lesions. 
Conclusion: Thus, intravascular lesions in the pulmonary arteries, prob- 
ably manifestation of in situ-developed thrombosis or, alternatively, of athero- 
sclerotic plaques, are frequent in COPD. Clinical and therapeutic implications 
may derive from these findings. 
~ Catheter Fragmentation Prolonged and 
Pulmonary Arterial Thrombolysis in Massive 
Pulmonary Embolism 
Niall Mulvihill, Joe Murphy 1 , Jerome B. Foley, Martin Molloy I . IDepartments 
of Cardiology and Diagnostic Imaging, St. James's Hospital, Dublin, Ireland 
Background: Recent data suggest prolonged thrombolysis is superior to 
standard thrombolytic regimens in treating massive pulmonary embolism 
(PE). Percutaneous catheter and guide-wire fragmentation is also an effective 
treatment in massive PE. We combined these two modalities of therapy to 
treat massive PE's. 
Methods: All patients underwent diagnostic pulmonary angiography. 
Catheter and guide-wire fragmentation was performed in all patients and 
locally administered 10 mg boluses of recombinant tissue plasminogen ac- 
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tivator (rTPA) were given during the procedure. An infusion of rTPA at 10 
rag/hour was continued for the next 16 hours via a pulmonary artery catheter. 
All patients had pulmonary angiography after completing the thrombolytic 
infusion. 
Results: All 6 patients treated to date have survived. There was marked 
improvement in measured indices of respiratory function as well as significant 
reduction in the Miller score from the pre-treatment o the post treatment 
angiogram (24 5:3 v's 11 5: 3, p = 0.001). There were no major bleeding 
complications. 
Miller score (0-34) Pre-treatment Post-treatment 
Patient no. 1 24 15 
Patient no. 2 22 13 
Patient no. 3 27 13 
Patient no. 4 19 8 
Patient no. 5 27 10 
Patient no. 6 23 7 
Conclusion: Mechanical fragmentation followed by a prolonged pul- 
monary arterial infusion of rTPA combines the beneficial effects of both 
modalities of treatment and is a safe and effective therapeutic option in 
massive PE. 
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• Prostacyclin Gene Transfer Protects Synthase 
Renal Function and Attenuates the Development 
of Hypertension in Spontaneously Hypertensive 
Rats 
Yasushi Numaguchi, Keiji Naruse, Takahito Tomida, Mitsunod Harada, 
Hiroyuki Osanai, Hideo Matsui, Yukio Toki, Takayuki Ito, Kenji Okumura. 
Nagoya Universi~ Nagoya, Japan 
Prostacyclin (PGI2) is an important factor regulating vascular function through 
its vasodilatory and anti-platelet actions. With the progression of hyperten- 
sion, PGI2 synthesis is diminished in peripheral vessels. We hypothesized 
that a continuous supply of endogenous PGI2 may prevent the progression 
of hypertension. We have developed the vectors for PGI2 synthase (PCS) to 
study the effects of overexpression of PGI2 in spontaneously hypertensive 
rats (SHR). The 1.6-kb rat PCS cDNA was cloned in the cytomegalovirus 
promoter-directed vector (pPCS). pPCS or the control plasmid carrying the 
lacZ gene (placZ) was injected to male SHR at the age of 5 weeks via right 
common carotid vein (n = 8 each). The transgene efficiency was confirmed 
by/~-galactosidase assay, which demonstrated prominent expression in the 
kidney, liver, and skeletal muscle in placZ rats. PCS mRNA expression was 
twofold higher in the kidney of pPCS rats than placZ rats (248 • 8 vs 517 
± 7 attomole//zL, p < 0.05). The reduction in blood pressure was observed 
at 2 weeks after injection and lasted for 7 weeks (maximal difference; 143 
5:3.8 and 172 5:4.6 mmHg for pPCS and placZ at 4 weeks after injection, 
respectively, p < 0.01). PCS gene transfer did not affect body weight, water 
intake, urine volume, food consumption and bleeding time. The gene transfer 
decreased urinary excretion of protein (28.7 5:0.3 and 51.5 ± 0.7 mg/day for 
pPCS and placZ, respectively, p < 0.01) and increased that of 6-keto PGFlc~ 
(32.0 5:0.29 vs 16.2 5:0.19 ng/day, p < 0.01) and glomerular filtration rate 
(0.75 5:0.03 vs 1.25 5:0.04 ml/min, p < 0.01). Renal histological analysis 
demonstrated that the glomerutar damage was less in pPCS than in placZ 
rats (37 ± 5 vs 68 5:7 points in score, p < 0.05). 
Conclusion: PCS gene transfer compensated the diminished PCS gene 
expression. Overexpression of PGI2 may attenuate the development of hy- 
pertension in SHR partly by protecting renal function. 
~ Effects of Nitric Oxide Inhibitor Cardiac on 
Autonomic Tone in Spontaneously Hypertensive 
Rat: A Spectral Analysis Approach 
Kazutoshi Komatsu, Satoru Ito, Wataru Usui, Osamu Isogai, 
Toshiyuki Kurihara, Kazuyoshi Tsukamoto, Katsuo Kanmatsuse. Second 
Department of Internal Medicine, Nihon University School of Medicine, 
Tokyo, Japan 
Background: Endothelium-derived Nitric Oxide (NO) plays a major role in 
regulation of vascular tone. However the role of NO in the cardiac autonomic 
tone is not completely understood. In this study, we investigated the effects 
of NO on autonomic nervous system using spectral analysis. 
Methods: Cardiac hemodynamic responses to NO synthesis inhibitor 
(L-NAME; 10 mg/kg iv) were studied in the anesthetized male SHR and 
WKY (17 wks old). The cardiac output (CO) was measured by the pulsed 
Doppler flowmeter. The spectral analysis of HR variability was performed 
using maximum entropy method (low frequency LF; 0.025-O.6Hz and high 
frequency HF; 0.6-2.0Hz). 
Results: L-NAME increased MAP and total peripheral resistance and 
decreased CO significantly in both strains. LF/HF ratio (sympathetic index) 
were increased, Although, L-NAME decreased HR and increased HF power 
(parasympathetic index) in WKY, these changes were attenuated in SHR m 
5: SE, "p < 0.01 vs control, tp < 0.01 vs WKY-L-NAME 
WKY (n = 9) SHR (n = 10) 
Control L-NAME Control L-NAME 
MAP (mmHg) 140 5:5 151 5: 4* 178 5:4 189 5:4 "1 
HR (bpm) 298 5:6 232 5: 10" 320 5:11 314 5:171 
LF/HF 1.6 ± 0,4 3.9 ± 1.0" 1.4 5:0.5 6,5 ± 1.2" 
HF (msec 2) 0.9 5:0,2 33.4 ± 15.9" 0.7 ± 0.2 0.7 ± 0.31 
Conclusions: These results suggest 1) NO inhibition increases cardiac 
sympathetic nervous tone. 2) the disorder of parasympathetic nervous sys- 
tem exists in SHR, NO modulates cardiac autonomic nervous system, and 
that NO may be involved in the hypertension of SHR, 
• Changes in Mesenteric Vascular and Reactivity 
Blood Pressure During Chronic Alcohol Ingestion 
and Withdrawal 
Stan S. Greenberg, Bin Kang, Christine Parrish, Ouyang Jie, Xinfang Zhao, 
E. Kenneth Kerut, Thomas D. Giles, Louisiana State Univ Med. Center at 
New Orleans, New Orleans, LA, USA 
Background: Chronic consumption of ethanol, a well known vasodilator, 
produces hypertension. It is uncertain whether this is mediated by enhanced 
micro vascular reactivity to cateoholamines or is a compensatory response 
to ethanol withdrawal during periods of abstinence. This study was designed 
to resolve this question. 
Methods: Male sprague Dawley rats were fed a solid food diet and given 
ethanol (0%, 12% and 20% w/v) in drinking water containing 0.01% saccharin 
for 7 month. Blood pressure was monitored with tailcuff plethysmography 
bimonthly. After 7 months one cohort of rats (n = 5-8 rats/gp) was utilized for 
measurement of LV function and in vivo pressor responses to angiotensin 
I and angiotensin I1. An addition cohort of rats (0, 12 and 20% ethanol) 
were anesthetized and the responses of the mesenteric artery perfused at 
constant flow with Krebs Henseleit buffer (KHB) to KCI, NE, serotonin (5-HT) 
and angiotensin II were measured. Finally, rats on 20% ethanol for 7 month 
were given water and their pressures and vascular reactivity measured 1, 3 
and 7 days after sudden withdrawal from alcohol ingestion. 
Results: Blood pressure increased more in the 12% and 20% ethanol 
groups in anesthetized compared to awake rats. The micro vascular re- 
sponses of the perfused mesenteric artery to NE, 5-HT and KCI were de- 
pressed, rather than enhanced in alcoholic rats. Withdrawal from ethanol 
enhanced the responses to vasoactive agents. 
Conclusion: The data suggests that the enhanced reactivity and elevated 
pressure of alcoholism results during periods of withdrawal and that alcohol 
is a vascular depressant rather than a vascular stimulant. 
~ Alteration Coronary Epicardial in and 
Microvascular Endothelial Function in 
Experimental Renovascular Hypertension 
James L. Velianou, Lilach O. Lerman, Jassim AI Suwaidi, Darcy 
M. Richardson, James D. Krier, Amir Lerman. Mayo Clinic, Rochester, MN, 
USA 
Hypertension is associated with endothelial dysfunction and myocardial is- 
chemia. This study was designed to test the hypothesis that renovascular 
hypertension (RVHT) in the pig is associated with attenuated coronary epi- 
cardial and microvascular relaxation in vitro in response to the endothelial- 
dependent vasorelaxant bradykinin. Unilateral renal artery stenosis (RAS) 
was induced by implantation of an irritant stent. In the RVHT group, renal 
artery stenosis (88 5: 6%) was associated with a gradually progressive (over 
7-10 days) increase in mean arterial pressure (117 5:11 to 171 + 16 mm 
Hg, p = 0.004), simulating human RVHT. Coronary epicardial arteries and 
microvessels (327 5: 22/zm) with intact endothelium were harvested from 
pigs 6-8 weeks after induction of RAS/RVHT and compared to normal pigs. 
Vessels were precontracted with 10 -7 M of endothelin-1, and dose response 
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relaxation to bradykinin (10 TM to 10 -6 M) was obtained. There was no dif- 
ference in the maximal vascular contraction to endothelin-1 between the 
groups. Relaxation to bradykinin was significantly blunted (see graphs). 
Epicirdial Ve~l  Relponr, e 
i 
M ~"oyessel response 
Btadykklltl (Io~ M) 
This study demonstrates alteration in coronary epicardial and microvas- 
cular endothelial function in experimental RVHT, which may play a role in 
regulation of myocardial perfusion in hypertension, 
1223-7"( 1 Does Blood Pressure fnfluence the 
Hypercoagulable State in Atrial Fibrillation? 
Foo Li-Saw-Hee, Andrew D. B/ann, Gregory' Y.H. Lip. Haemostasis, 
Thrombosis and Vascular Biology Unit, University Department of Medicine, 
City Hospital, Birmingham, UK 
Background: Clinical tdals suggest hypertension contributes to the in- 
creased stroke risk in chronic nonvalvular atrial fibrillation (NVAF). Recent 
studies haste sh,3w~ that NVAE co,fees a hygecc~ac~cdab~e state. 
Blood pressures (BP) were analysed according to tert~)es. Leve~s of von 
Willebrand factor (vWF, a marker of endothelial dysfunction), and markers 
of thromb~eneais ffibdnoqpn and fibrin D-dimefl were analv.sed by. ELISA. 
Results: Patients with NVAF had higher levels of D-dimer (800 vs 45) 
and vWF (137 vs 103) (P < 0.05 for both) but no significant difference for 
fibrinogen (3.4 vs 3.2, P = 0.33) compared to controls in sinus rhythm. 
Systolic BP < 125 mmHg 125-140 mmHg > 140 mmHg 
vWF (IU/dL) 139 ± 19 131 ± 24 132 = 24 
D-dirner (ng/ml) 534 • 880 341 ± 601 368 ± 364 
Fibrinogen (g/L) 3.5 :t- 1.2 3.5 ± 1 3.9 =I: 1 
Diastolic BP 50-75 mmHg 76-85 mmHg >85 mmHg 
vWF (tUldL) 132 ± 24 132 ± 24 131 ± 24 
D-dimer (ng/ml) 552 :~ 829 518 ± 773 247 ± 277 
Fibnnogen (g/L) 3.6 ± 1.1 3.3 ~- 1.1 3.9 ± 1 
P = Non-Significant (ANOVA). Results are mean 9- SD. There were no 
significant correlation between vWF, D-dimer, fibrinogen and blood pressure 
levels (Spearman, P = NS) 
Conclusion: Patients with NVAF had abnormal thrombogeneis (fibrin 
D-dimer) and endothelial dysfunction (vWF) compared to controls in in sinus 
rhythm. There was no significant relationship between haemostatic markers 
and the degree of hypertension. 
1223-721 Serum Levels in Patients With Mild to Amylold a 
i Moderate Hypertension, Before and After 
Treatment With a Calcium Antagonist 
Emanuel V. Economou, Chnstos P. Pitsavos, Christodoulos I. Stefanadis, 
Athanasios G. Trikas, Marina G. Toutouza, John S. Elefsiniotis, 
Konstantinos P. Tsioufis, Konstantinos I. Kapetanios, Pavlos K. Toutouzas. 
Department of Cardiology, Athens University, Athens, Greece 
Background: Hypertension has been documented to be associated to vas- 
cular endothelial cell damage. On the other hand, inflammation has been 
considered to be the consequence of most forms of tissue damage. How- 
ever, whether inflammation is associated to chronic hypertension remains to 
be clarified. It is generally accepted that it is difficult to monitor inflammation 
and, in this context, test sensitivity is very important. Serum amyloid A (SAA) 
is an acute phase protein found to be more sensitive, although less specific, 
indicator of inflammation than plasma C-reactive protein (CRP). The objec- 
tive of this study was to evaluate SAA levels in relation to CRP plasma levels 
as well as to soluble form of E-sel (sE-sel) implicated in endothelium-depen- 
dent adhesion of leukocytes to endothelium, thus proposed as marker of 
endothelial dysfunction and assess the effect of antihypertensive treatment 
with the calcium antagonist isradipine SRO on them. 
Methods: Fifty two patients with mild to moderate hypertension, no ev- 
idence of any immune disease including antiphospholipid syndrome or any 
trivial or chronic inflammation or obvious intercurrent infection, treated by 
isradipine SRO, 4 mg daily, were evaluated for SAA levels (measured by 
ELISA), EDTA plasma levels of CRP (measured by nephelometry) and hep- 
arine plasma levels of sE-sel (measured by ELISA), before and after four 
months of therapy and compared to forty-five age- and sex-matched healthy 
controls. 
Results: Blood pressure was normalized (161/101 to 133/86 mmHg, p < 
0.0001). Before treatment, hypertensives had SAA and sE-sel levels signifi- 
cantly higher compared to those of healthy controls (5.51 4- 0.47 ng/mL vs 4.7 
+ 0.47 ng/mL, p = 0.03 ned 37.9 ± 2.9 ng/mL vs 23.6 4- 1.8 ng/mL, p = 0.001, 
respectively). However, plasma levels of CRP were as high as those of healthy 
controls [2.03 :L 0.13 #g/L vs 2.05 4- 0.35 ,t~g/L, p = 0.8 (NS)]. After calcium 
antagonist treatment, hypertensives had SAA and sE-sel levels significantly 
lower compared to those before treatment (4.41 4- 1.96 ng/mL, p = 0.03 and 
32.5 4- 2.1 ng/mL p = 0.007, respectively) but CRP levels remained unaf- 
fected, compared to those before treatment (1.75 + 0.59 ,u g/L, p = 0.7 (NS). 
SAA levels correlated significantly to plasma CRP levels, before as well as 
after treatment (r = 0.532, p = 0.041 and r = 0.683, p = 0.005, respectively). No 
significant correlation was noticed between SAA levels and plasma CRP lev- 
els neither before nor alter treatment possibly due to an indirect participation 
of endothelial cell activation to inflammatory response e.g. through activation 
of macrophages. No other significant correlations were found. 
Conclusions: It is suggested that, in mild to moderate hypertension, an 
inflammatory response might be noticed by evaluating SAA levels, although 
it could not be directly associated to endothelial cell dysfunction. Antihy- 
pertensive treatment with the calcium antagonist isradipine SRO may be 
effective not only in normalizing blood pressure, but also in decreasing this 
inflammatory response. 
~ Aortic Energetics are Improved After Enalaprilat 
Administration in Hypertensive Patients 
Hippokration Hospital, Athens Medical School, Greece 
Background: The aorta (Ao), by virtue of its elastic properties, stores a 
considerable amount of the power generated by the LV during cardiac systole, 
which is returned by recoiling during diastole. ACE inhibitors are widely used 
in the treatment of essential hypertension. However, their effect on regional 
Ao energetics has not been investigated. 
Methods: For this purpose, serial pressure (P)-volume (V) loops were 
obtained from simultaneous recordings of the thoracic Ao V per unit length 
and P, before and for 30 min after the i.v. administration of enalaprilat (1.25 
mg over 5 min.) during diagnostic catheterization in 10 hypertensive pts. Ao V 
was measured by an intravascular ultrasonic dimension catheter, developed 
in our institution (Circulation 1995;92:2210-9) and Ao P by a Millar micro- 
manometer. The area under the systolic (ascending) portion of the clockwise 
• loop (left fig., areas A + B), represents the energy stored by the Ao, the area 
under the diastolic (descending) portion of the loop represents the energy 
returned by the Ao (area B), whereas the area within the loop (area A) the 
energy dissipated by the Ao due to its viscosity. 
Results: Efficiency index of the Ao (= energy returned/stored) was signif- 
icantly increased with enalaprilat (right fig.), indicating decreased Ao energy 
loss. 
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Conclusions: Ao energetics are improved and energy loss is reduced 
after enalaprilat administration. This effect may contribute to the beneficial 
effects of enalapril on hypertensive patients. 
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1224-1161 Patterns of Cardiac Rehabilitation Referral and 
J Attendance in a Northern Canadian Setting 
Kathryn M. King, Dennis P. Humen, Koon K. Teo. University of Alberta, 
Edmonton, Alberta, Canada 
Background: Despite evidence demonstrating benefits of cardiac rehabilita- 
tion (CR) programs, and the existence of clinical practice guidelines to direct 
appropriate referral, referral and attendance remains notably poor. The ob- 
jectives of this study were to examine patterns of practice in CR referral 
of patients following AMI, PTCA, and/or CABG, and patient-related factors 
(health, demographic) which may also influence CR referral and attendance. 
Methods: Systematic review of health records from 09/96 to 98/97 of 
1328 cardiac patients discharged from a tertiary care centre and registration 
records from the only two associated CR programs. 
Results: Evidence of CR referral for the 1245 surviving patients was 
23.9%. Logistic regression revealed English-speaking (OR 9.56), city living 
(OR 3.97), and current smoking (OR 1.51) were associated with an increased 
likelihood, while history of COPD/asthma (OR 0.53), age >_ 70 years (OR 
0.42), PTCA admission (OR 0.32), and history of neurological or cognitive 
impairment (OR 0.26) were associated with a decreased likelihood of CR 
attendance. Sex, type of CAD risk factor, pre-event cardiac status (NYHA 
class, number of previous events), and post-event complications were not 
associated with CR attendance. 
Conclusion: This study confirms that CR referral patterns are erratic and 
in need of improvement. Those who are at particular risk for not attending CR 
programs include those who are non-English speaking, rural-living, elderly, 
and having PTCA. Study findings will provide a foundation for development 
and testing mechanisms of enhanced referral, and innovative means to 
identify and target interventions for those most at risk for not accessing and 
attending CR programs. 
L 1  224-117/  The Association Between Survival Long-Term J and Hospital-Specific Rates of Coronary 
Angiography and Revascularization After Acute 
Myocardial Infarction in the Elderly 
David R. Thiemann, Josef Coresh, William J. Oetgen, Nell R. Powe. Johns 
Hopkins Hospital, Baltimore, MD, and De/marva Foundation, USA 
Background: Use of invasive procedures after acute myocardial infarction 
varies widely according to available hospital technology and local practice, 
with unknown implications for long-term outcome. 
Methods: Using the HCFA Cooperative Cardiovascular Project database, 
we conducted a chart-based cohort study of 74,113 Medicare patients > 65 
years old admitted directly from home with acute MI. For each hospital we cal- 
culated rates of angiography and revascularization within 30 days, including 
procedures at another hospital. We used Cox proportional-hazards meth- 
ods to adjust for 34 patient and health-system variables, including hospital 
volume of acute MI cases, hospital technology and physician specialty. 
Results: Patients in the lowest hospital-angiography quartile had a crude 
one-year mortality of 29.8% vs. 24.4% in the highest quartile. In separate 
Cox analyses high hospital-specific angiography and revascularization rates 
were associated with significantly better long-term survival. There was a 
consistent close-response effect, even among octogenarians. 
Procedure Hospital-specific rate Mortality Hazard 
Angiography 38% (25thpercentile) 1.00 (reference) 
60% (75 th percentile) 0.922 (0.90-0.94) 
Revascularization 25% (25 th percenlile) 1.00 (reference) 
43% (75 th percentile) 0.916 (0.90-0.94) 
Conclusion: Elderly acute MI patients admitted to hospitals that have 
high angiography and revascularization rates have better long-term survival, 
suggesting that in older patients these procedures may be underused at 
other hospitals. 
1 8J Treatment of Acute Myocardial Infarction 
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224-1 1 Cost of 
in the United States and Canada 
Arik Azoulay, Mark Eisenberg, Louise Pilote. For the INCCUS Investigators; 
Jewish Genera/Hospital, Montreal, Quebec, Canada 
Background: Rates of angiography and coronary revascularization following 
acute myocardial infarction (AMi) are higher in the United States (US) than in 
Canada. Because costing data are difficult o obtain from Canadian hospitals, 
little information is available regarding differences in cost for the treatment of 
AMI between these two countries. 
Methods: We compared the cost of treatment of AMI between January 1 
and March 31 1997 at 6 hospitals (5 US and 1 Canadian). Each of the hos- 
pitals used the Transition System Incorporated (TSI) accounting system to 
provide clinical and costing data (in US dollars, excluding professional fees). 
Results: A total of 437 patients were admitted with AMI (mean age 73 
years, 63% men, length of stay 6.4 days). US patients were more likely to 
undergo cardiac procedures than Canadian patients including angiography 
(59% vs 43%), PTCA (41% vs 19%), and CABG (15% vs 11%). Total hospi- 
talization costs for US patients were 4 times greater than costs for Canadian 
patients (mean $17,493 vs $4,215). Direct costs averaged $10,038 in the 
US and $3,237 in Canada (57% and 77% of total cost, respectively). Indirect 
costs averaged $7,455 in the US and $978 in Canada (43% and 23% of total 
cost, respectively). Mean cost for angiography and coronary revasculariza- 
tion was $10,434 in the US and $3,133 in Canada. The percentage of total 
costs attributable to angiography and coronary revascularization was similar 
in the US and Canada (20% vs 18%, respectively). 
Conclusions: Our data suggest that the cost of treating a patient with AMI 
in the US is several-fold higher than the cost in Canada. While angiography 
and coronary revascularization procedures are more common in the US, they 
do not account for the differences in total hospitalization cost between the 
two countries. 
I1 91 Predicting Future Mortality From Acute 
1 
224-1 1 
Myocardial Infarction in a Western Society 
Considering Population Shift, Present Trends 
and Risk Factor Intervention 
Niall G. Mahon, Mary B. Codd, Jan Poloniecki 1 , Hugh A. McCann, Declan 
D. Sugrue. Dept of Clinical Cardiology, Epidemiology and Biostatistics, 
Mater Hospital, Dublin, Ireland; 1Dept. of Cardiological Sciences, St 
Georges Hospital Medical School, London, UK 
Background: The success of primary prevention and improved treatment 
of acute myocardial infarction (AMI) has led to a decline in AMI mortality in 
most Western societies and the use of statin therapy premises further gains. 
However demographic changes will impact upon future trends. 
Methods: Projections were carried out for an Irish population which, like 
most Western populations, has a declining AMI mortality and is ageing. To 
predict modality figures for AMI to 2026, census population projections were 
combined with current trends in age and gender specific mortality data. To 
evaluate the relative impact of various strategies of population cholesterol re- 
duction, a logistic risk function of the relation between population cholesterol 
and mortality was used to construct spreadsheets from which the impact of 
cholesterol modifications could be assessed. 
Results: The number of deaths from AMI decreased by 24% between 
1985 and 1995. If this rate continues the number of deaths from AMI in 2026 
would be just 35% lower than 1991 figures, not 87% as might be expected. 
The effects of cholesterol manipulations are shown (table). 
Simulation Cholesterol reduction Deaths prevented 
West of Scotland study 20% 318 
population 
Pravastatin in all > 45 yr 20% 1186 
AHA step one diet 6% 547 
Conclusion: Even if current rates of mortality decline continue the ab- 
solute reduction in AMI deaths will be modest. Of different strategies of 
population cholesterol modification the use of statin therapy in patients aged 
45 and greater without gender or upper age limitations has the greatest 
potential impact on AMI mortality. 
1224-1 J Cost Effectiveness of Implantable 
] 
20 Csrdioverter 
Defibrillators and Amiodarone After Myocardial 
Infarction 
Gillian D. Sanders, Nathan R. Every, Kathryn M. McDonald, Lori S. Parsons, 
Paul A. Heidenreich, Mark A. Hlatky, Douglas K. Owens. Stanford 
Universi~ Stanford, CA, University of Washington, Seattle, WA, USA 
Background: Recent randomized clinical trials have evaluated the cost and 
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benefits of implantable cardioverter defibrillators (ICDs) and amiodarone 
in patients with symptomatic ventricular arrhythmias. We evaluated the cost 
effectiveness of these two antiarrhythmic treatments for prevention of sudden 
cardiac death (SCD) in post-AMI patients. 
Methods: We used a Markov model to evaluate the costs and bene- 
fits of ICD and amiodarone relative to no antiarrhythmic therapy in patients 
who had suffered an AMI, had either a normal or depressed EF, but had 
not experienced symptomatic ventricular arrhythmia. We estimated the co- 
hort's underlying mortality rates and inpatient cost information based on 
approximately 3000 AMI patients from the MITI Registry. Using a published 
meta-analysis of 15 randomized trials, we estimated that amiodarone re- 
duced total mortality by 10% as compared to no treatment. Our base case 
assumes that an ICD is 80% effective in reducing SCD. We stratified patients 
according to their EF during initial hospitalization. 
Results: 
Marginal cost effectiveness (S/quality adjusted life year saved) 
EF Cohort AMIO vs NoTx ICD vs NoTx ICD vs AMtO 
EF _< 30 31,100 46,500 57,900 
EF 31-40 43,500 97,100 271,300 
EF > 40 104,700 252,600 1,459,800 
The marginal cost effectiveness is sensitive to the efficacy of the ICD and 
to potential misclassification of SCD and nonsudden cardiac death. 
Conclusions: For prevention of SCD after AMI, amiodarone appears 
cost effective in patients with EF < 40. ICDs may be cost effective relative to 
amiodarone in patients with EF <_ 30. These results highlight the importance 
of clinical trials of prophylactic ICD implantation in patients with low EF. 
L1224-121 I Infarction In Women. Acute Myocardial J Epidemiologic Variables from a Low Risk 
Mediterranean Population 
Elias T. Himenas, George K. Andrikopoulos, Dimitri J. Richter, Polychronis 
E, Dilaveds, Apostolos A. Zaharoulis, John E. Gialafoe, PavIos 
K. Toutouzas. From the investigators of the Greek Multlbenter Study for 
Acute Myocardial Infarction; 251 Airforce General Hospital, Athens, Greece 
Background: Epidemiologic research focused on acute myocardial infarc- 
tion (AMI) in women has been limited, especially concerning a low risk 
Mediterranean population. 
Methods: The study population was obtained from the Greek multicenter 
study for AMI. A total of 1678 women and 5755 men, hospitalized in 76 Greek 
hospitals from May 1993 to May 1994 with the diagnosis of AMI, were enrolled 
in this study. We compared men and women as far as the following clinical 
features are concerned; mean age, in-hospital mortality rates, coronary artery 
disease risk factors, prior AMI, thrombolysis, thrombolytic agents used and 
treatment with aspirin and beta-blockers. 
Results: The results are presented in the table below: 
Women, n = 1678 Men, n = 5755 P value 
Age (years) 69 ± 13 60 ± 14 <:0.001 
Mortality 17.1% 8.5% <0.001 
Cigarette Smoking 23.2% 80.7% <0.001 
Diabetes 41.5% 20.5% <0.001 
Hypercholesterolemia 41.9% 32.8% <0.001 
Hypertension 64.1% 39.4% <0.00t 
Heredity 25% 28.4% 0.014 
Prior AMI 14.2% 18.9% <0.001 
Thrombolysed pts 31.1% 51% <0.001 
Streptocinase 48% 35% <0.001 
APSAC / r-tPA 12%/40% 12%/53% NS/<0.001 
Aspirine / b-blockers 81.7%/39.3% 86.6%/55.9% <0.001/<0.001 
In-hospital mortality was higher in women than in men. Multivariate anal- 
ysis after adjustment for age, diabetes and thrombolysis showed that non- 
thrombolysed women older than 60 years old, were in particular high risk 
(18.2% vs 13%, P = 0.008). Women had increased incidence of the major 
modifiable coronary risk factors, while men were more likely to have had a 
previous myocardial infarction. Men were also more likely to receive thrombol- 
ysis, aspirin and b-blockers. Interestingly, thrombolysed women were mostly 
treated with streptocinase, while men were mostly treated with recombined 
tissue plasminogen activator (r-tPA). 
Conclusions: Our data suggest that women who develop AMI are at 
greater risk for in-hospital mortality and consequently deserve more aggres- 
sive in- and posthospital assessment and treatment. 
ORAL 
[~7-]  Dilating Blood Vessels: Benefits and Risks 
Wednesday, March 10, 1999, 10:30 a.rn.-Noon 
Modal Convention Center, La Louisiane A 
10:30 a.m. 
~- -~ Hemodynamic, Functional, Echocardiographic and 
Survival Benefits of Long-Term Continuous 
Intravenous Prostacyclin Infusions in Primary 
Pulmonary Hypertension 
Srinivas Mural±, Kimberly Bollinger, Tammy Tokarczyk, Mary Trost, 
Amy Palmer, Ren6 J. Alvarez Jr., Guy A. MacGowan, Dennis 
M. McNamara, Warren D. Rosenblum, Arthur M. Feldman. University of 
Pittsburgh Health Systems, Pittsburgh, PA, USA 
Short-term and intermediate-term continuous intravenous prostacyclin (P) 
infusions in pts with primary pulmonary hypertension (PPH) improve exercise 
capacity, right ventricular (RV) function and possibly survival. The benefits 
of long-term P infusions have, however, not been clearly demonstrated. We 
evaluated hemodynamics, exercise capacity, echocardiographic measures 
of RV function and survival in 50 pts (mean age 43 ± 10 yrs, 41 females, 9 
males) with severe symptomatic PPH (NYHA III, n = 28; NYHA IV, n = 22) 
receiving chronic P infusions (mean dose 34 ± 24 ng/kg/min, range 12-115) 
at baseline (B) and after 17 • 12 months (range 4-52) of therapy (T). 
PAM (mmHg) PVR (Wood units) CO (Vrnin) D (ft) 
B 60 ± 11 18 ± 7 3.2 ~: 1 763 ± 232 
T 50 ± 10" 10 ± 4* 4.7 ~ 1.9* 958 ± 360" 
*p < 0.05, T vs B; PAM = pulmonary mean pressure; PVR = pulmonary vascular resis- 
tance; CO = cardiac output; D = 6 min. walk distance. 
There were no differences in RV diastolic area (32 ± 8 vs 34 ± 12 cm2), 
% change in RV systolic area (23 ~E 9 vs 24 ± 12), and tricuspid regurgitation 
velocity (4.1 ± 0.7 vs 3.9 5:0.8 m/sec) between B and T. 12 pts (24%) 
received pulmonary transplantation and 2 pts (4%) were withdrawn from P 
due to adverse effects during follow-up. Actuarial 1, 2 and 3 year survival 
was 81%, 70% and 42% respectively. 
Conclusions: In severe symptomatic PPH, long-term P infusions are 
1) well tolerated, 2) associated with hemodynamic and functional benefit, 
3) attenuate progressive RV remodeling, and 4) possibly associated with 
improved survival. 
10:45 a.m. 
[ -8 -7~ The Effectiveness of Prostacyclin as a Therapy for 
Secondary Pulmonary Hypertension 
Vallerie V. McLaughlin, Diane E. Genthner, Maureen M. Panella, Dina 
M. Hess, Stuart Rich. The Rush Heart Institute, Chicago, IL, USA 
Background: Intravenous prostacyclin (PGI2) improves exercise tolerance, 
hemodynamics and survival in patients with primary pulmonary hypertension 
(PPH). The effect of PGI2 on secondary forms of pulmonary hypertension 
has not been characterized. 
Methods: We studied 33 patients (NYHA Class III & IV) with secondary 
pre-capillary pulmonary hypertension (congenital heart disease (CHD) n = 7, 
collagen vascular disease (CVD) n = 14, portopulmonary hypertension (PH) n 
= 7, sarcoidosis n = 2, and thromboembolic disease n = 3), who were treated 
with PGI2 for at least three months. Baseline and follow-up hemodynamics 
and treadmill testing were obtained in 30 of the 33 patients. 
Results: Patients included 26 women and 7 men with a mean age of 
48.8 ~: 13.9 years. PGI2 caused a 23% reduction in mean pulmonary artery 
pressure (P < 0.01), a 62% increase in cardiac output (P < 0.001), and a 
50% reduction in pulmonary vascular resistance (P < 0.001). Treadmill time 
also increased 164% from 194 to 491 seconds (P < 0.001 ). Functional class 
improved in all patients (P < 0.001). The baseline PVR was similar in the 
CHD (14.6 units), CVD (12.9 units) and PH (12.8 units) groups. There was 
a significant fall in pulmonary vascular resistance in all three groups of 40%, 
46%, and 60% respectively. 
Conclusion: PGI2 appears to be as effective in patients with secondary 
forms of pre-capillary pulmonary hypertension as it is in PPH. 
Baseline PG12 
MPAP (mmHg) 60 ± 13 46 ~- 14 
CO (!.Jmin) 3.84 ± 1.24 6.30 :h 2.49 
PVR (units) 14.3 ± 5 7.2 ± 3.9 
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11:00 a.m.  
r~-~ Omapatrilet, A Novel Vasopeptidase Inhibitor, 
Reduces Blood Pressure in Normotensive Subjects 
Wei-chi Liao, Carol L. Delaney, Floyd A. Beiede, Irene M. Ferreira, Kathy 
D, Davis, Alan Meier, Ole Vesterqvist, Neville F. Ford, Howard D. Uderman. 
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, N J, 
USA 
B=ac'K~]roun~: ma, Da'[fl~a~. "~ne %rs'~ vaso.ce.D%~ase 'm'd~'mr. m~s'{s bo~'n 
Because pure ACE inhibitors rarely lower blood pressure in normotensive 
subjects, the blood pressura-lowedng effect of omapatdlat as a new pharma- 
cological class agent was examined in a Phase I, multiple-dose, double-blind, 
placebo-controlled study. 
Methods: Normotensive subjects (n = 36) were randomized to receive 
orma.~hfi~l 0oses dr "~T~. Zb. "~. anb -Pb m p or .151acu=~Do ~lail,v "ror ~1"0 bays. 
Salt intake (8 g Na~ daiiy was ~ven 4 days before dosing ar~ throughout he 
study. 
Results: Supine cuff mean arterial pressure (MAP) changes from base- 
lire (ram Hq;. Mean =E SO( were reqoKe<f for doses of fG,. Z5,. 5(I. and 7"E mq 
(n = 6 each) on day 1, as peak effect (3-8 hr post dose): -7.6 ± 3.9, -17.6 ± 
8.4, -17.9 ± 10.0, -18.7 ± 3.7, and as 24-hr trough effect: -0.1 ± 9.8, --3.5 
± 8.6, -12.5 :E 8.6, -12.0 ± 10.0; and on day 10, as peak effect (3-8 hr post 
dose>: -')3.tb ~ 5.9, -')9.2 4- £>.~. -3~,.'~ ± 9.I5, -2~.~ ± £>.2, an~ as 2~,-br 
trough effect: -6.8 ± 7.1, --8.3 ± 4.7, -8.8 ± 13.4, -13.3 ± 10.5 mm Hg, 
r~esDec%v~. T-'narmac~)oo~c6) matxets:'~fiT~D~on 6~'N"~-~'~ omaDaz~%m was 
supported by elevation in both unnary ANP and plasma cGMP. Significant 
serum ACE inhibition was demonstrated over 24 hours at all doses, and a 
dose-dependent increase in PRA was seen. 
Conclusion: Omapatdlat demonstrated a potent and sustained lowering 
of MAP in a dose-dependent manner in norrnotensive subjects. This supe- 
nor ant)hypertensive ffect is attributed to the NEP and ACE inhibition by 
omapatdlat 
11:15 a.m.  
~-- )  Chronic Transdermal Estradiol-17/3 Therapy Lowers 
Blood Pressure in Newly Diagnosed Hypertensive 
Postmenopausal Women 
C{~)use.D_~e .C. Bosano. F~)~j~o "Leonard0. E~a)a Parbna. 
(~)use.~.~e Dermanb, ~ass~rno'~o)~e. )st)tuto )-). San 7Ya~e)e-Dn)ve~)ty 'J.a 
fBack.¢lround: Hypertension has been considered as a contraindication for 
i'ormanes used (h menopause were s(m(i'ar ~o ~hose or" as~roqens conga(ned 
in oral contraceptive pil~s. 
Methods: In a double blinded placebo controlled trial, the effect of chronic 
therapy with estradiol-17/~ (E2) on 24-hr ambulatory blood pressure moni- 
toring (ABPM) was evaluated in 12 postmenopausal women (age: 54 ± 2.4 
yrs) with newly diagnosed mild hypertension (SBP < 180, DBP < 100 mm 
Hg). All had menopausal symptoms and none was on hormone replacement 
therapy or antihypertensNe drugs. 
Results: After a 2-week run-in period, pts were randomized to receive 
E2 transdermal patches (50 mcg/day) or matched placebo for 4 weeks, after 
which they were crossed to complementar t eatment after a 2 week washout 
period. AI5I:~ was pe~ormed a'[ base'/me, an0 a'{ ~e end o~ eac'n '~reatmen'~ 
period. F_.2 '[rea'[men'[ s'~gd~can~y owered 24 'nour mean "D'~ood pressure as 
well as mean daytime and night)me blood pressure: 
Baseline E2 Placebo 
24 h SBP 162 ± 11 142 ± 9"§ 166 :E 12 
24 h DBP 94 ± 6 86 ± 6 **§~ 94/ :  7 
Day SBP 173 ± 10 156 ± 10-§§ 172 :E 12 
Day DBP 96 ± 6 88 ± 7"§§ 94 =E 7 
Night SBP 138 :E 14 122 ± 12"§ 135 :E 16 
Night DBP 88 ± 9 76 :E 8 *§ 86 ± 10 
• = p < 0.05, *" = p < 0.01 E2 vs baseline; § = p < 0.05, §§ = p < 0.01 E2 vs placebo 
Conclusion: Chronic estrogen replacement therapy lowers blood pres- 
sure in untreated newly diagnosed hypertensive menopausal women. This 
therapeutic option should be considered when early menopausal women with 
recent onset hypertension are evaluated. 
11:30 a.m.  
~-7~ Cardiovascular Safety of Sildenefil in the Treatment 
of Erectile Dysfunction (ED) 
Randall Zusman, Mike Col)ins. Massachusetts General Hospital, Boston, 
MA, USA; Pfizer Central Research, Sandwich, UK 
Background: Sildenafil, a phosphodiesterase type 5 inhibitor that enhances 
the effects of neurally released nitric oxide (NO) in the penis, is an effective, 
we~'~-~o~era'md ~realman~ "~or ~:D. ~nce  car~ovascu~r ~D'9> ns~ ~¢ '~ are 
CV adverse events in 28 studies of sildenafil in men with ED. 
Methods: The CV safety profile of sildenafil was assessed in 18 dou- 
ble-blind, placebo-controlled studies and 10 long-term open studies. In the 
18 placebo-controlled studies, 4274 patients (2722 sildenafil, 1552 placebo; 
aged 18-87 y) with ED (mean duration 5 y) received treatment (5-200 mg) for 
U D to T5 morffns: ~Zl"DT9 ,~t~erfts rece~vet~ |orb-term qoen ~ilden6lil ]reatment 
(25-?00 rr~) f~" up to ? year. 
Results: Sildenafil was well tolerated, with headache, flushing, and dys- 
pepsia being the most common adverse events. The incidences of all serious 
CV at(verse events <mv, ocarff(a( (hfarcffQn 6/vf((,. anajha., corana[~ arter~ cffs- 
order, etc) and of MI were comparable to placebo for men who received 
sildanafil in placebo-controlled studies and those who received sildenafil in 
open studies. 
Incidence (95% CI) per 100 man-years of treatment 
,*;'t~,~,'b ~ ~%~/ ;  ~-¢ ~tc-'e~'~ ~,~ f/'d~ 
controlled studies open studies 
All serious CV events 5.7 (3.3-8.2) 4.1 (2.7-5.5) 3.5 (2.3-4.7) 
MI 1.4 (0.2-2.5) 1.7 (0.8-2.6) 1.0 (0.31-1.6) 
Conclusion: Sildenafil demonstrates a good CV safety profile. The inci- 
dence of all serious CV adverse events, including MI, in patients with ED is 
similar for those receiving placebo and those receiving sildenafiL 
11:45 a.m.  
~6- ]  V IAGRA ® (Sildenafi l  Citrate) Potentiates the 
Hypotensive Effects of Nitrates in Men With Stable 
Angina 
David J. Webb, C-=m7 Muithead. Fortbe Sflde~afll Jnves~@atom~. UrliyeIsJt~/DY 
{BPj} a.o~l heaJ~ ~a)e [J-J~J weY8 studJed Jr) ~oen JakJnff Jsoso;bJd~ mo~o/l,J,l/aJe 
IJSMN) of 9Jycerj/J ].,J.oJ).ra{e /~TN> J=,O,r stz3b.le ,ar)gjn.~. 
Methods: k~en (1.5-1.6 9er group) a~3ed 45-78 years ~ere receiving 
chronic oral nitrate therapy for stable angina. In two double-blind, placebo- 
controlled, two-way crossover studies, sitting BP and HR were measured 
immediately prior to sildenafil (50 rag) dosing and for 6 hours after dosing. 
Study 1: oral ISMN (20 rag, bid) dosing began 5 to 7 days prior to the first 
dose of sildenafil or placebo and continued until the second dose of sildenafil 
or placebo 7 days later. Study2. sublingual GTN (500 #g) was administered 
1 hour after sildenafil or placebo on each of 2 study days that were 7 days 
apart. BP was expressed as mean change from baseline (~BP). 
Results: Differences in ABp for sildenafil vs placebo were maximal 1 to 3 
hours gest-d.~se ~ both s.t~dles. Study I- sikier~iil ÷ I.S~N. 9r~d~ced. ~e~ter. 
reahcr/ar~s (P' < ~.~t~ ~ me, a.r~ max(mu0m s~st~6b, ( -~  ~ ~,  ~e -z:6 
to -TG~ and diastofic z~P (-26 mm Hg, range - f  5 to -4~ than ptacebo 
+ ISMN (-22 mm Hg, range -2  to -34; and -13 mm Hg, range -1 to 
-'25, resp.y, h~creases ?~ HR were not s~r(r~at~/ d#e~er~ [or s~a~?~ ~s 
in mean max imum systolic (-36 mm Hg, range -15 to -84) and diastolic 
~BP (-21 mm Hg, range -11 to -34) than placebo + GTN (-26 mm Hg, 
range -3  to -52; and -11 mm Hg, range 4 to -25, resp.). Sildenafil + GTN 
produced greater increases in HR than GTN + placebo (P < 0.01). 
Conclusion: Consistent with its mechanism of action, sBdenafil ampU- 
fled the activity of NO within vascular smooth muscle, resulting in clinically 
significant reductions in BP  when coadministered with either ISMN or GTN. 
Coadministration of sildenafil with nitrates or nitrate donors is strictly con- 
traindicated. 
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ORAL 
[ -~ Pathophysiology and Treatment of Aortic 
Diseases 
Wednesday ,  March  10, 1999, 10:30 a .m. -Noon 
Moda l  Convent ion  Center ,  Room 210 
10:30 a.m.  
~0-~ls  Aortic Atherosclerosis Heritable? Familial 
Aggregation of Lumbar Aortic Calcification in the 
Framingham Study 
Christopher J. O'Donnell, L. Adrienne Cupples, Douglas Kiel, Peter 
W.F. Wilson. National Heart, Lung and Blood Institute's Framingham Heart 
Study, Framingham, MA, USA 
Background: The discovery of human vascular disease genes requires iden- 
tification of heritable atherosclerosis phenotypes. Lumbar aortic calcification 
(LAC) is a marker of aortic atherosclerosis. Data are sparse regarding the 
role, if any, of genetic influences in the onset of LAC. 
Methods: We investigated the familial aggregation of LAC in 727 sibling 
pairs and 589 spouse pairs (mean age 60.8 years) in the Framingham Study. 
Lateral lumbar radiographs, obtained in 1967-69, were graded according to 
severity of anterior and posterior aortic wall calcific deposits in the L1-L4 
region. A lumbar aortic composite score (range 0-24 points) was calculated 
by summing the anterior and posterior gradings. Multiple linear regression 
was used to calculate age-and multivariable-adjusted (MVA) correlations of 
the LAC score among sibling pairs and spouse pairs. Covariates in the MVA 
models included diabetes, systolic BP, total cholesterol and HDL-cholesterol. 
Results: Adjusted correlation coefficients for sibling pairs strongly sug- 
gest that heritability plays a role in the presence of LAC (Table). 
Sibling pair p-value Spouse pair p-value 
correlation correlation 
LAC, Age-adjusted 0.35 0.0001 -0.01 NS 
LAC, MVA adjusted 0.38 0.0001 -0.06 NS 
(NS = not statistically significant) 
Conclusion: The magnitude of familial correlations for LAC are com- 
parable to those for highly heritable atherosclerosis risk factors such as 
lipoprotein(a) and HDL-C. LAC is a heritable phenotype which is noninva- 
sively detected and which may be useful for identification of variants of genes 
implicated in the onset of aortic atherosclerosis. 
1 0:45 a.m.  
~80~ Plasma Concentrations of Interleukin-6 and 
Abdominal Aortic Diameter Among Subjects 
Without Aortic Dilatation 
Luis E. Rohde, Luis H. Arroyo, Neder Rifai, Mark A. Creager, Peter Libby, 
Paul M. Ridker, Richard T. Lee. Brigham and Women's Hospital, Boston, 
MA, USA 
Background: Previous studies suggest that cytokine-induced tissue inflam- 
mation may participate in the pathogenesis of abdominal aortic aneurysms. 
Serum inflammatory markers may reflect arterial inflammation in asymp- 
tomatic phases of the aneurysmal disease. 
Methods: We studied 120 outpatients (62 men, age 65 ± 9 years) by 
ultrasound evaluation of the abdominal aorta to evaluate the association 
of circulating levels of interleukio-6 (IL-6) with abdominal aortic diameter 
in subjects with normal aortic size. Aortic diameter was measured at the 
infra-renal level and indexed for body surface area. Seven patients with 
abdominal aortic dilatation (indexed aortic diameter > 1.3 cm/m 2) were also 
identified. Plasma concentration of IL-6, serum amyloid A (SAA), C-reactive 
protein (CRP), total homooysteine and lipids were measured. 
Results: Among the 113 subjects without aortic dilatation, indexed aortic 
diameter was positively associated with serum levels of IL-6 (p < 0.01), 
SAA (p < 0.01) and total homocysteine (p = 0.01). IL-6 levels increased 
in a stepwise fashion among dichotomized groups of aortic size (low and 
high aortic diameters) and peaked in patients with aortic dilatation (2.3 ± 
1.2 vs. 2.7 ± 0.9 vs. 3.2 ± 0.9 pg/ml, respectively, p for trend = 0.039). 
None of the serum lipid measurements correlated with abdominal aortic 
diameter. In multivariate analysis, levels of IL-6 (p = 0.02), SAA (p = 0.001) 
and homocysteine (p < 0.001) were independent correlates of aortic size. 
Conclusion: Circulating levels of IL-6, SAA and total homocysteine may 
reflect processes involved in the early phases of abdominal aortic aneurysm 
formation, before dilation of the abdominal aorta is established. These data 
support a role for chronic inflammation in the progression of asymptomatic 
aortic disease. 
11:00 a.m.  
~-- )  Practice Variations in Utilization of Diagnostic 
Techniques to Evaluate Acute Aortic Dissection - 
Results from the International Registry of Aortic 
Dissection (IRAD) 
Sugata Das, Eric Isselbacher, Peter Hogan, Arturo Evangelista, 
Rossella Fatted, Toru Suzuki, Jae K. Oh, Udo Sechtem, Jose 
Robles Maroos, Hans-Joseph Deutsch, Dan Gilon, Dean Karavite, 
Pamela Russman, William F. Armstrong, G. Michael Deeb, 
David Bruckman, Christoph Nienhaber, Kim A. Eagle. University of 
Michigan Medical Center, Coordinating Center for IRAD Investigators, USA 
Background: Multiple imaging modalities are currently available to confirm 
diagnosis of acute aortic dissection (AoD). Each medality has certain advan- 
tages and disadvantages with respect to accuracy, speed, convenience, risk 
and cost. Recently, studies have argued that TEE and MRI should emerge 
as the most expeditious (TEE) and accurate (MRI) tools for this purpose. 
Methods and Results: 375 patients (pts) with a diagnosis of AoD in 
1996-1997, defined as presentation within 14 days of symptom onset, were 
enrolled in an international registry involving 12 centers. 225 (60.0%) pts were 
type A and 150 (40.0%) were type B. 7 (1.8%) pts had no imaging study. 
120 (32.0%) pts had one imaging study, 178 (47.5%) pts had two, while the 
remainder (18.7%) had three or four studies. CT was the first modality utilized 
on 231 (61.6%) pts, second on 47 (12.5%) pts, or not used on 93 (24.8%) 
pts. TEE was the first modality on 105 (28.0%) pts, second on 128 (34.1%) 
pts, or was not performed on 133 (35.5%). MRI was used in only 64 (17.1%) 
pts, and aortography in 89 (23.7%) pts, primarily to follow either CT or TEE. 
CT was used as the first choice of study equally in European and US centers, 
(60.0% vs 59.7%), as was TEE (29.5% vs 28.7%). TEE was used on 38.4% 
and 58.1% of European and US pts. CT utilization was similar in Europe and 
US (73.7% vs 74.4%). US, Europe and one site in Japan do not differ in the 
average number of imaging modalities performed. A major Japanese center 
had a high preference for CT, 94.6%, 71.4% of whom underwent CT as the 
initial modality. 55.4% of this group underwent TEE subsequently. 
Conclusions: 1. CT is currently the preferred initial choice of imaging 
medality for AoD, perhaps because of its wide availability. 2. Aortography use 
has declined substantially; it can no longer be considered the gold standard 
test. 3. Interesting regional variations exist in utilization. Their implications on 
cost and outcomes will be the subject of future evaluations. 
11:15 a.m.  
[~-~ Percutaneous, Intravascular Ultrasound-Guided 
Fenestration of Dissection Membranes in Patients 
With Aortic Dissection and Abdominal Ischemia 
J. Schaar, G. G~rge, J. Ge, O. Oldenburg, M.H. Raus, D. Baumgart, 
R. Erbel. University Clinic of Essen, Department of Cardiology, Essen, 
Germany 
Background: Aortic dissection can lead to ischemic syndromes in the ab- 
domen and lower limbs. Explaining the high postoperative mortality. 
Aim: We studied the usefulness of intravascular ultrasound (IVUS) guided 
percutaneous fenestration of dissection membranes to treat patients with 
signs of ischemia in aortic dissection. 
Methods: IVUS guided fenestration was performed in five patients with 
aortic dissection Type III (DeBakey classification). Three of these patients 
had renal failure with decreased limb perfusion and 2 pts with mesenteri- 
cal ischemia. Age was 51-79 years. After aortic angiography a 10 French 
mechanical 10 MHz IVUS catheter was placed into the false lumen. A 8 
French introducer sheath was placed into the contralateral groin. Under 
IVUS monitoring and fluoroscopy the dissection membrane was punctered 
with a Brockenbrough needle to place a guide-wire from trough to the false 
lumen. We crossed the membrane with a balloon catheter (5-11 mm) and 
created one ore more windows pulling back the inflated balloon across the 
dissection membrane. Peripheral perfusion was restored in all patients. One 
patient was sent to surgery because of limited anatomical complications. 
Results: In all patients with impaired renal peffusion elevated creatinine 
decreased to normal ranges. No patient developed a chronic renal failure. 
Signs of limb ischemia and abdominal ischemia disapaard. 
Patient-ID 1 2 3 4 5 
Creatinine before PFD (mg]dl) 5.9 5.2 2.6 1.0 1.1 
Creatinine after PFD (mg/dl) 1.9 1.4 1.7 0.9 0.9 
Conclusion: Percutaneous fenestration of dissection membranes is a 
safe new treatment of acute organ failure in aortic dissection and may be 
an altemative to surgical management o restore perfusion. Further studies 
have to be conducted to establish this new method. 
11:30 a.m.  
~0-~ Nonsurgical Reconstruction of Thoracic Aortic 
Dissection 
C.A. Nienaber, R. Fattori, G. Lund, C. Dieckmann, W. Wolf, V. Nicolas, 
A. Pierangeli. University of Hamburg, Germany; Coordinating Center for 
IRAD Investigators, USA 
Background: While type A dissection requires surgical repair, the treatment 
of distal arch and thoracic aortic dissection is not settled since surgery 
is ass~,%=,,d '.~';'fi', ~,';~", ~ "and 'm~-a';';t-.} ~,.'~ 'was ' f ' z~ ~.'b ','n-,~.~e 
prognosis. 
Methods and Results: Using a prospective case-control design safety 
and efficacy of transluminal endovascular stent-graft insertion for type B 
aortic dissection was compared to elective conventional surgery with simi- 
lar pathoanatomic features; all 24 patients (20 M, 4 F) were diagnosed in 
the 6~.~,:,~e t,~;vi.~ ~'~." ~ ,~ '~C ,~'~A:~'~'~'. P,~9~'~' ,~'tu"6Y'~ i'h'e" ~,~',.~ 
cal resection of the dissection (n = 12) or placement of custom-designed 
end©~a~fi)ar s~f~-exDan{~)no shen3-pra~s )n = ")"2> "th~qp~ ~n~a~e~a') f~e- 
riotomy. Transesophageal echocardiography (TEE) was used for interven- 
evaluatbn. 
FResults: Stentcclraft placement was free of morbidi.tv and mortality while 
surgery for type B dissection was associated with 3 deaths (25%) and 5 
the stent-graft prothes)s was documente~ in a)) pat'tents w)~ no endo)eaX. 
age; complete sealing of the entry was monitored during the procedure by 
TEE and angiography, and thrombosis of the false lumen was confirmed 
in all 12 patients at 6 ± 1 month by repeat magnetic resonance imaging. 
No ~)ea~b, parap~e..5)a, s'~rD~e, 5)sta'~ embe~)za~)on, s)[~ebrar)cY) DOC')~)Dn, D~ 
infer)on were no'~eO. ~ne pa1~en'~s'na~ ~DO s~)m,~') an'[a'/) on s.vn~rome W)~b ~ran- 
sient elevation of c-reactive protein levels and body temperature, and mild 
leucocytosis. Full physical recovery was seen in all patients with stent-grafts 
(100%) and in 8 patients (67%) after surgery for type B dissection (p < 0.05). 
~Conc)udmns: T)re))rr~na~ resu)ts document ha~,oercutaneous endovas- 
cular stent-grafting in selected patients with thoracic aortic dissection (and 
inditca'/}on ']or surgery) }s sa~e an~) df/}cad)ou~, an(~ )n~uces aott}c remo~e~m 9. 
Endoluminal repair has potential for interventional reconstruction of thoracic 
aortic dissection. 
11:45 a.m.  
~ - ~  D~ferent  C(inical  Features  of  Aor t i c  Intramura~ 
Hematoma Versus Dissection Involving the 
Ascending Aorta 
Jae-Kwan Song, Hyun-Sook Kim, Duk-Hyun Kang, You-He Kim, 
tion, has been applied for patients with aortic dissection (AD) and aortic 
clinical data to test the hypothesis that AIH may be different from AD, as it 
does not have an intima( tear and direct flow communicat/on. 
Results: From 1990 to July 1998, clinical evaluation with various imaging 
modalities confirmed the diagnosis of AD and AIH in 59, 18 patients (pts) 
respectively. The incidence of hypertension and syncope was not different 
in two groups. Pts with AIH were eider (69 4- ~0 vs. 48 ± 14) and fema)e 
was pr~=b~:~e,,~;, ~n ~5 ~'~i~O~ ,~. "~,.~?. T~ b~,~'~ ~ ~',o~z~,,~) 
hemorrhage, pencardial and pleural effusion was more frequent in AIH than 
in AD. In-hospital mortality was same in both groups. Although medical 
medical conditions, the mortality rate was lower in this group (9% vs. 56%). 
Six-year survival rate was not different in both groups. 
n=4 
,...Operation ~ Death 
AD / (n=50) n= ~ (n=9) (n=59) 
t.. Medical Tx ~._~']:~Survived 
(n=9) (n=50) 
n =1 
AIH i.--Ol~e, ra..~'on ~ Death 
(n=18) I ,n:..'|~,=; n='1~ (n=2) 
L- Medical Tx ~::: : : : : : :~ S u ~'iv~l 
(troll) (n=16) 
Conclusions: AIH may be a different disease entity, and medical treat- 
ment can be an option in selected pts with AIH involving the ascending 
aorta. 
ORAL 
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10:30 a.m. 
~ T h e  Effects of a High-Fat Meal on Endothelial 
Function in Patients With Type 2 Diabetes Mellitus 
All Fard, Joshua A. Denis, Marco R. Di Tullio, Henry Wu, Lynette 
M. Mendoza, Inna V. Titova, Rajasekhar Ramakrishnan, 
Margarita Torres-Tamayo, Catherine Tuck, Lars Berglund, Henry Giesberg, 
Shunichi Homma. Columbia University, New York, NY, USA 
Background: Endothelial dysfunction has been associated with the develop- 
ment of coronary artery disease (CAD). Studies have shown that the ingestion 
ics. The effects of a fat load on endothelial-dependent vasodilation in patients 
with type 2 diabetes mellitus, however, have not been investigated. In this 
study we assessed the effects of in(]#stion of a hieoh-fat containinoJi~d meal 
hyperemia in patients with type 2 diabetes mellitus. 
,45E=Cdto~f~; ;"~/cteew ¢¢r'~'r~dee~ ~r/¢r~ ¢yFe Z~'~d~tes ~e#'Ft~ rere FcrcYcc~eo" 
for the study. An image of the brachial artery was obtained by ultrasound 
followed by the inflation of an arm cuff at a pressure greater than the sys- 
tolic blood pressure for 4 minutes. After the release of the cuff, images of 
the brachial artery were again obtained. The volunteers were then 1ed a 
Iiq~zid meal o~ 75% fat (40% satcrated, 20% mono(znsaturated, f5% polyun- 
saturated), t5% c¢cb~kydr~te, ¢oc/ h2% (]rote/n. Actedal c~c#t4ty was re- 
assessed 5 hours thereafter. Serum TG levels were measured before and 5 
hours after the meal. 
Results: With ino~estion of the meal, serum TG levels increased from 
dilation decreased from 8.57 ± 7.6% to 2.24 ± 4.2% (p < 0.05), as depicted 
.,,.r,~ ~ 
CQI~C[IJISiQn: FQtl.owinc~ i.n~e~tio~ o( & ~t~ mea~ ~e~iat ~ I t ta t i .~  
dunng reactive hyperemia, an endothelial-dependent function, is impaired in 
patients with type 2 diabetes mellitus. This study prov)c~es further insight into 
the importance of timiting ~atty intake for the prevention of CAD in type 2 
diabetics. 
10:45 a.m. 
~ Expression of Human Cytomegalovirus Immediate 
Early Genes Increases Rat Smooth Muscle Cell 
Yi Fu Zhou, Zu Xi Yu, Marie Shou, Stephen E. Epstein. NHLBI, NIH, 
Bethesda, MD; Washington Hospital Center, DC, USA 
Background: Human cytomegalovirus (HCMV) has been found to be as- 
sociated with atherosclerosis and restenosis following coronary angioplasty, 
disease processes in which smooth muscle cell (SMC) proliferation is a cru- 
cial component of the vasculopathy. However, the effect of HCMV infection 
on cell cycling and cell proliferation is controversial; DNA replication and 
progression through the cell cycle has been found to be either increased 
or decreased. We sought to determine whether HCMV infection increases 
vascular SMC proliferation. We were particularly interested in whether the 
immediate early lIE) gene products of HCMV were in themselves capable 
of increasing proliferation, as these are the only gone products expressed 
dudng abortive (nfect(ons. Because expression of early and late viral gone 
products might mask the effects of the IE gone products, we employed for 
the present investigation a model of HCMV infection of SMCs we devel- 
oped in which only IE gene expression occurs and no cytopathic effects are 
observed: HCMV infection of rat SMCs. 
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Methods and Results: Primary cultured rat aortic SMCs (RSMCs) were 
seeded in 12-well plates; at 80% confluence they were inoculated with HCMV 
(Towne strain) at 200 MOI. Two hours later virus was removed and the cells 
refed with normal growth medium. The number of RSMCs in non-infected 
and infected cultures were similar the first week following infection. However, 
beginning on day 7 the number of cells in HCMV infected cultures was 
significantly greater. Byday 11, there were 1.4 × 10 s ± 0.051 × 106 cells/well 
in the infected RSMCs compared to 0.9 × 106 ± 0.024 × 106 cells/well in 
the non-infected controls (p < 0.001). 
Conclusion: HCMV, through its immediate early genes, increases rat 
vascular SMC proliferation, a mechanism that may contribute to the devel- 
opment of atherosclerosis and of rsstenosis. 
11:00 a.m.  
l -~-~ Coronary Endothelial Function and ACE 
Polymorphism. The intervention CArdiology Risk 
Strat i f icat ion (ICARIS) Study 
Pieter-Jan de Kam, Stefan H.J. Monnink, Ad J. van Boven, Peter P, van 
Geel, Lisa Pont, Nic J.G.M. Veeger. University Hospital Groningen, The 
Netherlands 
Background: An important determinant for cardiovascular disease is the 
endothelial function, determined by intracoronary infusion of acefylcholine 
(i.e. the presence of paradoxical vasoconstriction if endothelial dysfunction 
is present). ACE polymorphism DD genotype has been proven to be an 
important determinant in atherosclerotic progression. In the present ICARIS 
study we correlated ACE polymorphism with coronary NO-activity. 
Methods: Using off-line quantitative coronary angiography, coronary re- 
sponse on incremental acetylcholine infusion in the CX was determined in 
patients with angina pectoris, accepted for diagnostic coronary angiography. 
Multiple regression was performed on maximal vasoconstdctive response to 
acetylcholine with predictors nitroglycerine (NTG), ACE polymorphism and 
their interaction. 
Results: Of the first 100 patients (67 males, mean age 60 years), 25 had 
DD, 44 ID and 31 II ACE-genotype. The figure shows that a small decrease 
in vasodilative capacity on nitroglycerin results in a more pronounced vaso- 
constrictive acetylcholine response in patients with DD genotype compared 
to II/ID genotype (P = 0,001). 
0-  
- :z  - P -O .  SO l  
-4 -  
~ -4 -  
"~ -ZO - 
-12  - - -  XI/XD ~ t y p e  
-14  - , 
-Z4  • 
2 ,1~ 2 , l  3,0  3r 2 3 ,4  3 ,4  3,11 
ys /ocLt . la  I" :l, ve  Ca~ r.,JL *~lt  
Conclusion: Endothelial dysfunction in CX coronary artedes with im- 
paired vasodilative capacity by nitroglycerin is more pronounced in ACE 
genotype DD patients than in patients with II/ID genotype. 
11:15 a.m. 
I -8 -~ The Genetic Control of Coronary Vasomotor Tone: 
Role of Angiotensin Converting Enzyme Gene 
Polymorphism 
Abhiram Prasad, Suresh Narayanan, Neal Epstein, Arshed A. Quyyumi. 
NHLBI, NIH, Bethesda, Maryland, USA 
Presence of the deletion (D) allele in the converting enzyme (ACE) gene is 
a risk factor for adverse events in coronary artery disease. We hypothesized 
that this deleterious effect is due to its impact on coronary vascular function. 
In 133 patients with coronary artery disease or its risks, endothelium-depen- 
dent and smooth muscle function were assessed with intracoronary (i.c.) 
acetylcholine (ACH) and nitroprusside (NTP) respectively. Basal nitric oxide 
(NO) activity was estimated with i.c. L-N a monornethy L-arginine (L-NMMA) 
in 76 patients. Coronary epicardial diameter (ED) and Doppler blood flow 
velocity were measured. ACE genotypas were determined by PCR. Serum 
ACE levels were higher in DD patients (P < 0.01), Dilation in response to 
ACH did not differ between genotypes, but the response to NTP was de- 
pressed in those with the D allele. L-NMMA induced greater vasoconstriction 
in patients with the DD genotype (table). Our results indicate that the D al- 
lele of the ACE gene is associated with: (I) increased basal smooth muscle 
tone demonstrated as a reduced response to NTP, and (ii) a compensatory 
enhancement in basal NO activity. Thus, ACE gene polymorphism, by mod- 
ulating vascular angiotensin II activity, contributes to vasomotor tone and 
function in patients with coronary artery disease. 
ACH/30 p,g/min NTP/40/~g/min L-NMMN64 p,g/min 
$ CVR ED J. CVR ED ¢ CVR ED 
DD -44% 0.90 -49% 17% 17% -7.0% 
ID -42% -1.14% -54% 18% 13% -6.0% 
II -47% 1.7% -61% 22% 4% -4.8% 
P value 1" 0.7 0.7 0.019 0.04 0.03 0.2 ° 
*In patients with coronary artery disease alone P = 0.01, CVR-coronary vascular esis- 
tance; tDD vs. II 
11:30 a .m.  
~5- ]  Interact ion o f /9  Fibrinogen Gene Polymorphism 
With Diabetes Mellitus: The Framingham Offspring 
Study 
DaLi Feng ~ , Klaus Lindpalntner 2, Martin G. Larson 3, Christopher 
J. O'DonnelP, Izabella Lipinska 1 , Patrice A. Suthedand 3 , Daniel Levy 3, 
Geoffrey H. Tofler ~ . ~lnstitute for Prevention of Cardiovascular Disease, 
Beth israel Deaconess Medical Center; 2Brigham & Women's Hospital, 
Boston; 3NHLBI's Framingham Heart Study, Framingham, IdA, USA 
Background: An elevation of fibrinogen may be one mechanism by which 
diabetes mellitus exerts its effect on cardiovascular disease. Although poly- 
morphisms of the/~ fibdnogen gene have been shown to modify fibdnogen 
levels, the interaction between these polymorphisms and diabetes has not 
been well defined. We therefore studied subjects from the Framingham Off- 
spring Study to determine if an interaction was present. 
Methods and Results: Genotype and phenotypic data were obtained in 
1850 subjects enrolled in the study, of whom 125 subjects were diabetics. 
Evaluation of the Hind lll ~-148 polymorphism revealed frequencies of cutting 
(H1) and no cutting (H2) alleles of 0.81 and 0.19, respectively, Fibrinogen 
levels, which were measured by Clause Assay, differed significantly among 
genotypes; 307 ± 2 mg/dl for H1/H1; 316 :E 2 mg/dl for H1/H2; and 323 ± 7 
mg/dl for H2/H2, p < 0.0001. A greater difference in fibdnogen levels among 
genotypes was observed among diabetic subjects than among non-diabetics, 
p < 0.0001 for the interaction term. 
Subjects (n) Fibdnogen level by genotype P value 
H1/HI H1/H2 H2/H2 
No diabetes (1725) 300 ± 1.5 307 4- 2.2 308 ± 6.5 0.01 
Diabetes (125) 324 ± 7.1 365 ± 10.2 429 ± 27.4 <0.0001 
Conclusion: The Hind III/~-148 polymorphism significantly modified fib- 
rinogen levels, such that the H2 allele was associated with higher levels. 
Further study of this relationship, which was particulady marked among dia- 
betics, may help to identify subjects at increased cardiovascular risk. 
11:45 a.m.  
~ T h e  Contr ibut ion o f  Genet ic  (4G/5G Polymorphism) 
and Environmental Factors to Plasminogen 
Activator Inhibitor-1 Antigen Levels: The 
Framingham Offspring Study 
DaLi Feng 1 , Klaus Lindpaintner 2, Martin G. Larson 3, Christopher 
J. O'Donnell 3, Izabella Lipinska 1 , Patdce A. Sutherland 3, Daniel Levy 3, 
Geoffrey H. Tofler 1 . 1 Institute for Prevention of Cardiovascular Disease, 
Beth Israel Deaconess Medical Center; 2Brigham & Women's Hospital 
Boston; 3NHLBI'S Framingham Heart Study, Framingham, MA, USA 
Background: Elevated levels of plasminogen activator inhibitor (PAl-l) have 
been associated with increased cardiovascular isk. To determine the relative 
extent o which genetic and environmental factors contribute to PAl-1 levels, 
we studied subjects from the Framingham Offspring Study. We evaluated a 
4G/5G polymorphism in the promoter egion of PAl-1 gene, which has been 
shown to modify PAl-1 levels. 
Methods and Results: Genotype and phenotypic data (PAl-1 antigen, 
using ELISA method, Biopool) were determined in 1492 subjects enrolled 
in the study. The allele frequencies of 4G and 5G were 0.54 and 0.46. 
There was a moderate, but highly statistically significant (p < 0.0001) effect 
of the polymorphism on PAl-1 antigen levels; 24.0 i 17.3 ng/ml for the 
4G/4G genotype, 22.0 ± 15,9 ng/ml for the 4G/5G genotype, and 20.6 ± 
15.9 ng/ml for the 5G/5G genotype. The 4G/5G polymorphism accounted 
for 0.8% of the total PAl-1 variance, which was less than the contribution 
of the following risk factors: body mass index (21.4%), triglyceride levels 
(9.2%), systolic blood pressure (2.6%), smoking (1.4%), all p < 0.0001. 
Other significant contributors included alcohol intake (0.7%, p < 0.0001), 
total cholesterol (0.7%, p < 0.0001), HDL cholesterol (0.6%, p = 0.0003), 
hormone replacement herapy (0.2%, p = 0.02), and age (0.2%, p = 0.03). 
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Conclusion: In the Framingham Offspring Study, both genetic and en- 
vironmewtal '(acto'm cor~t~b~t~ o PAl-1%vels, al~ough '~  ContTibt~tion '[o 
the variance by the 4G/5G polymorphism is small compared with that of risk 
factors such as body mass index and triglycedde levels. The effect of rood- 
study. 
ORAL  
Cardiovascular Disease Prevention and 
Management 
Wednesday ,  March  10, 1999,  2:00 p .m. -3 :30  p.m. 
Moda l  Convent ion  Center ,  Room 275 
2:00 p.m.  
~f~ue~ces 
its Use to Triage Chest Pain Patients in the 
Emergency Department 
James E. Ca}v}n, Thomas D. Statues, L;,nda C. Batt}ett, Pau) K. Hartash}ro, 
Uoyd W. Klein, Joseph E. Parnllo. Rush Medical College, Chicago, Illinois, 
USA 
Background and Methods: To determine the value of a clinical algorithm 
i~eritfr,J ')rit)uencas 'm hs ~s~, ~CSb ')ew ' /~  ~a'i~a'rhs "~T~ Dr~]p~.9 .b~m, ~x) 
heart failure, hypotension, or enzyme elevation and no more than one of 
the following: age > 65 y, ST depression or DM), were admitted to an ED 
observation unit for a 12 h stress echo. These observation unit patients 
(OUPs) were compared to concurrent and consecufive)y adm~t)ed pat.tents 
lAPs) with similar risk characteristics who were admitted to the hospital at 
their physician's discretion without completing an algorithm (n = 535). 
Results: APs were older (51 4- 14 vs. 57 4- 15 y, p = 0.0001) and more 
frequently had T wave inversion (27% vs. 0%, p = 0.001), diabetes (27% 
vs. 14%, p = 0.001) previous myocardial infarction (15% vs. 8%, p = 0.004), 
and revasculadzation (22% vs. 8%, p = 0.001). Multiple logistic regression 
~an~}vs~s reve~aeb'tna~ t l )~cs  anb.pa'6e'n'ts >%% v v~n ]are~rous ~nary  
~ ~'~? ' ~r~P~-~ ,~ '~ ,m~q~P ,'ik~y '~ 3~" .~.~ ~'~.'~ i~ '3  = = ~.S',~3- ~ ,~. 3L~, 
respectively). Twenty pemer~t o'[ OUPS were admitt,ad because of abnorma( 
testing (echo, enzymes, and ECG). APs had coronary angiography (29% vs. 
performed in 1% of OUPs and 3% of APs (PNS). There were no in-hospital 
Conclusions: We conclude that this clinical algorithm was highly effective 
akjontPva car be w '~y ~#,'ed ~ ,~az  e~ec~ver~ss a~ sa f~ a~ 
with concomitant cost savings and decreased hospital admissions. 
2 :15 p.m. 
~-9-~ Acute Myocardial (AMI): Infarction Statewide 
Ou(comes for- Ot'barui~urat Adn~'ss(~ns - ExpetCence 
from the Pennsylvania Health Care Cost 
Containment Council (PHC4) 
Cad A. Sirio, Judith R. Lave, Howell C. Sasser, Stephen R. Wisniewski. 
University of Pittsburgh Schools of Medicine and Public Health, Pittsburgh, 
PA, USA 
Background: The availability of advanced cardiac services and the timing 
of administration of interventions following AMI has an effect on survival. We 
hypothesized that patients living in rural areas would have worse outcomes 
(mortality) than urban patients following an AMI because they potentially 
have less direct access to advanced care. 
Methods: Data were collected from 148 acute care Pennsylvania hospi- 
tals, with varying degrees of advanced cardiac care services, on all patients 
admitted in calendar 1993, having AMI as the principal diagnosis in an initial 
episode of care. 
This statewide cohort was collected as part of an ongoing evaluation of 
care by the PHC4. Demographic and clinical data were collected to case mix 
adjust patients. Mortality was examined using logistic regression. Analysis 
was performed on all patients except hose: admitted to hospitals closed since 
1993, leaving against medical advice, under 30/over 99 years, involved in 
two or more interhospital transfers, meeting clinical complexity criteria (e.g, 
concurrent multiple trauma on admission, metastatic cancer), or admitted to 
a hospital with fewer than 30 AMI admissions. Episodes of illness related 
to the incident AMI were created using linked patient specific identifiers 
across hospitals for transferred patients. Patients were evaluated for all 
cause mortality at one year using state death records. To define urban/rural 
gradations, established US Department of Agriculture criteria were utilized. 
O~tc~s  '~ I~ as~ss~:,,d at disch~r~je ~ '~he, final hospital ~'~rir~j e 
acute AMI episode and at one year. 
Results: The total sample size was 43,093. Overall hospital mortality 
14,356 were '/ransfened. There were no slatistical'~y signil.icant dFderences 
in outcome between any urban or rural category of patient residence after 
adjusting for severity. Patients who were transferred tended to have a lower 
predicted risk of hospital death (OR = 0.004) when compared to the entire 
sample. Men (OR = 1.481) and those living in a rural area (OR = 1.261) 
were significantly more likely to be transferred, after adjusting for sevedty of 
illness. 
Conclusion: Data from this large, comprehensive statewide database 
suggests that the location of residence for patients presenting with AMI 
does not significantly impact outcome. These data suggest that the triage of 
patients for transfer for advanced cardiac sewices is most often made ap- 
propriately and that geographic location does not adversely impact survival. 
2 :30 ,p .m.  
~-9-~ Effect of Cigarette Smoking on Health Status 
Improvement After Percutaneous Coronary 
Revascularization 
Deborah A. Taira, Todd B. Seto, Ronna Berezin, Donald E. Cutlip, Kalon 
K.L Ho, Richard E. Kuntz, David J. Cohen. Beth Israel Deaconess Medica/ 
Center, Boston MA, USA 
I~lC~FFOtlno': .~moEih~ rs {he i'eao~h~ mog~~[dCe rls~: l~c['or 'oF {he Q'evel'o .p-- 
men[' ar~ prograssron" or'coron~[ry heart" df~e~[se. ,a{({hoffgrl" pr~bus" s¢u~es 
have found that smoking increases late mortality after PTCA, the effect of 
smoking on health-related quality of life (HRQOL) following percutaneous 
corena~ revascu|arizal.ion is unknown. 
Methods: Quali~t of life outcomes {SF-36 instrument) were assessed 
at baseline, 6 month follow-up and l-year follow-up for 1425 patients who 
underwent percutaneous coronary revascularizaton as part of 2 large-scale 
interventional device trials. Changes from baseline were compared for current 
smokers (n = 357), non-smokers (n = 984), and recent quitters (< t yr prior, 
n = 84), after adjustment for differences in sociodemographic factors (age, 
gender, education, marital status), clinical factors (extent of CAD, ejection 
Results: All groups reported significant improvement in their HRQOL at 
6 mo and 1 yr. However, adjusted HRQOL gains at 6 mo were smaller for 
~Qkers cQm~ad with n.o~-smok~rs for all subsca[es (~see tabLe~. Recent 
quitters demonstrated health status improvements similar to non-smokers 
for all scales. Similar results were obtained at 1 yr. 
Adjusted change in HRQOL scales at 6 me 
QOL scale Current Smokers Non-smokers Recent Quitters 
Physical 11.8 15.7" 19.3" 
Function Role Physical 17.1 24.2' 25.8 
Pain 14.4 18.2" 2t .6" 
%;t,'dit~.~ R.,.'X, t,q,F~- tA...'X* 
Social Function 6.1 13.0" 16.3" 
• p < 0.01 VS. current smokers 
Conclusion: While smokers benefit from percutaneous coronary revas- 
cularization, their HRQOL does not improve to the same extent as that 
of non-smokers or recent quitters, To maximize the benefit from coronary 
revascularization, patients should be encouraged to quit smoking. 
2:45 p.m, 
[-8-9-~ Calcium Beta blockers for Antagonists Versus 
Stable Angina: A Meta-Analysis 
Paul A. Heidenreich, Kathryn M. McDonald, Trevor Hastie, Bahaa Fadel, 
Vivian Hagan, Byron K. Lee, Mark A. Hlatky. Pale Alto VA Medical Center; 
Stanford Universi~ Stanford, California, USA 
Background: Beta-blockers and calcium antagonists are often used as first- 
line therapy for stable angina. Most studies comparing these agents have 
been too small to detect differences in effectiveness. 
Methods: We identified published studies comparing calcium antagonists 
and beta-blockers in patients with stable angina in the MEDLINE and EM- 
BASE databases. Randomized parallel and crossover studies that were at 
least 1 week in duration were reviewed. Data on cardiac death, myocardial in- 
farction, study withdrawal due to adverse events and angina frequency were 
extracted by two independent reviewers. We pooled the data using odds 
ratios (OR) for adverse events and mean differences for angina episodes. 
Results: Ninety-one studies met the inclusion criteria. Beta-blockers were 
discontinued due to adverse events less often than were calcium antagonists, 
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OR 0.71 (95% Cl: 0.59, 0.85). There were no differences in cardiac death 
or myocardial infarction: OR for risk with beta-blockade 0.94 (95% CI: 0.65, 
1.4), but the median follow-up was only 4 weeks. Beta-blockers led to fewer 
angina episodes per week: mean difference 0.31 (0.0, 0.60). Trials comparing 
nifedipine with a beta-blocker showed significantly fewer angina episodes per 
week (0.6 95% CI: 1.0, 0.2), and fewer adverse events (OR 0.59 95% CI: 
0.46, 0.76) with beta-blockade. Trials comparing non-nifedipine drugs with 
beta-blockers showed no significant differences in adverse events or angina 
relief. Trials comparing long acting calcium antagonists with beta blockers 
showed fewer adverse events with beta-blockers (OR 0.74 95% Ch 0.57, 
0.95), but similar angina frequency. 
Conclusions: Beta-blockers were associated with fewer adverse events 
and provided equivalent or greater angina relief when compared with calcium 
antagonists in randomized trials of patients with stable angina. 
3:00 p.m. 
~-~ Effect of Amlodipine on Cardiovascular Events and 
Procedures 
Robert P. Byington, John Chen, Curt D. Furberg, Bertram Pitt. Wake Forest 
University School of Medicine, Winston-Salem, NC, USA 
Background: The Prospective Randomized Evaluation of the Vascular Ef- 
fects of Norvasc Trial (PREVENT) was a 3-year, randomized, masked, 
placebo-controlled, multicenter, clinical trial designed to test the antiathero- 
genic effect of the calcium channel blocker amlodipine in 825 patients (PTS) 
with coronary artery disease (417 amlodipine pts/408 placebo). The primary 
hypothesis was that amlodipine would reduce the progression of early ath- 
erosclerosis as measured by quantitative coronary angiography. A secondary 
objective was to examine the effect of amlodipine on the 3-year occurrence 
of cardiovascular disease (CVD) events and procedures. 
Methods: The CVD events of interest were prespecified. "Major Vascular 
Events" included myocardial infarctions (MIs), strokes, and any fatal vascular 
event. "Major Procedures" included coronary bypass, stents, athrectomies, 
and catheterizations. All suspected events were reviewed by an external 
committee of physicians not otherwise associated with the trial. Treatment 
group-specific rates, proportional model hazard ratios (HRs) and 95% confi- 
dence intervals (CIs), and lifetable p-values have been calculated. 
Results: 
# of Pts with Event HR 95% CI 
Amlodipine Placebo 
Any Death 6 8 0.74 026-2.12 NS 
Fatal/Nonfatal MI 19 20 0.94 0.59-1.76 NS 
Maior Vascular Event 23 28 0.82 0.47-1.42 NS 
Documented Angina 60 85 0.67 0.48-0.93 0.01 
Major Procedure 52 88 0.55 0.39-0.77 0.001 
Any Major/Documented 
Event/Procedure 87 117 0.70 0.53-0.92 0.01 
Conclusion: The reduction in angina and major vascular procedures 
attributable to amlodipine may translate to a reduction in health care costs. 
3:15 p.m. 
~ Chlamydia, H. Pylori and Cytomegalovirus 
SeroposiUvity and Risk of Cardiovascular Disease: 
The Framingham Heart Study 
Agha W. Haider, Peter W.F. Wilson, Martin G. Larson, Patrice Suthedand, 
Jane C. Evans, Christopher J. O'Donnell, Philip A. Wolf, Eric L. Michelson, 
Daniel Levy. Astra Pharm, Wayne, PA and Framingham Heart Study, 
NHLBI, Framingham, MA, USA 
Background: A persistent inflammatory response accompanying chronic 
Helicobacter pylori ( HP), Chlamydia pneumoniae ( CP) and Cytomegalovirus 
(CMV) infections may contribute to risk of cardiovascular disease (CVD). 
Methods: We measured serum HP, CP, and CMV IgG levels in Framing- 
ham Heart Study cohort participants. Blood samples were drawn during the 
16th biennial examination cycle (1979-1982) from 1503 (mean age 70 years) 
participants and stored at -20~C. A pooled primary endpoint of myocardial 
infarction, atherothrombotic stroke and CHD deaths was studied in relation 
to serology results. Using a Cox model, hazards ratios (HR) and 95% con- 
fidence intervals (95% CI) were calculated adjusting for age, sex, smoking, 
body mass index, total and HDL cholesterol and diabetes mellitus. 
Results: During 10 years of follow-up, incident CVD occurred in 12.5% of 
participants. The prevalence of positive serology and the relations of infection 
to CVD are summarized in the Table. 
tip > 6.4 CP > 1:128 CMV > 3.52 
Prevalence 20% 47% 69% 
HR t .24 0.89 0.88 
(95% CI) (0 .89-1 .74)  (0.66-1.19) (0.64-1.21) 
Conclusion: In this elderly study cohort, chronic HP, CP and CMV in- 
fections were not associated with increased risk for CVD. Additional studies 
are needed to determine the relations of chronic infections to CVD risk in 
younger persons. 
ORAL 
~3]  Cellular Pathways of Disease 
Wednesday, March 10, 1999, 2:00 p.m.-3:30 p.m. 
Modal Convention Center, Room 228 
2:00 p.m. 
~ - ]  Adrenomedullin: A Unique Inodilator In Vivo 
John G. Lainchbury, Michihisa Jougasaki, John C. Bumett Jr, Margaret 
M. Redfield. Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN, 
USA 
Background: Adrenomedullin (ADM) is a recently described vasodilatory 
peptide demonstrated to be activated in heart failure (CHF). In vitro studies 
suggest that ADM may possess positive inotropic actions. It remains un- 
clear if inotropic effects occur at levels of ADM observed in CHF or only at 
pharmacological doses. 
Methods: We investigated the myocardial actions of pathophysiological 
and pharmacological concentrations of ADM in normal dogs. ADM was ad- 
ministered after/~-blockade to five chronically instrumented, conscious dogs 
in doses of 20 and 100 ng/kg/min IV. To achieve pharmacological intracoro- 
nary concentrations, ADM was then infused at 200 ng/kg/min into the left 
ventricular (LV) cavity. All infusions lasted 30 minutes. 
Results: 
Baseline 20 ng/kg/min 100 ng/kg/min 200 ng/kg/min 
LVpeak 133±7 126±8 ° 121 ±7" 109±9" 
Ees 8.8 ± 1.3 9.0 ± 1.4 8.9 ± 2.7 10.6 ± 2.0* 
EF 27±7 28±8 31 ±8 38±10" 
dP/dt 2101 ± 144 2106 ~: 174 2066 ± 123 2305 ± 205" 
Tau 29.4 ± 3.6 27.0 ± 3.5 27.0 • 4.5 23.4 ± 3.2" 
* p < 0.05 vs Baseline. LVpeak, LV peak systolic pressure (mmHg); Ees, end systolic 
elastance (mmHg/ml); El=, ejection fraction (%); dP/dt, maximum dP/dt (mmHg/sec); Tau, 
time constant of LV isovolumic pressure fall (ms). 
End diastolic pressure and volume were unchanged. Plasma venous 
concentrations of ADM were within the pathophysiological range (31.5 ± 6.5 
pg/ml) at the lowest dose but well beyond this range at the highest dose 
(322.6 ± 151.5 pg/ml). Plasma cAMP was unchanged. 
Conclusion: These results suggest that at plasma concentrations imilar 
to those in heart failure, ADM functions as an endogenous vasodilator without 
positive inotropic actions. The vasodilating and inotropic actions of ADM at 
pharmacolgic concentrations uggest a therapeutic potential. 
2:30 p.m. 
~3-~- ]  ~-Adrenergic Subsensitivity and Decreased Cardiac 
Function After Prolonged Cardioselective 
Norepinephrine Stimulation in Transgenic Mice 
Overexpressing Nerve Growth Factor 
Erdan Dong, Hiroya Kawai, Andrew I. Brooks, Howard J. Federoff, 
Chang-seng Liang. University of Rochester Medical Ctr., Rochester, NY, 
USA 
Background: We have shown that cardioselective sympathetic hyper-inner- 
vat±on (CSH) causes/~-adrenoceptor (/~AR)-G protein uncoupling in 4-week 
old transgenic (TG) mice overexpressing nerve growth factor (NGF). To deter- 
mine whether chronic exposure of the heart to CSH produces post-receptor 
changes or myocardial systolic dysfunction is unknown. 
Methods and Results: Studies were carried out in 6-month-old NGF 
overexpressed TG mice. We measured the heart weight (HW, rag), /~AR 
density (fmol/mg), net increases of cAMP (pmol/mg/min) in response to 
isoproterenol (Iso), Gpp(NH)p (Gpp) and forskolin (For), and LV fractional 
shortening (FS, %) at rest and net increase by Iso. TG mice showed increased 
HW and ,BAR density, but decreased LVFS compared to control. In addition 
inotropic and cAMP responses to Iso, Gpp and For were reduced in TG mice. 
Increase of cAMP FS 
HW BAR Iso Gpp For Rest Iso 
Control 144±4 19±2 2.7±0.6 26±3 78±6 58±2 19±2 
TG 171±9" 34~3" 1.2±0.3" 17±1" 48±4* 52±2* 10±2" 
N = 9-12. Values are means ± SE. "p < 0.05 vs control. 
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Conclusion: NGF-induced CSH causes cardiac hypertrophy, EAR up- 
regulation, and depressed cardiac function. In addition to uncoupling of 
fl-receptor-G protein seen in young mice, defects exist in G-protein and 
adenylyl cyclase in older mice. Thus, chronic CSH in the absence of gen- 
eralized heightened sympathetic tone results in myocardial dysfunction and 
/~AR subsensitivity. 
2 :45 p.m. 
~-- ]  Cardiotrophin-I Induces Cardiomyocyte 
Hypertrophy Through Stimulation of the 
Renin-Angiotensin System 
Jun Fukuzawa, David E. Dostal, George W. Booz, Rachel A. Hunt, Anna 
M. Kempinski, Kenneth M. Baker. Henry Hood Research Program, Weis 
Center for Research, Penn State University, Danville PA, USA 
Background: Cardiotrophin-1 (CT-1), a newly isolated cytokine that activates 
the JAK/STAT pathway, is a potent inducer of cardiac hypertrophy. CT-1 
could therefore activate the St-domain, a STAT consensus DNA binding 
site in the promoter of the angiotensinogen (Ao) gene. Angiotenisin II, the 
effector peptide of the renin-angiotensin system (RAS) has been shown to 
induce cardiac hypertrophy via the type I (AT1), G-protein coupled receptor 
(GPCR). In this study, we tested the hypothesis that CT-1 indirectly induces 
cardiomyccyte hypertrophy by activation of a local RAS. 
Methods and Results: In primary cultured neonatal rat cardiac myocytes, 
STAT3 tyrosine phosphorylation (5 min) by CT-1 (1 nM) was confirmed by 
immunoblot analysis. Electrophoretic mobility shift and supershift assays 
showed CT-l-activated STAT3 from the nuclear extract bound St-domain (15 
min). Multiplex quantitative RT-PCR demonstrated CT-1 stimulated Ao mRNA 
(435.7%; 4 h exposure) and Ao reporter gene analysis displayed augmen- 
tation of promoter activation (90.8%) with CT-1 exposure. CT-1 accelerated 
the protein synthesis rate (15.9%; 3H-Leu, 24 h) and increased protein con- 
tent (27.7%) and the protein/DNA ratio (27.8%) at 72 h. These hypertrophic 
effects were significantly (p < 0.05) attenuated (61.6%, 66.5%, 66.8% less 
than CT-1 alone, respectively), by pretreating with 1 /zM of Iosartan, an AT1 
nonpeptide receptor antagonist. 
Conclusion: CT-1 induces cardiac hypertrophy that is partially mediated 
by RAS activation through the JAK/STAT pathway. These results suggest 
crosstalk between GPC and cytokine receptors, in the mediation of cardiac 
hypertrophy. 
3 :00  p.m. 
~~-1 Phosphatidylinositol 3-Kinase-Dependent Activation 
of Akt by the Endothelial Receptor Tyrosine Kinase 
Tie1 
Christopher D. Kontos, Kevin G. Peters. Duke University Medical Center, 
Durham, NC, USA 
The endothelial receptor tyrosine kinases Tie1 and Tie2 are required for 
normal embryonic vascular development and beth play roles in pathologic 
angiogenesis, yet their precise physiologic functions and signaling pathways 
remain poorly defined. We recently demonstrated that activation of Tie2 re- 
sults in downstream activation of phosphatidylinositol (PI) 3-kinase and Akt to 
mediate endothelial cell survival. Because of structural similarities between 
Tie1 and Tie2, we sought to determine whether Tie1 might also activate 
the PI 3-kinase/Akt signaling pathway. To evaluate signal transduction in the 
absence of an activating ligand for Tie1, we constructed a chimeric receptor 
consisting of the extracellular domain of c-fms, the colony stimulating factor-1 
(CSF-1) receptor, and the cytoplasmic kinase domain of Tie1 (f-Fie1). Stimu- 
lation of fTiel in NIH 3T3 fibroblasts with CSF-1 resulted in phosphorylation 
and activation of Akt. These effects were completely blocked by pretreatment 
with the specific PI 3-kinase inhibitor wortmannin, suggesting that Tie1 acti-. 
vates PI 3-kinase upstream of Akt. Activation of the PI 3-kinase/Akt pathway 
is likely mediated by binding of PI 3-kinase to tyrosine 1113 of Tie1, which 
matches the consensus binding motif for PI 3-kinase, These results are the 
first demonstration of a signaling pathway activated by Tie1 and suggest that 
one role of Tie1 in angiogenesis and vascular integrity might be to medi.. 
ate an endothelial cell survival signal. These findings could have important 
therapeutic implications for diseases in which angiogenesis plays a role. 
3 :15 p.m. 
[-~-3--~ Initiation of Hormone Replacement Therapy After 
Acute Myocardial Infarction is Associated With More 
Angina but Less Death/Mi During Follow-up 
Karen P. Alexander, L. Kristin Newby, Robert A. Harrington, Eric 
D, Paterson, Angelina C. Casas, Linda Jett, Victor Hassleblad, Chris 
M. O'Connor, Robert M Califf, Steven Khan, Valentin Fuster. Duke Clinical 
Research Institute, Duke Universi~ Durham NC, USA 
Background: Observational studies of hormone replacement herapy (HRT) 
for secondary prevention of CAD show a reduction in death/Ml. A recent 
randomized trial found no overall effect, but an association between the 
initiation of HRT and early cardiac events. 
Methods: We looked at the incidence of post-MI cardiac events at 1 year 
in 1,853 postmenopausal women enrolled in CARS in relation to their use 
of HRT. Patients were classified as prior/current HRT users (n = 411) if they 
took HRT before enrollment and on follow-up, new HRT users (n = 126) if 
they took HRT during follow-up only, and never HRT users (n = 1316) if they 
had no recorded use. 
Results: Of the 29% of postmenopausal women in CARS who were 
treated with HRT, 23% were new users. Patients treated with HRT were 
younger and more frequently Caucasian, college educated and hypercholes- 
terolemic than those not treated with HRT. After adjustment for baseline 
differences, new HRT use was associated with a higher relative risk of hos- 
pitalization for unstable angina, but a lower risk of death/MI compared with 
no use. 
Unstable Angina (RR) Death or MI (RR) 
Prior/current HRT 1,16 (p = 0.25) 0.75 (p = 0.14) 
New HRT 1.96 (p < 0.0001) 0.39 (p < 0.02) 
Conclusions: Consistent with prior observational studies, we found a 
lower overall risk of death/MI in HRT users. However, the higher incidence 
of unstable angina in new HRT users may support the notion of an early risk 
after initiation of HRT. 
ORAL  
Pathophysiology of Endothelial Function: 
Clinical 
Wednesday ,  March  10, 1999, 2:00 p .m. -3 :30  p.m. 
Mor ia l  Convent ion  Center ,  Room 210 
2:00 p.m. 
~9-~)-~-] Hyperglycemia Rapidly Suppresses Flow-Mediated 
Endothelium-Dependent Vasodilation of Brachial 
Artery 
Hiroaki Kawano, Takeshi Motoyama, Nobutaka Hirai, Tomohiro Sakamoto, 
Hirofumi Yasue. Division of Cardiology, Kumamoto Universi~ Kumamoto, 
Japan 
Background: Endothelial dysfunction has been shown to occur in patients 
with diabetes mellitus (DM), and chronic hyperglycemia is implicated as a 
cause of endothelial dysfunction. However, in many patients with Type 2 DM 
and in those with impaired glucose tolerance (IGT), fasting blood glucose 
may be within normal limits, and hyperglycemia occurred only post-prandially. 
The objective of this study was to examine whether endothelial dysfunction 
occurs when acute hyperglycemia is induced by oral glucose loading. 
Method: With ultrasound technique, we measured the flow-mediated en- 
dothelium-dependent vasodilation during an oral glucose tolerance test in 65 
subjects: [17 control subjects (Cont.), 24 patients with IGT, and 24 patients 
with Type 2 DM]. In addition, we measured the levels of thiobarbituric acid re- 
active substances (TBARS), as a marker of lipid peroxide, and nitrite/nitrate, 
as metabolites of nitric oxide. 
Results: Flow-mediated vasodilation decreased after glucose loading 
(Cont.: 7.53 ± 0.40, 4.24 ± 0,28 and 6.35 • 0.4, in fasting state, at 60 
min. and at 120 min., respectively, IGT: 6.33 -{- 0.51, 1.46 5: 0.44** and 
3.83 :E 0.43*, respectively, DM: 4.92 ± 0.46, 1.21 ± 0.30** and 1.25 ± 
0.23%**, respectively; *p < 0.01 vs. fasting, **p < 0.005 vs. fasting). TBARS 
concentration increased in parallel with plasma glucose level in each group 
(Cont.: 1.62 ± 0.13, 2.03 ± 0.12 and 1.80 • 0.12, respectively, IGT: 1.54 ± 
0.07, 2.52 ± 0.11"* and 1.98 ± 0.07", respectively, DM: 1.83 ± 0.07, 2.46 ± 
0.07** and 2.59 ± 0.08** nmol/ml, respectively; *p < 0.05 vs. fasting, **p < 
0.01 vs. fasting). Glucose loading did not change nitrite/nitrate concentration 
in any of the groups. 
Conclusion: Hyperglycemia in response to oral glucose loading rapidly 
suppresses endothelium-dependent vasedilation, probably through increased 
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production of oxygen-derived free radicals in humans. These findings strongly 
suggest that prolonged and repeated post-prandial hyperglycemia may play 
an important role in the development and progression of atherosclerosis. 
2:15 p.m. 
~-9~ Intracoronary 17/3-Estradiol Reduces Plasma 
Endothelin-1 Levels in Postmenopausal Women 
With Coronary Artery Disease 
Carolyn M. Webb, Mohammed Ghatei 1 , John G. McNeill, Peter Collins. 
ISCM at the National Heart & Lung Institute, and Royal Brompton & 
Harefield Hospital; ~ Hammersmith Hospital, London, UK 
Estrogen (E) beneficially affects coronary reactivity by an endothelium- 
dependent mechanism in postmenopausal women with coronary artery dis- 
ease, at least in part via nitric oxide. Postmenopausal E therapy is known 
to decrease systemic plasma levels of the potent vasoconstrictor endothelin 
(ET), however the effects of intracoronary E administration on ET production 
is unknown. We therefore investigated the effects of a 20 min intracore- 
nary 178-estradiol (E2; 60 ng/min) or vehicle control (VC; 0.001 ml 15% 
ethanol/rain) infusion on ET-1 levels in 20 postmenopausal women [14 pa- 
tients (mean ~ SEM; aged 65 5:2 years) and 6 controls (63 ± 3 years)] with 
coronary artery disease (CAD). Immediately before and after the E2 infusion, 
2-minute intracorenary infusions of substance P (10 and 25 pmol/ml; SP10 
and SP25 respectively) were given. A catheter was positioned the ostium of 
an irregular coronary artery for the infusions, and another into the coronary 
sinus for blood sampling. Blood sampling for analysis of plasma ET-t levels 
took place at baseline, then at 5 minute intervals during the infusion of E2. 
Plasma ET-1 levels in the coronary sinus were significantly decreased after 
20 min of E2 infusion compared to baseline (0.86 -~ 0.16 vs 1.12 5:0.18 
pmol/I, P = 0.05; coronary sinus vs baseline). In the control group there was 
no significant change in ET-1 levels after VC compared to baseline. Levels of 
coronary sinus ET-1 after SPt 0 and SP25 were decreased after the E2 infu- 
sion (1.29 5:0.17 vs 1.03 5:0.15 pmol/I (P = 0.04) and 1.3 5:0.15 vs 0.99 :E 
0.17 pmol/I (P = 0.024); SPt0 and SP25 before vs after E2 respectively). We 
conclude that intracoronary E may beneficially affect endothelium-dependent 
coronary reactivity in postmenopausal women with CAD at least in part via a 
decrease in ET-f production. 
2 :30 p.m. 
I~~ Circulating Vascular Endothelial Growth Factor 
(VEGF) Levels Are Elevated in Patients With 
Peripheral Vascular Disease and Increase Further 
After Exercise 
Robert J. Lederman, James J. Crowley, Laura H. Gaulden, Farrell 
O. Mendelsohn, Michael A. Thompson, Thomas E Zioncheck, Frederick 
R. Cobb, Harry R. Phillips, Richard S. Stack, Kevin G. Peters, Brian 
H. Annex. Duke University Medical Center, Durham, NC, USA 
Background: Angiogenic growth factors are emerging as treatments for 
peripheral vascular disease (PVD). We sought to determine how PVD and 
exercise-induced skeletal muscle ischemia affect endogenous VEGF levels. 
Methods: Nineteen subjects had ankle-brachial indices (ABI) recorded 
at baseline and after symptom-limited treadmill exercise. Thirteen pts with 
claudication had abnormal post-exercise ABI and constitute the ISCHEMIA 
group. Three healthy subjects, along with 3 pts with normal ABI before- and 
after exercise, constitute the CONTROL group. None had clinical or ECG ev- 
idence of myocardial ischemia. Blood was collected at baseline, immediately 
after exercise, and after one hour of recovery. VEGF was assayed before and 
after hepann-adsorption, using two different antibodies recognizing either all 
VEGF species or solely the 165kD homodimer, using ELISA (detection limit 
< 10 pg/mL) and Western blot. 
Results: Baseline plasma VEGF was higher in ISCHEMIA than in CON- 
TROL (80.4 5:38.2 vs 27.4 + 20.1, p < 0.01). VEGF levels increased 48% 
with exercise in ISCHEMIA but not in CONTROL and remained elevated after 
60 minutes. In two ISCHEMIA pts, exercise increased VEGF up to eight-fold. 
After heparin-adsorption, homodimeric 165 kD VEGF levels were similar in 
all groups and time-points, suggesting the 121 kD VEGF constitutes the 
circulating species. 
Conclusion: Plasma VEGF levels are elevated at rest in pts with PVD 
compared with healthy controls. Exercise acutely increases circulating VEGF 
in some pts with skeletal muscle ischemia but not in healthy controls. These 
results suggest a mechanism of benefit of exercise training for PVD, and may 
have implications for angiogenic drug therapy. 
2 :45 p.m. 
~-~ Long-Term Effects of the Ace Inhibitor, Ramipril, on 
Atherosclerosis in Patients With Coronary Heart 
Disease or Other Occlusive Arterial Disease. Final 
Results From the Part-2 Trial 
Stephen MacMahon, Norman Sharpe, Greg Gamble, Alison Clague, 
Colleen Ciobo, Susan Flett, Gillian Whalley, Hamish Hart, John Scott, 
Harvey White. Clinical Trials Research Unit, University of Auckland, New 
Zealand 
Background: In animal studies, ACE inhibitors have been shown to retard 
the development of atherosclerosis. To investigate the effects of these agents 
on the progression of atherosclerosis in man, we randomised 617 patients 
with coronary, cerebral or peripheral arterial disease to receive ramipril (5-10 
mg daily) or placebo. 
Methods: Treatment and follow-up was scheduled to continue for a min- 
imum of 4 years. Ultrasound examinations were performed at baseline, 2 
years and 4 years. B-mode ultrasound was used to measure the common 
carotid artery (CCA) wall and to characterize plaques in the CCA and internal 
carotid artery. M-mode echocardiography was used to measure left ventric- 
ular mass. Deaths and other serious adverse events were documented over 
an average of 5 years. 
Results: Most patients had a history of myocardial infarction (42%) and/or 
angina (61%). The average entry blood pressure was 146/80 mmHg, and 
this was reduced by 9/4 mmHg in the ramipril group compared to the placebo 
group. About three-quarters of all patients were still on randomised therapy 
after 4 years. At the 2 and 4 year ultrasound examinations, there were no 
differences between randomized groups in the thickness of the CCA wall (2P 
= 0.6) or in the mean carotid plaque score (2P= 0.9). However, left ventricular 
mass was reduced by about 10g (2P= 0.038) in the ramipdl group compared 
to the placebo group. There were also somewhat fewer cardiovascular deaths 
in the ramipril group (relative risk: 0.43, 95% confidence interval 0.18-0.99). 
Conclusions: These results are consistent with the thesis that ACE 
inhibitors have little or no effect on atherosclerosis, but reduce left ventdcular 
hypertrophy and the risk of death from cardiovascular disease. 
3 :00 p.m. 
~ Vasoconstriction in Primary Pulmonary 
Hypertension by Potassium Channel Blockade 
Ernst Wellnhofer, Angelika von Stammer, Rail Ewerf 1 , Christian Opitz 2, 
Eckart Fleck, Franz X. Kleber 2. DepL oflnL Med./CardioL, Campus 
Virchow, CharitY, HU & DHZB; I Dept. of InL Med, Unfallkrankenhaus 
Berlin; 2 DepL of Cardiothoracic &Vasc. Surg. DHZB, Berlin, Germany 
Objective: Assessment of the role of endothelium-dependent hyperpolariz- 
ing factor (EDHF) opposing the pulmonary vasoconstriction in primary pul- 
monary hypertension (PPH) was the goal of the study. EDHF acts via Ca ++ 
dependent K + channels, which are blocked by miconazol. 
Methods: In 7 patients with severe primary pulmonary hypertension 
(mean pulmonary artery pressure 54 ± 9 mmHg; pulmonary vascular resis- 
tance 17 5:7 mmHg f 1 min) local vasoreactMty was tested in a pulmonary 
branch adery by infusion of 10 s M acetylcholine (ACH) at baseline and 
after blockade of K + channels (K ÷ blockade) using 10 s M miconazol. Aver- 
age peak blood flow-velocity (APV) was determined using a 0.014" Doppler 
guidewire. Local diameters were controlled by intravascular ultrasound. 
Results: Significant changes of systemic hemodynamics could be avoided 
by local testing. Local diameter changes could be ruled out. A reduction of 
local flow velocity (8 cm/s to 4 cm/s, p < 0.05) was associated with K + 
blockade. A similar increase in flow velocity was observed following infusion 
of ACH before and after K + blockade. 
t ~M 
Conclusions: Hyperpolarization via Ca ++ dependent K ÷ channels (prob- 
ably by EDHF) is involved in maintaining pulmonary vascular resistance 
in PPH. Acetylcholine-mediated flow increase was not compromised by 
K ÷ blockade suggesting that non-EDHF mediated endothelial relaxation 
(PGI2/EDRF) is operative as an independent mechanism in PPH. 
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3:15 p.m. 
-9 - -~ Tamoxifen's  Versus Estrogen's Effect on the 
Microvasculature of Postmenopausal Women 
Dadene L. Eyster, Joanne Mortimer, Diana Knapp, Benico Barzilai, Linda 
R. Peterson. Washington Universi~ SL Louis, MO, USA 
Background: Tamoxifen has been associated with a decrease in cardio- 
vascular events in women. Although it is primarily an estrogen receptor 
antagonist, it does have some estrogen-like effects. Thus, its effect on the 
microvascular is unpredictable. We therefore used laser Doppler fluximetry 
to assess the effects on tamoxiten on microvascular flow and compared it 
with that in patients on estrogen and patients on no drug. 
Methods: We studied 49 nonsmoking, postmenopausal women who were 
on tamoxifen, estrogen, or no drug. A laser Doppler device was used 1o 
measure forearm capillary blood flow velocity before (BASE) and after relief 
of 2 minutes of artedal occlusion, i.e., during hyperemia (PK.HYP). Forearm 
capillary blood flow velocity (mean ± SE) in flux units were as follows: 
N BASE PK. H YP 
NO DRUG 15 14.4 ± 2.3 *59.7 ± 4.6 
TAMOXIFEN 16 17.3 ± 2.3 72.0 ± 5.2 
ESTROGEN 18 17.6 :E 3.2 "87.3 ± 4.6 
Results: The PK.HYP values in women on tamoxifen were less than 
those in women on estrogen and more than those in women on neither drug 
('p < 0.006 by ANOVA). Multiple regression analysis showed that hormonal 
status was an independent predictor of PK.HYP. 
Conclusion: Tamoxifen is associated with an improved hyperemic re- 
sponse of the microvasculature, although this improvement is not as great 
as that in women on ERT. 
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~-- ]  C-Reactive Protein and Antibody Cytomegalovirus 
Levels Predict Mortality in Patients With 
Angiographically Defined Coronary Artery Disease 
Joseph B. Muhlestein, Benjamin D. Home, John F. Cadquist, Troy 
E. Madsen, Tami L. Bair, Marlene J. Egger, Megan Morris, Chad 
R. Peterson, Jessica Habashi, Jeffrey L. Anderson. LDS Hospital and 
University of Utah, Salt Lake Ci~ Utah, USA 
Background: The role of inflammation in coronary artery disease (CAD) is 
being increasingly recognized. Markers of inflammation (e.g. c-reactive pro- 
tein [CRP]) and infection (e.g. antibodies to Chlamydia pneumoniae [C pn], 
cytomegalovirus [CMV], and Helicobacter pylori [H pyl]) have been proposed 
as risk factors for CAD, but this association requires further evaluation. 
Methods: We prospectively tested whether serum CRP and levels of 
antibodies to Cpn (IgG, IgA), CMV (IgG), and Hpyl(IgG), collected at the time 
of angiography, are predictors of subsequent mortality in 975 consecutive 
consenting patients with angiographically demonstrated CAD (stenosis >_ 
70%). IgG or IgA antibody levels were determined by ELISA tests and 
CRP levels by a high-sensitivity FPIA test, quantified, and then divided into 
quartiles prior to analysis. Patients were followed-up (f/u) to death or to 8/1/98 
(mean, 2.7 years [y], maximum, 4.0 y f/u). 
Results: Patients averaged 65 ± 11 y of age; 77% were mate; and 105 
died during f/u. Of the 5 inflammatory/infectious factors, univariate predictors 
of mortality included CRP (hazard ratio [HR]/quartile [Q] = 1.37, p = 0.0005) 
and CMV (HPJQ = 1.41, p = 0.0002) (Cox). HR for a baseline value in 
the 4 th vs. the I st quartile was 3.79 (p = 0.0001) for CRP and 3.12 (p 
= 0.0007) for CMV. In multiple vadable Cox regression, controlling for 10 
clinical and 9 laboratory variables (including age, sex, EF, and the other 
inflammatory/infectious markers), independent predictive value for mortality 
was retained for both CRP (HR/Q = 1.38, p = 0.005) and CMV (HR/Q = 1.24, 
p = 0.05), as well as age (HP,/y = 1.07, p < 0.0001), EF (HR/% = 0.97, p < 
0.0001), and diabetes (HR = 1.86, p = 0.02). 
Conclusion: A single CRP, drawn at diagnostic angiography, is inde- 
pendently predictive of future mortality in patients with CAD; in addition, 
elevated anti-CMV, but not other infectious serologies, adds predictive value 
and should be further studied. 
2 :15 p.m. 
-9 -0 -~ Increased Level of Advanced Oxidation Protein 
Products in Patients With Coronary Artery Disease 
Hideaki Kaneda, Junich Taguchi, Yukihiro Kuwada, Misako Hangaishi, 
Toru Aizawa, Ken Ogasawara 1, Tadanori Aizawa 1 , Minoru Ohno. University 
of Tokyo, Tokyo; ~ Cardiovascular Institute, Tokyo, Japan 
Background: it has recently been reported that advanced oxidation protein 
products (AOPPs) are proteins produced by oxidative stress and are present 
at high levels in the plasma of uremic patients. Thus, it is speculated that 
AOPPs are reliable indicators of oxidant-mediated protein damages. Since 
oxidative stress might play an important role in the pathogenesis of athero- 
sclerosis, we measured AOPP levels in the plasma of patients with coronary 
heart disease. 
Methods: A total of 406 patients who underwent coronary angiography 
were enrolled. AOPP levels were determined by the Witko-Sarsat V method. 
The plasma was diluted by adding PBS, and the OD at 340 nm was measured 
after adding potassium ionide and acetic acid. Coronary artery disease (CAD) 
was defined as having one or more significant coronary artery stenoses (more 
than 50% luminal obstruction). 
Result: AOPP levels were significantly higher in the plasma of patients 
with CAD (n = 266) compared with those of patients without CAD (n = 140) 
(OD 0.917 ± 0.034 vs. 0.71 ± 0.036 p < 0.0005). Logistic regression analysis 
revealed that male gender, advanced age, habit of smoking, high triglycedde 
and low HDL-cholesterol levels contributed 1o AOPP levels. Oxidation of 
albumin or plasma by hypechlorous acid increased OD at 340 nm. Using 
size-exclusion chromatography, a high activity of AOPPs was detected at 
around 200 kD in plasma from both CAD and uremic patients, but not from 
healthy young controls. 
Conclusion: AOPP levels are associated with CAD. Oxidative stress 
could play an important role in the pathogenesis and progression of CAD. 
2:30 p.m. 
-0 -~ Molsidomine Improves Dysfunction Endothelial in 
Patients With Coronary Heart Disease 
Laurent Bethassen, Claudine Carville, Said Sediame, 
Jean-Luc Dubois-Rande, Serge Adnot. HSpital Henri Mondor, Cr~.teil, 
France 
Background: Flow-dependent vasodilation of human blood vessels is me- 
diated by endogenously produced nitric oxide, and is essential to adaptation 
and regulation of peripheral blood flow. This phenomenon is impaired in 
many pathological states, especially in coronary heart disease. We ques- 
tioned in this study whether molsidomine, as an exogenous NO donor, could 
restore endothelial dysfunction in coronary heart disease, in addition to its 
vasodilator effect. 
Methods and Results: We used computerized B-mode ultrasonography 
to measure systolic and diastolic diameters of the humeral artery before and 
after hyperemia reaction in 12 healthy subjects and 18 patients with coronary 
heart disease. Patients received placebo or molsidomine in a randomized 
double-blind assay. Before any treatment, patients with coronary heart dis- 
ease showed an impairment of their FDV as compared to controls (3.2 ± 0.5% 
vs 5.27 ± 0.4% p = 0.01). In the patients group, after a 48-hour treatment 
with 12 mg molsidomine a day, 4 mg molsidomine increased significantly 
diastolic diameter (0.5 ± 0.67 mm in the molsidomine group vs -0.06 ± 0.33 
mm in the placebo group, p = 0.04). Flow-dependant vasodilation, calculated 
as the percentage of increase of diastolic arterial diameter before and after 
hyperemia, was significantly higher 2 hours after the first 4 mg molsidomine 
(4.58 ± 0.68% in patient vs 2.88 ± 0.42% in controls, p = 0.04). 
Conclusions: Exogenous NO donor molsidomine increases flow-medi- 
ated vasodilation in addition to its basal vasodilator effect. Thus, molsidomine 
increases the biodisponibility of endogenous NO. Restoration of endothelial 
dysfunction by molsidomine in patients with CHD may contribute in lowering 
thrombosis, cell adhesion to the endothelium, vasodilation and atherosclero- 
sis evolution. 
2:45 p.m. 
[-90-0-~ Anticardiolipin Antibodies Are Independent 
Predictors of Survival in Patients With Chronic 
Peripheral Arterial Disease 
Francois Puisieux, Pascal de Groote, Jean-Paul Beregi, Eric Masy, 
Alain Millaire, Philippe Dewailly, G~rard Ducloux, Jean-Marc Lablanche. 
University of Lille, France 
Background: Antiphospholipid antibodies (Apl) predict survival in patients 
(pts) with coronary or cerebrovascular atherosclerosis. Few studies have 
analyzed the prognostic information of Apl in pts with chronic peripheral 
arterial disease (PAD). 
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Methods: We prospectively determined Apl (lupus anticoagulant, anticar- 
diolipin antibodies (AcA) IgG and IgM) in 232 pts with PAD (209 men, age: 59 
4- 11 years). We excluded all the pts with infectious diseases, active cancer, 
acute coronary syndrome and inflammatory disorders. 
Results: Apl were present in 46 pts (19.2%): lupus anticoagulant in 6, 
AcAIgG in 35, AcAIgM in 8 and 1 pt had both lupus anticoagulant and 
AcAIgG. Risk factors were similar in pts with or without Apl. During a mean 
follow-up period of 31.4 + 19 months, there were 58 deaths, of whom 23 
were cardiac related and 3 pts were lost to follow-up. The multivariate Cox 
analysis selected 3 independent predictors of survival- history of cancer (p 
= 0.00001), age (p = 0.001) and AcAIgG (p = 0.018). History of cancer (p 
= 0.0002), age (p = 0.04) and ACAIgG (p = 0.005) were also independent 
predictors of cardiac survival. In a second analysis, we excluded 10 pts 
with an history of cancer (4 had Apl). There were 51 deaths, of whom 19 
were cardiac related. The Cox analysis selected 3 independent predictors of 
survival: age (p = 0.008), Leriche classification (p = 0.02) and AcAIgG (p = 
0.03). The only independent predictor of cardiac survival was AcAIgG (p = 
o.0o2). 
conclusion: In patients with PAD, presence of AcAIgG is an independent 
predictor of survival and of cardiac survival. AcAIgG could play a role in the 
progression of atherosclerosis. 
3 :00 p.m. 
~'~ Post-Prandial Lipaemia Is Associated With 
Augmented Free Radical Release and Endothelial 
Dysfunction in Diabetics Compared With Healthy 
Controls 
R.A. Anderson, L.M. Evans, G.R. Ellis, S.K. Jackson, M.J. Lewis, A. Rees, 
M.P. Frenneaux. Cardiovascular Sciences Research Group, University of 
Wales College of Medicine, Heath Park, Cardiff, UK 
Background: Post-prandial lipaemia (PPL) diminishes flow-mediated arte- 
rial dilatation and by implication induces endothelial dysfunction (ED). PPL 
also predicts angiographic coronary artery disease (CAD) progression and 
severity. Non-insulin dependent diabetes (NIDDM) results in both abnormal 
PPL and accelerated atherosclerosis. We therefore studied the relationship 
of PPL, free radical (FR) release and ED in healthy and diabetic subjects. 
Methods: 12 NIDDM subjects with moderate glycaemic control (Av. 
HbAlc 8.4) and no overt vascular disease were studied and compared 
with 12 age and sex-matched healthy controls. All subjects had an overnight 
fast and received a standard fat meal. Endothelial function (EF), lipid profiles, 
and venous FR's were measured in the fasting and post-prandial phase (at 
4 hours). Flow mediated dilatation (FMD) of the brachial artery, was used as 
a measure of EF. Lipid-derived FR levels were measured by electron para- 
magnetic resonance (EPR) spectroscopy; venous samples were taken into 
preprepared spin trap, <x-phenyl N-ted butyl nitrone (PBN) containing tubes 
and analysed immediately for FR levels. The PBN adduct was analysed 
using a Varian Spectrometer, results expressed in arbitrary units. 
Results: There was a significant increase in PP venous FR in both groups 
[(mean • S.D) 0 to 4 hours, NIDDM vs. controls; 0.22 ± 0.04 to 0.45 ± 0.13 
vs 0.24 • 0.01 to 0.33 ± 0.02 p < 0.05]. However the increase in NIDDM 
patients was significantly greater than controls p < 0.05. This was mirrored 
by a similar pattern of PP rise in TG levels in NIDDM (in mmols/I) [3.5 :E 2.1 
to 9.1 ± 8.2] compared to controls [1.3 ~ 0.5 to 2.2 ~: 0.7] p < 0.05. The 
% deterioration in FMD was greater in NIDDM than controls 2.65 ± 0.96 vs 
1.45 ± 1 (45%) compared to 6.26 :E 1.3 to 4.77 ± 1.4 (23%). 
Conclusion: PPL is associated with augmented FR formation and ED in 
NIDDM compared to controls. This is associated with a greater rise in TG 
levels implicating TG-rich lipoproteins in the mechanism of ED via increased 
oxidative stress. It may in part explain in part the widespread CAD disease 
seen in NIDDM. 
3 :15 p.m. 
~ Mutation in the Promoter Region of 
Thrombomodulin Gene Is an Independent Risk 
Factor of Coronary Artery Disease 
Yi-Heng Li, Jyh-Hong Chen, Hua-Lin Wu, Guey-Yueh Shi, Ting-Hsing Chao, 
Wei-Chuan Tsai, Liang-Miin Tsai, How-Ran Guo, Wen-Shiann Wu, 
Zhih-Chemg Chert. National Cheng Kung University Medical College and 
Hospital, Tainan; Chi-Mei Foundation Hospital, Tainan, Taiwan, China 
Background: Thrombomodulin (TM) is an important endothelial anticoagu- 
lant protein. Thrombin-bound TM activates protein C, which inhibits thrombin 
generation by degrading factor Va and Villa. The aim of the study was to 
investigate the frequency of -33G~A mutation in the TM promoter egion in 
patients (pts) with coronary artery disease (CAD) and to determine whether 
this mutation contribute a risk for CAD or myocardial infarction (MI). 
Methods: We analyzed 249 consecutive pts (mean age 63 years; 75% 
male) with CAD proved by angiography and 141 control pts (mean age 
55 years; 57% male) without clinical evidence of CAD. The TM promoter 
mutation was screened by PCR, single strand conformation polymorphism 
and direct sequencing of PCR products. 
Results: The frequency of -33G--,A mutation (G/A + NA) was signifi- 
cantly higher in the CAD group than in the control group (25.7% vs 16.3%, 
p = 0.032, OR = 1.78). Multiple logistic regression analysis showed that this 
mutation was an independent risk factor (p = 0.021, OR = 2.07) for CAD, 
as was age (p < 0.001, OR = 1.05), gender (p = 0.005, OR = 0.40), hy- 
pertension (p < 0.001, OR = 0.34) and diabetes mellitus (p = 0.051, OR = 
0.55). However, there was no difference in the mutation frequency between 
pts with or without a history of MI (20.9% vs 23.1%, p = 0.61). Nevertheless, 
in younger pts (age _< 50 years), this mutation occurred more frequently in 
pts with MI (36.0% vs 13.6%, p = 0.041, OR = 3.58). The mutation is also 
the only independent risk factor (p = 0.031, OR = 0.27) for MI in younger pts 
when compared with other conventional risk factors. 
Conclusions: Our observations suggest that there is a significant as- 
sociation of the -33G-*A mutation in TM promoter region with coronary 
atherosclerosis. This mutation is also important in the pathogenesis of MI in 
younger pts. 
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~ Anti-Adhesion Monoclonal Antibodies Against ICAM 
Inhibit  Arteriogenesis 
Ivo Buschmann, Imo Hoefer, Mathias Heil, Wolfgang Schaper. 
Max-Planck-lnstitute, Bad Nauheim, Germany 
In previous studies we have shown that circulating monocytes adhere to 
shear stress activated endothelium of preexisting collateral arteries following 
occlusion of coronary or femoral arteries in dogs or rabbits. This is an impor- 
tant initial step during arteriogenesis (collateral artery growth). We now tested 
the hypothesis that inhibition of monocyte adhesion by monoclonal antibod- 
ies against ICAM, directly influences arteriogenesis. 18 New Zealand white 
rabbits were randomly assigned to receive either PBS, MCP- 1 (3 #g) plus 
ICAM-MAb (4 rag) or MCP-1 (3/~g) alone locally via an osmotic mini-pump 
into the collateral circulation of the hindlimb. The right femoral artery was can- 
nulated with a catheter, which itself was connected to the minipump (infusion 
rate 10 #LJh). After 7 days of infusion the animals were again anaesthetized 
and a pump-driven shunt between the carotid artery and the abdominal aortic 
artery was installed. At 6 different perfusion pressures (30--90 mmHg) differ- 
ently labelled microspheres were injected. Peripheral perfusion pressures, 
and total and regional flows (FACS-analysis of fluorescent microspheres) 
were measured. 
Results: Collateral Conductance: PBS = 5, MCP-1 plus ICAM-MAb = 9 vs 
MCP-1 alone = 36 ml/min/100 mmHg. The number of visible collateral arteries 
in stereoscopic postmorten images also revealed a significant difference: 
(PBS: 12; MCP-I: 36, MCP-1 plus ICAM-MAb: 14). 
Conclusion: This is the first report about inhibition of collateral artery 
growth in vivo by interference with monocyte-endothelial interaction, con- 
firming the central role of monocytes during arteriogenesis. 
4 :15 p.m. 
~ Effects of Estrogen vs on Droloxi fene Adhesion 
Molecules and Cytokines in Healthy 
Poetmenopausal Women 
David M. Herdngton, K. Bridget Brosnihan. Wake Forest University School 
of Medicine, Winston-Salem, NC; David MacLean, Pfizer, Inc., Groton, CT, 
USA 
Background: Adhesion molecules and inflammatory cytokines mediate leu- 
kocyte-vessel wall interactions that contribute to the development of athero- 
sclerosis. Preliminary data suggest that estrogen use may result in lower 
levels of circulating adhesion molecules. We sought to compare the effects 
of conjugated equine estrogen (E) and a new selective estrogen-receptor 
modulator, droloxifene (D), on vascular inflammation by measuring plasma 
levels of the soluble adhesion molecules ICAM-1, VCAM-1, E-selectin, and 
MCP-1 as well as the cytokines IL-6 and IL-1/~. 
Methods: We obtained plasma samples from 24 healthy postmenopausal 
women before and after 6 wk of hormone treatment with either E 0.625 mg/d 
or D 60 rag/d, with a 4-wk washout period between treatments. 
JAC'E. ~rwary  'D~--Y~ A%%'7'~4C'~% -'~ypenen'd]on,'~ascd~arTJzsease, an6~rreverlflon ~3J"}~ 
Resu l ts :  Both E and D resulted in a 11% decrease in circulating levels 
(pg/ml) of E-selectin compared to baseline (E: 47.3 ± 18.5 vs 42.3 ± 21.2; 
D: 46.3 ± 17.4 vs 41.2 4- 18.6; p < 0.05 for both). E also resulted in a 8% 
decrease in VCAM-1 (pg/ml) (487.3 ± 156.9 vs 446.7 ± 115.2; p = 0.01), 
wh~reas'b was a~st~5~a'mb-~ilt~ a h"~.'~cmas~,)~$,3 .~ ~-3~.~ ws~'3bT~ 
183.1, p = 0.009). E had these favorable effects despite a 67% increase in 
11_-6 (pg/ml) (0.6 ~ 0.5 vs 0.9 ± 0.6, p < 0.001). 
Conclusion: 6 wk of estrogen replacement resulted in lower circulating 
irene may share E's effects on E-selectin but not VCAM-1 or 11_-6. The mixture 
of pro- and anti-inflammatory effects of these steroid hormones may play an 
important role in the pathogenesis or prevention of heart disease in women. 
4 :30 p.m. 
~-~]  Bradykinin is a Potent Dose-Dependent Stimulus for 
Release of Tissue Plasminogen Activator (tPA) in the 
Human Forearm Circulation 
Catherine Labinjoh ~ , David E. Newby 2, Nicholas A. Boon 2 , David J. Webb 1 . 
University of Edinburgh; t Western General Hospital; 2 Royal Infirmary of 
Edinburgh, Edinburgh, UK 
Background: The use of angiotensin-converting enzyme (ACE) inhibitors in 
ischaemic heart disease is known to be associated with fewer coronary throm- 
botic evenls. The mechanism may involve enhanced bradykinin-mediafed 
tPA release. We examined the effects of intra-arterial infusion of bradykinin 
on blood flow, fibrinolysis and coagulation in the human forearm circulation. 
Methods: Bradykinin at 10-3000 pmol/min was infused into the brachial 
artery of the non-dominant forearm in 8 healthy non-smokers. Blood flow 
msas~rements, ~s~o4] venous ~oc~usk~ p(et~ysmo~ra~y, a~ vex~us sam- 
ples for tPA, plasminogeo activator inhibitor (PAl) and yon Wiliebrand factor 
(vWF) were obtained from both forearms during saline and bradykinin infu- 
sions. 
Results: Bradykinin caused a dose-dependent local increase in forearm 
blood flow, tPA antigen and tPA activity (p < 0.01 for all) in the infused arm 
without changes in PAl-1 or vWE 
"~"  15o- 
~ ---o-- tPA activity 
~ ...~ _ 
30 300 3000 
Bradykinin pmol/min 
Conc lus ions :  Bradykinin causes a substantial dose-dependent release 
of tPA in the forearm vascular bed. This has potentially important implications 
for the understanding of the mechanism of action of ACE inhibitors and their 
role in ischaemic heart disease. 
4 :45 p.m. 
~ Hygertr(~Iyeer(dem(a (s ~ssoc(ated W(th an 
Enhanced Resistance to Oxidative Stress 
Fdls H. de Man, Hans M. Pnncen, Wire van Du'~envoorde, Leny HoBaar, 
Augustinus H. Smelt, Jan A. Gevers Leuven, Arnoud van der Laarse. 
Ttne Nethedands 
Background: Hypertnglyceridemia (HTG) is an independent cardiovascular 
resistance to in vitro oxidation and may contribute to the atherogenesis in 
HTG. Thfs study was designed to study the suscept~bifity of VLOL and LOL 
to oxidation in HTG and evaluate the affects of tdglyceride-lowedng therapy. 
Methods: Patients with endogenous HTG (n = 18) were randomized to 
rece(ve ir~ a doub~e-bl(nd cross-over fast~io~ 400 mg bezafibrate ooce daily, 
err dmceioo ~ror % weeks. 'in a0dff~on, age-an0 sex-ma~n~0 cortlrd~s ".(n =~Z~} 
were included. Cu2*-induced oxidation of VLDL and LDL were assessed by 
sehaJ spec~re, D'ne'mmshr,j d~'tne cofi)~Da'm~ d~e~es '~c,n'h'~. 
Controls HTG-placebo HTG-bezafibrate 
VLDL  lag time 143 4- 30 ~ 226 4- 43 195 4- 43* 
VLDL  prop. rate 12.0 4- 3,1 # 10.0 4- 3.0 9,7 Pc 3.5 
L[DL, ta9 time 89 4- 7 `# 108 4- 17 95 4- 9* 
LDL, prop. rate 12.t 4- 1.1 ~ 9.5 4- 1.8 9.9 4- 1,9 
# p < 0.05 vs HTG patients on placebo; *p < 0.05 vs placebo 
Results: At baseline, the HTG patients had 154old higher tr~yceddes 
and small dense LDL particles (23.4 vs 25.2 nm, p < 0.001) compared to 
controls. Plasma lipids and LDL size improved upon bezafibrate. As shown 
in the table, the lag times in the patient group were higher than in the control 
Concluelon: Small dense LDL is not associated with low resistance to 
oxidative stress in HTG. Moreover, VLDL and LDL of HTG patients show 
an enhanced resistance to oxidative stress that is partially reversed upon 
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[ - -~-~ Long-Term Estrogen Therapy Improves 
Acetylcholine-lnduced Nitric-Oxide Mediated 
Vasodilation but not Matabolic-lnduced Vasodilation 
~n the Skeletal Resistance Vessels of B~ological 
Males 
Gishel New, Stephen J. Duffy, Richard W. Harper, lan T. Meredith. Heart 
and Chest Research Centre, Monash University; Monash Medical Centre, 
Melbourne, Australia 
Long-term estrogen ~E) enhances acetylchotine ~ACh)-induced endo~heliu~rn- 
dependent vasodilalion in male to female transsexuals (TX). Whether this is 
mediated via nitric-oxide (NO) mechanisms and whether E has an effect on 
metabofic-induced vasodilation in biological ma~es is unclear. Using venous 
occlusion plethysmography, we assessed ACh-induced endothelium-depen- 
dent forearm blood flow (FBF) and functional hyperemic blood flow (FHBF, 
metabolic vasodiietion) alter isotonic forearm exercise, before and alter the 
inhibition of NO with the NO synthase inhibitor NG-monomethyI-L-arginine 
(L-NMMA: 2 mg!min) in 15 TX (being prescribed E) with 14 age-matched 
healthy males (M). Basal FBF was similar between the two qroups ~p = NS) 
a significant upward and leftward shift in the dose-response relationship to 
ACh in the TX compared with M (20.2 ± 2.5 vs 12.2 ± 2.1 ml/min/100 ml at 
the highest dose, TX vs M, p < 0.01). Alter the infusion of L-NMMA however, 
the difference in FBF responses between the 2 groups to ACh was abolished 
(14.2 ± 2.0 vs 9.2 ± 2.2 mr/rain/tO0 mt at the highest dose, TX vs M, p = 
NS). There were no differences in FHBF responses between the two groups 
(peak FHBF; 2t.1 ± 2.9 vs 20.8 ± 2.0 mt/min/100 ml, TX vs M, p = NS). 
L-NMMA significantly reduced peak FHBF (p < 0.01) and the volume repaid 
at 1 (p = 0.0001) and 5 minutes (p < 0.0001), however, the reductions were 
similar for the two groups (peak FHBF; 18.2 ± 2.7 vs 16.6 ± 1.9 ml/min/100 
ml, TX vs M, p = NS). 
Conclusion: These data suggest that although E therapy may improve 
ACh-induced NO-mediated endothelium-dependent vasodilation, E does not 
appear to effect metabolic vasodilation in the skeletal resistance vessels of 
4 :15 p.m. 
,I 912-2J  Vascular Effects of  Oral L-Arginine Therapy in 
T-.altmn~s'IWttn t,oronary ~f tery -d~se  
Amen Blum, William H. Schenke, Londa Hathaway, Rita Mincemoyer, Julio 
A. Panza, Richard O. Cannon II1. NHLBI, NIH, Bethesda, MD, USA 
Backgro~fTd: Ac~.Re ?ePLtgtofl o? L-arg'rnine, ['he sobs~ra~e h3r rft~(tc oxtde {~O~ 
synthesis, acutely improves endothelium-dependent vasomotor esponsive- 
ness in patients with coronary artery disease (CAD). 
Methods: To determine whether oral L-arginine therapy also has NO- 
nitrogen oxides (chemiluminescence technique) on a nitrate-restdcted iet 
tion by ultrasound following forearm ischemia (as an index of NO bioactivity), 
and soluble cell adhesion molecule levels (as an index of NO-regulated 
inflammatory markers) in 18 CAD patients (17 men) on conventional medi- 
cal management (18-aspirin, 12-beta blockers, 11-statins, 5-calcium channel 
blockers, 4-~CE inhibitors, 2-chronic nitrates~. Patients were randor~y as- 
siqn¢~l to L-aKjinine 9 ~n or placebo daily for 1 month, with crossover to the 
Results: Compared with placebo, L-arginine therapy" increased serum 
L-arginine levels (mean ± SD: 70.6 ± 15.2 vs. 121.7 ± 49.4 pmol/L, P < 
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0.001). However, there were no significant differences in serum nitrogen 
oxides (16.7 ± 4.7 vs 18.3 ± 8.8/~mol/L, P = 0.28), flow-mediated dilation 
(11.4 ± 5.5 vs. 10.4 :l: 4.3%, P = 0.54), or serum levels of E-selectin (46.2 
± 15.6 vs. 47.6 ± 15.2 ng/mL, P = 0.42), P-selectin (102 ± 28 vs. 106 ± 27 
ng/mL, P = 0.26), intercellular adhesion molecule-1 (253 ± 53 vs. 252 ± 55 
ng/mL, P = 0.98), and vascular cell adhesion molecule-1 (613 ± 134 vs. 597 
± 113 ng/mL, P = 0.26). 
Conclusion: Oral L-arginine therapy does not improve NO-dependent 
vascular function in chronic stable CAD patients on conventional medical 
management, and accordingly is likely not of atheroprotective benefit to this 
group of patients. 
4 :30  p .m.  
I - ~  Relation Between Compensatory Dilatat ion 
(Coronary Artery Remodelling) and Stenosis in 
Human Native Coronary Atherosclerosis 
Amanda M. Varnava, Michael J. Davies. St George's Hospital Medical 
School, London, UK 
Background: As plaques evolve in human coronary arteries the vessel 
wall increases its external diameter to accommodate the plaque without a 
reduction in lumen size. Failure of this compensatory change may contribute 
to stenosis. Human coronary arteries perfused post mortem at systemic 
pressure provide an ideal method for studying the relation between the 
degree of remodelling of the artery wall and stenosis. 
Methods: In 12 subjects with IHD less than 68 years in age (5 M, 7 F) 
90 AHA type V plaques were studied. Lumen area and cross sectional area 
of the vessel (XSA) were measured at the target site and at a proximal and 
distal reference site (judged to be free of plaque formation on histology) by 
quantitative microscopy. The degree of diameter stenosis was calculated and 
the degree of remodelling of the artery calculated as a percentage change in 
XSA relative to the mean of the proximal and distal reference segment. 
Results: The degree of compensatory dilatation ranged from -40% to 
+90%. 21% of lesions showed negative remodelling ie, a reduction of the 
XSA of the artery relative to normal, 24% of lesions showed minimal positive 
remodelling (0-9%), 40% of lesions showed positive remodelling of 10-39%, 
and 12% of tesions more than +40% remodelling. 10 patients showed a 
mixture of positive and negative remodelling, 3 showed all plaques with 
positive remodelling. The relation between the degree of stenosis and the 
mean degree of remodelling is shown. 
Degree of stenosis Mean % Remodelling (SEM) 
>50% 1.8 (8.3) P = 0.01 
30-49% 9.8 (4.4) P = 0.01 
1-29% 18.7 (2.9) P = 0.01 
0% 17.8 (4.9) P = 0.01 
Conclusions: A failure of compensatory dilatation (negative or minimal 
positive change) is a major factor in the generation of high grade stenosis. 
Remodelling of the artery wall is plaque not patient specific. 
4 :45  p .m.  
I -~-~ Vascular Responsiveness to Angiotensin II is 
Correlated With LDL-Cholesterol in 
Normocholesterolemic Humans 
S. John, A. Klingbeil, M.P. Schlaich, J. Jacobi, R.E. Schmieder. Department 
of Medicine IV, University Erlangen-NOmberg, Germany 
Background: Angiotensin (Ang) AT1 receptor expression is supposed to 
be upregulated by hypemholesterolemia. We investigated, whether vascular 
responsiveness to Ang II-infusion, as an indicator of ATl-receptor density, 
depends on serum LDL-cholesterol levels in humans even in a "normocholes- 
terolemic" population, and whether there are differences in these responses 
between the renal and systemic vasculature. 
Methods: Changes in blood pressure (BP), aldosteron secretion and 
renal I plasma flow to Ang II infusion (3.0 ng/kg/min) were investigated in 
103 normocholesterolemic (LDL-C < 160 mg/dl), normotensive or mildly 
hypertensive young white men (26 ± 3 yrs, 24 hr-BP: 128 ± 10/75 ± 7 
mmHg) without cardiovascular disease. According to their LDL-cholesterol 
levels they were arbitrarily classified into tertiles 
Results: Blood pressure responses to Ang II infusion were significantly 
increased in the group with the highest LDL-C levels (s. table). This holds 
even true when baseline BP was entered as a cofactor in the ANOVA. In 
contrast, we found no differences in renal plasma flow (RPF) and aldosteron 
serum levels after Ang II infusion between the groups with different LDL-C. 
LDL-C (mg/dl) ~.syst. BP L~diast. BP RPF (ml/min) Aldosteron (pg/ml) 
<85 n = 34 +13 ± 7 +11 ± 6 -125 ± 86 +78 ± 52 
85-111 n=35 +13±9 +11 ±6 -124 4- 68 +102±79 
>111 n=34 +18 ± 9" +16±8"  -126±68 +93±60 
p-value 0.02 0.01 n.s. n.s. 
Conclusion: 1. The increased systemic vascular responsiveness to Ang 
II infusion in the group with the highest LDL-C levels points to a cholesterol 
dependent ATl-receptor expression in the systemic vasculature in humans, 
already in the so called "normal" range of LDL-C. 2. In contrast, LDL-C seems 
not to affect the renal vasculature. 
